PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Deshiere, A; Duchemin-Pelletier, E; Spreux, E; Ciais, D; Combes, F; Vandenbrouck, Y; Coute, Y; Mikaelian, I; Giusiano, S; Charpin, C; Cochet, C; Filhol, O				Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Combes, F.; Vandenbrouck, Y.; Coute, Y.; Mikaelian, I.; Giusiano, S.; Charpin, C.; Cochet, C.; Filhol, O.			Unbalanced expression of CK2 kinase subunits is sufficient to drive epithelial-to-mesenchymal transition by Snail1 induction	ONCOGENE			English	Article						EMT; protein kinase CK2; Snail1; epithelial plasticity; breast cancer	BREAST-CANCER CELLS; FACTOR-KAPPA-B; BETA-CATENIN; STEM-CELLS; TUMOR PROGRESSION; CASEIN KINASE-2; ALPHA-CATENIN; MAMMARY-GLAND; PHENOTYPE; PHOSPHORYLATION	Epithelial-to-mesenchymal transition (EMT) is closely linked to conversion of early-stage tumours into invasive malignancies. Many signalling pathways are involved in EMT, but the key regulatory kinases in this important process have not been clearly identified. Protein kinase CK2 is a multi-subunit protein kinase, which, when overexpressed, has been linked to disease progression and poor prognosis in various cancers. Specifically, overexpression of CK2 alpha in human breast cancers is correlated with metastatic risk. In this article, we show that an imbalance of CK2 subunits reflected by a decrease in the CK2 beta regulatory subunit in a subset of breast tumour samples is correlated with induction of EMT-related markers. CK2 beta-depleted epithelial cells displayed EMT-like morphological changes, enhanced migration, and anchorage-independent growth, all of which require Snail1 induction. In epithelial cells, Snail1 stability is negatively regulated by CK2 and GSK3 beta through synergistic hierarchal phosphorylation. This process depends strongly on CK2 beta, thus confirming that CK2 functions upstream of Snail1. In primary breast tumours, CK2 beta underexpression also correlates strongly with expression of EMT markers, emphasizing the link between asymmetric expression of CK2 subunits and EMT in vivo. Our results therefore highlight the importance of CK2 beta in controlling epithelial cell plasticity. They show that CK2 holoenzyme activity is essential to suppress EMT, and that it contributes to maintaining a normal epithelial morphology. This study also suggests that unbalanced expression of CK2 subunits may drive EMT, thereby contributing to tumour progression. Oncogene (2013) 32, 1373-1383; doi:10.1038/onc.2012.165; published online 7 May 2012	[Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Cochet, C.; Filhol, O.] INSERM, U1036, Grenoble, France; [Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Cochet, C.; Filhol, O.] Univ Grenoble 1, U1036, Grenoble, France; [Deshiere, A.; Duchemin-Pelletier, E.; Spreux, E.; Ciais, D.; Cochet, C.; Filhol, O.] CEA, Dept Sci Vivant, Inst Rech Technol & Sci Vivant, F-38054 Grenoble, France; [Combes, F.; Vandenbrouck, Y.; Coute, Y.] CEA, DSV, iRTSV, Lab Etud Dynam Proteomes, F-38054 Grenoble, France; [Mikaelian, I.] Univ Lyon 1, Ctr Rech Cancerol Lyon, INSERM, CNRS,UMR5286,U1052, F-69365 Lyon, France; [Giusiano, S.; Charpin, C.] Univ Aix Marseille 2, Marseille, France; [Giusiano, S.; Charpin, C.] Univ Aix Marseille 2, INSERM, UMR 624, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Filhol, O (corresponding author), CEA, INSERM, DSV, iRTSV,U1036, 17 Rue Martyrs, F-38054 Grenoble, France.	odile.filhol-cochet@cea.fr	Filhol-Cochet, Odile/I-3962-2016; Couté, Yohann/G-2695-2015; VANDENBROUCK, Yves/Q-2675-2017; Ciais, Delphine/O-9435-2016	Couté, Yohann/0000-0003-3896-6196; VANDENBROUCK, Yves/0000-0002-1292-373X; GIUSIANO, sophie/0000-0003-3490-5556; Combes, Florence/0000-0001-7384-4587; Cochet, Claude/0000-0002-1772-4270; Ciais, Delphine/0000-0002-1649-897X; Filhol, Odile/0000-0003-1964-7958	INSERM; CEA; Ligue Nationale contre le Cancer; UJF; French National Research Agency [PCV-08 CoCCINet]; ARC	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CEA(French Atomic Energy Commission); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); UJF; French National Research Agency(French National Research Agency (ANR)); ARC(Australian Research Council)	This research was supported by recurrent institutional funding from INSERM, CEA, Ligue Nationale contre le Cancer (accredited team 2010-2012), UJF, and grants from the French National Research Agency (PCV-08 CoCCINet), ARC. We thank L Larue and BP Zhou for promoter reporter constructs, AG de Herreros for Snail1 antibody, M Thery and S Ansieau for critical reading of the manuscript.	Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Bek S, 2002, J CELL SCI, V115, P4743, DOI 10.1242/jcs.00154; Bibby AC, 2005, INT J BIOL SCI, V1, P67; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Buchou T, 2003, MOL CELL BIOL, V23, P908, DOI 10.1128/MCB.23.3.908-915.2003; Bussard KM, 2010, CANCER RES, V70, P6336, DOI 10.1158/0008-5472.CAN-10-0591; Canton DA, 2006, CELL SIGNAL, V18, P267, DOI 10.1016/j.cellsig.2005.07.008; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Charpin C, 2009, INT J CANCER, V124, P2124, DOI 10.1002/ijc.24177; COCHET C, 1983, J BIOL CHEM, V258, P1403; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Deshiere A, 2011, MOL CELL BIOCHEM, V316, P107; Deshiere A, 2008, MOL CELL BIOCHEM, V316, P107, DOI 10.1007/s11010-008-9845-y; Filhol O, 2003, MOL CELL BIOL, V23, P975, DOI 10.1128/MCB.23.3.975-987.2003; Filhol O, 2009, CELL MOL LIFE SCI, V66, P1830, DOI 10.1007/s00018-009-9151-1; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Giusiano S, 2011, EUR J CANCER, V47, P792, DOI 10.1016/j.ejca.2010.11.028; Gort EH, 2008, CURR MOL MED, V8, P60; Gyenis L, 2008, MOL CELL BIOCHEM, V316, P5, DOI 10.1007/s11010-008-9830-5; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002; Huillard E, 2010, MOL CELL BIOL, V30, P2737, DOI 10.1128/MCB.01566-09; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Laramas M, 2007, EUR J CANCER, V43, P928, DOI 10.1016/j.ejca.2006.11.021; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pluemsampant S, 2008, INT J CANCER, V122, P333, DOI 10.1002/ijc.23094; Poletto G, 2008, BIOCHEMISTRY-US, V47, P8317, DOI 10.1021/bi800216d; MacPherson MR, 2010, MOL BIOL CELL, V21, P244, DOI 10.1091/mbc.E09-06-0504; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rozanov DV, 2008, CANCER RES, V68, P4086, DOI 10.1158/0008-5472.CAN-07-6458; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN GENET DEV, V13, P365, DOI 10.1016/S0959-437X(03)00088-1; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Wu H, 2009, J CELL BIOCHEM, V108, P52, DOI 10.1002/jcb.22260; Xu Y, 2010, ONCOGENE, V29, P3124, DOI 10.1038/onc.2010.77; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	54	58	61	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1373	1383		10.1038/onc.2012.165	http://dx.doi.org/10.1038/onc.2012.165			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22562247				2022-12-17	WOS:000316455600004
J	Law, ME; Corsino, PE; Jahn, SC; Davis, BJ; Chen, S; Patel, B; Pham, K; Lu, J; Sheppard, B; Norgaard, P; Hong, J; Higgins, P; Kim, JS; Luesch, H; Law, BK				Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Chen, S.; Patel, B.; Pham, K.; Lu, J.; Sheppard, B.; Norgaard, P.; Hong, J.; Higgins, P.; Kim, J-S; Luesch, H.; Law, B. K.			Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms	ONCOGENE			English	Article						E-cadherin; breast cancer; invasion; glucocorticoid; HDAC inhibitor; PAI-1	DOMAIN-CONTAINING PROTEIN-1; EPITHELIAL TUMOR-CELLS; E-CADHERIN; TYROSINE PHOSPHORYLATION; BETA-CATENIN; BIOLOGICAL SIGNIFICANCE; ADHERENS JUNCTIONS; LOBULAR CARCINOMA; STATISTICAL-MODEL; DOWN-REGULATION	Aggressive cancers often express E-cadherin in cytoplasmic vesicles rather than on the plasma membrane and this may contribute to the invasive phenotype of these tumors. Therapeutic strategies are not currently available that restore the anti-invasive function of E-cadherin in cancers. MDA-MB-231 cells are a frequently used model of invasive triple-negative breast cancer, and these cells express low levels of E-cadherin that is mislocalized to cytoplasmic vesicles. MDA-MB-231 cell lines stably expressing wild-type E-cadherin or E-cadherin fused to glutathione S-transferase or green fluorescent protein were used as experimental systems to probe the mechanisms responsible for cytoplasmic E-cadherin localization in invasive cancers. Although E-cadherin expression partly reduced cell invasion in vitro, E-cadherin was largely localized to the cytoplasm and did not block the invasiveness of the corresponding orthotopic xenograft tumors. Further studies indicated that the glucocorticoid dexamethasone and the highly potent class I histone deacetylase (HDAC) inhibitor largazole cooperated to induce E-cadherin localization to the plasma membrane in triple-negative breast cancers, and to suppress cellular invasion in vitro. Dexamethasone blocked the production of the cleaved form of the CDCP1 (that is, CUB domain-containing protein 1) protein (cCDCP1) previously implicated in the pro-invasive activities of CDCP1 by upregulating the serine protease inhibitor plasminogen activator inhibitor-1. E-cadherin preferentially associated with cCDCP1 compared with the full-length form. In contrast, largazole did not influence CDCP1 cleavage, but increased the association of E-cadherin with gamma-catenin. This effect on E-cadherin/gamma-catenin complexes was shared with the nonisoform selective HDAC inhibitors trichostatin A (TSA) and vorinostat (suberoylanilide hydroxamic acid, SAHA), although largazole upregulated endogenous E-cadherin levels more strongly than TSA. These results demonstrate that glucocorticoids and HDAC inhibitors, both of which are currently in clinical use, cooperate to suppress the invasiveness of breast cancer cells through novel, complementary mechanisms that converge on E-cadherin. Oncogene (2013) 32, 1316-1329; doi:10.1038/onc.2012.138; published online 30 April 2012	[Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Pham, K.; Kim, J-S; Law, B. K.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Law, M. E.; Corsino, P. E.; Jahn, S. C.; Davis, B. J.; Patel, B.; Pham, K.; Lu, J.; Kim, J-S; Luesch, H.; Law, B. K.] Univ Florida, UF & Shands Canc Ctr, Gainesville, FL 32610 USA; [Chen, S.] Univ Florida, Dept Biol, Gainesville, FL 32610 USA; [Patel, B.; Lu, J.] Univ Florida, Dept Biochem, Gainesville, FL 32610 USA; [Sheppard, B.] Univ Florida, Dept Infect Dis & Pathol, Gainesville, FL 32610 USA; [Norgaard, P.] Univ Copenhagen, Herlev Hosp, Dept Pathol, DK-2730 Herlev, Denmark; [Hong, J.] Duke Univ, Dept Chem, Durham, NC 27706 USA; [Higgins, P.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Kim, J-S] Univ Florida, Dept Surg, Gainesville, FL 32610 USA; [Luesch, H.] Univ Florida, Dept Med Chem, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Copenhagen; Herlev & Gentofte Hospital; Duke University; Albany Medical College; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Law, BK (corresponding author), Univ Florida, Dept Pharmacol & Therapeut, 1600 SW Archer Rd,Acad Res Bldg,Room R5-210,POB 1, Gainesville, FL 32610 USA.	bklaw@pharmacology.ufl.edu	Law, Brian/L-6043-2019; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	Komen for the Cure grant [KG080510]; Florida Department of Health [07BB-8, 09BB-10]; NIH [R01CA138544, DK079879, GM057242]; NATIONAL CANCER INSTITUTE [R01CA093651, R01CA138544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK090115, R01DK079879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057242] Funding Source: NIH RePORTER	Komen for the Cure grant; Florida Department of Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Al Reynolds, Vanderbilt University, Nashville, TN for generously providing the E-cadherin/LZRS and pMS vectors and for instruction regarding their use. The Proteomics Division at the Interdisciplinary Center for Biotechnology Research (ICBR) (http://www.biotech.ufl.edu/proteomics/) is acknowledged for the mass spectrometry analysis. This work was supported in part by Komen for the Cure grant KG080510 and Florida Department of Health grants 07BB-8 and 09BB-10 to B Law, and NIH grants R01CA138544 (H Luesch and J Hong), DK079879 (J-S Kim), and GM057242 (PJ Higgins).	Baum B, 2011, J CELL BIOL, V192, P907, DOI 10.1083/jcb.201009141; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Boulos F, 2011, AM J SURG PATHOL, V35, P154, DOI 10.1097/PAS.0b013e3182028f79; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; BUSE P, 1995, J BIOL CHEM, V270, P28223; BUSSO N, 1987, CANCER RES, V47, P364; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Chytil A, 2004, J BIOL CHEM, V279, P47688, DOI 10.1074/jbc.M405938200; Cole KE, 2011, J AM CHEM SOC, V133, P12474, DOI 10.1021/ja205972n; Corsino PE, 2008, NEOPLASIA, V10, P1240, DOI 10.1593/neo.08710; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Daniel JM, 2007, BBA-MOL CELL RES, V1773, P59, DOI 10.1016/j.bbamcr.2006.08.052; Dawson S J, 2009, Eur J Cancer, V45 Suppl 1, P27, DOI 10.1016/S0959-8049(09)70013-9; Facina G, 2010, DIAGN CYTOPATHOL, V38, P235, DOI 10.1002/dc.21181; Feltes CM, 2002, CANCER RES, V62, P6688; Gomez-Hernandez J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-692; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Hiscox S, 1999, BIOCHEM BIOPH RES CO, V261, P406, DOI 10.1006/bbrc.1999.1002; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Liu YX, 2010, J PHARMACOL EXP THER, V335, P351, DOI 10.1124/jpet.110.172387; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Meyers MO, 2011, ANN SURG ONCOL, V18, P2851, DOI 10.1245/s10434-011-1665-8; Miyagawa R, 2010, CORONARY ARTERY DIS, V21, P144, DOI 10.1097/MCA.0b013e328335790e; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; NORDT TK, 1995, CIRCULATION, V91, P764, DOI 10.1161/01.CIR.91.3.764; Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032; Pan D, 2011, CANCER RES, V71, P6360, DOI 10.1158/0008-5472.CAN-11-0362; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Pazaiti A, 2011, WOMENS HEALTH, V7, P181, DOI [10.2217/whe.11.5, 10.2217/WHE.11.5]; Pishvaian MJ, 1999, CANCER RES, V59, P947; Querzoli P, 2010, BRIT J CANCER, V103, P1835, DOI 10.1038/sj.bjc.6605991; Rakha EA, 2010, AM J SURG PATHOL, V34, P1472, DOI 10.1097/PAS.0b013e3181f01916; Rubenstein NM, 2003, J BIOL CHEM, V278, P10353, DOI 10.1074/jbc.M213121200; Sheffield J, 2006, PROTEOMICS, V6, P1588, DOI 10.1002/pmic.200500503; Singh R, 2009, EXP CELL RES, V315, P2899, DOI 10.1016/j.yexcr.2009.07.002; Smith AL, 2012, MOL BIOL CELL, V23, P99, DOI 10.1091/mbc.E11-06-0497; Swift S, 2001, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1017cs31; Taori K, 2008, J AM CHEM SOC, V130, P1806, DOI 10.1021/ja7110064; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Ying YC, 2008, ORG LETT, V10, P4021, DOI 10.1021/ol801532s; Ying YC, 2008, J AM CHEM SOC, V130, P8455, DOI 10.1021/ja8013727; ZETTL KS, 1992, P NATL ACAD SCI USA, V89, P9069, DOI 10.1073/pnas.89.19.9069; Zhang XC, 2009, PATHOL RES PRACT, V205, P375, DOI 10.1016/j.prp.2008.08.009; Zhu MM, 2010, J PROTEOMICS, V73, P790, DOI 10.1016/j.jprot.2009.11.002	64	58	58	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1316	1329		10.1038/onc.2012.138	http://dx.doi.org/10.1038/onc.2012.138			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22543582	Green Accepted			2022-12-17	WOS:000316454500012
J	Iida, M; Brand, TM; Campbell, DA; Li, C; Wheeler, DL				Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.			Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor	ONCOGENE			English	Article						nuclear EGFR; SFK; Yes; Lyn	SRC-FAMILY KINASES; SQUAMOUS-CELL CARCINOMA; TYROSINE KINASES; C-SRC; ACQUIRED-RESISTANCE; BREAST-CANCER; EGF RECEPTOR; LUNG-CANCER; SIGNALING NETWORK; PROGNOSTIC VALUE	The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in human cancers. Cetuximab is an anti-EGFR antibody that has been approved for use in oncology. Previously we investigated mechanisms of resistance to cetuximab using a model derived from the non-small cell lung cancer line NCI-H226. We demonstrated that cetuximab-resistant clones (Ctx(R)) had increased nuclear localization of the EGFR. This process was mediated by Src family kinases (SFKs), and nuclear EGFR had a role in resistance to cetuximab. To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved. Analyses of mRNA and protein expression indicated upregulation of the SFK members Yes (v-Yes-1 yamaguchi sarcoma viral oncogene) and Lyn (v-yes-1 Yamaguchi sarcoma viral-related oncogene homolog) in all Ctx(R) clones. Further, immunoprecipitation analysis revealed that EGFR interacts with Yes and Lyn in Ctx(R) clones, but not in cetuximab-sensitive (Ctx(S)) parental cells. Using RNAi interference, we found that knockdown of either Yes or Lyn led to loss of EGFR translocation to the nucleus. Conversely, overexpression of Yes or Lyn in low nuclear EGFR-expressing Ctx(S) parental cells led to increased nuclear EGFR. Chromatin imnnunoprecipitation (Chip) assays confirmed nuclear EGFR complexes associated with the promoter of the known EGFR target genes B-Myb and iNOS. Further, all Ctx(R) clones exhibited upregulation of B-Myb and iNOS at the mRNA and protein levels. siRNAs directed at Yes or Lyn led to decreased binding of EGFR complexes to the B-Myb and iNOS promoters based on ChIP analyses. SFKs have been shown to phosphorylate EGFR on tyrosines 845 and 1101 (Y845 and Y1101), and mutation of Y1101, but not Y845, impaired nuclear entry of the EGFR. Taken together, our findings demonstrate that Yes and Lyn phosphorylate EGFR at Y1101, which influences EGFR nuclear translocation in this model of cetuximab resistance. Oncogene (2013) 32, 759-767; doi:10.1038/onc.2012.90; published online 19 March 2012	[Iida, M.; Brand, T. M.; Campbell, D. A.; Li, C.; Wheeler, D. L.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Human Oncol, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Ctr Comprehens Canc, Dept Human Oncol, 1111 Highland Ave,WIMR 3159, Madison, WI 53705 USA.	dlwheeler@wisc.edu	Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	National Cancer Institute [P30CA014520]; Clinical and Translational Science Award program of the National Center for Research Resources [1UL1RR025011]; National Institutes of Health (DUN) from the American Cancer Society [RSG-10-193-01-TBG]; NIH from Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases [T32 GM08.1061-01A2]; NATIONAL CANCER INSTITUTE [P30CA014520] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000427, KL2TR000428] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, KL2RR025012] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM081061] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Clinical and Translational Science Award program of the National Center for Research Resources; National Institutes of Health (DUN) from the American Cancer Society; NIH from Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This project was supported, in part, by grant P30CA014520 from the National Cancer Institute, grant 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources and the National Institutes of Health (DUN) by grant RSG-10-193-01-TBG from the American Cancer Society (DLW), and by NIH grant T32 GM08.1061-01A2 from Graduate Training in Cellular and Molecular Pathogenesis of Human Diseases (TMB).	Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Brand TM, 2011, DISCOV MED, V12, P419; Brand TM, 2011, CANCER BIOL THER, V12, P436, DOI 10.4161/cbt.12.5.16394; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hadzisejdic I, 2010, MODERN PATHOL, V23, P392, DOI 10.1038/modpathol.2009.166; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Hung LY, 2008, NUCLEIC ACIDS RES, V36, P4337, DOI 10.1093/nar/gkn417; Jaganathan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019605; Kasai A, 2005, GENES CELLS, V10, P1175, DOI 10.1111/j.1365-2443.2005.00909.x; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Li CF, 2012, ANN SURG ONCOL, V19, P443, DOI 10.1245/s10434-011-1942-6; Li CR, 2010, RADIOTHER ONCOL, V97, P330, DOI 10.1016/j.radonc.2010.06.010; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; Piccione EC, 2012, ONCOGENE, V31, P2953, DOI 10.1038/onc.2011.465; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Su T, 2010, NAT CELL BIOL, V12, P1143, DOI 10.1038/ncb2118; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Wheeler DL, 2009, ONCOLOGIST, V14, P667, DOI 10.1634/theoncologist.2009-0009; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200	58	58	60	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					759	767		10.1038/onc.2012.90	http://dx.doi.org/10.1038/onc.2012.90			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22430206	Green Accepted			2022-12-17	WOS:000315746700009
J	Li, X; Gao, L; Cui, Q; Gary, BD; Dyess, DL; Taylor, W; Shevde, LA; Samant, RS; Dean-Colomb, W; Piazza, GA; Xi, Y				Li, X.; Gao, L.; Cui, Q.; Gary, B. D.; Dyess, D. L.; Taylor, W.; Shevde, L. A.; Samant, R. S.; Dean-Colomb, W.; Piazza, G. A.; Xi, Y.			Sulindac inhibits tumor cell invasion by suppressing NF-kappa B-mediated transcription of microRNAs	ONCOGENE			English	Article						sulindac; invasion; microRNA; NF-kappa B	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER; BREAST-CANCER; REDUCED EXPRESSION; E-CADHERIN; RT-PCR; APOPTOSIS; INDUCTION; GENES; METASTASIS	Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely reported to display strong efficacy for cancer chemoprevention, although their mechanism of action is poorly understood. The most well-documented effects of NSAIDs include inhibition of tumor cell proliferation and induction of apoptosis, but their effect on tumor cell invasion has not been well studied. Here, we show that the NSAID, sulindac sulfide (SS) can potently inhibit the invasion of human MDA-MB-231 breast and HCT116 colon tumor cells in vitro at concentrations less than those required to inhibit tumor cell growth. To study the molecular basis for this activity, we investigated the involvement of microRNA (miRNA). A total of 132 miRNAs were found to be altered in response to SS treatment, including miR-10b, miR-17, miR-21 and miR-9, which have been previously implicated in tumor invasion and metastasis. We confirmed that these miRNA can stimulate tumor cell invasion and show that SS can attenuate their invasive effects by downregulating their expression. Employing luciferase and chromatin immunoprecipitation assays, NF-kappa B was found to bind the promoters of all four miRNAs to suppress their expression at the transcriptional level. We show that SS can inhibit the translocation of NF-kappa B to the nucleus by decreasing the phosphorylation of IKK beta and I kappa B. Analysis of the promoter sequences of the miRNAs suppressed by SS revealed that 81 of 115 sequences contained NF-kappa B-binding sites. These results show that SS can inhibit tumor cell invasion by suppressing NF-kappa B-mediated transcription of miRNAs. Oncogene (2012) 31, 4979-4986; doi:10.1038/onc.2011.655; published online 30 January 2012	[Li, X.; Gao, L.; Gary, B. D.; Taylor, W.; Shevde, L. A.; Samant, R. S.; Dean-Colomb, W.; Piazza, G. A.; Xi, Y.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36604 USA; [Cui, Q.] Peking Univ, Hlth Sci Ctr, Dept Biomed Informat, Beijing 100871, Peoples R China; [Dyess, D. L.] Univ S Alabama, Dept Surg, Mobile, AL 36604 USA	University of South Alabama; Peking University; University of South Alabama	Xi, Y (corresponding author), Univ S Alabama, Mitchell Canc Inst, 1660 Springhill Ave, Mobile, AL 36604 USA.	xi@usouthal.edu		Xi, Yaguang/0000-0003-3681-9352; Samant, Rajeev/0000-0001-5681-4976; Piazza, Gary/0000-0003-4418-887X	National Cancer Institute [R01CA148817]; NATIONAL CANCER INSTITUTE [R01CA148817, R01CA155638, R01CA140472, R21CA160280, R01CA131378] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the institutional start-up funding (Dr Yaguang Xi) and the National Cancer Institute grant R01CA148817 (Dr Gary A Piazza). We sincerely appreciate Mrs Margaret Sullivan for proof-reading the manuscript.	Agarwal B, 2003, APOPTOSIS, V8, P649, DOI 10.1023/A:1026199929747; ALBERTS DS, 1995, J CELL BIOCHEM, P18; Altuvia Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Brown JWS, 2008, TRENDS PLANT SCI, V13, P335, DOI 10.1016/j.tplants.2008.04.010; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Gefen N, 2010, LEUKEMIA, V24, P89, DOI 10.1038/leu.2009.208; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Huang GL, 2009, ONCOL REP, V21, P673, DOI 10.3892/or_00000270; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jiang MC, 2001, BIOCHEM BIOPH RES CO, V282, P671, DOI 10.1006/bbrc.2001.4637; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kashfi K, 2005, BIOCHEM PHARMACOL, V70, P969, DOI 10.1016/j.bcp.2005.05.004; Lee HC, 2005, J CELL BIOCHEM, V94, P597, DOI 10.1002/jcb.20312; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; LUNDHOLM K, 1994, CANCER RES, V54, P5602; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Mahmoud NN, 1998, CARCINOGENESIS, V19, P87, DOI 10.1093/carcin/19.1.87; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2909; Piazza GA, 1997, CANCER RES, V57, P2452; Piazza GA, 2009, CANCER PREV RES, V2, P572, DOI 10.1158/1940-6207.CAPR-09-0001; Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918; Seo AM, 2009, APOPTOSIS, V14, P913, DOI 10.1007/s10495-009-0367-1; Shah SA, 2006, INT J CANCER, V118, P532, DOI 10.1002/ijc.21365; Singh B, 2006, J SURG RES, V131, P267, DOI 10.1016/j.jss.2005.11.582; Slaby O, 2007, ONCOLOGY-BASEL, V72, P397, DOI 10.1159/000113489; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29; Stein U, 2011, NEOPLASIA, V13, P131, DOI 10.1593/neo.101172; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Thompson HJ, 1997, CANCER RES, V57, P267; Varkonyi-Gasic E, 2007, PLANT METHODS, V3, DOI 10.1186/1746-4811-3-12; Wang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017167; Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907; Xi YG, 2006, CLIN CANCER RES, V12, P2014, DOI 10.1158/1078-0432.CCR-05-1853; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhou R, 2010, NUCLEIC ACIDS RES, V38, P3222, DOI 10.1093/nar/gkq056; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	73	58	60	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	48					4979	4986		10.1038/onc.2011.655	http://dx.doi.org/10.1038/onc.2011.655			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048CU	22286762	Green Accepted			2022-12-17	WOS:000311888600002
J	Wee, EJH; Peters, K; Nair, SS; Hulf, T; Stein, S; Wagner, S; Bailey, P; Lee, SY; Qu, WJ; Brewster, B; French, JD; Dobrovic, A; Francis, GD; Clark, SJ; Brown, MA				Wee, E. J. H.; Peters, K.; Nair, S. S.; Hulf, T.; Stein, S.; Wagner, S.; Bailey, P.; Lee, S. Y.; Qu, W. J.; Brewster, B.; French, J. D.; Dobrovic, A.; Francis, G. D.; Clark, S. J.; Brown, M. A.			Mapping the regulatory sequences controlling 93 breast cancer-associated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer	ONCOGENE			English	Article						MicroRNA; miR-200b; promoter; DNA methylation; breast cancer; prognosis	EPITHELIAL-MESENCHYMAL TRANSITION; MICRORNA EXPRESSION; CPG METHYLATION; MIR-200 FAMILY; ESTROGEN-RECEPTOR; CELLS; TRANSCRIPTION; INACTIVATION; REPRESSION; INVASION	MicroRNAs (miRNAs) are small non-coding RNAs of similar to 20 nt in length that are capable of modulating gene expression post-transcriptionally. Although miRNAs have been implicated in cancer, including breast cancer, the regulation of miRNA transcription and the role of defects in this process in cancer is not well understood. In this study we have mapped the promoters of 93 breast cancer-associated miRNAs, and then looked for associations between DNA methylation of 15 of these promoters and miRNA expression in breast cancer cells. The miRNA promoters with clearest association between DNA methylation and expression included a previously described and a novel promoter of the Hsa-mir-200b cluster. The novel promoter of the Hsa-mir-200b cluster, denoted P2, is located similar to 2 kb upstream of the 5' stemloop and maps within a CpG island. P2 has comparable promoter activity to the previously reported promoter (P1), and is able to drive the expression of miR-200b in its endogenous genomic context. DNA methylation of both P1 and P2 was inversely associated with miR-200b expression in eight out of nine breast cancer cell lines, and in vitro methylation of both promoters repressed their activity in reporter assays. In clinical samples, P1 and P2 were differentially methylated with methylation inversely associated with miR-200b expression. P1 was hypermethylated in metastatic lymph nodes compared with matched primary breast tumours whereas P2 hypermethylation was associated with loss of either oestrogen receptor or progesterone receptor. Hypomethylation of P2 was associated with gain of HER2 and androgen receptor expression. These data suggest an association between miR-200b regulation and breast cancer subtype and a potential use of DNA methylation of miRNA promoters as a component of a suite of breast cancer biomarkers. Oncogene (2012) 31, 4182-4195; doi:10.1038/onc.2011.584; published online 9 January 2012	[Wee, E. J. H.; Peters, K.; Bailey, P.; Lee, S. Y.; Brewster, B.; French, J. D.; Brown, M. A.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Stein, S.; Wagner, S.; Francis, G. D.] Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia; [Nair, S. S.; Hulf, T.; Qu, W. J.; Clark, S. J.] Garvan Inst Med Res, Canc Program, Epigenet Grp, Sydney, NSW, Australia; [Dobrovic, A.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia	University of Queensland; Garvan Institute of Medical Research; Peter Maccallum Cancer Center	Brown, MA (corresponding author), Univ Queensland, Sch Chem & Mol Biosci, Coopers Rd, St Lucia, Qld 4072, Australia.	melissa.brown@uq.edu.au	Clark, Susan J/B-2272-2008; Brown, Melissa A/F-1451-2010; French, Juliet D/A-4982-2011; French, Juliet/AAV-4435-2020; Clark, Susan J/U-7365-2019	Clark, Susan J/0000-0001-5925-5030; French, Juliet/0000-0002-9770-0198; Clark, Susan J/0000-0001-5925-5030; Dobrovic, Alexander/0000-0003-3414-112X	National Breast Cancer Foundation (NBCF); Cancer Australia; National Health and Medical Research Council (NHMRC)	National Breast Cancer Foundation (NBCF); Cancer Australia; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	This project was funded by grants from the National Breast Cancer Foundation (NBCF), Cancer Australia and National Health and Medical Research Council (NHMRC). We are grateful to Dr Maja Klug for generously providing the CpG-Less reporter plasmid.	[Anonymous], 2005, Nat Methods, V2, P629; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartels CL, 2009, CLIN CHEM, V55, P623, DOI 10.1373/clinchem.2008.112805; Boyd SD, 2008, LAB INVEST, V88, P569, DOI 10.1038/labinvest.2008.32; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Han L, 2007, CANCER BIOL THER, V6, P1284; Hiroki E, 2010, CANCER SCI, V101, P241, DOI 10.1111/j.1349-7006.2009.01385.x; Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Klug M, 2006, EPIGENETICS-US, V1, P127, DOI 10.4161/epi.1.3.3327; Korpal M, 2008, RNA BIOL, V5, P115, DOI 10.4161/rna.5.3.6558; Lee JW, 2011, GYNECOL ONCOL, V120, P56, DOI 10.1016/j.ygyno.2010.09.022; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maillot G, 2009, CANCER RES, V69, P8332, DOI 10.1158/0008-5472.CAN-09-2206; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24; Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006; Monteys AM, 2010, RNA, V16, P495, DOI 10.1261/rna.1731910; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang XW, 2009, GENOME RES, V19, P266, DOI 10.1101/gr.081638.108; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013; Xu G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015519; Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214; Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808; Zhou XF, 2007, PLOS COMPUT BIOL, V3, P412, DOI 10.1371/journal.pcbi.0030037	47	58	60	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	38					4182	4195		10.1038/onc.2011.584	http://dx.doi.org/10.1038/onc.2011.584			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008SC	22231446	hybrid, Green Published			2022-12-17	WOS:000308975800002
J	Feng, H; Liu, KW; Guo, P; Zhang, P; Cheng, T; McNiven, MA; Johnson, GR; Hu, B; Cheng, SY				Feng, H.; Liu, K. W.; Guo, P.; Zhang, P.; Cheng, T.; McNiven, M. A.; Johnson, G. R.; Hu, B.; Cheng, S. Y.			Dynamin 2 mediates PDGFR alpha-SHP-2-promoted glioblastoma growth and invasion	ONCOGENE			English	Article						Dyn2; PDGFR alpha; SHP-2; Src; glioma tumor growth; invasion	TYROSINE-PHOSPHATASE SHP-2; CELL-MIGRATION; MALIGNANT GLIOMAS; ACTIVATION; SRC; PHOSPHORYLATION; FAMILY; CYTOSKELETON; PROTEINS; BINDING	Dynamin 2 (Dyn2), a large GTPase, is involved in receptor tyrosine kinase (RTK)-promoted cell migration. However, the molecular mechanisms by which Dyn2 regulates RTK-induced cell migration have not been established. Recently, we reported that tyrosine-protein phosphatase non-receptor type 11 (SHP-2) and phosphatidylinositol 3-kinase (PI3K) mediate platelet-derived growth factor receptor-alpha (PDGFR alpha)-promoted glioma tumor growth and invasion. Here, we show that Dyn2 is an effector downstream of the PDGFR alpha-PI3K/SHP-2 signaling in glioma cells. Depletion of endogenous Dyn2 by short hairpin RNAs (shRNAs) inhibited PDGFR alpha-stimulated phosphorylation of Akt, Erk1/2, Rac1 and Cdc42 activities, glioma cell migration and survival in vitro and tumor growth and invasion in the brains of mice. Dyn2 binds to SHP-2 and PI3K and colocalizes with PDGFR alpha at the invasive fronts in PDGF-A-stimulated glioma cells. Inhibition of SHP-2 by siRNA knockdown abrogated Dyn2 association with activated PDGFR alpha and PDGFR alpha activation of Rac1 and Cdc42, and glioma cell migration, thereby establishing a link between SHP-2 interaction with Dyn2 and the PDGFR alpha signaling. Furthermore, a dominant-negative SHP-2 C459S mutant inhibited PDGF-A-stimulated glioma cell migration, phosphorylation of Dyn2 and concomitantly blocked PDGFR alpha-induced Src activation. Inhibition of Src by Src inhibitors attenuated PDGF-A-stimulated phosphorylation of Akt and Dyn2 and glioma cell migration. Additionally, mutations of binding sites to PI3K, SHP-2 or Src of PDGFR alpha impaired PDGFR alpha-stimulated phosphorylation of Akt and Dyn2, and Dyn2 association with activated PDGFR alpha. Taken together, this study identifies Dyn2 as an effector that mediates PDGFR alpha-SHP-2-induced glioma tumor growth and invasion, suggesting that targeting the PDGFR alpha-SHP-2-Dyn2 pathway may be beneficial to patients with malignant glioblastomas. Oncogene (2012) 31, 2691-2702; doi:10.1038/onc.2011.436; published online 26 September 2011	[Hu, B.] Univ Pittsburgh, Dept Med, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Feng, H.; Liu, K. W.; Guo, P.; Cheng, S. Y.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; [Guo, P.] Childrens Hosp, Div Pediat Gen & Thorac Surg, Pittsburgh, PA 15213 USA; [Zhang, P.; Cheng, T.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; [Cheng, T.] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin, Peoples R China; [Cheng, T.] Chinese Acad Med Sci, Blood Dis Hosp, Ctr Stem Cell Med, Tianjin, Peoples R China; [Cheng, T.] Peking Union Med Coll, Tianjin, Peoples R China; [McNiven, M. A.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [McNiven, M. A.] Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN USA; [Johnson, G. R.] US FDA, Chem Lab, Div Therapeut Prot, Bethesda, MD 20014 USA; [Johnson, G. R.] US FDA, Ctr Drug Evaluat & Res, Bethesda, MD 20014 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Mayo Clinic; Mayo Clinic; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Hu, B (corresponding author), Univ Pittsburgh, Dept Med, Inst Canc, Hillman Canc Ctr, Suite 2-26,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	hub@upmc.edu; chengs@upmc.edu	Liu, Kun-Wei/A-9370-2013; Zhang, Peng/B-6898-2014; Feng, Haizhong/E-5795-2017	Zhang, Peng/0000-0001-5574-0899; Feng, Haizhong/0000-0003-3552-6865	ACS (RSG) [CSM-107144]; NIH [CA130966]; Pennsylvania Department of Health; Hillman Foundation; James S McDonnell Foundation; NATIONAL CANCER INSTITUTE [R01CA104125, R01CA130966] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER	ACS (RSG)(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; Hillman Foundation; James S McDonnell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Y Zhou and E Van Meir for providing glioma cell lines and Dr H Damke and L Vance for proofreading of this manuscript. This work was supported in part by a grant from ACS (RSG CSM-107144), grants from NIH (CA130966), a grant with the Pennsylvania Department of Health, and Innovative Research Scholar Awards of the Hillman Foundation to SY Cheng and B Hu, and a James S McDonnell Foundation Researching Award in Brain Cancer to B Hu.	Baldassarre M, 2003, MOL BIOL CELL, V14, P1074, DOI 10.1091/mbc.E02-05-0308; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Calzolari F, 2010, BRAIN PATHOL, V20, P527, DOI 10.1111/j.1750-3639.2009.00335.x; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cao H, 2010, MOL CELL BIOL, V30, P781, DOI 10.1128/MCB.00330-09; Carver KC, 2010, J BIOL CHEM, V285, P8003, DOI 10.1074/jbc.M109.066480; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Coyne CB, 2007, EMBO J, V26, P4016, DOI 10.1038/sj.emboj.7601831; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Gold ES, 1999, J EXP MED, V190, P1849, DOI 10.1084/jem.190.12.1849; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Haberler C, 2006, J NEURO-ONCOL, V76, P105, DOI 10.1007/s11060-005-4570-9; Imanishi Y, 2007, CANCER RES, V67, P4254; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Joshi S, 2010, MOL CANCER THER, V9, P1995, DOI 10.1158/1535-7163.MCT-10-0161; Kawada K, 2009, MOL CELL BIOL, V29, P4508, DOI 10.1128/MCB.00015-09; Kowalski JR, 2005, J CELL SCI, V118, P79, DOI 10.1242/jcs.01586; Kruchten AE, 2006, J CELL SCI, V119, P1683, DOI 10.1242/jcs.02963; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Liu KW, 2011, J CLIN INVEST, V121, P905, DOI 10.1172/JCI43690; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mitola S, 2006, CIRC RES, V98, P45, DOI 10.1161/01.RES.0000199355.32422.7b; Navis AC, 2010, ACTA NEUROPATHOL, V119, P157, DOI 10.1007/s00401-009-0614-0; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Orth JD, 2003, CURR OPIN CELL BIOL, V15, P31, DOI 10.1016/S0955-0674(02)00010-8; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Tallquist M, 2004, CYTOKINE GROWTH F R, V15, P205, DOI 10.1016/j.cytogfr.2004.03.003; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Waters CM, 2005, CELL SIGNAL, V17, P263, DOI 10.1016/j.cellsig.2004.07.011; Weller SG, 2010, P NATL ACAD SCI USA, V107, P5863, DOI 10.1073/pnas.0915123107; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	42	58	58	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2691	2702		10.1038/onc.2011.436	http://dx.doi.org/10.1038/onc.2011.436			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	21996738	Green Accepted, Green Submitted			2022-12-17	WOS:000304523500008
J	Gajate, C; Matos-da-Silva, M; Dakir, EH; Fonteriz, RI; Alvarez, J; Mollinedo, F				Gajate, C.; Matos-da-Silva, M.; Dakir, El-H; Fonteriz, R. I.; Alvarez, J.; Mollinedo, F.			Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum	ONCOGENE			English	Article						endoplasmic reticulum stress; apoptotic signaling; pancreatic cancer; xenograft animal model; alkyl-lysophospholipid analog; edelfosine	FAS/CD95 DEATH RECEPTOR; CYTOCHROME-C RELEASE; INTACT HELA-CELLS; BCL-X-L; LIPID RAFTS; ET-18-OCH3 EDELFOSINE; TUMOR-CELLS; BH3-ONLY PROTEINS; MULTIPLE-MYELOMA; LEUKEMIC-CELLS	Pancreatic cancer remains as one of the most deadly cancers, and responds poorly to current therapies. The prognosis is extremely poor, with a 5-year survival of less than 5%. Therefore, search for new effective therapeutic drugs is of pivotal need and urgency to improve treatment of this incurable malignancy. Synthetic alkyl-lysophospholipid analogs (ALPs) constitute a heterogeneous group of unnatural lipids that promote apoptosis in a wide variety of tumor cells. In this study, we found that the anticancer drug edelfosine was the most potent ALP in killing human pancreatic cancer cells, targeting endoplasmic reticulum (ER). Edelfosine was taken up in significant amounts by pancreatic cancer cells and induced caspase-and mitochondrial-mediated apoptosis. Pancreatic cancer cells show a prominent ER and edelfosine accumulated in this subcellular structure, inducing a potent ER stress response, with caspase-4, BAP31 and c-Jun NH2-terminal kinase (JNK) activation, CHOP/GADD153 upregulation and phosphorylation of eukaryotic translation initiation factor 2 alpha-subunit that eventually led to cell death. Oral administration of edelfosine in xenograft mouse models of pancreatic cancer induced a significant regression in tumor growth and an increase in apoptotic index, as assessed by TUNEL assay and caspase-3 activation in the tumor sections. The ER stress-associated marker CHOP/GADD153 was visualized in the pancreatic tumor isolated from edelfosine-treated mice, indicating a strong in vivo ER stress response. These results suggest that edelfosine exerts its pro-apoptotic action in pancreatic cancer cells, both in vitro and in vivo, through its accumulation in the ER, which leads to ER stress and apoptosis. Thus, we propose that the ER could be a key target in pancreatic cancer, and edelfosine may constitute a prototype for the development of a new class of antitumor drugs targeting the ER. Oncogene (2012) 31, 2627-2639; doi:10.1038/onc.2011.446; published online 7 November 2011	[Gajate, C.; Matos-da-Silva, M.; Dakir, El-H; Mollinedo, F.] Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, E-37007 Salamanca, Spain; [Gajate, C.; Matos-da-Silva, M.] Hosp Univ Salamanca, Unidad Invest, Salamanca, Spain; [Fonteriz, R. I.; Alvarez, J.] Univ Valladolid, CSIC, Dept Bioquim & Biol Mol, Inst Biol & Genet Mol, Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Gajate, C (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, Ctr Invest Canc, CSIC, Campus Miguel de Unamuno, E-37007 Salamanca, Spain.	cgajate@usal.es	Alvarez, Javier/K-8210-2014; Fonteriz, Rosalba I/L-1212-2014; DAKIR, EL HABIB/O-1383-2015; Fonteriz, Rosalba/ABE-3175-2021	Alvarez, Javier/0000-0003-0636-5521; Fonteriz, Rosalba I/0000-0001-8349-6264; DAKIR, EL HABIB/0000-0002-8482-3412; Fonteriz, Rosalba/0000-0001-8349-6264; Gajate, Consuelo/0000-0003-0604-6459	Fondo de Investigacion Sanitaria; European Commission [FIS-FEDER PS09/01915]; Ministerio de Ciencia e Innovacion (from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III) [SAF2008-02251, BFU 2008-01871, RD06/0020/1037]; European Community [HEALTH-F2-2011-256986]; Junta de Castilla y Leon [CSI052A11-2, GR15]; Ministerio de Ciencia e Innovacion of Spain	Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); European Commission(European CommissionEuropean Commission Joint Research Centre); Ministerio de Ciencia e Innovacion (from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III); European Community(European Commission); Junta de Castilla y Leon(Junta de Castilla y Leon); Ministerio de Ciencia e Innovacion of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants from Fondo de Investigacion Sanitaria and European Commission (FIS-FEDER PS09/01915), Ministerio de Ciencia e Innovacion (SAF2008-02251, BFU 2008-01871 and RD06/0020/1037 from Red Tematica de Investigacion Cooperativa en Cancer, Instituto de Salud Carlos III), European Community's Seventh Framework Programme FP7-2007-2013 (Grant HEALTH-F2-2011-256986) and Junta de Castilla y Leon (CSI052A11-2, GR15-Experimental Therapeutics and Translational Oncology Program, Biomedicine Project 2009 and Biomedicine Project 2010-2011). CG is supported by the Ramon y Cajal Program from the Ministerio de Ciencia e Innovacion of Spain.	Alvarez J, 2002, CELL CALCIUM, V32, P251, DOI 10.1016/S0143416002001860; Ausili A, 2008, J PHYS CHEM B, V112, P11643, DOI 10.1021/jp802165n; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Busto JV, 2007, BBA-BIOMEMBRANES, V1768, P1855, DOI 10.1016/j.bbamem.2007.04.025; Busto Jon V, 2008, J Chem Biol, V1, P89, DOI 10.1007/s12154-008-0009-z; Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169; Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062; de Mendoza AEH, 2009, CLIN CANCER RES, V15, P858, DOI 10.1158/1078-0432.CCR-08-1654; Fonseca SG, 2009, CURR OPIN PHARMACOL, V9, P763, DOI 10.1016/j.coph.2009.07.003; Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2000, CANCER RES, V60, P2651; Gajate C, 2004, J EXP MED, V200, P353, DOI 10.1084/jem.20040213; Gajate C, 2002, CURR DRUG METAB, V3, P491, DOI 10.2174/1389200023337225; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824; Gajate C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005044; Gajate C, 2009, BIOCHEM BIOPH RES CO, V380, P780, DOI 10.1016/j.bbrc.2009.01.147; Hirota Morihiko, 2006, Journal of Toxicological Sciences, V31, P149, DOI 10.2131/jts.31.149; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169; KLIMSTRA DS, 1992, AM J SURG PATHOL, V16, P815, DOI 10.1097/00000478-199209000-00001; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Minnnaugh EG, 2004, MOL CANCER THER, V3, P551; Mollinedo F, 1997, CANCER RES, V57, P1320; Mollinedo F, 2004, CURR MED CHEM, V11, P3163, DOI 10.2174/0929867043363703; Mollinedo F, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.41; Mollinedo F, 2010, ONCOGENE, V29, P3748, DOI 10.1038/onc.2010.131; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Mollinedo F, 2010, FUTURE ONCOL, V6, P811, DOI [10.2217/fon.10.34, 10.2217/FON.10.34]; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; Montero M, 1997, J CELL BIOL, V139, P601, DOI 10.1083/jcb.139.3.601; Neoptolemos JP, 2003, ANN ONCOL, V14, P675, DOI 10.1093/annonc/mdg207; Nieto-Miguel T, 2007, CANCER RES, V67, P10368, DOI 10.1158/0008-5472.CAN-07-0278; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oakes SA, 2006, CURR MOL MED, V6, P99, DOI 10.2174/156652406775574587; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SKARDA JS, 1994, DIAGN CYTOPATHOL, V10, P20, DOI 10.1002/dc.2840100106; Torrecillas A, 2006, INT J PHARMACEUT, V318, P28, DOI 10.1016/j.ijpharm.2006.03.008; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van Riel JMGH, 1999, ANN ONCOL, V10, P157, DOI 10.1023/A:1008342315262; Zaremberg V, 2005, J BIOL CHEM, V280, P38047, DOI 10.1074/jbc.M502849200; Zerp SF, 2008, ANTI-CANCER DRUG, V19, P65, DOI 10.1097/CAD.0b013e3282f16d36; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	57	58	59	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	21					2627	2639		10.1038/onc.2011.446	http://dx.doi.org/10.1038/onc.2011.446			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	948SS	22056873	Green Submitted			2022-12-17	WOS:000304523500003
J	Mancuso, M; Pasquali, E; Leonardi, S; Rebessi, S; Tanori, M; Giardullo, P; Borra, F; Pazzaglia, S; Naus, CC; Di Majo, V; Saran, A				Mancuso, M.; Pasquali, E.; Leonardi, S.; Rebessi, S.; Tanori, M.; Giardullo, P.; Borra, F.; Pazzaglia, S.; Naus, C. C.; Di Majo, V.; Saran, A.			Role of connexin43 and ATP in long-range bystander radiation damage and oncogenesis in vivo	ONCOGENE			English	Article						Cx43; GJIC; radiation; bystander effect; ATP; brain tumor	DOUBLE-STRAND BREAKS; GENOMIC INSTABILITY; IONIZING-RADIATION; SPINAL-CORD; CELLS; EXPRESSION; INVOLVEMENT; METABOLISM	Ionizing radiation is a genotoxic agent and human carcinogen. Recent work has questioned long-held dogmas by showing that cancer-associated genetic alterations occur in cells and tissues not directly exposed to radiation, questioning the robustness of the current system of radiation risk assessment. In vitro, diverse mechanisms involving secreted soluble factors, gap junction intercellular communication (GJIC) and oxidative metabolism are proposed to mediate these indirect effects. In vivo, the mechanisms behind long-range 'bystander' responses remain largely unknown. Here, we investigate the role of GJIC in propagating radiation stress signals in vivo, and in mediating radiation-associated bystander tumorigenesis in mouse central nervous system using a mouse model in which intercellular communication is downregulated by targeted deletion of the connexin43 (Cx43) gene. We show that GJIC is critical for transmission of oncogenic radiation damage to the non-targeted cerebellum, and that a mechanism involving adenosine triphosphate release and upregulation of Cx43, the major GJIC constituent, regulates transduction of oncogenic damage to unirradiated tissues in vivo. Our data provide a novel hypothesis for transduction of distant bystander effects and suggest that the highly branched nervous system, similar to the vascular network, has an important role. Oncogene (2011) 30, 4601-4608; doi: 10.1038/onc.2011.176; published online 23 May 2011	[Mancuso, M.; Pasquali, E.; Leonardi, S.; Rebessi, S.; Tanori, M.; Borra, F.; Pazzaglia, S.; Di Majo, V.; Saran, A.] Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy; [Pasquali, E.; Giardullo, P.] Univ Guglielmo Marconi, Dept Radiat Phys, Rome, Italy; [Naus, C. C.] Univ British Columbia, Inst Life Sci, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada	Italian National Agency New Technical Energy & Sustainable Economics Development; Guglielmo Marconi University; University of British Columbia	Mancuso, M (corresponding author), Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy.	mariateresa.mancuso@enea.it; anna.saran@enea.it	Pasquali, Emanuela/CAG-4451-2022	Saran, Anna/0000-0002-5587-064X	Associazione Italiana Ricerca sul Cancro (AIRC) [10357]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Grant 10357 from the Associazione Italiana Ricerca sul Cancro (AIRC) to AS. We are grateful to Maria Pia Toni and Maria Pimpinella for assistance with dosimetry and Monte Carlo simulation. We also thank Alessandro Pannicelli for help with photographs and John Bechberger (University of British Columbia, Canada) for assistance with transfer of Cx43<SUP>+/</SUP> mice.	Amino M, 2006, CARDIOVASC RES, V72, P412, DOI 10.1016/j.cardiores.2006.09.010; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; BEIR VII, 2006, COMM ASS HLTH RISKS; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Chai Yunfei, 2009, Acta Medica Nagasakiensia, V53, P65; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Huang L, 2007, CANCER RES, V67, P1099, DOI 10.1158/0008-5472.CAN-06-3697; Kasper M, 1996, HISTOCHEM CELL BIOL, V106, P419; Liu K, 1997, RADIAT RES, V147, P437, DOI 10.2307/3579500; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Mancuso M, 2008, P NATL ACAD SCI USA, V105, P12445, DOI 10.1073/pnas.0804186105; Mothersill C, 2004, NAT REV CANCER, V4, P158, DOI 10.1038/nrc1277; NAGASAWA H, 1992, CANCER RES, V52, P6394; Ojima M, 2011, RADIAT RES, V175, P90, DOI 10.1667/RR2223.1; Pazzaglia S, 2006, ONCOGENE, V25, P5575, DOI 10.1038/sj.onc.1209544; Qu Y, 2002, P NATL ACAD SCI USA, V99, P697, DOI 10.1073/pnas.022324499; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Sinclair CJD, 2000, J NEUROCHEM, V75, P1528, DOI 10.1046/j.1471-4159.2000.0751528.x; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Tsuda M, 1999, BRIT J PHARMACOL, V127, P449, DOI 10.1038/sj.bjp.0702582; Tsukimoto M, 2010, RADIAT RES, V173, P298, DOI 10.1667/RR1732.1; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082	29	58	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4601	4608		10.1038/onc.2011.176	http://dx.doi.org/10.1038/onc.2011.176			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21602884				2022-12-17	WOS:000296890700007
J	Lossaint, G; Besnard, E; Fisher, D; Piette, J; Dulic, V				Lossaint, G.; Besnard, E.; Fisher, D.; Piette, J.; Dulic, V.			Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional	ONCOGENE			English	Article						G2-M checkpoint; cyclin B1; cell cycle; Chk2; ATM	CELL-CYCLE EXIT; G(2) CHECKPOINT; ATAXIA-TELANGIECTASIA; P53-DEFICIENT CELLS; GENOMIC INSTABILITY; MITOTIC CATASTROPHE; CARCINOMA CELLS; PROTEIN-KINASE; P53; CANCER	In the presence of sustained DNA damage occurring in S-phase or G2, normal cells arrest before mitosis and eventually become senescent. The checkpoint kinases Chk1/Chk2 and the CDK inhibitor p21 are known to have important complementary roles in this process, in G2 arrest and cell cycle exit, respectively. However, additional checkpoint roles have been reported for these regulators and it is not clear to what extent their functions are redundant. Here we compared the respective roles of Chk1, Chk2 and p21 in DNA damage-induced G2 arrest in normal human fibroblasts, normal epithelial cells and frequently used p53 proficient cancer cells. We show that in normal cells, Chk1, but not Chk2, is involved in G2 arrest whereas neither are essential. In contrast, p21 is required. However, Chk1, but not Chk2, becomes necessary for arrest in U2OS osteosarcoma cells. We find that their ATM/p53/p21 response in G2 phase is defective, like in other cancer cells with wild-type p53, and conclude that cross-talk between the Chk1 and p21 pathways allows them to switch dependency for G2 arrest onto Chk1. Using the specific ATM inhibitor KU-55933 we confirm the essential role of ATM in the induction of p21 for G2 arrest of normal cells. Efficient p21 induction is required for nuclear sequestration of inactive cyclin B1-Cdk1 complexes preceding irreversible cell cycle exit in G2. Our results demonstrate that p21 is able to fulfill the Chk1 functions in G2 arrest under continuous genotoxic stress, which has important implications for cancer chemotherapy. Oncogene (2011) 30, 4261-4274; doi: 10.1038/onc.2011.135; published online 2 May 2011	[Lossaint, G.; Fisher, D.; Piette, J.; Dulic, V.] Univ Montpellier I, Inst Genet Mol Montpellier, CNRS, UMR 5535, F-34293 Montpellier, Herault, France; [Lossaint, G.; Fisher, D.; Piette, J.; Dulic, V.] Univ Montpellier 2, F-34293 Montpellier, Herault, France; [Besnard, E.] CNRS, INSERM, Inst Genet Fonct, UMR 5203,U661, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Piette, J (corresponding author), Univ Montpellier I, Inst Genet Mol Montpellier, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier, Herault, France.	jacques.piette@igmm.cnrs.fr; vjekoslav.dulic@igmm.cnrs.fr	Fisher, Daniel/D-6915-2018; Besnard, Emilie/K-6161-2015	Fisher, Daniel/0000-0002-0822-3482; Dulic, Vjekoslav/0000-0003-1201-3901	ARC [3631, 3793]; Canceropole du Grand Sud Ouest; Ministere de l'Education Nationale et de la Recherche (MENR); LNCC	ARC(Australian Research Council); Canceropole du Grand Sud Ouest; Ministere de l'Education Nationale et de la Recherche (MENR); LNCC	This work was supported by grants of ARC (grant N<SUP>o</SUP> 3631 to JP and N<SUP>o</SUP>3793 to VD) the Canceropole du Grand Sud Ouest and the Ministere de l'Education Nationale et de la Recherche (MENR, EB). The team (GL, VD and DF) is 'Equipe labellise' by the Ligue Nationale Contre le Cancer (LNCC, N<SUP>o</SUP> EL2010.LNCC/DF). GL was recipient of a PhD fellowship from LNCC. We are grateful to KUDOS Pharmaceuticals for gift KU-55933, Dr AM Creighton for gift ICRF-193, Dr D Galloway (Seattle, USA) for the E6 retroviral vector and Dr A Constantinou for DNA-PKcs-specific antibodies. We thank Dr D Fraillery for helping us in analysis of HeLa and U2OS cells, Drs V Gire and J Loncarek for the retroviral transduction of the HMEC-derived cell lines, Drs E Julien, C Sardet, A Camasses, P Coopman and N Taylor for critical reading of the manuscript and Dr A Constantinou for encouragement. We acknowledge the Montpellier RIO imaging facility (Head Dr P Travo) for their help. Finally, we thank the reviewers for insightful suggestions.	Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Andreassen PR, 2001, CANCER RES, V61, P7660; Arlander SJH, 2008, CANCER RES, V68, P89, DOI 10.1158/0008-5472.CAN-07-0675; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Bruno T, 2006, CANCER CELL, V10, P473, DOI 10.1016/j.ccr.2006.10.012; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; Charrier-Savournin FB, 2004, MOL BIOL CELL, V15, P3965, DOI 10.1091/mbc.E03-12-0871; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Foijer F, 2005, CANCER CELL, V8, P455, DOI 10.1016/j.ccr.2005.10.021; Gavet O, 2010, J CELL BIOL, V189, P247, DOI 10.1083/jcb.200909144; Gillis LD, 2009, CELL CYCLE, V8, P253, DOI 10.4161/cc.8.2.7550; Gire W, 2004, EMBO J, V23, P2554, DOI 10.1038/sj.emboj.7600259; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jin J, 2008, J BIOL CHEM, V283, P19322, DOI 10.1074/jbc.M802474200; Jurvansuu J, 2007, J MOL BIOL, V372, P397, DOI 10.1016/j.jmb.2007.06.077; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee J, 2009, MOL BIOL CELL, V20, P1891, DOI 10.1091/mbc.E08-08-0818; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lobrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248; Meek DW, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000950; Meng S, 2009, CELL CYCLE, V8, P2238, DOI 10.4161/cc.8.14.8998; Merry C, 2010, CELL CYCLE, V9, P279, DOI 10.4161/cc.9.2.10445; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Palmero EI, 2010, CURR OPIN ONCOL, V22, P64, DOI 10.1097/CCO.0b013e328333bf00; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; Shibata A, 2010, MOL CELL BIOL, V30, P3371, DOI 10.1128/MCB.01644-09; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shimada M, 2008, CELL, V132, P221, DOI 10.1016/j.cell.2007.12.013; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; STAMPFER M, 1980, IN VITRO CELL DEV B, V16, P415; Syljuasen RG, 2006, CANCER RES, V66, P10253, DOI 10.1158/0008-5472.CAN-06-2144; Takemura H, 2006, J BIOL CHEM, V281, P30814, DOI 10.1074/jbc.M603747200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Toettcher JE, 2009, P NATL ACAD SCI USA, V106, P785, DOI 10.1073/pnas.0806196106; Tomimatsu N, 2009, EMBO REP, V10, P629, DOI 10.1038/embor.2009.60; van Vugt MATM, 2010, CELL CYCLE, V9, P2097, DOI 10.4161/cc.9.11.11840; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhang YW, 2005, MOL CELL, V19, P607, DOI 10.1016/j.molcel.2005.07.019	65	58	59	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	41					4261	4274		10.1038/onc.2011.135	http://dx.doi.org/10.1038/onc.2011.135			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21532626				2022-12-17	WOS:000296356300004
J	Ling, H; Sylvestre, JR; Jolicoeur, P				Ling, H.; Sylvestre, J-R; Jolicoeur, P.			Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors	ONCOGENE			English	Article						mammary tumors; stem cells; Notch1	HEMATOPOIETIC STEM-CELLS; NOTCH PROMOTES SURVIVAL; HUMAN BREAST-CANCER; SIGNALING PATHWAY; TRANSGENIC MICE; UP-REGULATION; C-MYC; D1; TRANSFORMATION; ONCOGENESIS	Members of the Notch family are involved in the development of breast cancer in animal models and in humans. In young transgenic mice, expressing intracellular activated Notch1 (N1(IC)) in mammary cells, we found that CD24(+) CD29(high) progenitor cells had enhanced survival, and were expanded through a cyclin D1-dependent pathway. This expansion positively correlated with the later cyclin D1-dependent formation of basal-like ductal tumors. This expanded population exhibited abnormal differentiation skewed toward the basal cells, showed signs of pre-malignancy (low PTEN/p53 and high c-myc) and contained stem cells with impaired self-renewal in vivo, and more numerous multipotent, ductal-restricted progenitors. Our data suggest that N1(IC) can favor transformation of progenitor cells early in life through a cyclin D1-dependent pathway. Oncogene (2010) 29, 4543-4554; doi: 10.1038/onc.2010.186; published online 21 June 2010	[Ling, H.; Sylvestre, J-R; Jolicoeur, P.] Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; [Jolicoeur, P.] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Jolicoeur, P.] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Universite de Montreal	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	paul.jolicoeur@ircm.qc.ca			Canadian Institute of Heath Research (CIHR); Canada Research Chair	Canadian Institute of Heath Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by grant to PJ from the Canadian Institute of Heath Research (CIHR). PJ is a recipient of a Canada Research Chair and HL of a Postdoctoral Fellowship from CIHR Training grant in cancer. We are grateful to Annie Lavallee as well as to Eric Massicotte and Martine Dupuis for excellent assistance with tissue sections and flow cytometry, respectively, and to Dominic Filion for image analysis.	Ahmed KM, 2008, ONCOGENE, V27, P6738, DOI 10.1038/onc.2008.265; Asselin-Labat ML, 2006, J NATL CANCER I, V98, P1011, DOI 10.1093/jnci/djj267; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Brown JM, 1999, CANCER RES, V59, P1391; Buono KD, 2006, DEV BIOL, V293, P565, DOI 10.1016/j.ydbio.2006.02.043; Callahan R, 2004, J MAMMARY GLAND BIOL, V9, P145, DOI 10.1023/B:JOMG.0000037159.63644.81; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; DEOME KB, 1959, CANCER RES, V19, P515; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Gusterson B, 2009, NAT REV CANCER, V9, P128, DOI 10.1038/nrc2571; Hanna Z, 2009, J VIROL, V83, P9743, DOI 10.1128/JVI.00125-09; Hu CY, 2006, AM J PATHOL, V168, P973, DOI 10.2353/ajpath.2006.050416; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200; Martinez-Rumayor A, 2008, AM J CARDIOL, V101, p3A, DOI 10.1016/j.amjcard.2007.11.012; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Michels KB, 2004, NEW ENGL J MED, V351, P1679, DOI 10.1056/NEJMe048229; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Oishi K, 2004, DEV BIOL, V276, P172, DOI 10.1016/j.ydbio.2004.08.039; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Roue G, 2008, ONCOGENE, V27, P4909, DOI 10.1038/onc.2008.126; Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Smith GH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1856; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stahl M, 2006, CANCER RES, V66, P7562, DOI 10.1158/0008-5472.CAN-06-0974; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	42	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4543	4554		10.1038/onc.2010.186	http://dx.doi.org/10.1038/onc.2010.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20562911				2022-12-17	WOS:000280862300005
J	Yang, WL; Zhang, X; Lin, HK				Yang, W-L; Zhang, X.; Lin, H-K			Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development	ONCOGENE			English	Review						protein kinase; ubiquitination; phosphorylation; Akt; TRAF6; tumorigenesis	NF-KAPPA-B; CYCLIN D1; ONCOGENIC FUNCTION; AKT ACTIVATION; RECEPTOR; LIGASE; PTEN; P53; POLYUBIQUITINATION; BINDING	Ubiquitination is an important post-translational modification that has a pivotal role in numerous biological functions, such as cell growth, proliferation, apoptosis, DNA damage response, innate immune response and neuron degeneration. Although ubiquitination is thought to achieve these functions by targeting proteins for proteasome-dependent degradation, recent studies suggest that ubiquitination also has nonproteolytic functions, such as protein trafficking, kinase and phosphatase activation, which are involved in cell survival and cancer development. These progresses have advanced our current understanding of the novel functions of ubiquitination in signal transduction pathways and may provide novel paradigms for the treatment of human cancers. Oncogene (2010) 29, 4493-4503; doi: 10.1038/onc.2010.190; published online 7 June 2010	[Yang, W-L; Zhang, X.; Lin, H-K] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Yang, W-L; Zhang, X.; Lin, H-K] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center	Lin, HK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	hklin@mdanderson.org	Yang, Wei-Lei/E-2598-2012	Zhang, Xian/0000-0001-9674-7886	NCI; Department of Defense; MD Anderson Research Trust; NATIONAL CANCER INSTITUTE [R01CA149321] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); MD Anderson Research Trust; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Lin's laboratory for their comments and suggestions. We extend our special thanks to Yuan Gao for her critical reading and for editing the paper. We apologize to many investigators whose important works were not cited here due to space limitations. This work is supported by the MD Anderson Research Trust Scholar Fund, a RO1 grant from NCI, and New Investigator Award from the Department of Defense to HK Lin.	Adhikari A, 2009, DEV CELL, V16, P485, DOI 10.1016/j.devcel.2009.04.001; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Amati B, 2007, NAT CELL BIOL, V9, P729, DOI 10.1038/ncb0707-729; Ashida H, 2010, NAT CELL BIOL, V12, P66, DOI 10.1038/ncb2006; Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brooks CL, 2007, ONCOGENE, V26, P7262, DOI 10.1038/sj.onc.1210531; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Conze DB, 2008, MOL CELL BIOL, V28, P3538, DOI 10.1128/MCB.02098-07; Cummins JM, 2004, CELL CYCLE, V3, P689, DOI 10.4161/cc.3.6.924; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De Schutter J, 2009, J BIOL CHEM, V284, P36062, DOI 10.1074/jbc.M109.064923; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Dickey CA, 2008, P NATL ACAD SCI USA, V105, P3622, DOI 10.1073/pnas.0709180105; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fallon L, 2006, NAT CELL BIOL, V8, P834, DOI 10.1038/ncb1441; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335; Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962; Heemers HV, 2009, CANCER CELL, V15, P245, DOI 10.1016/j.ccr.2009.03.009; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Inohara N, 2000, J BIOL CHEM, V275, P27823; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Klein S, 2009, CURR OPIN CELL BIOL, V21, P185, DOI 10.1016/j.ceb.2008.12.006; Kon N, 2010, ONCOGENE, V29, P1270, DOI 10.1038/onc.2009.427; Kong M, 2007, J BIOL CHEM, V282, P29712, DOI 10.1074/jbc.M703159200; Korchnak AC, 2009, CELL SIGNAL, V21, P1620, DOI 10.1016/j.cellsig.2009.06.008; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lazar DF, 2006, NAT REV DRUG DISCOV, V5, P333, DOI 10.1038/nrd2007; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Lynch OT, 2004, MOL INTERV, V4, P144, DOI 10.1112/4.3.3; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; McConnell JL, 2010, BIOCHEMISTRY-US, V49, P1713, DOI 10.1021/bi901837h; Meulmeester E, 2005, CELL CYCLE, V4, P1166, DOI 10.4161/cc.4.9.1981; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Monami G, 2008, J CELL PHYSIOL, V216, P426, DOI 10.1002/jcp.21405; Novak U, 2009, BLOOD, V113, P4918, DOI 10.1182/blood-2008-08-174110; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Rong SB, 2001, J MED CHEM, V44, P898, DOI 10.1021/jm000493i; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sehat B, 2008, CANCER RES, V68, P5669, DOI 10.1158/0008-5472.CAN-07-6364; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Solit DB, 2003, CANCER RES, V63, P2139; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567; Suizu F, 2009, DEV CELL, V17, P800, DOI 10.1016/j.devcel.2009.09.007; Sun SC, 2010, CELL DEATH DIFFER, V17, P25, DOI 10.1038/cdd.2009.43; Sun SC, 2008, NAT REV IMMUNOL, V8, P501, DOI 10.1038/nri2337; [孙雪涛 Sun Xuetao], 2004, [中国工程科学, Engineering science], V6, P1; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Toker A, 2009, DEV CELL, V17, P752, DOI 10.1016/j.devcel.2009.12.003; Tremblay ML, 2008, CELL METAB, V7, P101, DOI 10.1016/j.cmet.2008.01.004; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Van Themsche C, 2009, J BIOL CHEM, V284, P20462, DOI 10.1074/jbc.C109.009522; Varghese B, 2008, MOL CELL BIOL, V28, P5275, DOI 10.1128/MCB.00350-08; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xiang T, 2008, CANCER RES, V68, P10040, DOI 10.1158/0008-5472.CAN-08-3009; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Yamazaki K, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000387; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	107	58	64	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4493	4503		10.1038/onc.2010.190	http://dx.doi.org/10.1038/onc.2010.190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20531303	Green Accepted			2022-12-17	WOS:000280862300001
J	Barbachano, A; Ordonez-Moran, P; Garcia, JM; Sanchez, A; Pereira, F; Larriba, MJ; Martinez, N; Hernandez, J; Landolfi, S; Bonilla, F; Palmer, HG; Rojas, JM; Munoz, A				Barbachano, A.; Ordonez-Moran, P.; Garcia, J. M.; Sanchez, A.; Pereira, F.; Larriba, M. J.; Martinez, N.; Hernandez, J.; Landolfi, S.; Bonilla, F.; Palmer, H. G.; Rojas, J. M.; Munoz, A.			SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumourigenicity	ONCOGENE			English	Article						colon cancer; E-cadherin; SPROUTY-2; vitamin D; ZEB1	TRANSCRIPTION FACTOR SNAIL; VITAMIN-D-RECEPTOR; ACTIVATED PROTEIN-KINASE; EPITHELIAL TUMOR-CELLS; CARCINOMA-CELLS; GENE-EXPRESSION; DOWN-REGULATION; BETA-CATENIN; EPIGENETIC INACTIVATION; GROWTH	SPROUTY-2 (SPRY2) regulates receptor tyrosine kinase signalling and therefore cell growth and differentiation. In this study, we show that SPRY2 expression in colon cancer cells is inhibited by the active vitamin D metabolite 1 alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) through E-cadherin-dependent and -independent mechanisms. In turn, SPRY2 represses both basal and 1,25(OH)(2)D(3)-induced E-cadherin expression. In line with this, SPRY2 induces ZEB1 RNA and protein, but not that of other epithelial-to-mesenchymal transition inducers that repress the CDH1/E-cadherin promoter. Consistently, SPRY2 and E-cadherin protein levels inversely correlate in colon cancer cell lines and xenografted tumours. Moreover, SPRY2 knockdown by small hairpin RNA increases CDH1/E-cadherin expression and, reciprocally, CDH1/E-cadherin knockdown increases that of SPRY2. In colon cancer patients, SPRY2 is upregulated in undifferentiated high-grade tumours and at the invasive front of low-grade carcinomas. Quantification of protein expression in 34 tumours confirmed an inverse correlation between SPRY2 and E-cadherin. Our data demonstrate a tumourigenic action of SPRY2 that is based on the repression of E-cadherin, probably by the induction of ZEB1, and a reciprocal regulation of SPRY2 and E-cadherin that dictates cell phenotype. We propose SPRY2 as a candidate novel marker for high-grade tumours and a target of therapeutic intervention in colon cancer. Oncogene (2010) 29, 4800-4813; doi:10.1038/onc.2010.225; published online 14 June 2010	[Barbachano, A.; Ordonez-Moran, P.; Pereira, F.; Larriba, M. J.; Munoz, A.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, E-28049 Madrid, Spain; [Garcia, J. M.; Bonilla, F.] Hosp Univ Puerta Hierro, Madrid, Spain; [Sanchez, A.; Martinez, N.; Rojas, J. M.] Inst Salud Carlos III, Unidad Biol Celular, Area Biol Celular & Desarrollo, Ctr Nacl Microbiol, Madrid, Spain; [Hernandez, J.; Landolfi, S.] Hosp Univ Vall dHebron, Serv Anat Patol, Barcelona, Spain; [Palmer, H. G.] Vall dHebron Inst Oncol, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; Instituto de Salud Carlos III; Centro Nacional de Microbiologa (CNM); Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, Arturo Duperier 4, E-28049 Madrid, Spain.	amunoz@iib.uam.es	Munoz, Alberto/O-6393-2014; Barbachano, Antonio/O-7731-2015; Palmer, Héctor G./AAG-8332-2019; Rojas, José M/D-3718-2018; LARRIBA, MARIA JESUS/O-4652-2014; Rojas, José M./AAA-3354-2021; Seoane, Joan/AAG-9173-2019; Ordonez-Moran, Paloma/B-6371-2016	Munoz, Alberto/0000-0003-3890-4251; Barbachano, Antonio/0000-0002-1248-5143; Rojas, José M/0000-0002-5383-3482; LARRIBA, MARIA JESUS/0000-0001-9035-7414; Rojas, José M./0000-0002-7547-2825; Seoane, Joan/0000-0002-6541-5974; Landolfi, Stefania/0000-0002-1059-635X; Palmer, Hector/0000-0002-9823-5638; Ordonez-Moran, Paloma/0000-0001-7688-1252; Pires Pereira, Fabio/0000-0002-9991-2805	Ministerio de Ciencia e Innovacion of Spain; Fondo Europeo de Desarrollo Regional [SAF2007-60341, RD06/0020/0009, RD06/0020/0020, SAF2006-04247, RD06/0020/0003, PS09/00562]; Comunidad de Madrid [S-GEN-0266/2006]; Spanish Association Against Cancer; European Union [MRTN-CT-2005-019496]	Ministerio de Ciencia e Innovacion of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fondo Europeo de Desarrollo Regional(European Commission); Comunidad de Madrid(Comunidad de Madrid); Spanish Association Against Cancer; European Union(European Commission)	We thank Drs R Bouillon, A Verstuyf, JP van de Velde, A Fabra, H Clevers, C Carlberg, E Batlle, L Sastre and A Garcia de Herreros for kindly providing us reagents, Dr M Pollan for help with statistical analysis, T Martinez for technical assistance, and R Rycroft for help with the English language editing of the paper. This study was supported by the Ministerio de Ciencia e Innovacion of Spain and Fondo Europeo de Desarrollo Regional (SAF2007-60341 and RD06/0020/0009 to AM, RD06/0020/0020 to FB, and SAF2006-04247, RD06/0020/0003 and FIS-Intrasalud (PS09/00562) to JMR), Comunidad de Madrid (S-GEN-0266/2006 to AM and FB), Spanish Association Against Cancer (to JMR), and European Union (MRTN-CT-2005-019496, NucSys, to AM).	Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Bremm A, 2008, CANCER RES, V68, P707, DOI 10.1158/0008-5472.CAN-07-1588; Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Campbell MJ, 2006, EXPERT OPIN THER TAR, V10, P735, DOI 10.1517/14728222.10.5.735; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Ding W, 2007, J CELL PHYSIOL, V212, P796, DOI 10.1002/jcp.21078; Eelen G, 2007, CURR MED CHEM, V14, P1893; Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; *IARC, 2008, INT AGENCY RES CANC, V5, P305; *IARC, 2008, INT AGENCY RES CANC, V5, P186; IARC, 2008, IARC WORK GROUP REP, V5, P1; *IARC, 2008, INT AGENCY RES CANC, V5, P216; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Kim HJ, 2007, CURR BIOL, V17, P455, DOI 10.1016/j.cub.2007.01.059; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Martinez N, 2007, CELL SIGNAL, V19, P2277, DOI 10.1016/j.cellsig.2007.07.008; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Miyaki M, 1995, ONCOGENE, V11, P2547; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ordonez-Moran P, 2008, J CELL BIOL, V183, P697, DOI 10.1083/jcb.200803020; Palmer HG, 2004, NAT MED, V10, P917, DOI 10.1038/nm1095; Palmer HG, 2003, CANCER RES, V63, P7799; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Perrais M, 2007, MOL BIOL CELL, V18, P2013, DOI 10.1091/mbc.E06-04-0348; Pike JW, 2007, J STEROID BIOCHEM, V103, P389, DOI 10.1016/j.jsbmb.2006.12.050; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sanchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Swat A, 2009, MOL CELL BIOL, V29, P3332, DOI 10.1128/MCB.01955-08; TOMITA N, 1992, CANCER RES, V52, P6840; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WIESE RJ, 1992, J BIOL CHEM, V267, P20082; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493	51	58	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4800	4813		10.1038/onc.2010.225	http://dx.doi.org/10.1038/onc.2010.225			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20543868	Green Submitted			2022-12-17	WOS:000281326400006
J	Favre, C; Zhdanov, A; Leahy, M; Papkovsky, D; O'Connor, R				Favre, C.; Zhdanov, A.; Leahy, M.; Papkovsky, D.; O'Connor, R.			Mitochondrial pyrimidine nucleotide carrier (PNC1) regulates mitochondrial biogenesis and the invasive phenotype of cancer cells	ONCOGENE			English	Article						PNC1; IGF-I; mitochondria; ROS; EMT in cancer; metabolism	ACTIVATED PROTEIN-KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-I; AEROBIC GLYCOLYSIS; SKELETAL-MUSCLE; OXIDATIVE STRESS; DNA-REPLICATION; INSULIN; METABOLISM; OXYGEN	The insulin-like growth factor (IGF-I) signalling pathway is essential for metabolism, cell growth and survival. It induces expression of the mitochondrial pyrimidine nucleotide carrier 1 (PNC1) in transformed cells, but the consequences of this for cell phenotype are unknown. Here we show that PNC1 is necessary to maintain mitochondrial function by controlling mitochondrial DNA replication and the ratio of transcription of mitochondrial genes relative to nuclear genes. PNC1 suppression causes reduced oxidative phosphorylation and leakage of reactive oxygen species (ROS), which activates the AMPK-PGC1 alpha signalling pathway and promotes mitochondrial biogenesis. Overexpression of PNC1 suppresses mitochondrial biogenesis. Suppression of PNC1 causes a profound ROS-dependent epithelial-mesenchymal transition (EMT), whereas overexpression of PNC1 suppresses both basal EMT and induction of EMT by TGF-beta. Overall, our findings indicate that PNC1 is essential for mitochondria maintenance and suggest that its induction by IGF-I facilitates cell growth whereas protecting cells from an ROS-promoted differentiation programme that arises from mitochondrial dysfunction. Oncogene (2010) 29, 3964-3976; doi:10.1038/onc.2010.146; published online 10 May 2010	[Favre, C.; Leahy, M.; O'Connor, R.] Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland; [Zhdanov, A.; Papkovsky, D.] Univ Coll Cork, Dept Biochem, Lab Biophys & Bioanal, Cork, Ireland	University College Cork; University College Cork	O'Connor, R (corresponding author), Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Coll Rd, Cork, Ireland.	r.oconnor@ucc.ie	O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422; Papkovsky, Dmitri/0000-0003-1556-1145; Zhdanov, Alexander/0000-0001-5787-2035	Science Foundation Ireland; Health Research Board	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board	We thank Kurt Tidmore for assistance with illustrations and to our colleagues in the Cell Biology Laboratory for helpful discussions. This work was funded by Science Foundation Ireland and the Health Research Board.	Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028; Ferraro D, 2006, ONCOGENE, V25, P3689, DOI 10.1038/sj.onc.1209409; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Floyd S, 2007, MOL BIOL CELL, V18, P3545, DOI 10.1091/mbc.E06-12-1109; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Huang C, 2005, J BIOL CHEM, V280, P19426, DOI 10.1074/jbc.M412317200; Hynes J, 2009, ANAL BIOCHEM, V390, P21, DOI 10.1016/j.ab.2009.04.016; Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Jager S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104; Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200; Jeng JY, 2008, J CELL BIOCHEM, V103, P347, DOI 10.1002/jcb.21625; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052; Marshall Stephen, 2006, Sci STKE, V2006, pre7; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Naito A, 2008, CANCER SCI, V99, P1584, DOI 10.1111/j.1349-7006.2008.00879.x; Owusu-Ansah E, 2008, NAT GENET, V40, P356, DOI 10.1038/ng.2007.50; Pankratz SL, 2009, J BIOL CHEM, V284, P2031, DOI 10.1074/jbc.M804776200; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9; Perez R, 2008, WORLD J GASTROENTERO, V14, P2731, DOI 10.3748/wjg.14.2731; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rhyu DY, 2005, J AM SOC NEPHROL, V16, P667, DOI 10.1681/ASN.2004050425; Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1; Unterluggauer Hermann, 2008, Biotechnology Journal, V3, P813, DOI 10.1002/biot.200700254; VANDYCK E, 1995, MOL GEN GENET, V246, P426, DOI 10.1007/BF00290446; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Will Y, 2006, NAT PROTOC, V1, P2563, DOI 10.1038/nprot.2006.351; Witczak CA, 2008, CELL MOL LIFE SCI, V65, P3737, DOI 10.1007/s00018-008-8244-6; Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8; Zhdanov AV, 2008, J BIOL CHEM, V283, P5650, DOI 10.1074/jbc.M706439200	46	58	60	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 8	2010	29	27					3964	3976		10.1038/onc.2010.146	http://dx.doi.org/10.1038/onc.2010.146			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20453889				2022-12-17	WOS:000279603200009
J	Kwon, IK; Wang, R; Thangaraju, M; Shuang, H; Liu, K; Dashwood, R; Dulin, N; Ganapathy, V; Browning, DD				Kwon, I-K; Wang, R.; Thangaraju, M.; Shuang, H.; Liu, K.; Dashwood, R.; Dulin, N.; Ganapathy, V.; Browning, D. D.			PKG inhibits TCF signaling in colon cancer cells by blocking beta-catenin expression and activating FOXO4	ONCOGENE			English	Article						PKG; cGMP; FOXO; beta-catenin; TCF; colon cancer	DEPENDENT PROTEIN-KINASE; CYCLIC-GMP; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; FUNCTIONAL-ANALYSIS; TUMOR-DEVELOPMENT; BINDING PARTNERS; BREAST-CANCER; PATHWAY	Activation of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechanisms are not fully understood. This study has examined the regulation of beta-catenin/TCF signaling, as this pathway has been highlighted as central to the anti-tumor effects of PKG. We show that PKG activation in SW620 cells results in reduced beta-catenin expression and a dramatic inhibition of TCF-dependent transcription. PKG did not affect protein stability, nor did it increase phosphorylation of the amino-terminal Ser33/37/Thr41 residues that are known to target beta-catenin for degradation. However, we found that PKG potently inhibited transcription from a luciferase reporter driven by the human CTNNB1 promoter, and this corresponded to reduced beta-catenin mRNA levels. Although PKG was able to inhibit transcription from both the CTNNB1 and TCF reporters, the effect on protein levels was less consistent. Ectopic PKG had a marginal effect on beta-catenin protein levels in SW480 and HCT116 but was able to inhibit TCF-reporter activity by over 80%. Investigation of alternative mechanisms revealed that cJun-N-terminal kinase (JNK) activation was required for the PKG-dependent regulation of TCF activity. PKG activation caused beta-catenin to bind to FOXO4 in colon cancer cells, and this required JNK. Activation of PKG was also found to increase the nuclear content of FOXO4 and increase the expression of the FOXO target genes MnSOD and catalase. FOXO4 activation was required for the inhibition of TCF activity as FOXO4-specific short-interfering RNA completely blocked the inhibitory effect of PKG. These data illustrate a dual-inhibitory effect of PKG on TCF activity in colon cancer cells that involves reduced expression of beta-catenin at the transcriptional level, and also beta-catenin sequestration by FOXO4 activation. Oncogene (2010) 29, 3423-3434; doi:10.1038/onc.2010.91; published online 29 March 2010	[Kwon, I-K; Wang, R.; Thangaraju, M.; Shuang, H.; Liu, K.; Ganapathy, V.; Browning, D. D.] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Dashwood, R.] Oregon State Univ, Linus Pauling Inst, Canc Chemoprotect Program, Corvallis, OR 97331 USA; [Dulin, N.] Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA	University System of Georgia; Augusta University; Oregon State University; University of Chicago	Browning, DD (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, CB2605,1459 Laney Walker Blvd,1120,15th St, Augusta, GA 30912 USA.	dbrowning@mcg.edu	Dashwood, Roderick/AAF-2025-2020	Liu, Kebin/0000-0003-1965-7240; Browning, Darren/0000-0003-0497-7620; Wang, Rui/0000-0001-5794-7201	American Cancer Society [RSG-07-174-01-CSM, RSG-09-209-01-TBG]; National Institutes of Health [CA133085]; NATIONAL CANCER INSTITUTE [R01CA133085] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the American Cancer Society (RSG-07-174-01-CSM to DDB and RSG-09-209-01-TBG to KL) and the National Institutes of Health (CA133085 to KL).	Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200; Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Browning DD, 2008, EXPERT OPIN THER TAR, V12, P367, DOI 10.1517/14728222.12.3.367; Browning DD, 2001, J BIOL CHEM, V276, P13039, DOI 10.1074/jbc.M009187200; Burgering B, 2008, ONCOGENE, V27, P2258, DOI 10.1038/onc.2008.29; Burgoyne JR, 2007, SCIENCE, V317, P1393, DOI 10.1126/science.1144318; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Cen B, 2008, CANCER RES, V68, P5355, DOI 10.1158/0008-5472.CAN-07-6869; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Deguchi A, 2004, CANCER RES, V64, P3966, DOI 10.1158/0008-5472.CAN-03-3740; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Forte LR, 2004, PHARMACOL THERAPEUT, V104, P137, DOI 10.1016/j.pharmthera.2004.08.007; Forte LR, 2000, ANNU REV PHYSIOL, V62, P673, DOI 10.1146/annurev.physiol.62.1.673; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goluboff ET, 2001, EXPERT OPIN INV DRUG, V10, P1875, DOI 10.1517/13543784.10.10.1875; Haanen C, 2001, Curr Opin Investig Drugs, V2, P677; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200; Hoogeboom D, 2009, BBA-REV CANCER, V1796, P63, DOI 10.1016/j.bbcan.2009.02.002; Hou YL, 2006, CANCER LETT, V240, P60, DOI 10.1016/j.canlet.2005.08.035; Hou YL, 2006, CELL SIGNAL, V18, P882, DOI 10.1016/j.cellsig.2005.07.015; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kwon IK, 2008, CANCER-AM CANCER SOC, V112, P1462, DOI 10.1002/cncr.23334; Li H, 2002, CANCER BIOL THER, V1, P621, DOI 10.4161/cbt.309; Li QJ, 2004, GENOMICS, V83, P231, DOI 10.1016/j.ygeno.2003.08.004; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Liu L, 2001, J PHARMACOL EXP THER, V299, P583; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709; Maiese K, 2008, CELL CYCLE, V7, P3829, DOI 10.4161/cc.7.24.7231; Pitari GM, 2001, P NATL ACAD SCI USA, V98, P7846, DOI 10.1073/pnas.141124698; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769; Shailubhai K, 2000, CANCER RES, V60, P5151; Soh JW, 2008, MOL CARCINOGEN, V47, P519, DOI 10.1002/mc.20409; Soh JW, 2000, CLIN CANCER RES, V6, P4136; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Sparks AB, 1998, CANCER RES, V58, P1130; Strate LL, 2005, CANCER CAUSE CONTROL, V16, P201, DOI 10.1007/s10552-004-3488-4; Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Thompson WJ, 2000, CANCER RES, V60, P3338; Uzzau S, 2000, CELL MICROBIOL, V2, P83, DOI 10.1046/j.1462-5822.2000.00041.x; van der Vos KE, 2008, ONCOGENE, V27, P2289, DOI 10.1038/onc.2008.22; Weidinger C, 2008, ENDOCR-RELAT CANCER, V15, P917, DOI 10.1677/ERC-08-0153; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Zhu B, 2005, J CELL BIOCHEM, V94, P336, DOI 10.1002/jcb.20286	61	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2010	29	23					3423	3434		10.1038/onc.2010.91	http://dx.doi.org/10.1038/onc.2010.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20348951	Green Accepted			2022-12-17	WOS:000278622700010
J	Szabo, PM; Tamasi, V; Molnar, V; Andrasfalvy, M; Tombol, Z; Farkas, R; Kovesdi, K; Patocs, A; Toth, M; Szalai, C; Falus, A; Racz, K; Igaz, P				Szabo, P. M.; Tamasi, V.; Molnar, V.; Andrasfalvy, M.; Tombol, Z.; Farkas, R.; Kovesdi, K.; Patocs, A.; Toth, M.; Szalai, C.; Falus, A.; Racz, K.; Igaz, P.			Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed	ONCOGENE			English	Article						adrenocortical tumour; meta-analysis; mRNA profiling; comparative genome hybridization; pathway analysis	GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; MOLECULAR CLASSIFICATION; HYBRIDIZATION ANALYSIS; RETINOIC ACID; ADRENAL-GLAND; RECEPTOR; CANCER; MICROARRAY; MALIGNANCY	Sporadic adrenocortical tumours are common, but their pathogenesis is poorly elucidated. In this study, we present a meta-analysis and review of gene expression microarray and comparative genome hybridization (CGH) studies performed to date on these tumours, including our own data. Data of whole genome microarray studies from altogether 164 tumours (97 benign, 67 malignant) and 18 normal tissues were reclassified and reanalysed. Significant gene sets and cytogenetic changes from publications without available genomic data were also examined including 269 benign, 215 malignant tumour and 30 normal tissues. In our experimental study, 11 tumour and four normal samples were analysed by parallel mRNA and CGH profiling. Data were examined by an integrative bioinformatics approach (GeneSpring, Gene Set Enrichment Analysis and Ingenuity Pathway Analysis softwares) searching for common gene expression changes and paralleling chromosome aberrations. Both meta-analysis of available mRNA and CGH profiling data and our experimental study revealed three major pathogenetic pathways: (1) cell cycle, (2) retinoic acid signalling (including lipopolysaccharide/Toll like receptor 4 pathway), (3) complement system and antigen presentation. These pathways include novel, previously undescribed pathomechanisms of adrenocortical tumours, and associated gene products may serve as diagnostic markers of malignancy and therapeutic targets. Oncogene (2010) 29, 3163-3172; doi: 10.1038/onc.2010.80; published online 22 March 2010	[Szabo, P. M.; Tombol, Z.; Farkas, R.; Kovesdi, K.; Toth, M.; Racz, K.; Igaz, P.] Semmelweis Univ, Fac Med, Dept Med 2, H-1088 Budapest, Hungary; [Tamasi, V.; Molnar, V.; Falus, A.] Semmelweis Univ, Fac Med, Dept Genet Cell & Immunobiol, H-1088 Budapest, Hungary; [Andrasfalvy, M.] Kromat Ltd, Budapest, Hungary; [Patocs, A.] Hungarian Acad Sci, Mol Med Res Grp, Budapest, Hungary; [Szalai, C.; Falus, A.] Hungarian Acad Sci, Inflammat Biol & Immune Genom Res Grp, Budapest, Hungary; [Szalai, C.] Heim Pal Pediat Hosp, Mol Biol Lab, Budapest, Hungary	Semmelweis University; Semmelweis University; Hungarian Academy of Sciences; Hungarian Academy of Sciences	Igaz, P (corresponding author), Semmelweis Univ, Fac Med, Dept Med 2, Szentkiralyi Str 46, H-1088 Budapest, Hungary.	igapet@bel2.sote.hu	Igaz, Peter/D-3081-2014	Igaz, Peter/0000-0003-2192-554X; Falus, Andras/0000-0002-6843-6789; Patocs, Attila/0000-0001-7506-674X	Hungarian Scientific Research Fund (OTKA) [PD72306]; Hungarian Ministry of Health [ETT 040/09]	Hungarian Scientific Research Fund (OTKA)(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Hungarian Ministry of Health	This work was supported by the Hungarian Scientific Research Fund (OTKA, PD72306) and the Hungarian Ministry of Health (ETT 040/09).	Bertherat J, 2003, CANCER RES, V63, P5308; Betz MJ, 2005, J CLIN ENDOCR METAB, V90, P3886, DOI 10.1210/jc.2004-1267; Bourcigaux N, 2000, J CLIN ENDOCR METAB, V85, P322, DOI 10.1210/jc.85.1.322; Cummins CL, 2006, J CLIN INVEST, V116, P1902, DOI 10.1172/JCI28400; de Fraipont F, 2005, J CLIN ENDOCR METAB, V90, P1819, DOI 10.1210/jc.2004-1075; de Reynies A, 2009, J CLIN ONCOL, V27, P1108, DOI 10.1200/JCO.2008.18.5678; Dohna M, 2000, GENE CHROMOSOME CANC, V28, P145, DOI 10.1002/(SICI)1098-2264(200006)28:2<145::AID-GCC3>3.0.CO;2-7; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Faggad A, 2009, MODERN PATHOL, V22, P579, DOI 10.1038/modpathol.2009.14; Fernandez-Ranvier GG, 2008, ARCH SURG-CHICAGO, V143, P841, DOI 10.1001/archsurg.143.9.841; Fernandez-Ranvier GG, 2008, WORLD J SURG, V32, P873, DOI 10.1007/s00268-008-9521-0; Ferruzzi P, 2005, J CLIN ENDOCR METAB, V90, P1332, DOI 10.1210/jc.2004-0978; Figueiredo BC, 2005, J CLIN ENDOCR METAB, V90, P615, DOI 10.1210/jc.2004-0942; Figueiredo BC, 1999, J CLIN ENDOCR METAB, V84, P1116, DOI 10.1210/jc.84.3.1116; Ghose Romi, 2004, Nucl Recept, V2, P4, DOI 10.1186/1478-1336-2-4; Giordano TJ, 2009, CLIN CANCER RES, V15, P668, DOI 10.1158/1078-0432.CCR-08-1067; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Haselbeck RJ, 1997, ENDOCRINOLOGY, V138, P3035, DOI 10.1210/en.138.7.3035; Hong FX, 2008, BIOINFORMATICS, V24, P374, DOI 10.1093/bioinformatics/btm620; Kanczkowski W, 2009, MOL CELL ENDOCRINOL, V300, P57, DOI 10.1016/j.mce.2008.10.028; Kjellman M, 1996, CANCER RES, V56, P4219; Laurell C, 2009, EUR J ENDOCRINOL, V161, P141, DOI 10.1530/EJE-09-0068; Libe R, 2007, ENDOCR-RELAT CANCER, V14, P13, DOI 10.1677/erc.1.01130; Marx C, 1996, J CLIN ENDOCR METAB, V81, P4488, DOI 10.1210/jc.81.12.4488; Ondrey F, 2009, CLIN CANCER RES, V15, P2, DOI 10.1158/1078-0432.CCR-08-0326; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Patalano A, 2009, HORM RES, V71, P99, DOI 10.1159/000178049; Russell AJ, 1999, BRIT J CANCER, V81, P684, DOI 10.1038/sj.bjc.6690748; Scripture CD, 2005, LANCET ONCOL, V6, P780, DOI 10.1016/S1470-2045(05)70388-0; Shimizu M, 2009, CANCER SCI, V100, P369, DOI 10.1111/j.1349-7006.2008.01045.x; Sidhu S, 2002, J CLIN ENDOCR METAB, V87, P3467, DOI 10.1210/jc.87.7.3467; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Slater EP, 2006, EUR J ENDOCRINOL, V154, P587, DOI 10.1530/eje.1.02116; Soon PSH, 2009, ENDOCR-RELAT CANCER, V16, P573, DOI 10.1677/ERC-08-0237; Soon PSH, 2008, ONCOLOGIST, V13, P548, DOI 10.1634/theoncologist.2007-0243; Stephan EA, 2008, MOL CANCER THER, V7, P425, DOI 10.1158/1535-7163.MCT-07-0267; Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thorngate FE, 2002, J LIPID RES, V43, P1920, DOI 10.1194/jlr.M200205-JLR200; Tombol Z, 2009, ENDOCR-RELAT CANCER, V16, P895, DOI 10.1677/ERC-09-0096; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Vakharia K, 2005, ENDOCRINOLOGY, V146, P1398, DOI 10.1210/en.2004-0882; Velazquez-Fernandez D, 2005, SURGERY, V138, P1087, DOI 10.1016/j.surg.2005.09.031; West AN, 2007, CANCER RES, V67, P600, DOI 10.1158/0008-5472.CAN-06-3767; Wolkersdorfer GW, 2005, J CLIN ENDOCR METAB, V90, P1768, DOI 10.1210/jc.2004-1406; Ye P, 2007, J ENDOCRINOL, V195, P39, DOI 10.1677/JOE-07-0037; Zacharowski K, 2006, P NATL ACAD SCI USA, V103, P6392, DOI 10.1073/pnas.0601527103; Zhao JM, 1999, AM J PATHOL, V155, P1039, DOI 10.1016/S0002-9440(10)65205-4; Zhao JM, 2002, GENE CHROMOSOME CANC, V34, P48, DOI 10.1002/gcc.10035	49	58	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3163	3172		10.1038/onc.2010.80	http://dx.doi.org/10.1038/onc.2010.80			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20305693				2022-12-17	WOS:000278133100013
J	Nilsson, MB; Zage, PE; Zeng, L; Xu, L; Cascone, T; Wu, HK; Saigal, B; Zweidler-McKay, PA; Heymach, JV				Nilsson, M. B.; Zage, P. E.; Zeng, L.; Xu, L.; Cascone, T.; Wu, H. K.; Saigal, B.; Zweidler-McKay, P. A.; Heymach, J. V.			Multiple receptor tyrosine kinases regulate HIF-1 alpha and HIF-2 alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors	ONCOGENE			English	Article						neuroblastoma; sunitinib; sorafenib; HIF-1 alpha; HIF-2 alpha; RTKs	EPIDERMAL-GROWTH-FACTOR; BONE-MARROW-TRANSPLANTATION; TUMOR ANGIOGENESIS; PROSTATE-CANCER; FACTOR VEGF; EXPRESSION; CELLS; ACTIVATION; PATHWAY; ANTITUMOR	Novel treatment approaches are needed for children with advanced neuroblastoma. Studies with neuroblastoma cells have indicated the presence of a hypoxiadriven vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-1 autocrine loop modulating hypoxia-inducible factor-1alpha (HIF-1 alpha). Whether other receptor tyrosine kinases (RTKs) are capable of modulating HIF-1 alpha levels and whether RTKs can regulate HIF-2 alpha as well is largely unknown. We evaluated neuroblastoma cell lines for expression of various RTKs. Although cell lines were heterogeneous in the expression of VEGFR-1, -3, c-Kit and RET, most cells expressed PDGFR-alpha and -beta. Ligand-induced activation of multiple RTKs upregulated HIF-1 alpha levels, whereas activation of VEGFR-1 alone upregulated HIF-2 alpha. Multitargeted tyrosine kinase inhibitor sunitinib reduced hypoxia-induced rises in HIF-1 alpha and HIF-2 alpha through mechanisms involving effects on both mRNA levels and protein stability. In addition, sunitinib and sorafenib had direct effects on tumor cell viability in vitro. In a neuroblastoma xenograft model, tumor growth inhibition by sunitinib was associated with inhibition of angiogenesis and reduced HIF-1 alpha levels. These findings show that multiple RTKs may regulate the HIF axis in normoxia and hypoxia and suggest that multikinase inhibitors may exert antiangiogenic effects not only by direct effects on endothelial cells, but also by blocking compensatory hypoxia- and ligand-induced changes in HIF-1 alpha and HIF-2 alpha. Oncogene (2010) 29, 2938-2949; doi:10.1038/onc.2010.60; published online 8 March 2010	[Nilsson, M. B.; Xu, L.; Cascone, T.; Wu, H. K.; Saigal, B.; Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Zage, P. E.; Zeng, L.; Zweidler-McKay, P. A.] Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Div Pediat, Houston, TX 77030 USA; [Heymach, J. V.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Heymach, JV (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Unit 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	jheymach@mdanderson.org	Heymach, John/AAG-2361-2019	Heymach, John/0000-0001-9068-8942; Zweidler-McKay, Patrick/0000-0001-6621-523X	Damon Runyon Cancer Research Foundation [CI 24-04]; MD Anderson Cancer Center Physician Scientist; Lorrie Olivier Neuroblastoma Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Damon Runyon Cancer Research Foundation; MD Anderson Cancer Center Physician Scientist; Lorrie Olivier Neuroblastoma Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JVH is a Damon Runyon-Lilly Clinical Investigator supported in part by the Damon Runyon Cancer Research Foundation (CI 24-04) and the MD Anderson Cancer Center Physician Scientist Award. This work was also supported in part by the Lorrie Olivier Neuroblastoma Research Fund.	Beaudry P, 2008, MOL CANCER THER, V7, P418, DOI 10.1158/1535-7163.MCT-07-0568; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Bruns CJ, 2000, CANCER RES, V60, P2926; Canete A, 2000, J CLIN ONCOL, V18, P27, DOI 10.1200/JCO.2000.18.1.27; COHEN PS, 1994, BLOOD, V84, P3465; Das B, 2005, CANCER RES, V65, P7267, DOI 10.1158/0008-5472.CAN-04-4575; Donfrancesco A, 2004, ACTA PAEDIATR, V93, P6, DOI 10.0180/08035320310021165; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Fakhari M, 2002, J PEDIATR SURG, V37, P582, DOI 10.1053/jpsu.2002.31614; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hishiki T, 1998, CANCER RES, V58, P2158; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kane RC, 2009, ONCOLOGIST, V14, P95, DOI 10.1634/theoncologist.2008-0185; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Katzenstein HM, 2001, MED PEDIATR ONCOL, V36, P190, DOI 10.1002/1096-911X(20010101)36:1<190::AID-MPO1045>3.0.CO;2-I; Kaushal V, 2005, CLIN CANCER RES, V11, P584; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Komuro H, 2001, J CANCER RES CLIN, V127, P739; Kushner BH, 2000, MED PEDIATR ONCOL, V35, P468, DOI 10.1002/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P; Ladenstein R, 1998, J CLIN ONCOL, V16, P953, DOI 10.1200/JCO.1998.16.3.953; Langer I, 2000, MED PEDIATR ONCOL, V34, P386, DOI 10.1002/(SICI)1096-911X(200006)34:6<386::AID-MPO2>3.0.CO;2-3; Lesslie DP, 2006, BRIT J CANCER, V94, P1710, DOI 10.1038/sj.bjc.6603143; Maris JM, 2008, PEDIATR BLOOD CANCER, V50, P581, DOI 10.1002/pbc.21232; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Peddinti R, 2007, CLIN CANCER RES, V13, P3499, DOI 10.1158/1078-0432.CCR-07-0237; Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Phillips RJ, 2005, J BIOL CHEM, V280, P22473, DOI 10.1074/jbc.M500963200; Pickering LM, 2009, NAT CLIN PRACT ONCOL, V6, P6, DOI 10.1038/ncponc1283; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shusterman S, 2005, CANCER LETT, V228, P171, DOI 10.1016/j.canlet.2005.01.049; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Wey JS, 2005, CANCER-AM CANCER SOC, V104, P427, DOI 10.1002/cncr.21145; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Witte D, 2002, ANTICANCER RES, V22, P1463; Yamagata K, 2002, GLIA, V37, P1, DOI 10.1002/glia.10003; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang JC, 2004, CLIN CANCER RES, V10, p6367S, DOI 10.1158/1078-0432.CCR-050006; Yoshida D, 2006, J NEURO-ONCOL, V76, P13, DOI 10.1007/s11060-005-3279-0; Zhang LB, 2009, NEOPLASIA, V11, P426, DOI 10.1593/neo.09166; Zhong H, 2000, CANCER RES, V60, P1541	49	58	64	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2938	2949		10.1038/onc.2010.60	http://dx.doi.org/10.1038/onc.2010.60			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208561				2022-12-17	WOS:000277890400005
J	Hagiwara, S; Murakumo, Y; Mii, S; Shigetomi, T; Yamamoto, N; Furue, H; Ueda, M; Takahashi, M				Hagiwara, S.; Murakumo, Y.; Mii, S.; Shigetomi, T.; Yamamoto, N.; Furue, H.; Ueda, M.; Takahashi, M.			Processing of CD109 by furin and its role in the regulation of TGF-beta signaling	ONCOGENE			English	Article						CD109; furin; processing; TGF-beta; cell proliferation	GROWTH-FACTOR-BETA; SQUAMOUS-CELL CARCINOMA; TRANSFORMING GROWTH-FACTOR-BETA-1; PROPROTEIN CONVERTASES; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; HUMAN CANCER; EXPRESSION; PROTEINS; MECHANISMS	CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, whose expression is upregulated in squamous cell carcinomas of the lung, esophagus, uterus and oral cavity. CD109 negatively regulates transforming growth factor (TGF)-beta signaling in keratinocytes by directly modulating receptor activity. In this study, we further characterized CD109 regulation of TGF-beta signaling and cell proliferation. We found that CD109 is produced as a 205 kDa glycoprotein, which is then processed in the Golgi apparatus into 180 kDa and 25 kDa proteins by furin (furinase). 180 kDa CD109 associated with GPI-anchored 25 kDa CD109 on the cell surface and was also secreted into the culture medium. To investigate whether furinase cleavage of CD109 is necessary for its biological activity, we mutated arginine 1273 in the CD109 furinase cleavage motif (amino acid 1270-RRRR-1273) to serine (R1273S). Interestingly, CD109 R1273S neither significantly impaired TGF-beta signaling nor affected TGF-beta-mediated suppression of cell growth, although it was expressed on the cell surface as a 205 kDa protein. Consistent with this finding, the 180 kDa and 25 kDa CD109 complex, but not CD109 R1273S, associated with the type I TGF-beta receptor. These findings indicate that processing of CD109 into 180 kDa and 25kDa proteins by furin, followed by complex formation with the type I TGF-beta receptor is required for the regulation of TGF-beta signaling in cancer cells and keratinocytes. Oncogene (2010) 29, 2181-2191; doi: 10.1038/onc.2009.506; published online 25 January 2010	[Hagiwara, S.; Murakumo, Y.; Mii, S.; Takahashi, M.] Nagoya Univ, Grad Sch Med, Dept Pathol, Nagoya, Aichi 4648601, Japan; [Hagiwara, S.; Shigetomi, T.; Yamamoto, N.; Furue, H.; Ueda, M.] Nagoya Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Nagoya, Aichi 4648601, Japan; [Takahashi, M.] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Pathol, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University; Nagoya University	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; Mii, Shinji/I-7480-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Mii, Shinji/0000-0001-8266-3235; 	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by Grants-in-Aid for Global Center of Excellence (GCOE) research, Scientific Research (A) and Scientific Research on Priority Area 'Cancer' commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to MT).	Arnold JN, 2006, J BIOL CHEM, V281, P6955, DOI 10.1074/jbc.M511432200; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Dennler S, 2002, J LEUKOCYTE BIOL, V71, P731; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Finnson KW, 2006, FASEB J, V20, P1525, DOI 10.1096/fj.05-5229fje; GARCIA M, 1993, J CELL SCI, V104, P1281; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Giesert C, 2003, ANN NY ACAD SCI, V996, P227, DOI 10.1111/j.1749-6632.2003.tb03250.x; GUARNACCIA SP, 1983, P NATL ACAD SCI-BIOL, V80, P1551, DOI 10.1073/pnas.80.6.1551; Hagiwara S, 2008, CANCER SCI, V99, P1916, DOI 10.1111/j.1349-7006.2008.00949.x; HAREGEWOIN A, 1994, CELL IMMUNOL, V156, P357, DOI 10.1006/cimm.1994.1181; Hasegawa M, 2008, PATHOL INT, V58, P288, DOI 10.1111/j.1440-1827.2008.02225.x; Hasegawa M, 2007, PATHOL INT, V57, P245, DOI 10.1111/j.1440-1827.2007.02097.x; Hashimoto M, 2004, ONCOGENE, V23, P3716, DOI 10.1038/sj.onc.1207418; Jakowlew SB, 2006, CANCER METAST REV, V25, P435, DOI 10.1007/s10555-006-9006-2; KELTON JG, 1990, BLOOD, V75, P2172; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lin M, 2002, BLOOD, V99, P1683, DOI 10.1182/blood.V99.5.1683; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Murray LJ, 1999, EXP HEMATOL, V27, P1282, DOI 10.1016/S0301-472X(99)00071-5; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; OUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Sato T, 2007, PATHOL INT, V57, P719, DOI 10.1111/j.1440-1827.2007.02168.x; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; SUTHERLAND DR, 1991, BLOOD, V77, P84; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; Tam BYY, 2003, J BIOL CHEM, V278, P49610, DOI 10.1074/jbc.M308492200; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; WAECHTER CJ, 1977, ARCH BIOCHEM BIOPHYS, V181, P185, DOI 10.1016/0003-9861(77)90497-0; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang XM, 2009, MOL BIOL REP, V36, P861, DOI 10.1007/s11033-008-9256-x; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Zhang JM, 2005, PATHOL INT, V55, P165, DOI 10.1111/j.1440-1827.2005.01807.x	40	58	60	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2181	2191		10.1038/onc.2009.506	http://dx.doi.org/10.1038/onc.2009.506			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101215				2022-12-17	WOS:000276685200004
J	Peschiaroli, A; Skaar, JR; Pagano, M; Melino, G				Peschiaroli, A.; Skaar, J. R.; Pagano, M.; Melino, G.			The ubiquitin-specific protease USP47 is a novel beta-TRCP interactor regulating cell survival	ONCOGENE			English	Article						ubiquitin; F-box proteins; beta-Trcp; degradation	F-BOX PROTEINS; KAPPA-B-ALPHA; REPEAT-CONTAINING PROTEIN; MEDIATED DEGRADATION; LIGASE; INHIBITION; BETA-TRCP1; PATHWAY; PLAYERS; CDC25A	Ubiquitin-specific proteases (USPs) are a subclass of cysteine proteases that catalyze the removal of ubiquitin (either monomeric or chains) from substrates, thus counteracting the activity of E3 ubiquitin ligases. Although the importance of USPs in a multitude of processes, from hereditary cancer to neurodegeneration, is well established, our knowledge on their mode of regulation, substrate specificity and biological function is quite limited. In this study we identify USP47 as a novel interactor of the E3 ubiquitin ligase, Skp1/Cul1/F-box protein beta-transducin repeat-containing protein (SCF beta-Trcp). We found that both beta-Trcp1 and beta-Trcp2 bind specifically to USP47, and point mutations in the beta-Trcp WD-repeat region completely abolished USP47 binding, indicating an E3-substrate-type interaction. However, unlike canonical beta-Trcp substrates, USP47 protein levels were neither affected by silencing of beta-Trcp nor modulated in a variety of processes, such as cell-cycle progression, DNA damage checkpoint responses or tumor necrosis factor (TNF) pathway activation. Notably, genetic or siRNA-mediated depletion of USP47 induced accumulation of Cdc25A, decreased cell survival and augmented the cytotoxic effects of anticancer drugs. In conclusion, we showed that USP47, a novel beta-Trcp interactor, regulates cell growth and survival, potentially providing a novel target for anticancer therapies. Oncogene (2010) 29, 1384-1393; doi:10.1038/onc.2009.430; published online 7 December 2009	[Peschiaroli, A.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, IDI IRCCS Biochem Lab, I-00173 Rome, Italy; [Skaar, J. R.; Pagano, M.] NYU, Sch Med, Dept Pathol, NYU Canc Inst, New York, NY USA; [Pagano, M.] NYU, Sch Med, Howard Hughes Med Inst, New York, NY USA; [Melino, G.] Univ Leicester, Toxicol Unit, MRC, Leicester, Leics, England	University of Rome Tor Vergata; New York University; Howard Hughes Medical Institute; New York University; University of Leicester	Melino, G (corresponding author), Univ Rome, Dept Expt Med & Biochem Sci, IDI IRCCS Biochem Lab, Via Montpellier, I-00133 Rome, RM, Italy.	gerry.melino@uniroma2.it		PESCHIAROLI, ANGELO/0000-0001-6311-2382; pagano, michele/0000-0003-3210-2442	EU [LSHB-CT-019067]; Alleanza contro il Cancro [ACC12/6]; MIUR/PRIN [RBIP06LCA9_0023]; AIRC [2008-2010_33-08]; ISS 'Program Italia-USA' [N526D5]; Italian Human ProteomeNet [RBRN07BMCT_007]; Telethon; National Institutes of Health [R01-GM57587, R37-CA76584, R21-CA125173]; Multiple Myeloma Research Foundation; Philip Morris USA Inc.; Philip Morris International; American Cancer Society; MRC [MC_U132670600] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R21CA125173, R37CA076584, R21CA161108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; Medical Research Council [MC_U132670600] Funding Source: researchfish	EU(European Commission); Alleanza contro il Cancro; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); ISS 'Program Italia-USA'; Italian Human ProteomeNet; Telethon(Fondazione Telethon); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Multiple Myeloma Research Foundation; Philip Morris USA Inc.; Philip Morris International; American Cancer Society(American Cancer Society); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by grants from EU EPISTEM (LSHB-CT-019067), 'Alleanza contro il Cancro' (ACC12/6), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-2010_33-08), ISS 'Program Italia-USA' N526D5, Italian Human ProteomeNet RBRN07BMCT_007 and Telethon to GM; and grants from the National Institutes of Health (R01-GM57587, R37-CA76584 and R21-CA125173) and Multiple Myeloma Research Foundation to MP. Research described in this article was also supported in part by Philip Morris USA Inc. and Philip Morris International to GM. JRS was supported by the American Cancer Society-Mr and Mrs William G Campbell Postdoctoral Fellowship in Memory of Carolyn Cabott. MP is an Investigator with the Howard Hughes Medical Institute.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Lantinga-van Leeuwen IS, 2004, HUM MOL GENET, V13, P3069, DOI 10.1093/hmg/ddh336; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Syljuasen RG, 2004, CANCER RES, V64, P9035, DOI 10.1158/0008-5472.CAN-04-2434; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039	39	58	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1384	1393		10.1038/onc.2009.430	http://dx.doi.org/10.1038/onc.2009.430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19966869	Green Accepted			2022-12-17	WOS:000275170600013
J	Lee, JH; Kang, Y; Khare, V; Jin, ZY; Kang, MY; Yoon, Y; Hyun, JW; Chung, MH; Cho, SI; Jun, JY; Chang, IY; You, HJ				Lee, J-H; Kang, Y.; Khare, V.; Jin, Z-Y; Kang, M-Y; Yoon, Y.; Hyun, J-W; Chung, M-H; Cho, S-I; Jun, J. Y.; Chang, I-Y; You, H. J.			The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage	ONCOGENE			English	Article						PIG3; DNA damage response; DNA damage checkpoint; gamma-H2AX; DNA repair	DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; HISTONE H2AX; ATAXIA-TELANGIECTASIA; ATM ACTIVATION; MRE11-RAD50-NBS1 COMPLEX; ULTRAVIOLET-RADIATION; IONIZING-RADIATION; STRESS RESPONSES; GENOTOXIC STRESS	The p53-inducible gene 3 (PIG3) is originally isolated as a p53 downstream target gene, but its function remains unknown. Here, we report a role of PIG3 in the activation of DNA damage checkpoints, after UV irradiation or radiomimetic drug neocarzinostatin (NCS). We show that depletion of endogenous PIG3 sensitizes cells to DNA damage agents, and impaired DNA repair. PIG3 depletion also allows for UV- and NCS-resistant DNA synthesis and permits cells to progress into mitosis, indicating that PIG3 knockdown can suppress intra-S phase and G2/M checkpoints. PIG3-depleted cells show reduced Chk1 and Chk2 phosphorylation after DNA damage, which may directly contribute to checkpoint bypass. PIG3 exhibited diffuse nuclear staining in the majority of untreated cells and forms discrete nuclear foci in response to DNA damage. PIG3 colocalizes with gamma-H2AX and 53BP1 to sites of DNA damage after DNA damage, and binds to a gamma-H2AX. Notably, PIG3 depletion decreases the efficient induction and maintenance of H2AX phosphorylation after DNA damage. Moreover, PIG3 contributes to the recruitment of 53BP1, Mre11, Rad50 and Nbs1 to the sites of DNA break lesions in response to DNA damage. Our combined results suggest that PIG3 is a critical component of the DNA damage response pathway and has a direct role in the transmission of the DNA damage signal from damaged DNA to the intra-S and G2/M checkpoint machinery in human cells. Oncogene (2010) 29, 1431-1450; doi:10.1038/onc.2009.438; published online 21 December 2009	[Lee, J-H; Kang, Y.; Khare, V.; Jin, Z-Y; Kang, M-Y; Yoon, Y.; You, H. J.] Chosun Univ, Dept Biomat, DNA Repair Res Ctr, Kwangju 501759, South Korea; [Lee, J-H; Kang, Y.; Kang, M-Y; Yoon, Y.; You, H. J.] Chosun Univ, Sch Med, Dept Pharmacol, Kwangju 501759, South Korea; [Hyun, J-W] Cheju Natl Univ, Sch Med, Dept Biochem, Jeju Si, South Korea; [Chung, M-H] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea; [Cho, S-I] Chosun Univ, Sch Med, Dept Otorhinolaryngol, Kwangju 501759, South Korea; [Jun, J. Y.] Chosun Univ, Sch Med, Dept Physiol, Kwangju 501759, South Korea; [Chang, I-Y] Chosun Univ, Sch Med, Dept Anat, Kwangju 501759, South Korea	Chosun University; Chosun University; Jeju National University; Seoul National University (SNU); Chosun University; Chosun University; Chosun University	You, HJ (corresponding author), 2F Chosun Univ, Sch Med, Dept Pharmacol, DNA Repair Res Ctr & Bioengn BD, 375 Seosuk Dong, Kwangju 501759, Chonnam, South Korea.	hjyou@chosun.ac.kr		You, Ho Jin/0000-0002-0530-4017; Lee, Jung-Hee/0000-0002-6889-9126	Ministry of Education, Science and Technology [M 2009-0065519, M 20706000032]; Korean government; Chosun University	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean government(Korean Government); Chosun University	This research was supported by grants (M 2009-0065519 and M 20706000032) from the Ministry of Education, Science and Technology, the Korean government and from the Chosun University, 2002.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2000, CANCER RES, V60, P5934; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Costanzo V, 2004, PLOS BIOL, V2, P600, DOI 10.1371/journal.pbio.0020110; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Garg R, 2004, MOL CANCER RES, V2, P362; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Jazayeri A, 2008, EMBO J, V27, P1953, DOI 10.1038/emboj.2008.128; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Liu QH, 2000, GENE DEV, V14, P1448; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Nicholls CD, 2004, J BIOL CHEM, V279, P24171, DOI 10.1074/jbc.M401049200; Nicholls CD, 2008, BBA-GENE REGUL MECH, V1779, P838, DOI 10.1016/j.bbagrm.2008.08.009; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Porte S, 2009, J BIOL CHEM, V284, P17194, DOI 10.1074/jbc.M109.001800; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Stucki M, 2006, DNA REPAIR, V5, P534, DOI 10.1016/j.dnarep.2006.01.012; Su TT, 2006, ANNU REV GENET, V40, P187, DOI 10.1146/annurev.genet.40.110405.090428; Tanaka T, 2007, CELL, V130, P638, DOI 10.1016/j.cell.2007.08.001; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	63	58	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1431	1450		10.1038/onc.2009.438	http://dx.doi.org/10.1038/onc.2009.438			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20023697				2022-12-17	WOS:000275392400003
J	Miller, SJ; Lan, ZD; Hardiman, A; Wu, J; Kordich, JJ; Patmore, DM; Hegde, RS; Cripe, TP; Cancelas, JA; Collins, MH; Ratner, N				Miller, S. J.; Lan, Z. D.; Hardiman, A.; Wu, J.; Kordich, J. J.; Patmore, D. M.; Hegde, R. S.; Cripe, T. P.; Cancelas, J. A.; Collins, M. H.; Ratner, N.			Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis	ONCOGENE			English	Article						EYA4; MPNST; NF1; DACH1; SOX9; Ras	DETERMINATION GENE NETWORK; FATE DETERMINATION FACTOR; NEUROFIBROMATOSIS TYPE-1; SCHWANN-CELLS; SIX1 OVEREXPRESSION; BINDING-PROTEIN; BREAST-CANCER; RAS-GTP; GROWTH; SURVIVAL	Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas without effective therapeutics. Bioinformatics was used to identify potential therapeutic targets. Paired Box (PAX), Eyes Absent (EYA), Dachsund (DACH) and Sine Oculis (SIX) genes, which form a regulatory interactive network in Drosophila, were found to be dysregulated in human MPNST cell lines and solid tumors. We identified a decrease in DACH1 expression, and increases in the expressions of PAX6, EYA1, EYA2, EYA4, and SIX1-4 genes. Consistent with the observation that half of MPNSTs develop in neurofibromatosis type 1 (NF1) patients, subsequent to NF1 mutation, we found that exogenous expression of the NF1-GTPase activating protein-related domain normalized DACH1 expression. EYA4 mRNA was elevated more than 100-fold as estimated by quantitative real-time PCR in most MPNST cell lines. In vitro, suppression of EYA4 expression using short hairpin RNA reduced cell adhesion and migration and caused cellular necrosis without affecting cell proliferation or apoptotic cell death. MPNST cells expressing shEYA4 either failed to form tumors in nude mice or formed very small tumors, with extensive necrosis but similar levels of proliferation and apoptosis as control cells. Our findings identify a role of EYA4 and possibly interacting SIX and DACH proteins in MPNSTs and suggest the EYA4 pathway as a rational therapeutic target. Oncogene (2010) 29, 368-379; doi:10.1038/onc.2009.360; published online 9 November 2009	[Miller, S. J.; Lan, Z. D.; Hardiman, A.; Wu, J.; Kordich, J. J.; Patmore, D. M.; Cancelas, J. A.; Ratner, N.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; [Hegde, R. S.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Res Fdn, Div Dev Biol,Dept Pediat, Cincinnati, OH 45229 USA; [Cripe, T. P.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Hematol Oncol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA; [Collins, M. H.] Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Pathol, Dept Pediat,Coll Med, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Ratner, N (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Res Fdn, Div Expt Hematol & Canc Biol, Dept Pediat,Coll Med, 3333 Burnet Ave,MLC 7013,Room S7-244, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org	Cancelas, Jose/AAR-9324-2020	RATNER, NANCY/0000-0001-5030-9354	DAMD [DOD W81XWH-04-1-0273]; NINDS Translational Neuroscience Award [K01-NS049191-01A1]; NATIONAL EYE INSTITUTE [R21EY019125, R01EY014648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840, K01NS049191] Funding Source: NIH RePORTER	DAMD; NINDS Translational Neuroscience Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Viral vectors were produced by the Viral Vector Core at the Translational Core Laboratories, Cincinnati Children's Hospital Research Foundation, Cincinnati, OH, USA. We thank Yonatan Y Mahller for assistance with the xenograft experiments. This study was supported by an award from the DAMD ( DOD W81XWH-04-1-0273) to NR and an NINDS Translational Neuroscience Award K01-NS049191-01A1 to SM.	Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Behbakht K, 2007, CANCER RES, V67, P3036, DOI 10.1158/0008-5472.CAN-06-3755; Borsani G, 1999, HUM MOL GENET, V8, P11, DOI 10.1093/hmg/8.1.11; Carli M, 2005, J CLIN ONCOL, V23, P8422, DOI 10.1200/JCO.2005.01.4886; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Casella CTB, 1996, GLIA, V17, P327, DOI 10.1002/(SICI)1098-1136(199608)17:4<327::AID-GLIA7>3.0.CO;2-W; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2008, CANCER RES, V68, P2204, DOI 10.1158/0008-5472.CAN-07-3141; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; DAIMARU Y, 1985, AM J SURG PATHOL, V9, P434, DOI 10.1097/00000478-198506000-00005; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Ferner RE, 2002, CANCER RES, V62, P1573; Friedman JM, 1997, AM J MED GENET, V70, P138, DOI 10.1002/(SICI)1096-8628(19970516)70:2<138::AID-AJMG7>3.0.CO;2-U; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Holtkamp N, 2004, BRAIN PATHOL, V14, P258; Hsiao FC, 2001, DEV CELL, V1, P51, DOI 10.1016/S1534-5807(01)00011-9; Ikeda K, 2002, MOL CELL BIOL, V22, P6759, DOI 10.1128/MCB.22.19.6759-6766.2002; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; Josephson R, 1998, DEVELOPMENT, V125, P3087; KIM HA, 1995, ONCOGENE, V11, P325; Klose A, 1998, HUM GENET, V102, P367, DOI 10.1007/s004390050706; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Kobayashi M, 2001, DEV BIOL, V232, P315, DOI 10.1006/dbio.2001.0185; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Krysko DV, 2008, METHOD ENZYMOL, V442, P307, DOI [10.1016/S0070-6879(08)01416-X, 10.1016/S0076-6879(08)01416-X]; Leroy K, 2001, ARCH DERMATOL, V137, P908; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Mahller YY, 2007, MOL THER, V15, P279, DOI 10.1038/sj.mt.6300038; Mahller YY, 2006, PEDIATR BLOOD CANCER, V46, P745, DOI 10.1002/pbc.20565; Maris JM, 1997, CANCER-AM CANCER SOC, V79, P1438, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.3.CO;2-A; MCCONNELL JD, 1995, BRIT J UROL, V76, P5; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Ng KT, 2006, BRIT J CANCER, V95, P1050, DOI 10.1038/sj.bjc.6603399; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Osborn NK, 2006, CLIN GASTROENTEROL H, V4, P212, DOI 10.1016/j.cgh.2005.11.009; Ramdas L, 2001, GENOME BIOL, V2; Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118; Rayapureddi JP, 2003, NATURE, V426, P295, DOI 10.1038/nature02093; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Silver SJ, 2003, MOL CELL BIOL, V23, P5989, DOI 10.1128/MCB.23.17.5989-5999.2003; Silver SJ, 2005, DEVELOPMENT, V132, P3, DOI 10.1242/dev.01539; Tootle TL, 2003, NATURE, V426, P299, DOI 10.1038/nature02097; Viskochil David, 1992, Journal of Dermatology (Tokyo), V19, P873; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Waring P, 1999, CELL DEATH DIFFER, V6, P624, DOI 10.1038/sj.cdd.4400540; Watson MA, 2004, BRAIN PATHOL, V14, P297; WESTON KM, 1994, CYTOMETRY, V15, P141, DOI 10.1002/cyto.990150207; Wu KM, 2008, P NATL ACAD SCI USA, V105, P6924, DOI 10.1073/pnas.0802085105; Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06; Wu KM, 2009, CANCER RES, V69, P3347, DOI 10.1158/0008-5472.CAN-08-3821; Xu LZ, 1996, J BIOL CHEM, V271, P24711; Zhu CQC, 2002, DEVELOPMENT, V129, P2835; Zou HZ, 2005, CANCER EPIDEM BIOMAR, V14, P830, DOI 10.1158/1055-9965.EPI-04-0506	62	58	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					368	379		10.1038/onc.2009.360	http://dx.doi.org/10.1038/onc.2009.360			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19901965	Green Accepted			2022-12-17	WOS:000273793200006
J	Walerych, D; Olszewski, MB; Gutkowska, M; Helwak, A; Zylicz, M; Zylicz, A				Walerych, D.; Olszewski, M. B.; Gutkowska, M.; Helwak, A.; Zylicz, M.; Zylicz, A.			Hsp70 molecular chaperones are required to support p53 tumor suppressor activity under stress conditions	ONCOGENE			English	Article						p53; molecular chaperones; Hsp70; Hsp90; protein folding	WILD-TYPE P53; HEAT-SHOCK PROTEINS; DNA-BINDING ACTIVITY; MUTANT P53; CORE DOMAIN; HSP90 INHIBITORS; CANCER-THERAPY; IN-VIVO; STABILIZATION; DEGRADATION	p53 as an unstable protein in vitro likely requires stabilizing factors to act as a tumor suppressor in vivo. Here, we show that in human cells transfected with wildtype (WT) p53, Hsp90 and Hsp70 molecular chaperones maintain the p53 native conformation under heat-shock conditions (42 degrees C) as well as assist p53 refolding at 37 degrees C, during the recovery from heat shock. We also show that the interaction of WT p53 with WAF1 promoter in cells is sensitive to Hsp70 and Hsp90 inhibition already at 37 degrees C and further decreased on heat shock. The influence of chaperones on p53 binding to the WAF1 promoter sequence has been confirmed in vitro, using highly purified proteins. Hsp90 stabilizes the binding of p53 to the promoter sequence at 37 degrees C, whereas under heat-shock conditions the requirement for the Hsp70-Hsp40 system and its cooperation with Hsp90 increases. Hop co-chaperone additionally stimulates these reactions. Interestingly, the combined Hsp90 and Hsp70-Hsp40 allow for a limited in vitro restoration of the DNA-binding activity by the p53 oncogenic variant R249S and affect its conformation in cells. Our results indicate for the first time that, especially under stress conditions, not only Hsp90 but also Hsp70 is required for the chaperoning of WT and R249S p53. Oncogene (2009) 28, 4284-4294; doi: 10.1038/onc.2009.281; published online 14 September 2009	[Walerych, D.; Olszewski, M. B.; Gutkowska, M.; Helwak, A.; Zylicz, M.; Zylicz, A.] Int Inst Mol & Cell Biol Warsaw, Dept Mol Biol, PL-02109 Warsaw, Poland; [Gutkowska, M.] Nencki Inst Expt Biol PAS, Warsaw, Poland; [Helwak, A.] Inst Biochem & Biophys PAS, Warsaw, Poland	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Zylicz, M (corresponding author), Int Inst Mol & Cell Biol Warsaw, Dept Mol Biol, 4 Ksiecia Trojdena St, PL-02109 Warsaw, Poland.	mzylicz@iimcb.gov.pl; alicja.zylicz@iimcb.gov.pl	Walerych, Dawid/I-2517-2016; Olszewski, Maciej/C-2021-2015; Olszewski, Maciej/G-8396-2016	Olszewski, Maciej/0000-0003-0961-0801; Olszewski, Maciej/0000-0003-0961-0801; Gutkowska, Malgorzata/0000-0001-6584-7964; Zylicz, Alicja/0000-0003-4174-3073; Walerych, Dawid/0000-0002-8440-1375	Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw; Polish Ministry of Science and Higher Education	Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	We thank Dr Marcin Klejman for sharing purified Hsp90b proteins; Professor Peter Csermely for the plasmid encoding human Hsp90a; Professor Ted Hupp for plasmid for p53 overexpression; Professor Richard Morimoto for plasmids encoding human Hsp70, Hdj1 and Hop; and Professor Kazutoyo Terada for construct for the Hdj2 overexpression. Dawid Walerych is the recipient of a scholarship from the Postgraduate School of Molecular Medicine affiliated with the Medical University of Warsaw. This work was supported by a grant from the Polish Ministry of Science and Higher Education.	Agashe VR, 2000, SEMIN CELL DEV BIOL, V11, P15, DOI 10.1006/scdb.1999.0347; Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Butler JS, 2006, PROTEIN SCI, V15, P2457, DOI 10.1110/ps.062324206; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daugaard M, 2007, FEBS LETT, V581, P3702, DOI [10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039]; Dearth LR, 2007, CARCINOGENESIS, V28, P289, DOI 10.1093/carcin/bgl132; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Friedler A, 2004, J MOL BIOL, V336, P187, DOI 10.1016/j.jmb.2003.12.005; Hansen S, 1996, J BIOL CHEM, V271, P3917; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Klucken J, 2004, BIOCHEM BIOPH RES CO, V325, P367, DOI 10.1016/j.bbrc.2004.10.037; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lee DW, 2005, J CELL SCI, V118, P4311, DOI 10.1242/jcs.02548; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Muller P, 2008, ONCOGENE, V27, P3371, DOI 10.1038/sj.onc.1211010; Muller P, 2005, J BIOL CHEM, V280, P6682, DOI 10.1074/jbc.M412767200; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Pacey S, 2006, HANDB EXP PHARM, V172, P331; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sangster TA, 2004, BIOESSAYS, V26, P348, DOI 10.1002/bies.20020; Sasaki M, 2007, J BIOL CHEM, V282, P14626, DOI 10.1074/jbc.M610514200; Schulte TW, 1998, CANCER CHEMOTH PHARM, V42, P273, DOI 10.1007/s002800050817; Selivanova G, 2007, ONCOGENE, V26, P2243, DOI 10.1038/sj.onc.1210295; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Sreedhar AS, 2004, FEBS LETT, V562, P11; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Wells M, 2008, P NATL ACAD SCI USA, V105, P5762, DOI 10.1073/pnas.0801353105; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	47	58	59	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2009	28	48					4284	4294		10.1038/onc.2009.281	http://dx.doi.org/10.1038/onc.2009.281			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DS	19749793				2022-12-17	WOS:000272876300006
J	Sasai, K; Parant, JM; Brandt, ME; Carter, J; Adams, HP; Stass, SA; Killary, AM; Katayama, H; Sen, S				Sasai, K.; Parant, J. M.; Brandt, M. E.; Carter, J.; Adams, H. P.; Stass, S. A.; Killary, A. M.; Katayama, H.; Sen, S.			Targeted disruption of Aurora A causes abnormal mitotic spindle assembly, chromosome misalignment and embryonic lethality	ONCOGENE			English	Article						mouse Aurora kinase A (Aurka) gene; mitotic spindle; chromosome segregation; Cre-LoxP recombination; morula/blastocyst	MAMMALIAN-CELLS; MESSENGER-RNA; PROTEIN; CHECKPOINT; KINASE; MICE; PHOSPHORYLATION; ENTRY; HURP; LOCALIZATION	Aurora A ( also known as STK15/BTAK in humans), a putative oncoprotein naturally overexpressed in many human cancers, is a member of the conserved Aurora protein serine/threonine kinase family that is implicated in the regulation of G(2)-M phases of the cell cycle. In vitro studies utilizing antibody microinjection, siRNA silencing and small molecule inhibitors have indicated that Aurora A functions in early as well as late stages of mitosis. However, due to limitations in specificity of the techniques, exact functional roles of the kinase remain to be clearly elucidated. In order to identify the physiological functions in vivo, we have generated Aurora A null mouse embryos, which show severe defects at 3.5 d.p.c. ( days post-coitus) morula/blastocyst stage and lethality before 8.5 d.p.c. Null embryos at 3.5 d.p.c. reveal growth retardation with cells in mitotic disarray manifesting disorganized spindle, misaligned and lagging chromosomes as well as micronucleated cells. These findings provide the first unequivocal genetic evidence for an essential physiological role of Aurora A in normal mitotic spindle assembly, chromosome alignment segregation and maintenance of viability in mammalian embryos.	[Sasai, K.; Brandt, M. E.; Carter, J.; Katayama, H.; Sen, S.] Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77054 USA; [Parant, J. M.; Adams, H. P.; Killary, A. M.] Univ Texas MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77054 USA; [Stass, S. A.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Sen, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol Pathol, 7435 Fannin, Houston, TX 77054 USA.	ssen@mdanderson.org			NCI NIH HHS [CA16672, R01 CA89716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089716, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Conte N, 2003, ONCOGENE, V22, P8102, DOI 10.1038/sj.onc.1206972; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Du J, 2004, P NATL ACAD SCI USA, V101, P8975, DOI 10.1073/pnas.0308484101; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Girdler F, 2006, J CELL SCI, V119, P3664, DOI 10.1242/jcs.03145; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; Koffa MD, 2006, CURR BIOL, V16, P743, DOI 10.1016/j.cub.2006.03.056; Liu Q, 2006, P NATL ACAD SCI USA, V103, P5811, DOI 10.1073/pnas.0601425103; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; Ma CQ, 2003, MOL CELL BIOL, V23, P1703, DOI 10.1128/MCB.23.5.1703-1716.2003; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Perera D, 2007, DEV CELL, V13, P566, DOI 10.1016/j.devcel.2007.08.008; Rieder CL, 2005, CHROMOSOMA, V114, P310, DOI 10.1007/s00412-005-0028-2; Satinover DL, 2006, CELL CYCLE, V5, P2268, DOI 10.4161/cc.5.19.3316; Sillje HHW, 2006, CURR BIOL, V16, P731, DOI 10.1016/j.cub.2006.02.070; Tay J, 2000, DEV BIOL, V221, P1, DOI 10.1006/dbio.2000.9669; Tulu US, 2006, CURR BIOL, V16, P536, DOI 10.1016/j.cub.2006.01.060; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005	32	58	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4122	4127		10.1038/onc.2008.47	http://dx.doi.org/10.1038/onc.2008.47			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18345035				2022-12-17	WOS:000257325100012
J	Fukunaga-Kalabis, M; Martinez, G; Telson, SM; Liu, ZJ; Balint, K; Juhasz, I; Elder, DE; Perbal, B; Herlyn, M				Fukunaga-Kalabis, M.; Martinez, G.; Telson, S. M.; Liu, Z-J; Balint, K.; Juhasz, I.; Elder, D. E.; Perbal, B.; Herlyn, M.			Downregulation of CCN3 expression as a potential mechanism for melanoma progression	ONCOGENE			English	Article						melanoma; CCN3; matricellular protein; matrix metalloproteinase	BREAST-CANCER CELLS; MATRIX-METALLOPROTEINASE; MALIGNANT-MELANOMA; INVASION; MIGRATION; GROWTH; LINES; GENE; PROLIFERATION; COMMUNICATION	Coculture of human melanocytes with keratinocytes upregulates CCN3, a matricellular protein critical to maintenance of normal homeostasis of melanocytes in the skin. CCN3 affects two fundamental features of melanocyte physiology: it inhibits melanocyte proliferation and stimulates their adhesion to the basement membrane. Here we report that expression of CCN3 is downregulated in advanced melanomas. Aggressive melanoma cell lines did not respond to treatment with CCN3 inducers, such as interleukin-1 beta (IL-beta), while less aggressive melanoma cell lines responded similarly to melanocytes. Immunostaining analyses revealed that CCN3 was present in melanoma cells close to the epidermal-dermal interface, but not in melanoma cells that had invaded deep into the dermis or had metastasized to lymph nodes. Contrary to our expectations, overexpression of CCN3 in 1205Lu metastatic melanoma cells did not affect their adhesion to collagen IV. However, CCN3 decreased the transcription and activation of matrix metalloproteinases and suppressed the invasion of 1205Lu melanoma cells. These results suggest that the lack of CCN3 in advanced melanoma cells contributes to their invasive phenotype. Whereas major matricellular proteins, such as osteopontin, tenascin or secreted protein acidic and rich in cysteine (SPARC), are strongly upregulated in melanoma cells; CCN3 is the first member of this family that is downregulated.	[Fukunaga-Kalabis, M.; Martinez, G.; Telson, S. M.; Liu, Z-J; Balint, K.; Herlyn, M.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Juhasz, I.] Univ Debrecen, Med & Hlth Sci Ctr, Dept Dermatol & Venerol, Debrecen, Hungary; [Elder, D. E.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Perbal, B.] Univ Paris 7D, Lab Oncol Virale & Mol, Paris, France	The Wistar Institute; University of Debrecen; University of Pennsylvania; UDICE-French Research Universities; Universite Paris Cite	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	Balint, Klara/ABB-8816-2021		NCI NIH HHS [R01 CA047159, CA76674, R01 CA080999, CA25874, CA80999, P30 CA010815, CA47159, R01 CA076674, P01 CA025874, CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, R01CA080999, R01CA076674, P30CA010815, R01CA047159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CLARK WH, 1991, BRIT J CANCER, V64, P631, DOI 10.1038/bjc.1991.375; Denkert C, 2002, CLIN EXP METASTAS, V19, P79, DOI 10.1023/A:1013857325012; Fukunaga-Kalabis M, 2006, J CELL BIOL, V175, P563, DOI 10.1083/jcb.200602132; Gilles C, 1998, CANCER RES, V58, P5529; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Haass NK, 2004, J MOL HISTOL, V35, P309; Haass NK, 2005, PIGM CELL RES, V18, P150, DOI 10.1111/j.1600-0749.2005.00235.x; HERLYN M, 1991, CANCER RES, V51, P4853; Hofmann UB, 1999, BRIT J CANCER, V81, P774, DOI 10.1038/sj.bjc.6690763; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Kalembeyi I, 2003, INT J CANCER, V105, P53, DOI 10.1002/ijc.11037; Kleer CG, 2004, NEOPLASIA, V6, P179, DOI 10.1593/neo.03316; Kuphal S, 2005, CANCER METAST REV, V24, P195, DOI 10.1007/s10555-005-1572-1; Lake AC, 2003, AM J PATHOL, V162, P219, DOI 10.1016/S0002-9440(10)63813-8; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; MAILLARDM, 2001, MOL PATHOL, V54, P275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; Matic M, 2002, J INVEST DERMATOL, V118, P110, DOI 10.1046/j.0022-202x.2001.01623.x; McCallum L, 2006, BLOOD, V108, P1716, DOI 10.1182/blood-2006-04-016113; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Perbal B, 2003, J CLIN PATHOL-MOL PA, V56, P80, DOI 10.1136/mp.56.2.80; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Philip S, 2001, J BIOL CHEM, V276, P44926, DOI 10.1074/jbc.M103334200; Planque N, 2006, J CELL BIOCHEM, V99, P105, DOI 10.1002/jcb.20887; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Welch DR, 2000, CANCER RES, V60, P1552; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x	35	58	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2552	2560		10.1038/sj.onc.1210896	http://dx.doi.org/10.1038/sj.onc.1210896			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17968313	Green Accepted			2022-12-17	WOS:000255057000005
J	Park, HJ; Wang, Z; Costa, RH; Tyner, A; Lau, LF; Raychaudhuri, P				Park, H. J.; Wang, Z.; Costa, R. H.; Tyner, A.; Lau, L. F.; Raychaudhuri, P.			An N-terminal inhibitory domain modulates activity of FoxM1 during cell cycle	ONCOGENE			English	Article						FoxM1; cell cycle regulation; FoxM1-inhibitory domain; transforming activity	TRANSCRIPTION FACTOR TRIDENT; S-PHASE; HEPATOCYTE ENTRY; FACTOR HFH-11B; LIVER; TRANSACTIVATION; PROLIFERATION; PROGRESSION; CARCINOMAS; EXPRESSION	The FoxM1 transcription factor plays critical roles in the expression of genes that are essential for cell proliferation. FoxM1 null or depleted cells fail to progress through mitosis, as expression of several mitotic genes depends upon FoxM1. The transcriptional activity of FoxM1 is stimulated by cyclin-cdk-mediated phosphorylation at a site within the transcriptional activation domain. Here, we characterize the role of an N-terminal inhibitory domain in the transcriptional activity of FoxM1. Deletion of the N-terminal 232 amino-acid residues increases the transcriptional and transforming activities of FoxM1. Moreover, while the activity of the full-length FoxM1 is stimulated by growth factors, the activity of the N-terminal deletion mutant is constitutively high in all phases of the cell cycle. The N-terminal deletion also eliminates the requirement for cyclin-cdk to activate FoxM1. We provide evidence that the N-terminal domain interacts with the C-terminal half of the transcription factor to attenuate its transcriptional activity. Moreover, the N-terminal fragment inhibits the transcriptional activity of FoxM1 in G(1)/S cells, but not in G(2)/M cells. Our results suggest that cyclin-cdk phosphorylates FoxM1 to counteract the inhibition by the N-terminal domain to fully activate FoxM1 in G(2)/M phase.	[Park, H. J.; Wang, Z.; Costa, R. H.; Tyner, A.; Lau, L. F.; Raychaudhuri, P.] Univ Illinois, Coll Med, Dept Biochem & Mol Genet M C 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet M C 669, 900 S Ashland Ave, Chicago, IL 60607 USA.	pradip@uic.edu		Tyner, Angela/0000-0001-7448-8625; Lau, Lester/0000-0002-4364-2914	NATIONAL CANCER INSTITUTE [R01CA046565, R01CA124488, R01CA100035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044525, R01DK054687, R55DK044525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021842] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100035, CA100035, R01 CA100035-04, CA46565, CA124488, R01 CA124488, R01 CA124488-02, R01 CA046565] Funding Source: Medline; NIA NIH HHS [R01 AG021842, R01 AG021842-05] Funding Source: Medline; NIDDK NIH HHS [R01 DK054687, R01 DK044525, DK044525, R01 DK054687-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Wierstra I, 2006, BIOCHEM BIOPH RES CO, V348, P99, DOI 10.1016/j.bbrc.2006.07.008; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; Wierstra I, 2006, BIOL CHEM, V387, P963, DOI 10.1515/BC.2006.120; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626	20	58	60	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2008	27	12					1696	1704		10.1038/sj.onc.1210814	http://dx.doi.org/10.1038/sj.onc.1210814			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891172	Green Accepted, Green Submitted			2022-12-17	WOS:000253962100005
J	Wang, X; Pan, L; Feng, Y; Wang, Y; Han, Q; Han, L; Han, S; Guo, J; Huang, B; Lu, J				Wang, X.; Pan, L.; Feng, Y.; Wang, Y.; Han, Q.; Han, L.; Han, S.; Guo, J.; Huang, B.; Lu, J.			p300 plays a role in p16(INK4a) expression and cell cycle arrest	ONCOGENE			English	Article						p16; p300; Sp1; transcriptional regulation	GENE-EXPRESSION; SP1; TRANSCRIPTION; INHIBITOR; BINDING; PROTEIN; PROLIFERATION; SENESCENCE; RECRUITMENT; LOCUS	As a cyclin-dependent kinase inhibitor, p16(INK4a) plays a key role in cell cycle progression and cellular differentiation, and its expression is frequently altered in human cancers through epigenetically mediated transcriptional silencing. In this report, we demonstrate that p300 was able to induce cell cycle arrest, and this process was reversed by p16(INK4a) silencing by RNA interference in HeLa cells. We also show that p300 was involved in activation of p16(INK4a) expression in 293T cells. Specifically, p300 cooperated with Sp1 to stimulate both p16(INK4a) promoter activity and mRNA expression. Co-immunoprecipitation and mammalian two-hybrid assays revealed that p300 and Sp1 formed a complex through interaction between the Q domain of p300 and the N-terminal domain of Sp1. The chromatin immunoprecipitation assays verified that p300 was recruited to p16(INK4a) promoter, and the histone acetyltransferase domain of p300 participated in p16(INK4a) activation through inducing hyperacetylation of histone H4 at p16(INK4a) gene. These data suggest that p300 plays a critical role in transcriptional regulation of p16(INK4a) and in cell cycle arrest.	[Wang, X.; Pan, L.; Feng, Y.; Wang, Y.; Han, Q.; Han, L.; Han, S.; Huang, B.; Lu, J.] NE Normal Univ, Inst Cytol & Genet, Changchun 130024, Peoples R China; [Guo, J.] NE Normal Univ, Key Lab Appl Stat MOS, Changchun, Peoples R China	Northeast Normal University - China; Northeast Normal University - China	Lu, J (corresponding author), NE Normal Univ, Inst Cytol & Genet, 5268 Renmin St, Changchun 130024, Peoples R China.	luj809@nenu.edu.cn	Han, Songyan/D-8351-2012					Bond J, 2004, EXP CELL RES, V292, P151, DOI 10.1016/j.yexcr.2003.09.021; Chan HM, 2001, J CELL SCI, V114, P2363; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Deng QD, 2005, CANCER RES, V65, P8298, DOI 10.1158/0008-5472.CAN-05-0054; Gizard F, 2005, J CLIN INVEST, V115, P3228, DOI 10.1172/JCI22756; Han LP, 2006, BIOCHEM BIOPH RES CO, V348, P799, DOI 10.1016/j.bbrc.2006.07.147; Han SY, 2006, BIOCHEM J, V400, P439, DOI 10.1042/BJ20061085; Kivinen L, 1999, ONCOGENE, V18, P6252, DOI 10.1038/sj.onc.1203000; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu J, 2005, CYTOKINE, V31, P46, DOI 10.1016/j.cyto.2005.03.001; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Ray S, 2002, MOL ENDOCRINOL, V16, P824, DOI 10.1210/me.16.4.824; RUAS M, 1998, BIOCHIM BIOPHYS ACTA, V115, pF177; RUMI M, 2003, EXP HEMATOL, V31, P355; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhao YM, 2005, J EXP BIOL, V208, P697, DOI 10.1242/jeb.01439	27	58	60	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2008	27	13					1894	1904		10.1038/sj.onc.1210821	http://dx.doi.org/10.1038/sj.onc.1210821			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906698	Bronze			2022-12-17	WOS:000254150600009
J	Simmons, MJ; Fan, G; Zong, WX; Degenhardt, K; White, E; Gelinas, C				Simmons, M. J.; Fan, G.; Zong, W-X; Degenhardt, K.; White, E.; Gelinas, C.			Bfl-1/A1 functions, similar to Mcl-1, as a selective tBid and Bak antagonist	ONCOGENE			English	Article						Bfl-1; A1; Bcl2a1; tBid; Bak; apoptosis	CYTOCHROME-C RELEASE; BCL-2 FAMILY-MEMBER; NF-KAPPA-B; BH3 MIMETIC ABT-737; MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL-CHANGE; APOPTOSIS; PROTEINS; SURVIVAL; HOMOLOG	The prosurvival Bcl-2-family member Bfl-1/A1 is a transcriptional target of nuclear factor-kappa B (NF-kappa B) that is overexpressed in many human tumors and is a means by which NF-kappa B inhibits apoptosis, but its mode of action is controversial. To better understand how Bfl-1 functions, we investigated its interaction with proapoptotic multidomain proteins Bax and Bak, and the BH3-only proteins Bid and tBid. We demonstrate that in living cells Bfl-1 selectively interacts with Bak and tBid, but not with Bax or Bid. Bfl-1/Bak interaction is functional as Bfl-1 suppressed staurosporine (STS)-induced apoptosis in wild-type and Bax-deficient cells, but not in Bak-/- cells. We also show that Bfl-1 blocks tumor necrosis factor-alpha (TNF alpha)-induced activation of Bax indirectly, via association with tBid. C-terminal deletion decreased Bfl-1's interaction with Bak and tBid and reduced its ability to suppress Bak- and tBid-mediated cell death. These data indicate that Bfl-1 utilizes different mechanisms to suppress apoptosis depending on the stimulus. Bfl-1 associates with tBid to prevent activation of proapoptotic Bax and Bak, and it also interacts directly with Bak to antagonize Bak- mediated cell death, similar to Mcl-1. Thus, part of the protective function of NF-kappa B is to induce Mcl-1-like activity by upregulating Bfl-1.	[Simmons, M. J.; Fan, G.; Zong, W-X; Degenhardt, K.; White, E.; Gelinas, C.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, CABM, Piscataway, NJ 08854 USA; [Fan, G.; Zong, W-X; Degenhardt, K.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Program Biochem & Mol Biol, Piscataway, NJ 08854 USA; [White, E.] Rutgers State Univ, Dept Mol Biol & Biochem, New Brunswick, NJ 08903 USA; [White, E.; Gelinas, C.] Canc Inst New Jersey, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, CABM, Room 137,679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu	White, Eileen/ABD-6745-2021; Fan, gaofeng/H-2996-2013	White, Eileen/0000-0003-2961-3065; Fan, gaofeng/0000-0002-6729-2867	NCI NIH HHS [CA083937, R01 CA083937, R37 CA053370-17, R37 CA053370, R37 CA053370-16] Funding Source: Medline; NIGMS NIH HHS [GM08360, T32 GM008360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA083937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cuconati A, 2002, J VIROL, V76, P4547, DOI 10.1128/JVI.76.9.4547-4558.2002; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Holmgreen SP, 1999, CELL DEATH DIFFER, V6, P525, DOI 10.1038/sj.cdd.4400519; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Kucharczak JF, 2005, CELL DEATH DIFFER, V12, P1225, DOI 10.1038/sj.cdd.4401684; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Letai A, 2006, CANCER CELL, V10, P343, DOI 10.1016/j.ccr.2006.10.014; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Somogyi RD, 2001, CELL DEATH DIFFER, V8, P785, DOI 10.1038/sj.cdd.4400879; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yi XL, 2003, J BIOL CHEM, V278, P16992, DOI 10.1074/jbc.M300039200; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	41	58	58	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1421	1428		10.1038/sj.onc.1210771	http://dx.doi.org/10.1038/sj.onc.1210771			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17724464	Green Accepted			2022-12-17	WOS:000253548200009
J	Anastasi, S; Baietti, MF; Frosi, Y; Alema, S; Segatto, O				Anastasi, S.; Baietti, M. F.; Frosi, Y.; Alema, S.; Segatto, O.			The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity	ONCOGENE			English	Article						EGFR; RALT; MIG6; feedback inhibition; negative signalling; tumour suppression	GROWTH-FACTOR RECEPTOR; NEGATIVE REGULATOR; TYROSINE KINASE; ERBB RECEPTORS; ENDOCYTOSIS; DOMAIN; SIGNAL; INHIBITION; RALT; UBIQUITYLATION	Physiological signalling by the epidermal growth factor receptor ( EGFR) controls developmental processes and tissue homeostasis, whereas aberrant EGFR activity drives oncogenic cell transformation. Under normal conditions, the EGFR must therefore generate outputs of defined strength and duration. To this aim, cells balance EGFR activity via different modalities of negative signalling. Increasing attention is being drawn on transcriptionally controlled feedback inhibitors of EGFR, namely RALT/MIG6, LRIG1, SOCS4 and SOCS5. Genetic studies in mice have revealed the essential role of Ralt/Mig6 in regulating Egfr-driven skin morphogenesis and tumour formation, yet the mechanisms through which RALT abrogates EGFR activity are still undefined. We report that RALT suppresses EGFR function by inhibiting its catalytic activity. The evolutionarily conserved ErbB-binding region (EBR) is necessary and sufficient to carry out RALT-dependent suppression of EGFR kinase activity in vitro and in intact cells. The mechanism involves binding of the EBR to the 953RYLVIQ958 sequence, which is located in the alpha I helix of the EGFR kinase and has been shown to participate in allosteric control of EGFR catalytic activity. Our results uncover a novel mechanism of temporal regulation of EGFR activity in vertebrate organisms.	[Anastasi, S.; Baietti, M. F.; Frosi, Y.; Segatto, O.] Regina Elena Inst Canc Res, Immunol Lab, Dept Expt Oncol, I-00158 Rome, Italy; [Alema, S.] CNR, Inst Cell Biol, I-00016 Monterotondo, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR)	Anastasi, S (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Dept Expt Oncol, Via Delle Messi Oro 156-158, I-00158 Rome, Italy.	anastasi@ifo.it; segatto@ifo.it	anastasi, sergio/AAB-9585-2020; Baietti, Maria Francesca/AAA-6749-2019	anastasi, sergio/0000-0003-1009-6117; Baietti, Maria Francesca/0000-0002-1495-226X; Alema, Stefano/0000-0002-9869-6354; Segatto, Oreste/0000-0003-2561-1142				Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Ballaro C, 2005, EMBO REP, V6, P755, DOI 10.1038/sj.embor.7400458; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2001, FEBS LETT, V490, P132, DOI 10.1016/S0014-5793(01)02116-0; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Haslekas C, 2005, MOL BIOL CELL, V16, P5832, DOI 10.1091/mbc.E05-05-0456; Hendriks BS, 2003, CANCER RES, V63, P1130; HSU CYJ, 1991, J BIOL CHEM, V266, P603; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kochupurakkal BS, 2005, J BIOL CHEM, V280, P8503, DOI 10.1074/jbc.M413919200; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Nicholson SE, 2005, P NATL ACAD SCI USA, V102, P2328, DOI 10.1073/pnas.0409675102; Polo S, 2004, CURR OPIN CELL BIOL, V16, P156, DOI 10.1016/j.ceb.2004.02.003; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; Zhang YW, 2007, ONCOGENE, V26, P269, DOI 10.1038/sj.onc.1209790	39	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2007	26	57					7833	7846		10.1038/sj.onc.1210590	http://dx.doi.org/10.1038/sj.onc.1210590			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17599051				2022-12-17	WOS:000252163500002
J	Tchougounova, E; Kastemar, M; Brasater, D; Holland, EC; Westermark, B; Uhrbom, L				Tchougounova, E.; Kastemar, M.; Brasater, D.; Holland, E. C.; Westermark, B.; Uhrbom, L.			Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma	ONCOGENE			English	Article						oligodendroglioma; PDGF; mouse model; ink4a; Arf; p70S6K	GROWTH-FACTOR RECEPTOR; NEURAL PROGENITORS; STEM-CELL; INK4A LOCUS; EXPRESSION; SUPPRESSION; P16(INK4A); P19(ARF); MICE; DIFFERENTIATION	In a subset of gliomas, the platelet-derived growth factor ( PDGF) signaling pathway is perturbed. This is usually an early event occurring in low-grade tumors. In high-grade gliomas, the subsequent loss of the INK4a-ARF locus is one of the most common mutations. Here, we dissected the separate roles of Ink4a and Arf in PDGFB-induced oligodendroglioma development in mice. We found that there were differential functions of the two tumor suppressor genes. In tumors induced from astrocytes, both Ink4a-loss and Arf-loss caused a significantly increased incidence compared to wild-type mice. In tumors induced from glial progenitor cells there was a slight increase in tumor incidence in Ink4a -/- mice and Ink4a- Arf -/- mice compared to wild-type mice. In both progenitor cells and astrocytes, Arf-loss caused a pronounced increase in tumor malignancy compared to Ink4a- loss. Hence, Ink4a- loss contributed to tumor initiation from astrocytes and Arf-loss caused tumor progression from both glial progenitor cells and astrocytes. Results from in vitro studies on primary brain cell cultures suggested that the PDGFB-induced activation of the mitogen-activated protein kinase pathway via extracellular signal-regulated kinase was involved in the initiation of low-grade oligodendrogliomas and that the additional loss of Arf may contribute to tumor progression through increased levels of cyclin D1 and a phosphoinositide 3-kinase-dependent activation of p70 ribosomal S6 kinase causing a strong proliferative response of tumor cells.	Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA	Uppsala University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden.	lene.uhrbom@genpat.uu.se		Westermark, Bengt/0000-0001-7153-5545				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bigner S H, 1999, Neuro Oncol, V1, P52, DOI 10.1093/neuonc/1.1.52; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Charest A, 2006, CANCER RES, V66, P7473, DOI 10.1158/0008-5472.CAN-06-1193; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Di Rocco F, 1998, NEUROSURGERY, V42, P341, DOI 10.1097/00006123-199802000-00080; FISCHER AN, 2006, ONCOGENE; Grewe M, 1999, CANCER RES, V59, P3581; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; IOFFE E, 1995, P NATL ACAD SCI USA, V92, P7357, DOI 10.1073/pnas.92.16.7357; JEN J, 1994, CANCER RES, V54, P6353; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KLEIHUES P, 1997, PATHOLOGY GENETICS; Reifenberger J, 1996, AM J PATHOL, V149, P29; SCHERER H. J., 1938, AMER JOUR CANCER, V34, P333; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schumacher A, 2003, MOL CELL NEUROSCI, V23, P669, DOI 10.1016/S1044-7431(03)00170-2; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VanBrocklyn JR, 1997, J NEUROCHEM, V69, P116; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	24	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	2007	26	43					6289	6296		10.1038/sj.onc.1210455	http://dx.doi.org/10.1038/sj.onc.1210455			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	212GW	17438529				2022-12-17	WOS:000249583300005
J	Jacobs, AMF; Nicol, SM; Hislop, RG; Jaffray, EG; Hay, RT; Fuller-Pace, FV				Jacobs, A-M F.; Nicol, S. M.; Hislop, R. G.; Jaffray, E. G.; Hay, R. T.; Fuller-Pace, F. V.			SUMO modifcation of the DEAD box protein p68modulates its transcriptional activity and promotes its interaction with HDAC1	ONCOGENE			English	Article						p68; DEAD box protein; SUMO modifcation; transcriptional activity	P68 RNA HELICASE; ACTIVATION; UBIQUITIN; NUCLEAR; P53; COACTIVATOR; IDENTIFICATION; BINDING; ACTS	The nuclear protein p68 ( also known as Ddx5) is a prototypic member of the 'DEAD box' family of RNA helicases, which has been shown to be abnormally expressed and modified in colorectal tumors and to function as an important transcriptional regulator. Here, we show that p68 is modified in vivo on a single site ( K53) by the small ubiquitin-like modifier-2 ( SUMO-2). We demonstrate that the SUMO E3 ligase PIAS1 interacts with p68 and enhances its SUMO modi. cation in vivo. To determine the functional consequences of SUMO modi. cation, we compared the transcriptional activity of p68 and a K53R mutant that could not be SUMO-modified. Our data show that SUMO modi. cation enhances p68 transcriptional repression activity and inhibits the ability of p68 to function as a coactivator of p53. These findings may be explained by the ability of wild type, but not K53R p68, to alter the modification state of chromatin by recruitment of histone deacetylase 1 ( HDAC1).	Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Canc Biol Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Div Gene Regulat & Epxress, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Fuller-Pace, FV (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Pathol & Neurosci, Canc Biol Grp, Ninewells Dr, Dundee DD1 9SY, Scotland.	f.v.fullerpace@dundee.ac.uk	Hay, Ronald T/F-9338-2011; Hay, Ronald/S-3233-2019	Hay, Ronald T/0000-0001-7113-9024; Hay, Ronald/0000-0001-7113-9024				Bates GJ, 2005, EMBO J, V24, P543, DOI 10.1038/sj.emboj.7600550; Bond AT, 2001, MOL CELL BIOL, V21, P7366, DOI 10.1128/MCB.21.21.7366-7379.2001; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guil S, 2003, MOL CELL BIOL, V23, P2927, DOI 10.1128/MCB.23.8.2927-2941.2003; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee MB, 2005, MOL CELL BIOL, V25, P1879, DOI 10.1128/MCB.25.5.1879-1890.2005; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Liu G, 2006, BIOCHEM BIOPH RES CO, V349, P360, DOI 10.1016/j.bbrc.2006.08.049; Liu ZR, 2002, MOL CELL BIOL, V22, P5443, DOI 10.1128/MCB.22.15.5443-5450.2002; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rossow KL, 2003, ONCOGENE, V22, P151, DOI 10.1038/sj.onc.1206067; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Vertegaal ACO, 2004, J BIOL CHEM, V279, P33791, DOI 10.1074/jbc.M404201200; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wilson BJ, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-11; Yang LQ, 2006, CELL, V127, P139, DOI 10.1016/j.cell.2006.08.036; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	40	58	61	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5866	5876		10.1038/sj.onc.1210387	http://dx.doi.org/10.1038/sj.onc.1210387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369852				2022-12-17	WOS:000249123100004
J	Ma, J; Arnold, HK; Lilly, MB; Sears, RC; Kraft, AS				Ma, J.; Arnold, H. K.; Lilly, M. B.; Sears, R. C.; Kraft, A. S.			Negative regulation of Pim-1 protein kinase levels by the B56 beta subunit of PP2A	ONCOGENE			English	Article						Pim-1; PP2A; B56 beta; protein kinase; Pin1	CONSTITUTIVELY ACTIVATED FLT3; PHOSPHATASE 2A; C-MYC; ALPHA-SUBUNIT; TRANSFORMATION; GROWTH; PIN1; DEGRADATION; STABILITY; SURVIVAL	The Pim protein kinases are serine threonine protein kinases that regulate important cellular signaling pathway molecules, and enhance the ability of c-Myc to induce lymphomas. We demonstrate that a cascade of events controls the cellular levels of Pim. We find that overexpression of the protein phosphatase ( PP) 2A catalytic subunit decreases the activity and protein levels of Pim-1. This effect is reversed by the application of okadaic acid, an inhibitor of PP2A, and is blocked by SV40 small T antigen that is known to disrupt B subunit binding to PP2A A and C subunits. Pim-1 can coimmunoprecipitate with th e PP2A regulatory B subunit, B56 beta, but not B56 alpha, c, delta, e or B55 alpha. Using short hairpin RNA targeted at B56b, we demonstrate that decreasing the level of B56b increases the half-life of Pim-1 from 0.7 to 2.8 h, and decreases the ubiquitinylation level of Pim-1. We also find that Pin1, a prolyl-isomerase, is capable of binding Pim-1 and leads to a decrease in the protein level of Pim-1. On the basis of these observations, we hypothesize that phosphorylated Pim-1 binds Pin1 allowing the interaction of PP2A through B56b. Dephosphorylation of Pim-1 then allows for ubiquitinylation and protein degradation of Pim-1.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA	Medical University of South Carolina; Oregon Health & Science University; University of California System; University of California Irvine	Kraft, AS (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	kraft@musc.edu			NATIONAL CANCER INSTITUTE [R01CA100855, K01CA086957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008617] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA086957, R01 CA100855] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Boudreau RTM, 2005, INT IMMUNOPHARMACOL, V5, P1507, DOI 10.1016/j.intimp.2005.05.007; Campaner S, 2005, MOL CELL BIOL, V25, P6660, DOI 10.1128/MCB.25.15.6660-6672.2005; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cibull TL, 2006, J CLIN PATHOL, V59, P285, DOI 10.1136/jcp.2005.027672; CUYPERS HT, 1984, CELL, V37, P141; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Ionov Y, 2003, ANTICANCER RES, V23, P167; Janssens IA, 2005, BIOGEOSCIENCES, V2, P15, DOI 10.5194/bg-2-15-2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Losman JA, 2003, J BIOL CHEM, V278, P4800, DOI 10.1074/jbc.M208246200; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Qian KC, 2005, ACTA CRYSTALLOGR F, V61, P96, DOI 10.1107/S1744309104029963; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Richardson Paul G, 2005, Future Oncol, V1, P161, DOI 10.1517/14796694.1.2.161; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shay KP, 2005, MOL CANCER RES, V3, P170; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang Z, 2001, J Vet Sci, V2, P167; Xu Y, 2005, J SURG ONCOL, V92, P326, DOI 10.1002/jso.20325; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	49	58	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5145	5153		10.1038/sj.onc.1210323	http://dx.doi.org/10.1038/sj.onc.1210323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17297438				2022-12-17	WOS:000248487400013
J	Miller, SL; Antico, G; Raghunath, PN; Tomaszewski, JE; Clevenger, CV				Miller, S. L.; Antico, G.; Raghunath, P. N.; Tomaszewski, J. E.; Clevenger, C. V.			Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells	ONCOGENE			English	Article						prolactin; breast neoplasms; invasion; Vav2; Rac; paxillin	FOCAL ADHESION KINASE; RHO-GTPASES; BINDING PROTEIN; V-SRC; PAXILLIN; GROWTH; ACTIN; VAV2; ACTIVATION; CDC42	Prolactin (PRL) stimulates the cytoskeletal re-organization and motility of breast cancer cells. During PRL receptor signaling, Vav2 becomes phosphorylated and activated, an event regulated by the serine/ threonine kinase Nek3. Given the regulatory role of Vav2, the function of Nek3 in PRL-mediated motility and invasion was examined. Overexpression of Nek3 in Chinese hamster ovary transfectants potentiated cytoskeletal re-organization in response to PRL. In contrast, downregulation of Nek3 expression by small-interfering RNA (siRNA) attenuated PRL-mediated cytoskeletal reorganization, activation of GTPase Rac1, cell migration and invasion of T47D cells. In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. Analysis of breast tissue microarrays also demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens. These data suggest that Nek3 contributes to PRL-mediated breast cancer motility through mechanisms involving Rac1 activation and paxillin phosphorylation.	Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Northwestern University; Memorial Sloan Kettering Cancer Center; University of Pennsylvania	Clevenger, CV (corresponding author), Northwestern Univ, Dept Pathol, Lurie 4-107,303 E Super St, Chicago, IL 60611 USA.	clevenger@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA069294, R01CA092265] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69294, R01CA92265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; BHATAVDEKAR JM, 1990, CANCER, V65, P2028, DOI 10.1002/1097-0142(19900501)65:9&lt;2028::AID-CNCR2820650924&gt;3.0.CO;2-9; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; de Oca PM, 2005, LAB INVEST, V85, P633, DOI 10.1038/labinvest.3700256; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gao J, 1999, CELL SIGNAL, V11, P205, DOI 10.1016/S0898-6568(98)00067-9; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; ILLC D, 1995, NATURE, V377, P539; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; Kline JB, 2001, MOL ENDOCRINOL, V15, P832, DOI 10.1210/me.15.5.832; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; LISSONI P, 1995, ONCOLOGY, V52, P439; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Miller SL, 2005, MOL ENDOCRINOL, V19, P939, DOI 10.1210/me.2004-0443; NAWROCKI RB, 2001, INT J CANCER, V93, P644; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 2000, J CELL SCI, V113, P3673; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Salcedo R, 2002, CLIN CANCER RES, V8, P2655; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SCHUPP G, 1996, COMPRAIL 96 COMPUTER, V2, P13; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435	48	58	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4668	4678		10.1038/sj.onc.1210264	http://dx.doi.org/10.1038/sj.onc.1210264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297458				2022-12-17	WOS:000248037900007
J	Liu, J; Lin, A				Liu, J.; Lin, A.			Wiring the cell signaling circuitry by the NF-kappa B and JNK1 crosstalk and its applications in human diseases	ONCOGENE			English	Review						NF-kappa B; JNK1; TNF-alpha; UV; signaling; crosstalk	TERMINAL KINASE ACTIVATION; TNF RECEPTOR 1; C-JUN KINASE; PROTEIN-KINASE; MAP KINASE; IKK-BETA; TRANSCRIPTION FACTOR; HA-RAS; SUPPRESSES APOPTOSIS; IONIZING-RADIATION	Integration of the cell signaling circuitry determines the ultimate response of a cell to extracellular stimuli. The transcription factor nuclear factor-kappa B (NF-kappa B) and mitogen-activated protein kinase JNK1 are major players in the cell signaling circuitry, regulating numerous cellular events and being implicated in the process of many human diseases and certain types of cancer. The interplay between NF-kappa B and JNK1 provides a paradigm that shows how the crosstalk between different signaling pathways decides the function of the cell signaling circuitry. Understanding the wiring of the cell signaling circuitry may hold the key for cell signaling-based therapy of human diseases.	Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA	University of Chicago	Lin, A (corresponding author), Univ Chicago, Ben May Dept Canc Res, 929 E 57th St, Chicago, IL 60637 USA.	alin@huggins.bsd.uchicago.edu						ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Cripe LD, 2002, LEUKEMIA, V16, P799, DOI 10.1038/sj.leu.2402457; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; He HP, 1999, CELL DEATH DIFFER, V6, P987, DOI 10.1038/sj.cdd.4400572; Herrlich P, 1997, BIOL CHEM, V378, P1217; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Lee SA, 1998, J BIOL CHEM, V273, P32889, DOI 10.1074/jbc.273.49.32889; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIN A, 2006, JNK SIGNALING PATHWA; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu J, 2006, MOL CELL, V21, P467, DOI 10.1016/j.molcel.2005.12.020; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okazawa Hitohi, 2002, Am J Alzheimers Dis Other Demen, V17, P79, DOI 10.1177/153331750201700209; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Park JM, 2004, GENE DEV, V18, P584, DOI 10.1101/gad.1168104; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Purcell NH, 2001, AM J PHYSIOL-GASTR L, V280, pG669, DOI 10.1152/ajpgi.2001.280.4.G669; Reimold A. M., 2002, Current Drug Targets - Inflammation and Allergy, V1, P377, DOI 10.2174/1568010023344535; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Sadoshima J, 2002, J CLIN INVEST, V110, P271, DOI 10.1172/JCI200214938; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; She QB, 2002, CANCER RES, V62, P1343; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Uehara T, 2005, J HEPATOL, V42, P850, DOI 10.1016/j.jhep.2005.01.030; VAN AD, 1996, SCIENCE, V274, P787; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Xia XG, 2001, P NATL ACAD SCI USA, V98, P10433, DOI 10.1073/pnas.181182298; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Yu CF, 2004, MOL CELL, V13, P329, DOI 10.1016/S1097-2765(04)00028-0; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang JY, 2006, MOL CELL BIOL, V26, P1223, DOI 10.1128/MCB.26.4.1223-1234.2006; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	101	58	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2007	26	22					3267	3278		10.1038/sj.onc.1210417	http://dx.doi.org/10.1038/sj.onc.1210417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169PH	17496921				2022-12-17	WOS:000246603600014
J	Cosentino, C; Di Domenico, M; Porcellini, A; Cuozzo, C; De Gregorio, G; Santillo, MR; Agnese, S; Di Stasio, R; Feliciello, A; Migliaccio, A; Avvedimento, EV				Cosentino, C.; Di Domenico, M.; Porcellini, A.; Cuozzo, C.; De Gregorio, G.; Santillo, M. R.; Agnese, S.; Di Stasio, R.; Feliciello, A.; Migliaccio, A.; Avvedimento, E. V.			p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival	ONCOGENE			English	Article						cAMP; PI3K; p21Ras; growth	CELL-CYCLE PROGRESSION; STIMULATING-HORMONE; SIGNALING PATHWAY; KINASE; ACTIVATION; RECEPTOR; FIBROBLASTS; EXPRESSION; BETA; TOR	Cyclic adenosine 3050 monophosphate (cAMP) and protein kinase A (PKA) cooperate with phosphatidylinositol 30 kinase (PI3K) signals in the control of growth and survival. To determine the molecular mechanism(s) involved, we identified and mutagenized a specific serine (residue 83) in p85 alpha(PI3K), which is phosphorylated in vivo and in vitro by PKA. Expression of p85 alpha(PI3K) mutants (alanine or aspartic substitutions) significantly altered the biological responses of the cells to cAMP. cAMP protection from anoikis was reduced in cells expressing the alanine version p85 alpha(PI3K). These cells did not arrest in G1 in the presence of cAMP, whereas cells expressing the aspartic mutant p85D accumulated in G1 even in the absence of cAMP. S phase was still efficiently inhibited by cAMP in cells expressing both mutants. The binding of PI3K to Ras p21 was greatly reduced in cells expressing p85A in the presence or absence of cAMP. Conversely, expression of the aspartic mutant stimulated robustly the binding of PI3K to p21 Ras in the presence of cAMP. Mutation in the Ser 83 inhibited cAMP, but not PDGF stimulation of PI3K. Conversely, the p85D aspartic mutant amplified cAMP stimulation of PI3K activity. Phosphorylation of Ser 83 by cAMP - PKA in p85 alpha(PI3K) was also necessary for estrogen signaling as expression of p85A or p85D mutants inhibited or amplified, respectively, the binding of estrogen receptor to p85 alpha and AKT phosphorylation induced by estrogens. The data presented indicate that: (1) phosphorylation of Ser 83 in p85a PI3K is critical for cAMP - PKA induced G1 arrest and survival in mouse 3T3. broblasts; (2) this site is necessary for amplification of estrogen signals by cAMP - PKA and related receptors. Finally, these data suggest a general mechanism of PI3K regulation by cAMP, operating in various cell types and under different conditions.	CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Cellulaire, Naples, Italy; Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; Univ Roma La Sapienza, Dipartimento Sperimentale & Patol, I-00161 Rome, Italy; INM Neuromed, Pozzilli, Italy; Univ Naples Federico II, Dipartimento Neurosci, Sez Fisiol, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli; Sapienza University Rome; IRCCS Neuromed; University of Naples Federico II	Avvedimento, EV (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Via S Pansini 5, Naples, Italy.	avvedim@unina.it	Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019; Cosentino, Claudia/AAF-1100-2019; Migliaccio, Antimo/AAB-3376-2019	Porcellini, Antonio/0000-0001-6882-9518; Migliaccio, Antimo/0000-0002-4197-2055; Feliciello, Antonio/0000-0002-7932-2170; Di Domenico, Marina/0000-0002-6201-4200				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Alvarez B, 2003, J BIOL CHEM, V278, P26466, DOI 10.1074/jbc.M300663200; Ariga M, 2000, BIOCHEM J, V348, P409, DOI 10.1042/0264-6021:3480409; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; DEGREGORIA G, 2006, IN PRESS ONCOGENE; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KNECHT M, 1984, ENDOCRINOLOGY, V115, P41, DOI 10.1210/endo-115-1-41; Kurokawa K, 1998, CELL STRUCT FUNCT, V23, P357, DOI 10.1247/csf.23.357; Lee Y. Z., 1998, Annals of Noninvasive Electrocardiology, V3, P244, DOI 10.1111/j.1542-474X.1998.tb00350.x; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Zurita-Martinez SA, 2005, EUKARYOT CELL, V4, P63, DOI 10.1128/EC.4.1.63-71.2005	23	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2095	2103		10.1038/sj.onc.1210027	http://dx.doi.org/10.1038/sj.onc.1210027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016431				2022-12-17	WOS:000245313400011
J	Wang, Z; Wade, P; Mandell, KJ; Akyildiz, A; Parkos, CA; Mrsny, RJ; Nusrat, A				Wang, Z.; Wade, P.; Mandell, K. J.; Akyildiz, A.; Parkos, C. A.; Mrsny, R. J.; Nusrat, A.			Raf 1 represses expression of the tight junction protein occludin via activation of the zinc-finger transcription factor Slug	ONCOGENE			English	Article						TJ; occluding; Slug; Raf 1	EPITHELIAL-MESENCHYMAL TRANSITIONS; MEMBRANE-PROTEIN; DOWN-REGULATION; FACTOR SNAIL; TUMOR-CELLS; CANCER; KINASE; BREAST; RAS; DIFFERENTIATION	Although dysregulation of tight junction (TJ) proteins is observed in epithelial malignancy, their participation in epithelial transformation is poorly understood. Recently we demonstrated that expression of oncogenic Raf 1 in Pa4 epithelial cells disrupts TJs and induces an oncogenic phenotype by downregulating expression of the TJ protein, occludin. Here we report the mechanism by which Raf 1 regulates occludin expression. Raf 1 inhibited occludin transcription by repressing a minimal segment of the occludin promoter in concert with upregulation of the transcriptional repressor, Slug without influencing the well-documented transcriptional repressor, Snail. Overexpression of Slug in Pa4 cells recapitulated the effect of Raf 1 on occludin expression, and depletion of Slug by small interfering RNA abrogated the effect of Raf 1 on occludin. Finally, chromatin immunoprecipitation assays and site- directed mutagenesis demonstrated a direct interaction between Slug and an E-box within the minimal Raf 1-responsive segment of the occludin promoter. These findings support a role of Slug in mediating Raf 1-induced transcriptional repression of occludin and subsequent epithelial to mesenchymal transition.	Emory Univ, Dept Pathol, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; Unity Pharmaceut, Los Altos Hills, CA USA	Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Nusrat, A (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Room 105E, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nusrat, Asma/B-3887-2009; Parkos, Charles a/B-3896-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059888, R01DK061379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK 61379, DK 59888] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1993, J CELL SCI, P159; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BULKHOLM IK, 1998, J PATHOL, V185, P262; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kimura Y, 1997, AM J PATHOL, V151, P45; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Matter K, 1998, J CELL SCI, V111, P511; McCarthy KM, 1996, J CELL SCI, V109, P2287; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nottage M, 2002, CURR PHARM DESIGN, V8, P2231, DOI 10.2174/1381612023393107; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Ruch RJ, 1998, EXP LUNG RES, V24, P523, DOI 10.3109/01902149809087384; Tobioka H, 2004, VIRCHOWS ARCH, V445, P472, DOI 10.1007/s00428-004-1054-9; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wang ZL, 2005, ONCOGENE, V24, P4412, DOI 10.1038/sj.onc.1208634; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	37	58	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1222	1230		10.1038/sj.onc.1209902	http://dx.doi.org/10.1038/sj.onc.1209902			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924233				2022-12-17	WOS:000244406400012
J	Goldoni, S; Iozzo, RA; Kay, P; Campbell, S; McQuillan, A; Agnew, C; Zhu, JX; Keene, DR; Reed, CC; Iozzo, RV				Goldoni, S.; Iozzo, R. A.; Kay, P.; Campbell, S.; McQuillan, A.; Agnew, C.; Zhu, J-X; Keene, D. R.; Reed, C. C.; Iozzo, R. V.			A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity	ONCOGENE			English	Article						leucine-rich protein; decorin; kekkon1; epidermal growth factor receptor; tumor growth inhibition	LEUCINE-RICH PROTEOGLYCANS; FACTOR RECEPTOR; DECORIN BINDS; LUNG-CANCER; C-TERMINUS; GENE; PROTEIN; DROSOPHILA; GRB2; ENDOCYTOSIS	Leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1) is a transmembrane protein with an ectodomain containing 15 leucine-rich repeats (LRRs) homologous to mammalian decorin and the Drosophila kekkon1 gene. In this study, we demonstrate that a soluble ectodomain of LRIG1, containing only the LRRs, inhibits ligand-independent epidermal growth factor receptor (EGFR) activation and causes growth inhibition of A431, HeLa and MDA-468 carcinoma cells. In contrast, cells that do not express detectable levels of EGFR fail to respond to soluble LRIG1. However, when a functional EGFR gene is introduced in these cells, they become growth-inhibited by soluble LRIG1 protein. Furthermore, we demonstrate the existence of high-affinity (K-d = 10 nM) binding sites on the A431 cells that can be competitively displaced (up to 75%) by molar excess of EGF. Even more powerful effects are obtained with a chimeric proteoglycan harboring the N-terminus of decorin, substituted with a single glycosaminoglycan chain, fused to the LRIG1 ectodomain. Both proteins also inhibit ligand-dependent activation of the EGFR and extracellular signal-regulated protein kinase 1/2 signaling in a rapid and dose-dependent manner. These results suggest a novel mechanism of action evoked by a soluble ectodomain of LRIG1 protein that could modulate EGFR signaling and its growth-promoting activity. Attenuation of EGFR activity without physical downregulation of the receptor could represent a novel therapeutic approach toward malignancies in which EGFR plays a primary role in tumor growth and survival.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Shriners Hosp Children, Portland, OR 97201 USA; Thomas Jefferson Univ, Cellular Biol & Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locus St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Pranić, Shelly Melissa/E-1974-2017; Iozzo, Renato/AAS-1980-2020	Pranić, Shelly Melissa/0000-0001-5524-1723; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarado D, 2004, GENETICS, V167, P187, DOI 10.1534/genetics.167.1.187; Alvarado D, 2004, GENETICS, V166, P201, DOI 10.1534/genetics.166.1.201; Bailly M, 2000, MOL BIOL CELL, V11, P3873, DOI 10.1091/mbc.11.11.3873; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Derheimer FA, 2004, GENETICS, V166, P213, DOI 10.1534/genetics.166.1.213; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 2003, DEVELOPMENT, V130, P4483, DOI 10.1242/dev.00617; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Gonzalez EM, 2005, J BIOL CHEM, V280, P7080, DOI 10.1074/jbc.M409841200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Guo DS, 2004, GENOMICS, V84, P157, DOI 10.1016/j.ygeno.2004.01.013; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Holmlund C, 2004, GENE, V332, P35, DOI 10.1016/j.gene.2004.02.002; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nilsson J, 2003, CELL TISSUE RES, V312, P65, DOI 10.1007/s00441-003-0697-1; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Schlessinger J, 2003, SCIENCE, V300, P750, DOI 10.1126/science.1082024; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; YARDEN Y, 1985, J BIOL CHEM, V260, P315; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	62	58	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					368	381		10.1038/sj.onc.1209803	http://dx.doi.org/10.1038/sj.onc.1209803			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16847455				2022-12-17	WOS:000243544000006
J	Clarke, AR				Clarke, A. R.			Wnt signalling in the mouse intestine	ONCOGENE			English	Review						Wnt; Apc; intestine	K-RAS ONCOGENE; BETA-CATENIN; COLORECTAL-CANCER; CELL DIFFERENTIATION; GENE-EXPRESSION; MAJOR MODIFIER; COLON-CANCER; SELF-RENEWAL; STEM-CELLS; E-CADHERIN	The Apc(Min/+) mouse has emerged as a powerful model of human intestinal tumour predisposition. As such, it has provided a platform for studying genetic and epigenetic modifiers of adenoma predisposition, and for assessing the chemotherapeutic potential of a plethora of different agents. The development of new conditional and hypomorphic Apc alleles, together with models carrying mutations in other Wnt pathway components, has greatly extended the scope of experimentation. Together these approaches are being used to identify and validate key critical targets of the Wnt pathway, such as Mash2, Tiam1 and the Eph/Ephrins. They have also established a fundamental role for Wnt in the development and maintenance of normal intestinal physiology, and in particular control of the stem cell niche. These activities are now being dissected at the level of individual Wnt components, with some surprising dependencies revealed. In terms of adenoma development, these models also support a 'just right' notion for tightly controlled beta-catenin activity both in normal physiology and neoplastic development. They also indicate a two-stage dependency for some Wnt pathway targets, with an initial requirement that is subsequently overcome to permit progression. Finally, these models establish that the Wnt pathway does not operate in isolation, and that both normal and diseased physiology develops in a dynamic interplay with other pathways such as the Notch, Hedgehog and BMP pathways. The comprehensive understanding arising from these studies should lead the identification of novel prognostic markers and therapeutic targets, and also open the possibility of tissue engineering in the intestine.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales	Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	clarkear@cf.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X	MRC [G0301154] Funding Source: UKRI; Medical Research Council [G0301154] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Chia IV, 2005, MOL CELL BIOL, V25, P4371, DOI 10.1128/MCB.25.11.4371-4376.2005; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; Corpet DE, 2005, EUR J CANCER, V41, P1911, DOI 10.1016/j.ejca.2005.06.006; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DORUDI S, 1993, AM J PATHOL, V142, P981; Eads CA, 2002, CANCER RES, V62, P1296; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Giannakis M, 2006, J BIOL CHEM, V281, P11292, DOI 10.1074/jbc.M512118200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Haines J, 2005, P NATL ACAD SCI USA, V102, P2868, DOI 10.1073/pnas.0500039102; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; Hamamoto T, 2002, CANCER RES, V62, P5955; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim BM, 2005, DEV CELL, V8, P611, DOI 10.1016/j.devcel.2005.01.015; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; MILLS JC, 2002, GASTROENTEROLOGY, V125, P266; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Pretlow TP, 2003, AM J PATHOL, V163, P1757, DOI 10.1016/S0002-9440(10)63535-3; Prokhortchouk A, 2006, MOL CELL BIOL, V26, P199, DOI 10.1128/MCB.26.1.199-208.2006; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Reichling T, 2005, CANCER RES, V65, P166; Reitmair AH, 1996, CANCER RES, V56, P2922; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sieber OM, 2004, CANCER RES, V64, P8876, DOI 10.1158/0008-5472.CAN-04-2958; Silverman KA, 2002, GENOME RES, V12, P88, DOI 10.1101/gr.206002; Singla DK, 2006, BIOCHEM BIOPH RES CO, V345, P789, DOI 10.1016/j.bbrc.2006.04.125; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Takaku K, 1999, CANCER RES, V59, P6113; Takano-Maruyama M, 2006, AM J PHYSIOL-GASTR L, V291, pG163, DOI 10.1152/ajpgi.00019.2006; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wilding J, 2002, CANCER RES, V62, P4562; Wong MH, 2002, J BIOL CHEM, V277, P15843, DOI 10.1074/jbc.M200184200; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Zecchini V, 2005, GENE DEV, V19, P1686, DOI 10.1101/gad.341705; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	102	58	68	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7512	7521		10.1038/sj.onc.1210065	http://dx.doi.org/10.1038/sj.onc.1210065			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143295				2022-12-17	WOS:000242514900009
J	Deng, R; Li, W; Guan, Z; Zhou, JM; Wang, Y; Mei, YP; Li, MT; Feng, GK; Huang, W; Liu, ZC; Han, Y; Zeng, YX; Zhu, XF				Deng, R.; Li, W.; Guan, Z.; Zhou, J-M; Wang, Y.; Mei, Y-P; Li, M-T; Feng, G-K; Huang, W.; Liu, Z-C; Han, Y.; Zeng, Y-X; Zhu, X-F			Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis	ONCOGENE			English	Article						acetylcholinesterase (AChE); c-Jun NH2-terminal kinase (JNK); apoptosis; mitogen-activated protein kinase ( MAPK); extracellular signal regulated kinase ( ERK)	CYTOCHROME-C RELEASE; JUN; ACTIVATION; JNK; CELLS; DEATH; BAX; PHOSPHORYLATION; INDUCTION; RAT	It has been shown that acetylcholinesterase (AChE) expression was induced during apoptosis and the antisense oligonucleotides and siRNA of AChE may prevent apoptosis in various cell types. However, the mechanisms underlying AChE upregulation remain elusive. We demonstrated here that c-Jun NH2-terminal kinase (JNK) could mediate AChE expression. In this study, both etoposide and excisanin A, two anticancer agents, induced apoptosis in colon cancer cell line SW620 as determined by Annexin V staining, the cleavage of caspase-3 and the proteolytic degradation of poly (ADPribose) polymerase (PARP). The results showed that both the agents upregulated AChE in SW620 cells. In the meantime, JNK was also activated and the expression and phosphorylation of c-Jun increased in SW620 cells exposed to the two agents. The induced AChE mRNA and protein expression could be blocked by SP600125, a specific inhibitor of SAPK/JNK, and small interfering RNA directed against JNK1/2. Transfection with adenovirus-mediated dominant negative c-Jun also blocked the upregulation of AChE expression. Together, these results suggest that AChE expression may be mediated by the activation of JNK pathway during apoptosis through a c-Jun-dependent mechanism.	Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, Guangzhou 510060, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Sun Yat Sen Univ, Dept Pharmacol, Proteom Lab, Guangzhou, Peoples R China	Sun Yat Sen University; Hong Kong University of Science & Technology; Sun Yat Sen University	Zhu, XF (corresponding author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol So China, 651 DongFeng Rd E, Guangzhou 510060, Peoples R China.	bcyfhan@ust.hk; xfzhu70@public.guangzhou.gd.cn		Han, Yifan/0000-0002-5833-069X				Chen YR, 2000, INT J ONCOL, V16, P651; Cohen TV, 2004, J NEUROCHEM, V90, P1059, DOI 10.1111/j.1471-4159.2004.02564.x; Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233; Cuadrado A, 2004, ONCOGENE, V23, P4673, DOI 10.1038/sj.onc.1207636; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; GAO YH, 2000, CHIN TRADIT HERB DRU, V31, P645; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hamdi M, 2005, ONCOGENE, V24, P7135, DOI 10.1038/sj.onc.1208875; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; Khelifi AF, 2005, CELL DEATH DIFFER, V12, P724, DOI 10.1038/sj.cdd.4401559; Kirkland RA, 2003, ANTIOXID REDOX SIGN, V5, P589, DOI 10.1089/152308603770310257; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kuntzen C, 2005, CANCER RES, V65, P6780, DOI 10.1158/0008-5472.CAN-04-2618; Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Meshorer E, 2005, MOL PSYCHIATR, V10, P985, DOI 10.1038/sj.mp.4001735; Meshorer E, 2004, J BIOL CHEM, V279, P29740, DOI 10.1074/jbc.M402752200; Park SE, 2004, CANCER RES, V64, P2652, DOI 10.1158/0008-5472.CAN-04-0649; Perry C, 2002, ONCOGENE, V21, P8428, DOI 10.1038/sj.onc.1205945; Small DH, 1996, NEUROCHEM INT, V28, P453, DOI 10.1016/0197-0186(95)00099-2; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Teraishi F, 2005, CANCER RES, V65, P6380, DOI 10.1158/0008-5472.CAN-05-0575; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRANUMJENSEN J, 1981, EUR J CELL BIOL, V24, P281; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Zhang XJ, 2002, CELL DEATH DIFFER, V9, P790, DOI 10.1038/sj.cdd.4401034; Zhou JM, 2006, ONCOGENE, V25, P503, DOI 10.1038/sj.onc.1209067; Zhu XF, 2005, MOL PHARMACOL, V67, P1444, DOI 10.1124/mol.104.009894; Zhu XF, 2002, LIFE SCI, V70, P1259, DOI 10.1016/S0024-3205(01)01501-6; Zou W, 2004, CANCER RES, V64, P7570, DOI 10.1158/0008-5472.CAN-04-1238	34	58	60	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7070	7077		10.1038/sj.onc.1209686	http://dx.doi.org/10.1038/sj.onc.1209686			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16715131				2022-12-17	WOS:000241910500006
J	Roylance, R; Gorman, P; Papior, T; Wan, YL; Ives, M; Watson, JE; Collins, C; Wortham, N; Langford, C; Fiegler, H; Carter, N; Gillett, C; Sasieni, P; Pinder, S; Hanby, A; Tomlinson, I				Roylance, R.; Gorman, P.; Papior, T.; Wan, Y-L; Ives, M.; Watson, J. E.; Collins, C.; Wortham, N.; Langford, C.; Fiegler, H.; Carter, N.; Gillett, C.; Sasieni, P.; Pinder, S.; Hanby, A.; Tomlinson, I.			A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH	ONCOGENE			English	Article						array CGH; Chromosome 169; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; DIFFERENT GENETIC PATHWAYS; TUMOR-SUPPRESSOR GENES; E-CADHERIN; HISTOLOGICAL GRADE; ALLELIC IMBALANCE; RECEPTOR STATUS; CANCER; HETEROZYGOSITY; CARCINOGENESIS	We analysed chromosome 16q in 106 breast cancers using tiling-path array-comparative genomic hybridization (aCGH). About 80% of ductal cancers (IDCs) and all lobular cancers (ILCs) lost at least part of 16q. Grade I (GI) IDCs and ILCs often lost the whole chromosome arm. Grade II (GII) and grade III ( GIII) IDCs showed less frequent whole-arm loss, but often had complex changes, typically small regions of gain together with larger regions of loss. The boundaries of gains/losses tended to cluster, common sites being 54.5-55.5 Mb and 57.4-58.8 Mb. Overall, the peak frequency of loss (83% cancers) occurred at 61.9-62.9 Mb. We also found several 'minimal' regions of loss/gain. However, no mutations in candidate genes (TRADD, CDH5, CDH8 and CDH11) were detected. Cluster analysis based on copy number changes identified a large group of cancers that had lost most of 16q, and two smaller groups ( one with few changes, one with a tendency to show copy number gain). Although all morphological types occurred in each cluster group, IDCs ( especially GII/GIII) were relatively over-represented in the smaller groups. Cluster groups were not independently associated with survival. Use of tiling-path aCGH prompted re-evaluation of the hypothetical pathways of breast carcinogenesis. ILCs have the simplest changes on 16q and probably diverge from the IDC lineage close to the stage of 16q loss. Higher-grade IDCs probably develop from low-grade lesions in most cases, but there remains evidence that some GII/GIII IDCs arise without a GI precursor.	Canc Res UK, Mol & Populat Genet Lab, London WC2A 3PX, England; UCSF, Collins Lab, S151, Ctr Canc, San Francisco, CA USA; Wellcome Trust Sanger Inst, Cambridge, England; Guys Hosp, CRUK Breast Pathol Lab, London SE1 9RT, England; Barts & London Med Sch, London, England; Addenbrookes Hosp, Dept Histopathol, Cambridge, England; St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England; Univ Leeds, Acad Unit Pathol, Leeds LS2 9JT, W Yorkshire, England	Cancer Research UK; University of California System; University of California San Francisco; Wellcome Trust Sanger Institute; Guy's & St Thomas' NHS Foundation Trust; University of London; Queen Mary University London; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Saint James's University Hospital; University of Leeds	Roylance, R (corresponding author), Canc Res UK, Mol & Populat Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England.	rebecca.roylance@cancer.org.uk	Wan, Y Louise/AAU-1839-2021	Wan, Y Louise/0000-0003-1441-6050; Sasieni, Peter/0000-0003-1509-8744; /0000-0003-4167-8910	Wellcome Trust [077008] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barnes DM, 2004, ENDOCR-RELAT CANCER, V11, P85, DOI 10.1677/erc.0.0110085; Berx G, 1996, ONCOGENE, V13, P1919; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B; Cleton-Jansen AM, 2004, GENE CHROMOSOME CANC, V41, P109, DOI 10.1002/gcc.20070; Cleton-Jansen AM, 2002, BREAST CANCER RES, V4, P5, DOI 10.1186/bcr416; Cleton-Jansen AM, 1999, BRIT J CANCER, V79, P1049, DOI 10.1038/sj.bjc.6690168; Cleton-Jansen AM, 2001, CANCER RES, V61, P1171; Cooper LS, 1999, CANCER-AM CANCER SOC, V86, P2053, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2053::AID-CNCR24>3.0.CO;2-H; Crawford J, 1999, GENOMICS, V56, P90, DOI 10.1006/geno.1998.5676; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; DORIONBONNET F, 1995, GENE CHROMOSOME CANC, V14, P171, DOI 10.1002/gcc.2870140304; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Droufakou S, 2001, INT J CANCER, V92, P404, DOI 10.1002/ijc.1208; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Frengen E, 2000, GENOMICS, V70, P273, DOI 10.1006/geno.2000.6389; Hwang ES, 2004, CANCER, V100, P2562, DOI 10.1002/cncr.20273; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kern SE, 2002, CANCER BIOL THER, V1, P571, DOI 10.4161/cbt.1.5.225; Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658; Millis RR, 1998, EUR J CANCER, V34, P548, DOI 10.1016/S0959-8049(97)10072-7; Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.0.CO;2-6; Pandis N, 1996, INT J CANCER, V66, P191, DOI 10.1002/(SICI)1097-0215(19960410)66:2<191::AID-IJC9>3.0.CO;2-Y; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Roylance R, 1999, CANCER RES, V59, P1433; Roylance R, 2003, J PATHOL, V200, P53, DOI 10.1002/path.1326; Roylance R, 2002, J PATHOL, V196, P32, DOI 10.1002/path.1006; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; Tomlinson IPM, 2002, GENE CHROMOSOME CANC, V34, P349, DOI 10.1002/gcc.10085; TSUDA H, 1994, CANCER RES, V54, P513; Watson JEV, 2004, ONCOGENE, V23, P3487, DOI 10.1038/sj.onc.1207474; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316	34	58	60	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6544	6553		10.1038/sj.onc.1209659	http://dx.doi.org/10.1038/sj.onc.1209659			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16702952	Green Accepted			2022-12-17	WOS:000241395100011
J	Niizuma, H; Nakamura, Y; Ozaki, T; Nakanishi, H; Ohira, M; Isogai, E; Kageyama, H; Imaizumi, M; Nakagawara, A				Niizuma, H.; Nakamura, Y.; Ozaki, T.; Nakanishi, H.; Ohira, M.; Isogai, E.; Kageyama, H.; Imaizumi, M.; Nakagawara, A.			Bcl-2 is a key regulator for the retinoic acid-induced apoptotic cell death in neuroblastoma	ONCOGENE			English	Article						apoptosis; Bcl-2; neuroblastoma; retinoic acid	NEURONAL DIFFERENTIATION; NEURAL DIFFERENTIATION; SIGNALING PATHWAY; EXPRESSION; PROTEIN; CHEMOTHERAPY; ACTIVATION; FAMILY; LINE; BAX	Retinoic acid (RA) has been shown to induce neuronal differentiation and/or apoptosis, and is widely used as a chemotherapeutic agent for treating the patients with neuroblastoma. However, the therapeutic effect of RA is still limited. To unveil the molecular mechanism(s) inducing differentiation and apoptosis in neuroblastoma cells, we compared CHP134 and NB-39-nu cell lines, in which all-trans-RA (ATRA) induces apoptosis, with LAN-5 and RTBM1 cell lines, in which it induces neuronal differentiation. Here, we found that Bcl-2 was strongly downregulated in CHP134 and NB-39-nu cells, whereas it was abundantly expressed in LA-N-5 and RTBM1 cells. ATRA-mediated apoptosis in CHP134 and NB-39-nu cells was associated with a significant activation of caspase-9 and caspase-3 as well as cytoplasmic release of cytochrome c from mitochondria in a p53-independent manner. Enforced expression of Bcl-2 significantly inhibited ATRA-mediated apoptosis in CHP134 cells. In addition, treatment of RTBM1 cells with a Bcl-2 inhibitor, HA14-1, enhanced apoptotic response induced by ATRA. Of note, two out of 10 sporadic neuroblastomas expressed bcl-2 at undetectable levels and underwent cell death in response to ATRA in primary cultures. Thus, our present results suggest that overexpression of Bcl-2 is one of the key mechanisms to give neuroblastoma cells the resistance against ATRA-mediated apoptosis. This may provide a new therapeutic strategy against the ATRA-resistant and aggressive neuroblastomas by combining treatment with ATRA and a Bcl-2 inhibitor.	Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Tohoku Univ, Sch Med, Dept Pediat, Aoba Ku, Sendai, Miyagi 980, Japan; Miyagi Childrens Hosp, Dept Hematol & Oncol, Aoba Ku, Sendai, Miyagi, Japan	Chiba Cancer Center; Tohoku University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Niizuma, Hidetaka/L-9023-2019					Abel F, 2005, EUR J CANCER, V41, P635, DOI 10.1016/j.ejca.2004.12.021; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; DOLE M, 1994, CANCER RES, V54, P3253; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Gallo G, 2003, ANTICANCER RES, V23, P777; Kim R, 2004, CANCER-AM CANCER SOC, V101, P2491, DOI 10.1002/cncr.20696; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Lippman SC, 2000, J NUTR, V130, p479S, DOI 10.1093/jn/130.2.479S; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Maden M, 2001, INT REV CYTOL, V209, P1; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; McCaffery PJ, 2003, EUR J NEUROSCI, V18, P457, DOI 10.1046/j.1460-9568.2003.02765.x; Melino G, 1997, J NEURO-ONCOL, V31, P65, DOI 10.1023/A:1005733430435; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nagai J, 2004, CANCER RES, V64, P7910, DOI 10.1158/0008-5472.CAN-04-1178; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 1997, CANCER RES, V57, P4578; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura Y, 2003, BIOCHEM BIOPH RES CO, V307, P206, DOI 10.1016/S0006-291X(03)01138-0; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAMANI P, 1994, J PATHOL, V172, P273, DOI 10.1002/path.1711720308; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Schor NF, 1999, J NEURO-ONCOL, V41, P159, DOI 10.1023/A:1006171406740; Shi LY, 2005, NEUROSCI LETT, V375, P7, DOI 10.1016/j.neulet.2004.10.082; Takada N, 2001, MED PEDIATR ONCOL, V36, P122, DOI 10.1002/1096-911X(20010101)36:1<122::AID-MPO1029>3.0.CO;2-R; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; VILLABLANCA JG, 1995, J CLIN ONCOL, V13, P894, DOI 10.1200/JCO.1995.13.4.894; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124	46	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					5046	5055		10.1038/sj.onc.1209515	http://dx.doi.org/10.1038/sj.onc.1209515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568081				2022-12-17	WOS:000239921300010
J	De la Cueva, E; Garcia-Cao, I; Herranz, M; Lopez, P; Garcia-Palencia, P; Flores, JM; Serrano, M; Fernandez-Piqueras, J; Martin-Caballero, J				De la Cueva, E.; Garcia-Cao, I.; Herranz, M.; Lopez, P.; Garcia-Palencia, P.; Flores, J. M.; Serrano, M.; Fernandez-Piqueras, J.; Martin-Caballero, J.			Tumorigenic activity of p21(Waf1/Cip1) in thymic lymphoma	ONCOGENE			English	Article						p21; p53; apoptosis; cell cycle; lymphoma	TUMOR-FORMATION; INHIBITOR P21; SKIN CARCINOGENESIS; MICE LACKING; P21(CIP1); DEFICIENCY; P27(KIP1); RADIATION; APOPTOSIS; P53	The cell cycle inhibitor p21(Waf1/Cip1) is among the most important mediators of the tumor suppressor p53. However, there is increasing evidence indicating that p21 could favor tumorigenesis in specific cell types. In particular, the absence of p21 delays the development of thymic lymphomas induced either by ataxia-telangiectasia mutated deficiency or by ionizing irradiation. Here, we extend these observations to the context of p53-deficient mice. The absence of p21 results in a significant extension of the lifespan of p53-null and p53-haploin sufficient mice, and this effect can be attributed exclusively to a decrease in the incidence of spontaneous thymic lymphomas. Specifically, despite the occurrence of a variety of tumor types in the context of p53 deficiency, the only tumors that were significantly impaired by the absence of p21 were thymic lymphomas. Moreover, the absence of p21 also delays the incidence of radiation-induced thymic lymphomas in p53-deficient mice. Interestingly, p21-deficient lymphomas have a higher apoptotic rate than p21-proficient lymphomas, and this could be on the basis of the delayed incidence of thymic lymphomas in the absence of p21. Together, our results indicate that p21 plays an oncogenic role restricted to thymic lymphomas that is mechanistically independent of p53 and associated to a lower tumor apoptotic rate.	Spanish Natl Canc Ctr CNIO, Dept Mol Oncol, Unit Anim Experimentat, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Tumor Suppress Grp, Madrid 28029, Spain; Spanish Natl Canc Ctr CNIO, Canc Epigenet Grp, Madrid 28029, Spain; Univ Autonoma Madrid, Human Mol Genet Lab, Madrid, Spain; Univ Complutense Madrid, Sch Vet, Dept Anim Surg & Med, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Autonomous University of Madrid; Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr CNIO, Dept Mol Oncol, Unit Anim Experimentat, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Herranz, Michel/L-2561-2016; Serrano, Manuel/H-2634-2015	Serrano, Manuel/0000-0001-7177-9312; de la Cueva, Ernesto/0000-0001-7078-0901; Garcia Palencia, Pilar/0000-0002-4077-3732				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Bearss DJ, 2002, CANCER RES, V62, P2077; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gartel AL, 2002, MOL CANCER THER, V1, P639; HARPER JW, 1993, CELL, V75, P805; Jackson RJ, 2003, CANCER RES, V63, P3021; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WC, 2001, CANCER RES, V61, P565	29	58	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 6	2006	25	29					4128	4132		10.1038/sj.onc.1209432	http://dx.doi.org/10.1038/sj.onc.1209432			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	060KZ	16462758				2022-12-17	WOS:000238802400014
J	Fang, Y; Liu, T; Wang, X; Yang, YM; Deng, H; Kunicki, J; Traganos, F; Darzynkiewicz, Z; Lu, L; Dai, W				Fang, Y.; Liu, T.; Wang, X.; Yang, Y-M; Deng, H.; Kunicki, J.; Traganos, F.; Darzynkiewicz, Z.; Lu, L.; Dai, W.			BubR1 is involved in regulation of DNA damage responses	ONCOGENE			English	Article							POLY(ADP-RIBOSE) POLYMERASE-1; SPINDLE CHECKPOINT; HUMAN CANCERS; APOPTOSIS; P53; ANEUPLOIDY; MUTATIONS; ARREST	Defective mitotic spindles or an impaired spindle-kinetochore interaction activates the spindle checkpoint. We have previously shown that BubR1 haplo-insufficiency results in enhanced genomic instability and tumorigenesis in mice. Here we report that BubR1 deficiency also leads to a compromised response to DNA damage. Following treatment with doxorubicin, BubR1(+/-) murine fibroblast cells (MEF) were defective in undergoing G(2)/M arrest. Thus, whereas in the presence of DNA damage BubR1(+/+) MEF cells remained arrested in mitosis, BubR1(+/-) MEFs rapidly exited from mitosis and divided. The impaired mitotic arrest of BubR1(+/-) MEFs was associated with low levels of phospho-histone H2AX, p53, and p21 after DNA damage caused by treatment with both doxorubicin and ultraviolet light (UV). The impaired expression of p53 and p21 was also confirmed in human cell lines with BubR1 knockdown via RNA interference. Affinity pull-down coupled with mass spectrometry identified Poly(ADPribose) polymerase 1 (PARP-1) as one of the proteins interacting with BubR1. Reciprocal co-immunoprecipitation analysis confirmed the physical interaction between BubR1 and PARP-1. Our further study revealed that the ability of retaining intact PARP-1 or its cleavage product p89 was compromised in BubR1(+/-) MEFs upon treatment with doxorubicin or UV. Given that PARP-1 mediates DNA damage responses and regulates the activity of p53, our studies suggest that there exists a cross-talk between the spindle checkpoint and the DNA damage checkpoint and that BubR1 may play an important role in mediating the cross-talk.	New York Med Coll, Dept Med, Div Mol Carcinogenesis, Valhalla, NY 10595 USA; Rockefeller Univ, Proteom Core Facil, New York, NY 10021 USA; New York Med Coll, Brander Canc Inst, Valhalla, NY 10595 USA; Univ Calif Los Angeles, Harbor UCLA Med Ctr, Div Mol Med, Torrance, CA 90502 USA	New York Medical College; Rockefeller University; New York Medical College; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Dai, W (corresponding author), New York Med Coll, Dept Med, Div Mol Carcinogenesis, Basic Sci Bldg,A22, Valhalla, NY 10595 USA.	wei_dai@nymc.edu	Traganos, Frank/B-8021-2012	Dai, Wei/0000-0003-0169-8327; Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA028704, R01CA090658] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704-27, R01-CA90658, R01 CA028704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affar EB, 2001, J BIOL CHEM, V276, P2935, DOI 10.1074/jbc.M007269200; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chang P, 2004, NATURE, V432, P645, DOI 10.1038/nature03061; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Hamid T, 2003, HISTOL HISTOPATHOL, V18, P245, DOI 10.14670/HH-18.245; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; Lew DJ, 2003, ANNU REV GENET, V37, P251, DOI 10.1146/annurev.genet.37.042203.120656; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pirrotta V, 2004, CELL, V119, P735, DOI 10.1016/j.cell.2004.12.002; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Saxena A, 2002, J BIOL CHEM, V277, P26921, DOI 10.1074/jbc.M200620200; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	31	58	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3598	3605		10.1038/sj.onc.1209392	http://dx.doi.org/10.1038/sj.onc.1209392			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449973				2022-12-17	WOS:000238448200012
J	Richardson, DS; Lai, AZ; Mulligan, LM				Richardson, D. S.; Lai, A. Z.; Mulligan, L. M.			RET ligand-induced internalization and its consequences for downstream signaling	ONCOGENE			English	Article						RET; receptor mediated endocytosis; Akt; MAP kinase	CLATHRIN-MEDIATED ENDOCYTOSIS; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; DYNAMIN BINDS; SH3 DOMAINS; MAP KINASE; ACTIVATION; CELLS; TRANSDUCTION	RET is a receptor tyrosine kinase (RTK) with roles in cell growth, differentiation and survival. Ligand-induced activation of RET results in stimulation of multiple signal transduction pathways, including the MAP kinase/Erk and PI3 kinase/Akt pathways. However, the mechanisms governing receptor internalization and signal downregulation have not been explored. As other RTKs are internalized through the clathrin-coated pit pathway in a ligand-dependant manner, we have investigated whether RET is internalized through a similar process. Using a highly sensitive fluorescence resonance energy transfer (FRET)-based assay, we have shown that RET is internalized from the plasma membrane in a ligand-dependant manner that requires RET kinase activity as well as the GTPase activity of the clathrin-coated vesicle scission protein dynamin 2. Further, we have demonstrated that RET colocalizes with Rab5a, a marker of clathrin-coated vesicles and early endosomes, after internalization. Finally, we demonstrated that RET internalization is required for complete activation of Erk1/2, but not for activation of Akt signaling. Our data suggest that ligand-induced internalization of RET not only plays an overall role in downregulation and termination of signaling, but also functions to traffic RET to subcellular locations where it can fully activate certain downstream signaling pathways.	Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Canc Res Inst, Dept Pathol & Mol Med, Div Canc Biol & Genet, Rm 329 Botterell Hall, Kingston, ON K7L 3N6, Canada.	mulligal@post.queensu.ca	Richardson, Douglas/K-9922-2016	Richardson, Douglas/0000-0002-3189-2190				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arighi E, 2005, CYTOKINE GROWTH F R, V16, P441, DOI 10.1016/j.cytogfr.2005.05.010; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Foster-Barber A, 1998, P NATL ACAD SCI USA, V95, P4673, DOI 10.1073/pnas.95.8.4673; Freche B, 2005, J BIOL CHEM, V280, P36584, DOI 10.1074/jbc.M505707200; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grimes ML, 1996, J NEUROSCI, V16, P7950; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Kirchhausen T, 2002, CELL, V109, P413, DOI 10.1016/S0092-8674(02)00751-1; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Maeda K, 2004, BIOCHEM BIOPH RES CO, V323, P345, DOI 10.1016/j.bbrc.2004.08.095; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Myers SM, 2004, CANCER RES, V64, P4453, DOI 10.1158/0008-5472.CAN-03-3605; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Okamoto PM, 2001, J BIOL CHEM, V276, P48458, DOI 10.1074/jbc.M104927200; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Santoro M, 2004, ENDOCRINOLOGY, V145, P5448, DOI 10.1210/en.2004-0922; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Schuetz G, 2004, J CELL BIOL, V167, P945, DOI 10.1083/jcb.200404108; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; van Rheenen J, 2004, BIOPHYS J, V86, P2517, DOI 10.1016/S0006-3495(04)74307-6; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wiedlocha A, 2004, CURR TOP MICROBIOL, V286, P45; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wunderlich L, 1999, CELL SIGNAL, V11, P25, DOI 10.1016/S0898-6568(98)00027-8; Zaccolo M, 2000, IUBMB LIFE, V49, P375	38	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2006	25	22					3206	3211		10.1038/sj.onc.1209349	http://dx.doi.org/10.1038/sj.onc.1209349			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MK	16418724				2022-12-17	WOS:000237951000011
J	Alberici, P; Jagmohan-Changur, S; De Pater, E; Van Der Valk, M; Smits, R; Hohenstein, P; Fodde, R				Alberici, P; Jagmohan-Changur, S; De Pater, E; Van Der Valk, M; Smits, R; Hohenstein, P; Fodde, R			Smad4 haploinsufficiency in mouse models for intestinal cancer	ONCOGENE			English	Article						Smad4; Apc; haploinsufficiency; TGF-beta signaling; LOH; Wnt signaling; gastrointestinal cancer	STEM-CELL DIFFERENTIATION; COLORECTAL CANCERS; JUVENILE POLYPOSIS; BETA-CATENIN; GENE; APC; TUMORIGENESIS; PATHWAY; TUMORS; MUTATIONS	The Smad4(+/E6sad) mouse carries a null mutation in the endogenous Smad4 gene resulting in serrated adenomas and mixed polyposis of the upper gastrointestinal (GI) tract with 100% penetrance. Here, we show by loss of heterozygosity (LOH) analysis and immunohistochemistry (IHC) that, although the majority of the tumors appear at 9 months of age, somatic loss of the wild-type Smad4 allele occurs only at later stages of tumor progression. Hence, haploinsufficiency underlies Smad4-driven tumor initiation in the GI tract. As both the Apc and Smad4 tumor suppressor genes map to mouse chromosome 18, we have bred Smad4(+/E6sad) with the Apc(+/1638N) model to generate two distinct compound heterozygous lines carrying both mutations either in cis ( CAS) or in trans ( TAS). Strikingly, both models show increased tumor multiplicities when compared with the single mutant littermates, although CAS mice are more severely affected and became moribund at only 5-6 weeks of age. Phenotypic and molecular analyses indicate that Smad4 haploinsufficiency is sufficient to significantly affect tumor initiation and progression both prior to and upon loss of Apc function. Moreover, complete loss of Smad4 strongly enhances Apc-driven tumor formation.	ErasmusMC, Dept Pathol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Leiden Univ, Med Ctr, Ctr Human & Clin Genet, Leiden, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, Amsterdam, Netherlands; MRC, Human Genet Unit, Edinburgh, Midlothian, Scotland	Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; University of Edinburgh	Fodde, R (corresponding author), ErasmusMC, Dept Pathol, Josephine Nefkens Inst, POB 1738, NL-3000 DR Rotterdam, Netherlands.	r.fodde@erasmusmc.nl	Fodde, Riccardo/AAW-9394-2021; Hohenstein, Peter/Y-2428-2018	Fodde, Riccardo/0000-0001-9839-4324; Hohenstein, Peter/0000-0001-8548-4734; de Pater, Emma/0000-0002-7195-6769				Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Gaspar C, 2004, INT J DEV BIOL, V48, P377, DOI 10.1387/ijdb.041807cg; Haigis KM, 2003, NAT GENET, V33, P33, DOI 10.1038/ng1055; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hohenstein P, 2003, GENE CHROMOSOME CANC, V36, P273, DOI 10.1002/gcc.10169; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Jass JR, 2001, J PATHOL, V193, P283, DOI 10.1002/1096-9896(200103)193:3<283::AID-PATH799>3.0.CO;2-9; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Koyama M, 1999, MUTAT RES-GENOMICS, V406, P71, DOI 10.1016/S1383-5726(99)00003-5; Lei S, 2004, J BIOL CHEM, V279, P42492, DOI 10.1074/jbc.M404025200; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Satterwhite DJ, 2004, CELL CYCLE, V3, P1069; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Woodford-Richens K, 2000, CANCER RES, V60, P2477; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504	33	58	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1841	1851		10.1038/sj.onc.1209226	http://dx.doi.org/10.1038/sj.onc.1209226			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16288217				2022-12-17	WOS:000236224800001
J	Beaujouin, M; Baghdiguian, S; Glondu-Lassis, M; Berchem, G; Liaudet-Coopman, E				Beaujouin, M; Baghdiguian, S; Glondu-Lassis, M; Berchem, G; Liaudet-Coopman, E			Overexpression of both catalytically active and -inactive cathepsin D by cancer cells enhances apoptosis-dependent chemo-sensitivity	ONCOGENE			English	Article						protease; cathepsin D; chemo-cytotoxicity; apoptosis; etoposide; catalytic activity	CYTOCHROME-C RELEASE; BREAST-CANCER; CASPASE ACTIVATION; RAT CARDIOMYOCYTES; TNF-ALPHA; DEATH; INVOLVEMENT; DEFICIENT; GROWTH; FIBROBLASTS	The aspartic protease cathepsin D (cath-D) is a key mediator of induced-apoptosis and its proteolytic activity has been generally involved in this event. During apoptosis, cath-D is translocated to the cytosol. Because cath-D is one of the lysosomal enzymes that requires a more acidic pH to be proteolytically active relative to the cysteine lysosomal enzymes such as cath-B and -L, it is therefore open to question whether cytosolic cath-D might be able to cleave substrate(s) implicated in the apoptotic cascade. Here, we have investigated the role of wild-type cath-D and its proteolytically inactive counterpart overexpressed by 3Y1-Ad12 cancer cells during chemotherapeutic-induced cytotoxicity and apoptosis, as well as the relevance of cath-D catalytic function. We demonstrate that wild-type or mutated catalytically inactive cath-D strongly enhances chemo- sensitivity and apoptotic response to etoposide. Both wild-type and mutated inactive cath-D are translocated to the cytosol, increasing the release of cytochrome c, the activation of caspases-9 and -3 and the induction of a caspase-dependent apoptosis. In addition, pretreatment of cells with the aspartic protease inhibitor, pepstatin A, does not prevent apoptosis. Interestingly therefore, the stimulatory effect of cath- D on cell death is independent of its catalytic activity. Overall, our results imply that cytosolic cath- D stimulates apoptotic pathways by interacting with a member of the apoptotic machinery rather than by cleaving specific substrate( s).	Univ Montpellier I, INSERM U540, F-34090 Montpellier, France; Univ Montpellier 2, CNRS, UMR 5554, Montpellier, France; Ctr Hosp Luxembourg, CRP Sante, Lab Hematocancerol Expt, Luxembourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Liaudet-Coopman, E (corresponding author), Univ Montpellier I, INSERM U540, 60 Rue Navacelles, F-34090 Montpellier, France.	liaudet@montp.inserm.fr	Liaudet-Coopman, Emmanuelle/N-4744-2017; Berchem, Guy/C-9364-2014	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Berchem, Guy/0000-0003-0157-2257; Baghdiguian, Stephen/0000-0002-2992-9708				Berchem G, 2002, ONCOGENE, V21, P5951, DOI 10.1038/sj.onc.1205745; Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Demoz M, 2002, BIOL CHEM, V383, P1237, DOI 10.1515/BC.2002.137; Emert-Sedlak L, 2005, MOL CANCER THER, V4, P733, DOI 10.1158/1535-7163.MCT-04-0301; Ferrandina G, 1997, BRIT J CANCER, V76, P661, DOI 10.1038/bjc.1997.442; Foekens JA, 1999, BRIT J CANCER, V79, P300, DOI 10.1038/sj.bjc.6990048; GARCIA M, 1990, ONCOGENE, V5, P1809; Glondu M, 2001, ONCOGENE, V20, P6920, DOI 10.1038/sj.onc.1204843; Glondu M, 2002, ONCOGENE, V21, P5127, DOI 10.1038/sj.onc.1205657; Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654; Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382; Johansson AC, 2003, CELL DEATH DIFFER, V10, P1253, DOI 10.1038/sj.cdd.4401290; Kagedal K, 2001, FASEB J, V15, P1592, DOI 10.1096/fj.00-0708fje; Koike M, 2003, MOL CELL NEUROSCI, V22, P146, DOI 10.1016/S1044-7431(03)00035-6; Koike M, 2000, J NEUROSCI, V20, P6898, DOI 10.1523/JNEUROSCI.20-18-06898.2000; Laurent-Matha V, 2005, J CELL BIOL, V168, P489, DOI 10.1083/jcb.200403078; LIAUDET E, 1994, ONCOGENE, V9, P1145; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Nakanishi H, 2001, J NEUROSCI, V21, P7526, DOI 10.1523/JNEUROSCI.21-19-07526.2001; Ollinger K, 2000, ARCH BIOCHEM BIOPHYS, V373, P346, DOI 10.1006/abbi.1999.1567; Reiners JJ, 2002, CELL DEATH DIFFER, V9, P934, DOI 10.1038/sj.cdd.4401048; Roberg K, 1998, AM J PATHOL, V152, P1151; Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0; Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222; Rochefort H, 1996, EUR J CANCER, V32A, P7, DOI 10.1016/0959-8049(95)00637-0; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Takuma K, 2003, NEUROCHEM INT, V42, P153, DOI 10.1016/S0197-0186(02)00077-3; Tardy C, 2003, CELL DEATH DIFFER, V10, P1090, DOI 10.1038/sj.cdd.4401272; Terman A, 2002, EXP CELL RES, V274, P9, DOI 10.1006/excr.2001.5441; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755	37	58	65	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1967	1973		10.1038/sj.onc.1209221	http://dx.doi.org/10.1038/sj.onc.1209221			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16331270	Green Accepted, Green Submitted			2022-12-17	WOS:000236224800013
J	Duong, V; Licznar, A; Margueron, R; Boulle, N; Busson, M; Lacroix, M; Katzenellenbogen, BS; Cavailles, V; Lazennec, G				Duong, V; Licznar, A; Margueron, R; Boulle, N; Busson, M; Lacroix, M; Katzenellenbogen, BS; Cavailles, V; Lazennec, G			ER alpha and ER beta expression and transcriptional activity are differentially regulated by HDAC inhibitors	ONCOGENE			English	Article						estrogen receptor; histone deacetylase; breast cancer; transcription; proliferation	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; HISTONE DEACETYLASE INHIBITION; ANDROGEN RECEPTOR; CARCINOMA-CELLS; TRICHOSTATIN-A; PROLIFERATION; ACETYLATION; TRANSACTIVATION; ACTIVATION	The proliferative action of ER alpha largely accounts for the carcinogenic activity of estrogens. By contrast, recent data show that ER beta displays tumor-suppressor properties, thus supporting the interest to identify compounds that could increase its activity. Here, we show that histone deacetylase inhibitors (HDI) upregulated ER beta protein levels, whereas it decreased ER alpha expression. Part of this regulation took place at the mRNA level through a mechanism independent of de novo protein synthesis. In addition, we found that, in various cancer cells, the treatment with different HDI enhanced the ligand-dependent activity of ER beta more strongly than that of ER alpha. On the other hand, in MDA-MB231 and HeLa cells, the expression of ERs modified the transcriptional response to HDI. The use of deletion mutants of both receptors demonstrated that AF1 domain of the receptors was required. Finally, we show that ER beta expression led to a dramatic increased in the antiproliferative activity of HDI, which correlated with a modi. cation of the transcription of genes involved in cell cycle control by HDI. Altogether, these data demonstrate that the interference of ER beta and HDAC on the control of transcription and cell proliferation constitute a promising approach for cancer therapy.	INSERM, U540, F-34090 Montpellier, France; Hop Arnaud Villeneuve, Lab Biol Cellulaire & Hormonale, Montpellier, France; INRA, UMR 866, F-34060 Montpellier, France; Univ Illinois, Coll Med, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; INRAE; Universite de Montpellier; University of Illinois System; University of Illinois Urbana-Champaign	Cavailles, V (corresponding author), INSERM, U540, 60,Rue Navacelles, F-34090 Montpellier, France.	v.cavailles@montp.inserm.fr; lazennec@montp.inserm.fr	Cavailles, Vincent/Y-5379-2019; Lacroix, Matthieu/O-1928-2018; Margueron, Raphael F/B-9996-2015; cavailles, vincent/C-6277-2017	Cavailles, Vincent/0000-0002-7160-3074; Lacroix, Matthieu/0000-0002-1268-9058; Margueron, Raphael F/0000-0002-9093-7977; Lazennec, Gwendal/0000-0002-8522-1763	NATIONAL CANCER INSTITUTE [R01CA018119, R37CA018119] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA018119, CA18119] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Campbell-Thompson M, 2001, CANCER RES, V61, P632; Cheng J, 2004, FEBS LETT, V566, P169, DOI 10.1016/j.febslet.2004.04.025; Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037; Cohen LA, 1999, ANTICANCER RES, V19, P4999; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; de Cremoux P, 2002, BIOCHEM PHARMACOL, V64, P507, DOI 10.1016/S0006-2952(02)01187-5; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Fajas L, 2003, ONCOGENE, V22, P4186, DOI 10.1038/sj.onc.1206530; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Harrington WR, 2003, MOL CELL ENDOCRINOL, V206, P13, DOI 10.1016/S0303-7207(03)00255-7; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENDERSON BE, 1988, CANCER RES, V48, P246; Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031; Margueron R, 2003, J ENDOCRINOL, V179, P41, DOI 10.1677/joe.0.1790041; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/en.143.7.2461; Minucci S, 1997, P NATL ACAD SCI USA, V94, P11295, DOI 10.1073/pnas.94.21.11295; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Pettersson K, 2001, ANNU REV PHYSIOL, V63, P165, DOI 10.1146/annurev.physiol.63.1.165; Pujol P, 1998, CANCER RES, V58, P5367; Roger P, 2001, CANCER RES, V61, P2537; Ruh MF, 1999, ENDOCRINE, V11, P157, DOI 10.1385/ENDO:11:2:157; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; STANLEY F, 1984, J BIOL CHEM, V259, P9768; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Yang XW, 2000, CANCER RES, V60, P6890	36	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	12					1799	1806		10.1038/sj.onc.1209102	http://dx.doi.org/10.1038/sj.onc.1209102			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	021VJ	16158045	Green Submitted, Green Accepted			2022-12-17	WOS:000236013700011
J	Gong, J; Zhu, J; Goodman, OB; Pestell, RG; Schlegel, PN; Nanus, DM; Shen, R				Gong, J; Zhu, J; Goodman, OB; Pestell, RG; Schlegel, PN; Nanus, DM; Shen, R			Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells	ONCOGENE			English	Article						bombesin; neuropeptides; p300; androgen receptor; acetylation; androgen-independent prostate cancer	FOCAL ADHESION KINASE; CREB-BINDING PROTEIN; GROWTH-FACTOR; PHOSPHORYLATION; EXPRESSION; TRANSACTIVATION; DIFFERENTIATION; IDENTIFICATION; COREGULATORS; RECRUITMENT	Androgen receptor signaling in prostate cancer cells is augmented by the androgen receptor (AR) coactivator p300, which transactivates and acetylates the AR in the presence of dihydrotestosterone (DHT). As prostate cancer (PC) cells progress to androgen independence, AR signaling remains intact, indicating that other factors stimulate AR activities in the absence of androgen. We previously reported that neuropeptide growth factors could transactivate the AR in the presence of very low concentrations of DHT. Here, we examine the involvement of p300 in neuropeptide activation of AR signaling. Transfection of increasing concentrations of p300 in the presence of bombesin into PC-3 cells resulted in a linear increase in AR transactivation, suggesting that p300 acts as a coactivator in neuropeptide-mediated AR transactivation. P300 is endowed with histone acetyltransferase ( HAT) activity. Therefore, we examine the effect of bombesin on p300 HAT activity. At 4 h after the addition of bombesin, p300 HAT activity increased 2.0-fold (P < 0.01). Incubation with neutral endopeptidase, which degrades bombesin, or bombesin receptor antagonists blocked bombesin-induced p300 HAT activity. To explore the potential signaling pathways involved in bombesin-induced p300 HAT activity, we examined Src and PKC delta pathways that mediate bombesin signaling. Inhibitors of Src kinase activity or Src kinase siRNA blocked bombesin-induced p300 HAT activity, whereas PKCd inhibitors or PKCd siRNA significantly increased bombesin-induced p300 HAT activity suggesting that Src kinase and PKCd kinase are involved in the regulation of p300 HAT activity. As AR is acetylated in the presence of 100 nM DHT, we next examined whether bombesin-induced p300 HAT activity would result in enhanced AR acetylation. Bombesin-induced AR acetylation at the same motif KLKK observed in DHT-induced acetylation. Elimination of p300 using p300 siRNA reduced AR acetylation, demonstrating that AR acetylation was mediated by p300. AR acetylation results in AR transactivation and the expression of the AR-regulated gene prostate-specific antigen (PSA). Therefore, we examined bombesin-induced AR transactivation and PSA expression in the presence and absence of p300 siRNA and found inhibition of p300 expression reduced bombesin-induced AR transactivation and PSA expression. Together these results demonstrate that bombesin, via Src and PKCd signaling pathways, activates p300 HAT activity which leads to enhanced acetylation of AR resulting in increased expression of AR-regulated genes.	Cornell Univ, Weill Med Coll, Dept Urol, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA; Cornell Univ, Weill Med Coll, Dept Med, New York, NY USA; Georgetown Univ, Med Ctr, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; Georgetown University	Shen, R (corresponding author), Cornell Univ, Weill Med Coll, Dept Urol, Rm E-300,Box 23,1300 York Ave, New York, NY 10021 USA.	rshen@med.cornell.edu		Goodman, Oscar/0000-0002-0882-3621	NATIONAL CANCER INSTITUTE [R01CA093596, R01CA080240, P30CA051008, R01CA107382, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060908] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80240, P30CA51008-14, R01CA93596-01, R01CA86072, R01CA107382] Funding Source: Medline; NIDDK NIH HHS [R01 DK060908-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aprikian AG, 1998, PROSTATE, P52; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; BOLOGNA M, 1989, CANCER, V63, P1714; Borre M, 2000, CLIN CANCER RES, V6, P1882; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chan HM, 2001, J CELL SCI, V114, P2363; Chim CS, 2004, CANCER GENET CYTOGEN, V150, P164, DOI 10.1016/j.cancergencyto.2003.09.006; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Culig Z, 2000, MICROSC RES TECHNIQ, V51, P447; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; CULIG Z, 1994, CANCER RES, V54, P5474; Dai J, 2002, CLIN CANCER RES, V8, P2399; Darne C, 1998, EUR J BIOCHEM, V256, P541, DOI 10.1046/j.1432-1327.1998.2560541.x; Debes JD, 2005, CANCER RES, V65, P5965, DOI 10.1158/0008-5472.CAN-04-2837; Debes JD, 2002, CANCER RES, V62, P5632; Debes JD, 2003, CANCER RES, V63, P7638; Fu MF, 2004, BIOCHEM PHARMACOL, V68, P1199, DOI 10.1016/j.bcp.2004.05.037; Fu MF, 2005, J BIOL CHEM, V280, P29728, DOI 10.1074/jbc.M503188200; Fu MF, 2004, J BIOL CHEM, V279, P29436, DOI 10.1074/jbc.M313466200; Fu MF, 2003, MOL CELL BIOL, V23, P8563, DOI 10.1128/MCB.23.23.8563-8575.2003; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2002, CYTOKINE GROWTH F R, V13, P259, DOI 10.1016/S1359-6101(02)00003-5; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Gaughan L, 2002, J BIOL CHEM, V277, P25904, DOI 10.1074/jbc.M203423200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kasper S, 1999, J MOL ENDOCRINOL, V22, P313, DOI 10.1677/jme.0.0220313; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Levine L, 2003, CANCER RES, V63, P3495; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Shen RQ, 2000, MOL CELL ENDOCRINOL, V170, P131, DOI 10.1016/S0303-7207(00)00326-9; Shigeno K, 2004, CANCER LETT, V213, P11, DOI 10.1016/S0304-3835(03)00442-7; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Sumitomo M, 2000, CANCER RES, V60, P6590; Sumitomo M, 2001, CANCER RES, V61, P3294; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wang C, 2004, METH MOL B, V241, P207; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200	49	58	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2011	2021		10.1038/sj.onc.1209231	http://dx.doi.org/10.1038/sj.onc.1209231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434977				2022-12-17	WOS:000236359700004
J	Dang, L; Fan, X; Chaudhry, A; Wang, M; Gaiano, N; Eberhart, CG				Dang, L; Fan, X; Chaudhry, A; Wang, M; Gaiano, N; Eberhart, CG			Notch3 signaling initiates choroid plexus tumor formation	ONCOGENE			English	Article						choroid plexus papilloma; Notch3	MULTIPLE FUNCTIONAL ROLES; RADIAL GLIAL IDENTITY; BRAIN-DEVELOPMENT; TRANSGENIC MICE; GROWTH; EXPRESSION; CANCER; DIFFERENTIATION; TUMORIGENESIS; DELTA-LIKE-1	Notch3 has been studied in the context of brain development, but whether it plays a role in the formation of brain tumors is unclear. We demonstrate that the introduction of constitutively active Notch3 into periventricular cells of embryonic day 9.5 mice causes the formation of choroid plexus tumors (CPTs). Tumors arose in the fourth ventricles in 83% of animals and were associated with hydrocephalus. They were microscopically highly similar to choroid plexus papillomas in humans, with an ongoing proliferation rate of 4-6%. Signs of Notch pathway activity were also present in human choroid plexus lesions, and receptor mRNA levels in papillomas were elevated over those in non-neoplastic choroid plexus. Notch2 was overexpressed approximately 500-fold in one case, suggesting that the role of this pathway in CPTs may not be specific to Notch3. Our findings indicate that activated Notch3 can function as an oncogene in the developing brain, and link the Notch pathway to human CPT pathogenesis.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; Johns Hopkins University	Eberhart, CG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, 720 Rutland Ave,Ross Bldg 558, Baltimore, MD 21205 USA.	gaiano@jhmi.edu; ceberha@jhmi.edu		Dang, Louis/0000-0003-4853-4952	NINDS NIH HHS [K08NS041342, K08NS43279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041342, K08NS043279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Irvin DK, 2001, J COMP NEUROL, V436, P167, DOI 10.1002/cne.1059.abs; Irvin DK, 2004, J NEUROSCI RES, V75, P330, DOI 10.1002/jnr.10843; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; KLEIHUES P, 2000, TUMORS NERVOUS SYSTE; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; Rickert CH, 2002, AM J PATHOL, V160, P1105, DOI 10.1016/S0002-9440(10)64931-0; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Weng AP, 2004, CURR OPIN GENET DEV, V14, P48, DOI 10.1016/j.gde.2003.11.004; Yoon KJ, 2004, J NEUROSCI, V24, P9497, DOI 10.1523/JNEUROSCI.0993-04.2004	21	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					487	491		10.1038/sj.onc.1209074	http://dx.doi.org/10.1038/sj.onc.1209074			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186803				2022-12-17	WOS:000234714100017
J	Prentice, LM; Shadeo, A; Lestou, VS; Miller, MA; DeLeeuw, RJ; Makretsov, N; Turbin, D; Brown, LA; Macpherson, N; Yorida, E; Cheang, MCU; Bentley, J; Chia, S; O Nielsen, T; Gilks, CB; Lam, W; Huntsman, DG				Prentice, LM; Shadeo, A; Lestou, VS; Miller, MA; DeLeeuw, RJ; Makretsov, N; Turbin, D; Brown, LA; Macpherson, N; Yorida, E; Cheang, MCU; Bentley, J; Chia, S; O Nielsen, T; Gilks, CB; Lam, W; Huntsman, DG			NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis	ONCOGENE			English	Article						NRG1; breast cancer; amplicon; SPFH2; 8p	COMPARATIVE GENOMIC HYBRIDIZATION; IN-SITU HYBRIDIZATION; CHROMOSOME ARM 8P; TISSUE MICROARRAY; GAMMA-HEREGULIN; GROWTH-FACTOR; CELL-LINES; FUSION GENE; CARCINOMA; TRANSLOCATION	Rearrangements of the neuregulin (NRG1) gene have been implicated in breast carcinoma oncogenesis. To determine the frequency and clinical significance of NRG1 aberrations in clinical breast tumors, a breast cancer tissue microarray was screened for NRG1 aberrations by fluorescent in situ hybridization (FISH) using a two-color split-apart probe combination. flanking the NRG1 gene. Rearrangements of NRG1 were identified in 17/382 cases by FISH, and bacterial artifi. cial chromosome array comparative genomic hybridization was applied to. five of these cases to further map the chromosome 8p abnormalities. In all. five cases, there was a novel amplicon centromeric to NRG1 with a minimum common region of amplifi. cation encompassing two genes, SPFH2 and FLJ14299. Subsequent FISH analysis for the novel amplicon revealed that it was present in 63/262 cases. Abnormalities of NRG1 did not correlate with patient outcome, but the novel amplicon was associated with poor prognosis in univariate analysis, and in multivariate analysis was of prognostic significance independent of nodal status, tum or grade, estrogen receptor status, and human epidermal growth factor receptor (HER)2 overexpression. Of the two genes in the novel amplicon, expression of SPFH2 correlated most significantly with amplication. This amplicon may emerge as a result of breakpoints and chromosomal rearrangements within the NRG1 locus.	British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada; Vancouver Gen Hosp, Genet Pathol Evaluat Ctr, Dept Pathol & Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Pathol & Lab Med, British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Res Ctr, Dept Canc Genet & Dev Biol, Vancouver, BC V5Z 1L3, Canada; Hosp Sick Children, Dept Paediat Lab Med, Toronto, ON M5G 1X8, Canada; British Columbia Canc Agcy, Dept Med Oncol, Victoria, BC V8R 6V5, Canada; British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of British Columbia; British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); British Columbia Cancer Agency; British Columbia Cancer Agency	Huntsman, DG (corresponding author), British Columbia Canc Agcy, Dept Pathol & Lab Med, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	dhuntsman@bccancer.bc.ca	Huntsman, David/ABE-6082-2020	Cheang, Maggie Chon U/0000-0001-5718-2501; Shadeo, Ashleen/0000-0002-0866-0519; Brown, Lindsay/0000-0002-2790-5112				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Adelaide J, 2000, INT J ONCOL, V16, P683; Atlas E, 2003, MOL CANCER RES, V1, P165; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bernardino L, 1998, GENE CHROMOSOME CANC, V23, P100, DOI 10.1002/(SICI)1098-2264(199810)23:2<100::AID-GCC2>3.0.CO;2-6; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Cuny M, 2000, CANCER RES, V60, P1077; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Jacobson KK, 2004, GENE CHROMOSOME CANC, V40, P19, DOI 10.1002/gcc.20019; Jong K, 2003, LECT NOTES COMPUT SC, V2611, P54; Khoury H, 2003, MODERN PATHOL, V16, P716, DOI 10.1097/01.MP.0000077515.68734.85; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Liu CL, 2002, AM J PATHOL, V161, P1557, DOI 10.1016/S0002-9440(10)64434-3; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Makretsov N, 2004, GENE CHROMOSOME CANC, V40, P152, DOI 10.1002/gcc.20028; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; Makretsov NA, 2004, CLIN CANCER RES, V10, P6143, DOI 10.1158/1078-0432.CCR-04-0429; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Parker RL, 2002, AM J CLIN PATHOL, V117, P723; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; Sprenger RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/elps.200305675; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Wiseman SM, 2005, CANCER-AM CANCER SOC, V103, P1770, DOI 10.1002/cncr.20970; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	38	58	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7281	7289		10.1038/sj.onc.1208892	http://dx.doi.org/10.1038/sj.onc.1208892			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16027731				2022-12-17	WOS:000233142100004
J	Ishitsuka, K; Hideshima, T; Hamasaki, M; Raje, N; Kumar, S; Podar, K; Le Gouill, S; Shiraishi, N; Yasui, H; Roccaro, AM; Tai, YZ; Chauhan, D; Fram, R; Tamura, K; Jain, J; Anderson, KC				Ishitsuka, K; Hideshima, T; Hamasaki, M; Raje, N; Kumar, S; Podar, K; Le Gouill, S; Shiraishi, N; Yasui, H; Roccaro, AM; Tai, YZ; Chauhan, D; Fram, R; Tamura, K; Jain, J; Anderson, KC			Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway	ONCOGENE			English	Article						multiple myeloma; IMPDH inhibitor; VX-944; apoptosis; AIF/Endo G pathway	GUANINE-NUCLEOTIDE DEPLETION; MYCOPHENOLIC-ACID; BENZAMIDE RIBOSIDE; DRUG-RESISTANCE; IMPDH INHIBITOR; CLINICAL-TRIAL; T-LYMPHOCYTES; GROWTH-FACTOR; DEATH; EXPRESSION	Inosine monophosphate dehydrogenase (IMPDH) is a rate-limiting enzyme required for the de novo synthesis of guanine nucleotides from IMP. VX-944 (Vertex Pharmaceuticals, Cambridge, MA, USA) is a small-molecule, selective, noncompetitive inhibitor directed against human IMPDH. In this report, we show that VX-944 inhibits in vitro growth of human multiple myeloma (MM) cell lines via induction of apoptosis. Interleukin-6, insulin-like growth factor-1, or co-culture with bone marrow stromal cells (BMSCs) do not protect against VX-944-induced MM cell growth inhibition. VX-944 induced apoptosis in MM cell lines with only modest activation of caspases 3, 8, and 9. Furthermore, the pan-caspase inhibitor z-VAD-fmk did not inhibit VX-944-induced apoptosis and cell death. During VX-944-induced apoptosis, expressions of Bax and Bak were enhanced, and both apoptosis-inducing factor (AIF) and endonuclease G (Endo G) were released from the mitochondria to cytosol, suggesting that VX-944 triggers apoptosis in MM cells primarily via a caspase-independent, Bax/AIF/Endo G pathway. Importantly, VX-944 augments the cytotoxicity of doxorubicin and melphalan even in the presence of BMSCs. Taken together, our data demonstrate a primarily non-caspase-dependent apoptotic pathway triggered by VX-944, thereby providing a rationale to enhance MM cell cytotoxicity by combining this agent with conventional agents which trigger caspase activation.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Vertex Pharmaceut Inc, Cambridge, MA 02139 USA; Fukuoka Univ, Dept Internal Med 1, Fukuoka 8140180, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; Fukuoka University	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Hamasaki, Makoto/AAO-2229-2020; Roccaro, Aldo/AAA-8957-2022; Ishitsuka, Kenji/O-9296-2019; Podar, Klaus/ABD-1112-2020	Roccaro, Aldo/0000-0002-1872-5128; Ishitsuka, Kenji/0000-0002-7030-497X; Podar, Klaus/0000-0002-7414-3632; le gouill, steven/0000-0001-9840-2128; Yasui, Hiroshi/0000-0003-0905-6855	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [1P50 CA10070-01, R01- CA50947] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; AHLUWALIA GS, 1984, BIOCHEM PHARMACOL, V33, P1195, DOI 10.1016/0006-2952(84)90170-9; Ahn HJ, 2004, J CELL BIOCHEM, V91, P1043, DOI 10.1002/jcb.20006; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; EUGUI EM, 1990, P NATL ACAD SCI USA, V87, P1305, DOI 10.1073/pnas.87.4.1305; EUGUI EM, 1991, SCAND J IMMUNOL, V33, P161, DOI 10.1111/j.1365-3083.1991.tb03746.x; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ge NL, 2000, BLOOD, V96, P2856; Gu JJ, 2003, BLOOD, V101, P4958, DOI 10.1182/blood-2002-08-2547; Hayashi T, 2002, MOL CANCER THER, V1, P851; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hunakova L, 2000, NEOPLASMA, V47, P274; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jain J, 2001, J PHARM SCI-US, V90, P625, DOI 10.1002/1520-6017(200105)90:5<625::AID-JPS1019>3.0.CO;2-1; Jelinek DF, 1997, J IMMUNOL, V159, P487; Kagawa S, 2001, CLIN CANCER RES, V7, P1474; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KNUDTZON S, 1972, CANCER CHEMOTH REP 1, V56, P221; Laliberte J, 1998, BLOOD, V91, P2896, DOI 10.1182/blood.V91.8.2896.2896_2896_2904; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lockshin RA, 2004, ONCOGENE, V23, P2766, DOI 10.1038/sj.onc.1207514; McCafferty-Grad J, 2003, MOL CANCER THER, V2, P1155; McLean JE, 2004, BIOCHEM J, V379, P243, DOI 10.1042/BJ20031585; Messina E, 2004, INT J CANCER, V108, P812, DOI 10.1002/ijc.11642; Miyashita T, 1998, CELL DEATH DIFFER, V5, P1034, DOI 10.1038/sj.cdd.4400442; NAGAI M, 1991, CANCER RES, V51, P3886; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Richardson P, 2004, MAYO CLIN PROC, V79, P875, DOI 10.4065/79.7.875; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood-2002-03-0996; SENDA M, 1994, LIFE SCI, V54, P1917, DOI 10.1016/0024-3205(94)90150-3; SWEENEY MJ, 1972, CANCER RES, V32, P1795; Szekeres T, 2002, CURR MED CHEM, V9, P759, DOI 10.2174/0929867024606911; Takebe N, 2004, CLIN CANCER RES, V10, P8301, DOI 10.1158/1078-0432.CCR-04-0747; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; UCHIYAMA H, 1993, BLOOD, V82, P3712; Wright DG, 1996, ANTICANCER RES, V16, P3349; Yalowitz JA, 2002, CURR MED CHEM, V9, P749, DOI 10.2174/0929867024606867; Yalowitz JA, 2002, CANCER LETT, V181, P31, DOI 10.1016/S0304-3835(02)00045-9; Zimmermann AG, 1998, PROG NUCLEIC ACID RE, V61, P181, DOI 10.1016/S0079-6603(08)60827-2	45	58	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	38					5888	5896		10.1038/sj.onc.1208739	http://dx.doi.org/10.1038/sj.onc.1208739			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960KW	15940263				2022-12-17	WOS:000231590400011
J	Lu, CH; Shen, Q; DuPre, E; Kim, H; Hilsenbeck, S; Brown, PH				Lu, CH; Shen, Q; DuPre, E; Kim, H; Hilsenbeck, S; Brown, PH			cFos is critical for MCF-7 breast cancer cell growth	ONCOGENE			English	Article						cFos; cJun; AP-1; breast cancer; cell proliferation	DOMINANT-NEGATIVE MUTANT; C-FOS; AP-1 ACTIVITY; MATRIX-METALLOPROTEINASE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; KINASE-ACTIVITY; RETINOIC ACID; ANTISENSE RNA; JUN	The activating protein-1 (AP-1) transcription factor is a converging point of multiple signal transduction pathways in many cells. We have previously demonstrated that overexpressing Tam67, a dominant-negative (DN) form of cJun, blocks AP-1 activity and inhibits breast cancer cell growth. We hypothesized that Tam67 forms dimers with other AP-1 proteins to suppress the growth of breast cancer cells. In the present study, we used immunoprecipitation-Western blotting to demonstrate that Tam67 binds all Jun and Fos proteins in breast cancer cells. In addition, we used two variants of the Tam67 mutant to investigate whether Jun or Fos protein was required for breast cancer cell growth. We created a Tam/Fos mutant in which the cJun dimerization domain was replaced by the cFos dimerization domain, and a Tam/Squelcher mutant in which the cJun dimerization domain was deleted. We then isolated MCF-7 cell lines that stably expressed these cJun-DN mutants under the control of an inducible promoter. Using AP-1-dependent reporter assays, we observed that Tam67 and Tam/Fos mutants inhibited AP-1 transcriptional activity, while the Tam/Squelcher mutant did not. We then determined whether Tam/Fos or Tam/Squelcher inhibited breast cell growth as well as Tam67. We found that while Tam67 repressed cell growth, neither Tam/Fos nor Tam/Squelcher mutant affected cell growth. These results indicate that Tam67 likely inactivates Fos family member proteins to suppress breast cancer cell growth. Finally, we performed antisense experiments to knock down the expression of individual family members (cJun or cFos). Our results demonstrated that antisense cFos inhibited breast cancer cell proliferation and colony formation, while antisense cJun did not. These results suggest that Tam67 suppresses breast cancer cell growth by interacting with Fos family members, specifically with cFos, to produce an inactive AP-1 complex.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Dept Biol Celular, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Brown, PH (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Pl,MS600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu		Brown, Powel/0000-0002-3398-163X; Shen, Qiang/0000-0002-1491-5434				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Arteaga CL, 1996, CANCER RES, V56, P1098; Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BLAND KI, 1995, ANN SURG, V221, P706, DOI 10.1097/00000658-199506000-00010; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; DeNardo DG, 2005, MOL ENDOCRINOL, V19, P362, DOI 10.1210/me.2004-0267; Gajate C, 1996, BIOCHEM BIOPH RES CO, V218, P267, DOI 10.1006/bbrc.1996.0047; GEE JMW, 1995, INT J CANCER, V64, P269, DOI 10.1002/ijc.2910640410; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lin F, 2000, CANCER RES, V60, P3271; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; MACKAY AR, 1992, INVAS METAST, V12, P168; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; Preston GA, 1996, MOL CELL BIOL, V16, P211; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROBINSONBENION C, 1994, LEUKEMIA, V8, pS152; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; RofflerTarlov S, 1996, DEVELOPMENT, V122, P1; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	47	58	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6516	6524		10.1038/sj.onc.1208905	http://dx.doi.org/10.1038/sj.onc.1208905			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16027729				2022-12-17	WOS:000232204100005
J	Zhu, YH; Denhardt, DT; Cao, HB; Sutphin, PD; Koong, AC; Giaccia, AJ; Le, QT				Zhu, YH; Denhardt, DT; Cao, HB; Sutphin, PD; Koong, AC; Giaccia, AJ; Le, QT			Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a ras-activated enhancer	ONCOGENE			English	Article						Akt; hypoxia; osteopontin; ras; regulation	ENDOTHELIAL GROWTH-FACTOR; SOLID TUMORS; GENE-EXPRESSION; MESSENGER-RNA; SECRETED PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; TRANSFORMED-CELLS; SIGNALING PATHWAY; CANCER-THERAPY; PROTEIN	Osteopontin (OPN) is a secreted phosphoglycoprotein that has been linked to tumor progression and survival in several solid tumors, including head and neck cancers. Previous studies showed that OPN expression is induced by tumor hypoxia, and its plasma levels can serve as a surrogate marker for tumor hypoxia and treatment outcome in head and neck cancer patients. In this study, we investigate the transcriptional mechanism by which hypoxia enhances OPN expression. We found that OPN is induced in head and neck squamous cell carcinoma (HNSCC) cell lines and in NIH3T3 cells by hypoxia at both mRNA and protein levels in a time-dependent manner. Actinomycin D chase experiments showed that hypoxic induction of OPN was not due to increased mRNA stability. Deletion analyses of the mouse OPN promoter regions indicated that a ras-activated enhancer (RAE) located at -731 to -712 relative to the transcription start site was essential for hypoxia-enhanced OPN transcription. Using electrophoretic mobility shift assays with the RAE DNA sequence, we found that hypoxia induced sequence-specific DNA-binding complexes. Furthermore, hypoxia and ras exposure resulted in an additive induction of OPN protein and mRNA levels that appeared to be mediated by the RAE. Induction of OPN through the RAE element by hypoxia is mediated by an Akt-kinase signaled pathway as decreasing Akt levels with dominant negative constructs resulted in inhibition of OPN induction by hypoxia. Taken together, these results have identified a new hypoxia responsive transcriptional enhancer that is regulated by Akt signaling.	Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08855 USA	Stanford University; Rutgers State University New Brunswick	Le, QT (corresponding author), Stanford Univ, Dept Radiat Oncol, 875 Blake Wilbur Dr,R CC-G228, Stanford, CA 94305 USA.	qle@stanford.edu		Koong, Albert/0000-0001-9824-1643; Le, Quynh Thu/0000-0002-3682-1439	NCI NIH HHS [CA 67166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA067166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSSERER WA, 1994, MOL CELL BIOL, V14, P5032, DOI 10.1128/MCB.14.8.5032; Bedogni B, 2004, CANCER RES, V64, P2552, DOI 10.1158/0008-5472.CAN-03-3327; Brizel DM, 1996, CANCER RES, V56, P5347; Brown JM, 1998, CANCER RES, V58, P1408; CHAMBERS AF, 1992, ANTICANCER RES, V12, P43; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; CHOI HS, 1990, J BIOL CHEM, V265, P18005; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CRAIG AM, 1989, J BIOL CHEM, V264, P9682; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P27142; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Furger Kara A., 2001, Current Molecular Medicine (Hilversum), V1, P621, DOI 10.2174/1566524013363339; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; HARROLD S, 1991, ANAL BIOCHEM, V198, P19, DOI 10.1016/0003-2697(91)90500-S; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; Hockel M, 1996, CANCER RES, V56, P4509; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HWANG SM, 1994, J CELL PHYSIOL, V160, P61, DOI 10.1002/jcp.1041600108; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Koong AC, 2000, CANCER RES, V60, P883; Koszewski NJ, 1996, J STEROID BIOCHEM, V59, P377, DOI 10.1016/S0960-0760(96)00127-6; Le QT, 2003, CLIN CANCER RES, V9, P59; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Liaw L, 1998, J CLIN INVEST, V101, P1468; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Noiri E, 1999, KIDNEY INT, V56, P74, DOI 10.1046/j.1523-1755.1999.00526.x; Pollmann C, 2001, CANCER RES, V61, P8416; Sodhi CP, 2001, DIABETES, V50, P1482, DOI 10.2337/diabetes.50.6.1482; Sodhi CP, 2000, KIDNEY INT, V58, P691, DOI 10.1046/j.1523-1755.2000.00215.x; TEICHER BA, 1990, CANCER RES, V50, P3339; Teramoto H, 2003, ONCOGENE, V22, P2689, DOI 10.1038/sj.onc.1206364; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Weber Georg F., 1996, Cytokine and Growth Factor Reviews, V7, P241, DOI 10.1016/S1359-6101(96)00030-5; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X; Zhu YH, 2002, CELL GROWTH DIFFER, V13, P431; Zhu YH, 1999, BIOCHEM BIOPH RES CO, V258, P87, DOI 10.1006/bbrc.1999.0586; Zhu YH, 2003, STROKE, V34, P2483, DOI 10.1161/01.STR.0000088644.60368.ED	52	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	43					6555	6563		10.1038/sj.onc.1208800	http://dx.doi.org/10.1038/sj.onc.1208800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	968ZV	16007184				2022-12-17	WOS:000232204100009
J	Zhang, YD; Lu, YJ; Yuan, BZ; Castranova, V; Shi, XL; Stauffer, JL; Demers, LM; Chen, F				Zhang, YD; Lu, YJ; Yuan, BZ; Castranova, V; Shi, XL; Stauffer, JL; Demers, LM; Chen, F			The human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer	ONCOGENE			English	Article						mineral dust; mdig; lung cancer	MESSENGER-RNA; ASBESTOS; EXPRESSION; HAIRLESS; SILICA	Environmental or occupational exposure to mineral dusts, mainly silica and asbestos, is associated with an increased incidence of lung inflammation, fibrosis, and/or cancer. To better understand the molecular events associated with these pulmonary diseases, we attempted to identify genes that are regulated by mineral dusts. Using a differential display reverse transcription polymerase chain reaction technique and mRNAs of alveolar macrophages from both normal individuals and coal miners, we identified a novel mineral dust-induced gene named mdig, which had not been fully characterized. The expression of mdig mRNA was detected in alveolar macrophages from coal miners but not from normal subjects. The inducible expression of mdig could be observed in A549 cells exposed to silica particles in a time-dependent manner. The full-length mdig mRNA was expressed in human lung cancer tissues but was barely detectable in the adjacent normal tissues. In addition, a number of lung cancer cell lines constitutively express mdig. Alternative spliced transcripts of mdig were detected in some lung cancer cell lines. Silencing mdig mRNA expression in A549 lung cancer cells by siRNA-mediated RNA interference inhibits cell proliferation and sensitizes the cells to silica-induced cytotoxicity. These results suggest that the mdig gene may be involved in the regulation of cell growth and possibly the development of cancer.	NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Morgantown, WV 26505 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China; Penn State Univ, Coll Med, Dept Med, Hershey, PA 17033 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, F (corresponding author), NIOSH, Hlth Effects Lab Div, Pathol & Physiol Res Branch, Mail Stop 2015,1095 Willowdale Rd, Morgantown, WV 26505 USA.	LFD3@cdc.gov	Hu, Ruogu/B-2203-2008; Shi, Xianglin/B-8588-2012; Chen, Fei/A-3056-2008					BRODY AR, 1982, LAB INVEST, V47, P533; *CDC NIOSH, 2003, WORK REL LUNG DIS SU; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Garcia-Blanco MA, 2004, NAT BIOTECHNOL, V22, P535, DOI 10.1038/nbt964; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298, DOI 10.1164/ajrccm/136.2.298; Kuempel Eileen D., 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P15; LIANG P, 1992, CANCER RES, V52, P6966; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Martin RG, 1996, J BACTERIOL, V178, P2216, DOI 10.1128/jb.178.8.2216-2223.1996; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Nelson HH, 2002, ONCOGENE, V21, P7284, DOI 10.1038/sj.onc.1205804; Ortiz LA, 1999, AM J RESP CELL MOL, V20, P825, DOI 10.1165/ajrcmb.20.4.3193; Ortiz LA, 2001, AM J RESP CRIT CARE, V163, P244, DOI 10.1164/ajrccm.163.1.2002123; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; ROM WN, 1991, AM REV RESPIR DIS, V143, P408, DOI 10.1164/ajrccm/143.2.408; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; Tsuneoka M, 2002, J BIOL CHEM, V277, P35450, DOI 10.1074/jbc.M204458200; WEISSMAN DN, 1986, AM J MED SCI, V292, P187, DOI 10.1097/00000441-198610000-00001	20	58	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4873	4882		10.1038/sj.onc.1208668	http://dx.doi.org/10.1038/sj.onc.1208668			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897898				2022-12-17	WOS:000230646500001
J	Kim, D; Pemberton, H; Stratford, AL; Buelaert, K; Watkinson, JC; Lopes, V; Franklyn, JA; McCabe, CJ				Kim, D; Pemberton, H; Stratford, AL; Buelaert, K; Watkinson, JC; Lopes, V; Franklyn, JA; McCabe, CJ			Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells	ONCOGENE			English	Article						PTTG; thyroid cancer; ISSR-PCR; genetic instability	IN-SITU HYBRIDIZATION; GENOMIC INSTABILITY; CAUSES ANEUPLOIDY; HUMAN SECURIN; FISSR-PCR; EXPRESSION; CANCER; PAPILLARY; GROWTH; HPTTG	Cancer reflects the progressive accumulation of genetic alterations and subsequent genetic instability of cells. Cytogenetic studies have demonstrated the importance of aneuploidy in differentiated thyroid cancer development. The pituitary tumour transforming gene (PTTG), also known as securin, is a mitotic checkpoint protein which inhibits sister chromatid separation during mitosis. PTTG is highly expressed in many cancers and overexpression of PTTG induces aneuploidy in vitro. Using fluorescent intersimple sequence repeat PCR (FISSR-PCR), we investigated the relationship between PTTG expression and the degree of genetic instability in normal and tumorous thyroid samples. The genomic instability index (GI index) was 6.7 - 72.7% higher in cancers than normal thyroid tissues. Follicular thyroid tumours exhibited greater genetic instability than papillary tumours (27.6% (n =9) versus 14.5% (n = 10), P = 0.03). We also demonstrated a strong relationship between PTTG expression and the degree of genetic instability in thyroid cancers (R-2 = 0.80, P = 0.007). To further investigate PTTG's role in genetic instability, we transfected FTC133 thyroid follicular cells and observed increased genetic instability in cells overexpressing PTTG compared with vector-only-transfected controls (n = 3, GI Index VO = 29.7 +/- 5.2 versus PTTG = 63.7 +/- 6.4, P = 0.013). Further, we observed a dose response in genetic instability and PTTG expression ( GI Index low dose (0.5 mu g DNA/ six-well plate) PTTG = 15.3% +/- 1.7 versus high dose (3 mu g DNA) PTTG = 50.8% +/- 3.3, P = 0.006). Overall, we describe the first use of FISSR-PCR in human cancers, and demonstrate that PTTG expression correlates with genetic instability in vivo, and induces genetic instability in vitro. We conclude that PTTG may be an important gene in the mutator phenotype development in thyroid cancer.	Univ Birmingham, Div Med Sci, Birmingham B12 5TT, W Midlands, England	University of Birmingham	Kim, D (corresponding author), Univ Birmingham, Div Med Sci, 2nd Floor IBR, Birmingham B12 5TT, W Midlands, England.	daekim72@yahoo.co.uk						Barril N, 2000, CANCER GENET CYTOGEN, V117, P50, DOI 10.1016/S0165-4608(99)00143-0; Basik M, 1997, GENE CHROMOSOME CANC, V18, P19, DOI 10.1002/(SICI)1098-2264(199701)18:1<19::AID-GCC3>3.0.CO;2-4; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Dobosz T, 2000, ONCOLOGY-BASEL, V58, P305, DOI 10.1159/000012117; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Kumar LD, 2001, FORENSIC SCI INT, V116, P63, DOI 10.1016/S0379-0738(00)00350-9; LOEB LA, 1991, CANCER RES, V51, P3075; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; Mu YM, 2003, ENDOCR J, V50, P771, DOI 10.1507/endocrj.50.771; Nagao K, 2004, NATURE, V430, P1044, DOI 10.1038/nature02803; Nagaraju J, 2002, MOL CELL PROBE, V16, P67, DOI 10.1006/mcpr.2001.0404; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Saez C, 2002, ONCOGENE, V21, P8173, DOI 10.1038/sj.onc.1205954; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Stoler DL, 2002, HEAD NECK-J SCI SPEC, V24, P290, DOI 10.1002/hed.10050; TARUSCIO D, 1994, GENE CHROMOSOME CANC, V9, P180, DOI 10.1002/gcc.2870090306; Viswanathan M, 2003, CLIN CANCER RES, V9, P1057; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P825, DOI 10.1002/hed.10292; Yu R, 2000, J BIOL CHEM, V275, P36502, DOI 10.1074/jbc.C000546200; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200; ZIETKIEWICZ E, 1994, GENOMICS, V20, P176, DOI 10.1006/geno.1994.1151	33	58	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 14	2005	24	30					4861	4866		10.1038/sj.onc.1208659	http://dx.doi.org/10.1038/sj.onc.1208659			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15897900				2022-12-17	WOS:000230477900013
J	Soenen-Cornu, V; Tourino, C; Bonnet, ML; Guillier, M; Flamant, S; Kotb, R; Bernheim, A; Bourhis, JH; Preudhomme, C; Fenaux, P; Turhan, AG				Soenen-Cornu, V; Tourino, C; Bonnet, ML; Guillier, M; Flamant, S; Kotb, R; Bernheim, A; Bourhis, JH; Preudhomme, C; Fenaux, P; Turhan, AG			Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro	ONCOGENE			English	Article						mesenchymal stem cells; hematopoiesis; myelodysplasia	BONE-MARROW-TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; STEM-CELLS; SITU HYBRIDIZATION; PROGENITOR CELLS; STROMAL CELLS; SYNDROME MDS; CHEMOTHERAPY; INVOLVEMENT; ENGRAFTMENT	Myelodysplastic syndromes (MDS) are clonal malignant stem cell disorders characterized by inefficient hematopoiesis. The role of the marrow microenvironment in the pathogenesis of the disease has been controversial and no study has been performed so far to characterize mesenchymal cells ( MC) from MDS patients and to analyse their ability to support hematopoiesis. To this end, we have isolated and characterized MC at diagnostic marrow samples (n = 12) and have purified their CD34+CD38- and CD34+CD38- counterparts ( n = 7) before using MC as a short- and long-term hematopoietic support. We show that MC can be readily isolated from MDS marrow and exhibit a major expansion potential as well as an intact osteoblastic differentiation ability. They do not harbor the abnormal marker identified by FISH in the hematopoietic cells and they stimulate the growth of autologous clonogenic cells. Conversely, highly purified stem cells and their cytokine-expanded progeny harbor the clonal marker with variable frequencies, and both normal and abnormal long-term culture-initiating cell-derived progeny can be effectively supported by autologous MC. Thus, we demonstrate that MDS marrow is an abundant source of MC appearing both cytogenetically and functionally noninvolved by the malignant process and able to support hematopoiesis, suggesting their possible usefulness in future cell therapy approaches.	Inst Gustave Roussy, INSERM, U362, Dept Biol Clin, Villejuif, France; CHU Lille, INSERM, U524, F-59037 Lille, France; CHU Lille, Hematol Lab, F-59037 Lille, France; Inst Gustave Roussy, Translat Res Cell Therapy Lab, Villejuif, France; Inst Gustave Roussy, Dept Med, Villejuif, France; Inst Gustave Roussy, Dept Pathol, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Turhan, AG (corresponding author), Inst Gustave Roussy, INSERM, U362, Dept Biol Clin, Rue Camille Desmoulins, Villejuif, France.	turali@igr.fr	Soenen, Valérie/U-9080-2018; Preudhomme, Claude/T-8553-2018	Soenen, Valérie/0000-0002-4618-9377; Preudhomme, Claude/0000-0002-1267-9546; FLAMANT, Stephane/0000-0003-2295-5943; TURHAN, Ali/0000-0002-4861-0137				Aizawa S, 1999, LEUKEMIA RES, V23, P239, DOI 10.1016/S0145-2126(98)00163-5; Angelopoulou M, 2003, EXP HEMATOL, V31, P413, DOI 10.1016/S0301-472X(03)00042-0; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Bensidhoum M, 2004, BLOOD, V103, P3313, DOI 10.1182/blood-2003-04-1121; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; COUTINHO LH, 1990, BRIT J HAEMATOL, V75, P16, DOI 10.1111/j.1365-2141.1990.tb02611.x; Deans RJ, 2000, EXP HEMATOL, V28, P875, DOI 10.1016/S0301-472X(00)00482-3; Deeg HJ, 2000, LEUKEMIA LYMPHOMA, V37, P405, DOI 10.3109/10428190009089441; Deeg HJ, 2002, LEUKEMIA RES, V26, P687, DOI 10.1016/S0145-2126(02)00015-2; Delforge M, 1998, BRIT J HAEMATOL, V102, P486, DOI 10.1046/j.1365-2141.1998.00797.x; DeWitte T, 1997, BLOOD, V90, P3853; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guardiola P, 2002, BLOOD, V99, P4370, DOI 10.1182/blood.V99.12.4370; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963-6897(96)00279-5; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Mauritzson N, 1999, EUR J HAEMATOL, V62, P95; Nevill TJ, 1998, BLOOD, V92, P1910, DOI 10.1182/blood.V92.6.1910.418k30_1910_1917; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Saitoh K, 1998, BLOOD, V92, P2886, DOI 10.1182/blood.V92.8.2886.420k11_2886_2892; SOENEN V, 1995, BRIT J HAEMATOL, V90, P701, DOI 10.1111/j.1365-2141.1995.tb05604.x; 't Anker PS, 2003, EXP HEMATOL, V31, P881, DOI 10.1016/S0301-472X(03)00202-9; Thanopoulou E, 2004, BLOOD, V103, P4285, DOI 10.1182/blood-2003-09-3192; Tourino C, 2001, Hematol J, V2, P108, DOI 10.1038/sj.thj.6200083; TURHAN AG, 1995, BLOOD, V85, P2154, DOI 10.1182/blood.V85.8.2154.bloodjournal8582154; Wattel E, 1999, LEUKEMIA, V13, P524, DOI 10.1038/sj.leu.2401387	30	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2441	2448		10.1038/sj.onc.1208405	http://dx.doi.org/10.1038/sj.onc.1208405			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735749				2022-12-17	WOS:000228180600002
J	Wei, LH; Lai, KP; Chen, CA; Cheng, CH; Huang, YJ; Chou, CH; Kuo, ML; Hsieh, CY				Wei, LH; Lai, KP; Chen, CA; Cheng, CH; Huang, YJ; Chou, CH; Kuo, ML; Hsieh, CY			Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappa B	ONCOGENE			English	Article						arsenic trioxide; irradiation; matrix metalloproteinase-9; metastasis; nuclear factor kappa B	ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN CERVICAL-CANCER; CELL LUNG-CANCER; MATRIX METALLOPROTEINASES; IONIZING-RADIATION; HUMAN GLIOBLASTOMA; INDUCED APOPTOSIS; CLINICAL-TRIALS; GLIOMA-CELLS; IN-VITRO	Arsenic trioxide (ATO) has been implicated as a promising anticancer agent by inhibiting cell growth and inducing apoptosis in certain types of cancer cells. This study explored the antimetastasis property of arsenic, drew potential link between arsenic use and radiotherapy, and uncovered the specific mechanisms underlying these remarkable responses. Using gelatin invasion assay and intravasation assay, we report the novel finding that low-dose ATO (1 muM) reduced the intrinsic migration ability of HeLa cells and significantly inhibited radiation-promoted tumor invasive potential of CaSki cells without inducing apoptotic cell death. Using the murine Lewis lung carcinoma model, the control animals and ATO treatment animals (1 mg/kg i.p., twice weekly) displayed similar in vivo growth kinetics, where as the radiation (30 Gy in one fraction) and concurrent treatment groups showed considerable growth inhibition. Importantly, although concurrent treatment did not enhance the effectiveness of radiation therapy to the primary tumor, further examination of the lungs revealed that all animals succumbed to radiation-accelerated lung metastases could be effectively treated by combination of ATO and radiation. Radiation-induced matrix metalloproteinase-9 (MMP-9) expression was significantly inhibited by ATO using sequential analysis of the expression of MMPs in xenografts. Supporting this observation, ATO directly downregulates radiation-induced MMP-9 mRNA expression by inhibiting nuclear factor kappaB activity in human cervical cancer cells. In sum, concurrent arsenic radiation therapy not only achieves local tumor control but also inhibits distant metastasis. Experimental results of this study highlight a novel strategy in cancer treatment.	Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hsieh, CY (corresponding author), Natl Taiwan Univ Hosp, Dept Obstet & Gynecol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	cyhsieh@ha.mc.ntu.edu.tw	Wei, Lin-Hung/B-1188-2008; Huang, Ruby Yun-Ju/AAE-8854-2019; Kuo, Min-Liang/C-4872-2009	Huang, Ruby Yun-Ju/0000-0001-6376-3185; Wei, Lin-Hung/0000-0001-8789-0859; KUO, MIN-LIANG/0000-0002-7139-0144; CHEN, CHI-AN/0000-0001-6670-7939; CHENG, JASON CHIA-HSIEN/0000-0002-2007-0220				Achanzar WE, 2002, JNCI-J NATL CANCER I, V94, P1888, DOI 10.1093/jnci/94.24.1888; Azria D, 2003, B CANCER, V90, pS202; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Camphausen K, 2001, CANCER RES, V61, P2207; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Choy H, 1998, J CLIN ONCOL, V16, P3316, DOI 10.1200/JCO.1998.16.10.3316; Choy H, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00268-9; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Chun YJ, 2002, FEBS LETT, V519, P195, DOI 10.1016/S0014-5793(02)02765-5; Criswell T, 2003, ONCOGENE, V22, P5813, DOI 10.1038/sj.onc.1206680; Didelot C, 2001, INT J RADIAT ONCOL, V51, P1354, DOI 10.1016/S0360-3016(01)02608-6; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eichholtz-Wirth H, 2000, APOPTOSIS, V5, P255, DOI 10.1023/A:1009656513307; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gorski DH, 2003, CANCER RES, V63, P308; Hughes MF, 2002, TOXICOL LETT, V133, P1, DOI 10.1016/S0378-4274(02)00084-X; Inanami O, 2002, INT J RADIAT BIOL, V78, P267, DOI 10.1080/09553000110105695; Isaac N, 2002, CANCER, V95, P696, DOI 10.1002/cncr.10744; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Kondraganti S, 2000, CANCER RES, V60, P6851; Kwong YL, 1997, BLOOD, V89, P3487, DOI 10.1182/blood.V89.9.3487; Lew YS, 2002, CANCER RES, V62, P4202; LIEBMANN J, 1994, J NATL CANCER I, V86, P441, DOI 10.1093/jnci/86.6.441; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; McGinn CJ, 1996, J NATL CANCER I, V88, P1193, DOI 10.1093/jnci/88.17.1193; Miller WH, 2002, CANCER RES, V62, P3893; Miyamoto S, 2004, CANCER RES, V64, P665, DOI 10.1158/0008-5472.CAN-03-1916; Murgo AJ, 2001, ONCOLOGIST, V6, P22, DOI 10.1634/theoncologist.6-suppl_2-22; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Qian LW, 2002, CLIN CANCER RES, V8, P1223; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Sienel W, 2003, INT J CANCER, V103, P647, DOI 10.1002/ijc.10841; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Strand S, 2004, ONCOGENE, V23, P3732, DOI 10.1038/sj.onc.1207387; Tanioka Y, 2003, BRIT J CANCER, V89, P2116, DOI 10.1038/sj.bjc.6601372; van Kempen LCL, 2002, CANCER CELL, V2, P251, DOI 10.1016/S1535-6108(02)00157-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; Wick W, 2002, CANCER RES, V62, P1915; Wild-Bode C, 2001, CANCER RES, V61, P2744; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047; Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437	56	58	62	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					390	398		10.1038/sj.onc.1208192	http://dx.doi.org/10.1038/sj.onc.1208192			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531921				2022-12-17	WOS:000226279700010
J	Hwang, CY; Ryu, YS; Chung, MS; Kim, KD; Park, SS; Chae, SK; Chae, HZ; Kwon, KS				Hwang, CY; Ryu, YS; Chung, MS; Kim, KD; Park, SS; Chae, SK; Chae, HZ; Kwon, KS			Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1	ONCOGENE			English	Article						tumor progression; redox signaling; transcription coactivator; cell cycle	DOMAIN-BINDING PROTEIN-1; NF-KAPPA-B; COP9 SIGNALOSOME; TRANSCRIPTION FACTORS; INHIBITOR P27(KIP1); DIRECT ASSOCIATION; OXIDATIVE STRESS; REDOX REGULATION; CELL-CYCLE; EXPRESSION	Thioredoxin (Trx) is a cellular redox enzyme that plays multiple roles in regulating cell growth and apoptosis. Jun activation domain-binding protein 1 (Jab1) was originally identified as a coactivator of activator protein 1 (AP-1) transcription and was also shown to promote degradation of the cyclin-dependent kinase inhibitor, p27Kip1. Recently, Jab1 expression was associated with the progression and poor prognosis of pituitary, epithelial ovarian, and breast cancers, suggesting that it plays a role in oncogenesis. Here, we report that Trx specifically interacts with and modulates the function of Jab1. Fluorescence resonance energy transfer and co-immunoprecipitation studies revealed that Trx and Jab1 colocalize and directly interact with each other. Further, Trx negatively regulates two important Jab1-controlled signaling pathways, activation of AP-1 transcription and degradation of p27Kip1, probably through a direct interaction between Trx and C-terminal of Jab1. The negative effect of Trx on AP-1 activity is Jab1-dependent, as it disappears when Jab1 levels are suppressed by an antisense approach. In addition, Trx competes with p27Kip1 for Jab1 binding. Taken together, our results suggest that Trx may regulate cell cycle and growth through a novel modulation of Jab1-mediated proliferation signals, further indicating that Trx may have the ability to control tumor progression.	Korea Res Inst Biosci & Biotechnol, Ctr Syst Biol, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305333, South Korea; PaiChai Univ, Div Life Sci, Taejon 302735, South Korea; Chonnam Natl Univ, Sch Biol Sci & Technol, Kwangju 500757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Pai Chai University; Chonnam National University	Kwon, KS (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Syst Biol, 52 Oun Dong, Taejon 305333, South Korea.	kwonks@kribb.re.kr		Chae, Suhn-Kee/0000-0003-2164-1053				Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chen XX, 2003, J BIOL CHEM, V278, P49022, DOI 10.1074/jbc.M304057200; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Deng XW, 2000, TRENDS GENET, V16, P202, DOI 10.1016/S0168-9525(00)01982-X; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ito Y, 2003, ANTICANCER RES, V23, P4121; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Karpova TS, 2003, J MICROSC-OXFORD, V209, P56, DOI 10.1046/j.1365-2818.2003.01100.x; Kleemann R, 1999, EUR J BIOCHEM, V261, P753, DOI 10.1046/j.1432-1327.1999.00327.x; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P2635, DOI 10.1210/jc.87.6.2635; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li SH, 2000, J BIOL CHEM, V275, P13386, DOI 10.1074/jbc.275.18.13386; Lu CR, 2002, FASEB J, V16, P90, DOI 10.1096/fj.01-0506fje; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Patterson GH, 2000, ANAL BIOCHEM, V284, P438, DOI 10.1006/abio.2000.4708; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Senkevich TG, 2000, P NATL ACAD SCI USA, V97, P12068, DOI 10.1073/pnas.210397997; Sui L, 2001, CLIN CANCER RES, V7, P4130; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Truong K, 2001, CURR OPIN STRUC BIOL, V11, P573, DOI 10.1016/S0959-440X(00)00249-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yodoi J, 2001, BIOFACTORS, V15, P107, DOI 10.1002/biof.5520150212	40	58	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8868	8875		10.1038/sj.onc.1208116	http://dx.doi.org/10.1038/sj.onc.1208116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15480426				2022-12-17	WOS:000225354600002
J	Shiozawa, T; Miyamoto, T; Kashima, H; Nakayama, K; Nikaido, T; Konishi, I				Shiozawa, T; Miyamoto, T; Kashima, H; Nakayama, K; Nikaido, T; Konishi, I			Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence	ONCOGENE			English	Article						endometrium; endometrial carcinoma; estrogen; cyclin; AP-1	BREAST-CANCER CELLS; GENE-EXPRESSION; IMMUNOHISTOCHEMICAL ANALYSIS; PROMOTER; PROTEIN; GROWTH; FOS; RECEPTOR; ELEMENT; PROTOONCOGENE	To explore the mechanism of estrogen-induced growth of normal endometrium, the transactivation system of the cyclin D1 gene was analysed using cultured normal endometrial glandular cells. Estradiol (E2) treatment of cultured normal endometrial glandular cells induced upregulation of c-Jun, and then cyclin D1 proteins, followed by serial expressions of cyclins E, A and B1 proteins. Increase in the mRNA expression of cyclin D1 preceded the protein expression of cyclin D1 under E2 treatment. A luciferase assay using deletion constructs of the cyclin D1 promoter indicated that E2-induced increase in transcriptional activity was observed in reporters containing AP-1-binding site sequence, and that in the absence of E2, cotransfection of c-Jun also showed increase of transcriptional activity in the same reporters with AP-1 sequence. A gel shift assay using nuclear extract from E2-treated endometrial glandular cells and AP-1 sequences of the cyclin D1 promoter indicated specific binding between c-Jun protein and the promoter. Transfection of c-jun antisense oligonucleotides to the glandular cells resulted in the suppression of the E2-induced upregulation of cyclin D1 mRNA and protein. These findings suggest that E2-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to the AP-1 sequences.	Shinshu Univ, Sch Med, Dept Obstet & Gynecol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Anat 2, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Grad Sch Med, Dept Organ Regenerat, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University; Shinshu University	Shiozawa, T (corresponding author), Shinshu Univ, Sch Med, Dept Obstet & Gynecol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tanri@hsp.md.shinshu-u.ac.jp	Miyamoto, Tsutomu/ADW-0798-2022	Miyamoto, Tsutomu/0000-0002-1513-9473				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Altucci L, 1996, ONCOGENE, V12, P2315; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; GIUDICE LC, 1994, FERTIL STERIL, V61, P1; GRONROOS M, 1987, ANN CHIR GYNAECOL FE, V76, P76; HERBER B, 1994, ONCOGENE, V9, P1295; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; Kaneuchi M, 2003, INT J ONCOL, V22, P159; Kawasaki S, 1999, BIOCHEM BIOPH RES CO, V263, P560, DOI 10.1006/bbrc.1999.1402; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; LESSEY BA, 1988, J CLIN ENDOCR METAB, V67, P334, DOI 10.1210/jcem-67-2-334; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Li SF, 1996, CANCER, V77, P321, DOI 10.1002/(SICI)1097-0142(19960115)77:2<321::AID-CNCR15>3.0.CO;2-3; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; LURAIN JR, 2002, UTERINE CANC NOVAKS, P1143; Miao ZH, 2003, CANCER RES, V63, P4527; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; Nikaido T, 1996, CANCER, V78, P1248, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1248::AID-CNCR12>3.3.CO;2-U; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Salmi A, 1998, J CLIN ENDOCR METAB, V83, P1788, DOI 10.1210/jc.83.5.1788; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shiozawa T, 2001, CANCER, V92, P3005, DOI 10.1002/1097-0142(20011215)92:12<3005::AID-CNCR10153>3.0.CO;2-6; Shiozawa T, 1997, CANCER, V80, P2250, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2250::AID-CNCR5>3.0.CO;2-Y; Shiozawa T, 2001, ENDOCRINOLOGY, V142, P4182, DOI 10.1210/en.142.10.4182; Shiozawa T, 1996, MOL HUM REPROD, V2, P745, DOI 10.1093/molehr/2.10.745; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SPEROFF L, 1999, FEMALE INFERTILITY C, P1014; STRAUSS J, 1999, ENDOMETRIUM MYOMETRI, P218; Takano Y, 2000, AM J PATHOL, V156, P585, DOI 10.1016/S0002-9440(10)64763-3; TSENG L, 1980, CYCLIC CHANGE ESTRAD, P211; WEBB DK, 1993, ENDOCRINOLOGY, V133, P20, DOI 10.1210/en.133.1.20; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Yan YX, 1997, J BIOL CHEM, V272, P33181, DOI 10.1074/jbc.272.52.33181	44	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8603	8610		10.1038/sj.onc.1207849	http://dx.doi.org/10.1038/sj.onc.1207849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467760	Bronze			2022-12-17	WOS:000224988800006
J	Beyne-Rauzy, O; Recher, C; Dastugue, N; Demur, C; Pottier, G; Laurent, G; Sabatier, L; Mansat-De Mas, V				Beyne-Rauzy, O; Recher, C; Dastugue, N; Demur, C; Pottier, G; Laurent, G; Sabatier, L; Mansat-De Mas, V			Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells	ONCOGENE			English	Article						TNF alpha; senescence; AML cells; genetic instability	COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; OXIDATIVE DNA-DAMAGE; INDUCED APOPTOSIS; TELOMERASE ACTIVITY; ULCERATIVE-COLITIS; TNF-ALPHA; CERAMIDE; EXPRESSION; LINES	Previous studies have documented that Tumor necrosis factor alpha (TNFalpha) is a potent negative regulator of normal hematopoiesis. However, the mechanism by which TNFalpha acts at the cellular level is not totally understood. Although apoptotic cell killing appears to be the most common cellular effect of TNFalpha, other studies suggest that this cytokine may elicit other cellular responses such as prolonged growth inhibition. In this context, we have investigated whether TNFalpha may induce senescence in hematopoietic cells, which display intrinsic defect in the apoptotic machinery. The present study described that, in the leukemic KG1 cells, TNFalpha induced no apoptosis but a senescence state characterized by prolonged growth arrest, increased beta-galactosidase activity, p21(WAF-1) induction, decreased telomerase activity, telomeric disturbances ( shortening, losses, fusions), and additional chromosomal aberrations. Telomerase inhibition correlated with reduced levels of hTERT transcripts. GM-CSF prevented TNFalpha effects and allowed leukemic cells to recover growth capacity. Finally, our study shows for the first time that, at least in some hematopoietic cells, TNFalpha may induce senescence with important functional consequences, including sustained growth inhibition and genetic instability, and that this cellular response is efficiently regulated by hematopoietic growth factors.	Ctr Physiopathol Toulouse Purpan, INSERM, U563, F-31059 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France; CHU Purpan, Hematol Lab, F-31059 Toulouse, France; CEA, DSV, DRR, LRO, F-92265 Fontenay Aux Roses, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; CHU de Toulouse; CEA	Mansat-De Mas, V (corresponding author), Hop Purpan, Hematol Lab, Pavillon Caubet,Pl Dr Baylac, F-31059 Toulouse, France.	demas.v@chu-toulouse.fr	De Mas, Véronique/P-2414-2014; Beyne-Rauzy, Odile OBR/G-6560-2013; Beyne-Rauzy, Odile/AAN-1873-2020	Beyne-Rauzy, Odile/0000-0003-0321-6029; Sabatier, Laure/0000-0003-0552-6549				Akiyama M, 2002, CANCER RES, V62, P3876; BALOCH Z, 1990, J IMMUNOL, V145, P2908; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, J ANAT, V197, P529, DOI 10.1046/j.1469-7580.2000.19740529.x; Dybedal I, 2001, BLOOD, V98, P1782, DOI 10.1182/blood.V98.6.1782; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Kitagawa M, 1997, LEUKEMIA, V11, P2049, DOI 10.1038/sj.leu.2400844; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Mathieu N, 2004, CELL MOL LIFE SCI, V61, P641, DOI 10.1007/s00018-003-3296-0; MURASE T, 1987, BLOOD, V69, P467; Nathan I, 2000, CYTOKINE, V12, P881, DOI 10.1006/cyto.1999.0638; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; OSTER W, 1989, J CLIN INVEST, V84, P451, DOI 10.1172/JCI114186; Park YM, 1998, J CELL PHYSIOL, V174, P27, DOI 10.1002/(SICI)1097-4652(199801)174:1<27::AID-JCP4>3.0.CO;2-I; Quentmeier H, 2000, EXP HEMATOL, V28, P1008, DOI 10.1016/S0301-472X(00)00516-6; QuilletMary A, 1996, LEUKEMIA, V10, P417; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; TOBLER A, 1987, BLOOD, V70, P200; Tsukada Y, 2002, AM J GASTROENTEROL, V97, P2820; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Young NS, 2000, SEMIN HEMATOL, V37, P3, DOI 10.1016/S0037-1963(00)90026-X; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	31	58	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7507	7516		10.1038/sj.onc.1208024	http://dx.doi.org/10.1038/sj.onc.1208024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326480				2022-12-17	WOS:000224176500007
J	Chang, YS; Wang, L; Suh, YA; Mao, L; Karpen, SJ; Khuri, FR; Hong, WK; Lee, HY				Chang, YS; Wang, L; Suh, YA; Mao, L; Karpen, SJ; Khuri, FR; Hong, WK; Lee, HY			Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer	ONCOGENE			English	Article						insulin-like growth factor-binding protein-3; methyl-CpG-binding protein; non-small-cell lung cancer	HISTONE DEACETYLASE INHIBITOR; BRONCHIAL EPITHELIAL-CELLS; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; CPG METHYLATION; RETINOIC ACID; HEPATOCELLULAR-CARCINOMA; CHROMOSOMAL PROTEIN; INDUCED APOPTOSIS; GENE-EXPRESSION	Expression of insulin-like growth factor-binding protein-3, which (IGFBP-3) inhibits the proliferation of non-small-cell lung cancer (NSCLC) cells by inducing apoptosis, is lost in about half of stage I NSCLC cases. Since promoter methylation can silence gene expression, we investigated whether hypermethylation of the IGFBP-3 promoter is involved in loss of IGFBP-3 expression in NSCLC. We found the IGFBP-3 promoter to be methylated in seven of 13 NSCLC cell lines and in 16 of 23, seven of 9, eight of 11, and six of six tumor specimens from patients with stage I, II, III, and IV NSCLC, respectively. Methylation status correlated with IGFBP-3 mRNA and protein levels in a subset of NSCLC cell lines tested in our study. However, treatment with 5'-aza-2'-deoxycytidine (5'-aza- dC) restored IGFBP-3 expression in four of seven NSCLC cell lines with the methylated promoter, suggesting that multiple mechanisms regulate IGFBP-3 expression in NSCLC. Gel shift and chromatin immunoprecipitation assays showed that methylation of the Sp-1/ Sp-3-binding element in the IGFBP-3 promoter influenced the binding of Sp-1, methyl-CpG-binding protein-2 (MeCP2), and histone deacetylase ( HDAC). A luciferase construct expressing IGFBP-3 promoter in which the Sp1/ Sp-3-binding element was methylated showed significantly reduced transcriptional activity. The reduction in promoter activity was further suppressed by overexpression of MeCP2, which was rescued by 5'-aza- dC. Thus interference with Sp-1 transactivation by MeCP2 may contribute to the transcriptional defect of IGFBP-3 expression in NSCLC cells with methylated promoter.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Texas Childrens Liver Ctr, Houston, TX 77030 USA; Emory Univ, Sch Med, Winship Canc Ctr, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Emory University	Lee, HY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	hlee@mdanderson.org	Mao, Li/C-7570-2011; Khuri, Fadlo R./AAU-4942-2020	Mao, Li/0000-0001-7263-3358; Khuri, Fadlo R./0000-0002-8638-7618; Chang, Yoon Soo/0000-0003-3340-4223; Lee, Ho-Young/0000-0001-7556-9312	NCI NIH HHS [1R01 CA10081-01A1] Funding Source: Medline; NIDDK NIH HHS [R01 DK056239] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Chang YS, 2002, CLIN CANCER RES, V8, P3796; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Clark SJ, 1997, GENE, V195, P67, DOI 10.1016/S0378-1119(97)00164-9; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; DEAR C, 2001, J CLIN ENDOCR METAB, V86, P1274; Fowler CA, 2000, INT J CANCER, V88, P448, DOI 10.1002/1097-0215(20001101)88:3<448::AID-IJC18>3.3.CO;2-M; Graessmann M, 1993, EXS, V64, P404; Gray SG, 2000, INT J MOL MED, V5, P33; Gucev ZS, 1996, CANCER RES, V56, P1545; Hanafusa T, 2002, CANCER LETT, V176, P149, DOI 10.1016/S0304-3835(01)00736-4; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kaludov NK, 2000, NUCLEIC ACIDS RES, V28, P1921, DOI 10.1093/nar/28.9.1921; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kim SK, 1997, CANCER RES, V57, P400; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lee HY, 1998, J CLIN INVEST, V101, P1012, DOI 10.1172/JCI1329; Lee HY, 2002, CANCER RES, V62, P3530; Lee HY, 1997, CELL GROWTH DIFFER, V8, P283; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Nakao M, 2001, BRAIN DEV-JPN, V23, pS174, DOI 10.1016/S0387-7604(01)00348-5; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; ZHANG XY, 1986, NUCLEIC ACIDS RES, V14, P8387, DOI 10.1093/nar/14.21.8387; Zi XL, 2000, CANCER RES, V60, P5617	50	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6569	6580		10.1038/sj.onc.1207882	http://dx.doi.org/10.1038/sj.onc.1207882			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15247904				2022-12-17	WOS:000223530800004
J	Theodorou, V; Boer, M; Weigelt, B; Jonkers, J; van der Valk, M; Hilkens, J				Theodorou, V; Boer, M; Weigelt, B; Jonkers, J; van der Valk, M; Hilkens, J			Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas	ONCOGENE			English	Article						mammary cancer; Fgf10; Wnt1; MMTV; insertional mutagenesis	KERATINOCYTE GROWTH-FACTOR; PROVIRAL INSERTION; IN-VIVO; EXPRESSION; GENE; CANCER; VIRUS; DIFFERENTIATION; TUMORIGENESIS; RECEPTOR	Mouse mammary tumor virus (MMTV) infection causes a high incidence of murine mammary carcinomas by insertion of its proviral DNA in the genome of mammary epithelial cells. Retroviral insertion can activate flanking proto-oncogenes by a process called insertional mutagenesis. By sequencing the DNA adjacent to MMTV proviral insertions in mammary tumors from BALB/c mice infected with C3H-MMTV, we have found a common MMTV insertion site in the Fgf10 locus. RT-PCR studies showed that Fgf10 is expressed only in those tumors harboring a MMTV proviral insertion in this locus, suggesting that Fgf10 is a proto-oncogene. The oncogenicity of Fgf10 was evaluated in vivo by subcutaneous transplantation of retrovirally transduced HC11 mammary epithelial cells into BALB/c mice. Highly vascularized invasive subcutaneous tumors developed indicating that Fgf10 can act as an oncogene. A survey of primary human breast carcinomas revealed strongly elevated Fgf10 mRNA levels in approximately 10% of the tumors tested, suggesting that Fgf10 may also be involved in oncogenicity of a subset of human breast cancers.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Oncol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Hilkens, J (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.hilkens@nki.nl	Theodorou, Vasiliki/GON-4996-2022; Jonkers, Jos/AAG-3246-2019; Theodorou, Vasiliki/H-1576-2016	Jonkers, Jos/0000-0002-9264-9792; Theodorou, Vasiliki/0000-0003-1614-700X; Hilkens, John/0000-0002-0932-7793				Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bansal GS, 1997, BRIT J CANCER, V75, P1567, DOI 10.1038/bjc.1997.269; BANSAL GS, 1995, BRIT J CANCER, V72, P1420, DOI 10.1038/bjc.1995.524; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bittner J J, 1939, Am J Cancer, V35, P90; Bosma AJ, 2002, CLIN CANCER RES, V8, P1871; Callahan R, 2000, ONCOGENE, V19, P992, DOI 10.1038/sj.onc.1203276; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Igarashi M, 1998, J BIOL CHEM, V273, P13230, DOI 10.1074/jbc.273.21.13230; IVANYI D, 1989, J PATHOL, V159, P7, DOI 10.1002/path.1711590105; Jackson D, 1997, J MAMMARY GLAND BIOL, V2, P385, DOI 10.1023/A:1026351414004; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Mailleux AA, 2002, DEVELOPMENT, V129, P53; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MERLO GR, 1993, ANN NY ACAD SCI, V698, P108, DOI 10.1111/j.1749-6632.1993.tb17195.x; Michiels F, 2000, METHOD ENZYMOL, V325, P295; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mikkers H, 2002, ONCOGENE, V21, P6559, DOI 10.1038/sj.onc.1205930; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; MORRIS VL, 1991, ONCOGENE RES, V6, P53; Ngan ESW, 2002, P NATL ACAD SCI USA, V99, P11187, DOI 10.1073/pnas.172366199; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Ornitz DM, 2001, GENOME BIOL, V2; Palmieri C, 2003, J ENDOCRINOL, V177, P65, DOI 10.1677/joe.0.1770065; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; QURESHI SJ, 1994, GENET ANAL-BIOMOL E, V11, P95, DOI 10.1016/1050-3862(94)90046-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Spencer-Dene B, 2001, ENDOCR-RELAT CANCER, V8, P211, DOI 10.1677/erc.0.0080211; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; Suzuki K, 2000, FEBS LETT, V481, P53, DOI 10.1016/S0014-5793(00)01968-2; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka A, 2002, VIRCHOWS ARCH, V441, P380, DOI 10.1007/s00428-002-0687-9; Taniguchi F, 2003, J CLIN ENDOCR METAB, V88, P773, DOI 10.1210/jc.2002-021062; VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P45; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	51	58	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6047	6055		10.1038/sj.onc.1207816	http://dx.doi.org/10.1038/sj.onc.1207816			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208658				2022-12-17	WOS:000223261000004
J	Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A				Kamio, M; Yoshida, T; Ogata, H; Douchi, T; Nagata, Y; Inoue, M; Hasegawa, M; Yonemitsu, Y; Yoshimura, A			SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein	ONCOGENE			English	Article						cytokine; SOCS; papilloma viruses; interferon gamma; E7; proteasome	HUMAN PAPILLOMAVIRUS TYPE-16; SENDAI-VIRUS; SIGNAL-TRANSDUCTION; GROWTH-SUPPRESSION; NEGATIVE REGULATOR; GENE-TRANSFER; CELL-LINES; BOX MOTIF; INTERFERON; SOCS-1	Human papilloma viruses (HPVs) are small double-stranded DNA viruses that infect mucosal and cutaneous epithelium and induce cervical cancer. It has been shown that interferon (IFN)gamma suppresses proliferation of HPV-infected cells by suppressing expression of HPV E7. Here, we found that IFNgamma induces not only suppression of E7 transcription but also proteasome-dependent degradation. Suppressor of cytokine signaling-1 (SOCS1)/JAB, a suppressor of cytokine signaling, is known to be induced by IFNgamma, and functions as an antioncogene against various hematopoietic oncogenic proteins. SOCS1 contains the SOCS-box, which is shown to recruit ubiquitin transferase to the molecules that interact with SOCS1. We found that SOCS1 interacted with HPV E7 protein and induced ubiquitination and degradation of E7 in a SOCS-box-dependent manner. SOCS1 overexpression also increased Rb protein levels and suppressed proliferation of cervical cancer cell lines infected with HPV. Moreover, E7 protein levels were higher and Rb protein levels were lower in SOCS1-deficient fibroblasts infected with retrovirus vector carrying E7 gene than in wild-type fibroblasts. E7 induced anchorage-independent growth in SOCS1-deficient fibroblasts, but not in wild-type cells. These data suggested that SOCS1 plays an important role in regulating the levels of E7 protein and their transforming potential, and could be a new therapeutic tool for HPV-mediated tumors.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kagoshima Univ, Fac Med, Dept Obstet & Gynecol, Kagoshima 8900054, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higash Ku, Fukuoka 8128582, Japan	Kyushu University; Kagoshima University; DNAVEC Corporation; Kyushu University	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Galm O, 2003, BLOOD, V101, P2784, DOI 10.1182/blood-2002-06-1735; Gross G, 1997, INTERVIROLOGY, V40, P368, DOI 10.1159/000150569; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Ilangumaran S, 2003, J BIOL CHEM, V278, P41871, DOI 10.1074/jbc.M308382200; Jeon JH, 2002, EXP MOL MED, V34, P496, DOI 10.1038/emm.2002.69; Jones DL, 1996, SEMIN CANCER BIOL, V7, P327, DOI 10.1006/scbi.1996.0042; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; Kawazoe Y, 2001, J EXP MED, V193, P263, DOI 10.1084/jem.193.2.263; Kim KY, 2000, J GEN VIROL, V81, P695, DOI 10.1099/0022-1317-81-3-695; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Koromilas AE, 2001, CYTOKINE GROWTH F R, V12, P157, DOI 10.1016/S1359-6101(00)00023-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MUNGER K, 1989, J VIROL, V63, P4417; Nagai H, 2003, J HUM GENET, V48, P65, DOI 10.1007/s100380300008; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAN TMC, 1995, CANCER RES, V55, P4599; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Um SJ, 2000, INT J CANCER, V85, P416, DOI 10.1002/(SICI)1097-0215(20000201)85:3<416::AID-IJC19>3.3.CO;2-V; Venturini F, 1999, NUCLEIC ACIDS RES, V27, P1585, DOI 10.1093/nar/27.7.1585; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WOODWORTH CD, 1992, CANCER RES, V52, P456; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yonemitsu Y, 1998, INT J ONCOL, V12, P1277; Yonemitsu Y, 2000, NAT BIOTECHNOL, V18, P970, DOI 10.1038/79463; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	48	58	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3107	3115		10.1038/sj.onc.1207453	http://dx.doi.org/10.1038/sj.onc.1207453			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15021916	Bronze			2022-12-17	WOS:000220845200015
J	Bedrosian, I; Lu, KH; Verschraegen, C; Keyomarsi, K				Bedrosian, I; Lu, KH; Verschraegen, C; Keyomarsi, K			Cyclin E deregulation alters the biologic properties of ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; cyclin E; cell cycle; lovastatin	TUMOR BREAST CELLS; POTENTIAL PROGNOSTIC MARKER; E EXPRESSION; LUNG-CANCER; G1 ARREST; SURVIVAL; OVEREXPRESSION; PROLIFERATION; AMPLIFICATION; SENSITIVITY	We have previously shown that the low molecular weight (LMW) forms (trunk 1 and trunk 2) of cyclin E are biochemically hyperactive and induce G1/S progression in normal epithelial cells. Here we investigate the biologic consequences of LMW cyclin E expression in ovarian cancer cells. Using a panel of ovarian carcinoma tumors we find that cyclin E overexpression is invariably due to the presence of LMW forms and that expression of these forms appears to correlate with more advanced grade and stage of disease. Despite similar expression of p21 and p27, cyclin E overexpressing tumors have higher kinase function. Using an isogenic ovarian cancer model, we find that clones that overexpress the trunk 1 (T1) protein have a 10-fold increase in cyclin E kinase function, a 20% increase in S-phase fraction, a 10-15% decrease in doubling time and a 20% increase in colony formation compared to parental cells that express only the FL cyclin E protein. T1 clones were resistant to G1 arrest but more sensitive to cisplatin. Therefore, in ovarian tumors, the presence of LMW cyclin E forms confers altered biologic properties. Our data provides a potential mechanism for the poor prognosis of patients with LMW cyclin E expressing tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA; Univ New Mexico, Canc Res & Treatment Ctr, Dept Expt Therapeut, Albuquerque, NM 87131 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of New Mexico	Keyomarsi, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Box 66, Houston, TX 77030 USA.	kkeyomar@mdanderson.org	Verschraegen, Claire/AAE-7620-2020; Keyomarsi, Khandan/H-2716-2016	Verschraegen, Claire/0000-0001-6544-3089; Keyomarsi, Khandan/0000-0002-5440-0849	NCI NIH HHS [T32-CA09599-14, R01-CA87548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009599, R01CA087548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKLI S, 2003, CANCER BIOL THER, V2, P16; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cappella P, 2001, INT J CANCER, V93, P401, DOI 10.1002/ijc.1351; Chen XM, 1999, ONCOGENE, V18, P5691, DOI 10.1038/sj.onc.1202948; Del Pizzo JJ, 1999, AM J PATHOL, V155, P1129, DOI 10.1016/S0002-9440(10)65216-9; Farley J, 2003, CANCER RES, V63, P1235; Fukuse T, 2000, CANCER RES, V60, P242; GrayBablin J, 1997, CANCER RES, V57, P604; Harwell RM, 2000, CANCER RES, V60, P481; Itamochi H, 2002, ONCOLOGY-BASEL, V62, P349, DOI 10.1159/000065067; Jang SJ, 1999, EUR J SURG ONCOL, V25, P157, DOI 10.1053/ejso.1998.0619; Johnson KR, 1997, CLIN CANCER RES, V3, P1739; KEYOMARSI K, 1994, CANCER RES, V54, P380; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; Kolfschoten GM, 2000, BRIT J CANCER, V83, P921, DOI 10.1054/bjoc.2000.1373; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Mishina T, 2000, CLIN CANCER RES, V6, P11; Muller-Tidow C, 2001, CANCER RES, V61, P647; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Sangfelt O, 1999, ONCOGENE, V18, P2798, DOI 10.1038/sj.onc.1202609; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith ML, 2000, ANTICANCER RES, V20, P2537; Sui L, 2001, GYNECOL ONCOL, V83, P56, DOI 10.1006/gyno.2001.6308; Wang XD, 2003, ONCOGENE, V22, P769, DOI 10.1038/sj.onc.1206166; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wingate H, 2003, CELL CYCLE, V2, P461, DOI 10.4161/cc.2.5.464	35	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2648	2657		10.1038/sj.onc.1207408	http://dx.doi.org/10.1038/sj.onc.1207408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	15007381				2022-12-17	WOS:000220714900006
J	Montano, MM; Deng, HY; Liu, M; Sun, XY; Singal, R				Montano, MM; Deng, HY; Liu, M; Sun, XY; Singal, R			Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications	ONCOGENE			English	Article						estrogen receptor; antiestrogens; glutathione-S-transferase; gamma-glutamylcysteine synthetase	GLUTATHIONE-S-TRANSFERASE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; QUINONE REDUCTASE GENE; BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; SUBUNIT GENE; P1 GENE; TELOMERASE ACTIVITY; DRUG-RESISTANCE; EXPRESSION	We previously reported that antiestrogen-liganded estrogen receptor beta (ERbeta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR)(NAD(P) H:-quinone oxidoreductase). Our studies also indicate that upregulation of QR, either by overexpression or induction by tamoxifen, can protect breast cells against oxidative DNA damage caused by estrogen metabolites. We now report on the upregulation of glutathione S-transferases Pi (GST-Pi) and gamma-glutamylcysteine synthetase heavy subunit (GCSh) expression by antiestrogens. Studies indicate the regulation of GST-Pi and GCSh transcriptional activity by ER. While ER regulation is mediated by an electrophile response element (EpRE), we identified mechanistic differences in the involvement of other transcription factors. Regardless of these differences, ERbeta-mediated regulation of GST-Pi and GCSh point towards an important role for ERbeta in cellular protection against oxidative stress. A protective role is supported by our observation of inhibition of estrogen-induced DNA damage upon upregulation of GST-Pi and GCSh expression.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44102 USA; Univ Miami, Dept Med, Miami, FL 33136 USA	Case Western Reserve University; University of Miami	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu			NCI NIH HHS [CA80959] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bianco NR, 2002, ONCOGENE, V21, P5233, DOI 10.1038/sj.onc.1205645; CHA YN, 1982, CANCER RES, V42, P2609; Dahl EL, 2001, TOXICOL SCI, V61, P265, DOI 10.1093/toxsci/61.2.265; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Esteller M, 1998, CANCER RES, V58, P4515; Gamcsik MP, 2002, BIOCHEM PHARMACOL, V63, P843, DOI 10.1016/S0006-2952(01)00931-5; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hellriegel ET, 1996, BIOCHEM PHARMACOL, V52, P1561, DOI 10.1016/S0006-2952(96)00560-6; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jhaveri MS, 1998, BBA-GENE STRUCT EXPR, V1396, P179, DOI 10.1016/S0167-4781(97)00187-5; Kyo S, 1999, CANCER RES, V59, P5917; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; Matsumoto M, 2000, BIOCHEM J, V349, P225, DOI 10.1042/0264-6021:3490225; Maugard CM, 2001, INT J CANCER, V91, P334, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1057>3.0.CO;2-H; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229; Mizutani K, 2000, J HYPERTENS, V18, P1833, DOI 10.1097/00004872-200018120-00018; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nanni S, 2002, J CLIN INVEST, V110, P219, DOI 10.1172/JCI200215552; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; STRANGE RC, 2001, MUTAT RES, V82, P21; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237; TEW KD, 1994, CANCER RES, V54, P4313; Walsh AC, 2001, TOXICOL SCI, V61, P218, DOI 10.1093/toxsci/61.2.218; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zhang Y, 2003, J STEROID BIOCHEM, V85, P401, DOI 10.1016/S0960-0760(03)00230-9	44	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2442	2453		10.1038/sj.onc.1207358	http://dx.doi.org/10.1038/sj.onc.1207358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676828				2022-12-17	WOS:000220558000002
J	Black, EJ; Clair, T; Delrow, J; Neiman, P; Gillespie, DAF				Black, EJ; Clair, T; Delrow, J; Neiman, P; Gillespie, DAF			Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun	ONCOGENE			English	Article						v-Jun; autotaxin; microarray; lysophospholipase; angiogenesis	HYPOXIA-INDUCIBLE FACTOR-1; ESTROGEN RECEPTOR CHIMERA; C-JUN; TRANSCRIPTIONAL ACTIVATION; GROWTH; GENE; PROTEIN; DNA; FIBROBLASTS; EXPRESSION	We have used chicken cDNA microarrays to investigate gene-expression changes induced during transformation of chick embryo fibroblasts (CEF) by the viral Jun oncoprotein encoded by ASV17. This analysis reveals that v-Jun induces increases and decreases of varying magnitude in the expression of genes involved in diverse cellular functions, most of which have not been detected in previous screens for putative v-Jun targets. In all, 27 individual genes were identified, whose expression is increased threefold or more in v-Jun-transformed cells, including genes involved in energy generation, protein synthesis, and gene transcription. Interestingly, this group includes the hypoxia-inducible factor-1 alpha (Hif-1alpha) transcription factor and the glycolytic enzyme enolase, suggesting that adaptation to hypoxia could play a role in tumorigenesis by v-Jun. We also identified 32 genes whose expression is decreased threefold or more, including chaperones, components of the cytoskeleton, and, unexpectedly, DNA replication factors. The gene whose expression is upregulated most dramatically (similar to100-fold) encodes Autotaxin (ATX), a secreted tumor motility-promoting factor with lysophospholipase D activity. Strikingly, v-Jun-transformed CEF secrete catalytically active ATX and chemotactic activity, which can be detected in conditioned medium. ATX is not detectably expressed in normal CEF or CEF transformed by the v-Src or v-Myc oncoproteins, indicating that induction of this putative autocrine/paracrine factor is a specific consequence of cell transformation by v-Jun. ATX has been implicated in both angiogenesis and invasion, and could therefore play an important role in tumorigenesis by v-Jun in vivo.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Dept Human Biol, Seattle, WA 98109 USA	University of Glasgow; Beatson Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Gillespie, DAF (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544	NATIONAL CANCER INSTITUTE [R01CA020068] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA20068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bates S, 1996, ONCOGENE, V13, P1103; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dunn CA, 2003, BBA-GENE STRUCT EXPR, V1628, P147, DOI 10.1016/S0167-4781(03)00136-2; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Hadman M, 1996, ONCOGENE, V12, P135; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kilbey A, 1996, ONCOGENE, V12, P2409; Koh E, 2003, CANCER RES, V63, P2042; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; MORGAN IM, 1993, ONCOGENE, V8, P1135; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; NISHIMURA T, 1988, ONCOGENE, V3, P659; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WONG WY, 1992, ONCOGENE, V7, P2077	46	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2357	2366		10.1038/sj.onc.1207377	http://dx.doi.org/10.1038/sj.onc.1207377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691447	Bronze			2022-12-17	WOS:000220427700010
J	Staber, PB; Linkesch, W; Zauner, D; Beham-Schmid, C; Guelly, C; Schauer, S; Sill, H; Hoefler, G				Staber, PB; Linkesch, W; Zauner, D; Beham-Schmid, C; Guelly, C; Schauer, S; Sill, H; Hoefler, G			Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia	ONCOGENE			English	Article						AML; relapse; proliferation; RAF/MEK/ERK; c-DNA subtraction; c-DNA microarray	ACUTE MYELOGENOUS LEUKEMIA; RESISTANCE PROTEIN BCRP; N-RAS; P-GLYCOPROTEIN; CLINICAL-SIGNIFICANCE; NUCLEAR ANTIGEN; C-FOS; RELAPSE; MUTATIONS; CANCER	Recurrent disease following high-dose chemotherapy is a major problem in patients with acute myeloid leukemia (AML). To identify its characteristics, we performed expression profiling in blasts from untreated AML and relapse, using a specific cDNA microarray comprising 4128 genes generated by cDNA subtraction supplemented with cancer-associated genes. Expression analysis of 18 AML bone marrow specimens showed that recurrent AML is commonly associated with the mRNA expression changes in a set of 58 genes. Increased cellular proliferation was indicated by the overexpression of the transferrin receptor, proliferating cell nuclear antigen, and G1 cyclins. An immunohistochemical study for Ki-67-positive blasts in 18 paired bone marrow biopsy samples confirmed a highly significant (P < 0.0001) increase in the proliferation fraction at relapse. In addition, we found enhanced activation of the RAF/MEK/ERK cascade as mRNAs of MKP-1, c-jun, c-fos, and egr-1 were significantly increased at relapse. Immunohistochemistry and immunoblotting analyses for biphosphorylated ERK1/2 protein provide additional evidence for enhanced activation of the RAF/MEK/ERK pathway. The degree of increase is significantly correlated with the increased proliferation. Furthermore, the genes identified provide a rationale for further studies on predictive diagnosis and therapeutic intervention.	Karl Franzens Univ Graz, Univ Hosp, Dept Pathol, A-8036 Graz, Austria; Graz Univ, Dept Internal Med, Div Hematol, Graz, Austria	University of Graz; University of Graz	Hoefler, G (corresponding author), Karl Franzens Univ Graz, Univ Hosp, Dept Pathol, Auenbruggerpl 25, A-8036 Graz, Austria.	gerald.hoefler@uni-graz.at	Hoefler, Gerald/B-7006-2008; Sill, Heinz/AAV-4643-2021; Staber, Philipp Bernhard/ADK-1536-2022; Hoefler, Gerald/H-1796-2016	Sill, Heinz/0000-0003-0993-4371; Staber, Philipp Bernhard/0000-0001-6729-7708; Hoefler, Gerald/0000-0002-9056-3063				APPELBAUM FR, 2001, ACUTE MYELOID LEUKEM, P62; Baer MR, 2001, BLOOD, V97, P3574, DOI 10.1182/blood.V97.11.3574; BORELLA L, 1979, BLOOD, V54, P64; BOS JL, 1987, BLOOD, V69, P1237; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ESTEY E, 1995, LEUKEMIA, V9, P972; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Gale RP, 1996, LEUKEMIA, V10, P13; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; GARSON OM, 1989, CANCER GENET CYTOGEN, V40, P187, DOI 10.1016/0165-4608(89)90024-1; GERDES J, 1984, J IMMUNOL, V133, P1710; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDIE JH, 1983, CANCER TREAT REP, V67, P923; GUERCI A, 1995, BLOOD, V85, P2147, DOI 10.1182/blood.V85.8.2147.bloodjournal8582147; HARTIGAN JA, 1973, ANNU REV BIOPHYS BIO, V2, P81, DOI 10.1146/annurev.bb.02.060173.000501; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hur M, 2001, CLIN LAB HAEMATOL, V23, P173, DOI 10.1046/j.1365-2257.2001.00389.x; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kiyoi H, 1999, BLOOD, V93, P3074; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Leith CP, 1999, BLOOD, V94, P1086; MARIE JP, 1991, BLOOD, V78, P586; MUSTO P, 1990, TUMORI, V76, P353, DOI 10.1177/030089169007600410; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Padua RA, 1998, LEUKEMIA, V12, P887, DOI 10.1038/sj.leu.2401044; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PUI CH, 1986, BLOOD, V68, P1306; RADICH JP, 1990, BLOOD, V76, P801; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; TERADA N, 1993, EXP CELL RES, V204, P260, DOI 10.1006/excr.1993.1032; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; van den Heuvel-Eibrink MM, 2001, BLOOD, V97, P3605, DOI 10.1182/blood.V97.11.3605; van der Kolk DM, 2002, BLOOD, V99, P3763, DOI 10.1182/blood.V99.10.3763; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	40	58	64	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	2004	23	4					894	904		10.1038/sj.onc.1207192	http://dx.doi.org/10.1038/sj.onc.1207192			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749762				2022-12-17	WOS:000188486600004
J	Shinozaki, T; Nota, A; Taya, Y; Okamoto, K				Shinozaki, T; Nota, A; Taya, Y; Okamoto, K			Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export	ONCOGENE			English	Article						p53; Mdm2; ATR	RING-FINGER DOMAIN; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; DNA; ACTIVATION; CHECKPOINT; AKT; REPLICATION; DEGRADATION; UBIQUITINATION	Mdm2 oncoprotein plays a major role in inhibiting the p53 tumor suppressor protein. Here, we investigate phosphorylation of Mdm2 at serine 407 (S407). S407 is phosphorylated in cells after treatment with camptothecin (CPT) or hydroxyurea, inhibitors of DNA replication. S407 phosphorylation after CPT treatment is induced upon cell cycle arrest during S phase and prevented if entry into S phase of cell cycle is blocked. We found that a major kinase responsible for S407 phosphorylation is ATR, a DNA damage checkpoint protein that induces cell cycle arrest and promotes DNA repair in response to impaired DNA replication; induction of S407 phosphorylation is enhanced after expression of wild-type ATR, while it is inhibited by a dominant-negative form of ATR. Further, S407 is specifically phosphorylated by ATR in vitro. Substitution of S407 with aspartate (S407D), but not with alanine (S407A), promotes nuclear localization of p53. Taken together, our data indicate that S407 phosphorylation of Mdm2 by ATR reduces Mdm2-dependent export of p53 from nuclei to cytoplasm.	Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki, Japan	National Cancer Center - Japan; Japan Science & Technology Agency (JST)	Okamoto, K (corresponding author), Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	kojokamo@gan2.res.ncc.go.jp						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brown EJ, 2000, GENE DEV, V14, P397; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Taya Yoichi, 2003, Methods Mol Biol, V223, P17; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang HY, 2002, CANCER RES, V62, P2483; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	63	58	60	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8870	8880		10.1038/sj.onc.1207176	http://dx.doi.org/10.1038/sj.onc.1207176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654783				2022-12-17	WOS:000186982200008
J	Vit, JP; Rosselli, F				Vit, JP; Rosselli, F			Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis	ONCOGENE			English	Article						ionizing radiations; apoptosis; ceramide; DNA damage	ATAXIA-TELANGIECTASIA; CELL-DEATH; PROTEIN; ATM; P53; GROWTH; INHIBITION; CHECKPOINT; RESISTANCE; GENES	Ionizing radiations (IR) exposure leads to damage on several cellular targets. How signals from different targets are integrated to determine the cell fate remains a controversial issue. Understanding the pathway(s) responsible(s) for the cell killing effect of the IR exposure is of prime importance in light of using radiations as anticancer agent or as diagnostic tool. In this study, we have established that IR-induced cell damage initiates two independent signaling pathways that lead to a biphasic intracellular ceramide increase. A transitory increase of ceramide is observed within minutes after IR exposure as a consequence of DNA damage-independent acid sphingomyelinase activation. Several hours after irradiation, a second wave of ceramide accumulation is observed depending on the DNA damage-dependent activation of ceramide synthase, which requires a signaling pathway involving ATM. Importantly, we have demonstrated that the late ceramide accumulation is also dependent on the first one and is rate limiting for the apoptotic process induced by IR. In conclusion, our observations suggest that ceramide is a major determinant of the IR-induced apoptotic process at the cross-point of different signal transduction pathways.	Inst Gustave Roussy, IFR 54, CNRS, UPR 2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rosselli, F (corresponding author), Inst Gustave Roussy, IFR 54, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	rosselli@vjf.cnrs.fr	vit, jean-philippe/Q-7286-2019; Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745; Vit, Jean-Philippe/0000-0001-5057-8554				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chmura SJ, 1997, CANCER RES, V57, P1270; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Duchaud E, 1996, CANCER RES, V56, P1400; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAREL R, 1993, J BIOL CHEM, V268, P14476; HARPER JW, 1993, CELL, V75, P805; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANNA KK, 1993, ONCOGENE, V8, P3307; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Meijer AE, 1999, INT J RADIAT BIOL, V75, P709, DOI 10.1080/095530099140041; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takagi M, 1998, CANCER RES, V58, P4923; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	42	58	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8645	8652		10.1038/sj.onc.1207087	http://dx.doi.org/10.1038/sj.onc.1207087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647458	Bronze			2022-12-17	WOS:000186844900001
J	Turner, SD; Tooze, R; Maclennan, K; Alexander, DR				Turner, SD; Tooze, R; Maclennan, K; Alexander, DR			Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase	ONCOGENE			English	Article						NPM-ALK; lymphoma; mouse model; Jun kinase	NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA; C-JUN; T-CELL; SIGNAL-TRANSDUCTION; HELICOBACTER-PYLORI; NH2-TERMINAL KINASE; GENE REARRANGEMENT; EXPRESSION	Anaplastic large-cell lymphoma is associated with a chromosomal translocation generating an oncogenic fusion protein: the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). We have generated several independent lines of human NPM-ALK transgenic mice using the haematopoietic cell-specific Vav promoter. Lymphomas develop in two transgenic lines in which the Vav promoter regulates NPM-ALK expression. The transgenic line with higher copy number displays an early-onset phenotype in which all mice succumb to aggressive lymph node tumours with intestinal involvement, whereas the second line displays late-onset tumour development in the spleen and/or liver. Lymphomas from both lines are phenotypically distinct and display B-lineage characteristics with aberrant coexpression of myeloid markers. The NPM-ALK kinase is active in primary tumour tissue and forms a multimeric complex with tyrosine-phosphorylated proteins, that is, Shc. Jun and ERK kinase activities in tumours are elevated by up to 30-fold and fivefold, respectively, in comparison with sIgM-stimulated primary B cells. The new transgenic models provide a system for investigating the oncogenic events mediated by NPM-ALK in situ and a physiologically relevant context for developing tyrosine kinase inhibitor therapies of potential use in the clinic.	Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; St James Univ Hosp, Canc Med Unit, Leeds LS9 7TF, W Yorkshire, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Saint James's University Hospital	Alexander, DR (corresponding author), Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England.	denis.alexander@bbsrc.ac.uk	Turner, Suzanne Dawn/K-4405-2013	Turner, Suzanne Dawn/0000-0002-8439-4507; Tooze, Reuben/0000-0003-2915-7119				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bost F, 1999, MOL CELL BIOL, V19, P1938; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HESTDAL K, 1991, J IMMUNOL, V147, P22; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jaffe ES, 2001, TUMOURS HAEMATOPOIET; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kanda M, 2001, LEUKEMIA LYMPHOMA, V42, P639, DOI 10.3109/10428190109099324; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LANIER LL, 1995, LEUCOCYTE TYPING, V5, P1398; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; Maes B, 2001, ANN ONCOL, V12, P853, DOI 10.1023/A:1011195708834; Mason DY, 1998, CANCER RES, V58, P1057; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1995, BLOOD, V86, P647; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Ogilvy S, 2003, J IMMUNOL, V171, P1792, DOI 10.4049/jimmunol.171.4.1792; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; ONCIU M, 2003, IN PRESS BLOOD; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Rabbitts TH, 1998, NEW ENGL J MED, V338, P192, DOI 10.1056/NEJM199801153380311; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; STEWART M, 1993, INT J CANCER, V53, P1023; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Weisenburger DD, 2001, AM J HEMATOL, V67, P172, DOI 10.1002/ajh.1102; Yang YM, 2003, CLIN CANCER RES, V9, P391; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S; ZUKERBERG LR, 1991, AM J PATHOL, V139, P475	56	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7750	7761		10.1038/sj.onc.1207048	http://dx.doi.org/10.1038/sj.onc.1207048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586401				2022-12-17	WOS:000186240200005
J	Krause, DR; Jonnalagadda, JC; Gatei, MH; Sillje, HHW; Zhou, BB; Nigg, EA; Khanna, K				Krause, DR; Jonnalagadda, JC; Gatei, MH; Sillje, HHW; Zhou, BB; Nigg, EA; Khanna, K			Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1	ONCOGENE			English	Article						ATM; NBS1; checkpoints; DNA damage; Chk1; TLK	S-PHASE CHECKPOINT; CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; PROTEIN-KINASE; HUMAN ASF1; GENE; ACTIVATION; PATHWAYS; REPAIR	The human Tousled-like kinases 1 and 2 (TLK) have been shown to be active during S phase of the cell cycle. TLK activity is rapidly suppressed by DNA damage and by inhibitors of replication. Here we report that the signal transduction pathway, which leads to transient suppression of TLK activity after the induction of double-strand breaks (DSBs) in the DNA, is dependent on the presence of a functional ataxia-telangiectasia-mutated kinase (ATM). Interestingly, we have discovered that rapid suppression of TLK activity after low doses of ultraviolet (UV) irradiation or aphidicolin-induced replication block is also ATM-dependent. The nature of the signal that triggers ATM-dependent downregulation of TLK activity after UVC and replication block remains unknown, but it is not due exclusively to DSBs in the DNA. We also demonstrate that TLK suppression is dependent on the presence of a functional Nijmegan Breakage Syndrome protein (NBS1). ATM-dependent phosphorylation of NBS1 is required for the suppression of TLK activity, indicating a role for NBS1 as an adaptor or scaffold in the ATM/TLK pathway. ATM does not phosphorylate TLK directly to regulate its activity, but Chk1 does phosphorylate TLK1 GST-fusion proteins in vitro. Using Chk1 siRNAs, we show that Chk1 is essential for the suppression of TLK activity after replication block, but that ATR, Chk2 and BRCA1 are dispensable for TLK suppression. Overall, we propose that ATM activation is not linked solely to DSBs and that ATM participates in initiating signaling pathways in response to replication block and UV-induced DNA damage.	Queensland Inst Med Res, Canc & Cell Biol Div, Signal Transduct Lab, 300 Herston Rd, Herston, Qld 4029, Australia; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Incyte Genom Inc, Newark, DE 19714 USA	QIMR Berghofer Medical Research Institute; Max Planck Society; DuPont; Incyte	Krause, DR (corresponding author), Queensland Inst Med Res, Canc & Cell Biol Div, Signal Transduct Lab, 300 Herston Rd, Herston, Qld 4029, Australia.	darrenk@qimr.edu.au		Khanna, Kum Kum/0000-0001-8650-5381; nigg, erich/0000-0003-4835-5719				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; GATEI M, 2003, J BIOL CHEM; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Jackson JR, 2000, CANCER RES, V60, P566; KAUFMANN WK, 1995, CANCER METAST REV, V14, P31, DOI 10.1007/BF00690209; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Li Y, 2001, ONCOGENE, V20, P726, DOI 10.1038/sj.onc.1204147; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Mello JA, 2002, EMBO REP, V3, P329, DOI 10.1093/embo-reports/kvf068; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; ROE JL, 1993, CELL, V75, P939, DOI 10.1016/0092-8674(93)90537-Z; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Schar P, 2001, CELL, V104, P329, DOI 10.1016/S0092-8674(01)00220-3; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; Sillje HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu B, 2002, CANCER RES, V62, P4588; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; ZDZIENICKA MZ, 1989, CANCER RES, V49, P1481; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou XY, 2002, CANCER RES, V62, P1598	48	58	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5927	5937		10.1038/sj.onc.1206691	http://dx.doi.org/10.1038/sj.onc.1206691			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955071				2022-12-17	WOS:000185137800001
J	Almholt, K; Nielsen, BS; Frandsen, TL; Brunner, N; Dano, K; Johnsen, M				Almholt, K; Nielsen, BS; Frandsen, TL; Brunner, N; Dano, K; Johnsen, M			Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice	ONCOGENE			English	Article						plasminogen activator inhibitor-1 (PAI-1); metastasis; breast cancer; angiogenesis	MATRIX-DEGRADING PROTEASES; UROKINASE-TYPE; MESSENGER-RNA; EXTRACELLULAR PROTEOLYSIS; IMMUNOHISTOCHEMICAL LOCALIZATION; PROGNOSTIC-SIGNIFICANCE; CELL-ADHESION; TUMOR-GROWTH; PAI-1; INVASION	The plasminogen activator inhibitor-1 (PAI-1) blocks the activation of plasmin(ogen), an extracellular protease vital to cancer invasion. PAI-1 is like the corresponding plasminogen activator uPA (urokinase-type plasminogen activator) consistently expressed in human breast cancer. Paradoxically, high levels of PAI-1 as well as uPA are equally associated with poor prognosis in cancer patients. PAI-1 is thought to play a vital role for the controlled extracellular proteolysis during tumor neovascularization. We have studied the effect of PAI-1 deficiency in a transgenic mouse model of metastasizing breast cancer. In these tumors, the expression pattern of uPA and PAI-1 resembles that of human ductal breast cancer and plasminogen is required for efficient metastasis. In a cohort of 63 transgenic mice that were either PAI-1-deficient or wild-type sibling controls, primary tumor growth and vascular density were unaffected by PAI-1 status. PAI-1 deficiency also did not significantly affect the lung metastatic burden. These results agree with the virtual lack of spontaneous phenotype in PAI-1-deficient mice and humans and may reflect that the plasminogen activation reaction is not rate limiting for tumor vascularization and metastasis, or that there is a functional redundancy between PAI-1 and other inhibitors of the uPA/plasmin system, masking the effect of PAI-1 deficiency.	Rigshosp, Finsen Lab, Dept 8621, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen	Almholt, K (corresponding author), Rigshosp, Finsen Lab, Dept 8621, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.	kasper@finsenlab.dk	Frandsen, Thomas L/H-7784-2017; Almholt, Kasper/D-6133-2013; Johnsen, Morten/L-8016-2014	Frandsen, Thomas L/0000-0001-8495-5274; Johnsen, Morten/0000-0003-3763-2362; Almholt, Kasper/0000-0002-9250-514X				ALMHOLT K, IN PRESS RECENT RESU, V162; ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BIANCHI E, 1995, INT J CANCER, V60, P597, DOI 10.1002/ijc.2910600505; BIANCHI E, 1994, CANCER RES, V54, P861; Biliran H, 2001, CANCER RES, V61, P8676; BROWN T, 1997, CURRENT PROTOCOLS MO, V1; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; DANO K, 1993, PORTL PR P, P239; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Fay WP, 1997, BLOOD, V90, P204; Feng Q, 2001, PLACENTA, V22, P186, DOI 10.1053/plac.2000.0607; Frandsen TL, 2001, CANCER RES, V61, P532; Garlanda C, 1997, EUR J CELL BIOL, V73, P368; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Gutierrez LS, 2000, CANCER RES, V60, P5839; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HACKEL C, 1995, ANAT EMBRYOL, V192, P363, DOI 10.1007/BF00710105; Harbeck N, 1999, BREAST CANCER RES TR, V54, P147, DOI 10.1023/A:1006118828278; Hewitt R, 1996, ENZYME PROTEIN, V49, P163, DOI 10.1159/000468623; HOFMANN GE, 1994, AM J OBSTET GYNECOL, V170, P671, DOI 10.1016/S0002-9378(94)70246-2; JANICKE F, 1991, SEMIN THROMB HEMOST, V17, P303, DOI 10.1055/s-2007-1002624; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; KRISTENSEN P, 1990, HISTOCHEMISTRY, V93, P559, DOI 10.1007/BF00272198; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lijnen HR, 2001, ANN NY ACAD SCI, V936, P226; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Lund LR, 2000, DEVELOPMENT, V127, P4481; Maglione JE, 2001, CANCER RES, V61, P8298; Matrisian LM, 1999, CURR BIOL, V9, pR776, DOI 10.1016/S0960-9822(00)80011-1; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Montemurro P, 1999, BRIT J HAEMATOL, V107, P294, DOI 10.1046/j.1365-2141.1999.01698.x; NEKARDA H, 1994, CANCER RES, V54, P2900; Nielsen BS, 1996, LAB INVEST, V74, P168; Nielsen BS, 2001, LAB INVEST, V81, P1485, DOI 10.1038/labinvest.3780363; Nielsen BS, 2001, AM J PATHOL, V158, P1997, DOI 10.1016/S0002-9440(10)64671-8; Parfyonova YV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P119, DOI 10.1023/A:1013964517211; PEDERSEN H, 1994, CANCER RES, V54, P120; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1993, CANCER RES, V53, P1911; Riisbro R, 2002, CLIN CANCER RES, V8, P1132; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SAPPINO AP, 1991, J CLIN INVEST, V87, P962, DOI 10.1172/JCI115104; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; SHULMAN M, 1978, NATURE, V276, P269, DOI 10.1038/276269a0; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tapiovaara H, 1996, ADV CANCER RES, V69, P101, DOI 10.1016/S0065-230X(08)60861-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Werb Z, 1996, BRAZ J MED BIOL RES, V29, P1087; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	74	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4389	4397		10.1038/sj.onc.1206601	http://dx.doi.org/10.1038/sj.onc.1206601			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853975				2022-12-17	WOS:000183978900008
J	Oien, KA; Vass, JK; Downie, I; Fullarton, G; Keith, WN				Oien, KA; Vass, JK; Downie, I; Fullarton, G; Keith, WN			Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach	ONCOGENE			English	Article						stomach; stomach neoplasms; adenocarcinoma; gene expression profiling; serial analysis of gene expression (SAGE)	SERIAL ANALYSIS; CANCER-CELLS; DIFFERENTIAL DISPLAY; TREFOIL PEPTIDES; BREAST-CANCER; IDENTIFICATION; PROTEIN; TRANSCRIPTOMES; ADENOCARCINOMA; DISCOVERY	Gastric carcinoma is the fourth most common cause of cancer death worldwide but its molecular biology is poorly understood. We catalogued the genes expressed in two gastric adenocarcinomas and normal stomach, using serial analysis of gene expression (SAGE), and compared the profiles on-line with other glandular epithelia. Candidates were validated by Northern blotting and immunohistochemistry. A total of 29480 transcripts, derived from 10 866 genes, were identified. In all, 1% of the genes were differentially expressed (greater than or equal tofivefold difference plus P-value less than or equal to0.01) between cancers and normal stomach. The most abundant transcripts included ribosomal and mitochondrial proteins, of which most were upregulated in the tumours, as were other widely expressed genes including transcription factors, signalling molecules (serine/threonine protein kinases), thymosin beta 10 and collagenase I. Transcripts abundant in normal stomach were functionally important, including gastrin, immunoglobulin alpha, lysozyme, MUC5, pS2 and pepsinogens, which were among 55 gastric-specific genes. Many transcripts were minimally characterized or new, some cancer-associated genes reflected their intestinal morphology, and some normal gastric genes had previously been considered as pancreatic carcinoma markers. The gastric carcinoma profiles resembled other tumours', supporting the existence of common cancer-associated targets. These data provide a catalogue from which to develop markers for better diagnosis and therapy of gastric carcinoma.	Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Glasgow Royal Infirm, Univ Dept Pathol, Glasgow G4 0SF, Lanark, Scotland; Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Gartnavel Royal Hosp, Dept Surg, Glasgow G12 0YN, Lanark, Scotland	Beatson Institute; Cancer Research UK; University of Glasgow; University of Glasgow; Beatson Institute; Cancer Research UK; Gartnavel Royal Hospital	Oien, KA (corresponding author), Univ Glasgow, Dept Med Oncol, Canc Res UK, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	k.oien@beatson.gla.ac.uk	Oien, Karin/AAH-3849-2019; Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580				Argani P, 2001, CANCER RES, V61, P4320; Bahrenberg G, 2000, BIOCHEM BIOPH RES CO, V275, P783, DOI 10.1006/bbrc.2000.3393; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; BERNER A, 1991, HISTOL HISTOPATHOL, V6, P317; Blok P, 1997, QJM-INT J MED, V90, P735; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Breitwieser GE, 1997, AM J PHYSIOL-CELL PH, V272, pC957, DOI 10.1152/ajpcell.1997.272.3.C957; Carulli JP, 1998, J CELL BIOCHEM, P286; Chan AOO, 1999, J GASTROEN HEPATOL, V14, P1150, DOI 10.1046/j.1440-1746.1999.02000.x; Chang K, 1996, P NATL ACAD SCI USA, V93, P136, DOI 10.1073/pnas.93.1.136; de Waard V, 1999, GENE, V226, P1, DOI 10.1016/S0378-1119(98)00577-0; Ebert MPA, 2000, CANCER RES, V60, P1995; El-Rifai W, 2001, INT J CANCER, V92, P832, DOI 10.1002/ijc.1264; Friedl A, 1999, HISTOCHEM J, V31, P433, DOI 10.1023/A:1003708808934; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Gibson PR, 1999, CARCINOGENESIS, V20, P539, DOI 10.1093/carcin/20.4.539; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris RM, 2000, LIFE SCI, V67, P2051, DOI 10.1016/S0024-3205(00)00791-8; Harris V, 1998, CANC REGISTRATION ST, P182; Hibi K, 1998, CANCER RES, V58, P5690; Hippo Y, 2001, CANCER RES, V61, P889; Hippo Y, 2002, CANCER RES, V62, P233; Hough CD, 2000, CANCER RES, V60, P6281; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; ISAACSON P, 1982, GUT, V23, P578, DOI 10.1136/gut.23.7.578; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Lal A, 1999, CANCER RES, V59, P5403; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Ma TH, 1999, J PHYSIOL-LONDON, V517, P317, DOI 10.1111/j.1469-7793.1999.0317t.x; Machado JC, 2000, J PATHOL, V190, P437; Mitani M, 2000, WORLD J SURG, V24, P455, DOI 10.1007/s002689910072; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Nacht M, 1999, CANCER RES, V59, P5464; Norton JD, 2000, J CELL SCI, V113, P3897; OWEN DA, 1986, AM J SURG PATHOL, V10, P48, DOI 10.1097/00000478-198601000-00006; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Roukos DH, 2000, CANCER TREAT REV, V26, P243, DOI 10.1053/ctrv.2000.0164; SALESIOTIS AN, 1995, CANCER LETT, V91, P47, DOI 10.1016/0304-3835(95)03717-B; Scheurle D, 2000, CANCER RES, V60, P4037; SESSA F, 1990, GASTROENTEROLOGY, V98, P1655, DOI 10.1016/0016-5085(90)91104-E; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Waghray A, 2001, CANCER RES, V61, P4283; Wang G, 2001, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V18, P43; Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; Yoshikawa Y, 2000, JPN J CANCER RES, V91, P459, DOI 10.1111/j.1349-7006.2000.tb00967.x; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	54	58	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2003	22	27					4287	4300		10.1038/sj.onc.1206615	http://dx.doi.org/10.1038/sj.onc.1206615			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698CJ	12833151	Green Published			2022-12-17	WOS:000183979800015
J	Sasaki, S; Kitagawa, Y; Sekido, Y; Minna, JD; Kuwano, H; Yokota, J; Kohno, T				Sasaki, S; Kitagawa, Y; Sekido, Y; Minna, JD; Kuwano, H; Yokota, J; Kohno, T			Molecular processes of chromosome 9p21 deletions in human cancers	ONCOGENE			English	Article						9p21 deletion; p16/CDKN2A; lung cancer; DNA double-strand break; nonhomologous end joining	DOUBLE-STRAND BREAK; FRAGILE REGION; GENE; RECOMBINATION; MECHANISM; SEQUENCE; REPAIR; DAMAGE; P15	Interstitial deletions of the chromosome 9p21 segment encoding the p16/CDKN2A tumor suppressor gene (i.e., 9p21 deletions) are frequently observed in a variety of human cancers. A majority of these deletions in lymphoid leukemia have been indicated to be mediated by illegitimate V(D)J recombination. In the present study, to elucidate the molecular processes of 9p21 deletions in nonlymphocytic malignancies, breakpoints for these deletions were analysed in 21 lung cancer cell lines and 32 nonlymphocytic cancer cell lines of nine other histological types. In all, 32 breakpoints in 21 lung cancer cell lines and 56 breakpoints in 32 nonlung cancer cell lines were mapped in a 450-kb segment encompassing the CDKN2A locus with a 10-kb resolution. The largest number of breakpoints (i.e., seven breakpoints in lung cancer and 12 breakpoints in noulung cancers) was mapped in a 10-kb region containing the CDKN2A gene. More precise mapping of these seven and 12 breakpoints revealed that none of these breakpoints were located within 50-bp intervals to each other in this 10kb region. Cloning and sequencing of breakpoints in 18 representative cell lines (six lung and 12 nonlung cancers) further revealed that there were no significant homologies among breakpoints in these 18 cell lines. In 11 (61%) cell lines, 1-5-bp nucleotides were overlapped at breakpoint junctions. These results indicate that DNA double-strand breaks triggering 9p21 deletions do not occur at specific DNA sequences, although they preferentially occur in or near the CDKN2A locus. It was also indicated that two broken DNA ends are rejoined by nonhomologous end-joining repair, preferentially utilizing microhomologies of DNA ends, in the occurrence of 9p21 deletions.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Gunma Univ, Sch Med, Dept Surg 1, Maebashi, Gumma 3718511, Japan; Nagoya Univ, Sch Med, Dept Clin Prevent Med, Nagoya, Aichi 4668550, Japan; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA	National Cancer Center - Japan; Gunma University; Nagoya University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp	Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; Cayuela JM, 1997, BLOOD, V90, P3720, DOI 10.1182/blood.V90.9.3720; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Hamada K, 1998, GENE CHROMOSOME CANC, V22, P232, DOI 10.1002/(SICI)1098-2264(199807)22:3<232::AID-GCC9>3.0.CO;2-X; Hamada K, 2000, GENE CHROMOSOME CANC, V27, P308, DOI 10.1002/(SICI)1098-2264(200003)27:3<308::AID-GCC12>3.0.CO;2-W; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kitagawa Y, 2002, J BIOL CHEM, V277, P46289, DOI 10.1074/jbc.M208353200; Kohno T, 1996, DNA Res, V3, P421, DOI 10.1093/dnares/3.6.421; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Nishioka M, 2000, ONCOGENE, V19, P6251, DOI 10.1038/sj.onc.1204031; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OCHMAN H, 1988, GENETICS, V120, P621; OHNISHI H, 1995, BLOOD, V86, P1269, DOI 10.1182/blood.V86.4.1269.bloodjournal8641269; Park MJ, 2003, CANCER GENET CYTOGEN, V141, P5, DOI 10.1016/S0165-4608(02)00645-3; POMYKALA HM, 1994, MOL CELL BIOL, V14, P7604, DOI 10.1128/MCB.14.11.7604; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Sherr CJ, 2000, CANCER RES, V60, P3689; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Smith J, 2001, NUCLEIC ACIDS RES, V29, P4783, DOI 10.1093/nar/29.23.4783; Tanaka H, 1997, INT J CANCER, V70, P437, DOI 10.1002/(SICI)1097-0215(19970207)70:4<437::AID-IJC11>3.3.CO;2-I; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; Wistuba II, 1997, JNCI-J NATL CANCER I, V89, P1366, DOI 10.1093/jnci/89.18.1366	29	58	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2003	22	24					3792	3798		10.1038/sj.onc.1206589	http://dx.doi.org/10.1038/sj.onc.1206589			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802286				2022-12-17	WOS:000183551000013
J	Zhu, G; Reynolds, L; Crnogorac-Jurcevic, T; Gillett, CE; Dublin, EA; Marshall, JF; Barnes, D; D'Arrigo, C; Van Trappen, PO; Lemoine, NR; Hart, IR				Zhu, G; Reynolds, L; Crnogorac-Jurcevic, T; Gillett, CE; Dublin, EA; Marshall, JF; Barnes, D; D'Arrigo, C; Van Trappen, PO; Lemoine, NR; Hart, IR			Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer	ONCOGENE			English	Article						breast cancer; invasion; microarrays; microdissection	LASER CAPTURE MICRODISSECTION; BINDING PROTEIN; INVASION; PROGRESSION; METASTASIS; PATTERNS; ADENOCARCINOMA; GROWTH; ALPHA; CDNA	Comparison of gene expression changes between cancer cells at the periphery and in the centre of breast cancers was performed using a combination of microdissection and microarray analysis. Cancer cells from the two areas were pooled separately from five patients with ductal carcinoma in situ and separately from five patients with frankly invasive cancer. Limited total RNA, 100-200 ng, from this microdissected tissue required use of the Atlas SMART(TM) Probe Amplification Kit to synthesize and amplify cDNA and make P-33-labelled probes. Probes were then hybridized to Atlas Human Cancer 1.2 Arrays containing 1176 known genes. Triplicate analysis revealed that 22 genes changed their expression levels in the periphery relative to the central region: 15 upregulated and seven down-regulated (arbitrary threshold of 1.5-fold or greater). Differences in RNA levels were confirmed by quantitative real-time PCR for two of the genes and by changes in protein levels, detected by immunohistochemistry, for a couple of representative gene products. Thus, changes in gene expression associated with variation in microanatomical location of neoplastic cells can be detected within even small developing tumour masses.	St Thomas Hosp, Canc Res UK Lab, Richard Dimbleby Dept Canc Res, GKT Sch Med, London SE1 7EH, England; St Thomas Hosp, Rayne Inst, Canc Res UK, Cell Adhes & Dis Lab, London SE1 7EH, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Mol Oncol Unit, Canc Res UK, London, England; Guys Hosp, Clin Oncol Dept, Hedley Atkins Breast Pathol Lab, London, England; St Bartholomews Hosp, Sch Med, Canc Res UK, Translat Oncol Lab,Queen Mary Coll, London, England	Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Cancer Research UK; Imperial College London; Guy's & St Thomas' NHS Foundation Trust; Cancer Research UK; University of London; Queen Mary University London	Hart, IR (corresponding author), St Thomas Hosp, Canc Res UK Lab, Richard Dimbleby Dept Canc Res, GKT Sch Med, 4th Floor,Lambeth Wing, London SE1 7EH, England.		Van Trappen, Philippe/ABF-7431-2021	Van Trappen, Philippe/0000-0002-9784-7974; Marshall, John/0000-0002-0494-2295				Assmann V, 2001, J PATHOL, V195, P191, DOI 10.1002/path.941; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DeRisi J, 1996, NAT GENET, V14, P457; Edmonds BT, 1996, J CELL SCI, V109, P2705; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; HALL PA, 1994, BRIT J CANCER, V70, P244, DOI 10.1038/bjc.1994.287; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Luzzi V, 2001, AM J PATHOL, V158, P2005, DOI 10.1016/S0002-9440(10)64672-X; Mariani L, 2001, CANCER RES, V61, P4190; Marshall JF, 1996, SEMIN CANCER BIOL, V7, P129, DOI 10.1006/scbi.1996.0018; Meyer T, 1998, EUR J CANCER, V34, P214, DOI 10.1016/S0959-8049(97)10129-0; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Scheidl SJ, 2002, AM J PATHOL, V160, P801, DOI 10.1016/S0002-9440(10)64903-6; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schutze K, 1998, CELL MOL BIOL, V44, P735; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Talbot DC, 1996, EUR J CANCER, V32A, P2528; Van Trappen PO, 2001, LANCET, V357, P15, DOI 10.1016/S0140-6736(00)03566-2; Zhumabayeva B, 2001, BIOTECHNIQUES, V30, P158, DOI 10.2144/01301pf01	24	58	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3742	3748		10.1038/sj.onc.1206428	http://dx.doi.org/10.1038/sj.onc.1206428			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802281				2022-12-17	WOS:000183551000008
J	Russo, M; Palumbo, R; Mupo, A; Tosto, M; Iacomino, G; Scognamiglio, A; Tedesco, I; Galano, G; Russo, GL				Russo, M; Palumbo, R; Mupo, A; Tosto, M; Iacomino, G; Scognamiglio, A; Tedesco, I; Galano, G; Russo, GL			Flavonoid quercetin sensitizes a CD95-resistant cell line to apoptosis by activating protein kinase C alpha	ONCOGENE			English	Article						quercetin; PKC alpha; CD95/Fas/Apol; flavonoids; HPB-ALL; apoptosis	PHOSPHOINOSITIDE 3-KINASE; DOWN-REGULATION; DNA-SYNTHESIS; DEATH DOMAIN; COLON-CANCER; IN-VITRO; FAS; INHIBITION; GROWTH; PKC	We previously demonstrated that quercetin, a naturally occurring flavonoid with strong antioxidant properties, was able to enhance programmed cell death in HPB-acute lymphoblastic leukemia (ALL) cell line, derived from a human tymoma, when associated with the agonistic antiCD95 monoclonal antibody. Here, we report that HPBALL cells are normally resistant to Cd95-mediated apoptosis, and quercetin is able to sensitize this cell line through a mechanism independent of its antioxidant properties. In fact, other compounds structurally and functionally similar to quercetin, when associated with anti-CD95 antibody did not induce any CD95-mediated apoptosis, still maintaining their antioxidant capacity. We found that quercetin effects are mediated by the activation of PKCalpha. Treatment of HPB-ALL cells with quercetin slightly decreased PKCa activity, but when the flavonoid was associated with anti-CD95, the kinase activity increased by 12-fold with respect to the treatment with quercetin. In addition, overexpression of PKCalpha induced programmed cell death in the absence of any additional stimulus, while a kinase-defective mutant of PKCalpha was ineffective. Our data confirm the involvement of specific PKC isoforms in CD95 signaling and suggest, for the first time, that quercetin targets this pathway increasing apoptogenic response in a cell line resistant to CD95-mediated apoptosis.	CNR, Ist Sci Alimentaz, I-83100 Avellino, Italy; Staz Zool Anton Dohrn, I-80121 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); Stazione Zoologica Anton Dohrn di Napoli	Russo, GL (corresponding author), CNR, Ist Sci Alimentaz, Via Roma 52 A-C, I-83100 Avellino, Italy.	russogl@inwind.it	Russo, Maria/AAJ-9424-2020; russo, maria/E-8585-2011; RUSSO, GIAN LUIGI/GQB-0962-2022; Iacomino, Giuseppe/AAV-2456-2021	russo, maria/0000-0001-8385-9184; IACOMINO, GIUSEPPE/0000-0001-5231-2231; PALUMBO, ROSANNA/0000-0002-3858-4529; Mupo, Annalisa/0000-0002-2771-0462; RUSSO, GIAN LUIGI/0000-0001-9321-1613				Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7; Alberts DS, 1999, CANCER RES, V59, P4743; ALDERSON MR, 1994, INT IMMUNOL, V6, P1799, DOI 10.1093/intimm/6.11.1799; AVILA MA, 1994, CANCER RES, V54, P2424; Avila MA, 1996, ADV EXP MED BIOL, V401, P101; BORS W, 1990, METHOD ENZYMOL, V186, P343; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5; Casagrande F, 2001, BIOCHEM PHARMACOL, V61, P1205, DOI 10.1016/S0006-2952(01)00583-4; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEBATIN KM, 1995, LEUKEMIA, V9, P815; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAUTZ R, 1991, MUTAT RES, V253, P173, DOI 10.1016/0165-1161(91)90130-Z; Ferrandina G, 1998, INT J CANCER, V77, P747, DOI 10.1002/(SICI)1097-0215(19980831)77:5<747::AID-IJC14>3.0.CO;2-Z; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Galati G, 2000, Drug Metabol Drug Interact, V17, P311; Gamet-Payrastre L, 1999, GEN PHARMACOL-VASC S, V32, P279, DOI 10.1016/S0306-3623(98)00220-1; GILLIS S, 1980, J EXP MED, V152, P1709, DOI 10.1084/jem.152.6.1709; Goldberg DM, 1996, ANAL CHEM, V68, P1688, DOI 10.1021/ac951083i; Gomez-Angelats M, 2000, J BIOL CHEM, V275, P19609, DOI 10.1074/jbc.M909563199; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; HAGIWARA M, 1988, BIOCHEM PHARMACOL, V37, P2987; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ishikawa Y, 2000, BIOCHEM BIOPH RES CO, V279, P629, DOI 10.1006/bbrc.2000.4016; Iwao K, 1999, BBA-GEN SUBJECTS, V1427, P112, DOI 10.1016/S0304-4165(99)00007-0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; JARVIS WD, 1994, CANCER RES, V54, P1707; Kang TB, 1997, BIOCHEM PHARMACOL, V54, P1013, DOI 10.1016/S0006-2952(97)00260-8; Kang ZC, 1999, NUTR CANCER, V35, P175, DOI 10.1207/S15327914NC352_12; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krammer PH, 1998, ADV CANCER RES, V75, P251, DOI 10.1016/S0065-230X(08)60744-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larocca LM, 1997, INT J CANCER, V73, P75, DOI 10.1002/(SICI)1097-0215(19970926)73:1<75::AID-IJC13>3.0.CO;2-4; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Mahmoud NN, 2000, CARCINOGENESIS, V21, P921, DOI 10.1093/carcin/21.5.921; Mandil R, 2001, CANCER RES, V61, P4612; Middleton E, 1986, FLAVONOIDS ADV RES 1, V1993, P619; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; MORIKAWA S, 1978, INT J CANCER, V21, P166, DOI 10.1002/ijc.2910210207; Mouria M, 2002, INT J CANCER, V98, P761, DOI 10.1002/ijc.10202; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Noroozi M, 2000, EUR J CLIN NUTR, V54, P143, DOI 10.1038/sj.ejcn.1600908; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Plaumann B, 1996, ONCOGENE, V13, P1605; Ranelletti FO, 2000, INT J CANCER, V85, P438, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;438::AID-IJC22&gt;3.0.CO;2-F; Reddy BS, 2000, CANCER EPIDEM BIOMAR, V9, P239; Rong Y, 2000, ANTICANCER RES, V20, P4339; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Russo M, 1999, FEBS LETT, V462, P322, DOI 10.1016/S0014-5793(99)01544-6; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; STAVRIC B, 1994, CLIN BIOCHEM, V27, P319, DOI 10.1016/0009-9120(94)00039-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9; Weber G, 1999, ADV ENZYME REGUL, V39, P51, DOI 10.1016/S0065-2571(98)00027-2; Weisburger JH, 2000, AM J CLIN NUTR, V71, p1710S, DOI 10.1093/ajcn/71.6.1710S; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381	73	58	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3330	3342		10.1038/sj.onc.1206493	http://dx.doi.org/10.1038/sj.onc.1206493			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761503				2022-12-17	WOS:000183040000015
J	Vooijs, M; te Riele, H; van der Valk, M; Berns, A				Vooijs, M; te Riele, H; van der Valk, M; Berns, A			Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells	ONCOGENE			English	Article						Rb; p107; Trp53; conditional knockout; retinoblastoma; photoreceptor cells	SITE-SPECIFIC RECOMBINATION; HUMAN PITUITARY-TUMORS; TRANSGENIC MICE; MOUSE RETINA; CRE RECOMBINASE; MUTANT MICE; RB; P53; DIFFERENTIATION; MUTATIONS	The retinoblastoma suppressor gene product Rb has been assigned a critical role in cell cycle regulation, the induction of differentiation, and inhibition of oncogenic transformation. Inheritance of a mutant RB allele in humans is responsible for bilateral retinoblastoma, a malignant tumor of the retina. Trilateral retinoblastoma (TRB) is a rare variant of familial retinoblastoma in which, in addition to retinal tumors, tumors develop from the pineal gland, an organ ontologically related to the retina. Germline inactivation of Rb in mice leads to mid-gestational lethality with defects in erythropoeisis and neurogenesis. This embryonic lethality prohibits the analysis of Rb function in selected cell types at later stages of development or in the adult. Here, we describe the Cre-LoxP mediated somatic inactivation of Rb in a subset of neuroendocrine cells, including photoreceptor cells. We observed neuroendocrine tumors of the pineal and pituitary gland. These tumors invariably showed inactivation of Rb and Trp53. Remarkably, loss of Rb in photoreceptor cells does not lead to retinoblastoma or any phenotypic changes, not even when photoreceptor cells are made deficient in Rb, p107 and Trp53. Our results highlight the important differences that exist in tumor susceptibility between mice and man (e.g pineal gland) and question the photoreceptor cell origin of human retinoblastoma.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Expt Anim Pathol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	a.berns@nki.nl	Vooijs, Marc/K-3522-2019					Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; ALUBAIDI MR, 1992, J CELL BIOL, V119, P1681, DOI 10.1083/jcb.119.6.1681; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BOGENMANN E, 1988, SCIENCE, V240, P76, DOI 10.1126/science.2451289; CARTERDAWSON LD, 1978, INVEST OPHTH VIS SCI, V17, P489; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; Cepko CL, 1996, P NATL ACAD SCI USA, V93, P589, DOI 10.1073/pnas.93.2.589; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Claudio PP, 2000, CANCER RES, V60, P372; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gallie BL, 1999, CANCER RES, V59, p1731S; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GONZALEZFERNANDEZ F, 1992, AM J PATHOL, V141, P363; Griep AE, 1998, INVEST OPHTH VIS SCI, V39, P2723; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HOWES KA, 1994, INVEST OPHTH VIS SCI, V35, P342; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBIEC FA, 1977, CANCER-AM CANCER SOC, V39, P2048, DOI 10.1002/1097-0142(197705)39:5<2048::AID-CNCR2820390522>3.0.CO;2-9; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEVY A, 1994, CLIN ENDOCRINOL, V41, P809, DOI 10.1111/j.1365-2265.1994.tb02797.x; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; MARGO C, 1983, ARCH OPHTHALMOL-CHIC, V101, P1519, DOI 10.1001/archopht.1983.01040020521003; Marino S, 2000, GENE DEV, V14, P994; Metzger D, 1999, CURR OPIN BIOTECH, V10, P470, DOI 10.1016/S0958-1669(99)00012-9; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Moll AC, 1997, OPHTHALMIC GENET, V18, P27, DOI 10.3109/13816819709057880; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; NORK TM, 1995, ARCH OPHTHALMOL-CHIC, V113, P791, DOI 10.1001/archopht.1995.01100060117046; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; ROBANUSMAANDAG EC, 1994, EMBO J, V13, P4260; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Tsumanuma I, 1995, Noshuyo Byori, V12, P39; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Woloschak M, 1997, MOL CARCINOGEN, V19, P221, DOI 10.1002/(SICI)1098-2744(199708)19:4<221::AID-MC1>3.0.CO;2-F; WOLOSCHAK M, 1994, CANCER, V74, P693, DOI 10.1002/1097-0142(19940715)74:2<693::AID-CNCR2820740223>3.0.CO;2-P; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215; YOUNG RW, 1985, DEV BRAIN RES, V21, P229, DOI 10.1016/0165-3806(85)90211-1	53	58	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 11	2002	21	30					4635	4645		10.1038/sj.onc.1205575	http://dx.doi.org/10.1038/sj.onc.1205575			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096340				2022-12-17	WOS:000176625100005
J	Shin, MS; Kim, HS; Lee, SH; Lee, JW; Song, YH; Kim, YS; Park, WS; Kim, SY; Lee, SN; Park, JY; Lee, JH; Xiao, WS; Jo, KH; Wang, YP; Lee, KY; Park, YG; Kim, SH; Lee, JY; Yoo, NJ				Shin, MS; Kim, HS; Lee, SH; Lee, JW; Song, YH; Kim, YS; Park, WS; Kim, SY; Lee, SN; Park, JY; Lee, JH; Xiao, WS; Jo, KH; Wang, YP; Lee, KY; Park, YG; Kim, SH; Lee, JY; Yoo, NJ			Alterations of Fas-pathway genes associated with nodal metastasis in non-small cell lung cancer	ONCOGENE			English	Article						Fas; FADD; caspase 10; lung cancer; metastasis	APO-1/CD95 GENE; APOPTOSIS; DEATH; CARCINOMAS; RECEPTOR; RESISTANCE; MUTATIONS; MELANOMA	Many types of cancer cells are resistant to Fas-mediated apoptosis by several mechanisms, including the mutations of the genes involved in Fas-mediated apoptosis. In this study, to explore the possibility that the mutations of the genes involved in the proximal pathway of Fas-mediated apoptosis (Fas, FADD, caspase 8 and caspase 10) are involved in cancer metastasis, we have analysed somatic mutation and deletion of these genes in 80 non-small cell lung cancers (NSCLCs) with (n=43) and without (n=37) metastasis to the regional lymph nodes. We found 12 mutations (four Fas, four FADD, and four caspase 10 mutations) in 11 of 80 NSCLCs (13.8%). Interestingly, of these mutations, most mutations (10 out of 12) were detected in the NSCLCs with metastasis, and the frequency in the metastasis lesions (23%) was higher than that in the primary lesions of the NSCLCs without metastasis (5.4%). Furthermore, transfection study revealed that the tumor-derived mutants have decreased apoptosis inductions compared to the wild types. These data suggest that the inactivating mutations of the genes in the proximal pathway of Fas-mediated apoptosis may lead to a decreased cancer cell death and play a role in the metastasis of NSCLC.	Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Thorac Surg, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Dept Biostat, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Yoo, NJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea.		kim, Hong Sug/G-2731-2014; Yoo, Nam Jin/GNM-9060-2022	Park, Yong Gyu/0000-0002-8721-3230				Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan ASK, 1996, LUNG CANCER-J IASLC, V15, P51, DOI 10.1016/0169-5002(96)00570-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOBZIK L, 1999, LUNG ROBBINS PATHOLO, P697; Lee JY, 1998, VIRCHOWS ARCH, V433, P305, DOI 10.1007/s004280050253; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Maeda T, 1999, J EXP MED, V189, P1063, DOI 10.1084/jem.189.7.1063; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NATOLI G, 1995, ONCOGENE, V11, P1157; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Petersen S, 2000, BRIT J CANCER, V82, P65; Shin MS, 2001, CANCER RES, V61, P4942; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4	21	58	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4129	4136		10.1038/sj.onc.1205527	http://dx.doi.org/10.1038/sj.onc.1205527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037669				2022-12-17	WOS:000176186000007
J	Simone, C; Bagella, L; Bellan, C; Giordano, A				Simone, C; Bagella, L; Bellan, C; Giordano, A			Physical interaction between pRb and cdk9/cyclinT2 complex	ONCOGENE			English	Article						cdk9; cyclin T2; pRb; phosphorylation	RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; CYCLIN-CDK COMPLEXES; P-TEFB KINASE; RETINOBLASTOMA PROTEIN; CELL-CYCLE; HIV-1 TAT; IN-VITRO; FUNCTIONAL INACTIVATION; MUSCLE DIFFERENTIATION	Cyclin-dependent kinase 9 (cdk9) is a multifunctional kinase with roles in different cellular pathways such as transcriptional elongation, differentiation and apoptosis. Cdk9/cyclin T differs functionally from other cdk/cyclin complexes that regulate cell cycle progression, but maintains structural affinity with those complexes. In addition, previous reports have demonstrated that the cdk9 complex is able to phosphorylate p56/pRb in vitro. In this report we show in vitro and in vivo interaction between cdk9/cyclinT2 and the protein product of the retinoblastoma gene (pRb) in human cell lines. The interaction involves the region composed of residues 129-195 of cdk9, cyctinT2 (1-642 aa) and the C-terminal domain of pRb (835-928 aa). We located the minimal region of cdk9 phosphorylation on the C-terminus of pRb, by identifying the residues between 793 and 834. This region contains at least three proline-directed serines (sp), S795, S807 and S811, which have been reported to be phosphorylated in vivo and which could be targeted by the cdk9 complex. These data suggest that, in logarithmically growing cells, cdk9/cyclin T2 and pRb are located in a nuclear multiprotein complex probably involved in transduction of cellular signals to the basal transcription machinery and that one of these signals could be the cdk9 phosphorylation of pRb.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ Bari, Div Med Genet, Dept Internal Med & Publ Med, I-70124 Bari, Italy; Univ Siena, Inst Pathol Anat & Histol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Universita degli Studi di Bari Aldo Moro; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.		BELLAN, CRISTIANA/ABG-4750-2021; Simone, Cristiano/K-3452-2018; Giordano, Antonio/F-1927-2010; BELLAN, CRISTIANA/L-3903-2013	BELLAN, CRISTIANA/0000-0001-6119-9007; Simone, Cristiano/0000-0002-2628-7658; Giordano, Antonio/0000-0002-5959-016X; BELLAN, CRISTIANA/0000-0001-6119-9007; BAGELLA, Luigi/0000-0003-2815-037X				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Bagella L, 2000, J CELL BIOCHEM, V78, P170, DOI 10.1002/(SICI)1097-4644(20000701)78:1<170::AID-JCB16>3.3.CO;2-1; CORBEIL HB, 1995, ONCOGENE, V11, P909; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; De Luca P, 1998, J CELL BIOCHEM, V70, P281, DOI 10.1002/(SICI)1097-4644(19980801)70:2<281::AID-JCB13>3.0.CO;2-Q; DECAPRIO JA, 1998, CELL, V54, P257; DEFALCO G, 2002, IN PRESS CANC BIOL T; DeLuca A, 1997, J CELL PHYSIOL, V172, P265, DOI 10.1002/(SICI)1097-4652(199708)172:2<265::AID-JCP13>3.3.CO;2-C; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LIS JT, 2000, GENE DEV, V11, P2633; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Pan WJ, 2001, CANCER RES, V61, P2885; Pan WJ, 1998, CARCINOGENESIS, V19, P765, DOI 10.1093/carcin/19.5.765; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Simone C., 2001, FRONT BIOSCI, V6, P1073; Stiegler P, 2001, CRIT REV EUKAR GENE, V11, P59; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	52	58	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4158	4165		10.1038/sj.onc.1205511	http://dx.doi.org/10.1038/sj.onc.1205511			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037672				2022-12-17	WOS:000176186000010
J	Uhlmann, EJ; Apicelli, AJ; Baldwin, RL; Burke, SP; Bajenaru, ML; Onda, H; Kwiatkowski, D; Gutmann, DH				Uhlmann, EJ; Apicelli, AJ; Baldwin, RL; Burke, SP; Bajenaru, ML; Onda, H; Kwiatkowski, D; Gutmann, DH			Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2 +/- cells	ONCOGENE			English	Article						tuberin; hamartin; glia; astrocytoma; tumor suppressor gene	NF1 TUMOR-SUPPRESSOR; MISSENSE MUTATIONS; ALLELIC LOSS; HAMARTIN; MICE; PROLIFERATION; PROTEIN; GROWTH; LESIONS; IDENTIFICATION	Tuberous sclerosis complex (TSC) is an autosomal dominant tumor predisposition syndrome characterized by benign proliferations (hamartomas). In the brain, individuals with TSC develop autism, mental retardation and seizures associated with focal cortical dysplasias, subependymal nodules, and subependymal giant cell astrocytomas (SEGAs). We hypothesize that dysregulated astrocyte function due to mutations in they tumor suppressor genes, TSC1 and TSC2, may contribute to the pathogenesis of these brain abnormalities. In this report, we demonstrate that mice heterozygous for a targeted defect in either the Tsc1 or Tsc2 genes (Tsc1+/- and Tsc2+/- mice) exhibit a 1.5-fold increase in the number of astrocytes in vivo. Whereas increased astrocyte numbers in vivo were suggestive of a proliferative advantage, Tsc2+/- primary astrocyte cultures did not show a cell-autonomous growth advantage, anchorage-independent growth, increased saturation density, or increased fluid-phase endocytosis compared to wild type astrocytes. Tsc2 null mouse embryonic fibroblasts (MEFs) however, did exhibit increased saturation density compared to Tsc2 wild type controls. In both Tsc2+/- astrocytes and Tsc2 null mouse embryonic fibroblasts, p27-Kip1 expression was decreased compared to wild type cells, and was reversed by tuberin re-expression in Tsc2-/- MEFs. In contrast, no change in endocytosis was observed upon tuberin re-expression in Tsc2-/- MEFs. Collectively, these results suggest Tsc heterozygosity may provide a non-cell-autonomous growth advantage for astrocytes that may involve p27-Kip1 expression.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.		Apicelli, Anthony/AAB-8879-2021	Apicelli, Anthony/0000-0001-6791-8113; Burke, Stephen/0000-0002-8489-6953; Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS031535, R01NS031535] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31535] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bajenaru ML, 2001, GLIA, V33, P314, DOI 10.1002/1098-1136(20010315)33:4<314::AID-GLIA1030>3.0.CO;2-Q; Crino PB, 1999, NEUROLOGY, V53, P1384, DOI 10.1212/WNL.53.7.1384; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; GOMEZ MR, 1999, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 2000, ACTA NEUROPATHOL, V99, P223, DOI 10.1007/PL00007431; Gutmann DH, 1997, ONCOGENE, V15, P1611, DOI 10.1038/sj.onc.1201314; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Henske EP, 1996, AM J HUM GENET, V59, P400; HEWETT SJ, 1995, NEUROREPORT, V6, P1505; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kleymenova E, 2001, MOL CELL, V7, P823, DOI 10.1016/S1097-2765(01)00226-X; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lantuejoul S, 1997, HISTOPATHOLOGY, V30, P570, DOI 10.1046/j.1365-2559.1997.4600811.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Maheshwar MM, 1997, HUM MOL GENET, V6, P1991, DOI 10.1093/hmg/6.11.1991; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Mouchel Y, 1995, NEUROREPORT, V7, P205; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Niida Y, 2001, AM J HUM GENET, V69, P493, DOI 10.1086/321972; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Parry L, 2000, HUM GENET, V107, P350, DOI 10.1007/s004390000390; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Rizvi TA, 1999, BRAIN RES, V816, P111, DOI 10.1016/S0006-8993(98)01133-0; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1999, J MED GENET, V36, P285; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wolf HK, 1997, ACTA NEUROPATHOL, V93, P93, DOI 10.1007/s004010050587; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	46	58	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					4050	4059		10.1038/sj.onc.1205435	http://dx.doi.org/10.1038/sj.onc.1205435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037687				2022-12-17	WOS:000175869900011
J	Tanghetti, E; Ria, R; Dell'Era, P; Urbinati, C; Rusnati, M; Ennas, MG; Presta, M				Tanghetti, E; Ria, R; Dell'Era, P; Urbinati, C; Rusnati, M; Ennas, MG; Presta, M			Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts	ONCOGENE			English	Article						cell adhesion; cell proliferation; angiogenesis; integrin; FGF; tyrosine kinase; FGF receptor	EXTRACELLULAR-MATRIX; INTEGRIN EXPRESSION; IN-VITRO; ANGIOGENESIS; UROKINASE; PROTEIN; ACTIVATION; BINDING; INVITRO; ALPHA(V)BETA(3)	Substrate-bound FGF2 promotes endothelial cell adhesion by interacting With alpha(nu)beta(3) integrin. Here, endothelial GM7373 cells spread and organize focal adhesion plaques on immobilized FGF2, fibronectin (FN), and vitronectin (VN). alpha(nu)beta(3) integrin, paxillin, focal adhesion kinase, vinculin and pp60(src) localize in cell-substratum contact sites on FGF2, FN or VN. However, only immobilized FGF2 induces a long-lasting activation of extracellular signal-regulated kinases(1/2) (ERK1/2) and cell proliferation that was inhibited by the ERK1/2 inhibitor PD 098059 and the tyrosine kinase (TK) inhibitor tyrphostin 23, pointing to the engagement of FGF receptor (FGFR) at the basal side of the cell. To assess this hypothesis, GM7373 cells were transfected with a dominant negative TK--DeltaFGFR1 mutant (GM7373-DeltaFGFR1 cells) or with the full-length receptor (GM7373-FGFR1 cells). Both transfectants adhere and spread on FGF2 but GM7373-DeltaFGFR1 cells do not proliferate. Also, parental and GM7373-FGFR1 cells, but not GM7373-DeltaFGFR1 cells, undergo morphological changes and increased motility on FGF2-coated plastic. Finally, FGFR1, but not TK--DeltaFGFR1, localizes in cell adhesion contacts on immobilized FGF2. In conclusion, substrate-bound FGF2 induces endothelial cell proliferation, motility, and the recruitment of FGFR1 in cell-substratum contacts. This may contribute to the cross talk among intracellular signaling pathways activated by FGFR1 and alpha(nu)beta(3) integrin in endothelial cells.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Cagliari, Dept Cytomorphol, Cagliari, Italy; Univ Bari, Sch Med, Dept Biomed Sci & Human Oncol, Bari, Italy	University of Brescia; University of Cagliari; Universita degli Studi di Bari Aldo Moro	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.		Dell'Era, Patrizia/ABD-5848-2020; Rusnati, Marco/F-1168-2010; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/G-5294-2010; Dell'Era, Patrizia/N-6964-2019; Ria, Roberto/I-4263-2015	Rusnati, Marco/0000-0001-9968-5908; Dell'Era, Patrizia/0000-0001-6682-6321; Ennas, Maria Grazia/0000-0002-9448-715X; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871; Ria, Roberto/0000-0002-1515-0090				ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAIRD A, 1988, P NATL ACAD SCI USA, V85, P2324, DOI 10.1073/pnas.85.7.2324; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767; BROADLEY KN, 1989, LAB INVEST, V61, P571; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; CULP LA, 1976, BIOCHEMISTRY-US, V15, P4094, DOI 10.1021/bi00663a028; DAVIS CM, 1993, J CELL BIOCHEM, V51, P206, DOI 10.1002/jcb.240510213; DELROSSO M, 1992, EXP CELL RES, V203, P427; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Giuliani R, 1999, J CELL SCI, V112, P2597; GRINSPAN JB, 1983, J CELL PHYSIOL, V114, P328, DOI 10.1002/jcp.1041140312; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; ISACCHI A, 1991, P NATL ACAD SCI USA, V88, P2628, DOI 10.1073/pnas.88.7.2628; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LI Y, 1994, MOL CELL BIOL, V14, P7600; LYALL RM, 1989, J BIOL CHEM, V264, P14503; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; RIBATTI D, 1995, DEV BIOL, V170, P39, DOI 10.1006/dbio.1995.1193; Ribatti D, 1999, J CELL SCI, V112, P4213; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449; Rusnati M, 1996, MOL BIOL CELL, V7, P369, DOI 10.1091/mbc.7.3.369; SCHUBERT D, 1987, J CELL BIOL, V104, P635, DOI 10.1083/jcb.104.3.635; SMITH JC, 1982, NATURE, V296, P154, DOI 10.1038/296154a0; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stromblad S, 1996, TRENDS CELL BIOL, V6, P462, DOI 10.1016/0962-8924(96)84942-7; TSUBOI R, 1990, J CELL BIOL, V110, P511, DOI 10.1083/jcb.110.2.511; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; ZHANG WW, 1994, CANCER GENE THER, V1, P4	47	58	64	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 30	2002	21	24					3889	3897		10.1038/sj.onc.1205407	http://dx.doi.org/10.1038/sj.onc.1205407			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032827				2022-12-17	WOS:000175847200008
J	Bangur, CS; Switzer, A; Fan, LQ; Marton, MJ; Meyer, MR; Wang, TT				Bangur, CS; Switzer, A; Fan, LQ; Marton, MJ; Meyer, MR; Wang, TT			Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis	ONCOGENE			English	Article						small cell lung carcinoma (SCLC); microarray; subtractive hybridization; real-time PCR; gene expression	TUMOR-TRANSFORMING GENE; NEUROENDOCRINE CARCINOMA; BRONCHIAL EPITHELIUM; CANCER; PROTEINS; TISSUE; COMBINATION; MULTIPLE; REGIONS; FAMILY	To identify genes that are differentially over-expressed in Small Cell Lung Carcinoma (SCLC) we have used a combination of suppression subtractive hybridization and cDNA microarray to analyse the expression profiles of 2400 cDNAs clones. Genes that are over-expressed in SCLC were identified using 32 pairs of fluorescence-labeled cDNA samples representing various lung tumors and normal tissues. This comprehensive approach has resulted in the identification of 209 genes that are differentially over-expressed in SCLC. Quantitative real-time PCR was used to further validate the expression of 43 genes in SCLC tumors and various normal tissues. Discussed in this report are nine genes, which showed the most promising SCLC tumor to normal tissue differential expression profiles, including seven known and two novel genes. The large number of differentially expressed genes identified from this analysis and the characterization of these genes will provide valuable information in better understanding the biology of SCLC and help us in developing these gene products as potential targets for diagnostic as well as therapeutic usage.	Corixa Corp, Tumor Antigen Discovery, Seattle, WA 98104 USA; Rosetta Inpharm, Washington, WA 98034 USA	Corixa	Bangur, CS (corresponding author), Corixa Corp, Tumor Antigen Discovery, 1124 Columbia St, Seattle, WA 98104 USA.	bangur@corixa.com						Anbazhagan R, 1999, CANCER RES, V59, P5119; Backert S, 1999, INT J CANCER, V82, P868, DOI 10.1002/(SICI)1097-0215(19990909)82:6<868::AID-IJC16>3.0.CO;2-W; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FELD R, 2000, STAGING PROGNOSTIC F, P612; GIACCONE G, 1994, ANTICANCER RES, V14, P269; GINSBERG RJ, 1997, NONSMALL CELL LUNG C, P858; Girard L, 2000, CANCER RES, V60, P4894; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; GUINEE DG, 1994, AM J CLIN PATHOL, V102, P406, DOI 10.1093/ajcp/102.4.406; Gure AO, 2000, P NATL ACAD SCI USA, V97, P4198, DOI 10.1073/pnas.97.8.4198; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Honnorat J, 1999, EUR J NEUROSCI, V11, P4226, DOI 10.1046/j.1460-9568.1999.00864.x; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; IHDE DC, 1997, SMALL CELL LUNG CARC, P911; JACKSONYORK GL, 1991, CANCER, V68, P374, DOI 10.1002/1097-0142(19910715)68:2<374::AID-CNCR2820680227>3.0.CO;2-2; KALEMKERIAN GP, 2000, GROWTH FACTORS, P181; KIM J, 1992, INT J CANCER, V52, P718, DOI 10.1002/ijc.2910520509; Kitahara O, 2001, CANCER RES, V61, P3544; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Nacht M, 1999, CANCER RES, V59, P5464; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Ono K, 2000, CANCER RES, V60, P5007; OSBORNE MA, 1994, J CELL BIOL, V125, P853, DOI 10.1083/jcb.125.4.853; OUD PS, 1989, CANCER, V64, P1304, DOI 10.1002/1097-0142(19890915)64:6<1304::AID-CNCR2820640623>3.0.CO;2-K; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Puri R, 2001, CANCER LETT, V163, P131, DOI 10.1016/S0304-3835(00)00688-1; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.3.CO;2-S; Sgroi DC, 1999, CANCER RES, V59, P5656; Shih JY, 2001, JNCI-J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tannoch VJ, 2000, ADV EXP MED BIOL, V465, P127; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Williams C L, 1997, Chest Surg Clin N Am, V7, P1; Wistuba II, 2000, CANCER RES, V60, P1949; Wistuba II, 2000, CLIN CANCER RES, V6, P2604; Xia Y, 2000, CANCER RES, V60, P6303; Xu JC, 2000, CANCER RES, V60, P1677; YAMAGUCHI K, 1983, CANCER RES, V43, P3932; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Yu R, 2000, J BIOL CHEM, V275, P36502, DOI 10.1074/jbc.C000546200; Yu ZY, 2001, ANN NEUROL, V49, P146; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	51	58	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3814	3825		10.1038/sj.onc.1205480	http://dx.doi.org/10.1038/sj.onc.1205480			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032850				2022-12-17	WOS:000175676000017
J	Nam, SY; Amoscato, AA; Lee, YJ				Nam, SY; Amoscato, AA; Lee, YJ			Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway	ONCOGENE			English	Article						akt; apoptosis; FLIP; glucose deprivation; TRAIL	APOPTOSIS-INDUCING LIGAND; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; HIGH LACTATE LEVELS; DEATH DOMAIN; IONIZING-RADIATION; DECOY RECEPTORS; HUMAN-TUMORS; IN-VIVO	To examine whether the tumor microenvironment alters cytokine-induced cytotoxicity, human prostate adenocarcinoma DU-145 cells were exposed to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and/or glucose deprivation, a common characteristic of the tumor microenvironment. TRAIL alone reduced cell survival in a dose-dependent manner. Glucose deprivation alone induced no cytotoxicity within 4 h. However, the combination of TRAIL (50 ng/ml) and glucose deprivation for 4 h increased cell death and PARP cleavage by promoting activation of caspase-8 and caspase-3, relative to that of TRAIL alone. Similar results were observed in human colorectal carcinoma CX-1 cells. Data from immunoblotting analysis reveal that glucose deprivation-enhanced TRAIL cytotoxicity is inversely related to the intracellular level of FLICE inhibitory protein (FLIP) but not that of death receptor 5 (DR5). Results from mass spectrometry show that glucose deprivation elevates ceramide. The elevation of ceramide may cause dephosphorylation of Akt and maintain dephosphorylation of Akt in the presence of TRAIL and then subsequently down-regulate the expression of FLIP. Taken together, the present studies suggest that glucose deprivation enhances TRAIL-induced cytotoxicity through the ceramide - Akt - FLIP pathway.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, E1056 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.			Amoscato, Andrew/0000-0002-1340-9150	NCI NIH HHS [CA48000] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burow ME, 1998, CANCER RES, V58, P4940; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gong BD, 2000, CANCER RES, V60, P5754; Griffith TS, 1998, J IMMUNOL, V161, P2833; GULLINO PM, 1975, CANCER, V3, P327; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; IRMIER M, 1997, NATURE, V388, P190; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee YJ, 2001, J CELL SCI, V114, P677; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane DF, 1997, DERMATOL SURG, V23, P848, DOI 10.1111/j.1524-4725.1997.tb00434.x; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MUELLERKLIESER WF, 1989, PREDICTION TUMOR TRE, P265; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2000, CANCER RES, V60, P847; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; SARTORELLI A C, 1988, Cancer Research, V48, P775; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; SCHWICKERT G, 1995, CANCER RES, V55, P4757; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VAUPEL P, 1991, CANCER RES, V51, P3316; VAUPEL P, 1989, CANCER RES, V49, P6449; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Walenta S, 1997, AM J PATHOL, V150, P409; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	71	58	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					337	346		10.1038/sj.onc.1205068	http://dx.doi.org/10.1038/sj.onc.1205068			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821946				2022-12-17	WOS:000173311200002
J	Liu, SKW; Berry, DM; McGlade, CJ				Liu, SKW; Berry, DM; McGlade, CJ			The role of Gads in hematopoietic cell signalling	ONCOGENE			English	Article						Gads; T cell receptor; SLP-76; LAT; RasGRP	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; ADAPTER PROTEIN SLP-76; TERMINAL SH3 DOMAIN; T-CELLS; ANTIGEN-RECEPTOR; MOLECULAR-CLONING; THYMOCYTE DEVELOPMENT; RAS ACTIVATION; NUCLEAR FACTOR	Gads is a member of the family of SH2 and SH3 domain containing adaptor proteins that is expressed specifically in hematopoietic cells and functions in the coordination of tyrosine kinase mediated signal transduction. Gads plays a critical role in signalling from the T cell receptor by promoting the formation of a complex between SLP-76 and LAT. This complex couples the T cell receptor to Ras through a novel pathway involving PLC-gamma1, Tec family kinases, and RasGRP. Studies with Gads-deficient mice have highlighted its importance for thymocyte proliferation during T cell maturation. Emerging evidence suggests that Gads may also play additional roles in antigen-receptor signalling and receptor tyrosine kinase mediated signalling in other hematopoietic lineages. Gads is a unique member of the Grb2 adaptor family, because its activity can be regulated by caspase cleavage. Gads nucleates multiprotein complexes that are required for tyrosine kinase-dependent signalling in immune cells and may also represent a point of modulation for these pathways through the activation of caspase-dependent signalling events.	Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			Liu, Stanley/0000-0001-6851-0857				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Asada H, 1999, J EXP MED, V189, P1383, DOI 10.1084/jem.189.9.1383; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clements JL, 1998, J IMMUNOL, V161, P3880; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Ebinu JO, 2000, BLOOD, V95, P3199; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Ellis JH, 2000, J IMMUNOL, V164, P5805, DOI 10.4049/jimmunol.164.11.5805; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gobel TWF, 2000, CURR TOP MICROBIOL, V248, P303; Gong K, 2001, NAT IMMUNOL, V2, P29, DOI 10.1038/83134; Ishiai M, 2000, J EXP MED, V192, P847, DOI 10.1084/jem.192.6.847; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kikuchi K, 2001, INT IMMUNOL, V13, P777, DOI 10.1093/intimm/13.6.777; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; REIF K, 1994, J BIOL CHEM, V269, P14081; Roose J, 2000, NAT IMMUNOL, V1, P275, DOI 10.1038/79713; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASTRY L, 1995, ONCOGENE, V11, P1107; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; Su YW, 1999, EUR J IMMUNOL, V29, P3702, DOI 10.1002/(SICI)1521-4141(199911)29:11<3702::AID-IMMU3702>3.0.CO;2-R; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Topham MK, 2001, J CELL BIOL, V152, P1135, DOI 10.1083/jcb.152.6.1135; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; Weber JR, 1998, J EXP MED, V187, P1157, DOI 10.1084/jem.187.7.1157; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Yankee TM, 2001, P NATL ACAD SCI USA, V98, P6789, DOI 10.1073/pnas.111158598; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	69	58	60	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6284	6290		10.1038/sj.onc.1204771	http://dx.doi.org/10.1038/sj.onc.1204771			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607830				2022-12-17	WOS:000171640600003
J	Kihara-Negishi, F; Yamamoto, H; Suzuki, M; Yamada, T; Sakurai, T; Tamura, T; Oikawa, T				Kihara-Negishi, F; Yamamoto, H; Suzuki, M; Yamada, T; Sakurai, T; Tamura, T; Oikawa, T			In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression	ONCOGENE			English	Article						PU.1; HDAC1; transcriptional repression	HISTONE DEACETYLASES; ACTIVATION DOMAIN; ETS FAMILY; BINDING PROTEIN; THYROID-HORMONE; EXPRESSION; RECEPTOR; P300; P53; DIFFERENTIATION	We previously reported that overexpression of PU.1, a member of the Ets family of transcription factors, induces differentiation inhibition and apoptosis associated with c-Myc down-regulation in murine erythroleukemia (MEL) cells. To understand the molecular mechanism by which c-Myc is down-regulated due to overexpression of PU.1, we performed luciferase reporter assays using the mouse c-myc promoter. PU.1 repressed the activities of not only the c-myc promoter but also several other promoters. Experiments with deletion mutants of PU.1 revealed that the C-terminal region spanning amino acids (aa) 123-272 including the PEST and ETS domains but not the activation domain was sufficient for this transcriptional repression. It was unlikely that the repression was due to sequestration of a limited amount of CBP/p300 nor pCAF, because overexpression of these co-activators did not relieve PU.1-mediated transcriptional repression. Instead, it was found that the C-terminal aa 101-272 of PU.1 formed a complex with mSin3A and HDAC1 in vivo, which was speculated to be associated with the repression. The C-terminal region of PU.1 also formed a complex with the basic transcription factor TBP in vitro and in vivo. Our results suggest that overexpression of PU.1 induces transcriptional repression in several gene promoters including the c-myc promoter which may be mediated by its complex formation with HDACs.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Chiba University	Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	oikawa@sasaki.or.jp						Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fisher RC, 1998, MOL CELL BIOL, V18, P4347, DOI 10.1128/MCB.18.7.4347; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kihara-Negishi F, 1998, INT J CANCER, V76, P523, DOI 10.1002/(SICI)1097-0215(19980518)76:4<523::AID-IJC14>3.0.CO;2-8; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSS IL, 1994, ONCOGENE, V9, P121; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	48	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6039	6047		10.1038/sj.onc.1204756	http://dx.doi.org/10.1038/sj.onc.1204756			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593411				2022-12-17	WOS:000171056300011
J	Wang, Q; Zhang, HT; Guerrette, S; Chen, JQ; Mazurek, A; Wilson, T; Slupianek, A; Skorski, T; Fishel, R; Greene, MI				Wang, Q; Zhang, HT; Guerrette, S; Chen, JQ; Mazurek, A; Wilson, T; Slupianek, A; Skorski, T; Fishel, R; Greene, MI			Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1	ONCOGENE			English	Article						BRCA1; MSH2; DNA mismatch repair; transcription-coupled DNA damage repair	TRANSCRIPTION-COUPLED REPAIR; NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR; CELL-CYCLE; DNA-DAMAGE; NUCLEAR PHOSPHOPROTEIN; MOLECULAR SWITCH; COLON-CANCER; IN-VIVO; C-MYC	We have identified the physical interaction between the Breast Cancer susceptibility gene product BRCA1 and the Hereditary Non-Polyposis Colorectal Cancer (HNPCC) and DNA mismatch repair (MMR) gene product hMSH2, both in vitro and in vivo. The BRCA1-hMSH2 association involved several well-defined regions of both proteins which include the adenosine nucleotide binding domain of hMSH2. Moreover, the interaction of BRCA1 with purified hMSH2-hMSH6 appears to be modulated by adenosine nucleotide much like G protein downstream interaction/signaling is modulated by guanosine nucleotide. BARD1, another BRCA1-interacting protein, was also found to interact with hMSH2. In addition, BRCA1 was found to associate with both hMSH3 and hMSH6, the heterodimeric partners of IMSH2. These observations implicate BRCA1/BARD1 as downstream effectors of the adenosine nucleotide-activated hMSH2-hMSH6 signaling complex, and suggest a global role for BRCA1 in DNA damage processing. The functional interaction between BRCA1 and hMSH2 may provide a partial explanation for the background of gynecological and colorectal cancer in both HNPCC and BRCA1 kindreds, respectively.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Genet & Mol Biol Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA	University of Pennsylvania; Pennsylvania Medicine; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fishel, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.		Wang, Qiang/N-7310-2015	Wang, Qiang/0000-0001-9409-0251; Zhang, Hongtao/0000-0001-9173-0049	NATIONAL CANCER INSTITUTE [R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; de Boer J, 1998, CANCER RES, V58, P89; Dietmaier W, 1997, CANCER RES, V57, P4749; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; EASTON DF, 1995, AM J HUM GENET, V56, P265; FISHEL R, 1994, CANCER RES, V54, P5539; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gradia S, 2000, J BIOL CHEM, V275, P3922, DOI 10.1074/jbc.275.6.3922; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Schmutte C, 1998, CANCER RES, V58, P4537; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang Y, 2000, GENE DEV, V14, P927; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; WILSON TM, 1995, CANCER RES, V55, P5146; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang H, 1999, CANCER RES, V59, P3021; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang HT, 1997, ONCOGENE, V14, P2863, DOI 10.1038/sj.onc.1201140; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	55	58	58	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4640	4649		10.1038/sj.onc.1204625	http://dx.doi.org/10.1038/sj.onc.1204625			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498787				2022-12-17	WOS:000170208600005
J	Liu, Y; Wang, Y; Yamakuchi, M; Masuda, S; Tokioka, T; Yamaoka, S; Maruyama, I; Kitajima, I				Liu, Y; Wang, Y; Yamakuchi, M; Masuda, S; Tokioka, T; Yamaoka, S; Maruyama, I; Kitajima, I			Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax	ONCOGENE			English	Article						PI3K; Akt; NF-kappa B; Tax; transformation; PI5K; HTLV-I; IKK gamma	NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; PROTEIN; AKT; APOPTOSIS; ONCOGENE; SUBUNIT	Activated phosphoinositide 3-kinase (PI3K) and its downstream target Akt are essential for the fibroblast transformation induced by many viral products. Tax, encoded by human T-cell leukemia virus type I (HTLVI), has been demonstrated to induce the transformation of rat fibroblast Rat-1 cell through NF-kappaB activation, By stable transfection of Rat-1 cells with expressing constructs of Tax and its mutant M47, which is defective in HTLV-I LTR transactivation, we selected their transformed clones, which have characteristics of NF-kappaB activation and colony formation beyond the cell monolayer (a malignant phenotype), However, these two characteristics in the transformed clones of Tax and M47 disappear after these cells have been treated with wortmannin, a specific inhibitor of PI3K. Further, increased activity of the PI3K/Akt is observed in the transformed clones of Tax and M47 as compared to the clones of empty vector Neo and the M148, which is defective in NF-kappaB activation and cell transformation, Increased activity of PI5K is present in the transformed clones of both Tax and M47 and in the M148 clone as compared to that in the Neo cell, It is known that the efficiency of Tax-induced cell transformation is not high; a minority of Tax-expressing clones show transformation, although the majority of Tax-expressing clones show activated NF-kappaB, A Tax-expressing, nontransformed clone after transfection with an active form of the catalytic subunit of PI3K, p110 alpha, becomes transformed, Consistent with these results, a Tax highly-expressing human T-cell line MT2 exhibits both higher polyphosphoinositide turnover and higher activities of PI3K and PI5K than those of Jurkat or MT1 and HTLV-I-negative and a Tax-unexpressing cell line, respectively, These results demonstrate that the activation of the PI3K/Akt signaling pathway, excepting for the NF-kappaB, is also required for the cell transformation induced by Tax.	Toyama Med & Pharmaceut Univ, Dept Lab Med, Toyama 9300194, Japan; Kagoshima Univ, Fac Med, Dept Lab & Mol Med, Kagoshima 8908520, Japan; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Toyama; Kagoshima University; Tokyo Medical & Dental University (TMDU)	Kitajima, I (corresponding author), Toyama Med & Pharmaceut Univ, Dept Lab Med, 2630 Sugitani, Toyama 9300194, Japan.							Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2000, J BIOL CHEM, V275, P6267, DOI 10.1074/jbc.275.9.6267; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BEIMLING P, 1989, ONCOGENE, V4, P511; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Borlado LR, 2000, FASEB J, V14, P895; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Coscoy L, 1998, VIROLOGY, V248, P332, DOI 10.1006/viro.1998.9298; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; FERRELL JE, 1984, J CELL BIOL, V98, P1992, DOI 10.1083/jcb.98.6.1992; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUKUI Y, 1989, ONCOGENE RES, V4, P283; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GIAM CZ, 1986, P NATL ACAD SCI USA, V83, P7192, DOI 10.1073/pnas.83.19.7192; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kitajima I, 1997, ARTHRITIS RHEUM, V40, P2118, DOI 10.1002/art.1780401205; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1991, J CLIN INVEST, V88, P1315, DOI 10.1172/JCI115436; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mori N, 1999, BLOOD, V93, P2360; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; Osada M, 1999, MOL CELL BIOL, V19, P6333; Ozes ON, 1999, NATURE, V401, P82; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RIZZO MT, 1994, CANCER RES, V54, P2611; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SINGHAL RL, 1994, CANCER RES, V54, P5574; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	61	58	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2001	20	20					2514	2526		10.1038/sj.onc.1204364	http://dx.doi.org/10.1038/sj.onc.1204364			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420661				2022-12-17	WOS:000168652500002
J	Huang, YP; Ohtani, K; Iwanaga, R; Matsumura, Y; Nakamura, M				Huang, YP; Ohtani, K; Iwanaga, R; Matsumura, Y; Nakamura, M			Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I	ONCOGENE			English	Article						cell cycle; CREB; HTLV-I; NF-kappa B; tax; cyclin D2	EXPRESSION; PROTEIN; E2F; CANCER; LINES; ESTABLISHMENT; TRANSCRIPTION; ACCUMULATION; LYMPHOCYTES; PROGRESSION	Cyclins are one of the pivotal determinants regulating cell cycle progression. We previously reported that the trans-activator Tax of human T-cell leukemia virus type I(HTLV-I) induces endogenous cyclin D2 expression along with cell cycle progression in a resting human T-cell line, Kit 225, suggesting a role of cyclin D2 in Tax-mediated cell cycle progression, The cyclin D2 gene has a typical E2F binding element, raising the possibility that induction of cyclin D2 expression is a consequence of cell cycle progression. In this study, we examined the role and molecular mechanism of induction of the endogenous human cyclin D2 gene by Tax. Introduction of p19(INK4d), a cyclin dependent kinase (CDK) inhibitor of the INK4 family specific for D-type CDK, inhibited Tax-mediated activation of E2F, indicating requirement of D-type CDK in Tax-mediated activation of E2F, Previously indicated E2F binding element and, two NF-kappaB-like binding elements in the 1.6 kbp cyclin D2 promoter fragment had little, if any, effect on responsiveness to Tax, We found that trans-activation of the cyclin D2 promoter by Tax was mainly mediated by a newly identified NF-kappaB-like element with auxiliary contribution of a CRE-like element residing in sequences downstream of -444 which were by themselves sufficient for transactivation by Tax. These results indicate that Tax directly trans-activates the cyclin D2 gene, resulting in growth promotion and perhaps leukemogenesis through activation of D-type CDK.	Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Ohtani, K (corresponding author), Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.							AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akagi T, 1996, ONCOGENE, V12, P1645; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; Brooks AR, 1996, J BIOL CHEM, V271, P9090, DOI 10.1074/jbc.271.15.9090; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HORI T, 1987, BLOOD, V70, P1069; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Matsumoto K, 1997, J VIROL, V71, P4445, DOI 10.1128/JVI.71.6.4445-4451.1997; MINOWADA J, 1972, J NATL CANCER I, V49, P891; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NAKAMURA M, 1989, NUCLEIC ACIDS RES, V17, P5207, DOI 10.1093/nar/17.13.5207; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OHTANI K, 1987, EMBO J, V6, P389, DOI 10.1002/j.1460-2075.1987.tb04767.x; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takano Y, 1999, J PATHOL, V189, P194; Tanaka Y, 1996, J VIROL, V70, P8508, DOI 10.1128/JVI.70.12.8508-8517.1996; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	31	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1094	1102		10.1038/sj.onc.1204198	http://dx.doi.org/10.1038/sj.onc.1204198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314046	Bronze			2022-12-17	WOS:000167232100009
J	Mitsutake, N; Namba, H; Shklyaev, SS; Tsukazaki, T; Ohtsuru, A; Ohba, M; Kuroki, T; Ayabe, H; Yamashita, S				Mitsutake, N; Namba, H; Shklyaev, SS; Tsukazaki, T; Ohtsuru, A; Ohba, M; Kuroki, T; Ayabe, H; Yamashita, S			PKC delta mediates ionizing radiation-induced activation of c-Jun NH2-terminal kinase through MKK7 in human thyroid cells	ONCOGENE			English	Article						PKC delta; JNK; MKK7; thyroid cell; ionizing radiation	SIGNAL-TRANSDUCTION PATHWAYS; CERAMIDE-INDUCED APOPTOSIS; N-TERMINAL KINASE; KIDNEY 293 CELLS; PROTEIN-KINASE; MAP KINASE; TYROSINE KINASE; PROTEOLYTIC ACTIVATION; REGULATED KINASE; ISOFORMS	The thyroid gland is one of the most sensitive organs in ionizing radiation (IR)-induced carcinogenesis. To determine, therefore, the specific cascade of IR-induced signal transduction in human thyroid cells, we investigated the functional role of protein kinase C (PKC), especially its interlocking activation of c-Jun NH2-terminal kinase (JNK) pathway. In the present study, using adenovirus expression vectors for diverse dominant-negative (DN) types of PKC isoforms (alpha, beta2, delta, epsilon and zeta) expressed in primary cultured human thyroid cells, only DN/PKC delta suppressed IR-induced JNK activation. In addition, Rottlerin, a PKC delta specific inhibitor, inhibited IR-induced JNK activation. IR-induced activation of transcription factor AP-1, downstream target of JNK, was also attenuated by DN/PKC delta. To examine the involvement of upstream kinases of JNK, we performed immune-complex kinase assays of mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. IR activated MKK7 but not MKK4, and this activation was inhibited by Rottlerin. Furthermore, IR-induced JNK activation was suppressed by overexpression of kinase-deficient MKK7. Our results indicate that IR selectively activates the cascade of PKC delta -MKK7-JNK-AP-1 in human thyroid cells, suggesting a not apoptotic but radio-resistant role of PKC delta in human thyroid cells following IR.	Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Surg 1, Nagasaki 8528523, Japan; Nagasaki Univ, Sch Med, Dept Anat 1, Nagasaki 8528523, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428555, Japan	Nagasaki University; Nagasaki University; Nagasaki University; Showa University	Namba, H (corresponding author), Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan.		Kuroki, Toshio/A-9500-2011; Yamashita, Shunichi/GVS-9508-2022; Mitsutake, Norisato/U-9626-2018	Kuroki, Toshio/0000-0001-6369-4351; Mitsutake, Norisato/0000-0002-2744-8046; Yamashita, Shunichi/0000-0001-6399-6261				Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hara T, 1998, BIOCHEM BIOPH RES CO, V244, P41, DOI 10.1006/bbrc.1998.8210; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAWABE Y, 1989, J CLIN ENDOCR METAB, V68, P1174, DOI 10.1210/jcem-68-6-1174; Kawakami Y, 1998, J IMMUNOL, V161, P1795; Kuroki T, 1999, J INVEST DERM SYMP P, V4, P153, DOI 10.1038/sj.jidsp.5640200; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu XH, 1997, J BIOL CHEM, V272, P24751, DOI 10.1074/jbc.272.40.24751; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NAMBA H, 1995, CANCER RES, V55, P2075; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sautin Y, 2000, THYROID, V10, P733, DOI 10.1089/thy.2000.10.733; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WANG XD, 1995, THYROID, V5, P137, DOI 10.1089/thy.1995.5.137; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Xu X, 1996, ONCOGENE, V13, P135; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yamauchi J, 1997, J BIOL CHEM, V272, P7602, DOI 10.1074/jbc.272.12.7602; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	54	58	61	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					989	996		10.1038/sj.onc.1204179	http://dx.doi.org/10.1038/sj.onc.1204179			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314034				2022-12-17	WOS:000167097000010
J	Thomsen, P; van Deurs, B; Norrild, B; Kayser, L				Thomsen, P; van Deurs, B; Norrild, B; Kayser, L			The HPV16 E5 oncogene inhibits endocytic trafficking	ONCOGENE			English	Article						cytoskeleton; endocytic; human; papillomavirus; trafficking	HUMAN-PAPILLOMAVIRUS; H+-ATPASE; ONCOPROTEIN; ENDOSOMES; ACIDIFICATION; BAFILOMYCINS; EXPRESSION; LYSOSOMES; TRANSPORT; PROTEINS	The small hydrophobic E5 protein of Human Papillomavirus type 16 (HPV16) binds to the 16-kDa subunit of the V-H+-ATPase, This binding has been suggested to interfere with acidification of late endocytic structures. We here used video microscopy, ratio imaging and confocal microscopy of living C127 fibroblasts to study the effects of E5, Various endocytic markers including the pH-sensitive probe DM-NERF coupled to dextran, TransFluoSpheres and TRITC-concanavalin A, were applied. In ES-transfected cells, none of these markers colocalized with the membrane permeable probe Lyso-Tracker Red, which accumulates in acidic, late endocytic structures, or with a green fluorescent version of the small GTPase Rab7 labeling late endocytic structures. Importantly, however, late endocytic structures accumulating LysoTracker were still present in the E5-transfected cells. It is therefore concluded that HPV16 E5 perturbs trafficking from early to late endocytic structures rather than acidification.	Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Inst Mol Pathol, DK-2200 Copenhagen N, Denmark	University of Copenhagen; University of Copenhagen	van Deurs, B (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.							Bar-Ziv R, 1999, P NATL ACAD SCI USA, V96, P10140, DOI 10.1073/pnas.96.18.10140; Barois N, 1998, J CELL SCI, V111, P1791; BERGMAN P, 1988, ONCOGENE, V2, P453; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BUBB V, 1988, VIROLOGY, V163, P243, DOI 10.1016/0042-6822(88)90259-0; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Drose S, 1997, J EXP BIOL, V200, P1; Evans LL, 1998, J CELL SCI, V111, P2055; FAGOTTO F, 1994, J CELL SCI, V107, P3325; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; HALBERT CL, 1988, J VIROL, V62, P1071, DOI 10.1128/JVI.62.3.1071-1075.1988; Harada M, 1997, LIVER, V17, P244; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ishiguro H, 1996, J PHYSIOL-LONDON, V495, P179, DOI 10.1113/jphysiol.1996.sp021583; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Johnsen CK, 1995, INTERVIROLOGY, V38, P339, DOI 10.1159/000150461; Lee RJ, 1996, BBA-MOL CELL RES, V1312, P237, DOI 10.1016/0167-4889(96)00041-9; Lin HJ, 1999, ANAL BIOCHEM, V269, P162, DOI 10.1006/abio.1999.4011; LYASS LA, 1984, P NATL ACAD SCI-BIOL, V81, P3098, DOI 10.1073/pnas.81.10.3098; Magez S, 1997, J CELL BIOL, V137, P715, DOI 10.1083/jcb.137.3.715; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MCCANCE DJ, 1994, INFECT DIS CLIN N AM, V8, P751; MCCANCE DJ, 1985, BRIT J OBSTET GYNAEC, V92, P1101, DOI 10.1111/j.1471-0528.1985.tb03019.x; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Raposo G, 1999, MOL BIOL CELL, V10, P1477, DOI 10.1091/mbc.10.5.1477; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; SPARKOWSKI J, 1995, EMBO J, V14, P3055, DOI 10.1002/j.1460-2075.1995.tb07308.x; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Syrjanen SM, 1999, ANN MED, V31, P175, DOI 10.3109/07853899909115976; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; zur Hausen H, 1999, P ASSOC AM PHYSICIAN, V111, P581, DOI 10.1046/j.1525-1381.1999.99723.x	52	58	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6023	6032		10.1038/sj.onc.1204010	http://dx.doi.org/10.1038/sj.onc.1204010			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146554				2022-12-17	WOS:000165827900009
J	Lin, WC; Kao, HW; Robinson, D; Kung, HJ; Wu, CW; Chen, HC				Lin, WC; Kao, HW; Robinson, D; Kung, HJ; Wu, CW; Chen, HC			Tyrosine kinases and gastric cancer	ONCOGENE			English	Review						gastric cancer; protein-tyrosine kinase profile	EPIDERMAL GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; FACTOR-RECEPTOR EXPRESSION; IN-SITU HYBRIDIZATION; CARCINOMA CELL-LINES; K-SAM GENE; C-MET; HELICOBACTER-PYLORI; MESSENGER-RNA; FACTOR-ALPHA	Carcinoma of the stomach is one of the most prevalent cancer types in the world today, Two major forms of gastric cancer are distinguished according to their morphological and clinicopathological classifications (well differentiated/intestinal type and poorly differentiated/diffuse type), characteristics that could also be attributed to the altered expression of different types of oncogenes or tumor suppressor genes. Significant differences exist for gastric cancer incidence comparing people of different ethnic origins, implicating various genetic and epigenetic factors for gastric oncogenesis, There are only a limited number of molecular markers available for gastric cancer detection and prognostic evaluation, among which are tyrosine kinases, There is convincing evidence that tyrosine kinases are involved in oncogenesis and disease progression for many human cancers. Amplifications of certain tyrosine kinases (c-met, k-sam and cr erb2/neu) have been associated with human gastric cancer progression. Alternatively spliced transcripts and enhanced protein-expression levels for some of these tyrosine kinases are correlated,vith clinical outcomes for gastric cancer patients. With advent of high throughput techniques, it is now possible to detect nearly all expressed tyrosine kinases in a single screen. This increases the chance to identify additional tyrosine kinases as predictive markers for gastric cancers. In this article, we will first review the literature data concerning certain tyrosine kinases implicated in gastric carcinogenesis and then summarize more recent work which pro, ide comprehensive tyrosine kinase profiles for gastric cancer specimens and cell lines, Two new gastric cancer molecular markers (tie-1 and mkk4) have been identified through the use of these profiles and demonstrated effective as clinical prognostic indicators.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Univ Calif Davis, Ctr Canc, Sch Med, Dept Biol Chem, Sacramento, CA 95817 USA; Vet Gen Hosp, Dept Surg, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; Natl Hlth Res Inst, Div Biotechnol & Pharmaceut Res, Taipei 115, Taiwan	Academia Sinica - Taiwan; University of California System; University of California Davis; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan	Lin, WC (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.		Lin, Wen-chang/ABH-7976-2020; Kung, Hsing-Jien/C-7651-2013; Lin, Wen-chang/B-3100-2011	Lin, Wen-chang/0000-0003-0194-1745; Lin, Wen-chang/0000-0003-0194-1745				Agus DB, 1999, CANCER RES, V59, P4761; AJANI JA, 1995, WORLD J SURG, V19, P216, DOI 10.1007/BF00308629; Albino A P, 1995, Eur J Surg Oncol, V21, P56, DOI 10.1016/S0748-7983(05)80069-1; Anzai H, 1998, EUR J CANCER, V34, P558, DOI 10.1016/S0959-8049(97)10075-2; BALL M, 1997, NEUROBIOL AGING, V18, P1; BARRANCO SC, 1983, CANCER RES, V43, P1703; Baselga J, 1998, CANCER RES, V58, P2825; BEAUCHAMP RD, 1989, J CLIN INVEST, V84, P1017, DOI 10.1172/JCI114223; BORLINGHAUS P, 1993, CLIN INVESTIGATOR, V71, P903; Choi JH, 1997, CANCER-AM CANCER SOC, V79, P1879, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1879::AID-CNCR6>3.0.CO;2-B; Collesi C, 1996, MOL CELL BIOL, V16, P5518; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coyle WJ, 1999, AM J GASTROENTEROL, V94, P2885, DOI 10.1111/j.1572-0241.1999.01432.x; *DEP HLTH, 2000, LEAD CAUS DEATH CANC; DeRisi J, 1996, NAT GENET, V14, P457; Elitsur Y, 1999, LIFE SCI, V65, P1373, DOI 10.1016/S0024-3205(99)00376-8; Ernst SI, 1998, LAB INVEST, V78, P1633; FILIPE MI, 1995, BRIT J CANCER, V71, P30, DOI 10.1038/bjc.1995.7; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; FORMAN D, 1993, LANCET, V341, P1359; Gebhardt F, 1998, BIOCHEM BIOPH RES CO, V247, P319, DOI 10.1006/bbrc.1998.8779; Gospodarowicz Denis, 1989, Critical Reviews in Oncogenesis, V1, P1; Hara T, 1998, LAB INVEST, V78, P1143; Haruma K, 2000, INT J MOL MED, V5, P185; Hashiyama M, 1996, BLOOD, V87, P93; Hassan S, 1998, DIGEST DIS SCI, V43, P8, DOI 10.1023/A:1018851415704; Hattori Y, 1996, CLIN CANCER RES, V2, P1373; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; Hirao T, 1999, CANCER GENE THER, V6, P423, DOI 10.1038/sj.cgt.7700058; HIRONO Y, 1995, ONCOLOGY, V52, P182; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; ILEKIS JV, 1995, MOL REPROD DEV, V41, P149, DOI 10.1002/mrd.1080410205; ISHII H, 1995, MOL CELL BIOL, V15, P3664; ISHII H, 1994, CANCER RES, V54, P518; ITOH H, 1994, CANCER RES, V54, P3237; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jonjic N, 1997, ANTICANCER RES, V17, P3883; Jung T, 1999, EUR J IMMUNOL, V29, P864, DOI 10.1002/(SICI)1521-4141(199903)29:03<864::AID-IMMU864>3.0.CO;2-T; Kaji M, 1996, CANCER GENE THER, V3, P393; KAMEDA T, 1990, CANCER RES, V50, P8002; KAMEDA T, 1992, PATHOL RES PRACT, V188, P37, DOI 10.1016/S0344-0338(11)81153-2; Kang JJ, 1997, METHODS, V13, P437, DOI 10.1006/meth.1997.0549; KARAMERIS A, 1993, PATHOL RES PRACT, V189, P133, DOI 10.1016/S0344-0338(11)80082-8; Kataoka H, 1998, LIFE SCI, V63, P553, DOI 10.1016/S0024-3205(98)00306-3; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KIM SJ, 1995, BIOCHEM BIOPH RES CO, V214, P60, DOI 10.1006/bbrc.1995.2256; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; KIYAMA T, 1992, GASTROENTEROL JPN, V27, P459; KIYOKAWA E, 1994, CANCER RES, V54, P3645; Koizumi H, 1998, PATHOL INT, V48, P93, DOI 10.1111/j.1440-1827.1998.tb03877.x; Kono K, 2000, TUMOR BIOL, V21, P139, DOI 10.1159/000030120; Kuniyasu H, 2000, LANGENBECK ARCH SURG, V385, P69, DOI 10.1007/s004230050248; KUNIYASU H, 1993, INT J CANCER, V55, P72, DOI 10.1002/ijc.2910550114; KUNIYASU H, 1992, BIOCHEM BIOPH RES CO, V189, P227, DOI 10.1016/0006-291X(92)91548-5; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; Lee H, 1998, ONCOGENE, V16, P3243, DOI 10.1038/sj.onc.1201866; Lee HR, 1996, ONCOLOGY-BASEL, V53, P192; Lin JS, 1998, J BIOMED SCI, V5, P101, DOI 10.1159/000025319; LIN JT, 1995, CANCER RES, V55, P1428; Lin WC, 1999, CLIN CANCER RES, V5, P1745; Liu SI, 1997, ANTICANCER RES, V17, P3575; LIVINGSTONE JI, 1995, BRIT J CANCER, V72, P976, DOI 10.1038/bjc.1995.445; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masaki T, 2000, AM J GASTROENTEROL, V95, P2135; McCulloch P, 1997, EUR J SURG ONCOL, V23, P304, DOI 10.1016/S0748-7983(97)90669-7; MCCULLOCH PG, 1995, CANCER, V75, P920, DOI 10.1002/1097-0142(19950215)75:4<920::AID-CNCR2820750405>3.0.CO;2-E; Meyer-ter-Vehn T, 2000, J BIOL CHEM, V275, P16064, DOI 10.1074/jbc.M000959200; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Ming Si-Chun, 1998, Gastric Cancer, V1, P31, DOI 10.1007/s101200050053; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Molina R, 1997, TUMOR BIOL, V18, P188, DOI 10.1159/000218029; MOTOJIMA K, 1994, SURGERY, V115, P349; Nakajima M, 1999, CANCER, V85, P1894; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Neugut AI, 1996, SEMIN ONCOL, V23, P281; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; OHNISHI Y, 1995, BRIT J CANCER, V71, P969, DOI 10.1038/bjc.1995.187; Okino T, 1999, INT J ONCOL, V15, P709; ONeill AJ, 1997, J PATHOL, V183, P325, DOI 10.1002/(SICI)1096-9896(199711)183:3<325::AID-PATH941>3.0.CO;2-A; Ooi A, 1998, LAB INVEST, V78, P345; Orita H, 1997, HEPATO-GASTROENTEROL, V44, P294; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 2000, APMIS, V108, P195, DOI 10.1034/j.1600-0463.2000.d01-44.x; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PERNG CL, 1994, CHUNG HUA I HSUEH TS, V54, P82; Ries L, 2000, SEER CANC STAT REV 1; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Romano M, 1998, J CLIN INVEST, V101, P1604, DOI 10.1172/JCI1174; Saily M, 1999, ANN HEMATOL, V78, P173, DOI 10.1007/s002770050496; Sakurai S, 1999, JPN J CANCER RES, V90, P1321, DOI 10.1111/j.1349-7006.1999.tb00715.x; Santoro E, 1997, HEPATO-GASTROENTEROL, V44, P826; Sanz-Ortega J, 2000, HISTOL HISTOPATHOL, V15, P455, DOI 10.14670/HH-15.455; Sato T, 1997, PATHOL INT, V47, P179, DOI 10.1111/j.1440-1827.1997.tb03737.x; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; Sayani F, 2000, BLOOD, V95, P461, DOI 10.1182/blood.V95.2.461; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; Scott CD, 2000, J CELL PHYSIOL, V182, P62, DOI 10.1002/(SICI)1097-4652(200001)182:1<62::AID-JCP7>3.0.CO;2-X; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; SEKI T, 1985, JPN J CANCER RES, V76, P907; SEKIGUCHI M, 1978, JPN J EXP MED, V48, P61; SERUCA R, 1995, CANCER GENET CYTOGEN, V82, P140, DOI 10.1016/0165-4608(95)00033-L; SHIMIZU Y, 1991, CANCER RES, V51, P6153; Slesak B, 1998, ANTICANCER RES, V18, P2727; Stebbing J, 2000, CANCER TREAT REV, V26, P287, DOI 10.1053/ctrv.2000.0182; SUZUKI S, 1995, BRIT J CANCER, V72, P663, DOI 10.1038/bjc.1995.391; TAHARA E, 1995, CANCER, V75, P1410, DOI 10.1002/1097-0142(19950315)75:6+<1410::AID-CNCR2820751504>3.0.CO;2-O; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Takaishi S, 2000, BIOCHEM BIOPH RES CO, V267, P658, DOI 10.1006/bbrc.1999.2010; TAKESHIMA E, 1991, JPN J CANCER RES, V82, P1428, DOI 10.1111/j.1349-7006.1991.tb01816.x; TAKI T, 1985, J BIOCHEM-TOKYO, V98, P887, DOI 10.1093/oxfordjournals.jbchem.a135368; Taniguchi K, 1998, CANCER, V82, P2112, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2112::AID-CNCR5>3.3.CO;2-U; Tokuda Y, 1996, BRIT J CANCER, V73, P1362, DOI 10.1038/bjc.1996.259; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; Tsugawa K, 1998, ONCOLOGY-BASEL, V55, P475, DOI 10.1159/000011898; TSUGAWA K, 1993, ONCOLOGY, V50, P418; Tsujimoto H, 1997, VIRCHOWS ARCH, V431, P383, DOI 10.1007/s004280050115; Turner JR, 2000, AM J PHYSIOL-GASTR L, V278, pG805, DOI 10.1152/ajpgi.2000.278.5.G805; UCHINO S, 1993, CANCER, V72, P3179, DOI 10.1002/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#; Ueda T, 1999, CANCER RES, V59, P6080; Ueda T, 1999, BIOCHEM BIOPH RES CO, V265, P739, DOI 10.1006/bbrc.1999.1735; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Vidgren V, 1999, GENE CHROMOSOME CANC, V24, P24, DOI 10.1002/(SICI)1098-2264(199901)24:1<24::AID-GCC4>3.0.CO;2-H; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; Wu CW, 1998, ONCOL REP, V5, P817; Wu CW, 2000, AM J PATHOL, V156, P2007, DOI 10.1016/S0002-9440(10)65073-0; Wu CW, 2000, WORLD J SURG, V24, P465, DOI 10.1007/s002689910074; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4; Yasui W, 1999, PATHOL INT, V49, P763, DOI 10.1046/j.1440-1827.1999.00951.x; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; YONEMURA Y, 1991, CANCER RES, V51, P1034; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; YONEMURA Y, 1992, ONCOLOGY, V49, P157; YONEMURA Y, 1991, ANAL CELL PATHOL, V3, P343; YONEMURA Y, 1989, ONCOLOGY, V46, P158; YOSHIDA K, 1989, VIRCHOWS ARCH B, V57, P285, DOI 10.1007/BF02899093; YOSHIDA K, 1990, JPN J CANCER RES, V81, P43, DOI 10.1111/j.1349-7006.1990.tb02505.x	144	58	64	1	11	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2000	19	49					5680	5689		10.1038/sj.onc.1203924	http://dx.doi.org/10.1038/sj.onc.1203924			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379TV	11114748				2022-12-17	WOS:000165659300015
J	Lee, TH; Chuang, LY; Hung, WC				Lee, TH; Chuang, LY; Hung, WC			Induction of p21(WAF1) expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells	ONCOGENE			English	Article						tamoxifen; p21(WAF1); protein kinase A; estrogen receptor	PROTEIN-KINASE-C; TRANSCRIPTION FACTOR SP1; SIGNAL-TRANSDUCTION; WAF1/CIP1 GENE; BREAST-CANCER; DNA-BINDING; GROWTH; PHOSPHORYLATION; ACTIVATION; INHIBITION	Although originally synthesized as an anti-estrogen, tamoxifen (Tam) was found to be able to inhibit proliferation of estrogen receptor (ER)-negative cancer cells in vitro. However, the molecular basis of such ER-independent growth inhibition is largely unknown. We have previously demonstrated that Tam induces p21(WAF1) and p27(KIP1) expression in human lung cancer cells which lack ER-alpha and -beta. We found that Tam induced p21(WAF1) expression via transcriptional activation. In order to determine the molecular mechanism responsible for p21(WAF1) induction by Tam, we performed a deletion analysis on the p21(WAF1) promoter. The minimal region in the p21(WAF1) promoter required for Tam-activated induction mas mapped to a contiguous stretch of 10 bp located 83 bases upstream of the transcription initiation site. Our results showed that transcription factor Sp1 and Sp3 bound to this GC-rich region and mutation of Sp1-binding sites dramatically attenuated Tam-induced p21(WAF1) promoter activity. We also tried to elucidate the signaling pathway that mediated the activation of p21(WAF1) by Tam, Inhibition of mitogen-activated protein kinase pathways did not block Tam-induced p21(WAF1). Similarly, protein kinase C inhibitor calphostin C could not suppress Tam-induced p21(WAF1). Conversely, pretreatment of a specific protein kinase A inhibitor H89 significantly attenuated the induction of p21(WAF1) by Tam, Furthermore, PKA activators forskolin and dibutyryl-cAMP activated p21(WAF1) promoter activity and increased p21(WAF1) protein level in lung cancer cells. Taken together, these results demonstrate that Tam activates the p21(WAF1) promoter via Sp1-binding sites and suggest that PKA may be involved in the induction of p21(WAF1) by Tam in ER-negative Lung cancer cells.	Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Biochem, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Grad Inst Med, No 100 Shih-Chuan 1st Rd, Kaohsiung 807, Taiwan.		Chuang, Lea-Yea/C-7450-2009					Ahlgren R, 1999, J BIOL CHEM, V274, P19422, DOI 10.1074/jbc.274.27.19422; ANDREW NC, 1991, NUC ACIDS RES, V19, P6418; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Bennett WP, 1998, CLIN CANCER RES, V4, P1499; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1996, ONCOGENE, V13, P2047; Caputi M, 1998, AM J RESP CELL MOL, V18, P213, DOI 10.1165/ajrcmb.18.2.2937m; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Catzavelos C, 1999, CANCER RES, V59, P684; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COULDWELL WT, 1993, NEUROSURGERY, V32, P485, DOI 10.1227/00006123-199303000-00034; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; DUHL JL, 1997, PHARMACEUT RES, V14, P186; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Komiya T, 1997, CLIN CANCER RES, V3, P1831; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Menard S, 2000, CANCER RES, V60, P273; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rao S, 1999, EXP CELL RES, V252, P211, DOI 10.1006/excr.1999.4620; Robinson EK, 1998, ANN SURG ONCOL, V5, P342, DOI 10.1007/BF02303498; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; Rohlff C, 1998, PROSTATE, V37, P51, DOI 10.1002/(SICI)1097-0045(19980915)37:1<51::AID-PROS8>3.0.CO;2-B; ROWLANDS MG, 1990, BIOCHEM PHARMACOL, V40, P283, DOI 10.1016/0006-2952(90)90689-I; White LA, 1997, J NEUROSCI RES, V47, P242, DOI 10.1002/(SICI)1097-4547(19970201)47:3<242::AID-JNR2>3.0.CO;2-I; Yatabe Y, 1998, CANCER RES, V58, P1042; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	48	58	58	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3766	3773		10.1038/sj.onc.1203715	http://dx.doi.org/10.1038/sj.onc.1203715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949931				2022-12-17	WOS:000088568400009
J	Ceballos, E; Delgado, MD; Gutierrez, P; Richard, C; Muller, D; Eilers, M; Ehinger, M; Gullberg, U; Leon, J				Ceballos, E; Delgado, MD; Gutierrez, P; Richard, C; Muller, D; Eilers, M; Ehinger, M; Gullberg, U; Leon, J			c-Myc antagonizes the effect of p53 on apoptosis and p21(WAF1) transactivation in K562 leukemia cells	ONCOGENE			English	Article						myc; p53; leukemia; K562; apoptosis; transactivation	WILD-TYPE P53; CHRONIC MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR GENE; TEMPERATURE-SENSITIVE MUTANT; CHRONIC MYELOGENOUS LEUKEMIA; GROWTH ARREST; MEDIATED APOPTOSIS; BLASTIC CRISIS; TARGET GENES; CYCLE ARREST	c-myc protooncogene positively regulates cell proliferation and overexpression of c-myc is found in many solid tumors and leukemias, In the present study we used the K562 human myeloid leukemia cell line as a model to study the functional interaction between c-Myc and p53. Using two different methods, we generated K562 transfectant cell lines with conditional expression of either c-Myc or p53. The cells expressed the p53(Vall35) mutant, which adopts a mild-type conformation at 32 degrees C, while c-Myc induction was achieved with a zinc-inducible expression vector. We found that p53 in mild-type conformation induces growth arrest and apoptosis of K562. Expression of c-Myc significantly attenuated apoptosis and impaired the transcriptional activity of D53 on p21(WAF1), fax and cytomegalovirus promoters. The impairment of p21(WAF1) transactivation by c-Myc was confirmed by transfection of a c-Myc-estrogen receptor fusion protein and by induction of c-myc by zinc in transfected cells. Also, p53-mediated up-regulation of p21(WAF1) mRNA protein mere significantly reduced by Myc, while Bas levels were unaffected. Consistently, c- Myc increased cyclin-dependent kinase 2 activity in K562 cells expressing p53 in wild-type conformation These results suggest that c-Myc overexpression may antagonize the pro-apoptotic function of p53, thus providing a molecular mechanism for frequently observed deregulation of c-myc in human cancer.	Hosp Marques de Valdecilla, Serv Hematol, Santander, Spain; Univ Marburg, Inst Mol Biol & Tumor Res, Marburg, Germany; Lund Univ, Dept Hematol, Lund, Sweden	Hospital Universitario Marques de Valdecilla (HUMV); Philipps University Marburg; Lund University	Leon, J (corresponding author), Fac Med, Dept Biol Mol, Santander 39011, Spain.		Ehinger, Mats/H-8457-2016; Leon, Javier/K-4615-2014; Delgado, M. Dolores/K-9056-2014	Ehinger, Mats/0000-0003-2342-1679; Leon, Javier/0000-0001-5803-0112; Delgado, M. Dolores/0000-0003-4682-4040; Eilers, Martin/0000-0002-0376-6533				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Alarcon RM, 1996, CANCER RES, V56, P4315; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; AMATI B, 1998, FRONT BIOSCI, V3, pD520; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Beck Z, 1998, LEUKEMIA LYMPHOMA, V30, P293, DOI 10.3109/10428199809057542; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BERNS EMJJ, 1992, CANCER RES, V52, P1107; BI S, 1993, LEUKEMIA, V7, P1840; BLYTH K, 1995, ONCOGENE, V10, P1717; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delgado MD, 2000, ONCOGENE, V19, P783, DOI 10.1038/sj.onc.1203384; DELGADO MD, 1995, ONCOGENE, V10, P1659; Donzelli M, 1999, ONCOGENE, V18, P439, DOI 10.1038/sj.onc.1202309; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Handa H, 1997, LEUKEMIA RES, V21, P479, DOI 10.1016/S0145-2126(97)00006-4; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JACKSON P, 1993, ONCOGENE, V8, P589; Jennings BA, 1998, LEUKEMIA RES, V22, P899, DOI 10.1016/S0145-2126(98)00097-6; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1995, ONCOGENE, V11, P2311; Kremenetskaya OS, 1997, ONCOL RES, V9, P155; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; Melo JV, 1996, LEUKEMIA, V10, P751; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; NAKAI H, 1995, LEUKEMIA LYMPHOMA, V19, P213, DOI 10.3109/10428199509107891; NEWCOMB EW, 1995, LEUKEMIA LYMPHOMA, V17, P211, DOI 10.3109/10428199509056825; Peller S, 1998, GENE CHROMOSOME CANC, V21, P2, DOI 10.1002/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; PREISLER HD, 1990, EUR J CANCER, V26, P960, DOI 10.1016/0277-5379(90)90620-9; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAGIMOV N, 1993, ONCOGENE, V8, P1183; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Sakamuro D, 1995, ONCOGENE, V11, P2411; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Sonenshein GE, 1997, J IMMUNOL, V158, P1994; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAYLOR WR, 1992, ONCOGENE, V7, P1383; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Trepel M, 1997, LEUKEMIA, V11, P1842, DOI 10.1038/sj.leu.2400824; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Waikel RL, 1999, ONCOGENE, V18, P4870, DOI 10.1038/sj.onc.1203040; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; WU R, 1988, J EXP MED, V187, P1671; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zeng YX, 1996, ONCOGENE, V12, P1557; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	89	58	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2000	19	18					2194	2204		10.1038/sj.onc.1203541	http://dx.doi.org/10.1038/sj.onc.1203541			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZP	10822369				2022-12-17	WOS:000086974100004
J	Brandt, R; Eisenbrandt, R; Leenders, F; Zschiesche, W; Binas, B; Juergensen, C; Theuring, F				Brandt, R; Eisenbrandt, R; Leenders, F; Zschiesche, W; Binas, B; Juergensen, C; Theuring, F			Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation	ONCOGENE			English	Article						adenocarcinoma; epidermal growth factor receptor; mammary gland; transgenic mice; differentiation	EPIDERMAL GROWTH-FACTOR; HUMAN BREAST-CANCER; FACTOR-ALPHA; TGF-ALPHA; FUNCTIONAL-DIFFERENTIATION; BETA-LACTOGLOBULIN; GENE-EXPRESSION; EGF-RECEPTOR; HUMAN COLON; MICE	The epidermal growth factor receptor (EGFR) is overexpressed in about 48% of human breast cancer tissues. To analyse the role of the EGFR in mammary tumor development me generated transgenic mice expressing the human EGFR under the control of either the MMTV-LTR (MHERc) or the beta-lactoglobulin promoter (BLGHERc), The BLGHERc-transgene was expressed exclusively in the female mammary. gland, whereas the MHERc transgene was expressed more promiscuously in other organs, such as ovary, salivary gland and testis, Female virgin and lactating transgenic mice of both strains have impaired mammary gland development. Virgin EGFR transgenic mice developed mammary epithelial hyperplasias, whereas in lactating animals progression to dysplasias and tubular adenocarcinomas was observed. In both strains the number of dysplasias increased after multiple pregnancies. The transgene expression pattern mas heterogeneous, but generally restricted to regions of impaired mammary gland development. Highest EGFR transgene expression was observed in adenocarcinomas. By using a whole mount organ culture sa stem to study the differentiation potential of the mammary epithelium, we observed a reduced number of fully developed alveoli and a decrease in whey acidic protein expression. Taken together, EGFR overexpression results in a dramatic effect of impaired mammary gland development in vitro as well as in vitro, reducing the differentiation potential of the mammary epithelium and inducing epithelial cell transformation.	Univ Hosp Berlin, Inst Pharmacol & Toxicol, Charite, D-10117 Berlin, Germany; Schering Res Labs, D-13342 Berlin, Germany; MDC Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Theuring, F (corresponding author), Univ Hosp Berlin, Inst Pharmacol & Toxicol, Charite, Dorotheen Str 94, D-10117 Berlin, Germany.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALKASSPOOLES M, 1993, INT J CANCER, V54, P213, DOI 10.1002/ijc.2910540209; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; ARCHIBALD AL, 1990, P NATL ACAD SCI USA, V87, P5178, DOI 10.1073/pnas.87.13.5178; BANERJEE MR, 1973, IN VITRO CELL DEV B, V9, P129, DOI 10.1007/BF02616011; BARASH I, 1994, TRANSGENIC RES, V3, P141, DOI 10.1007/BF01973981; BASELGA J, 1994, BREAST CANCER RES TR, V29, P127, DOI 10.1007/BF00666188; BORG A, 1991, ONCOGENE, V6, P137; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1989, ONCOGENE, V4, P831; FAN Z, 1993, CANCER RES, V53, P4322; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; GOLDENRING JR, 1993, REGUL PEPTIDES, V43, P37, DOI 10.1016/0167-0115(93)90405-W; GRAMLICH TL, 1994, AM J CLIN PATHOL, V101, P493; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; HARRIS AL, 1987, REGULATORY MECHANISM, P93; HENNIGHAUSEN L, 1994, CELL GROWTH DIFFER, V5, P607; Hinrichs S H, 1991, Princess Takamatsu Symp, V22, P259; KLIJN JGM, 1992, ENDOCR REV, V13, P3, DOI 10.1210/er.13.1.3; Krane IM, 1996, ONCOGENE, V12, P1781; LEE PPH, 1995, ENDOCRINOLOGY, V136, P1718, DOI 10.1210/en.136.4.1718; LIU TH, 1995, CHINESE MED J-PEKING, V108, P653; Matsui Y., 1990, CELL, V61, P1137; MCCLENAGHAN M, 1995, BIOCHEM J, V310, P637, DOI 10.1042/bj3100637; MULLANEY BP, 1992, MOL ENDOCRINOL, V6, P2103, DOI 10.1210/me.6.12.2103; MULLER WJ, 1991, CANCER METAST REV, V10, P217, DOI 10.1007/BF00050793; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; RAJAGOPAL S, 1995, INT J CANCER, V62, P661, DOI 10.1002/ijc.2910620603; RIVERA EM, 1967, METHODS MAMMAL EMBRY, V31, P442; Salomon D S, 1991, Cancer Treat Res, V53, P107; SIMONS JP, 1987, NATURE, V328, P530, DOI 10.1038/328530a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPITZER E, 1995, J CELL BIOCHEM, V57, P495, DOI 10.1002/jcb.240570315; THEURING F, 1995, FIBRINOLYSIS, V9, P277, DOI 10.1016/S0268-9499(95)80016-6; TORTORA G, 1989, FEBS LETT, V242, P363, DOI 10.1016/0014-5793(89)80502-2; Whitelaw C B, 1991, Transgenic Res, V1, P3, DOI 10.1007/BF02512991; YEE LD, 1989, SEMIN DIAGN PATHOL, V6, P110; YULL F, 1996, TRANSGENIC RES, V6, P7	42	58	61	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 20	2000	19	17					2129	2137		10.1038/sj.onc.1203520	http://dx.doi.org/10.1038/sj.onc.1203520			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815804				2022-12-17	WOS:000086728000006
J	Yang, XH; He, ZM; Xin, BZ; Cao, L				Yang, XH; He, ZM; Xin, BZ; Cao, L			LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16(INK4a) expression	ONCOGENE			English	Article						EBV/LMP1; senescense; p16(INK4a); p21(WAF1)	LYMPHOCYTE GROWTH TRANSFORMATION; LATENT MEMBRANE PROTEIN-1; NF-KAPPA-B; HUMAN-DIPLOID FIBROBLASTS; REPLICATIVE SENESCENCE; NASOPHARYNGEAL CARCINOMAS; TUMOR-SUPPRESSOR; POINT MUTATION; P53 GENE; CELLS	Epstein-Barr virus is associated with a number of human proliferative and malignant diseases. It is capable of immortalizing human primary B-lymphocytes in vitro. Studies indicate that latent membrane protein LMP1 is one of the viral proteins essential for this process. In this report, LMP1 was shown to prevent primary mouse embryonic fibroblasts from entering into replicative senescence in vitro. It further suppresses the senescence-associated induction of p16(INK4a), commonly believed to be a key regulator of replicative senescence. In addition, LMP1 was shown to prevent premature senescence provoked by oncogenic ras in mouse embryonic fibroblasts, and to inhibit the oncogene ras-mediated induction of p16(INK4a) and p21(WAF1). In parallel, LMP1 also prevents ras-induced premature senescence in rat embryonic fibroblasts REF52 and human diploid fibroblasts IMR90. Moreover, LMP1 is capable of suppressing the p16(INK4a) promoter in REF52 and Saos-2 cells in a promoter reporter assay. Our findings suggest that with the expression of p16(INK4a) and replicative senescence being suppressed, LMP1 may play a key role in Epstein-Barr virus-associated proliferative diseases, and it may further contribute to cancer development by preventing premature senescence induced by mitogenic oncogenes.	Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Cao, L (corresponding author), Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China.		Cao, Liang/K-7806-2017	Cao, Liang/0000-0001-7293-8338				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; BAICHWAL VR, 1989, ONCOGENE, V4, P67; Bond J, 1996, ONCOGENE, V13, P2097; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; Gulley ML, 1998, AM J PATHOL, V152, P865; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARVEY M, 1993, ONCOGENE, V8, P2457; HAUSEN HZ, 1970, NATURE, V227, P245, DOI 10.1038/227245a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENLE G, 1969, J NATL CANCER I, V43, P1147; HUEN DS, 1995, ONCOGENE, V10, P549; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; JARRETT RF, 1991, J CLIN PATHOL, V44, P844, DOI 10.1136/jcp.44.10.844; Kaye KM, 1999, J VIROL, V73, P10525, DOI 10.1128/JVI.73.12.10525-10530.1999; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kieff E., 1996, FIELDS VIROLOGY, P2343; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PURTILO DT, 1975, LANCET, V1, P936; RAABTRAUB N, 1986, CELL, V47, P883, DOI 10.1016/0092-8674(86)90803-2; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SPRUCK CH, 1992, CANCER RES, V52, P4787; Stein GH, 1999, MOL CELL BIOL, V19, P2109; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Yang XH, 2000, J VIROL, V74, P883, DOI 10.1128/JVI.74.2.883-891.2000; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	70	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2000	19	16					2002	2013		10.1038/sj.onc.1203515	http://dx.doi.org/10.1038/sj.onc.1203515			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803461				2022-12-17	WOS:000086613200004
J	Javelaud, D; Wietzerbin, J; Delattre, O; Besancon, F				Javelaud, D; Wietzerbin, J; Delattre, O; Besancon, F			Induction of p21(Waf1/Cip1) by TNF alpha requires NF-kappa B activity and antagonizes apoptosis in Ewing tumor cells	ONCOGENE			English	Article						Ewing tumor; NF-kappa B; TNF alpha; apoptosis; p21(Waf1/Cip1)	COLORECTAL-CARCINOMA CELLS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; FUSION PROTEIN; SARCOMA CELLS; GENE FUSION; TRANSLOCATION; FAMILY; INHIBITION	The Ewing family of tumors is characterized by recurrent reciprocal translocations that generate chimeric proteins, either EWS-FLI-1 or EWS-ERG, These proteins are potent transcriptional activators and are responsible for maintaining the oncogenic properties of tumor cells. Since apoptosis appears to be the main mechanism whereby chemotherapy and radiation kill tumor cells, identification of events that can antagonize apoptosis in Ewing tumors is essential for improving their response to conventional therapies. Here, we report that the transcriptional factor NF-kappa B is a survival factor for Ewing tumor-derived cells. In fact, inhibition of NF-kappa B activation as a consequence of the overexpression of a degradation-resistant form of I kappa B alpha, I kappa-B alpha (A32/36), sensitized these cells to TNF alpha-induced killing. Although treatment with TNF alpha did not modify the cellular expression of Bcl-2, c-IAP1, c-IAP2, D53 and EWS-FLI-1 proteins, it increased p21(Waf1/Cip1) levels. This induction required NF-kappa B activation since it mas not observed in the I kappa B alpha (A32/36) expressing cells. Moreover, overexpression of p21(Waf1/Cip1) in these I kappa B alpha (A32/ 36)-expressing cells, in which NF-kappa B and consequently p21(Waf1/Cip1) are no longer inducible by TNF alpha, decreased their susceptibility to TNF alpha-induced killing. Our results therefore identify p21(Waf1/Cip1) as a mediator of the antiapoptotic effect of TNF alpha-induced NF-kappa B in Ewing tumor cells.	Inst Curie, INSERM, U365, F-75005 Paris, France; Inst Curie, INSERM, U509, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75005 Paris, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739; delattre, olivier/0000-0002-8730-2276				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertrand F, 1998, J BIOL CHEM, V273, P2931, DOI 10.1074/jbc.273.5.2931; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DeLuca C, 1998, VIROLOGY, V244, P27, DOI 10.1006/viro.1998.9085; FISHER LJ, 1993, CAN J ANIM SCI, V73, P539, DOI 10.4141/cjas93-058; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Horowitz Marc E., 1997, P831; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jiang YL, 1998, BIOCHEM BIOPH RES CO, V245, P691, DOI 10.1006/bbrc.1998.8390; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; LIPINSKI M, 1987, CANCER RES, V47, P183; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; MUNOZ E, 1994, J VIROL, V68, P8035; NOGUERA R, 1992, LAB INVEST, V66, P143; OHNO T, 1993, CANCER RES, V53, P5859; OREGAN S, 1995, J NEUROCHEM, V64, P69; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	57	58	58	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					61	68		10.1038/sj.onc.1203246	http://dx.doi.org/10.1038/sj.onc.1203246			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644980				2022-12-17	WOS:000084844300007
J	Blagosklonny, MV; An, WG; Melillo, G; Nguyen, P; Trepel, JB; Neckers, LM				Blagosklonny, MV; An, WG; Melillo, G; Nguyen, P; Trepel, JB; Neckers, LM			Regulation of BRCA1 by protein degradation	ONCOGENE			English	Article						BRCA1; protein degradation; proteasome; acidic proteases; cathepsin; calpain	SUSCEPTIBILITY GENE-PRODUCT; BREAST-CANCER CELLS; NUCLEAR EXPORT; P53 PROTEIN; TRANSCRIPTIONAL ACTIVATION; PROTEOLYTIC CLEAVAGE; MUTATED P53; DNA-DAMAGE; IN-VIVO; EXPRESSION	BRCA1, a tumor suppressor protein implicated in hereditary forms of breast and ovarian cancer, is transcriptionally regulated in a proliferation-dependent manner. In this study, we demonstrate a substantial role for proteolysis in regulating the BRCA1 steady-state protein level in several cell lines. N-acetyl-leu-leu-norleucinal (ALLN), an inhibitor of the proteasome, calpain, and cathepsins, caused BRCA1 protein to accumulate in the nucleus of several human breast, prostate, and melanoma cell lines which express low or undetectable basal levels of BRCA1 protein, but not in cells with high basal expression of BRCA1. Protease inhibition did not increase BRCA1 synthesis, nor change its mRNA level, but it dramatically prolonged the protein's half-life. In contrast to ALLN, lactacystin and PS341, two specific proteasome inhibitors, as well as calpastatin peptide and PD150606, two selective calpain inhibitors, had no effect on BRCA1 stability, whereas ALLM, an effective calpain and cathepsin inhibitor but weak proteasome inhibitor, did stimulate accumulation of BRCA1. Moreover, three inhibitors of acidic cysteine proteases, chloroquine, ammonium chloride and bafilomycin, were as effective as ALLN. These results demonstrate that degradation by a cathepsin-like protease in fine balance with BRCA1 transcription is responsible for maintaining the low steady-state level of BRCA1 protein seen in many cancer cells.	NCI, Med Branch, Dept Therapeut, NIH, Rockville, MD 20850 USA; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, LM (corresponding author), NCI, Med Branch, Dept Therapeut, NIH, 9610 Med Ctr Dr,Suite 300, Rockville, MD 20850 USA.				NATIONAL CANCER INSTITUTE [ZIASC010074, Z01SC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Aprelikova O, 1996, ONCOGENE, V13, P2487; Bishop DT, 1997, SEMIN CANCER BIOL, V8, P45, DOI 10.1006/scbi.1997.0053; Blackwood MA, 1998, J CLIN ONCOL, V16, P1969, DOI 10.1200/JCO.1998.16.5.1969; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fu YHF, 1998, FEBS LETT, V421, P89, DOI 10.1016/S0014-5793(97)01541-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; GUDAS JM, 1995, CANCER RES, V55, P4561; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; INOUE S, 1991, J BIOL CHEM, V266, P13311; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KASTAN MB, 1991, CANCER RES, V51, P6304; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Maki CG, 1996, CANCER RES, V56, P2649; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NISHI K, 1994, J BIOL CHEM, V269, P6320; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Paoletti F, 1997, J CELL PHYSIOL, V172, P63, DOI 10.1002/(SICI)1097-4652(199707)172:1<63::AID-JCP7>3.3.CO;2-F; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Scheffner M, 1998, PHARMACOL THERAPEUT, V78, P129, DOI 10.1016/S0163-7258(98)00003-5; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	54	58	59	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6460	6468		10.1038/sj.onc.1203068	http://dx.doi.org/10.1038/sj.onc.1203068			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597248				2022-12-17	WOS:000083709200008
J	Morinaka, K; Koyama, S; Nakashima, S; Hinoi, T; Okawa, K; Iwamatsu, A; Kikuchi, A				Morinaka, K; Koyama, S; Nakashima, S; Hinoi, T; Okawa, K; Iwamatsu, A; Kikuchi, A			Epsin binds to the EH domain of POB1 and regulates receptor-mediated endocytosis	ONCOGENE			English	Article						Epsin; POB1; EH domain; endocytosis	NUCLEOTIDE DISSOCIATION STIMULATOR; TYROSINE KINASE SUBSTRATE; RAS-INDUCED TRANSFORMATION; INSULIN-RECEPTOR; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; NERVE-TERMINALS; EPS15 HOMOLOGY; DUAL ROLE	POB1 has been identified as a RalBP1-binding protein and has the Eps15 homology (EH) domain. The EH domain-containing proteins have been suggested to be involved in clathrin-dependent endocytosis. To clarify the function of POB1, we purified a protein which binds to the EH domain of POB1 from bovine brain cytosol and identified it as Epsin, which is known to bind to the EH domain of Eps15. Epsin has three Asn-Pro-Phe (NPF) motifs in the C-terminal region, which are known to form the core sequence for the binding to the EH domain. The EH domain of POB1 interacted directly with the region containing the NPF motifs of Epsin. Expression of Epsin in CHO-IR cells inhibited internalization of insulin although it affected neither insulin-binding nor autophosphorylation activities of the insulin receptor. Taken together with the observations that Epsin is involved in internalization of the receptors for epidermal growth factor and transferrin, these results suggest that Epsin is a binding partner of POB1 and their binding regulates receptor-mediated endocytosis.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Hiroshima University; Kirin Brewery Company Limited	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Carbone R, 1997, CANCER RES, V57, P5498; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hamer I, 1997, J BIOL CHEM, V272, P21685, DOI 10.1074/jbc.272.35.21685; HARI J, 1987, J BIOL CHEM, V262, P15341; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Kay BK, 1999, PROTEIN SCI, V8, P435; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Koshiba S, 1999, FEBS LETT, V442, P138, DOI 10.1016/S0014-5793(98)01644-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Okazaki M, 1996, CANCER RES, V56, P2387; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Paoluzi S, 1998, EMBO J, V17, P6541, DOI 10.1093/emboj/17.22.6541; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	50	58	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5915	5922		10.1038/sj.onc.1202974	http://dx.doi.org/10.1038/sj.onc.1202974			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557078				2022-12-17	WOS:000083270700008
J	Boukamp, P; Popp, S; Bleuel, K; Tomakidi, E; Burkle, A; Fusenig, NE				Boukamp, P; Popp, S; Bleuel, K; Tomakidi, E; Burkle, A; Fusenig, NE			Tumorigenic conversion of immortal human skin keratinocytes (HaCaT) by elevated temperature	ONCOGENE			English	Article						transformation; heat; comparative genomic hybridization; PARP activity; chromosome 11	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMAS; RAS ONCOGENE EXPRESSION; SINGLE-STRAND BREAKS; MAMMALIAN-CELLS; ACTION SPECTRUM; P53 MUTATIONS; CANCER; DNA; HYPERTHERMIA	UV-radiation is a major risk factor for non-melanoma skin cancer causing specific mutations in the p53 tumor suppressor gene and other genetic aberrations. We here propose that elevated temperature, as found in sunburn areas, may contribute to skin carcinogenesis as well. Continuous exposure of immortal human HaCaT skin keratinocytes (possessing UV-type p53 mutations) to 40-C reproducibly resulted in tumorigenic conversion and tumorigenicity was stably maintained after recultivation of the tumors. Growth at 40 degrees C was correlated with the appearance of PARP, an enzyme activated by DNA strand breaks and the level corresponded to that seen after 5 Gy gamma-radiation. Concomitantly, comparative genomic hybridization (CGH) analyis demonstrated that chromosomal gains and losses a;ere present in cells maintained at 40 degrees C while largely absent at 37 degrees C, Besides individual chromosomal aberrations, all tumor-derived cells showed gain of chromosomal material on. 11q with the smallest common region being 11q13.2 to q14.1. Cyclin DI, a candidate gene of that region was overexpressed in all tumor-derived cells but cyclinD1/cdk4/cdk6 kinase activity was not increased. Thus, these data demonstrate that long-term thermal stress is a potential carcinogenic factor in this relevant skin cancer model, mediating its effect through induction of genetic instability which results in selection of tumorigenic cells characterized by gain of 11q.	Deutsch Krebsforschungszentrum, Div Carcinogenesis & Differentiat, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumor Virol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Boukamp, P (corresponding author), Deutsch Krebsforschungszentrum, Div Carcinogenesis & Differentiat, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ANANTHASWAMY HN, 1992, PROG CLIN BIOL RES, V376, P61; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Bockmuhl U, 1996, CANCER RES, V56, P5325; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brinkschmidt C, 1997, J PATHOL, V181, P394; BURKLE A, 1993, CARCINOGENESIS, V14, P559, DOI 10.1093/carcin/14.4.559; CERUTTI P, 1990, PROG CLIN BIOL RES, V347, P183; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; deGruijl FR, 1996, PHOTOCHEM PHOTOBIOL, V63, P372; deLaat A, 1997, CARCINOGENESIS, V18, P1013, DOI 10.1093/carcin/18.5.1013; DeLaat JMT, 1996, CANCER SURV, V26, P173; DUMANOIR S, 1995, CYTOMETRY, V19, P4, DOI 10.1002/cyto.990190103; HILL M, 1991, IN VITRO CELL DEV B, V27, P270; Inohara S, 1996, INT J DERMATOL, V35, P609, DOI 10.1111/j.1365-4362.1996.tb03681.x; JONSSON GG, 1988, CANCER RES, V48, P4240; JONSSON GG, 1988, CANCER RES, V48, P4233; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Mahlamaki EH, 1997, GENE CHROMOSOME CANC, V20, P383, DOI 10.1002/(SICI)1098-2264(199712)20:4<383::AID-GCC10>3.0.CO;2-O; MARCZYNSKA B, 1980, EXP CELL BIOL, V48, P114; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MENDONCA MS, 1991, INT J RADIAT BIOL, V59, P1195, DOI 10.1080/09553009114551071; NAITOH H, 1995, AM J PATHOL, V146, P1161; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; PEAK MJ, 1982, PHOTOCHEM PHOTOBIOL, V35, P675, DOI 10.1111/j.1751-1097.1982.tb02628.x; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sheyn I, 1997, HUM PATHOL, V28, P270, DOI 10.1016/S0046-8177(97)90123-4; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C	36	58	58	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	1999	18	41					5638	5645		10.1038/sj.onc.1202934	http://dx.doi.org/10.1038/sj.onc.1202934			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	243UW	10523843				2022-12-17	WOS:000083016500004
J	Khoo, US; Ozcelik, H; Cheung, ANY; Chow, LWC; Ngan, HYS; Done, SJ; Liang, ACT; Chan, VWY; Au, GKH; Ng, WF; Poon, CSP; Leung, YF; Loong, F; Ip, P; Chan, GSW; Andrulis, IL; Lu, J; Ho, FCS				Khoo, US; Ozcelik, H; Cheung, ANY; Chow, LWC; Ngan, HYS; Done, SJ; Liang, ACT; Chan, VWY; Au, GKH; Ng, WF; Poon, CSP; Leung, YF; Loong, F; Ip, P; Chan, GSW; Andrulis, IL; Lu, J; Ho, FCS			Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer	ONCOGENE			English	Article						BRCA1; somatic mutations; breast cancer; ovarian cancer; Chinese	EXPRESSION; GERMLINE; TUMOR	Inherited mutations in the BRCA1 gene confer increased susceptibility to breast and ovarian cancer. Its role in sporadic carcinogenesis is not well defined. Somatic mutations in breast cancers have not been reported and to date there are only three reports of somatic mutations in sporadic ovarian cancers. To investigate the contribution of BRCA1 mutations to sporadic breast and ovarian cancer in the Chinese population, we analysed 62 samples from Chinese women using the protein truncation test. There were 40 cases of breast cancer under age 50 and 22 cases of ovarian cancer, all unselected for family history. There was no age selection for the ovarian cancers. We found two somatic BRCA1 mutations in exon 11, one in a breast cancer and the other in an ovarian cancer, both of which result in truncated proteins. Our results indicate that somatic BRCA1 mutations, like somatic mutations in the BRCA2 gene, though very rare, can be found in both breast and ovarian cancers and support a tumor suppressor function for BRCA1 in sporadic tumors.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Peoples R China; Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada; Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Obstet & Gynecol, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Radiat Therapy & Oncol, Hong Kong, Peoples R China; Ruttonjee Hosp, Dept Pathol, Hong Kong, Peoples R China; Pamela Youde Nethersole Hosp, Dept Pathol, Hong Kong, Peoples R China; Jockey Club Polyclin, Inst Pathol, Hong Kong, Peoples R China; CCO, Div Prevent Oncol, Toronto, ON M5G 2L7, Canada; Monash Univ, Dept Pathol & Immunol, Melbourne, Vic 3004, Australia	University of Hong Kong; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Hong Kong; University of Hong Kong; University of Hong Kong; Pamela Youde Nethersole Eastern Hospital; Monash University	Khoo, US (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Pokfulam Rd, Hong Kong, Peoples R China.		Poon, Chi Sun/H-4152-2015; Ip, Philip/AAV-5995-2021; Khoo, Ui Soon/C-1345-2014; Khoo, Ui Soon/C-4293-2009; Khoo, Ui Soon/K-2041-2019; Ozcelik, Hilmi/A-3952-2011; Andrulis, Irene L./E-7267-2013; Cheung, Annie Nga Yin/C-4231-2009	Ip, Philip/0000-0002-0493-9838; Khoo, Ui Soon/0000-0003-2200-7505; Khoo, Ui Soon/0000-0003-2200-7505; Ngan, Hextan Y S/0000-0003-3945-159X; Cheung, Annie Nga Yin/0000-0002-1584-7568; Done, Susan/0000-0002-1770-988X				Berchuck A, 1998, CLIN CANCER RES, V4, P2433; Foster KA, 1996, CANCER RES, V56, P3622; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Katagiri T, 1996, HUM MUTAT, V7, P334, DOI 10.1002/(SICI)1098-1004(1996)7:4<334::AID-HUMU7>3.0.CO;2-8; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; Ozcelik H, 1998, INT J CANCER, V77, P1; Ozcelik H, 1996, HUM GENET, V98, P310, DOI 10.1007/s004390050212; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Szabo CI, 1997, AM J HUM GENET, V60, P1013; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Weber BHF, 1996, AM J HUM GENET, V59, P962	16	58	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4643	4646		10.1038/sj.onc.1202847	http://dx.doi.org/10.1038/sj.onc.1202847			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467410				2022-12-17	WOS:000082018600015
J	Venot, C; Maratrat, M; Sierra, V; Conseiller, E; Debussche, L				Venot, C; Maratrat, M; Sierra, V; Conseiller, E; Debussche, L			Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains	ONCOGENE			English	Article						p53; apoptosis; transactivation; repression; PIG3	CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION DOMAIN; WILD-TYPE P53; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE; BINDING-SITE; APOPTOSIS; PROTEIN; MDM2; GENE	The wild-type protein product of the p53 tumor suppressor gene can activate transcription of genes which are involved in mediating either growth arrest, e.g. WAF1 or apoptotis, e.g. BAX and PIG3. Additionally, p53 can repress a variety of promoters, which, in turn, may be responsible for the functional activities exhibited by p53. This study shows that the Q22, S23 double mutation, which is known to inactivate a p53 transactivation subdomain located within the initial 40 residues of the protein, while abrogating transactivation from the WAF1 promoter, only attenuates apoptosis triggering, transactivation from other p53-responsive promoters and repression of promoters by p53. The Q53, S54 double mutation, which inactivates another p53 transactivation subdomain situated between amino acids 43 and 73 results in attenuation of all of the aforementioned p53 activities. In contrast to the Q22, S23 double mutation, this latter mutation set does not alter mdm-2-mediated inhibition and degradation of p53. Finally, mutation of all four residues results in complete abrogation of every p53 activity mentioned above.	Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, F-94403 Vitry Sur Seine, France	Sanofi-Aventis; Sanofi France	Debussche, L (corresponding author), Rhone Poulenc Rorer, Ctr Rech Vitry Alfortville, 13 Quai Jules Guesde, F-94403 Vitry Sur Seine, France.							BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Conseiller E, 1998, J CLIN INVEST, V101, P120, DOI 10.1172/JCI1140; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; REGIER JL, 1993, P NATL ACAD SCI USA, V88, P7605; Roemer K, 1996, ONCOGENE, V12, P2069; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	47	58	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2405	2410		10.1038/sj.onc.1202539	http://dx.doi.org/10.1038/sj.onc.1202539			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327062				2022-12-17	WOS:000079595500014
J	Coccia, EM; Del Russo, N; Stellacci, E; Orsatti, R; Benedetti, E; Marziali, G; Hiscott, J; Battistini, A				Coccia, EM; Del Russo, N; Stellacci, E; Orsatti, R; Benedetti, E; Marziali, G; Hiscott, J; Battistini, A			Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2	ONCOGENE			English	Article						interferon regulatory factors; cell growth; p21 (WAF1/CP1); 2-5A synthetase	REGULATORY FACTOR-I; INTERFERON-INDUCIBLE GENES; TRANSCRIPTION FACTOR IRF-1; CELL-GROWTH INHIBITION; PROTEIN-KINASE; DNA-DAMAGE; P21(WAF1/CIP1) EXPRESSION; CONSTITUTIVE EXPRESSION; LEUKEMIA-CELLS; INDUCTION	The Interferon Regulatory Factors-1 and -2 (IRF-1 and IRF-2) were originally identified as transcriptional regulators of the interferon (IFN) and IFN-stimulated genes, These factors also modulate immune response and play a role in cell growth regulation, In this study we analysed the effect of the ectopic expression of IRF-1 and IRF-2 on the regulation of two potential IRF target genes involved in cell growth regulation, 2-5A synthetase and p21 (WAF/CP1), both of which contain consensus binding sites for IRF family members within their promoters. Following ectopic expression, IRF-1 transactivated 2-5A synthetase and p21 genes, an effect that was counterbalanced by concomitant ectopic expression of IRF-2, These effects were mediated by direct binding of IRF to the gene promoters. A construct expressing an IRF-2 antisense (FRI-2) was able to revert the inhibitory effect of IRF-2 on the IRF-1 transactivation, IRF-1 also induced expression of its homologous repressor IRF-2 as indicated by EMSA analysis using an IRF-E probe from the IRF-2 promoter; and by cotransfection of IRF-1 together with an IRF-2 promoter CAT construct, Therefore, the induction of IRF-1 by IFNs or other stimuli acts as a transactivator of genes involved in cell growth regulation, as web as of its own repressor IRF-2, thus providing autoinhibitory regulation of IRF-1 activated genes.	Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Lady Davis Institute; McGill University	Battistini, A (corresponding author), Ist Super Sanita, Virol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Coccia, Eliana M/B-4752-2013; BATTISTINI, ANGELA/C-2944-2016; Marziali, Giovanna/J-9808-2016; stellacci, emilia/J-2747-2014	Coccia, Eliana M/0000-0002-1606-2949; Marziali, Giovanna/0000-0001-7450-1017; stellacci, emilia/0000-0003-0415-3285				BATTISTINI A, 1991, BLOOD, V78, P2098, DOI 10.1182/blood.V78.8.2098.bloodjournal7882098; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; CHIN IE, 1996, SCIENCE, V272, P729; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; COCCIA EM, 1995, VIROLOGY, V211, P113, DOI 10.1006/viro.1995.1384; COCCIA EM, 1991, J VIROL, V65, P2081, DOI 10.1128/JVI.65.4.2081-2087.1991; COCCIA EM, 1988, J INTERFERON RES, V7, P113; Demaeyer E., 1988, INTERFERONS OTHER RE; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARADA H, 1994, ONCOGENE, V9, P3313; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HIRAMA T, 1995, BLOOD, V86, P841; HISCOTT J, 1995, SEMIN VIROL, V6, P161, DOI 10.1006/smvy.1995.0021; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; JACOBSEN H, 1983, P NATL ACAD SCI-BIOL, V80, P4954, DOI 10.1073/pnas.80.16.4954; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LIN RT, 1994, J BIOL CHEM, V269, P17542; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NGUYEN H, 1995, ONCOGENE, V11, P537; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; OZAWA H, 1996, NATURE, V382, P816; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; REIS LF, 1994, EMBO J, V11, P185; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; VILCEK J, 1994, FIELDS VIROLOGY, P717; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WILLIAMS BRG, 1985, 2 5A SYSTEM; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; YAMAMOTO H, 1994, ONCOGENE, V9, P1423; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1995, CANCER RES, V55, P668	61	58	58	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2129	2137		10.1038/sj.onc.1202536	http://dx.doi.org/10.1038/sj.onc.1202536			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321737				2022-12-17	WOS:000079346200010
J	Lai, A; Marcellus, RC; Corbeil, HB; Branton, PE				Lai, A; Marcellus, RC; Corbeil, HB; Branton, PE			RBP1 induces growth arrest by repression of E2F-dependent transcription	ONCOGENE			English	Article						growth arrest; transcriptional repression; E2F; retinoblastoma protein; pocket binding protein; cell cycle	RETINOBLASTOMA GENE-PRODUCT; HUMAN ADENOVIRUS TYPE-5; CELL-CYCLE; BINDING PROTEIN; FACTOR E2F; E1B PROTEIN; DNA; PHOSPHORYLATION; COMPLEX; FAMILY	Growth arrest and cell cycle progression are regulated by the retinoblastoma tumour suppressor pRB and related proteins p130 and p107 that bind to and inhibit the E2F family of transcription factors. Although the precise mechanism of this inhibition remains to be established, previous studies indicated the presence of transcriptional repression activity in the 'pocket' of RE family members. We show here that RBP1, a known pRB pocket-binding protein, possesses transcriptional repression activity and associates with p130-E2F and pRB-E2F complexes specifically during growth arrest. Overexpression of RBP1 both inhibited E2F-dependent gene expression and suppressed cell growth. Thus repression of E2F-dependent transcription by RBP1 via RE family members may play a central role in inducing growth arrest.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Branton, PE (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Bldg,3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.							Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; FATTAEY AR, 1993, ONCOGENE, V8, P3149; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Huang TH, 1996, NUCLEIC ACIDS RES, V24, P1695, DOI 10.1093/nar/24.9.1695; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITSUDOMI T, 1992, ONCOGENE, V7, P171; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OTTERSON GA, 1993, ONCOGENE, V8, P949; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; TEODORO JG, 1994, J VIROL, V68, P776, DOI 10.1128/JVI.68.2.776-786.1994; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; WEINTRAUB SJ, 1992, MOL CELL BIOL, V12, P512, DOI 10.1128/MCB.12.2.512; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	49	58	66	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2091	2100		10.1038/sj.onc.1202520	http://dx.doi.org/10.1038/sj.onc.1202520			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321733				2022-12-17	WOS:000079346200006
J	Schneider, E; Montenarh, M; Wagner, P				Schneider, E; Montenarh, M; Wagner, P			Regulation of CAK kinase activity by p53	ONCOGENE			English	Article						cyclin H; tms1; CAK kinase; TFIIH; p53; CTD phosphorylation	CDK-ACTIVATING KINASE; RNA-POLYMERASE-II; DNA-BINDING ACTIVITY; RING FINGER PROTEIN; FISSION YEAST; INDUCED APOPTOSIS; GROWTH ARREST; CELL-CYCLE; TRANSCRIPTIONAL ACTIVATION; SUBSTRATE-SPECIFICITY	The growth suppressor p53 is an important key element which controls cell cycle progression in response to cellular stress like DNA damage. Its ability to act as transcriptional activator or repressor links transcription and cell cycle control. Several target genes selectively transactivated by p53 are implicated in growth control, apoptosis and DNA repair. Here we report the interaction of p53 with another important dual player of cell cycle control and transcription, the protein kinase complex CDK7/cyclin H/Mat1 (CDK activating kinase, CAK kinase). This is implicated in the activating phosphorylation of CDK2/cyclin A kinase required to allow cells to proceed through the G(1)/S transition, and on the other hand, as a component of the basal transcription factor TFIIH found to be necessary for CTD phosphorylation of RNA polymerase II in order to allow elongation of transcription. Based on previous binding studies of p53 with other C-terminal interaction partners of p53 we demonstrate a direct physical interaction of p53 with cyclin H in vitro and in vivo. As a consequence of this interaction we tested the influence of p53 on the kinase activity of CAK kinase for CTD and CDK2 phosphorylation. The addition of wild type p53 to the kinase reactions resulted in a significant downregulation of CDK2 phosphorylation and CTD phosphorylation by the CDK activating kinase. On the other hand addition of a mutant p53His175 failed to downregulate CDK2 and CTD phosphorylation by the CDK activating kinase. In an attempt to support our findings in vivo we measured CAK kinase activity in p21(-/-) and p53(-/-) mice embryonal fibroblasts under conditions when p53 gets activated by irradiation. In the case of p21(-/-) cells this led to a significant reduction of CTD phosphorylation activity of the CDK activating kinase by irradiation of the cells. On the other hand in p53(-/-) cells no downregulation of CTD phosphorylation activity of CAK kinase was observed indicating that this kind of negative regulation of CAK kinase activity is exclusively due to a functional p53. These findings imply a direct involvement of p53 in triggering growth arrest by its interaction with the CDK activating kinase complex without the need of cyclin-dependent kinase inhibitors (CKIs) and potentially suggest a new mechanism for p53-dependent apoptosis.	Univ Saarland, D-66421 Homburg, Germany	Saarland University	Wagner, P (corresponding author), Univ Saarland, Bldg 44, D-66421 Homburg, Germany.							Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; APPEL K, 1995, ONCOGENE, V11, P1971; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bureik M, 1997, BIOL CHEM, V378, P1361, DOI 10.1515/bchm.1997.378.11.1361; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; Hecker D, 1996, ONCOGENE, V12, P953; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; Knippschild U, 1996, ONCOGENE, V13, P1387; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Koumenis C, 1997, MOL CELL BIOL, V17, P7306, DOI 10.1128/MCB.17.12.7306; LEGROS Y, 1994, ONCOGENE, V9, P3689; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 1996, ONCOGENE, V13, P823; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; Steegenga WT, 1996, J MOL BIOL, V263, P103, DOI 10.1006/jmbi.1996.0560; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; WAGNER P, 1993, EUR J BIOCHEM, V217, P731, DOI 10.1111/j.1432-1033.1993.tb18299.x; WAGNER P, 1991, ONCOGENE, V6, P1539; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	43	58	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	1998	17	21					2733	2741		10.1038/sj.onc.1202504	http://dx.doi.org/10.1038/sj.onc.1202504			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840937				2022-12-17	WOS:000077146700006
J	Blaydes, JP; Wynford-Thomas, D				Blaydes, JP; Wynford-Thomas, D			The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2	ONCOGENE			English	Article						p53; mdm2; p21(WAF-1); cell proliferation	TUMOR-SUPPRESSOR GENE; TRANSCRIPTIONAL ACTIVATION; ONCOPROTEIN MDM2; MUTANT P53; PROTEIN; TRANSACTIVATION; SENESCENCE; EXPRESSION; INDUCTION; MUTATIONS	Loss of function of the tumour suppressor gene p53 is a key event in most human cancers. Although usually occurring through mutation, in some tumour types this appears to be achieved via an indirect mechanism involving inappropriate expression of functional inhibitor, mdm2, which binds to the transactivation domain of p53. This interaction offers an ideal potential target for novel cancer therapies. However, therapeutic specificity may depend on the extent to which this p53-inhibitory action of mdm2 is also required by normal cells. Transgenic data have already established that mdm2 is needed to prevent embryonic lethality, but the situation in adult cells is still unclear. Here we show that micro-injection of normal human fibroblasts with an antibody directed against the p53-binding domain of mdm2 induces expression of p53-responsive genes, and furthermore results in p53-dependent growth arrest. We conclude that normal cell proliferation can be dependent on negative regulation of p53 by mdm2, a finding which raises an important note of caution for mdm2-directed cancer therapies.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.		Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bottger V, 1996, ONCOGENE, V13, P2141; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DubsPoterszman MC, 1995, ONCOGENE, V11, P2445; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OCALUAN RM, 1995, NATURE, V378, P203; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	32	58	58	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3317	3322		10.1038/sj.onc.1201880	http://dx.doi.org/10.1038/sj.onc.1201880			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681831				2022-12-17	WOS:000074343600013
J	D'Sa-Eipper, C; Chinnadurai, G				D'Sa-Eipper, C; Chinnadurai, G			Functional dissection of Bfl-1, a Bcl-2 homolog: anti-apoptosis, oncogene-cooperation and cell proliferation activities	ONCOGENE			English	Article						BCL-2 family; mutational analysis; conserved domains; apoptosis; p53; cell transformation; cell proliferation; gain-of-function	NECROSIS-FACTOR-ALPHA; DNA-DAMAGING AGENTS; ADENOVIRUS E1B 19K; CONSERVED DOMAINS; BHRF1 PROTEIN; VIRAL HOMOLOG; FAMILY MEMBER; B-CELLS; C-MYC; DEATH	The human Bfl-1 gene codes for a 175-amino acid BCL-2 family protein that has an anti-apoptosis activity and is overexpressed in certain human epithelial and hematopoietic malignancies. Bfl-1 efficiently suppresses apoptosis induced by the p53 tumor suppressor protein and cooperates with a dominant nuclear oncogene. EIA, in transformation of primary epithelial cells in vitro. Unlike other BCL-2 family proteins, expression of BFL-1 permits limited cell proliferation over an extended period of time when cells are induced to undergo apoptosis. We have carried out mutational analysis to dissect the various activities encoded by Bfl-1 and to determine the sequence requirements for these activities. BFL-1 shares four conserved domains, BH1, BH2, BH3 and BH4 with other BCL-2 family proteins. Mutations within BH1, BH2 and BH4 domains abolish or greatly attenuate the anti-apoptotic, oncogene cooperation and proliferation facilitating activities of BFL-1. In contrast, a mutation within the BH3 domain (which is essential for the activity of pro-apoptotic members of the BCL-2 family) does not significantly affect the BFL-1 functions. Although BFL-1 does not contain a well-defined C-terminal transmembrane domain, deletion of the C-terminal 24 amino acid region (corresponding to the transmembrane domain of other BCL-2 family proteins) partially reduces the various activities of BFL-1. All the mutants defective in the anti-apoptosis activity are also defective in the oncogene cooperation activity suggesting that these two activities may be linked. A unique feature of BFL-1 is the presence of a Gin-rich N-terminal region that overlaps with the BH4 domain. The GIn residues appear to be essential for the proliferation permitting activity of BFL-1. Since mutations of the GIn residues located within the BH4 domain appear to confer an extended cell survival activity in the absence of cell proliferation, our results suggest that BFL-1 communicates with both cell proliferation and apoptosis machineries and suggest a link between these two activities.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA.				NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1995, ONCOGENE, V11, P1921; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; DAWSON CW, 1995, ONCOGENE, V9, P69; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DSaEipper C, 1996, CANCER RES, V56, P3879; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Han J, 1996, MOL CELL BIOL, V16, P5857; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Kenny JJ, 1997, ONCOGENE, V14, P997, DOI 10.1038/sj.onc.1200898; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Mangeney M, 1996, ONCOGENE, V13, P1441; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nava VE, 1997, J VIROL, V71, P4118, DOI 10.1128/JVI.71.5.4118-4122.1997; NEVINS JR, 1992, SCIENCE, V258, P424; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SMITH CA, 1995, TRENDS CELL BIOL, V5, P344, DOI 10.1016/S0962-8924(00)89061-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TARODI B, 1993, INT J ONCOL, V3, P467; Theodorakis P, 1996, ONCOGENE, V12, P1707; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Vairo G, 1996, ONCOGENE, V13, P1511; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	57	58	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3105	3114		10.1038/sj.onc.1201851	http://dx.doi.org/10.1038/sj.onc.1201851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671389				2022-12-17	WOS:000074261300003
J	Klugbauer, S; Demidchik, EP; Lengfelder, E; Rabes, HM				Klugbauer, S; Demidchik, EP; Lengfelder, E; Rabes, HM			Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpoints in papillary thyroid carcinomas of children after Chernobyl	ONCOGENE			English	Article						RET oncogene; RT-PCR; reciprocal transcript; breakpoint; Chernobyl	RET PROTOONCOGENE; RET/PTC ONCOGENE; REACTOR ACCIDENT; ACTIVATION; CANCER; GENES; FORM	A high prevalence of RET rearrangements is found in papillary thyroid carcinomas (PTC) of children from Belarus after the Chernobyl reactor accident. The ELE/RET rearrangement (PTC3) is prevailing. Aberrant types of ELE/RET rearrangement have been found with a truncated ELE1 gene: As compared with the common form (PTC3r1) one aberrant type is shorter by one 144 bp exon (PTC3r2) (three cases); in the second atypic form (PTC3r3) the ELE1 part is 18 bp shorter than in PTC3r1. In agreement with the observation that the oncogenic RET is generated by a paracentric inversion at chromosome 10, we found not only ELE/RET, but also RET/ELE transcripts in these tumors. Sequencing of the breakpoint regions at the genomic DNA level revealed DNA modifications that might be relevant for illegitimate recombination after DNA doublestrand breaks. The high prevalence of ELE/RET rearrangements and various subtypes appears to be typical for radiation-induced thyroid carcinomas of children after the Chernobyl reactor accident.	Univ Munich, Inst Pathol, D-80337 Munich, Germany; Med High Sch Minsk, Chair Oncol, Minsk, BELARUS; Univ Munich, Inst Radiat Biol, Munich, Germany	University of Munich; University of Munich	Rabes, HM (corresponding author), Univ Munich, Inst Pathol, Thalkirchner Str 36, D-80337 Munich, Germany.							BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1997, IN PRESS GENOMICS; Fugazzola L, 1996, ONCOGENE, V13, P1093; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1996, ONCOGENE, V13, P1099; Klugbauer S, 1995, ONCOGENE, V11, P2459; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; Nikiforov YE, 1997, CANCER RES, V57, P1690; RABES HM, 1997, IN PRESS VERH DTSCH; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; TSUZUKI T, 1995, ONCOGENE, V10, P191	16	58	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	1998	16	5					671	675		10.1038/sj.onc.1201526	http://dx.doi.org/10.1038/sj.onc.1201526			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482114				2022-12-17	WOS:000071816600013
J	Olson, MF; Sterpetti, P; Nagata, K; Toksoz, D; Hall, A				Olson, MF; Sterpetti, P; Nagata, K; Toksoz, D; Hall, A			Distinct roles for DH and PH domains in the Lbc oncogene	ONCOGENE			English	Article						oncogene; Rho; Dbl; Pleckstrin-homology; exchange factor; actin	PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTORS; STRUCTURAL SIMILARITIES; G(BETA-GAMMA) SUBUNITS; EXPRESSION CLONING; PLASMA-MEMBRANE; PROTEIN-RHO; DBL FAMILY; BINDING; TRANSDUCTION	Members of the Dbl-homology (DH) family of proteins promote guanine nucleotide exchange on Rho GTPases, Lbc, which specifically acts on Rho but not Rac or Cdc42, was isolated as a transforming oncogene and is composed of a DH and a Pleckstrin-homology (PH) domain, We show here that the Lbc DH domain alone is capable of stimulating new DNA synthesis in quiescent fibroblasts and Rho-dependent actin stress fiber assembly. However, the PH domain is required for subcellular localization of Lbc along actin stress fibers and for efficient transformation of NIH3T3 cells, The results show that, in contrast to other Dbl-homology proteins, the PH domain of Lbc is dispensable for activation of Rho in vivo, The PH domain-dependent subcellular localization of Lbc may, however, be important for growth factor activation of endogenous Lbc and for oncogenic transformation.	UCL, CRC, SIGNAL TRANSDUCT & ONCOGENE GRP, LONDON WC1E 6BT, ENGLAND; UCL, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	University of London; University College London; University of London; University College London; University of London; University College London; Tufts University			Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 				Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sambrook J, 1989, MOL CLONING LAB MANU; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; WANG YL, 1987, J CELL BIOL, V105, P2811, DOI 10.1083/jcb.105.6.2811; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	30	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2827	2831		10.1038/sj.onc.1201594	http://dx.doi.org/10.1038/sj.onc.1201594			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419973				2022-12-17	WOS:A1997YJ80300008
J	Andrew, SE; Reitmair, AH; Fox, J; Hsiao, L; Francis, A; McKinnon, M; Mak, TW; Jirik, FR				Andrew, SE; Reitmair, AH; Fox, J; Hsiao, L; Francis, A; McKinnon, M; Mak, TW; Jirik, FR			Base transitions dominate the mutational spectrum of a transgenic reporter gene in MSH2 deficient mice	ONCOGENE			English	Article						mismatch repair; MSH2; lacI transgenic; mutation	NONPOLYPOSIS COLON-CANCER; MISMATCH REPAIR PROTEINS; CARCINOMA CELL-LINES; ESCHERICHIA-COLI; MICROSATELLITE INSTABILITY; COLORECTAL TUMORIGENESIS; MUTATOR PHENOTYPES; LACI GENE; DNA; INACTIVATION	Tumors derived from individuals with hereditary nonpolyposis colorectal cancer syndrome frequently demonstrate mutations in both alleles of hMSH2, a key gene in DNA mismatch repair (MMR). Sporadic tumors also frequently exhibit MMR deficiency. In keeping with the role of MMR in the maintenance of genome integrity, mice deficient in MSH2 via gene targeting demonstrate a high incidence of thymic lymphomas and small intestinal adenocarcinomas. To investigate the effects of MSH2 deficiency in normal tissues, mice containing a retrievable transgenic lad reporter gene for mutation detection were crossed with MSH2(-/-) mice, Mice homozygous for MSH2 deficiency revealed 4.8, 11.0 and 15.2-fold elevations in spontaneous mutation frequency in DNA obtained from brain, small intestine, and thymus, respectively, as compared to heterozygous or wild-type mice. Mutations most frequently recovered from MSH2(-/-) mice were single base substitutions (77%), particularly base transitions (64%), Frameshifts occurred less frequently (19%) and fell within very short (3-5 bp) mononucleotide runs. Thus the number of key growth control genes potentially impacted by MMR deficiency extends beyond those containing repetitive sequences. These results highlight the capacity for MSH2 deficiency to serve as a potent driving force during the multi-step evolution of tumors.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,CTR MOL MED & THERAPEUT,VANCOUVER,BC V6T 1Z3,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,AMGEN INST,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,AMGEN INST,TORONTO,ON M5G 2M9,CANADA	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto				McKinnon, Margaret/0000-0002-3161-414X				Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P147, DOI 10.1093/nar/24.1.147; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COX EC, 1976, ANNU REV GENET, V10, P135, DOI 10.1146/annurev.ge.10.120176.001031; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DOHET C, 1985, P NATL ACAD SCI USA, V82, P503, DOI 10.1073/pnas.82.2.503; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; GLAZER PM, 1986, P NATL ACAD SCI USA, V83, P1041, DOI 10.1073/pnas.83.4.1041; GU M, 1994, MUTAT RES, V307, P533, DOI 10.1016/0027-5107(94)90264-X; HAWN MT, 1995, CANCER RES, V55, P3721; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KOHLER SW, 1990, GENET ANAL-BIOMOL E, V7, P212, DOI 10.1016/0735-0651(90)90003-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEONG PM, 1986, J BACTERIOL, V168, P412, DOI 10.1128/jb.168.1.412-416.1986; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MIRSALIS JC, 1995, ANNU REV PHARMACOL, V35, P145; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; REENAN RAG, 1992, GENETICS, V132, P963; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238	45	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 10	1997	15	2					123	129		10.1038/sj.onc.1201180	http://dx.doi.org/10.1038/sj.onc.1201180			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244348				2022-12-17	WOS:A1997XK37200001
J	Vincent, F; Nagashima, M; Takenoshita, S; Khan, MA; Gemma, A; Hagiwara, K; Bennett, WP				Vincent, F; Nagashima, M; Takenoshita, S; Khan, MA; Gemma, A; Hagiwara, K; Bennett, WP			Mutation analysis of the transforming growth factor-beta type II receptor in human cell Lines resistant to growth inhibition by transforming growth factor-beta	ONCOGENE			English	Article						single-strand conformation polymorphism analysis; somatic mutation; polymerase chain reaction; genomic DNA; microsatellite instability	TGF-BETA; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CARCINOMA-CELLS; GENE; EXPRESSION; GROWTH-FACTOR-BETA-1; BINDING; COLON; OVEREXPRESSION	The transforming growth factor-beta (TGF-beta) binds the type II TGF-beta growth factor receptor (RII) to inhibit the growth of most epithelial tissues, Most human colon and gastric cancers with microsatellite instability (MI) have frameshift mutations in polynucleotide repeats within the RII coding region; these mutations truncate the receptor protein and disable the serine/threonine kinase to produce TGF-beta resistance, To further investigate the type, frequency and tissue distribution of RII mutations, we selected 24 human cancer cell lines from various tissues which were previously reported to be resistant to the inhibitory effects of TGF-beta, We developed protocols for non-isotopic SSCP analysis of PCR products from genomic DNA samples, and we tested them for microsatellite instability, PCR-SSCP analysis followed by DNA sequencing identified deletion mutations in the exon 3 poly-adenine tract in three colon tumor cell lines: LS174T and SW48 had a single base deletion and LS411 had a two base deletion. Among the 24 previously unreported cell lines, only these three demonstrated microsatellite instability. These and other recent data indicate that RII mutations are essentially confined to colon and gastric cancers with microsatellite instability. The narrow spectrum of tissues containing RII mutations illustrates the complexity of genetic checkpoints in human carcinogenesis.	NCI, HUMAN CARCINOGENESIS LAB, NIH, BETHESDA, MD 20892 USA; IFREMER, F-44311 NANTES 03, FRANCE; GUNMA UNIV, SCH MED, DEPT SURG, MAEBASHI, GUMMA 371, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ifremer; Gunma University				VINCENT-HUBERT, Francoise/0000-0002-2266-9237				ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; *AM TYP CULT COLL, 1992, AM TYP CULT COLL CAT; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARRIGUEANTAR L, 1995, CANCER RES, V55, P3982; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HOWE PH, 1993, J BIOL CHEM, V268, P21448; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; LIN HY, 1994, CELL MOL BIOL, V40, P337; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MYEROFF LL, 1995, CANCER RES, V55, P5545; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REISS M, 1993, CANCER RES, V53, P899; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Schutte M, 1996, CANCER RES, V56, P2527; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takenoshita S, 1996, GENOMICS, V36, P341, DOI 10.1006/geno.1996.0471; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; TAKENOSHITA S, 1997, IN PRESS CARCINOGENE; VINCENT F, BIOCHEM BIOPH RES CO, V223, P561; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN ZF, 1994, J BIOL CHEM, V269, P13231; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; ZABRENETZKY V, 1994, INT J CANCER, V59, P191, DOI 10.1002/ijc.2910590209	45	58	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					117	122		10.1038/sj.onc.1201166	http://dx.doi.org/10.1038/sj.onc.1201166			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233784				2022-12-17	WOS:A1997XH58600013
J	Fan, JG; Bertino, JR				Fan, JG; Bertino, JR			K-ras modulates the cell cycle via both positive and negative regulatory pathways	ONCOGENE			English	Article						ras; cell cycle; gene regulation	BREAST-CANCER CELLS; DNA-BINDING ACTIVITY; GENE-EXPRESSION; E2F FAMILY; IN-VIVO; S-PHASE; P53-REGULATED PROTEIN; SIGNAL-TRANSDUCTION; GROWTH SUPPRESSION; TUMOR-SUPPRESSOR	The effect of activated human K-ras on cell cycle proteins was studied by use of a stable MCF-7 transfectant expressing inducible activated K-ras under the control of a tetracycline (Tet)-responsive promoter. Induction of activated K-ras by Tet withdrawal accelerated cell growth and entry into S-phase, To understand the mechanism(s) by which activated K-ras exerts its effect on the cell cycle, expression of both cell cycle stimulatory proteins as well as cell cycle inhibitors was examined. Upon induction of activated K-ras, several cell cycle stimulators were up-regulated, including cyclins A, D3, and E, and the E2F family of transcription factors, which was accompanied by increased cyclin A-associated kinase activity and E2F transcriptional activity, respectively. Up-regulation of cyclin A occurred at the transcriptional level and in a serum-dependent manner, Furthermore, induction of activated K-ras down-regulated p27(Kip1) and up-regulated p53. Up-regulation of p53 was correlated with enhanced p53 transactivation and accompanied by up-regulation of p21(Waf1) and Gadd 45, two p53 effecters and negative cell cycle regulators. In addition, activated K-ras upregulates bcl-2 but has no effect on bax or bcl-x expression. Taken together, these data indicate that activated K-ras affects the cell cycle by modulating both positive and negative cell cycle regulatory pathways.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA062948, P01CA047179] Funding Source: NIH RePORTER; NCI NIH HHS [CA62948-02, P01-CA-47179] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrams SI, 1996, SEMIN ONCOL, V23, P118; ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAE IS, 1995, CANCER RES, V55, P2387; BALCERKUBICZEK EK, 1995, RADIAT RES, V142, P256, DOI 10.2307/3579133; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLUME E, 1993, J NATL CANCER I, V85, P1542, DOI 10.1093/jnci/85.19.1542; BORTNER DM, 1995, CELL GROWTH DIFFER, V6, P1579; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCK V, 1995, ONCOGENE, V11, P31; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; CARBONAROHALL D, 1993, ONCOGENE, V8, P1649; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CASEY G, 1991, ONCOGENE, V6, P1791; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN J, 1997, IN PRESS BIOCH PHARM; Fan JG, 1997, ONCOGENE, V14, P1191, DOI 10.1038/sj.onc.1200940; FILMUS J, 1994, ONCOGENE, V9, P3627; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTARDIS MM, 1995, ENDOCRINOLOGY, V136, P5659, DOI 10.1210/en.136.12.5659; Gotz C, 1996, REV PHYSIOL BIOCH P, V127, P65, DOI 10.1007/BFb0048265; GRAHAM KA, 1986, BREAST CANCER RES TR, V8, P29, DOI 10.1007/BF01805922; HALDAR S, 1994, CANCER RES, V54, P2095; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOHNSON LF, 1994, J CELL BIOCHEM, V54, P387, DOI 10.1002/jcb.240540405; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY E, 1994, CARCINOGENESIS, V15, P845, DOI 10.1093/carcin/15.5.845; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mangues R, 1992, Semin Cancer Biol, V3, P229; MARX J, 1994, SCIENCE, V264, P1846, DOI 10.1126/science.8009205; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; NEGRINI M, 1994, CANCER RES, V54, P1818; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAN BT, 1994, J BIOL CHEM, V269, P5968; PINES J, 1992, CIBA F SYMP, V170, P187; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; TAKAHASHI K, 1992, JPN J CANCER RES, V83, P358, DOI 10.1111/j.1349-7006.1992.tb00115.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINBERG RA, 1996, CELL, V85, P242; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Winston JT, 1996, ONCOGENE, V12, P127; WU CL, 1995, MOL CELL BIOL, V15, P2536; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; WU H, 1993, GENE DEV, V7, P1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; YAMATO K, 1995, ONCOGENE, V11, P1; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	84	58	63	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2595	2607		10.1038/sj.onc.1201105	http://dx.doi.org/10.1038/sj.onc.1201105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191059				2022-12-17	WOS:A1997XA94900011
J	Verkerk, AJMH; Ariel, I; Dekker, MC; Schneider, T; vanGurp, RJHLM; deGroot, N; Gillis, AJM; Oosterhuis, JW; Hochberg, AA; Looijenga, LHJ				Verkerk, AJMH; Ariel, I; Dekker, MC; Schneider, T; vanGurp, RJHLM; deGroot, N; Gillis, AJM; Oosterhuis, JW; Hochberg, AA; Looijenga, LHJ			Unique expression patterns of H19 in human testicular cancers of different etiology	ONCOGENE			English	Article						testis; germ cell tumors; non-germ cell tumors; H19 expression; genomic imprinting; germ cell development	GERM-CELL TUMORS; SPERMATOCYTIC SEMINOMA; IMPRINTED GENES; WILMS-TUMOR; IMMUNOHISTOCHEMICAL MARKERS; BIALLELIC EXPRESSION; ALLELIC METHYLATION; BLADDER-CARCINOMA; IGF2 EXPRESSION; HUMAN-DISEASES	The expression pattern of the imprinted human H19 gene was investigated in testicular cancers of different etiology, as well as in normal testicular parenchyma, parenchyma without germ cells, and adjacent to testicular germ cell tumors of adolescents and adults (TGCTs), using RNase protection analysis, mRNA in situ hybridization and reverse-transcription polymerase chain reaction. While different total expression levels were detected in spermatocytic seminomas, lymphomas, a Sertoli cell tumor and Leydig cell tumors, none showed a disturbance of monoallelic expression. Strikingly, the majority of invasive TGCTs revealed expression of both parental alleles. The total level of expression highly correlated with differentiation lineage and stage of maturation, similar to that as reported during early normal embryogenesis. Biallelic expression could also be determined specifically in testis parenchyma containing the preinvasive lesion of this cancer. We therefore conclude that within the adult testis, biallelic H19 expression is specific for TGCTs, and that the level of expression is dependent on differentiation lineage and maturation stage. This is in agreement with the proposed primordial germ cell-origin of this cancer, and might be related to retention of embryonic characteristics in TGCTs. In addition, our data argue against H19 being a tumor suppressor gene.	UNIV ROTTERDAM HOSP,LAB EXPT PATHOONCOL,DR DANIEL DEN HOED CANC CTR,ROTTERDAM,NETHERLANDS; HADASSAH UNIV HOSP,DEPT PATHOL,MT SCOPUS,ISRAEL; HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Hebrew University of Jerusalem; Hebrew University of Jerusalem			Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; ARIEL I, 1995, UROLOGY, V45, P335, DOI 10.1016/0090-4295(95)80030-1; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BARTON SC, 1991, DEVELOPMENT, V113, P679; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BOSMAN FT, 1993, INT J DEV BIOL, V37, P203; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; Burke A, 1993, J UROL PATHOL, V1, P21; COOPER MJ, 1996, IN PRESS J UROL; CUMMINGS OW, 1994, HUM PATHOL, V25, P54, DOI 10.1016/0046-8177(94)90171-6; DEGROOT N, 1993, MOL REPROD DEV, V36, P390, DOI 10.1002/mrd.1080360316; DEKKER I, 1992, CANCER, V69, P993, DOI 10.1002/1097-0142(19920215)69:4<993::AID-CNCR2820690427>3.0.CO;2-8; Donjacour A A, 1991, Cancer Treat Res, V53, P335; DoucRasy S, 1996, ONCOGENE, V12, P423; DUGIMONT T, 1995, MOL CELL, V85, P117; EBLE JN, 1994, HUM PATHOL, V25, P1035, DOI 10.1016/0046-8177(94)90062-0; ELKIN M, 1995, FEBS LETT, V374, P57, DOI 10.1016/0014-5793(95)01074-O; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUNDELE RH, 1994, DEV GENET, V15, P515, DOI 10.1002/dvg.1020150610; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GOODFELLOW PN, 1982, NATURE, V300, P107, DOI 10.1038/300107a0; HALL JG, 1990, AM J HUM GENET, V46, P857; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hibi K, 1996, CANCER RES, V56, P480; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; JORGENSEN N, 1995, LAB INVEST, V72, P223; JORGENSEN N, 1993, HISTOPATHOLOGY, V22, P373; KONDO M, 1995, ONCOGENE, V10, P1193; Latham KE, 1995, DIFFERENTIATION, V59, P269; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LOTHE RA, 1993, GENE CHROMOSOME CANC, V7, P96, DOI 10.1002/gcc.2870070206; LUSTIG O, 1994, MOL REPROD DEV, V38, P239, DOI 10.1002/mrd.1080380302; MANIATIS T, 1982, MOL CLONING LABORATO, P280; Meyts E. Rajpert-De, 1994, International Journal of Andrology, V17, P85, DOI 10.1111/j.1365-2605.1994.tb01225.x; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; MOSTOFI FK, 1987, SEMIN DIAGN PATHOL, V4, P320; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; NAKASHIMA N, 1988, HUM PATHOL, V19, P1144, DOI 10.1016/S0046-8177(88)80145-X; OHLSSON R, 1994, DEVELOPMENT, V120, P361; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; RACHMILEWITZ J, 1992, MOL REPROD DEV, V32, P196, DOI 10.1002/mrd.1080320303; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; REED ML, 1994, NAT GENET, V6, P163, DOI 10.1038/ng0294-163; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; ROMANENKO AM, 1983, VOP ONKOL, V19, P61; ROSENBERG SA, 1982, CANCER, V49, P2112; ROSSANT J, 1993, CURR BIOL, V3, P47, DOI 10.1016/0960-9822(93)90148-H; Sasaki H, 1995, DEVELOPMENT, V121, P4195; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; SOLTER D, 1988, ANNU REV GENET, V22, P127; Solter Davor, 1992, Current Opinion in Biotechnology, V3, P632, DOI 10.1016/0958-1669(92)90007-6; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SVENSSON K, 1995, MECH DEVELOP, V51, P31, DOI 10.1016/0925-4773(94)00345-N; SZABO P, 1994, DEVELOPMENT, V120, P1651; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; TALERMAN A, 1984, LAB INVEST, V51, P343; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; WALSH C, 1995, CANCER RES, V55, P1111; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	68	58	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					95	107		10.1038/sj.onc.1200802	http://dx.doi.org/10.1038/sj.onc.1200802			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010236				2022-12-17	WOS:A1997WB76000009
J	Gotz, C; Wagner, P; Issinger, OG; Montenarh, M				Gotz, C; Wagner, P; Issinger, OG; Montenarh, M			p21(WAF1/CIP1) interacts with protein kinase CK2	ONCOGENE			English	Article						p21(WAF1/CIP1); protein kinase CK2; phosphorylation; p53	DNA-BINDING FUNCTION; BETA-SUBUNIT; CASEIN KINASE-2; CELLULAR-REGULATION; SUPPRESSOR PROTEIN; ALPHA-SUBUNITS; XENOPUS-LAEVIS; HUMAN TUMORS; II ACTIVITY; P53	p21(WAF1/CIP1) which belongs to a class of regulatory proteins that interact with cyclin dependent kinases is a potent inhibitor of these kinases. The inhibition of the cyclin dependent kinases induces an arrest of cells in the G(1) phase of the cell cycle. In addition p21(WAF1/CIP1) associates with PCNA and inhibits DNA replication. Here, we show that p21(WAF1/CIP1) binds to the regulatory beta-subunit of protein kinase CK2 but not to the catalytic alpha-subunit. Binding of p21(WAF1/CIP1) down regulates the kinase activity of CK2 with respect to the phosphorylation of the beta-subunit of CK2, casein and the C-terminus of p53. This study demonstrates a new binding partner for the regulatory beta-subunit of protein kinase CK2 which regulates the activity of the holoenzyme.	UNIV SAARLAND, INST MED BIOCHEM, D-66421 HOMBURG, GERMANY; ODENSE UNIV, INST BIOKEM, DK-5230 ODENSE, DENMARK	Saarland University; University of Southern Denmark			Montenarh, Mathias/AAB-6689-2020					ALGHISI GC, 1994, CELL MOL BIOL RES, V40, P563; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; BOLDYREFF B, 1993, EUR J BIOCHEM, V218, P515, DOI 10.1111/j.1432-1033.1993.tb18404.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1995, INT J ONCOL, V7, P889; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOTZ C, 1995, EUR J BIOCHEM, V233, P327, DOI 10.1111/j.1432-1033.1995.327_1.x; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINRICHS MV, 1993, BIOCHEMISTRY-US, V32, P7310, DOI 10.1021/bi00079a030; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KRAISS S, 1990, ONCOGENE, V5, P845; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ A, 1992, INT J ONCOL, V1, P571; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAENPAA PH, 1977, BIOCHIM BIOPHYS ACTA, V498, P294, DOI 10.1016/0304-4165(77)90267-7; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; MURRAY A, 1993, CELL CYCLE; NASTAINCZYK W, 1995, HYBRIDOMA, V14, P335, DOI 10.1089/hyb.1995.14.335; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PROWALD K, 1984, FEBS LETT, V176, P479, DOI 10.1016/0014-5793(84)81222-3; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SCHMIDTSPANIOL I, 1992, HYBRIDOMA, V11, P53, DOI 10.1089/hyb.1992.11.53; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; STURZBECHER HW, 1990, ONCOGENE, V5, P795; WAGNER P, 1994, INT J ONCOL, V4, P491; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	66	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					391	398						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710378				2022-12-17	WOS:A1996VA25200018
J	Kyritsis, AP; Zhang, BH; Zhang, W; Xiao, M; Takeshima, H; Bondy, ML; Cunningham, JE; Levin, VA; Bruner, J				Kyritsis, AP; Zhang, BH; Zhang, W; Xiao, M; Takeshima, H; Bondy, ML; Cunningham, JE; Levin, VA; Bruner, J			Mutations of the p16 gene in gliomas	ONCOGENE			English	Article						astrocytoma; brain tumor; MTS1; glioblastoma	SSCP ANALYSIS; CELLS	In the present study we investigated the frequency of p16 gene exon 2 mutations in 35 malignant gliomas, using either direct sequencing of the PCR products or cloning into the pCRII vector and sequencing of the cloned PCR products. No mutations were detected during direct sequencing of the PCR products. However, after sequencing ofindividual clones, we found multiple mutations in 5 tumors involving codons 73(GCC to ACC, Ala to Thr), 76 (GCC to GTC, Ala to Va), 85(GCT to ACT, Ala to Thr), 98(CAC to TAC, His to Tyr), 102 (GCG to GTG, Ala to Val), 106 (GTG to ATG, Val to Met), 107 (CGC to TGC, Arg to Cys), 127 (GCA to GTA, Ala to Val), 128 (CGG to TGG, Arg to Trp) and 136 (GGC to GAG, Gly to Asp). Mutations were found only in glioblastomas and were either C to T or G to A transitions. Each mutation was detected in a small percentage of tumor cells (1.3-22%) using individual colony sequencing and southern hybridization with mutant oligonucleotides, consistent with the heterogenous cell population of glioblastomas. The presence of p16 gene mutations only in glioblastomas suggests that they are late events in glioma development.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT EPIDEMIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kyritsis, AP (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT NEUROONCOL,1515 HOLCOMBE BLVD,BOX 100,HOUSTON,TX 77030, USA.		Cunningham, John/GWB-9698-2022	Cunningham, John/0000-0002-1805-9743	NCI NIH HHS [CCSG-CA16672, P01-CA55261] Funding Source: Medline; NINDS NIH HHS [R29 NS32269-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055261, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS032269] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; FAN E, 1993, MUTAT RES, V288, P85, DOI 10.1016/0027-5107(93)90210-7; GIANI C, 1994, CANCER RES, V54, P6338; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HE J, 1994, CANCER RES, V54, P5804; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KYRITSIS AP, 1992, INT J ONCOL, V1, P149; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI Y, 1994, CANCER RES, V54, P6078; MOULTON T, 1995, AM J PATHOL, V146, P613; NELSON JS, 1983, CANCER, V52, P550, DOI 10.1002/1097-0142(19830801)52:3<550::AID-CNCR2820520327>3.0.CO;2-C; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WU JK, 1993, AM J HUM GENET, V52, P1273; ZHOU XL, 1994, ONCOGENE, V9, P3737	22	58	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					63	67						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552400				2022-12-17	WOS:A1996TQ01400008
J	Liu, Q; Ji, X; Breitman, ML; Hitchcock, PF; Swaroop, A				Liu, Q; Ji, X; Breitman, ML; Hitchcock, PF; Swaroop, A			Expression of the bZIP transcription factor gene Nrl in the developing nervous system	ONCOGENE			English	Article						neuronal development; gene expression; transcription factor	LEUCINE-ZIPPER; MAF ONCOGENE; V-MAF; RETINA; DOMAIN; FOS; MECHANISMS; DIVERSITY; PROTEINS; ENCODES	Proteins of the Maf/Nrl subfamily of bZIP transcription factors are involved in the regulation of tissue-specific gene expression. The Nrl gene, initially identified from a subtracted retinal library, is expressed in all cell layers of the adult retina, including photoreceptors. The Nrl protein has high sequence homology with Maf proteins, binds to an AP-1 like sequence element, and in photoreceptors appears to be involved in regulating the expression of rhodopsin. In the present study, we investigated the expression of Nrl in the developing and adult mouse using in situ hybridization and RT-PCR. We demonstrate that beginning at embryonic day 12.5 Nrl is expressed throughout the developing central and peripheral nervous system, with the exception of the nasal epithelium. The spatial pattern of hybridization suggests that Nrl is transcribed in post-mitotic, differentiating neurons, the developing cephalic mesenchyme and lens. Nrl expression is downregulated postnatally in the brain, and becomes restricted to neocortex and brainstem in the adult. High levels of Nrl transcripts, however, persist in the mature photoreceptors and other retinal neurons. Our studies suggest a role for the Nrl protein in neuronal differentiation and in mature neurons of the adult retina.	UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT OPHTHALMOL, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT ANAT & CELL BIOL, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, WK KELLOGG EYE CTR, DEPT HUMAN GENET, ANN ARBOR, MI 48105 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1X5, CANADA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Hitchcock, Peter/AAY-9559-2020	Hitchcock, Peter/0000-0001-9454-2684; Swaroop, Anand/0000-0002-1975-1141	NEI NIH HHS [EY07003, EY07060] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BLAY HM, 1992, ANNU REV BIOCHEM, V6, P1213; BOK D, 1989, RETINA, P69; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; FARJO Q, 1993, GENOMICS, V18, P216, DOI 10.1006/geno.1993.1458; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; REHEMTULLA A, IN PRESS P NATL ACAD; Sidman RL, 1961, STRUCTURE EYE, P487; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOUNG RW, 1985, ANAT REC, V212, P199, DOI 10.1002/ar.1092120215	28	58	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	1996	12	1					207	211						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552394				2022-12-17	WOS:A1996TQ01400026
J	Rochefort, P; Caillou, B; Michiels, FM; Ledent, C; Talbot, M; Schlumberger, M; Lavelle, F; Monier, R; Feunteun, J				Rochefort, P; Caillou, B; Michiels, FM; Ledent, C; Talbot, M; Schlumberger, M; Lavelle, F; Monier, R; Feunteun, J			Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter	ONCOGENE			English	Article						transgenic mice; activated ras; papillary thyroid carcinoma; thyroid dysgenesis	TISSUE-SPECIFIC EXPRESSION; ONCOGENE ACTIVATION; INTESTINAL NEOPLASIA; HIGH-FREQUENCY; TRANSFORMATION; MUTATIONS; TUMORS; CARCINOMA; CELLS; INHIBITION	Four transgenic mice carrying the human activated c-Ha-Ras gene, the expression of which was driven into the thyroid gland by a bovine thyroglobulin promoter, have been produced. The M1 and M2 mice developed papillary thyroid carcinomas and the M2 mouse also developed a lung carcinoma, however none of them transmitted the transgene. Both the M3 and the M4 mice gave rise to transgenic lines. M3 progeny mice develop a goitre with morphological aspects of hyperplasia as well as a thymus hyperplasia, M4 developed a papillary thyroid carcinoma and a lung carcinoma. Lung tumors but not thyroid tumors were observed in M4 adult transgenic progeny. In this M4 line, thyroid dysgenesis leading to growth retardation and premature death was observed upon serial backcross that enhanced the DBA/2J genetic background. The development of thyroid tumors in M1, M2, M4 transgenic mice demonstrates the oncogenic potential of activated Ras gene in the thyroid gland. The M4 line raises interesting questions relative to the interference between the Ras-mediated signal transduction pathway and thyroid morphogenesis.	INST GUSTAVE ROUSSY,CNRS,URA 1967,LAB GENET ONCOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,SERV HISTOPATHOL A,VILLEJUIF,FRANCE; FREE UNIV BRUSSELS,INST RECH INTERDISCIPLINAIRE,BRUSSELS,BELGIUM; INST GUSTAVE ROUSSY,NUCL MED SERV,VILLEJUIF,FRANCE; RHONE POULENC RORER,VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Universite Libre de Bruxelles; Vrije Universiteit Brussel; UNICANCER; Gustave Roussy; Sanofi-Aventis			Feunteun, Jean/AAZ-1267-2020	Feunteun, Jean/0000-0003-1212-9189				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ANDRES AC, 1991, ONCOGENE, V6, P771; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BIANCIFIORI C, 1979, PATHOLOGY TUMORS ANI, P451; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOS JL, 1989, CANCER RES, V49, P4682; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHRISTOPHE D, 1994, MOL CELL ENDOCRINOL, V64, P5; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; FOWLIS DJ, 1993, EUR J CANCER, V29A, P638, DOI 10.1016/S0959-8049(05)80170-4; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GUAZZI S, 1994, EMBO J, V13, P3339, DOI 10.1002/j.1460-2075.1994.tb06636.x; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Hogan B., 1986, MANIPULATING MOUSE E; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LEMOINE NR, 1988, ONCOGENE, V3, P541; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SANTELLI G, 1993, CANCER RES, V53, P5523; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SCHLUMBERGER M, 1986, J CLIN ENDOCR METAB, V63, P960; SHI YF, 1991, CANCER RES, V51, P2690; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9; WRIGHT PA, 1991, ONCOGENE, V6, P471; YUKAWA K, 1989, J EXP MED, V170, P711, DOI 10.1084/jem.170.3.711	40	58	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					111	118						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552381				2022-12-17	WOS:A1996TQ01400014
J	CIOSSEK, T; LERCH, MM; ULLRICH, A				CIOSSEK, T; LERCH, MM; ULLRICH, A			CLONING, CHARACTERIZATION, AND DIFFERENTIAL EXPRESSION OF MDK2 AND MDK5, 2 NOVEL RECEPTOR TYROSINE KINASES OF THE ECK/EPH FAMILY	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASE; EPH/ECK FAMILY; EMBRYONIC DEVELOPMENT	GROWTH-FACTOR RECEPTOR; EPH GENE; MOUSE; DNA; SEQUENCES; CELLS; ELK	Using a polymerase chain reaction-based strategy for the cloning of developmentally regulated receptor tyrosine kinases, we identified two novel members of the eck/eph-related subfamily which, in analogy with the recently identified mouse developmental kinase 1 (MDK1), were designated MDK2 and MDK5. MDK2 is highly homologous to the mouse kinase Myk-1 and the human kinase Htk, whereas MDK5 represents the mouse homologue of human Hek2. Northern blot analyses of adult mouse tissues revealed a 4.7 kb transcript of MDK2 and a 4.8 kb transcript of MDK5 in various organ systems, including lung, liver, kidney, intestine, muscle, heart, and, in the case of MDK5, also the brain, In addition to the full-length transcripts, smaller fragments were identified that probably represent truncated receptors. Northern blot analysis and in situ hybridization of mouse embryos indicated abundant expression during embryonic development, with preferential involvement of tissues of epithelial and endothelial origin for both kinases and of the spinal cord gray matter for MDK5, Unlike most other members of the eck/eph-related subfamily, the expression of MDK2 and MDK5 is not primarily restricted to neuronal structures, and their abundant presence in various organ systems during embryonic development suggests an important role in gestational growth and differentiation.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BOHME B, 1993, ONCOGENE, V8, P2857; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIOSSEK T, 1995, ONCOGENE, V9, P97; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENDLY BM, 1990, CANCER RES, V50, P1550; FLETCHER FA, 1994, ONCOGENE, V9, P3241; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P445; HEIJNE GV, 1986, NUCLEIC ACIDS RES, V14, P4683; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAHER PA, 1991, J CELL BIOL, V112, P955, DOI 10.1083/jcb.112.5.955; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1989, P NATL ACAD SCI USA, V88, P5449; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SDAMBROOK J, 1989, MOL CLONING LABORATO; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SHAO HN, 1995, J BIOL CHEM, V270, P3467, DOI 10.1074/jbc.270.8.3467; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TAYLOR V, 1994, ONCOGENE, V63, P163; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONDERGEER P, 1994, ANN REV CELL BIOL, V10, P251; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117	56	58	64	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2085	2095						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478528				2022-12-17	WOS:A1995TF29700019
J	JOOSS, K; LAM, EWF; BYBEE, A; GIRLING, R; MULLER, R; LATHANGUE, NB				JOOSS, K; LAM, EWF; BYBEE, A; GIRLING, R; MULLER, R; LATHANGUE, NB			PROTOONCOGENIC PROPERTIES OF THE DP FAMILY OF PROTEINS	ONCOGENE			English	Article						DP/E2F; CELL CYCLE; TRANSCRIPTION; ONCOGENE	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; ADENOVIRUS-E1A PREVENTS; CELL-PROLIFERATION; COMPLEX-FORMATION; BINDING PROTEIN; CYCLIN-A; TRANSACTIVATION; P107; FIBROBLASTS	The cellular transcription factor DRTF1/E2F is implicated in the control of cellular proliferation due to its interaction with key regulators of cell cycle progression, such as the retinoblastoma tumour suppressor gene product, cyclins and cyclin-dependent kinases. DRTF1/E2F is a heterodimeric DNA binding activity which arises when a member of two distinct families of proteins, DP and E2F, interact as DP/E2F heterodimers, for example, DP-1 and E2F-1, Tn DRTF1/E2F the activity of DP-1 is under cell cycle control, possibly by phosphorylation, and in many types of cells it is a frequent, if not general DNA binding component of DRTF1/E2F. The expression of other DP proteins, such as DP-2, is tissue-restricted. Here, we show that DP-1 and DP-2 are integrated with another growth regulating pathway which involves signal transduction emanating from activated Ras protein. Thus, activated Ha-ras can co-operate with DP-1 or DP-2 in the transformation of rat embryo fibroblasts, establishing for the first time that DP proteins are endowed with proto-oncogenic activity. Moreover, an analysis of a dominant-negative and mutant DP-l proteins suggests that the primary target through which DP-1 mediates its oncogenic activity is unlikely to be due to the regulation of E2F site-transcription, suggesting an E2F-independent effector function for DP-1, These results therefore establish DP genes as proto-oncogenes and thus argue that deregulating the normal control of DP protein activity will be important in promoting aberrant cellular proliferation.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	MRC National Institute for Medical Research; Philipps University Marburg			Müller, Rolf/L-4997-2016; Lam, Eric W-F/AAW-8566-2020	Müller, Rolf/0000-0003-3339-4248; Lam, Eric W-F/0000-0003-1274-3576				BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANDARA LR, 1992, J CELL SCI, P77; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kouzarides Tony, 1993, Trends in Cell Biology, V3, P211, DOI 10.1016/0962-8924(93)90113-F; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LATHANGUE NB, 1987, CELL, V49, P507, DOI 10.1016/0092-8674(87)90453-3; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOVEC H, 1994, ONCOGENE, V9, P323; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; TSAI LH, 1993, ONCOGENE, V8, P1593; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	41	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1529	1536						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731707				2022-12-17	WOS:A1995QU68100008
J	JOHNSON, TS; KNIGHT, CRL; ELALAOUI, S; MIAN, S; REES, RC; GENTILE, V; DAVIES, PJA; GRIFFIN, M				JOHNSON, TS; KNIGHT, CRL; ELALAOUI, S; MIAN, S; REES, RC; GENTILE, V; DAVIES, PJA; GRIFFIN, M			TRANSFECTION OF TISSUE TRANSGLUTAMINASE INTO A HIGHLY MALIGNANT HAMSTER FIBROSARCOMA LEADS TO A REDUCED INCIDENCE OF PRIMARY TUMOR-GROWTH	ONCOGENE			English	Article							PROGRAMMED CELL-DEATH; RAT-LIVER; HUMAN LEUKEMIA; APOPTOSIS; EXPRESSION; METASTASIS; ACTIVATION; RECEPTOR; ADHESION; IDENTIFICATION	Reduced expression of the tissue transglutaminase in both murine and human tumours has been consistently associated with tumour growth and progression. To investigate the functional effects of transglutaminase expression are have transfected a constitutive human tissue transglutaminase expression construct into a highly malignant hamster fibrosarcoma cell line Met B. - Met B clones expressing the exogenous tissue transglutaminase exhibited a reduced incidence of primary tumour formation and an increased adherence to tissue culture plastic and fibronectin coated surfaces when compared to transfected and non transfected control cells. Transglutaminase transfected clones exhibited no significant differences in their growth rates measured in vitro, cell morphology or levels of spontaneous apoptosis measured by the determination of detergent insoluble apoptotic envelopes. The data demonstrates a suppressive effect of tissue transglutaminase on tumour growth and confirms its importance in the phenotypic changes associated with the cancer process.	NOTTINGHAM POLYTECH,DEPT LIFE SCI,NOTTINGHAM NG11 8NS,ENGLAND; UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,HOUSTON,TX; UNIV SHEFFIELD,SCH MED,INST CANC STUDIES,SHEFFIELD S10 2RX,ENGLAND	Nottingham Trent University; University of Texas System; University of Texas Health Science Center Houston; University of Sheffield			Gentile, Vittorio/A-3045-2008; Gentile, Vittorio/N-1685-2019	Gentile, Vittorio/0000-0001-7792-8294; Gentile, Vittorio/0000-0001-7792-8294; MIAN, SYED SHARIQ/0000-0001-7563-5121; Griffin, Martin/0000-0003-3824-306X				ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1991, J BIOL CHEM, V266, P15308; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARNES RN, 1985, CARCINOGENESIS, V6, P459, DOI 10.1093/carcin/6.3.459; BIRKBICHLER PJ, 1977, CANCER RES, V37, P1340; BOWNESS JM, 1987, J BIOL CHEM, V262, P1022; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DE LUCA LM, 1990, METHOD ENZYMOL, V190, P81; DELCROS JG, 1986, FEBS LETT, V196, P325, DOI 10.1016/0014-5793(86)80272-1; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FESUS L, 1989, FEBS LETT, V245, P150, DOI 10.1016/0014-5793(89)80210-8; FESUS L, 1991, EUR J CELL BIOL, V56, P170; FESUS L, 1981, MOL IMMUNOL, V18, P633, DOI 10.1016/0161-5890(81)90034-1; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FUKUDA K, 1993, HEPATOLOGY, V17, P118, DOI 10.1002/hep.1840170121; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRIFFIN M, 1989, BIOCHEM SOC T, V17, P714, DOI 10.1042/bst0170714; GRIFFIN M, 1982, ANAL BIOCHEM, V124, P406, DOI 10.1016/0003-2697(82)90057-4; HAND D, 1987, BIOCHIM BIOPHYS ACTA, V930, P432, DOI 10.1016/0167-4889(87)90016-4; HAND D, 1988, BIOCHIM BIOPHYS ACTA, V970, P137, DOI 10.1016/0167-4889(88)90172-3; HAND D, 1989, BIOCHIM BIOPHYS ACTA, V970, P137; HAND D, 1986, BIOSCIENCE REP, V5, P1079; JIANG SY, 1992, JNCI-J NATL CANCER I, V84, P580, DOI 10.1093/jnci/84.8.580; KERR JFR, 1973, VIRCHOWS ARCH B, V13, P87; KNIGHT CRL, 1993, IMMUNOLOGY, V79, P535; KNIGHT CRL, 1991, BIOCHIM BIOPHYS ACTA, V1096, P312, DOI 10.1016/0925-4439(91)90067-J; KNIGHT CRL, 1990, BIOCHIM BIOPHYS ACTA, V1053, P13, DOI 10.1016/0167-4889(90)90019-A; KNIGHT RL, 1993, EUR J CELL BIOL, V60, P210; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; LENNON SV, 1992, CLIN EXP IMMUNOL, V87, P465; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1972, ANN ACAD SCI, V206, P6; PIACENTINI M, 1991, CELL TISSUE RES, V263, P227, DOI 10.1007/BF00318764; RICE RH, 1978, J CELL BIOL, V76, P705, DOI 10.1083/jcb.76.3.705; ROCH AM, 1991, INT J CANCER, V48, P215, DOI 10.1002/ijc.2910480211; SCHMIDT R, 1985, FEBS LETT, V186, P201, DOI 10.1016/0014-5793(85)80708-0; TEALE DM, 1987, INVAS METAST, V7, P129; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZIRVI KA, 1991, CANCER LETT, V60, P85, DOI 10.1016/0304-3835(91)90052-J	46	58	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2935	2942						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916148				2022-12-17	WOS:A1994PG82200019
J	BEG, AA; BALDWIN, AS				BEG, AA; BALDWIN, AS			ACTIVATION OF MULTIPLE NF-KAPPA-B/REL DNA-BINDING COMPLEXES BY TUMOR-NECROSIS-FACTOR	ONCOGENE			English	Note							B P50; SUBUNIT; REL; TRANSCRIPTION; PRECURSOR; PRODUCT; GENE; P65	NF-kappa B is an inducible transcription factor that regulates the expression of numerous genes involved in immune and inflammation responses and in cellular growth control. Typically, NF-kappa B is localized in the cytoplasm complexed with members of the I kappa B family. The most well characterized form of NF-kappa B is comprised of a heterodimer of a 50 kD (p50/NFKB1) and a 65 kD (p65/RelA) protein. This heterodimeric protein was thought to be primarily responsible for transcriptional regulation of target genes. However, recent studies have led to the identification of other kappa B binding proteins such as c-Rel, RelB and p52 (NFKB2/lyt-10) although their role in gene regulation has been less clear. Here, using gel mobility shift assays as well as a highly sensitive DNA-protein crosslinking assay, we provide evidence for the existence of multiple tumor necrosis factor (TNF)inducible kappa B binding complexes containing various members of the NF-kappa B/Rel family, namely p50 and p65 as well as the c-Rel and p52 oncoproteins. Dimeric complexes containing various combinations of these proteins appear rapidly in nuclei of TNF-alpha-stimulated cells and include, along with a p50-p65 heterodimer, p50-c-Rel, p65-c-Rel, p52-c-Rel and p52-p65 complexes. The presence of multiple inducible complexes containing distinct combinations of NF-kappa B/Rel family members indicate that specific kappa B responsive genes may be regulated in an NF-kappa B subunit-dependent manner.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA52515] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SPRINGER TA, 1989, CURRENT PROTOCOLS MO, V2; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	25	58	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1487	1492						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152812				2022-12-17	WOS:A1994NH40100023
J	NEGISHI, Y; NISHITA, Y; SAEGUSA, Y; KAKIZAKI, I; GALLI, I; KIHARA, F; TAMAI, K; MIYAJIMA, N; IGUCHIARIGA, SMM; ARIGA, H				NEGISHI, Y; NISHITA, Y; SAEGUSA, Y; KAKIZAKI, I; GALLI, I; KIHARA, F; TAMAI, K; MIYAJIMA, N; IGUCHIARIGA, SMM; ARIGA, H			IDENTIFICATION AND CDNA CLONING OF SINGLE-STRANDED-DNA BINDING-PROTEINS THAT INTERACT WITH THE REGION UPSTREAM OF THE HUMAN C-MYC GENE	ONCOGENE			English	Article							TRANSCRIPTIONAL ENHANCER; SACCHAROMYCES-CEREVISIAE; GEL-ELECTROPHORESIS; REPLICATION ORIGIN; MESSENGER-RNA; SEQUENCES; PROMOTER; ELEMENT; NUCLEAR; INITIATION	We have previously reported that a c-myc protein complex binds to the region upstream of the c-myc gene, where exist an origin of cellular DNA replication (ori) and a transcriptional enhancer. Both functions require a 21 bp long sequence, while the c-myc protein complex recognizes a 7 bp consensus therein. It was recently reported that single-stranded DNA binding proteins bound specifically to sequences that play roles in DNA replication or transcription. We examined for proteins binding to the single-stranded DNAs of the 21 bp element (myc(H-P)21). In a band shift assay with HL60 cells nuclear extract, probes of either the plus strand or the minus strand gave rise to specific signals. Mutation introduced within a short consensus (A/(T)CT(A)/T(A)/(T)T) present in both strands completely abolished binding in either case. Southwestern blotting analysis showed that proteins of molecular weight 105, 80, 50, 45, 40, 39.5 and 14 kDa bound sequence-specifically to either strand and 22 kDa to minus strand to the cognate A/(T)CT(A)/(T)A/(T)T consensus. These single-stranded DNA binding proteins were named MSSP, c-myc gene single strand binding proteins. We attempted to isolate the cDNAs encoding these proteins by screening a human cDNA library with the plus single-stranded oligonucleotide as a probe. Among several positive clones, we have characterized one, termed MSSP-1. MSSP-1 produced in E. coli as a fusion protein with GST specifically interacted with single-stranded TCTTAT (plus myc(H-P)21) and ACT-ATT (in minus myc(H-P)21), the consensus of which can be referred to as A/(T)CT(A)/T(A)/(T)T. Sequence analysis of MSSP-1 cDNA revealed that two domains thereof are homologous to the RNA binding motifs common to several ribonucleoproteins. Interestingly, the MSSP-1/GST fusion protein specifically recognized myc(H-P)21 not only in single-stranded but also in double-stranded forms. Binding properties of MSSP-1 imply its functions in DNA replication. Furthermore, when the AT stretch in the SV40 ori core was substituted by TCTTAT, MSSP-1 promoted viral DNA replication depending on the consensus sequences.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,KITA 12 NISHI 6,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; MBL CO LTD,INA LABS,INA 396,JAPAN; INST PHYS & CHEM RES,TSUKUBA,IBARAKI 305,JAPAN; HOKKAIDO UNIV,COLL MED TECHNOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; RIKEN; Hokkaido University			Kakizaki, Ikuko/AAO-5489-2020; Tamai, Katsuyuki/F-4743-2013; Ariga, Hiroyoshi/B-5895-2013	Kakizaki, Ikuko/0000-0002-6702-5830; Tamai, Katsuyuki/0000-0003-4094-3911; Ariga, Hiroyoshi/0000-0001-7384-2143				ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; BRUNEL F, 1991, NUCLEIC ACIDS RES, V19, P5237, DOI 10.1093/nar/19.19.5237; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FINOCCHIARO LME, 1991, NUCLEIC ACIDS RES, V19, P4279, DOI 10.1093/nar/19.15.4279; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6501; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GALLI I, 1992, NUCLEIC ACIDS RES, V20, P3333, DOI 10.1093/nar/20.13.3333; GALLI I, 1993, FEBS LETT, V318, P335, DOI 10.1016/0014-5793(93)80541-2; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4471; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOFFMANN J, 1991, CELL, V64, P951; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KITAURA H, 1991, FEBS LETT, V289, P1; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMANO M, 1992, FEBS LETT, V309, P146, DOI 10.1016/0014-5793(92)81083-X; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NEGISHI Y, 1992, ONCOGENE, V7, P543; PAN WT, 1990, J BIOL CHEM, V265, P7022; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SIERAKOWSKA H, 1986, NUCLEIC ACIDS RES, V14, P5241, DOI 10.1093/nar/14.13.5241; SINGH H, 1988, CELL, V52, P514; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SWANSON MS, 1988, EMBO J, V11, P3519; TOMILIN NV, 1990, FEBS LETT, V263, P69, DOI 10.1016/0014-5793(90)80707-P; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949	49	58	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1133	1143						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134115				2022-12-17	WOS:A1994NC04800016
J	FISCH, P; FORSTER, A; SHERRINGTON, PD; DYER, MJS; RABBITTS, TH				FISCH, P; FORSTER, A; SHERRINGTON, PD; DYER, MJS; RABBITTS, TH			THE CHROMOSOMAL TRANSLOCATION T(X14)(Q28Q11) IN T-CELL PRO-LYMPHOCYTIC LEUKEMIA BREAKS WITHIN ONE GENE AND ACTIVATES ANOTHER	ONCOGENE			English	Article							ATAXIA TELANGIECTASIA; MOLECULAR ANALYSIS; LEUKEMIA; SEQUENCE; PATIENT; MECHANISM; INVERSION; CLONING; LOCUS; DNA	Chromosomal translocation t(X;14)(q28;q11) has been observed in patients with pro-lymphocytic T-cell leukaemia (T-PLL). In two cases of T-PLL, one of which was associated with Ataxia telangiectasia (AT), the chromosomal break occurred in two different introns of a gene c6.1A, located at the Xq28 locus. Fusion transcripts, consisting of 5' sequences of c6.1A and the TCR alpha constant (C) region, were expressed at high levels in the leukaemic cells from both patients, but in only one case did this fusion generate an in-frame c6.1A-C alpha mRNA. However, the breaks within c6.1A seem to affect another gene, cd.1B, which is transcribed from the same CpG rich island as c6.1A but in the opposite transcriptional orientiation. The c6.1B gene is not damaged by the translocation but is transcribed in both T-PLL cases. Furthermore, c6.1B may lack protein coding capacity and thus this translocation might result in a novel mechanism in tumorigenesis. In any event, this is the first cloned gene which is implicated in pathogenesis of chronic/pro-lymphocytic leukaemia of the T-cell lineage.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, CAMBS, ENGLAND; ROYAL CANC HOSP, INST CANC RES, SUTTON SM2 5NG, SURREY, ENGLAND	MRC Laboratory Molecular Biology; University of London; Institute of Cancer Research - UK			Dyer, Martin/F-2691-2014; Rabbitts, Terence/D-6262-2016	Dyer, Martin/0000-0002-5033-2236; Rabbitts, Terence/0000-0002-4982-2609				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAER R, 1987, CELL, V50, P97, DOI 10.1016/0092-8674(87)90666-0; BAER R, 1988, EMBO J, V7, P1611; BANKIER AT, 1987, METHOD ENZYMOL, V155, P51; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDMAN MA, 1992, NAT GENET, V2, P169, DOI 10.1038/ng1192-169; KAISERMCCAW B, 1975, P NATL ACAD SCI USA, V72, P2071; KENWRICK S, 1992, HUM MOL GENET, V1, P179, DOI 10.1093/hmg/1.3.179; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LEVITT R, 1978, BLOOD, V52, P1003; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1986, NUCLEIC ACIDS RES, V14, P217, DOI 10.1093/nar/14.1.217; TAYLOR AMR, 1986, INT J CANCER, V37, P511, DOI 10.1002/ijc.2910370407; TAYLOR AMR, IN PRESS LEUKAEMIA; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WINOTO A, 1989, EMBO J, V8, P729, DOI 10.1002/j.1460-2075.1989.tb03432.x	26	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1993	8	12					3271	3276						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247530				2022-12-17	WOS:A1993MG78200010
J	OTTO, A; DEPPERT, W				OTTO, A; DEPPERT, W			UP-REGULATION OF MDM-2 EXPRESSION IN METH A TUMOR-CELLS TOLERATING WILD-TYPE P53	ONCOGENE			English	Article							A MOUSE CELLS; MUTANT P53; BREAST-CANCER; CYCLE CONTROL; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; SUPPRESSOR GENE; GROWTH ARREST; SARCOMA-CELLS; NORMAL 3T3	Overexpression of mouse wild-type p53 (wt p53) in mouse Meth A tumor cells after transfection of wt p53 encoding vectors induced a strong growth-inhibitory response. Cells of only few of randomly selected surviving colonies contained and expressed the transfected wt p53 specific DNA. Despite expressing authentic wt p53, such cells (MethAp53wt) exhibited a similar phenotype as the parental Meth A cells. These cells overexpressed the mdm-2 (mouse double minute-2) gene, both at the RNA and at the protein level. Recently, the MDM-2 protein has been identified as a cellular target of p53, which can abolish its tumor suppressor activity. We, therefore, suggest that MDM-2 has mitigated the growth-inhibitory effect of wt p53 in MethAp53wt cells. Upregulation of mdm-2 expression in MethAp53wt cells was mediated by wt p53, as analysis of Meth A cells carrying a tsp53 (p53Val135) revealed a strict dependence of mdm-2 upregulation upon wt p53 expression. Our results propose that a balanced ratio of MDM-2 and p53 will allow cells to tolerate a limited expression of wt p53. This tolerance is not mediated by a direct inactivation of wt p53 via complex formation with MDM-2, as the majority of both MDM-2 and wt p53 in MethAp53wt cells was not complexed to each other.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 20,GERMANY	Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BARTEK J, 1990, ONCOGENE, V5, P893; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN YM, 1991, ONCOGENE, V6, P1799; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1989, NATO ASI SER, P399; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEINBERG AP, 1983, ANAL BIOCHEM, V136, P6; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1992, CELL, V69, P1237; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J, 1989, J SAMBROOK MOL CLONI; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHOHAT O, 1987, ONCOGENE, V1, P277; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKAHASHI T, 1992, CANCER RES, V52, P2340; WEISSKER SN, 1992, ONCOGENE, V7, P1921; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZERRAHN J, 1992, ONCOGENE, V7, P1371	65	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2591	2603						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361769				2022-12-17	WOS:A1993LT36800033
J	CARTWRIGHT, CA; MAMAJIWALLA, S; SKOLNICK, SA; ECKHART, W; BURGESS, DR				CARTWRIGHT, CA; MAMAJIWALLA, S; SKOLNICK, SA; ECKHART, W; BURGESS, DR			INTESTINAL CRYPT CELLS CONTAIN HIGHER LEVELS OF CYTOSKELETAL-ASSOCIATED PP60C-SRC PROTEIN TYROSINE KINASE-ACTIVITY THAN DO DIFFERENTIATED ENTEROCYTES	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; HUMAN-COLON CARCINOMA; GAP JUNCTION PROTEIN; ISOLATED MICROVILLUS CYTOSKELETON; INSOLUBLE CELLULAR MATRIX; EXPRESSED RAT FIBROBLASTS; CHICK-EMBRYO DEVELOPMENT; MIDDLE TUMOR-ANTIGEN; HERBIMYCIN-A; MORPHOLOGICAL TRANSFORMATION	Undifferentiated crypt cells from chicken small intestine contain 15-fold higher levels of tyrosine-phosphorylated proteins than do differentiated enterocytes located at the villus apex. The tyrosine kinase activity and the tyrosine-phosphorylated proteins are associated with the Triton-insoluble cytoskeleton. To determine whether: (1) pp60c-src is an active tyrosine kinase in crypt cell cytoskeletons and (2) cytoskeletal-associated pp60c-src activity decreases as crypt cells differentiate, we isolated pp60c-src from subcellular fractions of cells along the crypt-villus axis of chicken small intestine and measured its protein kinase activity. We observed that pp60c-src activity in crypt cytoskeleton was higher (on average, fourfold as measured by enolase phosphorylation or sevenfold as measured by autophosphorylation) than that in cytoskeletons from differentiated enterocytes. Moreover, nearly 70% of pp60c-src activity in crypt cells, like that of pp60v-src, pp60c-src mutants with elevated kinase, activity or pp60v-src from activated platelets, localized to the cellular cytoskeleton. In contrast, less than 20% of pp60c-src activity in differentiated enterocytes, like that of kinase-inactive pp60v-src or pp60c-src from fibroblasts or resting platelets, associated with the cytoskeleton. Furthermore, in crypt cells, unlike differentiated enterocytes, cytoskeletal-associated pp60c-src appeared to have higher specific protein tyrosine kinase activity than did soluble pp60c-src. The data suggest that a kinase-active form of pp60c-src located in the cytoskeleton of crypt cells may be responsible for phosphorylating proteins on tyrosine and regulating growth and differentiation of the cells.	UNIV PITTSBURGH,DEPT BIOL SCI,PITTSBURGH,PA 15260; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Salk Institute	CARTWRIGHT, CA (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MED,MED SCH LAB,SURGE BLDG,P304,STANFORD,CA 94305, USA.				NCI NIH HHS [CA-13884] Funding Source: Medline; NIDDK NIH HHS [P30-DK38707, R29 DK43743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA013884, R01CA013884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R29DK043743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BREIMER ME, 1981, EXP CELL RES, V135, P1, DOI 10.1016/0014-4827(81)90293-7; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; CROW DS, 1992, ONCOGENE, V7, P999; FATH KR, 1990, DEVELOPMENT, V109, P449; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; FOSS FM, 1989, ONCOGENE RES, V5, P13; GARCIA R, 1991, ONCOGENE, V6, P1983; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GLENNEY J, 1986, P NATL ACAD SCI USA, V83, P4258, DOI 10.1073/pnas.83.12.4258; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GOULD KL, 1984, J CELL BIOL, V98, P487, DOI 10.1083/jcb.98.2.487; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KMIECK TE, 1987, CELL, V49, P75; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MURAKAMI Y, 1988, CANCER RES, V48, P1587; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SUZUKAKETSUCHIY.K, 1989, J ANTIBIIOT, V12, P1831; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; WEISER MM, 1973, J BIOL CHEM, V248, P2536; WEISER MM, 1986, INT REV CYTOL, V101, P1, DOI 10.1016/S0074-7696(08)60245-4; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	54	58	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1033	1039						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	7681158				2022-12-17	WOS:A1993KT22000027
J	BENVENISTY, N; ORNITZ, DM; BENNETT, GL; SAHAGAN, BG; KUO, A; CARDIFF, RD; LEDER, P				BENVENISTY, N; ORNITZ, DM; BENNETT, GL; SAHAGAN, BG; KUO, A; CARDIFF, RD; LEDER, P			BRAIN-TUMORS AND LYMPHOMAS IN TRANSGENIC MICE THAT CARRY HTLV-I LTR/C-MYC AND IG/TAX GENES	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; E-MU-MYC; T-CELL; B-CELL; TAX GENE; EXPRESSION; TUMORS; HYBRIDIZATION; RNA; TRANSFORMATION	The human T-cell leukemia virus type 1 (HTLV-I) is associated with adult CD4+ T-cell leukemia (ATL) and tropical spastic paraparesis (TSP). In as much as only a small percentage of individuals infected with HTLV-I develop either disease, we set out to model a genetic partner for this virus in an effort to understand and possibly reproduce its pathophysiology. To this end we have developed a binary set of transgenic mice, one bearing the relatively inactive HTLV-I long terminal repeat (LTR) positioned to drive the c-myc oncogene and another bearing a fusion transgene consisting of the immunoglobulin promoter/enhancer driving the gene for the HTLV-I transcription activator, tax. Alone, the tax construct, though expressed in the thymus, spleen, lung and brain, has no deleterious effect. Alone, the HTLV-I LTR/c-myc construct is expressed at very low levels in lymphoid cells and occasionally induces lymphomas in older animals. When these two transgenic lines are mated, bigenic offspring harboring both transgenes exhibit dramatic tumor formation. As in the human, these animals develop CD4+ T-cell lymphomas, but they also develop central nervous system tumors by 25-90 days of age. The syndrome, which is 100% penetrant and lethal, provides an animal model for adult T-cell lymphoma and a source of cultured cells of neurogenic origin.	UNIV CALIF DAVIS, SCH MED, DEPT PATHOL, DAVIS, CA 95616 USA	University of California System; University of California Davis	BENVENISTY, N (corresponding author), HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, 25 SHATTUCK ST, BOSTON, MA 02115 USA.			Ornitz, David/0000-0003-1592-7629				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FURUTA Y, 1989, J VIROL, V63, P3185, DOI 10.1128/JVI.63.7.3185-3189.1989; GESSAIN A, 1985, LANCET, V2, P407; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN JE, 1989, NATURE, V341, P72, DOI 10.1038/341072a0; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; ITO Y, 1985, CURR TOP MICROBIOL, V115, P99; IWAKURA Y, 1991, SCIENCE, V253, P1026, DOI 10.1126/science.1887217; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KOIZUMI T, 1989, INT J CANCER, V44, P701, DOI 10.1002/ijc.2910440425; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERENBERG MI, 1991, J VIROL, V65, P3349, DOI 10.1128/JVI.65.6.3349-3353.1991; PIGOTT T J D, 1990, British Journal of Neurosurgery, V4, P287, DOI 10.3109/02688699008992738; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; XU YL, 1990, J BIOL CHEM, V265, P20285; ZELLER R, 1987, GENE DEV, V1, P693, DOI 10.1101/gad.1.7.693	36	58	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2399	2405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461648				2022-12-17	WOS:A1992KA85600004
J	LAUTENBERGER, JA; BURDETT, LA; GUNNELL, MA; QI, SM; WATSON, DK; OBRIEN, SJ; PAPAS, TS				LAUTENBERGER, JA; BURDETT, LA; GUNNELL, MA; QI, SM; WATSON, DK; OBRIEN, SJ; PAPAS, TS			GENOMIC DISPERSAL OF THE ETS GENE FAMILY DURING METAZOAN EVOLUTION	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; PROTO-ONCOGENE; C-ETS; CHROMOSOMAL LOCALIZATION; TRANSCRIPTION FACTOR; DEVELOPMENTAL EXPRESSION; MOLECULAR-ORGANIZATION; C-ETS-1 PROTOONCOGENE; TRANSFORMING GENE; LEUKEMIA-VIRUS	Evolutionary homologs of the ets proto-oncogene have been discovered in the genomes of widely divergent eucaryote species from Drosophila to sea urchin to vertebrates. The prototype mammalian ets-1 and ets-2 genes are divided into three coding domains that differ in their rate of accumulation of sequence divergence. An analysis of sequence divergence of ets gene homologs in various species has produced a phylogenetic history of the ets gene family in the context of metazoan evolutionary radiation. A minimum of five duplication events of ets primordial genes were evident, namely (1) a duplication that separates primitive ets genes (Drosophila precursor of 74E, mouse PU.1 and human ELK1) from the ets-1, ets-2, erg ancestor; (2) and (3) two duplications that established separate ets, erg and elg/GABP-alpha lineages which occurred prior to invertebrate-vertebrate divergence; (4) divergence of ets-1 and ets-2 gene family also associated with vertebrate-invertebrate divergence; (5) duplication of ets-1 and ets-2 in Xenopus laevis to produce two ets-1 genes and two ets-2 genes during genomic tetraploidation in the recent ancestry of this species.	FREDERICK CANC RES & DEV CTR, PROGRAM RESOURCES INC, FREDERICK, MD 21702 USA; NCI, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	LAUTENBERGER, JA (corresponding author), NCI, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA.		OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757				BAUD V, 1991, GENOMICS, V11, P223, DOI 10.1016/0888-7543(91)90124-W; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN ZQ, 1988, DEV BIOL, V125, P432, DOI 10.1016/0012-1606(88)90224-2; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; DEVEREAUX J, 1991, SEQUENCE ANAL SOFTWA; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; JORCYK CL, 1991, ONCOGENE, V6, P523; JUNIEN C, 1990, CYTOGENET CELL GENET, V55, P153, DOI 10.1159/000133007; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KINGSLEY DM, 1989, GENETICS, V123, P165; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, ONCOGENE, V5, P941; MYERS G, 1991, HUMAN RETROVIRUSES A, P25; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1988, ONCOGENE, V3, P497; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REEVES RH, 1988, J VIROL, V62, P4372, DOI 10.1128/JVI.62.11.4372-4375.1988; REITZ MS, 1991, NATURE, V351, P358, DOI 10.1038/351358a0; SACCHI N, 1988, Genomics, V3, P110, DOI 10.1016/0888-7543(88)90140-1; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; SWOFFORD DL, 1984, PHYLOGENETIC ANAL US; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VALENTINE JW, 1991, EVOLUTIONARY BIOL, V25, P279; VANCONG N, 1990, HUM GENET, V84, P542; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1990, ADV AP BIOT, V6, P221; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1986, P NATL ACAD SCI USA, V83, P1792, DOI 10.1073/pnas.83.6.1792; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; [No title captured]	58	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1713	1719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501883				2022-12-17	WOS:A1992JJ37600006
J	HAMEL, PA; GILL, RM; PHILLIPS, RA; GALLIE, BL				HAMEL, PA; GILL, RM; PHILLIPS, RA; GALLIE, BL			REGIONS CONTROLLING HYPERPHOSPHORYLATION AND CONFORMATION OF THE RETINOBLASTOMA GENE-PRODUCT ARE INDEPENDENT OF DOMAINS REQUIRED FOR TRANSCRIPTIONAL REPRESSION	ONCOGENE			English	Article							LARGE-T-ANTIGEN; ADENOVIRUS E1A PROTEINS; VIRUS-40 LARGE-T; SV40 LARGE-T; CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION SITES; RNA-POLYMERASE; NUCLEAR LAMINA; CDC2 KINASE	Cell cycle-dependent phosphorylation appears to control the function of the retinoblastoma gene product, p110RB1. We have previously shown that both the N-terminal portion and the portion corresponding to exon 23 are important in the hyperphosphorylation of p110RB1. To gain further insight into the domains involved in these phosphorylations, we have created a series of mutations in the murine cDNA and investigated their effects on phosphorylation, protein conformation and transcription of genes controlled by an E2 element. Three series of p110RB1 constructs were made: (1) mutations and/or deletions in the cluster of potential p34cdc2 consensus sequences of exon 23, (2) deletions for the entire region C-terminal to the large T antigen (TAg)-binding domains or (3) mutations in eight potential p34cdc2 sites, including four in exon 23. Following transfections into COS cells, phosphorylation, TAg binding and protein conformation were evaluated. Constructs were also tested for their ability to repress transcription from the adenovirus early promoter. All mutant proteins bound to SV40 TAg. Mutation of Ser-781, Ser-787 and Ser-788 had no detectable effect on the phosphorylation pattern of p110RB1, producing both the fast-migrating, hypophosphorylated and slower migrating, hyperphosphorylated bands on SDS-PAGE gels. However, mutation or deletion of Ser-800 and Ser-804 resulted in proteins which failed to show the characteristic shift in molecular weight associated with the hyperphosphorylated form of p110RB1. A protein mutated only at Pro-805, the residue adjacent to Ser-804, behaved similarly to mutants with both Ser-800 and Ser-804 altered; mutation of Pro-801 had no effect on the mobility of the hyperphosphorylated species. While differences were seen in the ability of these proteins to be hyperphosphorylated, the wild-type function of repression of adenovirus early promoter activity was retained. These results are consistent with the large shift in apparent molecular weight of p110RB1 upon hyperphosphorylation being due to phosphorylation of Ser-804. Phosphorylation of this p34cdc2 consensus sequence and the subsequent conformational change in p110RB1 detected in denaturing gels is not necessary, however, for the phosphorylation-dependent modulation of p110RB1-TAg interaction.	UNIV TORONTO,DEPT IMMUNOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MINERAL & PETROL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT OPHTHALMOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto	HAMEL, PA (corresponding author), HOSP SICK CHILDREN,RES INST,DIV IMMUNOL & CANC,ROOM 8130,TORONTO M5G 1X8,ONTARIO,CANADA.			Gallie, Brenda/0000-0002-9697-9211				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRADBURY EM, 1974, NATURE, V249, P553, DOI 10.1038/249553a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4594; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHULZEGAHMEN U, 1988, J BIOL CHEM, V263, P17100; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; STARNAUD R, 1988, ONCOGENE, V3, P553; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	47	58	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					693	701						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1565466				2022-12-17	WOS:A1992HQ68200011
J	STOBERGRASSER, U; BRYDOLF, B; BIN, X; GRASSER, F; FIRTEL, RA; LIPSICK, JS				STOBERGRASSER, U; BRYDOLF, B; BIN, X; GRASSER, F; FIRTEL, RA; LIPSICK, JS			THE MYB DNA-BINDING DOMAIN IS HIGHLY CONSERVED IN DICTYOSTELIUM-DISCOIDEUM	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; MOUSE ERYTHROLEUKEMIA-CELLS; AMINO-TERMINAL REGION; HUMAN LYMPHOCYTES-T; ONCOGENE C-MYB; V-MYB; PROTO-ONCOGENE; NUCLEOTIDE-SEQUENCE; GENE-EXPRESSION; CELLULAR PROGENITOR	The c-myb proto-oncogene encodes a protein that is highly conserved among birds and mammals. The amino-terminal domain of c-Myb contains three imperfect tandem repeats of approximately 50 amino acids each. This domain is required for DNA binding and has also been conserved to varying degrees in invertebrates, plants and yeast. Given that myb-related genes appear to control cellular differentiation in a variety of eucaryotic systems, the presence of a myb gene in the cellular slime mold Dictyostelium discoideum might provide a tractable system for studying the role of myb in differentiation. Degenerate oligonucleotide primers encoding regions that are highly conserved in the vertebrate and Drosophila Myb DNA-binding domains were used to amplify a related domain from Dictyostelium genomic DNA, which was then used to isolate a genomic clone. The putative DNA-binding domain of Dictyostelium Myb is as closely related to vertebrate c-Myb as is Drosophila Myb (65% identity), whereas the known Myb-related proteins of plants and yeast are more distantly related. The conserved domain of Dictyostelium Myb is capable of binding to the same DNA sequence as the vertebrate and Drosophila Myb proteins. The remainder of the deduced amino acid sequence of Dictyostelium Myb shows no homology to the divergent domains of the known animal, plant and yeast Myb-related proteins. Evolutionary analysis implies that the duplications that generated the repeats of the Myb DNA-binding domain began prior to the divergence of animals, plants, cellular slime molds and yeast.	SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [P01-CA-28146, K04-CA-01457] Funding Source: Medline; NIGMS NIH HHS [GM-30693] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001457, P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030693] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; CHEN JH, 1980, J VIROL, V36, P162, DOI 10.1128/JVI.36.1.162-170.1980; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DEVREOTES P, 1989, SCIENCE, V245, P1054, DOI 10.1126/science.2672337; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P659; DOONER HK, 1983, MOL GEN GENET, V189, P136, DOI 10.1007/BF00326066; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; DVORAK M, 1989, NUCLEIC ACIDS RES, V17, P5651; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HAHN SL, 1989, MOL CELL BIOL, V9, P837, DOI 10.1128/MCB.9.2.837; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1987, J VIROL, V61, P933, DOI 10.1128/JVI.61.3.933-936.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; MCCLINTOCK B, 1989, YB 48, P142; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Spudich JA, 1987, METHODS CELL BIOL, V28; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	71	58	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					589	596						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1549373				2022-12-17	WOS:A1992HK00500029
J	SAKSELA, K; MAKELA, TP; HUGHES, K; WOODGETT, JR; ALITALO, K				SAKSELA, K; MAKELA, TP; HUGHES, K; WOODGETT, JR; ALITALO, K			ACTIVATION OF PROTEIN-KINASE-C INCREASES PHOSPHORYLATION OF THE L-MYC TRANSACTIVATOR DOMAIN AT A GSK-3 TARGET SITE	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; DNA-BINDING PROTEINS; HUMAN SMALL CELL; NUCLEOTIDE-SEQUENCE; OKADAIC ACID; GENE; ONCOGENE; TUMOR; EXPRESSION; LINES	The L-myc protein migrates as three distinct differentially phosphorylated bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This phosphorylation can be rapidly increased either by treatment with the protein kinase C (PKC) activator phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) or by inhibition of serine/threonine protein phosphatases with okadaic acid. In vitro mutagenesis and phosphoamino acid analyses define the N-terminal serine residues 38 and 42 of L-myc as critical targets for the PKC-dependent phosphorylation. These are the exclusive sites of phosphorylation in the N-terminal third of the L-myc protein, and can be phosphorylated in vitro by glycogen synthase kinase 3-beta (GSK-3-beta). A mutant L-myc protein in which these serines have been replaced by alanine residues does not show heterogeneous electrophoretic migration or hyperphosphorylation in response to PKC activation, and is not a substrate for GSK-3-beta in vitro. Similar potential phosphorylation sites are present in c-myc and N-myc in a highly conserved region thought to represent a transcriptional activation domain. We suggest that N-terminal phosphorylation of the L-myc protein is a means of rapid regulation of this oncoprotein, possibly mediated in vivo by the action of GSK-3.	UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINKATU 3, SF-00290 HELSINKI 29, FINLAND; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00290 HELSINKI 29, FINLAND	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki			Woodgett, Jim/F-1087-2010; Alitalo, Kari K/J-5013-2014; makela, tomi/B-3734-2009	Woodgett, Jim/0000-0003-3731-5797; Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044; Saksela, Kalle/0000-0003-0827-122X				ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEGREVE J, 1988, MOL CELL BIOL, V8, P4381, DOI 10.1128/MCB.8.10.4381; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS BA, 1981, EUR J BIOCHEM, V119, P443, DOI 10.1111/j.1432-1033.1981.tb05628.x; HUGHES K, 1991, ADV PROTEIN PHOSPHAT, V6, P483; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOORE JP, 1987, ONCOGENE RES, V2, P65; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; SAKSELA K, 1989, EMBO J, V8, P149, DOI 10.1002/j.1460-2075.1989.tb03359.x; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	48	58	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1992	7	2					347	353						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG982	1312697				2022-12-17	WOS:A1992HG98200021
J	CRUMLEY, G; BELLOT, F; KAPLOW, JM; SCHLESSINGER, J; JAYE, M; DIONNE, CA				CRUMLEY, G; BELLOT, F; KAPLOW, JM; SCHLESSINGER, J; JAYE, M; DIONNE, CA			HIGH-AFFINITY BINDING AND ACTIVATION OF A TRUNCATED FGF-RECEPTOR BY BOTH AFGF AND BFGF	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; EARLY XENOPUS EMBRYOS; CELL-GROWTH; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; FACTOR CDNA; ACIDIC FGF; GENE; EXPRESSION	We recently reported the cloning and overexpression of full-length forms of human fibroblast growth factor (FGF) receptors, bek and flg. These receptors contain three immunoglobulin (Ig)-like domains and an unusual acidic motif in the extracellular region, a single transmembrane segment and a protein tyrosine kinase cytoplasmic domain containing a 14 amino acid insert. Each of the related full-length gene products interacts at high affinity with both acidic FGF and basic FGF. We now report the isolation of cDNA clones encoding two variant forms of human bek. One variant form encodes a potentially secreted bek protein containing only the first Ig-like domain and acidic motif, whereas the other variant includes all of the full-length bek protein except the first Ig-like domain and acidic motif. Overexpression of the latter bek form in NIH3T3 cells has been used to demonstrate that the N-terminal Ig-like domain and acidic region are not required for binding or activation of bek by aFGF or bFGF.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University	CRUMLEY, G (corresponding author), RHONE POULENC RORER CENT RES, 680 ALLENDALE RD, KING OF PRUSSIA, PA 19406 USA.							ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BELLOT F, 1991, IN PRESS EMBO J; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; KAN M, 1988, J BIOL CHEM, V263, P11306; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TOGARI A, 1985, J NEUROSCI, V5, P307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	63	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2255	2262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722570				2022-12-17	WOS:A1991GX73500012
J	CHAN, J; WATT, VM				CHAN, J; WATT, VM			EEK AND ERK, NEW MEMBERS OF THE EPH SUBCLASS OF RECEPTOR PROTEIN-TYROSINE KINASES	ONCOGENE			English	Article							PHOSPHOTYROSINE ANTIBODY; GEL-ELECTROPHORESIS; DNA FRAGMENTS; GENE; PDGF; FAMILY; BRAIN; PHOSPHORYLATION; LOCALIZATION; EXPRESSION	We have identified human and rat DNAs encoding two novel members of the eph subclass of putative receptor protein-tyrosine kinases. Rat cDNA clones encoding eek (eph- and elk-related kinase) were isolated from a brain cDNA library probed with DNA encoding the kinase region of the insulin receptor-related receptor. The predicted eek protein contains all the amino acid residues conserved in the catalytic domains of protein-tyrosine kinases and is most similar to two putative receptor protein-tyrosine kinases of the eph subclass, elk (69%) and eph (57%). Human genomic DNAs encoding part of eek (EEK) as well as another putative protein-tyrosine kinase most similar to elk (90%), ERK (elk-related kinase), were isolated and partially characterized. The novel identity of these two eph-family genes was further supported by Southern blot analyses and localization to human chromosome 1. In Northern blot analysis of rat RNA, DNAs encoding rat eek and human ERK hybridized to transcripts most abundant in brain and lung, respectively. These two new members of the eph subclass of receptor protein-tyrosine kinases, eek and erk, may therefore have tissue-specific functions distinct from those of other eph family members.	UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,ROOM 3360,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto	WATT, VM (corresponding author), UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,ROOM 3360,1 KINGS COLL CIRCLE,TORONTO M5S 1A8,ONTARIO,CANADA.							ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCHBERG AM, 1989, GENETICS, V122, P153; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIER P, 1990, CYTOGENET CELL GENET, V54, P80, DOI 10.1159/000132963; SHIER P, 1989, J BIOL CHEM, V264, P14605; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WATT VM, 1990, HUM GENET, V85, P651; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	39	58	130	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1057	1061						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1648701				2022-12-17	WOS:A1991GU62200023
J	MORAN, MF; KOCH, CA; SADOWSKI, I; PAWSON, T				MORAN, MF; KOCH, CA; SADOWSKI, I; PAWSON, T			MUTATIONAL ANALYSIS OF A PHOSPHOTRANSFER MOTIF ESSENTIAL FOR V-FPS TYROSINE KINASE-ACTIVITY	ONCOGENE			English	Article									UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto	MORAN, MF (corresponding author), MT SINAI HOSP,RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA.		Moran, Michael/GYD-3631-2022; Pawson, Tony J/E-4578-2013					BARKER WC, 1982, P NATL ACAD SCI-BIOL, V79, P2836, DOI 10.1073/pnas.79.9.2836; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BRENNER S, 1987, NATURE, V329, P21, DOI 10.1038/329021a0; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; BUECHLER JA, 1988, IN PRESS BIOCHEMISTR; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHEN LH, 1986, VIROLOGY, V155, P106, DOI 10.1016/0042-6822(86)90172-8; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Corbin J D, 1974, Methods Enzymol, V38, P287; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FINCHAM VJ, 1986, J VIROL, V58, P694, DOI 10.1128/JVI.58.2.694-699.1986; FOSTER D, 1984, J VIROL, V48, P744; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; HUNTER T, 1986, ENZYMES, V17, P191; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MECKLINGHANSEN K, 1987, EMBO J, V6, P659, DOI 10.1002/j.1460-2075.1987.tb04805.x; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; SADOWSKI I, 1987, ONCOGENE, V1, P181; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STONE JC, 1985, J VIROL, V55, P721, DOI 10.1128/JVI.55.3.721-727.1985; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER G, 1986, J BIOL CHEM, V261, P328; WEINMASTER G, 1983, J VIROL, V45, P29; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZOLLER MJ, 1987, METHOD ENZYMOL, V154, P329	44	58	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					665	672						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577868				2022-12-17	WOS:A1988R646000007
J	DER, CJ; WEISSMAN, B; MACDONALD, MJ				DER, CJ; WEISSMAN, B; MACDONALD, MJ			ALTERED GUANINE-NUCLEOTIDE BINDING AND H-RAS TRANSFORMING AND DIFFERENTIATING ACTIVITIES	ONCOGENE			English	Article									CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027	Children's Hospital Los Angeles	DER, CJ (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037, USA.			Der, Channing/0000-0002-7751-2747				ADARI H, 1988, IN PRESS SCIENCE; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; COPELAND NG, 1979, CELL, V16, P347, DOI 10.1016/0092-8674(79)90011-4; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; DER CJ, 1983, CELL, V32, P201, DOI 10.1016/0092-8674(83)90510-X; DER CJ, 1978, CELL, V15, P1241, DOI 10.1016/0092-8674(78)90050-8; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOODRICH GA, 1982, ANAL BIOCHEM, V127, P395, DOI 10.1016/0003-2697(82)90193-2; HALLIDAY K, 1984, J CYCLIC NUCLEOTIDE, V9, P431; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; LEBERMAN R, 1984, EMBO J, V3, P339, DOI 10.1002/j.1460-2075.1984.tb01808.x; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PROUD CG, 1986, TRENDS BIOCHEM SCI, V11, P73, DOI 10.1016/0968-0004(86)90269-0; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646	46	58	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					105	112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400015
J	WAGHORNE, C; KERBEL, RS; BREITMAN, ML				WAGHORNE, C; KERBEL, RS; BREITMAN, ML			METASTATIC POTENTIAL OF SP1 MOUSE MAMMARY ADENOCARCINOMA CELLS IS DIFFERENTIALLY INDUCED BY ACTIVATED AND NORMAL FORMS OF C-H-RAS	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto					NCI NIH HHS [R01-CA-41233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALSTONMILLS B, 1985, EUR J CANCER CLIN ON, V21, P1233, DOI 10.1016/0277-5379(85)90021-5; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARLOW DA, 1985, J NATL CANCER I, V75, P291; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLARD JG, 1985, INT J CANCER, V35, P207, DOI 10.1002/ijc.2910350211; DENNIS JW, 1987, IN PRESS SCIENCE; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GALLICK GE, 1985, P NATL ACAD SCI USA, V82, P1795, DOI 10.1073/pnas.82.6.1795; GRIEG RG, 1985, P NATL ACAD SCI USA, V82, P3698; HAGMAR B, 1984, TUMOUR BIOL, V5, P141; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1263, DOI 10.1073/pnas.84.5.1263; LAEMMLI UK, 1979, NATURE, V277, P359; LING V, 1985, CANCER METAST REV, V4, P173, DOI 10.1007/BF00050694; MILLER FR, 1981, CANCER RES, V41, P3863; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; SANTER UV, 1984, CANCER RES, V44, P3730; SCHIRRMACHER V, 1982, Invasion and Metastasis, V2, P313; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAGA TJ, 1983, MECHANISMS TUMOR PRO, V1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; UNEMORI EN, 1984, BR J CANCER, V46, P603; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; Weiss L., 1985, PRINCIPLES METASTASI	33	58	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					149	155						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325879				2022-12-17	WOS:A1987J635200007
J	Wei, QY; Qian, Y; Yu, J; Wong, CC				Wei, Qinyao; Qian, Yun; Yu, Jun; Wong, Chi Chun			Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTORS; PREDICTS POOR-PROGNOSIS; CELL LUNG-CANCER; COA SYNTHETASE 2; TUMOR PROGRESSION; GLUCOSE-METABOLISM; COLORECTAL-CANCER; SIGNALING PATHWAY; HEPATOCELLULAR-CARCINOMA	Tumor metastasis is the major cause of mortality from cancer. Metabolic rewiring and the metastatic cascade are highly intertwined, co-operating to promote multiple steps of cancer metastasis. Metabolites generated by cancer cells influence the metastatic cascade, encompassing epithelial-mesenchymal transition (EMT), survival of cancer cells in circulation, and metastatic colonization at distant sites. A variety of molecular mechanisms underlie the prometastatic effect of tumor-derived metabolites, such as epigenetic deregulation, induction of matrix metalloproteinases (MMPs), promotion of cancer stemness, and alleviation of oxidative stress. Conversely, metastatic signaling regulates expression and activity of rate-limiting metabolic enzymes to generate prometastatic metabolites thereby reinforcing the metastasis cascade. Understanding the complex interplay between metabolism and metastasis could unravel novel molecular targets, whose intervention could lead to improvements in the treatment of cancer. In this review, we summarized the recent discoveries involving metabolism and tumor metastasis, and emphasized the promising molecular targets, with an update on the development of small molecule or biologic inhibitors against these aberrant situations in cancer.	[Wei, Qinyao; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China; [Wei, Qinyao; Yu, Jun; Wong, Chi Chun] Chinese Univ Hong Kong, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Qian, Yun] Shenzhen Univ, Dept Gastroenterol & Hepatol, Gen Hosp, Shenzhen, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Shenzhen University	Wong, CC (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.; Wong, CC (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.	chichunwong@cuhk.edu.hk	; Jun, Yu/D-8569-2015	Wong, Chi Chun/0000-0003-1362-3541; Jun, Yu/0000-0001-5008-2153	National Natural Science Foundation of China (NSFC) [81772501]; Research Grants Council-General Research Fund (RGC-GRF), Hong Kong [14101917, 14108718, 14163817, 14110819]; Heath and Medical Research Fund (HMRF) [06170686]; Science and Technology Program Grant Shenzhen [JCYJ20170413161534162]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Research Grants Council-General Research Fund (RGC-GRF), Hong Kong; Heath and Medical Research Fund (HMRF); Science and Technology Program Grant Shenzhen	This project was supported by funds from National Natural Science Foundation of China (NSFC; 81772501); Research Grants Council-General Research Fund (RGC-GRF; 14101917, 14108718, 14163817 and 14110819), Hong Kong; Heath and Medical Research Fund (HMRF) (06170686); Science and Technology Program Grant Shenzhen (JCYJ20170413161534162).	Al Tameemi W, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00004; Nguyen AT, 2017, CANCER CELL, V32, P639, DOI 10.1016/j.ccell.2017.10.001; Aspuria PJP, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-21; Atlante S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0802-8; Bae JM, 2017, MODERN PATHOL, V30, P267, DOI 10.1038/modpathol.2016.172; Bauerle T, 2011, INT J CANCER, V128, P2453, DOI 10.1002/ijc.25563; Baillie GS, 2019, NAT REV DRUG DISCOV, V18, P770, DOI 10.1038/s41573-019-0033-4; Belkaid A, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-7; Boon L, 2016, BIOCHEM J, V473, P1471, DOI 10.1042/BJ20151154; Brunetti L, 2019, J MED CHEM, V62, P10995, DOI 10.1021/acs.jmedchem.9b00885; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Bu PC, 2018, CELL METAB, V27, P1249, DOI 10.1016/j.cmet.2018.04.003; Butti R, 2018, MOL CANCER, V17; Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006; Carbonneau M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12700; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Celia-Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556-018-0145-9; Cen B, 2020, GASTROENTEROLOGY, V158, P971, DOI 10.1053/j.gastro.2019.11.013; Chen M, 2018, NAT GENET, V50, P206, DOI 10.1038/s41588-017-0027-2; Cheng CX, 2011, HELL J NUCL MED, V14, P15; Cheng G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10042-1; Cheng TY, 2018, ONCOGENE, V37, P1730, DOI 10.1038/s41388-017-0086-y; Chugh S, 2018, GASTROENTEROLOGY, V155, P1608, DOI 10.1053/j.gastro.2018.08.007; Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019; Colvin H, 2016, SCI REP-UK, V6, DOI 10.1038/srep36289; Conradi LC, 2017, ANGIOGENESIS, V20, P599, DOI 10.1007/s10456-017-9573-6; Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Dinndorf PA, 2007, ONCOLOGIST, V12, P991, DOI 10.1634/theoncologist.12-8-991; Dong Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143577; Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Gan L, 2018, ONCOGENE, V37, P744, DOI 10.1038/onc.2017.363; Garcia MR, 2017, CELL METAB, V26, P842, DOI 10.1016/j.cmet.2017.09.018; Grassian AR, 2012, J BIOL CHEM, V287, P42180, DOI 10.1074/jbc.M112.417832; Gulati S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4322; Hah YS, 2019, ONCOL REP, V42, P1805, DOI 10.3892/or.2019.7315; Ham SA, 2014, AM J CANCER RES, V4, P674; Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77; Hu B, 2019, BIOCHEM BIOPH RES CO, V509, P373, DOI 10.1016/j.bbrc.2018.12.127; Huang R, 2017, CRIT REV ONCOL HEMAT, V115, P13, DOI 10.1016/j.critrevonc.2017.04.005; Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815; Hur H, 2015, J SURG ONCOL, V112, P585, DOI 10.1002/jso.24043; Incio J, 2016, CLIN CANCER RES, V22, P2993, DOI 10.1158/1078-0432.CCR-15-1839; Ji RC, 2014, CANCER LETT, V346, P6, DOI 10.1016/j.canlet.2013.12.001; Jiang SY, 2019, CANCER RES, V79, P3063, DOI 10.1158/0008-5472.CAN-18-3295; Jin UH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-498; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim JH, 2013, BIOCHEM PHARMACOL, V86, P1285, DOI 10.1016/j.bcp.2013.08.022; Kiuru M, 2004, CURR MOL MED, V4, P869, DOI 10.2174/1566524043359638; Klutzny S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0202-5; Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465; Kolli-Bouhafs K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.329; Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654; Kumazoe M, 2017, ONCOGENE, V36, P2643, DOI 10.1038/onc.2016.426; Kumazoe M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02162-9; Kuo YL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46439-7; Kutil Z, 2018, ACS CHEM BIOL, V13, P685, DOI 10.1021/acschembio.7b00942; Laezza C, 2012, EUR J CANCER, V48, P3112, DOI 10.1016/j.ejca.2012.02.062; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lang LW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0623-3; Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173; Lee SY, 2012, CANCER RES, V72, P3607, DOI 10.1158/0008-5472.CAN-12-0006; Leslie PL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12222-5; Letouze E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018; Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1; Li J, 2016, ONCOGENE, V35, P6378, DOI 10.1038/onc.2016.168; Li QG, 2017, CELL PHYSIOL BIOCHEM, V42, P397, DOI 10.1159/000477484; Li WL, 2018, ONCOGENE, V37, P4903, DOI 10.1038/s41388-018-0341-x; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Lim JCW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102860; Lim SH, 2015, BRIT J CANCER, V113, P1421, DOI 10.1038/bjc.2015.371; Lin LC, 2014, CLIN EXP METASTAS, V31, P881, DOI 10.1007/s10585-014-9677-y; Lincet H, 2015, ONCOGENE, V34, P3751, DOI 10.1038/onc.2014.320; Liu NH, 2016, CANCER LETT, V378, P38, DOI 10.1016/j.canlet.2016.05.010; Liu P, 2020, HEPATOL RES, V50, P246, DOI 10.1111/hepr.13433; Liu WS, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0953-7; Lomelino CL, 2017, J BIOL CHEM, V292, P19952, DOI 10.1074/jbc.R117.819060; Lu M, 2019, CELL METAB, V29, P886, DOI 10.1016/j.cmet.2018.12.019; Luo M, 2018, CELL METAB, V27, P947, DOI 10.1016/j.cmet.2018.04.012; Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3; Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777; McDonald PC, 2019, GASTROENTEROLOGY, V157, P823, DOI 10.1053/j.gastro.2019.05.004; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Mishra D, 2019, CANCERS, V11, DOI 10.3390/cancers11060750; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Morris JP, 2019, NATURE, V573, P595, DOI 10.1038/s41586-019-1577-5; Nagarajan A, 2016, TRENDS CANCER, V2, P365, DOI 10.1016/j.trecan.2016.06.002; Palmieri EM, 2017, CELL REP, V20, P1654, DOI 10.1016/j.celrep.2017.07.054; Papa S, 2019, ONCOGENE, V38, P2223, DOI 10.1038/s41388-018-0582-8; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001; Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Peng MX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1475-7; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726; Pozza ED, 2020, SEMIN CELL DEV BIOL, V98, P4, DOI 10.1016/j.semcdb.2019.04.013; Punekar Salman, 2019, Am Soc Clin Oncol Educ Book, V39, pe79, DOI 10.1200/EDBK_238499; Qian XC, 2015, INT J CLIN EXP MED, V8, P7855; Qiu GZ, 2017, TRENDS PHARMACOL SCI, V38, P669, DOI 10.1016/j.tips.2017.05.002; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rey S, 2017, TRENDS CANCER, V3, P529, DOI 10.1016/j.trecan.2017.05.002; Saha SK, 2014, NATURE, V513, P110, DOI 10.1038/nature13441; Sahin M, 2010, CANCER METAST REV, V29, P655, DOI 10.1007/s10555-010-9253-0; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001; Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shaul YD, 2014, CELL, V158, P1094, DOI 10.1016/j.cell.2014.07.032; Shen B, 2012, BRIT J CANCER, V106, P1486, DOI 10.1038/bjc.2012.130; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Sun L, 2017, CANCER SCI, V108, P1338, DOI 10.1111/cas.13252; Sundberg TB, 2014, P NATL ACAD SCI USA, V111, P12468, DOI 10.1073/pnas.1412308111; Svensson RU, 2016, NAT MED, V22, P1108, DOI 10.1038/nm.4181; Tahanian E, 2010, CHEM BIOL DRUG DES, V75, P481, DOI 10.1111/j.1747-0285.2010.00961.x; Tai LH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431082; Taras D, 2007, J HEPATOL, V46, P69, DOI 10.1016/j.jhep.2006.06.015; Tian HN, 2015, MOL CARCINOGEN, V54, P1159, DOI 10.1002/mc.22186; Tripathi SC, 2019, CANCER REP-US, V2, DOI 10.1002/cnr2.1131; Tzeng SF, 2018, FASEB J, V32, P6869, DOI 10.1096/fj.201800687; Vatrinet R, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0165-0; Waitkus MS, 2018, CANCER CELL, V34, P186, DOI 10.1016/j.ccell.2018.04.011; Wang DZ, 2015, GASTROENTEROLOGY, V149, P1884, DOI 10.1053/j.gastro.2015.07.064; Wang HY, 2016, TRANSL ONCOL, V9, P512, DOI 10.1016/j.tranon.2016.09.009; Wang SJ, 2018, ONCOGENE, V37, P4164, DOI 10.1038/s41388-018-0252-x; Wang T, 2020, ONCOGENE, V39, P3179, DOI 10.1038/s41388-020-1207-6; Wang ZY, 2019, TRENDS CANCER, V5, P30, DOI 10.1016/j.trecan.2018.11.003; Warburg O, 1924, BIOCHEM Z, V152, P309; Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041; Wen H, 2019, BBA-MOL CELL BIOL L, V1864, P413, DOI 10.1016/j.bbalip.2018.06.005; Wen J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1391-9; Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Wong CC, 2017, ONCOGENE, V36, P3359, DOI 10.1038/onc.2016.485; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Xu LH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008455; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264; Yang J, 2017, SCI REP-UK, V7, DOI 10.1038/srep43864; Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697; Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang Y, 2019, CANCER LETT, V453, P170, DOI 10.1016/j.canlet.2019.03.054; Yao L, 2018, CELL PHYSIOL BIOCHEM, V45, P984, DOI 10.1159/000487293; Yin YF, 2018, CANCER LETT, V426, P14, DOI 10.1016/j.canlet.2018.04.001; Zhang J, 2016, MOL CELL BIOCHEM, V411, P331, DOI 10.1007/s11010-015-2595-8; Zhang WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116634; Zhang XD, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0892-2; Zhao WN, 2016, CANCER RES, V76, P2037, DOI 10.1158/0008-5472.CAN-15-1970; Zhou YF, 2013, MOL CANCER THER, V12, P2782, DOI 10.1158/1535-7163.MCT-13-0098; Zhu WP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0098-0; Zuo XS, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91419	154	57	57	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6139	6156		10.1038/s41388-020-01432-7	http://dx.doi.org/10.1038/s41388-020-01432-7		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32839493	Green Published, hybrid			2022-12-17	WOS:000562336400001
J	Sung, JS; Kang, CW; Kang, S; Jang, Y; Chae, YC; Kim, BG; Cho, NH				Sung, Jin Sol; Kang, Chan Woo; Kang, Suki; Jang, Yeonsue; Chae, Young Chan; Kim, Baek Gil; Cho, Nam Hoon			ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts	ONCOGENE			English	Article							AEROBIC GLYCOLYSIS; OXIDATIVE STRESS; MITOPHAGY; EXPRESSION; CAVEOLIN-1; AUTOPHAGY; CELLS; PROGRESSION; APOPTOSIS; WARBURG	Integrin beta 4 (ITGB4) overexpression in cancer cells contributes to cancer progression. However, the role of stromal ITGB4 expression in cancer progression remains poorly understood, despite stromal ITGB4 overexpression in malignant cancers. In our study, ITGB4-overexpressing triple negative breast cancer (TNBC) cells provided cancer-associated fibroblasts (CAFs) with ITGB4 proteins via exosomes, which induced BNIP3L-dependent mitophagy and lactate production in CAFs. In coculture assays, the ITGB4-induced mitophagy and glycolysis were suppressed in CAFs by knocking down ITGB4 or inhibiting exosome generation in MDA-MB-231, or blocking c-Jun or AMPK phosphorylation in CAFs. ITGB4-overexpressing CAF-conditioned medium promoted the proliferation, epithelial-to-mesenchymal transition, and invasion of breast cancer cells. In a co-transplant mouse model, MDA-MB-231 made a bigger tumor mass with CAFs than ITGB4 knockdown MDA-MB-231. Herein, we presented how TNBC-derived ITGB4 protein triggers glycolysis in CAFs via BNIP3L-dependent mitophagy and suggested the possibility that ITGB4-induced mitophagy could be targeted as a cancer therapy.	[Sung, Jin Sol; Kang, Chan Woo; Kim, Baek Gil; Cho, Nam Hoon] Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Seoul, South Korea; [Kang, Suki; Jang, Yeonsue; Kim, Baek Gil; Cho, Nam Hoon] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; [Kang, Suki; Cho, Nam Hoon] Yonsei Univ, SBSI, Coll Med, Seoul, South Korea; [Chae, Young Chan] Ulsan Natl Inst Sci & Technol, Sch Life Sci, Ulsan, South Korea; [Cho, Nam Hoon] Yonsei Univ, Global 5 5 10 Syst Biol, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Ulsan National Institute of Science & Technology (UNIST); Yonsei University	Kim, BG; Cho, NH (corresponding author), Yonsei Univ, Coll Med, Brain Korea 21 Plus Project Med Sci, Seoul, South Korea.; Kim, BG; Cho, NH (corresponding author), Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea.; Cho, NH (corresponding author), Yonsei Univ, SBSI, Coll Med, Seoul, South Korea.; Cho, NH (corresponding author), Yonsei Univ, Global 5 5 10 Syst Biol, Seoul, South Korea.	bbaekiri@yuhs.ac; cho1988@yuhs.ac		jo, namhun/0000-0002-0045-6441; Jang, Yeonsue/0000-0001-5683-0001; kang, chan woo/0000-0001-5822-5235; KANG, SUKI/0000-0002-9957-3479; Sung, Jin Sol/0000-0002-7899-8814; KIM, BAEK GIL/0000-0001-6270-1433	Mid-Career Researcher Program through a National Research Foundation of Korea [2019R1A2B5B01069934]; Challenges in Creative Research through a National Research Foundation of Korea [2019R1I1A1A01060549]; Health Fellowship Foundation - Yuhan Corporation; Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine	Mid-Career Researcher Program through a National Research Foundation of Korea(National Research Foundation of Korea); Challenges in Creative Research through a National Research Foundation of Korea(National Research Foundation of Korea); Health Fellowship Foundation - Yuhan Corporation; Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine	This study was supported by the Mid-Career Researcher Program (no. 2019R1A2B5B01069934; NHC) and Challenges in Creative Research (no. 2019R1I1A1A01060549; BGK) through a National Research Foundation of Korea grant, and The Health Fellowship Foundation grants funded by Yuhan Corporation. The authors thank Medical Illustration & Design, a part of the Medical Research Support Services of Yonsei University College of Medicine, for all artistic support related to this work.	Cicenas J, 2018, CANCERS, V10, DOI 10.3390/cancers10010001; Esteban-Martinez L, 2017, EMBO J, V36, P1688, DOI 10.15252/embj.201695916; Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007; Fu YJ, 2017, ONCOTARGET, V8, P57813, DOI 10.18632/oncotarget.18175; Jezek J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7010013; Ke HN, 2010, CANCER RES, V70, P3080, DOI 10.1158/0008-5472.CAN-09-2923; Kim BG, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.73; Kim BG, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3203; Kim BG, 2011, AM J PATHOL, V178, P373, DOI 10.1016/j.ajpath.2010.11.028; Kosgodage US, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00889; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kubli DA, 2012, CIRC RES, V111, P1208, DOI 10.1161/CIRCRESAHA.112.265819; Li X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00596-9; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liu MH, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0160-x; Liu SY, 2016, ONCOTARGET, V7, P16282, DOI 10.18632/oncotarget.7646; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P2504, DOI 10.4161/cc.10.15.16585; Martins D, 2013, CELL CYCLE, V12, P2684, DOI 10.4161/cc.25794; Maycotte P, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698391; McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256; Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; PETERKOFSKY B, 1982, CANCER RES, V42, P1809; Quelo I, 2004, J BIOL CHEM, V279, P43893, DOI 10.1074/jbc.M406310200; Ratnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198; Renschler MF, 2004, EUR J CANCER, V40, P1934, DOI 10.1016/j.ejca.2004.02.031; Roach PJ, 2011, MOL CELL BIOL, V31, P3082, DOI 10.1128/MCB.05565-11; Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vallejo Abbe N, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4861; Witkiewicz AK, 2009, CANCER BIOL THER, V8, P1071, DOI 10.4161/cbt.8.11.8874; Wu KN, 2011, CELL CYCLE, V10, P4250, DOI 10.4161/cc.10.24.18551; Xiao B, 2017, J BIOL CHEM, V292, P16697, DOI 10.1074/jbc.M117.787739; Yang L, 2015, ONCOTARGET, V6, P25755, DOI 10.18632/oncotarget.4697	39	57	63	6	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					664	676		10.1038/s41388-019-1014-0	http://dx.doi.org/10.1038/s41388-019-1014-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31534187				2022-12-17	WOS:000509718300013
J	Kolb, R; Kluz, P; Tan, ZW; Borcherding, N; Bormann, N; Vishwakarma, A; Balcziak, L; Zhu, PC; Davies, BSJ; Gourronc, F; Liu, LZ; Ge, X; Jiang, BH; Gibson-Corley, K; Klingelhutz, A; Tan, NS; Zhu, YW; Sutterwala, FS; Shen, X; Zhang, Wz				Kolb, Ryan; Kluz, Paige; Tan, Zhen Wei; Borcherding, Nicholas; Bormann, Nicholas; Vishwakarma, Ajaykumar; Balcziak, Louis; Zhu, Pengcheng; Davies, Brandon S. J.; Gourronc, Francoise; Liu, Ling-Zhi; Ge, Xin; Jiang, Bing-Hua; Gibson-Corley, Katherine; Klingelhutz, Aloysius; Tan, Nguan Soon; Zhu, Yuwen; Sutterwala, Fayyaz S.; Shen, Xian; Zhang, Weizhou			Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4	ONCOGENE			English	Article							CELL-LINE; ANGPTL4; METASTASIS; BEVACIZUMAB; PROGRESSION; MIGRATION; BETA-1; TUMORS; VEGF	Obesity is a risk factor for breast cancer and also predicts poor clinical outcomes regardless of menopausal status. Contributing to the poor clinical outcomes is the suboptimal efficacy of standard therapies due to dose limiting toxicities and obesity-related complications, highlighting the need to develop novel therapeutic approaches for treating obese patients. We recently found that obesity leads to an increase in tumor-infiltrating macrophages with activated NLRC4 inflammasome and increased interleukin (IL)-1 beta production. IL-1 beta, in turn, leads to increased angiogenesis and cancer progression. Using Next Generation RNA sequencing, we identified an NLRC4/IL-1 beta-dependent upregulation of angiopoietin-like 4 (ANGPTL4), a known angiogenic factor in cancer, in tumors from obese mice. ANGPTL4-deficiency by genetic knockout or treatment with a neutralizing antibody led to a significant reduction in obesity-induced angiogenesis and tumor growth. At a mechanistic level, ANGPTL4 expression is induced by IL-1 beta from primary adipocytes in a manner dependent on NF-kappa B- and MAP kinase-activation, which is further enhanced by hypoxia. This report shows that adipocyte-derived ANGPTL4 drives disease progression under obese conditions and is a potential therapeutic target for treating obese breast cancer patients.	[Kolb, Ryan; Kluz, Paige; Borcherding, Nicholas; Vishwakarma, Ajaykumar; Liu, Ling-Zhi; Ge, Xin; Jiang, Bing-Hua; Gibson-Corley, Katherine; Zhang, Weizhou] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA; [Kolb, Ryan; Zhang, Weizhou] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA; [Kluz, Paige; Zhang, Weizhou] Univ Iowa, Free Rad & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA; [Tan, Zhen Wei; Zhu, Pengcheng; Tan, Nguan Soon] Nanyang Technol Univ, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Borcherding, Nicholas; Zhang, Weizhou] Univ Iowa, Med Scientist Training Program, Carver Coll Med, Iowa City, IA 52242 USA; [Borcherding, Nicholas; Vishwakarma, Ajaykumar; Zhang, Weizhou] Univ Iowa, Canc Biol Grad Program, Carver Coll Med, Iowa City, IA 52242 USA; [Bormann, Nicholas] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Balcziak, Louis] Univ Iowa, Interdisciplinary Neurosci Grad Program, Carver Coll Med, Iowa City, IA 52242 USA; [Davies, Brandon S. J.] Univ Iowa, Dept Biochem, Fraternal Order Eagles Diabet Res Ctr, Iowa City, IA 52242 USA; [Davies, Brandon S. J.] Univ Iowa, Obes Res & Educ Initiat, Iowa City, IA 52242 USA; [Gourronc, Francoise; Klingelhutz, Aloysius] Univ Iowa, Dept Microbiol & Immunol, Carver Coll Med, Iowa City, IA 52242 USA; [Tan, Nguan Soon] Nanyang Technol Univ, Lee Kong Chian Sch Med, 50 Nanyang Dr, Singapore 639798, Singapore; [Tan, Nguan Soon] Agcy Sci Technol & Res, Inst Mol Cell Biol, Proteos, 61 Biopolis Dr, Singapore 138673, Singapore; [Tan, Nguan Soon] KK Womens & Children Hosp, KK Res Ctr, 100 Bukit Timah Rd, Singapore 229899, Singapore; [Zhu, Yuwen] Univ Colorado, Dept Surg, Denver Anschutz Med Campus, Aurora, CO 80045 USA; [Sutterwala, Fayyaz S.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Shen, Xian] Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China	University of Iowa; State University System of Florida; University of Florida; University of Iowa; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; Cedars Sinai Medical Center; Wenzhou Medical University	Kolb, R; Zhang, Wz (corresponding author), Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA.; Kolb, R; Zhang, Wz (corresponding author), Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.; Zhang, Wz (corresponding author), Univ Iowa, Free Rad & Radiat Biol, Carver Coll Med, Iowa City, IA 52242 USA.; Zhang, Wz (corresponding author), Univ Iowa, Med Scientist Training Program, Carver Coll Med, Iowa City, IA 52242 USA.; Zhang, Wz (corresponding author), Univ Iowa, Canc Biol Grad Program, Carver Coll Med, Iowa City, IA 52242 USA.; Shen, X (corresponding author), Wenzhou Med Univ, Div Gastrointestinal Surg, Affiliated Hosp 2, Wenzhou 325035, Zhejiang, Peoples R China.	ryankolb@ufl.edu; shenxian1120@126.com; zhangw@ufl.edu	Bormann, Nicholas/AFK-0303-2022; Bormann, Nicholas/AAF-7338-2022; Kluz, Paige/AAT-4892-2021; Cassel, Suzanne/AAI-3947-2021; Tan, Nguan Soon/A-2220-2011; Sutterwala, Fayyaz/AAH-5859-2021; Klingelhutz, Aloysius/L-9081-2018	Cassel, Suzanne/0000-0003-2492-1923; Tan, Nguan Soon/0000-0003-0136-7341; Hartl, Carla/0000-0001-9769-7462; Klingelhutz, Aloysius/0000-0003-4258-5046; Bormann, Nicholas/0000-0001-8847-8727; Gibson-Corley, Katherine/0000-0002-1846-1580; Kolb, Ryan/0000-0001-6305-2885; Davies, Brandon/0000-0002-7168-8522; Jiang, Bing-Hua/0000-0003-4526-2031; Borcherding, Nicholas/0000-0003-1427-6342; Liu, Ling-Zhi/0000-0001-9234-457X	NIH [CA200673, CA203834, T32 AI007260, F30 CA206255, R01HL130146, R01 AI118719]; Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa [P30CA086862]; Department of Microbiology, University of Iowa; Ministry of Education, Singapore [MOE2014-T2-1-012]; NATIONAL CANCER INSTITUTE [R01CA203834, F30CA206255, P30CA086862, R01CA200673, R01CA193511] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL130146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118719, R01AI104706, T32AI007260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oberley Award (National Cancer Institute Award) from Holden Comprehensive Cancer Center at the University of Iowa; Department of Microbiology, University of Iowa; Ministry of Education, Singapore(Ministry of Education, Singapore); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	RK: NIH T32 AI007260; WZ: NIH R01 grants CA200673 and CA203834, Oberley Award (National Cancer Institute Award P30CA086862) from Holden Comprehensive Cancer Center at the University of Iowa; NB: NIH F30 CA206255; AK: Mark Stinski Developmental Grant from the Department of Microbiology, University of Iowa; BD: NIH R01HL130146; NST: grant from Ministry of Education, Singapore (MOE2014-T2-1-012); FSS: NIH R01 AI118719.	Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Bai L, 2015, SCI REP-UK, V5, DOI 10.1038/srep17717; Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018; Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Choi J, 2018, PROG LIPID RES, V69, P11, DOI 10.1016/j.plipres.2017.11.002; DeCicco-Skinner KL, 2014, JOVE-J VIS EXP, DOI 10.3791/51312; Fukumura D, 2016, MICROCIRCULATION, V23, P191, DOI 10.1111/micc.12270; Gealekman O, 2008, AM J PHYSIOL-ENDOC M, V295, pE1056, DOI 10.1152/ajpendo.90345.2008; Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505; Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Gu JW, 2011, CANCER BIOL THER, V11, P910, DOI 10.4161/cbt.11.10.15473; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hata S, 2017, ONCOL REP, V38, P120, DOI 10.3892/or.2017.5669; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Huang ZQ, 2016, ARCH ORAL BIOL, V71, P144, DOI 10.1016/j.archoralbio.2016.07.011; Incio J, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aag0945; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Kim SH, 2011, CANCER RES, V71, P7010, DOI 10.1158/0008-5472.CAN-11-1262; Kolb R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13007; Kolb R, 2016, CURR OPIN PHARMACOL, V29, P77, DOI 10.1016/j.coph.2016.07.005; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lara-Tejero M, 2006, J EXP MED, V203, P1407, DOI 10.1084/jem.20060206; Lei X, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.217638; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Li L, 2015, CELL REP, V10, P654, DOI 10.1016/j.celrep.2015.01.011; Lichtenstein L, 2010, CELL METAB, V12, P580, DOI 10.1016/j.cmet.2010.11.002; Lohmann AE, 2012, CURR TREAT OPTION ON, V13, P249, DOI 10.1007/s11864-012-0181-9; Malinda Katherine M., 2009, V467, P287, DOI 10.1007/978-1-59745-241-0_17; Markan KR, 2014, DIABETES, V63, P4057, DOI 10.2337/db14-0595; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; SUGIURA K, 1952, CANCER, V5, P382, DOI 10.1002/1097-0142(195203)5:2<382::AID-CNCR2820050229>3.0.CO;2-3; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vu BG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077988; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102; Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385	42	57	58	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2351	2363		10.1038/s41388-018-0592-6	http://dx.doi.org/10.1038/s41388-018-0592-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30518876	Green Accepted			2022-12-17	WOS:000462588000009
J	Wang, LH; Zhang, ZY; Yu, XD; Huang, X; Liu, Z; Chai, YH; Yang, L; Wang, Q; Li, M; Zhao, J; Hou, J; Li, F				Wang, Lianghai; Zhang, Zhiyu; Yu, Xiaodan; Huang, Xuan; Liu, Zheng; Chai, Yuhang; Yang, Lei; Wang, Qian; Li, Man; Zhao, Jin; Hou, Jun; Li, Feng			Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma	ONCOGENE			English	Article							YAP; SOX9; TAZ; EXPRESSION; PATHWAY; SUPPRESSES; PROLIFERATION; ACTIVATION; LANDSCAPE; ONCOGENE	Yes-associated protein (YAP) has been identified as a key regulator of tissue homeostasis. However, the precise role and regulatory mechanism of YAP in esophageal squamous cell carcinoma (ESCC) remains unclear. Here we report that the genetic or pharmacological inhibition of YAP repressed cancer stem cell (CSC)-like properties, including tumorsphere-forming potential, cell motility, and chemoresistance in vitro, and was sufficient to attenuate tumor growth and CSC marker expression in ESCC xenografts. Mechanistically, YAP transcriptionally activated its downstream target SOX9 via TEAD1-mediated binding. We also observed a positive correlation between YAP signaling and SOX9 expression in two independent clinical cohorts. Intriguingly, YAP-targeting microRNAs, including miR-506-3p, which were induced by SOX9, post-transcriptionally repressed YAP expression, contributing to a negative feedback mechanism. Dual inhibition of YAP and SOX9 robustly suppressed malignant phenotypes. Notably, ESCC samples from The Cancer Genome Atlas (TCGA) dataset had frequent (44%) instances of YAP gene amplification and genetic inactivation of Hippo pathway regulators. Nuclear YAP expression was elevated in 197 ESCC tissues from a Chinese cohort. Together, our findings provide evidence that genetic hyperactivation of YAP unbalances the YAP-SOX9 feedback loop and confers CSC-like features in ESCC, suggesting that this YAP-SOX9 circuit represents a potential therapeutic target.	[Wang, Lianghai; Zhang, Zhiyu; Yu, Xiaodan; Chai, Yuhang; Wang, Qian; Li, Man; Zhao, Jin; Hou, Jun; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol Immunol, Shihezi, Xinjiang, Peoples R China; [Wang, Lianghai; Zhang, Zhiyu; Yu, Xiaodan; Chai, Yuhang; Wang, Qian; Li, Man; Zhao, Jin; Hou, Jun; Li, Feng] Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China; [Zhang, Zhiyu; Huang, Xuan; Liu, Zheng; Yang, Lei; Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China; [Zhang, Zhiyu; Huang, Xuan; Liu, Zheng; Yang, Lei; Li, Feng] Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing, Peoples R China; [Wang, Lianghai] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA; [Yu, Xiaodan] Shihezi Univ, Affiliated Hosp 1, Dept Stomatol, Sch Med, Shihezi, Peoples R China	Shihezi University; Shihezi University; Capital Medical University; Capital Medical University; Cornell University; Shihezi University	Hou, J; Li, F (corresponding author), Shihezi Univ, Sch Med, Dept Pathol Immunol, Shihezi, Xinjiang, Peoples R China.; Hou, J; Li, F (corresponding author), Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Shihezi, Xinjiang, Peoples R China.; Li, F (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Pathol, Beijing, Peoples R China.; Li, F (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Med Res Ctr, Beijing, Peoples R China.	houjun229@163.com; lifeng7855@126.com	YANG, LEI/GQH-4271-2022	Wang, Lianghai/0000-0003-3128-7780	National Natural Science Foundation of China [81460416, 81560399, 81602810]; Ministry of Science and Technology of China [2012AA02A503]; State Scholarship Foundation of China [201608650002]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); State Scholarship Foundation of China	This work was supported by the National Natural Science Foundation of China (No. 81460416, 81560399, 81602810), the Ministry of Science and Technology of China (2012AA02A503), and the State Scholarship Foundation of China (201608650002).	Ciamporcero E, 2016, ONCOGENE, V35, P1541, DOI 10.1038/onc.2015.219; Deng J, 2015, TUMOR BIOL, V36, P6823, DOI 10.1007/s13277-015-3364-8; Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Galuppini F, 2017, VIRCHOWS ARCH, V471, P651, DOI 10.1007/s00428-017-2227-7; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hansen CG, 2015, TRENDS CELL BIOL, V25, P499, DOI 10.1016/j.tcb.2015.05.002; Hayashi H, 2015, CANCER RES, V75, P4985, DOI 10.1158/0008-5472.CAN-15-0291; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Hu N, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1919-0; Jiang SS, 2010, CLIN CANCER RES, V16, P4363, DOI 10.1158/1078-0432.CCR-10-0138; Jiang YQ, 2010, ANN THORAC SURG, V90, P908, DOI 10.1016/j.athoracsur.2010.05.060; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Leung CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3251; Liu CG, 2016, HEPATOLOGY, V64, P117, DOI 10.1002/hep.28509; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Sawada G, 2016, GASTROENTEROLOGY, V150, P1171, DOI 10.1053/j.gastro.2016.01.035; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Shi ZC, 2015, NUCLEIC ACIDS RES, V43, P6257, DOI 10.1093/nar/gkv568; Slemmons KK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140781; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465; Tanaka K, 2017, CANCER LETT, V385, P215, DOI 10.1016/j.canlet.2016.10.020; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Vermeulen L, 2012, LANCET ONCOL, V13, pE83, DOI 10.1016/S1470-2045(11)70257-1; Wang LH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0658-2; Wang LH, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0065-x; Xu J, 2018, J CELL BIOCHEM, V119, P2492, DOI 10.1002/jcb.26343; Yeo MK, 2012, ANTICANCER RES, V32, P3835; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang SK, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1096-1	41	57	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2042	2055		10.1038/s41388-018-0476-9	http://dx.doi.org/10.1038/s41388-018-0476-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30401982	Green Published, hybrid			2022-12-17	WOS:000461822600004
J	Tan, S; Li, H; Zhang, WJ; Shao, YY; Liu, Y; Guan, HY; Wu, J; Kang, YN; Zhao, JS; Yu, Q; Gu, YZ; Ding, KS; Zhang, M; Qian, WC; Zhu, Y; Cai, HY; Chen, CY; Lobie, PE; Zhao, XD; Sun, JL; Zhu, T				Tan, Sheng; Li, Hua; Zhang, Weijie; Shao, Yunying; Liu, Yuan; Guan, Haiyang; Wu, Jun; Kang, Yani; Zhao, Junsong; Yu, Qing; Gu, Yunzhao; Ding, Keshuo; Zhang, Min; Qian, Wenchang; Zhu, Yong; Cai, Huayong; Chen, Changyu; Lobie, Peter E.; Zhao, Xiaodong; Sun, Jielin; Zhu, Tao			NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression	ONCOGENE			English	Article							CLEAVAGE FACTOR-I; CANCER; REVEALS; CELLS; RECOGNITION; MECHANISM; TUMORS; SITES	Alternative polyadenylation (APA) is an important post-transcriptional regulatory mechanism and involved in many diseases, including cancer. CFIm25, a subunit of the cleavage factor I encoded by NUDT21, is required for 3'RNA cleavage and polyadenylation. Although it has been recently reported to be involved in glioblastoma tumor suppression, its roles and the underlying functional mechanism remain unclear in other types of cancer. In this study, we characterized NUDT21 in hepatocellular carcinoma (HCC). Reduced expression of NUDT21 was observed in HCC tissue compared to adjacent non-tumorous compartment. HCC patients with lower NUDT21 expression have shorter overall and disease-free survival times than those with higher NUDT21 expression after surgery. Knockdown of NUDT21 promotes HCC cell proliferation, metastasis, and tumorigenesis, whereas forced expression of NUDT21 exhibits the opposite effects. We then performed global APA site profiling analysis in HCC cells and identified considerable number of genes with shortened 3'UTRs upon the modulation of NUDT21 expression. In particular, we further characterized the NUDT21-regulated genes PSMB2 and CXXC5. We found NUDT21 knockdown increases usage of the proximal polyadenylation site in the PSMB2 and CXXC5 3'UTRs, resulting in marked increase in the expression of PSMB2 and CXXC5. Moreover, knockdown of PSMB2 or CXXC5 suppresses HCC cell proliferation and invasion. Taken together, our study demonstrated that NUDT21 inhibits HCC proliferation, metastasis and tumorigenesis, at least in part, by suppressing PSMB2 and CXXC5, and thereby provided a new insight into understanding the connection of HCC suppression and APA machinery.	[Tan, Sheng; Zhang, Weijie; Shao, Yunying; Liu, Yuan; Guan, Haiyang; Zhao, Junsong; Yu, Qing; Zhang, Min; Qian, Wenchang; Zhu, Yong; Cai, Huayong; Zhu, Tao] Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; [Li, Hua; Wu, Jun; Kang, Yani; Gu, Yunzhao] Shanghai Jiao Tong Univ, BioID Ctr, Sch Biomed Engn, Shanghai 200240, Peoples R China; [Ding, Keshuo] Anhui Med Univ, Dept Pathol, Meishan Rd, Hefei 230031, Anhui, Peoples R China; [Chen, Changyu] Anhui Med Univ, Affiliated Hosp 1, Meishan Rd, Hefei 230031, Anhui, Peoples R China; [Lobie, Peter E.] Tsinghua Univ, Precis Med & Healthcare Res Ctr, Tsinghua Berkeley Shenzhen Inst, Shenzhen 518055, Peoples R China; [Zhao, Xiaodong; Sun, Jielin] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, 800 Dongchuan Rd, Shanghai 200240, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Shanghai Jiao Tong University; Anhui Medical University; Anhui Medical University; Tsinghua University; Shanghai Jiao Tong University	Zhu, T (corresponding author), Univ Sci & Technol China, Sch Life Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.; Zhao, XD; Sun, JL (corresponding author), Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Minist Educ, Key Lab Syst Biomed, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.	xiaodongzhao@sjtu.edu.cn; jlsun@sjtu.edu.cn; zhut@ustc.edu.cn	Wu, Jun/GRS-5039-2022; Kang, Yani/AAQ-1503-2020; tan, sheng/GSN-2599-2022	Wu, Jun/0000-0002-3381-2561; Kang, Yani/0000-0002-6753-386X; LI, HUA/0000-0003-2153-2500; Zhang, Weijie/0000-0002-6462-6067	National Key Scientific Programme of China [2016YFC1302305]; National Natural Science Foundation of China [81672609, 31671299, 81502282, 81472494]; Shenzhen Development and Reform Commission Subject Construction Project [[2017] 1434]	National Key Scientific Programme of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shenzhen Development and Reform Commission Subject Construction Project	This work was supported by The National Key Scientific Programme of China (2016YFC1302305), The National Natural Science Foundation of China (81672609, 31671299, 81502282, 81472494,) and the Shenzhen Development and Reform Commission Subject Construction Project [2017] 1434. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.	Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Collavoli A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/757960; Coseno M, 2008, NUCLEIC ACIDS RES, V36, P3474, DOI 10.1093/nar/gkn079; Di Giammartino DC, 2011, MOL CELL, V43, P853, DOI 10.1016/j.molcel.2011.08.017; Elkon R, 2013, NAT REV GENET, V14, P496, DOI 10.1038/nrg3482; Erson-Bensan AE, 2016, MOL CANCER RES, V14, P507, DOI 10.1158/1541-7786.MCR-15-0489; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110; Gennarino VA, 2015, ELIFE, V4, DOI 10.7554/eLife.10782; Knappskog S, 2011, ANN ONCOL, V22, P2208, DOI 10.1093/annonc/mdq737; Lai DP, 2015, HUM MOL GENET, V24, P3410, DOI 10.1093/hmg/ddv089; Lembo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031129; Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]; Llovet JM, 2014, NAT REV CLIN ONCOL, V11, P506, DOI 10.1038/nrclinonc.2014.136; Martin G, 2012, CELL REP, V1, P753, DOI 10.1016/j.celrep.2012.05.003; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Miles WO, 2016, CANCER RES, V76, P7231, DOI 10.1158/0008-5472.CAN-16-0844; Morris AR, 2012, CLIN CANCER RES, V18, P5256, DOI 10.1158/1078-0432.CCR-12-0543; Sandberg R, 2008, SCIENCE, V320, P1643, DOI 10.1126/science.1155390; Shi YS, 2009, MOL CELL, V33, P365, DOI 10.1016/j.molcel.2008.12.028; Singh P, 2009, CANCER RES, V69, P9422, DOI 10.1158/0008-5472.CAN-09-2236; Tan S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3644; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Venkataraman K, 2005, GENE DEV, V19, P1315, DOI 10.1101/gad.1298605; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yang Q, 2010, P NATL ACAD SCI USA, V107, P10062, DOI 10.1073/pnas.1000848107	27	57	59	4	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2018	37	35					4887	4900		10.1038/s41388-018-0280-6	http://dx.doi.org/10.1038/s41388-018-0280-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS0BA	29780166				2022-12-17	WOS:000443146000009
J	Yue, JN; Lv, DC; Wang, CY; Li, L; Zhao, QN; Chen, HZ; Xu, L				Yue, Jinnan; Lv, Dacheng; Wang, Caiyun; Li, Ling; Zhao, Qingnan; Chen, Hongzhuan; Xu, Lu			Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin beta 3	ONCOGENE			English	Article							CELL LUNG-CANCER; CONVENTIONAL CARE REGIMENS; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITION; MICRORNA; EXPRESSION; ERLOTINIB; TKI; PROLIFERATION; DEREGULATION	All lung cancers patients with epidermal growth factor receptor (EGFR) mutation inevitably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI). In up to 30% of cases, the mechanism underlying acquired resistance remains unknown. MicroRNAs (miRNAs) is a group of small non-coding RNAs commonly dysregulated in human cancers and have been implicated in therapy resistance. The aim of this study was to understand the roles of novel miRNAs in acquired EGFR TKI resistance in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we reported the evidence of miR-483-3p silencing and epithelial-to-mesenchymal transition (EMT) phenotype in both in vitro and in vivo EGFR-mutant NSCLC models with acquired resistance to gefitinib. In those tumor models, forced expression of miR-483-3p efficiently increased sensitivity of gefitinib-resistant lung cancer cells to gefitinib by inhibiting proliferation and promoting apoptosis. Moreover, miR-483-3p reversed EMT and inhibited migration, invasion, and metastasis of gefitinib-resistant lung cancer cells. Mechanistically, miR-483-3p directly targeted integrin beta 3, and thus repressed downstream FAK/Erk signaling pathway. Furthermore, the silencing of miR-483-3p in gefitinib-resistant lung cancer cells was due to hypermethylation of its own promoter. Taken together, our data identify miR-483-3p as a promising target for combination therapy to overcome acquired EGFR TKI resistance in EGFR-mutant NSCLC.	[Yue, Jinnan; Lv, Dacheng; Wang, Caiyun; Li, Ling; Zhao, Qingnan; Chen, Hongzhuan; Xu, Lu] Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China	Shanghai Jiao Tong University	Chen, HZ; Xu, L (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China.	hongzhuan_chen@hotmail.com; luxuluxu@yahoo.com	xu, lu/AAI-6516-2020		National Natural Science Foundation of China [81372522, 81773747]; Science and Technology Commission of Shanghai Municipality [12ZR1416000, 12140901400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	The work was supported by National Natural Science Foundation of China (81372522 and 81773747), Science and Technology Commission of Shanghai Municipality (12ZR1416000 and 12140901400).	Adams BD, 2014, CURR BIOL, V24, pR762, DOI 10.1016/j.cub.2014.06.043; Allen KE, 2010, MOL CANCER THER, V9, P3126, DOI 10.1158/1535-7163.MCT-10-0397; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bertero T, 2013, CELL CYCLE, V12, P2183, DOI 10.4161/cc.25330; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Chung JH, 2011, LUNG CANCER, V73, P176, DOI 10.1016/j.lungcan.2010.11.011; Doghman M, 2010, CANCER RES, V70, P4666, DOI 10.1158/0008-5472.CAN-09-3970; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Golubovskaya VM, 2014, FRONT BIOSCI-LANDMRK, V19, P687, DOI 10.2741/4236; Guled M, 2009, GENE CHROMOSOME CANC, V48, P615, DOI 10.1002/gcc.20669; Hao J, 2011, FEBS LETT, V585, P207, DOI 10.1016/j.febslet.2010.11.039; Hayakawa H, 2013, CANCER SCI, V104, P1440, DOI 10.1111/cas.12284; Ju LX, 2010, J CELL BIOCHEM, V111, P1565, DOI 10.1002/jcb.22888; Kanda R, 2013, CANCER RES, V73, P6243, DOI 10.1158/0008-5472.CAN-12-4502; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kong D, 2012, ONCOGENE, V31, P3949, DOI 10.1038/onc.2011.558; La Monica S, 2016, J THORAC ONCOL, V11, P1051, DOI 10.1016/j.jtho.2016.03.006; Lee DH, 2017, PHARMACOL THERAPEUT, V174, P1, DOI 10.1016/j.pharmthera.2017.02.001; Li B, 2014, LUNG CANCER, V83, P146, DOI 10.1016/j.lungcan.2013.11.003; Li L, 2017, ONCOTARGET, V8, P92240, DOI 10.18632/oncotarget.21170; Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Ozata DM, 2011, ENDOCR-RELAT CANCER, V18, P643, DOI 10.1530/ERC-11-0082; Rupaimoole R, 2016, CANCER DISCOV, V6, P235, DOI 10.1158/2159-8290.CD-15-0893; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shen H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103305; Shien K, 2013, CANCER RES, V73, P3051, DOI 10.1158/0008-5472.CAN-12-4136; Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008; Suda K, 2011, J THORAC ONCOL, V6, P1152, DOI 10.1097/JTO.0b013e318216ee52; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang CP, 2015, TUMOR BIOL, V36, P9447, DOI 10.1007/s13277-015-3690-x; Wang W, 2012, WORLD J GASTROENTERO, V18, P5442, DOI 10.3748/wjg.v18.i38.5442; Wang W, 2012, CARCINOGENESIS, V33, P1113, DOI 10.1093/carcin/bgs113; Yamamoto C, 2010, CANCER RES, V70, P8715, DOI 10.1158/0008-5472.CAN-10-0043; Yi C, 2012, ONCOGENE, V31, P4421, DOI 10.1038/onc.2011.629; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou JY, 2014, CANCER LETT, V351, P265, DOI 10.1016/j.canlet.2014.06.010	44	57	60	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2018	37	31					4300	4312		10.1038/s41388-018-0276-2	http://dx.doi.org/10.1038/s41388-018-0276-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP1HN	29717264	Green Published, hybrid			2022-12-17	WOS:000440566100008
J	Sirkisoon, SR; Carpenter, RL; Rimkus, T; Anderson, A; Harrison, A; Lange, AM; Jin, GX; Watabe, K; Lo, HW				Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Anderson, Ashley; Harrison, Alexandria; Lange, Allison M.; Jin, Guangxu; Watabe, Kounosuke; Lo, Hui-Wen			Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR RECEPTOR; SONIC-HEDGEHOG; SPLICE VARIANT; SELF-RENEWAL; STEM-CELLS; GLI GENE; EXPRESSION; PROTEIN; ACTIVATION	Signal transducer and activator of transcription 3 (STAT3), glioma oncogene homolog 1 (GLI1), and truncated GLI1 (tGLI1) are oncogenic transcription factors playing important roles in breast cancer. tGLI1 is a gain-of-function GLI1 isoform. Whether STAT3 physically and/or functionally interacts with GLI1/tGLI1 has not been explored. To address this knowledge gap, we analyzed 47 node-positive breast cancer specimens using immunohistochemical staining and found that phosphorylated-STAT3 (Y705), GLI1, and tGLI1 are co-overexpressed in the majority of triple-negative breast carcinomas (64%) and HER2-enriched (68%) breast carcinomas, and in lymph node metastases (65%). Using gene set enrichment analysis, we analyzed 710 breast tumors and found that STAT3 activation and GLI1/tGLI1 activation signatures are co-enriched in triple-negative subtypes of breast cancers and HER2-enriched subtypes of breast cancers, but not in luminal subtypes of breast cancers. Patients with high levels of STAT3 and GLI1/tGLI1 co-activation in their breast tumors had worse metastasis-free survival compared to those with low levels. Since these proteins co-overexpress in breast tumors, we examined whether they form complexes and observed that STAT3 interacted with both GLI1 and tGLI1. We further found that the STAT3-GLI1 and STAT3-tGLI1 complexes bind to both consensus GLI1-binding and STAT3-binding sites using chromatin immunoprecipitation (ChIP) assay, and that the co-overexpression markedly activated a promoter controlled by GLI1-binding sites. To identify genes that can be directly co-activated by STAT3 and GLI1/tGLI1, we analyzed three ChIP-seq datasets and identified 34 potential target genes. Following validations using reverse transcription polymerase chain reaction and survival analysis, we identified three genes as novel transcriptional targets of STAT3 and GLI1/tGLI1, R-Ras2, Cep70, and UPF3A. Finally, we observed that co-overexpression of STAT3 with GLI1/tGLI1 promoted the ability of breast cancer cells to form mammospheres and that STAT3 only cooperates with tGLI1 in immortalized mammary epithelial cells. In summary, our study identified novel physical and functional cooperation between two families of oncogenic transcription factors, and the interaction contributes to aggressiveness of breast cancer cells and poor prognosis of triple-negative breast cancers and HER2-enriched breast cancers.	[Sirkisoon, Sherona R.; Carpenter, Richard L.; Rimkus, Tadas; Anderson, Ashley; Harrison, Alexandria; Lange, Allison M.; Watabe, Kounosuke; Lo, Hui-Wen] Dept Canc Biol, Winston Salem, NC 27104 USA; [Jin, Guangxu] Dept Radiol, Winston Salem, NC USA; [Watabe, Kounosuke; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27109 USA	Wake Forest University; Wake Forest Baptist Medical Center	Lo, HW (corresponding author), Dept Canc Biol, Winston Salem, NC 27104 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27109 USA.	hlo@wakehealth.edu		Carpenter, Richard/0000-0001-9986-6493	NIH [R01NS087169, T32CA079448, R01NS087169-3S1, P30CA012197]; DoD grant [W81XWH17-1-0044]; NATIONAL CANCER INSTITUTE [T32CA079448, P30CA012197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087169] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to acknowledge our colleagues Dr. Shadi Qasem for providing pathology support, and funding support for this project from NIH grants R01NS087169 (to H-WL), T32CA079448 (to SK, RLC), R01NS087169-3S1 (to H-WL and SRS), P30CA012197 (to BP; core facility), and DoD grant W81XWH17-1-0044 (to H-WL).	Abou-Bakr AA, 2013, ECANCERMEDICALSCIENC, V7, DOI 10.3332/ecancer.2013.317; Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Balko JM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3001; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Brouckaert O, 2012, INT J WOMENS HEALTH, V4, P511, DOI 10.2147/IJWH.S18541; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOGENE, V34, P546, DOI 10.1038/onc.2013.582; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Clark GJ, 1996, ONCOGENE, V12, P169; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dahmane N, 2001, DEVELOPMENT, V128, P5201; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; De Brot M, 2009, REV ASSOC MED BRAS, V55, P529, DOI 10.1590/S0104-42302009000500014; Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Fu XY, 1999, CELL DEATH DIFFER, V6, P1201, DOI 10.1038/sj.cdd.4400613; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; Han W, 2013, MOL CARCINOGEN, V52, P959, DOI 10.1002/mc.21936; Kameda C, 2009, ANTICANCER RES, V29, P871; Kim VN, 2001, SCIENCE, V293, P1832, DOI 10.1126/science.1062829; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuba S, 2014, JPN J CLIN ONCOL, V44, P1025, DOI 10.1093/jjco/hyu126; Langlois B, 2014, ONCOTARGET, V5, P10529, DOI 10.18632/oncotarget.2470; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Milla LA, 2012, BIOL RES, V45, P223, DOI 10.4067/S0716-97602012000300004; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Peterson KA, 2012, GENE DEV, V26, P2802, DOI 10.1101/gad.207142.112; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shi T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013054; Shi XJ, 2017, AM J PATHOL, V187, P679, DOI 10.1016/j.ajpath.2016.11.005; Shi XJ, 2015, FEBS LETT, V589, P1771, DOI 10.1016/j.febslet.2015.06.017; Shi XJ, 2012, CELL CYCLE, V11, P1554, DOI 10.4161/cc.19954; Shi XJ, 2011, J BIOL CHEM, V286, P33401, DOI 10.1074/jbc.M111.252262; Shum EY, 2016, CELL, V165, P382, DOI 10.1016/j.cell.2016.02.046; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; ten Haaf A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-298; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; Xu LS, 2010, BREAST CANCER RES TR, V123, P59, DOI 10.1007/s10549-009-0617-5; Yang Q, 2012, EXP MOL PATHOL, V93, P227, DOI 10.1016/j.yexmp.2012.04.009; Yang XP, 2011, NAT IMMUNOL, V12, P247, DOI 10.1038/ni.1995; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014; Zhu H, 2010, CURR GENOMICS, V11, P238, DOI 10.2174/138920210791233108	66	57	59	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2502	2514		10.1038/s41388-018-0132-4	http://dx.doi.org/10.1038/s41388-018-0132-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29449694	Green Accepted			2022-12-17	WOS:000431873400004
J	Solomon, H; Dinowitz, N; Pateras, IS; Cooks, T; Shetzer, Y; Molchadsky, A; Charni, M; Rabani, S; Koifman, G; Tarcic, O; Porat, Z; Kogan-Sakin, I; Goldfinger, N; Oren, M; Harris, CC; Gorgoulis, VG; Rotter, V				Solomon, Hilla; Dinowitz, Nathan; Pateras, Ioannis S.; Cooks, Tomer; Shetzer, Yoav; Molchadsky, Alina; Charni, Meital; Rabani, Stav; Koifman, Gabriela; Tarcic, Ohad; Porat, Ziv; Kogan-Sakin, Ira; Goldfinger, Naomi; Oren, Moshe; Harris, Curtis C.; Gorgoulis, Vassilis G.; Rotter, Varda			Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers	ONCOGENE			English	Article							INFLAMMATION; ACTIVATION; HALLMARKS; PARADIGM; CULTURE; CRYPT	Emerging notion in carcinogenesis ascribes tumor initiation and aggressiveness to cancer stem cells (CSCs). Specifically, colorectal cancer (CRC) development was shown to be compatible with CSCs hypothesis. Mutations in p53 are highly frequent in CRC, and are known to facilitate tumor development and aggressiveness. Yet, the link between mutant p53 and colorectal CSCs is not well-established. In the present study, we set to examine whether oncogenic mutant p53 proteins may augment colorectal CSCs phenotype. By genetic manipulation of mutant p53 in several cellular systems, we demonstrated that mutant p53 enhances colorectal tumorigenesis. Moreover, mutant p53-expressing cell lines harbor larger sub-populations of cells highly expressing the known colorectal CSCs markers: CD44, Lgr5, and ALDH. This elevated expression is mediated by mutant p53 binding to CD44, Lgr5, and ALDH1A1 promoter sequences. Furthermore, ALDH1 was found to be involved in mutant p53-dependent chemotherapy resistance. Finally, analysis of ALDH1 and CD44 in human CRC biopsies indicated a positive correlation between their expression and the presence of oncogenic p53 missense mutations. These findings suggest novel insights pertaining the mechanism by which mutant p53 enhances CRC development, which involves the expansion of CSCs sub-populations within CRC tumors, and underscore the importance of targeting these sub-populations for CRC therapy.	[Solomon, Hilla; Dinowitz, Nathan; Shetzer, Yoav; Molchadsky, Alina; Charni, Meital; Rabani, Stav; Koifman, Gabriela; Tarcic, Ohad; Kogan-Sakin, Ira; Goldfinger, Naomi; Oren, Moshe; Rotter, Varda] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel; [Pateras, Ioannis S.; Gorgoulis, Vassilis G.] Univ Athens, Sch Med, Dept Histol Embryol, Mol Carcinogenesis Grp, Athens, Greece; [Cooks, Tomer; Harris, Curtis C.] NCI, Lab Human Carcinogenesis, NIH, Bldg 37, Bethesda, MD 20892 USA; [Porat, Ziv] Weizmann Inst Sci, Life Sci Fac, Flow Cytometry Unit, Rehovot, Israel	Weizmann Institute of Science; Athens Medical School; National & Kapodistrian University of Athens; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.	varda.rotter@weizmann.ac.il	Porat, Ziv/K-1672-2012; Ponce, Richard/A-3109-2017; Gorgoulis, Vassilis/AAD-3630-2019	Porat, Ziv/0000-0003-3059-181X; Ponce, Richard/0000-0001-5077-8417; Gorgoulis, Vassilis/0000-0001-9001-4112; koifman, gabriela/0000-0002-7728-5214; Cooks, Tomer/0000-0003-0853-3437; Charni-Natan, Meital/0000-0003-0221-1664; Oren, Moshe/0000-0003-4311-7172	Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI); Israel Science Foundation ISF-MOKED; Philip Garoon grant; NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC011496] Funding Source: NIH RePORTER	Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI); Israel Science Foundation ISF-MOKED; Philip Garoon grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Dr. Ori Brenner for tumor histology analysis, to Dr. Ayala Sharp and Eitan Ariel for their help with the FACS experiments and to Dr. Tamar Unger for cloning consultation. This research was supported by a Center of Excellence grant from Flight Attendant Medical Research Institute (FAMRI), Israel Science Foundation ISF-MOKED and Philip Garoon grant. V.R. is the incumbent of the Norman and Helen Asher Professorial Chair for Cancer Research at the Weizmann Institute.	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Aloni-Grinstein R, 2014, FEBS LETT, V588, P2580, DOI 10.1016/j.febslet.2014.02.011; Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721; Barker N, 2010, GASTROENTEROLOGY, V138, P1681, DOI 10.1053/j.gastro.2010.03.002; Boman BM, 2008, J CLIN ONCOL, V26, P2828, DOI 10.1200/JCO.2008.17.6941; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cammareri P, 2008, METHOD CELL BIOL, V86, P311, DOI 10.1016/S0091-679X(08)00014-9; Charni M, 2016, CELL DEATH DIFFER, V23, P509, DOI 10.1038/cdd.2015.119; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Deng Y, 2014, BRIT J CANCER, V110, P430, DOI 10.1038/bjc.2013.767; Di Fiore R, 2014, BONE, V60, P198, DOI 10.1016/j.bone.2013.12.021; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Milyavsky M, 2003, CANCER RES, V63, P7147; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Molchadsky A, 2017, CARCINOGENESIS, V38, P347, DOI 10.1093/carcin/bgw092; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sarig R, 2010, J EXP MED, V207, P2127, DOI 10.1084/jem.20100797; Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Shetzer Y, 2014, CELL DEATH DIFFER, V21, P1419, DOI 10.1038/cdd.2014.57; Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073; Solomon H, 2012, J CELL SCI, V125, P3144, DOI 10.1242/jcs.099663; Solomon H, 2011, J PATHOL, V225, P475, DOI 10.1002/path.2988; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Zeilstra J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072849; Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	45	57	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1669	1684		10.1038/s41388-017-0060-8	http://dx.doi.org/10.1038/s41388-017-0060-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29343849	hybrid, Green Accepted			2022-12-17	WOS:000428626700009
J	Wang, J; Jia, Y; Zhao, S; Zhang, X; Wang, X; Han, X; Wang, Y; Ma, M; Shi, J; Liu, L				Wang, J.; Jia, Y.; Zhao, S.; Zhang, X.; Wang, X.; Han, X.; Wang, Y.; Ma, M.; Shi, J.; Liu, L.			BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR BIN1; INTEGRATOR 1 BIN1; PD-L1 EXPRESSION; INFILTRATING LYMPHOCYTES; UP-REGULATION; APOPTOSIS; EGFR; ACTIVATION; DOWNSTREAM; MECHANISMS	Non-small cell lung cancer (NSCLC) is one of the most common and malignant carcinoma worldwide, and the incidence and mortality are increasing rapidly. Immunotherapy targeting programmed death 1/programmed death ligand 1 (PD-L1) signaling has shown prominent clinical effects in treating NSCLC; however, a poor understanding of the associated regulating molecular mechanisms of PD-L1 has become one of the biggest obstacles for further improving efficacy. Bridging integrator-1 (BIN1) can regulate numerous cancer-related molecules to exert multiple tumor-suppressing effects by either interacting or not interacting with c-MYC. In the present study, we observed that there exists a negative correlation between the expression of PD-L1 and BIN1 in NSCLC tissues. The expression levels of BIN1 and PD-L1 were significantly related to the tumor, lymph node and metastasis grade (TNM) stage, invasion range and lymph node metastasis. Simultaneously, for NSCLC patients, the expression statuses of BIN1 and PD-L1 might be independent prognostic factors. Furthermore, the expression of tumor-infiltrating lymphocytes was positively associated with BIN1 expression and negatively related to PD-L1 expression in NSCLC tissues. Importantly, we showed that PD-L1 was under the control of BIN1. In addition, the overexpression of BIN1 could inhibit the c-MYC and epithelial growth factor receptor (EGFR)-dependent PD-L1 expression and reverse the suppressive immuno-microenvironment in vivo. Taken together, our findings indicated that BIN1 restoration in NSCLC could reverse PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/mitogen-activated protein kinase pathways.	[Wang, J.; Jia, Y.; Zhang, X.; Wang, X.; Han, X.; Wang, Y.; Liu, L.] Hebei Med Univ, Hosp 4, Dept Tumor Immunotherapy, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China; [Wang, J.; Jia, Y.; Zhang, X.; Wang, X.; Han, X.; Wang, Y.; Ma, M.; Liu, L.] Hebei Canc Inst, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China; [Zhao, S.] Hebei Med Univ, Dept Pathol, Shijiazhuang, Hebei, Peoples R China; [Ma, M.] Hebei Med Univ, Hosp 4, Res Ctr, Shijiazhuang, Hebei, Peoples R China; [Shi, J.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Mol Biol, Beijing, Peoples R China; [Shi, J.] Peking Union Med Coll, Beijing, Peoples R China	Hebei Medical University; Hebei Medical University; Hebei Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Liu, L (corresponding author), Hebei Med Univ, Hosp 4, Dept Tumor Immunotherapy, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China.; Liu, L (corresponding author), Hebei Canc Inst, 169 Tianshan St, Shijiazhuang 050035, Hebei, Peoples R China.	cdlihualiu@aliyun.com			National Natural Science Foundation of China [81201607]; Postdoctoral Fund of China [2013M540883]; Outstanding Youth Foundation of Hebei Province [H2014206320]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Fund of China(China Postdoctoral Science Foundation); Outstanding Youth Foundation of Hebei Province	This work was supported by the National Natural Science Foundation of China (81201607), Postdoctoral Fund of China (2013M540883), and Outstanding Youth Foundation of Hebei Province (H2014206320).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; [Anonymous], 2015, CANCER DISCOV, V5, P1232, DOI 10.1158/2159-8290.CD-ND2015-004; Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242; Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cassimere EK, 2009, CELL DEATH DIFFER, V16, P1641, DOI 10.1038/cdd.2009.98; Chang MY, 2007, CANCER RES, V67, P7605, DOI 10.1158/0008-5472.CAN-07-1100; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001; Dieci MV, 2014, ANN ONCOL, V25, P611, DOI 10.1093/annonc/mdt556; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; DuHadaway JB, 2001, CANCER RES, V61, P3151; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; Elliott K, 2000, ONCOGENE, V19, P4669, DOI 10.1038/sj.onc.1203681; Ettinger DS, 2013, J NATL COMPR CANC NE, V11, P645, DOI 10.6004/jnccn.2013.0084; Fusi A, 2015, LANCET ONCOL, V16, P1285, DOI 10.1016/S1470-2045(15)00307-1; Ge K, 2000, INT J CANCER, V85, P376; Hirano F, 2005, CANCER RES, V65, P1089; Horne ZD, 2011, J SURG RES, V171, P1, DOI 10.1016/j.jss.2011.03.068; Jia YL, 2015, INT J CANCER, V137, P1095, DOI 10.1002/ijc.29481; Laghi L, 2009, LANCET ONCOL, V10, P877, DOI 10.1016/S1470-2045(09)70186-X; Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362; Liu LH, 2009, CELL IMMUNOL, V258, P181, DOI 10.1016/j.cellimm.2009.05.002; Ma M, 2016, SCI REP-UK, V6, DOI 10.1038/srep31315; Martin-Orozco N, 2006, J IMMUNOL, V177, P8291, DOI 10.4049/jimmunol.177.12.8291; Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Nurieva RI, 2009, IMMUNOL REV, V229, P88, DOI 10.1111/j.1600-065X.2009.00769.x; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Pan K, 2012, MOL MED, V18, P507, DOI 10.2119/molmed.2011.00319; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Prokic I, 2014, J MOL MED, V92, P453, DOI 10.1007/s00109-014-1138-1; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Schalper KA, 2014, CLIN CANCER RES, V20, P2773, DOI 10.1158/1078-0432.CCR-13-2702; Schumacher K, 2001, CANCER RES, V61, P3932; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Tajiri T, 2003, CLIN CANCER RES, V9, P3345; Tan MS, 2013, TRENDS MOL MED, V19, P594, DOI 10.1016/j.molmed.2013.06.004; Telfer JF, 2005, CELL SIGNAL, V17, P701, DOI 10.1016/j.cellsig.2004.10.009; Wahlin BE, 2007, CLIN CANCER RES, V13, P388, DOI 10.1158/1078-0432.CCR-06-1734; Wang XX, 2017, ONCOTARGET, V8, P19661, DOI 10.18632/oncotarget.14914; Zhang Y, 2010, CELL MOL IMMUNOL, V7, P389, DOI 10.1038/cmi.2010.28; Zhao LM, 2015, MOL MED REP, V11, P871, DOI 10.3892/mmr.2014.2874	45	57	64	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2017	36	45					6235	6243		10.1038/onc.2017.217	http://dx.doi.org/10.1038/onc.2017.217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM1WY	28714960				2022-12-17	WOS:000414774800003
J	Deguchi, S; Katsushima, K; Hatanaka, A; Shinjo, K; Ohka, F; Wakabayashi, T; Zong, H; Natsume, A; Kondo, Y				Deguchi, S.; Katsushima, K.; Hatanaka, A.; Shinjo, K.; Ohka, F.; Wakabayashi, T.; Zong, H.; Natsume, A.; Kondo, Y.			Oncogenic effects of evolutionarily conserved noncoding RNA ECONEXIN on gliomagenesis	ONCOGENE			English	Article							TOPOISOMERASE-II; MOSAIC ANALYSIS; DOUBLE MARKERS; REVEALS; CELL; CANCER; GLIOMA; CERNA; TRANSCRIPTION; PLURIPOTENCY	Accumulating studies have demonstrated the importance of long noncoding RNAs (lncRNAs) during oncogenic transformation. However, because most lncRNAs are currently uncharacterized, the identification of novel oncogenic lncRNAs is difficult. Given that intergenic lncRNA have substantially less sequence conservation patterns than protein-coding genes across species, evolutionary conserved intergenic lncRNAs are likely to be functional. The current study identified a novel intergenic lncRNA, LINC00461 (ECONEXIN) using a combined approach consisting of searching lncRNAs by evolutionary conservation and validating their expression in a glioma mouse model. ECONEXIN was the most highly conserved intergenic lncRNA containing 83.0% homology with the mouse ortholog (C130071C03Rik) for a region over 2500 bp in length within its exon 3. Expressions of ECONEXIN and C130071C03Rik were significantly upregulated in both human and mouse glioma tissues. Moreover, the expression of C130071C03Rik was upregulated even in precancerous conditions and markedly increased during glioma progression. Functional analysis of ECONEXIN in glioma cell lines, U87 and U251, showed it was dominantly located in the cytoplasm and interacted with miR-411-5p via two binding sites within ECONEXIN. Inhibition of ECONEXIN upregulated miR-411-5p together with the downregulation of its target, Topoisomerase 2 alpha (TOP2A), in glioma cell lines, resulting in decreased cell proliferation. Our data demonstrated that ECONEXIN is a potential oncogene that regulates TOP2A by sponging miR-411-5p in glioma. In addition, our investigative approaches to identify conserved lncRNA and their molecular characterization by validation in mouse tumor models may be useful to functionally annotate novel lncRNAs, especially cancer-associated lncRNAs.	[Deguchi, S.; Katsushima, K.; Hatanaka, A.; Shinjo, K.; Kondo, Y.] Nagoya City Univ, Grad Sch Med Sci, Dept Epigenom, Nagoya, Aichi, Japan; [Deguchi, S.; Ohka, F.; Wakabayashi, T.; Natsume, A.] Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan; [Zong, H.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	Nagoya City University; Nagoya University; University of Virginia	Kondo, Y (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Epigenom, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	ykondo@med.nagoya-cu.ac.jp	katsushima, keisuke/AAD-5945-2019; katsushima, keisuke/AAV-5204-2020; Natsume, Atsushi/I-7364-2014; Ohka, Fumiharu/A-3420-2016	katsushima, keisuke/0000-0001-7770-432X; Natsume, Atsushi/0000-0002-9113-0470; Zong, Hui/0000-0002-4263-9633; Ohka, Fumiharu/0000-0002-5569-5626	Japan Society for the Promotion of Science [25290048]; Grants-in-Aid for Scientific Research [17K14995] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was performed as research programs of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan (YK), of the Project for Cancer Research And Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and development, AMED (YK), of the PRESTO, JST (YK) and of the Grant-in-Aid for Scientific Research, the Japan Society for the Promotion of Science (25290048, YK).	Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Chen T, 2015, ONCOGENE, V34, P4019, DOI 10.1038/onc.2014.332; CLARK PI, 1994, J CLIN ONCOL, V12, P1427, DOI 10.1200/JCO.1994.12.7.1427; Denzler R, 2014, MOL CELL, V54, P766, DOI 10.1016/j.molcel.2014.03.045; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hezroni H, 2015, CELL REP, V11, P1110, DOI 10.1016/j.celrep.2015.04.023; Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454; Ideue T, 2009, RNA, V15, P1578, DOI 10.1261/rna.1657609; Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083; Katsushima K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13616; Ke J, 2015, ONCOTARGET, V6, P21934, DOI 10.18632/oncotarget.4290; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; Kutter C, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002841; Labreche K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8207; Leonard A, 2013, ANTICANCER RES, V33, P3307; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Lin NW, 2014, MOL CELL, V53, P1005, DOI 10.1016/j.molcel.2014.01.021; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Mistry AR, 2005, NEW ENGL J MED, V352, P1529, DOI 10.1056/NEJMoa042715; Mo CF, 2015, STEM CELL RES THER, V6, DOI 10.1186/scrt535; Moran I, 2012, CELL METAB, V16, P435, DOI 10.1016/j.cmet.2012.08.010; Oliver PL, 2015, CEREB CORTEX, V25, P3572, DOI 10.1093/cercor/bhu196; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Quinn JJ, 2016, GENE DEV, V30, P191, DOI 10.1101/gad.272187.115; Sauvageau M, 2013, ELIFE, V2, DOI 10.7554/eLife.01749; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Ulitsky I, 2016, NAT REV GENET, V17, P601, DOI 10.1038/nrg.2016.85; Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055; Wahlestedt C, 2013, NAT REV DRUG DISCOV, V12, P433, DOI 10.1038/nrd4018; Washietl S, 2014, GENOME RES, V24, P616, DOI 10.1101/gr.165035.113; Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012; Zong H, 2005, CELL, V121, P479, DOI 10.1016/j.cell.2005.02.012	44	57	57	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4629	4640		10.1038/onc.2017.88	http://dx.doi.org/10.1038/onc.2017.88			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368417				2022-12-17	WOS:000407246200010
J	Harris, NLE; Vennin, C; Conway, JRW; Vine, KL; Pinese, M; Cowley, MJ; Shearer, RF; Lucas, MC; Herrmann, D; Allam, AH; Pajic, M; Morton, JP; Biankin, AV; Ranson, M; Timpson, P; Saunders, DN				Harris, N. L. E.; Vennin, C.; Conway, J. R. W.; Vine, K. L.; Pinese, M.; Cowley, M. J.; Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Allam, A. H.; Pajic, M.; Morton, J. P.; Biankin, A. V.; Ranson, M.; Timpson, P.; Saunders, D. N.		Australian Pancreatic Canc Genome	SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-2; MATRIX METALLOPROTEINASES; EXPRESSION; CARCINOMA; RECEPTOR; PAI-2; ADENOCARCINOMA; SURVIVAL; THERAPY; BIOLOGY	Pancreatic cancer has a devastating prognosis, with an overall 5-year survival rate of similar to 8%, restricted treatment options and characteristic molecular heterogeneity. SerpinB2 expression, particularly in the stromal compartment, is associated with reduced metastasis and prolonged survival in pancreatic ductal adenocarcinoma (PDAC) and our genomic analysis revealed that SERPINB2 is frequently deleted in PDAC. We show that SerpinB2 is required by stromal cells for normal collagen remodelling in vitro, regulating fibroblast interaction and engagement with collagen in the contracting matrix. In a pancreatic cancer allograft model, co-injection of PDAC cancer cells and SerpinB2(-/-) mouse embryonic fibroblasts (MEFs) resulted in increased tumour growth, aberrant remodelling of the extracellular matrix (ECM) and increased local invasion from the primary tumour. These tumours also displayed elevated proteolytic activity of the primary biochemical target of SerpinB2-urokinase plasminogen activator (uPA). In a large cohort of patients with resected PDAC, we show that increasing uPA mRNA expression was significantly associated with poorer survival following pancreatectomy. This study establishes a novel role for SerpinB2 in the stromal compartment in PDAC invasion through regulation of stromal remodelling and highlights the SerpinB2/uPA axis for further investigation as a potential therapeutic target in pancreatic cancer.	[Harris, N. L. E.; Vine, K. L.; Ranson, M.] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia; [Harris, N. L. E.; Vine, K. L.; Ranson, M.] Univ Wollongong, Ctr Med & Mol Biosci, Wollongong, NSW, Australia; [Harris, N. L. E.; Vine, K. L.; Ranson, M.] Univ Wollongong, Sch Biol Sci, Wollongong, NSW, Australia; [Conway, J. R. W.; Pinese, M.; Cowley, M. J.; Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Allam, A. H.; Pajic, M.; Timpson, P.; Saunders, D. N.] Garvan Inst Med Res, Kinghorn Canc Ctr, Victoria St, Darlinghurst, NSW 2010, Australia; [Vennin, C.; Conway, J. R. W.; Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Pajic, M.] Univ New South Wales, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW, Australia; [Morton, J. P.] Canc Res UK Beatson Inst, Glasgow, Lanark, Scotland; [Biankin, A. V.] Univ Glasgow, Inst Canc Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland; [Saunders, D. N.] Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia	University of Wollongong; University of Wollongong; University of Wollongong; Garvan Institute of Medical Research; University of New South Wales Sydney; Beatson Institute; University of Glasgow; University of New South Wales Sydney	Timpson, P; Saunders, DN (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Victoria St, Darlinghurst, NSW 2010, Australia.; Saunders, DN (corresponding author), Univ New South Wales, Sch Med Sci, Sydney, NSW 2052, Australia.; Ranson, M; Timpson, P; Saunders, DN (corresponding author), Illawarra Hlth & Med Res Inst, Bldg 32,Northfields Ave, Wollongong, NSW 2522, Australia.	mranson@uow.edu.au; p.timpson@garvan.org.au; d.saunders@unsw.edu.au	Timpson, Paul/A-9429-2016; Morton, Jennifer/AAJ-5113-2021; Ranson, Marie/GRO-5792-2022; Ranson, Marie/AAC-4468-2019; Cowley, Mark/K-8731-2019; Ranson, Marie/A-6324-2008; Morton, Jennifer P/E-1633-2011; Lucas, Morghan/S-4982-2018; Lucas, Morghan C/Y-6452-2019	Morton, Jennifer/0000-0001-5766-9141; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Cowley, Mark/0000-0002-9519-5714; Ranson, Marie/0000-0002-5570-9645; Morton, Jennifer P/0000-0001-5766-9141; Lucas, Morghan/0000-0001-7654-9137; Lucas, Morghan C/0000-0001-7654-9137; Vennin, Claire/0000-0001-9088-4177; Allam, Amr/0000-0002-8743-3639; Vine, Kara/0000-0001-6871-1149; Pinese, Mark/0000-0001-5078-6687; Conway, James/0000-0003-3787-277X; Timpson, Paul/0000-0002-5514-7080; Pajic, Marina/0000-0002-3871-3829; Herrmann, David/0000-0002-9514-7501	National Health and Medical Research Council; Cancer Institute NSW; Cancer Council NSW; Tour De Cure; Cure Cancer Australia Foundation; Australian Research Council; University of Wollongong; Illawarra Health and Medical Research Institute; Mostyn Family Foundation; Garvan Research Foundation; Sydney Catalyst; Lens Ainsworth Pancreatic Cancer Fellowship; University of Wollongong Vice Chancellor's Fellowship; Australian Postgraduate Award PhD scholarship; Guest Family Fellowship; Cancer Research UK [22311] Funding Source: researchfish	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute NSW; Cancer Council NSW(Cancer Council New South Wales); Tour De Cure; Cure Cancer Australia Foundation; Australian Research Council(Australian Research Council); University of Wollongong; Illawarra Health and Medical Research Institute; Mostyn Family Foundation; Garvan Research Foundation; Sydney Catalyst; Lens Ainsworth Pancreatic Cancer Fellowship; University of Wollongong Vice Chancellor's Fellowship; Australian Postgraduate Award PhD scholarship; Guest Family Fellowship; Cancer Research UK(Cancer Research UK)	This work was supported by funding from the National Health and Medical Research Council (DS, PT, MP); Cancer Institute NSW (DS, PT, MR); Cancer Council NSW (PT, MP); Tour De Cure (PT); Cure Cancer Australia Foundation (KLV); Australian Research Council (PT); University of Wollongong (MR) and Illawarra Health and Medical Research Institute (MR); Mostyn Family Foundation and Guest Family Fellowship (DS) and Garvan Research Foundation (DS, PT), Sydney Catalyst (CV). PT is a recipient of the Lens Ainsworth Pancreatic Cancer Fellowship, KLV was a recipient of a University of Wollongong Vice Chancellor's Fellowship. NLH is supported by an Australian Postgraduate Award PhD scholarship. The authors acknowledge use of the facilities and the assistance of Dr Tony Romeo and Dr Mitchell Nancarrow at the UOW Electron Microscopy Centre, the assistance of Alice Boulghourjian and Anaiis Zaratzian at The Kinghorn Cancer Centre Histopathology facility, and other technical assistance of Elahe Minaei at Illawarra Health and Medical Research Institute.	Al-Ejeh F, 2004, EXP CELL RES, V297, P259, DOI 10.1016/j.yexcr.2004.03.030; Babur O, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0612-6; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Barry SC, 2001, HUM GENE THER, V12, P1103, DOI 10.1089/104303401750214311; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Boyd ZS, 2009, J MOL DIAGN, V11, P290, DOI 10.2353/jmoldx.2009.080124; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cicchi R, 2010, J BIOPHOTONICS, V3, P34, DOI 10.1002/jbio.200910062; Cochran BJ, 2011, J BIOL CHEM, V286, P24467, DOI 10.1074/jbc.M111.225706; Cochran BJ, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-43; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Croucher D, 2006, J BIOL CHEM, V281, P10206, DOI 10.1074/jbc.M513645200; Croucher DR, 2008, NAT REV CANCER, V8, P535, DOI 10.1038/nrc2400; Croucher DR, 2007, BIOCHEM J, V408, P203, DOI 10.1042/BJ20070767; Duffy MJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0428-4; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53; Goldstein D, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju413; Gore J, 2014, CANCER CELL, V25, P711, DOI 10.1016/j.ccr.2014.05.026; Harris L, 2007, J CLIN ONCOL, V25, P5287, DOI 10.1200/JCO.2007.14.2364; Herrmann D, 2014, CARCINOGENESIS, V35, P1671, DOI 10.1093/carcin/bgu108; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hinz B, 2016, EXP EYE RES, V142, P56, DOI 10.1016/j.exer.2015.07.009; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; LeBeau AM, 2015, CANCER RES, V75, P1225, DOI 10.1158/0008-5472.CAN-14-2185; Lee J, 2015, CLIN CANCER RES, V21, P4482, DOI 10.1158/1078-0432.CCR-15-0226; Lee JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130136; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Li J, 2010, AAPS J, V12, P223, DOI 10.1208/s12248-010-9181-5; Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Neesse A, 2015, GUT, V64, P1476, DOI 10.1136/gutjnl-2015-309304; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; Nurmenniemi S, 2009, AM J PATHOL, V175, P1281, DOI 10.2353/ajpath.2009.081110; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Ozdemir B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107407; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Rowe RG, 2000, CANCER EPIDEM BIOMAR, V9, P1647; Schroder WA, 2010, PARASITE IMMUNOL, V32, P764, DOI 10.1111/j.1365-3024.2010.01241.x; SEYMOUR AB, 1994, CANCER RES, V54, P2761; Shearer RF, 2015, GENES CELLS, V20, P1, DOI 10.1111/gtc.12183; Shekouh AR, 2003, PROTEOMICS, V3, P1988, DOI 10.1002/pmic.200300466; Shiomi H, 2000, AM J PATHOL, V156, P567, DOI 10.1016/S0002-9440(10)64761-X; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; Smith R, 2007, WORLD J SURG, V31, P493, DOI 10.1007/s00268-006-0289-9; Stutchbury TK, 2007, MOL CANCER THER, V6, P203, DOI 10.1158/1535-7163.MCT-06-0264; TAKEUCHI Y, 1993, AM J GASTROENTEROL, V88, P1928; Telgenhoff D, 2005, CELL DEATH DIFFER, V12, P695, DOI 10.1038/sj.cdd.4401632; Timpson P, 2011, JOVE-J VIS EXP, DOI 10.3791/3089; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744; Xue A, 2008, PANCREAS, V36, P160, DOI 10.1097/MPA.0b013e31815750f0	61	57	60	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4288	4298		10.1038/onc.2017.63	http://dx.doi.org/10.1038/onc.2017.63			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28346421	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000406360600006
J	Kim, HS; Jung, M; Kang, HN; Kim, H; Park, CW; Kim, SM; Shin, SJ; Kim, SH; Kim, SG; Kim, EK; Yun, MR; Zheng, Z; Chung, KY; Greenbowe, J; Ali, SM; Kim, TM; Cho, BC				Kim, H. S.; Jung, M.; Kang, H. N.; Kim, H.; Park, C-W; Kim, S-M; Shin, S. J.; Kim, S. H.; Kim, S. G.; Kim, E. K.; Yun, M. R.; Zheng, Z.; Chung, K. Y.; Greenbowe, J.; Ali, S. M.; Kim, T-M; Cho, B. C.			Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition	ONCOGENE			English	Article							SEQUENCING DATA; IMPROVED SURVIVAL; TARGETED THERAPY; MUTATED MELANOMA; MUTANT MELANOMA; MEK INHIBITION; RAF INHIBITORS; GENE FUSIONS; CANCER; MUTATIONS	Despite remarkable progress in cutaneous melanoma genomic profiling, the mutational landscape of primary mucosal melanomas (PMM) remains unclear. Forty-six PMMs underwent targeted exome sequencing of 111 cancer-associated genes. Seventy-six somatic nonsynonymous mutations in 42 genes were observed, and recurrent mutations were noted on eight genes, including TP53 (13%), NRAS (13%), SNX31 (9%), NF1 (9%), KIT (7%) and APC (7%). Mitogen-activated protein kinase (MAPK; 37%), cell cycle (20%) and phosphatidylinositol 3-kinase (PI3K)-mTOR (15%) pathways were frequently mutated. We biologically characterized a novel ZNF767-BRAF fusion found in a vemurafenib-refractory respiratory tract PMM, from which cell line harboring ZNF767-BRAF fusion were established for further molecular analyses. In an independent data set, NFIC-BRAF fusion was identified in an oral PMM case and TMEM178B-BRAF fusion and DGKI-BRAF fusion were identified in two malignant melanomas with a low mutational burden (number of mutation per megabase, 0.8 and 4, respectively). Subsequent analyses revealed that the ZNF767-BRAF fusion protein promotes RAF dimerization and activation of the MAPK pathway. We next tested the in vitro and in vivo efficacy of vemurafenib, trametinib, BKM120 or LEE011 alone and in combination. Trametinib effectively inhibited tumor cell growth in vitro, but the combination of trametinib and BKM120 or LEE011 yielded more than additive anti-tumor effects both in vitro and in vivo in a melanoma cells harboring the BRAF fusion. In conclusion, BRAF fusions define a new molecular subset of PMM that can be targeted therapeutically by the combination of a MEK inhibitor with PI3K or cyclin-dependent kinase 4/ 6 inhibitors.	[Kim, H. S.; Jung, M.; Shin, S. J.; Cho, B. C.] Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med,Yonsei Canc Ctr, 50 Yonsei Ro, Seoul 120752, South Korea; [Kim, H. S.] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Dept Pharmacol, Seoul, South Korea; [Kang, H. N.; Kim, H.; Park, C-W; Kim, S-M; Kim, S. G.; Yun, M. R.] JEUK Co Ltd, JEUK Inst Canc Res, Gumi, Kyungbuk, South Korea; [Kim, S. H.; Kim, E. K.] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea; [Kim, S. H.] Seegene Med Fdn, Anat Pathol Reference Lab, Seoul, South Korea; [Zheng, Z.] Yanbian Univ Hosp, Dept Dermatol, Yanji, Peoples R China; [Chung, K. Y.] Yonsei Univ, Coll Med, Dept Dermatol, Seoul, South Korea; [Greenbowe, J.; Ali, S. M.] Fdn Med Inc, Cambridge, MA 02141 USA; [Kim, T-M] Catholic Univ Korea, Dept Med Informat, Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yanbian University; Yonsei University; Yonsei University Health System; Foundation Medicine; Catholic University of Korea	Cho, BC (corresponding author), Yonsei Univ, Div Med Oncol, Dept Internal Med, Coll Med,Yonsei Canc Ctr, 50 Yonsei Ro, Seoul 120752, South Korea.; Ali, SM (corresponding author), Fdn Med Inc, Cambridge, MA 02141 USA.; Kim, TM (corresponding author), Catholic Univ Korea, Seoul 137701, South Korea.	sali@foundationmedicine.com; tmkim@catholic.ac.kr; cbc1971@yuhs.ac	Kim, Han Sang/R-3768-2019; Ali, Siraj/AAE-2958-2019; Kim, Eun-Kyung/E-5211-2017	Kim, Han Sang/0000-0002-6504-9927; Chung, Kee Yang/0000-0003-3257-0297; Kim, Eun-Kyung/0000-0002-3368-5013; Shin, Sang Joon/0000-0001-5350-7241; Jung, Minkyu/0000-0001-8281-3387; Cho, Byoung Chul/0000-0002-5562-270X	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [2014R1A1A1004823]; NRF by the Korean government (MEST) [2012R1A2A2A01046927]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; NRF by the Korean government (MEST)	This study was supported in part by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (2014R1A1A1004823 to M Jung), and the NRF by the Korean government (MEST; 2012R1A2A2A01046927 to B Cho). The results of the analysis of mutation frequencies in cutaneous melanomas compared with corresponding frequencies in PMM were based on TCGA Research Network generated data (http://cancergenome.nih.gov/).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chang AE, 1998, CANCER, V83, P1664, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Dessars B, 2007, J INVEST DERMATOL, V127, P1468, DOI 10.1038/sj.jid.5700725; Deuker MM, 2015, CANCER DISCOV, V5, P143, DOI 10.1158/2159-8290.CD-14-0856; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Ge HY, 2011, BIOINFORMATICS, V27, P1922, DOI 10.1093/bioinformatics/btr310; Ghai R, 2011, P NATL ACAD SCI USA, V108, P7763, DOI 10.1073/pnas.1017110108; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Iyer MK, 2011, BIOINFORMATICS, V27, P2903, DOI 10.1093/bioinformatics/btr467; Jeuken JWM, 2010, J PATHOL, V222, P324, DOI 10.1002/path.2780; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; McVey M, 2008, TRENDS GENET, V24, P529, DOI 10.1016/j.tig.2008.08.007; Mihajlovic M, 2012, INT J CLIN EXP PATHO, V5, P739; NCCN, 2017, NCCN CLIN PRACT GUID; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Seetharamu N, 2010, ONCOLOGIST, V15, P772, DOI 10.1634/theoncologist.2010-0067; Stark MS, 2012, NAT GENET, V44, P165, DOI 10.1038/ng.1041; Sullivan RJ, 2013, ONCOGENE, V32, P2373, DOI 10.1038/onc.2012.345; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Van Allen EM, 2014, NAT MED, V20, P682, DOI 10.1038/nm.3559; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Worm J, 2004, ONCOGENE, V23, P5215, DOI 10.1038/sj.onc.1207647; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982	52	57	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3334	3345		10.1038/onc.2016.486	http://dx.doi.org/10.1038/onc.2016.486			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28092667				2022-12-17	WOS:000402869800012
J	Liu, WT; Huang, KY; Lu, MC; Huang, HL; Chen, CY; Cheng, YL; Yu, HC; Liu, SQ; Lai, NS; Huang, HB				Liu, W-T; Huang, K-Y; Lu, M-C; Huang, H-L; Chen, C-Y; Cheng, Y-L; Yu, H-C; Liu, S-Q; Lai, N-S; Huang, H-B			TGF-beta upregulates the translation of USP15 via the PI3K/AKT pathway to promote p53 stability	ONCOGENE			English	Article							CELL SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITION; P53-MDM2 PATHWAY; DNA-DAMAGE; ACTIVATION; USP7/HAUSP; RESPONSES; SMADS; MDM2	Crosstalk between transforming growth factor beta (TGF-beta) signaling and p53 has a critical role in cancer progression. TGF-beta signals via Smad and non-Smad pathways. Under normal conditions, wild-type p53 forms a complex with Smad2/3 and co-activates transcription of a variety of tumor suppressor genes, resulting in tumor suppressive effects. Thus, p53 stability is essential in progression of tumor suppressive responses mediated by TGF-beta signaling. However, it remains unknown whether p53 stability is regulated by TGF-beta. In the current study, we identify that USP15 binds to and stabilizes p53 through deubiquitination in U2OS and HEK293 cells. TGF-beta promotes the translation of USP15 through activation of mammalian target of rapamycin by the phosphoinositide 3-kinase/AKT pathway. Upregulation of USP15 translation links the crosstalk between TGF-beta signaling and p53 stability, allowing this cytokine to have a critical role in cancer progression.	[Liu, W-T; Huang, K-Y; Chen, C-Y; Cheng, Y-L; Yu, H-C; Huang, H-B] Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan; [Liu, W-T; Huang, K-Y; Chen, C-Y; Cheng, Y-L; Yu, H-C; Huang, H-B] Natl Chung Cheng Univ, Inst Mol Biol, 168 Univ Rd, Chiayi 62102, Taiwan; [Huang, K-Y; Lu, M-C; Yu, H-C; Liu, S-Q; Lai, N-S] DaLin Tzu Chi Buddhist Hosp, Dept Med, Sect Allergy Immunol & Rheumatol, Chiayi, Taiwan; [Huang, K-Y; Lu, M-C; Lai, N-S] Tzu Chi Univ, Coll Med, Dept Med, Hualien, Taiwan; [Huang, H-L] Fooyin Univ, Dept Nutr & Hlth Sci, Kaohsiung, Taiwan	National Chung Cheng University; National Chung Cheng University; Buddhist Tzu Chi General Hospital; Tzu Chi University; Fooyin University	Huang, HB (corresponding author), Natl Chung Cheng Univ, Dept Life Sci, 168 Univ Rd, Chiayi 62102, Taiwan.; Huang, HB (corresponding author), Natl Chung Cheng Univ, Inst Mol Biol, 168 Univ Rd, Chiayi 62102, Taiwan.; Lai, NS (corresponding author), DaLin Tzu Chi Buddhist Hosp, Dept Med, Sect Allergy Immunol & Rheumatol, Chiayi, Taiwan.	Q12015@tzuchi.com.tw; biohbh@ccu.edu.tw			DaLin Tzu-Chi Buddhist Hospital [DTCRD 97-14, DTCRD 102-E-06, DTCRD103(2)-I-10]; National Science Council, ROC [NSC 102-2320-B194-002]	DaLin Tzu-Chi Buddhist Hospital; National Science Council, ROC(Ministry of Science and Technology, Taiwan)	This work was supported by grants from the DaLin Tzu-Chi Buddhist Hospital (DTCRD 97-14, DTCRD 102-E-06 and DTCRD103(2)-I-10) and from the National Science Council, ROC (NSC 102-2320-B194-002).	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; Dupont S, 2004, CANCER LETT, V213, P129, DOI 10.1016/j.canlet.2004.06.008; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Huang T, 2011, EMBO J, V30, P1263, DOI 10.1038/emboj.2011.54; Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004; Inui M, 2011, NAT CELL BIOL, V13, P1368, DOI 10.1038/ncb2346; Khoronenkova SV, 2012, CELL CYCLE, V11, P2409, DOI 10.4161/cc.20800; Khoronenkova SV, 2012, MOL CELL, V45, P801, DOI 10.1016/j.molcel.2012.01.021; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kurz EU, 2004, J BIOL CHEM, V279, P53272, DOI 10.1074/jbc.M406879200; Lamouille S, 2007, J CELL BIOL, V178, P437, DOI 10.1083/jcb.200611146; Lee H, 2000, INT J CANCER, V88, P454, DOI 10.1002/1097-0215(20001101)88:3<454::AID-IJC19>3.0.CO;2-T; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Li PX, 2008, MOL CELL BIOL, V28, P4745, DOI 10.1128/MCB.01747-07; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2008, MOL CELL, V29, P149, DOI 10.1016/j.molcel.2008.01.006; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Takebayashi-Suzuki K, 2003, DEVELOPMENT, V130, P3929, DOI 10.1242/dev.00615; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; Vos RM, 2009, J VIROL, V83, P8885, DOI 10.1128/JVI.00605-09; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; WYLLIE FS, 1991, MOL CELL ENDOCRINOL, V76, P13, DOI 10.1016/0303-7207(91)90255-Q; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Zhang XN, 2011, EMBO J, V30, P2177, DOI 10.1038/emboj.2011.125; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885	36	57	60	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2715	2723		10.1038/onc.2016.424	http://dx.doi.org/10.1038/onc.2016.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893708	Green Published, hybrid			2022-12-17	WOS:000401120900009
J	Zamborszky, J; Szikriszt, B; Gervai, JZ; Pipek, O; Poti, A; Krzystanek, M; Ribli, D; Szalai-Gindl, JM; Csabai, I; Szallasi, Z; Swanton, C; Richardson, AL; Szuts, D				Zamborszky, J.; Szikriszt, B.; Gervai, J. Z.; Pipek, O.; Poti, A.; Krzystanek, M.; Ribli, D.; Szalai-Gindl, J. M.; Csabai, I.; Szallasi, Z.; Swanton, C.; Richardson, A. L.; Szuets, D.			Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions	ONCOGENE			English	Article							DNA-REPLICATION; HOMOLOGOUS RECOMBINATION; TRANSLESION SYNTHESIS; H2AX PHOSPHORYLATION; MUTATIONAL PROCESSES; HISTONE H2AX; REPAIR; CANCER; INSTABILITY; DAMAGE	Loss-of-function mutations in the BRCA1 and BRCA2 genes increase the risk of cancer. Owing to their function in homologous recombination repair, much research has focused on the unstable genomic phenotype of BRCA1/2 mutant cells manifest mainly as large-scale rearrangements. We used whole-genome sequencing of multiple isogenic chicken DT40 cell clones to precisely determine the consequences of BRCA1/2 loss on all types of genomic mutagenesis. Spontaneous base substitution mutation rates increased sevenfold upon the disruption of either BRCA1 or BRCA2, and the arising mutation spectra showed strong and specific correlation with a mutation signature associated with BRCA1/2 mutant tumours. To model endogenous alkylating damage, we determined the mutation spectrum caused by methyl methanesulfonate (MMS), and showed that MMS also induces more base substitution mutations in BRCA1/2-deficient cells. Spontaneously arising and MMS-induced insertion/deletion mutations and large rearrangements were also more common in BRCA1/2 mutant cells compared with the wild-type control. A difference in the short deletion phenotypes of BRCA1 and BRCA2 suggested distinct roles for the two proteins in the processing of DNA lesions, as BRCA2 mutants contained more short deletions, with a wider size distribution, which frequently showed microhomology near the breakpoints resembling repair by non-homologous end joining. An increased and prolonged gamma-H2AX signal in MMS-treated BRCA1/2 cells suggested an aberrant processing of stalled replication forks as the cause of increased mutagenesis. The high rate of base substitution mutagenesis demonstrated by our experiments is likely to significantly contribute to the oncogenic effect of the inactivation of BRCA1 or BRCA2.	[Zamborszky, J.; Szikriszt, B.; Gervai, J. Z.; Poti, A.; Szuets, D.] Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary; [Pipek, O.; Ribli, D.; Szalai-Gindl, J. M.; Csabai, I.] Eotvos Lorand Univ, Dept Phys Complex Syst, Budapest, Hungary; [Krzystanek, M.; Szallasi, Z.] Tech Univ Denmark, Ctr Biol Sequence Anal, Dept Syst Biol, Lyngby, Denmark; [Szallasi, Z.] Boston Childrens Hosp, CHIP, Boston, MA USA; [Szallasi, Z.] Harvard Med Sch, Boston, MA USA; [Szallasi, Z.] Semmelweis Univ, Dept Pathol 2, Brain Metastasis Res Grp, MTA SE NAP, Budapest, Hungary; [Swanton, C.] UCL Canc Inst, CRUK Lung Canc Ctr Excellence, London, England; [Swanton, C.] Francis Crick Inst, 44 Lincolns Inn Fields, London WCA2 3PX, England; [Richardson, A. L.] Johns Hopkins Med, Sibley Pathol Dept, Dept Pathol, 5255 Loughboro Rd NW, Washington, DC 20016 USA	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Technical University of Denmark; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Semmelweis University; University of London; University College London; Johns Hopkins University; Johns Hopkins Medicine	Szuts, D (corresponding author), Hungarian Acad Sci, Res Ctr Nat Sci, Inst Enzymol, Magyar Tudosok Krt 2, H-1117 Budapest, Hungary.; Swanton, C (corresponding author), Francis Crick Inst, 44 Lincolns Inn Fields, London WCA2 3PX, England.; Richardson, AL (corresponding author), Johns Hopkins Med, Sibley Pathol Dept, Dept Pathol, 5255 Loughboro Rd NW, Washington, DC 20016 USA.	charles.swanton@crick.ac.uk; aricha58@jhmi.edu; szuts.david@ttk.mta.hu	Csabai, Istvan/F-6045-2011; Pipek, Orsolya/J-3124-2018; Szalai-Gindl, Janos M/I-4734-2017; Szuts, David/N-1149-2016	Csabai, Istvan/0000-0001-9232-9898; Pipek, Orsolya/0000-0001-8109-0340; Szalai-Gindl, Janos M/0000-0002-0169-0547; Swanton, Charles/0000-0002-4299-3018; Szuts, David/0000-0001-7985-0136; Szallasi, Zoltan/0000-0001-5395-7509	Momentum of the Hungarian Academy of Sciences [LP2011-015]; Breast Cancer Research Foundation of the National Research, Development and Innovation Office, Hungary [KMR-12-1-2012-0216]; Novo Nordisk Foundation Interdisciplinary Synergy Programme [NNF15OC0016584]; Basser Foundation; Cancer Research UK (TRACERx); CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C); Rosetrees Trust; Prostate Cancer Foundation; Breast Cancer Research Foundation; University College London Hospitals Biomedical Research Centre; Cancer Research UK University College London Experimental Cancer Medicine Centre; Szechenyi Progam, Hungary [KTIA_NAP_13-2014-0021]; Novo Nordisk Foundation [16584]; EU FP7 [259303]; European Research Council (THESEUS); National Institute for Health Research; Novo Nordisk Fonden [NNF15OC0016584] Funding Source: researchfish	Momentum of the Hungarian Academy of Sciences; Breast Cancer Research Foundation of the National Research, Development and Innovation Office, Hungary; Novo Nordisk Foundation Interdisciplinary Synergy Programme; Basser Foundation; Cancer Research UK (TRACERx); CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C); Rosetrees Trust(Rosetrees Trust); Prostate Cancer Foundation; Breast Cancer Research Foundation; University College London Hospitals Biomedical Research Centre(General Electric); Cancer Research UK University College London Experimental Cancer Medicine Centre; Szechenyi Progam, Hungary; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); EU FP7(European Commission); European Research Council (THESEUS)(European Research Council (ERC)); National Institute for Health Research(National Institute for Health Research (NIHR)); Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Janos Molnar for his assistance in data processing. This study was supported by Momentum Grant LP2011-015 of the Hungarian Academy of Sciences (DS), the Breast Cancer Research Foundation (AR, ZS, CS), grant KMR-12-1-2012-0216 of the National Research, Development and Innovation Office, Hungary (IC). and Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant NNF15OC0016584 (ZS and IC). ZS acknowledges support by the Basser Foundation and the Szechenyi Progam, Hungary (KTIA_NAP_13-2014-0021). CS is a senior Cancer Research UK clinical research fellow and is funded by Cancer Research UK (TRACERx), the CRUK Lung Cancer Centre of Excellence, Stand Up 2 Cancer (SU2C), the Rosetrees Trust, Novo Nordisk Foundation (ID 16584), EU FP7 (projects PREDICT and RESPONSIFY, ID: 259303), the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council (THESEUS) and support was provided to CS by the National Institute for Health Research, the University College London Hospitals Biomedical Research Centre, and the Cancer Research UK University College London Experimental Cancer Medicine Centre.	Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; Arakawa H, 2006, PLOS BIOL, V4, P1947, DOI 10.1371/journal.pbio.0040366; Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Branzei D, 2011, FEBS LETT, V585, P2810, DOI 10.1016/j.febslet.2011.04.053; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; COSMIC, SIGN MUT PROC HUM CA; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Edmunds CE, 2008, MOL CELL, V30, P519, DOI 10.1016/j.molcel.2008.03.024; Ensminger M, 2014, J CELL BIOL, V206, P29, DOI 10.1083/jcb.201312078; Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054; Faust GG, 2014, BIOINFORMATICS, V30, P2503, DOI 10.1093/bioinformatics/btu314; Feng ZZ, 2012, J PALAEOGEOG-ENGLISH, V1, P1, DOI 10.3724/SP.J.1261.2012.00001; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; HIGGINS NP, 1976, J MOL BIOL, V101, P417, DOI 10.1016/0022-2836(76)90156-X; JORGENSEN TJ, 1991, RADIAT RES, V127, P107, DOI 10.2307/3578096; Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; Loeb LA, 2011, NAT REV CANCER, V11, P450, DOI 10.1038/nrc3063; Lundin C, 2005, NUCLEIC ACIDS RES, V33, P3799, DOI 10.1093/nar/gki681; Martin RW, 2007, CANCER RES, V67, P9658, DOI 10.1158/0008-5472.CAN-07-0290; Mayle R, 2015, SCIENCE, V349, P742, DOI 10.1126/science.aaa8391; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Molnar J, 2014, G3-GENES GENOM GENET, V4, P2231, DOI 10.1534/g3.114.013482; Murugaesu N, 2015, CANCER DISCOV, V5, P821, DOI 10.1158/2159-8290.CD-15-0412; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ottaviani D, 2014, TRENDS GENET, V30, P85, DOI 10.1016/j.tig.2014.01.001; Pathania S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6496; Pathania S, 2011, MOL CELL, V44, P235, DOI 10.1016/j.molcel.2011.09.002; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pfeifer GP, 2006, CURR TOP MICROBIOL, V301, P259; Pipek O, ACCURATE MUTAT UNPUB; Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Qing Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002148; Ribli D, ISOMUT ROBUST METHOD; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; Sale JE, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012708; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Sedic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8505; Sonoda E, 2001, PHILOS T ROY SOC B, V356, P111, DOI 10.1098/rstb.2000.0755; Su X, 2008, NAT STRUCT MOL BIOL, V15, P1049, DOI 10.1038/nsmb.1490; Szuts D, 2008, NUCLEIC ACIDS RES, V36, P6767, DOI 10.1093/nar/gkn651; Szuts D, 2004, J CELL SCI, V117, P4897, DOI 10.1242/jcs.01374; Szuts D, 2006, MOL CELL BIOL, V26, P8032, DOI 10.1128/MCB.01291-06; Thorslund T, 2007, ONCOGENE, V26, P7720, DOI 10.1038/sj.onc.1210870; Timms KM, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0475-x; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Varga A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052472; Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/NMETH.1628, 10.1038/nmeth.1628]; Wyatt MD, 2006, CHEM RES TOXICOL, V19, P1580, DOI 10.1021/tx060164e; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018	58	57	57	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					746	755		10.1038/onc.2016.243	http://dx.doi.org/10.1038/onc.2016.243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27452521	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000394168200002
J	Cao, C; Vasilatos, SN; Bhargava, R; Fine, JL; Oesterreich, S; Davidson, NE; Huang, Y				Cao, C.; Vasilatos, S. N.; Bhargava, R.; Fine, J. L.; Oesterreich, S.; Davidson, N. E.; Huang, Y.			Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression	ONCOGENE			English	Article							SUBEROYLANILIDE HYDROXAMIC ACID; PHASE-II TRIAL; COLORECTAL-CANCER; STABILIZES LSD1; SILENCED GENES; CELLS; VORINOSTAT; INHIBITORS; USP28; DIFFERENTIATION	We have previously demonstrated that crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases (HDACs) facilitates breast cancer proliferation. However, the underlying mechanisms are largely unknown. Here, we report that expression of HDAC5 and LSD1 proteins were positively correlated in human breast cancer cell lines and tissue specimens of primary breast tumors. Protein expression of HDAC5 and LSD1 was significantly increased in primary breast cancer specimens in comparison with matched-normal adjacent tissues. Using HDAC5 deletion mutants and co-immunoprecipitation studies, we showed that HDAC5 physically interacted with the LSD1 complex through its domain containing nuclear localization sequence and phosphorylation sites. Although the in vitro acetylation assays revealed that HDAC5 decreased LSD1 protein acetylation, small interfering RNA (siRNA)-mediated HDAC5 knockdown did not alter the acetylation level of LSD1 in MDA-MB-231 cells. Overexpression of HDAC5 stabilized LSD1 protein and decreased the nuclear level of H3K4me1/me2 in MDA-MB-231 cells, whereas loss of HDAC5 by siRNA diminished LSD1 protein stability and demethylation activity. We further demonstrated that HDAC5 promoted the protein stability of USP28, a bona fide deubiquitinase of LSD1. Overexpression of USP28 largely reversed HDAC5-KD-induced LSD1 protein degradation, suggesting a role of HDAC5 as a positive regulator of LSD1 through upregulation of USP28 protein. Depletion of HDAC5 by shRNA hindered cellular proliferation, induced G1 cell cycle arrest, and attenuated migration and colony formation of breast cancer cells. A rescue study showed that increased growth of MDA-MB-231 cells by HDAC5 overexpression was reversed by concurrent LSD1 depletion, indicating that tumor-promoting activity of HDAC5 is an LSD1 dependent function. Moreover, overexpression of HDAC5 accelerated cellular proliferation and promoted acridine mutagen ICR191-induced transformation of MCF10A cells. Taken together, these results suggest that HDAC5 is critical in regulating LSD1 protein stability through post-translational modification, and the HDAC5-LSD1 axis has an important role in promoting breast cancer development and progression.	[Cao, C.; Vasilatos, S. N.; Bhargava, R.; Fine, J. L.; Oesterreich, S.; Davidson, N. E.; Huang, Y.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Cao, C.; Oesterreich, S.; Davidson, N. E.; Huang, Y.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Cao, C.; Vasilatos, S. N.; Bhargava, R.; Oesterreich, S.; Davidson, N. E.; Huang, Y.] Univ Pittsburgh, Womens Canc Res Ctr, Pittsburgh, PA USA; [Bhargava, R.; Fine, J. L.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Huang, Y (corresponding author), Magee Womens Res Inst, Room 406,204 Craft Ave, Pittsburgh, PA 15213 USA.	yih26@pitt.edu	Huang, Yi/AAW-7892-2021; Cao, Chunyu/J-8622-2018; Fine, Jeffrey/H-6175-2013	Huang, Yi/0000-0002-9982-117X; Cao, Chunyu/0000-0003-3043-5673; Fine, Jeffrey/0000-0002-2678-8014	US Army Breast Cancer Research Program [W81XWH-14-1-0237, W81XWH-14-1-0238]; Breast Cancer Research Foundation; UPCI Genomics Core Facility - NCI [P30CA047904]; NATIONAL CANCER INSTITUTE [P30CA047904] Funding Source: NIH RePORTER	US Army Breast Cancer Research Program(United States Department of Defense); Breast Cancer Research Foundation; UPCI Genomics Core Facility - NCI; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by US Army Breast Cancer Research Program (W81XWH-14-1-0237 to YH; W81XWH-14-1-0238 to NED), Breast Cancer Research Foundation (to NED and SO) and UPCI Genomics Core Facility supported by NCI P30CA047904.	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Blumenschein GR, 2008, INVEST NEW DRUG, V26, P81, DOI 10.1007/s10637-007-9075-2; Chen WD, 2000, J NATL CANCER I, V92, P480, DOI 10.1093/jnci/92.6.480; Diefenbacher ME, 2014, J CLIN INVEST, V124, P3407, DOI 10.1172/JCI73733; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Greco TM, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004317; Han X, 2014, MOL CELL, V55, P482, DOI 10.1016/j.molcel.2014.06.006; He P, 2015, INT J CLIN EXP MED, V8, P6510; Huang Y, 2003, CLIN CANCER RES, V9, P2769; Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104; Huang Y, 2006, J BIOL CHEM, V281, P19055, DOI 10.1074/jbc.M600910200; Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Huang Y, 2009, ESSAYS BIOCHEM, V46, P95, DOI [10.1042/BSE0460007, 10.1042/bse0460007]; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Ishibashi H, 2003, J CLIN ENDOCR METAB, V88, P2309, DOI 10.1210/jc.2002-021353; Katz TA, 2014, BREAST CANCER RES TR, V146, P99, DOI 10.1007/s10549-014-3012-9; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234; Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122; Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613; Martin M, 2009, INT J DEV BIOL, V53, P291, DOI 10.1387/ijdb.082698mm; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009; Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002; Nagasawa S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118002; Nowotarski SL, 2015, BIOORGAN MED CHEM, V23, P1601, DOI 10.1016/j.bmc.2015.01.049; Piao L, 2015, ONCOTARGET, V6, P16939, DOI 10.18632/oncotarget.4760; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sen N, 2013, MOL CELL, V52, P406, DOI 10.1016/j.molcel.2013.09.003; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shaw PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076220; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Traynor AM, 2009, J THORAC ONCOL, V4, P522, DOI 10.1097/JTO.0b013e3181952478; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhu QS, 2012, AMINO ACIDS, V42, P887, DOI 10.1007/s00726-011-1004-1; Zientek-Targosz H, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-51	47	57	67	4	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					133	145		10.1038/onc.2016.186	http://dx.doi.org/10.1038/onc.2016.186			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27212032	Green Accepted			2022-12-17	WOS:000394069100012
J	Ellert-Miklaszewska, A; Wisniewski, P; Kijewska, M; Gajdanowicz, P; Pszczolkowska, D; Przanowski, P; Dabrowski, M; Maleszewska, M; Kaminska, B				Ellert-Miklaszewska, A.; Wisniewski, P.; Kijewska, M.; Gajdanowicz, P.; Pszczolkowska, D.; Przanowski, P.; Dabrowski, M.; Maleszewska, M.; Kaminska, B.			Tumour-processed osteopontin and lactadherin drive the protumorigenic reprogramming of microglia and glioma progression	ONCOGENE			English	Article							INFILTRATING MICROGLIA/MACROPHAGES; CELLS; MACROPHAGES; EXPRESSION; INVASION; STEM; ALPHA(9)BETA(1); METASTASIS; INHIBITION; PHENOTYPE	Tumour tissue is infiltrated by myeloid cells that are reprogrammed into alternatively activated/regenerative (M2) macrophages. The contribution of major signalling pathways and their modulators/targets involved in the macrophage reprogramming is poorly known. Glioblastoma (malignant brain tumour) attracts and reprograms brain-resident microglia and peripheral macrophages into cells that increase invasion, angiogenesis and suppress antitumour immunity. Using a 'function-first' approach and glioma secretome proteomics we identified osteopontin and lactadherin as proteins that cooperatively activate amoeboid transformation, phagocytosis and motility of primary microglia cultures via integrins and FAK-Akt (focal adhesion kinase-Akt) signalling. A synthetic peptide interfering with integrin ligands blocks glioma-microglia communication, functional activation and M2 gene expression. We found that osteopontin/secreted phosphoprotein 1 (Spp1) produced by non-transformed cells acts as a proinflammatory factor inducing inflammatory signalling and M1 genes, and counteracts the action of lactadherin. Using constructs encoding functional mutants of osteopontin, we demonstrated sequential processing of Spp1 by thrombin and matrix metalloproteinase-3 and/or -7 (MMP-3 and/or -7) in glioma cells, which generates a microglia-activating form devoid of the inflammatory activity, while retaining the M2 reprogramming potential. A similar form of osteopontin is secreted by human glioma cells but not normal human astrocytes. Knockdown of osteopontin or lactadherin in glioma cells reduces intracranial glioma growth, blocks amoeboid transformation of myeloid cells and affects M2 reprogramming of microglia/macrophages. Our findings demonstrate how glioma cells misuse macrophage-activating signals and redesign primarily proinflammatory signals towards their advantage to induce M2 reprogramming of tumour-infiltrating brain macrophages.	[Ellert-Miklaszewska, A.; Wisniewski, P.; Kijewska, M.; Gajdanowicz, P.; Pszczolkowska, D.; Przanowski, P.; Dabrowski, M.; Maleszewska, M.; Kaminska, B.] Nencki Inst Expt Biol, Neurobiol Ctr, Mol Neurobiol Lab, Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kaminska, B (corresponding author), Nencki Inst Expt Biol, Mol Neurobiol Lab, 3 Pasteur St, PL-02093 Warsaw, Poland.	bozenakk@nencki.gov.pl	Kaminska, Bozena/H-4592-2011; Kaminska, Bozena/B-2915-2014; Ellert-Miklaszewska, Aleksandra/AAX-8715-2020; Ellert-Miklaszewska, Aleksandra/H-4423-2011; Dąbrowski, Michał/K-4384-2012	Kaminska, Bozena/0000-0002-2642-4616; Ellert-Miklaszewska, Aleksandra/0000-0002-7947-5660; Ellert-Miklaszewska, Aleksandra/0000-0002-7947-5660; Gajdanowicz, Pawel/0000-0003-3075-5992; Dabrowski, Michal/0000-0002-5335-158X; Maleszewska, Marta/0000-0001-8695-374X	National Science Center (Poland) [2012/04/A/NZ3/00630]; Ministry of Science and Higher Education [264173 Bio-Imagine, IP2011013171]	National Science Center (Poland)(National Science Centre, Poland); Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	We thank Beata Kaza and Marcin Sliwa for technical assistance. This work was supported by the Grant 2012/04/A/NZ3/00630 (to BK) from the National Science Center (Poland). PG was supported by GA no. 264173 Bio-Imagine and IP2011013171 from the Ministry of Science and Higher Education.	Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Anborgh PH, 2010, J CELL MOL MED, V14, P2037, DOI 10.1111/j.1582-4934.2010.01115.x; Badie B, 2000, NEUROSURGERY, V46, P957, DOI 10.1097/00006123-200004000-00035; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Ellert-Miklaszewska A, 2013, GLIA, V61, P1178, DOI 10.1002/glia.22510; Gabrusiewicz K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023902; Grassinger J, 2009, BLOOD, V114, P49, DOI 10.1182/blood-2009-01-197988; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Hussain SF, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-15; Hussain SF, 2005, EXPERT REV ANTICANC, V5, P777, DOI 10.1586/14737140.5.5.777; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Ku MC, 2013, ACTA NEUROPATHOL, V125, P609, DOI 10.1007/s00401-013-1079-8; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; Murray P.J., 2014, OSTEOARTHR CARTILAGE, V41, P14; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Okada M, 2009, INT J ONCOL, V34, P1621, DOI 10.3892/ijo_00000292; Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood-2011-02-339911; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Przanowski P, 2014, J MOL MED, V92, P239, DOI 10.1007/s00109-013-1090-5; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Raymond A, 2009, J CELL BIOCHEM, V106, P957, DOI 10.1002/jcb.22076; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Shao ZF, 2014, J BIOL CHEM, V289, P27146, DOI 10.1074/jbc.M114.572172; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Silvestre JS, 2005, NAT MED, V11, P499, DOI 10.1038/nm1233; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246; Wei J, 2010, CLIN CANCER RES, V16, P461, DOI 10.1158/1078-0432.CCR-09-1983; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Yamaguchi Y, 2013, J BIOL CHEM, V288, P3097, DOI 10.1074/jbc.M112.362954; Ye XZ, 2012, J IMMUNOL, V189, P444, DOI 10.4049/jimmunol.1103248; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090	41	57	57	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 15	2016	35	50					6366	6377		10.1038/onc.2016.55	http://dx.doi.org/10.1038/onc.2016.55			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TP	27041573				2022-12-17	WOS:000390247600002
J	Zhou, JZ; Riquelme, MA; Gu, S; Kar, R; Gao, X; Sun, L; Jiang, JX				Zhou, J. Z.; Riquelme, M. A.; Gu, S.; Kar, R.; Gao, X.; Sun, L.; Jiang, J. X.			Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis	ONCOGENE			English	Article							GAP-JUNCTION HEMICHANNELS; HUMAN-TUMOR-CELLS; PARATHYROID-HORMONE; IN-VIVO; INTERCELLULAR COMMUNICATION; PHYSICAL-ACTIVITY; ATP RELEASE; FLUID-FLOW; SURVIVAL; MICE	Although the skeleton is one of the predominant sites for breast cancer metastasis, why breast cancer cells often become dormant after homing to bone is not well understood. Here, we reported an intrinsic self-defense mechanism of bone cells against breast cancer cells: a critical role of connexin (Cx) 43 hemichannels in osteocytes in the suppression of breast cancer bone metastasis. Cx43 hemichannels allow passage of small molecules between the intracellular and extracellular environments. The treatment of bisphosphonate drugs, either alendronate (ALN) or zoledronic acid (ZOL), opened Cx43 hemichannels in osteocytes. Conditioned media (CM) collected from MLO-Y4 osteocyte cells treated with bisphosphonates inhibited the anchorage-independent growth, migration and invasion of MDA-MB-231 human breast cancer cells and Py8119 mouse mammary carcinoma cells, and this inhibitory effect was attenuated with Cx43(E2), a specific hemichannel-blocking antibody. The opening of osteocytic Cx43 hemichannels by mechanical stimulation had similar inhibitory effects on breast cancer cells and this inhibition was attenuated by Cx43(E2) antibody as well. These inhibitory effects on cancer cells were mediated by ATP released from osteocyte Cx43 hemichannels. Furthermore, both Cx43 osteocyte-specific knockout mice and osteocyte-specific.130-136 transgenic mice with impaired Cx43 gap junctions and hemichannels showed significantly increased tumor growth and attenuated the inhibitory effect of ZOL. However, R76W transgenic mice with functional hemichannels but not gap junctions in osteocytes did not display a significant difference. Together, our studies establish the specific inhibitory role of osteocytic Cx43 hemichannels, and exploiting the activity of this channel could serve as a de novo therapeutic strategy.	[Zhou, J. Z.; Riquelme, M. A.; Gu, S.; Kar, R.; Gao, X.; Jiang, J. X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Sun, L.] Dept Cellular & Struct Biol, San Antonio, TX USA; [Sun, L.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Jiang, JX (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jiangj@uthscsa.edu	Riquelme, Manuel/B-1082-2015	Riquelme, Manuel/0000-0002-1915-0434; Jiang, Jean/0000-0002-2185-5716	Welch Foundation [AQ-1507]; NIH [EY012085, ES022057]; NCI Cancer Center grant [2 P30 CA054174-17]; NATIONAL CANCER INSTITUTE [R01CA196214, P30CA054174] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012085, R29EY012085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES022057] Funding Source: NIH RePORTER	Welch Foundation(The Welch Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Hongyun Cheng for technical assistance, Dr Lesley Ellies at the University of California at San Diego for providing Py8119 cells, Dr Lynda Bonewald at the University of Missouri at Kansas City for MLO-Y4 osteocytic cells, Dr Stephen Harris at UTHSCSA for 10-kb dentin matrix protein 1 (DMP1)-Cre mice and Dr Klaus Willecke at the University of Bonn and Dr Roberto Civitelli for mice with floxed Cx43 gene. The work was supported by Welch Foundation grant AQ-1507 and NIH grant EY012085 to JXJ, ES022057 to LZS and the NCI Cancer Center grant 2 P30 CA054174-17 to Cancer Therapy and Research Center.	AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304; Avanzo JL, 2004, CARCINOGENESIS, V25, P1973, DOI 10.1093/carcin/bgh193; Bennett MVL, 2012, BRAIN RES, V1487, P3, DOI 10.1016/j.brainres.2012.08.042; Bivi N, 2013, J ORTHOP RES, V31, P1075, DOI 10.1002/jor.22341; Bivi N, 2012, J BONE MINER RES, V27, P374, DOI 10.1002/jbmr.548; Bonewald LF, 2007, ANN NY ACAD SCI, V1116, P281, DOI 10.1196/annals.1402.018; Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320; Brown Sue A, 2007, Curr Osteoporos Rep, V5, P120; Calder BW, 2015, TISSUE ENG PT A, V21, P1752, DOI [10.1089/ten.tea.2014.0651, 10.1089/ten.TEA.2014.0651]; Cheng BX, 2001, J BONE MINER RES, V16, P249, DOI 10.1359/jbmr.2001.16.2.249; Cherian PP, 2005, MOL BIOL CELL, V16, P3100, DOI 10.1091/mbc.E04-10-0912; Cherian PP, 2008, CELL COMMUN ADHES, V15, P43, DOI 10.1080/15419060802310208; Chung DJ, 2006, J CELL SCI, V119, P4187, DOI 10.1242/jcs.03162; Cronier L, 2009, ANTIOXID REDOX SIGN, V11, P323, DOI 10.1089/ars.2008.2153; D'hondt C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00348; Dbouk HA, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-4; Elzarrad MK, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-20; Evans WH, 2006, BIOCHEM J, V397, P1, DOI 10.1042/BJ20060175; Genetos DC, 2007, J CELL PHYSIOL, V212, P207, DOI 10.1002/jcp.21021; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Goodenough DA, 2003, NAT REV MOL CELL BIO, V4, P285, DOI 10.1038/nrm1072; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Holick CN, 2008, CANCER EPIDEM BIOMAR, V17, P379, DOI 10.1158/1055-9965.EPI-07-0771; Irwin ML, 2011, CANCER PREV RES, V4, P522, DOI 10.1158/1940-6207.CAPR-10-0295; Jiang JX, 2007, FRONT BIOSCI-LANDMRK, V12, P1450, DOI 10.2741/2159; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kato Y, 2001, J BONE MINER RES, V16, P1622, DOI 10.1359/jbmr.2001.16.9.1622; Klein-Nulend J, 2013, BONE, V54, P182, DOI 10.1016/j.bone.2012.10.013; Kohno N, 2008, INT J CLIN ONCOL, V13, P18, DOI 10.1007/s10147-007-0726-2; Kretschmann KL, 2012, CANCER METAST REV, V31, P579, DOI 10.1007/s10555-012-9378-4; Laird DW, 1999, CANCER RES, V59, P4104; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Loiselle AE, 2013, J ORTHOP RES, V31, P147, DOI 10.1002/jor.22178; Lynch ME, 2013, J BONE MINER RES, V28, P2357, DOI 10.1002/jbmr.1966; Matsuo K, 2009, CURR OPIN NEPHROL HY, V18, P292, DOI 10.1097/MNH.0b013e32832b75f1; Mesnil M, 2005, BBA-BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004; Mesnil M, 2002, BIOL CELL, V94, P493, DOI 10.1016/S0248-4900(02)00025-4; Milne HM, 2008, BREAST CANCER RES TR, V108, P279, DOI 10.1007/s10549-007-9602-z; Orellana JA, 2012, GLIA, V60, P53, DOI 10.1002/glia.21246; Orellana JA, 2011, J NEUROSCI, V31, P4962, DOI 10.1523/JNEUROSCI.6417-10.2011; Orellana JA, 2011, J NEUROCHEM, V118, P826, DOI 10.1111/j.1471-4159.2011.07210.x; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Plante I, 2011, ONCOGENE, V30, P1681, DOI 10.1038/onc.2010.551; Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Plotkin LI, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00131; RAPAPORT E, 1983, CANCER RES, V43, P4402; Riquelme MA, 2013, NEUROPHARMACOLOGY, V75, P525, DOI 10.1016/j.neuropharm.2013.02.021; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022; Saez JC, 2003, ACTA PHYSIOL SCAND, V179, P9, DOI 10.1046/j.1365-201X.2003.01196.x; Saez JC, 2003, PHYSIOL REV, V83, P1359, DOI 10.1152/physrev.00007.2003; Savariar EN, 2013, CANCER RES, V73, P855, DOI 10.1158/0008-5472.CAN-12-2969; Schwartz AL, 2007, ONCOL NURS FORUM, V34, P627, DOI 10.1188/07.ONF.627-633; Shabbir M, 2009, INT J UROL, V16, P143, DOI 10.1111/j.1442-2042.2008.02207.x; Siller-Jackson AJ, 2008, J BIOL CHEM, V283, P26374, DOI 10.1074/jbc.M803136200; Stains JP, 2005, BBA-BIOMEMBRANES, V1719, P69, DOI 10.1016/j.bbamem.2005.10.012; Sterling Julie A, 2011, Curr Osteoporos Rep, V9, P89, DOI 10.1007/s11914-011-0052-5; Stoletov K, 2013, J CELL SCI, V126, P904, DOI 10.1242/jcs.112748; Theis M, 2001, GENESIS, V29, P1, DOI 10.1002/1526-968X(200101)29:1<1::AID-GENE1000>3.0.CO;2-0; Theriault RL, 2012, CANCER CONTROL, V19, P92, DOI 10.1177/107327481201900203; Van der Pluijm G, 2001, J BONE MINER RES, V16, P1077, DOI 10.1359/jbmr.2001.16.6.1077; Welch D. R., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P30; White N, 2006, TRENDS PHARMACOL SCI, V27, P211, DOI 10.1016/j.tips.2006.02.004; Xu HY, 2014, J BONE MINER RES, V29, pS430; Xu HY, 2015, J BONE MINER RES, V30, P550, DOI 10.1002/jbmr.2374; Yang WC, 2005, J BIOL CHEM, V280, P20680, DOI 10.1074/jbc.M500104200; Zhang W, 2011, BIOCHEM PHARMACOL, V82, P411, DOI 10.1016/j.bcp.2011.05.009; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023516; Zhou JZ, 2015, ONCOGENE, V34, P1831, DOI 10.1038/onc.2014.113; Zhou JZ, 2014, FEBS LETT, V588, P1186, DOI 10.1016/j.febslet.2014.01.001	74	57	61	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5597	5607		10.1038/onc.2016.101	http://dx.doi.org/10.1038/onc.2016.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27041582	Green Accepted			2022-12-17	WOS:000386998300003
J	Borcherding, DC; Tong, W; Hugo, ER; Barnard, DF; Fox, S; LaSance, K; Shaughnessy, E; Ben-Jonathan, N				Borcherding, D. C.; Tong, W.; Hugo, E. R.; Barnard, D. F.; Fox, S.; LaSance, K.; Shaughnessy, E.; Ben-Jonathan, N.			Expression and therapeutic targeting of dopamine receptor-1 (D1R) in breast cancer	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; PERIPHERAL DOPAMINE; GUANYLATE-CYCLASE; NITRIC-OXIDE; TUMOR-GROWTH; AGONIST; CELLS; ANGIOGENESIS; FENOLDOPAM; NEURONS	Patients with advanced breast cancer often fail to respond to treatment, creating a need to develop novel biomarkers and effective therapeutics. Dopamine (DA) is a catecholamine that binds to five G protein-coupled receptors. We discovered expression of DA type-1 receptors (D1Rs) in breast cancer, thereby identifying these receptors as novel therapeutic targets in this disease. Strong to moderate immunoreactive D1R expression was found in 30% of 751 primary breast carcinomas, and was associated with larger tumors, higher tumor grades, node metastasis and shorter patient survival. DA and D1R agonists, signaling through the cGMP/protein kinase G (PKG) pathway, suppressed cell viability, inhibited invasion and induced apoptosis in multiple breast cancer cell lines. Fenoldopam, a peripheral D1R agonist that does not penetrate the brain, dramatically suppressed tumor growth in two mouse models with D1R-expressing xenografts by increasing both necrosis and apoptosis. D1R-expressing primary tumors and metastases in mice were detected by fluorescence imaging. In conclusion, D1R overexpression is associated with advanced breast cancer and poor prognosis. Activation of the D1R/cGMP/PKG pathway induces apoptosis in vitro and causes tumor shrinkage in vivo. Fenoldopam, which is FDA (Food and Drug Administration) approved to treat renal hypertension, could be repurposed as a novel therapeutic agent for patients with D1R-expressing tumors.	[Borcherding, D. C.; Hugo, E. R.; Barnard, D. F.; Fox, S.; Ben-Jonathan, N.] Univ Cincinnati, Dept Canc Biol, Cincinnati, OH 45267 USA; [Tong, W.] Univ Cincinnati, Dept Pathol, Cincinnati, OH 45267 USA; [LaSance, K.] Univ Cincinnati, Dept Radiol, Cincinnati, OH 45267 USA; [Shaughnessy, E.] Univ Cincinnati, Dept Surg, 231 Bethesda Ave, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Ben-Jonathan, N (corresponding author), Univ Cincinnati, Dept Canc Biol, Coll Med, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Nira.Ben-Jonathan@uc.edu	Hugo, Eric/ADA-3523-2022	Borcherding, Dana/0000-0002-8849-2139	NIH [CA096613, ES020909]; DOD [AR110050, BC122992]; University of Cincinnati Center for Clinical and Translational Science and Training (CCTST); Marlene Harris-Ride Cincinnati; NATIONAL CANCER INSTITUTE [R01CA096613, T32CA117846] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES020909, R01ES012212] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); University of Cincinnati Center for Clinical and Translational Science and Training (CCTST); Marlene Harris-Ride Cincinnati; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We dedicate this manuscript to Wilson Tong, M.D., whose untimely death was a major loss to all who knew him. We thank Dean Quaranta for technical assistance, and Drs Susan Waltz and Peter Stambrook for critical reviews of this manuscript. This investigation was funded by NIH grants CA096613 and ES020909, DOD grants AR110050 and BC122992, and pilot grants from Marlene Harris-Ride Cincinnati, and the University of Cincinnati Center for Clinical and Translational Science and Training (CCTST).	Almubarak M, 2009, ONCOLOGY-NY, V23, P255; Amenta F., 2002, Italian Journal of Anatomy and Embryology, V107, P145; Arcangeli S, 2013, J CEREBR BLOOD F MET, V33, P278, DOI 10.1038/jcbfm.2012.167; Azevedo MF, 2014, ENDOCR REV, V35, P195, DOI 10.1210/er.2013-1053; Basu S, 2004, CANCER RES, V64, P5551, DOI 10.1158/0008-5472.CAN-04-1600; Basu S, 2001, NAT MED, V7, P569, DOI 10.1038/87895; Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642; Bodei S, 2009, N-S ARCH PHARMACOL, V379, P413, DOI 10.1007/s00210-008-0384-6; Borcherding DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025537; Carlo RD, 1986, ANN NY ACAD SCI, V464, P559, DOI DOI 10.1111/J.1749-6632.1986.TB16068.X; Chakroborty D, 2009, CANCER RES, V69, P3727, DOI 10.1158/0008-5472.CAN-08-4289; Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116; Conole D, 2013, DRUGS, V73, P1967, DOI 10.1007/s40265-013-0149-5; Contreras F, 2002, J HUM HYPERTENS, V16, pS13, DOI 10.1038/sj.jhh.1001334; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Eisenhofer G, 1999, CLIN EXP PHARMACOL P, V26, pS41; Evgenov OV, 2006, NAT REV DRUG DISCOV, V5, P755, DOI 10.1038/nrd2038; FLAIM KE, 1985, LIFE SCI, V36, P1427, DOI 10.1016/0024-3205(85)90049-9; Ghosh D, 2007, CELL MOL LIFE SCI, V64, P2013, DOI 10.1007/s00018-007-7175-y; Goldstein DS, 1999, J CLIN ENDOCR METAB, V84, P2523, DOI 10.1210/jc.84.7.2523; GRANADOSPRINCIP.S, 2015, BREAST CANCER RES, V17, P527; Hoque KE, 2010, PSYCHOPHARMACOLOGY, V207, P571, DOI 10.1007/s00213-009-1687-0; JOHNSON DE, 1995, ANTI-CANCER DRUG, V6, P471, DOI 10.1097/00001813-199506000-00017; Li ZS, 2006, J NEUROSCI, V26, P2798, DOI 10.1523/JNEUROSCI.4720-05.2006; Lin DTS, 2010, SYNAPSE, V64, P460, DOI 10.1002/syn.20750; Maggio R, 2009, PARKINSONISM RELAT D, V15, pS2, DOI 10.1016/S1353-8020(09)70826-0; Michel MC, 2009, N-S ARCH PHARMACOL, V379, P385, DOI 10.1007/s00210-009-0395-y; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; Moreno-Smith M, 2011, CLIN CANCER RES, V17, P3649, DOI 10.1158/1078-0432.CCR-10-2441; Murphy MB, 2001, NEW ENGL J MED, V345, P1548, DOI 10.1056/NEJMra010253; Natarajan A, 2010, J PHARMACOL EXP THER, V332, P640, DOI 10.1124/jpet.109.159871; Ng SSW, 2000, BRIT J PHARMACOL, V129, P853, DOI 10.1038/sj.bjp.0703119; Proskuryakov SY, 2010, CURR PHARM DESIGN, V16, P56, DOI 10.2174/138161210789941793; Rubi B, 2010, ENDOCRINOLOGY, V151, P5570, DOI 10.1210/en.2010-0745; Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049; Sammut S, 2006, NEUROPSYCHOPHARMACOL, V31, P493, DOI 10.1038/sj.npp.1300826; Sarkar C, 2004, AM J PHYSIOL-HEART C, V287, pH1554, DOI 10.1152/ajpheart.00272.2004; Sarkar C, 2008, CLIN CANCER RES, V14, P2502, DOI 10.1158/1078-0432.CCR-07-1778; Sharma RK, 2014, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00056; Shen LH, J BIOMED BIOTECHNOL; Sidhu A, 2000, INT J DEV NEUROSCI, V18, P669, DOI 10.1016/S0736-5748(00)00033-2; Supuran CT, 2006, CURR PHARM DESIGN, V12, P3459, DOI 10.2174/138161206778343118; Wang PS, 2002, ARCH GEN PSYCHIAT, V59, P1147, DOI 10.1001/archpsyc.59.12.1147; WEBER RR, 1988, BRIT J CLIN PHARMACO, V25, P17, DOI 10.1111/j.1365-2125.1988.tb03276.x; Zaccolo M, 2007, CIRC RES, V100, P1569, DOI 10.1161/CIRCRESAHA.106.144501; Zhang L, 2006, BRAIN RES, V1118, P192, DOI 10.1016/j.brainres.2006.08.028; Zhao DL, 2007, NEUROPHARMACOLOGY, V53, P724, DOI 10.1016/j.neuropharm.2007.07.017; Zhu B, 2007, CURR TOP MED CHEM, V7, P437, DOI 10.2174/156802607779941198	48	57	68	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3103	3113		10.1038/onc.2015.369	http://dx.doi.org/10.1038/onc.2015.369			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26477316	Green Accepted			2022-12-17	WOS:000378092700003
J	Hubackova, S; Kucerova, A; Michlits, G; Kyjacova, L; Reinis, M; Korolov, O; Bartek, J; Hodny, Z				Hubackova, S.; Kucerova, A.; Michlits, G.; Kyjacova, L.; Reinis, M.; Korolov, O.; Bartek, J.; Hodny, Z.			IFN gamma induces oxidative stress, DNA damage and tumor cell senescence via TGF beta/SMAD signaling-dependent induction of Nox4 and suppression of ANT2	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; ADENINE-NUCLEOTIDE TRANSLOCATOR-2; NADPH OXIDASE NOX4; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSITION; SECRETORY PHENOTYPE; HUMAN FIBROBLASTS; GENE-EXPRESSION; UP-REGULATION	Cellular senescence provides a biological barrier against tumor progression, often associated with oncogene-induced replication and/or oxidative stress, cytokine production and DNA damage response (DDR), leading to persistent cell-cycle arrest. While cytokines such as tumor necrosis factor-alpha (TNF alpha) and interferon gamma (IFN gamma) are important components of senescence-associated secretome and induce senescence in, for example, mouse pancreatic beta-cancer cell model, their downstream signaling pathway(s) and links with oxidative stress and DDR are mechanistically unclear. Using human and mouse normal and cancer cell models, we now show that TNF alpha and IFN gamma induce NADPH oxidases Nox4 and Nox1, reactive oxygen species (ROS), DDR signaling and premature senescence. Unlike mouse tumor cells that required concomitant presence of IFN gamma and TNF alpha, short exposure to IFN gamma alone was sufficient to induce Nox4, Nox1 and DDR in human cells. siRNA-mediated knockdown of Nox4 but not Nox1 decreased IFN gamma-induced DDR. The expression of Nox4/Nox1 required Janus kinase (JAK)/signal transducers and activators of transcription (STAT) signaling and the effect was mediated by downstream activation of transforming growth factor-beta (TGF beta) secretion and consequent autocrine/paracrine activation of the TGF beta/Smad pathway. Furthermore, the expression of adenine nucleotide translocase 2 (ANT2) was suppressed by IFN gamma contributing to elevation of ROS and DNA damage. In contrast to mouse B16 cells, inability of TC-1 cells to respond to IFN gamma/TNF alpha by DDR and senescence correlated with the lack of TGF beta and Nox4 response, supporting the role of ROS induced by NADPH oxidases in cytokine-induced senescence. Overall, our data reveal differences between cytokine effects in mouse and human cells, and mechanistically implicate the TGF beta/SMAD pathway, via induction of NADPH oxidases and suppression of ANT2, as key mediators of IFN gamma/TNF alpha-evoked genotoxicity and cellular senescence.	[Hubackova, S.; Kucerova, A.; Kyjacova, L.; Bartek, J.; Hodny, Z.] Acad Sci Czech Republ, Dept Genome Integr, Inst Mol Genet, Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic; [Michlits, G.; Reinis, M.; Korolov, O.] Acad Sci Czech Republ, Dept Tumour Immunol, Inst Mol Genet, Vvi, CZ-14220 Prague 4, Czech Republic; [Bartek, J.] Danish Canc Soc, Res Ctr, Genome Integr Unit, Strandblvd 49, DK-2100 Copenhagen, Denmark; [Michlits, G.; Reinis, M.; Korolov, O.] Acad Sci Czech Republ, Immunol Lab, Czech Ctr Phenogen, Inst Mol Genet,Vvi, CZ-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Danish Cancer Society; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Bartek, J; Hodny, Z (corresponding author), Acad Sci Czech Republ, Dept Genome Integr, Inst Mol Genet, Vvi, Videnska 1083, CZ-14220 Prague 4, Czech Republic.; Bartek, J (corresponding author), Danish Canc Soc, Res Ctr, Genome Integr Unit, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk; hodny@img.cas.cz	Uvizl, Alena/AAL-8198-2021	Uvizl, Alena/0000-0002-5819-1482; Michlits, Georg/0000-0002-3337-8291; Stemberkova Hubackova, Sona/0000-0002-3454-6840	Grant Agency of the Czech Republic [13-17658S]; Grant Agency of the Ministry of Health of the Czech Republic [NT14461]; Academy of Sciences of the Czech Republic [L200521301]; Faculty of Science, Charles University, Prague;  [RVO 68378050]; Lundbeck Foundation [R93-2011-8990] Funding Source: researchfish; Novo Nordisk Fonden [NNF15OC0016584, NNF12OC0002290] Funding Source: researchfish; The Danish Cancer Society [R124-A7785] Funding Source: researchfish	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Grant Agency of the Ministry of Health of the Czech Republic; Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Faculty of Science, Charles University, Prague; ; Lundbeck Foundation(Lundbeckfonden); Novo Nordisk Fonden(Novo Nordisk Foundation); The Danish Cancer Society(Danish Cancer Society)	We thank Marketa Vancurova and Katerina Krejcikova for excellent technical assistance. This study was supported by the Grant Agency of the Czech Republic (Project 13-17658S), NT14461 grant from the Grant Agency of the Ministry of Health of the Czech Republic and Institutional Grant (Project RVO 68378050). SH was supported by Academy of Sciences of the Czech Republic (Project L200521301), LK was supported in part by the Faculty of Science, Charles University, Prague.	AARDEN LA, 1989, ANN NY ACAD SCI, V557, P192; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Altenhofer S, 2012, CELL MOL LIFE SCI, V69, P2327, DOI 10.1007/s00018-012-1010-9; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Barath P, 1999, EXP CELL RES, V248, P583, DOI 10.1006/excr.1999.4432; Bartek J, 2008, NAT CELL BIOL, V10, P887, DOI 10.1038/ncb0808-887; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Besancenot R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000476; Boudreau HE, 2012, FREE RADICAL BIO MED, V53, P1489, DOI 10.1016/j.freeradbiomed.2012.06.016; Boulanger CA, 2001, ONCOGENE, V20, P2264, DOI 10.1038/sj.onc.1204312; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Braumuller H, 2013, NATURE, V494, P361, DOI 10.1038/nature11824; Caja L, 2009, CANCER RES, V69, P7595, DOI 10.1158/0008-5472.CAN-09-1482; Carmona-Cuenca I, 2008, J HEPATOL, V49, P965, DOI 10.1016/j.jhep.2008.07.021; Chainiaux F, 2002, ANN NY ACAD SCI, V973, P44, DOI 10.1111/j.1749-6632.2002.tb04603.x; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chiantore MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036909; Chiera F, 2008, FREE RADICAL BIO MED, V44, P332, DOI 10.1016/j.freeradbiomed.2007.09.018; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di X, 2008, CANCER BIOL THER, V7, P864, DOI 10.4161/cbt.7.6.5861; Ding GH, 2001, EXP MOL PATHOL, V70, P43, DOI 10.1006/exmp.2000.2346; Evangelou K, 2013, CELL DEATH DIFFER, V20, P1485, DOI 10.1038/cdd.2013.76; Fazeli G, 2012, MUTAGENESIS, V27, P673, DOI 10.1093/mutage/ges033; Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200; Geiszt M, 2006, CARDIOVASC RES, V71, P289, DOI 10.1016/j.cardiores.2006.05.004; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris JE, 2007, FASEB J, V21, P356, DOI 10.1096/fj.06-6925com; Hiraga R, 2013, ANTICANCER RES, V33, P4431; Hu TS, 2005, AM J PHYSIOL-RENAL, V289, pF816, DOI 10.1152/ajprenal.00024.2005; Hubackova S, 2012, AGING-US, V4, P932, DOI 10.18632/aging.100520; Hubackova S, 2012, J BIOL CHEM, V287, P26702, DOI 10.1074/jbc.M111.316869; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Katakura Y, 2003, BIOSCI BIOTECH BIOCH, V67, P815, DOI 10.1271/bbb.67.815; Kaynor C, 2002, J INTERF CYTOK RES, V22, P1089, DOI 10.1089/10799900260442511; Kim HS, 2012, FREE RADICAL RES, V46, P21, DOI 10.3109/10715762.2011.636042; Kim KS, 2009, MECH AGEING DEV, V130, P179, DOI 10.1016/j.mad.2008.11.004; Kodama R, 2013, GENES CELLS, V18, P32, DOI 10.1111/gtc.12015; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Koziel R, 2013, BIOCHEM J, V452, P231, DOI 10.1042/BJ20121778; Kretova M, 2014, CELL SIGNAL, V26, P2903, DOI 10.1016/j.cellsig.2014.08.029; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Laberge RM, 2012, CANCER MICROENVIRON, V5, P39, DOI 10.1007/s12307-011-0069-4; Lena A, 2010, FEBS J, V277, P2853, DOI 10.1111/j.1742-4658.2010.07702.x; Lener B, 2009, BIOCHEM J, V423, P363, DOI 10.1042/BJ20090666; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luciakova K, 2003, J BIOL CHEM, V278, P30624, DOI 10.1074/jbc.M303530200; Luciakova K, 2008, BIOCHEM J, V412, P123, DOI 10.1042/BJ20071440; Luciakova K, 2011, BIOCHEM BIOPH RES CO, V411, P648, DOI 10.1016/j.bbrc.2011.07.017; Maghzal GJ, 2012, FREE RADICAL BIO MED, V53, P1903, DOI 10.1016/j.freeradbiomed.2012.09.002; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; Manea A, 2010, BIOCHEM BIOPH RES CO, V396, P901, DOI 10.1016/j.bbrc.2010.05.019; Manea A, 2010, ARTERIOSCL THROM VAS, V30, P105, DOI 10.1161/ATVBAHA.109.193896; Michaeloudes C, 2011, AM J PHYSIOL-LUNG C, V300, pL295, DOI 10.1152/ajplung.00134.2010; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Minamino T, 2003, CIRCULATION, V108, P2264, DOI 10.1161/01.CIR.0000093274.82929.22; Moiseeva O, 2006, MOL BIOL CELL, V17, P1583, DOI 10.1091/mbc.E05-09-0858; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Nagineni CN, 2007, J CELL PHYSIOL, V210, P192, DOI 10.1002/jcp.20839; Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x; Novakova Z, 2010, ONCOGENE, V29, P273, DOI 10.1038/onc.2009.318; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Panieri E, 2013, FREE RADICAL BIO MED, V57, P176, DOI 10.1016/j.freeradbiomed.2012.12.024; Rajagopalan S, 2012, P NATL ACAD SCI USA, V109, P20596, DOI 10.1073/pnas.1208248109; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sagiv A, 2013, ONCOGENE, V32, P1971, DOI 10.1038/onc.2012.206; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stadler M, 1995, ONCOGENE, V11, P2565; Sturrock A, 2006, AM J PHYSIOL-LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005; Takacova S, 2012, CANCER CELL, V21, P517, DOI 10.1016/j.ccr.2012.01.021; Tremain R, 2000, ONCOGENE, V19, P1698, DOI 10.1038/sj.onc.1203471; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vlasakova J, 2007, BLOOD, V109, P1373, DOI 10.1182/blood-2006-02-003418; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wieder T, 2013, CELL CYCLE, V12, P3146, DOI 10.4161/cc.26060; Xu PL, 2012, FEBS LETT, V586, P1871, DOI 10.1016/j.febslet.2012.05.010; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang KE, 2011, MOL CELLS, V32, P99, DOI 10.1007/s10059-011-0064-0; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Yu Q, 2000, GENE DEV, V14, P163	97	57	58	3	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1236	1249		10.1038/onc.2015.162	http://dx.doi.org/10.1038/onc.2015.162			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	25982278				2022-12-17	WOS:000371763100004
J	Hwangbo, C; Tae, N; Lee, S; Kim, O; Park, OK; Kim, J; Kwon, SH; Lee, JH				Hwangbo, C.; Tae, N.; Lee, S.; Kim, O.; Park, O. K.; Kim, J.; Kwon, S-H; Lee, J-H			Syntenin regulates TGF-beta 1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-beta type I receptor internalization	ONCOGENE			English	Article							HUMAN-MELANOMA CELLS; ADAPTER PROTEIN; SIGNAL-TRANSDUCTION; PDZ TANDEM; MDA-9/SYNTENIN; CANCER; DEGRADATION; METASTASIS; PATHWAYS; REQUIREMENTS	Syntenin, a tandem PDZ domain containing scaffold protein, functions as a positive regulator of cancer cell progression in several human cancers. We report here that syntenin positively regulates transforming growth factor (TGF)-beta 1-mediated Smad activation and the epithelial-to-mesenchymal transition (EMT) by preventing caveolin-1-mediated internalization of TGF-beta type I receptor (T beta RI). Knockdown of syntenin suppressed TGF-beta 1-mediated cell migration, transcriptional responses and Smad2/3 activation in various types of cells; however, overexpression of syntenin facilitated TGF-beta 1-mediated responses. In particular, syntenin knockdown abolished both the basal and TGF-beta 1-mediated repression of E-cadherin expression, as well as induction of vimentin expression along with Snail and Slug upregulation; thus, blocking the TGF-beta 1-induced EMT in A549 cells. In contrast, overexpression of syntenin exhibited the opposite effect. Knockdown of syntenin-induced ubiquitination and degradation of T beta RI, but not TGF-beta type II receptor, leading to decreased T beta RI expression at the plasma membrane. Syntenin associated with T beta RI at its C-terminal domain and a syntenin mutant lacking C-terminal domain failed to increase TGF-beta 1-induced responses. Biochemical analyzes revealed that syntenin inhibited the interaction between caveolin-1 and T beta RI and knockdown of syntenin induced a massive internalization of T beta RI and caveolin-1 from lipid rafts, indicating that syntenin may increase TGF-beta signaling by inhibiting caveolin-1-dependent internalization of T beta RI. Moreover, a positive correlation between syntenin expression and phospho-Smad2 levels is observed in human lung tumors. Taken together, these findings demonstrate that syntenin may act as an important positive regulator of TGF-beta signaling by regulating caveolin-1-mediated internalization of T beta RI; thus, providing a novel function for syntenin that is linked to cancer progression.	[Hwangbo, C.; Tae, N.; Lee, S.; Kim, O.; Kim, J.; Lee, J-H] Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Gangwon Do, South Korea; [Park, O. K.; Kwon, S-H] Korea Basic Sci Inst, Chuncheon Ctr, Div Bioimaging, Chunchon, Gangwon Do, South Korea	Kangwon National University; Korea Basic Science Institute (KBSI)	Lee, JH (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 200701, Gangwon Do, South Korea.	jhlee36@kangwon.ac.kr			Korean Health Technology RD Project [A111311]; Ministry of Health and Welfare, Republic of Korea; National Research Foundation of Korea (NRF) [2013R1A1A2009026]	Korean Health Technology RD Project; Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	This work was supported by grants from the Korean Health Technology R&D Project (A111311), Ministry of Health and Welfare, Republic of Korea and the National Research Foundation of Korea (NRF, 2013R1A1A2009026).	Allen JA, 2007, NAT REV NEUROSCI, V8, P128, DOI 10.1038/nrn2059; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Boukerche H, 2007, CANCER RES, V67, P1812, DOI 10.1158/0008-5472.CAN-06-3875; Browman DT, 2007, TRENDS CELL BIOL, V17, P394, DOI 10.1016/j.tcb.2007.06.005; Chen YG, 2009, CELL RES, V19, P58, DOI 10.1038/cr.2008.315; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Dasgupta S, 2013, CLIN CANCER RES, V19, P4621, DOI 10.1158/1078-0432.CCR-13-0585; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Grembecka J, 2006, BIOCHEMISTRY-US, V45, P3674, DOI 10.1021/bi052225y; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hwangbo C, 2010, CANCER RES, V70, P1645, DOI 10.1158/0008-5472.CAN-09-2447; Itoh S, 2007, CURR OPIN CELL BIOL, V19, P176, DOI 10.1016/j.ceb.2007.02.015; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Kang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lonn P, 2009, CELL RES, V19, P21, DOI 10.1038/cr.2008.308; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Razani B, 2001, J BIOL CHEM, V276, P6727, DOI 10.1074/jbc.M008340200; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Shi J, 2009, CANCER RES, V69, P7180, DOI 10.1158/0008-5472.CAN-08-4470; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; van Rheenen J, 2005, EMBO J, V24, P1664, DOI 10.1038/sj.emboj.7600655; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yang Y, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3442; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhao B, 2012, CELL RES, V22, P1467, DOI 10.1038/cr.2012.92; Zimmermann P, 2002, MOL CELL, V9, P1215, DOI 10.1016/S1097-2765(02)00549-X	43	57	65	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					389	401		10.1038/onc.2015.100	http://dx.doi.org/10.1038/onc.2015.100			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	25893292				2022-12-17	WOS:000369055300012
J	Helmke, C; Becker, S; Strebhardt, K				Helmke, C.; Becker, S.; Strebhardt, K.			The role of Plk3 in oncogenesis	ONCOGENE			English	Review							POLO-LIKE-KINASE; SPINDLE ASSEMBLY CHECKPOINT; CELL-CYCLE PROGRESSION; BOX DOMAIN; DNA-DAMAGE; C-JUN; GENE-EXPRESSION; SERINE/THREONINE KINASE; TUMOR-SUPPRESSOR; CRYSTAL-STRUCTURE	The polo-like kinases (Plks) encompass a family of five serine/threonine protein kinases that play essential roles in many cellular processes involved in the control of the cell cycle, including entry into mitosis, DNA replication and the response to different types of stress. Plk1, which has been validated as a cancer target, came into the focus of many pharmaceutical companies for the development of small-molecule inhibitors as anticancer agents. Recently, FDA (Food and Drug Administration) has granted a breakthrough therapy designation to the Plk inhibitor BI 6727 (volasertib), which provided a survival benefit for patients suffering from acute myeloid leukemia. However, the various ATP-competitive inhibitors of Plk1 that are currently in clinical development also inhibit the activities of Plk2 and Plk3, which are considered as tumor suppressors. Plk3 contributes to the control and progression of the cell cycle while acting as a mediator of apoptosis and various types of cellular stress. The aberrant expression of Plk3 was found in different types of tumors. Recent progress has improved our understanding of Plk3 in regulating stress signaling and tumorigenesis. When using ATP-competitive Plk1 inhibitors, the biological roles of Plk1-related family members like Plk3 in cancer cells need to be considered carefully to improve treatment strategies against cancer.	[Helmke, C.; Becker, S.; Strebhardt, K.] Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, D-60590 Frankfurt, Hessen, Germany; [Strebhardt, K.] German Canc Consortium DKTK, Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Sch Med, Dept Obstet & Gynecol, Theodor Stern Kai 7-9, D-60590 Frankfurt, Hessen, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Strebhardt, Klaus/0000-0003-2173-9763	German Cancer Consortium (DKTK) (Heidelberg); Sander-Stiftung; Carls-Stiftung; Deutsche Krebshilfe; BANSS Stiftung	German Cancer Consortium (DKTK) (Heidelberg); Sander-Stiftung; Carls-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); BANSS Stiftung	This work was supported by grants from the German Cancer Consortium (DKTK) (Heidelberg), Sander-Stiftung, Carls-Stiftung, Deutsche Krebshilfe and BANSS Stiftung.	Alberts GF, 2004, CELL CYCLE, V3, P678; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Archambault V, 2008, GENE DEV, V22, P2707, DOI 10.1101/gad.486808; Archambault V, 2009, NAT REV MOL CELL BIO, V10, P265, DOI 10.1038/nrm2653; Bahassi El Mustapha, 2002, Oncogene, V21, P6633; Bahassi ELM, 2004, ONCOGENE, V23, P2658, DOI 10.1038/sj.onc.1207425; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bai Y, 2012, CANCER RES, V72, P2501, DOI 10.1158/0008-5472.CAN-11-3015; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berg T, 2012, EXPERT OPIN INV DRUG, V21, P1069, DOI 10.1517/13543784.2012.691163; Bergeron M, 2014, NEUROSCIENCE, V256, P72, DOI 10.1016/j.neuroscience.2013.09.061; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Bieche I, 1998, ONCOL REP, V5, P267; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Bruinsma W, 2014, J CELL SCI, V127, P801, DOI 10.1242/jcs.137216; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cholewa BD, 2013, CANCER RES, V73, P6848, DOI 10.1158/0008-5472.CAN-13-2197; Conn CW, 2000, CANCER RES, V60, P6826; Craig SN, 2014, EXPERT OPIN DRUG DIS, V9, P773, DOI 10.1517/17460441.2014.918100; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; De Franceschi L, 2011, BLOOD, V118, P5652, DOI 10.1182/blood-2011-05-355339; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elia AEH, 2003, SCIENCE, V299, P1228, DOI 10.1126/science.1079079; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gauci S, 2009, ANAL CHEM, V81, P4493, DOI 10.1021/ac9004309; Gilmartin AG, 2009, CANCER RES, V69, P6969, DOI 10.1158/0008-5472.CAN-09-0945; Gjertsen BT, 2014, LEUKEMIA OFFICIAL J; Han ES, 2008, PHYSIOL GENOMICS, V34, P112, DOI 10.1152/physiolgenomics.00239.2007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Horner TJ, 2009, MOL CELL BIOL, V29, P1999, DOI 10.1128/MCB.00982-08; Iida M, 2008, BIOCHEM J, V411, P27, DOI 10.1042/BJ20071394; Inglis KJ, 2009, J BIOL CHEM, V284, P2598, DOI 10.1074/jbc.C800206200; Iuchi T, 2002, GENE CHROMOSOME CANC, V35, P170, DOI 10.1002/gcc.10080; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Jen KY, 2005, CANCER RES, V65, P7666, DOI 10.1158/0008-5472.CAN-05-1039; Jiang N, 2006, J BIOL CHEM, V281, P10577, DOI 10.1074/jbc.M513156200; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kettenbach AN, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001497; Kis E, 2006, INT J RADIAT ONCOL, V66, P1506, DOI 10.1016/j.ijrobp.2006.08.004; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Larsson E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.89; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee KS, 2008, CELL CYCLE, V7, P141, DOI 10.4161/cc.7.2.5272; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Li H, 2009, MOL CELL PROTEOMICS, V8, P1839, DOI 10.1074/mcp.M900030-MCP200; Li MJ, 2011, MED SCI MONITOR, V17, pBR290, DOI 10.12659/MSM.881976; Li ZG, 2014, MOL CELL BIOL, V34, P3642, DOI 10.1128/MCB.00814-14; Li ZK, 2005, J BIOL CHEM, V280, P16843, DOI 10.1074/jbc.M410119200; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lopez-Sanchez I, 2009, MOL CELL BIOL, V29, P1189, DOI 10.1128/MCB.01341-08; Lu JW, 2010, INVEST OPHTH VIS SCI, V51, P5034, DOI 10.1167/iovs.10-5501; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mamrosh JL, 2014, ELIFE, V3, DOI 10.7554/eLife.01694; Mbefo MK, 2010, J BIOL CHEM, V285, P2807, DOI 10.1074/jbc.M109.081950; McInnes C, 2005, CURR TOP MED CHEM, V5, P181, DOI 10.2174/1568026053507660; McInnes C, 2012, MOL CANCER THER, V11, P1683, DOI 10.1158/1535-7163.MCT-12-0006-T; McInnes C, 2011, DRUG DISCOV TODAY, V16, P619, DOI 10.1016/j.drudis.2011.05.002; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Myer DL, 2011, MUTAT RES-FUND MOL M, V714, P1, DOI 10.1016/j.mrfmmm.2011.02.006; Myer DL, 2005, ONCOGENE, V24, P299, DOI 10.1038/sj.onc.1208278; Palmada M, 2002, J CELL BIOL, V158, P453, DOI 10.1083/jcb.200112129; Pellegrino R, 2010, HEPATOLOGY, V51, P857, DOI 10.1002/hep.23467; Petronczki M, 2008, DEV CELL, V14, P646, DOI 10.1016/j.devcel.2008.04.014; Qian WJ, 2013, CHEM BIOL, V20, P1255, DOI 10.1016/j.chembiol.2013.09.005; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Raab M, 2014, CELL RES, V24, P1141, DOI 10.1038/cr.2014.86; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Reindl WG, 2008, CHEM BIOL, V15, P459, DOI 10.1016/j.chembiol.2008.03.013; Reindl W, 2009, CHEMBIOCHEM, V10, P1145, DOI 10.1002/cbic.200900059; Ruan Q, 2004, EXP CELL RES, V294, P51, DOI 10.1016/j.yexcr.2003.10.022; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Salvi M, 2012, BBA-PROTEINS PROTEOM, V1824, P1366, DOI 10.1016/j.bbapap.2012.07.003; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Shan HM, 2015, BIOCHEM BIOPH RES CO, V456, P780, DOI 10.1016/j.bbrc.2014.11.125; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Srinivasrao G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107432; Staib F, 2005, CANCER RES, V65, P10255, DOI 10.1158/0008-5472.CAN-05-1714; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; SUNKEL CE, 1988, J CELL SCI, V89, P25; Utada Y, 2000, CLIN CANCER RES, V6, P3193; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; van de Weerdt BCM, 2005, MOL CELL BIOL, V25, P2031, DOI 10.1128/MCB.25.5.2031-2044.2005; Wang JF, 2011, CELL SIGNAL, V23, P2030, DOI 10.1016/j.cellsig.2011.07.017; Wang L, 2008, J BIOL CHEM, V283, P25928, DOI 10.1074/jbc.M801326200; Wang L, 2007, J BIOL CHEM, V282, P32121, DOI 10.1074/jbc.M702791200; Wang L, 2011, INVEST OPHTH VIS SCI, V52, P3200, DOI 10.1167/iovs.10-6485; Wang L, 2011, J BIOL CHEM, V286, P1951, DOI 10.1074/jbc.M110.166009; Wang Q, 2002, MOL CELL BIOL, V22, P3450, DOI 10.1128/MCB.22.10.3450-3459.2002; Weichert W, 2005, VIRCHOWS ARCH, V446, P442, DOI 10.1007/s00428-005-1212-8; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Winkles JA, 2005, ONCOGENE, V24, P260, DOI 10.1038/sj.onc.1208219; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Xie SQ, 2002, CELL CYCLE, V1, P424, DOI 10.4161/cc.1.6.271; Xu DZ, 2010, J BIOL CHEM, V285, P39935, DOI 10.1074/jbc.M110.166462; Xu DZ, 2010, J BIOL CHEM, V285, P38944, DOI 10.1074/jbc.M110.160325; Xu J, 2013, NAT STRUCT MOL BIOL, V20, P1047, DOI 10.1038/nsmb.2623; Yang YL, 2008, CANCER RES, V68, P4077, DOI 10.1158/0008-5472.CAN-07-6182; Yuan JP, 2002, CANCER RES, V62, P4186; Yuan JP, 2011, AM J PATHOL, V179, P2091, DOI 10.1016/j.ajpath.2011.06.031; Zhang H, 2004, J BIOL CHEM, V279, P35726, DOI 10.1074/jbc.M403264200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou JX, 2013, CNS NEUROSCI THER, V19, P688, DOI 10.1111/cns.12124; Zhou T, 2006, ENVIRON HEALTH PERSP, V114, P553, DOI 10.1289/ehp.8026; Zimmerman WC, 2007, CELL CYCLE, V6, P1314, DOI 10.4161/cc.6.11.4275; Zimmerman WC, 2007, P NATL ACAD SCI USA, V104, P1847, DOI 10.1073/pnas.0610856104; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819	144	57	61	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2016	35	2					135	147		10.1038/onc.2015.105	http://dx.doi.org/10.1038/onc.2015.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB0JH	25915845				2022-12-17	WOS:000368193900001
J	Stolzenburg, S; Beltran, AS; Swift-Scanlan, T; Rivenbark, AG; Rashwan, R; Blancafort, P				Stolzenburg, S.; Beltran, A. S.; Swift-Scanlan, T.; Rivenbark, A. G.; Rashwan, R.; Blancafort, P.			Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SOX2; STEM-CELLS; EXPRESSION; GENES; DIFFERENTIATION; REPRESSION; EFFECTORS; PROTEINS; MEMORY; TUMORS	With the recent comprehensive mapping of cancer genomes, there is now a need for functional approaches to edit the aberrant epigenetic state of key cancer drivers to reprogram the epi-pathology of the disease. In this study we utilized a programmable DNA-binding methyltransferase to induce targeted incorporation of DNA methylation (DNAme) in the SOX2 oncogene in breast cancer through a six zinc finger (ZF) protein linked to DNA methyltransferase 3A (ZF-DNMT3A). We demonstrated long-lasting oncogenic repression, which was maintained even after suppression of ZF-DNMT3A expression in tumor cells. The de novo DNAme was faithfully propagated and maintained through cell generations even after the suppression of the expression of the chimeric methyltransferase in the tumor cells. Xenograft studies in NUDE mice demonstrated stable SOX2 repression and long-term breast tumor growth inhibition, which lasted for >100 days post implantation of the tumor cells in mice. This was accompanied with a faithful maintenance of DNAme in the breast cancer implants. In contrast, downregulation of SOX2 by ZF domains engineered with the Krueppel-associated box repressor domain resulted in a transient and reversible suppression of oncogenic gene expression. Our results indicated that targeted de novo DNAme of the SOX2 oncogenic promoter was sufficient to induce long-lasting epigenetic silencing, which was not only maintained during cell division but also significantly delayed the tumorigenic phenotype of cancer cells in vivo, even in the absence of treatment. Here, we outline a genome-based targeting approach to long-lasting tumor growth inhibition with potential applicability to many other oncogenic drivers that are currently refractory to drug design.	[Stolzenburg, S.; Rashwan, R.; Blancafort, P.] Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA, Australia; [Stolzenburg, S.; Rashwan, R.; Blancafort, P.] Univ Western Australia, Sch Anat Physiol & Human Biol, Nedlands, WA 6009, Australia; [Stolzenburg, S.; Beltran, A. S.; Blancafort, P.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC USA; [Swift-Scanlan, T.] Univ N Carolina, Sch Nursing, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Rivenbark, A. G.] Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Chapel Hill, NC USA	Harry Perkins Institute of Medical Research; University of Western Australia; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Blancafort, P (corresponding author), Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA, Australia.	pilar.blancafort@uwa.edu.au		Rashwan, Rabab/0000-0001-9557-0062; Blancafort, Pilar/0000-0002-3881-7396	Australian Research Council (ARC) Future Fellowship [FT130101767]; Cancer Council of Western Australia Research Fellowship; National Health and Medical Research Council [APP1069308]; National Institutes of Health [R01CA170370, R01DA036906]; National Breast Cancer Foundation [NC-14-024]; Barbara Senich Genomics Innovation Award; Barbara Senich Genomics Innovation Endowment Fund; Susan G Komen Foundation [KG090180]; NATIONAL CANCER INSTITUTE [R01CA170370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA036906] Funding Source: NIH RePORTER	Australian Research Council (ARC) Future Fellowship(Australian Research Council); Cancer Council of Western Australia Research Fellowship(Cancer Council Western Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Breast Cancer Foundation; Barbara Senich Genomics Innovation Award; Barbara Senich Genomics Innovation Endowment Fund; Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This research was supported by an Australian Research Council (ARC) Future Fellowship FT130101767, the Cancer Council of Western Australia Research Fellowship, National Health and Medical Research Council grant APP1069308, National Institutes of Health grants R01CA170370, R01DA036906, the National Breast Cancer Foundation NC-14-024 (PB) and the Barbara Senich Genomics Innovation Award, the Barbara Senich Genomics Innovation Endowment Fund and the Susan G Komen Foundation KG090180 (TSS).	Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932; Beltran AS, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3019; Blancafort P, 2013, MOL PHARMACOL, V83, P563, DOI 10.1124/mol.112.080697; Boch J, 2009, SCIENCE, V326, P1509, DOI 10.1126/science.1178811; Bogdanove AJ, 2011, SCIENCE, V333, P1843, DOI 10.1126/science.1204094; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brazel CY, 2005, AGING CELL, V4, P197, DOI 10.1111/j.1474-9726.2005.00158.x; Chaikind B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096931; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Groote ML, 2012, NUCLEIC ACIDS RES, V40, P10596, DOI 10.1093/nar/gks863; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Hathaway NA, 2012, CELL, V149, P1447, DOI 10.1016/j.cell.2012.03.052; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konermann S, 2013, NATURE; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lange UC, 2010, BIOESSAYS, V32, P659, DOI 10.1002/bies.201000030; Lara H, 2012, J BIOL CHEM, V287, P29873, DOI 10.1074/jbc.M112.360768; Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035; Nunna S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087703; Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507; Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105; Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008; Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696; Siddique A, 2013, J MOL BIOL, V425, P479, DOI 10.1016/j.jmb.2012.11.038; Sikorska M, 2008, J NEUROSCI RES, V86, P1680, DOI 10.1002/jnr.21635; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360; Stolzenburg S, 2010, METHODS MOL BIOL, V649, P117, DOI 10.1007/978-1-60761-753-2_7; Sussman RT, 2013, J BIOL CHEM, V288, P24234, DOI 10.1074/jbc.M113.469783; Wiedenheft B, 2012, NATURE, V482, P331, DOI 10.1038/nature10886; Xiang R, 2011, BRIT J CANCER, V104, P1410, DOI 10.1038/bjc.2011.94	39	57	58	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2015	34	43					5427	5435		10.1038/onc.2014.470	http://dx.doi.org/10.1038/onc.2014.470			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EM	25684141	Green Published, hybrid			2022-12-17	WOS:000363479700003
J	Bhat, AA; Pope, JL; Smith, JJ; Ahmad, R; Chen, X; Washington, MK; Beauchamp, RD; Singh, AB; Dhawan, P				Bhat, A. A.; Pope, J. L.; Smith, J. J.; Ahmad, R.; Chen, X.; Washington, M. K.; Beauchamp, R. D.; Singh, A. B.; Dhawan, P.			Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; E-CADHERIN EXPRESSION; DNA-METHYLATION; DOWN-REGULATION; TIGHT JUNCTION; UP-REGULATION; CANCER; INVASION; RAB25; METASTASIS	In normal colon, claudin-7 is one of the highly expressed claudin proteins and its knockdown in mice results in altered epithelial cell homeostasis and neonatal death. Notably, dysregulation of the epithelial homeostasis potentiates oncogenic transformation and growth. However, the role of claudin-7 in the regulation of colon tumorigenesis remains poorly understood. Using a large colorectal cancer (CRC) patient database and mouse models of colon cancer, we found claudin-7 expression to be significantly downregulated in cancer samples. Most notably, forced claudin-7 expression in poorly differentiated and highly metastatic SW620 colon cancer cells induced epithelial characteristics and inhibited their growth in soft agar and tumor growth in vivo. By contrast, knockdown of claudin-7 in HT-29 or DLD-1 cells induced epithelial-to-mesenchymal transition (EMT), colony formation, xenograft-tumor growth in athymic mice and invasion. Importantly, a claudin-7 signature gene profile generated by overlapping the DEGs (differentially expressed genes in a high-throughput transcriptome analysis using claudin-7-manipulated cells) with human claudin-7 signature genes identified high-risk CRC patients. Furthermore, Rab25, a colon cancer suppressor and regulator of the polarized cell trafficking constituted one of the highly upregulated DEGs in claudin-7 overexpressing cells. Notably, silencing of Rab25 expression counteracted the effects of claudin-7 expression and not only increased proliferation and cell invasion but also increased the expression of p-Src and mitogen-activated protein kinase-extracellular signal-regulated kinase 1/2 that were suppressed upon claudin-7 overexpression. Of interest, CRC cell lines, which exhibited decreased claudin-7 expression, also exhibited promoter DNA hypermethylation, a modification associated with transcriptional silencing. Taken together, our data demonstrate a previously undescribed role of claudin-7 as a colon cancer suppressor and suggest that loss of claudin-7 potentiates EMT to promote colon cancer, in a manner dependent on Rab25.	[Bhat, A. A.; Pope, J. L.; Ahmad, R.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37232 USA; [Pope, J. L.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Smith, J. J.; Beauchamp, R. D.; Singh, A. B.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; [Chen, X.; Singh, A. B.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Beauchamp, R. D.; Dhawan, P.] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; [Beauchamp, R. D.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dhawan, P (corresponding author), Vanderbilt Univ, Med Ctr, Div Surg Oncol, Dept Surg,MCN, B-2211,1161 21st Ave South, Nashville, TN 37232 USA.	punita.dhawan@vanderbilt.edu	Bhat, Ajaz/V-3642-2019; Smith, Jesse Joshua/AAN-5440-2020	Bhat, Ajaz/0000-0003-3640-6275; Smith, Jesse Joshua/0000-0003-2538-5456; Beauchamp, Robert Daniel/0000-0002-8446-4114	VA-merit [BX002086, CA124977, DK088902, CA158472, CA069457]; GI Cancer SPORE grant [CA095103]; Vanderbilt DDRC [P30DK058404, VICC P30CA68485]; StarBRITE funds [VR1258]; NATIONAL CANCER INSTITUTE [R01CA069457, R01CA124977, P50CA095103, R01CA158472, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088902, P30DK058404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM062459] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002086] Funding Source: NIH RePORTER	VA-merit; GI Cancer SPORE grant; Vanderbilt DDRC; StarBRITE funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We are thankful to John Neff and Jalal Hamaamen for their technical support. This work was supported by VA-merit BX002086 and CA124977 (to PD), DK088902 (to ABS), CA158472 (to XC and RDB), CA069457 (to RDB), GI Cancer SPORE grant CA095103, Vanderbilt DDRC P30DK058404, VICC P30CA68485 and StarBRITE funds (no. VR1258).	Bates RC, 2005, CANCER BIOL THER, V4, P365; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Boireau S, 2007, CARCINOGENESIS, V28, P246, DOI 10.1093/carcin/bgl120; Casanova JE, 1999, MOL BIOL CELL, V10, P47, DOI 10.1091/mbc.10.1.47; Caswell PT, 2007, DEV CELL, V13, P496, DOI 10.1016/j.devcel.2007.08.012; Caswell PT, 2006, TRAFFIC, V7, P14, DOI 10.1111/j.1600-0854.2005.00362.x; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cheng JM, 2006, INT J CANCER, V118, P2957, DOI 10.1002/ijc.21739; Cheng JM, 2010, INT J CANCER, V126, P2799, DOI 10.1002/ijc.24900; de Oliveira SS, 2005, FEBS LETT, V579, P6179, DOI 10.1016/j.febslet.2005.09.091; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Ding L, 2012, GASTROENTEROLOGY, V142, P305, DOI 10.1053/j.gastro.2011.10.025; Esteller M, 2001, CANCER RES, V61, P3225; Evron E, 2001, CANCER RES, V61, P2782; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fujita H, 2006, J HISTOCHEM CYTOCHEM, V54, P933, DOI 10.1369/jhc.6A6944.2006; Goldenring JR, 2011, BRIT J CANCER, V104, P33, DOI 10.1038/sj.bjc.6605983; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343; Lourenco SV, 2010, HISTOPATHOLOGY, V57, P689, DOI 10.1111/j.1365-2559.2010.03685.x; Lu Z, 2011, EXP CELL RES, V317, P1935, DOI 10.1016/j.yexcr.2011.05.019; Melchers LJ, 2013, ORAL ONCOL, V49, P998, DOI 10.1016/j.oraloncology.2013.07.008; Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477; Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978; Nam KT, 2010, J CLIN INVEST, V120, P840, DOI 10.1172/JCI40728; Park GB, 2014, INVEST OPHTH VIS SCI, V55, P1770, DOI 10.1167/iovs.13-12988; Pope JL, 2014, GUT, V63, P622, DOI 10.1136/gutjnl-2012-304241; Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Shiou SR, 2007, CANCER RES, V67, P1571, DOI 10.1158/0008-5472.CAN-06-1680; Singh AB, 2011, GASTROENTEROLOGY, V141, P2140, DOI 10.1053/j.gastro.2011.08.038; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toyota M, 1999, CANCER RES, V59, P5438; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turksen K, 2004, J CELL SCI, V117, P2435, DOI 10.1242/jcs.01235; Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018; Yoshizawa K, 2013, ONCOL REP, V29, P445, DOI 10.3892/or.2012.2161	46	57	60	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4570	4580		10.1038/onc.2014.385	http://dx.doi.org/10.1038/onc.2014.385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25500541	Green Accepted			2022-12-17	WOS:000360189300003
J	Lopez-Bertoni, H; Lal, B; Li, A; Caplan, M; Guerrero-Cazares, H; Eberhart, CG; Quinones-Hinojosa, A; Glas, M; Scheffler, B; Laterra, J; Li, Y				Lopez-Bertoni, H.; Lal, B.; Li, A.; Caplan, M.; Guerrero-Cazares, H.; Eberhart, C. G.; Quinones-Hinojosa, A.; Glas, M.; Scheffler, B.; Laterra, J.; Li, Y.			DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; C-MET PATHWAY; DNA METHYLATION; HUMAN GLIOBLASTOMA; MALIGNANT GLIOMA; INITIATING CELLS; GASTRIC-CANCER; TARGETS; DIFFERENTIATION; EXPRESSION	Cancer stem-like cells represent poorly differentiated multipotent tumor-propagating cells that contribute disproportionately to therapeutic resistance and tumor recurrence. Transcriptional mechanisms that control the phenotypic conversion of tumor cells lacking tumor-propagating potential to tumor-propagating stem-like cells remain obscure. Here we show that the reprogramming transcription factors Oct4 and Sox2 induce glioblastoma cells to become stem-like and tumor-propagating via a mechanism involving direct DNA methyl transferase (DNMT) promoter transactivation, resulting in global DNA methylation-and DNMT-dependent downregulation of multiple microRNAs (miRNAs). We show that one such downregulated miRNA, miRNA-148a, inhibits glioblastoma cell stem-like properties and tumor-propagating potential. This study identifies a novel and targetable molecular circuit by which glioma cell stemness and tumor-propagating capacity are regulated.	[Lopez-Bertoni, H.; Lal, B.; Li, A.; Caplan, M.; Laterra, J.; Li, Y.] Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Lopez-Bertoni, H.; Lal, B.; Laterra, J.; Li, Y.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Guerrero-Cazares, H.; Quinones-Hinojosa, A.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Eberhart, C. G.] Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA; [Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [Glas, M.; Scheffler, B.] MediClin Robert Janker Klin, Inst Reconstruct Neurobiol, Bonn, Germany; [Glas, M.; Scheffler, B.] Univ Bonn, Med Ctr, Bonn, Germany; [Glas, M.] MediClin Robert Janker Klin, Dept Neurol, Bonn, Germany; [Glas, M.] Univ Bonn, Med Ctr, Bonn, Germany; [Glas, M.] MediClin Robert Janker Klin, Clin Cooperat Unit Neurooncol, Bonn, Germany; [Laterra, J.; Li, Y.] Univ Bonn, Med Ctr, Bonn, Germany	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Bonn; University of Bonn; University of Bonn	Laterra, J (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, 707 N Broadway, Baltimore, MD 21205 USA.	Laterra@kennedykrieger.org; liyu@kennedykrieger.org	Lopez, Hernando/AAY-7655-2020; Scheffler, Björn/AAA-9361-2021	Lopez, Hernando/0000-0001-6618-1092; Scheffler, Bjorn/0000-0001-8316-6556; Guerrero-Cazares, Hugo/0000-0003-1307-719X; Li, Angela/0000-0002-2881-5557	American Brain Tumor Association; James S McDonnell Foundation; United States NIH [RO1NS073611, R01NS070024]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073611, R01NS070024] Funding Source: NIH RePORTER	American Brain Tumor Association; James S McDonnell Foundation; United States NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Daniel Trageser for technical assistance. This work was financially supported by grants from the American Brain Tumor Association (YL), James S McDonnell Foundation (JL), and the United States NIH grants RO1NS073611 (JL) and R01NS070024 (AQ-H).	Artner I, 2007, P NATL ACAD SCI USA, V104, P3853, DOI 10.1073/pnas.0700013104; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005; Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381; Card DAG, 2008, MOL CELL BIOL, V28, P6426, DOI 10.1128/MCB.00359-08; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502; Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Foltz G, 2009, ONCOGENE, V28, P2667, DOI 10.1038/onc.2009.122; Fowler A, 2011, EUR J CANCER, V47, P953, DOI 10.1016/j.ejca.2010.11.026; Gailhouste L, 2013, HEPATOLOGY, V58, P1153, DOI 10.1002/hep.26422; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Glas M, 2010, ANN NEUROL, V68, P264, DOI 10.1002/ana.22036; Guo SL, 2011, INT J BIOL SCI, V7, P567, DOI 10.7150/ijbs.7.567; Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Li MZ, 2012, TRENDS NEUROSCI, V35, P619, DOI 10.1016/j.tins.2012.06.003; Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946; Li YQ, 2012, CANCER RES, V72, P576, DOI 10.1158/0008-5472.CAN-11-3070; Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108; Li YQ, 2009, CANCER RES, V69, P7569, DOI 10.1158/0008-5472.CAN-09-0529; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Orr BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041036; Piccirillo SGM, 2009, ONCOGENE, V28, P1807, DOI 10.1038/onc.2009.27; Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2; Rath P, 2013, TRANSL ONCOL, V6, P104, DOI 10.1593/tlo.13127; Reijntjes S, 2010, INT J DEV BIOL, V54, P125, DOI 10.1387/ijdb.082783sr; Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011; Singh RP, 2009, CELL TRANSPLANT, V18, P1197, DOI 10.3727/096368909X12483162197204; Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003; Stricker SH, 2013, GENE DEV, V27, P654, DOI 10.1101/gad.212662.112; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398; Wang GY, 2013, P NATL ACAD SCI USA, V110, P2858, DOI 10.1073/pnas.1212769110; Watanabe S, 2010, COLD SH Q B, V75, P35, DOI 10.1101/sqb.2010.75.063; Zhang J. P., 2013, ONCOGENE, V33, P4069; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714	51	57	60	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3994	4004		10.1038/onc.2014.334	http://dx.doi.org/10.1038/onc.2014.334			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25328136	Green Accepted			2022-12-17	WOS:000358544200012
J	Weigel, C; Schmezer, P; Plass, C; Popanda, O				Weigel, C.; Schmezer, P.; Plass, C.; Popanda, O.			Epigenetics in radiation-induced fibrosis	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE INHIBITORS; DNA METHYLATION CHANGES; GROWTH-FACTOR; TGF-BETA; PROMOTER HYPERMETHYLATION; OXIDATIVE STRESS; MYOFIBROBLAST DIFFERENTIATION; FIBROBLAST ACTIVATION; MOLECULAR-MECHANISMS	Radiotherapy is a major cancer treatment option but dose-limiting side effects such as late-onset fibrosis in the irradiated tissue severely impair quality of life in cancer survivors. Efforts to explain radiation-induced fibrosis, for example, by genetic variation remained largely inconclusive. Recently published molecular analyses on radiation response and fibrogenesis showed a prominent role of epigenetic gene regulation. This review summarizes the current knowledge on epigenetic modifications in fibrotic disease and radiation response, and it points out the important role for epigenetic mechanisms such as DNA methylation, microRNAs and histone modifications in the development of this disease. The synopsis illustrates the complexity of radiation-induced fibrosis and reveals the need for investigations to further unravel its molecular mechanisms. Importantly, epigenetic changes are long-term determinants of gene expression and can therefore support those mechanisms that induce and perpetuate fibrogenesis even in the absence of the initial damaging stimulus. Future work must comprise the interconnection of acute radiation response and long-lasting epigenetic effects in order to assess their role in late-onset radiation fibrosis. An improved understanding of the underlying biology is fundamental to better comprehend the origin of this disease and to improve both preventive and therapeutic strategies.	[Weigel, C.; Schmezer, P.; Plass, C.; Popanda, O.] German Canc Res Ctr, Dept Epigen & Canc Risk Factors, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Popanda, O (corresponding author), German Canc Res Ctr, Dept Epigen & Canc Risk Factors C010, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	o.popanda@dkfz.de	Popanda, Odilia/P-6917-2019		Deutsche Krebshilfe [109394]; Helmholtz International Graduation School for Cancer Research	Deutsche Krebshilfe(Deutsche Krebshilfe); Helmholtz International Graduation School for Cancer Research	We apologize to all researchers whose relevant contributions were not cited due to space limitations. This work was supported by a grant from the Deutsche Krebshilfe, project number 109394. CW holds a stipend from the Helmholtz International Graduation School for Cancer Research.	Abderrahmani R, 2009, INT J RADIAT ONCOL, V74, P942, DOI 10.1016/j.ijrobp.2009.01.077; Abrass CK, 2011, AM J PHYSIOL-RENAL, V300, pF531, DOI 10.1152/ajprenal.00237.2010; Alimova I, 2013, NEURO-ONCOLOGY, V15, P149, DOI 10.1093/neuonc/nos285; Almeida C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053628; Amundson SA, 2003, ONCOGENE, V22, P5828, DOI 10.1038/sj.onc.1206681; Andreassen CN, 2009, RADIOTHER ONCOL, V92, P299, DOI 10.1016/j.radonc.2009.06.015; Antwih DA, 2013, EPIGENETICS-US, V8, P839, DOI 10.4161/epi.25498; Ao XP, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-6; Armstrong CA, 2012, EPIGENETICS-US, V7, P892, DOI 10.4161/epi.21094; Arora H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023802; Asuthkar S, 2012, ONCOTARGET, V3, P1439; Balli D, 2013, EMBO J, V32, P231, DOI 10.1038/emboj.2012.336; Bauersachs J, 2010, J CARDIOVASC PHARM, V56, P454, DOI 10.1097/FJC.0b013e3181ee81df; Bechtel W, 2010, NAT MED, V16, P544, DOI 10.1038/nm.2135; Bernardo BC, 2012, P NATL ACAD SCI USA, V109, P17615, DOI 10.1073/pnas.1206432109; Bhattacharyya S, 2005, ARTHRITIS RHEUM-US, V52, P1248, DOI 10.1002/art.20996; Bian EB, 2013, TOXICOLOGY, V309, P9, DOI 10.1016/j.tox.2013.04.008; Bian EB, 2012, TOXICOL APPL PHARM, V264, P13, DOI 10.1016/j.taap.2012.06.022; Bielefeld KA, 2013, CELL MOL LIFE SCI, V70, P2059, DOI 10.1007/s00018-012-1152-9; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bowen T, 2013, J PATHOL, V229, P274, DOI 10.1002/path.4119; Chailleux C, 2010, BIOCHEM J, V426, P365, DOI 10.1042/BJ20091329; Chang-Claude J, 2009, BRIT J CANCER, V100, P1680, DOI 10.1038/sj.bjc.6605036; Chaudhry MA, 2012, DNA CELL BIOL, V31, P908, DOI 10.1089/dna.2011.1509; Cheresh P, 2013, BBA-MOL BASIS DIS, V1832, P1028, DOI 10.1016/j.bbadis.2012.11.021; Chernikova SB, 2010, RADIAT RES, V174, P558, DOI 10.1667/RR2184.1; Chung YL, 2004, MOL CANCER THER, V3, P317; Cisneros J, 2012, AM J PHYSIOL-LUNG C, V303, pL295, DOI 10.1152/ajplung.00332.2011; Coppes RP, 2009, SEMIN RADIAT ONCOL, V19, P112, DOI 10.1016/j.semradonc.2008.11.005; Dai Y, 2013, HYPERTENSION, V61, P751, DOI 10.1161/HYPERTENSIONAHA.111.00654; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; Daugherity EK, 2012, CELL CYCLE, V11, P1918, DOI 10.4161/cc.20259; De Schutter H, 2009, INT J RADIAT ONCOL, V73, P904, DOI 10.1016/j.ijrobp.2008.10.032; Dees C, 2014, ANN RHEUM DIS, V73, P1232, DOI 10.1136/annrheumdis-2012-203194; Dickey JS, 2011, RADIAT ENVIRON BIOPH, V50, P491, DOI 10.1007/s00411-011-0386-5; Dickey JS, 2009, CARCINOGENESIS, V30, P1686, DOI 10.1093/carcin/bgp192; Dong QH, 2011, J INVEST DERMATOL, V131, P1216, DOI 10.1038/jid.2011.11; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; FitzGerald J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014714; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Fujii H, 2012, J GASTROENTEROL, V47, P215, DOI 10.1007/s00535-012-0527-x; Gaugler MH, 2005, RADIAT RES, V163, P479, DOI 10.1667/RR3302; Ghosh AK, 2004, J BIOL CHEM, V279, P47455, DOI 10.1074/jbc.M403477200; Ghosh AK, 2007, J CELL PHYSIOL, V213, P663, DOI 10.1002/jcp.21162; Goodarzi AA, 2011, NAT STRUCT MOL BIOL, V18, P831, DOI 10.1038/nsmb.2077; Gottlober P, 2001, INT J RADIAT ONCOL, V50, P159, DOI 10.1016/S0360-3016(00)01542-X; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo CY, 2000, CANCER RES, V60, P5667; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Haase MG, 2008, RADIAT RES, V169, P531, DOI 10.1667/RR0946.1; Hamama S, 2012, RADIOTHER ONCOL, V105, P305, DOI 10.1016/j.radonc.2012.08.023; Haydont V, 2008, AM J PHYSIOL-CELL PH, V294, pC1332, DOI 10.1152/ajpcell.90626.2007; He Y, 2012, CELL SIGNAL, V24, P2268, DOI 10.1016/j.cellsig.2012.07.023; Hinz B, 2007, AM J PATHOL, V170, P1807, DOI 10.2353/ajpath.2007.070112; Hofstetter B, 2010, INT J RADIAT ONCOL, V76, P1512, DOI 10.1016/j.ijrobp.2009.10.037; Hromas R, 2012, ONCOGENE, V31, P4245, DOI 10.1038/onc.2011.586; Hu B, 2011, AM J PATHOL, V178, P1500, DOI 10.1016/j.ajpath.2011.01.002; Hu B, 2010, AM J PATHOL, V177, P21, DOI 10.2353/ajpath.2010.090999; Hu SY, 2009, INT J RADIAT ONCOL, V75, P1537, DOI 10.1016/j.ijrobp.2009.07.1697; Huang N, 2012, BIOCHEM BIOPH RES CO, V422, P697, DOI 10.1016/j.bbrc.2012.05.061; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Imaeda M, J RADIAT RES, DOI [10.1093/jrr/rru005, DOI 10.1093/JRR/RRU005)]; Jiang X, 2010, FEBS J, V277, P2015, DOI 10.1111/j.1742-4658.2010.07632.x; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Kalash R, 2014, IN VIVO, V28, P147; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kaup S, 2006, MUTAT RES-FUND MOL M, V597, P87, DOI 10.1016/j.mrfmmm.2005.06.032; Khan S, 2004, ONCOGENE, V23, P6040, DOI 10.1038/sj.onc.1207824; Kim EH, 2010, ONCOGENE, V29, P4725, DOI 10.1038/onc.2010.223; Kim IG, 2014, BIOCHEM BIOPH RES CO, V443, P49, DOI 10.1016/j.bbrc.2013.11.038; Kis E, 2006, INT J RADIAT ONCOL, V66, P1506, DOI 10.1016/j.ijrobp.2006.08.004; Ko YA, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r108; Komatsu Y, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-5; Koturbash I, 2006, ONCOGENE, V25, P4267, DOI 10.1038/sj.onc.1209467; Koturbash I, 2007, CARCINOGENESIS, V28, P1831, DOI 10.1093/carcin/bgm053; Koturbash I, 2006, INT J RADIAT ONCOL, V66, P327, DOI 10.1016/j.ijrobp.2006.06.012; Kramer M, 2013, ANN RHEUM DIS, V72, P614, DOI 10.1136/annrheumdis-2012-201615; Krenning G, 2010, J CELL PHYSIOL, V225, P631, DOI 10.1002/jcp.22322; Kruse JJCM, 2009, RADIAT RES, V171, P188, DOI 10.1667/RR1526.1; Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048; Kumar A, 2011, INT J RADIAT BIOL, V87, P1086, DOI 10.3109/09553002.2011.605417; Lahtz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044858; Lakner AM, 2012, HEPATOLOGY, V56, P300, DOI 10.1002/hep.25613; Li CG, 1999, INT J CANCER, V84, P155, DOI 10.1002/(SICI)1097-0215(19990420)84:2<155::AID-IJC11>3.0.CO;2-S; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10; Linard C, 2008, J PHARMACOL EXP THER, V324, P911, DOI 10.1124/jpet.107.129122; Liu DG, 2008, CHINESE MED J-PEKING, V121, P1925, DOI 10.1097/00029330-200810010-00014; Malik IA, 2010, AM J PATHOL, V176, P1801, DOI 10.2353/ajpath.2010.090505; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Mancuso M, 2008, P NATL ACAD SCI USA, V105, P12445, DOI 10.1073/pnas.0804186105; Mann J, 2010, GASTROENTEROLOGY, V138, P705, DOI 10.1053/j.gastro.2009.10.002; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002; Milliat F, 2006, AM J PATHOL, V169, P1484, DOI 10.2353/ajpath.2006.060116; Moding EJ, 2013, NAT REV DRUG DISCOV, V12, P526, DOI 10.1038/nrd4003; Moriconi F, 2008, RADIAT RES, V169, P162, DOI 10.1667/RR1006.1; Mothersill Carmel, 2012, Frontiers in Genetics, V3, P74, DOI 10.3389/fgene.2012.00074; Nadlonek NA, 2012, J THORAC CARDIOV SUR, V144, P1466, DOI 10.1016/j.jtcvs.2012.08.041; Nawroth I, 2013, ACTA ONCOL, V52, P1730, DOI 10.3109/0284186X.2012.726373; Nguyen AT, 2011, GENE DEV, V25, P263, DOI 10.1101/gad.2018511; Niemantsverdriet M, 2010, RADIOTHER ONCOL, V97, P33, DOI 10.1016/j.radonc.2010.04.002; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Oliva J, 2009, WORLD J GASTROENTERO, V15, P705, DOI 10.3748/wjg.15.705; Ostrau C, 2009, RADIOTHER ONCOL, V92, P492, DOI 10.1016/j.radonc.2009.06.020; Pandit KV, 2011, TRANSL RES, V157, P191, DOI 10.1016/j.trsl.2011.01.012; Pandit KV, 2010, AM J RESP CRIT CARE, V182, P220, DOI 10.1164/rccm.200911-1698OC; Pandita TK, 2009, NUCLEIC ACIDS RES, V37, P1363, DOI 10.1093/nar/gkn1071; Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641; Patel V, 2012, CURR OPIN NEPHROL HY, V21, P410, DOI 10.1097/MNH.0b013e328354e559; Penicud K, 2014, ONCOGENE, V33, P525, DOI 10.1038/onc.2012.597; Perugorria MJ, 2012, HEPATOLOGY, V56, P1129, DOI 10.1002/hep.25754; Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074; Pohlers D, 2009, BBA-MOL BASIS DIS, V1792, P746, DOI 10.1016/j.bbadis.2009.06.004; Polistena A, 2011, J SURG RES, V167, pE137, DOI 10.1016/j.jss.2010.12.031; Popanda O, 2009, MUTAT RES-FUND MOL M, V667, P58, DOI 10.1016/j.mrfmmm.2008.10.014; Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011; Prunotto M, 2012, J PATHOL, V228, P131, DOI 10.1002/path.4049; Purrucker JC, 2010, ONCOL REP, V23, P263, DOI 10.3892/or_00000632; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Qin L, 2010, AM J PATHOL, V177, P1915, DOI 10.2353/ajpath.2010.100011; Rabinovich EI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033770; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Rave-Frank M, 2013, RADIAT ENVIRON BIOPH, V52, P321, DOI 10.1007/s00411-013-0468-7; Rivera AL, 2010, NEURO-ONCOLOGY, V12, P116, DOI 10.1093/neuonc/nop020; Roderburg C, 2011, HEPATOLOGY, V53, P209, DOI 10.1002/hep.23922; Rossetto D, 2010, CLIN CANCER RES, V16, P4543, DOI 10.1158/1078-0432.CCR-10-0513; Rugo RE, 2011, ONCOGENE, V30, P751, DOI 10.1038/onc.2010.480; Ruiz-Ortega M, 2007, CARDIOVASC RES, V74, P196, DOI 10.1016/j.cardiores.2007.02.008; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Sanders YY, 2008, AM J RESP CELL MOL, V39, P610, DOI 10.1165/rcmb.2007-0322OC; Sanders YY, 2012, AM J RESP CRIT CARE, V186, P525, DOI 10.1164/rccm.201201-0077OC; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Sequeira-Lopez MLS, 2010, J AM SOC NEPHROL, V21, P460, DOI 10.1681/ASN.2009090964; Shan B, 2003, J BIOL CHEM, V278, P44009, DOI 10.1074/jbc.M302671200; Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09; Shintani S, 2010, INT J ORAL MAX SURG, V39, P1115, DOI 10.1016/j.ijom.2010.02.027; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Simon M, 2006, ONCOL REP, V16, P127; Skalicka ZF, 2012, J PHOTOCH PHOTOBIO B, V117, P111, DOI 10.1016/j.jphotobiol.2012.08.009; Sparfel L, 2010, TOXICOL SCI, V114, P247, DOI 10.1093/toxsci/kfq007; Sperk E, 2012, BREAST CANCER RES TR, V135, P253, DOI 10.1007/s10549-012-2168-4; Srivastava SP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/125469; STONE HB, 1984, INT J RADIAT ONCOL, V10, P1053, DOI 10.1016/0360-3016(84)90177-9; Sun CY, 2012, KIDNEY INT, V81, P640, DOI 10.1038/ki.2011.445; Sun GD, 2010, J AM SOC NEPHROL, V21, P2069, DOI 10.1681/ASN.2010060633; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Suzuki M, 2003, ONCOGENE, V22, P8688, DOI 10.1038/sj.onc.1207182; Tampe B, 2014, J AM SOC NEPHROL, V25, P905, DOI 10.1681/ASN.2013070723; Tang XY, 2013, MOL PHARMACOL, V83, P283, DOI 10.1124/mol.112.081661; Tao H, 2011, TOXICOLOGY, V290, P327, DOI 10.1016/j.tox.2011.10.011; Thariat J, 2013, NAT REV CLIN ONCOL, V10, P52, DOI 10.1038/nrclinonc.2012.203; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; Veldwijk MR, 2009, STRAHLENTHER ONKOL, V185, P517, DOI 10.1007/s00066-009-1973-0; Volkmann I, 2013, CIRC RES, V113, P997, DOI 10.1161/CIRCRESAHA.113.301702; Wang YQ, 2006, ARTHRITIS RHEUM-US, V54, P2271, DOI 10.1002/art.21948; Weichenhan D, 2013, HUM MOL GENET, V22, pR1, DOI 10.1093/hmg/ddt348; Westbury CB, 2012, CLIN ONCOL-UK, V24, P657, DOI 10.1016/j.clon.2012.04.001; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu CH, 2012, J BIOL CHEM, V287, P25292, DOI 10.1074/jbc.M111.291195; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xiao CY, 2012, J BIOL CHEM, V287, P41903, DOI 10.1074/jbc.M112.415182; Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851; Xu B, 2012, AM J PHYSIOL-LUNG C, V303, pL89, DOI 10.1152/ajplung.00060.2012; Yang JJ, 2013, CELL SIGNAL, V25, P1202, DOI 10.1016/j.cellsig.2013.01.005; Yarnold J, 2010, RADIOTHER ONCOL, V97, P149, DOI 10.1016/j.radonc.2010.09.002; Zager RA, 2009, AM J PHYSIOL-RENAL, V296, pF1032, DOI 10.1152/ajprenal.00061.2009; Zeisberg EM, 2013, J PATHOL, V229, P264, DOI 10.1002/path.4120; Zeybel M, 2012, NAT MED, V18, P1369, DOI 10.1038/nm.2893; Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024680; Zhang Y, 2010, INT J RADIAT BIOL, V86, P964, DOI 10.3109/09553002.2010.496032; Zhao LQ, 2013, CELL SIGNAL, V25, P1625, DOI 10.1016/j.cellsig.2013.04.004; Zhao WL, 2009, CURR MED CHEM, V16, P130, DOI 10.2174/092986709787002790; Zhu FL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074535; Zhu NL, 2012, J BIOL CHEM, V287, P10355, DOI 10.1074/jbc.M111.312751; Zvaifler NJ, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1963	183	57	60	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2015	34	17					2145	2155		10.1038/onc.2014.145	http://dx.doi.org/10.1038/onc.2014.145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG7HG	24909163				2022-12-17	WOS:000353473000001
J	Robinson, JLL; Hickey, TE; Warren, AY; Vowler, SL; Carroll, T; Lamb, AD; Papoutsoglou, N; Neal, DE; Tilley, WD; Carroll, JS				Robinson, J. L. L.; Hickey, T. E.; Warren, A. Y.; Vowler, S. L.; Carroll, T.; Lamb, A. D.; Papoutsoglou, N.; Neal, D. E.; Tilley, W. D.; Carroll, J. S.			Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype	ONCOGENE			English	Article						androgen receptor; FOXA1; prostate cancer; CRPC; genomics	RESISTANT PROSTATE-CANCER; FORKHEAD-BOX A1; ESTROGEN-RECEPTOR; BREAST-CANCER; INCREASED SURVIVAL; TRANSCRIPTION; PROGRESSION; GENOME; COREGULATORS; EXPRESSION	Castration-resistant prostate cancer (CRPC) continues to pose a significant clinical challenge with new generation second-line hormonal therapies affording limited improvement in disease outcome. As the androgen receptor (AR) remains a critical driver in CRPC, understanding the determinants of its transcriptional activity is important for developing new AR-targeted therapies. FOXA1 is a key component of the AR transcriptional complex yet its role in prostate cancer progression and the relationship between AR and FOXA1 are not completely resolved. It is well established that FOXA1 levels are elevated in advanced prostate cancer and metastases. We mimicked these conditions by overexpressing FOXA1 in the androgen-responsive LNCaP prostate cancer cell line and observed a significant increase in AR genomic binding at novel regions that possess increased chromatin accessibility. High levels of FOXA1 resulted in increased proliferation at both sub-optimal and high 5 alpha-dihydrotestosterone (DHT) concentrations. Immunohistochemical staining for FOXA1 in a clinical prostate cancer cohort revealed that high FOXA1 expression is associated with shorter time to biochemical recurrence after radical prostatectomy (hazard ratio (HR) 5.0, 95% confidence interval (CI) 1.2-21.1, P = 0.028), positive surgical margins and higher stage disease at diagnosis. The gene expression program that results from FOXA1 overexpression is enriched for PTEN, Wnt and other pathways typically represented in CRPC gene signatures. Together, these results suggest that in an androgen-depleted state, elevated levels of FOXA1 enhance AR binding at genomic regions not normally occupied by AR, which in turn facilitates prostate cancer cell growth.	[Robinson, J. L. L.; Vowler, S. L.; Carroll, T.; Lamb, A. D.; Neal, D. E.; Carroll, J. S.] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge CB2 0RE, England; [Robinson, J. L. L.; Vowler, S. L.; Carroll, T.; Lamb, A. D.; Neal, D. E.; Carroll, J. S.] Univ Cambridge, Dept Oncol, Cambridge CB2 0RE, England; [Hickey, T. E.; Neal, D. E.; Tilley, W. D.] Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Labs, Adelaide, SA, Australia; [Hickey, T. E.; Neal, D. E.; Tilley, W. D.] Univ Adelaide, Sch Med, Adelaide Prostate Canc Res Ctr, Adelaide, SA, Australia; [Warren, A. Y.] Cambridge Univ Hosp NHS Foundat Trust, Dept Histopathol, Cambridge, England; [Lamb, A. D.; Papoutsoglou, N.] Cambridge Univ Hosp NHS Foundat Trust, Dept Urol, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Adelaide; University of Adelaide	Carroll, JS (corresponding author), Univ Cambridge, Canc Res UK Cambridge Inst, Robinson Way, Cambridge CB2 0RE, England.	jason.carroll@cruk.cam.ac.uk	Lamb, Alastair/AAD-6375-2019	Hickey, Theresa/0000-0002-2752-730X; Tilley, Wayne/0000-0003-1893-2626; Carroll, Jason/0000-0003-3643-0080; Neal, David/0000-0002-6033-5086	University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited; National Health and Medical Research Council of Australia [627185]; Cancer Australia [627229]; Prostate Cancer Foundation of Australia; US Department of Defense Breast Cancer Research Program (BCRP) [W81XWH-11-1-0592]; ERC starting grant; EMBO Young Investigator Award; Cancer Research UK [15602, 22310] Funding Source: researchfish; National Institute for Health Research [CL-2012-14-003] Funding Source: researchfish	University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); Hutchison Whampoa Limited; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Australia; Prostate Cancer Foundation of Australia; US Department of Defense Breast Cancer Research Program (BCRP)(United States Department of Defense); ERC starting grant(European Research Council (ERC)); EMBO Young Investigator Award(European Molecular Biology Organization (EMBO)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We would like to thank the members of the genomic, proteomic and histopathology core facilities at Cancer Research UK. We would like to acknowledge the support of The University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited. We are grateful to study volunteers for their participation and staff at the Welcome Trust Clinical Research Facility, Addenbrooke's Clinical Research Centre, Cambridge. WDT is supported by grants from the National Health and Medical Research Council of Australia (ID 627185), Cancer Australia (ID 627229) and the Prostate Cancer Foundation of Australia. TEH holds a Postdoctoral Fellowship Award from the US Department of Defense Breast Cancer Research Program (BCRP; #W81XWH-11-1-0592). JSC is supported by an ERC starting grant and an EMBO Young Investigator Award.	Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Cairns JM, 2008, BIOINFORMATICS, V24, P2921, DOI 10.1093/bioinformatics/btn557; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Decker KF, 2012, NUCLEIC ACIDS RES, V40, P10765, DOI 10.1093/nar/gks888; Deutsch L, 2012, GENE CHROMOSOME CANC, V51, P618, DOI 10.1002/gcc.21950; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311; Gao N, 2005, DEVELOPMENT, V132, P3431, DOI 10.1242/dev.01917; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gerhardt J, 2012, AM J PATHOL, V180, P848, DOI 10.1016/j.ajpath.2011.10.021; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Imamura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042456; Jain RK, 2011, HISTOPATHOLOGY, V58, P766, DOI 10.1111/j.1365-2559.2011.03796.x; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Jung C, 2004, CANCER RES, V64, P9185, DOI 10.1158/0008-5472.CAN-04-1330; Kikuchi M, 2009, BBA-MOL CELL RES, V1793, P1828, DOI 10.1016/j.bbamcr.2009.11.001; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Liao GQ, 2003, J BIOL CHEM, V278, P5052, DOI 10.1074/jbc.M206374200; Lin L, 2002, CANCER RES, V62, P5273; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Mahajan MC, 2005, P NATL ACAD SCI USA, V102, P15012, DOI 10.1073/pnas.0507596102; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Nucera C, 2009, CLIN CANCER RES, V15, P3680, DOI 10.1158/1078-0432.CCR-08-3155; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sahu B, 2013, CANCER RES, V73, P1570, DOI 10.1158/0008-5472.CAN-12-2350; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Scher HI, 2004, ENDOCR-RELAT CANCER, V11, P459, DOI 10.1677/erc.1.00525; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Sharma NL, 2013, CANCER CELL, V23, P35, DOI 10.1016/j.ccr.2012.11.010; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Waltering KK, 2012, MOL CELL ENDOCRINOL, V360, P38, DOI 10.1016/j.mce.2011.12.019; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang L, 2013, J CLIN NEUROSCI, V20, P654, DOI 10.1016/j.jocn.2012.03.055; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Whitaker HC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013363; Zhang CP, 2011, CANCER RES, V71, P6738, DOI 10.1158/0008-5472.CAN-11-1882	54	57	58	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5666	5674		10.1038/onc.2013.508	http://dx.doi.org/10.1038/onc.2013.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24292680	Green Accepted, Green Submitted			2022-12-17	WOS:000346089300002
J	Berger, AH; Imielinski, M; Duke, F; Wala, J; Kaplan, N; Shi, GX; Andres, DA; Meyerson, M				Berger, A. H.; Imielinski, M.; Duke, F.; Wala, J.; Kaplan, N.; Shi, G-X; Andres, D. A.; Meyerson, M.			Oncogenic RIT1 mutations in lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinoma; cancer genetics; RAS pathway; signal transduction; oncogene; GTPase	EML4-ALK FUSION GENE; NEURONAL DIFFERENTIATION; KINASE INHIBITOR; KRAS MUTATIONS; CANCER; GEFITINIB; PROTEIN; SENSITIVITY; ACTIVATION; GENOME	Lung adenocarcinoma is comprised of distinct mutational subtypes characterized by mutually exclusive oncogenic mutations in RTK/RAS pathway members KRAS, EGFR, BRAF and ERBB2, and translocations involving ALK, RET and ROS1. Identification of these oncogenic events has transformed the treatment of lung adenocarcinoma via application of therapies targeted toward specific genetic lesions in stratified patient populations. However, such mutations have been reported in only similar to 55% of lung adenocarcinoma cases in the United States, suggesting other mechanisms of malignancy are involved in the remaining cases. Here we report somatic mutations in the small GTPase gene RIT1 in similar to 2% of lung adenocarcinoma cases that cluster in a hotspot near the switch II domain of the protein. RIT1 switch II domain mutations are mutually exclusive with all other known lung adenocarcinoma driver mutations. Ectopic expression of mutated RIT1 induces cellular transformation in vitro and in vivo, which can be reversed by combined PI3K and MEK inhibition. These data identify RIT1 as a driver oncogene in a specific subset of lung adenocarcinomas and suggest PI3K and MEK inhibition as a potential therapeutic strategy in RIT1-mutated tumors.	[Berger, A. H.; Imielinski, M.; Duke, F.; Wala, J.; Meyerson, M.] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA; [Berger, A. H.; Imielinski, M.; Wala, J.; Kaplan, N.; Meyerson, M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Imielinski, M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Imielinski, M.; Meyerson, M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Wala, J.] MIT, Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Shi, G-X; Andres, D. A.] Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); University of Kentucky	Meyerson, M (corresponding author), Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Shi, Geng-Xian/AAK-6061-2021	Meyerson, Matthew/0000-0002-9133-8108	American Cancer Society; NCI Training Grant [T32CA9216]; NIH Training Grant [T32HG002295]; NIH [NS045103]; KSCHIRT [12-1A]; University of Kentucky Research Professorship; Department of Defense [W81XWH-12-1-0269]; National Cancer Institute [P01CA154303, R01CA109038]; Uniting Against Lung Cancer; Lung Cancer Research Foundation; American Lung Association; NATIONAL CANCER INSTITUTE [U24CA143867, T32CA009216, R01CA109038, P01CA154303] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG002295] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045103, R56NS045103] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NCI Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); KSCHIRT; University of Kentucky Research Professorship; Department of Defense(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Uniting Against Lung Cancer; Lung Cancer Research Foundation; American Lung Association; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank A. Brooks, P. Choi, H. Gannon, H. Greulich, L. De Waal, B. Kaplan, R. Liao, T. Sharifnia, J. Boehm and A. Koehler for critical advice and discussion. AHB is supported by a postdoctoral fellowship from the American Cancer Society. MI is supported by NCI Training Grant T32CA9216. JW is supported by NIH Training Grant T32HG002295. DAA is supported by NIH NS045103, KSCHIRT 12-1A, and a University of Kentucky Research Professorship. This work was supported by grants from the Department of Defense (#W81XWH-12-1-0269) National Cancer Institute (P01CA154303 and R01CA109038), Uniting Against Lung Cancer, the Lung Cancer Research Foundation and the American Lung Association to MM.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Aoki Y, 2013, AM J HUM GENET, V93, P173, DOI 10.1016/j.ajhg.2013.05.021; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Cai WK, 2011, MOL BIOL CELL, V22, P3231, DOI 10.1091/mbc.E11-05-0400; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Forbes S, 2006, BRIT J CANCER, V94, P318, DOI 10.1038/sj.bjc.6602928; Gomez-Segui I, 2013, LEUKEMIA, V27, P1943, DOI 10.1038/leu.2013.179; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Janne PA, 2012, J CLIN ONCOL, V30, P878, DOI 10.1200/JCO.2011.39.4197; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; O'Brien C, 2010, CLIN CANCER RES, V16, P3670, DOI 10.1158/1078-0432.CCR-09-2828; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pao W, 2012, NAT MED, V18, P349, DOI 10.1038/nm.2697; Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Seo JS, 2012, GENOME RES, V22, P2109, DOI 10.1101/gr.145144.112; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shi GX, 2006, MOL CELL BIOL, V26, P9136, DOI 10.1128/MCB.00332-06; Shi GX, 2005, MOL CELL BIOL, V25, P830, DOI 10.1128/MCB.25.2.830-846.2005; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/NMETH.1638, 10.1038/nmeth.1638]; Zenker M, 2007, J MED GENET, V44, P131, DOI 10.1136/jmg.2006.046300	43	57	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4418	4423		10.1038/onc.2013.581	http://dx.doi.org/10.1038/onc.2013.581			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24469055	Green Published, hybrid			2022-12-17	WOS:000341157800006
J	Kim, IG; Kim, SY; Choi, SI; Lee, JH; Kim, KC; Cho, EW				Kim, I. G.; Kim, S. Y.; Choi, S. I.; Lee, J. H.; Kim, K. C.; Cho, E. W.			Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH plus lung cancer stem cells through IGF1R signaling	ONCOGENE			English	Article						FBLN3; lung; EMT; cancer stem cells; IGF1R/PI3K/AKT/GSK3 beta pathway	GROWTH-FACTOR RECEPTOR; GLIOMA GROWTH; BETA-CATENIN; TGF-BETA; PATHWAY; RESISTANCE; INVASION; INSULIN; TARGET; PROGRESSION	Fibulins (FBLNs), a family of extracellular matrix proteins, have recently been shown to act as tumor suppressors or activators in different cancers, and the underlying molecular mechanisms of their action in cancer remain unclear. We have previously shown that the expression of FBLN3 is suppressed by promoter hypermethylation and is associated with invasiveness in aggressive non-small cell lung cancer. In this study, we evaluated the roles and signaling mechanism of FBLN3 in lung cancer stem cells (CSCs). Forced expression of FBLN3 suppressed invasion and migration of lung adenocarcinoma cells and decreased the expression of epithelial-to-mesenchymal transition (EMT) activators, including N-cadherin and Snail. Stemness activities of lung adenocarcinoma cells were also suppressed by FBLN3 as indicated by a decrease in spheroid formation and the levels of stemness markers such as Sox2 and beta-catenin. These effects of FBLN3 were mediated by the glycogen synthase kinase-3 beta, GSK3 beta/beta-catenin pathway, and the upstream regulators of GSK3 beta, including phosphoinositide 3-kinase (PI3K)/AKT and insulin-like growth factor-1 receptor (IGF1R), were inactivated by FBLN3. Moreover, IGF1R was shown to be a direct target of FBLN3, which competitively inhibited insulin-like growth factor (IGF) action. To confirm the effect of FBLN3 on lung CSCs, aldehyde dehydrogenase-positive (ALDH +) A549 lung CSCs were sorted and treated with recombinant FBLN3 protein. FBLN3 clearly suppressed EMT, stemness activity and the over-activated IGF1R/PI3K/AKT/GSK3 beta pathway of the ALDH + CSC subpopulation. In addition, injection of recombinant FBLN3 protein around subcutaneous xenografts established with ALDH + CSCs in athymic nude mice significantly suppressed tumor growth and progression. Overall, our results show that FBLN3 suppresses both EMT and self-renewal of the lung CSCs by modulating the IGF1R/PI3K/AKT/GSK3 beta pathway and that FBLN3 would be useful as an alternative CSC therapy.	[Kim, I. G.; Kim, S. Y.; Choi, S. I.; Lee, J. H.; Kim, K. C.] KAERI, Environm Radiat Res Grp, Dept Radiat Biol, Taejon 305353, South Korea; [Kim, I. G.; Choi, S. I.; Lee, J. H.] Univ Sci & Technol, Dept Radiat Biotechnol & Appl Radioisotope, Taejon, South Korea; [Cho, E. W.] Korea Res Inst Biosci & Biotechnol, Canc Biomarkers Dev Res Ctr, Taejon, South Korea	Korea Atomic Energy Research Institute (KAERI); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Kim, IG (corresponding author), KAERI, Environm Radiat Res Grp, Dept Radiat Biol, 989-111 Daedeok daero, Taejon 305353, South Korea.	igkim@kaeri.re.kr			Ministry of Science, ICT & Future Planning (Nuclear Research and Development Program) of the Republic of Korea; Korea Atomic Energy Research Institute	Ministry of Science, ICT & Future Planning (Nuclear Research and Development Program) of the Republic of Korea; Korea Atomic Energy Research Institute	We acknowledge the financial supports from the Ministry of Science, ICT & Future Planning (Nuclear Research and Development Program) of the Republic of Korea and basic program of Korea Atomic Energy Research Institute.	Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Araki K, 2011, BRIT J CANCER, V105, P1885, DOI 10.1038/bjc.2011.452; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Bill A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041179; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brognard J, 2001, CANCER RES, V61, P3986; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Cappuzzo F, 2010, ANN ONCOL, V21, P562, DOI 10.1093/annonc/mdp357; de Vega S, 2009, CELL MOL LIFE SCI, V66, P1890, DOI 10.1007/s00018-009-8632-6; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Desbois-Mouthon C, 2009, CLIN CANCER RES, V15, P5445, DOI 10.1158/1078-0432.CCR-08-2980; Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Esposito L, 2010, CURR GENOMICS, V11, P513, DOI 10.2174/138920210793175903; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gorelik E, 2010, ANTI-CANCER AGENT ME, V10, P164, DOI 10.2174/187152010790909308; Heist RS, 2009, PHARMACOGENOMICS, V10, P59, DOI 10.2217/14622416.10.1.59; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hu B, 2009, MOL CANCER RES, V7, P1756, DOI 10.1158/1541-7786.MCR-09-0207; Hu YJ, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-123; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Ischenko I, 2008, CURR MED CHEM, V15, P3171, DOI 10.2174/092986708786848541; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jiang TY, 2009, CANCER RES, V69, P845, DOI 10.1158/0008-5472.CAN-08-2762; Jiang YG, 2007, INT J UROL, V14, P1034, DOI 10.1111/j.1442-2042.2007.01866.x; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Kim EJ, 2012, INT J ONCOL, V40, P402, DOI 10.3892/ijo.2011.1191; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McCubrey JA, 2012, CURR PHARM DESIGN, V18, P1784; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Morrison R, 2011, J ONCOL, V2011, DOI 10.1155/2011/941876; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Perona R, 2011, CLIN TRANSL ONCOL, V13, P289, DOI 10.1007/s12094-011-0656-3; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838; Rivera C, 2011, J ONCOL, V2011, DOI 10.1155/2011/549181; Rui W, 2010, LUNG CANCER, V69, P239, DOI 10.1016/j.lungcan.2009.10.009; Schiemann WP, 2002, J BIOL CHEM, V277, P27367, DOI 10.1074/jbc.M200148200; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Ucar D, 2009, CHEM-BIOL INTERACT, V178, P48, DOI 10.1016/j.cbi.2008.09.029; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yang JL, 2011, CLIN CANCER RES, V17, P7563, DOI 10.1158/1078-0432.CCR-11-1707; Yue W, 2009, CANCER RES, V69, P6339, DOI 10.1158/0008-5472.CAN-09-0398	53	57	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3908	3917		10.1038/onc.2013.373	http://dx.doi.org/10.1038/onc.2013.373			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24013232				2022-12-17	WOS:000339394700003
J	Goard, CA; Schimmer, AD				Goard, C. A.; Schimmer, A. D.			Mitochondrial matrix proteases as novel therapeutic targets in malignancy	ONCOGENE			English	Review						mitochondrial protease; m-AAA; ClpP; Lon; AAA; protein quality control	M-AAA PROTEASE; DEPENDENT LON PROTEASE; HEREDITARY SPASTIC PARAPLEGIA; ESCHERICHIA-COLI CLPP; RESPIRATORY-CHAIN COMPLEXES; ELECTRON-TRANSPORT CHAIN; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; CRYSTAL-STRUCTURE; SERINE-PROTEASE	Although mitochondrial function is often altered in cancer, it remains essential for tumor viability. Tight control of protein homeostasis is required for the maintenance of mitochondrial function, and the mitochondrial matrix houses several coordinated protein quality control systems. These include three evolutionarily conserved proteases of the AAA + superfamily-the Lon, ClpXP and m-AAA proteases. In humans, these proteases are proposed to degrade, process and chaperone the assembly of mitochondrial proteins in the matrix and inner membrane involved in oxidative phosphorylation, mitochondrial protein synthesis, mitochondrial network dynamics and nucleoid function. In addition, these proteases are upregulated by a variety of mitochondrial stressors, including oxidative stress, unfolded protein stress and imbalances in respiratory complex assembly. Given that tumor cells must survive and proliferate under dynamic cellular stress conditions, dysregulation of mitochondrial protein quality control systems may provide a selective advantage. The association of mitochondrial matrix AAA + proteases with cancer and their potential for therapeutic modulation therefore warrant further consideration. Although our current knowledge of the endogenous human substrates of these proteases is limited, we highlight functional insights gained from cultured human cells, protease-deficient mouse models and other eukaryotic model organisms. We also review the consequences of disrupting mitochondrial matrix AAA + proteases through genetic and pharmacological approaches, along with implications of these studies on the potential of these proteases as anticancer therapeutic targets.	[Goard, C. A.; Schimmer, A. D.] Ontario Canc Inst, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Schimmer, AD (corresponding author), Ontario Canc Inst, Princess Margaret Canc Ctr, Univ Hlth Network, 610 Univ Ave,Room 9-516, Toronto, ON M5G 2M9, Canada.	aaron.schimmer@utoronto.ca		Schimmer, Aaron/0000-0003-4023-3899				Almajan ER, 2012, J CLIN INVEST, V122, P4048, DOI 10.1172/JCI64604; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Apweiler R, 2012, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/nar/gkr981; Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Augustin S, 2009, MOL CELL, V35, P574, DOI 10.1016/j.molcel.2009.07.018; Bakala H, 2003, EUR J BIOCHEM, V270, P2295, DOI 10.1046/j.1432-1033.2003.03598.x; Baker TA, 2012, BBA-MOL CELL RES, V1823, P15, DOI 10.1016/j.bbamcr.2011.06.007; Balsa E, 2012, CELL METAB, V16, P378, DOI 10.1016/j.cmet.2012.07.015; Banfi S, 1999, GENOMICS, V59, P51, DOI 10.1006/geno.1999.5818; Bayot A, 2008, BIOCHIMIE, V90, P260, DOI 10.1016/j.biochi.2007.10.010; Bayot A, 2010, J BIOL CHEM, V285, P11445, DOI 10.1074/jbc.M109.065425; Bender T, 2011, MOL BIOL CELL, V22, P541, DOI 10.1091/mbc.E10-08-0718; Bender T, 2010, PROTEOMICS, V10, P1426, DOI 10.1002/pmic.200800619; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Bernstein SH, 2012, BLOOD, V119, P3321, DOI 10.1182/blood-2011-02-340075; Bottcher T, 2008, J AM CHEM SOC, V130, P14400, DOI 10.1021/ja8051365; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Bonn F, 2011, EMBO J, V30, P2545, DOI 10.1038/emboj.2011.169; Bonn F, 2010, HUM MUTAT, V31, P617, DOI 10.1002/humu.21226; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2005, FREE RADICAL BIO MED, V38, P665, DOI 10.1016/j.freeradbiomed.2004.11.017; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Brotz-Oesterhelt H, 2005, NAT MED, V11, P1082, DOI 10.1038/nm1306; Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Chen B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004374; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; Chondrogianni N, 2012, PROG MOL BIOL TRANSL, V109, P41, DOI 10.1016/B978-0-12-397863-9.00002-X; Cole A, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.3603.3603; Corydon TJ, 2000, MAMM GENOME, V11, P899, DOI 10.1007/s003350010173; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; da Fonseca PCA, 2012, MOL CELL, V46, P54, DOI 10.1016/j.molcel.2012.03.026; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; de Sagarra MR, 1999, J MOL BIOL, V292, P819, DOI 10.1006/jmbi.1999.3121; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; Di Bella D, 2010, NAT GENET, V42, P313, DOI 10.1038/ng.544; Duvezin-Caubet S, 2007, MOL BIOL CELL, V18, P3582, DOI 10.1091/mbc.E07-02-0164; Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fishovitz J, 2011, ACS CHEM BIOL, V6, P781, DOI 10.1021/cb100408w; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Garcia-Nafria J, 2010, PROTEIN SCI, V19, P987, DOI 10.1002/pro.376; Gerdes F, 2012, BBA-MOL CELL RES, V1823, P49, DOI 10.1016/j.bbamcr.2011.09.015; Gersch M, 2013, ANGEW CHEM INT EDIT, V52, P3009, DOI 10.1002/anie.201204690; Granot Z, 2007, MOL ENDOCRINOL, V21, P2164, DOI 10.1210/me.2005-0458; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hartkamp J, 2010, MOL CELL, V37, P159, DOI 10.1016/j.molcel.2009.12.023; Haynes CM, 2013, TRENDS CELL BIOL, VS0962-8924; Haynes CM, 2007, DEV CELL, V13, P467, DOI 10.1016/j.devcel.2007.07.016; Haynes CM, 2010, MOL CELL, V37, P529, DOI 10.1016/j.molcel.2010.01.015; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103; Hornig-Do HT, 2012, EMBO J, V31, P1293, DOI 10.1038/emboj.2011.477; Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184; Jhaveri K, 2012, ADV PHARMACOL, V65, P471, DOI 10.1016/B978-0-12-397927-8.00015-4; Johnson F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007100; Kang SG, 2005, J BIOL CHEM, V280, P35424, DOI 10.1074/jbc.M507240200; Kang SG, 2004, J STRUCT BIOL, V148, P338, DOI 10.1016/j.jsb.2004.07.004; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Karlberg T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006975; Kehrein K, 2013, ANTIOXID REDOX SIGN, V19, P1928, DOI 10.1089/ars.2012.4896; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kita K, 2012, J BIOL CHEM, V287, P18163, DOI 10.1074/jbc.M112.362699; Koppen M, 2007, MOL CELL BIOL, V27, P758, DOI 10.1128/MCB.01470-06; Koppen M, 2009, MOL BIOL CELL, V20, P4216, DOI 10.1091/mbc.E09-03-0218; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lee BG, 2010, NAT STRUCT MOL BIOL, V17, P471, DOI 10.1038/nsmb.1787; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee HJ, 2011, DIABETOLOGIA, V54, P1437, DOI 10.1007/s00125-011-2074-z; Lee S, 2011, J BIOL CHEM, V286, P4404, DOI 10.1074/jbc.M110.158741; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li DHS, 2010, CHEM BIOL, V17, P959, DOI 10.1016/j.chembiol.2010.07.008; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Lowth BR, 2012, J STRUCT BIOL, V179, P193, DOI 10.1016/j.jsb.2012.06.001; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; Lu B, 2007, J BIOL CHEM, V282, P17363, DOI 10.1074/jbc.M611540200; Lu B, 2013, MOL CELL, V49, P121, DOI 10.1016/j.molcel.2012.10.023; Luciakova K, 1999, FEBS LETT, V444, P186, DOI 10.1016/S0014-5793(99)00058-7; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Major T, 2006, MOL CELL BIOL, V26, P762, DOI 10.1128/MCB.26.3.762-776.2006; Maltecca F, 2008, J NEUROSCI, V28, P2827, DOI 10.1523/JNEUROSCI.4677-07.2008; Maltecca F, 2012, HUM MOL GENET, V21, P3858, DOI 10.1093/hmg/dds214; Maltecca F, 2009, J NEUROSCI, V29, P9244, DOI 10.1523/JNEUROSCI.1532-09.2009; Martinelli P, 2009, HUM MOL GENET, V18, P2001, DOI 10.1093/hmg/ddp124; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; Micel LN, 2013, J CLIN ONCOL, V31, P1231, DOI 10.1200/JCO.2012.44.0958; Neher SB, 2006, MOL CELL, V22, P193, DOI 10.1016/j.molcel.2006.03.007; Ngo JK, 2011, J GERONTOL A-BIOL, V66, P1178, DOI 10.1093/gerona/glr145; Ngo JK, 2009, FREE RADICAL BIO MED, V46, P1042, DOI 10.1016/j.freeradbiomed.2008.12.024; Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307; Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003; Ondrovicova G, 2005, J BIOL CHEM, V280, P25103, DOI 10.1074/jbc.M502796200; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; Park YE, 2009, AUTOPHAGY, V5, P795, DOI 10.4161/auto.8901; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; Pellegrino MW, 2013, BBA-MOL CELL RES, V1833, P410, DOI 10.1016/j.bbamcr.2012.02.019; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pierson TM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002325; Pinti M, 2011, MITOCHONDRION, V11, P200, DOI 10.1016/j.mito.2010.09.010; Rath E, 2012, GUT, V61, P1269, DOI 10.1136/gutjnl-2011-300767; Rendon OZ, 2012, HUM MOL GENET, V21, P3815, DOI 10.1093/hmg/dds209; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Stanyer L, 2008, NEUROCHEM INT, V53, P95, DOI 10.1016/j.neuint.2008.06.004; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Szyk A, 2006, J STRUCT BIOL, V156, P165, DOI 10.1016/j.jsb.2006.03.013; Tatsuta T, 2007, EMBO J, V26, P325, DOI 10.1038/sj.emboj.7601514; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; Tian Q, 2011, J BIOL CHEM, V286, P26424, DOI 10.1074/jbc.M110.215772; Truscott KN, 2010, BIOCHEM CELL BIOL, V88, P97, DOI [10.1139/O09-167, 10.1139/o09-167]; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UniProt Consortium, 2013, UNIPROT KOWL; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Venditti P, 2013, MITOCHONDRION, V13, P71, DOI 10.1016/j.mito.2013.01.008; Venkatesh S, 2012, BBA-MOL CELL RES, V1823, P56, DOI 10.1016/j.bbamcr.2011.11.003; Wang HM, 2010, CANCER SCI, V101, P2612, DOI 10.1111/j.1349-7006.2010.01701.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; Yang JS, 2013, SCI REP-UK, V3, DOI 10.1038/srep01403; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yu AYH, 2007, FEBS LETT, V581, P3749, DOI 10.1016/j.febslet.2007.04.076; Zhang X, 2011, FREE RADICAL BIO MED, V50, P811, DOI 10.1016/j.freeradbiomed.2010.12.036; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zhu YF, 2002, EXP CELL RES, V280, P97, DOI 10.1006/excr.2002.5621; Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867	141	57	57	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2690	2699		10.1038/onc.2013.228	http://dx.doi.org/10.1038/onc.2013.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770858	Bronze			2022-12-17	WOS:000337231700002
J	Yu, M; Trobridge, P; Wang, Y; Kanngurn, S; Morris, SM; Knoblaugh, S; Grady, WM				Yu, M.; Trobridge, P.; Wang, Y.; Kanngurn, S.; Morris, S. M.; Knoblaugh, S.; Grady, W. M.			Inactivation of TGF-beta signaling and loss of PTEN cooperate to induce colon cancer in vivo	ONCOGENE			English	Article						colon cancer; transforming growth factor-beta; PTEN; p21(Cip1)	RECEPTOR-TYPE-II; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; MICROSATELLITE INSTABILITY; CELL-PROLIFERATION; APC MUTATION; GROWTH; GENE; EXPRESSION; PATHWAY	The accumulation of genetic and epigenetic alterations mediates colorectal cancer (CRC) formation by deregulating key signaling pathways in cancer cells. In CRC, one of the most commonly inactivated signaling pathways is the transforming growth factor-beta (TGF-beta) signaling pathway, which is often inactivated by mutations of TGF-beta type II receptor (TGFBR2). Another commonly deregulated pathway in CRC is the phosphoinositide-3-kinase (PI3K)-AKT pathway. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is an important negative regulator of PI3K-AKT signaling and is silenced in similar to B30% of CRC. The combination of TGFBR2 inactivation and loss of PTEN is particularly common in microsatellite-unstable CRCs. Consequently, we determined in vivo if deregulation of these two pathways cooperates to affect CRC formation by analyzing tumors arising in mice that lack Tgfbr2 and/or Pten specifically in the intestinal epithelium. We found that lack of Tgfbr2 (Tgfbr2(IEKO)) alone is not sufficient for intestinal tumor formation and lack of Pten (Pten(IEKO)) alone had a weak effect on intestinal tumor induction. However, the combination of Tgfbr2 inactivation with Pten loss (Pten(IEKO); Tgfbr(2IEKO)) led to malignant tumors in both the small intestine and colon in 86% of the mice and to metastases in 8% of the tumor-bearing mice. Moreover, these tumors arose via a beta-catenin-independent mechanism. Inactivation of TGF-beta signaling and loss of Pten in the tumors led to increased cell proliferation, decreased apoptosis and decreased expression of cyclin-dependent kinase inhibitors. Thus, inactivation of TGF-beta signaling and loss of PTEN cooperate to drive intestinal cancer formation and progression by suppressing cell cycle inhibitors.	[Yu, M.; Trobridge, P.; Kanngurn, S.; Morris, S. M.; Grady, W. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Wang, Y.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Wang, Y.; Grady, W. M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Kanngurn, S.] Prince Songkla Univ, Dept Pathol, Hat Yai, Thailand; [Knoblaugh, S.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Prince of Songkla University; Fred Hutchinson Cancer Center	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,Mailstop D4-100, Seattle, WA 98109 USA.	wgrady@fhcrc.org			NIH [RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, P01CA077852]; Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG); Interdisciplinary Training in Cancer Research Grant [T32 CA080416]; NATIONAL CANCER INSTITUTE [P30CA015704, U54CA143862, U01CA152756, T32CA080416, P01CA077852, R01CA115513] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG); Interdisciplinary Training in Cancer Research Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for these studies was provided by the NIH (RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, and P01CA077852 WMG), a Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG), and an Interdisciplinary Training in Cancer Research Grant (T32 CA080416 SMM).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039381; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Biswas S, 2004, CANCER RES, V64, P4687, DOI 10.1158/0008-5472.CAN-03-3255; Byun DS, 2011, AM J PHYSIOL-GASTR L, V301, pG856, DOI 10.1152/ajpgi.00178.2011; Chen CN, 2005, J CLIN ONCOL, V23, P7286, DOI 10.1200/JCO.2004.00.2253; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chittenden TW, 2008, GENOMICS, V91, P508, DOI 10.1016/j.ygeno.2008.03.002; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fearon ER., ANN REV PATHOL, V6, P479; Glick AB, 1996, CANCER RES, V56, P3645; Gomes LR, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-26; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Grady William M., 2008, P889; Grady WM, 1998, CANCER RES, V58, P3101; Grady WM, 2006, INT J CANCER, V118, P600, DOI 10.1002/ijc.21399; Grady WM, 1999, CANCER RES, V59, P320; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jung B, 2004, GASTROENTEROLOGY, V126, P654, DOI 10.1053/j.gastro.2004.01.008; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Langlois MJ, 2009, FASEB J, V23, P1835, DOI 10.1096/fj.08-123125; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; LEVY DB, 1994, CANCER RES, V54, P5953; Leystra AA, 2012, CANCER RES, V72, P2931, DOI 10.1158/0008-5472.CAN-11-4097; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Panopoulou E, 2005, CANCER RES, V65, P1877, DOI 10.1158/0008-5472.CAN-04-2828; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Philp AJ, 2001, CANCER RES, V61, P7426; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Samowitz WS, 1999, CANCER RES, V59, P1442; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Young LC, 2008, BRIT J DERMATOL, V158, P59, DOI 10.1111/j.1365-2133.2007.08249.x; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	69	57	58	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1538	1547		10.1038/onc.2013.102	http://dx.doi.org/10.1038/onc.2013.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23604118	Green Accepted			2022-12-17	WOS:000333244200007
J	Nakanishi, H; Taccioli, C; Palatini, J; Fernandez-Cymering, C; Cui, R; Kim, T; Volinia, S; Croce, CM				Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C. M.			Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway	ONCOGENE			English	Article						miRNA; MAPK; TACSTD2; HNSCC; miR-125b	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR; MICRORNA SIGNATURES; ORAL-CANCER; EXPRESSION; IDENTIFICATION; TROP2; HETEROZYGOSITY; PROLIFERATION; DEREGULATION	MicroRNAs (miRNAs) have important roles in the initiation and progression of human cancer, but their role in head and neck cancer development and progression is not well defined. We aimed to determine whether specific miRNAs and their target mRNAs contribute to head and neck cancer pathogenesis and progression. To identify miRNAs associated with head and neck squamous cell carcinomas (HNSCCs), we analyzed HNSCC cell lines, normal head and neck tissues and normal keratinocytes by miRNA profiling; a group of differentially expressed miRNAs was identified, which includes miR-125b. Decreased expression of miR-125b is known to occur in epithelial cancers and many target mRNAs for this miR have been reported. We found decreased expression of miR-125b-1 and hypermethylation of its promoter in HNSCC compared with its non-malignant counterpart. The TACSTD2 (also known as TROP2) gene was identified and validated as a direct target of miR-125b-1. Abnormal expression of TACSTD2 cell-surface glycoprotein has been reported in most epithelial tumors, and the overexpressions of this mRNA and protein product has been considered a useful tumor marker. We report that miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression. Thus, loss of miR-125b-1 may have a key role in the pathogenesis and progression of squamous cell carcinomas of head and neck and possibly of other tumors.	[Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C. M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Croce, CM (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Cui, Ri/P-8507-2014; Taccioli, Cristian/ABC-3379-2020; Volinia, Stefano/AAA-9264-2019; Taccioli, Cristian/F-8801-2010; Kim, Taewan/M-5867-2013; Volinia, Stefano/A-3029-2010; Young, Richard A/F-6495-2012	Cui, Ri/0000-0001-6202-8779; Taccioli, Cristian/0000-0003-2995-5612; Volinia, Stefano/0000-0003-0910-3893; Taccioli, Cristian/0000-0003-2995-5612; Kim, Taewan/0000-0002-7202-009X; Volinia, Stefano/0000-0003-0910-3893; Young, Richard A/0000-0001-8855-8647; Palatini, Jeffrey/0000-0001-9280-4417	NCI NIH HHS [U01 CA166905, P30 CA016058, P01 CA129242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA166905, P30CA016058, P01CA129242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677; Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Hui ABY, 2010, CLIN CANCER RES, V16, P1129, DOI 10.1158/1078-0432.CCR-09-2166; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kikkawa N, 2010, BRIT J CANCER, V103, P877, DOI 10.1038/sj.bjc.6605811; Kimura S, 2010, ONCOL REP, V23, P1625, DOI 10.3892/or_00000804; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee Y, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000730; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Muhlmann G, 2009, J CLIN PATHOL, V62, P152, DOI 10.1136/jcp.2008.060590; Nakanishi H, 2007, P NATL ACAD SCI USA, V104, P14442, DOI 10.1073/pnas.0703211104; Nakashima K, 2004, INT J CANCER, V112, P1029, DOI 10.1002/ijc.20517; NEGRINI M, 1995, CANCER RES, V55, P3003; Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961; RASIO D, 1995, CANCER RES, V55, P3988; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Yamada H, 2008, GENE CHROMOSOME CANC, V47, P810, DOI 10.1002/gcc.20582; Yamamoto N, 1999, ONCOL REP, V6, P1223; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435	40	57	59	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					702	712		10.1038/onc.2013.13	http://dx.doi.org/10.1038/onc.2013.13			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23416980	Green Published, Green Accepted			2022-12-17	WOS:000331129200005
J	Azar, WJ; Zivkovic, S; Werther, GA; Russo, VC				Azar, W. J.; Zivkovic, S.; Werther, G. A.; Russo, V. C.			IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells	ONCOGENE			English	Article						IGFBP-2; cancer cells; VEGF; angiogenesis and CAM assay; NLS; Importin alpha/beta	GROWTH-FACTOR-BINDING; ACID-LABILE SUBUNIT; LOCALIZATION SIGNAL; BREAST-CANCER; IN-VIVO; IMPORTIN-ALPHA; NUCLEOCYTOPLASMIC TRANSPORT; PROMOTER ACTIVITY; STRUCTURAL BASIS; PROTEIN IMPORT	IGFBP-2 is highly expressed in both the serum and tumor tissues of most cancers, and is considered one of the most significant genes in the signature of major cancers. IGFBP-2 mainly modulates IGF actions in the pericellular space; however, there is considerable evidence to suggest that IGFBP-2 may also act independently of the IGFs. These IGF-independent actions of IGFBP-2 are exerted either via interactions at the cell surface or intracellularly, via interaction with cytoplasmic or nuclear-binding partners. The precise mechanism underlying the intracellular/intranuclear localization of IGFBP-2 remains unclear. In this study, we investigated IGFBP-2 nuclear localization in several common cancer cells with the aim of dissecting the mechanism of its nuclear trafficking. IGFBP-2 is detected in the nuclei of common cancer cells, including breast, prostate and several neuroblastoma cell lines, using cell fractionation and confocal microscopy. Via nuclear import assays, we show that nuclear entry of IGFBP-2 is mediated by the classical nuclear import mechanisms, primarily through importin-alpha, as demonstrated by the use of blocking, competition and co-immunoprecipitation assays. Bioinformatics analysis of the IGFBP-2 protein sequence with PSORT II identified a classical nuclear localization signal (cNLS) sequence at 179PKKLRPP185, within the IGFBP-2 linker domain, mutagenesis of which abolishes IGFBP-2 nuclear import. Accordingly, the NLS(mut)IGFBP-2 fails to activate the VEGF promoter, which would otherwise occur in the presence of wild-type IGFBP-2. As a consequence, no activation of angiogenic processes were observed in NLS(mut)IGFBP-2 expressing SHEP cells when implanted onto our in vivo quail chorio-allantoic membrane model. Taken together, these data show for the first time that IGFBP-2 possesses a functional NLS sequence and that IGFBP-2 actively translocates into the nucleus by a classical nuclear import mechanism, involving formation of IGFBP-2 complexes with importin-alpha. Nuclear IGFBP-2 is required for the activation of VEGF expression and consequent angiogenesis.	[Azar, W. J.; Zivkovic, S.; Werther, G. A.; Russo, V. C.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Azar, W. J.; Werther, G. A.; Russo, V. C.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Russo, VC (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	vince.russo@mcri.edu.au			National Health and Medical Research Council (NHMRC) of Australia [1008062]; Melbourne University (MRS)	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Melbourne University (MRS)	We wish to thank Professor Dev Mukhopadhyay (Mayo Clinic, Rochester, MN, USA) for kindly supplying the VEGF constructs used in these studies, Dr Mark Denham (Neuroscience, University of Melbourne) for his assistance in developing the GFP-SHEP cells clones, Dr Donald Newgreen (MCRI) for his assistance in developing CAM assays and Dr Sheena Azar for constant assistance during manuscript preparation. This work was supported by the National Health and Medical Research Council (NHMRC) of Australia Project Grants 1008062 (to GAW and VCR). WJA is the recipient of a Melbourne University (MRS) PhD scholarship.	ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121; Ben-Shmuel A, 2012, ONCOGENE, V6, P340; Besnard V, 2001, BBA-MOL CELL RES, V1538, P47, DOI 10.1016/S0167-4889(00)00136-1; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUBOIS V, 1993, BIOCHEM BIOPH RES CO, V192, P295, DOI 10.1006/bbrc.1993.1413; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Firth SM, 2001, ENDOCRINOLOGY, V142, P2147, DOI 10.1210/en.142.5.2147; Flyvbjerg A, 1997, J CLIN ENDOCR METAB, V82, P2308, DOI 10.1210/jc.82.7.2308; Forwood JK, 2001, MOL BIOL CELL, V12, p500A; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fukushima T, 2007, J BIOL CHEM, V282, P18634, DOI 10.1074/jbc.M609567200; Fuller GN, 1999, CANCER RES, V59, P4228; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Higgins S, 2009, ENDOCRINOLOGY, V150, P4044, DOI 10.1210/en.2008-1797; Hodel AE, 2006, J BIOL CHEM, V281, P23545, DOI 10.1074/jbc.M601718200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hoeflich A, 2004, BIOCHEM BIOPH RES CO, V324, P705, DOI 10.1016/j.bbrc.2004.09.111; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; Iosef C, 2008, ENDOCRINOLOGY, V149, P1214, DOI 10.1210/en.2007-0959; Ivanova IA, 2007, CELL CYCLE, V6, P2186, DOI 10.4161/cc.6.17.4650; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Koike M, 1999, ONCOGENE, V18, P7495, DOI 10.1038/sj.onc.1203247; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Lufei CC, 2009, FEBS LETT, V583, P271, DOI 10.1016/j.febslet.2008.12.011; Marfori M, 2012, TRAFFIC, V13, P532, DOI 10.1111/j.1600-0854.2012.01329.x; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Miyako K, 2009, MOL ENDOCRINOL, V23, P169, DOI 10.1210/me.2008-0168; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; Oh Y, 1998, INT CONGR SER, V1151, P125; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Perks CM, 1999, J MOL ENDOCRINOL, V22, P141, DOI 10.1677/jme.0.0220141; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Rivera J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006433; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Russo V. C., 1995, Progress in Growth Factor Research, V6, P329, DOI 10.1016/0955-2235(95)00018-6; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Russo VC, 2004, 12 INT C END MED INT; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schedlich LJ, 2007, MOL ENDOCRINOL, V21, P2378, DOI 10.1210/me.2006-0558; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Shen XC, 2012, MOL CELL BIOL, V32, P4116, DOI 10.1128/MCB.01011-12; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; Terrien X, 2005, BIOCHEM J, V392, P457, DOI 10.1042/BJ20050517; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; Wang H, 2003, CANCER RES, V63, P4315; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Zhou GL, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-74	79	57	62	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					578	588		10.1038/onc.2012.630	http://dx.doi.org/10.1038/onc.2012.630			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23435424				2022-12-17	WOS:000331125100006
J	Lee, JM; Kim, B; Lee, SB; Jeong, Y; Oh, YM; Song, YJ; Jung, S; Choi, J; Lee, S; Cheong, KH; Kim, DU; Park, HW; Han, YK; Kim, GW; Choi, H; Song, PH; Kim, KA				Lee, J. M.; Kim, B.; Lee, S. B.; Jeong, Y.; Oh, Y. M.; Song, Y-J; Jung, S.; Choi, J.; Lee, S.; Cheong, K. H.; Kim, D. U.; Park, H. W.; Han, Y. K.; Kim, G. W.; Choi, H.; Song, P. H.; Kim, K. A.			Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody	ONCOGENE			English	Article						Met; Cbl; LRIG1; SAIT301; agonism	RECEPTOR TYROSINE KINASE; HEPATOCYTE GROWTH-FACTOR; C-MET; JUXTAMEMBRANE DOMAIN; DOWN-REGULATION; MUTATIONS; LRIG1; AMPLIFICATION; INHIBITORS; CANCER	The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer therapy. Disruptions in Met downregulation have been associated with aggressive tumor progression with several therapeutic strategies addressing this aspect of Met biology. Castias B-lineage lymphoma (Cbl) E3 ligase-mediated degradation, which attenuates Met signaling via ligand-dependent Met internalization, is a major negative regulator of Met expression. It is believed that one of the mechanisms by which the therapeutic anti-Met antibodies induce cancer cell death in Met overexpressing tumors is via internalization and subsequent degradation of Met from the cell surface. However, a previously reported Met-targeting antibody demonstrated intrinsic agonistic activity while being capable of inducing Cbl-mediated degradation of Met, suggesting that Cbl-mediated degradation requires receptor activation and impedes therapeutic application. We have developed a potent and selective bivalent Met-targeting antibody (SAIT301) that invokes Met degradation using an alternative regulator LRIG1. In this report, we demonstrate that LRIG1 mediates degradation of Met by SAIT301 and this degradation does not require Met activation. Furthermore, SAIT301 was able to downregulate Met and dramatically inhibit growth of tumors with low or no Cbl expression, as well as tumors with Met exon 14 deletion that prevents Met binding to Cbl. In summary, we demonstrate the enhanced therapeutic potential of a novel tumor-inhibiting anti-Met antibody, SAIT301, which utilizes a Cbl-independent, LRIG1-mediated Met degradation pathway and thereby avoids the agonism that limits the effectiveness of previously reported anti-Met antibodies.	[Lee, J. M.; Kim, B.; Lee, S. B.; Jeong, Y.; Oh, Y. M.; Song, Y-J; Jung, S.; Choi, J.; Lee, S.; Cheong, K. H.; Kim, D. U.; Park, H. W.; Han, Y. K.; Kim, G. W.; Choi, H.; Song, P. H.; Kim, K. A.] Samsung Elect Co Ltd, Samsung Adv Inst Technol, BioTherapeut Lab, Yongin 446712, Gyeonggi Do, South Korea	Samsung	Kim, KA (corresponding author), Samsung Elect Co Ltd, Samsung Adv Inst Technol, BioTherapeut Lab, 95 Samsung2 Ro, Yongin 446712, Gyeonggi Do, South Korea.	ka10.kim@samsung.com	Jeong, Yunju/GRS-0008-2022; Lee, Ji Min/ABE-7494-2021	Lee, Ji Min/0000-0003-2978-2440	Korea Healthcare technology R&D project, Ministry for Health & Welfare Affairs, Republic of Korea [A092255]	Korea Healthcare technology R&D project, Ministry for Health & Welfare Affairs, Republic of Korea	This study was supported by a grant of the Korea Healthcare technology R&D project, Ministry for Health & Welfare Affairs, Republic of Korea (A092255). We thank Dr Sangyeul Han for critical discussion and Dr Ogan Gurel for discussion and editing the manuscript. pcDNA-LRIG1 expression plasmid was kindly provided by Dr Hakan Hedman.	Ancot F, 2012, TRAFFIC, V13, P1261, DOI 10.1111/j.1600-0854.2012.01384.x; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Krumbach R, 2011, EUR J CANCER, V47, P1231, DOI 10.1016/j.ejca.2010.12.019; Lai AZ, 2012, J BIOL CHEM, V287, P8048, DOI 10.1074/jbc.M112.339820; Lefebvre J, 2012, FASEB J, V26, P1387, DOI 10.1096/fj.11-197723; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Ma PC, 2003, CANCER RES, V63, P6272; Nakagawa T, 2010, CANCER SCI, V101, P210, DOI 10.1111/j.1349-7006.2009.01343.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Oh YM, MOL CELLS IN PRESS; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Ordonez-Moran P, 2012, EMBO J, V31, P2064, DOI 10.1038/emboj.2012.73; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Qin SA, 2010, J CLIN INVEST, V120, P3617, DOI 10.1172/JCI41531; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Stellrecht CM, 2009, CANCER LETT, V280, P1, DOI 10.1016/j.canlet.2008.10.045; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749	42	57	59	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					34	43		10.1038/onc.2012.551	http://dx.doi.org/10.1038/onc.2012.551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208509				2022-12-17	WOS:000329212000005
J	Deng, M; Zhang, W; Tang, H; Ye, Q; Liao, Q; Zhou, Y; Wu, M; Xiong, W; Zheng, Y; Guo, X; Qin, Z; He, W; Zhou, M; Xiang, J; Li, X; Ma, J; Li, G				Deng, M.; Zhang, W.; Tang, H.; Ye, Q.; Liao, Q.; Zhou, Y.; Wu, M.; Xiong, W.; Zheng, Y.; Guo, X.; Qin, Z.; He, W.; Zhou, M.; Xiang, J.; Li, X.; Ma, J.; Li, G.			Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms	ONCOGENE			English	Article						nasopharyngeal carcinoma; LTF; AKT; PDK1; keratin 18; 14-3-3	LACTOFERRIN INHIBITS GROWTH; SIMPLE EPITHELIAL KERATINS; CYCLIN-DEPENDENT KINASES; INITIATED COLON-TUMOR; 14-3-3 PROTEINS; BOVINE LACTOFERRIN; DOWN-REGULATION; EXPRESSION; CANCER; PHOSPHORYLATION	LTF (lactotransferrin, also known as lactoferrin) is a key component of innate immune defense. It has recently been found to have anti-tumor and anti-metastatic activity in different cancers. We previously reported LTF to be the most significantly downregulated gene in nasopharyngeal carcinoma (NPC) specimens relative to normal nasopharyngeal epithelial tissues, and it was also negatively associated with the progression and metastasis of NPC. However, the mechanism underlying this remains unclear. In the current study, we revealed that LTF can suppress 3-phosphoinositide-dependent protein kinase 1 expression via the mitogen-activated protein kinase/c-Jun pathway and thus repress AKT signaling. We also showed that LTF interacts with keratin 18 (K18) and so blocks the formation of the K18-14-3-3 complex, leading to downregulation of K18-mediated AKT activation. Thus, LTF suppresses AKT signaling by two separate mechanisms, leading to inhibition of NPC tumorigenesis. This is the first report on the tumor suppressive effects of LTF through repression of AKT signaling in NPC. It suggests that both LTF and AKT signaling merit further study in the field of NPC research.	[Deng, M.; Zhang, W.; Tang, H.; Ye, Q.; Liao, Q.; Zhou, Y.; Wu, M.; Xiong, W.; Zheng, Y.; Guo, X.; Qin, Z.; He, W.; Zhou, M.; Xiang, J.; Li, X.; Ma, J.; Li, G.] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Hunan Key Lab Nonresolving Inflammat & Canc, Key Lab Carcinogenesis,Minist Hlth,Minist Educ,Ca, Changsha 410078, Hunan, Peoples R China; [Deng, M.; Tang, H.; Liao, Q.] Univ South China, Canc Res Inst, Hengyang, Peoples R China; [Deng, M.] Guangzhou Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Deng, M.] Guangzhou Med Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China	Central South University; University of South China; Guangzhou Medical University; Guangzhou Medical University	Ma, J (corresponding author), Cent S Univ, Canc Res Inst, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.	majian@csu.edu.cn; ligy@xysm.net			China 111 Project [111-2-12]; Nature Scientific Foundation of China [30871282, 81071756, 81171988, 91229122]; Ministry of Education [NCET-11-0520]; Hunan Province Natural Sciences Foundation of China [10JJ7003]	China 111 Project; Nature Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education; Hunan Province Natural Sciences Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported by the China 111 Project (No. 111-2-12), Nature Scientific Foundation of China (30871282, 81071756, 81171988, 91229122). Ministry of Education (NCET-11-0520, SRF for ROCS). Hunan Province Natural Sciences Foundation of China (10JJ7003).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810; BEZAULT J, 1994, CANCER RES, V54, P2310; CAMPBELL T, 1992, BRIT J CANCER, V65, P19, DOI 10.1038/bjc.1992.4; Damiens E, 1999, J CELL BIOCHEM, V74, P486, DOI 10.1002/(SICI)1097-4644(19990901)74:3<486::AID-JCB16>3.3.CO;2-Y; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; Deng M, 2011, J CELL SCI, V124, P2997, DOI 10.1242/jcs.085050; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Gonzalez-Chavez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020; Kholodnyuk ID, 2006, INT J CANCER, V119, P99, DOI 10.1002/ijc.21794; Kikani CK, 2005, J CELL BIOCHEM, V96, P1157, DOI 10.1002/jcb.20651; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kippenberger S, 2010, BBA-MOL CELL RES, V1803, P940, DOI 10.1016/j.bbamcr.2010.03.009; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Li WY, 2011, CANCER BIOTHER RADIO, V26, P477, DOI 10.1089/cbr.2010.0937; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Mariller C, 2007, FEBS J, V274, P2038, DOI 10.1111/j.1742-4658.2007.05747.x; Matsuda Y, 2007, CANCER LETT, V246, P41, DOI 10.1016/j.canlet.2006.01.034; MONTREUIL J, 1960, BIOCHIM BIOPHYS ACTA, V45, P413, DOI 10.1016/0006-3002(60)91478-5; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Obsilova V, 2008, PHYSIOL RES, V57, pS11, DOI 10.33549/physiolres.931598; Omary MB, 2009, J CLIN INVEST, V119, P1794, DOI 10.1172/JCI37762; Rodrigues L, 2009, CRIT REV FOOD SCI, V49, P203, DOI 10.1080/10408390701856157; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sekine K, 1997, JPN J CANCER RES, V88, P523, DOI 10.1111/j.1349-7006.1997.tb00413.x; Shaheduzzaman S, 2007, CANCER BIOL THER, V6, P1088, DOI 10.4161/cbt.6.7.4327; Son HJ, 2006, BIOCHEM CELL BIOL, V84, P345, DOI 10.1139/O06-048; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Tsuda H, 1998, ADV EXP MED BIOL, V443, P273; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; Ward PP, 2005, CELL MOL LIFE SCI, V62, P2540, DOI 10.1007/s00018-005-5369-8; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Wu MH, 2009, CURR GENOMICS, V10, P216, DOI 10.2174/138920209788488481; Xiao Y, 2004, CLIN CANCER RES, V10, P8683, DOI 10.1158/1078-0432.CCR-04-0988; Yang Y, 2003, CANCER LETT, V191, P155, DOI 10.1016/S0304-3835(02)00677-8; Yi HM, 2006, ONCOL RES, V16, P261, DOI 10.3727/000000006783981008; Zhang DH, 2005, PROTEOMICS, V5, P1797, DOI 10.1002/pmic.200401069; Zhou YH, 2008, INT J CANCER, V123, P2065, DOI 10.1002/ijc.23727	44	57	58	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4273	4283		10.1038/onc.2012.434	http://dx.doi.org/10.1038/onc.2012.434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23069661				2022-12-17	WOS:000324168000009
J	Pan, Y; Zhang, Q; Atsaves, V; Yang, H; Claret, FX				Pan, Y.; Zhang, Q.; Atsaves, V.; Yang, H.; Claret, F. X.			Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways	ONCOGENE			English	Article						nasopharyngeal carcinoma; Epstein-Barr virus-associated malignancy; cisplatin; ultraviolet radiation; ionizing radiation; RPPA	DOMAIN-BINDING PROTEIN-1; CELL-CYCLE CHECKPOINTS; HOMOLOGOUS RECOMBINATION; RAD51 PROTEIN; ACTIVATION; EXPRESSION; CISPLATIN; INHIBITION; OVEREXPRESSION; CONTRIBUTES	Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignancy most common in East Asia and Africa. Radiotherapy and cisplatin-based chemotherapy are the main treatment options. Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with NPC, and many cases are resistant to cisplatin. Increased DNA damage repair is one of the mechanisms contributing to this resistance. Jab1/CSN5 is a multifunctional protein that participates in controlling cell proliferation and the stability of multiple proteins. Jab1 overexpression has been found to correlate with poor prognosis in several tumor types. However, the biological significance of Jab1 activity in response to cancer treatment is unclear. In this study, we used three NPC cell lines (CNE1, CNE2 and HONE1) to investigate the hypothesis that Jab1 positively regulates the DNA repair protein Rad51 and, in turn, cellular response to treatment with DNA-damaging agents such as cisplatin, ionizing radiation (IR) and ultraviolet (UV) radiation. We found that Jab1 was overexpressed in two relatively cisplatin-, IR- and UV-resistant NPC cell lines, and knocking down its expression conferred sensitivity to cisplatin, IR and UV radiation. By contrast, exogenous Jab1 expression enhanced the resistance of NPC cells to cisplatin, IR and UV radiation. Moreover, we provide a mechanism by which Jab1 positively regulated Rad51 through p53-dependent pathway, and increased ectopic expression of Rad51 conferred cellular resistance to cisplatin, IR and UV radiation in Jab1-deficient cells. Taken together, our findings suggest that Jab1 has an important role in the cellular response to cisplatin and irradiation by regulating DNA damage and repair pathways. Therefore, Jab1 is a novel biomarker for predicting the outcome of patients with NPC who are treated with DNA-damaging agents.	[Pan, Y.; Zhang, Q.; Atsaves, V.; Claret, F. X.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Pan, Y.; Yang, H.] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510275, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University	Claret, FX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.	fxclaret@mdanderson.org	atsaves, vasileios/ABA-1599-2021; Claret, Francois X/R-2104-2016; Pan, Yunbao/J-9016-2013	Claret, Francois X/0000-0003-4629-6495; Pan, Yunbao/0000-0002-6311-2945; atsaves, vasileios/0000-0002-9234-4657	China Scholarship Council [2010638087]; National Cancer Institute [RO1-CA90853]; NCI Cancer Center Support Grant [CA16672]; National Natural Science Foundation of China [81071837, 30670627]; Natural Science Foundation of Guangdong Province, China [9251008901000005, 06021210]; Scientific and Technological Project of Guangdong, China [2008A030201009, 2010B050700016]; NATIONAL CANCER INSTITUTE [R01CA090853, P30CA016672] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148] Funding Source: NIH RePORTER	China Scholarship Council(China Scholarship Council); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Scientific and Technological Project of Guangdong, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Zahid H Siddik, Do Youn Oh for helpful discussions and Ronald Glaser for kindly providing HONE1 cells. This work was supported by a fellowship from the China Scholarship Council (2010638087 to YP) and a grant from the National Cancer Institute (RO1-CA90853 to FXC). The University of Texas MD Anderson Functional Proteomics Core Facility is supported by an NCI Cancer Center Support Grant (CA16672); the National Natural Science Foundation of China (81071837; 30670627); Natural Science Foundation of Guangdong Province, China (9251008901000005; 06021210) and Scientific and Technological Project of Guangdong, China (2008A030201009; 2010B050700016 to HY). We thank Kate J Newberry and Sunita Patterson for editing the manuscript.	Arias-Lopez C, 2006, EMBO REP, V7, P219, DOI 10.1038/sj.embor.7400587; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Cheung BW, 2005, CANCER RES, V65, P1450, DOI 10.1158/0008-5472.CAN-04-0567; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Cruet-Hennequart S, 2009, CELL CYCLE, V8, P3039; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Dmitrieva NI, 2011, P NATL ACAD SCI USA, V108, P20796, DOI 10.1073/pnas.1114677108; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feng ZZ, 2010, CANCER LETT, V297, P190, DOI 10.1016/j.canlet.2010.05.011; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; Hui EP, 2009, J CLIN ONCOL, V27, P242, DOI 10.1200/JCO.2008.18.1545; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Kouvaraki MA, 2006, CANCER RES, V66, P8581, DOI 10.1158/0008-5472.CAN-06-0975; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Le QT, 2003, INT J RADIAT ONCOL, V56, P1046, DOI 10.1016/S0360-3016(03)00117-2; Lee JH, 2010, ONCOGENE, V29, P1431, DOI 10.1038/onc.2009.438; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2012, SEMIN CANCER BIOL, V22, P79, DOI 10.1016/j.semcancer.2011.12.011; Ma W, 2012, ONCOGENE, V31, P1024, DOI 10.1038/onc.2011.300; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pabla N, 2011, J BIOL CHEM, V286, P10411, DOI 10.1074/jbc.M110.210989; Pan YB, 2012, CANCER RES, V72, P1890, DOI 10.1158/0008-5472.CAN-11-3472; Pedram A, 2009, MOL BIOL CELL, V20, P3374, DOI 10.1091/mbc.E09-01-0085; Qing Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002148; Raderschall E, 2002, CANCER RES, V62, P219; Rassidakis GZ, 2003, CLIN CANCER RES, V9, P1121; Revet I, 2011, P NATL ACAD SCI USA, V108, P8663, DOI 10.1073/pnas.1105866108; Russell JS, 2003, CANCER RES, V63, P7377; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Tian L, 2010, ONCOGENE, V29, P6125, DOI 10.1038/onc.2010.345; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Yip KW, 2005, CLIN CANCER RES, V11, P8131, DOI 10.1158/1078-0432.CCR-05-1266; Zhang QX, 2005, FEBS LETT, V579, P3932, DOI 10.1016/j.febslet.2005.06.012	44	57	60	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2756	2766		10.1038/onc.2012.294	http://dx.doi.org/10.1038/onc.2012.294			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22797071	Green Accepted			2022-12-17	WOS:000319808000007
J	Grkovic, S; O'Reilly, VC; Han, S; Hong, M; Baxter, RC; Firth, SM				Grkovic, S.; O'Reilly, V. C.; Han, S.; Hong, M.; Baxter, R. C.; Firth, S. M.			IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments	ONCOGENE			English	Article						autophagy; breast cancer; GRP78; IGFBP-3; starvation	UNFOLDED PROTEIN RESPONSE; GROWTH-INHIBITION; TUMOR-DEVELOPMENT; SURFACE BINDING; RECEPTOR; APOPTOSIS; CYCLE; EXPRESSION; INDUCTION; FIBRONECTIN	Despite the established role of insulin-like growth factor binding protein-3 (IGFBP-3) as a growth inhibitor in vitro, a high level of IGFBP-3 in breast tumor tissue is associated with the stimulation of xenograft growth in mice and poor prognosis in patients. To understand the contribution of IGFBP-3 to breast cancer progression, tandem affinity purification was used to identify novel interacting proteins. The endoplasmic reticulum protein, glucose-regulated protein 78 (GRP78), was shown to bind to IGFBP-3, confirmed by colocalization, coimmunoprecipitations, glutathione S-transferase (GST) pulldowns and a nanomolar binding affinity. GST pulldowns also indicated that the GRP78 ATPase domain mediated the interaction with IGFBP-3. The critical roles of GRP78 in the unfolded protein response and macroautophagy led to an investigation of possible links between IGFBP-3, GRP78 and cellular stress responses. IGFBP-3 was found to stimulate the survival of breast cancer cells subjected to glucose starvation and hypoxia. Pharmacological inhibitors and small interfering RNA knockdown established that the increased survival of IGFBP-3-expressing cells was dependent on an intact autophagy response, as well as GRP78. The contribution of autophagy was confirmed by the demonstration that IGFBP-3 expression increases both the formation of autophagic puncta and flux through the system. In conclusion, we have shown that IGFBP-3 stimulates autophagy and thereby promotes the survival of breast cancer cells exposed to conditions that represent the adverse microenvironments encountered by solid tumor cells in vivo.	[Grkovic, S.; O'Reilly, V. C.; Han, S.; Hong, M.; Baxter, R. C.; Firth, S. M.] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Grkovic, S (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	sgrkovic@yahoo.com.au	Hong, Martin/AAO-5432-2020; Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Hong, Martin/0000-0002-2327-4261	Cancer Institute NSW; Sydney Medical School, University of Sydney; Allan and Beryl Stephens Trust; University of Sydney	Cancer Institute NSW; Sydney Medical School, University of Sydney(University of Sydney); Allan and Beryl Stephens Trust; University of Sydney(University of Sydney)	We thank G Lu for his assistance with immunocytochemistry. SG and SMF were recipients of Cancer Institute NSW Early Career and Career Development Fellowships, respectively. SH and MH received Summer Research Scholarships from the Sydney Medical School, University of Sydney. This project was partly supported by the Allan and Beryl Stephens Trust and University of Sydney Bridging Support Grant.	BRUNNER M, 1973, CANCER RES, V33, P29; Butt AJ, 2004, J CLIN ENDOCR METAB, V89, P1950, DOI 10.1210/jc.2003-030914; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; Chan SSY, 2009, AM J PHYSIOL-ENDOC M, V296, pE654, DOI 10.1152/ajpendo.90846.2008; Chen WS, 2009, EUR J HUM GENET, V17, P1668, DOI 10.1038/ejhg.2009.86; Criollo A, 2007, CELL DEATH DIFFER, V14, P1029, DOI 10.1038/sj.cdd.4402099; Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625; DiPaola RS, 2008, PROSTATE, V68, P1743, DOI 10.1002/pros.20837; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Espina V, 2011, NAT REV CANCER, V11, P68, DOI 10.1038/nrc2950; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Feldser D, 1999, CANCER RES, V59, P3915; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Firth SM, 1998, BIOCHEM BIOPH RES CO, V246, P325, DOI 10.1006/bbrc.1998.8615; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Firth SM, 1999, J ENDOCRINOL, V160, P379, DOI 10.1677/joe.0.1600379; Firth Sue M., 1995, Progress in Growth Factor Research, V6, P223, DOI 10.1016/0955-2235(95)00009-7; Fu Y, 2007, CANCER RES, V67, P3734, DOI 10.1158/0008-5472.CAN-06-4594; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gonzalez-Gronow M, 2009, ANTIOXID REDOX SIGN, V11, P2299, DOI [10.1089/ars.2009.2568, 10.1089/ARS.2009.2568]; Grimberg A, 2005, J CLIN ENDOCR METAB, V90, P3568, DOI 10.1210/jc.2004-1213; Gui YT, 2001, J CLIN ENDOCR METAB, V86, P2104, DOI 10.1210/jc.86.5.2104; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709; Jogie-Brahim S, 2009, ENDOCR REV, V30, P417, DOI 10.1210/er.2008-0028; Kaminskyy V, 2011, AUTOPHAGY, V7, P83, DOI 10.4161/auto.7.1.13893; Kim HS, 2010, HORM METAB RES, V42, P165, DOI 10.1055/s-0029-1243190; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kratzner R, 2008, MOL PHARMACOL, V73, P509, DOI 10.1124/mol.107.035568; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Liu B, 2003, GROWTH HORM IGF RES, V13, P89, DOI 10.1016/S1096-6374(03)00007-8; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Martin JL, 2009, J BIOL CHEM, V284, P25542, DOI 10.1074/jbc.M109.007120; McIntosh J, 2010, J BIOL CHEM, V285, P38788, DOI 10.1074/jbc.M110.177311; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; O'Han MK, 2009, GROWTH FACTORS, V27, P394, DOI 10.3109/08977190903185032; Oufattole M, 2006, ENDOCRINOLOGY, V147, P2138, DOI 10.1210/en.2005-1269; Perks C, 2008, J MAMMARY GLAND BIOL, V13, P455, DOI 10.1007/s10911-008-9106-4; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Ren ZF, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1634; Rocha RL, 1997, CLIN CANCER RES, V3, P103; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 2007, MOL ENDOCRINOL, V21, P2378, DOI 10.1210/me.2006-0558; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Scriven P, 2009, BRIT J CANCER, V101; Sheen-Chen SM, 2009, ANTICANCER RES, V29, P1131; Vestey SB, 2005, BREAST CANCER RES, V7, pR119, DOI 10.1186/bcr963; Wang M, 2009, ANTIOXID REDOX SIGN, V11, P2307, DOI [10.1089/ars.2009.2485, 10.1089/ARS.2009.2485]; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Wisniewska M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008625; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1; Yu H, 1996, BRIT J CANCER, V74, P1242, DOI 10.1038/bjc.1996.523; Yu H, 1998, INT J CANCER, V79, P624, DOI 10.1002/(SICI)1097-0215(19981218)79:6<624::AID-IJC12>3.0.CO;2-9	60	57	59	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2412	2420		10.1038/onc.2012.264	http://dx.doi.org/10.1038/onc.2012.264			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751133				2022-12-17	WOS:000318694900005
J	Luwor, RB; Baradaran, B; Taylor, LE; Iaria, J; Nheu, TV; Amiry, N; Hovens, CM; Wang, B; Kaye, AH; Zhu, HJ				Luwor, R. B.; Baradaran, B.; Taylor, L. E.; Iaria, J.; Nheu, T. V.; Amiry, N.; Hovens, C. M.; Wang, B.; Kaye, A. H.; Zhu, H-J			Targeting Stat3 and Smad7 to restore TGF-beta cytostatic regulation of tumor cells in vitro and in vivo	ONCOGENE			English	Article						EGFR; TGF-beta Stat3; Smad7; cancer	EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; FACTOR RECEPTOR EGFR; BREAST-CANCER-CELLS; WILD-TYPE EGFR; LUNG-CANCER; SIGNAL TRANSDUCERS; CDDO-IMIDAZOLIDE; ACTIVATION; FAMILY	Transforming Growth Factor-beta (TGF-beta) and Epidermal Growth Factor (EGF) signaling pathways are both independently implicated as key regulators in tumor formation and progression. Here, we report that the tumor-associated overexpression of epidermal growth factor receptor (EGFR) desensitizes TGF-beta signaling and its cytostatic regulation through specific and persistent Stat3 activation and Smad7 induction in vivo. In human tumor cell lines, reduction of TGF-beta-mediated Smad2 phosphorylation, nuclear translocation and Smad3 target gene activation were observed when EGFR was overexpressed, but not in cells that expressed EGFR at normal levels. We identified Stat3, which is activated specifically and persistently by overexpressed EGFR, as a key signaling molecule responsible for the reduced TGF-beta sensitivity. Stable knockdown of Stat3 using small hairpin RNA(shRNA) in Head and Neck (HN5) and Epidermoid (A431) tumor cell lines resulted in reduced growth compared with control shRNA-transfected cells when grown as subcutaneous tumor xenografts. Furthermore, xenografts with Stat3 knockdown displayed increased Smad3 transcriptional activity, increased Smad2 phosphorylation and decreased Smad7 expression compared with control xenografts in vivo. Consistently, Smad7 mRNA and protein expression was also significantly reduced when EGFR activity was blocked by a specific tyrosine kinase inhibitor, AG1478, or in Stat3 knockdown tumors. Similarly, Smad7 knockdown also resulted in enhanced Smad3 transcriptional activity in vivo. Importantly, there was no uptake of subcutaneous HN5 xenografts with Smad7 knockdown. Taken together, we demonstrate here that targeting Stat3 or Smad7 for knockdown results in resensitization of TGF-beta's cytostatic regulation in vivo. Overall, these results establish EGFR/Stat3/Smad7/TGF-beta signaling axis driving tumor growth, which can be targeted therapeutically.	[Luwor, R. B.; Taylor, L. E.; Iaria, J.; Nheu, T. V.; Hovens, C. M.; Wang, B.; Kaye, A. H.; Zhu, H-J] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic 3050, Australia; [Baradaran, B.] Tabriz Univ Med Sci, Dept Immunol, Tabriz, Iran; [Amiry, N.; Hovens, C. M.] Epworth Med Fdn, Australian Prostate Canc Res Ctr, Richmond, Vic, Australia	Royal Melbourne Hospital; University of Melbourne; Tabriz University of Medical Science; Epworth Medical Foundation	Zhu, HJ (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Melbourne, Vic 3050, Australia.	hongjian@unimelb.edu.au	Baradaran, Behzad/AAQ-5177-2020	Baradaran, Behzad/0000-0002-8642-6795; Kaye, Andrew Henry/0000-0001-5049-8861; Hovens, Christopher/0000-0002-0610-1289; Luwor, Rodney/0000-0002-3020-4245; Zhu, Hong-Jian/0000-0002-1478-995X	National Health and Medical Research Council (NHMRC); University of Melbourne	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); University of Melbourne(University of Melbourne)	This work was supported by grants from the National Health and Medical Research Council (NHMRC) to H-JZ. RBL is a recipient of the Winter and Glover Fellowship for Cancer Research from the University of Melbourne.	Albanell J, 2001, CANCER RES, V61, P6500; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Brodin G, 2000, J BIOL CHEM, V275, P29023, DOI 10.1074/jbc.M002815200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Das P, 1999, CYTOKINE GROWTH F R, V10, P179, DOI 10.1016/S1359-6101(99)00014-3; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ettinger DS, 2006, ONCOLOGIST, V11, P358, DOI 10.1634/theoncologist.11-4-358; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; Itman C, 2009, DEV DYNAM, V238, P1688, DOI 10.1002/dvdy.21995; Janmaat ML, 2003, CLIN CANCER RES, V9, P2316; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kuang CZ, 2006, P NATL ACAD SCI USA, V103, P1858, DOI 10.1073/pnas.0508977103; Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009; Liby K, 2006, CLIN CANCER RES, V12, P4288, DOI 10.1158/1078-0432.CCR-06-0215; Luwor RB, 2004, ONCOGENE, V23, P6095, DOI 10.1038/sj.onc.1207870; Luwor RB, 2001, CANCER RES, V61, P5355; Luwor RB, GROWTH FACTORS, V29, P211; Luwor RB, 2008, J CLIN NEUROSCI, V15, P845, DOI 10.1016/j.jocn.2008.01.003; Massague J, 2000, GENE DEV, V14, P627; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588; OSBORNE CK, 1985, CANCER RES, V45, P584; Place AE, 2003, CLIN CANCER RES, V9, P2798; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sehgal PB, 2008, SEMIN CELL DEV BIOL, V19, P329, DOI 10.1016/j.semcdb.2008.07.003; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Tenney R, 2005, J CELL PHYSIOL, V202, P160, DOI 10.1002/jcp.20100; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Wild R, 2006, MOL CANCER THER, V5, P104, DOI 10.1158/1535-7163.MCT-05-0259; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424; Zhu Hong-Jian, 2001, Molecular Cell Biology Research Communications, V4, P321, DOI 10.1006/mcbr.2001.0301	51	57	61	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2013	32	19					2433	2441		10.1038/onc.2012.260	http://dx.doi.org/10.1038/onc.2012.260			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751114	Green Published, hybrid			2022-12-17	WOS:000318694900007
J	Al-Ansari, MM; Hendrayani, SF; Shehata, AI; Aboussekhra, A				Al-Ansari, M. M.; Hendrayani, S. F.; Shehata, A. I.; Aboussekhra, A.			p16(INK4A) Represses the paracrine tumor-promoting effects of breast stromal fibroblasts	ONCOGENE			English	Article						AUF1; breast cancer; cell nonautonomous tumor suppression; p16(INK4A); stromal fibroblasts	GENE-EXPRESSION; MOLECULAR CHARACTERIZATION; CANCER; SUPPRESSOR; MICROENVIRONMENT; CARCINOMAS; P21(WAF1/CIP1); INHIBITION; INDUCTION; INVASION	Cancer-associated fibroblasts (CAFs), the most abundant and probably the most active cellular component of breast cancer-associated stroma, promote carcinogenesis through paracrine effects; however, the molecular basis remains elusive. We have shown here that p16(INK4A) expression is reduced in 83% CAFs as compared with their normal adjacent counterparts cancer-free tissues isolated from the same patients. This decrease is mainly due to AUF1-dependent higher turnover of the CDKN2A mRNA in CAFs. Importantly, p16(INK4A) downregulation using specific siRNA activated breast fibroblasts and increased the expression/secretion levels of stromal cell-derived factor 1 (SDF-1) and matrix metalloproteinase (MMP)-2. Consequently, media conditioned with these cells stimulated the proliferation of epithelial cells. Furthermore, the migration/invasion of breast cancer cells was also enhanced in an SDF-1-dependent manner. This effect was mediated through inducing an epithelial-mesenchymal transition state. By contrast, increase in p16(INK4A) level through ectopic expression or AUF1 downregulation, reduced the secreted levels of SDF-1 and MMP-2 and suppressed the pro-carcinogenic effects of CAFs. In addition, p16(INK4A)-defective fibroblasts accelerated breast tumor xenograft formation and growth rate in mice. Importantly, tumors formed in the presence of p16(INK4A)-defective fibroblasts exhibited higher levels of active Akt, Cox-2, MMP-2 and MMP-9, showing their greater aggressiveness as compared with xenografts formed in the presence of p16(INK4A)-proficient fibroblasts. These results provide the first indication that p16(INK4A) downregulation in breast stromal fibroblasts is an important step toward their activation.	[Al-Ansari, M. M.; Hendrayani, S. F.; Aboussekhra, A.] Dept Mol Oncol, Riyadh, Saudi Arabia; [Shehata, A. I.] King Saud Univ, Dept Microbiol, Riyadh, Saudi Arabia	King Saud University	Aboussekhra, A (corresponding author), King Faisal Specialist Hosp & Res Ctr, DMO, MBC 03-66,POB 3354, Riyadh 11211, Saudi Arabia.	aboussekhra@kfshrc.edu.sa	Al-Ansari, Mysoon M/X-3875-2018; Al-Ansari, Mysoon/K-1915-2013	Al-Ansari, Mysoon M/0000-0002-2501-691X; Al-Ansari, Mysoon/0000-0002-2501-691X				Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa; Al-Mohanna MA, 2007, NUCLEIC ACIDS RES, V35, P223, DOI 10.1093/nar/gkl1075; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Arendt LM, 2010, SEMIN CELL DEV BIOL, V21, P11, DOI 10.1016/j.semcdb.2009.10.003; Atienza JM, 2006, ASSAY DRUG DEV TECHN, V4, P597, DOI 10.1089/adt.2006.4.597; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bourhis XFDL, 1997, INT J CANCER, V71, P42, DOI 10.1002/(SICI)1097-0215(19970328)71:1<42::AID-IJC9>3.0.CO;2-3; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Chintala SK, 1997, ONCOGENE, V15, P2049, DOI 10.1038/sj.onc.1201382; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Gao MQ, 2010, J CELL SCI, V123, P3507, DOI 10.1242/jcs.072900; Hawsawi NM, 2008, CANCER RES, V68, P2717, DOI 10.1158/0008-5472.CAN-08-0192; Hu M, 2008, EUR J CANCER, V44, P2760, DOI 10.1016/j.ejca.2008.09.038; Hua M, 2009, P NATL ACAD SCI USA, V106, P3372, DOI 10.1073/pnas.0813306106; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kiaris H, 2005, CANCER RES, V65, P1627, DOI 10.1158/0008-5472.CAN-04-3791; Kim JB, 2005, TUMOR BIOL, V26, P173, DOI 10.1159/000086950; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Mazan-Mamczarz K, 2009, NUCLEIC ACIDS RES, V37, P204, DOI 10.1093/nar/gkn929; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Moskovits N, 2006, CANCER RES, V66, P10671, DOI 10.1158/0008-5472.CAN-06-2323; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Sadlonova A, 2009, CANCER MICROENVIRON, V2, P9, DOI 10.1007/s12307-008-0017-0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shimoda M, 2010, SEMIN CELL DEV BIOL, V21, P19, DOI 10.1016/j.semcdb.2009.10.002; Singer CF, 2008, BREAST CANCER RES TR, V110, P273, DOI 10.1007/s10549-007-9725-2; Souza-Rodrigues E, 2007, PROTEOMICS, V7, P4102, DOI 10.1002/pmic.200700133; Sun P, 2010, J BIOL CHEM, V285, P27545, DOI 10.1074/jbc.M110.105767; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Trimis G, 2008, HUM MOL GENET, V17, P3596, DOI 10.1093/hmg/ddn252; Trimmer C, 2011, CANCER BIOL THER, V11, P383, DOI 10.4161/cbt.11.4.14101; vanRoozendaal KEP, 1996, INT J CANCER, V65, P120, DOI 10.1002/(SICI)1097-0215(19960103)65:1<120::AID-IJC20>3.0.CO;2-J; Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	41	57	61	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2013	32	18					2356	2364		10.1038/onc.2012.270	http://dx.doi.org/10.1038/onc.2012.270			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140VF	22751126	Green Published, hybrid			2022-12-17	WOS:000318683600012
J	Tomkiewicz, C; Herry, L; Bui, LC; Metayer, C; Bourdeloux, M; Barouki, R; Coumoul, X				Tomkiewicz, C.; Herry, L.; Bui, L-C; Metayer, C.; Bourdeloux, M.; Barouki, R.; Coumoul, X.			The aryl hydrocarbon receptor regulates focal adhesion sites through a non-genomic FAK/Src pathway	ONCOGENE			English	Article						AhR; cell plasticity; FAK; integrin; Src	PROTEIN-TYROSINE KINASES; AH DIOXIN RECEPTOR; CANCER CELL-LINE; C-SRC; SIGNAL-TRANSDUCTION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ENVIRONMENTAL-POLLUTANTS; GENE-EXPRESSION; HUMAN ENHANCER; KNOCKOUT MICE	The aryl hydrocarbon receptor (AhR) is commonly described as a transcription factor, which regulates xenobiotic-metabolizing enzymes. Recent studies have suggested that the binding of ligands to the AhR also activates the Src kinase. In this manuscript, we show that the AhR, through the activation of Src, activates focal adhesion kinase (FAK) and promotes integrin clustering. These effects contribute to cell migration. Further, we show that the activation of the AhR increases the interaction of FAK with the metastatic marker, HEF1/NEDD9/CAS-L, and the expression of several integrins. Xenobiotic exposure, thus, may contribute to novel cell-migratory programs. Oncogene (2013) 32, 1811-1820; doi: 10.1038/onc.2012.197; published online 4 June 2012	[Tomkiewicz, C.; Herry, L.; Bui, L-C; Metayer, C.; Bourdeloux, M.; Barouki, R.; Coumoul, X.] INSERM, UMR S Toxicol Pharmacol & Signalisat Cellulaire 7, Paris, France; [Tomkiewicz, C.; Herry, L.; Bui, L-C; Metayer, C.; Bourdeloux, M.; Barouki, R.; Coumoul, X.] Univ Paris 05, Sorbonne Paris Cite, Ctr Univ St Peres, F-75006 Paris, France; [Herry, L.; Barouki, R.] Hop Necker Enfants Malad, AP HP, Serv Biochim Metab, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Coumoul, X (corresponding author), Univ Paris 05, Sorbonne Paris Cite, 45 Rue St Peres, F-75006 Paris, France.	xavier.coumoul@parisdescartes.fr	COUMOUL, Xavier/AAR-3649-2020	COUMOUL, Xavier/0000-0003-2928-9648	ANSES (Agence Nationale de SEcurite Sanitaire de l'alimentation, de l'environnement et du travail); ANR (Agence Nationale de la Recherche) [06SEST26]; ARC (Association pour la Recherche sur le Cancer) [3927, SFI20101201842]; CNRS (Center Nationale de la recherche scientifique); Fondation pour la Recherche Medicale; Ecole Doctorale du Medicament; Hospitals Europeen Georges Pompidou and Necker Enfants Malade; INSERM (Institut National de la Sante et de la Recherche Medicale); Ligue contre le Cancer; Ministere de l'enseignement superieur et de la recherche; Region Ile de France; Universite Paris Descartes, Paris Sorbonne Cite	ANSES (Agence Nationale de SEcurite Sanitaire de l'alimentation, de l'environnement et du travail)(French National Research Agency (ANR)); ANR (Agence Nationale de la Recherche)(French National Research Agency (ANR)); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); CNRS (Center Nationale de la recherche scientifique); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ecole Doctorale du Medicament; Hospitals Europeen Georges Pompidou and Necker Enfants Malade; INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue contre le Cancer(Ligue nationale contre le cancer); Ministere de l'enseignement superieur et de la recherche; Region Ile de France(Region Ile-de-France); Universite Paris Descartes, Paris Sorbonne Cite	This work was supported by the ANSES (Agence Nationale de SEcurite Sanitaire de l'alimentation, de l'environnement et du travail; all authors), ANR (Agence Nationale de la Recherche, 06SEST26, Oncopop; all authors), ARC (Association pour la Recherche sur le Cancer, 3927 and SFI20101201842; all authors), CNRS (Center Nationale de la recherche scientifique), Fondation pour la Recherche Medicale, 'Ecole Doctorale du Medicament', Hospitals Europeen Georges Pompidou and Necker Enfants Malade, INSERM (Institut National de la Sante et de la Recherche Medicale; all authors), Ligue contre le Cancer (post-doctoral fellowship), Ministere de l'enseignement superieur et de la recherche, Region Ile de France (doctoral fellowship) and Universite Paris Descartes, Paris Sorbonne Cite. The FRNK-expressing vector is a generous gift of Dr Kenneth M Yamada (NIDCR, NIH, USA) and Dr Bernard Rothhut (CNRS UMR 6237, Reims). We warmly thank Dr Lawrence Aggerbeck for his critical reading of this manuscript.	Ahmed S, 2005, FEBS J, V272, P903, DOI 10.1111/j.1742-4658.2004.04519.x; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Garcia MA, 2010, TOXICOL LETT, V192, P195, DOI 10.1016/j.toxlet.2009.10.026; Ambolet-Camoit A, 2010, TOXICOL SCI, V115, P501, DOI 10.1093/toxsci/kfq082; Ashida H, 2008, EXPERT OPIN DRUG MET, V4, P1429, DOI 10.1517/17425255.4.11.1429 ; Backlund M, 2005, CELL SIGNAL, V17, P39, DOI 10.1016/j.cellsig.2004.05.010; Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046; Blankenship A, 1997, MOL PHARMACOL, V52, P667, DOI 10.1124/mol.52.4.667; Bui LC, 2009, ONCOGENE, V28, P3642, DOI 10.1038/onc.2009.224; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Roman AC, 2009, J BIOL CHEM, V284, P25135, DOI 10.1074/jbc.M109.013292; Carvajal-Gonzalez JM, 2009, J CELL SCI, V122, P1823, DOI 10.1242/jcs.047274; Carvajal-Gonzalez JM, 2009, MOL BIOL CELL, V20, P1715, DOI 10.1091/mbc.E08-05-0451; Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828; Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10-08-0725; Destaing O, 2011, CURR OPIN CELL BIOL, V23, P597, DOI 10.1016/j.ceb.2011.04.002; Diry M, 2006, ONCOGENE, V25, P5570, DOI 10.1038/sj.onc.1209553; Dong B, 2011, BBA-GEN SUBJECTS, V1810, P427, DOI 10.1016/j.bbagen.2010.11.007; Enan E, 1996, BIOCHEM PHARMACOL, V52, P1599, DOI 10.1016/S0006-2952(96)00566-7; Enan E, 1998, J BIOCHEM MOL TOXIC, V12, P263, DOI 10.1002/(SICI)1099-0461(1998)12:5<263::AID-JBT2>3.0.CO;2-J; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Gomez-Duran A, 2006, J CELL BIOCHEM, V97, P380, DOI 10.1002/jcb.20637; Hamadi A, 2009, CELL MOL LIFE SCI, V66, P324, DOI 10.1007/s00018-008-8424-4; Hamadi A, 2010, J ONCOL, V2010, DOI 10.1155/2010/932803; Hivert V, 2009, BIOCHEM PHARMACOL, V78, P1017, DOI 10.1016/j.bcp.2009.06.005; Hoelper P, 2005, ARCH TOXICOL, V79, P201, DOI 10.1007/s00204-004-0624-6; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Kim MJ, 2011, ENVIRON HEALTH PERSP, V119, P377, DOI 10.1289/ehp.1002848; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kohle C, 1999, ARCH TOXICOL, V73, P152, DOI 10.1007/s002040050600; Law SF, 1996, MOL CELL BIOL, V16, P3327; Lemaire G, 2004, LIFE SCI, V74, P2265, DOI 10.1016/j.lfs.2003.09.056; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; Matsumura F, 2009, BIOCHEM PHARMACOL, V77, P608, DOI 10.1016/j.bcp.2008.10.013; Mayati A, 2012, J BIOL CHEM, V287, P4041, DOI 10.1074/jbc.M111.319970; McMillan BJ, 2007, MOL PHARMACOL, V72, P487, DOI 10.1124/mol.107.037259; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; Pierre S, 2011, BIOCHEM PHARMACOL, V81, P304, DOI 10.1016/j.bcp.2010.10.003; Pontillo CA, 2011, TOXICOL SCI, V120, P284, DOI 10.1093/toxsci/kfq390; Powell-Coffman JA, 1998, P NATL ACAD SCI USA, V95, P2844, DOI 10.1073/pnas.95.6.2844; Provenzano PP, 2009, CELL ADHES MIGR, V3, P347, DOI 10.4161/cam.3.4.9458; Puga A, 2000, BIOCHEM PHARMACOL, V60, P1129, DOI 10.1016/S0006-2952(00)00403-2; Puga A, 2009, BIOCHEM PHARMACOL, V77, P713, DOI 10.1016/j.bcp.2008.08.031; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Randi AS, 2008, TOXICOL LETT, V177, P116, DOI 10.1016/j.toxlet.2008.01.003; Ratushny V, 2012, ONCOGENE, V31, P1217, DOI 10.1038/onc.2011.314; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Sciullo EM, 2009, CHEMOSPHERE, V74, P1531, DOI 10.1016/j.chemosphere.2008.11.010; Singh MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI 10.1007/s12013-007-0036-3; Singh MK, 2010, CANCER RES, V70, P8907, DOI 10.1158/0008-5472.CAN-10-0353; Tikhmyanova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022102; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Tompkins LM, 2007, J BIOCHEM MOL TOXIC, V21, P176, DOI 10.1002/jbt.20180; Vogel CFA, 2003, J BIOCHEM MOL TOXIC, V17, P305, DOI 10.1002/jbt.10096; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413	64	57	62	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1811	1820		10.1038/onc.2012.197	http://dx.doi.org/10.1038/onc.2012.197			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22665056				2022-12-17	WOS:000317043900007
J	Castillo-Lluva, S; Tan, CT; Daugaard, M; Sorensen, PHB; Malliri, A				Castillo-Lluva, S.; Tan, C-T; Daugaard, M.; Sorensen, P. H. B.; Malliri, A.			The tumour suppressor HACE1 controls cell migration by regulating Rac1 degradation	ONCOGENE			English	Article						HACE1; Rac1; ubiquitylation; migration; HGF	LIGASE HACE1; GTPASE; PROTEINS	The small GTPase Rac1 is a key regulator of cell motility. Multiple mechanisms regulate Rac1 activity including its ubiquitylation and subsequent degradation. Here, we identify the tumour suppressor HACE1 (HECT domain and Ankyrin repeat Containing E3 ubiquitin-protein ligase 1) as an E3 ubiquitin ligase responsible for Rac1 degradation following activation by a migration stimulus. We show that HACE1 and Rac1 interaction is enhanced by hepatocyte growth factor (HGF) signalling, a Rac activator and potent stimulus of cell migration. Furthermore, HACE1 catalyses the poly-ubiquitylation of Rac1 at lysine 147 following its activation by HGF, resulting in its proteasomal degradation. This negative feedback mechanism likely restricts cell motility. Consistent with this, HACE1 depletion is accompanied by increased total Rac1 levels and accumulation of Rac1 in membrane ruffles. Moreover, HACE1-depletion enhances cell migration independently of growth factor stimulation, which may have significance for malignant conversion. A non-ubiquitylatable Rac1 rescues the migration defect of Rac1-null cells to a greater extent than wild-type Rac1. These findings identify HACE1 as an antagonist of cell migration through its ability to degrade active Rac1. Oncogene (2013) 32, 1735-1742; doi:10.1038/onc.2012.189; published online 21 May 2012	[Castillo-Lluva, S.; Tan, C-T; Malliri, A.] Univ Manchester, Cell Signalling Grp, Canc Res UK Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; [Daugaard, M.; Sorensen, P. H. B.] Univ British Columbia, Dept Mol Oncol, BC Canc Res Ctr, Vancouver, BC V6T 1Z4, Canada; [Daugaard, M.; Sorensen, P. H. B.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z4, Canada	Cancer Research UK; University of Manchester; British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Malliri, A (corresponding author), Univ Manchester, Cell Signalling Grp, Canc Res UK Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	amalliri@picr.man.ac.uk	CASTILLO-LLUVA, SONIA/AAA-1776-2020; Daugaard, Mads/Y-6483-2018	Castillo-LLuva, Sonia/0000-0001-5357-7178; Malliri, Angeliki/0000-0001-6848-090X; Tan, Chong Teik/0000-0002-9503-8364; Daugaard, Mads/0000-0001-8383-055X	Cancer Research UK [C147/A12328]; Association for International Cancer Research grant [12-0037]; EMBO long-term fellowship; British Columbia Cancer Foundation; Danish Cancer Society Scientific Committee [R2-A189-B146]; Cancer Research UK [12937] Funding Source: researchfish; Worldwide Cancer Research [12-0037] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Association for International Cancer Research grant; EMBO long-term fellowship(European Molecular Biology Organization (EMBO)); British Columbia Cancer Foundation; Danish Cancer Society Scientific Committee; Cancer Research UK(Cancer Research UK); Worldwide Cancer Research	This work was supported by Cancer Research UK grant number C147/A12328 and the Association for International Cancer Research grant number 12-0037 to AM. SCL was additionally supported by an EMBO long-term fellowship. Also this work was supported in part by funds to PHBS from the British Columbia Cancer Foundation through generous donations from Team Finn and other riders in the Ride to Conquer Cancer. MD was supported by The Danish Cancer Society Scientific Committee (grant number R2-A189-B146). We thank Dr Trusolino, Dr Sanchez-Madrid and Dr Vidali for reagents, Dr Hurlstone and Dr Wilkinson for critical reading of the manuscript.	Anglesio MS, 2004, HUM MOL GENET, V13, P2061, DOI 10.1093/hmg/ddh215; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Castillo-Lluva S, 2010, NAT CELL BIOL, V12, P1078, DOI 10.1038/ncb2112; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Doye A, 2006, METHOD ENZYMOL, V406, P447, DOI 10.1016/S0076-6879(06)06033-2; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9; Gentile A, 2008, CANCER METAST REV, V27, P85, DOI 10.1007/s10555-007-9107-6; Hays JL, 2003, J BIOL CHEM, V278, P27456, DOI 10.1074/jbc.M210648200; Lynch EA, 2006, MOL BIOL CELL, V17, P2236, DOI 10.1091/mbc.E05-08-0779; Nethe M, 2010, J CELL SCI, V123, P1948, DOI 10.1242/jcs.062919; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Torrino S, 2011, DEV CELL, V21, P959, DOI 10.1016/j.devcel.2011.08.015; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; Vidali L, 2006, MOL BIOL CELL, V17, P2377, DOI 10.1091/mbc.E05-10-0955; Visvikis O, 2008, FEBS J, V275, P386, DOI 10.1111/j.1742-4658.2007.06209.x; Zhang L, 2007, NAT MED, V13, P1060, DOI 10.1038/nm1621	19	57	60	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 28	2013	32	13					1735	1742		10.1038/onc.2012.189	http://dx.doi.org/10.1038/onc.2012.189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116AY	22614015				2022-12-17	WOS:000316855800013
J	Nasr, Z; Robert, F; Porco, JA; Muller, WJ; Pelletier, J				Nasr, Z.; Robert, F.; Porco, J. A., Jr.; Muller, W. J.; Pelletier, J.			eIF4F suppression in breast cancer affects maintenance and progression	ONCOGENE			English	Article						elF4E; elF4A; PyMT mouse model; breast cancer; pulmonary metastasis	INITIATION-FACTOR 4E; MAMMARY-TUMOR PROGRESSION; CELL-GROWTH; C-MYC; THERAPEUTIC SUPPRESSION; EPITHELIAL-CELLS; MOUSE MODEL; TSC GENES; TRANSLATION; EXPRESSION	Levels of eukaryotic initiation factor 4E (eIF4E) are frequently elevated in human cancers and in some instances have been associated with poor prognosis and outcome. Here we utilize transgenic and allograft breast cancer models to demonstrate that increased mammalian target of rapamycin (mTOR) signalling can be a significant contributor to breast cancer progression in vivo. Suppressing mTOR activity, as well as levels and activity of the downstream translation regulators, elF4E and elF4A, delayed breast cancer progression, onset of associated pulmonary metastasis in vivo and breast cancer cell invasion and migration in vitro. Translation of vascular endothelial growth factor (VEGF), matrix metallopeptidase 9 (MMP9) and cyclin D1 mRNAs, which encode products associated with the metastatic phenotype, is inhibited upon eIF4E suppression. Our results indicate that the mTOR/eIF4F axis is an important contributor to tumor maintenance and progression programs in breast cancer. Targeting this pathway may be of therapeutic benefit. Oncogene (2013) 32, 861-871; doi:10.1038/onc.2012.105; published online 9 April 2012	[Nasr, Z.; Robert, F.; Muller, W. J.; Pelletier, J.] McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [Porco, J. A., Jr.] Boston Univ, Dept Chem, Ctr Chem Methodol & Lib Dev, Boston, MA 02215 USA; [Muller, W. J.; Pelletier, J.] McGill Univ, Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University; Boston University; McGill University	Pelletier, J (corresponding author), McGill Univ, McIntyre Med Sci Bldg,Room 810,3655 Promenade Sir, Montreal, PQ H3G 1Y6, Canada.	jerry.pelletier@mcgill.ca			Canadian Institutes of Health Research [MOP-89791, MOP-106530]; CRC Chair in Molecular Oncology; National Institutes of Health [GM-073855]; Canadian Cancer Society Research Institute (CCSRI) [17099]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM111625, R01GM073855] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); CRC Chair in Molecular Oncology; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	WJM is supported by the Canadian Institutes of Health Research (MOP-89791) and a CRC Chair in Molecular Oncology. JAP, Jr thanks the National Institutes of Health (GM-073855) for research support. This work was supported by the Canadian Institutes of Health Research (MOP-106530) and the Canadian Cancer Society Research Institute (CCSRI no. 17099) to JP.	Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bordeleau ME, 2008, J CLIN INVEST, V118, P2651, DOI 10.1172/JCI34753; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Brown CJ, 2011, J MOL BIOL, V405, P736, DOI 10.1016/j.jmb.2010.10.045; Cencic R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005223; Chakraborty S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-163; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dong K, 2009, BREAST CANCER RES TR, V113, P443, DOI 10.1007/s10549-008-9956-x; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Graff JR, 2007, J CLIN INVEST, V117, P2638, DOI 10.1172/JCI32044; GRAFF JR, 1995, INT J CANCER, V60, P255; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Iliopoulos D, 2011, CANCER RES, V71, P3196, DOI 10.1158/0008-5472.CAN-10-3471; Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Ko SY, 2009, CLIN CANCER RES, V15, P4336, DOI 10.1158/1078-0432.CCR-08-2924; Konicek BW, 2011, CANCER RES, V71, P1849, DOI 10.1158/0008-5472.CAN-10-3298; Larsson O, 2007, CANCER RES, V67, P6814, DOI 10.1158/0008-5472.CAN-07-0752; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li BDL, 1997, CANCER-AM CANCER SOC, V79, P2385; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lin CJ, 2008, CANCER RES, V68, P5326, DOI 10.1158/0008-5472.CAN-07-5876; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Maglione JE, 2001, CANCER RES, V61, P8298; Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Pons B, 2011, INT J ONCOL, V39, P1337, DOI 10.3892/ijo.2011.1118; PRICE JE, 1990, CANCER RES, V50, P717; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Soni A, 2008, MOL CANCER THER, V7, P1782, DOI 10.1158/1535-7163.MCT-07-2357; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42; Wendel HG, 2006, CANCER RES, V66, P7639, DOI 10.1158/0008-5472.CAN-06-0419; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wienecke R, 1997, ANN NEUROL, V42, P230, DOI 10.1002/ana.410420215; Xu ZF, 2009, LEUKEMIA RES, V33, P891, DOI 10.1016/j.leukres.2009.01.041; Zhou FF, 2011, MED ONCOL, V28, P1302, DOI 10.1007/s12032-010-9630-0; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420	57	57	63	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					861	871		10.1038/onc.2012.105	http://dx.doi.org/10.1038/onc.2012.105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22484424	Green Accepted			2022-12-17	WOS:000316581100006
J	Guo, J; Kim, D; Gao, J; Kurtyka, C; Chen, H; Yu, C; Wu, D; Mittal, A; Beg, AA; Chellappan, SP; Haura, EB; Cheng, JQ				Guo, J.; Kim, D.; Gao, J.; Kurtyka, C.; Chen, H.; Yu, C.; Wu, D.; Mittal, A.; Beg, A. A.; Chellappan, S. P.; Haura, E. B.; Cheng, J. Q.			IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer	ONCOGENE			English	Article						IKBKE; STAT3; tobacco carcinogen; chemosensitivity; lung cancer	B KINASE-EPSILON; PULMONARY NEUROENDOCRINE CELLS; TUMOR-SUPPRESSOR CYLD; IKK-EPSILON; BREAST-CANCER; NICOTINIC RECEPTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; SRC ONCOPROTEIN; IN-VIVO	Serine/threonine kinase IKBKE is a newly identified oncogene; however, its regulation remains elusive. Here, we provide evidence that IKBKE is a downstream target of signal transducer and activator of transcription 3 (STAT3) and that tobacco components induce IKBKE expression through STAT3. Ectopic expression of constitutively active STAT3 increased IKBKE mRNA and protein levels, whereas inhibition of STAT3 reduced IKBKE expression. Furthermore, expression levels of IKBKE are significantly associated with STAT3 activation and tobacco use history in non-small cell lung cancer (NSCLC) patients examined. In addition, we show induction of IKBKE by two components of cigarette smoke, nicotine and nicotine-derived nitrosamine ketone (NNK). Upon exposure to nicotine or NNK, cells express high levels of IKBKE protein and mRNA, which are largely abrogated by inhibition of STAT3. Characterization of the IKBKE promoter revealed two STAT3-response elements. The IKBKE promoter directly bound to STAT3 and responded to nicotine and NNK stimulation. Notably, enforcing expression of IKBKE induces chemoresistance, whereas knockdown of IKBKE not only sensitizes NSCLC cells to chemotherapy but also abrogates STAT3- and nicotine-induced cell survival. These data indicate for the first time that IKBKE is a direct target of STAT3 and is induced by tobacco carcinogens through STAT3 pathway. In addition, our study also suggests that IKBKE is an important therapeutic target and could have a pivotal role in tobacco-associated lung carcinogenesis. Oncogene (2013) 32, 151-159; doi:10.1038/onc.2012.39; published online 13 February 2012	[Guo, J.; Kim, D.; Gao, J.; Kurtyka, C.; Chen, H.; Yu, C.; Wu, D.; Mittal, A.; Cheng, J. Q.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL 33682 USA; [Beg, A. A.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Immunol, Tampa, FL 33682 USA; [Chellappan, S. P.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Tumor Biol, Tampa, FL 33682 USA; [Haura, E. B.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Thorac Oncol, Tampa, FL 33682 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	jin.cheng@moffitt.org	Chen, Huihua/D-9162-2019	Chen, Huihua/0000-0002-5045-6845; Wu, Danwei/0000-0003-3411-0382	NCI [CA137041, P50 CA119997]; James and Esther King Biomedical Research Program [1KG02, 1KD04, 1KN08]; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA137041, P50CA119997, R01CA160455] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); James and Esther King Biomedical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Tissue Procurement, DNA Sequence and Image Core Facilities at H Lee Moffitt Cancer Center for providing cancer specimens, sequencing and cell apoptosis analysis as well as Fumi Kinose for helping provide lung cancer cell lines from the Moffitt lung cancer cell line core. This work was supported by NCI Grants CA137041 (JQC) and P50 CA119997 (EBH) and James and Esther King Biomedical Research Program 1KG02 (JQC), 1KD04 (JG) and 1KN08 (DK).	Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200; Arredondo J, 2006, FASEB J, V20, P2093, DOI 10.1096/fj.06-6191com; Barre B, 2005, J BIOL CHEM, V280, P15673, DOI 10.1074/jbc.M413203200; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Chang KT, 2005, AM J PHYSIOL-LUNG C, V289, pL446, DOI 10.1152/ajplung.00089.2005; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Chen RJ, 2010, TOXICOL SCI, V115, P118, DOI 10.1093/toxsci/kfq028; Cheng AN, 2011, AM J CLIN PATHOL, V136, P60, DOI 10.1309/AJCP2JJGYNIUAS2V; Dasgupta P, 2006, CELL CYCLE, V5, P2324, DOI 10.4161/cc.5.20.3366; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fan J, 2007, EJSO-EUR J SURG ONC, V33, P639, DOI 10.1016/j.ejso.2007.02.001; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Guo JP, 2011, J BIOL CHEM, V286, P37389, DOI 10.1074/jbc.M111.287433; Guo JP, 2010, J BIOL CHEM, V285, P3676, DOI 10.1074/jbc.M109.078212; Guo JP, 2009, AM J PATHOL, V175, P324, DOI 10.2353/ajpath.2009.080767; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Hosur V, 2011, MOL PHARMACOL, V79, P167, DOI 10.1124/mol.110.066381; Hutti JE, 2009, MOL CELL, V34, P461, DOI 10.1016/j.molcel.2009.04.031; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Keen JC, 2006, IMMUNOLOGY, V117, P29, DOI 10.1111/j.1365-2567.2005.02260.x; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Liu XD, 2007, BIOCHEM BIOPH RES CO, V353, P121, DOI 10.1016/j.bbrc.2006.11.147; Liu Y, 2010, ANTI-CANCER AGENT ME, V10, P512, DOI 10.2174/187152010793498636; Mai HQ, 2003, J BIOL CHEM, V278, P1886, DOI 10.1074/jbc.M209044200; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Memmott RM, 2010, CLIN CANCER RES, V16, P4, DOI 10.1158/1078-0432.CCR-09-0234; Nadiminty N, 2006, P NATL ACAD SCI USA, V103, P7264, DOI 10.1073/pnas.0509808103; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wang NZ, 2005, GENE, V353, P118, DOI 10.1016/j.gene.2005.04.013; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Xie XD, 2011, P NATL ACAD SCI USA, V108, P6474, DOI 10.1073/pnas.1016132108; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	50	57	62	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2013	32	2					151	159		10.1038/onc.2012.39	http://dx.doi.org/10.1038/onc.2012.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078CK	22330135	Green Accepted			2022-12-17	WOS:000314075500003
J	Dudgeon, C; Peng, R; Wang, P; Sebastiani, A; Yu, J; Zhang, L				Dudgeon, C.; Peng, R.; Wang, P.; Sebastiani, A.; Yu, J.; Zhang, L.			Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3 beta and NF-kappa B to suppress tumor cell growth	ONCOGENE			English	Article						sorafenib; PUMA; apoptosis; NF-kappa B; GSK3 beta; colon cancer	MULTIKINASE INHIBITOR; DOWN-REGULATION; RAF/MEK/ERK PATHWAY; MEDIATED APOPTOSIS; ANTITUMOR-ACTIVITY; CANCER-THERAPY; UP-REGULATION; PHASE-II; KINASE; COMBINATION	Aberrant Ras/Raf/MEK/ERK signaling is one of the most prevalent oncogenic alterations and confers survival advantage to tumor cells. Inhibition of this pathway can effectively suppress tumor cell growth. For example, sorafenib, a multi-kinase inhibitor targeting c-Raf and other oncogenic kinases, has been used clinically for treating advanced liver and kidney tumors, and also has shown efficacy against other malignancies. However, how inhibition of oncogenic signaling by sorafenib and other drugs suppresses tumor cell growth remains unclear. In this study, we found that sorafenib kills cancer cells by activating PUMA (p53-upregulated modulator of apoptosis), a p53 target and a BH3-only Bcl-2 family protein. Sorafenib treatment induces PUMA in a variety of cancer cells irrespective of their p53 status. Surprisingly, the induction of PUMA by sorafenib is mediated by I kappa B-independent activation of nuclear factor (NF)-kappa B, which directly binds to the PUMA promoter to activate its transcription. NF-kappa B activation by sorafenib requires glycogen synthase kinase 3 beta activation, subsequent to ERK inhibition. Deficiency in PUMA abrogates sorafenib-induced apoptosis and caspase activation, and renders sorafenib resistance in colony formation and xenograft tumor assays. Furthermore, the chemosensitization effect of sorafenib is dependent on PUMA, and involves concurrent PUMA induction through different pathways. BH3 mimetics potentiate the anti-cancer effects of sorafenib, and restore sorafenib sensitivity in resistant cells. Together, these results demonstrate a key role of PUMA-dependent apoptosis in therapeutic inhibition of Ras/Raf/MEK/ERK signaling. They provide a rationale for manipulating the apoptotic machinery to improve sensitivity and overcome resistance to the therapies that target oncogenic kinase signaling.	[Zhang, L.] Univ Pittsburgh, Hillman Canc Ctr, Dept Pharmacol & Chem Biol, UPCI Res Pavil, Pittsburgh, PA 15213 USA; [Yu, J.] Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Pharmacol & Chem Biol, UPCI Res Pavil, Room 2-42A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	zhanglx@upmc.edu	Yu, Jian/A-8301-2009; Zhang, Lin/A-7389-2009	Yu, Jian/0000-0002-4021-1000; Zhang, Lin/0000-0003-0018-3903; Dudgeon, Crissy/0000-0001-9010-2569	NIH [CA106348, CA121105]; American Cancer Society [RSG-07-156-01-CNE, RGS-10-124-01-CCE]; Flight Attendant Medical Research Institute, NIH [CA129829]; NIH National Research Service [F32CA139882]; China Scholarship Council; NATIONAL CANCER INSTITUTE [R01CA121105, F32CA139882, R01CA106348, R01CA129829] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Flight Attendant Medical Research Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Monica E Buchanan, Brian Leibowitz, Mathew F Brown and other lab members for critical reading and helpful discussion, and Drs Jennifer R Grandis and Jing Hu for help with analyses of STAT1, STAT3, eIF4E and GSK3 beta. This work is supported by NIH grants CA106348 and CA121105 and American Cancer Society grant RSG-07-156-01-CNE (LZ); Flight Attendant Medical Research Institute, NIH grant CA129829 and American Cancer Society grant RGS-10-124-01-CCE (JY); NIH National Research Service Award postdoctoral fellowship grant F32CA139882 (CD); and China Scholarship Council (RP). LZ is a scholar of the V Foundation for Cancer Research.	Augustine CK, 2010, MOL CANCER THER, V9, P2090, DOI 10.1158/1535-7163.MCT-10-0073; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786; Clark JW, 2005, CLIN CANCER RES, V11, P5472, DOI 10.1158/1078-0432.CCR-04-2658; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Dudgeon C, 2010, MOL CANCER THER, V9, P2893, DOI 10.1158/1535-7163.MCT-10-0635; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Gomez-Benito M, 2005, MOL PHARMACOL, V67, P1991, DOI 10.1124/mol.104.007021; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Hikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836; Hong DS, 2009, CLIN CANCER RES, V15, P7061, DOI 10.1158/1078-0432.CCR-09-1241; Huang SB, 2010, MOL CANCER THER, V9, P742, DOI 10.1158/1535-7163.MCT-09-1004; Kim C, 2010, INVEST NEW DRUGS; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475; Lind JSW, 2010, CLIN CANCER RES, V16, P3078, DOI 10.1158/1078-0432.CCR-09-3033; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Martin AP, 2009, MOL PHARMACOL, V76, P327, DOI 10.1124/mol.109.056309; Martinelli E, 2010, CLIN CANCER RES, V16, P4990, DOI 10.1158/1078-0432.CCR-10-0923; Ming LH, 2008, CARCINOGENESIS, V29, P1878, DOI 10.1093/carcin/bgn150; Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200; Molhoek KR, 2005, J TRANSL MED, V3, P1, DOI 10.1186/1479-5876-3-39; Opferman JT, 2005, SCIENCE, V307, P1101, DOI 10.1126/science.1106114; Plastaras JP, 2007, CANCER RES, V67, P9443, DOI 10.1158/0008-5472.CAN-07-1473; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sun Q, 2009, ONCOGENE, V28, P2348, DOI 10.1038/onc.2009.108; Sun WJ, 2010, J CLIN ONCOL, V28, P2947, DOI 10.1200/JCO.2009.27.7988; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wilhelm S, 2002, CURR PHARM DESIGN, V8, P2255, DOI 10.2174/1381612023393026; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2006, CLIN CANCER RES, V12, P2928, DOI 10.1158/1078-0432.CCR-05-2429; Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267; Zhang G, 2008, CLIN CANCER RES, V14, P5385, DOI 10.1158/1078-0432.CCR-08-0469; Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002; Zhang W, 2008, LEUKEMIA, V22, P808, DOI 10.1038/sj.leu.2405098	51	57	58	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2012	31	46					4848	4858		10.1038/onc.2011.644	http://dx.doi.org/10.1038/onc.2011.644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	038YT	22286758	Green Accepted, Bronze			2022-12-17	WOS:000311210700005
J	Bai, H; Inoue, J; Kawano, T; Inazawa, J				Bai, H.; Inoue, J.; Kawano, T.; Inazawa, J.			A transcriptional variant of the LC3A gene is involved in autophagy and frequently inactivated in human cancers	ONCOGENE			English	Article						autophagy; microtubule-associated protein; human cancers; DNA methylation; ESCC	PROGNOSTIC RELEVANCE; LIGHT; TUMORIGENESIS; BECLIN-1; DEFICIENT; PATTERNS; PROTEIN; MAP1A; P62	Microtubule-associated protein 1 light chain 3 has an important role in autophagy. The human LC3 gene family has five members, LC3A (variant-1: v1 and -2: v2), LC3B, LC3B2 and LC3C. Although a form of LC3B modified by phosphatidylethanolamine (form-II) is localized in autophagosomes, it is not clear whether other LC3 proteins also function in autophagy. Here, we examined the association between autophagy and human LC3 proteins during starvation- or p53-induced autophagy in Saos-2 cells. In an analysis of the intracellular distribution of each LC3 protein fused with GFP, GFP-LC3Av1 was frequently localized in autophagosomes with a punctate pattern, similar to GFP-LC3B. Further, endogenous LC3Av1 generated form-II and mostly localized in LC3B-positive autophagosomes during the induced autophagy. Interestingly, LC3Av1, not LC3B, was frequently inactivated at the transcriptional level in various human cancer cell lines (111/244 cell lines, 45.5%) and its inactivation was due to aberrant DNA methylation in esophageal squamous cell carcinoma (ESCC) cell lines and primary tumors. Restoration of LC3Av1 expression in KYSE170 cells, an LC3Av1-inactivated ESCC cell line, showed the inhibition of tumor growth in vivo. These results suggest that LC3Av1, not only LC3B, functions in autophagy and further, LC3Av1 may be crucial in carcinogenesis. Oncogene (2012) 31, 4397-4408; doi: 10.1038/onc.2011.613; published online 16 January 2012	[Inazawa, J.] Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; [Bai, H.; Inoue, J.; Inazawa, J.] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Tokyo 1138510, Japan; [Kawano, T.] Tokyo Med & Dent Univ, Dept Surg, Grad Sch, Tokyo 1138510, Japan; [Bai, H.; Inazawa, J.] Tokyo Med & Dent Univ, Global Ctr, Excellence Program Frontier Res Mol Destruct & Re, Tokyo 1138510, Japan; [Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp			Japanese Ministry of Education Core Research for Evolutional Science and Technology of Japan Science and Technology (JST) Corporation; New Energy and Industrial Technology Development Organization (NEDO); Grants-in-Aid for Scientific Research [22134002] Funding Source: KAKEN	Japanese Ministry of Education Core Research for Evolutional Science and Technology of Japan Science and Technology (JST) Corporation; New Energy and Industrial Technology Development Organization (NEDO)(New Energy and Industrial Technology Development Organization (NEDO)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ayako Takahashi and Rumi Mori for technical assistance. This work is supported by Grant-in-Aid for Scientific Research on Priority Areas and Innovative Areas, young scientists (B) and a Global Center of Excellence (GCOE) Program from the Japanese Ministry of Education Core Research for Evolutional Science and Technology of Japan Science and Technology (JST) Corporation, and New Energy and Industrial Technology Development Organization (NEDO).	Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Cann GM, 2008, DEV DYNAM, V237, P187, DOI 10.1002/dvdy.21392; Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Faller EM, 2009, MOL CELL NEUROSCI, V41, P85, DOI 10.1016/j.mcn.2009.02.001; Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500; Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Inoue J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007099; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Komatsu M, 2011, AUTOPHAGY, V7, P1088, DOI 10.4161/auto.7.9.16474; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; KUZNETSOV SA, 1987, FEBS LETT, V212, P145, DOI 10.1016/0014-5793(87)81574-0; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; MANN SS, 1994, J BIOL CHEM, V269, P11492; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291; Shvets E, 2008, J CELL SCI, V121, P2685, DOI 10.1242/jcs.026005; Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947; Sivridis E, 2010, AUTOPHAGY, V6, P830, DOI 10.4161/auto.6.6.12588; Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Tanida I, 2004, J BIOL CHEM, V279, P47704, DOI 10.1074/jbc.M407016200; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726; Wu JX, 2006, BIOCHEM BIOPH RES CO, V339, P437, DOI 10.1016/j.bbrc.2005.10.211; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	38	57	61	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	40					4397	4408		10.1038/onc.2011.613	http://dx.doi.org/10.1038/onc.2011.613			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017LL	22249245				2022-12-17	WOS:000309591300006
J	Tkocz, D; Crawford, NT; Buckley, NE; Berry, FB; Kennedy, RD; Gorski, JJ; Harkin, DP; Mullan, PB				Tkocz, D.; Crawford, N. T.; Buckley, N. E.; Berry, F. B.; Kennedy, R. D.; Gorski, J. J.; Harkin, D. P.; Mullan, P. B.			BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers	ONCOGENE			English	Article						BRCA1; GATA3; FOXC1; basal-like; corepression	EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION PATTERNS; PROGNOSTIC-SIGNIFICANCE; MAMMARY-GLAND; CELLS; TUMORS; DIFFERENTIATION; METASTASIS; DOCETAXEL; SUBTYPES	In this study we describe a novel interaction between the breast/ovarian tumor suppressor gene BRCA1 and the transcription factor GATA3, an interaction, which is important for normal breast differentiation. We show that the BRCA1-GATA3 interaction is important for the repression of genes associated with triple-negative and basal-like breast cancer (BLBCs) including FOXC1, and that GATA3 interacts with a C-terminal region of BRCA1. We demonstrate that FOXC1 is an essential survival factor maintaining the proliferation of BLBCs cell lines. We define the mechanistic basis of this corepression and identify the GATA3-binding site within the FOXC1 distal promoter region. We show that BRCA1 and GATA3 interact on the FOXC1 promoter and that BRCA1 requires GATA3 for recruitment to this region. This interaction requires fully functional BRCA1 as a mutant BRCA1 protein is unable to localize to the FOXC1 promoter or repress FOXC1 expression. We demonstrate that this BRCA1-GATA3 repression complex is not a FOXC1-specific phenomenon as a number of other genes associated with BLBCs such as FOXC2, CXCL1 and p-cadherin were also repressed in a similar manner. Finally, we demonstrate the importance of our findings by showing that loss of GATA3 expression or aberrant FOXC1 expression contributes to the drug resistance and epithelial-to-mesenchymal transition-like phenotypes associated with aggressive BLBCs. Oncogene (2012) 31, 3667-3678; doi:10.1038/onc.2011.531; published online 28 November 2011	[Tkocz, D.; Crawford, N. T.; Buckley, N. E.; Kennedy, R. D.; Gorski, J. J.; Harkin, D. P.; Mullan, P. B.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Berry, F. B.] Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada	Queens University Belfast; University of Alberta	Mullan, PB (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, CCRCB Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	p.mullan@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Buckley, Niamh/0000-0001-9326-8513	Action Cancer Northern Ireland; Breast Cancer Campaign; Medical Research Council [G0600267] Funding Source: researchfish; MRC [G0600267] Funding Source: UKRI	Action Cancer Northern Ireland; Breast Cancer Campaign; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We would like to acknowledge the kind gift of mouse antihuman fibronectin antibody from Professor Philip Rudland (University of Liverpool). This work was supported by grants from the Action Cancer Northern Ireland (DT) and the Breast Cancer Campaign (NTC).	Ademuyiwa FO, 2010, MODERN PATHOL, V23, P270, DOI 10.1038/modpathol.2009.172; Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Arnold JM, 2010, BREAST CANCER RES TR, V119, P491, DOI 10.1007/s10549-008-0269-x; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Berry FB, 2008, HUM MOL GENET, V17, P490, DOI 10.1093/hmg/ddm326; Bierie B, 2008, CANCER RES, V68, P1809, DOI 10.1158/0008-5472.CAN-07-5597; Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Buckley NE, 2007, MOL CANCER RES, V5, P261, DOI 10.1158/1541-7786.MCR-06-0250; Buckley NE, 2011, CANCER RES, V71, P1933, DOI 10.1158/0008-5472.CAN-10-2717; Campora E, 2008, ANTICANCER RES, V28, P3993; D'Anello L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-300; Dejeux E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-68; Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jacquemier J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2249; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Kouroussis C, 1999, ANN ONCOL, V10, P547, DOI 10.1023/A:1026441804889; Laakso M, 2005, MODERN PATHOL, V18, P1321, DOI 10.1038/modpathol.3800456; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Marchini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014131; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Wang HQ, 2010, CHINESE MED J-PEKING, V123, P3212, DOI 10.3760/cma.j.issn.0366-6999.2010.22.007; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yang QF, 2001, CANCER-AM CANCER SOC, V92, P54, DOI 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8; Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	50	57	63	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	32					3667	3678		10.1038/onc.2011.531	http://dx.doi.org/10.1038/onc.2011.531			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	990TF	22120723				2022-12-17	WOS:000307653800002
J	Gallagher, EJ; Fierz, Y; Vijayakumar, A; Haddad, N; Yakar, S; LeRoith, D				Gallagher, E. J.; Fierz, Y.; Vijayakumar, A.; Haddad, N.; Yakar, S.; LeRoith, D.			Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia	ONCOGENE			English	Article						insulin resistance; diabetes; breast cancer; PI3K inhibitor	BREAST-CANCER; CELL-PROLIFERATION; GLUCOSE-UPTAKE; IGF-I; TRASTUZUMAB; PROGRESSION; CARCINOMA; ISOFORM; PATHWAY; KINASE	Women with type 2 diabetes mellitus (T2DM) are at a greater risk of developing and dying from breast cancer than women without T2DM. Insulin resistance and hyperinsulinemia underlie the pathogenesis of T2DM. In the MKR mouse model of insulin resistance, we have previously shown increased activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in association with accelerated mammary tumor growth. In this study, we demonstrate that inhibiting PI3K with the oral pan-class I PI3K inhibitor, NVP-BKM120 reduced the growth of Met-1 and MCNeuA mammary tumor orthografts in the MKR mouse. NVP-BKM120 treatment decreased phosphorylation of Akt and S6 ribosomal protein (S6rp); no change in Erk1/2 phosphorylation was seen. Hyperglycemia, hypertriglyceridemia and greater hyperinsulinemia developed in the MKR mice treated with NVP-BKM120. We previously reported reduced tumor growth using intraperitoneal rapamycin in the MKR mouse, with the development of hyperglycemia and hypertriglyceridemia. Therefore, we examined whether the oral PI3K/mTOR inhibitor NVP-BEZ235 augmented the tumor suppressing effects of PI3K inhibition. We also investigated the effect of targeted PI3K/mTOR inhibition on PI3K/Akt/mTOR and Erk1/2 signaling, and the potential effects on glycemia. NVP-BEZ235 suppressed the growth of Met-1 and MCNeuA tumor orthografts, and decreased Akt and S6rp phosphorylation, despite increased Erk1/2 phosphorylation in Met-1 orthografts of MKR mice. Less marked hyperglycemia and hyperinsulinemia developed with NVP-BEZ235 than NVP-BKM120. Overall, the results of this study demonstrated that inhibiting PI3K/Akt/mTOR signaling with the oral agents NVP-BKM120 and NVP-BEZ235 decreased mammary tumor growth in the hyperinsulinemic MKR mouse. Inhibiting PI3K alone led to more severe metabolic derangement than inhibiting both PI3K and mTOR. Therefore, PI3K may be an important target for the treatment of breast cancer in women with insulin resistance. Monitoring for hyperglycemia and dyslipidemia should be considered when using these agents in humans, given the metabolic changes detected in this study. Oncogene (2012) 31, 3213-3222; doi:10.1038/onc.2011.495; published online 31 October 2011	[Gallagher, E. J.; Fierz, Y.; Vijayakumar, A.; Haddad, N.; Yakar, S.; LeRoith, D.] Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	LeRoith, D (corresponding author), Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Box 1055,1 Gustave L Levy Pl, New York, NY 10029 USA.	Derek.LeRoith@mssm.edu			American Diabetes Association; National Cancer Institute [R01-5R01-CA128799]; Swiss National Science Foundation [PBBSB-120851, PBBSB3-120851]; Novartis Foundation; Roche Research Foundation; Oncosuisse Foundation; NATIONAL CANCER INSTITUTE [R01CA128799] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis); Roche Research Foundation; Oncosuisse Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DLR received a mentor award from the American Diabetes Association. This work was funded by National Cancer Institute grant R01-5R01-CA128799. YF received grants from the Swiss National Science Foundation [PBBSB-120851 and PBBSB3-120851] and the Novartis Foundation, the Roche Research Foundation and the Oncosuisse Foundation. NVP-BKM120 and NVP-BEZ235 were supplied by Novartis Pharma (Basel, Switzerland) free of charge.	Agnoli C, 2010, NUTR METAB CARDIOVAS, V20, P41, DOI 10.1016/j.numecd.2009.02.006; Arpino G, 2007, JNCI-J NATL CANCER I, V99, P694, DOI 10.1093/jnci/djk151; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; Campbell MJ, 2002, IN VITRO CELL DEV-AN, V38, P326; Cannata D, 2010, ENDOCRINOLOGY, V151, P5751, DOI 10.1210/en.2010-0792; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; Fierz Y, 2010, ENDOCR-RELAT CANCER, V17, P941, DOI 10.1677/ERC-10-0091; Foukas LC, 2010, P NATL ACAD SCI USA, V107, P11381, DOI 10.1073/pnas.0906461107; Goodwin PJ, 2002, J CLIN ONCOL, V20, P42, DOI 10.1200/JCO.20.1.42; Jia SD, 2008, NATURE, V454, P776, DOI 10.1038/nature07091; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Liu LZ, 2006, MOL BIOL CELL, V17, P2322, DOI 10.1091/mbc.E05-10-0969; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Novosyadlyy R, 2010, CANCER RES, V70, P741, DOI 10.1158/0008-5472.CAN-09-2141; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Patterson RE, 2010, BREAST CANCER RES TR, V122, P859, DOI 10.1007/s10549-010-0732-3; Peairs KS, 2011, J CLIN ONCOL, V29, P40, DOI 10.1200/JCO.2009.27.3011; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Sopasakis VR, 2010, CELL METAB, V11, P220, DOI 10.1016/j.cmet.2010.02.002; Tan SX, 2010, BIOCHEM J, V432, P191, DOI 10.1042/BJ20100750; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Wells V, 2007, ONCOGENE, V26, P7709, DOI 10.1038/sj.onc.1210580	26	57	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3213	3222		10.1038/onc.2011.495	http://dx.doi.org/10.1038/onc.2011.495			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22037215	Green Accepted			2022-12-17	WOS:000306113400001
J	Li, X; Cheung, KF; Ma, X; Tian, L; Zhao, J; Go, MYY; Shen, B; Cheng, ASL; Ying, J; Tao, Q; Sung, JJY; Kung, HF; Yu, J				Li, X.; Cheung, K. F.; Ma, X.; Tian, L.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Ying, J.; Tao, Q.; Sung, J. J. Y.; Kung, H-F; Yu, J.			Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients	ONCOGENE			English	Article						paired box gene 5; gastric cancer; tumor suppressor gene; epigenetic alteration; prognosis	TRANSCRIPTION FACTOR BSAP; HEPATOCYTE GROWTH-FACTOR; CPG ISLAND METHYLATION; DOWN-REGULATION; BREAST-CANCER; MATRIX METALLOPROTEINASES; MET PROTOONCOGENE; CELL-DEVELOPMENT; B-LYMPHOPOIESIS; LUNG-CANCER	Using genome-wide methylation screening, we identified that paired box gene 5 (PAX5) is involved in human cancer development. However, the function of PAX5 in gastric cancer (GC) development is largely unclear. We analyzed its epigenetic inactivation, biological functions and clinical application in GC. PAX5 was silenced in seven out of eight GC cell lines. A significant downregulation was also detected in paired gastric tumors compared with adjacent non-cancerous tissues. The downregulation of PAX5 was closely linked to the promoter hypermethylation status and could be restored with demethylation treatment. Ectopic expression of PAX5 in silenced GC cell lines (AGS and BGC823) inhibited colony formation and cell viability, arrested cell cycle, induced apoptosis, suppressed cell migration and invasion and repressed tumorigenicity in nude mice. Consistent with the induction of apoptosis by PAX5 in vitro, terminal deoxynucleotidyl transferase-mediated dUTP-digoxigenin nick end labeling (TUNEL) staining showed significantly enhanced apoptotic cells in PAX5-expressed tumors compared with the vector control tumors. On the other hand, knockdown of PAX5 by PAX5-short hairpin RNA increased the cell viability and proliferation. The anti-tumorigenic function of PAX5 was revealed to be mediated by upregulating downstream targets of tumor protein 53 (p53), p21, BCL2-associated X protein, metastasis suppressor 1 and tissue inhibitors of metalloproteinase 1, and downregulating BCL2, cyclin D1, mesenchymal-epithelial transition factor (MET) and matrix metalloproteinase 1. Immunoprecipitation assay demonstrated that PAX5 directly bound to the promoters of p53 and MET. Moreover, PAX5 hypermethylation was detected in 77% (144 of 187) of primary GCs compared with 10.5% (2/19) of normal gastric tissues (P<0.0001). GC patients with PAX5 methylation had a significant poor survival compared with the unmethylated cases as demonstrated by Cox regression model and log-rank test. In conclusion, PAX5 is a novel functional tumor suppressor in gastric carcinogenesis. Detection of methylated PAX5 can be utilized as an independent prognostic factor in GC. Oncogene (2012) 31, 3419-3430; doi:10.1038/onc.2011.511; published online 21 November 2011	[Li, X.; Cheung, K. F.; Ma, X.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Shatin, Hong Kong, Peoples R China; [Li, X.; Cheung, K. F.; Ma, X.; Zhao, J.; Go, M. Y. Y.; Shen, B.; Cheng, A. S. L.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Ma, X.] Hebei Med Univ, Hosp 1, Dept Neurol, Shijiazhuang, Peoples R China; [Tian, L.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Hong Kong, Hong Kong, Peoples R China; [Shen, B.] Guangzhou First Municipal Peoples Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China; [Ying, J.; Tao, Q.] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Kung, H-F] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Hebei Medical University; Chinese University of Hong Kong; South China University of Technology; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Tao, Qian/T-4743-2018; Tian, Linwei/A-9736-2009; Li, Xiao-xing/B-9114-2008; Cheng, Alfred SL/C-3327-2014; Yu, Jun/D-8569-2015	Sung, Joseph J. Y./0000-0003-3125-5199; Tao, Qian/0000-0001-5383-4808; Tian, Linwei/0000-0002-4739-1534; Li, Xiao-xing/0000-0001-8791-7505; Cheng, Alfred SL/0000-0003-2345-6951; Yu, Jun/0000-0001-5008-2153; Tian, Linwei/0000-0003-2240-8886	National Basic Research Program of China (973 Program) [2010CB529305]; Hong Kong General Research Fund [473008]; RFCID [11100022, 10090942]; CUHK Group Research Scheme [3110043]; Scheme C	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Hong Kong General Research Fund; RFCID; CUHK Group Research Scheme; Scheme C	This study was supported by research grants of National Basic Research Program of China (973 Program, 2010CB529305), Hong Kong General Research Fund (473008), RFCID (11100022, 10090942), CUHK Group Research Scheme (3110043) and Scheme C.	ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; Carotta S, 2006, CELL CYCLE, V5, P2452, DOI 10.4161/cc.5.21.3396; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; HALDAR S, 1994, CANCER RES, V54, P2095; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Holmes ML, 2006, GENE DEV, V20, P933, DOI 10.1101/gad.1396206; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kanteti R, 2009, LAB INVEST, V89, P301, DOI 10.1038/labinvest.2008.168; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; Kubetzko FBB, 2004, CARCINOGENESIS, V25, P1839, DOI 10.1093/carcin/bgh190; Lazzi S, 2009, HUM PATHOL, V40, P1252, DOI 10.1016/j.humpath.2009.01.007; Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232; Lee JH, 2004, ONCOGENE, V23, P4646, DOI 10.1038/sj.onc.1207588; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Levine A J, 1989, Princess Takamatsu Symp, V20, P221; Liu WL, 2011, HEPATOLOGY, V53, P843, DOI 10.1002/hep.24124; MALKIN D, 1994, CANCER RES, V54, P2077; Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801; Mhawech-Fauceglia P, 2007, J CLIN PATHOL, V60, P709, DOI 10.1136/jcp.2006.039917; MIYASHITA T, 1995, CELL, V80, P293; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Sauter W, 2008, CANCER EPIDEM BIOMAR, V17, P1127, DOI 10.1158/1055-9965.EPI-07-2840; Souabni A, 2002, IMMUNITY, V17, P781, DOI 10.1016/S1074-7613(02)00472-7; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Yu J, 2010, GASTROENTEROLOGY, V138, P694, DOI 10.1053/j.gastro.2009.09.058; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310	49	57	60	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	29					3419	3430		10.1038/onc.2011.511	http://dx.doi.org/10.1038/onc.2011.511			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	976FN	22105368				2022-12-17	WOS:000306566400003
J	Shah, PP; Fong, MY; Kakar, SS				Shah, P. P.; Fong, M. Y.; Kakar, S. S.			PTTG induces EMT through integrin alpha(V)beta(3)-focal adhesion kinase signaling in lung cancer cells	ONCOGENE			English	Article						PTTG; securin; lung cancer	TUMOR-TRANSFORMING GENE; EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX METALLOPROTEINASE-2 MMP-2; GROWTH-FACTOR-I; OVARIAN-CANCER; BREAST-CANCER; ALPHA-V-BETA-3 INTEGRIN; EXPRESSION; PROGRESSION; METASTASIS	Pituitary tumor transforming gene (PTTG) is a well-studied oncogene for its role in tumorigenesis and serves as a marker of malignancy in several cancer types including lung. In the present study, we defined the role of PTTG in actin cytoskeleton remodeling, cell migration and induction of epithelial mesenchymal transition (EMT) through the regulation of integrin alpha(V)beta(3)-FAK (focal adhesion kinase) signaling pathway. Overexpression of PTTG through an adenovirus vector resulted in a significant increase in the expression of integrins alpha(V) and beta(3), a process that was reversed with the downregulation of PTTG expression through the use of an adenovirus expressing PTTG-specific small interfering RNA (siRNA). Western blot analysis of cells infected with adenovirus PTTG cDNA resulted in increased FAK and enhanced expression of adhesion complex molecules paxillin, metavincullin, and talin. Furthermore, downstream signaling genes Rac1, RhoA, Cdc42 and DOCK180 showed upregulation upon PTTG overexpression. This process was dependent on integrin alpha(V), as blockage by antagonist echistatin (RGD peptide) or alpha(V)-specific siRNA resulted in a decrease in FAK and subsequent adhesion molecules. Actin cytoskeleton disruption was detected as a result of integrin-FAK signaling by PTTG as well as enhanced cell motility. Taken together, our results suggest for the first time an important role of PTTG in regulation of integrins alpha(V) and beta(3) and adhesion-complex proteins leading to induction of EMT. Oncogene (2012) 31, 3124-3135; doi:10.1038/onc.2011.488; published online 14 November 2011	[Fong, M. Y.; Kakar, S. S.] Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40202 USA; [Shah, P. P.; Kakar, S. S.] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville	Kakar, SS (corresponding author), Univ Louisville, Dept Physiol & Biophys, 505 S Hancock St,CTRB 322, Louisville, KY 40202 USA.	sskaka01@louisville.edu			NCI [CA 124630]; NATIONAL CANCER INSTITUTE [R01CA124630] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Stanley D'Souza for his critical input. The work was supported by a grant from NCI CA 124630 (SSK).	Agiostratidou G, 2007, J MAMMARY GLAND BIOL, V12, P127, DOI 10.1007/s10911-007-9044-6; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Becam IE, 2005, NAT CELL BIOL, V7, P510, DOI 10.1038/ncb1253; Berrier AL, 2007, J CELL PHYSIOL, V213, P565, DOI 10.1002/jcp.21237; Blanco D, 2004, LAB INVEST, V84, P999, DOI 10.1038/labinvest.3700129; Chamaon K, 2005, BIOCHEM BIOPH RES CO, V331, P86, DOI 10.1016/j.bbrc.2005.03.124; Chen XY, 2005, NEOPLASIA, V7, P271, DOI 10.1593/neo.04538; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Danen EHJ, 2002, J CELL BIOL, V159, P1071, DOI 10.1083/jcb.200205014; Deng BQ, 2010, MOL CELL BIOCHEM, V340, P21, DOI 10.1007/s11010-010-0396-7; El-Naggar SM, 2007, INT J ONCOL, V31, P137; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Firrincieli D, 2010, GASTROEN CLIN BIOL, V34, P523, DOI 10.1016/j.gcb.2010.04.017; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; Guillou H, 2008, EXP CELL RES, V314, P478, DOI 10.1016/j.yexcr.2007.10.026; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Hayashi I, 2002, NAT STRUCT BIOL, V9, P101, DOI 10.1038/nsb755; Heaney AP, 1999, BEST PRACT RES CL EN, V13, P367, DOI 10.1053/beem.1999.0028; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Honda S, 2003, ANTICANCER RES, V23, P3775; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Huveneers S, 2008, J BIOL CHEM, V283, P13243, DOI 10.1074/jbc.M800927200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jarzynka NJ, 2007, CANCER RES, V67, P7203, DOI 10.1158/0008-5472.CAN-07-0473; Jung CR, 2006, HEPATOLOGY, V43, P1042, DOI 10.1002/hep.21137; Kakar SS, 2006, INT J ONCOL, V29, P387; Kakar SS, 1999, CYTOGENET CELL GENET, V84, P211, DOI 10.1159/000015261; Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t; Kim K, 2002, CELL BIOL INT, V26, P463, DOI 10.1006/cbir.2002.0901; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Lee IA, 1999, BIOCHEM MOL BIOL INT, V47, P891; Liang HS, 2010, INT J BIOL MARKER, V25, P38, DOI 10.1177/172460081002500106; Liu GH, 2002, MOL CELL BIOL, V22, P2751, DOI 10.1128/MCB.22.8.2751-2760.2002; Malik MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-61; Martin KH, 2002, CELL MOTIL CYTOSKEL, V51, P76, DOI 10.1002/cm.10018; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mercado-Pimentel ME, 2007, CELLS TISSUES ORGANS, V185, P146, DOI 10.1159/000101315; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Ning SC, 2010, CANCER RES, V70, P7591, DOI 10.1158/0008-5472.CAN-10-1639; Nishiya N, 2001, MOL CELL BIOL, V21, P5332, DOI 10.1128/MCB.21.16.5332-5345.2001; ORLANDO RA, 1991, J BIOL CHEM, V266, P19543; Panguluri SK, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-577; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Reddig PJ, 2005, CANCER METAST REV, V24, P425, DOI 10.1007/s10555-005-5134-3; Rolli M, 2003, P NATL ACAD SCI USA, V100, P9482, DOI 10.1073/pnas.1633689100; Ross RS, 2004, CARDIOVASC RES, V63, P381, DOI 10.1016/j.cardiores.2004.04.027; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; RUOSLAHTI E, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P99; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Taneyhill LA, 2007, DEVELOPMENT, V134, P1481, DOI 10.1242/dev.02834; Tang Ming-hua, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P1712; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tsai SJ, 2005, J CLIN ENDOCR METAB, V90, P3715, DOI 10.1210/jc.2004-2303; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; Wang H, 2010, TUMOR BIOL, V31, P59, DOI 10.1007/s13277-009-0009-9; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zheng DQ, 1999, CANCER RES, V59, P1655; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; ZUK A, 1994, DEV DYNAM, V201, P378, DOI 10.1002/aja.1002010409	82	57	59	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	26					3124	3135		10.1038/onc.2011.488	http://dx.doi.org/10.1038/onc.2011.488			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22081074	Green Accepted			2022-12-17	WOS:000305934400002
J	Hsu, CH; Peng, KL; Jhang, HC; Lin, CH; Wu, SY; Chiang, CM; Lee, SC; Yu, WCY; Juan, LJ				Hsu, C-H; Peng, K-L; Jhang, H-C; Lin, C-H; Wu, S-Y; Chiang, C-M; Lee, S-C; Yu, W. C. Y.; Juan, L-J			The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription	ONCOGENE			English	Article						HMT; chromatin; HPV; E6; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; PROTEIN ARGININE METHYLATION; P53 ACTIVITY; NONHISTONE PROTEINS; LYSINE METHYLATION; HIGH-RISK; ACETYLATION; DEGRADATION; PRMT1; UBIQUITINATION	Expression of viral proteins causes important epigenetic changes leading to abnormal cell growth. Whether viral proteins directly target histone methyltransferases (HMTs), a key family enzyme for epigenetic regulation, and modulate their enzymatic activities remains elusive. Here we show that the E6 proteins of both low-risk and high-risk human papillomavirus (HPV) interact with three coactivator HMTs, CARM1, PRMT1 and SET7, and downregulate their enzymatic activities in vitro and in HPV-transformed HeLa cells. Furthermore, these three HMTs are required for E6 to attenuate p53 transactivation function. Mechanistically, E6 hampers CARM1- and PRMT1-catalyzed histone methylation at p53-responsive promoters, and suppresses the binding of p53 to chromatinized DNA independently of E6-mediated p53 degradation. p53 pre-methylated at lysine-372 (p53K372 monomethylation) by SET7 protects p53 from E6-induced degradation. Consistently, E6 downregulates p53K372 mono-methylation and thus reduces p53 protein stability. As a result of the E6-mediated inhibition of HMT activity, expression of p53 downstream genes is suppressed. Together, our results not only reveal a clever approach for the virus to interfere with p53 function, but also demonstrate the modulation of HMT activity as a novel mechanism of epigenetic regulation by a viral oncoprotein. Oncogene (2012) 31, 2335-2349; doi:10.1038/onc.2011.415; published online 3 October 2011	[Hsu, C-H; Peng, K-L; Jhang, H-C; Lin, C-H; Juan, L-J] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Peng, K-L; Juan, L-J] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Lin, C-H; Lee, S-C; Juan, L-J] Natl Taiwan Univ, Inst Mol Med, Coll Med, Taipei 10764, Taiwan; [Lin, C-H] Natl Hlth Res Inst, Inst Canc Res, Zhunan Town, Miaoli County, Taiwan; [Wu, S-Y; Chiang, C-M] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Wu, S-Y; Chiang, C-M] Univ Texas SW Med Ctr Dallas, Dept Biochem, Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Yu, W. C. Y.] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan Town, Miaoli County, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Taiwan University; National Health Research Institutes - Taiwan; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; National Health Research Institutes - Taiwan	Juan, LJ (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sec 2, Taipei 115, Taiwan.	ljjuan@gate.sinica.edu.tw	Juan, Li-Jung/H-6631-2015; Hsu, Chih-Hung/AEM-8298-2022; Yu, C.Y./E-3666-2010	Hsu, Chih-Hung/0000-0001-8071-0122; 	Academia Sinica; NRPGM/DOH; NHRI; National Institutes of Health [CA103867, CA124760]; NATIONAL CANCER INSTITUTE [R01CA124760, R01CA103867] Funding Source: NIH RePORTER	Academia Sinica(Academia Sinica - Taiwan); NRPGM/DOH; NHRI(National Health Research Institutes - Taiwan); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs WH Lee and Y Zhang for valuable suggestions; WH Lee for critical reading of the manuscript; MR Stallcup for providing pSG5HA, pSG5HA-CARM1, pSG5HA-CARM1 E267Q, pSG5HA-PRMT1 and pSG5HA-PRMT1 E153Q; D Reinberg for pcDNA3.1-SET7 and SET7H297A; G Trave for p513-16E66C/6S F47R; SY Shieh for p21-Luc and pcDNA3.1-p53; and CW Wu for partial funding support. We also thank the GRC Peptide Synthesis Core for providing the p53 peptide. This research was primarily supported by grants from Academia Sinica and NRPGM/DOH to L-JJ, and partly from NHRI to L-JJ, as well as Grants CA103867 and CA124760 from the National Institutes of Health to C-MC.	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Boisvert FM, 2005, GENE DEV, V19, P671, DOI 10.1101/gad.1279805; Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250; Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928; Camus S, 2007, ONCOGENE, V26, P4059, DOI 10.1038/sj.onc.1210188; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen YC, 2004, CANCER-AM CANCER SOC, V101, P1428, DOI 10.1002/cncr.20538; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Ganguly N, 2009, J BIOSCIENCES, V34, P113, DOI 10.1007/s12038-009-0013-7; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Howley Peter M, 2006, Trans Am Clin Climatol Assoc, V117, P113; Howley PM, 2009, VIROLOGY, V384, P256, DOI 10.1016/j.virol.2008.12.006; Howley PM., 2006, T AM CLIN CLIMAT ASS, V117, P126; Hsu CH, 2004, EMBO J, V23, P2269, DOI 10.1038/sj.emboj.7600239; Hu D, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2008.03.064; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kruse JP, 2008, CELL, V133, DOI 10.1016/j.cell.2008.05.020; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Lacey CJN, 2006, VACCINE, V24, P35, DOI 10.1016/j.vaccine.2006.06.015; Lee DY, 2007, MOL ENDOCRINOL, V21, P1381, DOI 10.1210/me.2006-0389; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051; Massimi P, 2008, ONCOGENE, V27, P1800, DOI 10.1038/sj.onc.1210810; McLaughlin-Drubin ME, 2009, VIRUS RES, V143, P195, DOI 10.1016/j.virusres.2009.06.008; Miremadi A, 2007, HUM MOL GENET, V16, pR28, DOI 10.1093/hmg/ddm021; Mujtaba S, 2008, NAT CELL BIOL, V10, P1114, DOI 10.1038/ncb1772; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Pahlich S, 2006, BBA-PROTEINS PROTEOM, V1764, P1890, DOI 10.1016/j.bbapap.2006.08.008; Pal S, 2007, J CELL PHYSIOL, V213, P306, DOI 10.1002/jcp.21180; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2010, APMIS, V118, P471, DOI 10.1111/j.1600-0463.2010.02618.x; Pradhan S, 2009, EPIGENETICS, V4, P282; Reeves M, 2006, J VIROL, V80, P9998, DOI 10.1128/JVI.01297-06; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shukla A, 2009, CELL MOL LIFE SCI, V66, P1419, DOI 10.1007/s00018-008-8605-1; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang YH, 2003, J BIOL CHEM, V278, P25568, DOI 10.1074/jbc.M212574200; Wolf SS, 2009, CELL MOL LIFE SCI, V66, P2109, DOI 10.1007/s00018-009-0010-x; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yu ZB, 2009, MOL CELL BIOL, V29, P2982, DOI 10.1128/MCB.00042-09; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	63	57	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	18					2335	2349		10.1038/onc.2011.415	http://dx.doi.org/10.1038/onc.2011.415			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	936SR	21963854	Green Published, hybrid			2022-12-17	WOS:000303610800008
J	Whipple, CA; Young, AL; Korc, M				Whipple, C. A.; Young, A. L.; Korc, M.			A Kras(G12D)-driven genetic mouse model of pancreatic cancer requires glypican-1 for efficient proliferation and angiogenesis	ONCOGENE			English	Article						pancreatic cancer; glypican-1; proliferation; angiogenesis; tumor microenvironment	FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE; CARCINOMA CELLS; K-RAS; EXPRESSION; PROGRESSION; ADENOCARCINOMA; PROTEOGLYCAN; CHEMOTHERAPY; METASTASIS	Pancreatic ductal adenocarcinomas (PDACs) exhibit multiple molecular alterations and overexpress heparin-binding growth factors (HBGFs) and glypican-1 (GPC1), a heparan sulfate proteoglycan that promotes efficient signaling by HBGFs. It is not known, however, whether GPC1 has a role in genetic mouse models of PDAC. Therefore, we generated a GPC1 null mouse that combines pancreas-specific Cre-mediated activation of oncogenic Kras (Kras(G12D)) with deletion of a conditional INK4A/Arf allele (Pdx1-Cre; LSL-Kras(G12D); INK4A/Arf(lox/lox); GPC1(-/-) mice). By comparison with Pdx1-Cre; LSL-Kras(G12D); INK4A/Arf(lox/lox) mice that were wild type for GPC1, the Pdx1-Cre; LSL-Kras(G12D); INK4A/Arf(lox/lox); GPC1(-/-) mice exhibited attenuated pancreatic tumor growth and invasiveness, decreased cancer cell proliferation and mitogen-activated protein kinase activation. These mice also exhibited suppressed angiogenesis in conjunction with decreased expression of messenger RNAs encoding several pro-angiogenic factors and molecules, including vascular endothelial growth factor-A (VEGF-A), SRY-box containing gene (SOX17), chemokine C-X3-C motif ligand 1 (CX3CL1) and integrin beta 3 (ITGB3). Moreover, pancreatic cancer cells isolated from the tumors of GPC1(-/-) mice were not as invasive in response to fibroblast growth factor-2 (FGF-2) as cancer cells isolated from wild-type mice, and formed smaller tumors that exhibited an attenuated metastatic potential. Similarly, VEGF-A and FGF-2 did not enhance the migration of hepatic endothelial cells and immortalized murine embryonic fibroblasts isolated from GPC1 null mice. These data demonstrate in an oncogenic Kras-driven genetic mouse model of PDAC that tumor growth, angiogenesis and invasion are enhanced by GPC1, and suggest that suppression of GPC1 may be an important component of therapeutic strategies in PDAC. Oncogene (2012) 31, 2535-2544; doi:10.1038/onc.2011.430; published online 26 September 2011	[Korc, M.] Dartmouth Hitchcock Med Ctr, Dept Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; [Whipple, C. A.; Young, A. L.; Korc, M.] Dartmouth Med Sch, Dept Med, Hanover, NH USA; [Whipple, C. A.; Young, A. L.; Korc, M.] Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Korc, M (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Med, Norris Cotton Canc Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	murray.korc@dartmouth.edu			US Public Health Service [CA-R37-075059]; National Cancer Institute [F32 CA-144579]; NATIONAL CANCER INSTITUTE [R37CA075059, F32CA144579, R01CA075059] Funding Source: NIH RePORTER	US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Daniel Longnecker (Dartmouth Medical School) for his expert assistance in the evaluation of pancreatic tumor pathology. This work was supported by two US Public Health Service Grant (CA-R37-075059) awarded to MK. CAW was supported by a Ruth L Kirschstein National Research Service Award, F32 CA-144579 from the National Cancer Institute.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Aikawa T, 2008, J CLIN INVEST, V118, P89, DOI 10.1172/JCI32412; Arnold NB, 2004, CANCER RES, V64, P3599, DOI 10.1158/0008-5472.CAN-03-2999; Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103; Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; Cepko CP, 1996, RETROVIRUS INFECT CE, P91411; CHANG SC, 1990, J NUTR, V120, P1228, DOI 10.1093/jn/120.10.1228; Chen RL, 2001, J BIOL CHEM, V276, P7507, DOI 10.1074/jbc.M008283200; Cheng N, 2002, MOL CANCER RES, V1, P2; Ding K, 2005, J CELL BIOL, V171, P729, DOI 10.1083/jcb.200508010; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gu GQ, 2003, MECH DEVELOP, V120, P35, DOI 10.1016/S0925-4773(02)00330-1; Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jen YHLD, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-33; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kim I, 2007, CELL, V130, P470, DOI 10.1016/j.cell.2007.06.011; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kleeff J, 1999, PANCREAS, V19, P281, DOI 10.1097/00006676-199910000-00009; Kleeff J, 2007, INT J CANCER, V121, P699, DOI 10.1002/ijc.22871; Korc M, 2003, Mol Cancer, V2, P8, DOI 10.1186/1476-4598-2-8; Korc M, 2007, AM J SURG, V194, pS84, DOI 10.1016/j.amjsurg.2007.05.004; Lander AD, 2002, DEV CELL, V2, P785, DOI 10.1016/S1534-5807(02)00179-X; Le Mercier M, 2009, NEOPLASIA, V11, P485, DOI 10.1593/neo.81526; Li AH, 2011, TRANSL ONCOL, V4, P20, DOI 10.1593/tlo.10184; Matsuda K, 2001, CANCER RES, V61, P5562; Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Preis M, 2010, CANCER BIOL THER, V9, P754, DOI 10.4161/cbt.9.10.11534; Rowland-Goldsmith MA, 2002, MOL CANCER THER, V1, P161; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Schneider Gunter, 2003, Mol Cancer, V2, P15, DOI 10.1186/1476-4598-2-15; Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Suyama E, 2003, P NATL ACAD SCI USA, V100, P5616, DOI 10.1073/pnas.1035850100; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Tuveson DA, 2005, COLD SH Q B, V70, P65, DOI 10.1101/sqb.2005.70.040; Vilar E, 2007, ENDOCR-RELAT CANCER, V14, P221, DOI 10.1677/ERC-06-0074; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; Vonlaufen A, 2008, CANCER RES, V68, P7707, DOI 10.1158/0008-5472.CAN-08-1132; Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70; Zetser A, 2006, CANCER RES, V66, P1455, DOI 10.1158/0008-5472.CAN-05-1811	46	57	63	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	20					2535	2544		10.1038/onc.2011.430	http://dx.doi.org/10.1038/onc.2011.430			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996748	Green Accepted			2022-12-17	WOS:000304191800004
J	Duran-Prado, M; Gahete, MD; Hergueta-Redondo, M; Martinez-Fuentes, AJ; Cordoba-Chacon, J; Palacios, J; Gracia-Navarro, F; Moreno-Bueno, G; Malagon, MM; Luque, RM; Castano, JP				Duran-Prado, M.; Gahete, M. D.; Hergueta-Redondo, M.; Martinez-Fuentes, A. J.; Cordoba-Chacon, J.; Palacios, J.; Gracia-Navarro, F.; Moreno-Bueno, G.; Malagon, M. M.; Luque, R. M.; Castano, J. P.			The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells	ONCOGENE			English	Article						somatostatin receptors; sst5TMD4; sst2; breast cancer; poor prognosis	PROTEIN MAP KINASE; SUBTYPE 2; PATHWAY; ACTIVATION; ANALOG; PHOSPHORYLATION; GROWTH; AKT; INHIBITION; EXPRESSION	Somatostatin receptors (sst1-5) are present in different types of tumors, where they inhibit key cellular processes such as proliferation and invasion. Although ssts are densely expressed in breast cancer, especially sst2, their role and therapeutic potential remain uncertain. Recently, we identified a new truncated sst5 variant, sst5TMD4, which is related to the abnormal response of certain pituitary tumors to treatment with somatostatin analogs. Here, we investigated the possible role of sst5TMD4 in breast cancer. This study revealed that sst5TMD4 is absent in normal mammary gland, but is abundant in a subset of poorly differentiated human breast tumors, where its expression correlated to that of sst2. Moreover, in the MCF-7 breast cancer model cell, sst5TMD4 expression increased malignancy features such as invasion and proliferation abilities (both in cell cultures and nude mice). This was likely mediated by sst5TMD4-induced increase in phosphorylated extracellular signal-regulated kinases 1 and 2 and p-Akt levels, and cyclin D3 and Arp2/3 complex expression, which also led to mesenchymal-like phenotype. Interestingly, sst5TMD4 interacts physically with sst2 and thereby alters its signaling, enabling disruption of sst2 inhibitory feedback and providing a plausible basis for our findings. These results suggest that sst5TMD4 could be involved in the pathophysiology of certain types of breast tumors. Oncogene (2012) 31, 2049-2061; doi: 10.1038/onc.2011.389; published online 19 September 2011	[Duran-Prado, M.; Gahete, M. D.; Martinez-Fuentes, A. J.; Cordoba-Chacon, J.; Gracia-Navarro, F.; Malagon, M. M.; Luque, R. M.; Castano, J. P.] Univ Cordoba, Dept Cell Biol Physiol & Immunol, Reina Sofia Univ Hosp, Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba 14014, Spain; [Duran-Prado, M.; Gahete, M. D.; Martinez-Fuentes, A. J.; Cordoba-Chacon, J.; Gracia-Navarro, F.; Malagon, M. M.; Luque, R. M.; Castano, J. P.] CIBER Fisiopatol Obesidad & Nutr CIBERobn, Cordoba, Spain; [Hergueta-Redondo, M.; Moreno-Bueno, G.] UAM, Inst Invest Biomed Alberto Sols, CSIC UAM, IdiPAZ Inst Invest Sanitaria La Paz,Dept Bioquim, Madrid, Spain; [Hergueta-Redondo, M.; Moreno-Bueno, G.] Fdn MD Anderson Int, Madrid, Spain; [Palacios, J.] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla IBIS, Serv Anat Patol, Seville, Spain	Universidad de Cordoba; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University Hospital	Castano, JP (corresponding author), Univ Cordoba, Dept Cell Biol Physiol & Immunol, Edificio Severo Ochoa,Planta 3,Campus Rabanales, Cordoba 14014, Spain.	justo@uco.es	Cordoba-Chacon, Jose/AAH-5753-2019; Malagon, Maria M/L-5386-2014; Raul, Luque Huertas/M-6948-2018; duran-prado, mario/M-6545-2014; Martinez-Fuentes, Antonio J/F-8198-2016; Moreno-Bueno, Gema/K-9354-2016; Castaño, Justo P/A-7124-2010; Romo, José A./J-3024-2012; Palacios, Jose/AAV-3765-2020; Gahete, Manuel D./C-4969-2009	Cordoba-Chacon, Jose/0000-0001-8787-2706; Malagon, Maria M/0000-0002-2419-2727; duran-prado, mario/0000-0001-9652-5765; Moreno-Bueno, Gema/0000-0002-5030-6687; Castaño, Justo P/0000-0002-3145-7287; Romo, José A./0000-0003-2907-580X; Gahete, Manuel D./0000-0002-4578-2179; Gracia Navarro, Francisco/0000-0003-2128-4228; Luque, Raul M./0000-0002-7585-1913	IPSEN;  [BIO-0139];  [CTS-01705];  [CTS-5051];  [BFU2004-03883];  [BFU2007-60180/BFI];  [BFU2008-01136-BFI];  [BFU2010-19300];  [FPU-AP20052473];  [FI06-00804];  [SAF2007-63075];  [SAF2007-63075/FMM07];  [SAF2010-201075];  [CD07/00246];  [RYC-2007-00186]	IPSEN(Ipsen); ; ; ; ; ; ; ; ; ; ; ; ; ; 	This work was supported by BIO-0139, CTS-01705, CTS-5051, BFU2004-03883, BFU2007-60180/BFI, BFU2008-01136-BFI, BFU2010-19300, FPU-AP20052473, FI06-00804, SAF2007-63075, SAF2007-63075/FMM07, SAF2010-201075, CD07/00246, RYC-2007-00186 and IPSEN. Ciber is an initiative of the Instituto de Salud Carlos III.	Ben-Shlomo A, 2010, TRENDS ENDOCRIN MET, V21, P123, DOI 10.1016/j.tem.2009.12.003; Benali N, 2000, P NATL ACAD SCI USA, V97, P9180, DOI 10.1073/pnas.130196697; Charland S, 2001, ENDOCRINOLOGY, V142, P121, DOI 10.1210/en.142.1.121; Cordoba-Chacon J, 2010, CELL MOL LIFE SCI, V67, P1147, DOI 10.1007/s00018-009-0240-y; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Duran-Prado M, 2007, ENDOCRINOLOGY, V148, P411, DOI 10.1210/en.2006-0920; Duran-Prado M, 2010, J CLIN ENDOCR METAB, V95, P2497, DOI 10.1210/jc.2009-2247; Duran-Prado M, 2009, J CLIN ENDOCR METAB, V94, P2634, DOI 10.1210/jc.2008-2564; Eralp Y, 2008, ANN ONCOL, V19, P669, DOI 10.1093/annonc/mdm522; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; He Y, 2009, ACTA PHARMACOL SIN, V30, P1053, DOI 10.1038/aps.2009.59; Hubina E, 2006, EUR J ENDOCRINOL, V155, P371, DOI 10.1530/eje.1.02213; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kahan Z, 1999, INT J CANCER, V82, P592, DOI 10.1002/(SICI)1097-0215(19990812)82:4<592::AID-IJC20>3.0.CO;2-0; Keri G, 1996, P NATL ACAD SCI USA, V93, P12513, DOI 10.1073/pnas.93.22.12513; Lee JF, 2006, HISTOCHEM CELL BIOL, V126, P297, DOI 10.1007/s00418-006-0143-z; Leu FP, 2008, MOL CANCER RES, V6, P1029, DOI 10.1158/1541-7786.MCR-07-2073; Liu W, 2007, FRONT BIOSCI-LANDMRK, V12, P4011, DOI 10.2741/2367; Moller LN, 2003, BBA-BIOMEMBRANES, V1616, P1, DOI 10.1016/S0005-2736(03)00235-9; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Nakanishi O, 2007, J BIOCHEM, V141, P319, DOI 10.1093/jb/mvm034; Orlando C, 2004, ENDOCR-RELAT CANCER, V11, P323, DOI 10.1677/erc.0.0110323; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; PREVOST G, 1993, EUR J CANCER, V29A, P1589, DOI 10.1016/0959-8049(93)90300-5; Rinke A, 2009, J CLIN ONCOL, V27, P4656, DOI 10.1200/JCO.2009.22.8510; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Schulz S, 1998, CLIN CANCER RES, V4, P2047; SETYONOHAN B, 1987, CANCER RES, V47, P1566; Sun LC, 2007, CANCER LETT, V246, P157, DOI 10.1016/j.canlet.2006.02.016; Umemura S, 2007, CANCER SCI, V98, P1889, DOI 10.1111/j.1349-7006.2007.00622.x; VANEIJCK CHJ, 1994, LANCET, V343, P640, DOI 10.1016/S0140-6736(94)92637-9; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Watt HL, 2008, MOL CELL ENDOCRINOL, V286, P251, DOI 10.1016/j.mce.2008.01.006; Xu Y, 1996, ENDOCRINOLOGY, V137, P5634, DOI 10.1210/en.137.12.5634; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	41	57	57	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2049	2061		10.1038/onc.2011.389	http://dx.doi.org/10.1038/onc.2011.389			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21927030				2022-12-17	WOS:000303008600006
J	Liu, Y; Mayo, MW; Nagji, AS; Smith, PW; Ramsey, CS; Li, D; Jones, DR				Liu, Y.; Mayo, M. W.; Nagji, A. S.; Smith, P. W.; Ramsey, C. S.; Li, D.; Jones, D. R.			Phosphorylation of RelA/p65 promotes DNMT-1 recruitment to chromatin and represses transcription of the tumor metastasis suppressor gene BRMS1	ONCOGENE			English	Article						DNMT-1; phosphorylation; RelA/p65; TNF; transcription	NF-KAPPA-B; CELL LUNG-CANCER; BREAST-CANCER; INDUCED APOPTOSIS; METHYLTRANSFERASE RECRUITMENT; DNA METHYLTRANSFERASES; TARGET PROMOTERS; DOWN-REGULATION; EXPRESSION; ACTIVATION	The majority of patients with lung cancer present with metastatic disease. Chronic inflammation and subsequent activation of nuclear factor-kappa B (NF-kappa B) have been associated with the development of cancers. The RelA/p65 subunit of NF-kappa B is typically associated with transcriptional activation. In this report we show that RelA/p65 can function as an active transcriptional repressor through enhanced methylation of the BRMS1 (breast cancer metastasis suppressor 1) metastasis suppressor gene promoter via direct recruitment of DNMT-1 (DNA (cytosine-5)-methyltransferase 1) to chromatin in response to tumor necrosis factor (TNF). TNF-mediated phosphorylation of S276 on RelA/p65 is required for RelA/p65-DNMT-1 interactions, chromatin loading of DNMT-1 and subsequent BRMS1 promoter methylation and transcriptional repression. The ability of RelA/p65 to function as an active transcriptional repressor is promoter specific, as the NF-kappa B-regulated gene cIAP2 (cellular inhibitor of apoptosis 2) is transcriptionally activated whereas BRMS1 is repressed under identical conditions. Small-molecule inhibition of either of the minimal interacting domains between RelA/p65-DNMT-1 and RelA/p65-BRMS1 promoter abrogates BRMS1 methylation and its transcriptional repression. The ability of RelA/p65 to directly recruit DNMT-1 to chromatin, resulting in promoter-specific methylation and transcriptional repression of tumor metastasis suppressor gene BRMS1, highlights a new mechanism through which NF-kappa B can regulate metastatic disease, and offers a potential target for newer-generation epigenetic oncopharmaceuticals. Oncogene (2012) 31, 1143-1154; doi:10.1038/onc.2011.308; published online 18 July 2011	[Liu, Y.; Nagji, A. S.; Smith, P. W.; Jones, D. R.] Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; [Mayo, M. W.; Ramsey, C. S.; Li, D.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Jones, DR (corresponding author), Univ Virginia, Dept Surg, Box 800679, Charlottesville, VA 22908 USA.	djones@virginia.edu	Smith, Philip/P-7736-2019	Smith, Philip/0000-0003-3441-1062; Jones, David/0000-0002-3318-0146	 [R01 CA136705];  [R01 CA104397];  [R01 CA132580]; NATIONAL CANCER INSTITUTE [R01CA136705, R01CA104397, R01CA132580] Funding Source: NIH RePORTER	; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01 CA136705 (to DRJ), R01 CA104397 (to MWM) and R01 CA132580 (to MWM). In addition, this project was supported in part by a gift provided to the University of Virginia by Philip Morris USA. The review and approval process was overseen by an independent National External Advisory Board without any affiliation with the University, Philip Morris USA or any other tobacco company.	Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Ceribelli M, 2008, MOL CELL BIOL, V28, P2047, DOI 10.1128/MCB.01861-07; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Denlinger Chadrick E, 2004, Semin Thorac Cardiovasc Surg, V16, P28, DOI 10.1053/j.semtcvs.2003.12.004; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hodge DR, 2005, CANCER RES, V65, P6255, DOI 10.1158/0008-5472.CAN-04-4482; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim S, 2004, J BIOL CHEM, V279, P4285, DOI 10.1074/jbc.M308383200; Kouba DJ, 1999, J IMMUNOL, V162, P4226; Liu Y, 2006, MOL CELL BIOL, V26, P8683, DOI 10.1128/MCB.00940-06; Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Meehan WJ, 2003, CLIN EXP METASTAS, V20, P45, DOI 10.1023/A:1022542519586; Mottet D, 2009, ONCOGENE, V28, P243, DOI 10.1038/onc.2008.371; Nagji AS, 2010, J PATHOL, V221, P229, DOI 10.1002/path.2707; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Puto LA, 2008, GENE DEV, V22, P998, DOI 10.1101/gad.1632208; Romano A, 2010, MOL CELL ENDOCRINOL, V314, P90, DOI 10.1016/j.mce.2009.08.008; Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50; Smith PW, 2009, CANCER LETT, V276, P196, DOI 10.1016/j.canlet.2008.11.024; Snyder M, 2010, J BIOL CHEM, V285, P23639, DOI 10.1074/jbc.M110.101063; Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341; Takada Y, 2005, ONCOGENE, V24, P6957, DOI 10.1038/sj.onc.1208845; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200; Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102; Zhang ZH, 2006, CLIN CANCER RES, V12, P6410, DOI 10.1158/1078-0432.CCR-06-1347; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	57	58	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	9					1143	1154		10.1038/onc.2011.308	http://dx.doi.org/10.1038/onc.2011.308			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765477	Green Accepted			2022-12-17	WOS:000300945900007
J	Gamble, LD; Kees, UR; Tweddle, DA; Lunec, J				Gamble, L. D.; Kees, U. R.; Tweddle, D. A.; Lunec, J.			MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63	ONCOGENE			English	Article						MYCN; neuroblastoma; MDM2-p53 antagonists; apoptosis; growth inhibition	DIRECT TRANSCRIPTIONAL TARGET; P53 GENE-MUTATIONS; N-MYC; P53-DEPENDENT APOPTOSIS; IN-VIVO; P53/MDM2/P14(ARF) PATHWAY; G(1) ARREST; DNA-DAMAGE; CELL-DEATH; AMPLIFICATION	MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN has contradictory roles in promoting cell growth and sensitizing cells to apoptosis. We have recently shown that p53 is a direct transcriptional target of MYCN in neuroblastoma and that p53-mediated apoptosis may be an important mechanism of MYCN-induced apoptosis. Although p53 mutations are rare in neuroblastoma at diagnosis, the p53/MDM2/p14(ARF) pathway is often inactivated through MDM2 amplification or p14(ARF) inactivation. We hypothesized that reactivation of p53 by inhibition of its negative regulator MDM2, using the MDM2-p53 antagonists Nutlin-3 and MI-63, will result in p53-mediated growth arrest and apoptosis especially in MYCN-amplified cells. Using the SHEP Tet21N MYCN-regulatable system, MYCN(-) cells were more resistant to both Nutlin-3 and MI-63 mediated growth inhibition and apoptosis compared with MYCN(+) cells and siRNA-mediated knockdown of MYCN in four MYCN-amplified cell lines resulted in decreased p53 expression and activation, as well as decreased levels of apoptosis following treatment with MDM2-p53 antagonists. In a panel of 18 neuroblastoma cell lines treated with Nutlin-3 and MI-63, the subset amplified for MYCN had a significantly lower mean GI(50) value (50% growth inhibition) and increased caspase 3/7 activity compared with the non-MYCN-amplified group of cell lines, but p53 mutant cell lines were resistant to the antagonists regardless of MYCN status. We conclude that amplification or overexpression of MYCN sensitizes neuroblastoma cell lines with wild-type p53 to MDM2-p53 antagonists and that these compounds may therefore be particularly effective in treating high-risk MYCN-amplified disease. Oncogene (2012) 31, 752-763; doi:10.1038/onc.2011.270; published online 4 July 2011	[Lunec, J.] Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Canc Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Kees, U. R.] Univ Western Australia, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia	Newcastle University - UK; Telethon Kids Institute; University of Western Australia	Lunec, J (corresponding author), Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Canc Ctr, Paul OGorman Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	John.Lunec@newcastle.ac.uk		Gamble, Laura D./0000-0001-8496-9705; Lunec, John/0000-0002-1878-8583	Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank the following for cell lines: Sue Cohn (NBLW and NBLS), Linda Harris (SJNB1), Penny Lovat (SHSY5Y, SHEP and IMR32), John Maris (NB69), Patrick Reynolds (SKNRA, SMSKCNR, LAN5, LAN6 and CHLA136), Manfred Schwab (LS and SHEP Tet21N), Rogier Versteeg (NGP), Barbara Spengler (SKNBe2C), Micro Ponzoni (GIMEN), Ursula Kees (PER108), Maria Lastowska (TR14), Clinton Stewart (NB1691) and Jean Benard (SKNAS, IGRN91). We are grateful to Mike Cole (Newcastle Cancer Centre, Newcastle University) for his statistical advice and to Cancer Research UK for funding this work. This study is supported by Cancer Research UK.	Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Amente S, 2007, FEBS LETT, V581, P821, DOI 10.1016/j.febslet.2007.01.062; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Bell E, 2006, CELL CYCLE, V5, P2639, DOI 10.4161/cc.5.22.3443; Canner JA, 2009, BRIT J CANCER, V101, P774, DOI 10.1038/sj.bjc.6605199; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Carr-Wilkinson J, 2010, CLIN CANCER RES, V16, P1108, DOI 10.1158/1078-0432.CCR-09-1865; Chen LD, 2010, CANCER RES, V70, P1377, DOI 10.1158/0008-5472.CAN-09-2598; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Cohn SL, 2004, EUR J CANCER, V40, P2639, DOI 10.1016/j.ejca.2004.07.025; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; CORVI R, 1995, ONCOGENE, V10, P1081; Demidenko ZN, 2010, P NATL ACAD SCI USA, V107, P9660, DOI 10.1073/pnas.1002298107; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; Fulda S, 2000, MED PEDIATR ONCOL, V35, P582, DOI 10.1002/1096-911X(20001201)35:6<582::AID-MPO19>3.0.CO;2-2; Goldman SC, 1996, AM J PATHOL, V148, P1381; Hogarty MD, 2003, CANCER LETT, V197, P173, DOI 10.1016/S0304-3835(03)00103-4; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Kang JH, 2006, BIOCHEM BIOPH RES CO, V351, P192, DOI 10.1016/j.bbrc.2006.10.020; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; Korotchkina LG, 2010, AGING-US, V2, P344, DOI 10.18632/aging.100160; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Michalak E, 2005, BIOCHEM BIOPH RES CO, V331, P786, DOI 10.1016/j.bbrc.2005.03.183; Muller CR, 2007, INT J CANCER, V121, P199, DOI 10.1002/ijc.22643; Petroni M, 2011, MOL CANCER RES, V9, P67, DOI 10.1158/1541-7786.MCR-10-0227; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Slack A, 2005, CELL CYCLE, V4, P857, DOI 10.4161/cc.4.7.1790; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Van Maerken T, 2006, CANCER RES, V66, P9646, DOI 10.1158/0008-5472.CAN-06-0792; Van Maerken T, 2011, MOL CANCER THER, V10, P983, DOI 10.1158/1535-7163.MCT-10-1090; van Noesel MM, 2004, GENE, V325, P1, DOI 10.1016/j.gene.2003.09.042; van Noesel MM, 2003, CANCER LETT, V197, P165, DOI 10.1016/S0304-3835(03)00101-0; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; VOGAN K, 1993, CANCER RES, V53, P5269; Wang P, 2006, ONCOGENE, V25, P3708, DOI 10.1038/sj.onc.1209411; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2012	31	6					752	763		10.1038/onc.2011.270	http://dx.doi.org/10.1038/onc.2011.270			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725357	Green Accepted, Bronze			2022-12-17	WOS:000300222100008
J	Katsurano, M; Niwa, T; Yasui, Y; Shigematsu, Y; Yamashita, S; Takeshima, H; Lee, MS; Kim, YJ; Tanaka, T; Ushijima, T				Katsurano, M.; Niwa, T.; Yasui, Y.; Shigematsu, Y.; Yamashita, S.; Takeshima, H.; Lee, M. S.; Kim, Y-J; Tanaka, T.; Ushijima, T.			Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction	ONCOGENE			English	Article						epigenetics; DNA methylation; inflammation; colon cancer; mouse	INFLAMMATORY-BOWEL-DISEASE; DEXTRAN SULFATE SODIUM; INTESTINAL EPITHELIAL-CELLS; PROMOTER HYPERMETHYLATION; HELICOBACTER-PYLORI; ULCERATIVE-COLITIS; GASTRIC MUCOSAE; CANCER; MICE; GENE	Epigenetic fields for cancerization are involved in development of human cancers, especially those associated with inflammation and multiple occurrences. However, it is still unclear when such field defects are formed and what component of inflammation is involved in induction of aberrant DNA methylation. Here, in a mouse colitis model induced by dextran sulfate sodium (DSS), we identified three CpG islands specifically methylated in colonic epithelial cells exposed to colitis. Their methylation levels started to increase as early as 8 weeks after DSS treatment and continued to increase until colon cancers developed at 15 weeks. In contrast to the temporal profile of DNA methylation levels, infiltration of inflammatory cells spiked immediately after the DSS treatment and then gradually decreased. Exposure of cultured colonic epithelial cells to DSS did not induce DNA methylation and it was indicated that inflammation triggered by the DSS treatment was responsible for methylation induction. To clarify components of inflammation involved, severe combined immunodeficiency (SCID) mice that lack functional T- and B-cells were similarly treated. Even in SCID mice, DNA methylation, along with colon tumors, were induced at the same levels as in their background strain of mice (C.B17). Comparative analysis of inflammation-related genes showed that Ifng, Il1b and Nos2 had expression concordant with methylation induction whereas Il2, Il6, Il10, Tnf did not. These results showed that an epigenetic field defect is formed at early stages of colitis-associated carcinogenesis and that functional T and B cells are non-essential for the formation. Oncogene (2012) 31, 342-351; doi:10.1038/onc.2011.241; published online 20 June 2011	[Ushijima, T.] Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, Tokyo 1040045, Japan; [Yasui, Y.; Tanaka, T.] Kanazawa Med Univ, Dept Oncol Pathol, Kanazawa, Ishikawa, Japan; [Lee, M. S.; Kim, Y-J] Yonsei Univ, Genome Regulat Ctr, Dept Biochem, Seoul 120749, South Korea	National Cancer Center - Japan; Kanazawa Medical University; Yonsei University	Ushijima, T (corresponding author), Natl Canc Ctr, Res Inst, Div Epigen, Chuo Ku, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817; Takeshima, Hideyuki/0000-0002-8552-2427	Ministry of Health, Labour and Welfare, Japan; Korea Foundation for International Cooperation of Science Technology; Foundation for Promotion of Cancer Research	Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Korea Foundation for International Cooperation of Science Technology; Foundation for Promotion of Cancer Research	We thank Dr H Fukamachi for his kind provision of the LIF-16 cell line. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan; and by the Global Research Laboratory Program from Korea Foundation for International Cooperation of Science & Technology. MK and YS are recipients of Research Resident Fellowships from the Foundation for Promotion of Cancer Research. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan (TU), and by the Global Research Laboratory Program from Korea Foundation for International Cooperation of Science & Technology (Y-JK and TU).	Araki Y, 2006, ONCOL REP, V16, P1357; Autschbach F, 2002, VIRCHOWS ARCH, V441, P500, DOI 10.1007/s00428-002-0684-z; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Braakhuis BJM, 2003, CANCER RES, V63, P1727; CAPPELLO M, 1992, GUT, V33, P1214, DOI 10.1136/gut.33.9.1214; CHENG H, 1984, GASTROENTEROLOGY, V86, P78; DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Garrity-Park MM, 2010, AM J GASTROENTEROL; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Hahn MA, 2008, CANCER RES, V68, P10280, DOI 10.1158/0008-5472.CAN-08-1957; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; Hmadcha A, 1999, J EXP MED, V190, P1595, DOI 10.1084/jem.190.11.1595; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Hsieh CJ, 1998, CANCER RES, V58, P3942; Hur K, 2011, CARCINOGENESIS, V32, P35, DOI 10.1093/carcin/bgq219; Issa JPJ, 2001, CANCER RES, V61, P3573; Ito R, 2006, CLIN EXP IMMUNOL, V146, P330, DOI 10.1111/j.1365-2249.2006.03214.x; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kass DH, 1997, GENETICA, V99, P1, DOI 10.1023/A:1018350810791; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; LIGUMSKY M, 1990, GUT, V31, P686, DOI 10.1136/gut.31.6.686; Maekita T, 2006, CLIN CANCER RES, V12, P989, DOI 10.1158/1078-0432.CCR-05-2096; McLaughlan JM, 1997, J PATHOL, V181, P87; Nagao M, 2001, MUTAT RES-FUND MOL M, V477, P119, DOI 10.1016/S0027-5107(01)00113-0; Nakajima T, 2006, CANCER EPIDEM BIOMAR, V15, P2317, DOI 10.1158/1055-9965.EPI-06-0436; Ni J, 1996, GUT, V39, P234, DOI 10.1136/gut.39.2.234; Niwa T, 2005, CANCER SCI, V96, P409, DOI 10.1111/j.1349-7006.2005.00068.x; Niwa T, 2010, CANCER RES, V70, P1430, DOI 10.1158/0008-5472.CAN-09-2755; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Qian XM, 2008, CANCER LETT, V263, P107, DOI 10.1016/j.canlet.2007.12.023; Riggs AD, 2004, P NATL ACAD SCI USA, V101, P4, DOI 10.1073/pnas.0307781100; Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109; Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x; Taniwaki K, 2007, CANCER RES, V67, P4311, DOI 10.1158/0008-5472.CAN-06-4761; Ushijima T, 2005, CANCER SCI, V96, P206, DOI 10.1111/j.1349-7006.2005.00035.x; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Vuillemenot BR, 2004, CARCINOGENESIS, V25, P623, DOI 10.1093/carcin/bgh038; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Yamashita S, 2008, CANCER RES, V68, P2112, DOI 10.1158/0008-5472.CAN-07-5282; Yamashita S, 2009, DNA RES, V16, P275, DOI 10.1093/dnares/dsp017; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521	51	57	59	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					342	351		10.1038/onc.2011.241	http://dx.doi.org/10.1038/onc.2011.241			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21685942				2022-12-17	WOS:000299542100007
J	Lee, YH; Judge, AD; Seo, D; Kitade, M; Gomez-Quiroz, LE; Ishikawa, T; Andersen, JB; Kim, BK; Marquardt, JU; Raggi, C; Avital, I; Conner, EA; MacLachlan, I; Factor, VM; Thorgeirsson, SS				Lee, Y-H; Judge, A. D.; Seo, D.; Kitade, M.; Gomez-Quiroz, L. E.; Ishikawa, T.; Andersen, J. B.; Kim, B-K; Marquardt, J. U.; Raggi, C.; Avital, I.; Conner, E. A.; MacLachlan, I.; Factor, V. M.; Thorgeirsson, S. S.			Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response	ONCOGENE			English	Article						hepatocellular carcinoma; CSN5; targeted siRNA therapeutics; SNALP	BINDING PROTEIN-1 EXPRESSION; CYCLE INHIBITOR P27(KIP1); COP9 SIGNALOSOME; RNA INTERFERENCE; BREAST-CANCER; IN-VIVO; PANCREATIC-CANCER; SYNTHETIC SIRNA; GENE-EXPRESSION; C-MYC	Development of targeted therapy for hepatocellular carcinoma (HCC) remains a major challenge. We have recently identified an elevated expression of the fifth subunit of COP9 signalosome (CSN5) in early HCC as compared with dysplastic stage. In the present study, we explored the possibility of CSN5 being a potential therapeutic target for HCC. Our results show that CSN5 knockdown by small-interfering (si) RNA caused a strong induction of apoptosis and inhibition of cell-cycle progression in HCC cells in vitro. The down-regulation of CSN5 was sufficient to interfere with CSN function as evidenced by the accumulation of neddylated Cullin 1 and changes in the protein levels of CSN-controlled substrates SKP2, p53, p27 and nuclear factor-kappa B, albeit to a different degree depending on the HCC cell line, which could account for the CSN5 knockdown phenotype. The transcriptomic analysis of CSN5 knockdown signature showed that the anti-proliferative effect was driven by a common subset of molecular alterations including down-regulation of cyclin-dependent kinase 6 (CDK6) and integrin beta 1 (ITGB1), which were functionally interconnected with key oncogenic regulators MYC and TGF beta 1 involved in the control of proliferation, apoptotic cell death and HCC progression. Consistent with microarray analysis, western blotting revealed that CSN5 depletion increased phosphorylation of Smad 2/3, key mediators of TGF beta 1 signaling, decreased the protein levels of ITGB1, CDK6 and cyclin D1 and caused reduced expression of anti-apoptotic Bcl-2, while elevating the levels of proapoptotic Bak. A chemically modified variant of CSN5 siRNA was then selected for in vivo application based on the growth inhibitory effect and minimal induction of unwanted immune response. Systemic delivery of the CSN5 3/8 variant by stable-nucleic-acid-lipid particles significantly suppressed the tumor growth in Huh7-luc(+) orthotopic xenograft model. Taken together, these results indicate that CSN5 has a pivotal role in HCC pathogenesis and maybe an attractive molecular target for systemic HCC therapy. Oncogene (2011) 30, 4175-4184; doi:10.1038/onc.2011.126; published online 18 April 2011	[Lee, Y-H; Seo, D.; Kitade, M.; Gomez-Quiroz, L. E.; Ishikawa, T.; Andersen, J. B.; Kim, B-K; Marquardt, J. U.; Raggi, C.; Conner, E. A.; Factor, V. M.; Thorgeirsson, S. S.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Judge, A. D.; MacLachlan, I.] Tekmira Pharmaceut Corp, Burnaby, BC, Canada; [Avital, I.] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, 37 Convent Dr Dr MSC,Room 4146A, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov	RAGGI, Chiara/U-3081-2017; Gomez-Quiroz, Luis/L-8415-2013	RAGGI, Chiara/0000-0003-2473-3535; Gomez-Quiroz, Luis Enrique/0000-0002-5704-5985; Andersen, Jesper B/0000-0003-1760-5244; Marquardt, Jens/0000-0002-8314-2682	Center for Cancer Research, NCI; NATIONAL CANCER INSTITUTE [ZIABC011175] Funding Source: NIH RePORTER	Center for Cancer Research, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by the Intramural Research Program of the Center for Cancer Research, NCI.	Adler AS, 2008, CANCER RES, V68, P506, DOI 10.1158/0008-5472.CAN-07-3060; Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Arsura M, 2005, CANCER LETT, V229, P157, DOI 10.1016/j.canlet.2005.07.008; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Berasain C, 2003, HEPATOLOGY, V38, P148, DOI 10.1053/jhep.2003.50269; Brasse D, 2010, INT J CANCER, V127, P1347, DOI 10.1002/ijc.25309; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839; Chamovitz DA, 2009, EMBO REP, V10, P352, DOI 10.1038/embor.2009.33; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esteva FJ, 2003, CLIN CANCER RES, V9, P5652; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukumoto A, 2004, ONCOL REP, V11, P277; Fukumoto A, 2006, FEBS LETT, V580, P5836, DOI 10.1016/j.febslet.2006.09.042; Goto A, 2004, PATHOL INT, V54, P675, DOI 10.1111/j.1440-1827.2004.01679.x; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hokaiwado N, 2008, IDRUGS, V11, P274; Ito Y, 2003, ANTICANCER RES, V23, P4121; Ivan D, 2004, MODERN PATHOL, V17, P811, DOI 10.1038/modpathol.3800123; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Judge AD, 2006, MOL THER, V13, P494, DOI 10.1016/j.ymthe.2005.11.002; Judge AD, 2009, J CLIN INVEST, V119, P661, DOI 10.1172/JCI37515; Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357; Kashiwakura Y, 2008, CANCER RES, V68, P8333, DOI 10.1158/0008-5472.CAN-08-0080; Kato JY, 2009, GENES CELLS, V14, P1209, DOI 10.1111/j.1365-2443.2009.01349.x; Kouvaraki MA, 2003, CANCER RES, V63, P2977; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Okabe H, 2001, CANCER RES, V61, P2129; Pai SI, 2006, GENE THER, V13, P464, DOI 10.1038/sj.gt.3302694; Panattoni M, 2008, J EXP MED, V205, P465, DOI 10.1084/jem.20070725; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Rossi JJ, 2006, GENE THER, V13, P583, DOI 10.1038/sj.gt.3302661; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Shackleford TJ, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-26; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Sui L, 2001, CLIN CANCER RES, V7, P4130; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Wei N, 2008, TRENDS BIOCHEM SCI, V33, P592, DOI 10.1016/j.tibs.2008.09.004; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	53	57	59	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4175	4184		10.1038/onc.2011.126	http://dx.doi.org/10.1038/onc.2011.126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21499307	Green Accepted			2022-12-17	WOS:000295924600004
J	Lind, GE; Raiborg, C; Danielsen, SA; Rognum, TO; Thiis-Evensen, E; Hoff, G; Nesbakken, A; Stenmark, H; Lothe, RA				Lind, G. E.; Raiborg, C.; Danielsen, S. A.; Rognum, T. O.; Thiis-Evensen, E.; Hoff, G.; Nesbakken, A.; Stenmark, H.; Lothe, R. A.			SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis	ONCOGENE			English	Article						colorectal neoplasia; cytokinesis; early detection; methylation; Spartin; SPG20	HEREDITARY SPASTIC PARAPLEGIA; TROYER-SYNDROME; PROTEIN SPARTIN; HYPERMETHYLATED GENES; DNA METHYLATION; FECAL DNA; CELLS; IDENTIFICATION; TUMORIGENESIS; INTERACTS	Colorectal cancer is a common disease with high mortality. Suitable biomarkers for detection of tumors at an early curable stage would significantly improve patient survival. Here, we show that the SPG20 (spastic paraplegia-20) promoter, encoding the multifunctional Spartin protein, is hypermethylated in 89% of colorectal carcinomas, 78% of adenomas and only 1% of normal mucosa samples. SPG20 methylation was also present in a pilot series of stool samples and corresponding tumors from colorectal cancer patients. SPG20 promoter hypermethylation resulted in loss of mRNA expression in various cancer types and subsequent depletion of Spartin. We further showed that Spartin down-regulation in cancer cells resulted in cytokinesis arrest, which was reversed when SPG20 methylation was inhibited. The present study identifies SPG20 promoter hypermethylation as a biomarker suitable for non-invasive detection of colorectal cancer, and a possible mechanism for cytokinesis arrest in colorectal tumorigenesis. Oncogene (2011) 30, 3967-3978; doi:10.1038/onc.2011.109; published online 18 April 2011	[Lind, G. E.; Danielsen, S. A.; Lothe, R. A.] Oslo Univ Hosp, Dept Canc Prevent, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway; [Lind, G. E.; Raiborg, C.; Danielsen, S. A.; Nesbakken, A.; Stenmark, H.; Lothe, R. A.] Univ Oslo, Ctr Canc Biomed, Fac Med, Oslo, Norway; [Raiborg, C.; Stenmark, H.] Oslo Univ Hosp, Dept Biochem, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway; [Rognum, T. O.] Oslo Univ Hosp, Inst Forens Med, Rikshosp, N-0310 Oslo, Norway; [Thiis-Evensen, E.] Oslo Univ Hosp, Dept Med, Rikshosp, N-0310 Oslo, Norway; [Hoff, G.] Telemark Hosp, Dept Med, Div Gastroenterol, Skien, Norway; [Nesbakken, A.] Oslo Univ Hosp, Dept Surg, Aker Hosp, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Telemark Hospital Trust; University of Oslo	Lothe, RA (corresponding author), Oslo Univ Hosp, Dept Canc Prevent, Inst Canc Res, Radiumhosp, N-0310 Oslo, Norway.	rlothe@rr-research.no	Stenmark, Harald/B-8868-2008	Lothe, Ragnhild A./0000-0002-1693-1032	Norwegian Cancer Society [PR-2008-0163, PR-2007-0063, PR-2006-0442, A95068]; European Research Council	Norwegian Cancer Society(Norwegian Cancer Society); European Research Council(European Research Council (ERC)European Commission)	We are grateful to Dr Hans Geir Eiken for providing expertise on stool DNA extraction and Hilde Honne, Mette Eknaes, Merete Hektoen and Kim Andresen for technical assistance. The breast cancer and pancreatic cancer cell lines were provided by Dr Anne Kallioniemi (Tampere University Hospital, Finland). The non-commercially available colon cancer cell lines were provided by Dr Richard Hamelin (INSERM, Paris, France). Financial support: This study is supported by grants from the Norwegian Cancer Society: GEL as a senior research fellow (PR-2008-0163), CR as a postdoctoral fellow (PR-2007-0063, HS) and SAD as a PhD student (PR-2006-0442, RAL), long-term grant (A95068, RAL). HS is supported by an Advanced Grant from the European Research Council.	Bakowska JC, 2005, BIOCHEM BIOPH RES CO, V334, P1042, DOI 10.1016/j.bbrc.2005.06.201; Bakowska JC, 2008, ARCH NEUROL-CHICAGO, V65, P520, DOI 10.1001/archneur.65.4.520; Bakowska JC, 2007, MOL BIOL CELL, V18, P1683, DOI 10.1091/mbc.E06-09-0833; Bu YQ, 2008, ONCOLOGY-BASEL, V74, P198, DOI 10.1159/000151367; Cabezas A, 2005, J CELL SCI, V118, P2625, DOI 10.1242/jcs.02382; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen WD, 2005, JNCI-J NATL CANCER I, V97, P1124, DOI 10.1093/jnci/dji204; Ciccarelli FD, 2003, GENOMICS, V81, P437, DOI 10.1016/S0888-7543(03)00011-9; Connell JW, 2009, TRAFFIC, V10, P42, DOI 10.1111/j.1600-0854.2008.00847.x; deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808; Eastman SW, 2009, J CELL BIOL, V184, P881, DOI 10.1083/jcb.200808041; Edwards TL, 2009, BIOCHEM J, V423, P31, DOI 10.1042/BJ20082398; Errico A, 2004, HUM MOL GENET, V13, P2121, DOI 10.1093/hmg/ddh223; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Goh L, 2007, BIOINFORMATICS, V23, P281, DOI 10.1093/bioinformatics/btl620; Hazan J, 1999, NAT GENET, V23, P296, DOI 10.1038/15472; Hooper C, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-72; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6; Kron K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004830; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lind GE, 2007, GASTROENTEROLOGY, V132, P1631, DOI 10.1053/j.gastro.2007.03.003; Lind GE, 2006, CELL ONCOL, V28, P259; Lu J, 2006, J NEUROCHEM, V98, P1908, DOI 10.1111/j.1471-4159.2006.04008.x; Milewska M, 2009, J NEUROCHEM, V111, P1022, DOI 10.1111/j.1471-4159.2009.06382.x; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Patel H, 2002, NAT GENET, V31, P347, DOI 10.1038/ng937; Pointis G, 2010, PHILOS T R SOC B, V365, P1607, DOI 10.1098/rstb.2009.0114; Proukakis C, 2004, J NEUROL, V251, P1105, DOI 10.1007/s00415-004-0491-3; Renvoise B, 2010, MOL BIOL CELL, V21, P3293, DOI 10.1091/mbc.E09-10-0879; Robay D, 2006, EXP CELL RES, V312, P2764, DOI 10.1016/j.yexcr.2006.05.003; Sagona AP, 2010, FEBS LETT, V584, P2652, DOI 10.1016/j.febslet.2010.03.044; Sagona AP, 2010, NAT CELL BIOL, V12, P362, DOI 10.1038/ncb2036; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Steigemann P, 2009, TRENDS CELL BIOL, V19, P606, DOI 10.1016/j.tcb.2009.07.008; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Tsang HTH, 2009, HUM MOL GENET, V18, P3805, DOI 10.1093/hmg/ddp324; Ventela S, 2003, MOL BIOL CELL, V14, P2768, DOI 10.1091/mbc.E02-10-0647; Vidulescu C, 2004, J CELL MOL MED, V8, P388, DOI 10.1111/j.1582-4934.2004.tb00328.x; Zhang WP, 2007, SCI CHINA SER G, V50, P1, DOI 10.1007/s11433-007-0010-5; Zitt M, 2007, DIS MARKERS, V23, P51, DOI 10.1155/2007/891967	46	57	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	37					3967	3978		10.1038/onc.2011.109	http://dx.doi.org/10.1038/onc.2011.109			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820FG	21499309	hybrid, Green Published			2022-12-17	WOS:000294890400006
J	Fagerli, UM; Ullrich, K; Stuhmer, T; Holien, T; Kochert, K; Holt, RU; Bruland, O; Chatterjee, M; Nogai, H; Lenz, G; Shaughnessy, JD; Mathas, S; Sundan, A; Bargou, RC; Dorken, B; Borset, M; Janz, M				Fagerli, U-M; Ullrich, K.; Stuehmer, T.; Holien, T.; Koechert, K.; Holt, R. U.; Bruland, O.; Chatterjee, M.; Nogai, H.; Lenz, G.; Shaughnessy, J. D., Jr.; Mathas, S.; Sundan, A.; Bargou, R. C.; Doerken, B.; Borset, M.; Janz, M.			Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells	ONCOGENE			English	Article						multiple myeloma; cytokines; SGK1; STAT3	PROTEIN-KINASE; BONE-MARROW; EPITHELIAL-CELLS; SURVIVAL; SERUM; PATHWAY; ACTIVATION; EXPRESSION; APOPTOSIS; DOWNSTREAM	Multiple myeloma (MM) is a paradigm for a malignant disease that exploits external stimuli of the microenvironment for growth and survival. A thorough understanding of the complex interactions between malignant plasma cells and their surrounding requires a detailed analysis of the transcriptional response of myeloma cells to environmental signals. We determined the changes in gene expression induced by interleukin (IL)-6, tumor necrosis factor-alpha, IL-21 or co-culture with bone marrow stromal cells in myeloma cell lines. Among a limited set of genes that were consistently activated in response to growth factors, a prominent transcriptional target of cytokine-induced signaling in myeloma cells was the gene encoding the serine/threonine kinase serum/glucocorticoid-regulated kinase 1 (SGK1), which is a down-stream effector of PI3-kinase. We could demonstrate a rapid, strong and sustained induction of SGK1 in the cell lines INA-6, ANBL-6, IH-1, OH-2 and MM.1S as well as in primary myeloma cells. Pharmacologic inhibition of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway abolished STAT3 phosphorylation and SGK1 induction. In addition, small hairpin RNA (shRNA)-mediated knock-down of STAT3 reduced basal and induced SGK1 levels. Furthermore, downregulation of SGK1 by shRNAs resulted in decreased proliferation of myeloma cell lines and reduced cell numbers. On the molecular level, this was reflected by the induction of cell cycle inhibitory genes, for example, CDKNA1/p21, whereas positively acting factors such as CDK6 and RBL2/p130 were downregulated. Our results indicate that SGK1 is a highly cytokine-responsive gene in myeloma cells promoting their malignant growth. Oncogene (2011) 30, 3198-3206; doi:10.1038/onc.2011.79; published online 11 April 2011	[Ullrich, K.; Koechert, K.; Nogai, H.; Lenz, G.; Mathas, S.; Doerken, B.; Janz, M.] Campus Virchow Klinikum, Univ Med Sch Berlin, Charite, Dept Hematol Oncol & Tumorimmunol, D-13092 Berlin, Germany; [Fagerli, U-M; Holien, T.; Holt, R. U.; Sundan, A.; Borset, M.] Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, N-7034 Trondheim, Norway; [Fagerli, U-M] St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway; [Ullrich, K.; Koechert, K.; Mathas, S.; Doerken, B.; Janz, M.] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; [Stuehmer, T.; Chatterjee, M.; Bargou, R. C.] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany; [Stuehmer, T.; Chatterjee, M.; Bargou, R. C.] Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Div Hematol, Wurzburg, Germany; [Holt, R. U.] Sor Trondelag Univ Coll, Fac Technol, Dept Biomed Sci, Trondheim, Norway; [Bruland, O.] Haukeland Univ Hosp Bergen, Ctr Med Genet & Mol Med, Bergen, Norway; [Shaughnessy, J. D., Jr.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; [Borset, M.] St Olavs Univ Hosp, Dept Immunol & Transfus Med, Trondheim, Norway	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Wurzburg; University of Wurzburg; Norwegian University of Science & Technology (NTNU); University of Bergen; Haukeland University Hospital; University of Arkansas System; University of Arkansas Medical Sciences; Norwegian University of Science & Technology (NTNU)	Janz, M (corresponding author), Campus Virchow Klinikum, Univ Med Sch Berlin, Charite, Dept Hematol Oncol & Tumorimmunol, Robert Rossle Str 10, D-13092 Berlin, Germany.	mjanz@mdc-berlin.de	Mathas, Stephan/I-5589-2015; Borset, Magne/AAY-1713-2021; Lenz, Georg/I-6844-2012; Holien, Toril/M-6253-2018	Borset, Magne/0000-0001-5179-2835; Kochert, Karl/0000-0002-5548-2022; Bruland, Oyvind Sverre/0000-0003-1631-3733; Janz, Martin/0000-0002-1127-0044; Holien, Toril/0000-0002-2051-5824	Deutsche Krebshilfe [10-2225-Ja 1]; Berlin Cancer Society; Deutsche Forschungsgemeinschaft [KFO 216]; Norwegian Cancer Society; St Olavs Hospital, Trondheim; Research Council of Norway	Deutsche Krebshilfe(Deutsche Krebshilfe); Berlin Cancer Society; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Norwegian Cancer Society(Norwegian Cancer Society); St Olavs Hospital, Trondheim; Research Council of Norway(Research Council of Norway)	We thank Brigitte Wollert-Wulf, Mandy Terne, Pia Herrmann (Berlin), Berit Stordal and Hanne Hella (Trondheim) for excellent technical assistance and Hans-Peter Rahn (Berlin) for cell sorting. Reuven Agami (Amsterdam, The Netherlands) kindly provided the pSUPER vector and Matthias Truss (Berlin) the pRepH1 construct. This work was supported by grants from the Deutsche Krebshilfe (10-2225-Ja 1), the Berlin Cancer Society, the Deutsche Forschungsgemeinschaft (KFO 216 to TS, MC and RCB), the Norwegian Cancer Society, the Cancer Fund of St Olavs Hospital, Trondheim, and the Research Council of Norway.	Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Meng FM, 2005, AM J PHYSIOL-CELL PH, V289, pC971, DOI 10.1152/ajpcell.00081.2005; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Ogata A, 1997, CLIN CANCER RES, V3, P1017; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Sahoo S, 2005, EUR J CANCER, V41, P2754, DOI 10.1016/j.ejca.2005.07.018; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Tu YP, 2000, CANCER RES, V60, P6763; van Zaanen HCT, 1998, BRIT J HAEMATOL, V102, P783; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zollinger A, 2008, BLOOD, V112, P3403, DOI 10.1182/blood-2007-11-119362	22	57	60	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	28					3198	3206		10.1038/onc.2011.79	http://dx.doi.org/10.1038/onc.2011.79			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21478911				2022-12-17	WOS:000292726300008
J	Serres, MP; Zlotek-Zlotkiewicz, E; Concha, C; Gurian-West, M; Daburon, V; Roberts, JM; Besson, A				Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Gurian-West, M.; Daburon, V.; Roberts, J. M.; Besson, A.			Cytoplasmic p27 is oncogenic and cooperates with Ras both in vivo and in vitro	ONCOGENE			English	Article						p27 Kip1; Ras; Myc; mouse model; lung tumors	CELL-CYCLE PROGRESSION; CDK INHIBITORS; LUNG-CANCER; P27(KIP1) MISLOCALIZATION; DEPENDENT PHOSPHORYLATION; TUMOR SUPPRESSION; NUCLEAR EXPORT; MYC; LOCALIZATION; PROTEOLYSIS	p27(Kip1) (p27) can have opposing roles during malignant transformation depending on cellular context: on one hand it functions as a tumor suppressor by inhibiting cyclin-cyclin-dependent kinase (CDK) activity in the nucleus and on the other it may adopt an oncogenic role that is less well understood. To gain further insight into the roles played by p27 during tumorigenesis, we compared the susceptibility with urethane-induced tumorigenesis of two p27 mouse models, p27(-/-) and p27(CK-) knockin, in which p27 cannot bind or inhibit cyclin-CDKs. In this K-Ras-driven tumorigenesis model, p27(CK-) mice had an increase in both tumor number and aggressiveness compared with p27(-/-), indicating a cooperation between p27(CK-) and activated Ras. In the lung, increased tumorigenesis was associated with cytoplasmic localization of p27(CK-) and bronchiolaveolar stem cell amplification. The ability of p27(CK-) to cooperate with other oncogenes was not universal. When c-Myc was used as a transforming agent, p27 status became irrelevant and c-Myc was equally potent in transforming p27(+/+), p27(-/-) and p27(CK-) cells. In fact, c-Myc induced the degradation of wild-type p27 via the Skp-Cullin-F-box (SCF)-Skp2 pathway. In contrast, p27(CK-) levels were not affected by c-Myc expression, as p27(CK-) is insensitive to Skp2-mediated degradation because of its inability to bind cyclin E/CDK2. However, in presence of c-Myc, p27(CK-) remained mostly nuclear, providing an explanation for its inability to cooperate with Myc during transformation. Thus, we propose that the p27(CK-) protein needs to be localized in the cytoplasm in order to function as an oncogene, otherwise it just behaves similar to a null allele. Oncogene (2011) 30, 2846-2858; doi:10.1038/onc.2011.9; published online 14 February 2011	[Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Daburon, V.; Besson, A.] CNRS, UMR 5088, ERL5294, F-31062 Toulouse 9, France; [Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Daburon, V.; Besson, A.] Canc Res Ctr Toulouse, INSERM, UMR1037, Toulouse, France; [Serres, M. P.; Zlotek-Zlotkiewicz, E.; Concha, C.; Daburon, V.; Besson, A.] Univ Toulouse, Toulouse, France; [Gurian-West, M.; Roberts, J. M.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Fred Hutchinson Cancer Center	Besson, A (corresponding author), CNRS, UMR 5088, ERL5294, 118 Route Narbonne,Batiment 4R3b1, F-31062 Toulouse 9, France.	abesson@cict.fr	zlotek-zlotkiewicz, ewa/M-1774-2015; Besson, Arnaud/J-6254-2014	Besson, Arnaud/0000-0002-9599-3943	Ministere de l'Enseignement Superieur et de la Recherche; Fondation pour la Recherche Medicale; NIH [1R01CA118043]; Association pour la Recherche sur le Cancer; Ligue Nationale Contre le Cancer; NATIONAL CANCER INSTITUTE [R01CA118043] Funding Source: NIH RePORTER	Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MPS is supported by a studentship from the Ministere de l'Enseignement Superieur et de la Recherche. CC is supported by a fellowship from the Fondation pour la Recherche Medicale. This work was supported by NIH grant # 1R01CA118043 to JMR. AB is supported by grants from the Association pour la Recherche sur le Cancer and Ligue Nationale Contre le Cancer.	Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Chu S, 2010, LEUKEMIA, V24, P779, DOI 10.1038/leu.2010.24; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Connor MK, 2003, MOL BIOL CELL, V14, P201, DOI 10.1091/mbc.E02-06-0319; Denicourt C, 2007, CANCER RES, V67, P9238, DOI 10.1158/0008-5472.CAN-07-1375; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2003, J BIOL CHEM, V278, P49254, DOI 10.1074/jbc.M306614200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hattori T, 2007, CANCER RES, V67, P10789, DOI 10.1158/0008-5472.CAN-07-2033; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Kelly-Spratt KS, 2009, ONCOGENE, V28, P3652, DOI 10.1038/onc.2009.226; Kfir S, 2005, MOL CELL BIOL, V25, P8239, DOI 10.1128/MCB.25.18.8239-8250.2005; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Larreaa MD, 2009, P NATL ACAD SCI USA, V106, P9268, DOI 10.1073/pnas.0805057106; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Li ZP, 2006, CANCER RES, V66, P9986, DOI 10.1158/0008-5472.CAN-06-1596; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Old JB, 2010, MOL CANCER RES, V8, P353, DOI 10.1158/1541-7786.MCR-09-0232; Papakonstanti EA, 2007, EMBO J, V26, P3050, DOI 10.1038/sj.emboj.7601763; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2005, J BIOL CHEM, V280, P6055, DOI 10.1074/jbc.M412367200; Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304	51	57	59	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2011	30	25					2846	2858		10.1038/onc.2011.9	http://dx.doi.org/10.1038/onc.2011.9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	781ZV	21317921				2022-12-17	WOS:000291977800005
J	Robinson, KS; Clements, A; Williams, AC; Berger, CN; Frankel, G				Robinson, K. S.; Clements, A.; Williams, A. C.; Berger, C. N.; Frankel, G.			Bax Inhibitor 1 in apoptosis and disease	ONCOGENE			English	Review						Bax inhibitor 1; apoptosis; ER stress; UPR; breast cancer	ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; BREAST-CANCER CELLS; ENTEROPATHOGENIC ESCHERICHIA-COLI; SIGNALING PATHWAYS; DEATH; EXPRESSION; CALCIUM; BCL-2; GENE	Bax inhibitor 1 (BI-1) was originally discovered as an inhibitor of Bax-induced apoptosis; this review highlights the fundamental importance of BI-1 in a wider context, including in tissue homeostasis and as a regulator of cellular stress. BI-1 has been shown to interact with a broad range of partners to inhibit many facets of apoptosis, such as reactive oxygen species production, cytosolic acidification and calcium levels as well as endoplasmic reticulum stress signalling pathways. BI-1's anti-apoptotic action initially enables the cell to adapt to stress, although if the stress is prolonged or severe the actions of BI-1 may promote apoptosis. This almost universal anti-apoptotic capacity has been shown to be manipulated during infection with enteropathogenic and enterohaemorrhagic Escherichia coli inhibiting host cell death through direct interaction between their effector NleH and BI-1. In addition, BI-1 activity is important in a large number of cancers, promoting metastasis by modulating actin dynamics, a process dependent upon the BI-1 C-terminus and BI-1: actin interaction. Manipulation of BI-1 therefore has the potential for significant therapeutic benefit in a wide range of human diseases. Oncogene (2011) 30, 2391-2400; doi:10.1038/onc.2010.636; published online 7 February 2011	[Robinson, K. S.; Clements, A.; Berger, C. N.; Frankel, G.] Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; [Williams, A. C.] Univ Bristol, Sch Med Sci, Univ Walk, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	Imperial College London; University of Bristol	Frankel, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Cell & Mol Biol, Ctr Mol Microbiol & Infect, Flowers Bldg, London SW7 2AZ, England.	g.frankel@imperial.ac.uk	Berger, Cedric N/AAY-1438-2021	Berger, Cedric N/0000-0002-1316-5985; Clements, Abigail/0000-0003-2285-777X; Williams, Ann/0000-0002-6009-7137	Marie Curie fellowship [FP7-PEOPLE-2009-IIF]; Wellcome Trust; Cancer Research UK [11975] Funding Source: researchfish	Marie Curie fellowship(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK)	Abigail Clements is supported by a Marie Curie fellowship FP7-PEOPLE-2009-IIF. This work was supported by a grant from the Wellcome Trust.	Ahn T, 2010, CELL CALCIUM, V47, P387, DOI 10.1016/j.ceca.2010.02.003; Ahn T, 2009, FEBS J, V276, P2285, DOI 10.1111/j.1742-4658.2009.06956.x; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Burns TF, 2001, J BIOL CHEM, V276, P37879; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Caron E, 2006, CURR OPIN MICROBIOL, V9, P40, DOI 10.1016/j.mib.2005.12.008; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022; Crane JK, 2001, CELL MICROBIOL, V3, P197, DOI 10.1046/j.1462-5822.2001.00103.x; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.0.CO;2-Y; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Hemrajani C, 2010, P NATL ACAD SCI USA, V107, P3129, DOI 10.1073/pnas.0911609106; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Jean JC, 1999, GENOMICS, V57, P201, DOI 10.1006/geno.1999.5761; Kim HR, 2008, J BIOL CHEM, V283, P15946, DOI 10.1074/jbc.M800075200; Kim HR, 2009, J CELL SCI, V122, P1126, DOI 10.1242/jcs.038430; Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kohno K, 2010, J BIOCHEM, V147, P27, DOI 10.1093/jb/mvp196; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; Kurokawa H, 1999, ONCOL REP, V6, P33; Kvansakul M, 2008, CELL DEATH DIFFER, V15, P1564, DOI 10.1038/cdd.2008.83; Lebiedzinska M, 2009, INT J BIOCHEM CELL B, V41, P1805, DOI 10.1016/j.biocel.2009.02.017; Lee GH, 2010, ONCOGENE, V29, P2130, DOI 10.1038/onc.2009.491; Lee GH, 2007, J BIOL CHEM, V282, P21618, DOI 10.1074/jbc.M700053200; Lee GH, 2010, MOL CELL BIOL, V30, P1800, DOI 10.1128/MCB.01357-09; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Nieto N, 2002, HEPATOLOGY, V35, P62, DOI 10.1053/jhep.2002.30362; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Ravi R, 2002, CANCER RES, V62, P1583; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; Rong JA, 2011, J BIOL CHEM, V286, P1453, DOI 10.1074/jbc.M110.175232; Rong YP, 2009, P NATL ACAD SCI USA, V106, P14397, DOI 10.1073/pnas.0907555106; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmits R, 2002, INT J CANCER, V98, P73, DOI 10.1002/ijc.10170; Shiraishi H, 2006, J CELL SCI, V119, P3958, DOI 10.1242/jcs.03160; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Tanaka R, 2006, CANCER-AM CANCER SOC, V106, P648, DOI 10.1002/cncr.21639; TANNOCK IF, 1989, CANCER RES, V49, P4373; Urano W, 2010, ANN RHEUM DIS, V69, P1232, DOI 10.1136/ard.2008.106856; Wahl ML, 2000, J CELL PHYSIOL, V183, P373, DOI 10.1002/(SICI)1097-4652(200006)183:3<373::AID-JCP10>3.0.CO;2-S; Wang E, 1999, J CELL BIOCHEM, P95; Wolgien MDGM, 2005, EUR J GYNAECOL ONCOL, V26, P501; Wyllie AH, 2010, MOL NEUROBIOL, V42, P4, DOI 10.1007/s12035-010-8125-5; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yang L, 2003, CANCER RES, V63, P6815	58	57	61	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	21					2391	2400		10.1038/onc.2010.636	http://dx.doi.org/10.1038/onc.2010.636			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21297665	Bronze			2022-12-17	WOS:000291008000001
J	He, M; Zhao, M; Shen, B; Prise, KM; Shao, C				He, M.; Zhao, M.; Shen, B.; Prise, K. M.; Shao, C.			Radiation-induced intercellular signaling mediated by cytochrome-c via a p53-dependent pathway in hepatoma cells	ONCOGENE			English	Article						irradiation; hepatoma cells; bystander effect; p53; cytochrome-c	ALPHA-PARTICLES; NITRIC-OXIDE; BYSTANDER RESPONSES; IONIZING-RADIATION; ADAPTIVE RESPONSE; HUMAN FIBROBLASTS; PIFITHRIN-ALPHA; GLIOMA-CELLS; P53; GROWTH	The tumor suppressor p53 has a crucial role in cellular response to DNA damage caused by ionizing radiation, but it is still unclear whether p53 can modulate radiation-induced bystander effects (RIBE). In the present work, three different hepatoma cell lines, namely HepG2 (wild p53), PLC/PRF/5 (mutation p53) and Hep3B (p53 null), were irradiated with c-rays and then co-cultured with normal Chang liver cell (wild p53) in order to elucidate the mechanisms of RIBE. Results showed that the radiosensitivity of HepG2 cells was higher than that of PLC/PRF/5 and Hep3B cells. Only irradiated HepG2 cells, rather than irradiated PLC/PRF/5 or Hep3B cells, could induce bystander effect of micronuclei (MN) formation in the neighboring Chang liver cells. When HepG2 cells were treated with 20 mu M pifithrin-alpha, an inhibitor of p53 function, or 5 lM cyclosporin A (CsA), an inhibitor of cytochrome- c release from mitochondria, the MN induction in bystander Chang liver cells was diminished. In fact, it was found that after irradiation, cytochrome- c was released from mitochondria into the cytoplasm only in HepG2 cells in a p53- dependent manner, but not in PLC/PRF/5 and Hep3B cells. Interestingly, when 50 lg/ml exogenous cytochrome- c was added into cell co- culture medium, RIBE was significantly triggered by irradiated PLC/PRF/5 and Hep3B cells, which previously failed to provoke a bystander effect. In addition, this exogenous cytochrome- c also partly recovered the RIBE induced by irradiated HepG2 cells even with CsA treatment. Our results provide new evidence that the RIBE can be modulated by the p53 status of irradiated hepatoma cells and that a p53- dependent release of cytochrome- c may be involved in the RIBE. Oncogene (2011) 30, 1947- 1955; doi: 10.1038/onc. 2010.567; published online 6 December 2010	[He, M.; Zhao, M.; Shen, B.; Shao, C.] Fudan Univ, Inst Radiat Med, Shanghai 200032, Peoples R China; [Prise, K. M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland	Fudan University; Queens University Belfast	Shao, C (corresponding author), Fudan Univ, Inst Radiat Med, 2094 Xie Tu Rd, Shanghai 200032, Peoples R China.	clshao@shmu.edu.cn	Prise, Kevin/N-7872-2015	Prise, Kevin/0000-0001-6134-7946; Shao, Chunlin/0000-0001-9336-9912	National Nature Science Foundation of China [30770644, 31070758]; Shanghai Health Bureau [08GWD09, 08GWZX0602]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Health Bureau	We thank the National Nature Science Foundation of China Grant numbers 30770644 and 31070758, the Shanghai Health Bureau (08GWD09, 08GWZX0602) for funding this work.	AIN JF, 1994, J SURG RES, V57, P366, DOI 10.1006/jsre.1994.1156; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 2003, ONCOGENE, V22, P7050, DOI 10.1038/sj.onc.1206961; BARTEK J, 1991, ONCOGENE, V6, P1699; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Chen HH, 2008, INT J RADIAT ONCOL, V72, P1560, DOI 10.1016/j.ijrobp.2008.07.038; Chen S, 2008, BRIT J CANCER, V98, P1839, DOI 10.1038/sj.bjc.6604358; Chhipa RR, 2007, J CELL BIOCHEM, V101, P68, DOI 10.1002/jcb.21153; Coates P, 2008, J PATHOL, V214, P610, DOI 10.1002/path.2321; Concin N, 2000, CANCER LETT, V150, P191, DOI 10.1016/S0304-3835(99)00393-6; Emerit I, 1996, P NATL ACAD SCI USA, V93, P12799, DOI 10.1073/pnas.93.23.12799; Han W, 2010, CARCINOGENESIS, V31, P275, DOI 10.1093/carcin/bgp301; Harada K, 2009, CANCER SCI, V100, P684, DOI 10.1111/j.1349-7006.2009.01093.x; Iyer R, 2000, CANCER RES, V60, P1290; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Lehnert BE, 1997, ENVIRON HEALTH PERSP, V105, P1095, DOI 10.2307/3433515; Luce A, 2009, CARCINOGENESIS, V30, P432, DOI 10.1093/carcin/bgp008; Ma SM, 2010, CANCER TREAT REV, V36, P157, DOI 10.1016/j.ctrv.2009.11.008; Mancuso M, 2008, P NATL ACAD SCI USA, V105, P12445, DOI 10.1073/pnas.0804186105; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mitchell SA, 2004, INT J RADIAT BIOL, V80, P465, DOI 10.1080/09553000410001725116; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 2007, MUTAT RES-FUND MOL M, V616, P159, DOI 10.1016/j.mrfmmm.2006.11.009; MOSES AC, 1983, J CLIN ENDOCR METAB, V56, P1003, DOI 10.1210/jcem-56-5-1003; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Murphy JEJ, 2005, MUTAT RES-GEN TOX EN, V585, P127, DOI 10.1016/j.mrgentox.2005.04.011; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Ng LT, 2006, AM J CHINESE MED, V34, P125, DOI 10.1142/S0192415X06003692; Peixoto PM, 2009, BIOCHEM BIOPH RES CO, V390, P38, DOI 10.1016/j.bbrc.2009.09.054; Preta G, 2009, BIOCHEM BIOPH RES CO, V389, P575, DOI 10.1016/j.bbrc.2009.09.021; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; Ryan LA, 2008, RADIAT RES, V169, P188, DOI 10.1667/RR1141.1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2008, ONCOGENE, V27, P434, DOI 10.1038/sj.onc.1210653; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2008, MUTAT RES-FUND MOL M, V638, P139, DOI 10.1016/j.mrfmmm.2007.09.007; Shao CL, 2010, NUCL INSTRUM METH B, V268, P627, DOI 10.1016/j.nimb.2009.12.024; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, FASEB J, V17, P1422, DOI 10.1096/fj.02-1115com; Shao CL, 2003, RADIAT ENVIRON BIOPH, V42, P183, DOI 10.1007/s00411-003-0202-y; Shao CL, 2003, RADIAT RES, V160, P318, DOI 10.1667/RR3044; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Tartier L, 2007, CANCER RES, V67, P5872, DOI 10.1158/0008-5472.CAN-07-0188; Tsai KKC, 2009, RADIAT RES, V172, P306, DOI 10.1667/RR1764.1; Viani P, 2003, J BIOL CHEM, V278, P9592, DOI 10.1074/jbc.M207729200; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang B, 2000, RADIAT RES, V154, P277, DOI 10.1667/0033-7587(2000)154[0277:ARIEIR]2.0.CO;2; Yang G, 2009, BRIT J CANCER, V100, P1912, DOI 10.1038/sj.bjc.6605087; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; Yuan DX, 2010, MUTAT RES-FUND MOL M, V688, P66, DOI 10.1016/j.mrfmmm.2010.03.010; Zhang XP, 2009, P NATL ACAD SCI USA, V106, P12245, DOI 10.1073/pnas.0813088106; Zhang Y, 2008, RADIAT RES, V169, P197, DOI 10.1667/RR1189.1; Zhou HN, 2005, P NATL ACAD SCI USA, V102, P14641, DOI 10.1073/pnas.0505473102; Zhou HN, 2008, CANCER RES, V68, P2233, DOI 10.1158/0008-5472.CAN-07-5278	61	57	64	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1947	1955		10.1038/onc.2010.567	http://dx.doi.org/10.1038/onc.2010.567			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21132005	Green Accepted			2022-12-17	WOS:000289777700010
J	Oleinik, NV; Krupenko, NI; Krupenko, SA				Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.			ALDH1L1 inhibits cell motility via dephosphorylation of cofilin by PP1 and PP2A	ONCOGENE			English	Article						ALDH1L1; cofilin; phosphatases; actin; folate	ACTIN-BINDING PROTEINS; 10-FORMYLTETRAHYDROFOLATE DEHYDROGENASE; REGULATES COFILIN; GENE-EXPRESSION; CARCINOMA-CELLS; DIETARY-FOLATE; BREAST-CANCER; DYNAMICS; MIGRATION; INVASION	Here we report that ALDH1L1 (FDH, a folate enzyme with tumor suppressor-like properties) inhibits cell motility. The underlying mechanism involves F-actin stabilization, re-distribution of cytoplasmic actin toward strong preponderance of filamentous actin and formation of actin stress fibers. A549 cells expressing FDH showed a much slower recovery of green fluorescent protein-actin fluorescence in a fluorescence recovery after photobleaching assay, as well as an increase in G-actin polymerization and a decrease in F-actin depolymerization rates in pyren-actin fluorescence assays indicating the inhibition of actin dynamics. These effects were associated with robust dephosphorylation of the actin depolymerizing factor cofilin by PP1 and PP2A serine/threonine protein phosphatases, but not the cofilin-specific phosphatases slingshot and chronophin. In fact, the PP1/PP2A inhibitor calyculin prevented cofilin dephosphorylation and restored motility. Inhibition of FDH-induced apoptosis by the Jun N-terminal kinase inhibitor SP600125 or the pan-caspase inhibitor zVAD-fmk did not restore motility or levels of phosphor-cofilin, indicating that the observed effects are independent of FDH function in apoptosis. Interestingly, cofilin small interfering RNA or expression of phosphorylation-deficient S3A cofilin mutant resulted in a decrease of G-actin and the actin stress fiber formation, the effects seen upon FDH expression. In contrast, the expression of S3D mutant, mimicking constitutive phosphorylation, prevented these effects further supporting the cofilin-dependent mechanism. Dephosphorylation of cofilin and inhibition of motility in response to FDH can also be prevented by the increased folate in media. Furthermore, folate depletion itself, in the absence of FDH, resulted in cofilin dephosphorylation and inhibition of motility in several cell lines. Our experiments showed that these effects were folate specific and not a general response to nutrient starvation. Overall, this study shows the presence of distinct intracellular signaling pathways regulating motility in response to folate status and points toward mechanisms involving folates in promoting a malignant phenotype. Oncogene (2010) 29, 6233-6244; doi:10.1038/onc.2010.356; published online 23 August 2010	[Oleinik, N. V.; Krupenko, N. I.; Krupenko, S. A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Krupenko, SA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,Room 512-B BSB, Charleston, SC 29425 USA.	krupenko@musc.edu			National Institutes of Health [DK054388, CA095030]; NATIONAL CANCER INSTITUTE [R01CA095030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054388] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The construct for expression of GFP/actin fusion was a kind gift from Dr Imhof. Vectors for expression of S3A and S3D cofilin mutants were generous gifts from Dr Shieh. The authors would like to thank Dr Condeelis for the helpful discussion. This work was supported by National Institutes of Health Grants DK054388 and CA095030.	Ambach A, 2000, EUR J IMMUNOL, V30, P3422, DOI 10.1002/1521-4141(2000012)30:12<3422::AID-IMMU3422>3.0.CO;2-J; Ananthakrishnan R, 2007, INT J BIOL SCI, V3, P303; Ballestrem C, 1998, J CELL SCI, V111, P1649; Bamburg JR, 2002, TRENDS CELL BIOL, V12, P598, DOI 10.1016/S0962-8924(02)02404-2; Chanson A, 2005, J NUTR, V135, P2524, DOI 10.1093/jn/135.11.2524; Chhabra D, 2005, BIOPHYS J, V89, P1902, DOI 10.1529/biophysj.105.062083; Cohen PTW, 2002, J CELL SCI, V115, P241; Crott JW, 2008, J NUTR BIOCHEM, V19, P328, DOI 10.1016/j.jnutbio.2007.05.003; Crott JW, 2004, CARCINOGENESIS, V25, P69, DOI 10.1093/carcin/bgg150; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Dos Remedios CG, 2003, PHYSIOL REV, V83, P433, DOI 10.1152/physrev.00026.2002; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Fox JT, 2008, VITAM HORM, V79, P1, DOI 10.1016/S0083-6729(08)00401-9; Franco C, 2006, AM J PATHOL, V168, P1697, DOI 10.2353/ajpath.2006.050613; Ghose S, 2009, MOL CANCER RES, V7, P99, DOI 10.1158/1541-7786.MCR-08-0309; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; HALL AL, 1989, DEV BIOL, V136, P517, DOI 10.1016/0012-1606(89)90277-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Jhaveri MS, 2001, MOL PHARMACOL, V60, P1288, DOI 10.1124/mol.60.6.1288; Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349; Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227; Lai FP, 2008, EMBO J, V27, P982, DOI 10.1038/emboj.2008.34; Lewis CM, 1998, CANCER RES, V58, P2952; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Montell DJ, 2008, SCIENCE, V322, P1502, DOI 10.1126/science.1164073; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Oleinik NV, 2007, ONCOGENE, V26, P7222, DOI 10.1038/sj.onc.1210526; Oleinik NV, 2006, BIOCHEM PHARMACOL, V72, P256, DOI 10.1016/j.bcp.2006.04.005; Oleinik NV, 2005, BIOCHEM J, V391, P503, DOI 10.1042/BJ20050533; Oleinik NV, 2003, MOL CANCER RES, V1, P577; Oser M, 2009, J CELL BIOCHEM, V108, P1252, DOI 10.1002/jcb.22372; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Roger L, 2006, BIOL CELL, V98, P141, DOI 10.1042/BC20050058; Song XY, 2006, J CELL SCI, V119, P2871, DOI 10.1242/jcs.03017; Turner DP, 2007, CANCER RES, V67, P1618, DOI 10.1158/0008-5472.CAN-06-2913; Tyagi SC, 1996, J CELL PHYSIOL, V167, P137, DOI 10.1002/(SICI)1097-4652(199604)167:1<137::AID-JCP16>3.0.CO;2-8; Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206; van Rheenen J, 2009, J CELL SCI, V122, P305, DOI 10.1242/jcs.031146; Wagner C, 1995, FOLATE HLTH DIS, P23; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wiggan O, 2005, NAT CELL BIOL, V7, P8, DOI 10.1038/ncb0105-8; Williams MJ, 2006, J CELL SCI, V119, P2015, DOI 10.1242/jcs.02920; Winder SJ, 2005, J CELL SCI, V118, P651, DOI 10.1242/jcs.01670; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zhan Q, 2003, CELL MOTIL CYTOSKEL, V54, P1, DOI 10.1002/cm.10079; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946; Zhao RB, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000969; Zhu HP, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-128	56	57	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	47					6233	6244		10.1038/onc.2010.356	http://dx.doi.org/10.1038/onc.2010.356			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729910	Green Accepted			2022-12-17	WOS:000284601700005
J	Holgren, C; Dougherty, U; Edwin, F; Cerasi, D; Taylor, I; Fichera, A; Joseph, L; Bissonnette, M; Khare, S				Holgren, C.; Dougherty, U.; Edwin, F.; Cerasi, D.; Taylor, I.; Fichera, A.; Joseph, L.; Bissonnette, M.; Khare, S.			Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas	ONCOGENE			English	Article						sprouty-2; colon; cancer; metastasis; Ras; c-Met	HEPATOCYTE GROWTH-FACTOR; PROTEIN-KINASE PATHWAY; COLORECTAL-CANCER; URSODEOXYCHOLIC ACID; TYROSINE KINASE; HEPATOCELLULAR-CARCINOMA; ORTHOTOPIC IMPLANTATION; LIVER METASTASES; PROSTATE-CANCER; RAS ACTIVATION	Sprouty negatively regulates receptor tyrosine kinase signals by inhibiting Ras/extracellular signal-regulated kinase (ERK) pathways. Sprouty is downregulated in breast, prostate and liver cancers and appears to function as a tumor suppressor. The role of sprouty in colonic neoplasia, however, has not been investigated. Sprouty-2 protein and mRNA transcripts were significantly upregulated in human colonic adenocarcinomas. Strikingly, the c-Met receptor was also upregulated in tumors with increased sprouty-2. To delineate a potential causal relationship between sprouty-2 and c-Met, K-ras mutant HCT-116 colon cancer cells were transduced with purified TAT-sprouty-2 protein or stably transfected with full-length human sprouty-2 gene. Sprouty-2 upregulation significantly increased cell proliferation by accelerating cell cycle transition. Sprouty-2 transfectants showed strong upregulation of c-Met protein and mRNA transcripts and hepatocyte growth factor-stimulated ERK and Akt phosphorylation and enhanced cell migration and invasion. In contrast, knockdown of c-Met by small interfering RNA (siRNA) significantly decreased cell proliferation, migration and invasion in sprouty-2 transfectants. Further, knockdown of sprouty-2 by siRNA in parental HT-29 and LS-174T colon cancer cells also decreased cell invasion. Sprouty-2 transfectants formed significantly larger tumor xenografts and showed increased proliferation and angiogenesis and suppressed apoptosis. Sprouty-2 tumors metastasized to the liver from cecal orthotopic implants, suggesting that sprouty-2 might also enhance metastatic signals. Thus, in colon cancer sprouty functions as an oncogene and its effects are mediated in part by c-Met upregulation. Oncogene (2010) 29, 5241-5253; doi:10.1038/onc.2010.264; published online 26 July 2010	[Holgren, C.; Khare, S.] Loyola Univ Chicago, Dept Med, Maywood, IL 60153 USA; [Holgren, C.; Khare, S.] Hines Vet Affairs Med Ctr, Hines, IL USA; [Dougherty, U.; Cerasi, D.; Taylor, I.; Bissonnette, M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Edwin, F.] Loyola Univ Chicago, Dept Pharmacol, Maywood, IL 60153 USA; [Fichera, A.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA; [Joseph, L.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; University of Chicago; Loyola University Chicago; University of Chicago; University of Chicago	Khare, S (corresponding author), Loyola Univ Chicago, Dept Med, Bldg 54,2160 S 1st Ave, Maywood, IL 60153 USA.	skhare@lumc.edu			VA merit award;  [CA036745]; NATIONAL CANCER INSTITUTE [R03CA097540, R37CA036745, R01CA036745] Funding Source: NIH RePORTER	VA merit award(US Department of Veterans Affairs); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were funded in part by Grant CA036745 (to M Bissonnette) and VA merit award (to S Khare).	Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Brett D, 2001, ONCOGENE, V20, P4581, DOI 10.1038/sj.onc.1204610; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; Dougherty U, 2009, CLIN CANCER RES, V15, P6780, DOI 10.1158/1078-0432.CCR-09-1678; Edwin F, 2006, J BIOL CHEM, V281, P4816, DOI 10.1074/jbc.M508300200; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Fujita S, 1997, JPN J CLIN ONCOL, V27, P378, DOI 10.1093/jjco/27.6.378; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guy GR, 2003, J CELL SCI, V116, P3061, DOI 10.1242/jcs.00652; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hall AB, 2003, CURR BIOL, V13, P308, DOI 10.1016/S0960-9822(03)00086-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Huerta S, 2006, AM J SURG, V191, P517, DOI 10.1016/j.amjsurg.2005.11.009; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kanayama M, 2007, AM J PHYSIOL-GASTR L, V293, pG230, DOI 10.1152/ajpgi.00068.2007; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Khare S, 2003, CANCER RES, V63, P3517; Khare S, 2008, NUTR CANCER, V60, P389, DOI 10.1080/01635580701883003; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kwabi-Addo B, 2004, CANCER RES, V64, P4728, DOI 10.1158/0008-5472.CAN-03-3759; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee M, 2006, BIOCHEM BIOPH RES CO, V350, P450, DOI 10.1016/j.bbrc.2006.09.067; Li N, 2007, J BIOL CHEM, V282, P16764, DOI 10.1074/jbc.M610835200; Lim J, 2002, MOL CELL BIOL, V22, P7953, DOI 10.1128/MCB.22.22.7953-7966.2002; Lito P, 2008, J BIOL CHEM, V283, P2002, DOI 10.1074/jbc.M709046200; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Minowada G, 2009, AM J RESP CELL MOL, V40, P31, DOI 10.1165/rcmb.2008-0147OC; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Pelletier G, 2003, HEPATOLOGY, V37, P887, DOI 10.1053/jhep.2003.50118; Poppleton HM, 2004, BIOCHEM BIOPH RES CO, V323, P98, DOI 10.1016/j.bbrc.2004.08.070; Rozen S, 2000, Methods Mol Biol, V132, P365; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Shoji T, 2003, CANCER LETT, V195, P235, DOI 10.1016/S0304-3835(02)00108-8; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Sutterluty H, 2007, MOL CANCER RES, V5, P509, DOI 10.1158/1541-7786.MCR-06-0273; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Teranishi N, 2007, INT J ONCOL, V30, P593; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Vaculova A, 2006, FEBS LETT, V580, P6565, DOI 10.1016/j.febslet.2006.11.004; Wang L., 2008, Experimental Oncology, V30, P42; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049; Zeng ZS, 2004, CLIN EXP METASTAS, V21, P409, DOI 10.1007/s10585-005-1617-4	57	57	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	38					5241	5253		10.1038/onc.2010.264	http://dx.doi.org/10.1038/onc.2010.264			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20661223	Green Accepted			2022-12-17	WOS:000282089100003
J	Lucas, JT; Salimath, BP; Slomiany, MG; Rosenzweig, SA				Lucas, J. T., Jr.; Salimath, B. P.; Slomiany, M. G.; Rosenzweig, S. A.			Regulation of invasive behavior by vascular endothelial growth factor is HEF1-dependent	ONCOGENE			English	Article						VEGF; invadopodia; cell migration; invasion; HEF1; NEDD9	SQUAMOUS-CELL CARCINOMA; FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX DEGRADATION; BREAST-CANCER METASTASIS; TYROSINE PHOSPHORYLATION; NECK-CANCER; 11Q13 AMPLIFICATION; FACTOR RECEPTOR; HEAD; CORTACTIN	We previously reported a vascular endothelial growth factor (VEGF) autocrine loop in head and neck squamous cell carcinoma (HNSCC) cell lines, supporting a role for VEGF in HNSCC tumorigenesis. Using a phosphotyrosine proteomics approach, we screened the HNSCC cell line, squamous cell carcinoma-9 for effectors of VEGFR2 signaling. A cluster of proteins involved in cell migration and invasion, including the p130Cas paralog, human enhancer of filamentation 1 (HEF1/Cas-L/Nedd9) was identified. HEF1 silencing and overexpression studies revealed a role for VEGF in regulating cell migration, invasion and matrix metalloproteinase (MMP) expression in a HEF1-dependent manner. Moreover, cells plated on extracellular matrix-coated coverslips showed enhanced invadopodia formation in response to VEGF that was HEF1-dependent. Immunolocalization revealed that HEF1 colocalized to invadopodia with MT1-MMP. Analysis of HNSCC tissue microarrays for HEF1 immunoreactivity revealed a 6.5-fold increase in the odds of having a metastasis with a high HEF1 score compared with a low HEF1 score. These findings suggest that HEF1 may be prognostic for advanced stage HNSCC. They also show for the first time that HEF1 is required for VEGF-mediated HNSCC cell migration and invasion, consistent with HEF1's recent identification as a metastatic regulator. These results support a strategy targeting VEGF: VEGFR2 in HNSCC therapeutics. Oncogene (2010) 29, 4449-4459; doi: 10.1038/onc.2010.185; published online 24 May 2010	[Lucas, J. T., Jr.; Salimath, B. P.; Rosenzweig, S. A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Slomiany, M. G.] Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; [Rosenzweig, S. A.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Rosenzweig, SA (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,MSC 505, Charleston, SC 29425 USA.	rosenzsa@musc.edu	Lucas, John T./K-5243-2013; Rosenzweig, Steven A/O-5062-2018	Lucas, John T./0000-0002-4139-4160; Rosenzweig, Steven/0000-0002-7022-6086	MUSC; PhRMA Foundation; Abney Foundation; Southeastern Pre-Doctoral Training in Clinical Research [T32]; NIH [CA78887, CA134845]; DOD [N6311601MD10004]; American Health Assistance Foundation; NATIONAL CANCER INSTITUTE [R01CA078887, R55CA078887, P30CA138313, R01CA134845] Funding Source: NIH RePORTER	MUSC; PhRMA Foundation; Abney Foundation; Southeastern Pre-Doctoral Training in Clinical Research; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); American Health Assistance Foundation(BrightFocus Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Amanda M Brock for excellent technical assistance, Jennifer Bethard and Dr Kevin Schey (MUSC Mass Spectrometry Facility), the HCC Cell and Molecular Imaging Shared Resource, the HCC Tissue Biorepository and Dr Elizabeth Garrett-Mayer, Director (HCC Biostatistics Shared Resource) for aid and consultations. We are indebted to Drs Terry Day and M Boyd Gillespie for human specimens and Drs Silvio Gutkind and Alfredo Molinolo (NIDCR) for tissue microarrays. This work was supported by a MUSC Summer Health Research Fellowship, a Paul Calabresi Fellowship (PhRMA Foundation), an Abney Foundation Award, the Southeastern Pre-Doctoral Training in Clinical Research T32 (JTL), NIH grants CA78887 and CA134845 (SAR), DOD award (N6311601MD10004) to HCC and the American Health Assistance Foundation (SAR). Portions of this work were presented at the Annual Meeting of the AACR, 2008, San Diego, CA, USA and the Annual Meeting of the Endocrine Society, 2008, San Francisco, CA, USA.	Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Arold ST, 2002, STRUCTURE, V10, P319, DOI 10.1016/S0969-2126(02)00717-7; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Bachelder RE, 2003, CANCER RES, V63, P5230; Badowski C, 2008, MOL BIOL CELL, V19, P633, DOI 10.1091/mbc.E06-01-0088; Bigbee WL, 2007, CLIN CANCER RES, V13, P3107, DOI 10.1158/1078-0432.CCR-07-0746; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Canel M, 2006, CLIN CANCER RES, V12, P3272, DOI 10.1158/1078-0432.CCR-05-1583; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Cohen LA, 2005, CURR CANCER DRUG TAR, V5, P629, DOI 10.2174/156800905774932798; Cooney MM, 2005, CANCER CHEMOTH PHARM, V55, P295, DOI 10.1007/s00280-004-0871-5; Descamps FJ, 2002, LAB INVEST, V82, P1607, DOI 10.1097/01.LAB.0000038556.54069.73; Fashena SJ, 2002, J CELL SCI, V115, P99; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Kyzas PA, 2005, MODERN PATHOL, V18, P485, DOI 10.1038/modpathol.3800295; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Michi Y, 2000, ORAL ONCOL, V36, P81, DOI 10.1016/S1368-8375(99)00059-7; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Mon NN, 2006, ANN NY ACAD SCI, V1086, P199, DOI 10.1196/annals.1377.019; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Patel AM, 1996, ONCOGENE, V12, P31; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ries L, 2004, SEER CANC STAT REV 1; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Sabe H, 2006, CURR OPIN CELL BIOL, V18, P558, DOI 10.1016/j.ceb.2006.08.002; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Simpson KJ, 2008, NAT CELL BIOL, V10, P1027, DOI 10.1038/ncb1762; Singh MK, 2008, MOL BIOL CELL, V19, P1627, DOI 10.1091/mbc.E07-09-0953; Singh MK, 2007, CELL BIOCHEM BIOPHYS, V48, P54, DOI 10.1007/s12013-007-0036-3; Slack-Davis JK, 2007, J BIOL CHEM, V282, P14845, DOI 10.1074/jbc.M606695200; Sloan EK, 2002, CELL MOL LIFE SCI, V59, P1491, DOI 10.1007/s00018-002-8524-5; Slomiany MG, 2007, CANCER LETT, V248, P269, DOI 10.1016/j.canlet.2006.08.004; Slomiany MG, 2006, BIOCHEM BIOPH RES CO, V342, P851, DOI 10.1016/j.bbrc.2006.02.043; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Timpson P, 2005, CANCER RES, V65, P3273, DOI 10.1158/0008-5472.CAN-04-2118; van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011; WEAVER AM, 2008, CANC LETT, V265, P15912; Yu YH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003215	58	57	58	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2010	29	31					4449	4459		10.1038/onc.2010.185	http://dx.doi.org/10.1038/onc.2010.185			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20498643	Green Accepted			2022-12-17	WOS:000280559100008
J	Nakahata, S; Yamazaki, S; Nakauchi, H; Morishita, K				Nakahata, S.; Yamazaki, S.; Nakauchi, H.; Morishita, K.			Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta 1-mediated growth suppression in adult T-cell leukemia/lymphoma	ONCOGENE			English	Article						ZEB1; Smad7; ATLL	FACTOR-BETA; POTENTIAL MECHANISM; LEUKEMIA-CELLS; LEUKEMOGENESIS; EXPRESSION; RECEPTOR; GENE; TAX; COREPRESSOR; DEGRADATION	Zinc-finger E-box binding homeobox 1 (ZEB1) is a candidate tumor-suppressor gene in adult T-cell leukemia/lymphoma ( ATLL). ZEB1 binds phosphorylated Smad2/3 to enhance transforming growth factor-beta 1 (TGF-beta 1) signaling. In addition to downregulation of ZEB1 mRNA, we found overexpression of inhibitory Smad, Smad7, in resistance of ATLL cells to growth suppression by TGF-beta 1. A protein complex of Smad7 and histone deacetylase constantly bound to the promoter region of TGF-beta 1 responsive genes with the Smad-responsive element (SRE) to inhibit TGF-beta 1 signaling; however, ectopic expression of ZEB1 reactivated TGF-beta 1 signaling by binding to Smad7 and recruiting the Smad3/p300 histone acetyltransferase complex to the promoter after TGF-beta 1 stimulation in ATLL. Conversely, because ZEB1 mRNA was detected in the late stages of T-cell development, we used CTLL2 cells with ZEB1 expression, a murine peripheral T-cell lymphoma, and found that a complex of Smad3, Smad7 and ZEB1 was bound to the SRE of the p21(CDKN1A) promoter after the induction of Smad7 by TGF-beta 1 treatment. Because the duration of TGF-beta 1-induced transcriptional activation of PAI-1 and p21 was shortened in shZEB1-expressing CTLL2 cells, ZEB1 may have a role in enhancing TGF-beta 1 signaling by binding not only to Smad3 but also to Smad7 in the nucleus. Altogether, these results suggest that both ZEB1 downregulation and Smad7 overexpression contribute to resistance to TGF-beta 1-mediated growth suppression in ATLL. Oncogene ( 2010) 29, 4157-4169; doi: 10.1038/onc.2010.172; published online 31 May 2010	[Nakahata, S.; Morishita, K.] Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, Miyazaki 8891692, Japan; [Yamazaki, S.; Nakauchi, H.] Univ Tokyo, Inst Med Sci, Ctr Med Expt, Lab Stem Cell Therapy, Tokyo, Japan	University of Miyazaki; University of Tokyo	Morishita, K (corresponding author), Miyazaki Univ, Fac Med, Dept Med Sci, Div Tumor & Cellular Biochem, 5200 Kihara, Miyazaki 8891692, Japan.	kmorishi@med.miyazaki-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan; Leukemia Research fund; Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST; Japan Society for the Promotion of Science [19790344]	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Leukemia Research fund; Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST(Japan Science & Technology Agency (JST)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research of Priority Area from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Leukemia Research fund; Research fund from Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence, JST (KM) and Young Scientists (B) (19790344) of Japan Society for the Promotion of Science (SN).	Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182/blood-2001-12-0372; Bai ST, 2000, J BIOL CHEM, V275, P8267, DOI 10.1074/jbc.275.12.8267; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hidaka T, 2008, BLOOD, V112, P383, DOI 10.1182/blood-2008-01-131185; INGE TH, 1992, J IMMUNOL, V148, P3847; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lin X, 2003, MOL CELL BIOL, V23, P9081, DOI 10.1128/MCB.23.24.9081-9093.2003; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; Mori N, 2001, BLOOD, V97, P2137, DOI 10.1182/blood.V97.7.2137; OKADA M, 1985, J IMMUNOL, V135, P3995; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 1998, J BIOL CHEM, V273, P25364, DOI 10.1074/jbc.273.39.25364; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; van Grunsven LA, 2001, J BONE JOINT SURG AM, V83A, pS40; Vermeer MH, 2008, CANCER RES, V68, P2689, DOI 10.1158/0008-5472.CAN-07-6398; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yasunaga JI, 2003, INT J HEMATOL, V78, P312, DOI 10.1007/BF02983555; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482; Zhang SP, 2007, MOL CELL BIOL, V27, P4488, DOI 10.1128/MCB.01636-06	31	57	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2010	29	29					4157	4169		10.1038/onc.2010.172	http://dx.doi.org/10.1038/onc.2010.172			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20514018				2022-12-17	WOS:000280151500004
J	Lee, KS; Lee, YS; Lee, JM; Ito, K; Cinghu, S; Kim, JH; Jang, JW; Li, YH; Goh, YM; Chi, XZ; Wee, H; Lee, HW; Hosoya, A; Chung, JH; Jang, JJ; Kundu, JK; Surh, YJ; Kim, WJ; Ito, Y; Jung, HS; Bae, SC				Lee, K-S; Lee, Y-S; Lee, J-M; Ito, K.; Cinghu, S.; Kim, J-H; Jang, J-W; Li, Y-H; Goh, Y-M; Chi, X-Z; Wee, H.; Lee, H-W; Hosoya, A.; Chung, J-H; Jang, J-J; Kundu, J. K.; Surh, Y-J; Kim, W-J; Ito, Y.; Jung, H-S; Bae, S-C			Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer	ONCOGENE			English	Article						RUNX3; lung; adenocarcinoma; adenoma; tumor suppressor	ATYPICAL ADENOMATOUS HYPERPLASIA; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; GASTRIC-CANCER; STEM-CELLS; GENE; EXPRESSION; GROWTH	Human lung adenocarcinoma, the most prevalent form of lung cancer, is characterized by many molecular abnormalities. K-ras mutations are associated with the initiation of lung adenocarcinomas, but K-ras-independent mechanisms may also initiate lung tumors. Here, we find that the runt-related transcription factor Runx3 is essential for normal murine lung development and is a tumor suppressor that prevents lung adenocarcinoma. Runx3-/- mice, which die soon after birth, exhibit alveolar hyperplasia. Importantly, Runx3-/- bronchioli exhibit impaired differentiation, as evidenced by the accumulation of epithelial cells containing specific markers for both alveolar (that is SP-B) and bronchiolar (that is CC10) lineages. Runx3-/- epithelial cells also express Bmi1, which supports self-renewal of stem cells. Lung adenomas spontaneously develop in aging Runx3+/- mice (similar to 18 months after birth) and invariably exhibit reduced levels of Runx3. As K-ras mutations are very rare in these adenomas, Runx3+/- mice provide an animal model for lung tumorigenesis that recapitulates the preneoplastic stage of human lung adenocarcinoma development, which is independent of K-Ras mutation. We conclude that Runx3 is essential for lung epithelial cell differentiation, and that downregulation of Runx3 is causally linked to the preneoplastic stage of lung adenocarcinoma. Oncogene (2010) 29, 3349-3361; doi:10.1038/onc.2010.79; published online 15 March 2010	[Lee, K-S] Chungbuk Natl Univ, Dept Biochem, Tumor Res Ctr, Sch Med,Inst Tumor Res,Coll Med, Cheongju 361763, Chungbuk, South Korea; [Lee, J-M; Jung, H-S] Yonsei Univ, Div Anat & Dev Biol, Coll Dent, Seoul 120749, South Korea; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Sakamoto Nagasaki, Japan; [Lee, H-W] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Lab Anim Res Ctr, Seoul 120749, South Korea; [Hosoya, A.] Matsumoto Dent Univ, Dept Oral Histol, Shiojiri Nagano, Japan; [Chung, J-H; Jang, J-J] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; [Kundu, J. K.; Surh, Y-J] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Kim, W-J] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 361763, Chungbuk, South Korea; [Kim, W-J] Inst Tumor Res, Cheongju, South Korea; [Ito, Y.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Chungbuk National University; Yonsei University; Yonsei University Health System; Nagasaki University; Yonsei University; Matsumoto Dental University; Seoul National University (SNU); Seoul National University (SNU); Chungbuk National University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Lee, KS (corresponding author), Chungbuk Natl Univ, Dept Biochem, Tumor Res Ctr, Sch Med,Inst Tumor Res,Coll Med, Cheongju 361763, Chungbuk, South Korea.	klee-2005@chungbuk.ac.kr; scbae@chungbuk.ac.kr	Jung, Han-Sung/I-3848-2012; Jang, JaJune/F-6647-2011; Chung, Jin-Haeng/F-3706-2011; Kundu, Joydeb/E-6004-2010	Lee, Jong-Min/0000-0002-9466-7644; Jung, Han-Sung/0000-0003-2795-531X; Jung, Han Sung/0000-0002-5563-7039	Korea Science and Engineering Foundation [R16-2003-002-0100102006, R13-2003-013-05001-0]; Korea Research Foundation [KRF-2005-217-E00002]	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Korea Research Foundation(National Research Foundation of Korea)	This work was supported by research grants from the Korea Science and Engineering Foundation (R16-2003-002-0100102006 to S-C Bae and R13-2003-013-05001-0 to H-S Jung) and a grant from the Basic Research Promotion Fund of the Korea Research Foundation (KRF-2005-217-E00002 to K-S Lee).	Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Bea S, 2001, CANCER RES, V61, P2409; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bishop AE, 2004, CELL PROLIFERAT, V37, P89, DOI 10.1111/j.1365-2184.2004.00302.x; Cardoso WV, 2006, DEVELOPMENT, V133, P1611, DOI 10.1242/dev.02310; Cazorla M, 1998, MOL CARCINOGEN, V21, P251, DOI 10.1002/(SICI)1098-2744(199804)21:4<251::AID-MC4>3.0.CO;2-N; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Collins LG, 2007, AM FAM PHYSICIAN, V75, P56; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Dimri GP, 2002, CANCER RES, V62, P4736; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Goel A, 2004, INT J CANCER, V112, P754, DOI 10.1002/ijc.20472; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2009, ONCOGENE, V28, P1379, DOI 10.1038/onc.2008.496; Ito T, 2008, ASIAN ECON POLICY R, V3, P237, DOI 10.1111/j.1748-3131.2008.00107.x; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim WJ, 2005, CANCER RES, V65, P9347, DOI 10.1158/0008-5472.CAN-05-1647; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Mori M, 1998, ULTRASTRUCT PATHOL, V22, P459, DOI 10.3109/01913129809032282; Mundlos S, 1997, FASEB J, V11, P125, DOI 10.1096/fasebj.11.2.9039954; Okuda, 1996, Mol Diagn, V1, P139, DOI 10.1016/S1084-8592(96)70029-2; Osanai M, 2001, ULTRASTRUCT PATHOL, V25, P367, DOI 10.1080/019131201317101243; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Peacock CD, 2008, J CLIN ONCOL, V26, P2883, DOI 10.1200/JCO.2007.15.2702; Petersen I, 2001, ANAL CELL PATHOL, V22, P111, DOI 10.1155/2001/374304; Reddy R, 2004, AM J PHYSIOL-LUNG C, V286, pL658, DOI 10.1152/ajplung.00159.2003; Sato K, 2006, ONCOL REP, V15, P129; Taniuchi I, 2002, MOL CELL, V10, P1083, DOI 10.1016/S1097-2765(02)00735-9; Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vonlanthen S, 2001, BRIT J CANCER, V84, P1372, DOI 10.1054/bjoc.2001.1791; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Westra WH, 1996, CANCER RES, V56, P2224; Wistuba II, 2006, ANNU REV PATHOL-MECH, V1, P331, DOI 10.1146/annurev.pathol.1.110304.100103; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Wuenschell CW, 1996, J HISTOCHEM CYTOCHEM, V44, P113, DOI 10.1177/44.2.8609367; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zochbauer-Muller S, 2000, Chest Surg Clin N Am, V10, P691	57	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3349	3361		10.1038/onc.2010.79	http://dx.doi.org/10.1038/onc.2010.79			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20228843				2022-12-17	WOS:000278622700004
J	Boukerche, H; Aissaoui, H; Prevost, C; Hirbec, H; Das, SK; Su, ZZ; Sarkar, D; Fisher, PB				Boukerche, H.; Aissaoui, H.; Prevost, C.; Hirbec, H.; Das, S. K.; Su, Z-Z; Sarkar, D.; Fisher, P. B.			Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappa B	ONCOGENE			English	Article						mda-9/syntenin; src; NF-kappa B	HUMAN-MELANOMA CELLS; PROTEIN-KINASE; PDZ DOMAINS; C-SRC; METASTATIC PHENOTYPE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ENDOTHELIAL-CELLS; TYROSINE KINASE; FAMILY KINASES	The scaffolding postsynaptic density-95/disks large/zonula occludens-1 (PDZ) domain-containing protein melanoma differentiation associated gene-9 (MDA-9)/syntenin is a tandem PDZ protein overexpressed in human melanoma, and breast and gastric cancer cells. MDA-9/syntenin affects cancer cell motility and invasion through distinct biochemical and signaling pathways, including focal adhesion kinase and p38 mitogen-activated protein kinase (MAPK), resulting in activation of the nuclear factor (NF)-kappa B pathway. MDA-9/syntenin also promotes melanoma metastasis by activating c-Src, but how c-Src regulates NF-kappa B activation is unclear. Using a human melanoma model, we document that MDA-9/synteninc-Src interactions are positive regulators of NF-kappa B activation. Inhibition of c-Src by PP2 treatment, by blocking c-Src or mda-9/syntenin expression with small interfering RNA, or in c-Src (-/-) knockout cell lines, reduces NF-kappa B activation following overexpression of mda-9/syntenin or c-Src. Deletion or point mutations of the PDZ binding motif preventing MDA-9/syntenin association with c-Src reveals that both PDZ domains, with PDZ2 being the dominant module, are required for activating downstream signaling pathways, including p38 MAPK and NF-kappa B. We also document that MDA-9/syntenin-c-Src complexes functionally cooperate with NF-kappa B to promote anchorage-independent growth, motility and invasion of melanoma cells. These findings underscore PDZ domains of MDA-9/syntenin as promising potential therapeutic targets for intervening in a decisive component of cancer progression, namely, metastatic tumor spread. Oncogene (2010) 29, 3054-3066; doi: 10.1038/onc.2010.65; published online 15 March 2010	[Fisher, P. B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Dept Human & Mol Genet, Richmond, VA 23298 USA; [Boukerche, H.] Univ Lyon 1, INSERM, Fac Med Rene Laennec, Unite Rech Hematol,EA4174, F-69372 Lyon 08, France; [Hirbec, H.] INSERM, U583, Montpellier, France; [Sarkar, D.; Fisher, P. B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Virginia Commonwealth University	Fisher, PB (corresponding author), Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Dept Human & Mol Genet, 1101 E Marshall St,Sanger Hall Bldg,Room 11-015, Richmond, VA 23298 USA.	habib.boukerche@sante.univ-lyon1.fr; pbfisher@vcu.edu	Hirbec, Helene/ABE-4188-2021	Hirbec, Helene/0000-0002-5593-5255	National Institutes of Health, National Cancer Institute [R01 CA035675, CA097318]; Samuel Waxman Cancer Research Foundation (SWCRF); National Foundation for Cancer Research (NFCR); Goldhirsh Foundation; Dana Foundation; Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer [1019]; NATIONAL CANCER INSTITUTE [R01CA097318, R01CA035675] Funding Source: NIH RePORTER	National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Samuel Waxman Cancer Research Foundation (SWCRF); National Foundation for Cancer Research (NFCR); Goldhirsh Foundation; Dana Foundation; Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health, National Cancer Institute Grants R01 CA035675 and CA097318, the Samuel Waxman Cancer Research Foundation (SWCRF), the National Foundation for Cancer Research (NFCR) (PBF); the Goldhirsh Foundation and the Dana Foundation (DS); and the Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer grant 1019 (HB). DS is the Harrison Endowed Scholar in Cancer Research and PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center. PBF is a SWCRF Investigator.	Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Baril P, 2002, INT J CANCER, V99, P315, DOI 10.1002/ijc.10324; Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228; Boukerche H, 2000, CANCER RES, V60, P5848; Boukerche H, 2005, CANCER RES, V65, P10901, DOI 10.1158/0008-5472.CAN-05-1614; Boukerche H, 2004, GENE, V343, P191, DOI 10.1016/j.gene.2004.09.002; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Boukerche H, 2007, CANCER RES, V67, P1812, DOI 10.1158/0008-5472.CAN-06-3875; Chen K, 2001, J BIOL CHEM, V276, P16045, DOI 10.1074/jbc.M011766200; Chu Quincy S C, 2007, Invest New Drugs, V25, P359, DOI 10.1007/s10637-006-9031-6; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; FIDLER IJ, 1991, ANTICANCER RES, V11, P17; Funakoshi-Tago M, 2005, J BIOCHEM, V137, P189, DOI 10.1093/jb/mvi018; Galliher-Beckley AJ, 2008, CARCINOGENESIS, V29, P244, DOI 10.1093/carcin/bgm245; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Helmke BM, 2004, ONCOL REP, V12, P221; Hirbec H, 2005, MOL CELL NEUROSCI, V28, P737, DOI 10.1016/j.mcn.2004.12.005; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lee HS, 2007, J IMMUNOL, V179, P7001, DOI 10.4049/jimmunol.179.10.7001; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Liu AMF, 2005, J BIOL CHEM, V280, P34617, DOI 10.1074/jbc.M504264200; Matsuo Y, 2006, J BIOL CHEM, V281, P36767, DOI 10.1074/jbc.M604371200; Meerschaert K, 2007, EXP CELL RES, V313, P1790, DOI 10.1016/j.yexcr.2007.03.014; Mikami F, 2005, J BIOL CHEM, V280, P36185, DOI 10.1074/jbc.M503941200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Perez DG, 2009, CANCER-AM CANCER SOC, V115, P119, DOI 10.1002/cncr.23987; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Rivas FV, 2004, MOL CELL BIOL, V24, P1628, DOI 10.1128/MCB.24.4.1628-1639.2004; Sarkar D, 2004, PHARMACOL THERAPEUT, V104, P101, DOI 10.1016/j.pharmthera.2004.08.004; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Sarkar FH, 2008, INT REV IMMUNOL, V27, P293, DOI 10.1080/08830180802276179; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sulka B, 2009, J BIOL CHEM, V284, P10659, DOI 10.1074/jbc.M807643200; Ten RM, 1999, J IMMUNOL, V163, P3851; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Warmuth M, 2003, CURR PHARM DESIGN, V9, P2043, DOI 10.2174/1381612033454126; Zhang Q, 2001, J BIOL CHEM, V276, P43216, DOI 10.1074/jbc.M105996200; Zhou J, 2004, INVEST OPHTH VIS SCI, V45, P2314, DOI 10.1167/iovs.03-1210	50	57	61	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 27	2010	29	21					3054	3066		10.1038/onc.2010.65	http://dx.doi.org/10.1038/onc.2010.65			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20228839	Green Accepted, Green Submitted			2022-12-17	WOS:000278133100003
J	Garamszegi, N; Garamszegi, SP; Samavarchi-Tehrani, P; Walford, E; Schneiderbauer, MM; Wrana, JL; Scully, SP				Garamszegi, N.; Garamszegi, S. P.; Samavarchi-Tehrani, P.; Walford, E.; Schneiderbauer, M. M.; Wrana, J. L.; Scully, S. P.			Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics	ONCOGENE			English	Article						attachment-independent signaling; extracellular matrix; gene expressional plasticity; Smads; TGF-beta and integrin receptors	TGF-BETA; ARTICULAR CHONDROCYTES; II COLLAGEN; CELLS; TGF-BETA-1; ADHESION; SUPERFAMILY; SPECIFICITY; ACTIVATION; TRANSDUCTION	Matrix remodeling, degradation, inflammation and invasion liberate peptide fragments that can subsequently interact with cells in an attachment-independent manner. Such 'soluble' matrix components, including collagens, fibronectin and laminin, induced Smad activation (termed crosstalk signaling), which follows a similar chronological sequence and R-Smad specificity as induced by transforming growth factor (TGF)-beta 1. Smad4 nuclear translocation occurred in response to collagen binding, indicating downstream signal propagation. TGF-beta scavenging antibody affected only TGF-beta 1, but not crosstalk-induced responses. TGF-beta type II receptor mutation (DR26 Delta 25), which is deficient in TGF-beta type I receptor recruitment to the ligand, induced a heterotetramer signaling complex, and propagated Smad2 activation only through collagen induction and not TGF-beta signaling. Consequentially, TGF-beta ligand participation is not required for crosstalk signaling. This signaling requires a functional integrin beta 1 receptor as showed by RNA interference. Co-immunoprecipitation (co-IP) and fluorescent microscopy indicate the involvement of focal adhesion kinase (FAK) and Src activity in collagen-induced signal propagation, and suggest a membrane signaling complex formation that includes both TGF-beta receptors and integrins. The related gene expressional responses are distinct from that evoked by TGF-beta 1, supporting its separate function. This signaling mechanism expands and partially explains TGF-beta receptor dynamics and consequential signaling diversity-related gene expressional plasticity. Oncogene (2010) 29, 2368-2380; doi:10.1038/onc.2009.514; published online 25 January 2010	[Garamszegi, N.; Schneiderbauer, M. M.; Scully, S. P.] Univ Miami, Dept Orthopaed, Leonard M Miller Sch Med, Miami, FL 33136 USA; [Garamszegi, N.; Garamszegi, S. P.; Walford, E.; Scully, S. P.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Samavarchi-Tehrani, P.; Wrana, J. L.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Miami; University of Miami; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Garamszegi, N (corresponding author), Univ Miami, Dept Orthopaed, Leonard M Miller Sch Med, Room 218,Papanicolau Bldg,Med Campus Locator M877, Miami, FL 33136 USA.	ngaramszegi@med.miami.edu	Wrana, Jeffrey/F-8857-2013		National Institutes of Health [CA-66088Y]; American Cancer Society [ACS 66105H]; Woman's Cancer Association [WCA 66461Y]; University of Miami Orthopaedics Department; Sylvester Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [S15CA066088] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); Woman's Cancer Association; University of Miami Orthopaedics Department; Sylvester Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Edward B Leof for the pSmad3-specific antibody, as well as for CCL 64 and R1B cells, Joan Massague for DR26 cells, Mary Goldring for C28 cells and Joel A Block for JJ012 cells. This work was supported by Grants CA-66088Y to SPS from National Institutes of Health, ACS 66105H to NG from the American Cancer Society and by the Woman's Cancer Association Madelon Ravlin Memorial Award WCA 66461Y to NG and SPS. Further support was provided by the University of Miami Orthopaedics Department, and the Sylvester Comprehensive Cancer Center.	Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BENYA PD, 1978, CELL, V15, P1313, DOI 10.1016/0092-8674(78)90056-9; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dumont N, 2002, DIFFERENTIATION, V70, P574, DOI 10.1046/j.1432-0436.2002.700910.x; Evans JG, 2006, EUR J CELL BIOL, V85, P145, DOI 10.1016/j.ejcb.2005.08.006; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Franz CM, 2005, J CELL SCI, V118, P5315, DOI 10.1242/jcs.02653; GALERA P, 1992, EXP CELL RES, V200, P379, DOI 10.1016/0014-4827(92)90186-C; Garamszegi N, 2001, MOL BIOL CELL, V12, P2881, DOI 10.1091/mbc.12.9.2881; Gonzales M, 2001, MOL BIOL CELL, V12, P85, DOI 10.1091/mbc.12.1.85; Groppe J, 2008, MOL CELL, V29, P157, DOI 10.1016/j.molcel.2007.11.039; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; HILL D J, 1992, Progress in Growth Factor Research, V4, P45, DOI 10.1016/0955-2235(92)90004-2; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Jones J, 1996, ONCOGENE, V12, P119; Kracklauer Martin P, 2003, Mol Cancer, V2, P28, DOI 10.1186/1476-4598-2-28; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Lee MS, 2005, MOL CELL BIOL, V25, P6921, DOI 10.1128/MCB.25.16.6921-6936.2005; Madan R, 2006, HUM PATHOL, V37, P9, DOI 10.1016/j.humpath.2005.09.024; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; PARSONS JT, 1994, J CELL SCI, P109; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Qi WN, 2003, J ORTHOPAED RES, V21, P282, DOI 10.1016/S0736-0266(02)00136-5; Qi WN, 1998, EXP CELL RES, V241, P142, DOI 10.1006/excr.1998.4032; Qi WN, 1997, J ORTHOPAED RES, V15, P483, DOI 10.1002/jor.1100150402; Qi WN, 2000, J ORTHOPAED RES, V18, P928, DOI 10.1002/jor.1100180612; Rechtman MM, 2009, J BIOL CHEM, V284, P7843, DOI 10.1074/jbc.M809215200; ROSIER RN, 1989, CONNECT TISSUE RES, V20, P295, DOI 10.3109/03008208909023900; Schneiderbauer MM, 2004, CELL SIGNAL, V16, P1133, DOI 10.1016/j.cellsig.2004.03.004; SEGARINI PR, 1990, ANN NY ACAD SCI, V593, P73, DOI 10.1111/j.1749-6632.1990.tb16101.x; Sheppard D, 2004, CURR OPIN CELL BIOL, V16, P552, DOI 10.1016/j.ceb.2004.06.017; SUZUKI F, 1992, ADV EXP MED BIOL, V324, P101; THORP BH, 1992, DEVELOPMENT, V114, P907; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	54	57	60	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	16					2368	2380		10.1038/onc.2009.514	http://dx.doi.org/10.1038/onc.2009.514			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20101206				2022-12-17	WOS:000276951500006
J	Hajji, N; Wallenborg, K; Vlachos, P; Fullgrabe, J; Hermanson, O; Joseph, B				Hajji, N.; Wallenborg, K.; Vlachos, P.; Fullgrabe, J.; Hermanson, O.; Joseph, B.			Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide	ONCOGENE			English	Article						cell death; topoisomerase inhibitor; HDAC inhibitor; hMOF; SIRT1; H4K16 acetylation	HISTONE DEACETYLASE INHIBITORS; CELL LUNG CARCINOMAS; DNA-DAMAGE; ANTICANCER AGENTS; H4 LYSINE-16; CANCER; PROTEIN; APOPTOSIS; ACETYLTRANSFERASE; RESPONSES	Various inhibitors of histone deacetylase (HDAC) activity can sensitize drug resistant cancer cells to chemotherapeutic agents. However, the mechanisms underlying such effects of distinct HDAC inhibitors (HDACi) remain poorly understood. Here we show that both the HDACi trichostatin A and valproic acid induced a sensitization of multidrug-resistant cancer cells to the topoisomerase II inhibitor etoposide/VP16. This effect was associated with increased acetylation of certain lysines on histones H3 and H4, including lysine 16 on histone H4 (H4K16). Overexpression of the histone acetyltransferase hMOF, known to target H4K16, was sufficient to mimic HDACi treatment on sensitization and H4K16 acetylation, and importantly, small-interfering RNA (siRNA)-mediated knockdown of hMOF abolished the HDACi-mediated sensitizing effects as well as the increase in H4K16 acetylation. Conversely, siRNA-mediated knockdown of the H4K16 deacetylase SIRT1 mimicked HDACi treatment whereas overexpression of SIRT1 abolished H4K16 acetylation and significantly reduced the sensitizing effects of HDACi. Interestingly, the effects of hMOF on H4K16 acetylation and sensitization to the topoisomerase II inhibitor could be directly counteracted by exogenous expression of increasing amounts of SIRT1 and vice versa. Our study results suggest that hMOF and SIRT1 activities are critical parameters in HDACi-mediated sensitization of multidrug-resistant cancer cells to topoisomerase II inhibitor and increased H4K16 acetylation. Oncogene (2010) 29, 2192-2204; doi: 10.1038/onc.2009.505; published online 1 February 2010	[Hajji, N.; Vlachos, P.; Fullgrabe, J.; Joseph, B.] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden; [Wallenborg, K.; Hermanson, O.] Karolinska Inst, CoE Dev Biol CEDB DBRM, Dept Neurosci, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Joseph, B (corresponding author), Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, R8 03, S-17176 Stockholm, Sweden.	bertrand.joseph@ki.se	, Ola/AAF-5126-2021; hajji, nabil/AAV-1435-2020	Fullgrabe, Jens/0000-0003-0047-4719; Hermanson, Ola/0000-0001-9320-7921; Joseph, Bertrand/0000-0001-5655-9979	Swedish Research Council; Swedish Cancer Society; Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer); Swedish Children's Cancer Foundation; Medical Research Council [G0801056B] Funding Source: researchfish	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Ake Wiberg Foundation; Swedish Medical Society; Karolinska Institutet Foundations (KI Cancer)(Karolinska Institutet); Swedish Children's Cancer Foundation; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank RG Roeder (The Rockefeller University), L Guarente (Massachusetts Institute of Technology) and M Henriksson (Karolinska Institutet) for providing us with hMOF DNA construct, SIRT1 DNA construct and SK-N-BE(2) cell line, respectively, and S Orrenius, T Perlmann and members of Hermanson and Joseph's labs for helpful comments. This work was supported by the Swedish Research Council, the Swedish Cancer Society, the Ake Wiberg Foundation, the Swedish Medical Society, the Karolinska Institutet Foundations (KI Cancer) (BJ and OH), SSF (CEDB & OBOE) and the Swedish Children's Cancer Foundation (OH).	Andersson T, 2009, J BIOL CHEM, V284, P3672, DOI 10.1074/jbc.M808119200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jepsen K, 2007, NATURE, V450, P415, DOI 10.1038/nature06270; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417; Keshelava N, 1998, CANCER RES, V58, P5396; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Napper AD, 2005, J MED CHEM, V48, P8045, DOI 10.1021/jm050522v; Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0; Nyman U, 2009, MOL CELL BIOL, V29, P1814, DOI 10.1128/MCB.00585-08; Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Villar-Garea A, 2004, INT J CANCER, V112, P171, DOI 10.1002/ijc.20372; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029	42	57	62	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2192	2204		10.1038/onc.2009.505	http://dx.doi.org/10.1038/onc.2009.505			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20118981				2022-12-17	WOS:000276685200005
J	Li, Y; Zhou, Z; Alimandi, M; Chen, C				Li, Y.; Zhou, Z.; Alimandi, M.; Chen, C.			WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer	ONCOGENE			English	Article						WWP1; ErbB4; PY motif; WW domain; ubiquitination; degradation	ESTROGEN-RECEPTOR; INTRACELLULAR DOMAIN; MITOTIC PROGRESSION; EPITHELIAL-CELLS; EXPRESSION; HER4; GROWTH; DIFFERENTIATION; FAMILY; PHOSPHORYLATION	ErbB4, a member of the epidermal growth factor receptor family, plays a role in normal breast and breast cancer development by regulating mammary epithelial cell proliferation, survival and differentiation. In this study, we show that WWP1, a C2-WW-HECT type E3 ubiquitin ligase, binds, ubiquitinates and destructs ErbB4-CYT1, but much less efficiently for CYT2, isoforms (both JMa and JMb). The protein-protein interaction occurs primarily between the first and third WW domains of WWP1 and the second PY motif of ErbB4. Knockdown of WWP1 by two different small interfering RNAs increases the endogenous ErbB4 protein levels in both MCF7 and T47D breast cancer cell lines. In addition, overexpression of the wild type, but not the catalytic inactive WWP1, dramatically decreases the endogenous ErbB4 protein levels in MCF7. Importantly, we found that WWP1 negatively regulates the heregulin-beta 1-stimulated ErbB4 activity as measured by the serum response element report assay and the BRCA1 mRNA expression. After a systematic screening of all WWP1 family members by small interfering RNA, we found that AIP4/Itch and HECW1/NEDL1 also negatively regulate the ErbB4 protein expression in T47D. Interestingly, the protein expression levels of both WWP1 and ErbB4 are higher in estrogen receptor-alpha-positive than in estrogen receptor-alpha-negative breast cancer cell lines. These data suggest that WWP1 and its family members suppress the ErbB4 expression and function in breast cancer. Oncogene (2009) 28, 2948-2958; doi:10.1038/onc.2009.162; published online 29 June 2009	[Li, Y.; Zhou, Z.; Chen, C.] Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; [Alimandi, M.] Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy	Albany Medical College; Sapienza University Rome	Chen, C (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MS355,Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	chenc@mail.amc.edu	Alimandi, Maurizio/AAG-9246-2019	Alimandi, Maurizio/0000-0002-1409-6803	Department of Defense BCRP [W81XWH-08-1-0557]; PCRP IDEA [W81XWH-07-1-0191]; American Cancer Society; Komen for the Cure [BCTR0503705]	Department of Defense BCRP(United States Department of Defense); PCRP IDEA; American Cancer Society(American Cancer Society); Komen for the Cure(Susan G. Komen Breast Cancer Foundation)	This work was supported in part by grants from the Department of Defense BCRP concept award (W81XWH-08-1-0557) and PCRP IDEA award (W81XWH-07-1-0191), a Research Scholar Award from the American Cancer Society and a Grant (BCTR0503705, Chen, C) from Komen for the Cure.	Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Chen C, 2007, ONCOGENE, V26, P2386, DOI 10.1038/sj.onc.1210021; Chen C, 2008, ONCOGENE, V27, P6845, DOI 10.1038/onc.2008.288; Chen C, 2007, INT J CANCER, V121, P2834; Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555-007-9091-x; Chen CS, 2009, INT J CANCER, V124, P2829, DOI 10.1002/ijc.24266; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Feng SM, 2007, MOL ENDOCRINOL, V21, P1861, DOI 10.1210/me.2006-0101; Feng SM, 2009, MOL CELL BIOL, V29, P892, DOI 10.1128/MCB.00595-08; Huu NSN, 2008, J PATHOL, V216, P93, DOI 10.1002/path.2385; Jackson-Fisher AJ, 2006, ONCOGENE, V25, P5664, DOI 10.1038/sj.onc.1209574; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Koutras AK, 2008, BRIT J CANCER, V99, P1775, DOI 10.1038/sj.bjc.6604769; Li Y, 2008, CELL DEATH DIFFER, V15, P1941, DOI 10.1038/cdd.2008.134; Li Y, 2008, ONCOGENE, V27, P3700, DOI 10.1038/sj.onc.1211032; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Maatta JA, 2006, MOL BIOL CELL, V17, P67, DOI 10.1091/mbc.E05-05-0402; Miyazaki K, 2004, J BIOL CHEM, V279, P11327, DOI 10.1074/jbc.M312389200; Muraoka-Cook RS, 2008, MOL ENDOCRINOL, V22, P2307, DOI 10.1210/me.2008-0055; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Omerovic J, 2007, FASEB J, V21, P2849, DOI 10.1096/fj.06-7925com; Pitfield SE, 2006, ONCOL RES, V16, P179, DOI 10.3727/000000006783981134; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Strunk KE, 2007, CANCER RES, V67, P6582, DOI 10.1158/0008-5472.CAN-06-4145; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Suo ZH, 2001, VIRCHOWS ARCH, V439, P62, DOI 10.1007/s004280000392; Tang CK, 1999, CANCER RES, V59, P5315; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	38	57	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2948	2958		10.1038/onc.2009.162	http://dx.doi.org/10.1038/onc.2009.162			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19561640				2022-12-17	WOS:000269142800003
J	Burris, HA				Burris, H. A., III			Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs	ONCOGENE			English	Review						NSCLC; non-small-cell lung cancer; EGFR; resistance; dual EGFR/VEGF inhibition; antiangiogenesis	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-III; CHEMOTHERAPY-NAIVE PATIENTS; CISPLATIN PLUS GEMCITABINE; ACQUIRED-RESISTANCE; KRAS MUTATIONS; EGFR MUTATION; TRIAL; CARBOPLATIN	Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which results in only a modest increase in survival and causes significant toxicity to the patient. Targeted agents are initially effective in certain small subpopulations of patients, but eventually nearly all patients become resistant to further treatment. The limitations in efficacy and safety associated with available treatments for NSCLC underscore the need for novel agents with improved efficacy and safety profiles. This review discusses the limitations of currently recommended therapies for patients with advanced NSCLC and discusses new agents in clinical development for this disease. Oncogene (2009) 28, S4-S13; doi:10.1038/onc.2009.196	Sarah Cannon Res Inst, Nashville, TN 37203 USA	Sarah Cannon Research Institute	Burris, HA (corresponding author), Sarah Cannon Res Inst, 250 25th Ave N, Nashville, TN 37203 USA.	howard.burris@scresearch.net			Boehringer Ingelheim Pharmaceuticals	Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim)	The author thanks Johnathan C Maher, PhD, of BlueSpark Healthcare for medical and editorial assistance in this paper. Financial support for medical and editorial assistance was provided by Boehringer Ingelheim Pharmaceuticals.	Abrams TJ, 2003, MOL CANCER THER, V2, P1011; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; [Anonymous], 2008, CLIN PRACT GUID NONS; Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032; Bolonaki I, 2007, J CLIN ONCOL, V25, P2727, DOI 10.1200/JCO.2006.10.3465; Brandes JC, 2006, CANCER INVEST, V24, P283, DOI 10.1080/07357900600629567; Breathnach OS, 2001, J CLIN ONCOL, V19, P1734, DOI 10.1200/JCO.2001.19.6.1734; Britten CD, 2004, MOL CANCER THER, V3, P1335; CAMPOS L, 1993, BLOOD, V81, P3091; Carney DN, 2002, NEW ENGL J MED, V346, P126, DOI 10.1056/NEJM200201103460211; Clark GM, 2006, CLIN LUNG CANCER, V7, P389, DOI 10.3816/CLC.2006.n.022; Crawford J, 2004, CANCER-AM CANCER SOC, V100, P228, DOI 10.1002/cncr.11882; DOLE M, 1994, CANCER RES, V54, P3253; Dubey Sarita, 2005, J Support Oncol, V3, P149; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Elkind NB, 2005, CANCER RES, V65, P1770, DOI 10.1158/0008-5472.CAN-04-3303; Engelman JA, 2008, CLIN CANCER RES, V14, P2895, DOI 10.1158/1078-0432.CCR-07-2248; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Eskens F, 2008, BRIT J CANCER, V98, P80, DOI 10.1038/sj.bjc.6604108; GATZEMEIER U, 2006, J CLIN ONCOL 1, V24; *GEN INC, 2008, AV BEV PRESCR INF; Gendreau SB, 2007, CLIN CANCER RES, V13, P3713, DOI 10.1158/1078-0432.CCR-06-2590; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Gridelli C, 2007, ONCOLOGIST, V12, P191, DOI 10.1634/theoncologist.12-2-191; Haber DA, 2005, CELL CYCLE, V4, P1057; Habib AA, 2003, MOL CANCER RES, V1, P219; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Herbst RS, 2007, J THORAC ONCOL, V2, pS335, DOI 10.1097/01.JTO.0000283144.91294.05; Herbst RS, 2004, CLIN CANCER RES, V10, p4245S, DOI 10.1158/1078-0432.CCR-040018; Heymach J, 2007, J CLIN ONCOL, V25; Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307; Hirsch FR, 2007, ANN ONCOL, V18, P752, DOI 10.1093/annonc/mdm003; Jackman DM, 2007, J CLIN ONCOL, V25, P760, DOI 10.1200/JCO.2006.07.5754; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Manegold C, 2008, J CLIN ONCOL, V26, P3979, DOI 10.1200/JCO.2007.12.5807; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Massarelli E, 2007, CLIN CANCER RES, V13, P2890, DOI 10.1158/1078-0432.CCR-06-3043; Metro G, 2006, ANN ONCOL, V17, P42, DOI 10.1093/annonc/mdj920; MILLER VA, 2008, J CLIN ONCOL S, V26; Mita AC, 2006, J CLIN ONCOL, V24, P552, DOI 10.1200/JCO.2004.00.9720; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Morse MA, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-9; Mross KB, 2005, J CLIN ONCOL, V23, p199S; NATALE RB, 2006, J CLIN ONCOL S, V24; Nemunaitis J, 2006, MOL THER, V13, pS424, DOI 10.1016/j.ymthe.2006.08.1209; O'Brien MER, 2004, ANN ONCOL, V15, P906, DOI 10.1093/annonc/mdh220; Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pirker R, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3; Rao G, 2007, J CLIN ONCOL, V25, P2867, DOI 10.1200/JCO.2007.10.8167; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; RIZVI N, 2007, J THORAC ONCOL, V2, pS737; Rosell R, 2008, ANN ONCOL, V19, P362, DOI 10.1093/annonc/mdm474; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; SCAGLIOTTI G, 2008, J THORAC ONCOL S1, V3, pS9; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shih JY, 2005, NEW ENGL J MED, V353, P207, DOI 10.1056/NEJM200507143530217; Socinski MA, 2008, J CLIN ONCOL, V26, P650, DOI 10.1200/JCO.2007.13.9303; Stinchcombe TE, 2008, ONCOLOGIST, V13, P28, DOI 10.1634/theoncologist.13-S1-28; Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; van Zandwijk N, 2007, ANN ONCOL, V18, P99, DOI 10.1093/annonc/mdl323; Von Pawel J, 2007, J CLIN ONCOL, V25; Wang Y, 2007, J CLIN ONCOL, V25; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Wissner A, 2008, ARCH PHARM, V341, P465, DOI 10.1002/ardp.200800009; YANG C, 2008, J CLIN ONCOL, V26; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	78	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28			1			S4	S13		10.1038/onc.2009.196	http://dx.doi.org/10.1038/onc.2009.196			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QF	19680296				2022-12-17	WOS:000269515400002
J	Hu, XT; Zhang, FB; Fan, YC; Shu, XS; Wong, AHY; Zhou, W; Shi, QL; Tang, HM; Fu, L; Guan, XY; Rha, SY; Tao, Q; He, C				Hu, X-T; Zhang, F-B; Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Zhou, W.; Shi, Q-L; Tang, H-M; Fu, L.; Guan, X-Y; Rha, S. Y.; Tao, Q.; He, C.			Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer	ONCOGENE			English	Article						Phospholipase C delta 1; tumor suppressor gene; methylation; 3p22; gastric cancer	ACTIN-DEPOLYMERIZING FACTOR; GTPASE-ACTIVATING PROTEIN; MATRIX METALLOPROTEINASE-7; BINDING PROTEIN; EXPRESSION; GENE; ESOPHAGEAL; MATRILYSIN; CELLS; NASOPHARYNGEAL	Located at the important tumor suppressor locus, 3p22, PLCD1 encodes an enzyme that mediates regulatory signaling of energy metabolism, calcium homeostasis and intracellular movements. We identified PLCD1 as a downregulated gene in aerodigestive carcinomas through expression pro. ling and epigenetic characterization. We found that PLCD1 was expressed in all normal adult tissues but low or silenced in 84% (16/19) gastric cancer cell lines, well correlated with its CpG island (CGI) methylation status. Methylation was further detected in 62% (61/98) gastric primary tumors, but none of normal gastric mucosa tissues. PLCD1 methylation was significantly correlated with tumor high stage. Detailed methylation analysis of 37 CpG sites at the PLCD1 CGI by bisulfite genomic sequencing confirmed its methylation. PLCD1 silencing could be reversed by pharmacological demethylation with 5-aza-2'-deoxycytidine, indicating a direct epigenetic silencing. Ectopic expression of PLCD1 in silenced gastric tumor cells dramatically inhibited their clonogenicity and migration, possibly through downregulating MMP7 expression and hampering the reorganization of cytoskeleton through cofilin inactivation by phosphorylation. Thus, epigenetic inactivation of PLCD1 is common and tumor-specific in gastric cancer, and PLCD1 acts as a functional tumor suppressor involved in gastric carcinogenesis. Oncogene (2009) 28, 2466-2475; doi: 10.1038/onc.2009.92; published online 18 May 2009	[Hu, X-T; Zhang, F-B; Shi, Q-L; Tang, H-M; He, C.] Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China; [Hu, X-T; Zhang, F-B; Shi, Q-L; Tang, H-M; He, C.] Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China; [Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Tao, Q.] Chinese Univ Hong Kong, Hong Kong Canc Inst, Canc Epigenet Lab,Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China; [Fan, Y-C; Shu, X-S; Wong, A. H. Y.; Tao, Q.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Zhou, W.; He, C.] Zhejiang Univ, Dept Colorectal Surg, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China; [Rha, S. Y.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea	Zhejiang University; Chinese University of Hong Kong; Chinese University of Hong Kong; Zhejiang University; Yonsei University; Yonsei University Health System	He, C (corresponding author), Zhejiang Univ, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310016, Zhejiang, Peoples R China.	qtao@clo.cuhk.edu.hk; drhe_srrsh@sina.com	Fu, Li/F-7182-2010; Hu, Xiao-tong/K-5820-2019; Tao, Qian/T-4743-2018; Guan, Xin-Yuan/A-3639-2009	Fu, Li/0000-0003-2643-6278; Tao, Qian/0000-0001-5383-4808; Rha, Sun Young/0000-0002-2512-4531; Guan, Xin-Yuan/0000-0002-4485-6017	Chinese University of Hong Kong; National Natural Science Foundation of China [30770920/C03030202]; Natural Science Foundation of Zhejiang Province [Y206090]	Chinese University of Hong Kong(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province)	This study was supported by a grant from the Chinese University of Hong Kong, a grant from National Natural Science Foundation of China ( Grant no. 30770920/C03030202) and a grant from Natural Science Foundation of Zhejiang Province ( Grant no. Y206090).	Adachi Y, 1998, INT J ONCOL, V13, P1031; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Carvou N, 2007, CELL SIGNAL, V19, P42, DOI 10.1016/j.cellsig.2006.05.023; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fu L, 2007, CANCER RES, V67, P10720, DOI 10.1158/0008-5472.CAN-07-2411; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; Fukami K, 2002, J BIOCHEM, V131, P293, DOI 10.1093/oxfordjournals.jbchem.a003102; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Honda M, 1996, GUT, V39, P444, DOI 10.1136/gut.39.3.444; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Irino Y, 2004, BIOCHEM BIOPH RES CO, V320, P537, DOI 10.1016/j.bbrc.2004.05.206; Janetopoulos C, 2006, J CELL BIOL, V174, P485, DOI 10.1083/jcb.200603156; Kaminishi M, 2005, ONCOLOGY-BASEL, V69, P1, DOI 10.1159/000086624; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kitoh T, 2004, J GASTROENTEROL, V39, P434, DOI 10.1007/s00535-003-1316-3; Liu XP, 2002, JPN J CANCER RES, V93, P291, DOI 10.1111/j.1349-7006.2002.tb02171.x; Maehara Y, 2000, BRIT J SURG, V87, P353, DOI 10.1046/j.1365-2168.2000.01358.x; Mori M, 2002, SURGERY, V131, pS39, DOI 10.1067/msy.2002.119292; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Nakahara M, 2005, J BIOL CHEM, V280, P29128, DOI 10.1074/jbc.M503817200; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ochocka AM, 2003, ACTA BIOCHIM POL, V50, P1097; Panani AD, 2008, CANCER LETT, V266, P99, DOI 10.1016/j.canlet.2008.02.053; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Qiu GH, 2008, J HEPATOL, V48, P433, DOI 10.1016/j.jhep.2007.11.015; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sako A, 2004, CANCER RES, V64, P3624, DOI 10.1158/0008-5472.CAN-04-0304; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Senota A, 1998, CLIN EXP METASTAS, V16, P313; Singer CF, 1999, EUR J BIOCHEM, V259, P40, DOI 10.1046/j.1432-1327.1999.00001.x; TAKAISHI K, 1994, ONCOGENE, V9, P273; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644; Yonemura Y, 2001, CLIN CANCER RES, V7, P1647; Yonemura Yutaka, 2000, Gastric Cancer, V3, P63, DOI 10.1007/PL00011698	43	57	60	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2466	2475		10.1038/onc.2009.92	http://dx.doi.org/10.1038/onc.2009.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448674				2022-12-17	WOS:000267601400005
J	Nikkila, J; Coleman, KA; Morrissey, D; Pylkas, K; Erkko, H; Messick, TE; Karppinen, SM; Amelina, A; Winqvist, R; Greenberg, RA				Nikkila, J.; Coleman, K. A.; Morrissey, D.; Pylkas, K.; Erkko, H.; Messick, T. E.; Karppinen, S-M; Amelina, A.; Winqvist, R.; Greenberg, R. A.			Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function	ONCOGENE			English	Article						RAP80; breast cancer; BRCA1; ubiquitin	DOUBLE-STRAND BREAKS; TARGETS BRCA1; STROMAL CELLS; PROTEIN; MUTATIONS; SUSCEPTIBILITY; REPAIR; COMPLEX; GENES; RNF8	Germline mutations in two major susceptibility genes, BRCA1 and BRCA2, account for nearly 20% of familial breast cancers. A majority of the remaining genetic factors involved in heritable breast cancer susceptibility are, however, unknown. Recently, a new BRCA1-interacting protein, receptor associated protein 80 (RAP80), was identified. RAP80 plays an important role in BRCA1-mediated DNA damage responses (DDRs) by recruiting BRCA1 to DNA double-strand breaks (DSBs). A comprehensive screening of DNA from affected index cases of 112 BRCA1/BRCA2 mutation-negative Finnish breast cancer families revealed altogether 10 alterations in RAP80, one of which, c.241-243delGAA, resulted in a single glutamic acid deletion at residue 81 in a highly conserved region of ubiquitin interaction motif 1. The resultant delE81 protein product displayed significantly reduced ubiquitin binding and DSB localization. Expression of the RAP80 delE81 allele impaired both BRCA1 and ABRA1 DSB recruitment, thus compromising BRCA1-mediated DDR signaling. Compared with wildtype RAP80, expression of the delE81 allele was associated with a significant increase in cytogenetically detectable chromosomal aberrations, particularly chromatid breaks. Although evidently quite rare, these results suggest that critical constitutional mutations in RAP80 abrogate DDR function and may be involved in genetic predisposition to cancer.	[Coleman, K. A.; Morrissey, D.; Messick, T. E.; Greenberg, R. A.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; [Nikkila, J.; Pylkas, K.; Erkko, H.; Karppinen, S-M; Amelina, A.; Winqvist, R.] Univ Oulu, Oulu Univ Hosp, Dept Clin Genet, Canc Genet Lab, Oulu, Finland; [Nikkila, J.; Pylkas, K.; Erkko, H.; Karppinen, S-M; Amelina, A.; Winqvist, R.] Univ Oulu, Oulu Univ Hosp, Bioctr Oulu, Oulu, Finland; [Greenberg, R. A.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Pathol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Oulu; University of Oulu; University of Pennsylvania; Pennsylvania Medicine	Greenberg, RA (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Canc Biol, 421 Curie Blvd,BRB 2-3 Rm 513, Philadelphia, PA 19104 USA.	robert.winqvist@oulu.fi; rogergr@mail.med.upenn.edu		Karppinen, Sanna/0000-0001-6233-9075; Messick, Troy/0000-0001-7914-1524; Pylkas, Katri/0000-0002-2449-0521; Winqvist, Robert/0000-0003-0932-9104	Finnish Breast Cancer Group; Cancer Foundation of Northern Finland; Orion-Farmos Research Foundation; Academy of Finland; Finnish Cancer Society; Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation; NIH [T32-GM-007229]; National Cancer Institute [1K08CA106597-01]; Sidney Kimmel Foundation Scholar Award; Mary Kay Ash Charitable Foundation Cancer Research; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE [K08CA106597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	Finnish Breast Cancer Group; Cancer Foundation of Northern Finland; Orion-Farmos Research Foundation; Academy of Finland(Academy of Finland); Finnish Cancer Society; Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sidney Kimmel Foundation Scholar Award; Mary Kay Ash Charitable Foundation Cancer Research; Abramson Family Cancer Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We would like to thank Dr Aki Mustonen, Dr Jaakko Ignatius, Dr Ylermi Soini, Dr Mervi Grip and Dr Arja Jukkola-Vuorinen for their contribution, and nurses Kari Mononen and Outi Kajula for their help in patient contacts and Ms Helmi Konola for technical assistance. We also gratefully acknowledge Dr Junjie Chen for the antibodies to ABRA1, and Dr David Livingston for critical discussion of the manuscript before submission. The Finnish Breast Cancer Group, the Cancer Foundation of Northern Finland, the Orion-Farmos Research Foundation, the Academy of Finland, the Finnish Cancer Society, the Foundation for the Finnish Cancer Institute and the Sigrid Juselius Foundation to RW, the NIH training grant T32-GM-007229 to KAC and the National Cancer Institute K08 award 1K08CA106597-01, the Sidney Kimmel Foundation Scholar Award, the Mary Kay Ash Charitable Foundation Cancer Research Grant and funds from the Abramson Family Cancer Research Institute to RAG financially supported this study.	Akbari MR, 2009, BREAST CANCER RES TR, V113, P377, DOI 10.1007/s10549-008-9938-z; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Greenberg RA, 2008, CHROMOSOMA, V117, P305, DOI 10.1007/s00412-008-0154-8; Greenberger JS, 2006, EXP HEMATOL, V34, P46; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Heikkinen K, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.12.e131; Heikkinen K, 2006, CARCINOGENESIS, V27, P1593, DOI 10.1093/carcin/bgi360; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Huusko P, 1998, AM J HUM GENET, V62, P1544, DOI 10.1086/301880; ISOLA J, 1994, AM J PATHOL, V145, P1301; Karppinen SM, 2006, EUR J CANCER, V42, P2647, DOI 10.1016/j.ejca.2006.05.030; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kim H, 2007, SCIENCE, V316, P1202, DOI 10.1126/science.1139621; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Korkko J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681; Liu ZX, 2007, NAT STRUCT MOL BIOL, V14, P716, DOI 10.1038/nsmb1279; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Novak DJ, 2009, BREAST CANCER RES TR, V117, P453, DOI 10.1007/s10549-008-0134-y; Osorio A, 2009, BREAST CANCER RES TR, V113, P371, DOI 10.1007/s10549-008-9933-4; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Rapakko K, 2001, BRIT J CANCER, V84, P116, DOI 10.1054/bjoc.2000.1530; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Schwab M, 2002, CANCER LETT, V175, P1, DOI 10.1016/S0304-3835(01)00752-2; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Tuhkanen H, 2004, INT J CANCER, V109, P247, DOI 10.1002/ijc.11733; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan J, 2008, CANCER LETT, V271, P179, DOI 10.1016/j.canlet.2008.04.046; Yan J, 2007, CANCER RES, V67, P6647, DOI 10.1158/0008-5472.CAN-07-0924; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	51	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	2009	28	16					1843	1852		10.1038/onc.2009.33	http://dx.doi.org/10.1038/onc.2009.33			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PW	19305427	Green Accepted			2022-12-17	WOS:000265640500003
J	Wicovsky, A; Henkler, F; Salzmann, S; Scheurich, P; Kneitz, C; Wajant, H				Wicovsky, A.; Henkler, F.; Salzmann, S.; Scheurich, P.; Kneitz, C.; Wajant, H.			Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation	ONCOGENE			English	Article						apoptosis; NF-kappa B; TNF; TNFR1; TNFR2; TRAF1	NF-KAPPA-B; FACTOR-ALPHA; CELL-DEATH; SUPEROXIDE-DISMUTASE; INDUCED APOPTOSIS; FACTOR (TRAF)-1; T-LYMPHOCYTES; LIPID RAFTS; ACTIVATION; TRAF2	It has been shown that tumor necrosis factor receptor-2 (TNFR2) stimulation leads to degradation of TNF receptor associated factor-2 (TRAF2) and inhibition of TNFR1-induced activation of NF kappa B and JNK. Here, we show that TRAF1 inhibits TNFR2-induced proteasomal degradation of TRAF2 and relieves TNFR1-induced activation of NF kappa B from the inhibitory effect of TNFR2. TRAF1 co-recruited with TRAF2 to both TNF receptors. Despite lackingan amino-terminal RING/zinc-finger domain, TRAF1 did not interfere with TNFR1-induced activation of JNK and NF kappa B. It is noted that physiological expression levels of TRAF1 enhanced NF kappa B activation and interleukin-8 (IL8) production induced by TNFR2. Thus, TRAF1 shifts the quality of integrated TNFR1-TNFR2 signaling from apoptosis induction to proinflammatory NF kappa B signaling.	[Wicovsky, A.; Henkler, F.; Salzmann, S.; Kneitz, C.; Wajant, H.] Univ Hosp Wurzburg, Div Mol Internal Med, Dept Internal Med 2, D-97070 Wurzburg, Germany; [Scheurich, P.] Univ Stuttgart, Inst Cell Biol & Immunol, Stuttgart, Germany	University of Wurzburg; University of Stuttgart	Wajant, H (corresponding author), Univ Hosp Wurzburg, Div Mol Internal Med, Dept Internal Med 2, Roentgenring 11, D-97070 Wurzburg, Germany.	harald.wajant@mail.uni-wuerzburg.de	Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949	Deutsche Forschungsgemeinschaft [B7, HE 5275/2-1, Wa1025/8-1]; IZKF Wurzburg [A-49]; Weyth Biopharma	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); IZKF Wurzburg; Weyth Biopharma	The project was supported by Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 487, project B7, HE 5275/2-1 and Wa1025/8-1), IZKF Wurzburg (project A-49) and Weyth Biopharma (Forschungspreis Rheumatologie 2007).	Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Baxter GT, 1999, J BIOL CHEM, V274, P9539, DOI 10.1074/jbc.274.14.9539; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Declercq W, 1998, J IMMUNOL, V161, P390; Dietz AB, 2006, TRANSFUSION, V46, P2083, DOI 10.1111/j.1537-2995.2006.01033.x; Eliopoulos AG, 2000, MOL CELL BIOL, V20, P5503, DOI 10.1128/MCB.20.15.5503-5515.2000; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Fotin-Mleczek M, 2004, J BIOL CHEM, V279, P677, DOI 10.1074/jbc.M310969200; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; Henkler F, 2003, J BIOL CHEM, V278, P29216, DOI 10.1074/jbc.M211090200; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Krippner-Heidenreich A, 2008, J IMMUNOL, V180, P8176, DOI 10.4049/jimmunol.180.12.8176; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Muppidi JR, 2004, IMMUNITY, V21, P461, DOI 10.1016/j.immuni.2004.10.001; Murray J, 1997, BLOOD, V90, P2772, DOI 10.1182/blood.V90.7.2772.2772_2772_2783; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Speiser DE, 1996, EUR J IMMUNOL, V26, P3055, DOI 10.1002/eji.1830261235; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Tsitsikov EN, 2001, IMMUNITY, V15, P647, DOI 10.1016/S1074-7613(01)00207-2; VANDENABEELE P, 1995, J IMMUNOL, V154, P2904; VERCAMMEN D, 1995, CYTOKINE, V7, P463, DOI 10.1006/cyto.1995.0063; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Weingartner M, 2002, J BIOL CHEM, V277, P34853, DOI 10.1074/jbc.M205149200; Weiss T, 1997, J IMMUNOL, V158, P2398; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Wu CJ, 2005, EMBO J, V24, P1886, DOI 10.1038/sj.emboj.7600649; Zhao YG, 2007, J BIOL CHEM, V282, P7777, DOI 10.1074/jbc.M609146200; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	43	57	60	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2009	28	15					1769	1781		10.1038/onc.2009.29	http://dx.doi.org/10.1038/onc.2009.29			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PV	19287455				2022-12-17	WOS:000265640400004
J	Veeramani, S; Yuan, TC; Lin, FF; Lin, MF				Veeramani, S.; Yuan, T-C; Lin, F-F; Lin, M-F			Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells	ONCOGENE			English	Article						p66Shc; prostate cancer; DHT; reactive oxygen species	66-KDA SHC ISOFORM; BREAST-CANCER; LIFE-SPAN; P66(SHC) PROTEIN; ACID-PHOSPHATASE; EXPRESSION; PATHWAY; LINES; PROLIFERATION; APOPTOSIS	p66Shc is shown to negatively regulate the life span in mice through reactive oxygen species (ROS) production. Recent reports, however, revealed that p66Shc protein level is significantly elevated in several human cancer tissues and growth-stimulated carcinoma cells, suggesting a mitogenic and carcinogenic role for p66Shc. In this communication, we demonstrate for the first time that p66Shc mediates androgenic growth signals in androgen-sensitive human prostate cancer cells through mitochondrial ROS production. Growth stimulation of prostate cancer cells with 5 alpha-dihydrotestosterone (DHT) is accompanied by increased p66Shc level and ROS production, which is abolished by antioxidant treatments. However, antioxidant treatments do not affect the transcriptional activity of androgen receptor (AR) as observed by its inability to block DHT-induced prostate-specific antigen expression, an AR-dependent correlate of prostate cancer progression. Elevated expression of p66Shc by cDNA transfection increases the basal cell proliferation and, thus, reduces additional DHT-induced cell proliferation. Furthermore, DHT increases the translocation of p66Shc into mitochondria and its interaction with cytochrome c. Conversely, both redox-negative p66Shc mutant (W134F), which is deficient in cytochrome c interaction, and p66Shc small interfering RNA decrease DHT-induced cell proliferation. These results collectively reveal a novel role for p66Shc-ROS pathway in androgen-induced prostate cancer cell proliferation and, thus, may play a role in early prostate carcinogenesis.	[Veeramani, S.; Yuan, T-C; Lin, F-F; Lin, M-F] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Coll Med, Omaha, NE 68198 USA; [Lin, M-F] Univ Nebraska Med Ctr, Eppley Inst Res Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Coll Med, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	mlin@unmc.edu	Veeramani, Suresh/P-7838-2019	Veeramani, Suresh/0000-0001-9217-0872	Department of Defense [W81XWH-04-1-0908, W81XWH-06-1-0070]; National Institutes of Health [R01 CA88184]; UNMC Graduate Student Fellowship; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA088184] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UNMC Graduate Student Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the technical supports from the Flow Cytometry core facility at UNMC and Eppley Cancer Center (P30CA036727). This study was supported in part by the Department of Defense Grants (W81XWH-04-1-0908 and W81XWH-06-1-0070), National Institutes of Health (R01 CA88184) and UNMC Graduate Student Fellowship. We thank Dr Ming-Shyue Lee for the initial study of DHT effect on serine-36 phosphorylation of p66Shc. We also acknowledge Dr Larry W Oberley at University of Iowa College of Medicine (Iowa City, IA, USA) and Dr Parmender P Mehta, University of Nebraska Medical Center (Omaha, NE, USA) for the plasmids Mn-SOD and pECFP-N1, respectively.	Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Davol PA, 2003, CANCER RES, V63, P6772; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Grossman SR, 2007, CLIN CANCER RES, V13, P5798, DOI 10.1158/1078-0432.CCR-07-0073; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Jackson JG, 2000, CLIN CANCER RES, V6, P1135; Khanday FA, 2006, J CELL BIOL, V172, P817, DOI 10.1083/jcb.200506001; Klein EA, 2001, J UROLOGY, V166, P1311, DOI 10.1016/S0022-5347(05)65759-X; Kuruma H, 2005, PROTEOMICS, V5, P1097, DOI 10.1002/pmic.200401115; Lee MS, 2004, ONCOGENE, V23, P3048, DOI 10.1038/sj.onc.1207451; Lee MS, 2004, INT J CANCER, V108, P672, DOI 10.1002/ijc.11621; Lim SD, 2005, PROSTATE, V62, P200, DOI 10.1002/pros.20137; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nemoto S, 2006, J BIOL CHEM, V281, P10555, DOI 10.1074/jbc.M511626200; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Pacini S, 2004, MOL CELL BIOL, V24, P1747, DOI 10.1128/MCB.24.4.1747-1757.2004; Pandolfi S, 2005, MECH AGEING DEV, V126, P839, DOI 10.1016/j.mad.2005.03.004; Park YJ, 2005, ENDOCRINOLOGY, V146, P2473, DOI 10.1210/en.2004-1588; Pinton P, 2007, SCIENCE, V315, P659, DOI 10.1126/science.1135380; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Stevenson LE, 1998, BREAST CANCER RES TR, V49, P119, DOI 10.1023/A:1006007227747; Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513; Veeramani S, 2005, ONCOGENE, V24, P7203, DOI 10.1038/sj.onc.1208852; Ventura A, 2004, J BIOL CHEM, V279, P2299, DOI 10.1074/jbc.M307655200; Xie YM, 1996, BIOCHEM BIOPH RES CO, V221, P140, DOI 10.1006/bbrc.1996.0559; Yang CPH, 2000, CANCER RES, V60, P5171	33	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5057	5068		10.1038/onc.2008.143	http://dx.doi.org/10.1038/onc.2008.143			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18504439	Green Accepted, Green Submitted, Bronze			2022-12-17	WOS:000258914800008
J	Kim, S; Park, SY; Yong, H; Famulski, JK; Chae, S; Lee, JH; Kang, CM; Saya, H; Chan, GK; Cho, H				Kim, S.; Park, S-Y; Yong, H.; Famulski, J. K.; Chae, S.; Lee, J-H; Kang, C-M; Saya, H.; Chan, G. K.; Cho, H.			HBV X protein targets hBubR1, which induces dysregulation of the mitotic checkpoint	ONCOGENE			English	Article						HBV X; BubR1; chromosome instability; mitotic checkpoint	ANAPHASE-PROMOTING COMPLEX; CENTROSOME AMPLIFICATION; CHROMOSOMAL INSTABILITY; TUMOR-DEVELOPMENT; BUBR1; CELLS; ONCOPROTEIN; INHIBITION; REGULATOR; MAD2	Accurate chromosomal segregation is monitored by the mitotic checkpoint, and an increased rate of chromosomal missegregation leads to chromosomal instability (CIN). Here, we demonstrate that the HBV X protein (HBx) binds BubR1, a component of the mitotic checkpoint complex and co-localizes with BubR1 at the kinetochores. HBx binding to BubR1 attenuates the association between BubR1 and CDC20, an activator of the anaphase-promoting complex/cyclosome (APC/C) and induces slippage of mitotic arrest in the presence of microtubule poisons. In addition, HBx binding to BubR1 results in the accumulation of lagging chromosomes and chromosome bridges. In contrast, a C-terminally truncated HBx mutant (HBx(1-100)) fails to bind BubR1 and does not cause aberrant chromosomal segregation. This provides a novel mechanism for dysregulation of the mitotic checkpoint by a viral pathogen linking it to the accumulation of chromosomal instability in HBV-associated hepa tocarcinogenesis.	[Kim, S.; Park, S-Y; Yong, H.; Chae, S.; Lee, J-H; Cho, H.] Ajou Univ, Dept Biochem, Sch Med, Suwon 443721, Kyunggi Do, South Korea; [Famulski, J. K.; Chan, G. K.] Univ Alberta, Dept Oncol, Cross Canc Inst, Edmonton, AB, Canada; [Kang, C-M] Korea Inst Radiol & Med Sci, Seoul, South Korea; [Saya, H.] Keio Univ, Sch Med, Div Gene Regulat, Inst Adv Med Res, Tokyo, Japan	Ajou University; University of Alberta; Korea Institute of Radiological & Medical Sciences; Keio University	Cho, H (corresponding author), Ajou Univ, Dept Biochem, Sch Med, 5 Wonchon Dong, Suwon 443721, Kyunggi Do, South Korea.	gkc@ualberta.ca; hscho@ajou.ac.kr	Chan, Gordon/AAN-7784-2020; Saya, Hideyuki/J-4325-2013	Chan, Gordon/0000-0003-0497-9407; Cho, Hyeseong/0000-0002-4672-8887				Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cotsiki M, 2004, P NATL ACAD SCI USA, V101, P947, DOI 10.1073/pnas.0308006100; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Fujii R, 2006, CANCER RES, V66, P9099, DOI 10.1158/0008-5472.CAN-06-1886; Gollin SM, 2004, CURR OPIN ONCOL, V16, P25, DOI 10.1097/00001622-200401000-00006; HENDERSON AS, 1988, CANCER GENET CYTOGEN, V30, P269, DOI 10.1016/0165-4608(88)90194-X; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kim S, 2007, J VIROL, V81, P1714, DOI 10.1128/JVI.01863-06; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200; Lin Y, 1997, CANCER RES, V57, P5137; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Madden CR, 2001, DIS MARKERS, V17, P153, DOI 10.1155/2001/571254; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOROI Y, 1980, P NATL ACAD SCI-BIOL, V77, P1627, DOI 10.1073/pnas.77.3.1627; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Yun C, 2004, MOL CANCER RES, V2, P159	28	57	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3457	3464		10.1038/sj.onc.1210998	http://dx.doi.org/10.1038/sj.onc.1210998			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18193091				2022-12-17	WOS:000256309900010
J	Lin, K; Rockliffe, N; Johnson, GG; Sherrington, PD; Pettitt, AR				Lin, K.; Rockliffe, N.; Johnson, G. G.; Sherrington, P. D.; Pettitt, A. R.			Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells	ONCOGENE			English	Article						p53; ATM; chronic lymphocytic leukaemia; Hsp90	ENDOTHELIAL GROWTH-FACTOR; GENE MUTATION STATUS; IN-VITRO; PURINE ANALOGS; HEAT-SHOCK-PROTEIN-90 HSP90; DISEASE PROGRESSION; PROTEIN EXPRESSION; ZAP-70 EXPRESSION; INDUCED APOPTOSIS; DRUG-RESISTANCE	In chronic lymphocytic leukaemia ( CLL), mutation/ deletion of TP53 is strongly associated with early disease progression, resistance to chemotherapy and short patient survival. Consequently, there is a pressing need to develop novel treatment protocols for this high- risk patient group. The present study was performed to evaluate Hsp90 inhibition as a possible therapeutic approach for such patients. Primary CLL cells of defined ataxia telangiectasia mutated ( ATM)/ p53 status were incubated with the Hsp90 inhibitor geldanamycin ( GA) and analysed by western blotting for the expression of p53, p21, MDM2 and Akt. GA downregulated overexpressed mutant p53 protein ( an oncogene) and upregulated wild- type ( wt) p53 ( a tumour suppressor). The upregulation of wt p53 by GA was independent of ATM and was accompanied by downregulation of Akt and the active form of MDM2, indicating a possible mechanism. GA also produced a p53/ ATM- independent increase in the levels of p21 - a potent inducer of cell- cycle arrest. In- vitro cytotoxicity studies showed that GA killed cultured CLL cells in a dose- and time- dependent fashion irrespective of their p53/ ATM status and more effectively than normal blood mononuclear cells. In summary, our findings reveal important consequences of inhibiting Hsp90 in CLL cells and strongly support the therapeutic evaluation of Hsp90 inhibitors in poor- prognosis patients with p53 defects.	[Lin, K.; Rockliffe, N.; Sherrington, P. D.; Pettitt, A. R.] Univ Liverpool, Dept Haematol, Sch Canc Studies, Div Haematol, Liverpool L69 3GA, Merseyside, England; [Lin, K.; Johnson, G. G.; Sherrington, P. D.; Pettitt, A. R.] Royal Liverpool & Broadgreen Univ Hosp Trust, Dept Haematol, Liverpool, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; University of Liverpool	Pettitt, AR (corresponding author), Univ Liverpool, Dept Haematol, Sch Canc Studies, Div Haematol, 2nd Floor Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.	A.R.Pettitt@liverpool.ac.uk	lin, ke/GZM-8300-2022					BARTEK J, 1991, ONCOGENE, V6, P1699; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Carter A, 2006, LEUKEMIA, V20, P737, DOI 10.1038/sj.leu.2404120; Castro JE, 2005, BLOOD, V106, P2506, DOI 10.1182/blood-2005-03-1099; Catovsky D, 2004, BLOOD, V104, p8A, DOI 10.1182/blood.V104.11.13.13; Chen HJ, 2000, BLOOD, V96, P3181; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Choi HJ, 2006, GLYCOBIOLOGY, V16, P573, DOI 10.1093/glycob/cwj105; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cordone I, 1998, BLOOD, V91, P4342, DOI 10.1182/blood.V91.11.4342.411k39_4342_4349; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; ELROUBY S, 1993, BLOOD, V82, P3452; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; GINE E, 2005, LEUK LYMPHOMA S1, V46, pS89; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Jones DT, 2004, BLOOD, V103, P1855, DOI 10.1182/blood-2003-05-1603; Jones DT, 2003, BLOOD, V101, P3174, DOI 10.1182/blood-2002-07-2143; Jones GG, 2004, ONCOGENE, V23, P1911, DOI 10.1038/sj.onc.1207318; Kamat CD, 2007, CANCER LETT, V249, P209, DOI 10.1016/j.canlet.2006.08.017; KIESER A, 1994, ONCOGENE, V9, P963; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Morabito F, 1997, HAEMATOLOGICA, V82, P16; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Oscier DG, 2002, BLOOD, V100, P1177, DOI 10.1182/blood.V100.4.1177.h81602001177_1177_1184; Pettitt AR, 1999, BRIT J HAEMATOL, V105, P986, DOI 10.1046/j.1365-2141.1999.01448.x; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P1049; Pettitt AR, 2000, BRIT J HAEMATOL, V109, P800, DOI 10.1046/j.1365-2141.2000.02068.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Romanov VV, 2005, ONCOGENE, V24, P6855, DOI 10.1038/sj.onc.1208895; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SILBER R, 1994, BLOOD, V84, P3440; Smith V, 2005, CANCER CHEMOTH PHARM, V56, P126, DOI 10.1007/s00280-004-0947-2; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; STILGENBAUER S, 2005, LEUK LYMPHOMA S1, V46, pS6; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Thornton PD, 2004, HEMATOL J, V5, P47, DOI 10.1038/sj.thj.6200325; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; Valganon M, 2005, BRIT J HAEMATOL, V129, P53, DOI 10.1111/j.1365-2141.2005.05405.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200	76	57	58	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2445	2455		10.1038/sj.onc.1210893	http://dx.doi.org/10.1038/sj.onc.1210893			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17982489				2022-12-17	WOS:000254844900009
J	Kfoury, Y; Nasr, R; Favre-Bonvin, A; El-Sabban, M; Renault, N; Giron, ML; Setterblad, N; El Hajj, H; Chiari, E; Mikati, AG; Hermine, O; Saib, A; de The, H; Pique, C; Bazarbachi, A				Kfoury, Y.; Nasr, R.; Favre-Bonvin, A.; El-Sabban, M.; Renault, N.; Giron, M-L; Setterblad, N.; El Hajj, H.; Chiari, E.; Mikati, A. G.; Hermine, O.; Saib, A.; de The, H.; Pique, C.; Bazarbachi, A.			Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome	ONCOGENE			English	Article						NF-kappa B; I kappa B kinase; centrosome; HTLV-I; Tax; ubiquitin	T-CELL LEUKEMIA; NF-KAPPA-B; VIRUS TYPE-1 TAX; I TAX; ACTIVATION; PROTEIN; UBIQUITINATION; ONCOPROTEIN; KINASE; AMPLIFICATION	Constitutive activation of the NF-kappa B pathway by the Tax oncoprotein plays a crucial role in the proliferation and transformation of HTLV-I infected T lymphocytes. We have previously shown that Tax ubiquitylation on C-terminal lysines is critical for binding of Tax to I kappa B kinase (IKK) and its subsequent activation. Here, we report that ubiquitylated Tax is not associated with active cytosolic IKK subunits, but binds endogenous IKK-alpha, -beta, -gamma, targeting them to the centrosome. K63-ubiquitylated Tax colocalizes at the centrosome with IKK-gamma, while K48-ubiquitylated Tax is stabilized upon proteasome inhibition. Altogether, these results support a model in which K63-ubiquitylated Tax activates IKK in a centrosome-associated signalosome, leading to the production of Tax-free active cytoplasmic IKK. These observations highlight an unsuspected link between Tax-induced IKK activation and the centrosome.	[Kfoury, Y.; Nasr, R.; El Hajj, H.; Mikati, A. G.; Bazarbachi, A.] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon; [Nasr, R.; Renault, N.; Giron, M-L; Saib, A.; de The, H.] CNRS, UMR 7151, Lab Associe Comite Paris Ligue Canc, Paris, France; [Favre-Bonvin, A.; Chiari, E.; Pique, C.] Univ Paris 05, Univ Paris 07, CNRS,Fac Med Rene Descartes,UMR 7151, Inst Cochin,Dept Biol Cellulaire,UMR3,INSERM U567, Paris, France; [El-Sabban, M.] Amer Univ Beirut, Dept Human Morphol, Beirut, Lebanon; [Giron, M-L] Inst Univ Hematol IFR105, Imagery Dept, Paris, France; [Hermine, O.] Hop Necker Enfants Malad, Dept Hematol, Paris, France; [Hermine, O.] CNRS, UMR 8603, Paris, France	American University of Beirut; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; American University of Beirut; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Bazarbachi, A (corresponding author), Amer Univ Beirut, Med Ctr, Dept Internal Med, Hamra St,POB 1136044, Beirut, Lebanon.	bazarbac@aub.edu.lb	Pique, Claudine/O-6088-2017; setterblad, niclas/GSN-1756-2022; Nasr, Rihab/AAF-1606-2020; Hermine, Olivier/Q-7072-2018	Pique, Claudine/0000-0001-8690-2440; Mikati, Mohamad/0000-0003-0363-8715; Nasr, Rihab/0000-0003-1166-4999; Bazarbachi, Ali/0000-0002-7171-4997; Hermine, Olivier/0000-0003-2574-3874				Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Cheng TS, 2006, LIFE SCI, V78, P1114, DOI 10.1016/j.lfs.2005.06.021; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128/JVI.78.21.11823-11832.2004; Ching YP, 2006, NAT CELL BIOL, V8, P717, DOI 10.1038/ncb1432; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074/jbc.M611031200; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961; Nejmeddine M, 2005, J BIOL CHEM, V280, P29653, DOI 10.1074/jbc.M502639200; Nitta T, 2006, CANCER SCI, V97, P836, DOI 10.1111/j.1349-7006.2006.00254.x; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pumfery A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-50; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384	20	57	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1665	1676		10.1038/sj.onc.1210804	http://dx.doi.org/10.1038/sj.onc.1210804			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891179				2022-12-17	WOS:000253962100002
J	Maekawa, T; Sano, Y; Shinagawa, T; Rahman, Z; Sakuma, T; Nomura, S; Licht, JD; Ishii, S				Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Sakuma, T.; Nomura, S.; Licht, J. D.; Ishii, S.			ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors	ONCOGENE			English	Article						ATF-2; GADD45 alpha; Maspin; p53; BRCA1; tumor suppressors	BRCA1; EXPRESSION; ELEMENT; BINDING; OCT-1; MICE	The activating transcription factor, ATF-2, is a target of p38 and JNK that are involved in stress-induced apoptosis. Heterozygous Atf-2 mutant ( Atf-2(+/-)) mice are highly prone to mammary tumors. The apoptosis-regulated gene GADD45 alpha and the breast cancer suppressor gene Maspin, both of which are known to be p53 target genes, are downregulated in the mammary tumors arisen in Atf-2(+/-) mice. Here, we have analysed how ATF-2 controls the transcription of GADD45a and Maspin. ATF-2 and p53 independently activate the GADD45a transcription. ATF-2 does not directly bind to the GADD45a promoter; instead, it is recruited via Oct-1 and NF-I. ATF-2 simultaneously binds to Oct-1, NF-I and breast cancer suppressor BRCA1 to activate transcription. With regard to Maspin, ATF-2 and p53 directly bind to different sites in the Maspin promoter to independently activate its transcription. Consistent with the observation that ATF-2 and p53 independently activate the transcription of Maspin and GADD45a is that the loss of one copy of p53 shortened the period required for mammary tumor development in Atf-2(+/-) mice. These studies suggest the functional link between the ATF-2 and the two tumor suppressors BRCA1 and p53.	[Maekawa, T.; Sano, Y.; Shinagawa, T.; Rahman, Z.; Ishii, S.] RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; [Sakuma, T.; Nomura, S.] Osaka Univ, Dept Pathol, Grad Sch Med, Suita, Osaka, Japan; [Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	RIKEN; Osaka University; Northwestern University; Feinberg School of Medicine	Maekawa, T (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	maekawa@rtc.riken.jp; sishii@rtc.riken.jp	Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020; Ishii, Shunsuke/A-5271-2016	Licht, Jonathan/0000-0002-3942-1369; Ishii, Shunsuke/0000-0002-6530-2478; Sakuma, Takahiko/0000-0002-9477-2196				Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Osada S, 1996, J BIOL CHEM, V271, P3891; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	23	57	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1045	1054		10.1038/sj.onc.1210727	http://dx.doi.org/10.1038/sj.onc.1210727			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17700520				2022-12-17	WOS:000253136700003
J	Suprynowicz, FA; Disbrow, GL; Krawczyk, E; Simic, V; Lantzky, K; Schlegel, R				Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.			HPV-16 E5 oncoprotein upregulates lipid raft components caveolin-1 and ganglioside GM1 at the plasma membrane of cervical cells	ONCOGENE			English	Article						HPV-16 E5 oncoprotein; caveolin-1; ganglioside GM1	EPIDERMAL-GROWTH-FACTOR; E5 PROTEIN; EPITHELIAL-CELLS; PAPILLOMAVIRUS; EXPRESSION; LOCALIZATION; MICRODOMAINS; INHIBIT; SYNAPSE	High-risk human papillomaviruses ( HPVs), especially HPV-16, play a primary role in the pathogenesis of cervical cancer. HPV-16 encodes the E5, E6 and E7 oncoproteins. Although the biological functions of E5 are poorly understood, recent studies indicate that its expression correlates with papillomavirus oncogenicity. In this study we demonstrate that the HPV-16 E5 oncoprotein increases plasma membrane expression of caveolin-1, which is a constituent of lipid rafts and regulator of cell signaling, and that this phenotype is mediated by the C-terminal 10 amino acids of E5. Moreover, E5 ( but not mutant E5) induces a 23- to 40-fold increase in the lipid raft component, ganglioside GM1, on the cell surface and mediates a dramatic increase in caveolin-1/ GM1 association. Since gangliosides strongly inhibit cytotoxic T lymphocytes, block immune synapse formation and are expressed at high levels on the surface of many tumor cells, our results suggest a potential mechanism for immune evasion by the papillomaviruses. Additionally, surface gangliosides are known to enhance proliferative signaling by the epidermal growth factor ( EGF) receptor, providing a possible mechanistic basis for observations that EGF signaling is enhanced in E5-expressing cells. Finally, the upregulation of caveolin-1 and ganglioside GM1 at the plasma membrane of E5-expressing cervical cells provides potential new therapeutic targets and diagnostic markers for high-risk HPV infections.	[Suprynowicz, F. A.; Disbrow, G. L.; Krawczyk, E.; Simic, V.; Lantzky, K.; Schlegel, R.] Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20057 USA	Georgetown University	Schlegel, R (corresponding author), Georgetown Univ, Sch Med, Dept Pathol, Washington, DC 20057 USA.	schleger@georgetown.edu						Ashrafi GH, 2006, INT J CANCER, V119, P2105, DOI 10.1002/ijc.22089; Bacia K, 2004, BIOPHYS J, V87, P1034, DOI 10.1529/biophysj.104.040519; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Bravo IG, 2005, ARCH VIROL, V150, P231, DOI 10.1007/s00705-004-0420-x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Cebo C, 2006, J IMMUNOL, V176, P864, DOI 10.4049/jimmunol.176.2.864; Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Davis DM, 2004, TRENDS IMMUNOL, V25, P323, DOI 10.1016/j.it.2004.03.007; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; Disbrow GL, 2003, VIROLOGY, V311, P105, DOI 10.1016/S0042-6822(03)00129-6; Fehrmann F, 2003, ONCOGENE, V22, P5201, DOI 10.1038/sj.onc.1206554; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Frazer IH, 1996, CURR OPIN IMMUNOL, V8, P484, DOI 10.1016/S0952-7915(96)80035-5; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HANSSON GC, 1986, EMBO J, V5, P483, DOI 10.1002/j.1460-2075.1986.tb04237.x; Hao MM, 2004, J BIOL CHEM, V279, P14171, DOI 10.1074/jbc.M309793200; McKallip R, 1999, J IMMUNOL, V163, P3718; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Nishio M, 2005, INT J ONCOL, V26, P191; O'Brien PM, 2002, VIRUS RES, V88, P103, DOI 10.1016/S0168-1702(02)00123-5; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Riley RR, 2003, CANCER RES, V63, P4862; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; Schiffman M, 2005, VIROLOGY, V337, P76, DOI 10.1016/j.virol.2005.04.002; Shurin GV, 2001, CANCER RES, V61, P363; SKIBBENS JE, 1989, J CELL BIOL, V108, P821, DOI 10.1083/jcb.108.3.821; Sotgia F, 2002, MOL CELL BIOL, V22, P3905, DOI 10.1128/MCB.22.11.3905-3926.2002; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Suprynowicz FA, 2005, VIROLOGY, V332, P102, DOI 10.1016/j.virol.2004.11.011; Suprynowicz FA, 2006, PAPILLOMAVIRUS RESEARCH: FROM NATURAL HISTORY TO VACCINES AND BEYOND, P97; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; Vyas YM, 2002, IMMUNOL REV, V189, P161, DOI 10.1034/j.1600-065X.2002.18914.x; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083	40	57	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1071	1078		10.1038/sj.onc.1210725	http://dx.doi.org/10.1038/sj.onc.1210725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17704805	Bronze			2022-12-17	WOS:000253136700006
J	Jung, HJ; Kim, EH; Mun, JY; Park, S; Smith, ML; Han, SS; Seo, YR				Jung, H. J.; Kim, E. H.; Mun, J-Y; Park, S.; Smith, M. L.; Han, S. S.; Seo, Y. R.			Base excision DNA repair defect in Gadd45a-deficient cells	ONCOGENE			English	Article						gadd45a; base excision repair; APE1/Ref1; PCNA	P53-REGULATED PROTEIN GADD45; P53 TUMOR-SUPPRESSOR; NUCLEAR ANTIGEN PCNA; IN-VIVO; DAMAGE; ENDONUCLEASE; ASSOCIATION; IRRADIATION; EXPRESSION; APOPTOSIS	As one of a number of p53-regulated genes, Gadd45a (growth arrest and DNA damage inducible gene) has been shown to delay carcinogenesis and decrease mutation frequency. Gadd45a is known to regulate nucleotide excision DNA repair (NER) in response to UV radiation. Here, we report an emerging role for Gadd45a in base excision repair (BER). Gadd45a-null mouse embryo fibroblasts MEF and gadd45a-deficient human colon cancer cells exhibited slow BER after treatment with methyl methanesulfonate (MMS) a pure base-damaging agent. In addition, removal of AP sites by apurinic/apyrimidinic endonuclease 1/redox factor 1 (APE1/Ref1) was significantly delayed in gadd45a-null cells. Moreover, the localization of APE1/Ref1 within the nucleus was observed in gadd45a wild-type cells, whereas APE1 become mainly distributed in the cytoplasm, and there is a reduced interaction with proliferating cell nuclear antigen (PCNA) in Gadd45a-deficient cells. Inasmuch as p53 has been shown to regulate BER in addition to the NER pathway, our data suggest that p53-regulated gene Gadd45a contributes to the BER response by affecting the interaction of cellular APE1/Ref1 with PCNA. Gadd45a might be a key component gene of the p53 pathway involved in protection from carcinogenic base damage and maintenance of genomic stability, although the downstream mechanism including APE1/Ref1 will need further study.	Kyung Hee Univ, Sch Med, Inst Basic Med Sci, Dept Pharmacol, Seoul 130701, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea; Indiana Univ, Sch Med, Indiana Univ Canc Ctr, Indianapolis, IN USA	Kyung Hee University; Korea University; Indiana University System; Indiana University-Purdue University Indianapolis	Seo, YR (corresponding author), Kyung Hee Univ, Sch Med, Inst Basic Med Sci, Dept Pharmacol, Dongdaemun-gu, Seoul 130701, South Korea.	dream21@khu.ac.kr						ABOUSSEKHRA A, 1995, EXP CELL RES, V221, P326, DOI 10.1006/excr.1995.1382; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Bae I, 1996, CANCER RES, V56, P840; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Fan JG, 1999, MOL PHARMACOL, V56, P966, DOI 10.1124/mol.56.5.966; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Hanson S, 2005, ONCOGENE, V24, P1641, DOI 10.1038/sj.onc.1208351; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hildesheim J, 2002, CLIN CANCER RES, V8, P2475; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 2001, CANCER RES, V61, P2487; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kelley MR, 2001, CLIN CANCER RES, V7, P824; Lee JH, 2003, BIOTECHNOL BIOPROC E, V8, P106, DOI 10.1007/BF02940265; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Offer H, 2001, CANCER RES, V61, P88; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Seo YR, 2004, EXP MOL MED, V36, P505, DOI 10.1038/emm.2004.64; Seo YR, 2002, P NATL ACAD SCI USA, V99, P14548, DOI 10.1073/pnas.212319799; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Shibata Y, 2002, J BIOL CHEM, V277, P746, DOI 10.1074/jbc.M109461200; SMITH ML, 1995, ONCOGENE, V10, P1053; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Xia LQ, 2005, J MOL BIOL, V346, P1259, DOI 10.1016/j.jmb.2005.01.014; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	29	57	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2007	26	54					7517	7525		10.1038/sj.onc.1210557	http://dx.doi.org/10.1038/sj.onc.1210557			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DB	17599061				2022-12-17	WOS:000251282100003
J	Tanaka, K; Imoto, I; Inoue, J; Kozaki, K; Tsuda, H; Shimada, Y; Aiko, S; Yoshizumi, Y; Iwai, T; Kawano, T; Inazawa, J				Tanaka, K.; Imoto, I.; Inoue, J.; Kozaki, K.; Tsuda, H.; Shimada, Y.; Aiko, S.; Yoshizumi, Y.; Iwai, T.; Kawano, T.; Inazawa, J.			Frequent methylation-associated silencing of a candidate tumor-suppressor, CRABP1, in esophageal squamous-cell carcinoma	ONCOGENE			English	Article						esophageal squamous-cell carcinoma; CRABP1; DNA methylation; BAMCA; tumor suppressor	ACID-BINDING-PROTEIN; PAPILLARY THYROID-CARCINOMA; CPG ISLAND AMPLIFICATION; RETINOIC-ACID; COLORECTAL-CANCER; I GENE; LYMPH-NODES; EXPRESSION; IDENTIFICATION; PROMOTER	Epigenetic alterations and the resulting inactivation of tumor suppressor genes often contribute to the development of various cancers. To identify novel candidates that may be silenced by aberrant methylation in esophageal squamous-cell carcinoma (ESCC), we analysed ESCC cell lines by a recently developed method known as bacterial artificial chromosome array-based methylated CpG island amplification (BAMCA), and selected candidates through BAMCA-assisted strategy. In the course of this program, we identified frequent CpG methylation-dependent silencing of the gene encoding cellular retinoic acid binding protein 1 (CRABP1) in our panel of ESCC cell lines. Expression of CRABP1 mRNA was restored in gene-silenced ESCC cells after treatment with 5-aza 2'-deoxycytidine. The DNA methylation status of the CRABP1 CpG island with clear promoter activity correlated inversely with expression of this gene. CpG methylation of CRABP1 was frequently observed in primary ESCC tissues as well. Restoration of CRABP1 expression in ESCC cells lacking the protein reduced cell growth by inducing arrest at G(0)-G(1), whereas knockdown of the gene in cells expressing CRABP1 promoted cell growth. Among 113 primary ESCC tumors, the absence of immunoreactive CRABP1 was significantly associated with de-differentiation of cancer cells and with distant lymph-node metastases in the patients. These results indicate that CRABP1 appears to have a tumor-suppressor function in esophageal epithelium, and its epigenetic silencing may play a pivotal role during esophageal carcinogenesis. Its expression status in biopsies or resected tumors might serve as an index for identifying ESCC patients for whom combined therapeutic modalities would be recommended.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Sch Biomed Sci, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Vasc & Appl Surg, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Dept Genome Med, Tokyo 1138510, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Japan; Natl Def Med Coll, Dept Basic Pathol, Tokorozawa, Saitama 359, Japan; Hyogo Med Univ, Dept Surg 1, Nishinomiya, Hyogo, Japan; Natl Def Med Coll, Dept Surg, Tokorozawa, Saitama 359, Japan; Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Mol Destruct, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); National Defense Medical College - Japan; Hyogo College of Medicine; University of Hyogo; National Defense Medical College - Japan; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020; Kozaki, Ken-ichi/M-6281-2014	Kozaki, Ken-ichi/0000-0003-3286-819X				DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; Dong D, 1999, J BIOL CHEM, V274, P23695, DOI 10.1074/jbc.274.34.23695; DONOVAN M, 1995, J STEROID BIOCHEM, V53, P459, DOI 10.1016/0960-0760(95)00092-E; DOWLATSHAHI K, 1984, CANCER, V54, P308, DOI 10.1002/1097-0142(19840715)54:2<308::AID-CNCR2820540221>3.0.CO;2-4; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Huang Y, 2003, INT J CANCER, V104, P735, DOI 10.1002/ijc.11006; Imoto I, 2001, CANCER RES, V61, P6629; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Ito T, 2003, CANCER RES, V63, P6320; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaifi JT, 2005, J NATL CANCER I, V97, P1840, DOI 10.1093/jnci/dji431; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; Kuroki T, 2003, CANCER RES, V63, P3724; Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045; Mandelker DL, 2005, CANCER RES, V65, P4963, DOI 10.1158/0008-5472.CAN-04-3923; Means AL, 2000, CELL GROWTH DIFFER, V11, P71; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Ohtsu Atsushi, 2004, Int J Clin Oncol, V9, P444, DOI 10.1007/s10147-004-0454-9; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pfoertner S, 2005, TUMOR BIOL, V26, P313, DOI 10.1159/000089262; Pimkhaokham A, 2000, JPN J CANCER RES, V91, P1126, DOI 10.1111/j.1349-7006.2000.tb00895.x; RODER JD, 1994, BRIT J SURG, V81, P410, DOI 10.1002/bjs.1800810330; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Shibata H, 2001, PATHOL RES PRACT, V197, P157, DOI 10.1078/0344-0338-00027; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shirakawa Y, 2000, CLIN CANCER RES, V6, P541; Sobin LH., 2002, INT UNION CANC UICC, V6; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Stein HJ, 2005, ANN SURG, V242, P566, DOI 10.1097/01.sla.0000184211.75970.85; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Toyota M, 1999, CANCER RES, V59, P2307; Venepally P, 1996, ARCH BIOCHEM BIOPHYS, V336, P231, DOI 10.1006/abbi.1996.0553; WEI LN, 1994, DEV DYNAM, V201, P1, DOI 10.1002/aja.1002010102; Wei LN, 1996, J BIOL CHEM, V271, P5073; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	43	57	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2007	26	44					6456	6468		10.1038/sj.onc.1210459	http://dx.doi.org/10.1038/sj.onc.1210459			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214KY	17438526				2022-12-17	WOS:000249737600010
J	Okuyama, R; Ogawa, E; Nagoshi, H; Yabuki, M; Kurihara, A; Terui, T; Aiba, S; Obinata, M; Tagami, H; Ikawa, S				Okuyama, R.; Ogawa, E.; Nagoshi, H.; Yabuki, M.; Kurihara, A.; Terui, T.; Aiba, S.; Obinata, M.; Tagami, H.; Ikawa, S.			p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity	ONCOGENE			English	Article						p51/p63; Notch; keratinocyte; stem cell; p53; tumor suppressor	NF-KAPPA-B; SPONTANEOUS TUMORS; MICE LACKING; IKK-ALPHA; P63; DIFFERENTIATION; EXPRESSION; MECHANISM; ONCOGENE; KINASE	p53 homologue, p51/p63, predominantly expressed in keratinocyte stem cells, is indispensable for the formation of epidermis. Notch1, another such gene indispensable for the process, induces growth arrest and differentiation in keratinocytes. We found that exogenous expression of Delta Np51B (Delta Np63 alpha), one of the isoforms of p51 specifically expressed in basal keratinocytes, blocked Notch 1-dependent growth arrest and differentiation in mouse keratinocytes by inhibiting p21 expression and maintaining integrins expression. Furthermore, DNp51B by itself was found to have ability to induce expression of integrin alpha 6 beta 4, which promotes attachment of basal cells to basal membrane thereby keeping the cells in immature state. Therefore, we conclude that DNp51B expression warrants integrin expression even under the influence of Notch1 and that Delta Np51B is a long-sought factor required to maintain basal cell keratinocytes immaturity by inhibiting Notch1 activity. We will postulate a plausible model explaining the maintenance of the squamous epithelium architectures as well as offering mechanistic explanations for pathological features of skin diseases, including cancers, psoriasis along with physiological wound healings.	Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Interdisciplinary Res Ctr, Ikawa Grp, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Cell Biol, Aoba Ku, Sendai, Miyagi, Japan; Tohoku Univ, Grad Sch Life Sci, Lab Cell Differentiat, Aoba Ku, Sendai, Miyagi, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University	Ikawa, S (corresponding author), Tohoku Univ, Interdisciplinary Res Ctr, Aoba Ku, Aramaki,6-3 Aoba, Sendai, Miyagi 9808578, Japan.	sikawa@cir.tohoku.ac.jp	井川, 俊太郎/L-5911-2015					Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; CUI R, 2005, IN PRESS BIOCH BIOPH; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Hagiwara K, 1999, CANCER RES, V59, P4165; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stiewe T, 2002, CANCER RES, V62, P3598; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Thelu Jacques, 2002, BMC Dermatol, V2, P7, DOI 10.1186/1471-5945-2-7; Uyttendaele H, 2004, DIFFERENTIATION, V72, P396, DOI 10.1111/j.1432-0436.2004.07208006.x; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	43	57	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4478	4488		10.1038/sj.onc.1210235	http://dx.doi.org/10.1038/sj.onc.1210235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17237812				2022-12-17	WOS:000247836100002
J	Sengupta, S; Kim, KS; Berk, MP; Oates, R; Escobar, P; Belinson, J; Li, W; Lindner, DJ; Williams, B; Xu, Y				Sengupta, S.; Kim, K. S.; Berk, M. P.; Oates, R.; Escobar, P.; Belinson, J.; Li, W.; Lindner, D. J.; Williams, B.; Xu, Y.			Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion	ONCOGENE			English	Article						lysophosphatidic acid; LPA receptors; metastasis; ovarian cancer; tissue inhibitor of metalloproteinases	OVARIAN-CANCER CELLS; ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; CARCINOMA CELLS; MIGRATION; EXPRESSION; LYSOPHOSPHOLIPIDS; PATHWAY; KINASE; LPA	Ovarian cancer is a highly metastatic disease. Lysophosphatidic acid (LPA) levels are elevated in ascites from ovarian cancer patients, but its potential role in ovarian cancer metastasis has just begun to be revealed. In this work, we show that LPA stimulates invasion of primary ovarian cancer cells, but not ovarian epithelial or borderline ovarian tumor cells, although these benign cells indeed respond to LPA in cell migration. We have found that LPA downregulates tissue inhibitor of metalloproteinases (TIMPs). TIMP2 and TIMP3 play functional role in LPA-induced invasion as negative regulators. G(i) protein, phosphatidylinositol-3 kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), cytosolic phospholipase A(2) and urokinase type plasminogen activator (uPA) are required for LPA-induced cells invasion. TIMP3 may affect two independent downstream targets, vascular endothelial growth factor receptor and p38 MAPK. In vivo, LPA stimulates tumor metastasis in an orthotopic ovarian tumor model, which can be inhibited by a PI3K inhibitor, LY294002. In summary, LPA is likely a key component for promoting ovarian metastasis in vivo. LPA downregulates TIMP3, which may have targets other than metalloproteinases. Our in vivo metastasis mouse model is useful for studying the efficacy of therapeutic regimes of ovarian cancer.	Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; Cleveland Clin, Dept Obstet & Gynecol, Cleveland, OH 44106 USA; Chonbuk Natl Univ, Sch Med, Dept Obstet & Gynecol, Chonju, Chonbuk, South Korea; Cleveland Clin, Taussig Canc Ctr, Dept Drug Discovery & Dev, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Harvard Inst Proteom, Cambridge, MA 02138 USA; Monash Inst Med Res, Clayton, Vic, Australia	Indiana University System; Indiana University-Purdue University Indianapolis; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Jeonbuk National University; Cleveland Clinic Foundation; Harvard University; Harvard Medical School; Monash University	Xu, Y (corresponding author), Indiana Univ, Dept Obstet & Gynecol, 975 W Walnut St IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.eud	Williams, Bryan R. G./A-5021-2009; Lindner, Daniel/ABB-5440-2020; Berk, Michael/M-7891-2013; Berk, Michael/M-3585-2019	Williams, Bryan R. G./0000-0002-4969-1151; Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-5554-6946	NCI NIH HHS [R01 CA095042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Cai Wei, 2002, Ai Zheng, V21, P91; Casey RC, 2003, CLIN EXP METASTAS, V20, P343, DOI 10.1023/A:1024009131191; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fishman DA, 2001, CANCER RES, V61, P3194; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hu LM, 2002, CANCER RES, V62, P1087; Hu LM, 2000, CLIN CANCER RES, V6, P880; Hu Xiao-Xia, 2004, Ai Zheng, V23, P1194; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; KIM KS, 2006, CANCER RES, V66, P3006; Krol J, 2003, BIOL CHEM, V384, P1097, DOI 10.1515/BC.2003.122; KROO J, 2003, BIOL CHEM, V384, P1085; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Manenti L, 2003, EUR J CANCER, V39, P1948, DOI 10.1016/S0959-8049(03)00427-1; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Qian L, 2003, J MED CHEM, V46, P5575, DOI 10.1021/jm034207p; Rauvala M, 2005, GYNECOL ONCOL, V99, P656, DOI 10.1016/j.ygyno.2005.07.009; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Sakamaki Y, 2002, ECOL RES, V17, P673, DOI 10.1046/j.1440-1703.2002.00525.x; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; So J, 2005, GYNECOL ONCOL, V97, P870, DOI 10.1016/j.ygyno.2005.03.004; So J, 2004, GYNECOL ONCOL, V95, P314, DOI 10.1016/j.ygyno.2004.08.001; Sugimoto N, 2006, EXP CELL RES, V312, P1899, DOI 10.1016/j.yexcr.2006.02.020; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Wang XP, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-25; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223	44	57	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2894	2901		10.1038/sj.onc.1210093	http://dx.doi.org/10.1038/sj.onc.1210093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17130843				2022-12-17	WOS:000246210800009
J	Aoki, K; Aoki, M; Sugai, M; Harada, N; Miyoshi, H; Tsukamoto, T; Mizoshita, T; Tatematsu, M; Seno, H; Chiba, T; Oshima, M; Hsieh, CL; Taketo, MM				Aoki, K.; Aoki, M.; Sugai, M.; Harada, N.; Miyoshi, H.; Tsukamoto, T.; Mizoshita, T.; Tatematsu, M.; Seno, H.; Chiba, T.; Oshima, M.; Hsieh, C-L; Taketo, M. M.			Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells	ONCOGENE			English	Article						APC; beta-catenin; chromosomal instability; cancer; Wnt signaling	ADENOMATOUS-POLYPOSIS-COLI; COLORECTAL TUMOR-CELLS; GASTRIC-CANCER; EXPRESSION; MUTATIONS; PROTEIN; MICE; GENE; TUMORIGENESIS; CARCINOMA	Adenomatous polyposis coli (APC/Apc) gene encodes a key tumor suppressor whose mutations activate beta-catenin/T-cell factor (TCF)-mediated transcription (canonical Wnt signaling). Here, we show that Wnt signaling can cause chromosomal instability (CIN). As an indicator of CIN, we scored anaphase bridge index (ABI) in mouse polyps and ES cells where Wnt signaling was activated by Apc or beta-catenin mutations. We found three to nine times higher ABI than in wild-type controls. Furthermore, karyotype analysis confirmed that the Wnt signal activated ES cells produced new chromosomal aberrations at higher rates; hence CIN. Consistently, expression of dominant-negative TCFs in these cells reduced their ABI. We also found that Wnt signal activation increased phosphorylation of Cdc2 (Cdk1) that inhibited its activity, and suppressed apoptosis upon exposure of the cells to nocodazole or colcemid. The data suggest that Wnt signaling stimulates the cells to escape from mitotic arrest and apoptosis, resulting in CIN. In human gastric cancer tissues with nuclear beta-catenin, ABI was significantly higher than in those without. These results collectively indicate that beta-catenin/TCF-mediated transcription itself increases CIN through dysregulation of G2/M progression.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Kyoto 6068501, Japan; Banyu Tsukuba Res Inst Merck, Ibaraki, Japan; Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Aichi, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto 6068501, Japan; Univ So Calif, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Kyoto University; Kyoto University; Merck & Company; Aichi Cancer Center; Kyoto University; University of Southern California; University of Southern California	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Tsukamoto, Tetsuya/ABD-4397-2020; Oshima, Masanobu/F-9958-2014; Aoki, Masahiro/A-5149-2016; Harada, Naomoto/Y-4591-2019; Aoki, Kazuhiro/I-5483-2019	Tsukamoto, Tetsuya/0000-0002-7502-8724; Oshima, Masanobu/0000-0002-3304-0004; Aoki, Masahiro/0000-0003-4316-9490; Aoki, Kazuhiro/0000-0001-7263-1555; Miyoshi, Hiroyuki/0000-0001-7400-0714; Seno, Hiroshi/0000-0002-8509-8128; Harada, Naomoto/0000-0003-1083-7253; Sugai, Manabu/0000-0003-1668-7647				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Danesi DT, 2000, CYTOMETRY, V42, P27, DOI 10.1002/(SICI)1097-0320(20000215)42:1<27::AID-CYTO5>3.0.CO;2-N; Dikovskaya D, 2004, MOL BIOL CELL, V15, P2978, DOI 10.1091/mbc.E03-08-0613; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Homfray TFR, 1998, HUM MUTAT, V11, P114, DOI 10.1002/(SICI)1098-1004(1998)11:2<114::AID-HUMU3>3.0.CO;2-J; HSIEH CL, 1997, CELL BIOL LAB HDB, P391; Ishikawa T, 2003, DEV BIOL, V253, P230, DOI 10.1016/S0012-1606(02)00020-9; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200; Sekiya T, 2002, CANCER RES, V62, P3322; Seno H, 2002, INT J ONCOL, V21, P769; Shih IM, 2001, CANCER RES, V61, P818; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Taketo MM, 2006, CANCER SCI, V97, P355, DOI 10.1111/j.1349-7006.2006.00190.x; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	42	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3511	3520		10.1038/sj.onc.1210141	http://dx.doi.org/10.1038/sj.onc.1210141			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160019				2022-12-17	WOS:000246799200007
J	Khwaja, FW; Svoboda, P; Reed, M; Pohl, J; Pyrzynska, B; Van Meir, EG				Khwaja, F. W.; Svoboda, P.; Reed, M.; Pohl, J.; Pyrzynska, B.; Van Meir, E. G.			Proteomic identification of the wt-p53-regulated tumor cell secretome	ONCOGENE			English	Article						p53; proteomics; secretion; glioma; brain cancer; two-dimensional electrophoresis	GLIOBLASTOMA CELLS; WILD-TYPE; STROMA INTERACTIONS; P53 ALLELES; TGF-BETA; ANGIOGENESIS; EXPRESSION; CANCER; PROTEINS; PATHWAY	Tumor-stroma interactions play a major role in tumor development, maintenance and progression. Yet little is known on how the genetic alterations that underlie cell transformation elicit cell extrinsic changes modulating heterotypic cell interactions. We hypothesized that these events involve a modi. cation in the complement of secreted proteins by the cell, acting as mediators of intercellular communication. To test this hypothesis, we examined the role of wt-p53, a major tumor suppressor, on the tumor microenvironment through its regulation of secreted factors. Using a combination of 2-DE and cICAT proteomic techniques, we found a total of 111 secreted proteins, 39 of which showed enhanced and 21 inhibited secretion in response to wt-p53 expression. The majority of these were not direct targets of p53 transcription factor activity, suggesting a novel role for wt-p53 in the control of intracellular protein trafficking and/or secreted protein stability. Evidence for p53-controlled post-translational modi. cations on nine secreted proteins was also found. These findings will enhance our understanding of wt-p53 modulated interactions of the tumor with its environment.	Emory Univ, Lab Mol NeuroOncol, Dept Neurosurg, Winship Canc Inst,Sch Med, Atlanta, GA 30322 USA; Emory Univ, Dept Hematol Oncol, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Microchem & Proteom Facil, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Lab Mol NeuroOncol, Dept Neurosurg, Winship Canc Inst,Sch Med, 1365C Clifton Rd,NE,C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	Pyrzyńska, Beata/T-2187-2018	Pyrzyńska, Beata/0000-0002-0490-618X; Van Meir, Erwin G./0000-0003-2444-7707	NATIONAL CANCER INSTITUTE [R01CA086335] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR002878, S10RR013948, S10RR012878] Funding Source: NIH RePORTER; NCI NIH HHS [CA 86335] Funding Source: Medline; NCRR NIH HHS [RR 12878, RR 13948, RR 02878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Bueter M, 2006, INT J ONCOL, V28, P519; Chiarugi V, 1998, INT J MOL MED, V2, P715; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Fulci G, 1999, MOL NEUROBIOL, V19, P61, DOI 10.1007/BF02741378; GOLDMAN D, 1980, CLIN CHEM, V26, P1317; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Gygi SP, 2002, J PROTEOME RES, V1, P47, DOI 10.1021/pr015509n; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; KHWAJA FW, 2006, IN PRESS CLIN CANC R; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Pietras K, 2002, CANCER RES, V62, P5476; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Steer M, 2005, IEEE T MICROW THEORY, V53, P3, DOI 10.1109/TMTT.2004.839957; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Tsai MS, 2000, CANCER RES, V60, P5603; Tsuzuki T, 1998, J CLIN PATHOL, V51, P13, DOI 10.1136/jcp.51.1.13; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Volmer MW, 2005, PROTEOMICS, V5, P2587, DOI 10.1002/pmic.200401188; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	37	57	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7650	7661		10.1038/sj.onc.1209969	http://dx.doi.org/10.1038/sj.onc.1209969			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	17043663				2022-12-17	WOS:000242655500010
J	Taketo, MM				Taketo, M. M.			Wnt signaling and gastrointestinal tumorigenesis in mouse models	ONCOGENE			English	Review						Wnt; Apc; beta-catenin; colon cancer; gastric cancer	FAMILIAL ADENOMATOUS POLYPOSIS; APC(DELTA-716) KNOCKOUT MICE; MULTIPLE INTESTINAL NEOPLASIA; HYPERPLASTIC GASTRIC TUMORS; COMPOUND MUTANT MICE; COLON-CANCER CELLS; PPAR-DELTA STATUS; BETA-CATENIN; CYCLOOXYGENASE-2 INHIBITOR; TRANSGENIC MICE	The canonical Wnt signaling plays important roles in embryonic development and tumorigenesis. For the latter, induced mutations in mice have greatly contributed to our understanding of the molecular mechanisms of cancer initiation and progression. Here, I will review recent reports on gastrointestinal cancer model mice, with an emphasis on the roles of the Wnt signal pathway. They include: mouse models for familial adenomatous polyposis; modifying factors that affect mouse intestinal polyposis, including the genes that help cancer progression; Wnt target genes that affect mouse intestinal polyposis; and a mouse model of gastric cancer that mimics Helicobacter pyroli infection.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp						Ahn B, 2001, CANCER RES, V61, P8357; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; AOKI K, 2006, IN PRESS ONCOGENE; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chulada PC, 2000, CANCER RES, V60, P4705; Correa P, 2003, CANCER EPIDEM BIOMAR, V12, p238S; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Gould TD, 2003, PHARMACOL RES, V48, P49, DOI 10.1016/S0143-6618(03)00096-3; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Higuchi T, 2003, CLIN CANCER RES, V9, P4756; Jansson EA, 2005, P NATL ACAD SCI USA, V102, P1460, DOI 10.1073/pnas.0405928102; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Leow CC, 2005, ANN NY ACAD SCI, V1059, P174, DOI 10.1196/annals.1339.048; Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; Lickert H, 2000, DEVELOPMENT, V127, P3805; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nishanian TG, 2004, CANCER BIOL THER, V3, P667; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA H, 2006, IN PRESS GASTROENTER; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 2005, CANCER RES, V65, P9147, DOI 10.1158/0008-5472.CAN-05-1936; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Oshima M, 2002, CURR PHARM DESIGN, V8, P1021, DOI 10.2174/1381612023394953; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reed KR, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-113; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Ristimaki A, 1997, CANCER RES, V57, P1276; Romagnolo B, 1999, CANCER RES, V59, P3875; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Scherer SJ, 2005, BIOCHEM SOC T, V33, P689, DOI 10.1042/BST0330689; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takeda H, 2003, CANCER RES, V63, P4872; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yamada T, 2003, CANCER RES, V63, P895; Yang WC, 2001, CANCER RES, V61, P565; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	70	57	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7522	7530		10.1038/sj.onc.1210058	http://dx.doi.org/10.1038/sj.onc.1210058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143296				2022-12-17	WOS:000242514900010
J	Baldwin, RM; Garratt-Lalonde, M; Parolin, DAE; Krzyzanowski, PM; Andrade, MA; Lorimer, IAJ				Baldwin, R. M.; Garratt-Lalonde, M.; Parolin, D. A. E.; Krzyzanowski, P. M.; Andrade, M. A.; Lorimer, I. A. J.			Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase C iota-mediated attenuation of p38 MAP kinase signaling	ONCOGENE			English	Article						glioblastoma; protein kinase C iota; glia maturation factor beta; p38 MAP kinase; cisplatin	GLIA MATURATION FACTOR; NF-KAPPA-B; GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; ACTIVATION; ISOFORMS; SURVIVAL; PATHWAY; TARGET	Glioblastoma multiforme is an aggressive form of brain cancer that responds poorly to chemotherapy and is generally incurable. The basis for the poor response of this cancer to chemotherapy is not well understood. The atypical protein kinases C ( PKC iota andPKC zeta) have previously been implicated in leukaemia cell chemoresistance. To assess the role of atypical PKC in glioblastoma cell chemoresistance, RNA interference was used to deplete human glioblastoma cells of PKC iota. Transfection of cells with either of two different RNA duplexes specific for PKC iota causeda partial sensitisation to cell death induced by the chemotherapy agent cisplatin. To screen for possible mechanisms for PKC iota- mediated chemoresistance, microarray analysis of gene expression was performed on RNA from glioblastoma cells that were either untreated or depleted of PKC iota. This identified sets of genes that were regulated either positively or negatively by PKC iota. Within the set of genes that were negatively regulated by PKC iota, the function of the gene coding for GMF beta, an enhancer of p38 mitogen- activated-protein kinase ( MAP kinase) signaling, was investigated further, as the p38 MAP kinase pathway has been previously identified as a key mediator of cisplatin cytotoxicity. The expression of both GMFb mRNA and protein increased upon PKC iota depletion, and this was accompanied by an increase in cisplatin- activated p38 MAP kinase signaling. Transient overexpression of GMFb increased cisplatin-activated p38 MAP kinase signaling and also sensitised cells to cisplatin cytotoxicity. The increase in cisplatin cytotoxicity seen with PKCi depletion was blocked by the p38 MAP kinase inhibitor SKF86002. These data show that PKCi can confer partial resistance to cisplatin in glioblastoma cells by suppressing GMF beta- mediated enhancement of p38 MAP kinase signaling.	Ottawa Hosp Reg Canc Ctr, Ctr Canc Therapeut, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; Ontario Genom Innovat Ctr, Ottawa, ON, Canada; Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa	Lorimer, IAJ (corresponding author), Ottawa Hosp Reg Canc Ctr, Ctr Canc Therapeut, Ottawa Hlth Res Inst, 3rd Floor,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	ilorimer@ohri.ca		Krzyzanowski, Paul/0000-0001-6430-5995				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Brigstock DR, 2003, J ENDOCRINOL, V178, P169, DOI 10.1677/joe.0.1780169; Choi BK, 2004, NEUROTOXICOLOGY, V25, P915, DOI 10.1016/j.neuro.2004.06.002; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Filomenko R, 2002, CANCER RES, V62, P1815; Garcia-Cao I, 2003, EMBO REP, V4, P307, DOI 10.1038/sj.embor.embor769; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanigan MH, 2005, AM J PHYSIOL-RENAL, V288, pF125, DOI 10.1152/ajprenal.00041.2003; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Inagaki M, 2004, BBA-GEN SUBJECTS, V1670, P208, DOI 10.1016/j.bbagen.2003.12.006; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Kaimori J, 2003, J BIOL CHEM, V278, P33519, DOI 10.1074/jbc.M301552200; Kanzaki M, 2004, J CELL BIOL, V164, P279, DOI 10.1083/jcb.200306152; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lim R, 2004, BRAIN RES, V1024, P225, DOI 10.1016/j.brainres.2004.08.003; Lim R, 1996, J BIOL CHEM, V271, P22953, DOI 10.1074/jbc.271.38.22953; Lorimer IAJ, 2002, CURR CANCER DRUG TAR, V2, P91, DOI 10.2174/1568009023333926; Lorimer IAJ, 2000, J IMMUNOL METHODS, V237, P147, DOI 10.1016/S0022-1759(99)00219-7; Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Lu Y, 2001, ONCOGENE, V20, P4777, DOI 10.1038/sj.onc.1204607; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Soloff RS, 2004, J IMMUNOL, V173, P3250, DOI 10.4049/jimmunol.173.5.3250; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Zaheer A, 2004, NEUROCHEM RES, V29, P1473, DOI 10.1023/B:NERE.0000029558.82943.00; Zhan Y, 2004, CANCER RES, V64, P8292, DOI 10.1158/0008-5472.CAN-03-3143	37	57	61	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2006	25	20					2909	2919		10.1038/sj.onc.1209312	http://dx.doi.org/10.1038/sj.onc.1209312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331246				2022-12-17	WOS:000237448200009
J	Tanaka, Y; Kanai, F; Tada, M; Asaoka, Y; Guleng, B; Jazag, A; Ohta, M; Ikenoue, T; Tateishi, K; Obi, S; Kawabe, T; Yokosuka, O; Omata, M				Tanaka, Y.; Kanai, F.; Tada, M.; Asaoka, Y.; Guleng, B.; Jazag, A.; Ohta, M.; Ikenoue, T.; Tateishi, K.; Obi, S.; Kawabe, T.; Yokosuka, O.; Omata, M.			Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients	ONCOGENE			English	Article						PIK3CA; mutation; HCC; pseudogene; PI3K	HUMAN CANCER; GENE; OVARIAN; PATHWAY	A recent study revealed that the p110 alpha ( PIK3CA), catalytic subunit of phosphatidylinositol 3- kinase ( PI3K), is somatically mutated in many types of cancer. For example, PIK3CA is mutated in an estimated 35.6% of hepatocellular carcinoma ( HCC) cases. To measure the frequency of PIK3CA hotspot mutations in Japanese HCC patients, exons 9 and 20 of the PIK3CA gene were sequenced in 47 clinical HCC samples. Contrary to expectations, no hotspot mutations were found any of the HCC samples. In addition, we found abnormally migrating waves near the end of exon 9 in the PCR chromatograms from 13 of the 47 samples. PCR amplification and subsequent cloning and sequencing revealed that these chromatograms contained two distinct sequences, the wild- type p110 alpha sequence and a different sequence found on human chromosome 22q11.2, the Cat Eye Syndrome region, which contains a putative pseudogene of PIK3CA. These abnormally migrating waves were also found in noncancerous liver tissue, indicating that this was not a result of HCC- associated mutations. Therefore, it is likely that the percentage of hotspot mutations in the PIK3CA gene of Japanese HCC patients is lower than was previously reported.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba, Japan	University of Tokyo; Chiba University	Kanai, F (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kanaif-int@h.u-tokyo.ac.jp	Asaoka, Yoshinari/ABC-5412-2021	Asaoka, Yoshinari/0000-0002-2805-8226; Tanaka, Yasuo/0000-0002-2917-3365				Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; McDermid HE, 2002, AM J HUM GENET, V70, P1077, DOI 10.1086/340363; OR YY, 2005, INT J CANC      0819; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	16	57	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2950	2952		10.1038/sj.onc.1209311	http://dx.doi.org/10.1038/sj.onc.1209311			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331247				2022-12-17	WOS:000237448200014
J	Alarcon-Vargas, D; Zhang, Z; Agarwal, B; Challagulla, K; Mani, S; Kalpana, GV				Alarcon-Vargas, D; Zhang, Z; Agarwal, B; Challagulla, K; Mani, S; Kalpana, GV			Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors	ONCOGENE			English	Article						rhabdoid; cyclin D1; 4-HPR; tamoxifen; cell cycle and apoptosis	BREAST-CANCER CELLS; ATYPICAL TERATOID/RHABDOID TUMOR; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; TAMOXIFEN; EXPRESSION; N-(4-HYDROXYPHENYL)RETINAMIDE; FENRETINIDE; APOPTOSIS; RECEPTOR	Rhabdoid tumors (RTs) are aggressive and currently incurable pediatric malignancies. INI1/hSNF5 is a tumor suppressor biallelically inactivated in RTs. Our previous studies have indicated that cyclin D1 is a key downstream target of INI1/hSNF5 and genesis and/or survival of RTs in vivo is critically dependent on the presence of cyclin D1. In this report, we have tested the hypothesis that therapeutic targeting of cyclin D1 is an effective means of treating RTs. We found that RNA interference of cyclin D1 in rhabdoid cells was sufficient to induce G1 arrest and apoptosis. Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines. 4-HPR in combination with 4-hydroxy-tamoxifen (4OH-Tam), synergistically inhibited survival as well as anchorage-dependent and -independent growth of rhabdoid cells and caused synergistic induction of cell cycle arrest and apoptosis. 4-HPR and tamoxifen exhibited synergistic growth inhibition of RTs in xenograft models in vivo. The effects of combination of drugs were correlated to the depletion of cyclin D1 levels both in in vitro and in vivo tumor models. These results demonstrate that 4-HPR and tamoxifen are effective chemotherapeutic agents for RTs. We propose that downmodulation of cyclin D1 is a novel and effective therapeutic strategy for RTs.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Mani, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, 1300 Morris Pk Ave,Ullman 821, Bronx, NY 10461 USA.	smani@montefiore.org; kalpana@aecom.yu.edu		Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Aoyama Yuko, 2002, Kurume Medical Journal, V49, P27; Appierto V, 2001, BRIT J CANCER, V84, P1528, DOI 10.1054/bjoc.2001.1826; Argiris A, 2004, CLIN CANCER RES, V10, P1409, DOI 10.1158/1078-0432.CCR-1060-02; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Biegel JA, 1999, CANCER RES, V59, P74; Biegel Jaclyn A., 2002, Cancer Research, V62, P323; Brockdorff BL, 2003, ENDOCR-RELAT CANCER, V10, P579, DOI 10.1677/erc.0.0100579; Chou T.-C., 1991, ENCY HUMAN BIOL, V2, P371; DiPietrantonio AM, 1998, INT J CANCER, V78, P53, DOI 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6; Dragnev KH, 2004, CLIN CANCER RES, V10, P2570, DOI 10.1158/1078-0432.CCR-03-0271; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Favoni RE, 1998, BRIT J CANCER, V77, P2138, DOI 10.1038/bjc.1998.358; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Hilden JM, 2004, J CLIN ONCOL, V22, P2877, DOI 10.1200/jco.2004.07.073; Jang TJ, 2001, CANCER LETT, V170, P109, DOI 10.1016/S0304-3835(01)00593-6; Koshida S, 2002, JPN J CANCER RES, V93, P1351, DOI 10.1111/j.1349-7006.2002.tb01244.x; Le Marchand L, 2003, JAMA-J AM MED ASSOC, V290, P2843, DOI 10.1001/jama.290.21.2843; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; Lee TH, 1999, ONCOGENE, V18, P4269, DOI 10.1038/sj.onc.1202755; Li WW, 2001, CLIN CANCER RES, V7, P2908; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Mitsiades CS, 2003, J ENDOCRINOL, V178, P205, DOI 10.1677/joe.0.1780205; Packer RJ, 2002, J PEDIAT HEMATOL ONC, V24, P337, DOI 10.1097/00043426-200206000-00004; Panigone S, 2000, ONCOGENE, V19, P4035, DOI 10.1038/sj.onc.1203743; Pirkmaier A, 2003, CLIN CANCER RES, V9, P1877; Pollack IF, 1997, CLIN CANCER RES, V3, P1109; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Rousseau C, 2003, J STEROID BIOCHEM, V86, P1, DOI 10.1016/S0960-0760(03)00255-3; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Singletary SE, 2002, CLIN CANCER RES, V8, P2835; Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6; Wu KM, 2002, MOL CANCER THER, V1, P695; Zeisig R, 2004, BREAST CANCER RES TR, V87, P245, DOI 10.1007/s10549-004-8699-6; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	40	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					722	734		10.1038/sj.onc.1209112	http://dx.doi.org/10.1038/sj.onc.1209112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16302003				2022-12-17	WOS:000235068800008
J	Mangoura, D; Sun, Y; Li, C; Singh, D; Gutmann, DH; Flores, A; Ahmed, M; Vallianatos, G				Mangoura, D; Sun, Y; Li, C; Singh, D; Gutmann, DH; Flores, A; Ahmed, M; Vallianatos, G			Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells	ONCOGENE			English	Article						neurofibromin; tumor suppressor; EGF signaling; PKC	NF1 GENE-PRODUCT; PROTEIN-KINASE; TYPE-1 GENE; TARGETED DISRUPTION; F-ACTIN; RAS; ACTIVATION; DOMAIN; GAP; EXPRESSION	Children with neurofibromatosis (NF1) typically develop central nervous system (CNS) abnormalities, including aberrant proliferation of astrocytes and formation of benign astrocytomas. The NF1 gene encodes neurofibromin, a Ras-GAP, highly expressed in developing neural cells; the mechanism of regulation of neurofibromin as a Ras-GAP, remains however unknown. We now show that, in response to EGF, neurofibromin is in vivo phosphorylated on serine residues by PKC-alpha, in human, rat, and avian CNS cells and cell lines. EGF-induced PKC phosphorylation was prominent in the cysteine/serine-rich domain (CSRD) of neurofibromin, which lies in the N-terminus and upstream of the Ras-GAP domain (GRD), and this modification significantly increased the association of neurofibromin with actin in co-immunoprecipitations. In addition, we show that Ras activation in response to EGF was significantly lowered when C62B cells overexpressed a construct encoding both CSRD+GRD. Moreover, when PKC-alpha was downregulated, the Ras-GAP activity of CSRD+GRD was significantly diminished, whereas overexpressed GRD alone acted as a weaker GAP and in a PKC-independent manner. Most importantly, functional Ras inhibition and EGF signaling shifts were established at the single cell level in C6-derived cell lines stably overexpressing CSRD+GRD, when transient co-overexpression of Ras and PKC-depletion prior to stimulation with EGF-induced mitosis. Taken together, these data provide the first evidence of a functional, allosteric regulation of GRD by CSRD, which requires neurofibromin phosphorylation by PKC and association with the actin cytoskeleton. Our data may suggest a novel mechanism for regulating biological responses to EGF and provide a new aspect for the understanding of the aberrant proliferation seen in the CNS of children with NF1.	Inst Biomed Res, Div Neurosci, GR-11527 Athens, Greece; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Washington Univ, Dept Neurol, St Louis, MO USA	University of Chicago; Washington University (WUSTL)	Mangoura, D (corresponding author), Inst Biomed Res, Div Neurosci, 4 Soranou Efesiou, GR-11527 Athens, Greece.	mangoura@bioacademy.gr	Vallianatos, George/AAF-2973-2019	Gutmann, David/0000-0002-3127-5045	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NICHD NIH HHS [HD09402] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chen JS, 2004, J BIOL CHEM, V279, P22076, DOI 10.1074/jbc.M311033200; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Cheng Y, 2000, J BIOL CHEM, V275, P23326, DOI 10.1074/jbc.M001837200; Cheng Y, 2000, J CELL SCI, V113, P3161; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Chodniewicz D, 2004, J BIOL CHEM, V279, P24460, DOI 10.1074/jbc.M312764200; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Crespo NC, 2002, CELL DEATH DIFFER, V9, P702, DOI 10.1038/sj.cdd.4401023; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Drugan JK, 2000, J BIOL CHEM, V275, P35021, DOI 10.1074/jbc.M004386200; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Edamatsu H, 1998, FEBS LETT, V440, P231, DOI 10.1016/S0014-5793(98)01457-4; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Frazier JA, 1997, CURR BIOL, V7, pR414, DOI 10.1016/S0960-9822(06)00205-3; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Goya L, 1996, INT J DEV NEUROSCI, V14, P409, DOI 10.1016/S0736-5748(96)00026-3; Gutmann DH, 1995, PROG BRAIN RES, V105, P327; Hiatt KK, 2001, J BIOL CHEM, V276, P7240, DOI 10.1074/jbc.M009202200; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Kornblum HI, 1999, EUR J NEUROSCI, V11, P3236, DOI 10.1046/j.1460-9568.1999.00744.x; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Li CJ, 2001, DEV BRAIN RES, V130, P231, DOI 10.1016/S0165-3806(01)00190-0; Mangoura D, 1998, J NEUROCHEM, V70, P130; Mangoura D, 1997, J NEUROSCI RES, V50, P391, DOI 10.1002/(SICI)1097-4547(19971101)50:3<391::AID-JNR5>3.0.CO;2-D; MANGOURA D, 1993, P NATL ACAD SCI USA, V90, P2915, DOI 10.1073/pnas.90.7.2915; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Represa A, 2001, EUR J NEUROSCI, V14, P452, DOI 10.1046/j.0953-816x.2001.01660.x; Riccardi VM, 1999, NEUROFIBROMATOSIS PH; Rose SD, 2001, J BIOL CHEM, V276, P36757, DOI 10.1074/jbc.M006518200; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Xie H, 1998, J CELL SCI, V111, P615; Yamashiro S, 2003, MOL BIOL CELL, V14, P1745, DOI 10.1091/mbc.E02-07-0427; YAN N, 1995, CANCER RES, V55, P3569	52	57	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	5					735	745		10.1038/sj.onc.1209113	http://dx.doi.org/10.1038/sj.onc.1209113			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	008VM	16314845				2022-12-17	WOS:000235068800009
J	Watanabe, H; Mizutani, T; Haraguchi, T; Yamamichi, N; Minoguchi, S; Yamamichi-Nishina, M; Mori, N; Kameda, T; Sugiyama, T; Iba, H				Watanabe, H; Mizutani, T; Haraguchi, T; Yamamichi, N; Minoguchi, S; Yamamichi-Nishina, M; Mori, N; Kameda, T; Sugiyama, T; Iba, H			SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines	ONCOGENE			English	Article						SWI/SNF complex; nonsmall cell lung carcinoma; NRSF; neuronal differentiation; histone deacetylation	RESTRICTIVE SILENCER FACTOR; SWI-SNF COMPLEX; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; POSTTRANSCRIPTIONAL LEVEL; REMODELING COMPLEXES; HISTONE DEACETYLASE; BRM GENES; EXPRESSION; CANCER	Mammalian chromatin remodelingfact or, SWI/ SNF complex contains a single molecule of either Brm or BRG1 as the ATPase catalytic subunit. Here, we show that the SWI/ SNF complex forms a larger complex with neuron-restrictive silencer factor (NRSF) and its corepressors, mSin3A and CoREST, in human nonsmall cell lung carcinoma cell lines. We also demonstrate that the strong transcriptional suppression of such neuron-specific genes as synaptophysin and SCG10 by NRSF in these non-neural cells requires the functional SWI/ SNF complex; these neuronal genes were elevated in cell lines deficient in both Brm and BRG1, whereas retrovirus vectors expressing siRNAs targeting integral components of SWI/ SNF complex (Brm/BRG1 or Ini1) induced expression of these neuronal genes in SWI/ SNF-competent cell lines. In cell lines deficient in both Brm and BRG1, exogenous Brm or BRG1 suppressed expression of these neuronal genes in an ATP-dependent manner and induced efficient and specific deacetylation of histone H4 around the NRSF binding site present in the synaptophysin gene by a large complex containing the recruited functional SWI/ SNF complex. Patients with Brm/BRG1 deficient lung carcinoma have been reported to carry poor prognosis; derepression of NRSF-regulated genes including these neuron-specific genes could contribute to enhance tumorigenicity and also would provide selective markers for Brm/BRG1-deficient tumors.	Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, Tokyo 1088639, Japan; Nagasaki Univ, Sch Med, Dept Anat & Neurobiol, Nagasaki 852, Japan; Akita Univ, Sch Med, Dept Biochem, Akita 010, Japan	University of Tokyo; Nagasaki University; Akita University	Iba, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Host Parasite Interact,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	iba@ims.u-tokyo.ac.jp	Watanabe, Hirotaka/GZA-8002-2022					Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Arai T, 1999, VIROLOGY, V260, P109, DOI 10.1006/viro.1999.9773; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Carnaghi C, 2001, ANN ONCOL, V12, pS119, DOI 10.1093/annonc/12.suppl_2.S119; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Coulson JM, 2000, CANCER RES, V60, P1840; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Furumai R, 2002, CANCER RES, V62, P4916; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Gurrola-Diaz C, 2003, ONCOGENE, V22, P5636, DOI 10.1038/sj.onc.1206790; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Iba H, 2003, REV MED VIROL, V13, P99, DOI 10.1002/rmv.378; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lietz M, 2003, EUR J BIOCHEM, V270, P2, DOI 10.1046/j.1432-1033.2003.03360.x; Linnoila RI, 1996, J CELL BIOCHEM, P92; LINNOILA RI, 1995, LUNG CANCER, P73; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Martens JA, 2003, CURR OPIN GENET DEV, V13, P136, DOI 10.1016/S0959-437X(03)00022-4; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roopra A, 2000, MOL CELL BIOL, V20, P2147, DOI 10.1128/MCB.20.6.2147-2157.2000; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tabuchi A, 2002, BIOCHEM BIOPH RES CO, V290, P415, DOI 10.1006/bbrc.2001.6194; Ui M, 1999, GENE THER, V6, P1670, DOI 10.1038/sj.gt.3301009; Van Lommel A, 1999, ARCH HISTOL CYTOL, V62, P1, DOI 10.1679/aohc.62.1; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong AKC, 2000, CANCER RES, V60, P6171; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Yamamichi-Nishina M, 2003, J BIOL CHEM, V278, P7422, DOI 10.1074/jbc.M208458200; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499	51	57	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					470	479		10.1038/sj.onc.1209068	http://dx.doi.org/10.1038/sj.onc.1209068			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16247481				2022-12-17	WOS:000234714100015
J	Manel, N; Battini, JL; Taylor, N; Sitbon, M				Manel, N; Battini, JL; Taylor, N; Sitbon, M			HTLV-1 tropism and envelope receptor	ONCOGENE			English	Review						HTLV-1; GLUT1; envelope glycoproteins; receptor; tropism; glucose transporter	T-CELL LEUKEMIA; VIRUS TYPE-I; HUMAN-IMMUNODEFICIENCY-VIRUS; MONKEYS SAIMIRI-SCIUREUS; UBIQUITOUS GLUCOSE-TRANSPORTER; MEDIATED SYNCYTIUM FORMATION; HUMAN-ENDOTHELIAL CELLS; AMINO-ACID TRANSPORTER; CENTRAL-NERVOUS-SYSTEM; SPASTIC PARAPARESIS	The identification of CD4 as the primary receptor for HIV followed shortly after the discovery of the virus, but the HTLV receptor remained long elusive, until its recent identification as the GLUT1 glucose transporter. In the present review, we describe the status of the literature that surrounded this discovery as well as the in vitro and in vivo observations that led to the identification of GLUT1. Also, we will explore a few tracks to conciliate the in vitro and in vivo data on HTLV-1 tropism within the context of the HTLV literature that has accumulated over the past 25 years. A close examination of these data leads us to conclude that the preferential detection of HTLV-1 in CD4+ T lymphocyte subsets in vivo, even in the absence of leukemia, is not likely to be directly related to envelope receptor interactions, but rather to an array of postentry selection bottlenecks in vivo. Furthermore, we propose that infection of other hematopoietic and nonhematopoietic cells is likely to take place during the lifetime of an individual, with a burst early during the infection.	CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 122, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Sitbon, M (corresponding author), CNRS, Inst Genet Mol Montpellier, UMR 5535, IFR 122, 1919 Route Mende, F-34293 Montpellier, France.	marc.sitbon@igmm.cnrs.fr	Sitbon, Marc/A-6771-2010; Manel, Nicolas/E-2128-2011; Taylor, Naomi/H-4016-2014	Sitbon, Marc/0000-0003-3616-2338; Manel, Nicolas/0000-0002-1481-4430; Battini, Jean-Luc/0000-0002-5884-9934				AKAGI T, 1985, JPN J CANCER RES, V76, P86; Al-Fahim A, 1999, CELL IMMUNOL, V198, P1, DOI 10.1006/cimm.1999.1580; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Anderson MM, 2000, SCIENCE, V287, P1828, DOI 10.1126/science.287.5459.1828; Basyuk E, 2003, DEV CELL, V5, P161, DOI 10.1016/S1534-5807(03)00188-6; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; BATTINI JL, 1995, J VIROL, V69, P713, DOI 10.1128/JVI.69.2.713-719.1995; Benit L, 2001, J VIROL, V75, P11709, DOI 10.1128/JVI.75.23.11709-11719.2001; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; BONVENTO G, 2005, IN PRESS J CEREB BLO; Brighty DW, 2001, J VIROL, V75, P10472, DOI 10.1128/JVI.75.21.10472-10478.2001; CHAKRABARTI R, 1994, J IMMUNOL, V152, P2660; CLAPHAM P, 1983, SCIENCE, V222, P1125, DOI 10.1126/science.6316502; CLAPHAM P, 1984, P NATL ACAD SCI-BIOL, V81, P2886, DOI 10.1073/pnas.81.9.2886; CORNFORD EM, 1994, J CEREBR BLOOD F MET, V14, P106, DOI 10.1038/jcbfm.1994.15; Daenke S, 1999, J GEN VIROL, V80, P1429, DOI 10.1099/0022-1317-80-6-1429; Daenke S, 2000, AIDS RES HUM RETROV, V16, P1731, DOI 10.1089/08892220050193227; Delamarre L, 1996, J ACQ IMMUN DEF SYND, V13, pS85, DOI 10.1097/00042560-199600001-00015; DENESVRE C, 1995, J VIROL, V69, P4149, DOI 10.1128/JVI.69.7.4149-4157.1995; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; Eiraku N, 1998, J IMMUNOL, V161, P6674; Ericsson TA, 2003, P NATL ACAD SCI USA, V100, P6759, DOI 10.1073/pnas.1138025100; EVANS LH, 1990, J VIROL, V64, P6176, DOI 10.1128/JVI.64.12.6176-6183.1990; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; FRANCHINI G, 1985, LEUKEMIA RES, V9, P1305, DOI 10.1016/0145-2126(85)90116-X; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; GAVALCHIN J, 1993, VIROLOGY, V194, P1, DOI 10.1006/viro.1993.1228; Geijtenbeek TBH, 2003, CURR TOP MICROBIOL, V276, P31; Goetz M, 1997, J PEPT SCI, V3, P347, DOI 10.1002/(SICI)1099-1387(199709)3:5<347::AID-PSC110>3.0.CO;2-E; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; HAYAMI M, 1984, JPN J CANCER RES, V75, P99; Heams T, 2003, BIOTECHNIQUES, V34, P712, DOI 10.2144/03344bm06; Hein S, 2003, J VIROL, V77, P5926, DOI 10.1128/JVI.77.10.5926-5932.2003; Hildreth JEK, 1998, J VIROL, V72, P9544, DOI 10.1128/JVI.72.12.9544-9552.1998; Hildreth JEK, 1997, J VIROL, V71, P1173, DOI 10.1128/JVI.71.2.1173-1180.1997; HO DD, 1984, P NATL ACAD SCI-BIOL, V81, P7588, DOI 10.1073/pnas.81.23.7588; Hocini H, 1999, J INFECT DIS, V179, pS448, DOI 10.1086/314802; HOFFMAN PM, 1992, P NATL ACAD SCI USA, V89, P11784, DOI 10.1073/pnas.89.24.11784; HOSHINO H, 1983, P NATL ACAD SCI-BIOL, V80, P7337, DOI 10.1073/pnas.80.23.7337; HOXIE JA, 1984, P NATL ACAD SCI-BIOL, V81, P7591, DOI 10.1073/pnas.81.23.7591; Hruz PW, 2001, MOL MEMBR BIOL, V18, P183; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; IMAI T, 1992, J IMMUNOL, V149, P2879; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; Jassal SR, 2001, J VIROL, V75, P8317, DOI 10.1128/JVI.75.17.8317-8328.2001; Jolly C, 2004, TRAFFIC, V5, P643, DOI 10.1111/j.1600-0854.2004.00209.X; Jones KS, 2005, J IMMUNOL, V174, P4262, DOI 10.4049/jimmunol.174.7.4262; Kacem K, 1998, GLIA, V23, P1; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2000, J VIROL, V74, P4860, DOI 10.1128/JVI.74.10.4860-4867.2000; Kim Felix J, 2004, Retrovirology, V1, P41, DOI 10.1186/1742-4690-1-41; Kim FJ, 2000, J BIOL CHEM, V275, P23417, DOI 10.1074/jbc.C901002199; Kim FJ, 2004, VIROLOGY, V318, P183, DOI 10.1016/j.virol.2003.09.026; Kim FJ, 2003, J VIROL, V77, P963, DOI 10.1128/JVI.77.2.963-969.2003; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; KOYANAGI Y, 1993, VIROLOGY, V196, P25, DOI 10.1006/viro.1993.1451; KUMAGAI AK, 1994, INVEST OPHTH VIS SCI, V35, P2887; Lavillette D, 1998, J VIROL, V72, P9955, DOI 10.1128/JVI.72.12.9955-9965.1998; LEHKY TJ, 1995, ANN NEUROL, V37, P167, DOI 10.1002/ana.410370206; LeVasseur R J, 1998, J Hum Virol, V1, P214; Levin MC, 1997, BLOOD, V89, P346; LONGO DL, 1984, NATURE, V310, P505, DOI 10.1038/310505a0; Loureiro P, 2000, AM J HEMATOL, V65, P256; Ludwig IS, 2004, J VIROL, V78, P8322, DOI 10.1128/jvi.78.15.8322-8332.2004; MACATONIA SE, 1992, AIDS RES HUM RETROV, V8, P1699, DOI 10.1089/aid.1992.8.1699; Malik HS, 2000, GENOME RES, V10, P1307, DOI 10.1101/gr.145000; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Manel N, 2004, FRONT BIOSCI-LANDMRK, V9, P3218, DOI 10.2741/1474; Manel N, 2003, BLOOD, V101, P1913, DOI 10.1182/blood-2002-09-2681; Marechal V, 1998, J VIROL, V72, P2208; Marechal V, 2001, J VIROL, V75, P11166, DOI 10.1128/JVI.75.22.11166-11177.2001; MILLER DG, 1994, P NATL ACAD SCI USA, V91, P78, DOI 10.1073/pnas.91.1.78; MOCHIZUKI M, 1996, J ACQ IMMUN DEF SYND, V13, P50; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Muul LM, 2003, BLOOD, V101, P2563, DOI 10.1182/blood-2002-09-2800; Nagai M, 2001, BLOOD, V98, P1858, DOI 10.1182/blood.V98.6.1858; Nath MD, 2003, BLOOD, V101, P3085, DOI 10.1182/blood-2002-07-2277; Nisole Sebastien, 2004, Retrovirology, V1, P9, DOI 10.1186/1742-4690-1-9; Nobile C, 2005, J VIROL, V79, P5386, DOI 10.1128/JVI.79.9.5386-5399.2005; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; Okuma K, 1999, VIROLOGY, V254, P235, DOI 10.1006/viro.1998.9530; Okuma K, 2003, J VIROL, V77, P8562, DOI 10.1128/JVI.77.15.8562-8569.2003; Pearson MN, 2002, J VIROL, V76, P5301, DOI 10.1128/JVI.76.11.5301-5304.2002; Pellerin L, 2003, J CEREBR BLOOD F MET, V23, P1282, DOI 10.1097/01.WCB.0000096064.12129.3D; Pinon JD, 2003, J VIROL, V77, P9922, DOI 10.1128/JVI.77.18.9922-9930.2003; Pique C, 2000, VIROLOGY, V276, P455, DOI 10.1006/viro.2000.0538; Quigley JG, 2000, BLOOD, V95, P1093, DOI 10.1182/blood.V95.3.1093.003k01_1093_1099; RALSTON S, 1989, J BIOL CHEM, V264, P16343; Rasko JEJ, 1999, P NATL ACAD SCI USA, V96, P2129, DOI 10.1073/pnas.96.5.2129; RICHARDSON JH, 1990, J VIROL, V64, P5682, DOI 10.1128/JVI.64.11.5682-5687.1990; ROCANCOURT D, 1990, J VIROL, V64, P2660, DOI 10.1128/JVI.64.6.2660-2668.1990; Sagara Y, 1996, J VIROL, V70, P1564, DOI 10.1128/JVI.70.3.1564-1569.1996; Sagara Y, 1998, J VIROL, V72, P535, DOI 10.1128/JVI.72.1.535-541.1998; Sagara Y, 2001, AIDS RES HUM RETROV, V17, P125, DOI 10.1089/08892220150217210; Setoyama M, 1998, AM J PATHOL, V152, P683; Setoyama M, 1999, INT J CANCER, V80, P652, DOI 10.1002/(SICI)1097-0215(19990301)80:5<652::AID-IJC3>3.0.CO;2-P; Smith TAD, 1998, NUCL MED COMMUN, V19, P97, DOI 10.1097/00006231-199802000-00002; SOMMERFELT MA, 1988, SCIENCE, V242, P1557, DOI 10.1126/science.3201246; SOMMERFELT MA, 1990, VIROLOGY, V176, P58, DOI 10.1016/0042-6822(90)90230-O; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; Spivack SD, 2004, CANCER RES, V64, P6805, DOI 10.1158/0008-5472.CAN-04-1771; Steinman RM, 2003, CURR TOP MICROBIOL, V276, P1; SUGA T, 1991, INT J CANCER, V49, P764, DOI 10.1002/ijc.2910490522; Sutton RE, 1996, J VIROL, V70, P7322, DOI 10.1128/JVI.70.10.7322-7326.1996; Tailor CS, 1999, J VIROL, V73, P6500, DOI 10.1128/JVI.73.8.6500-6505.1999; Tailor CS, 2003, CURR TOP MICROBIOL, V281, P29; Tailor CS, 1999, J VIROL, V73, P4470, DOI 10.1128/JVI.73.5.4470-4474.1999; Tajima Y, 1997, SOMAT CELL MOLEC GEN, V23, P225, DOI 10.1007/BF02721374; Tanaka M, 2001, J VIROL, V75, P4420, DOI 10.1128/JVI.75.9.4420-4423.2001; Tangy F, 1999, J INFECT DIS, V179, P497, DOI 10.1086/314588; Trejo SR, 2000, VIROLOGY, V268, P41, DOI 10.1006/viro.2000.0143; Uchiyama T, 1996, J ACQ IMMUN DEF SYND, V13, pS114, DOI 10.1097/00042560-199600001-00019; VANZEIJL M, 1994, P NATL ACAD SCI USA, V91, P1168, DOI 10.1073/pnas.91.3.1168; Virgintino D, 1997, J SUBMICR CYTOL PATH, V29, P365; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Wielgosz MM, 2005, AIDS RES HUM RETROV, V21, P43, DOI 10.1089/aid.2005.21.43; YAMAMOTO N, 1982, NATURE, V299, P367, DOI 10.1038/299367a0; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467; Yamano Y, 2002, BLOOD, V99, P88, DOI 10.1182/blood.V99.1.88; Younes M, 1996, CANCER RES, V56, P1164; Zhao TM, 2002, AIDS RES HUM RETROV, V18, P253, DOI 10.1089/088922202753472829	127	57	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					6016	6025		10.1038/sj.onc.1208972	http://dx.doi.org/10.1038/sj.onc.1208972			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155608				2022-12-17	WOS:000231623400011
J	Besnault-Mascard, L; Leprince, C; Auffredou, MT; Meunier, B; Bourgeade, MF; Camonis, J; Lorenzo, HK; Vazquez, A				Besnault-Mascard, L; Leprince, C; Auffredou, MT; Meunier, B; Bourgeade, MF; Camonis, J; Lorenzo, HK; Vazquez, A			Caspase-8 sumoylation is associated with nuclear localization	ONCOGENE			English	Article						caspase; SUMO; nuclear localization; apoptosis; human	DEATH DOMAIN PROTEIN; SUMO-1 MODIFICATION; INDUCED APOPTOSIS; EFFECTOR DOMAIN; P53 ACTIVITY; C-JUN; ACTIVATION; CELLS; RECEPTORS; UBIQUITIN	The cysteine protease caspase-8 plays a pivotal role in the initiation of different apoptotic pathways and controls the maturation and differentiation of various cell types including neurons, fibroblasts and lymphocytes. Specific substrates of caspase-8 are present in both the cytoplasm and the nucleus, which may determine the ultimate biological effect of caspase-8. However, the mechanisms regulating the cellular localization of caspase-8 are still unknown. We show here that, in contrast to other caspases such as caspase-9 and -3, caspase-8 can be sumoylated at lysine 156. This sumoylation (i) is associated with the nuclear localization of caspase-8 and (ii) did not impair caspase-8 activation.	Hop Paul Brousse, INSERM, U542, F-94807 Villejuif, France; Inst Curie, INSERM 528, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Vazquez, A (corresponding author), Hop Paul Brousse, INSERM, U542, Batiment Lavoisier,14 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	vazquez@vjf.inserm.fr	Leprince, Corinne/M-7109-2018; Lorenzo, Hans-Kristian/GLR-5785-2022	Leprince, Corinne/0000-0002-4462-5737; Lorenzo, Hans Kristian/0000-0002-7921-177X				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Benchoua A, 2002, J BIOL CHEM, V277, P34217, DOI 10.1074/jbc.M203941200; Besnault L, 2001, J IMMUNOL, V167, P733, DOI 10.4049/jimmunol.167.2.733; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chatfield K, 2004, BIOCHEM BIOPH RES CO, V323, P1313, DOI 10.1016/j.bbrc.2004.09.003; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Gomez-Angelats M, 2003, CELL DEATH DIFFER, V10, P791, DOI 10.1038/sj.cdd.4401237; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Sheikh MS, 2003, CELL CYCLE, V2, P346, DOI 10.4161/cc.2.4.421; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265	42	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3268	3273		10.1038/sj.onc.1208448	http://dx.doi.org/10.1038/sj.onc.1208448			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15782135				2022-12-17	WOS:000228881800005
J	Zheng, YH; Yamaguchi, H; Tian, CJ; Lee, MW; Tang, H; Wang, HG; Chen, Q				Zheng, YH; Yamaguchi, H; Tian, CJ; Lee, MW; Tang, H; Wang, HG; Chen, Q			Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cells	ONCOGENE			English	Article						apoptosis; arsenic trioxide; Bax; mitochondria; reactive oxygen species	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; ACUTE PROMYELOCYTIC LEUKEMIA; DEPENDENT ANION CHANNEL; INDUCED CONFORMATIONAL-CHANGE; MITOCHONDRIAL-MEMBRANE; CASPASE ACTIVATION; BCL-2; PROTEIN; DEATH	This study explores the roles of Bax and other Bcl-2 family members play in arsenic trioxide (As2O3)-induced apoptosis. We showed that As2O3 treatment triggered Bax conformational change and subsequent translocation from cytosol to mitochondria to form various multimeric homo-oligomers in IM-9 cells. On the other hand, human leukemic Jurkat cells deficient in Bax showed dramatically reduced apoptosis in response to As2O3. Stable overexpression of Bcl-2 in IM-9 cells (IM-9/Bcl-2) inhibited As2O3-mediated Bax activation and apoptosis, and this inhibition could be partially averted by cell-permeable Bid-Bcl-2 homology (BH)3 peptide. Meanwhile, Bax conformational change and oligomerization induced by As2O3 were not inhibited by the pancaspase inhibitor z-VAD-fmk, although Bid cleavage could be completely abolished. Bax activation by As2O3 seemed to require stress-induced intracellular reactive oxygen species (ROS), since the ROS scavengers (N-acetyl-L-cysteine and lipoic acid) could completely block the conformational change and translocation of Bax from cytosol to mitochondria. These data suggest that As2O3 might exert the cell killing in part by inducing Bax activation through a Bcl-2-suppressible pathway in hematopoietic cells that is caspase independent and intracellular ROS regulated.	Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrene Biotechnol, Beijing 100080, Peoples R China; Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; Chinese Acad Sci, Ctr Mol Immunol, Inst Microbiol, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Zoology, CAS; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Chinese Academy of Sciences; Institute of Microbiology, CAS	Chen, Q (corresponding author), Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrene Biotechnol, Beijing 100080, Peoples R China.	chenq@ioz.ac.cn	yang, zheng/HGC-7753-2022; Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Chen, Quan/0000-0001-7539-8728	NCI NIH HHS [CA82197, CA90315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082197, R01CA090315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Akao Y, 1998, BRIT J HAEMATOL, V102, P1055, DOI 10.1046/j.1365-2141.1998.00869.x; Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Buccellato LJ, 2004, J BIOL CHEM, V279, P6753, DOI 10.1074/jbc.M310145200; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Doza YN, 1998, ONCOGENE, V17, P19, DOI 10.1038/sj.onc.1202168; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kirkland RA, 2002, J NEUROSCI, V22, P6480; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li YM, 1999, CANCER RES, V59, P776; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maeda H, 2004, CELL DEATH DIFFER, V11, P737, DOI 10.1038/sj.cdd.4401389; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Miller WH, 2002, CANCER RES, V62, P3893; Murphy KM, 2000, J BIOL CHEM, V275, P17225, DOI 10.1074/jbc.C900590199; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Priault M, 2003, CELL DEATH DIFFER, V10, P1068, DOI 10.1038/sj.cdd.4401270; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Roucou X, 2002, BIOCHEM J, V363, P547, DOI 10.1042/0264-6021:3630547; Rousselot P, 1999, CANCER RES, V59, P1041; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Woo SH, 2002, INT J ONCOL, V21, P57; Xia T, 2002, CHINESE SCI BULL, V47, P553, DOI 10.1360/02tb9127; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yamaguchi H, 2002, CANCER RES, V62, P466; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	60	57	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2005	24	20					3339	3347		10.1038/sj.onc.1208484	http://dx.doi.org/10.1038/sj.onc.1208484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	923AU	15735709				2022-12-17	WOS:000228881800012
J	Sengupta, S; Shimamoto, A; Koshiji, M; Pedeux, R; Rusin, M; Spillare, EA; Shen, JC; Huang, LE; Lindor, NM; Furuichi, Y; Harris, CC				Sengupta, S; Shimamoto, A; Koshiji, M; Pedeux, R; Rusin, M; Spillare, EA; Shen, JC; Huang, LE; Lindor, NM; Furuichi, Y; Harris, CC			Tumor suppressor p53 represses transcription of RECQ4 helicase	ONCOGENE			English	Article						repression; histone deacetylases; trichostatin A; Rothmund-Thomson syndrome; SP1; promoter	ROTHMUND-THOMSON-SYNDROME; WILD-TYPE P53; TATA-BINDING PROTEIN; CELL-CYCLE; FUNCTIONAL INTERACTION; HISTONE DEACETYLASE; REPLICATION FORKS; FAMILY HELICASES; GENE-EXPRESSION; BREAST-CANCER	RECQ4 is a member of the RecQ helicase family, which has been implicated in the regulation of DNAreplication, recombination and repair. p53 modulates the functions of RecQ helicases including BLM and WRN. In this study, we demonstrate that p53 can regulate the transcription of RECQ4. Using nontransformed, immortalized normal human fibroblasts, we show that p53-dependent downregulation of RECQ4 expression occurred in G1-arrested cells, both in the absence or presence of exogenous DNA damage. Wild-type p53 ( but not the tumor-derived mutant forms) repressed RECQ4 promoter activity. The camptothecin or etoposide-dependent p53-mediated repression was attenuated by trichostatin A (TSA), an inhibitor of histone deacetylases (HDACs). Repression of the RECQ4 promoter was accompanied with an increased accumulation of HDAC1, and the loss of SP1 and p53 binding to the promoter. The simultaneous formation of a camptothecin-dependent p53-SP1 complex indicated its occurrence outside of the RECQ4 promoter. These data suggest that p53-mediated repression of RECQ4 transcription during DNA damage results from the modulation of the promoter occupancy of transcription activators and repressors.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Gene Care Res Inst, Kamakura, Kanagawa, Japan; Mayo Clin, Dept Med Genet, Rochester, MN 55905 USA; Marie Sklodowska Curie Mem Inst, Ctr Oncol, Dept Tumor Biol, PL-44101 Gliwice, Poland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Maria Sklodowska-Curie National Research Institute of Oncology	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Room 3068, Bethesda, MD 20892 USA.	Curtis_Harris@nih.gov	PEDEUX, Rémy M/I-2603-2014; Sengupta, Sagar/AGR-1063-2022	PEDEUX, Rémy M/0000-0002-2553-7934; Sengupta, Sagar/0000-0002-6365-1770; Huang, Eric/0000-0002-6444-1708; Rusin, Marek/0000-0002-0143-9192	NATIONAL CANCER INSTITUTE [Z01BC005795, ZIABC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Davalos AR, 2003, J CELL BIOL, V162, P1197, DOI 10.1083/jcb.200304016; DROUIN CA, 1993, J AM ACAD DERMATOL, V28, P301, DOI 10.1016/0190-9622(93)70040-Z; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ElKhoury JM, 1997, BRIT J RADIOL, V70, P215, DOI 10.1259/bjr.70.830.9135453; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Fuchs B, 2002, CLIN ORTHOP RELAT R, P40; Furuichi Y, 2001, ANN NY ACAD SCI, V928, P121; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hoki Y, 2003, HUM MOL GENET, V12, P2293, DOI 10.1093/hmg/ddg254; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kawabe T, 2000, ONCOGENE, V19, P4764, DOI 10.1038/sj.onc.1203841; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Pal S, 2001, CANCER RES, V61, P6952; PERREM K, 1995, ONCOGENE, V11, P1299; PuvionDutilleul F, 1997, GENE EXPRESSION, V6, P315; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shimamoto Akira, 2004, Int J Clin Oncol, V9, P288, DOI 10.1007/s10147-004-0426-0; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; VENNOS EM, 1995, DERMATOL CLIN, V13, P143, DOI 10.1016/S0733-8635(18)30117-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LL, 2003, J NATL CANCER I, V95, P669, DOI 10.1093/jnci/95.9.669; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Webster NJG, 1996, CANCER RES, V56, P2781; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhao RB, 2000, GENE DEV, V14, P981	66	57	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1738	1748		10.1038/sj.onc.1208380	http://dx.doi.org/10.1038/sj.onc.1208380			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674334				2022-12-17	WOS:000227345100010
J	Corcoran, CA; He, Q; Huang, Y; Sheikh, MS				Corcoran, CA; He, Q; Huang, Y; Sheikh, MS			Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis	ONCOGENE			English	Article						p53; COX-2; NSAIDs; transcription; apoptosis	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GENE-EXPRESSION; CANCER-CELLS; HUMAN FIBROBLASTS; GENOTOXIC STRESS; HUMAN COLON; DEATH; LOCALIZATION; INHIBITION; SYNTHASE-2	Cyclooxygenase-2 (COX-2) has been implicated in a variety of human malignancies and, accordingly, COX-2 selective inhibitors are being investigated as important chemopreventive and therapeutic agents. How COX-2 overexpression results in tumorigenesis and how COX-2 selective agents mediate their chemopreventive effects are issues that remain poorly understood. Here we report that the tumor suppressor p53 upregulates COX-2 expression and that COX-2 can in turn inhibit p53-dependent transcription. Additionally, a COX-2-selective inhibitor potentiates p53-induced apoptosis, which also supports the notion that COX-2 activity appears to interfere with p53 function. Expression of exogenous COX-2 in p53 wildtype cells does not affect the cytoplasmic or nuclear levels of p53, suggesting that COX-2 may not affect p53 turnover or subcellular localization. We further demonstrate that endogenous COX-2 interacts with p53 and that COX-2 and p53 interactions are a physiologically relevant event. Thus, p53 upregulates COX-2 and COX-2 in turn appears to negatively affect p53 activity via mechanisms that could involve physical interactions between COX-2 and p53. Based on our results, we propose that p53-dependent upregulation and activation of COX-2 appear to be yet another novel mechanism by which p53 could abate its own growth-inhibitory and apoptotic effects.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA.	sheikhm@upstate.edu			NCI NIH HHS [CA086945, CA105300] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086945, R03CA105300] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Corcoran CA, 2004, CANCER BIOL THER, V3, P721, DOI 10.4161/cbt.3.8.1068; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Gallo O, 2003, AM J PATHOL, V163, P723, DOI 10.1016/S0002-9440(10)63699-1; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grewal S, 2003, J CELL SCI, V116, P2303, DOI 10.1242/jcs.00446; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Huang Y, 2001, CANCER RES, V61, P6918; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008-5472.CAN-03-2396; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Liou JY, 2001, J BIOL CHEM, V276, P34975, DOI 10.1074/jbc.M105946200; Lloyd DR, 2002, CANCER RES, V62, P5288; Luo XQ, 2003, ONCOGENE, V22, P7247, DOI 10.1038/sj.onc.1207010; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Seo YR, 2002, ONCOGENE, V21, P731, DOI 10.1038/sj.onc.1205129; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, CANCER RES, V58, P1593; Shureiqi I, 2001, CANCER RES, V61, P4879; Smigel K, 2000, J NATL CANCER I, V92, P297, DOI 10.1093/jnci/92.4.297; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Swamy MV, 2003, CANCER RES, V63, P5239; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	35	57	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1634	1640		10.1038/sj.onc.1208353	http://dx.doi.org/10.1038/sj.onc.1208353			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15608668				2022-12-17	WOS:000227218200017
J	Gery, S; Tanosaki, S; Hofmann, WK; Koppel, A; Koeffler, HP				Gery, S; Tanosaki, S; Hofmann, WK; Koppel, A; Koeffler, HP			C/EBP delta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation	ONCOGENE			English	Article						C/EBP delta; BCR-ABL; granulocytic differentiation	CCAAT/ENHANCER-BINDING PROTEINS; CHRONIC MYELOCYTIC-LEUKEMIA; C-MYC; TRANSCRIPTION-FACTOR; ADIPOCYTE DIFFERENTIATION; HEMATOPOIETIC-CELLS; ALPHA EXPRESSION; CYCLIN-E; GENE; EPSILON	CCAAT/enhancer-binding proteins (C/EBPs) are a family of highly conserved transcription factors that have important roles in normal myelopoiesis as well as associated with myeloid disorders. The chronic myelogenous leukemia (CML) cell lines, KCL22 and K562, express exceptionally low levels of endogenous C/EBPs and provide a good model to test the effects of C/EBPs on myeloid differentiation. To explore the possibility that C/EBPdelta can promote differentiation in BCR-ABL-positive cells, we generated stable KCL22 and K562 clones that expressed an inducible C/EBPdelta gene. C/EBPdelta expression resulted in G0/G1 proliferative arrest and a moderate increase in apoptosis of the KCL22 and the K562 cells. Within 4 days of inducing expression of C/EBPdelta, myeloid differentiation of the CML blast cells occurred as shown by morphologic changes and induction of secondary granule-specific genes. We also showed that during granulocytic differentiation of KCL22 cells, the C/EBPdelta protein was detected in immunocomplexes with both Rb and E2F1. Furthermore, expression of C/EBPdelta was associated with downregulation of c-Myc and cyclin E and upregulation of the cyclin-dependent kinase inhibitor p27(Kip1) in both the KCL22 and K562 cell lines. These results show that expression of C/EBPdelta in BCR-ABL-positive leukemic cells in blast crisis is sufficient for neutrophil differentiation and point to the therapeutic potential of ectopic induction of C/EBPdelta in the acute phase of CML.	Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Gery, S (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Cedars Sinai Med Ctr, Davis Bldg 5066,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	gerys@cshs.org						AHUJA H, 1991, J CLIN INVEST, V87, P2042, DOI 10.1172/JCI115234; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Billiard J, 2001, J BIOL CHEM, V276, P15354, DOI 10.1074/jbc.M009973200; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gery S, 2004, BLOOD, V103, P828, DOI 10.1182/blood-2003-01-0159; Gheorghiu I, 2001, J BIOL CHEM, V276, P44331, DOI 10.1074/jbc.M107591200; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kubota T, 2001, LEUKEMIA RES, V25, P981, DOI 10.1016/S0145-2126(01)00065-0; Mori N, 1997, BLOOD, V90, P2010, DOI 10.1182/blood.V90.5.2010; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; SCOTT LM, 1992, BLOOD, V80, P1725; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tavor S, 2003, J BIOL CHEM, V278, P52651, DOI 10.1074/jbc.M307077200; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; Vegesna VA, 2002, LEUKEMIA RES, V26, P451, DOI 10.1016/S0145-2126(01)00150-3; Verbeek W, 1999, BLOOD, V93, P3327, DOI 10.1182/blood.V93.10.3327; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Yamanaka R, 1998, INT J MOL MED, V1, P213; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	38	57	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2005	24	9					1589	1597		10.1038/sj.onc.1208393	http://dx.doi.org/10.1038/sj.onc.1208393			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674331				2022-12-17	WOS:000227218200012
J	Hanson, S; Kim, E; Deppert, W				Hanson, S; Kim, E; Deppert, W			Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization	ONCOGENE			English	Article						redox factor 1; p53 DNA binding; p53 oligomerization	TUMOR-SUPPRESSOR P53; BASE EXCISION-REPAIR; WILD-TYPE P53; OLIGOMERIZATION DOMAIN; ACTIVATION; PROTEIN; CONFORMATION; TRANSACTIVATION; IDENTIFICATION; DIMERIZATION	Sequence-specific DNA binding is a major activity of the tumor suppressor p53 and a prerequisite for the transactivating potential of the protein. p53 interaction with target DNA is tightly regulated by various mechanisms, including binding of different components of the transcription machinery, post-translational modifications, and interactions with other factors that modulate p53 transactivation in a cell context-and promoter-specific manner. The bifunctional redox factor 1 (Ref-1/APE1) has been identified as one of the factors, which can stimulate p53 DNA binding by redox-dependent as well as redox-independent mechanisms. Whereas stimulation of p53 DNA binding by the redox activities of Ref-1 is understood quite well, little is known about mechanisms that underlie the redox-independent effects of Ref-1. We report in this study a previously unknown activity of Ref-1 as a factor promoting tetramerization of p53. We demonstrate that Ref-1 promotes association of dimers into tetramers, and de-stacking of higher oligomeric forms into the tetrameric form in vitro, thereby enhancing p53 binding to target DNA.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Deppert, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fritz G, 2003, TOXICOLOGY, V193, P67, DOI 10.1016/S0300-483X(03)00290-7; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; HAINAUT P, 1993, CANCER RES, V53, P4469; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Janus F, 1999, MOL CELL BIOL, V19, P2155; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; McCoy M, 1997, EMBO J, V16, P6230, DOI 10.1093/emboj/16.20.6230; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; Nourani A, 2003, J BIOL CHEM, V278, P19171, DOI 10.1074/jbc.C300036200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Tan ZQ, 2002, BRAIN RES, V929, P129, DOI 10.1016/S0006-8993(01)03360-1; Tom S, 2001, J BIOL CHEM, V276, P48781, DOI 10.1074/jbc.M109626200; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG Y, 1995, MOL CELL BIOL, V15, P2157; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Wolcke J, 2003, J BIOL CHEM, V278, P32587, DOI 10.1074/jbc.M303615200; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yakovleva T, 2002, TRENDS BIOCHEM SCI, V27, P612, DOI 10.1016/S0968-0004(02)02209-0; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	38	57	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1641	1647		10.1038/sj.onc.1208351	http://dx.doi.org/10.1038/sj.onc.1208351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674341				2022-12-17	WOS:000227218200018
J	Swarbrick, A; Akerfeldt, MC; Lee, CSL; Sergio, CM; Caldon, CE; Hunter, LJK; Sutherland, RL; Musgrove, EA				Swarbrick, A; Akerfeldt, MC; Lee, CSL; Sergio, CM; Caldon, CE; Hunter, LJK; Sutherland, RL; Musgrove, EA			Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1	ONCOGENE			English	Article						cell cycle; Id1; breast cancer	CANCER-CELLS; C-MYC; TRANSCRIPTIONAL REPRESSION; G(1) PROGRESSION; GENE-EXPRESSION; ID-1; ESTROGEN; GROWTH; D1; DIFFERENTIATION	The helix-loop-helix protein Id1 has been implicated in regulating mammary epithelial cell proliferation and differentiation but the underlying molecular mechanisms are not well characterized. Under low serum conditions, ectopic expression of Id1, but not Id2, allowed continued proliferation of immortalized mammary epithelial cells and breast cancer cells. Conversely, downregulation of Id1 impaired proliferation. The effects of short interfering RNA (siRNA)-mediated downregulation of Id1 were the same as those following downregulation of c-Myc: decreased expression of cyclins D1 and E, reduced phosphorylation of pRb at Ser780 ( a site targeted by cyclin D1-Cdk4) and reduced cyclin E-Cdk2 activity. Decreased cyclin D1 expression was an early response to Id1 antisense oligonucleotide treatment. Inhibition of c-Myc function by siRNA, antisense oligonucleotides or a dominant repressor resulted in downregulation of Id1, while ectopic expression of c-Myc resulted in rapid induction of Id1, suggesting that Id1 may be downstream of c-Myc. These data indicate that in mammary epithelial cells, Id1 has cell cycle regulatory functions that are similar to those of c-Myc, and suggest that cyclin D1 may be involved in Id1 regulation of cell cycle progression.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Musgrove, EA (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	e.musgrove@garvan.org.au	Caldon, Liz/C-1559-2009; Sutherland, Robert L/A-8378-2008; Swarbrick, Alexander/E-6107-2010	Caldon, Liz/0000-0003-1392-3472; Swarbrick, Alexander/0000-0002-3051-5676				Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carroll JS, 2002, CANCER RES, V62, P3126; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; Desprez PY, 2003, J MAMMARY GLAND BIOL, V8, P225, DOI 10.1023/A:1025957025773; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DUBIK D, 1987, CANCER RES, V47, P6517; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Guan XY, 1996, CANCER RES, V56, P3446; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARA E, 1994, J BIOL CHEM, V269, P2139; Holmes ML, 1999, MOL CELL BIOL, V19, P4182; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Itahana Y, 2003, CANCER RES, V63, P7098; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Lin CQ, 2000, CANCER RES, V60, P1332; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Miyoshi K, 2002, MOL ENDOCRINOL, V16, P2892, DOI 10.1210/me.2002-0128; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Musgrove EA, 2001, J BIOL CHEM, V276, P47675, DOI 10.1074/jbc.M106371200; MUSGROVE EA, 1995, INT J CANCER, V63, P584, DOI 10.1002/ijc.2910630420; Norton JD, 2000, J CELL SCI, V113, P3897; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prall OWJ, 1998, MOL CELL BIOL, V18, P4499, DOI 10.1128/MCB.18.8.4499; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Sutherland RL, 1998, J MAMMARY GLAND BIOL, V3, P63, DOI 10.1023/A:1018774302092; Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000; Tanner MM, 1996, CANCER RES, V56, P3441; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tournay O, 1996, MOL CELL BIOL, V16, P2418; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WATSON PH, 1991, CANCER RES, V51, P3996; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968	51	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					381	389		10.1038/sj.onc.1208188	http://dx.doi.org/10.1038/sj.onc.1208188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15489884				2022-12-17	WOS:000226279700009
J	Killian, A; Le Meur, N; Sesboue, R; Bourguignon, J; Bougeard, G; Gautherot, J; Bastard, C; Frebourg, T; Flaman, JM				Killian, A; Le Meur, N; Sesboue, R; Bourguignon, J; Bougeard, G; Gautherot, J; Bastard, C; Frebourg, T; Flaman, JM			Inactivation of the RRB1-Pescadillo pathway involved in ribosome biogenesis induces chromosomal instability	ONCOGENE			English	Article						cell cycle; chromosomal instability; mitosis; ribosome; yeast	CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; DYSKERATOSIS-CONGENITA; DNA-REPLICATION; HUMAN CANCERS; PROTEIN; GENE; CHECKPOINT; PROLIFERATION; MUTATIONS	Since chromosomal instability (CIN) is a hallmark of most cancer cells, it is essential to identify genes whose alteration results into this genetic instability. Using a yeast CIN indicator strain, we show that inactivation of the YMR131c/RRB1 gene, which is involved in early ribosome assembly and whose expression is induced when the spindle checkpoint is activated, alters chromosome segregation and blocks mitosis at the metaphase/anaphase transition. We demonstrate that RRB1 interacts with YPH1 (yeast pescadillo homologue 1) and other members of the Yph1 complex, RPL3, ERB1 and ORC6, involved in ribosome biogenesis and DNA replication. Transient depletion of the human homologues GRWD, Pescadillo, Rp13, Bop1 and Orc6L resulted in an increase of abnormal mitoses with appearance of binucleate or hyperploid cells, of cells with multipolar spindles and of aberrant metaphase plates. If deregulation of proteins involved in ribosome biogenesis, commonly observed in malignant tumors, could contribute to cancer through an aberrant protein synthesis, our study demonstrates that alteration of proteins linking ribosome biogenesis and DNA replication may directly cause CIN.	INSERM, U614, IFRMP, Fac Med, F-76183 Rouen, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Frebourg, T (corresponding author), INSERM, U614, IFRMP, Fac Med, 22 Blvd Gambetta, F-76183 Rouen, France.	Thierry.Frebourg@chu-rouen.fr	Flaman, Jean-Michel/K-8415-2018; BOUGEARD, Gaëlle/ABI-6642-2020; Frebourg, Thierry/AAK-8390-2020	Flaman, Jean-Michel/0000-0003-3544-0199; BOUGEARD, Gaëlle/0000-0002-1475-0254; 				Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bergoglio V, 2002, CANCER RES, V62, P3511; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DOKAL I, 1994, LEUKEMIA LYMPHOMA, V15, P1, DOI 10.3109/10428199409051671; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Iouk TL, 2001, MOL CELL BIOL, V21, P1260, DOI 10.1128/MCB.21.4.1260-1271.2001; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Mailand N, 2002, NAT CELL BIOL, V4, P317, DOI 10.1038/ncb777; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nomoto S, 1999, ONCOGENE, V18, P7180, DOI 10.1038/sj.onc.1203141; Prasanth SG, 2002, SCIENCE, V297, P1026, DOI 10.1126/science.1072802; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schaper S, 2001, CURR BIOL, V11, P1885, DOI 10.1016/S0960-9822(01)00584-X; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sigrist Christian J A, 2002, Brief Bioinform, V3, P265, DOI 10.1093/bib/3.3.265; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	34	57	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8597	8602		10.1038/sj.onc.1207845	http://dx.doi.org/10.1038/sj.onc.1207845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467761				2022-12-17	WOS:000224988800005
J	Gourdier, I; Crabbe, L; Andreau, K; Pau, B; Kroemer, G				Gourdier, I; Crabbe, L; Andreau, K; Pau, B; Kroemer, G			Oxaliplatin-induced mitochondrial apoptotic response of colon carcinoma cells does not require nuclear DNA	ONCOGENE			English	Article						oxaliplatin; p53; Bak; Bax; cytoplasts	IN-VITRO; BAX; CISPLATIN; CANCER; P53; CHEMOTHERAPY; PHARMACOLOGY; RESISTANCE; PROTEIN; ABSENCE	We previously established a model of acquired oxaliplatin resistance derived from the HCT116 oxaliplatin-sensitive cell line (HCT116S) and consisting in two resistant clones (HCT116R1, HCT116R2) and their total or partial revertants (HCT116Rev1 and HCT116Rev2, respectively). Using this cellular model, we explored the contribution of mitochondrial apoptosis and nuclear DNA to oxaliplatin-mediated apoptosis induction and oxaliplatin resistance. We showed that the activity of oxaliplatin is mediated by the induction of Bax/Bak-dependent mitochondrial apoptosis and that oxaliplatin resistance is mediated by a defect in Bax/Bak activation correlating with a reduced loss of the mitochondrial transmembrane potential (DeltaPsi(m)). In addition, we observed that p53 only contributed marginally to oxaliplatin-induced cytotoxicity and was not involved in oxaliplatin resistance. Moreover and surprisingly, depletion of the nucleus in HCT116S cells did not abolish the oxaliplatin-induced DeltaPsi(m) loss indicative of imminent apoptosis. Enucleation abolished the oxaliplatin resistance of HCT116R1 cells, while HCT116R2 cytoplasts conserved their resistant phenotype. Altogether, these data demonstrate that oxaliplatin exerts its cytotoxic effects by inducing mitochondrial apoptosis and that these effects can be initiated by interacting on other cellular structures than nuclear DNA. Resistance to oxaliplatin may imply both nuclear and cytoplasmic compartments.	Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; Inst Pasteur, Paris, France; CNRS, UMR 5160, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Crabbé, Laure/P-8955-2014	KROEMER, Guido/0000-0002-9334-4405; Crabbé, Laure/0000-0001-7764-3600; Andreau, Karine/0000-0002-9773-0733				Boulikas T, 2003, ONCOL REP, V10, P1663; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Castedo M, 1996, J IMMUNOL, V157, P512; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; ElAkawi Z, 1996, CANCER LETT, V105, P5, DOI 10.1016/0304-3835(96)04245-0; Fink D, 1997, CANCER RES, V57, P1841; Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hector S, 2001, CANCER CHEMOTH PHARM, V48, P398, DOI 10.1007/s002800100363; Ibrahim A, 2004, ONCOLOGIST, V9, P8, DOI 10.1634/theoncologist.9-1-8; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; Kollmannsberger C, 2004, J CLIN ONCOL, V22, P108, DOI 10.1200/JCO.2004.06.068; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Mishima M, 2002, EUR J CANCER, V38, P1405, DOI 10.1016/S0959-8049(02)00096-5; Misset JL, 2000, CRIT REV ONCOL HEMAT, V35, P75, DOI 10.1016/S1040-8428(00)00070-6; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Raymond E, 2002, MOL CANCER THER, V1, P227; Reardon JT, 1999, CANCER RES, V59, P3968; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Vekris A, 2004, CANCER RES, V64, P356, DOI 10.1158/0008-5472.CAN-03-2258; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920; WOYNAROWSKI JM, 1998, MOL PHARM, V54, P1998; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	31	57	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7449	7457		10.1038/sj.onc.1208047	http://dx.doi.org/10.1038/sj.onc.1208047			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334062				2022-12-17	WOS:000224176500001
J	Huang, CL; Liu, DG; Masuya, D; Kameyama, K; Nakashima, T; Yokomise, H; Ueno, M; Miyake, M				Huang, CL; Liu, DG; Masuya, D; Kameyama, K; Nakashima, T; Yokomise, H; Ueno, M; Miyake, M			MRP-1/CD9 gene transduction downregulates Wnt signal pathways	ONCOGENE			English	Article						MRP-1/CD9; Wnt; microarray; real-time PCR	ENDOTHELIAL GROWTH-FACTOR; CELL MOTILITY; BREAST-CANCER; UP-REGULATION; CYCLIN D1; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; MATRIX METALLOPROTEINASE-26; EPITHELIAL ORIGIN; COLON-CARCINOMA	Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/ CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/ CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.	Kagawa Univ, Fac Med, Dept Surg 2, Miki, Kagawa 7610793, Japan; Kagawa Univ, Fac Med, Dept Pathol & Host Def, Kagawa 7610793, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Osaka 5308480, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 5308480, Japan	Kagawa University; Kagawa University; Kitano Hospital; Kitano Hospital	Huang, CL (corresponding author), Kagawa Univ, Fac Med, Dept Surg 2, 1750-1, Miki, Kagawa 7610793, Japan.	chuang@kms.ac.jp						Adachi M, 1998, J CLIN ONCOL, V16, P1060, DOI 10.1200/JCO.1998.16.3.1060; Aoyama K, 1999, BLOOD, V93, P2586, DOI 10.1182/blood.V93.8.2586.408k23_2586_2594; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dale TC, 1998, BIOCHEM J, V329, P209; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; Desnoyers L, 2001, J BIOL CHEM, V276, P47599, DOI 10.1074/jbc.M108339200; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Gutierrez-Lopez MD, 2003, J BIOL CHEM, V278, P208, DOI 10.1074/jbc.M207805200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Katoh M, 2003, INT J MOL MED, V12, P811; Katoh M, 2003, INT J ONCOL, V22, P209; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kleer CG, 2002, ONCOGENE, V21, P3172, DOI 10.1038/sj.onc.1205462; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Masuya D, 2001, CANCER, V92, P2628, DOI 10.1002/1097-0142(20011115)92:10<2628::AID-CNCR1616>3.0.CO;2-F; Mine S, 2003, EXP CELL RES, V288, P189, DOI 10.1016/S0014-4827(03)00184-8; MITCHELL CE, 1995, ANAL BIOCHEM, V224, P148, DOI 10.1006/abio.1995.1020; Miyake M, 2000, ONCOGENE, V19, P5221, DOI 10.1038/sj.onc.1203919; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyazaki YJ, 2002, ONCOGENE, V21, P798, DOI 10.1038/sj.onc.1205126; Mori M, 1998, CLIN CANCER RES, V4, P1507; Park KR, 2000, MOL HUM REPROD, V6, P719, DOI 10.1093/molehr/6.8.719; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Ricken A, 2002, ENDOCRINOLOGY, V143, P2741, DOI 10.1210/en.143.7.2741; Ridley AJ, 2001, J CELL SCI, V114, P2713; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Saitoh T, 2002, INT J MOL MED, V9, P515; Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Uria JA, 2000, CANCER RES, V60, P4745; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Xie D, 2001, CANCER RES, V61, P8917; Xu LF, 2000, GENE DEV, V14, P585; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Zhang XB, 2001, CANCER RES, V61, P6050	50	57	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	2004	23	45					7475	7483		10.1038/sj.onc.1208063	http://dx.doi.org/10.1038/sj.onc.1208063			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334057				2022-12-17	WOS:000224176500004
J	Park, SS; Eom, YW; Kim, EH; Lee, JH; Min, DS; Kim, S; Kim, SJ; Choi, KS				Park, SS; Eom, YW; Kim, EH; Lee, JH; Min, DS; Kim, S; Kim, SJ; Choi, KS			Involvement of c-Src kinase in the regulation of TGF-beta 1-induced apoptosis	ONCOGENE			English	Article						TGF-beta 1; apoptosis; c-Src; hepatocellular carcinoma; caspases	FOCAL ADHESION KINASE; GROWTH-FACTOR-BETA; HUMAN HEPATOCELLULAR-CARCINOMA; FAO HEPATOMA-CELLS; TGF-BETA; TYROSINE KINASES; BINDING-SITE; II RECEPTOR; ACTIVATION; SMAD2	Transforming growth factor-beta1 (TGF-beta1) is a potent inducer of apoptosis in normal hepatocytes, and acquiring resistance to TGF-beta1 may be a critical step in the development of hepatocellular carcinoma (HCC). In this study, we investigated the possible involvement of c-Src in the regulation of TGF-beta1-induced apoptosis. TGF-beta1 induced transient activation of c-Src and its subsequent caspase-mediated degradation concomitant with cell death in FaO hepatoma cells, which are sensitive to TGF-beta1. In response to TGF-beta1, activated c-Src was translocated into the cytoplasmic membrane, then relocated to the nuclei of apoptotic cells during its cleavage. In TGF-beta1-induced apoptotic cells, c-Src maintained its tight association with p85 FAK fragment cleaved by caspases, possibly contributing to focal adhesion disassembly. TGF-beta1-induced apoptosis was enhanced by either inhibition of c-Src activity using PP1 or PP2, or by overexpression of dominant-negative c-Src. In contrast, overexpression of constitutively active c-Src inhibited apoptosis suppressing TGF-beta1-induced activation of p38, JNK and caspases. In many HCC cell lines resistant to TGF-beta1, enhanced c-Src activity was detected. We hypothesize that activated c-Src in HCC may contribute to resistance against the apoptotic and/or antiproliferative properties of TGF-beta1.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul, South Korea; LG Life Sci, Taejon, South Korea; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA	Ajou University; Catholic University of Korea; LG Life Sciences Ltd; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, 5 Wonchon Dong, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Eom, Young/AAW-4659-2021; Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Eom, Young Woo/0000-0002-5985-6490; Choi, Kyeong Sook/0000-0003-2331-0856	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Choi KS, 1998, HEPATOLOGY, V27, P415, DOI 10.1002/hep.510270215; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Crouch DH, 1996, ONCOGENE, V12, P2689; DECAESTECKER MP, 2000, J NATL CANCER I, V92, P555; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; ITO N, 1991, CANCER RES, V51, P4080; Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0; Jones RJ, 2000, EUR J CANCER, V36, P1595, DOI 10.1016/S0959-8049(00)00153-2; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; Kanamaru C, 2002, HEPATOL RES, V23, P211, DOI 10.1016/S1386-6346(01)00175-9; Kawate S, 1999, INT J ONCOL, V14, P127; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Lee JH, 1999, WORLD J GASTROENTERO, V5, P289; Lobo M, 2000, BIOCHEM BIOPH RES CO, V276, P1068, DOI 10.1006/bbrc.2000.3547; Masaki T, 1999, HEPATOLOGY, V29, P379, DOI 10.1002/hep.510290239; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; PARK JG, 1995, INT J CANCER, V62, P276, DOI 10.1002/ijc.2910620308; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Song K, 2003, J BIOL CHEM, V278, P38342, DOI 10.1074/jbc.M304583200; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866	36	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2004	23	37					6272	6281		10.1038/sj.onc.1207856	http://dx.doi.org/10.1038/sj.onc.1207856			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	847NC	15208664				2022-12-17	WOS:000223399000011
J	Tonini, T; Bagella, L; D'Andrilli, G; Claudio, PP; Giordano, A				Tonini, T; Bagella, L; D'Andrilli, G; Claudio, PP; Giordano, A			Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A	ONCOGENE			English	Article						polycomb; Ezh2; pRb2/p130	POLYCOMB-GROUP PROTEINS; RETINOBLASTOMA FAMILY PROTEINS; CDK2 KINASE; GROUP GENES; EXPRESSION; BMI-1; P107; PROLIFERATION; CLONING; DIFFERENTIATION	The polycomb group (PcG) proteins are known to be involved in maintaining the silenced state of several developmentally regulated genes. Enhancer of zeste homolog 2 (Ezh2), a member of this large protein family, has also been shown to be deregulated in different tumor types and its role, both as a potential primary effector and as a mediator of tumorigenesis, has become a subject of increased interest. We observed that Ezh2 binds to pRb2/p130, a member of the retinoblastoma family; as such, we were led to consider the possible ability of Ezh2 to modulate cell cycle progression. Both Ezh2 and pRb2/p130 repress gene expression by recruiting histone deacetylase (HDAC1), which decreases DNA accessibility for activating transcription factors. Additionally, we observed that Ezh2 interacts with the C-terminal region of pRb2/p130, essential for interaction with HDAC1. We show that Ezh2 is able to reverse pRb2/p130-HDAC1-mediated repression of the cyclin A promoter. This indicates a functional role of this complex in regulating cyclin A expression, known to be crucial in mediating cell cycle advancement. We also detected a significant decrease in the retention of HDAC1 activity associated with pRb2/p130 when Ezh2 was overexpressed. Finally, electromobility shift assays ( EMSA) demonstrated that overexpression of Ezh2 caused the abrogation of the pRb2/p130-HDAC1 complex on the cyclin A promoter. These data, taken together, suggest that Ezh2 competes with HDAC1 in binding to pRb2/p130, disrupting their occupancy on the cyclin A promoter. In this study, we propose a new mechanism for the functional inactivation of pRb2/p130 that ultimately contributes to cell cycle progression and malignant transformation.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Siena, Policlin La Scotte, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Dept Sci Odontostomatol & Maxillo Facciali, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Bio Life Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Claudio, Pier Paolo/AAW-7282-2021; Giordano, Antonio/F-1927-2010	Claudio, Pier Paolo/0000-0001-7790-1622; Giordano, Antonio/0000-0002-5959-016X; BAGELLA, Luigi/0000-0003-2815-037X				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Macaluso M, 2003, ONCOGENE, V22, P6472, DOI 10.1038/sj.onc.1206955; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MAYOL X, 1993, ONCOGENE, V8, P2561; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; Pupa SM, 1999, ONCOGENE, V18, P651, DOI 10.1038/sj.onc.1202363; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Raschella G, 1998, CELL DEATH DIFFER, V5, P401, DOI 10.1038/sj.cdd.4400359; Raschella G, 2001, MED PEDIATR ONCOL, V36, P104, DOI 10.1002/1096-911X(20010101)36:1<104::AID-MPO1024>3.0.CO;2-9; Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661; Sanseverino F, 2003, CANCER BIOL THER, V2, P636; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; Stiegler P, 1998, CANCER RES, V58, P5049; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Tonini T, 2002, J CELL PHYSIOL, V192, P138, DOI 10.1002/jcp.10117; TURNER BM, 1991, J CELL SCI, V99, P13; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x	56	57	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4930	4937		10.1038/sj.onc.1207608	http://dx.doi.org/10.1038/sj.onc.1207608			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15077161				2022-12-17	WOS:000222104200014
J	Brignone, C; Bradley, KE; Kisselev, AF; Grossman, SR				Brignone, C; Bradley, KE; Kisselev, AF; Grossman, SR			A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway	ONCOGENE			English	Article						p53; hHR23; Rad23; MDM2; proteasome; ubiquitin	DNA-REPAIR; UBA DOMAINS; PROTEASOME; PROTEIN; RAD23; BINDING; PROMOTES; SUBUNIT; STABILITY; INTERACT	Abrogation of ubiquitin/proteasome-dependent turnover of p53 is critical for its activation. UbL-UBA proteins, including human homolog of Rad23 (hHR23) proteins, may regulate proteasomal degradation of substrates such as p53, due to their ability to interact with both ubiquitinated substrates and the proteasome. siRNA-mediated depletion of hHR23A or hHR23B in human cell lines accelerated p53 degradation. In contrast, overexpression of hHR23 proteins led to the accumulation of ubiquitinated p53, and purified hHR23 proteins also blocked p53 proteasome degradation in vitro. An hHR23-MDM2 complex was identified, suggesting that MDM2 and hHR23 cooperate in the regulation of p53 proteasome degradation. Consistent with this hypothesis, an MDM2 mutant that demonstrated increased binding in vivo to hHR23A was able to ubiquitinate, but not degrade p53. Moreover, the defective phenotype of this MDM2 mutant was rescued by siRNA knockdown of hHR23A. Our data indicate that MDM2 acts at a step in the p53 degradation pathway after ubiquitination, to counteract hHR23 inhibition of p53 turnover. Moreover, our data suggest the possibility that ubiquitin ligase/UbL-UBA protein complexes, as exemplified by the MDM2/hHR23 complex, may serve a general role in regulating substrate degradation by the proteasome.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Grossman, SR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA.	steven.grossman@umassmed.edu			NCI NIH HHS [R01 CA107532-01, R01 CA107532] Funding Source: Medline; NIGMS NIH HHS [GM46147-10, GM51923-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147, R01GM051923] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Kisselev AF, 2002, J BIOL CHEM, V277, P22260, DOI 10.1074/jbc.M112360200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Lambertson D, 1999, GENETICS, V153, P69; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEI X, 2003, J BIOL CHEM; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Zhu QZ, 2001, CANCER RES, V61, P64; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	25	57	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4121	4129		10.1038/sj.onc.1207540	http://dx.doi.org/10.1038/sj.onc.1207540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064742				2022-12-17	WOS:000221520200010
J	Obad, S; Brunnstrom, H; Vallon-Christersson, J; Borg, A; Drott, K; Gullberg, U				Obad, S; Brunnstrom, H; Vallon-Christersson, J; Borg, A; Drott, K; Gullberg, U			Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells	ONCOGENE			English	Article						p53; Staf50; transcriptional target	WILD-TYPE P53; INTERFERON-ALPHA/BETA; TUMOR SUPPRESSION; DIFFERENTIATION; EXPRESSION; INDUCTION; FAMILY; P73; APOPTOSIS; RECEPTOR	The tumor suppressor gene p53 is a transcription factor that mediates both cell cycle arrest and apoptosis. Interestingly, p53 also induces differentiation of a number of tissues, including leukemic cells. However, although p53-mediated differentiation of leukemic U-937 cells depends on the transcriptional activity of p53, a p53 target gene mediating differentiation has hitherto not been identified. To screen for novel p53 target genes in leukemic cells, a cDNA microarray analysis was performed with U-937-4/ptsp53 cells, expressing a temperature-sensitive p53 mutant. We report that transcription of the Staf50 ( stimulated transacting factor of 50 kDa) gene is upregulated in response to wild-type p53 in U-937-4, K562 and MCF-7 cells. Staf50 was directly activated by p53, as determined by the independence of de novo protein synthesis. Moreover, while the proximal promoter of Staf50 was found not to be p53 responsive, a functional enhancer-like p53-response element in intron 1 of the Staf50 gene was identified that was also transactivated by the p53-family member p73. Direct binding of p53 to the response element was shown by electrophoretic mobility shift analysis. Ectopic expression of Staf50 in U-937 cells resulted in reduced clonogenic growth. Moreover, levels of endogenous Staf50 mRNA correlated to all-trans retinoic acid-induced differentiation of promyelocytic NB-4 and HL60 cells, suggesting that Staf50 could be involved in proliferation and/or differentiation of leukemic cells.	Lund Univ, BMC, Dept Hematol, S-22184 Lund, Sweden; Lund Univ, Dept Oncol, S-22184 Lund, Sweden	Lund University; Lund University	Gullberg, U (corresponding author), Lund Univ, BMC, Dept Hematol, C14, S-22184 Lund, Sweden.	urban.gullberg@hematologi.lu.se	Brunnström, Hans/AAZ-6803-2020	Brunnström, Hans/0000-0001-7402-138X; Vallon-Christersson, Johan/0000-0002-2195-0385				ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Asada M, 1998, LEUKEMIA, V12, P1944, DOI 10.1038/sj.leu.2401228; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P561; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Ehinger M, 1996, BLOOD, V87, P1064, DOI 10.1182/blood.V87.3.1064.bloodjournal8731064; Ehinger M, 1997, CELL GROWTH DIFFER, V8, P1127; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Fei PW, 2002, CANCER RES, V62, P7316; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Gongora C, 2000, J INTERF CYTOK RES, V20, P955, DOI 10.1089/10799900050198390; GULLBERG U, 1992, EUR J CELL BIOL, V58, P307; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; JACKSON P, 1993, ONCOGENE, V8, P589; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Momand J, 1997, J CELL BIOCHEM, V64, P343; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLSSON I, 1983, CANCER RES, V43, P5862; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; Pestka S, 2003, CANCER CELL, V4, P85, DOI 10.1016/S1535-6108(03)00193-4; Peters UR, 1999, CANCER RES, V59, P4233; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rizzo MG, 1998, BRIT J CANCER, V77, P1429, DOI 10.1038/bjc.1998.236; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sharma K, 1998, INT J CANCER, V76, P259, DOI 10.1002/(SICI)1097-0215(19980413)76:2<259::AID-IJC14>3.0.CO;2-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Song XD, 1999, J BIOL CHEM, V274, P1677, DOI 10.1074/jbc.274.3.1677; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swiatecka J, 2000, NEOPLASMA, V47, P15; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tissot C, 1996, GENOMICS, V34, P151, DOI 10.1006/geno.1996.0258; TISSOT C, 1995, J BIOL CHEM, V270, P14891, DOI 10.1074/jbc.270.25.14891; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang ZG, 1998, SCIENCE, V279, P1547; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	57	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4050	4059		10.1038/sj.onc.1207524	http://dx.doi.org/10.1038/sj.onc.1207524			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15064739				2022-12-17	WOS:000221520200002
J	Iha, H; Kibler, KV; Yedavalli, VRK; Peloponese, JM; Haller, K; Miyazato, A; Kasai, T; Jeang, KT				Iha, H; Kibler, KV; Yedavalli, VRK; Peloponese, JM; Haller, K; Miyazato, A; Kasai, T; Jeang, KT			Segregation of NF-kappa B activation through NEMO/IKK gamma by Tax and TNF alpha: implications for stimulus-specific interruption of oncogenic signaling	ONCOGENE			English	Article						Tax; HTLV-I; adult T-cell leukemia; NEMO/IKK gamma; TNF alpha; NF-kappa B; oncogenic transformation	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; SEVERE LIVER DEGENERATION; IKK-GAMMA; KINASE COMPLEX; DEFICIENT MICE; INCONTINENTIA PIGMENTI; MEDIATED ACTIVATION; SPINDLE CHECKPOINT; REGULATORY SUBUNIT	Nuclear factor-kappaB essential modulator (NEMO), also called IKKgamma, has been proposed as a 'universal' adaptor of the I-kappaB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-kappaB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-kappaB inhibition profiles segregating TNFalpha from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFalpha, IL-1beta, or Tax activation of NF-kappaB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-kappaB activation, but did not serve TNFalpha- or IL-1beta signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-kappaB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.	NIAID, Mol Microbiol Lab, Mol Virol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008	Peloponese, Jean-Marie/0000-0002-9677-9703; Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Bai JR, 2003, J BIOL CHEM, V278, P1433, DOI 10.1074/jbc.M208297200; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Iha H, 2000, AIDS RES HUM RETROV, V16, P1633, DOI 10.1089/08892220050193074; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; MORI N, 1994, BLOOD, V84, P2904; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Ranson M, 2002, ONCOLOGY-BASEL, V63, P17, DOI 10.1159/000066203; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTHWARF DM, 1999, SCI STKE, V26, pRE1; Rudolph D, 2000, GENE DEV, V14, P854; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	67	57	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8912	8923		10.1038/sj.onc.1207058	http://dx.doi.org/10.1038/sj.onc.1207058			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654787	Bronze			2022-12-17	WOS:000186982200012
J	Horiguchi, K; Tomizawa, Y; Tosaka, M; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N				Horiguchi, K; Tomizawa, Y; Tosaka, M; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N			Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors	ONCOGENE			English	Article						3p21.3; methylation; glioma; medulloblastoma; meningioma; schwannoma	PRIMITIVE NEUROECTODERMAL TUMORS; CHROMOSOME 3P; PROMOTER HYPERMETHYLATION; CPG ISLAND; LUNG; METHYLATION; BREAST; CELL; HETEROZYGOSITY; HYBRIDIZATION	The human Ras association domain family 1A (RASS-F1A) gene, recently isolated from the lung and breast tumor suppressor locus 3p21.3, is highly methylated in primary lung, breast, nasopharyngeal and other tumors, and re-expression of RASSF1A suppresses the growth of several types of cancer cells. Epigenetic inactivation of RASSF1A by promoter hypermethylation is also important in the development of several human cancers. The methylation status of the promoter region of RASSF1A was analysed in primary brain tumors and glioma cell lines by methylation-specific polymerase chain reaction. In primary brain tumors, 25 of 46 ( 54.3%) gliomas and five of five (100%) medulloblastomas showed RASSF1A methylation. In benign tumors, only one of 10 (10%) schwannomas and two of 12 (16.7%) meningiomas showed RASSF1A methylation. The RASSF1A promoter region was methylated in all four glioma cell lines. RASSF1A was re-expressed in all methylated cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine. Methylation of the promoter CpG islands of the RASSF1A may play an important role in the pathogenesis of glioma and medulloblastoma.	Gunma Univ, Sch Med, Dept Neurosurg, Gunma 3718511, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan	Gunma University; Gunma University	Horiguchi, K (corresponding author), Gunma Univ, Sch Med, Dept Neurosurg, 3-39-22 Showa Machi, Gunma 3718511, Japan.							Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; FULTS D, 1990, CANCER RES, V50, P5784; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanno H, 1997, CANCER RES, V57, P1035; Kleihues P, 2000, PATHOLOGY GENETICS T; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Lusher ME, 2002, CANCER RES, V62, P5906; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mollerup S, 1999, CANCER RES, V59, P3317; Morrissey C, 2001, CANCER RES, V61, P7277; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyooka S, 2001, CANCER RES, V61, P5727; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	28	57	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7862	7865		10.1038/sj.onc.1207082	http://dx.doi.org/10.1038/sj.onc.1207082			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586413				2022-12-17	WOS:000186240200017
J	Cantile, M; Cindolo, L; Napodano, G; Altieri, V; Cillo, C				Cantile, M; Cindolo, L; Napodano, G; Altieri, V; Cillo, C			Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas	ONCOGENE			English	Article						HOX gene network; HOX C locus; chromosome 12q13; bladder cancer	HUMAN-MELANOMA; MUTANT MICE; EXPRESSION; CANCER; HOMEOBOX; PATTERN; HOXD-11; IDENTIFICATION; AMPLIFICATION; ORGANIZATION	Bladder carcinogenesis remains unclear despite the identification of chemical, environmental and genetic factors. It has recently been reported that the chromosomal region 12q13-q15, containing crucial cancer genes such as MDM2, CDK4 and GLI, is amplified in bladder cancer. In the same region are also located the genes of the locus HOX C, flanked by keratin genes whose protein product may be a prognostic marker of bladder cancer. The HOX genes constitute a network of transcription factors controlling embryonal development and play an important role in crucial adult eukaryotic cell functions. The molecular organization of this 39-gene network is unique in the genome and probably acts by regulating phenotypical cell identity. We have analysed the expression of the whole HOX gene network in pairs of normal tumour bladder and in tumoral biopsies. Comparison between normal urothelium and bladder tumour has identified dramatic variations of expression in a block of three genes (HOX C4, HOX C5 and HOX C6) localized in the HOX C locus on the chromosome 12q13 and in the paralogous group 11 HOX genes, involved during normal development in the formation of the urogenital system. These data suggest a key involvement of the HOX gene network, and especially the locus C, in bladder cancer.	Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, I-80131 Naples, Italy; Univ Naples Federico II, Sch Med, Dept Urol, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Cillo, C (corresponding author), Univ Naples Federico II, Dept Clin & Expt Med, Sch Med, Via S Pansini 5, I-80131 Naples, Italy.	clecillo@unina.it	Cindolo, Luca/Q-8342-2016	Vincenzo, Altieri/0000-0002-1321-2817; Cantile, Monica/0000-0001-7840-3369				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Adshead JM, 1999, BJU INT, V83, P1039; AKAM M, 1987, DEVELOPMENT, V101, P1; Apiou F, 1996, CYTOGENET CELL GENET, V73, P114, DOI 10.1159/000134320; Cantile M, 2003, EUR J CANCER, V39, P257, DOI 10.1016/S0959-8049(02)00599-3; Cantile M, 2003, J CELL PHYSIOL, V194, P225, DOI 10.1002/jcp.10210; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Christoph F, 1999, INT J CANCER, V84, P169, DOI 10.1002/(SICI)1097-0215(19990420)84:2<169::AID-IJC13>3.0.CO;2-F; CILLO C, 1994, INVAS METAST, V14, P38; Cillo C, 1996, INT J CANCER, V66, P692, DOI 10.1002/(SICI)1097-0215(19960529)66:5<692::AID-IJC18>3.0.CO;2-6; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; CILLO C, 1995, INT J ONCOL, V7, P1145; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; CILLO C, 1995, P 86 AACR; Cordon-Cardo C, 1998, CANCER SURV, V32, P115; DAVIS AP, 1994, DEVELOPMENT, V120, P2187; DAVIS AP, 1995, NATURE, V375, P791, DOI 10.1038/375791a0; DEKKER EJ, 1992, DEVELOPMENT, P195; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; FAVIER B, 1995, P NATL ACAD SCI USA, V92, P310, DOI 10.1073/pnas.92.1.310; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; FUJIMOTO K, 1992, CANCER RES, V52, P1393; Gazzaniga P, 2001, CLIN CANCER RES, V7, P4288; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Gromova I, 1999, ELECTROPHORESIS, V20, P241, DOI 10.1002/(SICI)1522-2683(19990201)20:2<241::AID-ELPS241>3.3.CO;2-1; Hostikka SL, 1998, MECH DEVELOP, V70, P133, DOI 10.1016/S0925-4773(97)00182-2; Hu GZ, 2001, DEVELOPMENT, V128, P2373; Jave-Suarez LF, 2002, J BIOL CHEM, V277, P3718, DOI 10.1074/jbc.M101616200; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LUSSIER M, 1990, GENE, V95, P203, DOI 10.1016/0378-1119(90)90363-V; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MOLL R, 1988, AM J PATHOL, V132, P123; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nocito A, 2001, INT J CANCER, V94, P1, DOI 10.1002/ijc.1385; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reed SI, 1997, CANCER SURV, V29, P7; Sandberg AA, 2002, AM J MED GENET, V115, P173, DOI 10.1002/ajmg.10693; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Shinohara N, 2002, UROL RES, V30, P273, DOI 10.1007/s00240-002-0275-0; SIMEONE A, 1988, NUCLEIC ACIDS RES, V16, P5379, DOI 10.1093/nar/16.12.5379; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 2001, CANCER RES, V61, P4514; SMALL KM, 1993, GENE DEV, V7, P2318, DOI 10.1101/gad.7.12a.2318; Spitz F, 2003, CELL, V113, P405, DOI 10.1016/S0092-8674(03)00310-6; UICC/AJCC, 1997, TNM CLASS MAL TUM; Wada T, 2000, CLIN CANCER RES, V6, P610; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YOON SJ, 1994, GENOMICS, V24, P502, DOI 10.1006/geno.1994.1659	55	57	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6462	6468		10.1038/sj.onc.1206808	http://dx.doi.org/10.1038/sj.onc.1206808			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508527				2022-12-17	WOS:000185535300017
J	Yu, WM; Hawley, TS; Hawley, RG; Qu, CK				Yu, WM; Hawley, TS; Hawley, RG; Qu, CK			Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling	ONCOGENE			English	Article						SHP-2; tyrosine phosphatase; IL-3; hematopoietic cell proliferation and differentiation	COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELL DEVELOPMENT; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE PHOSPHATASE; BETA-SUBUNIT; SHC-PTB; T-CELL; PROTEIN; ACTIVATION; KINASE	SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells, however, the function of SHP-2 in hematopoietic cell signaling is not well understood. Here we focus on the role of SHP-2 phosphatase in the signal transduction of interleukin (IL)-3, a cytokine involved in hematopoietic cell survival, proliferation, and differentiation. We established immortalized SHP-2(-/-) hematopoietic cell pools and showed that IL-3-induced proliferative response was diminished in SHP-2(-/-) cells. Moreover, inhibition of the catalytic activity of SHP-2 in wild-type (WT) bone marrow hematopoietic progenitor cells and Ba/F3 cells by overexpression of catalytically inactive SHP-2 mutant suppressed their differentiative and proliferative responses to IL-3, demonstrating an important positive role for SHP-2 in IL-3 signal transduction. Further biochemical analyses revealed that IL-3-induced Jak/Stat, Erk, and PI3 kinase pathways in SHP-2(-/-) cells were impaired and reintroduction of WT SHP-2 into mutant cells partially restored IL-3 signaling. Interestingly, in catalytically inactive SHP-2-overexpressing Ba/F3 cells, although IL-3-induced activation of Jak2 and Erk kinases was reduced and shortened, PI3 kinase activation remained unaltered. Taken together, these results suggest that SHP-2 tyrosine phosphatase plays multiple roles in IL-3 signal transduction, functioning in both catalytic-dependent and -independent manners in the Jak/Stat, Erk, and PI3 kinase pathways.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Flow Cytometry Facil, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	quc@usa.redcross.org		Hawley, Robert/0000-0003-3512-5818	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066305, R01HL068212] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL66305, R01HL68212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HAWLEY RG, 1994, ONCOGENE, V9, P1; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; Manes S, 1999, MOL CELL BIOL, V19, P3125; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Okuda K, 1999, ANN NY ACAD SCI, V872, P305, DOI 10.1111/j.1749-6632.1999.tb08474.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yu WM, 2002, BLOOD, V100, P3828, DOI 10.1182/blood-2002-03-0937; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	43	57	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					5995	6004		10.1038/sj.onc.1206846	http://dx.doi.org/10.1038/sj.onc.1206846			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955078				2022-12-17	WOS:000185137800008
J	Chakraborty, S; Sinha, KK; Senyuk, V; Nucifora, G				Chakraborty, S; Sinha, KK; Senyuk, V; Nucifora, G			SUV39H1 interacts with AML1 and abrogates AML1 transactivity. AML1 is methylated in vivo	ONCOGENE			English	Article						AML1; SUV39H1; methylation; repression; Runt domain; EMSA	TRANSCRIPTION FACTOR GATA-1; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CBF-BETA-SMMHC; BINDING; ACETYLATION; GENE; HETEROCHROMATIN; PROTEIN; DOMAIN	Acute myeloid leukemia 1 (AML1) belongs to a family of DNA-binding proteins highly conserved through evolution. AML1 regulates the expression of several hematopoietic genes and is essential for murine fetal liver hematopoiesis. We report here that the histone methyltransferase SUV39H1, a mammalian ortholog of the Drosophila melanogaster SU(VAR) 3-9, forms complex with AML1. SUV39H1 methylates lysine 9 of the histone protein H3 leading to the formation of the high-affinity binding site on chromatin for proteins of the heterochromatin protein 1 family (HP1). The interaction of AML1 with SUV39H1 requires the N-terminus of AML1 where the Runt domain is located. Binding of AML1 to SUV39H1 abrogates the transactivating and DNA-binding properties of AML1 and dissociates the net-like nuclear structure of AML1. It has been reported that AML1 is capable of interaction with histone acetyl transferases (CBP, p300, and MOZ) and with component of the histone deacetylase complex (Sin3), and that the interaction with these coregulators affects the strength of AML1 in promoter regulation. Our data suggest that other enzymes are also involved in gene regulation by AML1 activity by modulating the affinity of AML1 for DNA.	Univ Illinois, Dept Pathol, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Nucifora, G (corresponding author), Univ Illinois, Dept Pathol, Mol Biol Res Bldg,M-C 737,900 S Ashland Ave, Chicago, IL 60607 USA.	nucifora@uic.edu		Sinha, Kislay/0000-0002-6978-4611	NATIONAL CANCER INSTITUTE [R01CA096448, R01CA072675] Funding Source: NIH RePORTER; NCI NIH HHS [CA72675, CA96448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barton K, 2000, BIOESSAYS, V22, P214, DOI 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.0.CO;2-I; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakraborty S, 2001, J BIOL CHEM, V276, P44936, DOI 10.1074/jbc.M106733200; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; El-Osta A, 2001, BIOCHEM BIOPH RES CO, V289, P733, DOI 10.1006/bbrc.2001.6023; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Firestein R, 2000, MOL CELL BIOL, V20, P4900, DOI 10.1128/MCB.20.13.4900-4909.2000; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kitabayashi I, 2001, EMBO J, V20, P7184, DOI 10.1093/emboj/20.24.7184; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 2001, INT J HEMATOL, V74, P245, DOI 10.1007/BF02982056; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Polanowska J, 2001, ONCOGENE, V20, P4115, DOI 10.1038/sj.onc.1204514; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; Sewalt RGAB, 2002, MOL CELL BIOL, V22, P5539, DOI 10.1128/MCB.22.15.5539-5553.2002; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Yamamoto K, 2003, BIOCHEM BIOPH RES CO, V301, P287, DOI 10.1016/S0006-291X(02)03021-8; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	44	57	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5229	5237		10.1038/sj.onc.1206600	http://dx.doi.org/10.1038/sj.onc.1206600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917624				2022-12-17	WOS:000184734900002
J	Morelli, C; Garofalo, C; Bartucci, M; Surmacz, E				Morelli, C; Garofalo, C; Bartucci, M; Surmacz, E			Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells	ONCOGENE			English	Article						estrogen receptor; insulin receptor substrate; proteasome degradation; cell survival; breast cancer	GROWTH-FACTOR-I; HUMAN PANCREATIC-CANCER; HUMAN SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL-3-OH KINASE; MEDIATED DEGRADATION; DOWN-REGULATION; 26S PROTEASOME; IRS-2 GENE	In breast cancer cells, 17-beta-estradiol (E2) upregulates the expression of insulin receptor substrate 1 (IRS-1), a molecule transmitting insulin-like growth factor-I (IGF-I) signals through the PI-3K/Akt survival pathways. The stimulation of IRS-1 by E2 has been documented on the transcriptional level. Here we studied whether the expression of estrogen receptor (ER)-alpha affects IRS molecules post-transcriptionally. We used ER-alpha-negative MDA-MB-231 breast cancer cells and MDA-MB-231 cells with re-expressed ER-alpha. In MDA-MB-231 cells cultured under serum-free conditions, IRS-1 and IRS-2 were degraded through the 26S proteasome and calpain pathways. Re-expression of ER-alpha in MDA-MB-231 cells correlated with enhanced stability of IRS molecules. This effect coincided with significantly reduced ubiquitination of IRS-1 and IRS-2, but did not involve increased IRS-1 and IRS-2 transcription. The interference of ER-alpha with IRS-1 and IRS-2 turnover could rely on the competition for common degradation pathways, as in MDA-MB-231/ER cells, ER-alpha processing was blocked by proteasome and calpain inhibitors. Notably, a fraction of the cytosolic ER-alpha colocalized and coprecipitated with IRS-1 and IRS-2, indicating a possible common destination for these proteins. The stabilization of IRS-1 in MDA-MB-231/ER cells was paralleled by the upregulation of the IRS-1/Akt/GSK-3 pathway and improved survival in the presence of IGF-I, whereas IRS-2 was not involved in IGF-I signaling.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calabria, Fac Pharm, Postgrad Sch Clin Pathol, I-87030 Commenda Di Rende, Italy	Jefferson University; University of Calabria	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.		Garofalo, Cecilia/B-3834-2017; Morelli, Catia/AAE-1886-2019	Garofalo, Cecilia/0000-0001-5334-8930; Morelli, Catia/0000-0002-9407-0805				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aguirre V., 2000, CURRENT OPIN ENDOCRI, V7, P1, DOI [10.1097/00060793-200002000-00001, DOI 10.1097/00060793-200002000-00001]; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; Ashok BT, 2001, INT J MOL MED, V8, P385; Bartucci M, 2001, CANCER RES, V61, P6747; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Dupont J, 1999, J ENDOCRINOL, V162, P67, DOI 10.1677/joe.0.1620067; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Giovannone B, 2000, DIABETES-METAB RES, V16, P434, DOI 10.1002/1520-7560(2000)9999:9999<::AID-DMRR159>3.0.CO;2-8; Guvakova MA, 1997, CANCER RES, V57, P2606; Jackson JG, 2001, ONCOGENE, V20, P7318, DOI 10.1038/sj.onc.1204920; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kahlert S, 2000, J BIOL CHEM, V275, P18447, DOI 10.1074/jbc.M910345199; Kornmann M, 1998, CANCER RES, V58, P4250; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Mauro L, 2001, BIOCHEM BIOPH RES CO, V288, P685, DOI 10.1006/bbrc.2001.5815; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; Powzaniuk MA, 2001, J IMMUNOL, V167, P242, DOI 10.4049/jimmunol.167.1.242; Prisco M, 2002, J BIOL CHEM, V277, P32078, DOI 10.1074/jbc.M204658200; RICE KM, 1993, BIOCHEM BIOPH RES CO, V190, P961, DOI 10.1006/bbrc.1993.1143; Richards RG, 2001, ENDOCRINOLOGY, V142, P3842, DOI 10.1210/en.142.9.3842; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sakoda H, 2000, DIABETES, V49, P1700, DOI 10.2337/diabetes.49.10.1700; Salerno M, 1999, INT J CANCER, V81, P299; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shiba E, 1996, ANTICANCER RES, V16, P773; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SMITH LK, 1993, BIOCHEM BIOPH RES CO, V196, P767, DOI 10.1006/bbrc.1993.2315; Smith LK, 1996, MOL CELL ENDOCRINOL, V122, P81, DOI 10.1016/0303-7207(96)03875-0; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Spector SA, 1999, J SURG RES, V83, P32, DOI 10.1006/jsre.1998.5553; Sun M, 2001, CANCER RES, V61, P5985; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; TURNBOW MA, 1994, J BIOL CHEM, V269, P2516; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhang H, 2000, J BIOL CHEM, V275, P22558, DOI 10.1074/jbc.M000412200; Zhang JD, 2001, P NATL ACAD SCI USA, V98, P3756, DOI 10.1073/pnas.071054598; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	53	57	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4007	4016		10.1038/sj.onc.1206436	http://dx.doi.org/10.1038/sj.onc.1206436			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821935				2022-12-17	WOS:000183707600004
J	Steinman, RA; Wentzel, A; Lu, YL; Stehle, C; Grandis, JR				Steinman, RA; Wentzel, A; Lu, YL; Stehle, C; Grandis, JR			Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2	ONCOGENE			English	Article						Stat3 (signal transducer and activator of; transcription-2) cdk2; confluence; cyclin-dependent; kinase; protein transduction	GROWTH IN-VIVO; KINASE INHIBITOR P27(KIP1); CARCINOMA-CELLS; PLASMA-MEMBRANE; NECK-CANCER; TGF-ALPHA; HEAD; DIFFERENTIATION; APOPTOSIS; PROTEIN	The signal transducing protein Stat3 activates gene transcription in cells in response to multiple cytokines. Constitutive activation of Stat3 has been observed in solid tumors including head and neck squamous cell carcinoma. Stat3 activation in cancer has been associated with autocrine stimulatory loops and is believed to convey a growth advantage to cells. We now demonstrate ligand-independent activation of Stat3 by high cell density in multiple cancer cell lines. Activation of Stat3 is associated with anti proliferative rather than proliferative conditions. Interference with cdk2 activity upregulates Stat3 phosphorylation and Stat3-directed DNA-binding activity. Our data supports a model in which Stat3 activity is partially suppressed by cdk2 in growing cells and derepressed upon cell confluence.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Steinman, RA (corresponding author), Hillman Canc Ctr, Suite 2,18 UPCI Res Pavil,5117 Ctr Ave, Pittsburgh, PA 15213 USA.				NATIONAL CANCER INSTITUTE [R01CA077308] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065172] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA77308] Funding Source: Medline; NHLBI NIH HHS [R01HL65172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bienvenu F, 2001, J BIOL CHEM, V276, P16840, DOI 10.1074/jbc.M100795200; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chapman RS, 2000, ADV EXP MED BIOL, V480, P129; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Dimanche-Boitrel MT, 1998, INT J CANCER, V77, P796, DOI 10.1002/(SICI)1097-0215(19980831)77:5<796::AID-IJC20>3.0.CO;2-Z; Endo S, 2000, GENE THER, V7, P1906, DOI 10.1038/sj.gt.3301315; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Garrido C, 1997, CANCER RES, V57, P2661; Gaulin JF, 2000, J BIOL CHEM, V275, P16658, DOI 10.1074/jbc.275.22.16658; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; He YK, 1998, JNCI-J NATL CANCER I, V90, P1080, DOI 10.1093/jnci/90.14.1080; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; LI L, 2002, J BIOL CHEM, V21, P21; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Steinman RA, 1999, LEUKEMIA, V13, P54, DOI 10.1038/sj.leu.2401253; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takeda K, 2000, CYTOKINE GROWTH F R, V11, P199, DOI 10.1016/S1359-6101(00)00005-8; Wang S, 1999, J GASTROINTEST SURG, V3, P200, DOI 10.1016/S1091-255X(99)80034-1; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Xie B, 2001, J BIOL CHEM, V276, P19512, DOI 10.1074/jbc.M009063200; Yaroslavskiy BB, 2001, MOL MED, V7, P49, DOI 10.1007/BF03401838; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	42	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3608	3615		10.1038/sj.onc.1206523	http://dx.doi.org/10.1038/sj.onc.1206523			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789269				2022-12-17	WOS:000183399200011
J	Jendrossek, V; Muller, I; Eibl, H; Belka, C				Jendrossek, V; Muller, I; Eibl, H; Belka, C			Intracellular mediators of erucylphosphocholine-induced apoptosis	ONCOGENE			English	Article						apoptosis; erucylphosphocholine; caspases; mitochondria; Bcl-2; FADD	DRUG-INDUCED APOPTOSIS; HEMATOPOIETIC PROGENITOR CELLS; RADIATION-INDUCED APOPTOSIS; BREAST-CANCER PATIENTS; HUMAN CARCINOMA-CELLS; HUMAN LEUKEMIC-CELLS; ETHER LIPID ANALOGS; PROTEIN-KINASE-C; CYTOCHROME-C; CASPASE ACTIVATION	Induction of apoptosis contributes to the cytotoxic action of the intravenously applicable alkylphosphocholine erucylphosphocholine (ErPC). To define molecular requirements for ErPC-induced apoptosis, activation of caspases-8, -9 and -3 and cleavage of the caspase-3 substrates PARP and ICAD were tested in normal Jurkat T cells, Jurkat cells resistant to death receptor (CD95 or TNFalpha-related apoptosis inducing ligand (TRAIL)-induced apoptosis, Jurkat cells lacking caspase-8 or Fas-associated death domain (FADD) Jurkat cells expressing a dominant-negative caspase-9 or overexpressing Bcl-2 as well as BJAB B-lymphoma cells expressing a dominant-negative FADD (FADD-DN). ErPC induced a time- and dose-dependent apoptotic cell death in Jurkat and BJAB cells, which was characterized by breakdown of the phosphatidylserine asymmetry, depolarization of the mitochondrial membrane potential, release of cytochrome c, activation of caspases-9, -8 and -3, cleavage of PARP and ICAD, as well as chromatin condensation. ErPC-induced apoptosis was independent from CD95-receptor signaling and FADD since CD95- and TRAIL-resistant, caspase-8- and FADD-negative Jurkat cells, as well as BJAB cells expressing FADD-DN were sensitive to ErPC-induced apoptosis. In contrast, inhibition of caspase-9 and overexpression of Bcl-2 significantly reduced ErPC-induced caspase activation and apoptosis. Thus, ErPC triggers apoptosis via a Bcl-2-dependent mitochondrial but death receptor-independent pathway.	Univ Tubingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Jendrossek, V (corresponding author), Univ Tubingen, Dept Radiat Oncol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BERGER MR, 1993, J CANCER RES CLIN, V119, P541, DOI 10.1007/BF01686464; BERGGREN MI, 1993, CANCER RES, V53, P4297; BERGMANN J, 1994, ANTICANCER RES, V14, P1549; Berkovic D, 1995, EUR J CANCER, V31A, P2080, DOI 10.1016/0959-8049(95)00350-9; Berkovic D, 1997, RADIOTHER ONCOL, V43, P293, DOI 10.1016/S0167-8140(97)01909-9; Berkovic D, 2001, EUR J CANCER, V37, P503, DOI 10.1016/S0959-8049(00)00394-4; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Chen M, 2002, APOPTOSIS, V7, P313, DOI 10.1023/A:1016167228059; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CINEK T, 1995, IMMUNOGENETICS, V41, P110, DOI 10.1007/BF00182321; Clive S, 1999, CANCER CHEMOTH PHARM, V44, pS29, DOI 10.1007/s002800051114; Cuvillier O, 1999, BLOOD, V94, P3583, DOI 10.1182/blood.V94.10.3583.422k31_3583_3592; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Engelmann J, 1996, ANTICANCER RES, V16, P1429; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Erdlenbruch B, 1999, CANCER CHEMOTH PHARM, V44, P484, DOI 10.1007/s002800051122; Ergezinger K, 1999, ANTICANCER RES, V19, P3213; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Fulda S, 1997, CANCER RES, V57, P4956; Gajate C, 2000, INT J CANCER, V85, P674, DOI 10.1002/(SICI)1097-0215(20000301)85:5<674::AID-IJC13>3.0.CO;2-Z; Gajate C, 2001, BLOOD, V98, P3860, DOI 10.1182/blood.V98.13.3860; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Georgieva MC, 2002, CANCER LETT, V182, P163, DOI 10.1016/S0304-3835(02)00088-5; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang HW, 1999, BIOPHYS J, V77, P1489, DOI 10.1016/S0006-3495(99)76996-1; Jendrossek V, 2001, ANTICANCER RES, V21, P3389; Jendrossek V, 1999, INT J ONCOL, V14, P15; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Konstantinov SM, 1998, CANCER CHEMOTH PHARM, V41, P210; Konstantinov SM, 1999, CANCER LETT, V144, P153, DOI 10.1016/S0304-3835(99)00219-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Lucas L, 2001, ONCOGENE, V20, P1110, DOI 10.1038/sj.onc.1204216; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matzke A, 2001, EUR J CELL BIOL, V80, P1, DOI 10.1078/0171-9335-00130; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MIYASHITA T, 1993, BLOOD, V81, P151; Mollinedo F, 1997, CANCER RES, V57, P1320; MOLLINEDO F, 1994, BIOCHEM J, V302, P325, DOI 10.1042/bj3020325; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nomura Y, 2000, LEUKEMIA, V14, P299, DOI 10.1038/sj.leu.2401649; NOSEDA A, 1989, EXP MOL PATHOL, V50, P69, DOI 10.1016/0014-4800(89)90057-9; NOSEDA A, 1988, CANCER RES, V48, P1788; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Ruiter GA, 2001, INT J RADIAT ONCOL, V49, P415, DOI 10.1016/S0360-3016(00)01476-0; Ruiter GA, 1999, CANCER RES, V59, P2457; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Smorenburg CH, 2000, ANTI-CANCER DRUG, V11, P825, DOI 10.1097/00001813-200011000-00006; STEKAR J, 1995, EUR J CANCER, V31A, P372, DOI 10.1016/0959-8049(94)00495-Q; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; UNGER C, 1992, PROG EXP TUMOR RES, V34, P153; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VEHMEYER K, 1992, EXP HEMATOL, V20, P1; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; ZHENG B, 1990, CANCER RES, V50, P3025; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	81	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2621	2632		10.1038/sj.onc.1206355	http://dx.doi.org/10.1038/sj.onc.1206355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730676				2022-12-17	WOS:000182569000010
J	Zhang, H; Morisaki, T; Nakahara, C; Matsunaga, H; Sato, N; Nagumo, F; Tadano, J; Katano, M				Zhang, H; Morisaki, T; Nakahara, C; Matsunaga, H; Sato, N; Nagumo, F; Tadano, J; Katano, M			PSK-mediated NF-kappa B inhibition augments docetaxel-induced apoptosis in human pancreatic cancer cells NOR-P1	ONCOGENE			English	Article						pancreatic cancer; docetaxel; PSK; apoptosis; NF-kappa B	PHASE-II; TUMOR-CELLS; ACTIVATION; CHEMOTHERAPY; AGENTS; LINE; PHOSPHORYLATION; SUPPRESSION; EXPERIENCE; EXPRESSION	Docetaxel, a member of the taxane family, has been shown to induce apoptosis in a variety of cancer cells. However, toxicity at therapeutic doses has precluded the use of docetaxel alone for the management of cancer patients. PSK, a protein-bound polysaccharide, is widely used in Japan as an immunopotentiating biological response modifier for cancer patients. Our previous study showed that PSK induced downregulation of several invasion-related factors, suggesting an interaction of PSK with transcriptional factors. In this study, we showed that PSK dose dependently enhanced apoptosis induced by 1 nM of docetaxel in a human pancreatic cancer cell line NOR-P1. Furthermore, PSK inhibited docetaxel-induced nuclear factor kappa B (NF-kappaB) activation. Moreover, the expression of cellular inhibitor of apoptosis protein (cIAP-1), which is transcriptionally regulated by NF-kappaB and functions as an antiapoptotic molecule through interrupting the caspase pathway, was also inhibited by treatment with PSK plus docetaxel. As a result, PSK enhanced the docetaxel-induced caspase-3 activation. In addition, treatment by transfection of NF-kappaB decoy oligodeoxynucleotides (ODNs), but not scramble ones, inhibited the expression of cIAP-1 in NOR-P1 cells and induced a significant increase in docetaxel-induced apoptosis. Our data indicate that PSK suppresses the docetaxel-induced NF-kappaB activation pathway. Combination of PSK with a low dose of docetaxel may be a new therapeutic strategy to treat patients with pancreatic cancer.	Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Saga Med Sch, Dept Hosp Clin Lab, Saga 8498501, Japan; Saga Med Sch, Dept Hosp Pharm, Saga 8498501, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Oncol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Saga University; Saga University; Kyushu University	Morisaki, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ANAI H, 1991, ANTI-CANCER DRUG, V2, P275; Aota K, 2000, BIOCHEM BIOPH RES CO, V273, P1168, DOI 10.1006/bbrc.2000.3072; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; BISSERY MC, 1995, ANTI-CANCER DRUG, V6, P339, DOI 10.1097/00001813-199506000-00001; Cascinu S, 1999, ANN ONCOL, V10, P1377, DOI 10.1023/A:1008394111533; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CORTES JE, 1995, J CLIN ONCOL, V13, P2643, DOI 10.1200/JCO.1995.13.10.2643; Cui XF, 2000, BBA-GEN SUBJECTS, V1524, P178, DOI 10.1016/S0304-4165(00)00155-0; EBINA T, 1992, JPN J CANCER RES, V83, P775, DOI 10.1111/j.1349-7006.1992.tb01979.x; Fisher M, 2002, ANTICANCER RES, V22, P1737; Fukushima M, 1996, SEMIN ONCOL, V23, P369; Haldar S, 1997, CANCER RES, V57, P229; Huang Y, 2000, CANCER RES, V60, P4426; IINO Y, 1992, ANTICANCER RES, V12, P2101; Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518; IWAGUCHI T, 1989, J BIOCHEM BIOPH METH, V18, P157, DOI 10.1016/0165-022X(89)90077-8; KAYE SB, 1995, SEMIN ONCOL, V22, P30; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kolfschoten GM, 2002, BIOCHEM PHARMACOL, V63, P733, DOI 10.1016/S0006-2952(01)00895-4; Lenzi R, 2002, CANCER INVEST, V20, P464, DOI 10.1081/CNV-120002146; MORI H, 1987, INT J IMMUNOPHARMACO, V9, P881, DOI 10.1016/0192-0561(87)90004-X; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Okada S, 1999, BRIT J CANCER, V80, P438, DOI 10.1038/sj.bjc.6690375; Rougier P, 2000, EUR J CANCER, V36, P1016, DOI 10.1016/S0959-8049(00)00072-1; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sato N, 2000, CANCER LETT, V155, P153, DOI 10.1016/S0304-3835(00)00421-3; Shibata M, 2002, CANCER INVEST, V20, P166, DOI 10.1081/CNV-120001142; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; Stathopoulos GP, 2001, ANN ONCOL, V12, P101, DOI 10.1023/A:1008310106171; Takahashi Y, 2001, Gan To Kagaku Ryoho, V28, P531; TSUKAGOSHI S, 1984, CANCER TREAT REV, V11, P131, DOI 10.1016/0305-7372(84)90005-7; Vos IHC, 2000, FASEB J, V14, P815, DOI 10.1096/fasebj.14.5.815; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1; Zhang H, 2000, CLIN EXP METASTAS, V18, P343	38	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2088	2096		10.1038/sj.onc.1206310	http://dx.doi.org/10.1038/sj.onc.1206310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687011				2022-12-17	WOS:000182066900003
J	Carboni, GL; Gao, BN; Nishizaki, M; Xu, K; Minna, JD; Roth, JA; Ji, L				Carboni, GL; Gao, BN; Nishizaki, M; Xu, K; Minna, JD; Roth, JA; Ji, L			CACNA2D2-mediated apoptosis in NSCLC cells is associated with alterations of the intracellular calcium signaling and disruption of mitochondria membrane integrity	ONCOGENE			English	Article						tumor suppressor genes; apoptosis; calcium channel proteins; human chromosome 3p21.3; lung cancer	CHANNEL SUBUNIT; GABAPENTIN BINDING; CHROMOSOME 3P21.3; TUMOR-SUPPRESSOR; CA2+ HOMEOSTASIS; MULTIPLE GENES; CYTOCHROME-C; ALPHA(2)DELTA; RELEASE; DEATH	The CACNA2D2 gene, a new subunit of the Ca2+-channel complex, was identified in the homozygous deletion region of chromosome 3p21.3 in human lung and breast cancers. Expression deficiency of the CACNA2D2 in cancer cells suggests a possible link of it to Ca2+ signaling in the pathogenesis of lung cancer and other cancers. We investigated the effects of overexpression of CACNA2D2 on intracellular Ca2+ contents, mitochondria homeostasis, cell proliferation, and apoptosis by adenoviral vector-mediated wild-type CACNA2D2 gene transfer in 3p21.3-deficient nonsmall cell lung cancer cell lines. Exogenous expression of CACNA2D2 significantly inhibited tumor cell growth compared with the controls. Overexpression of CACNA2D2 induced apoptosis in H1299 (12.5%), H358 (13.7%), H460 (22.3%), and A549 (50.1%) cell lines. Levels of intracellular free Ca2+ were elevated in AdCACNA2D2-transduced cells compared with the controls. Mitochondria membrane depolarization was observed prior to apoptosis in Ad-CACNA2D2 and Adp53-transduced H460 and A549 cells. Release of cyt c into the cytosol, caspase 3 activation, and PARP cleavage were also detected in these cells. Together, these results suggest that one of the pathways in CACNA2D2-induced apoptosis is mediated through disruption of mitochondria membrane integrity, the release of cyt c, and the activation of caspases, a process that is associated with regulation of cytosolic free Ca2+ contents.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Sect Thorac Mol Oncol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA; Univ Hosp Bern, Div Gen Thorac Surg, Bern, Switzerland	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Bern; University Hospital of Bern	Ji, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd,Box 445, Houston, TX 77030 USA.		Carboni, Giovanni/AAA-1780-2021	Carboni, Giovanni/0000-0003-3969-1227	NCI NIH HHS [P50 CA070907, 2P50-CA70907-04, CA16672, P30 CA016672, P01 CA078778, R01 CA071618, P01 CA78778-01A1, CA71618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA070907, P01CA078778, R01CA071618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2000, MOL CELL PROBE, V14, P53, DOI 10.1006/mcpr.1999.0277; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brown JP, 1998, J BIOL CHEM, V273, P25458, DOI 10.1074/jbc.273.39.25458; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; COSSARIZZA A, 1995, BIOCHEM BIOPH RES CO, V214, P503, DOI 10.1006/bbrc.1995.2315; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Fondon JW, 1998, P NATL ACAD SCI USA, V95, P7514, DOI 10.1073/pnas.95.13.7514; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hobom M, 2000, EUR J NEUROSCI, V12, P1217, DOI 10.1046/j.1460-9568.2000.01009.x; Hofmann F, 1999, REV PHYSIOL BIOCH P, V139, P33, DOI 10.1007/BFb0033648; Hurley JF, 2000, P NATL ACAD SCI USA, V97, P9293, DOI 10.1073/pnas.160589697; Ji L, 1999, CANCER RES, V59, P3333; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kochegarov AA, 2001, COMP BIOCHEM PHYS A, V128, P279, DOI 10.1016/S1095-6433(00)00306-8; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacinova L, 2000, GEN PHYSIOL BIOPHYS, V19, P121; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lerman MI, 2000, CANCER RES, V60, P6116; Marais E, 2001, MOL PHARMACOL, V59, P1243, DOI 10.1124/mol.59.5.1243; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Rutter GA, 2000, TRENDS BIOCHEM SCI, V25, P215, DOI 10.1016/S0968-0004(00)01585-1; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; Toyota M, 1999, CANCER RES, V59, P4535; Ueki T, 2000, CANCER RES, V60, P1835; Varadi G, 1999, CRIT REV BIOCHEM MOL, V34, P181, DOI 10.1080/10409239991209264; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Walker D, 1998, TRENDS NEUROSCI, V21, P148, DOI 10.1016/S0166-2236(97)01200-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang MH, 1999, BIOCHEM J, V342, P313, DOI 10.1042/0264-6021:3420313; Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	46	57	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					615	626		10.1038/sj.onc.1206134	http://dx.doi.org/10.1038/sj.onc.1206134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555074	Green Accepted			2022-12-17	WOS:000180538200014
J	Silva, FPG; Morolli, B; Storlazzi, CT; Anelli, L; Wessels, H; Bezrookove, V; Kluin-Nelemans, HC; Giphart-Gassler, M				Silva, FPG; Morolli, B; Storlazzi, CT; Anelli, L; Wessels, H; Bezrookove, V; Kluin-Nelemans, HC; Giphart-Gassler, M			Identification of RUNX1/AML1 as a classical tumor suppressor gene	ONCOGENE			English	Article						RUNX1; tumor suppressor gene; AML; leukemia	ACUTE MYELOID-LEUKEMIA; PROTEIN-PROTEIN INTERACTIONS; CORE-BINDING FACTOR; RUNT DOMAIN; DNA-BINDING; TRANSCRIPTIONAL REGULATION; AML1/PEBP2-ALPHA-B GENE; POINT MUTATIONS; VIRUS ENHANCERS; C/EBP-ALPHA	Based on our previous results indicating the presence of a tumor suppressor gene (TSG), chromosome 21 was analysed for loss of heterozygosity (LOH) in 18 patients with acute myeloid leukemia (17, AML-M0; one, AML-M1). Allelotyping at polymorphic loci was performed on purified material, allowing unequivocal detection of allelic loss and homozygous deletions. Six AML-M0 patients shared a common region of LOH harboring a single gene: RUNX1 (AML1), the most frequent site of translocations in acute leukemia and a well-known fusion oncogene. Fluorescence in situ hybridization allowed the identification of deletions with breakpoints within RUNX1 in two patients as the cause of LOH. In the four others the LOH pattern and the presence of two karyotypically normal chromosomes 21 were in line with mitotic recombination. Further molecular and cytogenetic analyses showed that this caused homozygosity of primary RUNX1 mutations: two point mutations, a partial deletion and, most significantly, a complete deletion of RUNX1. These findings identify RUNX1 as a classical TSG: both alleles are mutated or absent in cancer cells from four of the 17 AML-M0 patients examined. In contrast to AML-MO, the AML-M1 patient was trisomic for chromosome 21 and has two mutated - and one normal RUNX1 allele, suggesting that the order of mutagenic events leading to leukemia may influence the predominant tumor type.	Leiden Univ, Ctr Med, Dept Radiat Genet & Chem Mutagensis, NL-2600 RA Leiden, Netherlands; Univ Bari, Dept Genet, I-70126 Bari, Italy; Leiden Univ, Ctr Med, Dept Clin Cytogenet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Hematol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Universita degli Studi di Bari Aldo Moro; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Giphart-Gassler, M (corresponding author), Leiden Univ, Ctr Med, Dept Radiat Genet & Chem Mutagensis, POB 9503, NL-2600 RA Leiden, Netherlands.		Kluin-Nelemans, Johanna C/F-8658-2018; Silva, Fernando/N-1847-2014; Anelli, Luisa/K-2661-2016	Kluin-Nelemans, Johanna C/0000-0003-2617-9427; Silva, Fernando/0000-0003-2379-9137; Anelli, Luisa/0000-0002-9185-724X; Storlazzi, Clelia Tiziana/0000-0002-1696-0028				BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; de Nooij-van Dalen AG, 1998, GENE CHROMOSOME CANC, V21, P30, DOI 10.1002/(SICI)1098-2264(199801)21:1<30::AID-GCC5>3.0.CO;2-9; de Nooij-van Dalen AG, 2001, GENE CHROMOSOME CANC, V30, P323, DOI 10.1002/gcc.1098; Devilee P, 2001, TRENDS GENET, V17, P569, DOI 10.1016/S0168-9525(01)02416-7; Friedman AD, 1996, LEUKEMIA RES, V20, P809, DOI 10.1016/S0145-2126(96)00035-5; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Giphart-Gassler M, 1998, MUTAT RES-FUND MOL M, V400, P409, DOI 10.1016/S0027-5107(98)00022-0; Hiebert SW, 2001, CURR OPIN HEMATOL, V8, P197, DOI 10.1097/00062752-200107000-00003; Holt D, 1999, AM J HUM GENET, V65, P1423, DOI 10.1086/302614; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Langabeer SE, 2002, GENE CHROMOSOME CANC, V34, P24, DOI 10.1002/gcc.10031; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Mao SF, 1999, MOL CELL BIOL, V19, P3635; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Nagata T, 2001, J MOL BIOL, V308, P191, DOI 10.1006/jmbi.2001.4596; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Speck NA, 2002, NAT REV CANCER, V2, P502, DOI 10.1038/nrc840; SUDOL M, 1994, ONCOGENE, V9, P2145; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(02)02053-6; Tanaka Tomoyuki, 1997, Leukemia (Basingstoke), V11, P299; Tanke HJ, 1999, EUR J HUM GENET, V7, P2, DOI 10.1038/sj.ejhg.5200265; Uchida H, 1997, J IMMUNOL, V158, P2251; VANDAM FJ, 1992, MUTAT RES, V271, P231, DOI 10.1016/0165-1161(92)90018-H; Vrieling H, 2001, NAT GENET, V28, P101, DOI 10.1038/88794; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	48	57	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					538	547		10.1038/sj.onc.1206141	http://dx.doi.org/10.1038/sj.onc.1206141			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555067				2022-12-17	WOS:000180538200007
J	Ader, I; Toulas, C; Dalenc, F; Delmas, C; Bonnet, J; Cohen-Jonathan, E; Favre, G				Ader, I; Toulas, C; Dalenc, F; Delmas, C; Bonnet, J; Cohen-Jonathan, E; Favre, G			RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death	ONCOGENE			English	Article						radioresistance; farnesylation; Ras; RhoB	FIBROBLAST GROWTH-FACTOR; FARNESYLTRANSFERASE INHIBITORS; IN-VIVO; GERANYLGERANYLATED RHOB; ENDOTHELIAL-CELLS; RAS ONCOGENES; PROTEIN; RADIATION; PRENYLATION; FORMS	Farnesylated Ras oncoprotein induces a cellular resistance to ionizing radiation that can be reversed by farnesyltransferase inhibitors (FTI). We previously demonstrated that, expression of the 24 kDa FGF2 isoform in wild type ras bearing HeLa cells, induced radioresistance which was also reversed by FTI. We tested the hypothesis that wild type Ras or RhoB, which has been proposed as a potential FTI target, could control the FGF-2-induced radioresistance mechanisms. For this, we expressed inducible dominant negative forms of Ras (RasN17) and Rho (RhoBN19) in 24 kDa FGF2 transfected HeLa cells and analysed their survival after irradiation. While no cell survival modification was observed after RasN17 induction, the expression of RhoBN19 induced a radiosensitization of FGF2 radioresistant HeLa cells in the same range as the one observed after a 48 h treatment with the specific FTI, R115777. Moreover, we showed that activated RhoB but not RhoA induced radioresistance in NIH3T3 cells. The radiosensitizer effect of RhoBN19 expression was due to the induction of the radiation induced post-mitotic cell death. Taken together, these data demonstrate that 24 kDa FGF-2-induced radioresistance is controlled by Rho pathways and suggest that RhoB should be a major determinant in cellular resistance to ionizing radiation.	Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM U563, F-31052 Toulouse, France; Ctr Lutte Contre Canc Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Favre, G (corresponding author), Ctr Lutte Contre Canc Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM U563, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		delmas, caroline/O-9241-2014; FAVRE, Gilles/K-9189-2014; Toulas, Christine/P-3838-2014; Moyal, Elizabeth/A-9802-2015; Ader-Perarnau, Isabelle/F-7160-2017	FAVRE, Gilles/0000-0002-2344-1883; Toulas, Christine/0000-0003-1261-1725; Moyal, Elizabeth/0000-0002-6593-9276; ADER, isabelle/0000-0001-5103-8509				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BRUYNEEL EA, 1993, EUR J CANCER, V29A, P1958, DOI 10.1016/0959-8049(93)90452-L; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cohen-Jonathan E, 1999, RADIAT RES, V152, P404, DOI 10.2307/3580225; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; CohenJonathan E, 1997, CANCER RES, V57, P1364; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DECREMOUX P, 1994, INT J CANCER, V59, P408, DOI 10.1002/ijc.2910590320; Du W, 1999, MOL CELL BIOL, V19, P1831; End DW, 2001, CANCER RES, V61, P131; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; Fiorentini C, 1997, J BIOL CHEM, V272, P19532, DOI 10.1074/jbc.272.31.19532; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; FUKS Z, 1994, CANCER RES, V54, P2582; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; Lebowitz PF, 1998, CELL ADHES COMMUN, V6, P277, DOI 10.3109/15419069809010787; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Miquel K, 1997, CANCER RES, V57, P1846; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VAN AL, 1997, GENE DEV, V11, P2295; WHITE JH, 1994, BIO-TECHNOL, V12, P1003, DOI 10.1038/nbt1094-1003	38	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					5998	6006		10.1038/sj.onc.1205746	http://dx.doi.org/10.1038/sj.onc.1205746			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203112				2022-12-17	WOS:000177671300003
J	Muller, N; Reinacher-Schick, A; Baldus, S; van Hengel, J; Berx, G; Baar, A; van Roy, F; Schmiegel, W; Schwarte-Waldhoff, I				Muller, N; Reinacher-Schick, A; Baldus, S; van Hengel, J; Berx, G; Baar, A; van Roy, F; Schmiegel, W; Schwarte-Waldhoff, I			Smad4 induces the tumor suppressor E-cadherin and P-cadherin in colon carcinoma cells	ONCOGENE			English	Article						Smad4; tumor suppressor gene; TGF-beta; E-cadherin; invasion	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; MESENCHYMAL TRANSDIFFERENTIATION; COLORECTAL-CANCER; GENE; DPC4; MUTATIONS; EXPRESSION; PROTEINS	Smad4 is an intracellular transmitter of TGF-beta signals and its tumor suppressor function is presumed to reside in its capacity to mediate TGF-beta-induced growth inhibition. However, there is accumulating evidence that this hypothesis may be too simple. The roles of TGF-beta in carcinogenesis are complex and also comprise tumor promoting functions particularly in late stage carcinogenesis. Importantly, functional inactivation of Smad4 in colon carcinomas frequently occurs at late stages when tumors acquire invasive and metastatic capabilities. We have previously reported that stable re-expression of Smad4 in SW480 human colon carcinoma cells was adequate to suppress tumor growth in nude mice. However, it did not affect cell growth in vitro nor did it restore TGF-beta responsiveness. Here, we report that Smad4 transcriptionally induced classical cadherins including the invasion suppressor E-cadherin, presumably re-establishing epithelial morphology. Smad4-induced cadherins were able to recruit catenins to the plasma membrane and were functionally active in cell-cell adhesion. These results indicate a novel pathway of Smad4-mediated tumor suppression and suggest that Smad4 in colon cells may be involved in the maintenance of epithelial traits.	Ruhr Univ Bochum, IMBL, Dept Internal Med, D-4630 Bochum, Germany; Univ Cologne, Dept Pathol, Cologne, Germany; State Univ Ghent VIB, Dept Mol Biomed Res, Mol Cell Biol Unit, B-9000 Ghent, Belgium	Ruhr University Bochum; University of Cologne; Flanders Institute for Biotechnology (VIB); Ghent University	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus, Schornau 23-25, D-44892 Bochum, Germany.	irmgard.schwarte-waldhoff@ruhr-uni-bochum.de	van Roy, Frans M/C-6123-2009; Reinacher-Schick, Anke C/F-2722-2012	van Roy, Frans M/0000-0003-4358-1039; Berx, Geert/0000-0001-5770-2458				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Baldus SE, 1998, INT J CANCER, V79, P133, DOI 10.1002/(SICI)1097-0215(19980417)79:2<133::AID-IJC6>3.0.CO;2-U; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fink SP, 2001, CANCER RES, V61, P256; Giroldi LA, 1997, BIOCHEM BIOPH RES CO, V241, P453, DOI 10.1006/bbrc.1997.7831; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Hajra KM, 2002, CANCER RES, V62, P1613; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HENNIG G, 1995, ONCOGENE, V11, P475; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Kern Scott E., 1998, Current Opinion in Oncology, V10, P74, DOI 10.1097/00001622-199801000-00012; KINGSTON P, 1994, RES SOCIAL STRATIFIC, V13, P3; Kitagawa K, 1996, INT J CANCER, V66, P91, DOI 10.1002/(SICI)1097-0215(19960328)66:1<91::AID-IJC16>3.0.CO;2-E; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Montgomery E, 2001, AM J PATHOL, V158, P537, DOI 10.1016/S0002-9440(10)63995-8; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Piek E, 1999, J CELL SCI, V112, P4557; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Reiss M, 1997, ONCOL RES, V9, P447; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Sirard C, 2000, J BIOL CHEM, V275, P2063, DOI 10.1074/jbc.275.3.2063; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Verschueren K, 1999, CYTOKINE GROWTH F R, V10, P187, DOI 10.1016/S1359-6101(99)00012-X; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wilentz RE, 2000, CANCER RES, V60, P2002; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	64	57	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2002	21	39					6049	6058		10.1038/sj.onc.1205766	http://dx.doi.org/10.1038/sj.onc.1205766			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203117				2022-12-17	WOS:000177671300008
J	Smiraglia, DJ; Plass, C				Smiraglia, DJ; Plass, C			The study of aberrant methylation in cancer via restriction landmark genomic scanning	ONCOGENE			English	Review						DNA methylation; RLGS; cancer; genomic scanning; hypomethylation	ACUTE MYELOID-LEUKEMIA; CPG-ISLAND METHYLATION; CTCF-BINDING SITES; DNA METHYLATION; CELL-LINES; HEPATOCELLULAR-CARCINOMA; 2-DIMENSIONAL ELECTROPHORESIS; PROMOTER HYPERMETHYLATION; 5-METHYLCYTOSINE CONTENT; TRANSGENIC MICE	Restriction landmark genomic scanning (RLGS) has been used to study DNA methylation in cancer for nearly a decade. The strong bias of RLGS for assessing the methylation state of CpG islands genome wide makes this an attractive technique to study both hypo- and hypermethylation of regions of the genome likely to harbor genes. RLGS has been used successfully to identify regions of hypomethylation, candidate tumor suppressor genes, correlations between hypermethylation events and clinical factors, and quantification of hypermethylation in a multitude of malignancies. This review will examine the major uses of RLGS in the study of aberrant methylation in cancer and discuss the significance of some of the findings.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Smiraglia, DJ (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA.	Smiraglia.1@postbox.acs.ohio-state.edu	Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Smiraglia, Dominic/0000-0001-8852-1510; 	NIDCR NIH HHS [DE13123-02] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013123] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akama TO, 1997, CANCER RES, V57, P3294; ASAKAWA J, 1995, ELECTROPHORESIS, V16, P241, DOI 10.1002/elps.1150160140; BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello J F, 2000, Brain Tumor Pathol, V17, P49, DOI 10.1007/BF02482735; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 1997, CANCER RES, V57, P1250; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; Fruhwald MC, 2001, GENE CHROMOSOME CANC, V30, P38; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; HATADA I, 1991, P NATL ACAD SCI USA, V88, P9523, DOI 10.1073/pnas.88.21.9523; HAYASHIZAKI Y, 1993, ELECTROPHORESIS, V14, P251, DOI 10.1002/elps.1150140145; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1997, CANCER RES, V57, P837; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; HIROTSUNE S, 1992, CANCER RES, V52, P3642; HIROTSUNE S, 1993, BIOCHEM BIOPH RES CO, V194, P1406, DOI 10.1006/bbrc.1993.1981; Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Itano O, 2000, ONCOGENE, V19, P1676, DOI 10.1038/sj.onc.1203459; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; KAWAI J, 1994, MOL CELL BIOL, V14, P7421, DOI 10.1128/MCB.14.11.7421; Kim YS, 2000, INT J ONCOL, V17, P297; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Komatsu S, 2000, BIOCHEM BIOPH RES CO, V267, P109, DOI 10.1006/bbrc.1999.1937; Konishi N, 1997, PATHOL INT, V47, P735, DOI 10.1111/j.1440-1827.1997.tb04451.x; Konishi N, 1996, CELL MOL BIOL, V42, P1129; Kuick R, 1996, GENETICS, V144, P307; KUO KC, 1980, NUCLEIC ACIDS RES, V8, P4763, DOI 10.1093/nar/8.20.4763; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230; Merino R, 1999, ANN NY ACAD SCI, V887, P120, DOI 10.1111/j.1749-6632.1999.tb07927.x; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MIWA W, 1995, ELECTROPHORESIS, V16, P227, DOI 10.1002/elps.1150160138; Nagai H, 1998, CANCER, V82, P454, DOI 10.1002/(SICI)1097-0142(19980201)82:3<454::AID-CNCR5>3.0.CO;2-P; NAGAI H, 1994, CANCER RES, V54, P1545; Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219; Nagai H, 1999, GENE, V237, P15, DOI 10.1016/S0378-1119(99)00322-4; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Nakamura M, 1997, J NEURO-ONCOL, V35, P113, DOI 10.1023/A:1005712308061; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OHSUMI T, 1995, ELECTROPHORESIS, V16, P203, DOI 10.1002/elps.1150160135; Okazaki Y, 1996, NAT GENET, V13, P87, DOI 10.1038/ng0596-87; OKAZAKI Y, 1995, ELECTROPHORESIS, V16, P197, DOI 10.1002/elps.1150160134; OKUIZUMI H, 1995, ELECTROPHORESIS, V16, P253, DOI 10.1002/elps.1150160141; Plass C, 1997, DNA Res, V4, P253, DOI 10.1093/dnares/4.3.253; Plass C, 1999, ONCOGENE, V18, P3159, DOI 10.1038/sj.onc.1202651; Plass C, 1996, NAT GENET, V14, P106, DOI 10.1038/ng0996-106; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Rosas SLB, 2001, CANCER RES, V61, P939; Rouillard JM, 2001, GENOME RES, V11, P1453, DOI 10.1101/gr.181601; Rush LJ, 2002, BLOOD, V99, P1874, DOI 10.1182/blood.V99.5.1874; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SCHIRMACHER P, 1991, AM J PATHOL, V139, P231; SHIBATA H, 1995, ELECTROPHORESIS, V16, P210, DOI 10.1002/elps.1150160136; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Suzuki H, 1994, DNA Res, V1, P245, DOI 10.1093/dnares/1.5.245; Tada A, 1998, ONCOL REP, V5, P1137; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Tateno M, 2001, CANCER RES, V61, P1144; Thoraval D, 1996, GENE CHROMOSOME CANC, V17, P234, DOI 10.1002/(SICI)1098-2264(199612)17:4<234::AID-GCC5>3.0.CO;2-4; Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; WATANABE S, 1995, ELECTROPHORESIS, V16, P218, DOI 10.1002/elps.1150160137; Wimmer K, 1996, ELECTROPHORESIS, V17, P1741, DOI 10.1002/elps.1150171112; Wimmer K, 1997, BIOCHEM SOC T, V25, P262, DOI 10.1042/bst0250262; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yates PA, 1999, J BIOL CHEM, V274, P36357, DOI 10.1074/jbc.274.51.36357; Yoon BJ, 2002, NAT GENET, V30, P92, DOI 10.1038/ng795; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yoshikawa H, 1996, GENOMICS, V31, P28, DOI 10.1006/geno.1996.0005	110	57	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2002	21	35					5414	5426		10.1038/sj.onc.1205608	http://dx.doi.org/10.1038/sj.onc.1205608			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579VC	12154404				2022-12-17	WOS:000177197700008
J	Gery, S; Sawyers, CL; Agus, DB; Said, JW; Koeffler, HP				Gery, S; Sawyers, CL; Agus, DB; Said, JW; Koeffler, HP			TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen-regulated; epidermal growth factor; follistatin and antiproliferative	EPIDERMAL GROWTH-FACTOR; TRANSMEMBRANE PROTEIN; TYROSINE KINASE; RECEPTOR GENE; EXPRESSION; PROGRESSION; FOLLISTATIN; IDENTIFICATION; TRANSCRIPTION; INDEPENDENCE	We have identified a gene that is highly expressed in the androgen-dependent prostate cancer cell line, LNCaP. Sequence analysis revealed that it was identical to a recently cloned gene designated TMEFF2, which encodes a transmembrane protein containing an epidermal growth factor (EGF)-like motif and two follistatin domains. This gene was highly expressed only in primary samples of normal prostate and prostate cancer as well as normal brain. Expression of the gene was controlled by androgen as shown by dihydrotestosterone markedly increasing TMEFF2 expression in LNCaP cells. Also, androgen-dependent human prostate cancer xenografts (CWR22) expressed high levels of TMEFF2 and these levels markedly decreased by day 10 after castration of the mice. Furthermore, a large number of androgen-dependent xenografts (CWR22, LuCaP-35, LAPC-4AD, LAPC-9AD) exhibited higher levels of TMEFF2 mRNA than androgen-independent xenografts (CWR22R, LAPC-3AI, LAPC-4AI, LAPC-9AI). Ectopic expression of TMEFF2 in DU145 and PC3 cells resulted in their prominent inhibition of growth. Taken together, the results demonstrate that TMEFF2 is a androgen-regulated gene, which can suppress growth of prostate cancer cells and our xenograft data show that escape of prostate cancer cells from androgen modulation causes them to decrease their expression of this gene, which may result in their more malignant behavior.	Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Ctr Hlth Sci, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gery, S (corresponding author), Cedars Sinai Med Ctr, Div Hematol Oncol, Los Angeles, CA 90048 USA.		Sawyers, Charles/G-5327-2016	Agus, David B./0000-0002-7499-7822	NCI NIH HHS [CA26038-20] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Amler LC, 2000, CANCER RES, V60, P6134; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Benedit P, 2001, ONCOGENE, V20, P1455, DOI 10.1038/sj.onc.1204233; Campbell MJ, 2000, ONCOGENE, V19, P5091, DOI 10.1038/sj.onc.1203888; Chen TS, 2000, CANCER RES, V60, P2132; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; Gregory CW, 1998, CANCER RES, V58, P5718; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Horie M, 2000, GENOMICS, V67, P146, DOI 10.1006/geno.2000.6228; HSIEH TY, 1996, BIOCHEM BIOPH RES CO, V2231, P141; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lau KM, 2000, CANCER RES, V60, P3175; Liang GN, 2000, CANCER RES, V60, P4907; Millikan LE, 1999, CLIN DERMATOL, V17, P353, DOI 10.1016/S0738-081X(99)00018-8; Patel K, 1998, INT J BIOCHEM CELL B, V30, P1087, DOI 10.1016/S1357-2725(98)00064-8; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Russell PJ, 1998, CLIN CHEM, V44, P705; Tilley WD, 1996, CLIN CANCER RES, V2, P277; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; VELDSCHOLTE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P187, DOI 10.1016/0167-4889(90)90075-O; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Xu JC, 2001, CANCER RES, V61, P1563; Xu LL, 2000, GENOMICS, V66, P257, DOI 10.1006/geno.2000.6214; Young J, 2001, P NATL ACAD SCI USA, V98, P265, DOI 10.1073/pnas.011415298; Zhao XY, 2001, STEROIDS, V66, P293, DOI 10.1016/S0039-128X(00)00164-1; Zitzelsberger H, 2001, BRIT J CANCER, V84, P202, DOI 10.1054/bjoc.2000.1533	34	57	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4739	4746		10.1038/sj.onc.1205142	http://dx.doi.org/10.1038/sj.onc.1205142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101412				2022-12-17	WOS:000176716300003
J	Takakuwa, T; Dong, ZM; Nakatsuka, S; Kojka, S; Harabuchi, Y; Yang, WI; Nagata, S; Aozasa, K				Takakuwa, T; Dong, ZM; Nakatsuka, S; Kojka, S; Harabuchi, Y; Yang, WI; Nagata, S; Aozasa, K			Frequent mutations of Fas gene in nasal NK/T cell lymphoma	ONCOGENE			English	Article						nasal NK/T cell lymphoma.; Fas; apoptosis; mutation	LETHAL MIDLINE GRANULOMA; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; HELICOBACTER-PYLORI; GASTRIC LYMPHOMA; APO-1/CD95 GENE; LUNG-CANCER; KILLER-CELL; ANTIGEN	Fas (Apo-1/CD95) is a cell-surface, receptor involved in cell death signaling through binding of Fas ligand. Mutation of Fas gene in lymphoid cells results in accumulation of these cells, which might thus contribute to lymphomagenesis. We examined the open reading frame of Fas cDNA in 14 cases of nasal NK/T-cell lymphoma. Mutations of Fas gene were detected in seven (50%) of 14 cases which comprised four frameshift, two missense, and one silent mutations. Frameshift mutations were caused by insertion of 1 bp () at nucleotide 1095 in two cases and by deletion of 1 bp at nucleotide 597 and at 704, respectively, in one each. Mouse T-cell lymphoma cells transfected with two missense mutated genes and frameshift mutations caused by insertion of I bp (A) at nucleotide 1095 were resistant to apoptosis induced by the anti-Fas antibody. These findings suggested that accumulation of lymphoid cells with Fas mutations provides a basis for the development of nasal NK/T-cell lymphoma.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Univ Ryukyus, Dept Otorhinolaryngol, Fac Med, Okinawa 9030215, Japan; Asahikawa Med Coll, Dept Otorhinolaryngol, Asahikawa, Hokkaido 0788510, Japan; Osaka Univ, Dept Genet, Grad Sch Med, Osaka 5650871, Japan; Yonsei Univ, Dept Pathol, Coll Med, Seoul 120749, South Korea	Osaka University; University of the Ryukyus; Asahikawa Medical College; Osaka University; Yonsei University; Yonsei University Health System	Aozasa, K (corresponding author), Osaka Univ, Sch Med, Dept Pathol C3, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.		Nagata, Shigekazu/AAG-3203-2019; Nakatsuka, Shin-ichi/AAW-5968-2020	Nagata, Shigekazu/0000-0001-9758-8426; Nakatsuka, Shin-ichi/0000-0002-0055-8149				AOZASA K, 1992, INT J CANCER, V52, P673, DOI 10.1002/ijc.2910520429; Bertoni F, 2000, LEUKEMIA, V14, P446, DOI 10.1038/sj.leu.2401708; Boldrini L, 2001, ONCOGENE, V20, P6632, DOI 10.1038/sj.onc.1204727; ENNO A, 1995, AM J PATHOL, V147, P217; Gronbaek K, 1998, BLOOD, V92, P3018; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HOLM LE, 1985, NEW ENGL J MED, V312, P601, DOI 10.1056/NEJM198503073121001; Hongyo T, 2000, CANCER RES, V60, P2345; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jaffe ES, 1996, AM J SURG PATHOL, V20, P103, DOI 10.1097/00000478-199601000-00012; KATO I, 1985, JPN J CANCER RES, V76, P1085; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Lee SH, 1999, CANCER RES, V59, P3068; Li T, 2000, LAB INVEST, V80, P493, DOI 10.1038/labinvest.3780055; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muschen M, 2000, CANCER RES, V60, P5640; Ng CS, 1999, HUM PATHOL, V30, P48, DOI 10.1016/S0046-8177(99)90299-X; Ohsawa M, 1999, INT J CANCER, V81, P865, DOI 10.1002/(SICI)1097-0215(19990611)81:6<865::AID-IJC5>3.0.CO;2-S; Park WS, 2001, J PATHOL, V193, P162; PARSONS R, 1995, CANCER RES, V55, P5548; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Seeberger H, 2001, LAB INVEST, V81, P977, DOI 10.1038/labinvest.3780310; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takakuwa T, 2001, CANCER RES, V61, P1382; WEISS LM, 1992, BLOOD, V79, P1789; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	31	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 11	2002	21	30					4702	4705		10.1038/sj.onc.1205571	http://dx.doi.org/10.1038/sj.onc.1205571			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	569WH	12096347				2022-12-17	WOS:000176625100012
J	Qanungo, S; Basu, A; Das, M; Haldar, S				Qanungo, S; Basu, A; Das, M; Haldar, S			2-methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells	ONCOGENE			English	Article						apoptosis; mitochondria; 2-methoxyestradiol; pancreatic cancer	ENDOGENOUS MAMMALIAN METABOLITE; WILD-TYPE P53; ESTROGEN METABOLITE; CYTOCHROME-C; INHIBITS ANGIOGENESIS; BCL2 PHOSPHORYLATION; ACTIVATION; GROWTH; PATHWAY; ARREST	The antiproliferative action of 2-methoxyestradiol (2-ME), an endogenous estrogen metabolite is specific for cancer cells and is mediated by the induction of programmed cell death or apoptosis. But the identity of the downstream effectors of apoptotic signaling induced by 2-ME is not known. In the present study, we explored the effect of 2-ME on apoptosis in a panel of human pancreatic cancer cell lines. We have identified two categories of pancreatic cancer cell lines, which are either sensitive to 2-ME such as MIA PaCa-2, CFPAC-1, PANC-1, or non-sensitive to 2-ME such as Hs 766T. The results presented here indicated that the cell lines responsive to 2-ME could undergo apoptosis either by G2-M arrest (PANC-1) with Bcl-X-L phosphorylation or by the accumulation of tetraploid cells in G1-S region (MIA PaCa-2) without Bcl-2/Bcl-X-L phosphorylation. Furthermore, 2-ME induced apoptosis in pancreatic cancer cells is mitochondria dependent as evident by the release of cytochrome c into the cytosol. 2-ME exposed cells exhibit Bid cleavage that is accompanied by the translocation of Bax into the mitochondria. Also 2-ME could induce phosphorylation of Bcl-X-L in G2-M arrested cells, thus indicating the involvement of various anti- and pro-apoptotic regulators in the signaling cascade. The dissection of differential response of pancreatic cancer cell lines holds promise for future therapeutic intervention.	Case Western Reserve Univ, Metrohlth Med Ctr, Ireland Canc Ctr, Dept Res Pharmacol, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System	Haldar, S (corresponding author), Case Western Reserve Univ, Metrohlth Med Ctr, Ireland Canc Ctr, Dept Res Pharmacol, R456,Rammelkamp Bldg,2500 Metrohlth Dr, Cleveland, OH 44109 USA.	Shaldar@metrohealth.org			NATIONAL CANCER INSTITUTE [R01CA077328] Funding Source: NIH RePORTER; NCI NIH HHS [CA77328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe M, 2000, CANCER, V88, P2000, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B; Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ANDREAS G, 2000, CANCER RES, V60, P2163; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Attalla H, 1998, BIOCHEM BIOPH RES CO, V247, P616, DOI 10.1006/bbrc.1998.8870; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Basu A, 1998, INT J ONCOL, V13, P659; BASU A, 2002, IN PRESS NEOPLASIA, V4; Brady H J, 1999, Results Probl Cell Differ, V23, P127; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; Denmeade S R, 1997, Adv Pharmacol, V41, P553, DOI 10.1016/S1054-3589(08)61072-8; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; Huober JB, 2000, INT J RADIAT ONCOL, V48, P1127, DOI 10.1016/S0360-3016(00)00767-7; Ibrahim SM, 2001, PANCREAS, V23, P72, DOI 10.1097/00006676-200107000-00011; KARPINICH NO, 2002, IN PRESS J BIOL CHEM; KATOTAKA M, 1998, CANCER RES, V58, P4761; KHAN P, 1979, J CELL BIOL, V82, P1; Kitagawa H, 1999, FEBS LETT, V443, P181, DOI 10.1016/S0014-5793(98)01709-8; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin HL, 2000, CANCER-AM CANCER SOC, V89, P983, DOI 10.1002/1097-0142(20000901)89:5<983::AID-CNCR7>3.3.CO;2-7; Lin HL, 2001, CANCER, V92, P500, DOI 10.1002/1097-0142(20010801)92:3<500::AID-CNCR1348>3.0.CO;2-4; Lottering ML, 1996, CANCER LETT, V110, P181, DOI 10.1016/S0304-3835(96)04489-8; MacCarthy-Morrogh L, 2000, CANCER RES, V60, P5441; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; MACLUSKY NJ, 1983, CATECHOL ESTROGENS, P151; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MARTUCCI CP, 1979, ENDOCRINOLOGY, V105, P1288, DOI 10.1210/endo-105-6-1288; MARTUCCI CP, 1983, CATECHOL ESTROGENS, P115; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; Pan GH, 1998, FEBS LETT, V426, P151, DOI 10.1016/S0014-5793(98)00330-5; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Schumacher G, 1999, CLIN CANCER RES, V5, P493; Seegers JC, 1997, J STEROID BIOCHEM, V62, P253, DOI 10.1016/S0960-0760(97)00043-5; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; VANDERHEIDE MG, 2001, NATURE CELL BIOL, V1, pE209; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wassberg E, 1999, UPSALA J MED SCI, V104, P1; Wassberg E, 1999, AM J PATHOL, V154, P395, DOI 10.1016/S0002-9440(10)65286-8; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zoubine MN, 1999, INT J ONCOL, V15, P639	60	57	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2002	21	26					4149	4157		10.1038/sj.onc.1205508	http://dx.doi.org/10.1038/sj.onc.1205508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037671	Bronze			2022-12-17	WOS:000176186000009
J	Satoh, M; Toma, H; Sugahara, K; Etoh, K; Shiroma, Y; Kiyuna, S; Takara, M; Matsuoka, M; Yamaguchi, K; Nakada, K; Fujita, K; Kojima, S; Hori, E; Tanaka, Y; Kamihira, S; Sato, Y; Watanabe, T				Satoh, M; Toma, H; Sugahara, K; Etoh, K; Shiroma, Y; Kiyuna, S; Takara, M; Matsuoka, M; Yamaguchi, K; Nakada, K; Fujita, K; Kojima, S; Hori, E; Tanaka, Y; Kamihira, S; Sato, Y; Watanabe, T			Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S-stercoralis	ONCOGENE			English	Article						HTLV-1 provirus load; clonality; S. stercoralis antigen; IL-2; ATL	VIRUS TYPE-I; BLOOD MONONUCLEAR-CELLS; LEUKEMIA-VIRUS; PROVIRAL DNA; MONOCLONAL INTEGRATION; CLONAL PROLIFERATION; GENE-EXPRESSION; INFECTED-CELLS; INTERLEUKIN-2; LINES	The intermediate state of HTLV-1 infection, often found in individuals dually infected with Strongyloides stercoralis (S. stercoralis) and HTLV-1. is assumed to be a preleukemic state of adult T-cell leukemia (ATL). To investigate the effects of S. stercoralis superinfection on the natural history of HTLV-1 infection, we characterized peripheral blood samples of these individuals in Okinawa. Japan, an endemic area for both HTLV-1 and S. stercoralis and we studied effects of the parasite antigen on T-cells. The dually infected individuals showed a significantly higher provirus load and an increase in CD4(+)25(+) T cell population, with a significant, positive correlation. This increase was attributable to polyclonal expansion of HTLV-1-infected cells, as demonstrated by inverse-long PCR analysis of the integration sites. S. stercoralis antigen activated the IL-2 promoter in reporter gene assays, induced production of IL-2 by PBMC in vitro, and supported growth of IL-2 dependent cell lines immortalized by HTLV-1 infection or the transduction of Tax. Taken collectively, these results indicate that S. stercoralis infection induces polyclonal expansion of HTLV-1-infected cells by activating the IL-2/IL-2R system in dually infected carriers, an event which may be a precipitating factor for ATL and inflammatory diseases.	Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, Tokyo 1088639, Japan; Saitama Med Sch, Dept Med Zool, Moroyama, Saitama, Japan; Ryukoku Univ, Sch Med, Dept Parasitol, Okinawa, Japan; Nagasaki Univ, Sch Med, Dept Lab Med, Nagasaki 852, Japan; Kumamoto Univ, Sch Med, Dept Internal Med, Kumamoto 860, Japan; Izumizaki Hosp, Okinawa, Japan; Kyoto Univ, Inst Virus Res, Kyoto 606, Japan; Gushikawa Clin, Okinawa, Japan; Kumamoto Univ, Sch Med, Blood Transfus Serv, Kumamoto 8608556, Japan; Okinawa Kyodo Hosp, Okinawa, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Med Zool, Tokyo 113, Japan; Univ Tokyo, Inst Med Sci, Dept Parasitol, Tokyo, Japan; Univ Ryukyus, Fac Med, Okinawa Asia Res Ctr Med Sci, Dept Infect Dis & Immunol, Okinawa, Japan	University of Tokyo; Saitama Medical University; Ryukoku University; Nagasaki University; Kumamoto University; Kyoto University; Kumamoto University; Tokyo Medical & Dental University (TMDU); University of Tokyo; University of the Ryukyus	Watanabe, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tnabe@ims.u-tokyo.ac.jp		Matsuoka, Masao/0000-0002-0473-754X				AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Arakaki T., 1988, Japanese Journal of Tropical Medicine and Hygiene, V16, P11; BLANK A, 1993, LEUKEMIA LYMPHOMA, V9, P407, DOI 10.3109/10428199309148542; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; Etoh K, 1997, CANCER RES, V57, P4862; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJITA K, 1985, Tropical Medicine, V27, P203; FURUKAWA Y, 1992, BLOOD, V80, P1012; Gabet AS, 2000, ONCOGENE, V19, P4954, DOI 10.1038/sj.onc.1203870; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GREENBERG SJ, 1989, J INFECT DIS, V159, P741, DOI 10.1093/infdis/159.4.741; Grove DI, 1996, ADV PARASIT, V38, P251, DOI 10.1016/S0065-308X(08)60036-6; HATTORI T, 1981, BLOOD, V58, P645; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ITOYAMA Y, 1988, NEUROLOGY, V38, P816, DOI 10.1212/WNL.38.5.816; Kamihira S, 2000, INT J HEMATOL, V72, P79; Kreuzer KA, 1999, CANCER RES, V59, P3171; LAM KMC, 1991, LANCET, V337, P876, DOI 10.1016/0140-6736(91)90203-2; LANGRIDGE WHR, 1987, METHOD ENZYMOL, V153, P336; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MACCHIA G, 1990, MOL CELL BIOL, V10, P2731, DOI 10.1128/MCB.10.6.2731; MAEDA M, 1985, J EXP MED, V162, P2169, DOI 10.1084/jem.162.6.2169; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; MOCHIZUKI M, 1992, J INFECT DIS, V166, P943, DOI 10.1093/infdis/166.4.943; Mori N, 2000, BLOOD, V95, P3915; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NAKADA K, 1984, LANCET, V1, P633; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; NEVA FA, 1986, J INFECT DIS, V153, P397, DOI 10.1093/infdis/153.3.397; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Ono A, 1998, JPN J CANCER RES, V89, P608, DOI 10.1111/j.1349-7006.1998.tb03262.x; ONO A, 1995, BRIT J OPHTHALMOL, V79, P270, DOI 10.1136/bjo.79.3.270; OSAME M, 1986, LANCET, V1, P1031; PATEY O, 1992, AIDS, V6, P575, DOI 10.1097/00002030-199206000-00009; PLUMELLE Y, 1993, HEMATOL PATHOL, V7, P251; SATO Y, 1990, Japanese Journal of Parasitology, V39, P213; SATO Y, 1989, CLIN IMMUNOL IMMUNOP, V53, P430, DOI 10.1016/0090-1229(89)90005-6; SATO Y, 1985, T ROY SOC TROP MED H, V79, P51, DOI 10.1016/0035-9203(85)90233-0; SATOH M, 1991, INT ARCH ALLER A IMM, V96, P95, DOI 10.1159/000235541; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SUGAMURA K, 1984, INT J CANCER, V34, P221, DOI 10.1002/ijc.2910340213; TAJIMA K, 1986, HEMATOL ONCOL, V4, P31, DOI 10.1002/hon.2900040106; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TATEWAKI M, 1995, BLOOD, V86, P3109; UCHIYAMA T, 1985, J CLIN INVEST, V76, P446, DOI 10.1172/JCI111992; Watanabe T, 1997, INT J HEMATOL, V66, P257; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; YAMAGUCHI K, 1987, LANCET, V2, P94, DOI 10.1016/S0140-6736(87)92752-8; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1989, ANN NEUROL, V26, P331, DOI 10.1002/ana.410260304; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIMURA K, 1993, AM J OPHTHALMOL, V116, P156, DOI 10.1016/S0002-9394(14)71279-6	59	57	59	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2466	2475		10.1038/sj.onc.1205329	http://dx.doi.org/10.1038/sj.onc.1205329			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971181				2022-12-17	WOS:000174918400003
J	Saucier, C; Papavasiliou, V; Palazzo, A; Naujokas, MA; Kremer, R; Park, M				Saucier, C; Papavasiliou, V; Palazzo, A; Naujokas, MA; Kremer, R; Park, M			Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis	ONCOGENE			English	Article						receptor tyrosine kinase; transformation; tumorigenesis; metastasis; Grb2; She	GROWTH-FACTOR RECEPTOR; TPR-MET ONCOPROTEIN; PHOSPHOLIPASE C-GAMMA; BINDING-SITE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL MORPHOGENESIS; CARBOXY-TERMINUS; BETA-SUBUNIT; ACTIVATION; REQUIRES	Many human cancers have been associated with the deregulation of receptor tyrosine kinases (RTK). However, the individual contribution of receptor-associated signaling proteins in cellular transformation and metastasis is poorly understood. To examine the role of RTK activated signal transduction pathways to processes involved in cell transformation, we have exploited the oncogenic derivative of the Met RTK (Tpr-Met). Unlike other RTKs, twin tyrosine residues in the carboxy-terminal tail of the Met oncoprotein and receptor are required for all biological and transforming activities, and a mutant lacking these tyrosines is catalytically active but non transforming. Using this mutant we have inserted oligonucleotide cassettes, each encoding a binding site for a specific signaling protein derived from other RTKs. We have generated variant forms of the Tpr-Met oncoprotein with the ability to bind individually to the p85 subunit of P13'K, PLCgamma, or to the Grb2 or Shc adaptor proteins. Variants that recruit the Shc or Grb2 adaptor proteins generated foci of morphologically transformed fibroblast cells and induced anchorage-independent growth, scattering of epithelial cells and experimental metastasis. In contrast, variants that bind and activate P13'K or PLCgamma failed to generate readily detectable foci. Although cell lines expressing the P13'K variant grew in soft-agar, these cells were non metastatic. Using this unique RTK oncoprotein model, we have established that Grb2 or Shc dependent signaling pathways are sufficient for cell transformation and metastatic spread.	McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hosp, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada.	morag@molonc.mcgill.ca	Palazzo, Alexander/B-1270-2013; Saucier, Caroline/Q-9250-2019	Palazzo, Alexander/0000-0002-9700-1995; Saucier, Caroline/0000-0001-7678-9886; Kremer, Richard/0000-0002-7053-2139				Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chang JS, 1997, CANCER RES, V57, P5465; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SALCINI AE, 1994, ONCOGENE, V9, P2827; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU H, 1994, J BIOL CHEM, V269, P29943	51	57	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1800	1811		10.1038/sj.onc.1205261	http://dx.doi.org/10.1038/sj.onc.1205261			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896612	Bronze			2022-12-17	WOS:000174284500002
J	Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Abbondandolo, A; Resnick, MA; Fronza, G				Monti, P; Campomenosi, P; Ciribilli, Y; Iannone, R; Inga, A; Abbondandolo, A; Resnick, MA; Fronza, G			Tumour p53 mutations exhibit promoter selective dominance over wild type p53	ONCOGENE			English	Article						dominance; p53; mutation; yeast functional assay; p53 responsive element	CELL-CYCLE; MUTANTS; YEAST; INHIBITION; PROTEIN; DNA; IDENTIFICATION; TRANSCRIPTION; CANCERS; ARREST	The tumour suppressor gene p53 is frequently mutated in human cancer. Tumour derived p53 mutants are usually transcriptionally inactive, but some mutants retain the ability to transactivate a subset of p53 target genes. In addition to simple loss of function, some p53 mutants may be carcinogenic through a dominant negative mechanism. Aiming at a more general classification of p53 mutants into predictive functional categories it is important to determine (i) which p53 mutants are dominant, (ii) what features characterize dominant mutants and (iii) whether dominance is target gene specific. The ability of 71 p53 mutants to inhibit wild type p53 was determined using a simple yeast transcriptional assay. Approximately 30% of the mutants were dominant. They preferentially affect highly conserved amino acids (P < 0.005), which are frequently mutated in turnours (P < 0.005), and usually located near the DNA binding surface of the protein (P < 0.001). Different tumour-derived amino acid substitutions at the same codon usually have the same dominance phenotype. To determine whether the ability of p53 mutants to inhibit wild type p53 is target gene specific, the dominance towards p21, bax, and PIG3 binding sites was examined. Approximately 40% of the 45 mutants examined were dominant for the p21 (17/45) or PIG3 (20/45) responsive elements and 71% (32/45) were dominant for the bax responsive element. These differences are statistically significant (p21 vs bax, P < 0.003; bax vs PIG3, P < 0.02, Fisher's exact test) and defined a hierarchy of dominance. Finally, we extended the analysis to a group of mutants isolated in BRCA-associated tumours, some of which retained wild type level of transcription in yeast as well as in human cells, but show gain of function in transformation assays. Since transformation assays require transdominant inhibition of the endogenous wild type allele, one possible explanation for the behaviour of the BRCA-associated mutants is that they adopt conformations able to bind DNA alone but not in mixed tetramers with wild type p53. The yeast data do not support this explanation, because all BRCA-associated mutants that behaved as wild type in transcription assay were recessive in dominance assays.	Natl Canc Res Inst, IST, Mutagenesis Lab, I-16132 Genoa, Italy; Univ Insubria, DBSF, Human Genet Lab, Varese, Italy; NIEHS, Chromosome Stabil Grp, Res Triangle Pk, NC 27709 USA; Univ Genoa, Dept Oncol Biol & Genet, Genoa, Italy	University of Insubria; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Genoa	Fronza, G (corresponding author), Natl Canc Res Inst, IST, Mutagenesis Lab, Largo R Benzi 10, I-16132 Genoa, Italy.	gilberto.fronza@istge.it	resnick, Michael/F-1668-2019; Inga, Alberto/AAC-3815-2022; Monti, Paola/Y-1118-2019; Ciribilli, Yari/K-2751-2018; Campomenosi, Paola/C-9729-2011; Fronza, Gilberto/AAG-8735-2019	resnick, Michael/0000-0002-8473-7506; Inga, Alberto/0000-0002-8767-1637; Monti, Paola/0000-0002-1978-4998; Ciribilli, Yari/0000-0001-9231-379X; Campomenosi, Paola/0000-0002-8853-1134; Fronza, Gilberto/0000-0003-3722-553X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065079, Z01ES065079] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Di Como CJ, 1998, ONCOGENE, V16, P2527; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FREBOURG T, 1994, CANCER RES, V54, P878; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Inga A, 1997, CARCINOGENESIS, V18, P2019, DOI 10.1093/carcin/18.10.2019; Inga A, 1997, ONCOGENE, V14, P1307, DOI 10.1038/sj.onc.1200952; Inga A, 1999, CANCER RES, V59, P689; Inga A, 1998, CARCINOGENESIS, V19, P741, DOI 10.1093/carcin/19.5.741; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Kelly JD, 1999, J BIOL CHEM, V274, P18327, DOI 10.1074/jbc.274.26.18327; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marutani M, 1999, CANCER RES, V59, P4765; Monti P, 2000, MUTAGENESIS, V15, P127, DOI 10.1093/mutage/15.2.127; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Waterman MJF, 1996, CANCER RES, V56, P158	27	57	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	2002	21	11					1641	1648		10.1038/sj.onc.1205250	http://dx.doi.org/10.1038/sj.onc.1205250			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	527XX	11896595				2022-12-17	WOS:000174214200002
J	Movilla, N; Dosil, M; Zheng, Y; Bustelo, XR				Movilla, N; Dosil, M; Zheng, Y; Bustelo, XR			How Vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42	ONCOGENE			English	Article						Vav family; Rho GEFs; DH domain; RhoA; Rac; Cdc42; cytoskeleton	CRYSTAL-STRUCTURE; T-CELL; EXCHANGE; FAMILY; ACTIVATION; PROTOONCOGENE; PHOSPHORYLATION; THYMOCYTES; SELECTION; COMPLEX	Vav proteins are GDP/GTP exchange factors for Rho/Rac GTPases that are activated by tyrosine phosphorylation. These proteins activate Rac1, RhoG, and RhoA but not the highly related Cdc42 protein. At present, there is no available information to explain this substrate selectivity at the structural level. Here we show that the selection of Vav proteins substrates is achieved at two different levels. On one hand, Vav proteins utilize some residues of the beta2/beta3 region of Rho/Rac GTPases (D49 and E54) to assure the specific binding to its substrate. In addition, these exchange factors need a second structural signal located in the beta5 region of Rho/Rac proteins (residue K118) to promote proper GDP/GTP exchange. These results identify the amino acid residues that allow the discrimination of the Vav family substrates from Cdc42 and, in addition, demonstrate that the activation of specific Rho/Rac GTPases by these GEFs requires two concatenated events, binding and subsequent enzyme reaction, whose specificities are determined by two separate regions of Rho proteins.	Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain; Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA; Univ Salamanca, Dept Biochem, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Tennessee System; University of Tennessee Health Science Center; University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, Salamanca 37007, Spain.		Bustelo, Xose R./AAD-2081-2022; Zheng, Yi/J-7235-2015; Bustelo, Xose R./A-9526-2010; Dosil, Mercedes/A-9536-2016	Bustelo, Xose R./0000-0001-9398-6072; Zheng, Yi/0000-0001-7089-6074; Bustelo, Xose R./0000-0001-9398-6072; Dosil, Mercedes/0000-0001-8119-8263	NCI NIH HHS [CA73735-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0	17	57	63	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8057	8065		10.1038/sj.onc.1205000	http://dx.doi.org/10.1038/sj.onc.1205000			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781818				2022-12-17	WOS:000172396800002
J	Bartkova, J; Falck, J; Rajpert-De Meyts, E; Skakkebaek, NE; Lukas, J; Bartek, J				Bartkova, J; Falck, J; Rajpert-De Meyts, E; Skakkebaek, NE; Lukas, J; Bartek, J			Chk2 tumour suppressor protein in human spermatogenesis and testicular germ-cell tumours	ONCOGENE			English	Article						cell cycle checkpoints; Chk2; spermatogenesis; carcinoma in situ; testicular germ-cell tumours	DNA-DAMAGE RESPONSE; P53 PROTEIN; MEIOTIC CHROMOSOMES; ATM; CHECKPOINT; CANCER; KINASE; LINE; MICE; DIFFERENTIATION	Chk2 is a transducer of DNA damage signals and a tumour suppressor whose germ-line mutations predispose to diverse tumour types. Unlike its downstream targets such as the p53 tumour suppressor, the expression patterns of Chk2 in tissues and tumours remain unknown. As DNA breaks occur commonly during gametogenesis, and p53 is wild-type and overexpressed in testicular cancer, we examined abundance and localisation of the Chk2 protein during normal development of human testes, and at various stages of germ-cell tumour (GCT) pathogenesis. Our results show that Chk2 is abundant in foetal germ cells and adult spermatogonia, yet only weakly expressed or lacking during the meiotic and later stages of spermatogenesis. High levels of Chk2 are detected in the majority of GCTs including all preinvasive carcinoma-in-situ lesions, contrary to variable expression and even lack of Chk2 in subsets of invasive GCTs and some teratoma structures, respectively. Together with our analyses of cell culture models, these results indicate that downmodulation or lack of Chk2 is not simply attributable to quiescence or differentiation, they suggest a role for Chk2 in mitotic rather than meiotic divisions, support the concept of foetal origin of GCTs, and have implications for protein-based screening for tumour-associated aberrations of Chk2.	Inst Canc Biol, Danish Canc Soc, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Rigshosp, Dept Growth & Reprod, DK-2100 Copenhagen, Denmark	Danish Cancer Society; Rigshospitalet; University of Copenhagen	Bartek, J (corresponding author), Inst Canc Biol, Danish Canc Soc, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014; Rajpert-De Meyts, Ewa/H-6526-2019	Rajpert-De Meyts, Ewa/0000-0002-5946-7559; Lukas, Jiri/0000-0001-9087-506X				ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Bartkova J, 2000, ONCOGENE, V19, P4146, DOI 10.1038/sj.onc.1203769; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chaganti RSK, 2000, CANCER RES, V60, P1475; Chehab NH, 2000, GENE DEV, V14, P278; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Grigor KM, 1998, APMIS, V106, P221, DOI 10.1111/j.1699-0463.1998.tb01339.x; HARTLEY AL, 1989, CANCER GENET CYTOGEN, V42, P221, DOI 10.1016/0165-4608(89)90090-3; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaneko Y, 1999, ONCOGENE, V18, P3673, DOI 10.1038/sj.onc.1202706; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Schwartz D, 1999, CELL GROWTH DIFFER, V10, P665; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Shieh SY, 2000, GENE DEV, V14, P289; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	30	57	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5897	5902		10.1038/sj.onc.1204746	http://dx.doi.org/10.1038/sj.onc.1204746			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593395				2022-12-17	WOS:000171037200013
J	Rasmussen, SB; Kordon, E; Callahan, R; Smith, GH				Rasmussen, SB; Kordon, E; Callahan, R; Smith, GH			Evidence for the transforming activity of a truncated Int6 gene, in vitro	ONCOGENE			English	Article						Int6; eIF3-p48; transformation; mammary gland; epithelial cells	MAMMARY EPITHELIAL-CELLS; C-HA-RAS; HTLV-I TAX; RNA 5' CAP; TRANSLATION INITIATION; GROWTH-FACTOR; TUMOR VIRUS; MALIGNANT TRANSFORMATION; TRANSGENIC MICE; PROSTATE-CANCER	Int6/eIF3-p48 was first identified as a common integration site for MMTV in mouse mammary tumors. In all cases, the MMTV integration event resulted in an interruption of the normal Int6 transcript from one allele leaving the second allele intact and operative. We hypothesize that insertion of MMTV into Int6 results in a mutated allele that encodes a shortened Int6 mRNA and protein (Int6sh), which either modifies normal Int6 function or possesses a new independent function. To confirm the transforming potential of the mutation and its dominant function, we transfected two mammary epithelial cell lines, MCF10A (human), and HC11 (mouse), with Int6sh under the control of the elongation factor-la (eEF1A) promoter. Expression of Int6sh in MCF10A and HC11 mammary epithelial cells leads to anchorage-independent growth in soft agar indicative of a transformed phenotype. Colonies selected from agar exhibited high levels of mutated Int6sh and wild type Int6 RNA transcripts by RT-PCR and Northern blot analysis. In addition, Int6sh transformed MCF10A and HC11 cells formed nodular growths, in vivo, in immune compromised hosts. NIH3T3 cells, mouse embryo fibroblasts, were also transformed to anchorage-independent growth in vitro by Int6sh expression. These observations provide direct evidence that the Int6 mutations observed in MMTV-induced tumors and hyperplasia contribute to the malignant transformation of the mammary epithelial cells.	NCI, NIH, Tumor Immunol & Biol Lab, Bethesda, MD 20892 USA; Acad Nacl Med Buenos Aires, Buenos Aires, DF, Argentina	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Buenos Aires National Academy of Medicine	Smith, GH (corresponding author), NCI, NIH, Tumor Immunol & Biol Lab, 10 Center Dr,Room 8B07, Bethesda, MD 20892 USA.							Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1992, MOL CARCINOGEN, V6, P43, DOI 10.1002/mc.2940060108; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Diella F, 1997, DNA CELL BIOL, V16, P839, DOI 10.1089/dna.1997.16.839; Fedele M, 1998, ONCOGENE, V17, P413, DOI 10.1038/sj.onc.1201952; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Girard L, 1998, ONCOGENE, V16, P517, DOI 10.1038/sj.onc.1201562; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; Karniol B, 1998, FEBS LETT, V439, P173, DOI 10.1016/S0014-5793(98)01367-2; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Marchetti A, 2001, INT J ONCOL, V18, P175; Methot N, 1996, MOL CELL BIOL, V16, P5328; Miyazaki S, 1997, GENOMICS, V46, P155, DOI 10.1006/geno.1997.4996; MIYAZAKI S, 1995, GENOMICS, V27, P420, DOI 10.1006/geno.1995.1072; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Neuveut C, 1997, J BIOMED SCI, V4, P229, DOI 10.1007/BF02253422; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Nupponen NN, 1999, AM J PATHOL, V154, P1777, DOI 10.1016/S0002-9440(10)65433-8; Pauley R J, 1993, Eur J Cancer Prev, V2 Suppl 3, P67; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Sambrook J, 1989, MOL CLONING LAB MANU; SOULE HD, 1990, CANCER RES, V50, P6075; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wei N, 1999, TRENDS GENET, V15, P98, DOI 10.1016/S0168-9525(98)01670-9; WEN JY, 1995, MOL REPROD DEV, V41, P399, DOI 10.1002/mrd.1080410402	41	57	57	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5291	5301		10.1038/sj.onc.1204624	http://dx.doi.org/10.1038/sj.onc.1204624			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536042				2022-12-17	WOS:000170575500005
J	Gan, DD; Reiss, K; Carrill, T; Del Valle, L; Croul, S; Giordano, A; Fishman, P; Khalili, K				Gan, DD; Reiss, K; Carrill, T; Del Valle, L; Croul, S; Giordano, A; Fishman, P; Khalili, K			Involvement of Wnt signaling pathway in murine medulloblastoma induced by human neurotropic JC virus	ONCOGENE			English	Article						Wnt pathway; human polyomavirus; T-antigen; JCV; medulloblastoma	CADHERIN-CATENIN COMPLEX; TRANSGENIC MICE; BETA-CATENIN; EARLY PROTEIN; CELL-CYCLE; TUMORS; POLYOMAVIRUS; TRANSDUCTION; EXPRESSION; MUTATION	By using the early genome of the human neurotropic polyomavirus, JCV, we have created transgenic animals that develop cerebellar primitive neuroectodermal tumors which model human medulloblastoma. Expression of T-antigen was found in some, but not all, tumor cells, and examination of the clonal cell lines derived from the tumor population showed enhanced tumorigenicity of cells expressing T-antigen in comparison to T-antigen negative cells. Considering the earlier notion on the potential involvement of beta -catenin with human medulloblastoma, we investigated various components of the Wnt signaling pathway including beta -catenin, its partner transcription factor, LEF-1, and their downstream target gene c-myc in these two cell populations. Immunohistochemical staining of the cells revealed enhanced nuclear appearance of beta -catenin in T-antigen positive cells. Results from Western blot showed higher levels of beta -catenin and LEF-1 in T-antigen positive cells in comparison to those in T-antigen negative cells. The enhanced level of LEF-1 expression correlated with the increase in DNA binding activity of this protein in nuclear extracts of T-antigen positive cells. Results from Northern and Western blot analyses revealed that the level of c-myc expression is augmented both at the RNA and protein levels in T-antigen positive cells. These observations corroborated results from transfection studies indicating the ability of JCV T-antigen to stimulate c-myc promoter activity. Further, co-transfection experiments revealed that the amount of c-myc and T-antigen protein in tumor cells may dictate the activity of JCV early promoter in these cells. These observations are interesting in light of recent discoveries on the association of JCV with human medulloblastoma and suggest that communication between JCV and the Wnt pathway may be an important event in the genesis of these tumors.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Rabin Med Ctr, Felsenstein Res Ctr, Lab Tumor Immunol, Petah Tiqwa, Israel	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Rabin Medical Center	Khalili, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St 015-96,Room 203, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015; Giordano, Antonio/F-1927-2010	Del Valle, Luis/0000-0003-3894-9206; Giordano, Antonio/0000-0002-5959-016X; Croul, Sidney/0000-0002-2224-5485				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cogen PH, 1996, J NEURO-ONCOL, V29, P103, DOI 10.1007/BF00165523; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; Franks RR, 1996, ONCOGENE, V12, P2573; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; Howard CM, 2000, CANCER RES, V60, P2737; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; Marino S, 2000, GENE DEV, V14, P994; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TAGUCHI F, 1982, MICROBIOL IMMUNOL, V26, P1057, DOI 10.1111/j.1348-0421.1982.tb00254.x; WALKER DL, 1983, POLYOMAVIRUSES HUMAN, P99	29	57	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2001	20	35					4864	4870		10.1038/sj.onc.1204670	http://dx.doi.org/10.1038/sj.onc.1204670			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521197				2022-12-17	WOS:000170271800010
J	Rubin, E; Mittnacht, S; Villa-Moruzzi, E; Ludlow, JW				Rubin, E; Mittnacht, S; Villa-Moruzzi, E; Ludlow, JW			Site-specific and temporally-regulated retinoblastoma protein dephosphorylation by protein phosphatase type 1	ONCOGENE			English	Article						retinoblastoma protein; protein phosphatase type 1; pRB dephosphorylation; PP1 activity	CELL-CYCLE; SUSCEPTIBILITY GENE; PHOSPHORYLATION; PRODUCT; PRB; INACTIVATION; PATTERN; BINDING	pRb is dephosphorylated at mitotic exit by the type 1 serine/threonine protein phosphatases (PP1), Here we demonstrate for the first time that mitotic pRb dephosphorylation is a sequential, temporally-regulated event. We also provide evidence that the three mammalian isoforms of PP1, alpha, gamma -1, and delta, differ in their respective preferences for site-specific pRb dephosphorylation and that the mitotic and G(1) PP1-isoform counterparts exhibit differential activities towards mitotic pRb, Finally, the physiological relevance of the striking contrast between the patterns of Thr821 and Thr826 dephosphorylation, sites known to be important for disrupting binding of LXCXE-containing proteins to pRb, is addressed.	Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Univ Pisa, Dept Expt Pathol, Pisa, Italy; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Pisa; University of Rochester	Ludlow, JW (corresponding author), Incara Pharmaceut, POB 14287, Res Triangle Pk, NC 27709 USA.	JLudlow@incara.com			NCI NIH HHS [CA11198] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; LUSSOW AR, 1991, EUR J IMMUNOL, V21, P2297, DOI 10.1002/eji.1830211002; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Nelson DA, 1997, ONCOGENE, V14, P2407, DOI 10.1038/sj.onc.1201081; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Puntoni F, 1997, MOL CELL BIOCHEM, V171, P115, DOI 10.1023/A:1006892103306; Tamrakar S, 1999, ONCOGENE, V18, P7803, DOI 10.1038/sj.onc.1203211; Tamrakar S, 2000, J BIOL CHEM, V275, P27784; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; Tognarini M, 1998, METH MOL B, V93, P169; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UMSTOTTHALL K, 1999, J BIOL CHEM, V274, P3485; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	38	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 28	2001	20	29					3776	3785		10.1038/sj.onc.1204518	http://dx.doi.org/10.1038/sj.onc.1204518			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439341				2022-12-17	WOS:000169494700003
J	Ho, MKC; Wong, YH				Ho, MKC; Wong, YH			G(z) signaling: emerging divergence from G(i) signaling	ONCOGENE			English	Review						G protein; G(z); signal transduction	GUANINE-NUCLEOTIDE-BINDING; PROTEIN ALPHA-SUBUNIT; HETEROTRIMERIC G-PROTEINS; NEUROBLASTOMA SH-SY5Y CELLS; GTPASE-ACTIVATING PROTEIN; NATURAL-KILLER-CELLS; II ADENYLYL-CYCLASE; METABOTROPIC GLUTAMATE RECEPTORS; RETROGRADE AXONAL-TRANSPORT; RAT SYMPATHETIC NEURONS	A large variety of neurotransmitters, hormones, and chemokines regulate cellular functions via cell surface receptors that are coupled to guanine nucleotide-binding regulatory proteins (G proteins) belonging to the G(i) subfamily. All members of the G(i) subfamily, with the sole exception of G(z), are substrates for the pertussis toxin ADP-ribosyl transferase. G(z) also exhibits unique biochemical and regulatory properties, Initial portrayals of the cellular functions of G(z) bear high resemblance to those of other G(i) proteins both in terms of the receptors and effecters linked to G(z), However, recent discoveries have begun to insinuate a distinct role for G(z) in cellular communication. Functional interactions of the alpha subunit of G(z) (G alpha (z)) with the NKR-P1 receptor, G alpha (z)-specific regulator of G protein signaling, p21-activated kinase, G protein-regulated inducers of neurite outgrowth, and the Eya2 transcription cofactor have been demonstrated. These findings provide possible links for G(z) to participate in cellular development, survival, proliferation, differentiation and even apoptosis, In this review, we have drawn a sketch of a signaling network with G(z) as the centerpiece. The emerging picture is one that distinguishes G(z) from other members of the G(i) subfamily.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Biotechnol Res Inst, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Wong, YH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.		Ho, Maurice K/A-5993-2010; Ho, Maurice K/C-3145-2015	Ho, Maurice K/0000-0002-1211-2347; Ho, Maurice K/0000-0002-1211-2347				Al-Aoukaty A, 1998, IMMUNOLOGY, V95, P618; AlAoukaty A, 1996, BLOOD, V87, P4255, DOI 10.1182/blood.V87.10.4255.bloodjournal87104255; AlAoukaty A, 1997, J BIOL CHEM, V272, P31604, DOI 10.1074/jbc.272.50.31604; AMMER H, 1994, J NEUROCHEM, V62, P1310; AMMER H, 1993, BIOCHEM J, V295, P263, DOI 10.1042/bj2950263; Ammer H, 1996, BRAIN RES, V707, P235, DOI 10.1016/0006-8993(95)01265-6; Ammer H, 1996, EUR J PHARMACOL, V302, P199, DOI 10.1016/0014-2999(96)00082-9; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Bae H, 1997, J BIOL CHEM, V272, P32071, DOI 10.1074/jbc.272.51.32071; Bahia DS, 1998, BIOCHEMISTRY-US, V37, P11555, DOI 10.1021/bi980284o; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Belcheva MM, 2000, CELL SIGNAL, V12, P481, DOI 10.1016/S0898-6568(00)00095-4; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Blahos J, 1998, J BIOL CHEM, V273, P25765, DOI 10.1074/jbc.273.40.25765; BUTKERAIT P, 1995, J BIOL CHEM, V270, P18691, DOI 10.1074/jbc.270.31.18691; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; Chan ASL, 2000, J PHARMACOL EXP THER, V295, P1094; CHAN JSC, 1995, J NEUROCHEM, V65, P2682; Chan JSC, 1998, J NEUROCHEM, V71, P2203; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Corre I, 1999, ONCOGENE, V18, P6335, DOI 10.1038/sj.onc.1203010; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROUCH MF, 1994, EUR J NEUROSCI, V6, P626, DOI 10.1111/j.1460-9568.1994.tb00307.x; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Erlich R, 1998, MOL CELL ENDOCRINOL, V142, P87, DOI 10.1016/S0303-7207(98)00113-0; Fan XM, 2000, J BIOL CHEM, V275, P32129, DOI 10.1074/jbc.M004577200; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; Francken BJB, 2000, MOL PHARMACOL, V57, P1034; Franek M, 1999, NEUROPHARMACOLOGY, V38, P1657, DOI 10.1016/S0028-3908(99)00135-5; GARIBAY JLR, 1991, BIOCHIM BIOPHYS ACTA, V1094, P193, DOI 10.1016/0167-4889(91)90008-L; Garzon J, 1997, EUR J NEUROSCI, V9, P1194, DOI 10.1111/j.1460-9568.1997.tb01474.x; Garzon J, 1997, J PHARMACOL EXP THER, V281, P549; Garzon J, 1998, EUR J NEUROSCI, V10, P2557, DOI 10.1046/j.1460-9568.1998.t01-1-00267.x; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 2000, SCI STKE, V40; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HENDRY IA, 1995, BRAIN RES, V700, P157, DOI 10.1016/0006-8993(95)00945-M; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; HINTON DR, 1990, J NEUROSCI, V10, P2763; Ho MKC, 2000, MOL PHARMACOL, V58, P993, DOI 10.1124/mol.58.5.993; Ho MKC, 1997, J NEUROCHEM, V68, P2514; Ho MKC, 2000, BIOL SIGNAL RECEPT, V9, P21; Ho MKC, 1998, BIOL SIGNAL RECEPT, V7, P80; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jackson EK, 1999, J PHARMACOL EXP THER, V291, P329; Jeong SW, 1998, NEURON, V21, P1201, DOI 10.1016/S0896-6273(00)80636-4; Jiang MS, 1997, RECEPTOR CHANNEL, V5, P187; JIANG MS, 1991, P NATL ACAD SCI USA, V88, P3907, DOI 10.1073/pnas.88.9.3907; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.3.CO;2-I; Kelleher KL, 1998, DEV BRAIN RES, V107, P247, DOI 10.1016/S0165-3806(98)00020-0; KIMURA K, 1995, J BIOL CHEM, V270, P14672, DOI 10.1074/jbc.270.24.14672; Kostenis E, 1997, J BIOL CHEM, V272, P19107, DOI 10.1074/jbc.272.31.19107; Kostenis E, 1998, J BIOL CHEM, V273, P17886, DOI 10.1074/jbc.273.28.17886; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; LAI HWL, 1995, FEBS LETT, V360, P97, DOI 10.1016/0014-5793(95)00088-Q; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; Maghazachi AA, 1997, BIOCHEM BIOPH RES CO, V236, P270, DOI 10.1006/bbrc.1997.6937; MAGHAZACHI AA, 1994, J IMMUNOL, V153, P4969; Maghazachi AA, 1996, J IMMUNOL, V157, P5308; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Marsh SR, 1998, MOL PHARMACOL, V53, P981; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Mody SM, 2000, MOL PHARMACOL, V57, P13; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PARKER EM, 1991, J BIOL CHEM, V266, P519; Parmentier ML, 1998, MOL PHARMACOL, V53, P778, DOI 10.1124/mol.53.4.778; PAULSSEN EJ, 1991, MOL CELL ENDOCRINOL, V76, P45, DOI 10.1016/0303-7207(91)90258-T; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; Raap DK, 1999, J PHARMACOL EXP THER, V288, P561; Raap DK, 2000, NEUROPHARMACOLOGY, V39, P1823, DOI 10.1016/S0028-3908(99)00264-6; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; SanchezBlazquez P, 1995, J PHARMACOL EXP THER, V275, P1590; SANCHEZBLAZQUEZ P, 1994, LIFE SCI, V55, pPL445, DOI 10.1016/0024-3205(94)90098-1; SANCHEZBLAZQUEZ P, 1993, LIFE SCI, V53, pP381, DOI 10.1016/0024-3205(93)90166-Z; Serres F, 2000, J NEUROSCI, V20, P3095, DOI 10.1523/JNEUROSCI.20-09-03095.2000; SHAPIRO MS, 1994, NEURON, V12, P1319, DOI 10.1016/0896-6273(94)90447-2; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SHUM JK, 1995, BIOCHEM BIOPH RES CO, V208, P223, DOI 10.1006/bbrc.1995.1327; Sidhu A, 1998, J NEUROCHEM, V70, P2459; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Spiegel AM, 2000, HORM RES, V53, P17, DOI 10.1159/000023526; Sullivan BM, 2000, MOL BIOL CELL, V11, P3155, DOI 10.1091/mbc.11.9.3155; Tanaka M, 1999, P NATL ACAD SCI USA, V96, P14106, DOI 10.1073/pnas.96.24.14106; Tso PH, 2000, J NEUROCHEM, V74, P1685, DOI 10.1046/j.1471-4159.2000.0741685.x; Tso PH, 2000, J PHARMACOL EXP THER, V295, P168; TSU RC, 1995, MOL PHARMACOL, V47, P835; Tsu RC, 1997, MOL PHARMACOL, V52, P38, DOI 10.1124/mol.52.1.38; TSU RC, 1995, J NEUROCHEM, V64, P2700; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Wong M, 1998, J BIOL CHEM, V273, P309, DOI 10.1074/jbc.273.1.309; WONG YH, 1995, ONCOGENE, V10, P1927; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Yamaguchi T, 2000, FEBS LETT, V470, P25, DOI 10.1016/S0014-5793(00)01284-9; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	117	57	57	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1615	1625		10.1038/sj.onc.1204190	http://dx.doi.org/10.1038/sj.onc.1204190			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313909				2022-12-17	WOS:000168089800012
J	Nakaya, N; Lowe, SW; Taya, Y; Chenchik, A; Enikolopov, G				Nakaya, N; Lowe, SW; Taya, Y; Chenchik, A; Enikolopov, G			Specific pattern of p53 phosphorylation during nitric oxide-induced cell cycle arrest	ONCOGENE			English	Article						nitric oxide; p53; proliferation; cell cycle arrest; phosphorylation	DNA-DAMAGE; RIBONUCLEOTIDE REDUCTASE; DROSOPHILA DEVELOPMENT; GROWTH; APOPTOSIS; DIFFERENTIATION; PROLIFERATION; ACTIVATION; INHIBITION; RADIATION	Nitric oxide (NO) is an efficient inhibitor of cell proliferation. Here we show that part of the antiproliferative activity of NO in fibroblasts is mediated through p53 signaling pathway. Cells from p53-/- knockout mice are compromised in their ability to stop dividing in the presence of NO, NO strongly induces expression of genes which are transcriptional targets of p53, and p53 is necessary for some, but not all, of the transcription activation effects of NO, Furthermore, NO strongly increases the cellular level of p53 protein. Since phosphorylation of particular residues of the p53 molecule has been correlated with its functional activity, we determined the phosphorylation pattern of p53 molecule after exposure to NO and compared it with the phosphorylation patterns that develop upon treatment with gamma-irradiation, UV light, and adriamycin. We found that NO induces a specific signature pattern of p53 phosphorylation, distinct from the patterns evoked by other inducers. This study suggests that NO activates specific signaling pathways that may partially overlap, but that do not coincide, with signaling pathways activated by other known inducers of p53 activity.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; Clontech Labs Inc, Palo Alto, CA 94303 USA	Cold Spring Harbor Laboratory; National Cancer Center - Japan	Enikolopov, G (corresponding author), Cold Spring Harbor Lab, POB 100,1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Enikolopov, Grigori/P-5731-2019; Enikolopov, Grigori N/B-7771-2009	Enikolopov, Grigori/0000-0001-8178-8917; Enikolopov, Grigori N/0000-0001-8178-8917				BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Enikolopov G, 1999, CELL DEATH DIFFER, V6, P956, DOI 10.1038/sj.cdd.4400577; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; GARG UC, 1990, BIOCHEM BIOPH RES CO, V171, P474, DOI 10.1016/0006-291X(90)91417-Q; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Ishida A, 1997, J BIOL CHEM, V272, P10050; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Keefer LK, 1996, ADV EXP MED BIOL, V387, P177; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nicotera P, 1999, CELL DEATH DIFFER, V6, P931, DOI 10.1038/sj.cdd.4400583; Papapetropoulos A, 1997, AM J PATHOL, V150, P1835; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Tamir S, 1996, METHOD ENZYMOL, V269, P230; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	38	57	58	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6369	6375		10.1038/sj.onc.1204100	http://dx.doi.org/10.1038/sj.onc.1204100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175352				2022-12-17	WOS:000166210500021
J	Sitterlin, D; Bergametti, F; Tiollais, P; Tennant, BC; Transy, C				Sitterlin, D; Bergametti, F; Tiollais, P; Tennant, BC; Transy, C			Correct binding of viral X protein to UVDDB-p127 cellular protein is critical for efficient infection by hepatitis B viruses	ONCOGENE			English	Article						hepatitis B virus; X protein; UV-damaged DNA binding protein; virus-host interaction; therapeutic target	NUCLEOTIDE-SEQUENCE; GENE PRODUCT; IN-VIVO; REPLICATION; MUTATIONS; CELLS	A fully effective treatment of chronic human hepatitis B virus (I-IBV) infection is still missing and HBV remains the first etiological agent of liver cancer. Although the viral regulatory X protein is essential for infection, its mode of action remains obscure, due the lark of an in vitro infection system. In the accompanying study, we showed the functional importance of interaction between X and the host protein UVDDB-p127, in the transactivation and apoptotic properties of the viral protein, Here, we addressed the biological role of X-UVDDB interaction in the infectious process using a genetic approach in the woodchuck virus closely related to HBV. We show that (i) mutations in X, which markedly affect UVDDB-binding, also abolished productive infection in woodchucks, (ii) in the few cases where mutant viruses led to infection, compensatory mutations had occurred in the X gene of the viral progeny, which restored correct UVDDB-binding. We conclude that efficient viral replication in vivo requires proper X-UVDDB interaction. The interaction may thus provide a novel therapeutic target for the treatment of hepatitis B.	Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, F-75724 Paris 15, France; Cornell Univ, Coll Vet Med, Dept Clin Sci, Vet Med Ctr C2 005, Ithaca, NY 14853 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Cornell University	Transy, C (corresponding author), Inst Pasteur, Unite Recombinais & Express Genet, INSERM, U163, 28 Rue Dr Roux, F-75724 Paris 15, France.							BEASLEY RP, 1981, LANCET, V2, P1129; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GIRONES R, 1989, P NATL ACAD SCI USA, V86, P1846, DOI 10.1073/pnas.86.6.1846; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Kane MA, 1998, VACCINE, V16, pS104, DOI 10.1016/S0264-410X(98)00308-9; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Krogsgaard K, 1998, J VIRAL HEPATITIS, V5, P389, DOI 10.1046/j.1365-2893.1998.00118.x; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Nassal M, 1996, J VIRAL HEPATITIS, V3, P217, DOI 10.1111/j.1365-2893.1996.tb00047.x; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SCHODEL F, 1989, ADV VIRAL ONCOL, V8, P73; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Wei Y, 1998, J VIROL, V72, P6608, DOI 10.1128/JVI.72.8.6608-6613.1998; Zoulim F, 1998, J HEPATOL, V29, P151, DOI 10.1016/S0168-8278(98)80191-8; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	21	57	60	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4427	4431		10.1038/sj.onc.1203770	http://dx.doi.org/10.1038/sj.onc.1203770			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980618				2022-12-17	WOS:000089271900013
J	Arapshian, A; Kuppumbatti, YS; Mira-y-Lopez, R				Arapshian, A; Kuppumbatti, YS; Mira-y-Lopez, R			Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells	ONCOGENE			English	Article						DNA methylation; chromatin; bisulfite; 5-azacytidine; trichostatin A	TRANSCRIPTIONAL REGULATION; DNA METHYLATION; CARCINOMA CELLS; IN-VIVO; EXPRESSION; PROMOTER; LINES; 5-AZA-2'-DEOXYCYTIDINE; DEMETHYLATION; HETERODIMERS	We investigated the mechanism of retinoic acid receptor (RAR) beta 2 gene silencing in breast cancer cells. Transfection experiments indicated that MCF-7 cells transactivate an exogenous beta 2 promoter (-1470/+156) to the same extent as MTSV1.7 breast epithelial cells, which express endogenous RAR beta 2. This was true even in the context of replicated chromatin, suggesting a cis-acting rather than a trans-acting defect. Cytosine methylation, a cis-acting DNA modification, has been implicated in RAR beta 2 silencing in cancer cells. Upon bisulfite genomic sequencing, we found that 3 CpG sites in the beta 2 RARE region were variably methylated in MCF-7 cells but were not methylated in MTSV1.7 cells or in 2 MDA-MB-231 subclones that differed in RAR beta 2 expression (high in clone A2, low in clone A4). However, the 5'-UTR region was hypermethylated in clone A4 relative to clone A2 cells. Following 5-azacytidine treatment, RA and trichostatin A markedly induced RAR beta 2 expression in MCF-7 cells but not in MDA-MB-231 clone A4 cells. A beta 2 RARE reporter construct in which the methylation-susceptible cytosines in the sense strand were replaced by thymine displayed marked loss of activity in a replicated chromatin-dependent manner. We conclude that cytosine methylation contributes to RAR beta 2 gene silencing in MCF-7 cells and that methylation of the RARE region may be particularly important.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Mira-y-Lopez, R (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.				NCI NIH HHS [R01 CA54273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Baust C, 1996, INT J CANCER, V67, P409, DOI 10.1002/(SICI)1097-0215(19960729)67:3<409::AID-IJC16>3.0.CO;2-2; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; FERGUSON AT, 1995, CANCER RES, V55, P2279; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Jing YK, 1996, FASEB J, V10, P1064, DOI 10.1096/fasebj.10.9.8801168; KRUYT FAE, 1991, MECH DEVELOP, V33, P171, DOI 10.1016/0925-4773(91)90025-2; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEROY P, 1991, P NATL ACAD SCI USA, V88, P10138, DOI 10.1073/pnas.88.22.10138; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MIRAYLOPEZ R, 1991, J CELL PHYSIOL, V147, P46, DOI 10.1002/jcp.1041470107; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Moghal N, 1998, MOL CELL BIOL, V18, P6666, DOI 10.1128/MCB.18.11.6666; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Tycko B, 1997, MUTAT RES-REV MUTAT, V386, P131, DOI 10.1016/S1383-5742(96)00049-X; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu XC, 1997, CANCER RES, V57, P4992; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; ZHANG XK, 1994, CANCER RES, V54, P5663	30	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					4066	4070		10.1038/sj.onc.1203734	http://dx.doi.org/10.1038/sj.onc.1203734			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962564				2022-12-17	WOS:000088825300013
J	Pircher, TJ; Zhao, SQ; Geiger, JN; Joneja, B; Wojchowski, DM				Pircher, TJ; Zhao, SQ; Geiger, JN; Joneja, B; Wojchowski, DM			Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death	ONCOGENE			English	Article						Pim-1kinase; genotoxin-induced apoptosis	INHIBITS APOPTOSIS; C-MYC; IONIZING-RADIATION; GENE-EXPRESSION; TRANSGENIC MICE; MYELOID CELLS; BONE-MARROW; ACTIVATION; DIFFERENTIATION; ERYTHROPOIETIN	The hematopoietic cell S/T kinase Pim-1 was originally discovered as a target of murine leukemia provirus integration, and when expressed at increased levels is predisposing to lymphomagenesis. Recently, Pim-1 has been shown to enhance the activities of p100, c-Myb and cdc25a, and in part this might explain reported effects on mitogenesis. In the context of cytokine withdrawal, Pim-1 also can attenuate programmed cell death (PCD). Cytokine withdrawal, however, alters signaling pathways and can complicate the dissection of mitogenic vs apoptotic responses. To better study possible effects of Pim-1 on PCD, a hematopoietic cell model was developed in which proliferation was supported efficiently by SCF plus EPO in the absence of endogenous Pim-1 gene expression. This was provided by factor-dependent FDCW2 cells that express endogenous and functional c-Kit, and were transfected stably with truncated Epo receptor form mutated at a Y343 STAT5 binding site. In proliferating cells, exogenously expressed Pim-1 was observed to efficiently inhibit PCD as induced by either Co-60 or adriamycin, and the dose-dependent nature of this effect was established in several independent clones, By comparison, effects of exogenous Pim-1 on mitogenesis were nominal. In addition, in cell fractionation studies an estimated 25% of M-r 34 000 Pim-1 (but not M-r 44 000 Pim-1) was present in nuclear extracts. Thus, Pim-1 efficiently buffers hematopoietic progenitor cells against death as induced by several clinically important apoptotic agents, and may directly target nuclear effecters.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Program Immunobiol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, 115 Henning Bldg, University Pk, PA 16802 USA.				NHLBI NIH HHS [HLR0144491] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044491] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHUANG RY, 1979, BIOCHEMISTRY-US, V18, P2069, DOI 10.1021/bi00577a035; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; IHLE JN, 1982, J IMMUNOL, V129, P1377; ITOH N, 1993, J IMMUNOL, V151, P621; Joneja B, 1997, BLOOD, V90, P3533, DOI 10.1182/blood.V90.9.3533; KLEIN AK, 1985, RADIAT RES, V101, P332, DOI 10.2307/3576399; Koike N, 2000, FEBS LETT, V467, P17, DOI 10.1016/S0014-5793(00)01105-4; Konietzko U, 1999, EMBO J, V18, P3359, DOI 10.1093/emboj/18.12.3359; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; Leverson JD, 1998, MOL CELL, V2, P417, DOI 10.1016/S1097-2765(00)80141-0; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; Lilly M, 1997, CANCER RES, V57, P5348; LILLY M, 1992, ONCOGENE, V7, P727; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; Mochizuki T, 1997, ONCOGENE, V15, P1471, DOI 10.1038/sj.onc.1201326; Mochizuki T, 1999, J BIOL CHEM, V274, P18659, DOI 10.1074/jbc.274.26.18659; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; STEWART BE, 1995, J INVEST DERMATOL, V105, P699, DOI 10.1111/1523-1747.ep12324482; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Watters D, 1999, IMMUNOL CELL BIOL, V77, P263, DOI 10.1046/j.1440-1711.1999.00824.x; Weston K, 1999, ONCOGENE, V18, P3034, DOI 10.1038/sj.onc.1202728; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; Xu J, 1999, MOL CELL BIOL, V19, P12; Zeman SM, 1998, P NATL ACAD SCI USA, V95, P11561, DOI 10.1073/pnas.95.20.11561	43	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3684	3692		10.1038/sj.onc.1203684	http://dx.doi.org/10.1038/sj.onc.1203684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951575				2022-12-17	WOS:000088568300015
J	Jean, D; Tellez, C; Huang, SY; Davis, DW; Bruns, CJ; McConkey, DJ; Hinrichs, SH; Bar-Eli, M				Jean, D; Tellez, C; Huang, SY; Davis, DW; Bruns, CJ; McConkey, DJ; Hinrichs, SH; Bar-Eli, M			Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment	ONCOGENE			English	Article						melanoma; metastasis; apoptosis; transcriptional regulation	ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-I; WILD-TYPE P53; HUMAN MELANOCYTES; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; INDUCED APOPTOSIS; DOWN-REGULATION; C-KIT; CELLS	Activating transcription factor-1 (ATF-1) and cAMP-responsive element (CRE)-binding protein (CREB) have been implicated in cAMP and Ca2+-induced transcriptional activation. The expression of the transcription factors CREB and ATF-1 is upregulated in metastatic melanoma cells. However, how overexpression of ATF-1/CREB contributes to the acquisition of the metastatic phenotype remains unclear. Here, the effect of disrupting ATF-1 activity was investigated using intracellular expression of an inhibitory anti-ATF-1 single chain antibody fragment (ScFv), Intracellular expression of ScFv anti-ATF-1 in MeWo melanoma cells caused significant reduction in CRE-dependent promoter activation. In addition, expression of ScFv anti-ATF-1 in melanoma cells suppressed their tumorigenicity and metastatic potential in nude mice. ScFv anti-ATF-1 rendered the melanoma cells susceptible to thapsigargin-induced apoptosis in vitro and caused massive apoptosis in tumors transplanted subcutaneously into nude mice, suggesting that ATF-1 and its associated proteins act as survival factor for human melanoma cells. This is the first report to demonstrate the potential of ScFv anti-ATF-1 as an inhibitor of tumor growth and metastasis of solid tumor in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Texas System; UTMD Anderson Cancer Center; University of Nebraska System; University of Nebraska Medical Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404	NCI NIH HHS [CA76098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; Bussfeld D, 1997, IMMUNOBIOLOGY, V198, P291, DOI 10.1016/S0171-2985(97)80049-6; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Grim J, 1996, AM J RESP CELL MOL, V15, P348, DOI 10.1165/ajrcmb.15.3.8810638; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 1996, ONCOGENE, V13, P2339; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; ISHIKAWA M, 1988, CANCER RES, V48, P665; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; KOPF AW, 1995, CANCER-AM CANCER SOC, V75, P684, DOI 10.1002/1097-0142(19950115)75:2+<684::AID-CNCR2820751411>3.0.CO;2-B; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; LIU F, 1993, J BIOL CHEM, V268, P6714; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; RADINSKY R, 1994, ONCOGENE, V9, P1877; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINGH RK, 1995, CANCER RES, V55, P3669; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILE RG, 1994, CANCER RES, V54, P6228; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	53	57	60	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2721	2730		10.1038/sj.onc.1203569	http://dx.doi.org/10.1038/sj.onc.1203569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851072				2022-12-17	WOS:000087193000008
J	Meng, TC; Lee, MS; Lin, MF				Meng, TC; Lee, MS; Lin, MF			Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells	ONCOGENE			English	Article						androgen responsiveness; human prostate cancer; ErbB-2; prostatic acid phosphatase; tyrosine phosphorylation	NEGATIVE BREAST-CANCER; ACID-PHOSPHATASE; FACTOR RECEPTOR; CARCINOMA-CELLS; HORMONAL-THERAPY; MAMMARY-CARCINOMA; ESTROGEN-RECEPTOR; STEROID-HORMONES; ERBB RECEPTORS; POOR-PROGNOSIS	Steroid hormones play key roles in regulating cell proliferation and differentiation in targeting tissues. However, in advanced cancers, the steroid hormone regulation is frequently attenuated through a Set unknown mechanism even in the presence of functional steroid hormone receptors, We investigate the functional role of tyrosine phosphorylation signaling in the hormone-refractory growth of human prostate tumors. Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates,vith a low phosphotyrosine (p-Tyr) level of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine phosphatase. In prostate cancer cells, the p-Tyr le,el, but not the protein level, of ErbB-2 inversely correlates with the androgen-responsiveness of cell proliferation. Androgen-stimulated cell growth concurs with a down-regulation of cellular PAcP, an elevated p-Tyr level of ErbB-2, and the activation of mitogen-activated protein kinases, Furthermore, only the ErbB-2 inhibitor AG 879, but not the EGFR inhibitor AG 1478, abolishes androgen-induced cell proliferation. Forced expression of ErbB-2 can also attenuate androgen promotion of cell growth. Data taken collectively conclude that in human prostate cancer cells, the tyrosine phosphorylation of ErbB-2 regulated by cellular PAcP plays a key role in regulating androgen-mediated proliferation signaling.	Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.		Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021; LEE, MING-SHYUE/0000-0002-5884-4535	NCI NIH HHS [CA72274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L; Bacus SS, 1996, AM J PATHOL, V148, P549; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/edrv-17-6-587; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BRASS AL, 1995, CANCER RES, V55, P3197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEWINTER JAR, 1990, J PATHOL, V160, P329, DOI 10.1002/path.1711600409; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANGER BO, 1984, ARCH BIOCHEM BIOPHYS, V235, P141, DOI 10.1016/0003-9861(84)90262-5; FOTI AG, 1977, CANCER RES, V37, P4120; Gioeli D, 1999, CANCER RES, V59, P279; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GLAUBER JG, 1992, SEMIN ONCOL, V19, P308; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAYHACK JT, 1987, CANCER, V60, P589, DOI 10.1002/1097-0142(19870801)60:3+<589::AID-CNCR2820601526>3.0.CO;2-R; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISAACS JT, 1982, CANCER RES, V42, P5010; JANES PW, 1994, ONCOGENE, V9, P3601; Jensen E V, 1991, Curr Top Pathol, V83, P365; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KUHN EJ, 1993, J UROLOGY, V150, P1427, DOI 10.1016/S0022-5347(17)35799-3; LATIL A, 1994, INT J CANCER, V59, P637, DOI 10.1002/ijc.2910590510; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI HC, 1984, EUR J BIOCHEM, V138, P45, DOI 10.1111/j.1432-1033.1984.tb07879.x; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 2000, IN PRESS CELL BIOL I; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; LIU XH, 1993, J CLIN ENDOCR METAB, V77, P1472, DOI 10.1210/jc.77.6.1472; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Lu S, 1997, CANCER RES, V57, P4511; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; Marengo SR, 1997, MOL CARCINOGEN, V19, P165; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MILLER JI, 1992, J UROLOGY, V147, P956, DOI 10.1016/S0022-5347(17)37432-3; MURPHY LJ, 1986, CANCER RES, V46, P728; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1993, CANCER RES, V53, P4960; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; QUARMBY VE, 1990, CANCER RES, V50, P735; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/edrv-16-3-271; REIF AE, 1973, CANCER-AM CANCER SOC, V31, P689, DOI 10.1002/1097-0142(197303)31:3<689::AID-CNCR2820310331>3.0.CO;2-F; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SADI MV, 1993, CANCER, V71, P2574, DOI 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1; Sandberg A A, 1980, Prog Clin Biol Res, V37, P9; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SCHUURMANS ALG, 1991, J STEROID BIOCHEM, V40, P193, DOI 10.1016/0960-0760(91)90182-5; SCOTT WW, 1980, CANCER-AM CANCER SOC, V45, P1929, DOI 10.1002/cncr.1980.45.s7.1929; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STROHMEYER TG, 1994, J UROLOGY, V151, P1479, DOI 10.1016/S0022-5347(17)35284-9; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TENNISWOOD M, 1986, PROSTATE, V9, P375, DOI 10.1002/pros.2990090407; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WEISS C, 1990, LEUKEMIA RES, V14, P327, DOI 10.1016/0145-2126(90)90159-7; WRIGHT C, 1992, J CLIN PATHOL, V45, P459, DOI 10.1136/jcp.45.5.459-b; YAM LT, 1974, AM J MED, V56, P604, DOI 10.1016/0002-9343(74)90630-5; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YUAN SX, 1993, CANCER RES, V53, P1304; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386	90	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2664	2677		10.1038/sj.onc.1203576	http://dx.doi.org/10.1038/sj.onc.1203576			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851066				2022-12-17	WOS:000087193000002
J	Bahl, R; Arora, S; Nath, N; Mathur, M; Shukla, NK; Ralhan, R				Bahl, R; Arora, S; Nath, N; Mathur, M; Shukla, NK; Ralhan, R			Novel polymorphism in p21(waf1/cip1) cyclin dependent kinase inhibitor gene: association with human esophageal cancer	ONCOGENE			English	Article						p21(waf1/cip1); cyclin-dependent kinase inhibitor; p53; esophageal squamous cell carcinomas	TUMOR-SUPPRESSOR GENE; CELL NUCLEAR ANTIGEN; C-TERMINAL REGION; DNA-REPLICATION; BINDING DOMAINS; P53 GENE; P21; EXPRESSION; PCNA; MUTATIONS	p21(waf1/cip1), an important regulator of the cell cycle, binds to PCNA and acts as a mediator of the growth suppressing and apoptosis promoting functions of p53. We report a hitherto unobserved polymorphism in the carboxy terminal domain (codon 149) of p21(waf1/cip1) gene, the domain encoding the PCNA binding motif, The codon 149 polymorphism (G (A) under bar T-->G (G) under bar T) was observed in 42 of 50 (84%) esophageal squamous cell carcinomas (ESCCs) and eight of 50 (16%) normal individuals, The resultant amino acid substitution from aspartate to glycine may have vital implication in PCNA mediated cell cycle regulation by p21(waf1/cip1). The second polymorphism at codon 31, involving a C-->A transversion at nucleotide 168 (AG (C) under bar-->AG (A) under bar) changing the amino acid from serine to arginine, was observed in 2/50 (4%) ESCCs at a relatively lower frequency in the Indian population than that reported in the West. No significant association was observed between p21(waf1/cip1) polymorphism at codon 149 and p21(waf1/cip1) protein expression in ESCC in this cohort of patients. Interestingly, the frequency of p21(waf1/cip1) variants (codon 149) in ESCCs (18 of 19 cases) with wild-type p53 was significantly higher than in tumors with p53 mutations, suggesting that this polymorphism affects the p53 pathway and may play an important role in esophageal tumorigenesis, Analysis of p21(waf1/cip1) expression in relation to p53 gene and protein status revealed its induction by p53-dependent as well as independent pathways in esophageal tumorigenesis.	All India Inst Med Sci, Dept Biochem, New Delhi 110029, India; All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; Inst Rotary Canc Hosp, All India Inst Med Sci, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer Hospital	Ralhan, R (corresponding author), All India Inst Med Sci, Dept Biochem, New Delhi 110029, India.							AGARWAL S, 1998, ORAL ONCO EUR J CANC, V34, P1; Barbareschi M, 1996, BRIT J CANCER, V74, P208, DOI 10.1038/bjc.1996.339; Bukholm IK, 1997, INT J CANCER, V73, P38, DOI 10.1002/(SICI)1097-0215(19970926)73:1<38::AID-IJC7>3.0.CO;2-2; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHEN J, 1995, NATURE, V375, P386; Doglioni C, 1996, J PATHOL, V179, P248, DOI 10.1002/(SICI)1096-9896(199607)179:3<248::AID-PATH571>3.0.CO;2-6; Elbendary AA, 1996, CLIN CANCER RES, V2, P1571; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO;2-T; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gaur D, 1997, CLIN CANCER RES, V3, P2129; GOUBIN F, 1995, ONCOGENE, V10, P2281; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2; HUPPI K, 1994, ONCOGENE, V9, P3017; KOOPMANN J, 1995, BRIT J CANCER, V72, P1230, DOI 10.1038/bjc.1995.491; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Marchetti A, 1996, ONCOGENE, V12, P1319; MARCHETTI A, 1996, INT J ONCOL, V6, P187; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; Munoz N, 1996, CANC EPIDEMIOLOGY PR, P681; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NOTANI PN, 1988, E EPIDEMIOL COMM HLT, V187; RALHAN R, 1999, IN PRESS INT J CANC; SABIN LH, 1997, TNM CLASSIFICATIN MA; Sambrook J., 1989, MOL CLONING; Shimada Y, 1999, BRIT J CANCER, V80, P1281, DOI 10.1038/sj.bjc.6690499; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SIDDIQI MA, 1991, DIETARY SOURCES NNIT, P210; VIDAL MJ, 1995, MELANOMA RES, V5, P243, DOI 10.1097/00008390-199508000-00006; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P707; YU MC, 1988, CANCER RES, V48, P345	36	57	61	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2000	19	3					323	328		10.1038/sj.onc.1203325	http://dx.doi.org/10.1038/sj.onc.1203325			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656678				2022-12-17	WOS:000084873700001
J	Weber, CK; Slupsky, JR; Herrmann, C; Schuler, M; Rapp, UR; Block, C				Weber, CK; Slupsky, JR; Herrmann, C; Schuler, M; Rapp, UR; Block, C			Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes	ONCOGENE			English	Article						Ras; Raf; mitogenic signaling	COMPLETE CODING SEQUENCE; PROTEIN-KINASE; A-RAF; PLASMA-MEMBRANE; BIOCHEMICAL-PROPERTIES; B-RAF; ACTIVATION; BINDING; DOMAIN; EXPRESSION	In the mitogenic signaling cascade interaction of Ras with Raf represents a critical step for the regulation of cell growth and differentiation. The major effector of Ras, the serine/threonine kinase Raf exists as three isoforms with different tissue distributions. We demonstrate that transient transfection of oncogenic Ha-Ras leads to a preferential activation of endogenous c-Raf-l in HEK 293 cells as opposed to A-Raf, In vitro binding studies using purified Ras binding domains of Raf as well as in vivo bindings tests with full length molecules reveals significantly lower binding affinities of A-Raf to Ha-Ras as compared to other Raf isoforms, The Ras-binding interface of c-Raf differs from A-Raf by a conservative Arg to Lys exchange at residue 59 or 22 respectively. Mutational analysis reveals that this residue represents a point of isozyme discrimination: c-Raf-R59K binds Ha-Ras weaker than the wildtype, likewise A-Raf-K22R increases its affinity to Ha-Ras in vivo and in vitro. Differential binding affinities are reflected in downstream signaling. Immunecomplex kinase assays reveal that Ha-Ras mediated Raf activation is decreased for c-Raf-R59K and increased for A-Raf-K22R when compared to the respective wildtype forms. Thus our observations introduce a new level of isoform discrimination in Ras/ Raf signaling asa functional consequence of conservative amino acid exchange in the Ras binding domains.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97078 Wurzburg, Germany; Max Planck Inst Mol Physiol, Abt Strukt Biol, D-44026 Dortmund, Germany	University of Wurzburg; Max Planck Society	Weber, CK (corresponding author), Univ Ulm, Innere Med Abt 1, D-89070 Ulm, Germany.		Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004				BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CRAVCHIK A, 1993, GENE, V137, P139, DOI 10.1016/0378-1119(93)90262-2; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Flory E, 1998, J VIROL, V72, P2788, DOI 10.1128/JVI.72.4.2788-2794.1998; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jaitner BK, 1997, J BIOL CHEM, V272, P29927, DOI 10.1074/jbc.272.47.29927; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kerkhoff E, 1998, CANCER RES, V58, P1636; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; RAPP UR, 1988, ONCOGENE HDB; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SLUPSKY JR, 1998, CELL GROWTH ONCOGENE; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STORM SM, 1990, ONCOGENE, V5, P345; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Wixler V, 1996, FEBS LETT, V385, P131, DOI 10.1016/0014-5793(96)00363-8; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	57	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					169	176		10.1038/sj.onc.1203261	http://dx.doi.org/10.1038/sj.onc.1203261			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644994				2022-12-17	WOS:000084844400001
J	Macho, A; Calzado, MA; Jimenez-Reina, L; Ceballos, E; Leon, J; Munoz, E				Macho, A; Calzado, MA; Jimenez-Reina, L; Ceballos, E; Leon, J; Munoz, E			Susceptibility of HIV-1-TAT transfected cells to undergo apoptosis. Biochemical mechanisms	ONCOGENE			English	Article						Tat; apoptosis; Bcr-abl; CPP32; mitochondria	MITOCHONDRIAL-PERMEABILITY-TRANSITION; HIV-INFECTED PERSONS; CERAMIDE-INDUCED APOPTOSIS; NF-KAPPA-B; T-CELLS; CYTOCHROME-C; TAT PROTEIN; PROGRAMMED DEATH; LYMPH-NODES; ACTIVATION	The effects of HIV-1 Tat protein on mitochondria membrane permeability and apoptosis were analysed in lymphoid cells. In this report we show that stable-transfected HIV-Tat cells are primed to undergo apoptosis upon serum withdrawal. This effect was observed in both the Jhan T cell line and the K562 cells, the latter expressing the bcr-abl chimeric gene, which confers resistance to apoptosis induced by different stimuli. Using a cytofluorimetric approach we have determined that serum withdrawal induces a disruption of the transmembrane mitochondrial potential (Delta psi(m)) followed bq an increase of reactive oxygen species (ROS) and the subsequent DNA nuclear loss in K562-Tat cells but not in the K562-pcDNA cell line. These pre-apoptotic events were associated with the cleavage of the caspase-3, while the expression of Bcl-2, Bcl-X-L and Bas proteins was not affected by the presence of Tat, Regardless of the steady state of the Bar protein, we found that in both K562 and K562-Tat cells, this protein is located in the nucleus, but after serum withdrawal its localization was mainly in the cytoplasm, The activity of caspase-3 detected in K562-Tat cells after serum withdrawal paralleled with the mitochondria permeability transition. Nevertheless, in Jhan-Tat cells the inhibition of this caspase with the specific inhibitor, z-DEVD-cmk, did not affect the disruption of the mitochondria potential induced by serum withdrawal. Interestingly, ae found that HIV-Tat protein accumulates at the mitochondria in the K562-Tat cells cultured under low serum conditions, and this mitochondrial localization correlated with the Delta psi(m) disruption detected in these cells. In addition, HIV-Tat protein synergies with protoporphyrin IX (PPIX), a ligand of the mitochondrial benzodiazepine receptor, in the induction of apoptosis in both Jhan and K562 cells. Thus, HIV-1 Tat protein may induce apoptosis by a mechanism that involves mitochondrial PT and may contribute to the lymphocyte depletion seen in AIDS patients.	Univ Cordoba, Fac Med, Dept Fisiol & Inmunol, E-14071 Cordoba, Spain	Universidad de Cordoba	Munoz, E (corresponding author), Univ Cordoba, Fac Med, Dept Fisiol & Inmunol, Avda Menendez Pidal S-N, E-14071 Cordoba, Spain.		Munoz, Eduardo/I-5225-2012; Quirós, Antonio Macho/H-1403-2012; Calzado, Marco A./S-2295-2019; Leon, Javier/K-4615-2014; Calzado, Marco/E-9046-2016	Munoz, Eduardo/0000-0001-8478-5842; Quirós, Antonio Macho/0000-0002-9294-8709; Calzado, Marco A./0000-0002-5338-535X; Calzado, Marco/0000-0002-5338-535X; Jimenez Reina, Luis/0000-0003-4434-7308; Leon, Javier/0000-0001-5803-0112				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gougeon ML, 1996, J IMMUNOL, V156, P3509; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Herbein G, 1998, J VIROL, V72, P660, DOI 10.1128/JVI.72.1.660-670.1998; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kim CN, 1997, CANCER RES, V57, P3115; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; LEWIS DE, 1994, J IMMUNOL, V153, P412; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Macho A, 1998, CELL GROWTH DIFFER, V9, P277; MACHO A, 1995, BLOOD, V86, P2481; Macho A, 1997, J IMMUNOL, V158, P4612; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; McCloskey TW, 1997, J IMMUNOL, V158, P1014; MCGAHON AJ, 1995, J BIOL CHEM, V270, P22625, DOI 10.1074/jbc.270.38.22625; MEYAARD L, 1994, J CLIN INVEST, V93, P982, DOI 10.1172/JCI117105; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Munoz E, 1997, BIOCHEM J, V325, P23, DOI 10.1042/bj3250023; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; Nishita M, 1998, EXP CELL RES, V244, P357, DOI 10.1006/excr.1998.4203; Patki AH, 1996, CELL IMMUNOL, V169, P40, DOI 10.1006/cimm.1996.0088; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; ROTHWELL NJ, 1983, BIOSCIENCE REP, V3, P217, DOI 10.1007/BF01122453; Salomoni P, 1998, J EXP MED, V187, P1995, DOI 10.1084/jem.187.12.1995; Sastry KJ, 1996, ONCOGENE, V13, P487; Slater AFG, 1996, CELL DEATH DIFFER, V3, P57; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tuosto L, 1995, EUR J IMMUNOL, V25, P2907, DOI 10.1002/eji.1830251030; Wadia JS, 1998, J NEUROSCI, V18, P932; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zauli G, 1996, J IMMUNOL, V157, P2216; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	66	57	57	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	1999	18	52					7543	7551		10.1038/sj.onc.1203095	http://dx.doi.org/10.1038/sj.onc.1203095			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602513				2022-12-17	WOS:000084119600015
J	Brockhaus, F; Brune, B				Brockhaus, F; Brune, B			p53 accumulation in apoptotic macrophages is an energy demanding process that precedes cytochrome c release in response to nitric oxide	ONCOGENE			English	Article						apoptosis; nitric oxide; macrophages; p53; cytochrome c; Bcl-2	BCL-X-L; CELL-DEATH; P53-DEPENDENT APOPTOSIS; MITOCHONDRIAL CONTROL; PROTEASE ACTIVATION; CASPASE ACTIVATION; SIGNALING PATHWAYS; FAMILY; INHIBITION; COMPLEX	Apoptosis in response to stress signals activates effector caspases known to be regulated by the release of cytochrome c (Cyt c) from mitochondria and the subsequent ATP-dependent activation of the death regulator apoptotic protease-activating factor I (Apaf-1). Experiments were carried out to determine whether the release of Cyt c is evoked by NO. in RAW 264.7 macrophages and to position signaling components relative to mitochondria. S-nitrosoglutathione and spermine-NO caused a fast p53 accumulation, followed by Bcl-x(L) downregulation, Cyt c release, and caspase activation. These alterations mere absent in p53 antisense expressing macrophages (R Delta p53asn-11). In Bcl-2 overexpressing cells (Rbc12-14) Cyt c relocation and caspase activation were abrogated although p53 accumulation remained intact. The use of caspase inhibitors revealed Cyt c release and decreased Bcl-x(L) expression to be caspase independent. ATP-depIeted cells showed a shift from apoptosis towards necrosis and no p53 accumulation or caspase activation upon NO. addition. Conclusively, NO.-mediated apoptosis in macrophages is entirely controlled by the mitochondrial pathway with the implication that Cyt c relocation demands p53 accumulation. Moreover, pulse-chase-experiments in combination with the ATP-depletion protocol identified p53 accumulation and stabilization as an energy requiring process. This allowed to dissect two ATP-dependent steps, one is in association with Apaf-1 formation, while the other resides in p53 accumulation.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Div Expt, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Div Expt, Loschgestr 8, D-91054 Erlangen, Germany.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albina JE, 1996, J IMMUNOL, V157, P279; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brockhaus F, 1999, BIOCHEM J, V338, P295, DOI 10.1042/0264-6021:3380295; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Castedo M, 1996, J IMMUNOL, V157, P512; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Eguchi Y, 1997, CANCER RES, V57, P1835; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HART TW, 1985, TETRAHEDRON LETT, V26, P2013, DOI 10.1016/S0040-4039(00)98368-0; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lee JM, 1998, ONCOGENE, V17, P1653, DOI 10.1038/sj.onc.1202102; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; Messmer UK, 1998, EUR J PHARMACOL, V349, P333, DOI 10.1016/S0014-2999(98)00189-7; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; Moreno MB, 1996, J IMMUNOL, V157, P3845; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pitkanen K, 1998, ONCOGENE, V16, P459, DOI 10.1038/sj.onc.1201528; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Stassi G, 1997, J EXP MED, V186, P1193, DOI 10.1084/jem.186.8.1193; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WULFF K, 1985, METHOD ENZYMAT AN, V7, P357; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	46	57	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6403	6410		10.1038/sj.onc.1203058	http://dx.doi.org/10.1038/sj.onc.1203058			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597241				2022-12-17	WOS:000083709200001
J	Somasundaram, K; MacLachlan, TK; Burns, TF; Sgagias, M; Cowan, KH; Weber, BL; El-Deiry, WS				Somasundaram, K; MacLachlan, TK; Burns, TF; Sgagias, M; Cowan, KH; Weber, BL; El-Deiry, WS			BRCA1 signals ARF-dependent stabilization and coactivation of p53	ONCOGENE			English	Article						p53; BRCA1; p14(ARF)	CELL-CYCLE CONTROL; TUMOR-SUPPRESSOR; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; GENE BRCA1; DNA-DAMAGE; BREAST; EXPRESSION; APOPTOSIS; ARREST	The hereditary breast and ovarian tumor suppressor BRCA1 can activate p53-dependent gene expression. We show here that BRCA1 increases p53 protein levels through a post-transcriptional mechanism. BRCA1-stabilized p53 has increased sequence-specific DNA-binding and transcriptional activity, BRCA1 does not stabilize p53 in p14(ARF)-deficient cells. A deletion mutant of BRCA1 which inhibits p53-dependent transcription confers resistance to topoisomerase II-targeted chemotherapy, Our results suggest that BRCA1 may trigger the p53 pathway through two potentially separate mechanisms: accumulation of p53 through a direct or indirect induction of p14(ARF) as well as direct transcriptional coactivation of p53, BRCA1 may also enhance chemosensitivity and repair of DNA damage through binding to and coactivation of p53.	Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med & Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA; NCI, Med Branch, Bethesda, MD 20892 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Lab Mol Oncol & Cell Cycle Regulat, CRB 437A,415 Curie Blvd, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA7641701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076417] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; EASTON DF, 1995, AM J HUM GENET, V56, P265; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Garcia-Patino E, 1998, CANCER GENET CYTOGEN, V104, P119, DOI 10.1016/S0165-4608(97)00460-3; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Katayose D, 1995, CLIN CANCER RES, V1, P889; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	57	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6605	6614		10.1038/sj.onc.1203284	http://dx.doi.org/10.1038/sj.onc.1203284			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597265				2022-12-17	WOS:000083709200025
J	Huang, F; Adelman, J; Jiang, HP; Goldstein, NI; Fisher, PB				Huang, F; Adelman, J; Jiang, HP; Goldstein, NI; Fisher, PB			Identification and temporal expression pattern of genes modulated during irreversible growth arrest and terminal differentiation in human melanoma cells	ONCOGENE			English	Article						melanoma differentiation; high throughput gene expression arrays; differentially expressed cDNAs	KINASE INHIBITOR P21; DNA CHIPS; INTERFERON; PROGRESSION; MDA-7; HYBRIDIZATION; ENCODES; COMPLEX	Abnormalities in differentiation are common occurrences in human cancers, Treatment-of human melanoma cells with the combination of recombinant human fibroblast interferon (IFN-beta) and the antileukemic compound mezerein (MEZ) results in a loss of tumorigenic potential that correlates with an irreversible suppression in proliferative ability and induction of terminal differentiation. It is hypothesized that this is associated with the differential expression of genes that may directly regulate cancer cell growth and differentiation. To define the relevant gene expression changes that correlate with and potentially control these important cellular processes a differentiation induction subtraction hybridization (DISH) scheme is being used,A temporally spaced subtracted differentiation inducer treated (TSS) cDNA library was constructed and differentially expressed DISH clones were isolated and evaluated using a high throughput microchip cDNA (Synteni) array screening approach, Verification of differential, gene expression for specific cDNAs was confirmed by Northern blotting. The temporal kinetics of regulation and the expression pattern of DISH genes were also evaluated by microchip cDNA array screening. Using this approach with 1000 DISH cDNA clones (similar to 10% of the DISH library) has resulted in the identification and cloning of both 26 known and 11 novel cDNAs of potential relevance to growth control and terminal differentiation in human melanoma cells.	Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; GenQuest Inc, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.				NATIONAL CANCER INSTITUTE [R01CA035675] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alama A, 1997, PHARMACOL RES, V36, P171, DOI 10.1006/phrs.1997.0227; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1984, MECHANISMS TUMOR PRO, P57; GUARINI L, 1992, PIGM CELL RES, P123; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Jiang Hongping, 1994, Molecular and Cellular Differentiation, V2, P221; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1995, ONCOGENE, V11, P1179; Jiang HP, 1997, ONCOGENE, V14, P473, DOI 10.1038/sj.onc.1200858; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; KANG DC, 1998, IN PRESS INT J ONCOL; Lin JJ, 1996, MOL CELL DIFFER, V4, P317; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Marshall A, 1998, NAT BIOTECHNOL, V16, P27, DOI 10.1038/nbt0198-27; ONEILL MJ, 1995, DEVELOPMENT, V121, P561; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Su Zao-Zhong, 1995, Molecular and Cellular Differentiation, V3, P225; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; WAXMAN S, 1995, DIFFERENTIATION THER; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	57	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3546	3552		10.1038/sj.onc.1202715	http://dx.doi.org/10.1038/sj.onc.1202715			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376533				2022-12-17	WOS:000080850600013
J	Haapasalo, A; Saarelainen, T; Moshnyakov, M; Arumae, U; Kiema, TR; Saarma, M; Wong, G; Castren, E				Haapasalo, A; Saarelainen, T; Moshnyakov, M; Arumae, U; Kiema, TR; Saarma, M; Wong, G; Castren, E			Expression of the naturally occurring truncated trkB neurotrophin receptor induces outgrowth of filopodia and processes in neuroblastoma cells	ONCOGENE			English	Article						trkB; BDNF; NT-4; N2a; neuroblastoma	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; AFFINITY NGF RECEPTOR; DIFFERENTIAL RESPONSE; PROTOONCOGENE PRODUCT; SIGNAL-TRANSDUCTION; TISSUE DISTRIBUTION; RETINOIC ACID; BRAIN; ENCODES	We have investigated the effects of the truncated trkB receptor isoform T1 (trkB.T1) by transient transfection into mouse N2a neuroblastoma cells. We observed that expression of trkB.T1 leads to a striking change in cell morphology characterized by outgrowth of filopodia and processes. A similar morphological response was also observed in SH-SY5Y human neuroblastoma cells and NIH3T3 fibroblasts transfected with trkB.T1. N2a cells lack endogenous expression of trkB isoforms, but express barely detectable amounts of its ligands, brainderived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). The morphological change was ligand-independent, since addition of exogenous BDNF or NT-4 or blockade of endogenous trkB ligands did not influence this response. Filopodia and process outgrowth was significantly suppressed when full-length trkB.TK + was cotransfected together with trkS.T1 and this inhibitory effect was blocked by tyrosine kinase inhibitor K252a. Transfection of trkB.T1 deletion mutants showed that the morphological response is dependent on the extracellular, but not the intracellular domain of the receptor. Our results suggest a novel ligand-independent role for truncated trkB in the regulation of cellular morphology.	Univ Kuopio, AI Vir Tanen Inst, Mol Pharmacol Lab, Kuopio 70100, Finland; Univ Kuopio, Dept Psychiat, Kuopio 70100, Finland; Univ Helsinki, Inst Biotechnol, Helsinki 00014, Finland	University of Eastern Finland; University of Eastern Finland; University of Helsinki	Castren, E (corresponding author), Univ Kuopio, AI Vir Tanen Inst, Mol Pharmacol Lab, POB 1627, Kuopio 70100, Finland.		Castrén, Eero/A-4618-2010; Arumäe, Urmas/E-8290-2016	Arumäe, Urmas/0000-0003-3658-6464; Haapasalo, Annakaisa/0000-0003-0959-2957; Castren, Eero/0000-0002-1402-2791				ARMANINI MP, 1995, EUR J NEUROSCI, V7, P1403, DOI 10.1111/j.1460-9568.1995.tb01132.x; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARIK S, 1995, METH NEUROSCI, V26, P309; Baxter GT, 1997, J NEUROSCI, V17, P2683; BECK KD, 1993, J NEUROSCI, V13, P4001; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIFFO S, 1995, DEVELOPMENT, V121, P2461; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Eide FF, 1996, J NEUROSCI, V16, P3123; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1993, NEURON, V11, P321, DOI 10.1016/0896-6273(93)90187-V; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1991, CELL, V66, P968; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lucarelli E, 1994, Prog Clin Biol Res, V385, P185; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Ninkina N, 1996, EMBO J, V15, P6385, DOI 10.1002/j.1460-2075.1996.tb01029.x; PASTOR R, 1994, ONCOGENE, V9, P1081; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Rubio N, 1997, EUR J NEUROSCI, V9, P1847, DOI 10.1111/j.1460-9568.1997.tb00751.x; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SEEDS NW, 1970, P NATL ACAD SCI USA, V66, P160, DOI 10.1073/pnas.66.1.160; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; TANNAHILL L, 1995, EUR J NEUROSCI, V7, P1424, DOI 10.1111/j.1460-9568.1995.tb01136.x; TOMA JG, 1997, NEURAL NOTES, V111, P20; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VAUGHAN VC, 1979, NELSON TXB PEDIAT, P1444; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Zhou H, 1997, J NEUROSCI RES, V49, P281, DOI 10.1002/(SICI)1097-4547(19970801)49:3<281::AID-JNR3>3.0.CO;2-8	54	57	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1285	1296		10.1038/sj.onc.1202401	http://dx.doi.org/10.1038/sj.onc.1202401			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022810				2022-12-17	WOS:000078510900004
J	Sheng, HM; Shao, JY; O'Mahony, CA; Lamps, L; Albo, D; Isakson, PC; Berger, DH; DuBois, RN; Beauchamp, RD				Sheng, HM; Shao, JY; O'Mahony, CA; Lamps, L; Albo, D; Isakson, PC; Berger, DH; DuBois, RN; Beauchamp, RD			Transformation of intestinal epithelial cells by chronic TGF-beta 1 treatment results in downregulation of the type II TGF-beta receptor and induction of cyclooxygenase-2	ONCOGENE			English	Article						intestinal epithelial cells; transforming growth factor beta; cyclooxygenase-2; carcinogenesis	GROWTH-FACTOR-BETA; APC(DELTA-716) KNOCKOUT MICE; BREAST-CANCER-CELLS; BENIGN SKIN TUMORS; CYCLIN D1; DIFFERENTIAL SENSITIVITY; SELECTIVE-INHIBITION; MALIGNANT CONVERSION; CARCINOMA-CELLS; FAMILY SIGNALS	The precise role of TGF-P in colorectal carcinogenesis is not clear, The purpose of this study was to determine the phenotypic alterations caused by chronic exposure to TGF-beta in non-transformed intestinal epithelial (RIE-1) cells. Growth of RIE-1 cells was inhibited by >75% following TGF-beta 1 treatment for 7 days, after which the cells resumed a normal growth despite the presence of TGF-beta 1, These 'TGF-beta-resistant' cells (RIE-Tr) were continuously exposed to TGF-beta for >50 days, Unlike the parental RIE cells, RIE-Tr cells lost contact inhibition, formed foci in culture, grew in soft agarose, RIE-Tr cells demonstrated TGF-beta-dependent invasive potential in an in vitro assay and were resistant to Matrigel and Na-butyrate-induced apoptosis, The RIE-Tr cells were also tumorigenic in nude mice. The transformed phenotype of RIE-Tr cells was associated with a 95% decrease in the level of the type II TGF-P receptor (T beta RII) protein, a 40-fold increase in cyclooxygenase-2 (COX-2) protein, and 5.9-fold increase in the production of prostacyclin, Most RIE-Tr subclones that expressed low levels of T beta RII and high levels of COX-2 were tumorigenic. Those subclones that express abundant T beta RII and low levels of COX-2 were not tumorigenic in nude mice. A selective COX-2 inhibitor inhibited RIE-Tr cell growth in culture and tumor growth in nude mice. The reduced expression of T beta RII, increased expression of COX-2, and the ability to form colonies in Matrigel mere all reversible upon withdrawal of exogenous TGF-beta 1 for the RIE-Tr cells.	Vanderbilt Univ, Med Ctr N, Vanderbilt Canc Ctr, Dept Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Vanderbilt Canc Ctr, Dept Pathol, Nashville, TN 37232 USA; Vet Affairs Med Ctr, Nashville, TN 37232 USA; Searle Res & Dev, Dept Inflammatory Dis Res, St Louis, MO 63198 USA; Allegheny Univ Hlth Sci, Dept Surg, Philadelphia, PA 19102 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Pfizer; Drexel University	Beauchamp, RD (corresponding author), Vanderbilt Univ, Med Ctr N, Vanderbilt Canc Ctr, Dept Surg, CC2306, Nashville, TN 37232 USA.		DuBois, Raymond N./AAX-8869-2020	Beauchamp, Robert Daniel/0000-0002-8446-4114	NCI NIH HHS [CA68485, CA-69457] Funding Source: Medline; NIDDK NIH HHS [DK-52334] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, R01CA069457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052334] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; ARTEAGA CL, 1993, CELL GROWTH DIFFER, V4, P193; ARTEAGA CL, 1988, CANCER RES, V48, P3898; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; BEAUCHAMP RD, 1990, PANCREAS, V5, P369, DOI 10.1097/00006676-199007000-00001; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BLAY J, 1985, J CELL PHYSIOL, V124, P107, DOI 10.1002/jcp.1041240117; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHEN X, 1996, NATURE, V383, P791; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUI W, 1994, CANCER RES, V54, P5831; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DERYNCK R, 1987, CANCER RES, V47, P707; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1994, ONCOGENE, V9, P3627; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GILBERT RS, 1994, J CELL PHYSIOL, V159, P67, DOI 10.1002/jcp.1041590110; GILBERT RS, 1994, CELL MOL BIOL RES, V40, P653; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; HAFEZ MM, 1992, CELL GROWTH DIFFER, V3, P753; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Ko TC, 1998, ONCOGENE, V16, P3445, DOI 10.1038/sj.onc.1201902; KO TC, 1995, ONCOGENE, V10, P177; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAGNA G, 1996, NATURE, V383, P382; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Masferrer JL, 1996, GASTROENTEROL CLIN N, V25, P363, DOI 10.1016/S0889-8553(05)70252-1; Massague J, 1996, CANCER SURV, V27, P41; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; SCHROY P, 1990, CANCER RES, V50, P261; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 1997, CELL GROWTH DIFFER, V8, P463; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Winesett MP, 1996, CARCINOGENESIS, V17, P989, DOI 10.1093/carcin/17.5.989; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; Zhang T, 1997, CANCER RES, V57, P169; Zhang T, 1997, CANCER RES, V57, P1638; ZHANG XY, 1994, CANCER RES, V54, P6122; ZHAO J, 1995, CANCER RES, V55, P6181	73	57	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					855	867		10.1038/sj.onc.1202397	http://dx.doi.org/10.1038/sj.onc.1202397			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023661				2022-12-17	WOS:000078510600002
J	Mishra, L; Cai, T; Yu, P; Monga, SPS; Mishra, B				Mishra, L; Cai, T; Yu, P; Monga, SPS; Mishra, B			Elf3 encodes a novel 200-kD beta-spectrin: role in liver development	ONCOGENE			English	Article						spectrin; cloning; chromosome 11; mouse; liver; embryonic development; immunohistochemistry	PLASMA-MEMBRANE DOMAINS; POLARIZED EPITHELIAL-CELLS; BRAIN SPECTRIN; HEPATOCYTE DIFFERENTIATION; ERYTHROCYTE SPECTRIN; SELF-ASSOCIATION; CDNA LIBRARIES; MESSENGER-RNAS; MECHANISM; SEQUENCES	beta-spectrins are crucial for the maintenance of cell shape, the establishment of cell polarity, and the formation of distinct membrane domains. Our strategy for identifying genes important for hepatocyte polarity has been to utilize subtractive hybridization of early embryonic mouse cDNA liver libraries. As a result,,ve have cloned three isoforms of a novel beta-spectrin elf (embryonic liver beta-fodrin), and here we report the analysis of elf3, the longest isoform (8172 nt), ELF3 comprises 2154 residues with an overall similarity of 89.0% and 95.3% to mouse beta-spectrin (beta SpII Sigma 1) at the nucleotide and amino acid level, respectively. ELF3 is characterized by an actin-binding domain, a long repeat domain, and a short regulatory domain remarkable for the absence of a PH domain, Linkage analysis reveals that elf3 maps to mouse chromosome 11 between D11Bir6 and D11Xrf477, a different chromosomal locus from that of the other four spectrin genes, Northern blot analysis utilizing an elf3 3'-UTR probe demonstrates an abundant 9.0-kb transcript in brain, liver, and heart tissues. Western blot with a polyclonal antibody against ELF identifies a 200 kD protein in mouse liver, brain, kidney, and heart tissues. Immunohistochemical studies demonstrate ELF labeling of the basolateral or sinusoidal membranes surface as well as a granular cytoplasmic pattern in hepatocytes, Antisense studies utilizing cultured liver explants show a vital role of elf3 in hepatocyte differentiation and intrahepatic bile duct formation, The differential expression, tissue localization, and functional studies demonstrate the importance of elf3 in modulating interactions between various components of the cytoskeleton proteins controlling liver and bile duct development.	Dept Vet Affairs, Lab Dev Mol Biol, Washington, DC 20422 USA; Temple Univ, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Natl Human Genome Res Inst, Clin Gene Therapy Branch, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Mishra, L (corresponding author), Dept Vet Affairs, Lab Dev Mol Biol, Washington, DC 20422 USA.			Mishra, Lopa/0000-0002-6850-0808; Monga, Satdarshan/0000-0002-8437-3378; Cai, Tao/0000-0002-2877-8637	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050458] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29-DK50458-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1996, METHOD ENZYMOL, V266, P460; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BLAKESLEE D, 1977, J IMMUNOL METHODS, V17, P361, DOI 10.1016/0022-1759(77)90118-1; BOUWENS L, 1992, ENZYME, V46, P155, DOI 10.1159/000468782; CAI T, 1998, IN PRESS BIOCH BIOPH, V1390; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CASCIO S, 1991, DEVELOPMENT, V113, P217; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLEMAN TR, 1989, CELL MOTIL CYTOSKEL, V12, P225, DOI 10.1002/cm.970120405; COOK J, 1983, J CELL BIOL, V97, P1823, DOI 10.1083/jcb.97.6.1823; Engvall E, 1980, Methods Enzymol, V70, P419; GALLAGHER PG, 1993, SEMIN HEMATOL, V30, P4; GOODMAN SR, 1981, P NATL ACAD SCI-BIOL, V78, P7570, DOI 10.1073/pnas.78.12.7570; GOODMAN SR, 1984, BRAIN RES BULL, V13, P813, DOI 10.1016/0361-9230(84)90239-9; GOODMAN SR, 1984, AM J PHYSIOL, V247, pC61, DOI 10.1152/ajpcell.1984.247.1.C61; GOODMAN SR, 1988, CRIT REV BIOCHEM MOL, V23, P171, DOI 10.3109/10409238809088319; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS HW, 1980, J BIOL CHEM, V255, P1512; HARRISON P, 1995, J NEUROSURG ANESTH, V7, P121, DOI 10.1097/00008506-199504000-00008; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; HU RJ, 1992, J BIOL CHEM, V267, P18715; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kwon Y, 1997, PHARMACEUT RES, V14, P780, DOI 10.1023/A:1012158607766; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDOUARIN NM, 1975, MED BIOL, V53, P427; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; MA YP, 1993, MOL BRAIN RES, V18, P87, DOI 10.1016/0169-328X(93)90176-P; MAURICE M, 1988, J CELL SCI, V90, P79; Mishra L, 1997, ONCOGENE, V15, P2361, DOI 10.1038/sj.onc.1201405; MISHRA L, 1998, INT J DEV BIOL, V41, P747; Muller M, 1997, AM J PHYSIOL-GASTR L, V272, pG1285, DOI 10.1152/ajpgi.1997.272.6.G1285; NELSON WJ, 1991, BIOCHEM SOC T, V19, P1055, DOI 10.1042/bst0191055; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; RIEDERER BM, 1986, J CELL BIOL, V102, P2088, DOI 10.1083/jcb.102.6.2088; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEINFEST CW, 1990, GENET ANAL-BIOMOL E, V7, P64, DOI 10.1016/0735-0651(90)90042-E; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; Viel A, 1996, CURR OPIN CELL BIOL, V8, P49, DOI 10.1016/S0955-0674(96)80048-2; WINKELMANN JC, 1993, BLOOD, V81, P3173; ZIMMER WE, 1992, BRAIN RES, V594, P75, DOI 10.1016/0006-8993(92)91030-I	48	57	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	1999	18	2					353	364		10.1038/sj.onc.1202313	http://dx.doi.org/10.1038/sj.onc.1202313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927192				2022-12-17	WOS:000078166500008
J	Regev, A; Cohen, S; Cohen, E; Bar-Am, I; Lavi, S				Regev, A; Cohen, S; Cohen, E; Bar-Am, I; Lavi, S			Telomeric repeats on small polydisperse circular DNA (spcDNA) and genomic instability	ONCOGENE			English	Article						genomic instability; spcDNA; telomeres; mutator phenotype; two dimensional electrophoresis; cancer	GENE AMPLIFICATION; CHROMOSOMAL-ABERRATIONS; HUMAN-CELLS; SEQUENCES; RECOMBINATION; INVOLVEMENT; RESISTANCE; EXCISION; FAMILY; VIRUS	Small polydisperse circular DNA (spcDNA) is a heterogeneous population of extrachromosomal circular molecules present in a large variety of eukaryotic cells. Elevated amounts of total spcDNA are related to endogenous and induced genomic instability in rodent and human cells, We suggested spcDNA as a novel marker for genomic instability, and speculated that spcDNA might serve as a mutator, In this study, we examine the presence of telomeric sequences on spcDNA, We report for the first time the appearance of telomeric repeats in spcDNA molecules (tel-spcDNA) in rodent and human cells. Restriction enzyme analysis indicates that tel-spcDNA molecules harbor mostly, if not exclusively, telomeric repeats, In rodent cells, tel-spcDNA levels are higher in transformed than in normal cells and are enhanced by treatment with carcinogen, Tel-spcDNA is also detected in some human tumors and cell lines, but not in others. We suggest, that its levels in human cells may be primarily related to the amount of the chromosomal telomeric sequences. Tel-spcDNA may serve as a unique mutator, through specific mechanisms related to the telomeric repeats, which distinguish it from the total heterogeneous spcDNA population. It may affect telomere dynamics and genomic instability by clastogenic events, alterations of telomere size and sequestration of telomeric proteins.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lavi, S (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Balajee AS, 1996, MUTAT RES-FUND MOL M, V372, P163, DOI 10.1016/S0027-5107(96)00136-4; BARAM I, 1992, GENE CHROMOSOME CANC, V4, P314, DOI 10.1002/gcc.2870040407; Bassham S, 1998, MOL CELL BIOL, V18, P269, DOI 10.1128/MCB.18.1.269; BERTONI L, 1994, GENOMICS, V24, P53, DOI 10.1006/geno.1994.1581; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Cohen S, 1996, MOL CELL BIOL, V16, P2002; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENIS N, 1991, ONCOGENE, V6, P1453; Friedman SL, 1997, ONCOGENE, V15, P63, DOI 10.1038/sj.onc.1201149; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JONES RS, 1985, NUCLEIC ACIDS RES, V13, P1027, DOI 10.1093/nar/13.3.1027; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIYAMA R, 1987, J MOL BIOL, V198, P589, DOI 10.1016/0022-2836(87)90202-6; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Ohki R, 1995, NUCLEIC ACIDS RES, V23, P4971, DOI 10.1093/nar/23.24.4971; OKUMURA K, 1987, NUCLEIC ACIDS RES, V15, P7477, DOI 10.1093/nar/15.18.7477; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; RENAULT S, 1993, GENOME, V36, P244, DOI 10.1139/g93-034; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WINOCOUR E, 1992, VIROLOGY, V190, P316, DOI 10.1016/0042-6822(92)91218-J	31	57	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3455	3461		10.1038/sj.onc.1202250	http://dx.doi.org/10.1038/sj.onc.1202250			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030669				2022-12-17	WOS:000078086200006
J	Hemenway, CS; Halligan, BW; Levy, LS				Hemenway, CS; Halligan, BW; Levy, LS			The Bmi-1 oncoprotein interacts with dinG and MPh2: the role of RING finger domains	ONCOGENE			English	Article						RING finger protein; polycomb group proteins; Bmi-1 oncoprotein	MYC TRANSGENIC MICE; ZINC-FINGER; AXIAL SKELETON; POLYCOMB; PROTEIN; DROSOPHILA; TRANSFORMATION; PROTOONCOGENE; GENE; IDENTIFICATION	Experimentally-induced mutations in the C3HC4 RING finger domain of the Bmi-1 oncoprotein block its ability to induce lymphomas in mice. In this report, the role of the Bmi-1 RING finger in mediating protein-protein interactions is examined using the yeast two-hybrid system. Bmi-1 interacts directly with the RING finger protein dinG/RING1B. Heterodimerization of the two proteins requires the intact RING finger structures of both Bmi-1 and dinG. Although the RING finger domains are necessary for dimerization, they are not sufficient for this process as residues outside the C3HC4 motif are also required. Thus, binding specificity may be partly conferred by residues outside the RING motif. Both Bmi-1 and dinG interact with the Polyhomeotic protein MPh2 through binding domains apart from the RING finger. The data suggest a model whereby Bmi-1, dinG, and MPh2 form a stable heterotrimeric complex in which each protein contributes to the binding of the others.	Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA.				NATIONAL CANCER INSTITUTE [R55CA063483] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63483] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akasaka T, 1996, DEVELOPMENT, V122, P1513; ALKEMA MJ, 1993, HUM MOL GENET, V2, P1597, DOI 10.1093/hmg/2.10.1597; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bienstock RJ, 1996, CANCER RES, V56, P2539; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; CORMACK B, 1995, CURRENT PROTOCOLS MO; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN H, 1992, BIOESSAYS, V14, P411, DOI 10.1002/bies.950140612; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; James P, 1996, GENETICS, V144, P1425; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEVY LS, 1993, ONCOGENE, V8, P1833; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MULLER J, 1995, DEVELOPMENT, V121, P2847; PEARCE JJH, 1992, DEVELOPMENT, V114, P921; ROSE MD, 1990, METHODS YEAST GENETI; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; SINGH PB, 1994, J CELL SCI, V107, P2653; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430	39	57	61	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 14	1998	16	19					2541	2547		10.1038/sj.onc.1202042	http://dx.doi.org/10.1038/sj.onc.1202042			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN694	9627119				2022-12-17	WOS:000073672300011
J	de Launoit, Y; Audette, M; Pelczar, H; Plaza, S; Baert, JL				de Launoit, Y; Audette, M; Pelczar, H; Plaza, S; Baert, JL			The transcription of the intercellular adhesion molecule-1 is regulated by Ets transcription factors	ONCOGENE			English	Article						ICAM-1; Ets; ERM; transcription factor	INTERFERON-GAMMA; GENE-EXPRESSION; ONCOGENE FAMILY; RETINOIC ACID; ICAM-1 GENE; C-JUN; PROMOTER; BINDING; DISTINCT; CELLS	The Ets family of transcription factors comprises several members which are involved to regulate gene transcription. Although several consensus binding sites for Ets proteins can be found in a wide series of promoter, only a limited number of them are indeed activated by these transcription factors, The human intercellular adhesion molecule-1 (ICAM-1) plays a crucial role in immune responses by enabling the binding of effector cells to various target cell types. ICAM-1 is constitutively expressed at different levels in the absence of stimuli in different cell types, and its expression is upregulated by several proinflammatory cytokines. We hale here examined the transcriptional regulation of human ICAM-1 expression by Ets proteins, and more particularly by ERM, a member of this family of transcription factors, Transient transfection assays revealed that Ets-2 and ERM significantly activate the transcription of ICAM-1 promoter, whereas the less-related Ets family member, Spi-1/Pu.1, failed to do so, Transfection of a series of ICAM-1 promoter deletion mutants together with ERM expression plasmids have shown that an Ets responsive element is located within the first 176 bp upstream from the translational start site. Electrophoretic mobility shift assays and DNase I footprinting analysis have enabled us to identify two Ets binding sites at positions -158 and -138 from the ATG, respectively. Site directed mutagenesis of these elements has shown that the distal site is the major element required for the ERM-mediated activation of the ICAM-1 promoter, We can thus conclude that expression of ICAM-1 can be regulated by Ets transcription factors.	Inst Pasteur, Inst Biol, UMR 319 CNRS, F-59021 Lille, France; CHU Laval, Res Ctr, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Inst Pasteur, Inst Biol, EP 560 CNRS, F-59021 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Laval University; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	de Launoit, Y (corresponding author), Inst Pasteur, Inst Biol, UMR 319 CNRS, 1 Rue Calmette,BP 447, F-59021 Lille, France.		plaza, serge/F-5290-2015					ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTMANN DM, 1989, NATURE, V338, P512, DOI 10.1038/338512a0; AOUDJIT F, 1994, INT J CANCER, V58, P543, DOI 10.1002/ijc.2910580416; Aoudjit F, 1997, CELL GROWTH DIFFER, V8, P335; AOUDJIT F, 1995, CELL GROWTH DIFFER, V6, P515; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DUSTIN ML, 1988, J EXP MED, V167, P1323, DOI 10.1084/jem.167.4.1323; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; JAHNKE A, 1995, EUR J BIOCHEM, V228, P439; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JEON IS, 1995, ONCOGENE, V10, P1229; JOHNSON JP, 1991, CHEM IMMUNOL, V50, P143; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NATALI P, 1990, CANCER RES, V50, P1271; PLAZA S, 1995, ONCOGENE, V10, P329; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROEBUCK KA, 1995, J BIOL CHEM, V270, P18966, DOI 10.1074/jbc.270.32.18966; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; SATO H, 1993, ONCOGENE, V8, P395; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; STADE BG, 1990, IMMUNOBIOLOGY, V182, P79, DOI 10.1016/S0171-2985(11)80585-1; STRATOWA C, 1995, IMMUNOBIOLOGY, V193, P293, DOI 10.1016/S0171-2985(11)80558-9; VOGETSEDER W, 1989, INT J CANCER, V43, P768, DOI 10.1002/ijc.2910430504; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WAWRYK SO, 1991, INT IMMUNOL, V3, P83, DOI 10.1093/intimm/3.1.83; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	47	57	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 23	1998	16	16					2065	2073		10.1038/sj.onc.1201726	http://dx.doi.org/10.1038/sj.onc.1201726			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572487				2022-12-17	WOS:000073177200004
J	Hsu, CY; Yung, BYM				Hsu, CY; Yung, BYM			Down-regulation of nucleophosmin/B23 during retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells	ONCOGENE			English	Article						nucleophosmin/B23; retinoic acid; HL-60 differentiation	NUCLEOLAR PHOSPHOPROTEIN B23; NUCLEAR MATRIX PROTEIN; HELA-CELLS; RNA-SYNTHESIS; TRANSCRIPTIONAL REGULATION; ACTINOMYCIN-D; NUMATRIN B23; TUMOR-CELLS; C-MYC; GROWTH	Human promyelocytic leukemia HL-60 cells were induced to undergo granulocytic differentiation by treatment with retinoic acid (RA, 10 mu M, 1-5 days). The steady-state level of nucleophosmin/B23 mRNA decreased during the RA-induced differentiation. There was also decrease in the level of total cellular nucleophosmin/B23 protein during the RA-induced differentiation. Stabilization and nuclear run-on assays indicate that the decrease in nucleophosmin/B23 mRNA in RA-treated HL-60 cells was transcriptionally regulated. Unlike c-myc mRNA, there was virtually no decline of nucleophosmin/B23 mRNA during the growth arrest by serum-starvation. The decrease in nucleophosmin/B23 mRNA expression in HL-60 cells subsequent to retinoic acid treatment can thus be attributed to cellular differentiation rather than the growth arrest induced by RA. Nucleophosmin/B23 antisense oligomer treatment significantly potentiated RA-induced cellular differentiation. Results of this study suggest that nucleophosmin/B23 is one of the key elements in the down-regulation of nucleolar function for cellular differentiation.	Chang Gung Med & Engn Coll, Dept Pharmacol, Canc Biochem Lab, Tao Yuan 333, Taiwan; Natl Yang Ming Univ, Grad Inst Pharmacol, Taipei, Taiwan	National Yang Ming Chiao Tung University	Yung, BYM (corresponding author), Chang Gung Med & Engn Coll, Dept Pharmacol, Canc Biochem Lab, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.			Yung, Benjamin Yat Ming/0000-0003-0093-3196				ADACHI Y, 1993, J BIOL CHEM, V268, P13930; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREITMAN TR, 1980, EXP CELL RES, V126, P494, DOI 10.1016/0014-4827(80)90296-7; CHAN PK, 1989, CANCER RES, V49, P3271; CHAN PK, 1992, EXP CELL RES, V203, P174, DOI 10.1016/0014-4827(92)90053-B; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; DEAN M, 1986, MOL CELL BIOL, V6, P518, DOI 10.1128/MCB.6.2.518; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FONAGY A, 1992, CANCER RES, V52, P5250; GROSSO LE, 1985, CANCER RES, V45, P847; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITINGER N, 1993, J CELL BIOCHEM, V52, P153, DOI 10.1002/jcb.240520207; LI XZ, 1989, BIOCHEM BIOPH RES CO, V163, P72, DOI 10.1016/0006-291X(89)92100-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; TSIFTSOGLOU AS, 1985, INT J CELL CLONING, V3, P349, DOI 10.1002/stem.5530030602; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WU MH, 1995, BIOCHEM J, V305, P987, DOI 10.1042/bj3050987; YonedaKato N, 1996, ONCOGENE, V12, P265; YUNG BY, 1990, CANCER RES, V50, P5987; YUNG BYM, 1990, INT J CANCER, V46, P272, DOI 10.1002/ijc.2910460222; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1986, CANCER RES, V46, P922; YUNG BYM, 1992, INT J CANCER, V52, P317, DOI 10.1002/ijc.2910520227	43	57	57	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					915	923		10.1038/sj.onc.1201615	http://dx.doi.org/10.1038/sj.onc.1201615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484783				2022-12-17	WOS:000072053200011
J	Rao, L; Modha, D; White, E				Rao, L; Modha, D; White, E			The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis	ONCOGENE			English	Article						apoptosis; adenovirus E1B 19K; lamins	ADENOVIRUS TUMOR-ANTIGEN; PROGRAMMED CELL-DEATH; FATTY-ACID ACYLATION; BCL-2 HOMOLOG BAK; 19-KILODALTON PROTEIN; INTERMEDIATE FILAMENTS; TRANSFORMED-CELLS; NUCLEAR LAMINA; MEMBRANE; DNA	Expression of the E1B 19K protein is required to inhibit apoptosis induced by E1A during adenovirus infection and transformation. E1B 19K is homologous to Bcl-2 in function and the two proteins also share limited amino acid sequence homology. Consequently, the E1B 19K and Bcl-2 proteins bind to and inhibit the cellular death-inducing proteins Bax, Bak and Nbk/Bik. Both E1B 19K and Bcl-2 localize to membranes of the nucleus and the endoplasmic reticulum. In addition to membrane association, and unlike Bcl-2, the E1B 19K protein is found associated with intermediate filament proteins in the cytoplasm and the nuclear lamina and copurifies with the lamins both during infection and transformation. While a membrane targeting domain at the C-terminus of Bcl-2 ensures its proper localization, the mechanism by which the E1B 19K protein localizes is unknown. Not surprisingly, lamin A fragments were cloned from a yeast two-hybrid screen for E1B 19K-interacting proteins. The interaction was demonstrated in yeast and mammalian cells in vivo and in vitro and was unique and specific to E1B 19K, with no interaction evident between Bcl-2 and lamin A. Mutants of lamin A/C which localized inappropriately in the cytoplasm or nucleus but retained E1B 19K binding, interfered with the nuclear envelope and cytoplasmic membrane targeting of the E1B 19K protein. Improper localization impaired the ability of the E1B 19K protein to inhibit apoptosis. Thus, proper localization of the E1B 19K protein is required for its function and the interaction of the E1B 19K protein with lamin A/C may represent a means for nuclear envelope localization.	CANC INST NEW JERSEY, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA; CANC INST NEW JERSEY, DEPT MOL BIOL & BIOCHEM, PISCATAWAY, NJ 08854 USA; RUTGERS STATE UNIV, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRAND RJA, 1985, FEBS LETT, V181, P229, DOI 10.1016/0014-5793(85)80265-9; Han J, 1996, MOL CELL BIOL, V16, P5857; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCGLADE CJ, 1987, J VIROL, V61, P3227, DOI 10.1128/JVI.61.10.3227-3234.1987; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NIGG EA, 1993, CELL BIOL, V3, P245; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PERSSON H, 1982, J VIROL, V42, P905, DOI 10.1128/JVI.42.3.905-917.1982; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHLESINGER MJ, 1983, METHOD ENZYMOL, V96, P795; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TARODI B, 1993, INT J ONCOL, V3, P467; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WHITE E, 1994, SEMIN VIROL, V5, P341, DOI 10.1006/smvy.1994.1038; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZHANG S, 1992, J VIROL, V66, P2302, DOI 10.1128/JVI.66.4.2302-2309.1992	56	57	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	1997	15	13					1587	1597		10.1038/sj.onc.1201323	http://dx.doi.org/10.1038/sj.onc.1201323			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380411				2022-12-17	WOS:A1997XX36900010
J	Wang, D; Mayo, MW; Baldwin, AS				Wang, D; Mayo, MW; Baldwin, AS			Basic fibroblast growth factor transcriptional autoregulation requires EGR-1	ONCOGENE			English	Article						basic fibroblast growth factor; Egr-1; autoregulation	VASCULAR ENDOTHELIAL-CELLS; FACTOR GENE-EXPRESSION; TUMOR-NECROSIS-FACTOR; AP-1 BINDING-ACTIVITY; C-FOS; HUMAN GLIOMAS; 3T3 CELLS; IN-VIVO; JUN-B; PROMOTER	Basic fibroblast growth factor (bFGF) is an important growth factor for neuroectoderm- and mesoderm-derived cells. In addition bFGF is an important angiogenic factor and appears to contribute to tumorigenesis. This is exemplified by the fact that bFGF is expressed in a large majority of human gliomas and that bFGF expression is critical for the growth and tumorigenesis of these cells. It has been shown previously that bFGF can induce its own expression through an increase in bFGF mRNA. In this report, we show that bFGF leads to its own synthesis through an autoregulated transcriptional response that requires the transcription factor Egr-1 (also known as Krox24, Zif268 and NGFI-A). Egr-1 binds to two DNA elements in the bFGF promoter and positively regulates transcription. Mutation of these sites blocks the ability of bFGF to transcriptionally regulate the bFGF promoter. These data indicate a mechanism to explain how bFGF functions to autoregulate its expression and demonstrate that Egr-1 is as an essential transcription factor in this process.	UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill								ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ARENANDER AT, 1989, J NEUROSCI RES, V24, P107, DOI 10.1002/jnr.490240115; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; Biesiada E, 1996, J BIOL CHEM, V271, P18576, DOI 10.1074/jbc.271.31.18576; CAO XM, 1993, J BIOL CHEM, V268, P16949; Care A, 1996, MOL CELL BIOL, V16, P4842; COGSWELL P, 1997, IN PRESS J EXP MED; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FUKS Z, 1994, CANCER RES, V54, P2582; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; Gospodarowicz D, 1990, CLIN ORTHOP RELAT R, V257, P231; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HALL SH, 1991, ENDOCRINOLOGY, V129, P1243, DOI 10.1210/endo-129-3-1243; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; ITO E, 1990, ONCOGENE, V5, P1755; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPUGNANI MG, 1990, BLOOD, V76, P1173; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEE YJ, 1995, J BIOL CHEM, V270, P28790, DOI 10.1074/jbc.270.48.28790; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LOBB R, 1986, J BIOL CHEM, V261, P1924; MAASS A, 1994, BIOCHEM BIOPH RES CO, V202, P1337, DOI 10.1006/bbrc.1994.2077; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MURPHY PR, 1992, MOL ENDOCRINOL, V6, P877, DOI 10.1210/me.6.6.877; NAKAMOTO T, 1992, CANCER RES, V52, P571; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHIMOYAMA Y, 1991, JPN J CANCER RES, V82, P1263, DOI 10.1111/j.1349-7006.1991.tb01791.x; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; STAN AC, 1995, J NEUROSURG, V82, P1044, DOI 10.3171/jns.1995.82.6.1044; STEFANIK DF, 1991, CANCER RES, V51, P5760; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; UEBA T, 1994, NEUROSURGERY, V34, P221, DOI 10.1227/00006123-199402000-00003; WEICH HA, 1991, J CELL BIOCHEM, V47, P158, DOI 10.1002/jcb.240470209; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZUCK B, 1992, J STEROID BIOCHEM, V41, P659, DOI 10.1016/0960-0760(92)90400-D	62	57	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	1997	14	19					2291	2299		10.1038/sj.onc.1201069	http://dx.doi.org/10.1038/sj.onc.1201069			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178905				2022-12-17	WOS:A1997WY88300006
J	Okazaki, M; Kishida, S; Hinoi, T; Hasegawa, T; Tamada, M; Kataoka, T; Kikuchi, A				Okazaki, M; Kishida, S; Hinoi, T; Hasegawa, T; Tamada, M; Kataoka, T; Kikuchi, A			Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator	ONCOGENE			English	Article						RalGDS; Raf; Ras; Ral; c-fos promoter	PLASMA-MEMBRANE; PROTEIN-KINASE; EFFECTOR; TRANSFORMATION; GTPASES; RAC1; IDENTIFICATION; PATHWAY; CDC42HS; RHOA	Ral, a member of small GTP-binding protein (G protein) superfamily, has been suggested to act downstream of Ras, since Ral GDP dissociation stimulator (RalGDS) has been found to be an effector protein of Ras. In this study, we examined the effects of RalGDS and Ral on gene expression using c-fos promoter linked to the luciferase reporter gene (c-fos-luciferase). RalGDS interacted with Ras(G12V/E37G) (in which Gly-12 and Glu-37 were changed to Val and Gly, respectively) which failed to bind to Raf in COS cells, RafCAAX is an active Raf kinase targeted to the plasma membranes by virtue of the addition of a C-terminal localization signal from K-Ras. Transfection of either RalGDS or RafCAAX into NIH3T3 cells slightly stimulated c-fos-luciferase expression and cotransfection of both proteins greatly enhanced the expression. RalGDS and an activated Rac (Rac(G12V)) did not act synergistically to stimulate c-fos-luciferase expression. Transfection of an activated Ral (Ral(G23V)) stimulated c-fos-luciferase expression. Furthermore, cotransfection of Ral(G23V) and an activated Ras (Ras(G12V)) enhanced Ras(G12V)-dependent c-fos-luciferase expression. However, Ral(G23V) did not synergize with RafCAAX, Rac(G12V) or RalGDS to stimulate the expression. These results show that RalGDS and Ral regulate c-fos promoter activity and suggest that RalGDS may activate c-fas promoter synergistically with the signal from Raf by transmitting the signal to a target other than Ral.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Hiroshima University; Kobe University			Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177; kishida, shosei/0000-0003-0405-851X				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GORMAN CM, 1985, HIGH EFFICIENCY GENE; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Koyama S, 1996, FEBS LETT, V380, P113, DOI 10.1016/0014-5793(96)00018-X; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Lee T, 1996, DEVELOPMENT, V122, P409; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Okazaki M, 1996, CANCER RES, V56, P2387; Park SH, 1995, ONCOGENE, V11, P2349; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wolthuis RMF, 1996, ONCOGENE, V13, P353; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508	43	57	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 6	1997	14	5					515	521		10.1038/sj.onc.1200860	http://dx.doi.org/10.1038/sj.onc.1200860			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053849				2022-12-17	WOS:A1997WF52400002
J	Leverrier, Y; Thomas, J; Perkins, GR; Mangeney, M; Collins, MKL; Marvel, J				Leverrier, Y; Thomas, J; Perkins, GR; Mangeney, M; Collins, MKL; Marvel, J			In bone marrow derived Baf-3 cells, inhibition of apoptosis by IL-3 is mediated by two independent pathways	ONCOGENE			English	Article						apoptosis; Bcl-X; survival; IL-3; MAP-kinase	HEMATOPOIETIC-CELLS; CALCIUM IONOPHORES; BCL-2 PROTECTION; C-MYC; DEATH; GROWTH; INTERLEUKIN-3; SUPPRESSION; ACTIVATION; EXPRESSION	The inhibition of cell death by growth factors plays a key role in the maintenance of the haematopoietic system homeostasis. However the mechanisms involved in this inhibition are still poorly understood. In order to determine if inhibition of apoptosis by growth factors is dependent only on the expression of survival genes, we have studied that process in the bone marrow derived IL-3 dependent cell line Baf-3. We show that, following IL-3 starvation, mRNA and protein levels of Bcl-X but not Bcl-2 decrease rapidly preceeding the onset of death. The death of IL-3 starved cells is asynchronous, starting between 6 to 8 h with 50% death being reached after 10 to 12 h. At any time point, apoptosis can be rapidly inhibited by growth factor re-addition, This has allowed us to determine that the inhibition of apoptosis by growth factor takes place at two levels. The first one, which we have called short term inhibition, is independent of mRNA and protein synthesis i.e. it takes place in the absence of survival gene neosynthesis and can be demonstrated during the first 6 h following growth factor re-addition. The second one corresponds to long-term survival-more than 24 h survival-and is strongly correlated with the induction of Bcl-X but not Bcl-2 gene expression. This induction of Bcl-X by IL3 is shown to be dependent on MAP-kinase activation.	ECOLE NORMALE SUPER LYON,LBMC,CNRS UMR49,INRA LA 913,F-69364 LYON 07,FRANCE; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	INRAE; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			LEVERRIER, Yann/M-3767-2014; marvel, jacqueline/H-8638-2014	LEVERRIER, Yann/0000-0002-4227-5446; marvel, jacqueline/0000-0001-6241-459X; Mangeney, Marianne/0000-0002-9102-191X; Thomas, Joelle/0000-0002-0461-6131				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LIENHARD GE, 1994, NATURE, V372, P128, DOI 10.1038/372128a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MAY WS, 1994, J BIOL CHEM, V269, P26865; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTANI H, 1993, J BIOL CHEM, V268, P22733; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; WELHAM MJ, 1992, J IMMUNOL, V149, P1683	35	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 30	1997	14	4					425	430		10.1038/sj.onc.1200845	http://dx.doi.org/10.1038/sj.onc.1200845			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WE364	9053839				2022-12-17	WOS:A1997WE36400005
J	Arbeit, JM; Olson, DC; Hanahan, D				Arbeit, JM; Olson, DC; Hanahan, D			Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice	ONCOGENE			English	Article						fibroblast growth factors; growth factor receptors; human papillomavirus; epidermal carcinogenesis	HUMAN PANCREATIC-CANCER; SQUAMOUS-CELL CARCINOMAS; HUMAN BREAST-CANCER; FACTOR EXPRESSION; FGF FAMILY; FACTOR-I; DIFFERENTIAL EXPRESSION; HUMAN PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS	Upregulation of acidic and factors (FGF-1 and -2), and FGFR-1 and -2, has been demonstrated in a variety of epithelial malignancies, However, the patterns of FGF/FGFR expression at specific stages of epithelial carcinogenesis have not been extensively characterized. In this report, the levels of FGF-1, FGF-2, FGF-7 mRNA and their receptors FGFR-1 and FGFR-2, were investigated during epidermal carcinogenesis in transgenic mice expressing the early region of the 'high risk' papillomavirus type 16 (HPV16) under control of the human keratin-14 enhancer/promoter (K14-HPV16 transgenic mice). FGF-1 was first upregulated in dysplasias, while FGF-2 was constitutively expressed in non-transgenic, neoplastic, and malignant keratinocytes throughout carcinogenesis. Expression of FGF-7 was undetectable in non-transgenic epidermis, and remained at threshold levels at all stages of progression. In well differentiated squamous cancers, FGFR-1 was upregulated and co-localized with angiogenic capillaries in the dermis underlying dysplastic lesions and within papillary fronds of invasive cancers. Tn contrast, FGFR-1 was upregulated specifically within the malignant squamous cells of moderate-poorly differentiated squamous cancers. The expression of FGFR-2 was essentially constitutive in both non-transgenic and neoplastic epidermis. Collectively the data suggest that the FGF/FGFR signaling pathways may potentially contribute to several facets of multi-stage epithelial carcinogenesis, including auto- or paracrine growth stimulation, upregulation of angiogenesis, and stromal remodeling.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Arbeit, JM (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,503 PARNASSAS AVE,RM HSW 1090,SAN FRANCISCO,CA 94143, USA.		Arbeit, Jeffrey/K-6920-2019					ADNANE J, 1991, ONCOGENE, V6, P659; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1996, CANC SURVEYS, V26, P1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; HASEGAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P1435, DOI 10.1006/bbrc.1994.1611; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOGAN B, 1994, MANIPULATING MOUSE E, P153; HUGHES CJ, 1994, AM J SURG, V168, P381, DOI 10.1016/S0002-9610(05)80080-7; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JAYSON GC, 1994, CANCER RES, V54, P5718; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOBRIN MS, 1993, CANCER RES, V53, P4741; KULESZMARTIN M, 1985, CARCINOGENESIS, V6, P1245, DOI 10.1093/carcin/6.9.1245; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MACIAG T, 1994, RECENT PROG HORM RES, V49, P105; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORE JAW, 1991, DEVELOPMENT, V111, P741; MYOKEN Y, 1994, J ORAL PATHOL MED, V23, P451, DOI 10.1111/j.1600-0714.1994.tb00443.x; NAKAMOTO T, 1992, CANCER RES, V52, P571; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS KG, 1992, DEVELOPMENT, V114, P233; PEYRAT JP, 1992, J STEROID BIOCHEM, V43, P87, DOI 10.1016/0960-0760(92)90191-K; REED JA, 1994, AM J PATHOL, V144, P329; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Sambrook J, 1989, MOL CLONING LAB MANU; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SINGH RK, 1994, AM J PATHOL, V145, P365; SLACK J, 1994, MOL REPROD DEV, V39, P118, DOI 10.1002/mrd.1080390118; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAMAGUCHI TP, 1992, DEV BIOL, V152, P75, DOI 10.1016/0012-1606(92)90157-C; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	62	57	61	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1847	1857						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934530				2022-12-17	WOS:A1996VR79500003
J	Maity, A; Hwang, A; Janss, A; Phillips, P; McKenna, WG; Muschel, RJ				Maity, A; Hwang, A; Janss, A; Phillips, P; McKenna, WG; Muschel, RJ			Delayed cyclin B1 expression during the G2 arrest following DNA damage	ONCOGENE			English	Article						DNA damage; G2 delay; cyclin B1	CELL-CYCLE; IONIZING-RADIATION; HELA-CELLS; GENE-EXPRESSION; MESSENGER-RNA; NITROGEN-MUSTARD; ANTITUMOR DRUGS; TOPOISOMERASE-I; MAMMALIAN-CELLS; CDC25 PROTEIN	Exposure of cells to DNA damaging agents results in a G2 arrest. Exposure of HeLa cells to camptothecin, etoposide or nitrogen mustard for 1 h in S phase resulted in delayed expression of cyclin B1 mRNA during the G2 arrest. Initially the levels of cyclin B1 protein were low as well; however, with extended time the cells blocked in G2 regained higher levels of cyclin B1 protein. In the case of cells treated with nitrogen mustard the higher levels coincided with cells exiting the G2 block into G1. However, with camptothecin or etoposide treatment, while the accumulation of cyclin B1 protein was delayed, its levels eventually surpassed peak levels seen in control cells, in spite of the fact that cells were still blocked in G2. These cells did not continue to progress through the cell cycle indicating further complexity to the mechanisms underlying the G2 block. Decreased transcription and stability of cyclin B1 mRNA were shown to occur after treatment with these DNA damaging agents. These results indicate that suppression of cyclin B1 mRNA expression is one consequence of DNA damage in HeLa cells.	UNIV PENN, SCH MED, DEPT RADIAT ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV NEUROL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia				Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA064227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64227] Funding Source: Medline; NIGMS NIH HHS [GM 47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOU CF, 1994, J CELL SCI, V107, P1833; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DEAN SW, 1984, MUTAT RES, V132, P63, DOI 10.1016/0167-8817(84)90067-1; DELBINO G, 1990, CANCER RES, V50, P5746; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; GAZITT Y, 1993, CANCER RES, V53, P1899; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HENKEL AW, 1994, ANAL BIOCHEM, V223, P329, DOI 10.1006/abio.1994.1595; HERZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1989, CANCER RES, V49, P5077; HWANG A, 1995, J BIOL CHEM, V270, P28419; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; KRISHAN A, 1975, J CELL BIOL, V66, P521, DOI 10.1083/jcb.66.3.521; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI LH, 1972, CANCER RES, V32, P2643; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1993, INT J ONCOL, V3, P33; LOCK RB, 1994, CANCER RES, V54, P4933; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MATEOS S, 1994, MUTAT RES-DNA REPAIR, V315, P181, DOI 10.1016/0921-8777(94)90017-5; McKenna WG, 1996, ONCOGENE, V12, P237; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMEETS MFMA, 1994, RADIOTHER ONCOL, V33, P217, DOI 10.1016/0167-8140(94)90357-3; STEWART N, 1995, ONCOGENE, V10, P109; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TOBEY RA, 1972, CANCER RES, V32, P2720; TODD DG, 1994, CANCER RES, V54, P5224; TSAO YP, 1992, CANCER RES, V52, P1823; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; WOZNIAK AJ, 1983, CANCER RES, V43, P120; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009	56	57	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1647	1657						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895510				2022-12-17	WOS:A1996VM88700009
J	Pandita, TK; Hall, EJ; Hei, TK; Piatyszek, MA; Wright, WE; Piao, CQ; Pandita, RK; Willey, JC; Geard, CR; Kastan, MB; Shay, JW				Pandita, TK; Hall, EJ; Hei, TK; Piatyszek, MA; Wright, WE; Piao, CQ; Pandita, RK; Willey, JC; Geard, CR; Kastan, MB; Shay, JW			Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny	ONCOGENE			English	Article							ATAXIA-TELANGIECTASIA GENE; HUMAN COLORECTAL-CARCINOMA; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; CYTOGENETIC ANALYSIS; CELLULAR-RESPONSE; P53; RADIATION; PROTEIN; HYBRIDIZATION	Chromosome end-to-end associations seen at metaphase involve telomeres and are commonly observed in cells derived from individuals with ataxia telangiectasia and most types of human tumors, The associations may arise because of short telomeres and/or alterations of chromatin structure, There is a growing consensus that telomere length is stabilized by the activity of telomerase in immortal cells; however, it is not clear why some immortal cells display chromosome end-to-end associations. In the present study we evaluated chromosome end-to-end associations, telomere length and telomerase activity with the tumorigenic status of human bronchial epithelial cells immortalized with human papillomavirus. Oncogenic transformation was initiated using radon simulated alpha-particles and cells evaluated as primary, secondary and metastatic transformants, The fewest chromosome end associations and lowest telomerase activity were observed in the parental immortalized cells, However, increased levels of telomerase activity were detected in alpha-particle survivors while robust telomerase activity was seen in the tumorigenic cell lines, The tumorigenic cells that mere telomerase positive and had the highest frequency of cells with chromosome end-to-end associations mere also metastatic, No correlation was found between telomere length and the different stages of carcinogenicity.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL GENET, BRONX, NY 10461 USA; MED COLL OHIO, TOLEDO, OH 43699 USA; JOHNS HOPKINS MED SCH, DEPT PEDIAT ONCOL, BALTIMORE, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), COLUMBIA UNIV, CTR RADIOL RES, NEW YORK, NY 10032 USA.		Shay, Jerry W/F-7878-2011; Pandita, Tej K/AAM-9188-2020; Piatyszek, Mieczyslaw A./F-9365-2015	Piatyszek, Mieczyslaw A./0000-0003-0502-3239	NATIONAL CANCER INSTITUTE [P01CA012536, P01CA049062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [CA12536, CA49062] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRUZZO MA, 1991, CYTOGENET CELL GENET, V56, P149, DOI 10.1159/000133072; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; AGGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BENN PA, 1976, AM J HUM GENET, V28, P465; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEWALD GW, 1987, MAYO CLIN PROC, V62, P558, DOI 10.1016/S0025-6196(12)62293-9; DUTRILLAUX B, 1978, CYTOGENET CELL GENET, V20, P70, DOI 10.1159/000130841; FANG G, 1995, TELOMERES, P69; FITZGERALD PH, 1984, HUM GENET, V67, P385, DOI 10.1007/BF00291396; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GRIEDER CW, 1985, CELL, V43, P405; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; HITTELMAN WN, 1988, CANCER GENET CYTOGEN, V30, P301, DOI 10.1016/0165-4608(88)90199-9; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOVACS G, 1987, CANCER GENET CYTOGEN, V28, P363, DOI 10.1016/0165-4608(87)90225-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS1511; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANDAHL N, 1985, HUM GENET, V71, P321, DOI 10.1007/BF00388457; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; McClintock B, 1941, GENETICS, V26, P234; MEHLA C, 1994, CANCER RES, V554, P236; MOORHEAD PS, 1963, J CELL COMPAR PHYSL, V62, P57, DOI 10.1002/jcp.1030620109; MORGAN R, 1986, HUM GENET, V73, P260, DOI 10.1007/BF00401240; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Muller H., 1938, COLLECT NET, V13, P182; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; *NAT COUNC RAD PRO, 1984, 78 NCRP; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PANDITA TK, 1983, HUM GENET, V63, P189, DOI 10.1007/BF00291543; PATHAK S, 1988, CYTOGENET CELL GENET, V47, P227, DOI 10.1159/000132555; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SALTMAN D, 1989, CYTOGENET CELL GENET, V50, P230, DOI 10.1159/000132766; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YERGANIAN G., 1962, CYTOGENETICS [BASEL], V1, P314, DOI 10.1159/000129742; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	62	57	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1423	1430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875980				2022-12-17	WOS:A1996VL38400007
J	Sandhu, AK; Kaur, GP; Reddy, DE; Rane, NS; Athwal, RS				Sandhu, AK; Kaur, GP; Reddy, DE; Rane, NS; Athwal, RS			A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells	ONCOGENE			English	Article						cellular senescence; ovarian tumor; chromosome transfer; immortal cell growth	INDEFINITE DIVISION; SUPPRESSOR GENES; FREQUENT LOSS; HETEROZYGOSITY; CHROMOSOME-6; IDENTIFICATION; EXPRESSION; CARCINOMAS; INVITRO; CANCER	We have identified a gene on 6q14-21 which restores senescence to immortal ovarian tumor cells. Single gpt tagged human chromosomes, present in mouse/human monochromosomal hybrids, were introduced into immortal human and rat ovarian tumor cells via microcell fusion. Analysis of chromosome transfer clones for cell morphology and growth properties revealed that chromosome 6 or 6q restored senescence to both human and rat ovarian tumor cells while chromosomes 10 or 14 did not affect the proliferative potential of these cells. Reversion to immortal growth concordant with loss of the donor chromosome confirmed the presence of a senescence gene on 6q. During continuous maintenance of microcell hybrids in MX medium, rare immortal revertant clones grew out of the human and rat senescent cell populations. Analysis of independent revertant clones of rat cells, for chromosome 6 markers, revealed a common deletion of chromosomal region 6q14-21 in all revertants. Restoration of senescence following introduction of a gpt tagged chromosome segment 6q13-21 into human and rat ovarian tumor cells confirmed the location of a senescence gene in this region. In contrast, introduction of a chromosome 6 lacking the region 6q14-21 did not impart senescence in these cells. Based on these results we assigned the senescence gene (SEN 6A) to region 6q14-21.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ADAMS AT, 1985, EXP CELL BIOL, V53, P181; ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Del Senno L., 1992, Human Molecular Genetics, V1, P354; EHLEN T, 1990, ONCOGENE, V5, P219; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE JH, 1990, CANCER RES, V50, P2724; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NEGRINI M, 1994, CANCER RES, V54, P1331; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAITO S, 1992, CANCER RES, V52, P5815; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TESTA JR, 1994, CANCER RES, V54, P2778; TEYSSIER JR, 1992, ANTICANCER RES, V12, P997; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WELCH DR, 1994, ONCOGENE, V9, P255; [No title captured]	42	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					247	252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570202				2022-12-17	WOS:A1996TR53800004
J	King, AG; Ozanne, BW; Smythe, C; Ashworth, A				King, AG; Ozanne, BW; Smythe, C; Ashworth, A			Isolation and characterisation of a uniquely regulated threonine, tyrosine phosphatase (TYP 1) which inactivates ERK2 and p54(jnk)	ONCOGENE			English	Article						dual-specificity phosphatase; MAP kinase inhibitor	ACTIVATED PROTEIN-KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; CELL-PROLIFERATION; MESSENGER-RNAS; GROWTH; DEPHOSPHORYLATION; TRANSFORMATION; PURIFICATION; SEQUENCE	The recent discovery of the vaccinia virus protein phosphatase VH1, and its mammalian counterparts has highlighted a novel subfamily of protein tyrosine phosphatases that exhibit dual specificity toward phosphotyrosine- and phosphoserine/threonine-residues. We have identified further members of this subfamily. The characterisation of one clone in particular, which we have named threonine-tyrosine phosphatase 1 (TYP 1), encodes a protein homologous to CL100, but differs dramatically in its regulation, TYP 1 is not expressed in human fibroblasts unlike other CL100-like genes, Furthermore, northern analysis has demonstrated that following mitogenic stimulation of squamous cells, induction of TYP 1 mRNA reaches its maximal levels after four hours, in contrast to the immediate early CL100-like genes, Both TYP 1 and CL100 mRNAs are induced upon TGF-beta treatment of squamous cell lines sensitive to the growth factors antiproliferative effects, When TYP 1 is transfected into COS-1 cells, the gene product inhibits both ERK2 and p54 MAP kinase subfamilies, In addition, we show that purified TYP 1 protein efficiently inactivates recombinant ERK2 in vitro by the concomitant dephosphorylation of both its phosphothreonine and -tyrosine residues, TYP 1 encodes a nuclear protein, which when expressed in COS cells is stabilised by EGF treatment.	BEATSON INST CANC RES,CANC RES CAMPAIGN LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Beatson Institute; University of Dundee; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASHWORTH A, 1993, TRANSCRIPTION FACTOR, P125; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUFF JL, 1995, J BIOL CHEM, V270, P1; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1981, CANCER RES, V41, P1657; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J, 1989, MOL CLONING LAB MANU; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SARCEVIC B, 1993, J BIOL CHEM, V268, P25075; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SETH A, 1992, J BIOL CHEM, V267, P24796; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TROWBRIDGE IS, 1991, J BIOL CHEM, V266, P25317; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	65	57	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2553	2563						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545112				2022-12-17	WOS:A1995TP18800011
J	Miyaki, M; Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Takeichi, M				Miyaki, M; Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Takeichi, M			Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells	ONCOGENE			English	Article						E-cadherin; colon carcinoma; cell adhesion; gelatinase; cell growth	FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-CELLS; EXPRESSION; CANCER; PROGRESSION; MOLECULES; TUMORIGENICITY; SUPPRESSION; INVASION	Metastasis of colon carcinomas is assumed to be caused by multiple steps, which include a loss of cell adhesion that results in the release of carcinoma cells from the original tumor tissue, A human colon carcinoma cell line COKFu was established from a poorly differentiated metastatic adenocarcinoma without cell-cell adhesion and without expression of E-cadherin mRNA and protein, This cell line was co-transfected with mouse E-cadherin cDNA in an expression vector and a neomycin-resistant gene, The parental carcinoma cells had a spindle shape and were scattered, whereas the transfected cells, which expressed exogenous E-cadherin gene, showed a more compact shape with strong cell-cell adhesion and with increased adhesiveness to collagen gel, These cells showed a significantly low anchorage independency (2-7%) and decreased invasiveness (30%) compared to the parental cells, Growth rate of transfectants was decreased both in vitro and in the subcutis of nude mice, with decreased lymphnode metastasis in the case of intravenous injection, It was additionally found that activity of 62 kd gelatinase, secreted from parental cells, was lost or decreased in E-cadherin-transfected cells. These results suggest that E-cadherin is not only involved in the cell-cell adhesion of colon carcinomas, it also has a wider effect, including cell-substratum adhesion and the regulation of proteinase secretion from the cells resulting in partial suppression of invasiveness and tumorigenic growth.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	Miyaki, M (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BUSSEMAKERS MJG, 1992, CANCER RES, V52, P2916; CHEN WC, 1991, J CELL BIOL, V114, P319, DOI 10.1083/jcb.114.2.319; DIMANCHEBOITREL MT, 1994, INT J CANCER, V56, P512, DOI 10.1002/ijc.2910560410; DOKI M, 1992, CANCER RES, V53, P3421; DORUDI S, 1993, AM J PATHOL, V142, P981; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; HASHIMOTO M, 1989, JPN J CANCER RES, V80, P459, DOI 10.1111/j.1349-7006.1989.tb02336.x; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MIYAKI M, 1994, CANCER RES, V54, P3011; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCIPPER JH, 1991, CANCER RES, V51, P6328; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.bi.59.070190.001321; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANAKA K, 1993, ONCOGENE, V8, P2253; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	32	57	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2547	2552						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545111				2022-12-17	WOS:A1995TP18800010
J	PREVOSTEL, C; ALVARO, V; DEBOISVILLIERS, F; MARTIN, A; JAFFIOL, C; JOUBERT, D				PREVOSTEL, C; ALVARO, V; DEBOISVILLIERS, F; MARTIN, A; JAFFIOL, C; JOUBERT, D			THE NATURAL PROTEIN-KINASE C-ALPHA MUTANT IS PRESENT IN HUMAN THYROID NEOPLASMS	ONCOGENE			English	Article						TUMORIGENESIS; PROTEIN KINASE C; THYROID; ONCOGENE	H-RAS ONCOGENE; P53 MUTATIONS; FIBROBLASTS; OVEREXPRESSION; CARCINOMAS; GROWTH; CELLS; TUMORS; EXPRESSION; EPSILON	An altered protein expression of Ca2+-dependent protein kinase C (PKC) isoforms and a point mutation in the PKC alpha cDNA (position 908 of the nucleotide sequence, position 294 of the amino acid sequence, substitution of an aspartic acid by a glycine) have been previously described in a subpopulation of human pituitary tumors. In this work, we screened 16 thyroid tissue samples (four follicular adenomas, five colloid adenomas, three papillary carcinomas, one follicular carcinoma and three normal tissues adjacent to the tumors) for the presence of the PKC alpha point mutation and for PKC alpha, beta 1, beta 2, epsilon and delta protein expression. Screening for the presence of the PKC alpha mutant was performed by a subcloning technic. The polymerase chain reaction products were generated using reverse-transcribed cDNAs, subcloned and sequenced (10 clones were routinely sequenced). The PKC alpha point mutation at position 908 of the cDNA sequence was found in four out of the nine adenomas and in the follicular carcinoma. It was neither detected in the papillary carcinomas nor in the adjacent normal tissues (one was the adjacent normal tissue of the follicular carcinoma; in this sample, genomic DNA and cDNA were used to look for the presence of the mutant), demonstrating the somatic nature of this mutant. Western blot analysis of PKC isoforms showed that the expression of all isoforms was higher in the thyroid neoplasms as compared with their adjacent normal tissue (n=3). It was also higher in the samples containing the PKC mutant (two follicular adenomas, two colloid adenomas and the follicular carcinoma) as compared with the tumors where it was not detected (three papillary carcinomas and five adenomas). Samples could be ordered according to their increasing PKC expression as follows: normal adjacent tissue < follicular adenomas without PKC alpha mutant less than or equal to papillary carcinoma < follicular adenomas with PKC mutant < follicular carcinoma with PKC mutant. In conclusion, the discovery of the PKC alpha mutant in thyroid neoplasms demonstrates that this mutant is not particular to human pituitary tumors where it was originally detected. It is a somatic mutation and its presence is concomitant with high levels of all of the PKC isoforms analysed. The presence of the PKC mutant in thyroid neoplasms raises the question of its importance in thyroid tumorigenesis.	INSERM, U401, F-34094 MONTPELLIER 05, FRANCE; COLUMBIA UNIV, CTR COMPREHENS CANC, NEW YORK, NY USA; COLUMBIA UNIV, INST CANC RES, NEW YORK, NY USA; HOP LAPEYRONIE, F-34295 MONTPELLIER, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Columbia University; Columbia University; Universite de Montpellier; CHU de Montpellier			Prevostel, Corinne/AAO-1433-2020	PREVOSTEL, Corinne/0000-0002-7553-087X				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; ALVARO V, 1992, INT J CANCER, V50, P724, DOI 10.1002/ijc.2910500510; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DOCKHORNDWORNICZAK B, 1990, VERH DEUT G, V74, P415; ELDAR H, 1990, J BIOL CHEM, V265, P13290; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; FAGIN JA, 1994, ANNU REV MED, V45, P45; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GORETZKI PE, 1992, WORLD J SURG, V16, P576, DOI 10.1007/BF02067325; HAGIWARA M, 1990, CANCER RES, V50, P5515; HATADA T, 1992, CANCER, V70, P2918, DOI 10.1002/1097-0142(19921215)70:12<2918::AID-CNCR2820701231>3.0.CO;2-5; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; ITO T, 1992, CANCER RES, V52, P1369; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; KOPP P, 1994, J CLIN ENDOCR METAB, V79, P134, DOI 10.1210/jc.79.1.134; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; LEVY L, 1994, EUR J PHARM-MOLEC PH, V268, P327, DOI 10.1016/0922-4106(94)90057-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAPELLI E, 1994, INT J CANCER, V57, P281, DOI 10.1002/ijc.2910570225; MATSUO K, 1993, J CLIN ENDOCR METAB, V77, P991, DOI 10.1210/jc.77.4.991; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; NAMBA H, 1990, J CLIN ENDOCR METAB, V71, P223, DOI 10.1210/jcem-71-1-223; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; POWIS G, 1994, TUMORI J, V80, P69, DOI 10.1177/030089169408000201; SHI YF, 1991, CANCER RES, V51, P2690; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STRINGER BM, 1989, EXPERIENTIA, V45, P372, DOI 10.1007/BF01957483; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; ZOU MJ, 1993, J CLIN ENDOCR METAB, V77, P1054, DOI 10.1210/jc.77.4.1054	44	57	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					669	674						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651730				2022-12-17	WOS:A1995RQ46900008
J	KARLSSON, T; ZHOU, SY; LANDGREN, E; LAVERGNE, C; DIFIORE, PP; ANAFI, M; PAWSON, T; CANTLEY, LC; CLAESSONWELSH, L; WELSH, M				KARLSSON, T; ZHOU, SY; LANDGREN, E; LAVERGNE, C; DIFIORE, PP; ANAFI, M; PAWSON, T; CANTLEY, LC; CLAESSONWELSH, L; WELSH, M			MOLECULAR-INTERACTIONS OF THE SRC HOMOLOGY-2 DOMAIN PROTEIN SHB WITH PHOSPHOTYROSINE RESIDUES, TYROSINE KINASE RECEPTORS AND SRC HOMOLOGY-3 DOMAIN PROTEINS	ONCOGENE			English	Article						SRC HOMOLOGY 2 (SH2) DOMAIN; SRC HOMOLOGY 3 (SH3) DOMAIN; TYROSINE KINASE RECEPTORS; PROLINE-RICH MOTIFS; MITOGENIC SIGNAL TRANSDUCTION; ADAPTER SH2 DOMAIN PROTEIN	GROWTH-FACTOR RECEPTOR; PDGF BETA-RECEPTOR; SIGNAL TRANSDUCTION; AUTOPHOSPHORYLATION SITES; POINT MUTATION; C-SRC; RAS; IDENTIFICATION; GRB2; ASSOCIATION	The molecular interactions of the Src homology 2 (SH2) domain and the N-terminal proline-rich sequence motifs (pro-1 to pro-5) of the SH2 protein Shb with other components were presently characterised, Using a degenerate phosphopeptide library the preferred binding site for the Shb SH2 domain was determined to pTyr-Thr/Val/Ile-X-Leu at positions +1 to +3 relative the phosphotyrosine residue, Experiments with competing peptides and platelet-derived growth factor (PDGF) beta-receptor mutants with Y to F substitutions in autophosphorylation sites revealed multiple binding sites for the Shb SH2 domain in the receptor, The Shb SH2 domain also binds to in vitro phosphorylated fibroblast growth factor receptor-1 (FGFR-1) mainly through position Y776, The receptor experiments suggest that other residues besides the +1 to +3 positions may also be of significance for Shb binding, The pro-4/pro-5 motif of Shb binds in vitro particularly well to the Src, p85 alpha PI3-kinase and Eps8 SH3 domains expressed as GST fusion proteins, However, the GST-SH3 domain fusion proteins tested bind in vitro to peptides corresponding to the pro-1 to pro-5 motifs of Shb with low affinity and selectivity, suggesting that sequences outside the core proline motif may also be important for Shb-SH3 domain interactions, In vivo association between Shb-SH3 domain proteins v-Src and Eps8 was detected by coimmunoprecipitation. PDGF treatment did not affect the association between Eps8 and Shb. The data suggest that Shb is an adaptor protein linking SH3 domain proteins to tyrosine kinases or other tyrosine phosphorylated proteins.	UNIV UPPSALA, DEPT MED CELL BIOL, UPPSALA, SWEDEN; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DIV SIGNAL TRANSDUCT, BOSTON, MA USA; UPPSALA UNIV, LUDWIG INST CANC RES, UPPSALA, SWEDEN; HOP ROBERT DEBRE, INSERM, CJF 93-13, F-75019 PARIS, FRANCE; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	Uppsala University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Ludwig Institute for Cancer Research; Uppsala University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Di Fiore, Pier Paolo/K-2130-2012; Cantley, Lewis C/D-1800-2014; Pawson, Tony J/E-4578-2013	Di Fiore, Pier Paolo/0000-0002-2252-0950; Cantley, Lewis C/0000-0002-1298-7653; Welsh, Michael/0000-0002-5467-9755				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASTAGNINO P, 1995, IN PRESS ONCOGENE; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WELSH M, 1994, ONCOGENE, V9, P19; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; WENNSTROM S, 1994, ONCOGENE, V9, P651; Wennstrom S, 1991, GROWTH FACTORS, V4, DOI 10.3109/08977199109104816; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	41	57	61	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1475	1483						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7537362				2022-12-17	WOS:A1995QU68100002
J	GOLDSTONE, SD; LAVIN, MF				GOLDSTONE, SD; LAVIN, MF			PROLONGED EXPRESSION OF C-JUN AND ASSOCIATED ACTIVITY OF THE TRANSCRIPTION FACTOR AP-1, DURING APOPTOSIS IN A HUMAN LEUKEMIC-CELL LINE	ONCOGENE			English	Article							PROTO-ONCOGENE; IONIZING-RADIATION; CYCLE PROGRESSION; DNA FRAGMENTATION; GENE-EXPRESSION; LEUCINE ZIPPER; V-JUN; FOS; DEATH; GROWTH	The product of the c-jun gene is a component of the transcription factor AP-1, which plays a critical regulatory role in the cellular response to certain proliferative stimuli. In this report, we demonstrate the prolonged expression of c-jun mRNA during apoptosis induced in a human leukaemic T-cell line, CEM C7, by treatment with either dexamethasone or gamma-radiation. However, overexpression of the c-jun mRNA was not accompanied by either increased expression of jun protein, or increased AP-1 DNA binding activity. Indeed, a decrease in AP-1 DIVA binding activity was seen in response to both inducing stimuli. This decrease in AP-1.binding activity may be mediated by an increase in the activity of an AP-1 inhibitory factor, as the steady state levels of jun protein remained constant during the onset of apoptosis, and cytosolic AP-1 inhibitory activity was found to increase, concomitant with the decrease in AP-1 DNA binding activity. Our data demonstrate the complexity of the mechanisms involved in the regulation of c-jun expression during the onset of apoptosis, and suggest a novel mode for the regulation of AP-1 activity during the cessation of proliferation.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BANCROFT CTR,BRISBANE,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	GOLDSTONE, SD (corresponding author), UNIV SYDNEY,DEPT PATHOL,DO6,SYDNEY,NSW 2006,AUSTRALIA.		Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUWERX J, 1992, ONCOGENE, V7, P2271; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRIATA P, 1993, EXP CELL RES, V204, P136, DOI 10.1006/excr.1993.1018; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CARTER R, 1991, ONCOGENE, V6, P229; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GASSON JC, 1983, J CELL BIOL, V96, P409, DOI 10.1083/jcb.96.2.409; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; GUNJI H, 1991, CANCER RES, V51, P741; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HARRIGAN MT, 1989, MOL CELL BIOL, V9, P3438, DOI 10.1128/MCB.9.8.3438; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOSHIKAWA Y, 1988, ENDOCRINOL JAPON, V35, P429; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8454; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; YUH YS, 1989, J BIOL CHEM, V264, P10904; YUH YS, 1987, SOMAT CELL MOLEC GEN, V13, P33, DOI 10.1007/BF02422297; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	45	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2305	2311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036012				2022-12-17	WOS:A1994NX62900023
J	ZHANG, JD; CHANG, CC; LOMBARDI, L; DALLAFAVERA, R				ZHANG, JD; CHANG, CC; LOMBARDI, L; DALLAFAVERA, R			REARRANGED NFKB2 GENE IN THE HUT78 T-LYMPHOMA CELL-LINE CODES FOR A CONSTITUTIVELY NUCLEAR FACTOR LACKING TRANSCRIPTIONAL REPRESSOR FUNCTIONS	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING; RETICULOENDOTHELIOSIS VIRUS; ONCOPROTEIN BCL-3; REL; SUBUNIT; P50; ONCOGENE; CLONING; INHIBITION	Rearrangements of the NFKB2 gene are associated with lymphoid malignancies, but the functional significance of these alterations is not known. Here we characterize structurally and functionally a rearranged NFKB2 gene identified at the T cell lymphoma line, HUT78. The rearrangement has truncated NFKB2 sequences within the 3' ankyrin domain, leading to the production of truncated mRNA species and proteins as detected by Northern blot and immunoprecipitation analysis, respectively. Cloning and sequencing of the corresponding cDNAs indicates that, via alternative splicing, the rearranged gene codes for two proteins of 84 and 85 kD (p84/85) which retain the DNA-binding rel domain and the first five ankyrin repeats, but have lost their carboxy-terminus including the seventh ankyrin repeat. Immunofluorescence and immunoprecipitation analysis of HUT78 cells indicate that p84/85 are abnormally located in the nucleus in an unprocessed form, suggesting that these proteins can escape the cytoplasmic retention typical of the normal NFKB2 p100 protein before it is processed into p52. Electrophoretic mobility shift assays performed on HUT78 nuclear extracts indicate that the abnormal NFKB2 proteins bind kappa B sites specifically and alter the composition of NF-kappa B complexes in HUT78 cells. Transient co-transfection assays involving NFKB2 expression vectors and kappa B-driven reporter plasmids indicate that NFKB2 p85 has lost the transcriptional repressor functions typical of normal NFKB2 p52. These data indicate that the NFKB2 gene rearrangement detected in HUT78 cells leads to the production of abnormal NFKB2 proteins capable of altering the function of the NF-kappa B transcription system. Since analogous rearrangements are found in lymphoid malignancies, these findings further support a role of NFKB2 alterations in tumorigenesis.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,DIV ONCOL,NEW YORK,NY 10032; UNIV MILAN,OSPED MAGGIORE,IRCCS,IST SCI MED,EMATOL LAB,MILAN,ITALY	Columbia University; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan					NCI NIH HHS [CA 44029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044029] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1989, ONCOGENE, V4, P935; CHANG CC, 1994, ONCOGENE, V9, P923; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GAZDAR AF, 1980, BLOOD, V55, P409; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GRILLI M, 1992, INT REV CYTOL, V48, P1; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISRAEL DI, 1989, NUCLEIC ACIDS RES, V17, P4589, DOI 10.1093/nar/17.12.4589; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LU D, 1991, ONCOGENE, V6, P1235; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OFFIT K, 1991, BLOOD, V77, P1508; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SAGLIO G, 1986, CANCER RES, V46, P1413; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; YANO T, 1993, BLOOD, V82, P1813, DOI 10.1182/blood.V82.6.1813.bloodjournal8261813	38	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1931	1937						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208540				2022-12-17	WOS:A1994NR68500017
J	CAMPBELL, CE; HUANG, A; GURNEY, AL; KESSLER, PM; HEWITT, JA; WILLIAMS, BRG				CAMPBELL, CE; HUANG, A; GURNEY, AL; KESSLER, PM; HEWITT, JA; WILLIAMS, BRG			ANTISENSE TRANSCRIPTS AND PROTEIN-BINDING MOTIFS WITHIN THE WILMS-TUMOR (WT1) LOCUS	ONCOGENE			English	Article							DENYS-DRASH SYNDROME; ZINC-FINGER GENE; FAMILIAL PREDISPOSITION; HOMOZYGOUS DELETION; FUNCTIONAL-ANALYSIS; N-MYC; EXPRESSION; 11P13; PROMOTER; REGION	Transcription of the WT1 locus is restricted, both temporally and spatially, to a subset of epithelial cells in mammalian kidneys and gonads. WT1, one of the two divergent transcripts mapping to this locus encodes a zinc finger protein that is likely a transcriptional regulator. The other transcript, WIT1, encodes a product of unknown function that is subject to alternate splicing in the region immediately 5' of the WT1 gene. Analysis of the 5' end of this locus further revealed the presence of multiple transcriptional start sites for both genes, such that some of the WIT1 transcripts are encoded by the antisense strand of the first exon of WT1. The genomic region surrounding the transcriptional start sites appears to constitute part of a bi-directional promoter based on the ability of a DNA fragment derived from this region to direct expression of a chimeric CAT gene construct in transient transfection assays. Discrete sequences within the region are capable of interaction in vitro with nuclear extracts derived from a variety of rat and mouse tissues, Interestingly, recombinant WT1, representing the product of zinc finger region of the most abundant of the four alternatively spliced transcripts, is also capable of binding to sequences within this region.	UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Toronto	CAMPBELL, CE (corresponding author), CLEVELAND CLIN FDN,DEPT CANC BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; COPPES MJ, 1992, CANCER RES, V52, P6125; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; COWELL JK, 1991, ONCOGENE, V6, P595; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1991, AM J HUM GENET, V48, P997; KIKUCHI H, 1992, AM J PATHOL, V140, P781; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; KOUFOS A, 1989, AM J HUM GENET, V44, P711; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MAW MA, 1992, CANCER RES, V52, P3094; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TADOKORO K, 1992, ONCOGENE, V7, P1215; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H; WANG ZY, 1992, J BIOL CHEM, V267, P21999; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	50	57	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					583	595						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290269				2022-12-17	WOS:A1994MW24800026
J	JAMAL, HH; CANOGAUCI, DF; BUICK, RN; FILMUS, J				JAMAL, HH; CANOGAUCI, DF; BUICK, RN; FILMUS, J			ACTIVATED RAS AND SRC INDUCE CD44 OVEREXPRESSION IN RAT INTESTINAL EPITHELIAL-CELLS	ONCOGENE			English	Article							HUMAN-COLON CARCINOMA; PP60C-SRC PROTEIN-KINASE; RECEPTOR CD44; EXPRESSION; HYALURONATE; EXONS; MUTATIONS; ONCOGENE; MOLECULE; CONFERS	CD44 is an adhesion molecule that is involved in the progression of several tumor types, including those originating in the intestine. There are several alternatively spliced forms of CD44. Here we show that intestinal epithelial cells express the standard form of CD44 (CD44s). The same form of CD44 is found in IEC-18, a cell line derived from normal rat intestinal crypts. Upon transfection of IEC-18 cells with vas or src, two oncogenes that are frequently activated in intestinal tumors, a significant induction of CD44s is observed. A causal role for vas in this induction is shown by using IEC clones transfected with an inducible vas expression vector. The oncogene-transformed IEC clones display a high degree of hyaluronic acid-dependent cell-cell adhesion that is not observed in the parental IEC-18 cells suggesting that ras- and src-induced overexpression of CD44 c;ln alter the adhesion properties of intestinal cells.	SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO M4N 3M5,ON,CANADA; ONTARIO CANC INST,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON,CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRCH M, 1991, CANCER RES, V51, P6660; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; BUICK RN, 1987, EXP CELL RES, V170, P300, DOI 10.1016/0014-4827(87)90308-9; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; FILMUS J, 1992, ONCOGENE, V7, P521; FILMUS J, 1993, ONCOGENE, V8, P1017; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1993, CANCER RES, V53, P1516; KENNEL SJ, 1993, J CELL SCI, V104, P373; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; LIOTTA LA, 1976, CANCER RES, V36, P889; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; OUDEJANS J J, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P293; PATTERSON DJ, 1987, MOL IMMUNOL, V24, P1281; QUARONI A, 1981, J NATL CANCER I, V67, P1353; QURESHI SA, 1992, J BIOL CHEM, V267, P24149; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; UNDERHILL C, 1992, J CELL SCI, V103, P293; WARREN SL, 1988, MOL CELL BIOL, V8, P632, DOI 10.1128/MCB.8.2.632; ZHAO JM, 1993, EXP CELL RES, V204, P82, DOI 10.1006/excr.1993.1011	41	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					417	423						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	7507229				2022-12-17	WOS:A1994MW24800008
J	TAKADA, S; KIDO, H; FUKUTOMI, A; MORI, T; KOIKE, K				TAKADA, S; KIDO, H; FUKUTOMI, A; MORI, T; KOIKE, K			INTERACTION OF HEPATITIS-B VIRUS-X PROTEIN WITH A SERINE-PROTEASE, TRYPTASE TL(2) AS AN INHIBITOR	ONCOGENE			English	Article							EUKARYOTIC TRANSCRIPTIONAL ACTIVATORS; ERYTHROID-POTENTIATING ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; PROMOTER TRANS-ACTIVATION; LONG TERMINAL REPEAT; RAT MAST-CELLS; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; TRANSACTIVATION FUNCTION; HUMAN LYMPHOCYTES-T4+	X protein of hepatitis B virus (HBV) transactivates transcription of various viral and cellular genes. It has been suggested that X protein plays a major role in hepatocarcinogenesis by HBV. The protein possesses amino acid sequence homology to the functionally essential domain of Kunitz-type serine protease inhibitors. This Kunitz domain-like sequence in X protein is indispensable for the transactivation function. To clarify whether X protein has a serine protease inhibitor activity, a search was made for serine proteases which interact with, but not degrade X protein. Tryptase TL,, one of serine proteases in hepatic cells, was found to directly interact with X protein without degradation. Moreover, the activities of tryptase TL, and an analogous protease were substantially inhibited by X protein. These results suggest that transactivation function of X protein is exerted by modulation of the hepatic serine protease activity, giving rise to quantitative or qualitative change of cellular transcription factor(s) through protection from proteolytic degradation and/or suppression of processing.	JFCR,INST CANC,DEPT GENE RES,TOSHIMA KU,TOKYO,TOKYO 170,JAPAN; UNIV TOKUSHIMA,INST ENZYME RES,DIV ENZYME CHEM,TOKUSHIMA 770,JAPAN	Japanese Foundation for Cancer Research; Tokushima University								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANDERSON S, 1983, P NATL ACAD SCI-BIOL, V80, P6838, DOI 10.1073/pnas.80.22.6838; ARII M, 1992, ONCOGENE, V7, P397; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GILMAN M, 1993, NATURE, V361, P687, DOI 10.1038/361687a0; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATO I, 1979, FED PROC, V38, P832; KATUNUMA N, 1975, EUR J BIOCHEM, V52, P37, DOI 10.1111/j.1432-1033.1975.tb03970.x; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIDO H, 1988, J BIOL CHEM, V263, P18104; KIDO H, 1985, ARCH BIOCHEM BIOPHYS, V239, P436, DOI 10.1016/0003-9861(85)90709-X; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOBAYASHI M, 1984, GENE, V30, P227; KODAMA K, 1985, J VIROL, V56, P978, DOI 10.1128/JVI.56.3.978-986.1985; KOIKE K, 1989, MOL BIOL MED, V6, P151; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MAHE Y, 1991, J BIOL CHEM, V266, P13759; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCKEEHAN WL, 1986, J BIOL CHEM, V261, P5378; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OKAMOTO H, 1986, J GEN VIROL, V67, P2305, DOI 10.1099/0022-1317-67-11-2305; ONO Y, 1983, NUCLEIC ACIDS RES, V11, P1747, DOI 10.1093/nar/11.6.1747; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PATARCA R, 1985, NATURE, V318, P390, DOI 10.1038/318390a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; TAKADA S, 1990, JPN J CANCER RES, V81, P1191, DOI 10.1111/j.1349-7006.1990.tb02675.x; TANAKA K, 1992, NEW BIOL, V4, P173; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; TWU JS, 1989, J VIROL, V63, P2857, DOI 10.1128/JVI.63.6.2857-2860.1989; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZAHM P, 1988, ONCOGENE, V3, P169	54	57	59	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					341	348						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290248				2022-12-17	WOS:A1994MW24800001
J	MEDCALF, EA; MILNER, J				MEDCALF, EA; MILNER, J			TARGETING AND DEGRADATION OF P53 BY E6 OF HUMAN PAPILLOMAVIRUS TYPE-16 IS PREFERENTIAL FOR THE 1620+ P53 CONFORMATION	ONCOGENE			English	Note							MONOCLONAL-ANTIBODY; SIMIAN VIRUS-40; WILD-TYPE; MUTANT CONFORMATION; SUPPRESSOR; PROTEIN; EXPRESSION; TRANSFORMATION; MUTATIONS; DISTINCT	E6-mediated degradation of p53 is believed to play a role in the transformation of cells by high-risk types of human papillomavirus. In order to explore the structural requirements for targeting of p53 we have compared E6-mediated degradation of variant p53 forms expressed in vitro. Complete degradation was observed in samples containing monomers, dimers and higher molecular weight structures of wild-type p53, indicating that E6 targets all quaternary forms of wild-type p53. Wild-type human and murine p53s reactive with PAb 1620 (which recognizes a conformation-dependent epitope) were degraded when incubated with E6. Mutant p53 proteins were variably resistant to E6-mediated degradation, and this correlated with PAb 1620 reactivity. Thus, mutants hp53Val-154, hp53Val-266 and hp53Pro-273 (1620-degrees) were completely resistant to degradation, whereas hp53Ile-247 and hp53Trp-248 (1620+) were degraded. Mutants hp53Leu-273 and mp53Val-135, which are temperature sensitive for conformation, were completely degraded in the 1620+ form but degradation resistant in the 1620-degrees form. Although the PAb 1620+ conformation appeared important for recognition of p53 by E6, the epitope itself is unlikely to be the actual recognition target since the PAb 1620 monoclonal antibody failed to protect against E6-mediated degradation.	UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge								ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1591; HAINAUT P, 1993, CANCER RES, V53, P1739; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUSEN HZ, 1987, PAPOVAVIRIDAE, V2, P245; HUIGBREGTSE J, 1991, EMBO J, V10, P4129; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; MEDCALF EA, 1992, ONCOGENE, V7, P71; MILNER J, 1991, P ROY SOC B-BIOL SCI, V245, P139, DOI 10.1098/rspb.1991.0100; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1993, ONCOGENE, V8, P2001; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	33	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2847	2851						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	7690928				2022-12-17	WOS:A1993LX34300028
J	KOMADA, M; KITAMURA, N				KOMADA, M; KITAMURA, N			THE CELL-DISSOCIATION AND MOTILITY TRIGGERED BY SCATTER FACTOR HEPATOCYTE GROWTH-FACTOR ARE MEDIATED THROUGH THE CYTOPLASMIC DOMAIN OF THE C-MET RECEPTOR	ONCOGENE			English	Article							ANCHORAGE-INDEPENDENT GROWTH; TYROSINE KINASE-ACTIVITY; HUMAN-FIBROBLASTS; EPITHELIAL-CELLS; PROTO-ONCOGENE; SIGNAL TRANSDUCTION; CHIMERIC RECEPTOR; MOLECULAR-CLONING; RAT HEPATOCYTES; HEPATOPOIETIN-A	Scatter factor (SF), which dissociates epithelial cell colonies into individual cells and stimulates the migration of epithelial cells, is identical to hepatocyte growth factor (HGF), a mitogen for melanocytes, endothelial cells and epithelial cells, including hepatocytes. It was previously shown by cDNA transfection that the mitogenic effect of SF/HGF is mediated by activation of the tyrosine phosphorylation of the c-Met receptor (the c-met protooncogene product). In this study, we constructed a cDNA encoding a chimeric receptor composed of the extracellular domain of the epidermal growth factor (EGF) receptor and the transmembrane and cytoplasmic domains of the c-Met receptor. We transfected the cDNA into the B16-F1 mouse melanoma cell line to investigate whether the cell dissociation and motility were mediated through this chimeric receptor following ligand stimulation. The chimeric receptor cDNA was expressed in the transfected cells and the protein product was transported to the cell surface in the correct transmembrane orientation. EGF treatment of the chimeric receptor-expressing cells markedly enhanced tyrosine phosphorylation of the chimeric receptor and led to scattered morphology and enhanced motility. This scattered morphology was inhibited by a tyrosine kinase inhibitor. Based on these results, we concluded that the cell dissociation and motility triggered by SF/HGF were mediated through the cytoplasmic domain of the c-Met receptor by activation of its tyrosine kinase. Thus, it is likely that the different biological effects of SF/HGF are mediated by different intracellular signal cascades.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN	Kansai Medical University								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ARAKAKI N, 1992, J BIOL CHEM, V267, P7101; BARDELLI A, 1992, ONCOGENE, V7, P1973; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHAN AML, 1988, ONCOGENE, V2, P593; DAS M, 1978, P NATL ACAD SCI USA, V75, P2644, DOI 10.1073/pnas.75.6.2644; DEMOUZON SH, 1992, J CELL PHYSL, V150, P180; FIDLER IJ, 1975, CANCER RES, V35, P218; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HIGASHIO K, 1990, BIOCHEM BIOPH RES CO, V170, P397, DOI 10.1016/0006-291X(90)91287-3; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KING AC, 1982, J BIOL CHEM, V257, P3053; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOMADA M, 1992, EUR J BIOCHEM, V204, P857, DOI 10.1111/j.1432-1033.1992.tb16705.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEEDORF K, 1991, J BIOL CHEM, V266, P12424; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZARNEGAR R, 1989, CANCER RES, V49, P3314	65	57	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2381	2390						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689722				2022-12-17	WOS:A1993LT36800008
J	GUTMANN, DH; BOGUSKI, M; MARCHUK, D; WIGLER, M; COLLINS, FS; BALLESTER, R				GUTMANN, DH; BOGUSKI, M; MARCHUK, D; WIGLER, M; COLLINS, FS; BALLESTER, R			ANALYSIS OF THE NEUROFIBROMATOSIS TYPE-1 (NF1) GAP-RELATED DOMAIN BY SITE-DIRECTED MUTAGENESIS	ONCOGENE			English	Article							AFFINITY CAMP PHOSPHODIESTERASE; GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; RAS GTPASE; MAMMALIAN GAP; YEAST; IDENTIFICATION; SEQUENCE; ENCODES	The gene for von Recklinghausen neurofibromatosis type 1 (NF1) was recently identified by positional cloning and found to encode a protein with sequence similarity to a family of eucaryotic GTPase-activating proteins (GAPs). Expression of the NF1-GAP-related domain (NF1GRD) has been shown to complement yeast strains deficient in the yeast GAP homologs, IRA1 and IRA2, to interact with human RAS proteins and to accelerate the conversion of ras-GTP to ras-GDP. Further analysis of this region has revealed a number of residues that are highly conserved between members of the GAP family. Mutational analysis of a representative number of these residues produced one of three effects: (1) no change in NF1GRD function. (2) complete disruption of NF1GRD function and (3) intermediate retention of NF1GRD function. One of these mutations at residue 1423 was shown to have reduced ability to negatively regulate ras in yeast, which is interesting in tight of a recent report demonstrating a similar naturally occurring mutation in human malignancies.	UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109; NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; Cold Spring Harbor Laboratory				Gutmann, David/0000-0002-3127-5045; Marchuk, Douglas/0000-0002-3110-6671; Wigler, Michael/0000-0003-4396-1971	NINDS NIH HHS [NS23410] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023410] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, IN PRESS MOL CELL BI; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1992, NEW BIOL, V4, P247; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIBBS JB, 1987, P NATL ACAD SCI USA, V262, P10426; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LI Y, 1992, CELL, V69, P1; Maniatis T., 1982, MOL CLONING; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NISHI T, 1991, ONCOGENE, V6, P1555; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SHERMAN F, 1986, LABORATORY COURSE MA; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	39	57	57	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					761	769						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437860				2022-12-17	WOS:A1993KN00800029
J	LIU, JX; CAMPBELL, M; GUO, JQ; LU, D; XIAN, YM; ANDERSSON, BS; ARLINGHAUS, RB				LIU, JX; CAMPBELL, M; GUO, JQ; LU, D; XIAN, YM; ANDERSSON, BS; ARLINGHAUS, RB			BCR-ABL TYROSINE KINASE IS AUTOPHOSPHORYLATED OR TRANSPHOSPHORYLATES P160 BCR ON TYROSINE PREDOMINANTLY WITHIN THE 1ST BCR EXON	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PHILADELPHIA-CHROMOSOME; CELL-LINE; C-ABL; ONCOGENE PRODUCT; GENE-PRODUCTS; PROTEIN; MICE	The role of BCR gene sequences in Philadelphia (Ph) chromosome-positive leukemia is not well understood. Our previous studies demonstrated that P210 BCR-ABL co-precipitates with P160 BCR following immunoprecipitation with antibodies to the C-terminal domain of P160 BCR, sequences lacking in P210 BCR-ABL. We now report that tryptic peptides shared by both P160 BCR and P210 BCR-ABL are phosphorylated on tyrosine in vitro either when using immune complexes containing P160 BCR complexed to BCR-ABL or when P160 BCR is phosphorylated in trans by P210 BCR-ABL immune complexes from cells lacking functional P160 BCR. P185 BCR-ABL produced in a cell line derived from a Ph chromosome-positive acute lymphocytic leukemia patient also co-immunoprecipitated with P160 BCR. As with P210 BCR-ABL, P160 BCR tyrosine phosphopeptides were shared with P185 BCR-ABL, indicating that the major sites of tyrosine phosphorylation in vitro are contained within the first exon of P160 BCR. Similarly, BCR-ABL autophosphorylation was found to occur predominantly at tyrosines within BCR exon 1 sequences. These results raise the possibility that the activated ABL protein kinase of BCR-ABL proteins modulates the putative signal transduction activities of P160 BCR by tyrosine phosphorylation of exon 1 sequences.	UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON HOSP & TUMOR INST, DEPT HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON BS, 1987, CANCER GENET CYTOGEN, V24, P335, DOI 10.1016/0165-4608(87)90116-6; ARLINGHAUS RB, 1992, MOL CARCINOGEN, V5, P171, DOI 10.1002/mc.2940050302; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CAMPBELL ML, 1991, ADV CANCER RES, V57, P227; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHAMPLIN RE, 1985, BLOOD, V65, P1039; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; GUO JQ, 1991, CANCER RES, V51, P3048; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAXWELL SA, 1987, CANCER RES, V47, P1731; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NAUMOVSKI L, 1988, CANCER RES, V48, P2876; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRIEST JR, 1980, BLOOD, V56, P15; RON D, 1991, NEW BIOL, V3, P372; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH RG, 1981, J IMMUNOL, V126, P596; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TIMMONS MS, 1989, ONCOGENE, V4, P559	34	57	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					101	109						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423987				2022-12-17	WOS:A1993KN00500012
J	DUTHU, A; DEBUIRE, B; ROMANO, J; EHRHART, JC; FISCELLA, M; MAY, E; APPELLA, E; MAY, P				DUTHU, A; DEBUIRE, B; ROMANO, J; EHRHART, JC; FISCELLA, M; MAY, E; APPELLA, E; MAY, P			P53 MUTATIONS IN RAJI CELLS - CHARACTERIZATION AND LOCALIZATION RELATIVE TO OTHER BURKITTS LYMPHOMAS	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; CDNA CLONE; SUPPRESSOR GENE; ONCOGENE; TRANSFORMATION; EXPRESSION; PROTEIN; LINES; DNA; IMMORTALIZATION	The nuclear phosphoprotein p53 is an important regulator of cell proliferation in normal cells. Interestingly, the gene encoding p53 has usually undergone mutations in a wide range of tumor types. Recent studies of the p53 gene in Burkitt's lymphomas have demonstrated that mutations are extremely common, and in fact it is rare that both alleles of the p53 gene in these tumors are not inactivated by mutation or deletion. We present here genetic data regarding the status of the p53 gene in the Burkitt lymphoma cell line, Raji. As is typical for this type of tumor, both alleles have undergone point mutations. Further, statistical analysis of available data from a large number of Burkitt's lymphomas indicates an apparent tumor-specific distribution of p53 mutations. The possibility that specific mutations of the p53 gene may be important for different tumor types is discussed.	CNRS,UPR 275,BP 8,F-94801 VILLEJUIF,FRANCE; NCI,CELL BIOL LAB,BETHESDA,MD 20892	Centre National de la Recherche Scientifique (CNRS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EPSTEIN MA, 1986, EPSTEIN BARR VIRUS; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HATFULL G, 1988, VIROLOGY, V164, P334, DOI 10.1016/0042-6822(88)90546-6; HIROSE M, 1983, JPN J CANCER RES, V74, P106; HOLLSTEIN MC, 1991, CANCER RES, V51, P402; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3892; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MERCER WE, 1982, P NATL ACAD SCI USA, V79, P309; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLACK A, 1984, VIROLOGY, V133, P146, DOI 10.1016/0042-6822(84)90433-1; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; Sambrook J., 1989, MOL CLONING LAB MANU; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WIMAN KG, 1991, ONCOGENE, V6, P1633; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	43	57	59	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2161	2167						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437144				2022-12-17	WOS:A1992JW66500008
J	CARTIER, N; MIQUEROL, L; TULLIEZ, M; LEPETIT, N; LEVRAT, F; GRIMBER, G; BRIAND, P; KAHN, A				CARTIER, N; MIQUEROL, L; TULLIEZ, M; LEPETIT, N; LEVRAT, F; GRIMBER, G; BRIAND, P; KAHN, A			DIET-DEPENDENT CARCINOGENESIS OF PANCREATIC-ISLETS AND LIVER IN TRANSGENIC MICE EXPRESSING ONCOGENES UNDER THE CONTROL OF THE L-TYPE PYRUVATE-KINASE GENE PROMOTER	ONCOGENE			English	Article							C-MYC GENE; HORMONAL-REGULATION; ACINAR-CELLS; RAT; NEOPLASIA; ISOZYMES; TUMORS; TRANSCRIPTION	The liver-type pyruvate kinase (L-PK) gene is controlled positively by insulin and carbohydrates, negatively by glucagon and fasting. Diet-inducible models of carcinogenesis were obtained using the L-PK gene promoter and regulatory sequences to control the expression of c-myc and SV40 T oncogenes in transgenic mice. L-PK/c-myc and L-PK/Tag animals fed a carbohydrate-rich diet developed hepatocarcinomas. In addition, L-PK/Tag animals developed diet-dependent, aggressive endocrine pancreatic tumors, preceded by islet hyperplasia involving the different analysed cell populations (alpha, beta and delta). Expression of the L-PK gene was demonstrated in pancreatic tumors, in rat isolated islets and in rat insulinoma-derived cells (RIN line), revealing a new tissue specificity of the L-PK gene. Our results suggest that this gene may be expressed in islet progenitor cells from which the different mature endocrine cells derive.	HOP COCHIN,ANAT PATHOL LAB,F-75674 PARIS 14,FRANCE; HOP ST VINCENT DE PAUL,INSERM,U342,F-75674 PARIS 14,FRANCE; INSERM,INST COCHIN GENET MOLEC GENET & PATHOL EXPTL,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	CARTIER, N (corresponding author), INSERM,INST COCHIN GENET MOLEC GENET & PATHOL MOLEC,U129,F-75014 PARIS,FRANCE.		cartier, nathalie/C-3103-2012	cartier, nathalie/0000-0003-2298-5261				AKLI S, 1991, GENOMICS, V11, P124, DOI 10.1016/0888-7543(91)90109-R; ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; ANDRES AC, 1987, P NATL ACAD SCI USA, V84, P1299, DOI 10.1073/pnas.84.5.1299; CECI JD, 1991, ONCOGENE, V6, P323; CHATTERTON TA, 1982, BIOCHEM J, V204, P605, DOI 10.1042/bj2040605; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIMBALA MA, 1984, MOL BASIS INSULIN AC; COGNET M, 1987, J MOL BIOL, V196, P11, DOI 10.1016/0022-2836(87)90507-9; COGNET M, 1991, J BIOL CHEM, V266, P7368; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; Denton R M, 1979, Essays Biochem, V15, P37; DUBOIS N, 1991, J HEPATOL, V13, P227, DOI 10.1016/0168-8278(91)90819-W; DYER KR, 1989, AM J PATHOL, V135, P401; EFRAT S, 1990, MOL CELL BIOL, V10, P1779, DOI 10.1128/MCB.10.4.1779; FONTAINE J, 1977, J EMBRYOL EXP MORPH, V41, P209; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; HALL ER, 1978, INT J BIOCHEM, V9, P785, DOI 10.1016/0020-711X(78)90027-7; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hogan B., 1986, MANIPULATING MOUSE E; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; KAHN A, 1982, METHOD ENZYMOL, V90, P131; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; MACDONALD MJ, 1985, MOL CELL BIOCHEM, V68, P115; Maniatis T., 1982, MOL CLONING; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; ORCI L, 1982, DIABETES, V31, P538, DOI 10.2337/diab.31.6.538; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RINDI G, 1990, AM J PATHOL, V136, P1349; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1991, P NATL ACAD SCI USA, V88, P93, DOI 10.1073/pnas.88.1.93; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SEPULVEDA AR, 1989, CANCER RES, V49, P6108; SOUTHERN EM, 1975, J MOL BIOL, V98, P505; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TREMP GL, 1989, J BIOL CHEM, V264, P19904; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409	48	57	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1413	1422						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620553				2022-12-17	WOS:A1992HZ97100021
J	WARREN, W; EELES, RA; PONDER, BAJ; EASTON, DF; AVERILL, D; PONDER, MA; ANDERSON, K; EVANS, AM; DEMARS, R; LOVE, R; DUNDAS, S; STRATTON, MR; TROWBRIDGE, P; COOPER, CS; PETO, J				WARREN, W; EELES, RA; PONDER, BAJ; EASTON, DF; AVERILL, D; PONDER, MA; ANDERSON, K; EVANS, AM; DEMARS, R; LOVE, R; DUNDAS, S; STRATTON, MR; TROWBRIDGE, P; COOPER, CS; PETO, J			NO EVIDENCE FOR GERMLINE MUTATIONS IN EXONS 5-9 OF THE P53 GENE IN 25 BREAST-CANCER FAMILIES	ONCOGENE			English	Note							RISK	Recent studies have demonstrated that families with the Li-Fraumeni syndrome carry inherited point mutations of the p53 gene. In the present study 25 families with strong histories of breast cancer were screened for the presence of such mutations. Polymerase chain reaction products of exons 5-9 of the p53 gene were examined by single-stranded conformational polymorphism analysis and, in addition, exon 7 was further screened by direct sequencing. No mutations were detected in constitutive DNA by either method. These results indicate that familial breast cancer does not usually result from germ-line point mutations in the p53 gene.	ROYAL MARSDEN HOSP,ACAD UNIT RADIOTHERAPY,SUTTON SM2 5PT,SURREY,ENGLAND; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT HAEMATOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT PREVENT ONCOL,MADISON,WI 53706; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5NG,SURREY,ENGLAND; DEPT PATHOL,CANC RES CAMPAIGN,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 1QP,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of London; Institute of Cancer Research - UK; CRUK Cambridge Institute	WARREN, W (corresponding author), INST CANC RES,MOLEC CARCINOGENESIS SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.			Eeles, Rosalind/0000-0002-3698-6241	NIGMS NIH HHS [GM06993] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; HALL JM, 1990, SCIENCE, V250, P84; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LI FP, 1988, CANCER RES, V48, P5358; MACKAY J, 1988, LANCET, V2, P1384; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTTMAN R, 1983, LANCET, V2, P556; PROSSER J, 1990, ONCOGENE, V5, P1573; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VARLEY JM, 1991, ONCOGENE, V6, P413	13	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1043	1046						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570151				2022-12-17	WOS:A1992HP64200029
J	MOEN, CJA; SNOEK, M; HART, AAM; DEMANT, P				MOEN, CJA; SNOEK, M; HART, AAM; DEMANT, P			SCC-1, A NOVEL COLON CANCER SUSCEPTIBILITY GENE IN THE MOUSE - LINKAGE TO CD44 (LY-24, PGP-1) ON CHROMOSOME-2	ONCOGENE			English	Article							COLORECTAL CARCINOMAS; MUTATIONS; MODEL; MAPS; ARM	Mutations of proto-oncogenes and tumor-suppressor genes lead to neoplastic development. Some germline mutations of these genes increase the tumor susceptibility of their carriers, but the relationship between genes controlling tumor susceptibility and the known oncogenes and tumor-suppressor genes remains unelucidated. Moreover, as tumor susceptibility in mouse is controlled by multiple genes, their identification has been virtually impossible. We therefore developed a new system, the recombinant congenic strains (RCS), which separates individual susceptibility genes into different RC strains, thus facilitating their analysis. To map genes controlling the development of colon cancer, we used the Balb/c-c-STS (CcS/Dem) RC strains. Owing to several unidentified genes, Balb/cHeA mice are relatively resistant and STS/A mice highly susceptible to 1,2-dimethylhydrazine-(DMH)-induced colon adenocarcinomas. Each CcS/Dem strain carries a different subset of about 12.5% of genes of the STS strain on the Balb/c background, and individual STS susceptibility genes became segregated into different RC strains. Using CcS-19, one of the highly susceptible RC strains, we mapped a novel colon tumor susceptibility gene, Scc-1, different from the oncogenes and tumor-suppressor genes known to be involved in colon tumorigenesis, in the vicinity of CD44 (Ly-24, Pgp-1) on chromosome 2. The mapping of the Scc-1 gene indicates that the RCS system can be used to map and study the presently unknown genes which control cancer development.	NETHERLANDS CANC INST, DIV MOLEC GENET, PLESMANLAAN 121, 1066 CX AMSTERDAM, NETHERLANDS; NETHERLANDS CANC INST, DIV RADIOTHERAPY, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; Davisson MT, 1989, GENETIC VARIANTS STR, P432; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DEMANT P, 1989, ADV CANCER RES, V53, P117; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FLEISZER D, 1988, CURR TOP MICROBIOL, V137, P243; GLASER T, 1990, SCIENCE, V250, P823, DOI 10.1126/science.2173141; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HESTON WE, 1963, METHODOLOGY MAMMALIA, P247; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; LANDER ES, 1989, GENETICS, V121, P185; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MOCK B, 1987, NUCLEIC ACIDS RES, V15, P4700, DOI 10.1093/nar/15.11.4700; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; MURPHY ED, 1966, BIOL LABORATORY MOUS; NADEAU J, 1990, MOUSE GENOME, V87, P55; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205; WETSEL RA, 1987, BIOCHEMISTRY-US, V26, P737, DOI 10.1021/bi00377a013; [No title captured]	26	57	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1992	7	3					563	566						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1347918				2022-12-17	WOS:A1992HK00500024
J	RAMSAY, RG; ISHII, S; GONDA, TJ				RAMSAY, RG; ISHII, S; GONDA, TJ			INCREASE IN SPECIFIC DNA-BINDING BY CARBOXYL TRUNCATION SUGGESTS A MECHANISM FOR ACTIVATION OF MYB	ONCOGENE			English	Article							C-MYB; V-MYB; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIC-CELLS; TRANSFORMING GENE; INVITRO; SEQUENCE; PROTEINS; FOS	Oncogenic forms of the c-myb protein (Myb) often exhibit amino-terminal and/or carboxyl-terminal truncations. When the transcriptional activity of these proteins was examined it was found that carboxyl-truncated Myb is more effective as a transcriptional activator than full-length or amino-truncated Myb. In order to determine the effect of such truncations on sequence-specific DNA binding, we synthesized murine Myb in vitro and assessed DNA binding by using a mobility-shift assay. Compared with the full-length protein no difference in binding was observed following deletion of the amino terminus, despite the removal of much of the first repeat of the DNA-binding domain. However, the specific DNA-binding capacity of carboxyl-truncated Myb was 4-6 times greater than that of the full-length protein; moreover, DNA binding was independent of a 'leucine zipper' motif present in Myb. These observations suggest that the increased transforming and transactivating potential of carboxyl-truncated Myb is due, at least in part, to increased sequence-specific DNA binding.	RIKEN TSUKUBA LIFE SCI CTR,INST PHYS & CHEM RES,TSUKUBA,IBARAKI 305,JAPAN	RIKEN	RAMSAY, RG (corresponding author), PO ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA.		Ramsay, Robert G/C-3291-2015; Ishii, Shunsuke/A-5271-2016	Ramsay, Robert G/0000-0001-5003-0433; Ishii, Shunsuke/0000-0002-6530-2478				BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; COOK WD, 1985, MOL CELL BIOL, V5, P390, DOI 10.1128/MCB.5.2.390; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	33	57	58	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1875	1879						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923510				2022-12-17	WOS:A1991GX11800021
J	MULDER, MP; KEIJZER, W; VERKERK, A; BOOT, AJM; PRINS, MEF; SPLINTER, TAW; BOS, JL				MULDER, MP; KEIJZER, W; VERKERK, A; BOOT, AJM; PRINS, MEF; SPLINTER, TAW; BOS, JL			ACTIVATED RAS GENES IN HUMAN SEMINOMA - EVIDENCE FOR TUMOR HETEROGENEITY	ONCOGENE			English	Article									SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS; UNIV HOSP DIJKZIGT,DEPT MED ONCOL,ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT PATHOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam	MULDER, MP (corresponding author), ERASMUS UNIV,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; FURTH ME, 1987, ONCOGENE, V1, P47; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P245, DOI 10.1016/0165-4608(86)90053-1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAI H, 1988, BLOOD, V71, P256; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JANSSEN JWG, 1987, NUCLEIC ACIDS RES, V15, P5669, DOI 10.1093/nar/15.14.5669; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LEVINSON AD, 1986, TRENDS GENET, V2, P81, DOI 10.1016/0168-9525(86)90184-8; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MALONE PR, 1985, BRIT J UROL, V57, P664, DOI 10.1111/j.1464-410X.1985.tb07028.x; Maniatis T., 1982, MOL CLONING; MARSHALL CJ, 1986, ONCOGENES GROWTH CON, P192; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; MOSTOFI FK, 1980, CANCER, V45, P1735, DOI 10.1002/cncr.1980.45.s7.1735; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PADUA RA, 1988, LEUKEMIA, V2, P503; PECKHAM MJ, 1979, LANCET, V2, P267; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1988, CANCER RES, V48, P5738; SHEN WPV, 1987, ONCOGENE, V1, P157; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SUAREZ HG, 1988, ONCOGENE, V2, P403; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TOKSOZ D, 1987, ONCOGENE, V1, P409; VARMUS HE, 1984, ANNU REV GENET, V18, P553; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VERWEIJ CL, 1985, NUCLEIC ACIDS RES, V13, P4699, DOI 10.1093/nar/13.13.4699; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YUNIS JJ, 1989, ONCOGENE, V4, P609; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	51	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1345	1351						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2682461				2022-12-17	WOS:A1989AX65900011
J	KODURU, PRK; OFFIT, K; FILIPPA, DA				KODURU, PRK; OFFIT, K; FILIPPA, DA			MOLECULAR ANALYSIS OF BREAKS IN BCL-1 PROTO-ONCOGENE IN B-CELL LYMPHOMAS WITH ABNORMALITIES OF 11Q13	ONCOGENE			English	Article									MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,CANC GENET & CYTOGENET LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,LEUKEMIA & LYMPHOMA SERV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA034775] Funding Source: NIH RePORTER; NCI NIH HHS [CA34775] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKSHI A, 1987, P NATL ACAD SCI USA, V84, P2396; BAKSHI A, 1985, CELL, V41, P899; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CARE A, 1986, EMBO J, V5, P905, DOI 10.1002/j.1460-2075.1986.tb04302.x; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROCE CM, 1986, COLD SPRING HARB SYM, V51, P891, DOI 10.1101/SQB.1986.051.01.102; HALUSKA FG, 1987, TRENDS GENET, V3, P11, DOI 10.1016/0168-9525(87)90155-7; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; INCE C, 1988, LEUKEMIA, V2, P343; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; KLEIN G, 1986, CANCER RES, V46, P3211; KODURU PRK, 1987, BLOOD, V69, P97; LEE MS, 1987, BLOOD, V70, P90; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; NOWELL P, 1981, BLOOD, V57, P444; OFFIT K, 1989, IN PRESS BR J HEMATO; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RABBITTS PH, 1988, ONCOGENE, V3, P99; RABBITTS TH, 1986, COLD SPRING HARB SYM, V51, P923, DOI 10.1101/SQB.1986.051.01.105; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1988, ONCOGENE, V2, P347; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VANDENBERGHE H, 1984, CANCER GENET CYTOGEN, V11, P381, DOI 10.1016/0165-4608(84)90017-7; WEISENBURGER DD, 1987, BLOOD, V69, P1617; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; 1987, BLOOD, V70, P1554	33	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					929	934						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2787901				2022-12-17	WOS:A1989AE58400017
J	Wu, J; Li, L; Zhang, HB; Zhao, YQ; Zhang, HH; Wu, SY; Xu, B				Wu, Jie; Li, Lan; Zhang, Huibo; Zhao, Yaqi; Zhang, Haohan; Wu, Siyi; Xu, Bin			A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma	ONCOGENE			English	Article							PROGNOSTIC VALUE; MUTATIONS; IMMUNOTHERAPY; MACROPHAGE; LANDSCAPE; CELLS	Tumor microenvironment (TME) has been reported to exhibit a crucial effect in lung cancer. Therefore, this study was aimed to investigate the genes associated with TME and develop a risk score to predict the overall survival (OS) of patients with lung adenocarcinoma (LUAD) based on these genes. The immune and stromal scores were generated by the ESTIMATE algorithm for LUAD patients in The Cancer Genome Atlas (TCGA) database. Differentially expressed gene and weighted gene co-expression network analyses were used to derive immune- and stromal-related genes. The Least Absolute Shrinkage and Selection Operator (LASSO)-Cox regression was applied for further selection and the selected genes were inputted into stepwise regression to develop TME-related risk score (TMErisk) which was further validated in Gene Expression Omnibus (GEO) datasets. TMErisk-related biological phenotypes were analyzed in function enrichment, tumor immune signature, and tumor mutation signature. The patient's response to immunotherapy was inferred by the tumor immune dysfunction and exclusion (TIDE) score and immunophenoscore (IPS). According to our results, TMErisk was developed based on SERPINE1, CX3CR1, CD200R1, GBP1, IRF1, STAP1, LOX, and OR7E47P. Furthermore, high TMErisk was identified as a poor factor for OS in TCGA and GEO datasets, as well as in subgroup analysis with different gender, smoking status, age, race, anatomic site, therapies, and tumor-node-metastasis (TNM) stages. Higher TMErisk is also associated negatively with the abundance of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and other stromal or immune cells. Several genes of the human leukocyte antigen (HLA) family and immune checkpoints were less expressed in the high-TMErisk group. Mutations of 19 genes occurred more frequently in the high-TMErisk group. These mutations may be associated with TME change and indicate patients' response to immunotherapy. According to our analyses, a lower TMErisk score may indicate better response and OS outcome of immunotherapy.	[Wu, Jie; Li, Lan; Zhang, Huibo; Zhao, Yaqi; Zhang, Haohan; Wu, Siyi; Xu, Bin] Wuhan Univ, Renmin Hosp, Canc Ctr, Wuhan, Peoples R China	Wuhan University	Xu, B (corresponding author), Wuhan Univ, Renmin Hosp, Canc Ctr, Wuhan, Peoples R China.	xubin_oneology@whu.edu.cn	Wu, Jie/ABG-2502-2021	Wu, Jie/0000-0003-0935-342X; Zhang, Huibo/0000-0001-7312-6841	Wuhan University Medical Faculty Innovation Seed Fund Cultivation Project [TFZZ2018025]; Chen xiao-ping foundation for the development of science and technology of Hubei province [CXPJJH12000001-2020313]; National Natural Science Foundation of China [81670123, 81670144]	Wuhan University Medical Faculty Innovation Seed Fund Cultivation Project; Chen xiao-ping foundation for the development of science and technology of Hubei province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from Wuhan University Medical Faculty Innovation Seed Fund Cultivation Project (grant no. TFZZ2018025), Chen xiao-ping foundation for the development of science and technology of Hubei province (grant no. CXPJJH12000001-2020313), and the National Natural Science Foundation of China (grant nos. 81670123 and 81670144).	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Assoun S, 2019, LUNG CANCER, V132, P65, DOI 10.1016/j.lungcan.2019.04.005; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Camidge DR, 2019, NAT REV CLIN ONCOL, V16, P341, DOI 10.1038/s41571-019-0173-9; Carter BW, 2016, J THORAC IMAG, V31, P201, DOI 10.1097/RTI.0000000000000213; Choi H, 2018, THERANOSTICS, V8, P1956, DOI 10.7150/thno.23767; Conroy MJ, 2020, ADV EXP MED BIOL, V1231, P1, DOI 10.1007/978-3-030-36667-4_1; De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021; Denton AE, 2018, ADV EXP MED BIOL, V1060, P99, DOI 10.1007/978-3-319-78127-3_6; Duffy MJ, 2004, CURR PHARM DESIGN, V10, P39, DOI 10.2174/1381612043453559; Erin N, 2015, ONCOGENE, V34, P3860, DOI 10.1038/onc.2014.317; Frankel T, 2017, ADV EXP MED BIOL, V1036, P51, DOI 10.1007/978-3-319-67577-0_4; Garg N, 2010, J THROMB HAEMOST, V8, P1847, DOI 10.1111/j.1538-7836.2010.03907.x; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Giraldo NA, 2017, CLIN CANCER RES, V23, P4416, DOI 10.1158/1078-0432.CCR-16-2848; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Jamal-Hanjani M, 2015, CLIN CANCER RES, V21, P1258, DOI 10.1158/1078-0432.CCR-14-1429; Jia D, 2018, AGING-US, V10, P592, DOI 10.18632/aging.101415; Johnston RJ, 2019, NATURE, V574, P565, DOI 10.1038/s41586-019-1674-5; Kinoshita T, 2016, ANN ONCOL, V27, P2117, DOI 10.1093/annonc/mdw319; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Marinelli D, 2020, ANN ONCOL, V31, P1746, DOI 10.1016/j.annonc.2020.08.2105; Martinez-Terroba E, 2018, J PATHOL, V245, P421, DOI 10.1002/path.5096; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708; Rakaee M, 2019, NEOPLASIA, V21, P282, DOI 10.1016/j.neo.2019.01.005; Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC; Sun H, 2020, EBIOMEDICINE, V60, DOI 10.1016/j.ebiom.2020.102990; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Wang H, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01212; Wang SX, 2019, ELIFE, V8, DOI 10.7554/eLife.49020; Wojas-Krawczyk K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081915; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Xu WH, 2019, AGING-US, V11, P6999, DOI 10.18632/aging.102233; Yan HM, 2019, CANCER IMMUNOL IMMUN, V68, P1971, DOI 10.1007/s00262-019-02408-7; Yang S, 2020, J CELL PHYSIOL, V235, P1025, DOI 10.1002/jcp.29018; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhang YT, 2020, CANCER BIOL MED, V17, P32, DOI 10.20892/j.issn.2095-3941.2019.0372; Zhao LQ, 2020, AGING-US, V12, P14556, DOI 10.18632/aging.103502	49	56	56	13	65	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4413	4424		10.1038/s41388-021-01853-y	http://dx.doi.org/10.1038/s41388-021-01853-y		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108619				2022-12-17	WOS:000659470200004
J	Chen, ZL; Ren, R; Wan, DW; Wang, YL; Xue, XF; Jiang, M; Shen, JQ; Han, Y; Liu, F; Shi, JM; Kuang, YT; Li, W; Zhi, QM				Chen, Zhenlong; Ren, Rui; Wan, Daiwei; Wang, Yilin; Xue, Xiaofeng; Jiang, Min; Shen, Jiaqing; Han, Ye; Liu, Fei; Shi, Jianming; Kuang, Yuting; Li, Wei; Zhi, Qiaoming			Hsa_circ_101555 functions as a competing endogenous RNA of miR-597-5p to promote colorectal cancer progression	ONCOGENE			English	Article							REPLICATION PROTEIN-A; CIRCULAR RNA; CELL-PROLIFERATION; EXPRESSION; INVASION; SIGNATURE; APOPTOSIS; MIGRATION; ROLES; GENE	CircRNAs have been reported to exert momentous roles in regulating pathophysiological process and guiding clinical diagnosis and treatment in colorectal cancer (CRC). However, there are still a lot of circRNAs that need to be unearthed. In this study, we evaluated the expression profile of circRNAs in 10 CRC tissues and their corresponding normal-appearing tissues (NATs) by microarray, and identified that hsa_circ_101555 (circ101555) was significantly up-regulated in tumor tissues and closely related to the prognosis of CRC patients. A specific close loop structure of circ101555 was described, which was generated by back-splicing of the host gene CSNK1G1 and showed greater stability than the linear RNA. The results in vitro and in vivo showed that silencing circ101555 expression significantly suppressed cell proliferation, induced apoptosis and impaired the DNA repair capacity of CRC cells, while rescue experiments suggested that down-expression of miR-597-5p could significantly attenuate the biological effects of circ101555 knockdown on CRC cells. Subsequent experiments in vitro, including double fluorescence in situ hybridization (D-FISH) analysis, RIP analysis and biotin-coupled probe pull down assay, confirmed that miR-597-5p was effectively enriched by circ101555, and circ101555 might serve as a sponge of miR-597-5p. Moreover, two putative oncogenes (CDK6 and RPA3) were identified as the miR-597-5p potential targets. Taken together, our results proved that circ101555 might function as a competing endogenous RNA of miR-597-5p to up-regulate CDK6 and RPA3 expression in CRC. Circ101555 could be a useful prognostic indicator in patients with CRC, and silence of circ101555 provided a new attractive therapeutic measure for CRC.	[Chen, Zhenlong; Wan, Daiwei; Xue, Xiaofeng; Han, Ye; Kuang, Yuting; Zhi, Qiaoming] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Ren, Rui] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou 215000, Peoples R China; [Wang, Yilin] Fudan Univ, Dept Hepat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Wang, Yilin] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Jiang, Min; Li, Wei] Soochow Univ, Dept Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Shen, Jiaqing; Liu, Fei] Soochow Univ, Dept Gastroenterol, Affiliated Hosp 1, Suzhou 215006, Peoples R China; [Shi, Jianming] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Oncol, Suzhou Municipal Hosp, Suzhou 215002, Peoples R China	Soochow University - China; Soochow University - China; Fudan University; Fudan University; Soochow University - China; Soochow University - China; Nanjing Medical University	Zhi, QM (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Peoples R China.; Wang, YL (corresponding author), Fudan Univ, Dept Hepat Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.; Wang, YL (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Li, W (corresponding author), Soochow Univ, Dept Oncol, Affiliated Hosp 1, Suzhou 215006, Peoples R China.	linglingwangyi@126.com; liwei10@suda.edu.cn; strexboy@163.com		, Daiwei/0000-0001-8838-6144	Special Subject of Diagnosis Treatment of Key Clinical Diseases of Suzhou City Sci-tech Bureau [LCZX201401]; Jiangsu Provincial Medical Youth Talent [QNRC2016723]; Suzhou Gusu Medical Youth Talent [GSWS2019032]; Project of Invigorating Health Care through Science, Technology and Education	Special Subject of Diagnosis Treatment of Key Clinical Diseases of Suzhou City Sci-tech Bureau; Jiangsu Provincial Medical Youth Talent; Suzhou Gusu Medical Youth Talent; Project of Invigorating Health Care through Science, Technology and Education	This study was supported by grants from the Special Subject of Diagnosis Treatment of Key Clinical Diseases of Suzhou City Sci-tech Bureau (LCZX201401), the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Youth Talent (QNRC2016723) and Suzhou Gusu Medical Youth Talent (GSWS2019032).	Chen CC, 2017, CARCINOGENESIS, V38, P196, DOI 10.1093/carcin/bgw123; Chen GW, 2017, ONCOTARGETS THER, V10, P5783, DOI 10.2147/OTT.S150678; Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271; Chen S, 2018, ONCOL REP, V39, P2499, DOI 10.3892/or.2018.6372; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; Dragomir M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00179; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Givalos N, 2007, MODERN PATHOL, V20, P159, DOI 10.1038/modpathol.3800719; Guo JN, 2016, ONCOTARGETS THER, V9, P7451, DOI 10.2147/OTT.S123220; Haddad FGH, 2018, FUTURE ONCOL, V14, P2097, DOI 10.2217/fon-2017-0708; Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568; Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097; Holdt LM, 2018, CELL MOL LIFE SCI, V75, P1071, DOI 10.1007/s00018-017-2688-5; Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883; Jiang WQ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00034; Kanakis D, 2011, HUM PATHOL, V42, P1545, DOI 10.1016/j.humpath.2010.12.018; Li TW, 2018, J MOL MED, V96, P85, DOI 10.1007/s00109-017-1600-y; Pattison AM, 2016, WORLD J GASTROENTERO, V22, P8070, DOI 10.3748/wjg.v22.i36.8070; Pek M, 2017, ONCOGENE, V36, P4975, DOI 10.1038/onc.2017.120; Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sobecki M, 2017, CANCER RES, V77, P2722, DOI 10.1158/0008-5472.CAN-16-0707; Sun S, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/6514795; Wang XN, 2015, INT J CLIN EXP PATHO, V8, P16020; Wilkins T, 2018, AM FAM PHYSICIAN, V97, P658; Wu J, 2018, CANCER LETT, V430, P179, DOI 10.1016/j.canlet.2018.05.033; Xiao WB, 2017, DIGEST DIS, V36, P26, DOI 10.1159/000478977; Xiong DD, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1593-5; Xu N, 2018, CELL PHYSIOL BIOCHEM, V48, P2046, DOI 10.1159/000492543; Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86; Yang X, 2017, J CANCER, V8, P3456, DOI 10.7150/jca.19345; Yao ZC, 2017, MOL ONCOL, V11, P422, DOI 10.1002/1878-0261.12045; Yu DH, 2013, CELL BIOCHEM BIOPHYS, V67, P175, DOI 10.1007/s12013-013-9530-y; Yuan Y, 2018, BIOCHEM BIOPH RES CO, V503, P870, DOI 10.1016/j.bbrc.2018.06.089; Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8; Zeng YJ, 2017, INT J MOL MED, V40, P1818, DOI 10.3892/ijmm.2017.3189; Zhang R, 2018, EUR REV MED PHARMACO, V22, P118, DOI 10.26355/eurrev_201801_14108; Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008; Zhang XL, 2017, CELL BIOL INT, V41, P1056, DOI 10.1002/cbin.10826; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8; Zhou RY, 2018, CANCER LETT, V425, P134, DOI 10.1016/j.canlet.2018.03.035; Zhu MC, 2017, BIOMED PHARMACOTHER, V88, P138, DOI 10.1016/j.biopha.2016.12.097	46	56	57	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2019	38	32					6017	6034		10.1038/s41388-019-0857-8	http://dx.doi.org/10.1038/s41388-019-0857-8			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IP8XH	31300733				2022-12-17	WOS:000480329900002
J	Esteve-Arenys, A; Valero, JG; Chamorro-Jorganes, A; Gonzalez, D; Rodriguez, V; Dlouhy, I; Salaverria, I; Campo, E; Colomer, D; Martinez, A; Rymkiewicz, G; Perez-Galan, P; Lopez-Guillermo, A; Roue, G				Esteve-Arenys, A.; Valero, J. G.; Chamorro-Jorganes, A.; Gonzalez, D.; Rodriguez, V.; Dlouhy, I.; Salaverria, I.; Campo, E.; Colomer, D.; Martinez, A.; Rymkiewicz, G.; Perez-Galan, P.; Lopez-Guillermo, A.; Roue, G.			The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL LYMPHOMAS; ANTITUMOR-ACTIVITY; BCL2 INHIBITION; PHASE-I; MYC; BORTEZOMIB; CHEMOTHERAPY; DISTINCT; MCL-1	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, mostly known as double-hit lymphoma (DHL), is a rare entity characterized by morphologic and molecular features between Burkitt lymphoma and the clinically manageable diffuse large B-cell lymphoma (DLBCL). DHL patients usually undergo a rapidly progressing clinical course associated with resistance to standard chemo-immunotherapy. As a consequence, the prognosis of this entity is particularly poor with a median overall survival inferior to 1 year. ABT-199 (venetoclax) is a potent and selective small-molecule antagonist of BCL-2 recently approved for the treatment of a specific subtype of lymphoid neoplasm. In this study, we demonstrate that single-agent ABT-199 efficiently displaces BAX from BCL-2 complexes but fails to maintain a significant antitumor activity over time in most MYC+/BCL2+ DHL cell lines and primary cultures, as well as in a xenograft mouse model of the disease. We further identify the accumulation of the BCL2-like protein BFL-1 to be a major mechanism involved in acquired resistance to ABT-199. Noteworthy, this phenomenon can be counteracted by the BET bromodomain inhibitor CPI203, since gene expression profiling identifies BCL2A1, the BFL-1 coding gene, as one of the top apoptosis-related gene modulated by this compound. Upon CPI203 treatment, simultaneous downregulation of MYC and BFL-1 further overcomes resistance to ABT-199 both in vitro and in vivo, engaging synergistic caspase-mediated apoptosis in DHL cultures and tumor xenografts. Together, these findings highlight the relevance of BFL-1 in DH lymphoma-associated drug resistance and support the combined use of a BCL-2 antagonist and a BET inhibitor as a promising therapeutic strategy for patients with aggressive DHL.	[Esteve-Arenys, A.; Valero, J. G.; Chamorro-Jorganes, A.; Gonzalez, D.; Roue, G.] CIBERONC, Aggress B Cell Lymphoma Study Grp, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Esteve-Arenys, A.; Valero, J. G.; Chamorro-Jorganes, A.; Gonzalez, D.; Rodriguez, V.; Salaverria, I.; Campo, E.; Colomer, D.; Perez-Galan, P.; Lopez-Guillermo, A.; Roue, G.] CIBERONC, Div Hematol & Oncol, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Dlouhy, I.; Lopez-Guillermo, A.] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain; [Campo, E.; Colomer, D.; Martinez, A.] Hosp Clin Barcelona, Dept Pathol, Hematopathol Unit, Barcelona, Spain; [Rymkiewicz, G.] Maria Sklodowska Curie Mem Canc Ctr, Dept Pathol, Warsaw, Poland; [Rymkiewicz, G.] Inst Oncol, Warsaw, Poland; [Roue, G.] Vall dHebron Univ Hosp, Lab Expt Hematol, Dept Hematol, Vall dHebron Inst Oncol, Barcelona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Roue, G (corresponding author), CIBERONC, Aggress B Cell Lymphoma Study Grp, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.; Roue, G (corresponding author), CIBERONC, Div Hematol & Oncol, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.	groue@clinic.ub.es	Jorganes, Aranzazu Chamorro/N-7774-2019; Miquel, Josep Maria/AAG-3508-2019; Chamorro-Jorganes, Aranzazu/B-1871-2019; Rymkiewicz, Grzegorz/AAB-7301-2019; COLOMER, DOLORS/ABG-6894-2020; Lopez-Guillermo, Armando/Z-5684-2019; Campo, Elias/AAC-5593-2019; Esteve-Arenys, Anna/E-5544-2014; ROUÉ, GAËL/D-4759-2014	Jorganes, Aranzazu Chamorro/0000-0002-3505-7221; Chamorro-Jorganes, Aranzazu/0000-0002-3505-7221; Campo, Elias/0000-0001-9850-9793; Esteve-Arenys, Anna/0000-0003-1277-5906; ROUÉ, GAËL/0000-0003-0245-2257; Valero, Juan Garcia/0000-0003-3193-9099; Rymkiewicz, Grzegorz/0000-0002-3478-8014	Fondo de Investigacion Sanitaria [PI12/01847, PI15/00102, PI12/01536]; European Regional Development Fund (ERDF); Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III [RD12/0036/0004, RD12/0036/0039]; Generalitat de Catalunya [2014SGR346, 2014SGR795]; Ministerio de Ciencia e Innovacion (FPU); Agency for Management of University and Research (AGAUR) [2014 BP-B00177]	Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); European Regional Development Fund (ERDF)(European Commission); Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III; Generalitat de Catalunya(Generalitat de Catalunya); Ministerio de Ciencia e Innovacion (FPU)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Agency for Management of University and Research (AGAUR)	The authors thank Jocabed Roldan, Laura Jimenez, and Sandra Cabezas for expert technical assistance. This work was financially supported by Fondo de Investigacion Sanitaria PI12/01847 and PI15/00102 (to G.R.), PI12/01536 (to A.L.-G.), European Regional Development Fund (ERDF) "Una manera de hacer Europa", Redes Tematicas de Investigacion Cooperativa de Cancer from the Instituto de Salud Carlos III RD12/0036/0004 (to D.C.) and RD12/0036/0039 (to E.C.) and Generalitat de Catalunya 2014SGR346 (to D.C.) and 2014SGR795 (to E.C.). A.E.-A. was recipient of a predoctoral fellowship from Ministerio de Ciencia e Innovacion (FPU). A.C.-J. holds a postdoctoral fellowship from The Agency for Management of University and Research (AGAUR, Beatriu de Pinos 2014 BP-B00177). This work was carried out at the Esther Koplowitz Center, Barcelona, under the CERCA Program (Generalitat de Catalunya).	Anderson MA, 2016, THER ADV HEMATOL, V7, P52, DOI 10.1177/2040620715608091; Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Bose P, 2017, LEUKEMIA LYMPHOMA, V58, P2026, DOI 10.1080/10428194.2017.1283032; Brown Jennifer R, 2014, Am Soc Clin Oncol Educ Book, pe317, DOI 10.14694/EdBook_AM.2014.34.e317; Cang SD, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0224-3; Ceribelli M, 2014, P NATL ACAD SCI USA, V111, P11365, DOI 10.1073/pnas.1411701111; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chaidos A, 2015, THER ADV HEMATOL, V6, P128, DOI 10.1177/2040620715576662; Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458; Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722; Davids MS, 2017, J CLIN ONCOL, V35, P826, DOI 10.1200/JCO.2016.70.4320; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Devaiah BN, 2016, J LEUKOCYTE BIOL, V100, P679, DOI 10.1189/jlb.2RI0616-250R; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Drexler HG, 2016, LEUKEMIA LYMPHOMA, V57, P1015, DOI 10.3109/10428194.2015.1108414; Fan GF, 2010, BLOOD, V115, P3559, DOI 10.1182/blood-2009-08-236760; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fresquet V, 2014, BLOOD, V123, P4111, DOI 10.1182/blood-2014-03-560284; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Grygorowicz MA, 2017, CLIN EXP MED, V17, P193, DOI 10.1007/s10238-016-0411-8; Johnson-Farley N, 2015, LEUKEMIA LYMPHOMA, V56, P2146, DOI 10.3109/10428194.2014.981172; Karube K, 2015, SEMIN HEMATOL, V52, P97, DOI 10.1053/j.seminhematol.2015.01.009; Kawano Y, 2003, BLOOD, V101, P532, DOI 10.1182/blood-2002-04-1268; King B, 2013, CELL, V153, P1552, DOI 10.1016/j.cell.2013.05.041; Li L, 2015, LEUKEMIA, V29, P1702, DOI 10.1038/leu.2015.99; Li SY, 2013, ADV ANAT PATHOL, V20, P315, DOI 10.1097/PAP.0b013e3182a289f2; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Moros A, 2014, LEUKEMIA, V28, P2049, DOI 10.1038/leu.2014.106; Niu XJ, 2016, CLIN CANCER RES, V22, P4440, DOI 10.1158/1078-0432.CCR-15-3057; Oppermann S, 2016, BLOOD, V128, P934, DOI 10.1182/blood-2015-12-687814; Perez-Galan P, 2008, LEUKEMIA, V22, P1712, DOI 10.1038/leu.2008.175; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898; Rodriguez RM, 2012, J MOL MED, V90, P587, DOI 10.1007/s00109-011-0837-0; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Roue G, 2011, BLOOD, V117, P1270, DOI 10.1182/blood-2010-04-278853; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Siegel MB, 2015, ONCOTARGET, V6, P18921, DOI 10.18632/oncotarget.4214; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Turakhia SK, 2014, AM J CLIN PATHOL, V142, P339, DOI 10.1309/AJCPBWVHTF7RRSA4; Vandenberg CJ, 2013, BLOOD, V121, P2285, DOI 10.1182/blood-2013-01-475855; Xu XX, 2013, INT J CLIN EXP PATHO, V6, P788; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304	46	56	59	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1830	1844		10.1038/s41388-017-0111-1	http://dx.doi.org/10.1038/s41388-017-0111-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353886				2022-12-17	WOS:000429303300002
J	Yamaguchi, H; Du, Y; Nakai, K; Ding, M; Chang, SS; Hsu, JL; Yao, J; Wei, Y; Nie, L; Jiao, S; Chang, WC; Chen, CH; Yu, Y; Hortobagyi, GN; Hung, MC				Yamaguchi, H.; Du, Y.; Nakai, K.; Ding, M.; Chang, S-S; Hsu, J. L.; Yao, J.; Wei, Y.; Nie, L.; Jiao, S.; Chang, W-C; Chen, C-H; Yu, Y.; Hortobagyi, G. N.; Hung, M-C			EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer	ONCOGENE			English	Article							EPITHELIAL OVARIAN-CANCER; B-CELL LYMPHOMAS; SUPPRESSES METHYLATION; PROSTATE-CANCER; MAMMARY-TUMORS; DNA-DAMAGE; STEM-CELLS; BRCA1; PHOSPHORYLATION; RESISTANCE	Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted agents currently used to treat BRCA-mutant ovarian cancer and are in clinical trials for other cancer types, including BRCA-mutant breast cancer. To enhance the clinical response to PARP inhibitors (PARPis), understanding the mechanisms underlying PARPi sensitivity is urgently needed. Here, we show enhancer of zeste homolog 2 (EZH2), an enzyme that catalyzes H3 lysine trimethylation and associates with oncogenic function, contributes to PARPi sensitivity in breast cancer cells. Mechanistically, upon oxidative stress or alkylating DNA damage, PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2. PARylation of EZH2 by PARP1 then induces PRC2 complex dissociation and EZH2 downregulation, which in turn reduces EZH2-mediated H3 trimethylation. In contrast, inhibition of PARP by PARPi attenuates alkylating DNA damage-induced EZH2 downregulation, thereby promoting EZH2-mediated gene silencing and cancer stem cell property compared with PARPi-untreated cells. Moreover, the addition of an EZH2 inhibitor sensitizes the BRCA-mutant breast cells to PARPi. Thus, these results may provide a rationale for combining PARP and EZH2 inhibition as a therapeutic strategy for BRCA-mutated breast and ovarian cancers.	[Yamaguchi, H.; Du, Y.; Nakai, K.; Chang, S-S; Hsu, J. L.; Yao, J.; Wei, Y.; Nie, L.; Jiao, S.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA; [Ding, M.; Yu, Y.] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX USA; [Chang, W-C; Chen, C-H] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Chang, W-C; Hung, M-C] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan; [Chang, W-C; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; Academia Sinica - Taiwan; China Medical University Taiwan; China Medical University Taiwan; University of Texas System; UTMD Anderson Cancer Center; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Unit 108, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; NAKAI, KATSUYA/0000-0003-4142-8508; Du, Yi/0000-0002-3969-2652; Ding, Ming/0000-0002-9135-9275	National Institutes of Health [CA211615, CCSG CA016672, GM114160]; Patel Memorial Breast Cancer Endowment Fund; National Breast Cancer Foundation, Inc.; Breast Cancer Research Foundation; University of Texas MD Anderson Cancer Center-China Medical University; University of Texas MD Anderson Cancer Center-Hospital Sister Institution Fund; Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE) [MOST 105-2911-I-002-302]; Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence [MOHW106-TDU-B-212-144003]; Center for Biological Pathways; UT Southwestern Endowed Scholar Program; Welch Foundation [I-1800]; NATIONAL CANCER INSTITUTE [R01CA109311, R01CA211615, P01CA099031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM114160] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Patel Memorial Breast Cancer Endowment Fund; National Breast Cancer Foundation, Inc.; Breast Cancer Research Foundation; University of Texas MD Anderson Cancer Center-China Medical University(China Medical University); University of Texas MD Anderson Cancer Center-Hospital Sister Institution Fund; Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); International Research-intensive Centers of Excellence in Taiwan (I-RiCE); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence; Center for Biological Pathways; UT Southwestern Endowed Scholar Program; Welch Foundation(The Welch Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported in part by the following: the National Institutes of Health (CA211615 and CCSG CA016672); Patel Memorial Breast Cancer Endowment Fund; National Breast Cancer Foundation, Inc.; Breast Cancer Research Foundation; The University of Texas MD Anderson Cancer Center-China Medical University and Hospital Sister Institution Fund; Ministry of Science and Technology; International Research-intensive Centers of Excellence in Taiwan (I-RiCE; MOST 105-2911-I-002-302); Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHW106-TDU-B-212-144003); Center for Biological Pathways; The UT Southwestern Endowed Scholar Program, the Welch Foundation (I-1800) and National Institutes of Health (GM114160) to YY. Dr YY is a Virginia Murchison Linthicum Scholar in Medical Research and a CPRIT Scholar in Cancer Research.	Alekseyenko AA, 2014, P NATL ACAD SCI USA, V111, P2488, DOI 10.1073/pnas.1400648111; Barber LJ, 2013, J PATHOL, V229, P422, DOI 10.1002/path.4140; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Byers LA, 2012, CANCER DISCOV, V2, P798, DOI 10.1158/2159-8290.CD-12-0112; Campbell S, 2013, CELL CYCLE, V12, P2675, DOI 10.4161/cc.25795; Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chen SA, 2010, NAT CELL BIOL, V12, P1108, DOI 10.1038/ncb2116; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Chu CS, 2014, P NATL ACAD SCI USA, V111, P1355, DOI 10.1073/pnas.1323226111; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; DelloRusso C, 2007, MOL CANCER RES, V5, P35, DOI 10.1158/1541-7786.MCR-06-0234; Donizy P, 2014, ONCOL REP, V31, P1777, DOI 10.3892/or.2014.3024; Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Edelheit O, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-61; Elstrodt F, 2006, CANCER RES, V66, P41, DOI 10.1158/0008-5472.CAN-05-2853; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Jaspers JE, 2013, CANCER DISCOV, V3, P68, DOI 10.1158/2159-8290.CD-12-0049; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Ledermann JA, 2015, BRIT J CANCER, V113, pS10, DOI 10.1038/bjc.2015.395; Levaot N, 2011, CELL, V147, P1324, DOI 10.1016/j.cell.2011.10.045; Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398; Li JL, 2013, NAT NEUROSCI, V16, P1745, DOI 10.1038/nn.3564; Li T, 2014, CANCER BIOL THER, V15, P271, DOI 10.4161/cbt.27306; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042; Liu C, 2013, NUCLEIC ACIDS RES, V41, P1698, DOI 10.1093/nar/gks1278; Martin KA, 2015, MOL CELL BIOL, V35, P3934, DOI 10.1128/MCB.00635-15; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; Palacios D, 2010, CELL STEM CELL, V7, P455, DOI 10.1016/j.stem.2010.08.013; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Polotskaia A, 2015, P NATL ACAD SCI USA, V112, pE1220, DOI 10.1073/pnas.1416318112; Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150; Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200; Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105; Roy A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.119; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Sala A, 2008, PLOS BIOL, V6, P2329, DOI 10.1371/journal.pbio.0060252; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Sonnenblick A, 2015, NAT REV CLIN ONCOL, V12, P27, DOI 10.1038/nrclinonc.2014.163; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vilar E, 2011, CANCER RES, V71, P2632, DOI 10.1158/0008-5472.CAN-10-1120; Wang L, 2017, CLIN RES HEPATOL GAS, V2017, P1, DOI DOI 10.1371/J0URNAL.P0NE.01; Wang L, 2013, EMBO J, V32, P1584, DOI 10.1038/emboj.2013.95; Wang L, 2013, INT J BIOL SCI, V9, P472, DOI 10.7150/ijbs.5855; Wang YT, 2011, J MOL BIOL, V414, P1, DOI 10.1016/j.jmb.2011.09.027; Wei YK, 2011, NAT CELL BIOL, V13, P87, DOI 10.1038/ncb2139; Xu JH, 2010, BREAST CANCER RES TR, V120, P593, DOI 10.1007/s10549-009-0422-1; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yang CC, 2015, AM J TRANSL RES, V7, P1009; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Zhang YJ, 2013, NAT METHODS, V10, P981, DOI 10.1038/nmeth.2603	66	56	57	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					208	217		10.1038/onc.2017.311	http://dx.doi.org/10.1038/onc.2017.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925391	Green Accepted			2022-12-17	WOS:000422631700007
J	Lee, SH; Yu, J; Hwang, GH; Kim, S; Kim, HS; Ye, S; Kim, K; Park, J; Park, DY; Cho, YK; Kim, JS; Bae, S				Lee, S. H.; Yu, J.; Hwang, G-H; Kim, S.; Kim, H. S.; Ye, S.; Kim, K.; Park, J.; Park, D. Y.; Cho, Y-K; Kim, J-S; Bae, S.			CUT-PCR: CRISPR-mediated, ultrasensitive detection of target DNA using PCR	ONCOGENE			English	Article							CIRCULATING TUMOR DNA; LIQUID BIOPSY; RNA; MUTATIONS; CANCER; CAS9; BREAST; CELLS; QUANTIFICATION; ENDONUCLEASES	Circulating tumor DNA (ctDNA) has emerged as a tumor-specific biomarker for the early detection of various cancers. To date, several techniques have been devised to enrich the extremely small amounts of ctDNA present in plasma, but they are still insufficient for cancer diagnosis, especially at the early stage. Here, we developed a novel method, CUT (CRISPR-mediated, Ultrasensitive detection of Target DNA)-PCR, which uses CRISPR endonucleases to enrich and detect the extremely small amounts of tumor DNA fragments among the much more abundant wild-type DNA fragments by specifically eliminating the wild-type sequences. We computed that by using various orthologonal CRISPR endonucleases such as SpCas9 and FnCpf1, the CUT-PCR method would be applicable to 80% of known cancer-linked substitution mutations registered in the COSMIC database. We further verified that CUT-PCR together with targeted deep sequencing enables detection of a broad range of oncogenes with high sensitivity (<0.01%) and accuracy, which is superior to conventional targeted deep sequencing. In the end, we successfully applied CUT-PCR to detect sequences with oncogenic mutations in the ctDNA of colorectal cancer patients' blood, suggesting that our technique could be adopted for diagnosing various types of cancer at early stages.	[Lee, S. H.; Kim, S.; Kim, H. S.; Ye, S.; Kim, K.; Kim, J-S] Inst for Basic Sci Korea, Ctr Genome Engn, Seoul, South Korea; [Yu, J.] Seoul Natl Univ, Sch Biol Sci, Seoul, South Korea; [Hwang, G-H; Bae, S.] Hanyang Univ, Dept Chem, Room 36-316,222 Wangsimni Ro, Seoul 133791, South Korea; [Kim, H. S.; Kim, J-S] Seoul Natl Univ, Dept Chem, Seoul, South Korea; [Park, J.; Cho, Y-K] Inst Basic Sci, Ctr Soft & Living Matter, Ulsan, South Korea; [Park, D. Y.] Pusan Natl Univ, Sch Med, Dept Pathol, Busan, South Korea; [Park, D. Y.] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; [Cho, Y-K] Ulsan Natl Inst Sci & Technol, Dept Biomed Engn, Ulsan, South Korea; [Bae, S.] Hanyang Univ, Res Inst Convergence Basic Sci, Seoul, South Korea	Institute for Basic Science - Korea (IBS); Seoul National University (SNU); Hanyang University; Seoul National University (SNU); Institute for Basic Science - Korea (IBS); Pusan National University; Pusan National University; Pusan National University Hospital; Ulsan National Institute of Science & Technology (UNIST); Hanyang University	Bae, S (corresponding author), Hanyang Univ, Dept Chem, Room 36-316,222 Wangsimni Ro, Seoul 133791, South Korea.	sangsubae@hanyang.ac.kr	Cho, Yoon-Kyoung/ABF-9355-2021; Cho, Yoon-Kyoung/E-9082-2010; Yu, Jihyeon/U-4150-2019; Kim, Kyoungmi/AAR-3964-2020; KIM, Jin-Soo/M-6918-2013; Bae, Sangsu/E-5324-2017; Park, Juhee/P-5219-2017; Kim, Sang-Tae/U-9457-2018	Cho, Yoon-Kyoung/0000-0001-6423-1834; Cho, Yoon-Kyoung/0000-0001-6423-1834; Yu, Jihyeon/0000-0003-0247-7753; Kim, Kyoungmi/0000-0003-0941-806X; KIM, Jin-Soo/0000-0003-4847-1306; Bae, Sangsu/0000-0003-3615-8566; Park, Juhee/0000-0002-8109-6387; Kim, Sang-Tae/0000-0003-1645-6021	Ministry of Health and Welfare; Korea Healthcare technology R&D Project, Ministry for Health and Welfare Affairs [HI16C1012, HI12C1845]; Institute for Basic Science [IBS-R021-D1]	Ministry of Health and Welfare(Ministry of Health, Labour and Welfare, Japan); Korea Healthcare technology R&D Project, Ministry for Health and Welfare Affairs; Institute for Basic Science	We express our gratitude to all of the patients and healthy volunteers who contributed blood samples for this study. The biological specimens for this study were provided by the Pusan National University hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health and Welfare. All samples were obtained with informed consent according to the institutional review board-approved protocols. The deep-sequencing data are available at the NCBI Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) under accession number SRX1970116. This work was supported by a grant from the Korea Healthcare technology R&D Project, Ministry for Health and Welfare Affairs (HI16C1012) to SB, (HI12C1845) to JP, DP and YC and Institute for Basic Science (IBS-R021-D1) to J-SK.	Alix-Panabieres C, 2012, ANNU REV MED, V63, P199, DOI 10.1146/annurev-med-062310-094219; Anders C, 2014, NATURE, V513, P569, DOI 10.1038/nature13579; Baek K, 2016, SCI REP-UK, V6, DOI 10.1038/srep30620; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014; Chang NN, 2013, CELL RES, V23, P465, DOI 10.1038/cr.2013.45; Cheng FF, 2016, ONCOTARGET, V7, P48832, DOI 10.18632/oncotarget.9453; Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113; Cho SW, 2013, NAT BIOTECHNOL, V31, P230, DOI 10.1038/nbt.2507; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Mattos-Arruda L, 2016, MOL ONCOL, V10, P464, DOI 10.1016/j.molonc.2015.12.001; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Freidin MB, 2015, CLIN CHEM, V61, P1299, DOI 10.1373/clinchem.2015.242453; Friedland AE, 2013, NAT METHODS, V10, P741, DOI 10.1038/nmeth.2532; Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829; Kim D, 2016, NAT BIOTECHNOL, V34, P863, DOI 10.1038/nbt.3609; Kim H, 2014, NAT REV GENET, V15, P321, DOI 10.1038/nrg3686; Kim JM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4157; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Kleinstiver BP, 2015, NATURE, V523, P481, DOI 10.1038/nature14592; Kruglyak KM, 2014, EXPERT REV MOL DIAGN, V14, P635, DOI 10.1586/14737159.2014.916213; Lee SH, 2016, BMB REP, V49, P201, DOI 10.5483/BMBRep.2016.49.4.042; Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850; Narayan A, 2012, CANCER RES, V72, P3492, DOI 10.1158/0008-5472.CAN-11-4037; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Nishimasu H, 2014, CELL, V156, P935, DOI 10.1016/j.cell.2014.02.001; Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223; Park JY, 2013, NAT BIOTECHNOL, V31, P990, DOI 10.1038/nbt.2743; Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Song C, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw650; Sorber L, 2017, LUNG CANCER, V107, P100, DOI 10.1016/j.lungcan.2016.04.026; Tsao SCH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11198; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu YX, 2013, CELL STEM CELL, V13, P659, DOI 10.1016/j.stem.2013.10.016; Xu XR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/623509; Yamano T, 2016, CELL, V165, P949, DOI 10.1016/j.cell.2016.04.003; Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038; Zhang YL, 2014, SCI REP-UK, V4, DOI 10.1038/srep05405	43	56	57	8	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2017	36	49					6823	6829		10.1038/onc.2017.281	http://dx.doi.org/10.1038/onc.2017.281			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FP0IK	28846115	Green Published, hybrid			2022-12-17	WOS:000417282500008
J	Song, Y; Li, S; Ray, A; Das, DS; Qi, J; Samur, MK; Tai, YT; Munshi, N; Carrasco, RD; Chauhan, D; Anderson, KC				Song, Y.; Li, S.; Ray, A.; Das, D. S.; Qi, J.; Samur, M. K.; Tai, Y-T; Munshi, N.; Carrasco, R. D.; Chauhan, D.; Anderson, K. C.			Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; 26S PROTEASOME; MITOCHONDRIAL MORPHOLOGY; DEUBIQUITINATING ENZYMES; PROTEIN-DEGRADATION; SUBUNIT RPN11; UBIQUITIN; CYCLE; DEXAMETHASONE; COMBINATION	Proteasome inhibition is an effective therapy for multiple myeloma (MM) patients; however, the emergence of drug resistance is common. Novel therapeutic strategies to overcome proteasome inhibitor resistance are needed. In this study, we examined whether targeting deubiquitylating (DUB) enzymes upstream of 20S proteasome overcomes proteasome inhibitor resistance. Gene expression analysis, immunohistochemical studies of MM patient bone marrow, reverse transcription-PCR and protein analysis show that Rpn11/POH1, a DUB enzyme upstream of 20S proteasome, is more highly expressed in patient MM cells than in normal plasma cells. Importantly, Rpn11 expression directly correlates with poor patient survival. Loss-of-function studies show that Rpn11-siRNA knockdown decreases MM cell viability. Pharmacological inhibition of Rpn11 with O-phenanthroline (OPA) blocks cellular proteasome function, induces apoptosis in MM cells and overcomes resistance to proteasome inhibitor bortezomib. Mechanistically, Rpn11 inhibition in MM cells activates caspase cascade and endoplasmic stress response signaling. Human MM xenograft model studies demonstrate that OPA treatment reduces progression of tumor growth and prolongs survival in mice. Finally, blockade of Rpn11 increases the cytotoxic activity of anti-MM agents lenalidomide, pomalidomide or dexamethasone. Overall, our preclinical data provide the rationale for targeting DUB enzyme Rpn11 upstream of 20S proteasome to enhance cytotoxicity and overcome proteasome inhibitor resistance in MM.	[Song, Y.; Ray, A.; Das, D. S.; Samur, M. K.; Tai, Y-T; Munshi, N.; Carrasco, R. D.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, LeBow Inst Myeloma Therapeut, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA; [Song, Y.; Ray, A.; Das, D. S.; Samur, M. K.; Tai, Y-T; Carrasco, R. D.; Chauhan, D.; Anderson, K. C.] Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA; [Li, S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA; [Qi, J.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, LeBow Inst Myeloma Therapeut, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA.; Chauhan, D; Anderson, KC (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave,Mayer 553, Boston, MA 02115 USA.	Dharminder_Chauhan@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021	Samur, Mehmet/0000-0002-9978-5682	National Institutes of Health Specialized Programs of Research Excellence (SPORE) [P50100707, R01CA207237, RO1CA050947]; NATIONAL CANCER INSTITUTE [P01CA155258, R01CA050947, R01CA207237, P50CA100707] Funding Source: NIH RePORTER	National Institutes of Health Specialized Programs of Research Excellence (SPORE)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This investigation was supported by National Institutes of Health Specialized Programs of Research Excellence (SPORE) Grants P50100707, R01CA207237 and RO1CA050947. KCA is an American Cancer Society Clinical Research Professor.	Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Avet-Loiseau H, 2007, BLOOD, V109, P3489, DOI 10.1182/blood-2006-08-040410; Bassal S, 2001, GENOMICS, V77, P5, DOI 10.1006/geno.2001.6570; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bhattacharyya S, 2014, NAT REV MOL CELL BIO, V15, P122, DOI 10.1038/nrm3741; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2008, BLOOD, V111, P1654, DOI 10.1182/blood-2006-10-050476; Chauhan D, 2013, CLIN CANCER RES, V19, P3019, DOI 10.1158/1078-0432.CCR-12-3752; Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007; Chauhan D, 2009, CANCER CELL, V16, P309, DOI 10.1016/j.ccr.2009.08.019; D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536; Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607; Gallery M, 2007, MOL CANCER THER, V6, P262, DOI 10.1158/1535-7163.MCT-06-0542; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301-472X(03)00023-7; Hershko A, 2005, ANGEW CHEM INT EDIT, V44, P5932, DOI 10.1002/anie.200501724; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Koulich E, 2008, MOL BIOL CELL, V19, P1072, DOI 10.1091/mbc.E07-10-1040; Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888; Lander GC, 2012, NATURE, V482, P186, DOI 10.1038/nature10774; Lasker K, 2012, P NATL ACAD SCI USA, V109, P1380, DOI 10.1073/pnas.1120559109; Lee MJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.R110.003871; Lim KH, 2013, CURR PHARM DESIGN, V19, P4039, DOI 10.2174/1381612811319220013; Liu CW, 2013, TRENDS BIOCHEM SCI, V38, P103, DOI 10.1016/j.tibs.2012.11.009; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Menendez-Benito V, 2005, HUM MOL GENET, V14, P2787, DOI 10.1093/hmg/ddi312; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Ray A, 2015, LEUKEMIA, V29, P1441, DOI 10.1038/leu.2015.11; Richardson PG, 2014, BLOOD, V123, P1461, DOI 10.1182/blood-2013-07-517276; Richardson PG, 2014, BLOOD, V123, P1826, DOI 10.1182/blood-2013-11-538835; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; Richardson PG, 2009, J CLIN ONCOL, V27, P5713, DOI 10.1200/JCO.2009.22.2679; Rinaldi T, 1998, MOL BIOL CELL, V9, P2917, DOI 10.1091/mbc.9.10.2917; Rinaldi T, 2004, BIOCHEM J, V381, P275, DOI 10.1042/BJ20040008; Rinaldi T, 2002, GENE, V286, P43, DOI 10.1016/S0378-1119(01)00799-5; Song Y, 2016, LEUKEMIA, V30, P1877, DOI 10.1038/leu.2016.97; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Spataro V, 2002, ANTICANCER RES, V22, P3905; Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Wang B., 2015, COMPUT MATH METHOD M, V2015, P1, DOI [10.1155/2015/793697s, DOI 10.13140/RG.2.1.1735.6249]; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	47	56	57	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5631	5638		10.1038/onc.2017.172	http://dx.doi.org/10.1038/onc.2017.172			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581522	Green Accepted			2022-12-17	WOS:000412293600007
J	Riverso, M; Montagnani, V; Stecca, B				Riverso, M.; Montagnani, V.; Stecca, B.			KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth	ONCOGENE			English	Article							KRUPPEL-LIKE FACTORS; TUMOR-SUPPRESSOR; SELF-RENEWAL; STEM-CELL; MUTATIONS; CANCER; INDUCTION; GENE; BRAF; PHOSPHORYLATION	Melanoma is the most lethal form of skin cancer and treatment of metastatic melanoma remains challenging. BRAF/MEK inhibitors show only temporary benefit due the occurrence of resistance and immunotherapy is effective only in a subset of patients. To improve patient survival, there is a need to better understand molecular mechanisms that drive melanoma growth and operate downstream of the mitogen activated protein kinase (MAPK) signaling. The Kruppel-like factor 4 (KLF4) is a zinc-finger transcription factor that plays a critical role in embryonic development, stemness and cancer, where it can act either as oncogene or tumor suppressor. KLF4 is highly expressed in post-mitotic epidermal cells, but its role in melanoma remains unknown. Here, we address the function of KLF4 in melanoma and its interaction with the MAPK signaling pathway. We find that KLF4 is highly expressed in a subset of human melanomas. Ectopic expression of KLF4 enhances melanoma cell growth by decreasing apoptosis. Conversely, knock-down of KLF4 reduces melanoma cell proliferation and induces cell death. In addition, depletion of KLF4 reduces melanoma xenograft growth in vivo. We find that the RAS/RAF/MEK/ERK signaling positively modulates KLF4 expression through the transcription factor E2F1, which directly binds to KLF4 promoter. Overall, our data demonstrate the pro-tumorigenic role of KLF4 in melanoma and uncover a novel ERK1/2-E2F1-KLF4 axis. These findings identify KLF4 as a possible new molecular target for designing novel therapeutic treatments to control melanoma growth.	[Riverso, M.; Montagnani, V.; Stecca, B.] Ist Toscano Tumori, Core Res Lab, Viale Pieraccini 6, I-50139 Florence, Italy; [Stecca, B.] Careggi Univ Hosp, Dept Oncol, Florence, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; Azienda Ospedaliero Universitaria Careggi	Stecca, B (corresponding author), Ist Toscano Tumori, Core Res Lab, Viale Pieraccini 6, I-50139 Florence, Italy.	barbara.stecca@ittumori.it		Stecca, Barbara/0000-0003-1197-1622	AIRC (Associazione Italiana per la Ricerca sul Cancro) [IG-14184]	AIRC (Associazione Italiana per la Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro)	We thank Lorenzo Borgognoni, Gianni Gerlini (S. Maria Annunziata Hospital, Florence, Italy), Nicola Pimpinelli (Department of Dermatology, University of Florence, Florence, Italy) and Riccardo Gattai (Department of Medical-Surgical Critical Area, General and Oncological Surgery, University of Florence, Florence, Italy) for providing melanoma samples, Laura Poliseno (Istituto Toscano Tumori, Pisa, Italy) for providing SK-Mel-2, SK-Mel-5, SK-Mel-28 melanoma cell lines and pCDNA3.1-BRAF wt and pCDNA3.1-BRAF-V600E plasmids, Rosario Notaro (Istituto Toscano Tumori, Florence, Italy) for providing K562 cells, and Silvia Pietrobono for assistance with FACS analysis. This work was supported by a grant from AIRC (Associazione Italiana per la Ricerca sul Cancro IG-14184) to BS.	Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Brose MS, 2002, CANCER RES, V62, P6997; Camacho-Vanegas O, 2013, FASEB J, V27, P432, DOI 10.1096/fj.12-220319; Cercek A, 2015, INVEST NEW DRUG, V33, P1086, DOI 10.1007/s10637-015-0273-z; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delaney AM, 2002, MOL CELL BIOL, V22, P7593, DOI 10.1128/MCB.22.21.7593-7602.2002; Driscoll B, 1999, J BIOL CHEM, V274, P9463, DOI 10.1074/jbc.274.14.9463; El-Karim EA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-89; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Farrugia MK, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.65; FILMUS J, 1994, ONCOGENE, V9, P3627; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Gamper AM, 2012, MOL CELL, V45, P233, DOI 10.1016/j.molcel.2011.11.031; Garnovskaya MN, 2004, J BIOL CHEM, V279, P24899, DOI 10.1074/jbc.M311622200; Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591; Huang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.433; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Kharas MG, 2007, BLOOD, V109, P747, DOI 10.1182/blood-2006-03-011106; Kim MO, 2012, NAT STRUCT MOL BIOL, V19, P283, DOI 10.1038/nsmb.2217; Korotayev K, 2008, CELL SIGNAL, V20, P1221, DOI 10.1016/j.cellsig.2008.02.012; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Li H, 2013, CARCINOGENESIS, V34, P2262, DOI 10.1093/carcin/bgt189; Li J, 2012, CARCINOGENESIS, V33, P1239, DOI 10.1093/carcin/bgs143; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Montagnani V, 2016, ONCOTARGET, V7, P30365, DOI 10.18632/oncotarget.8758; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Muthusamy V, 2013, J INVEST DERMATOL, V133, P1827, DOI 10.1038/jid.2013.48; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Pandolfi S, 2015, CELL DEATH DIFFER, V22, P2006, DOI 10.1038/cdd.2015.56; Pandolfi S, 2013, ONCOGENE, V32, P4737, DOI 10.1038/onc.2012.502; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Putzer BM, 2010, EXPERT REV ANTICANC, V10, P1707, DOI 10.1586/ERA.10.153; Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Rubin SM, 2013, TRENDS BIOCHEM SCI, V38, P12, DOI 10.1016/j.tibs.2012.10.007; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Wei DY, 2008, CANCER RES, V68, P4631, DOI 10.1158/0008-5472.CAN-07-5953; Wei DY, 2016, CANCER CELL, V29, P324, DOI 10.1016/j.ccell.2016.02.005; Wei DY, 2010, GASTROENTEROLOGY, V139, P2135, DOI 10.1053/j.gastro.2010.08.022; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yang YZ, 2016, CANCER BIOL THER, V17, P422, DOI 10.1080/15384047.2016.1156260; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260; Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591; Yu T, 2016, CELL DEATH DIFFER, V23, P207, DOI 10.1038/cdd.2015.85; Zhang L, 2016, ONCOTARGET, V7, P30990, DOI 10.18632/oncotarget.8824	60	56	58	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3322	3333		10.1038/onc.2016.481	http://dx.doi.org/10.1038/onc.2016.481			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068326	Green Published, hybrid			2022-12-17	WOS:000402869800011
J	Feng, J; Li, L; Zhang, N; Liu, J; Zhang, L; Gao, H; Wang, G; Li, Y; Zhang, Y; Li, X; Liu, D; Lu, J; Huang, B				Feng, J.; Li, L.; Zhang, N.; Liu, J.; Zhang, L.; Gao, H.; Wang, G.; Li, Y.; Zhang, Y.; Li, X.; Liu, D.; Lu, J.; Huang, B.			Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms	ONCOGENE			English	Article							TANDEM MASS-SPECTROMETRY; SEX STEROID-HORMONES; GENE-EXPRESSION; POSTMENOPAUSAL WOMEN; RECEPTOR EXPRESSION; CHROMATIN IMMUNOPRECIPITATION; TESTOSTERONE LEVELS; SERUM TESTOSTERONE; DEMETHYLASE LSD1; DUCTAL CARCINOMA	The role of androgen and androgen receptor (AR) in breast carcinogenesis has long been a disputed issue. This report provides a mechanistic insight into how androgen and AR contributes to invasion and metastasis of breast cancer. We find that dihydrotestosterone (DHT) is able to induce the epithelial-to-mesenchymal transition in breast cancer cells in an AR-dependent/ estrogen receptor-independent manner. This process is dependent on the demethylation activity of lysine-specific demethylase 1A (LSD1) by epigenetically regulating the target genes E-cadherin and vimentin. In vivo, DHT promotes metastasis in a nude mouse model, and AR and LSD1 are indispensable in this process. We establish that higher expression of nucleus AR to cytoplasm AR associated with worse prognostic outcomes in breast cancer patient samples. This study maps an 'androgen-AR/LSD1-target genes' pathway in breast carcinogenesis, implicating the importance of hormonal balance in women, and the potential clinical significance of serum androgen and AR in prediction of breast cancer and selection of breast cancer therapy.	[Feng, J.; Li, L.; Liu, J.; Zhang, Y.; Huang, B.] Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, 5268 Renmin St', Changchun 130024, Peoples R China; [Li, L.] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Dept Bone & Soft Tissue Tumors, Tianjin, Peoples R China; [Zhang, N.; Li, X.; Lu, J.] Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China; [Zhang, L.; Gao, H.] Jilin Univ, Dept Pathol, Hosp 2, Changchun, Peoples R China; [Wang, G.; Li, Y.] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun, Peoples R China; [Liu, D.] Auckland Univ Technol, Sch Sci, Auckland, New Zealand	Northeast Normal University - China; Tianjin Medical University; Northeast Normal University - China; Jilin University; Northeast Normal University - China; Auckland University of Technology	Huang, B (corresponding author), Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, 5268 Renmin St', Changchun 130024, Peoples R China.; Lu, J (corresponding author), Northeast Normal Univ, Inst Genet & Cytol, 5268 Renmin St, Changchun 130024, Peoples R China.	luj809@nenu.edu.cn; huangbq705@nenu.edu.cn		Feng, Jing-Xin/0000-0003-0677-2792	National Natural Science Foundation of China [31570718, 31571478, 31571317, 31371294]; University S & T Innovation Platform of Jilin Province for Economic Fungi [2014B-1]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); University S & T Innovation Platform of Jilin Province for Economic Fungi	We thank Dr Wei Huang from School of Mathematics and Statistics of Northeast Normal University for kindly providing statistical analysis guidance. This work was supported by the grants from the National Natural Science Foundation of China (Grant numbers 31570718, 31571478, 31571317 and 31371294), and a grant from The University S & T Innovation Platform of Jilin Province for Economic Fungi (#2014B-1).	Abdulla A, 2014, J BIOL CHEM, V289, P29937, DOI 10.1074/jbc.M114.573659; Agrawal AK, 2008, FOLIA HISTOCHEM CYTO, V46, P269, DOI 10.2478/v10042-008-0039-y; Amente S, 2010, ONCOGENE, V29, P3691, DOI 10.1038/onc.2010.120; Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002; Amente S, 2010, CELL CYCLE, V9, P3002, DOI 10.4161/cc.9.15.12499; Berrino F, 2005, INT J CANCER, V113, P499, DOI 10.1002/ijc.20582; Biswas D, 2011, P NATL ACAD SCI USA, V108, P15751, DOI 10.1073/pnas.1111498108; Bui HN, 2013, STEROIDS, V78, P96, DOI 10.1016/j.steroids.2012.10.010; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Castellano I, 2010, BREAST CANCER RES TR, V124, P607, DOI 10.1007/s10549-010-0761-y; Chen J, 2013, J STEROID BIOCHEM, V137, P316, DOI 10.1016/j.jsbmb.2013.01.012; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dorgan JF, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2779; Feng JX, 2016, BREAST CANCER RES TR, V159, P443, DOI 10.1007/s10549-016-3959-9; Ferrari-Amorotti G, 2013, CANCER RES, V73, P235, DOI 10.1158/0008-5472.CAN-12-1739; Fourkala EO, 2012, ENDOCR-RELAT CANCER, V19, P137, DOI 10.1530/ERC-11-0310; Garay JP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3112; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gonzalez LO, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-149; Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanley K, 2008, HUM PATHOL, V39, P386, DOI 10.1016/j.humpath.2007.07.007; Harmeyer KM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1347; Harwood DT, 2009, CLIN CHIM ACTA, V409, P78, DOI 10.1016/j.cca.2009.09.003; He JH, 2012, MED ONCOL, V29, P406, DOI 10.1007/s12032-011-9832-0; Hickey TE, 2015, ONCOTARGET, V6, P44728, DOI 10.18632/oncotarget.6296; Honma N, 2013, BREAST CANCER-TOKYO, V20, P323, DOI 10.1007/s12282-012-0337-2; Hu DG, 2014, HORM CANCER-US, V5, P61, DOI 10.1007/s12672-014-0171-4; Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021; Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702; Kaaks R, 2005, JNCI-J NATL CANCER I, V97, P755, DOI 10.1093/jnci/dji132; Kaaks R, 2005, ENDOCR-RELAT CANCER, V12, P1071, DOI 10.1677/erc.1.01038; Kocaturk B, 2015, JOVE-J VIS EXP, DOI 10.3791/51967; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li YX, 2016, ONCOL REP, V35, P3586, DOI 10.3892/or.2016.4729; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Loibl S, 2011, BREAST CANCER RES TR, V130, P477, DOI 10.1007/s10549-011-1715-8; Luo HC, 2016, CELL REP, V15, P2665, DOI 10.1016/j.celrep.2016.05.050; Luo Xiang, 2010, Chin J Cancer, V29, P585; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; McNamara KM, 2010, J STEROID BIOCHEM, V121, P611, DOI 10.1016/j.jsbmb.2010.02.001; McNamara Keely M, 2013, Front Endocrinol (Lausanne), V4, P116, DOI 10.3389/fendo.2013.00116; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Micello D, 2010, VIRCHOWS ARCH, V457, P467, DOI 10.1007/s00428-010-0964-y; Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; Mrklic I, 2013, ACTA HISTOCHEM, V115, P344, DOI 10.1016/j.acthis.2012.09.006; Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nam HJ, 2014, MOL CELL, V53, P791, DOI 10.1016/j.molcel.2014.01.028; Narayanan R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103202; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ni L, 2013, MOL CELL BIOL, V33, P4766, DOI 10.1128/MCB.00647-13; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Ni M, 2011, CANCER CELL, V20, P119, DOI 10.1016/j.ccr.2011.05.026; Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159; Park S, 2011, ANN ONCOL, V22, P1755, DOI 10.1093/annonc/mdq678; Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Peters KM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-132; Qu Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082650; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; REMMELE W, 1986, VIRCHOWS ARCH A, V409, P127, DOI 10.1007/BF00708323; Robinson JLL, 2011, EMBO J, V30, P3019, DOI 10.1038/emboj.2011.216; Rothman MS, 2011, STEROIDS, V76, P177, DOI 10.1016/j.steroids.2010.10.010; Schippinger W, 2006, VIRCHOWS ARCH, V449, P24, DOI 10.1007/s00428-006-0213-6; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shufelt Chrisandra L, 2008, Menopause Int, V14, P117, DOI 10.1258/mi.2008.008015; Sieri S, 2009, CANCER EPIDEM BIOMAR, V18, P169, DOI 10.1158/1055-9965.EPI-08-0808; Spurdle AB, 1999, JNCI-J NATL CANCER I, V91, P961, DOI 10.1093/jnci/91.11.961; Subik K, 2010, BREAST CANCER-BASIC, V4, P35; Tang DB, 2012, MED ONCOL, V29, P526, DOI 10.1007/s12032-011-9948-2; Tsutsumi Y, 2012, JPN J CLIN ONCOL, V42, P375, DOI 10.1093/jjco/hys034; Vera-Badillo FE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt319; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Wang B, 2009, INT J CANCER, V124, P1892, DOI 10.1002/ijc.24132; Wang Y, 2011, ONCOGENE, V30, P4327, DOI 10.1038/onc.2011.144; Wang Y, 2013, HUM MOL GENET, V22, P2263, DOI 10.1093/hmg/ddt077; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Witzel I, 2013, J CANCER RES CLIN, V139, P809, DOI 10.1007/s00432-013-1382-8; Yu H, 2003, INT J CANCER, V105, P92, DOI 10.1002/ijc.11034; Yu Q, 2011, ANN ONCOL, V22, P1288, DOI 10.1093/annonc/mdq586; Zeleniuch-Jacquotte A, 2004, BRIT J CANCER, V90, P153, DOI 10.1038/sj.bjc.6601517	86	56	58	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2775	2790		10.1038/onc.2016.432	http://dx.doi.org/10.1038/onc.2016.432			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893717				2022-12-17	WOS:000401697800001
J	Leung, E; Xue, A; Wang, Y; Rougerie, P; Sharma, VP; Eddy, R; Cox, D; Condeelis, J				Leung, E.; Xue, A.; Wang, Y.; Rougerie, P.; Sharma, V. P.; Eddy, R.; Cox, D.; Condeelis, J.			Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; C-MET; CANCER METASTASIS; TYROSINE KINASE; MAMMARY-TUMORS; IN-VIVO; PROGNOSTIC MARKER; CARCINOMA CELLS; TRANSENDOTHELIAL MIGRATION; HEMATOGENOUS DISSEMINATION	During metastasis to distant sites, tumor cells migrate to blood vessels. In vivo, breast tumor cells utilize a specialized mode of migration known as streaming, where a linear assembly of tumor cells migrate directionally towards blood vessels on fibronectin-collagen I-containing extracellular matrix (ECM) fibers in response to chemotactic signals. We have successfully reconstructed tumor cell streaming in vitro by co-plating tumors cells, macrophages and endothelial cells on 2.5 mu m thick ECM-coated micro-patterned substrates. We found that tumor cells and macrophages, when plated together on the micro-patterned substrates, do not demonstrate sustained directional migration in only one direction (sustained directionality) but show random bi-directional walking. Sustained directionality of tumor cells as seen in vivo was established in vitro when beads coated with human umbilical vein endothelial cells were placed at one end of the micro-patterned 'ECM fibers' within the assay. We demonstrated that these endothelial cells supply the hepatocyte growth factor (HGF) required for the chemotactic gradient responsible for sustained directionality. Using this in vitro reconstituted streaming system, we found that directional streaming is dependent on, and most effectively blocked, by inhibiting the HGF/C-Met signaling pathway between endothelial cells and tumor cells. Key observations made with the in vitro reconstituted system implicating C-Met signaling were confirmed in vivo in mammary tumors using the in vivo invasion assay and intravital multiphoton imaging of tumor cell streaming. These results establish HGF/ C-Met as a central organizing signal in blood vessel-directed tumor cell migration in vivo and highlight a promising role for C-Met inhibitors in blocking tumor cell streaming and metastasis in vivo, and for use in human trials.	[Leung, E.; Xue, A.; Wang, Y.; Rougerie, P.; Sharma, V. P.; Eddy, R.; Cox, D.; Condeelis, J.] Albert Einstein Coll Med, Dept Anat & Struct Biol, 1301 Morris Pk Ave,Price 208, Bronx, NY 10461 USA; [Wang, Y.; Condeelis, J.] Albert Einstein Coll Med, Integrated Imaging Program, Bronx, NY 10467 USA; [Sharma, V. P.; Cox, D.; Condeelis, J.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Condeelis, J (corresponding author), Albert Einstein Coll Med, Dept Anat & Struct Biol, 1301 Morris Pk Ave,Price 208, Bronx, NY 10461 USA.	john.condeelis@einstein.yu.edu	; rougerie, pablo/I-9006-2017	Cox, Dianne/0000-0002-0591-9767; rougerie, pablo/0000-0001-5290-3939	NCI [CA100324, CA150344]; Integrated Imaging Program; Gruss Lipper Biophotonics Center; NATIONAL CANCER INSTITUTE [P01CA100324, P30CA013330, R01CA150344] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Integrated Imaging Program; Gruss Lipper Biophotonics Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank P Guo (Analytical Imaging Facility, Albert Einstein College of Medicine) for technical assistance. They also thank B Smith and D Flynn (Deciphera) for providing Rebastinib, DCC-3014 and Altiratinib. This work was supported by the NCI CA100324, CA150344, the Integrated Imaging Program and the Gruss Lipper Biophotonics Center.	Agarwal S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3318; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Anderson NG, 2001, INT J CANCER, V94, P774, DOI 10.1002/ijc.1557; Araki H, 2004, BLOOD, V103, P2973, DOI 10.1182/blood-2003-08-2742; Boimel PJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3108; Bravo-Cordero JJ, 2013, NAT REV MOL CELL BIO, V14, P405, DOI 10.1038/nrm3609; Brooks JP, 2005, INT J RADIAT ONCOL, V62, P785, DOI 10.1016/j.ijrobp.2004.12.001; Cabioglu N, 2004, J CLIN ONCOL, V22, p841S; Casbas-Hernandez P, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3476; Cassatella MC, 2012, FUTURE ONCOL, V8, P1253, DOI [10.2217/FON.12.119, 10.2217/fon.12.119]; Chan WW, 2011, CANCER CELL, V19, P556, DOI 10.1016/j.ccr.2011.03.003; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DesMarais V, 2009, CELL MOTIL CYTOSKEL, V66, P303, DOI 10.1002/cm.20361; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Eichler W, 2004, EXP CELL RES, V299, P68, DOI 10.1016/j.yexcr.2004.05.020; Entenberg D, 2011, NAT PROTOC, V6, P1500, DOI 10.1038/nprot.2011.376; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Flynn DL, 2014, AACR SPEC C CELL HET; Flynn DL, 2013, ACS NAT M 8 APR NEW; Forse CL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1468-6; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Giuliani N, 2003, BLOOD, V102, P638, DOI 10.1182/blood-2002-10-3257; Gligorijevic B, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001995; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Gupton SL, 2012, J CELL BIOL, V198, P657, DOI 10.1083/jcb.201202079; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Hellen E H, 1991, J Fluoresc, V1, P113, DOI 10.1007/BF00865207; Hernandez L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3074; Hernandez L, 2009, CANCER RES, V69, P3221, DOI 10.1158/0008-5472.CAN-08-2871; Hesselgesser J, 1998, J IMMUNOL, V160, P877; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; Ho-Yen CM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0547-6; Hughes SK, 2015, MOL BIOL CELL, V26, P3867, DOI 10.1091/mbc.E15-06-0442; Kang JY, 2003, CANCER RES, V63, P1101; Kedrin D, 2008, NAT METHODS, V5, P1019, DOI 10.1038/nmeth.1269; Knutsdottir H, 2016, INTEGR BIOL-UK, V8, P104, DOI 10.1039/c5ib00201j; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Locker J, 2011, AM J PATHOL, V178, P966, DOI 10.1016/j.ajpath.2010.12.013; Loureiro JJ, 2002, MOL BIOL CELL, V13, P2533, DOI 10.1091/mbc.E01-10-0102; Magbanua MJM, 2015, ONCOTARGET, V6, P30715, DOI 10.18632/oncotarget.5568; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Martins D, 2014, CYTOPATHOLOGY, V25, P225, DOI 10.1111/cyt.12158; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Minami T, 2009, J CLIN INVEST, V119, P2257, DOI 10.1172/JCI35738; Mouneimne G, 2006, CURR BIOL, V16, P2193, DOI 10.1016/j.cub.2006.09.016; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Oktay MH, 2012, J HISTOCHEM CYTOCHEM, V60, P168, DOI 10.1369/0022155411435153; Ottewell PD, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.10; Patsialou A, 2015, ONCOGENE, V34, P2721, DOI 10.1038/onc.2014.226; Patsialou Antonia, 2013, Intravital, V2, pe25294; Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Pignatelli J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005329; Rhodes LV, 2011, CANCER RES, V71, P603, DOI 10.1158/0008-5472.CAN-10-3185; Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179; Rohan TE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju136; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Roussos ET, 2011, CLIN EXP METASTAS, V28, P515, DOI 10.1007/s10585-011-9388-6; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Sharma VP, 2014, METHODS MOL BIOL, V1172, P115, DOI 10.1007/978-1-4939-0928-5_10; Sharma Ved P, 2012, Intravital, V1, P77; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; Sidani M, 2006, J MAMMARY GLAND BIOL, V11, P151, DOI 10.1007/s10911-006-9021-5; Smith BD, 2013, CANC RES S24, V73; Smith BD, 2013, P AACR SPEC C TUM IN; Smith BD, 2015, MOL CANCER THER, V14, P2023, DOI 10.1158/1535-7163.MCT-14-1105; Smith BD, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.CHTME14-A53; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Timofeevski SL, 2009, BIOCHEMISTRY-US, V48, P5339, DOI 10.1021/bi900438w; Underiner TL, 2010, ANTI-CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007; Wang WG, 2007, CANCER RES, V67, P3505, DOI 10.1158/0008-5472.CAN-06-3714; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Williams JK, 2015, INTRAVITAL IN PRESS; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2000, CANCER RES, V60, P5401; Wyckoff Jeffrey, 2011, Cold Spring Harb Protoc, V2011, P1232, DOI 10.1101/pdb.prot065912; Wyckoff Jeffrey, 2011, Cold Spring Harb Protoc, V2011, P1167, DOI 10.1101/pdb.top065904; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; Zhao Z, 2016, CANCER RES, V76, P2094, DOI 10.1158/0008-5472.CAN-15-2662	91	56	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2680	2692		10.1038/onc.2016.421	http://dx.doi.org/10.1038/onc.2016.421			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27893712	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000401120900006
J	Bernasconi-Elias, P; Hu, T; Jenkins, D; Firestone, B; Gans, S; Kurth, E; Capodieci, P; Deplazes-Lauber, J; Petropoulos, K; Thiel, P; Ponsel, D; Choi, SH; LeMotte, P; London, A; Goetcshkes, M; Nolin, E; Jones, MD; Slocum, K; Kluk, MJ; Weinstock, DM; Christodoulou, A; Weinberg, O; Jaehrling, J; Ettenberg, SA; Buckler, A; Blacklow, SC; Aster, JC; Fryer, CJ				Bernasconi-Elias, P.; Hu, T.; Jenkins, D.; Firestone, B.; Gans, S.; Kurth, E.; Capodieci, P.; Deplazes-Lauber, J.; Petropoulos, K.; Thiel, P.; Ponsel, D.; Choi, S. Hee; LeMotte, P.; London, A.; Goetcshkes, M.; Nolin, E.; Jones, M. D.; Slocum, K.; Kluk, M. J.; Weinstock, D. M.; Christodoulou, A.; Weinberg, O.; Jaehrling, J.; Ettenberg, S. A.; Buckler, A.; Blacklow, S. C.; Aster, J. C.; Fryer, C. J.			Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies	ONCOGENE			English	Article							NEGATIVE BREAST-CANCER; REGULATORY REGION; INSIGHTS; MICE; MATURATION	Notch receptors have been implicated as oncogenic drivers in several cancers, the most notable example being NOTCH1 in T-cell acute lymphoblastic leukemia (T-ALL). To characterize the role of activated NOTCH3 in cancer, we generated an antibody that detects the neo-epitope created upon gamma-secretase cleavage of NOTCH3 to release its intracellular domain (ICD3), and sequenced the negative regulatory region (NRR) and PEST (proline, glutamate, serine, threonine) domain coding regions of NOTCH3 in a panel of cell lines. We also characterize NOTCH3 tumor-associated mutations that result in activation of signaling and report new inhibitory antibodies. We determined the structural basis for receptor inhibition by obtaining the first co-crystal structure of a NOTCH3 antibody with the NRR protein and defined two distinct epitopes for NRR antibodies. The antibodies exhibit potent anti-leukemic activity in cell lines and tumor xenografts harboring NOTCH3 activating mutations. Screening of primary T-ALL samples reveals that 2 of 40 tumors examined show active NOTCH3 signaling. We also identified evidence of NOTCH3 activation in 12 of 24 patient-derived orthotopic xenograft models, 2 of which exhibit activation of NOTCH3 without activation of NOTCH1. Our studies provide additional insights into NOTCH3 activation and offer a path forward for identification of cancers that are likely to respond to therapy with NOTCH3 selective inhibitory antibodies.	[Bernasconi-Elias, P.; Gans, S.; Capodieci, P.; Goetcshkes, M.; Nolin, E.; Buckler, A.; Fryer, C. J.] Novartis Inst Biomed Res, Dev & Mol Pathways, 250 Massachusetts Ave,Bldg 600-5B263, Cambridge, MA 02139 USA; [Hu, T.] Novartis Inst Biomed Res, Ctr Prote Chem, Cambridge, MA USA; [Jenkins, D.; Firestone, B.; Kurth, E.; Jones, M. D.; Slocum, K.; Ettenberg, S. A.] Novartis Inst Biomed Res, Dept Oncol, Cambridge, MA USA; [Deplazes-Lauber, J.; Petropoulos, K.; Thiel, P.; Ponsel, D.; Jaehrling, J.] MorphoSys AG, Discovery Alliances & Technol, Martinsried, Germany; [Choi, S. Hee; Weinstock, D. M.; Christodoulou, A.; Blacklow, S. C.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Choi, S. Hee; Blacklow, S. C.; Aster, J. C.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [LeMotte, P.; London, A.] Novartis Inst Biomed Res, Dept Biol, Cambridge, MA USA; [Kluk, M. J.; Blacklow, S. C.; Aster, J. C.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Weinberg, O.] Children Hosp Boston, Pathol, Boston, MA USA; [Jenkins, D.] Tesaro, Waltham, MA USA; [Thiel, P.] IstQ Deutschland GmbH & Co KG, Mannheim, Germany; [Ponsel, D.] Roche AG, Penzberg, Germany; [Goetcshkes, M.; Buckler, A.] Biogen, Cambridge, MA USA; [Kluk, M. J.] Cornell Weill Med Coll, New York, NY USA; [Ettenberg, S. A.] Unum Therapeut, Cambridge, MA USA	Novartis; Novartis; Novartis; MorphoSys; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Novartis; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Biogen; Cornell University	Fryer, CJ (corresponding author), Novartis Inst Biomed Res, Dev & Mol Pathways, 250 Massachusetts Ave,Bldg 600-5B263, Cambridge, MA 02139 USA.	christy.fryer@novartis.com		Jones, Michael/0000-0001-7541-7634	Industrial Macromolecular Crystallography Association; Hauptman-Woodward Medical Research Institute; US Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357]; Dana Farber-Novartis DDP; National Institutes of Health [P01 CA119070]; Leukemia and Lymphoma Society [7003-13]; NATIONAL CANCER INSTITUTE [R01CA092433, P01CA119070] Funding Source: NIH RePORTER	Industrial Macromolecular Crystallography Association; Hauptman-Woodward Medical Research Institute; US Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); Dana Farber-Novartis DDP; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The JAGGED1 and DLL1 expressing cell lines were kindly provide by Dr Gerry Weinmaster (UCLA). HPB-ALL cells were kindly provided by Andreas Stasser (Walter and Eliza Hall Institute for Medical Research, Australia). We thank the Novartis Biologics Center including Thomas Pietzonka, Janine Shulok, Nadine Charara, Bill Tschantz and Tony Fleming. We also thank many senior Novartis leaders for supporting this project, including Jeff Porter and William Sellers. We thank Rajiv Chopra and Kirk Clark of Novartis Institutes for BioMedical Research for the instructive discussion on crystallography experiments. Use of the IMCA-CAT beamline 17-ID at the Advanced Photon Source was supported by the companies of the Industrial Macromolecular Crystallography Association through a contract with Hauptman-Woodward Medical Research Institute. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357. This work was financially supported in part by the Dana Farber-Novartis DDP, and grants from the National Institutes of Health (P01 CA119070) and the Leukemia and Lymphoma Society (7003-13).	Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Aste-Amezaga M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009094; Aster JC, 2012, J CLIN ONCOL, V30, P2418, DOI 10.1200/JCO.2012.42.0992; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Etemadmoghadam D, 2009, CLIN CANCER RES, V15, P1417, DOI 10.1158/1078-0432.CCR-08-1564; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Gordon WR, 2007, NAT STRUCT MOL BIOL, V14, P295, DOI 10.1038/nsmb1227; Gordon WR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006613; Gordon WR, 2009, BLOOD, V113, P4381, DOI 10.1182/blood-2008-08-174748; Guruharsha KG, 2012, NAT REV GENET, V13, P654, DOI 10.1038/nrg3272; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; Kluk MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067306; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Krebs LT, 2000, GENE DEV, V14, P1343; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malecki MJ, 2006, MOL CELL BIOL, V26, P4642, DOI 10.1128/MCB.01655-05; McCright B, 2001, DEVELOPMENT, V128, P491; Nakayama K, 2007, INT J CANCER, V120, P2613, DOI 10.1002/ijc.22609; Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018; Prassler J, 2011, J MOL BIOL, V413, P261, DOI 10.1016/j.jmb.2011.08.012; Prassler J, 2009, IMMUNOTHERAPY-UK, V1, P571, DOI [10.2217/imt.09.23, 10.2217/IMT.09.23]; Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Rauchenberger R, 2003, J BIOL CHEM, V278, P38194, DOI 10.1074/jbc.M303164200; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; Stoeck A, 2014, CANCER DISCOV, V4, P1154, DOI 10.1158/2159-8290.CD-13-0830; Tewhey R, 2009, NAT BIOTECHNOL, V27, P1025, DOI 10.1038/nbt.1583; Tiyanont K, 2013, J MOL BIOL, V425, P3192, DOI 10.1016/j.jmb.2013.05.025; Vooijs M, 2011, GASTROENTEROLOGY, V141, P448, DOI 10.1053/j.gastro.2011.06.003; Wang K, 2015, CLIN CANCER RES, V21, P1487, DOI 10.1158/1078-0432.CCR-14-1348; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Xu X, 2015, STRUCTURE, V23, P1227, DOI 10.1016/j.str.2015.05.001; Yamaguchi N, 2008, CANCER RES, V68, P1881, DOI 10.1158/0008-5472.CAN-07-1597	45	56	59	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6077	6086		10.1038/onc.2016.133	http://dx.doi.org/10.1038/onc.2016.133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27157619	Green Accepted, Green Submitted			2022-12-17	WOS:000388509800004
J	Shah, MY; Martinez-Garcia, E; Phillip, JM; Chambliss, AB; Popovic, R; Ezponda, T; Small, EC; Will, C; Phillip, MP; Neri, P; Bahlis, NJ; Wirtz, D; Licht, JD				Shah, M. Y.; Martinez-Garcia, E.; Phillip, J. M.; Chambliss, A. B.; Popovic, R.; Ezponda, T.; Small, E. C.; Will, C.; Phillip, M. P.; Neri, P.; Bahlis, N. J.; Wirtz, D.; Licht, J. D.			MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents	ONCOGENE			English	Article							DOUBLE-STRAND BREAKS; T(4/14) MULTIPLE-MYELOMA; STEM-CELL TRANSPLANTATION; HISTONE H3; HOMOLOGOUS RECOMBINATION; ALU ELEMENTS; LYSINE 36; CHROMATIN; MMSET; METHYLATION	MMSET/WHSC1 is a histone methyltransferase (HMT) overexpressed in t(4;14)+ multiple myeloma (MM) patients, believed to be the driving factor in the pathogenesis of this MM subtype. MMSET overexpression in MM leads to an increase in histone 3 lysine 36 dimethylation (H3K36me2), and a decrease in histone 3 lysine 27 trimethylation (H3K27me3), as well as changes in proliferation, gene expression and chromatin accessibility. Prior work linked methylation of histones to the ability of cells to undergo DNA damage repair. In addition, t(4;14)+ patients frequently relapse after regimens that include DNA damage-inducing agents, suggesting that MMSET may play a role in DNA damage repair and response. In U2OS cells, we found that MMSET is required for efficient non-homologous end joining as well as homologous recombination. Loss of MMSET led to loss of expression of several DNA repair proteins, as well as decreased recruitment of DNA repair proteins to sites of DNA double-strand breaks (DSBs). By using genetically matched MM cell lines that had either high (pathological) or low (physiological) expression of MMSET, we found that MMSET-high cells had increased damage at baseline. Upon addition of a DNA-damaging agent, MMSET-high cells repaired DNA damage at an enhanced rate and continued to proliferate, whereas MMSET-low cells accumulated DNA damage and entered cell cycle arrest. In a murine xenograft model using t(4;14)+ KMS11 MM cells harboring an inducible MMSET shRNA, depletion of MMSET enhanced the efficacy of chemotherapy, inhibiting tumor growth and extending survival. These findings help explain the poorer prognosis of t(4;14) MM and further validate MMSET as a potential therapeutic target in MM and other cancers.	[Shah, M. Y.; Martinez-Garcia, E.; Popovic, R.; Ezponda, T.; Small, E. C.; Will, C.; Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, 303 E Super St,Lurie 5-123, Chicago, IL 60611 USA; [Phillip, J. M.; Chambliss, A. B.; Phillip, M. P.; Wirtz, D.] Johns Hopkins Univ, Inst Nanobiotechnol, Dept Chem & Biomol Engn, Baltimore, MD USA; [Neri, P.; Bahlis, N. J.] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Neri, P.; Bahlis, N. J.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Neri, P.; Bahlis, N. J.] Tom Baker Canc Clin, Calgary, AB, Canada; [Wirtz, D.] Johns Hopkins Univ, Sch Med, Dept Oncol & Pathol, Baltimore, MD USA	Northwestern University; Feinberg School of Medicine; Johns Hopkins University; University of Calgary; University of Calgary; Tom Baker Cancer Clinic; University of Calgary; Johns Hopkins University	Licht, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, 303 E Super St,Lurie 5-123, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Phillip, Jude/AAR-6240-2020; Licht, Jonathan/AAL-9184-2020; Ezponda, Teresa/AAA-5040-2020	Licht, Jonathan/0000-0002-3942-1369; Ezponda, Teresa/0000-0003-3682-7125; Chambliss, Allison/0000-0002-0461-8137	NIH [R01CA123204, R01CA174388, U54CA143868]; Leukemia & Lymphoma Society Specialized Center for Research Award; Physical Sciences Oncology Center [U54CA143869]; Celgene; Samuel Waxman Cancer Research Foundation; Canadian Institute of Health and Research operating grant [287300]; NATIONAL CANCER INSTITUTE [R01CA195732, R01CA123204, U54CA210173, U54CA143868, U54CA143869, R01CA174388] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia & Lymphoma Society Specialized Center for Research Award; Physical Sciences Oncology Center; Celgene(Bristol-Myers SquibbCelgene Corporation); Samuel Waxman Cancer Research Foundation; Canadian Institute of Health and Research operating grant(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH grant R01CA123204, Leukemia & Lymphoma Society Specialized Center for Research Award, Physical Sciences Oncology Center U54CA143869, Celgene and the Samuel Waxman Cancer Research Foundation (to JDL); NIH grants R01CA174388 and U54CA143868 (to DW); and Canadian Institute of Health and Research operating grant (287300; to NJB). We thank Dr Gaelle Legube for the AsiSI-U2OS cells and members of the Licht lab for their helpful comments.	Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Banath JP, 2009, EXP CELL RES, V315, P1505, DOI 10.1016/j.yexcr.2008.12.007; Bergsagel PL, 2005, J CLIN ONCOL, V23, P6333, DOI 10.1200/JCO.2005.05.021; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Chambliss AB, 2013, FASEB J, V27, P2667, DOI 10.1096/fj.12-227108; Chen WC, 2013, INTEGR BIOL-UK, V5, P523, DOI 10.1039/c2ib20246h; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Cook G, 2014, LANCET ONCOL, V15, P874, DOI 10.1016/S1470-2045(14)70245-1; Deininger P, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-12-236; Efroni S, 2008, CELL STEM CELL, V2, P437, DOI 10.1016/j.stem.2008.03.021; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; Englander EW, 1997, MUTAT RES-DNA REPAIR, V385, P31, DOI 10.1016/S0921-8777(97)00036-0; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; Ezponda T, 2013, ONCOGENE, V32, P2882, DOI 10.1038/onc.2012.297; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Goldstein M, 2013, P NATL ACAD SCI USA, V110, P16874, DOI 10.1073/pnas.1306160110; Gourzones-Dmitriev C, 2013, CELL CYCLE, V12, P2760, DOI 10.4161/cc.25951; Guo QY, 2013, BIOMATERIALS, V34, P9365, DOI 10.1016/j.biomaterials.2013.08.061; Hajdu I, 2011, P NATL ACAD SCI USA, V108, P13130, DOI 10.1073/pnas.1110081108; Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066; Hudlebusch HR, 2011, CANCER RES, V71, P4226, DOI 10.1158/0008-5472.CAN-10-3810; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Jaksic W, 2005, J CLIN ONCOL, V23, P7069, DOI 10.1200/JCO.2005.17.129; Jha DK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4965; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lans H, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-4; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Li L, 2011, DNA REPAIR HUMAN HLT; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Liao WJ, 2009, METHODS, V48, P46, DOI 10.1016/j.ymeth.2009.02.016; Lupi M, 2006, CANCER CHEMOTH PHARM, V57, P443, DOI 10.1007/s00280-005-0044-1; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Min DJ, 2013, LEUKEMIA, V27, P686, DOI 10.1038/leu.2012.269; Oliver TG, 2010, GENE DEV, V24, P837, DOI 10.1101/gad.1897010; Pai CC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5091; Palumbo A, 2014, NEW ENGL J MED, V371, P895, DOI 10.1056/NEJMoa1402888; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Panier S, 2014, NAT REV MOL CELL BIO, V15, P7, DOI 10.1038/nrm3719; Pei HD, 2013, J IMMUNOL, V190, P756, DOI 10.4049/jimmunol.1201811; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; POVIRK LF, 1989, BIOCHEMISTRY-US, V28, P5808, DOI 10.1021/bi00440a016; Ransom M, 2010, CELL, V140, P183, DOI 10.1016/j.cell.2010.01.004; Roussel M, 2010, BLOOD, V115, P32, DOI 10.1182/blood-2009-06-229658; Silber JR, 2002, CLIN CANCER RES, V8, P3008; Soria G, 2012, MOL CELL, V46, P722, DOI 10.1016/j.molcel.2012.06.002; Sousa MML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055493; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Tuzon CT, 2014, CELL REP, V8, P429, DOI 10.1016/j.celrep.2014.06.013; Wang Q, 2016, CANC RES; Zheng YP, 2012, P NATL ACAD SCI USA, V109, P13549, DOI 10.1073/pnas.1205707109	62	56	59	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2016	35	45					5905	5915		10.1038/onc.2016.116	http://dx.doi.org/10.1038/onc.2016.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EB7IR	27109101	Green Accepted			2022-12-17	WOS:000387560800009
J	Qiao, Y; Lin, SJ; Chen, Y; Voon, DCC; Zhu, F; Chuang, LSH; Wang, T; Tan, P; Lee, SC; Yeoh, KG; Sudol, M; Ito, Y				Qiao, Y.; Lin, S. J.; Chen, Y.; Voon, D. C-C; Zhu, F.; Chuang, L. S. H.; Wang, T.; Tan, P.; Lee, S. C.; Yeoh, K. G.; Sudol, M.; Ito, Y.			RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer	ONCOGENE			English	Article							TUMOR-SUPPRESSOR RUNX3; HIPPO PATHWAY; WW DOMAIN; PROMOTES METASTASIS; SIGNALING PATHWAY; EPITHELIAL-CELLS; BREAST-CANCER; SIZE-CONTROL; PROTEIN; GROWTH	Runt-related transcription factor 3 (RUNX3) is a well-documented tumour suppressor that is frequently inactivated in gastric cancer. Here, we define a novel mechanism by which RUNX3 exerts its tumour suppressor activity involving the TEAD-YAP complex, a potent positive regulator of proliferative genes. We report that the TEAD-YAP complex is not only frequently hyperactivated in liver and breast cancer, but also confers a strong oncogenic activity in gastric epithelial cells. The increased expression of TEAD-YAP in tumour tissues significantly correlates with poorer overall survival of gastric cancer patients. Strikingly, RUNX3 physically interacts with the N-terminal region of TEAD through its Runt domain. This interaction markedly reduces the DNA-binding ability of TEAD that attenuates the downstream signalling of TEAD-YAP complex. Mutation of RUNX3 at Arginine 122 to Cysteine, which was previously identified in gastric cancer, impairs the interaction between RUNX3 and TEAD. Our data reveal that RUNX3 acts as a tumour suppressor by negatively regulating the TEAD-YAP oncogenic complex in gastric carcinogenesis.	[Qiao, Y.; Chen, Y.; Voon, D. C-C; Chuang, L. S. H.; Wang, T.; Tan, P.; Lee, S. C.; Ito, Y.] Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr,12-01 Ctr Translat Med,MD6, Singapore 117599, Singapore; [Lin, S. J.; Tan, P.] Genome Inst Singapore, Canc Therapeut & Stratified Oncol, Singapore, Singapore; [Zhu, F.; Lee, S. C.] Natl Univ Hlth Syst, Natl Univ Canc Inst, Dept Haematol & Oncol, Singapore, Singapore; [Tan, P.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore, Singapore; [Tan, P.] Natl Canc Ctr, Cellular & Mol Res, Singapore, Singapore; [Yeoh, K. G.; Sudol, M.] Natl Univ Singapore, NUS Yong Loo Lin Sch Med, Singapore 117599, Singapore; [Sudol, M.] Mechanobiol Inst MBI, Singapore, Singapore; [Sudol, M.] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Ito, Y (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr,12-01 Ctr Translat Med,MD6, Singapore 117599, Singapore.	csiitoy@nus.edu.sg	Lee, Soo Chin/S-9111-2016	Lee, Soo Chin/0000-0002-5835-6419; Voon, Dominic Chih-Cheng/0000-0002-2963-9305	Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme; Singapore Ministry of Health's National Medical Research Council [NMRC/TCR/001/2007, NMRC/TCR/009-NUHS/2013]; NUS-Medical School, MBI; IMCB A*STAR; National Research Foundation Singapore; Singapore Ministry of Education under its Research Centres of Excellence initiative	Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme(National Research Foundation, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore); NUS-Medical School, MBI; IMCB A*STAR; National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Education under its Research Centres of Excellence initiative(Ministry of Education, Singapore)	This research is supported by the National Research Foundation Singapore and the Singapore Ministry of Education under its Research Centres of Excellence initiative. The study was also supported by the Singapore National Research Foundation under its Translational and Clinical Research Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council (Grants NMRC/TCR/001/2007 and NMRC/TCR/009-NUHS/2013). M Sudol was supported by seed grants from The NUS-Medical School, MBI and IMCB A*STAR. We are grateful to Professor Stefano Piccolo for providing us the 8xGTIIC-luciferase plasmid via Addgene. We also thank Professor Kunliang Guan for providing us myc-TEAD1 plasmid via Addgene. We acknowledge valuable comments on the manuscript from Dr Megan Finch-Edmondson.	Anbanandam A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI 10.1073/pnas.0607171103; Avruch J, 2012, CELL CYCLE, V11, P1090, DOI 10.4161/cc.11.6.19453; Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brusgard JL, 2015, ONCOTARGET IN PRESS; Chakraborty PK, 2014, CANCER RES, V74, P3489, DOI 10.1158/0008-5472.CAN-13-2708; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Cinghu S, 2012, J CELL PHYSIOL, V227, P1071, DOI 10.1002/jcp.22820; Dembele D, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-14; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fan XY, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-92; Fukumoto Y, 2011, J BIOL CHEM, V286, P43537, DOI 10.1074/jbc.M111.308858; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jiang CG, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-122; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Karagiannis GS, 2012, ONCOTARGET, V3, P267, DOI 10.18632/oncotarget.451; Koh CP, 2013, LEUKEMIA, V27, P1793, DOI 10.1038/leu.2013.200; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee YS, 2013, CANCER CELL, V24, P603, DOI 10.1016/j.ccr.2013.10.003; Li H, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0539-5; Li P, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-52; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Lin YT, 2012, EXP CELL RES, V318, P1877, DOI 10.1016/j.yexcr.2012.05.005; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lochhead P, 2008, BRIT MED BULL, V85, P87, DOI 10.1093/bmb/ldn007; Min B, 2012, J CELL PHYSIOL, V227, P839, DOI 10.1002/jcp.22887; Oh YS, 2013, CELL, V152, P831, DOI 10.1016/j.cell.2013.01.014; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676; Rho SB, 2008, CANCER LETT, V271, P306, DOI 10.1016/j.canlet.2008.06.020; Shah MA, 2010, JAMA-J AM MED ASSOC, V303, P1753, DOI 10.1001/jama.2010.553; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; SUDOL M, 1994, ONCOGENE, V9, P2145; Tsang YH, 2010, ONCOGENE, V29, P5643, DOI 10.1038/onc.2010.304; Tsutsumi R, 2013, DEV CELL, V26, P658, DOI 10.1016/j.devcel.2013.08.013; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Voon DCC, 2012, STEM CELLS, V30, P2088, DOI 10.1002/stem.1183; Wang CQ, 2014, CELL REP, V8, P767, DOI 10.1016/j.celrep.2014.06.046; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210	59	56	57	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2664	2674		10.1038/onc.2015.338	http://dx.doi.org/10.1038/onc.2015.338			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364597				2022-12-17	WOS:000376165700013
J	Tanas, MR; Ma, S; Jadaan, FO; Ng, CKY; Weigelt, B; Reis-Filho, JS; Rubin, BP				Tanas, M. R.; Ma, S.; Jadaan, F. O.; Ng, C. K. Y.; Weigelt, B.; Reis-Filho, J. S.; Rubin, B. P.			Mechanism of action of a WWTR1(TAZ)-CAMTA1 fusion oncoprotein	ONCOGENE			English	Article							PROMOTES APOPTOSIS; CELL-PROLIFERATION; HIPPO PATHWAY; CAMTA1; GROWTH; DROSOPHILA; TAZ; ENCODES; PROTEIN; KINASE	The WWTR1 (protein is known as TAZ)-CAMTA1 (WC) fusion gene defines epithelioid hemangioendothelioma, a malignant vascular cancer. TAZ (transcriptional coactivator with PDZ binding motif) is a transcriptional coactivator and end effector of the Hippo tumor suppressor pathway. It is inhibited by phosphorylation by the Hippo kinases LATS1 and LATS2. Such phosphorylation causes cytoplasmic localization, 14-3-3 protein binding and the phorphorylation of a terminal phosphodegron promotes ubiquitin-dependent degradation (the phosphorylation of the different motifs has several effects). CAMTA1 is a putative tumor suppressive transcription factor. Here we demonstrate that TAZ-CAMTA1 (TC) fusion results in its nuclear localization and constitutive activation. Consequently, cells expressing TC display a TAZ-like transcriptional program that causes resistance to anoikis and oncogenic transformation. Our findings elucidate the mechanistic basis of TC oncogenic properties, highlight that TC is an important model to understand how the Hippo pathway can be inhibited in cancer, and provide approaches for targeting this chimeric protein.	[Tanas, M. R.; Ma, S.; Jadaan, F. O.; Rubin, B. P.] Cleveland Clin, Lerner Res Inst, Dept Mol Genet, NE2,9500 Euclid Ave, Cleveland, OH 44195 USA; [Tanas, M. R.; Rubin, B. P.] Cleveland Clin, Taussig Canc Ctr, Robert J Tomsich Pathol Inst, Lerner Res Inst, Cleveland, OH 44195 USA; [Ng, C. K. Y.; Weigelt, B.; Reis-Filho, J. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Memorial Sloan Kettering Cancer Center	Rubin, BP (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Mol Genet, NE2,9500 Euclid Ave, Cleveland, OH 44195 USA.	rubinb2@ccf.org	Ng, Charlotte K Y/AAA-1670-2020; Ng, Charlotte K Y/AAY-3178-2021	Ng, Charlotte K Y/0000-0002-6100-0026; Tanas, Munir/0000-0002-6779-2642	National Cancer Institute of the National Institutes of Health [U54CA168512]; Liddy Shriver Sarcoma Initiative; Center for Research and Analysis of Vascular Tumors (CRAVAT); Friends of EHE research; NATIONAL CANCER INSTITUTE [P30CA008748, U54CA168512] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Liddy Shriver Sarcoma Initiative; Center for Research and Analysis of Vascular Tumors (CRAVAT); Friends of EHE research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U54CA168512 to BR. This work was also supported by grants from the Liddy Shriver Sarcoma Initiative, the Center for Research and Analysis of Vascular Tumors (CRAVAT), and the Friends of EHE research to BR.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Antonescu CR, 2013, GENE CHROMOSOME CANC, V52, P775, DOI 10.1002/gcc.22073; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Errani C, 2011, GENE CHROMOSOME CANC, V50, P644, DOI 10.1002/gcc.20886; Finkler A, 2007, FEBS LETT, V581, P3893, DOI 10.1016/j.febslet.2007.07.051; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Henrich KO, 2012, CANCER RES, V72, P6079, DOI 10.1158/0008-5472.CAN-12-2230; Henrich KO, 2011, CANCER RES, V71, P3142, DOI 10.1158/0008-5472.CAN-10-3014; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang W, 2012, J BIOL CHEM, V287, P26245, DOI 10.1074/jbc.M112.382036; Huentelman MJ, 2007, HUM MOL GENET, V16, P1469, DOI 10.1093/hmg/ddm097; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Ma S, 2014, LAB INVEST, V94, P430, DOI 10.1038/labinvest.2014.13; Mendlick MR, 2001, AM J SURG PATHOL, V25, P684, DOI 10.1097/00000478-200105000-00019; Miller LA, 2011, PSYCHOGERIATRICS, V11, P135, DOI 10.1111/j.1479-8301.2011.00357.x; Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nguyen BA, 2009, BMC BIOINFORMATICS, V10, P202, DOI [10.1186/1471-2105-10-202, DOI 10.1186/1471-2105-10-202]; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Pandey N, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-216; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Schraivogel D, 2011, EMBO J, V30, P4309, DOI 10.1038/emboj.2011.301; Song K, 2006, CELL, V125, P453, DOI 10.1016/j.cell.2006.02.048; Tanas MR, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002409; Taylor BS, 2011, NAT REV CANCER, V11, P541, DOI 10.1038/nrc3087; Thevenon J, 2012, J MED GENET, V49, P400, DOI 10.1136/jmedgenet-2012-100856; Tremblay AM, 2014, CANCER CELL, V26, P273, DOI 10.1016/j.ccr.2014.05.029; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111	46	56	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					929	938		10.1038/onc.2015.148	http://dx.doi.org/10.1038/onc.2015.148			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961935	Green Accepted			2022-12-17	WOS:000370332200013
J	Mi, W; Lin, Q; Childress, C; Sudol, M; Robishaw, J; Berlot, CH; Shabahang, M; Yang, W				Mi, W.; Lin, Q.; Childress, C.; Sudol, M.; Robishaw, J.; Berlot, C. H.; Shabahang, M.; Yang, W.			Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration	ONCOGENE			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN PRENYLATION; YAP; GROWTH; GERANYLGERANYLTRANSFERASE; METASTASIS; MEVALONATE; INHIBITOR; RAS; TUMORIGENESIS	Protein geranylgeranylation (GGylation) is an important biochemical process for many cellular signaling molecules. Previous studies have shown that GGylation is essential for cell survival in many types of cancer. However, the molecular mechanism mediating the cell survival effect remains elusive. In this report, we show that the Hippo pathway mediates GGylation-dependent cell proliferation and migration in breast cancer cells. Blockade of GGylation enhanced phosphorylation of Mst1/2 and Lats1, and inhibited YAP and TAZ activity and the Hippo-YAP/TAZ pathway-dependent transcription. The effect of GGylation blockade on inhibition of breast cancer cell proliferation and migration is dependent on the Hippo-YAP/TAZ signaling, in which YAP appears to regulate cell proliferation and TAZ to regulate cell migration. Furthermore, GGylation-dependent cell proliferation is correlated with the activity of YAP/TAZ in breast cancer cells. Finally, G gamma and RhoA are the GGylated proteins that may transduce GGylation signals to the Hippo-YAP/TAZ pathway. Taken together, our studies have demonstrated that the Hippo-YAP/TAZ pathway is essential for GGylation-dependent cancer cell proliferation and migration.	[Mi, W.; Lin, Q.; Childress, C.; Sudol, M.; Robishaw, J.; Berlot, C. H.; Yang, W.] Weis Ctr Res, Danville, PA USA; [Lin, Q.] Jiangsu Univ, Sch Med Sci & Lab Med, Zhenjiang, Peoples R China; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Shabahang, M.] Weis Ctr Res, Geisinger Clin, Dept Gen Surg, Danville, PA 17822 USA	Jiangsu University; Icahn School of Medicine at Mount Sinai	Yang, W (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	wyang1@geisinger.edu	Yang, Wannian/K-4836-2019		Geisinger Research Large Grant [SRC-081]; NIH [R01GM050369]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050369] Funding Source: NIH RePORTER	Geisinger Research Large Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Pradines of the Departement Innovation Therapeutique et Oncologie Moleculaire, Centre de Physiopathologie, Institut Claudius Regaud for sending us wild-type and the farnesylated RhoA plasmids, Dr Steyger of Oregon Hearing Research Center for the retroviral plasmid pBabe-TRPV4 and Dr Kunliang Guan of University of California at San Diego for HEK293A cell line. This research was supported by Geisinger Research Large Grant (SRC-081, to WY) and NIH R01GM050369 (to CHB).	Ahmed SM, 2010, J BIOL CHEM, V285, P6538, DOI 10.1074/jbc.M109.069948; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Budman DR, 2007, BREAST CANCER RES TR, V104, P93, DOI 10.1007/s10549-006-9395-5; Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cuello M, 2013, REV MED CHILE, V141, P227, DOI 10.4067/S0034-98872013000200013; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; Falsetti SC, 2007, MOL CELL BIOL, V27, P8003, DOI 10.1128/MCB.00057-07; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x; Goard CA, 2014, BREAST CANCER RES TR, V143, P301, DOI 10.1007/s10549-013-2800-y; Hill VK, 2011, EPIGENETICS-US, V6, P326, DOI 10.4161/epi.6.3.14404; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kirui JK, 2010, J PHARMACOL EXP THER, V333, P393, DOI 10.1124/jpet.109.164814; Kubatka P, 2011, Klin Onkol, V24, P41; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Laufs U, 1999, J BIOL CHEM, V274, P21926, DOI 10.1074/jbc.274.31.21926; Lehmann DM, 2008, MOL PHARMACOL, V73, P410, DOI 10.1124/mol.107.041780; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Oka T, 2008, J BIOL CHEM, V283, P27534, DOI 10.1074/jbc.M804380200; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Onono F, 2013, J BIOL CHEM, V288, P27444, DOI 10.1074/jbc.M113.482307; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Radeff-Huang J, 2004, J CELL BIOCHEM, V92, P949, DOI 10.1002/jcb.20094; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Saini DK, 2007, J BIOL CHEM, V282, P24099, DOI 10.1074/jbc.M701191200; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shen F, 2007, MOL BIOL CELL, V18, P732, DOI 10.1091/mbc.E06-02-0142; Shibata MA, 2004, CARCINOGENESIS, V25, P1887, DOI 10.1093/carcin/bgh201; Sjogren AKM, 2007, J CLIN INVEST, V117, P1294, DOI 10.1172/JCI30868; Smrcka AV, 2008, CELL MOL LIFE SCI, V65, P2191, DOI 10.1007/s00018-008-8006-5; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; Song M, 2012, ANTICANCER RES, V32, P3827; Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sudol M, 2012, SEMIN CELL DEV BIOL, V23, P827, DOI 10.1016/j.semcdb.2012.05.002; Sung JZ, 1999, J BIOL CHEM, V274, P6930; Tang XY, 2011, J BIOL CHEM, V286, P13244, DOI 10.1074/jbc.M110.206615; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Vogt A, 1996, ONCOGENE, V13, P1991; Wang ZY, 2014, P NATL ACAD SCI USA, V111, pE89, DOI 10.1073/pnas.1319190110; Xiang SY, 2013, BBA-MOL CELL BIOL L, V1831, P213, DOI 10.1016/j.bbalip.2012.09.004; XU TA, 1995, DEVELOPMENT, V121, P1053; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303	62	56	58	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3095	3106		10.1038/onc.2014.251	http://dx.doi.org/10.1038/onc.2014.251			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25109332				2022-12-17	WOS:000356101100002
J	Krajewska, M; Fehrmann, RSN; Schoonen, PM; Labib, S; de Vries, EGE; Franke, L; van Vugt, MATM				Krajewska, M.; Fehrmann, R. S. N.; Schoonen, P. M.; Labib, S.; de Vries, E. G. E.; Franke, L.; van Vugt, M. A. T. M.			ATR inhibition preferentially targets homologous recombination-deficient tumor cells	ONCOGENE			English	Article							STRAND BREAK REPAIR; CANCER SUSCEPTIBILITY GENE; EMBRYONIC CELLULAR PROLIFERATION; INDUCED REPLICATIVE STRESS; RAD51 RECOMBINASE; MAMMALIAN-CELLS; BRCA2; TRANSFORMATION; MUTATIONS; MOUSE	Homologous recombination (HR) is required for faithful repair of double-strand DNA breaks. Defects in HR repair cause severe genomic instability and challenge cellular viability. Paradoxically, various cancers are HR defective and have apparently acquired characteristics to survive genomic instability. We aimed to identify these characteristics to uncover therapeutic targets for HR-deficient cancers. Cytogenetic analysis of 1143 ovarian cancers showed that the degree of genomic instability was correlated to amplification of replication checkpoint genes ataxia telangiectasia and Rad3-related kinase (ATR) and CHEK1. To test whether genomic instability leads to increased reliance on replication checkpoint signaling, we inactivated Rad51 to model HR-related genomic instability. Rad51 inactivation caused defective HR repair and induced aberrant replication dynamics. Notably, inhibition of Rad51 led to increased ATR/checkpoint kinase-1 (Chk1)-mediated replication stress signaling. Importantly, inhibition of ATR or Chk1 preferentially killed HR-deficient cancer cells. Combined, our data show that defective HR caused by Rad51 inhibition results in differential sensitivity for ATR and Chk1 inhibitors, implicating replication checkpoint kinases as potential drug targets for HR-defective cancers.	[Krajewska, M.; Fehrmann, R. S. N.; Schoonen, P. M.; Labib, S.; de Vries, E. G. E.; van Vugt, M. A. T. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9700 Groningen, Netherlands; [Franke, L.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Genet, NL-9700 Groningen, Netherlands	University of Groningen; University of Groningen	van Vugt, MATM (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9700 Groningen, Netherlands.	m.vugt@umcg.nl	Franke, Lude/P-7036-2016; Krajewska, Malgorzata/AAH-1158-2021; Fehrmann, Rudolf/E-2551-2011	Franke, Lude/0000-0002-5159-8802; Fehrmann, Rudolf/0000-0002-7516-315X; Krajewska, Malgorzata/0000-0002-2243-5924; de Vries, Elisabeth/0000-0002-8949-7425	NWO [917-3334]; Alpe d'HuZes/Dutch Cancer Society [RUG2013-5960]; Van der Meer-Boerema Foundation	NWO(Netherlands Organization for Scientific Research (NWO)); Alpe d'HuZes/Dutch Cancer Society; Van der Meer-Boerema Foundation	This work was financially supported by an NWO VIDI grant to MATMvV (917-3334), a Bas Mulder grant from the Alpe d'HuZes/Dutch Cancer Society (RUG2013-5960) to RSNF and funding from the Van der Meer-Boerema Foundation to MK. We thank Dr Maria Jasin for generously supplying materials.	Anantha RW, 2007, J BIOL CHEM, V282, P35910, DOI 10.1074/jbc.M704645200; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Fang Y, 2004, EMBO J, V23, P3164, DOI 10.1038/sj.emboj.7600315; Frappart PO, 2009, P NATL ACAD SCI USA, V106, P1880, DOI 10.1073/pnas.0806882106; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Greenblatt MS, 2001, CANCER RES, V61, P4092; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hashimoto Y, 2010, NAT STRUCT MOL BIOL, V17, P1305, DOI 10.1038/nsmb.1927; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; Huang F, 2011, ACS CHEM BIOL, V6, P628, DOI 10.1021/cb100428c; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karst AM, 2014, CANCER RES, V74, P1141, DOI 10.1158/0008-5472.CAN-13-2247; Krejci L, 2012, NUCLEIC ACIDS RES, V40, P5795, DOI 10.1093/nar/gks270; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu SZ, 2011, MOL CELL, V43, P192, DOI 10.1016/j.molcel.2011.06.019; Lopez-Contreras AJ, 2012, J EXP MED, V209, P455, DOI 10.1084/jem.20112147; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Moynahan ME, 2010, NAT REV MOL CELL BIO, V11, P196, DOI 10.1038/nrm2851; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Oza V, 2012, J MED CHEM, V55, P5130, DOI 10.1021/jm300025r; Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Schlacher K, 2012, CANCER CELL, V22, P106, DOI 10.1016/j.ccr.2012.05.015; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Smith L, 1998, NAT GENET, V19, P39, DOI 10.1038/ng0598-39; Sonoda E, 2006, DNA REPAIR, V5, P1021, DOI 10.1016/j.dnarep.2006.05.022; Sung P, 2003, J BIOL CHEM, V278, P42729, DOI 10.1074/jbc.R300027200; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	37	56	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3474	3481		10.1038/onc.2014.276	http://dx.doi.org/10.1038/onc.2014.276			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174396				2022-12-17	WOS:000356871700012
J	Lin, L; Huang, H; Liao, W; Ma, H; Liu, J; Wang, L; Huang, N; Liao, Y; Liao, W				Lin, L.; Huang, H.; Liao, W.; Ma, H.; Liu, J.; Wang, L.; Huang, N.; Liao, Y.; Liao, W.			MACC1 supports human gastric cancer growth under metabolic stress by enhancing the Warburg effect	ONCOGENE			English	Article							CELL-SURVIVAL; TUMOR-GROWTH; GLUCOSE DEPRIVATION; METASTASIS; KINASE; COLON; MET; DEHYDROGENASE; MITOCHONDRIA; PROGRESSION	Cancer cells mainly metabolize by glycolysis (the Warburg effect) and are better adapted to resist metabolic stress. Metastasis-associated in colon cancer-1 (MACC1) is an oncogene promoting gastric cancer (GC) growth and metastasis, and its expression positively correlates with GC progression. However, it is unknown why MACC1 elevates with GC progression and what is its role in cancer metabolism. In this study, we discovered that MACC1 expression was significantly upregulated via adenosine monophosphate-activated protein kinase signaling in response to glucose deprivation-induced metabolic stress. Clinical observation demonstrates that MACC1 expression was higher in advanced stage GC. MACC1 expression was proved to be positively correlated with the maximum standardized uptake value of F-18-deoxyglucose in the patients, and MACC1 enhanced F-18-deoxyglucose uptake in GC cells and the xenografts. The underlying mechanism was that MACC1 promoted the Warburg effect by upregulating the activities and expressions of a series of glycolytic enzymes, including hexokinase, pyruvate dehydrogenase kinase and lactate dehydrogenase, in GC cells. This metabolic shift enhanced cell viability and resistance to apoptosis by facilitating ATP generation, reducing the reactive oxygen species production and stabilizing the mitochondrial membrane potential. In contrast, MACC1-silenced or the Warburg effect-blocked GC cells were more vulnerable to metabolic stress. In conclusion, metabolic stress is one of the mechanisms that elevate MACC1 expression in GC, and MACC1 upregulation compensatively ensures GC growth against metabolic stress by facilitating the Warburg effect.	[Lin, L.; Huang, H.; Liao, W.; Ma, H.; Liu, J.; Wang, L.; Huang, N.; Liao, W.] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China; [Liao, Y.] Southern Med Univ, Nanfang Hosp, Dept Cardiol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Liao, W (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou 510515, Guangdong, Peoples R China.	nfyyliaowj@163.com	Liao, Yulin/AAP-6315-2021	Lin, Li/0000-0002-9719-4539; Wangjun, Liao/0000-0002-1364-8442	National Natural Science Foundation of China [31271564]; Guangzhou science and technology plan [134600108]; Team Program of Natural Science Foundation of Guangdong Province [S2011030003134]; Special Foundation for National Clinical Specialties of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou science and technology plan; Team Program of Natural Science Foundation of Guangdong Province; Special Foundation for National Clinical Specialties of China	This work was supported by the National Natural Science Foundation of China (31271564 to WL), Guangzhou science and technology plan (134600108 to WL), the Team Program of Natural Science Foundation of Guangdong Province (S2011030003134 to WL and YL) and the Special Foundation for National Clinical Specialties of China (to Department of Oncology, Nanfang Hospital). We thank Professor Quanshi Wang and Professor Hubing Wu for helping clinical PET data acquisition, Dr Yanjiang Han for assistance with microPET, Professor Zhenhua Ding for assistance with gamma-radiation activity monitor and Jingwen Zhang for language editing. QW, HW and YH are from PET Center, JZ is from Department of Cardiology, Nanfang Hospital and ZD is from Department of Radiation Medicine, School of Public Health and Tropical Medicine, Southern Medical University.	Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Galimi F, 2011, CLIN CANCER RES, V17, P3146, DOI 10.1158/1078-0432.CCR-10-3377; Gao M, 2014, ONCOGENE, V33, P745, DOI 10.1038/onc.2013.2; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Keller KE, 2012, SCIENCE, V338, P1069, DOI 10.1126/science.1224409; Kokoszynska K, 2009, ACTA BIOCHIM POL, V56, P317; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li GQ, 2014, CANCER CELL, V25, P455, DOI 10.1016/j.ccr.2014.02.007; Meng FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060821; Mimeault M, 2013, MOL ASPECTS MED, DOI DOI 10.1016/J.MAM.2013.2008.2001; Miniotis MF, 2013, CANCER RES, V73, P4039, DOI 10.1158/0008-5472.CAN-12-1969; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pate KT, 2014, EMBO J; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Wang G, 2012, ONCOL LETT, V4, P783, DOI 10.3892/ol.2012.784; Wang L, 2013, INT J CANCER, V133, P1419, DOI 10.1002/ijc.28140; Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470; Wu CA, 2013, BBA-MOL CELL RES, V1833, P1147, DOI 10.1016/j.bbamcr.2013.01.025; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Xie C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064235; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229; Zaugg K, 2011, GENE DEV, V25, P1041, DOI 10.1101/gad.1987211; Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303	32	56	60	2	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 21	2015	34	21					2700	2710		10.1038/onc.2014.204	http://dx.doi.org/10.1038/onc.2014.204			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI7XN	25043301				2022-12-17	WOS:000354979500003
J	Hsu, FF; Yeh, CT; Sun, YJ; Chiang, MT; Lan, WM; Li, FA; Lee, WH; Chau, LY				Hsu, F-F; Yeh, C-T; Sun, Y-J; Chiang, M-T; Lan, W-M; Li, F-A; Lee, W-H; Chau, L-Y			Signal peptide peptidase-mediated nuclear localization of heme oxygenase-1 promotes cancer cell proliferation and invasion independent of its enzymatic activity	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; VIRUS CORE PROTEIN; INTRAMEMBRANE PROTEOLYSIS; ENDOPLASMIC-RETICULUM; OXIDATIVE STRESS; EXPRESSION; OVEREXPRESSION; IDENTIFICATION; TRANSLOCATION; DEGRADATION	Heme oxygenase-1 (HO-1) is a heme-degrading enzyme anchored in the endoplasmic reticulum by a carboxyl-terminal transmembrane segment (TMS). HO-1 is highly expressed in various cancers and its nuclear localization is associated with the progression of some cancers. Nevertheless, the mechanism underlying HO-1 nuclear translocation and its pathological significance remain elusive. Here we show that the signal peptide peptidase (SPP) catalyzes the intramembrane cleavage of HO-1. Coexpression of HO-1 with wild-type SPP, but not a dominant-negative SPP, promoted the nuclear localization of HO-1 in cells. Mass spectrometry analysis of cytosolic HO-1 isolated from HeLa cells overexpressing HO-1 and SPP revealed two adjacent intramembrane cleavage sites located after S-275 and F-276 within the TMS. Mutations of S275F276 to A(275)L(276) significantly hindered SPP-mediated HO-1 cleavage and nuclear localization. Nuclear HO-1 was detected in A549 and DU145 cancer cell lines expressing high levels of endogenous HO-1 and SPP. SPP knockdown or inhibition significantly reduced nuclear HO-1 localization in A549 and DU145 cells. The positive nuclear HO-1 stain was also evident in lung cancer tissues expressing high levels of HO-1 and SPP. Overexpression of a truncated HO-1 (t-HO-1) lacking the TMS in HeLa and H1299 cells promoted cell proliferation and migration/invasion. The effect of t-HO-1 was not affected by a mutation in the catalytic site. However, blockade of t-HO-1 nuclear localization abolished t-HO-1-mediated effect. The tumorigenic effect of t-HO-1 was also demonstrated in the mouse model. These findings disclose that SPP-mediated intramembrane cleavage of HO-1 promotes HO-1 nuclear localization and cancer progression independent of HO-1 enzymatic activity.	[Hsu, F-F; Sun, Y-J; Chiang, M-T; Lan, W-M; Li, F-A; Chau, L-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Yeh, C-T] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Yeh, C-T; Lee, W-H] Taipei Med Univ, Shuang Ho Hosp, Ctr Canc, Taipei, Taiwan	Academia Sinica - Taiwan; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, 128,Sect 2,Acad Rd, Taipei 115, Taiwan.	lyc@ibms.sinica.edu.tw	Chau, Lee-Young/N-7659-2018; Li, Fu-An/M-8506-2019	Chau, Lee-Young/0000-0002-6316-2328; Li, Fu-An/0000-0002-0580-7765	National Science Council of Taiwan [NSC-100-2320-B-001-010-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by a grant from the National Science Council of Taiwan (NSC-100-2320-B-001-010-MY3). We thank the National Center for Genome Medicine at Academia Sinica, Taiwan for polymerase chain reaction of short-tandem repeat sequences analysis, and the IBMS proteomics core for LC-MS analysis.	Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104; Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159; Bindu S, 2011, J BIOL CHEM, V286, P39387, DOI 10.1074/jbc.M111.279893; Chang HT, 2007, J CELL BIOCHEM, V100, P1266, DOI 10.1002/jcb.21120; Collinson EJ, 2011, J BIOL CHEM, V286, P2205, DOI 10.1074/jbc.M110.187062; Converso DP, 2006, FASEB J, V20, P1236, DOI 10.1096/fj.05-4204fje; Degese MS, 2012, LUNG CANCER, V77, P168, DOI 10.1016/j.lungcan.2012.02.016; El Hage F, 2008, P NATL ACAD SCI USA, V105, P10119, DOI 10.1073/pnas.0802753105; Erez E, 2009, NATURE, V459, P371, DOI 10.1038/nature08146; Fluhrer R, 2009, J BIOL CHEM, V284, P13975, DOI 10.1074/jbc.R800040200; Gandini NA, 2012, EXP MOL PATHOL, V93, P237, DOI 10.1016/j.yexmp.2012.05.001; Giordano A, 2000, FEBS LETT, V487, P171, DOI 10.1016/S0014-5793(00)02217-1; Hwang HW, 2009, J BIOL CHEM, V284, P22672, DOI 10.1074/jbc.M109.028001; Jozkowicz A, 2007, ANTIOXID REDOX SIGN, V9, P2099, DOI 10.1089/ars.2007.1659; Kocanova S, 2007, APOPTOSIS, V12, P731, DOI 10.1007/s10495-006-0016-x; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Li MY, 2008, EUR RESPIR J, V32, P911, DOI 10.1183/09031936.00064508; Li Volti G, 2004, BIOCHEM BIOPH RES CO, V315, P517, DOI 10.1016/j.bbrc.2004.01.090; Lin PH, 2013, ONCOGENE, V32, P2325, DOI 10.1038/onc.2012.244; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Mayerhofer M, 2004, CANCER RES, V64, P3148, DOI 10.1158/0008-5472.CAN-03-1200; Mayerhofer M, 2008, BLOOD, V111, P2200, DOI 10.1182/blood-2006-11-055723; Okamoto K, 2004, J VIROL, V78, P6370, DOI 10.1128/JVI.78.12.6370-6380.2004; Okamoto K, 2008, J VIROL, V82, P8349, DOI 10.1128/JVI.00306-08; Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0; Sacca P, 2007, BRIT J CANCER, V97, P1683, DOI 10.1038/sj.bjc.6604081; Sunamura Makoto, 2003, Angiogenesis, V6, P15, DOI 10.1023/A:1025803600840; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; Targett-Adams P, 2006, J BIOL CHEM, V281, P29221, DOI 10.1074/jbc.M605373200; Wang XM, 2009, J IMMUNOL, V182, P3809, DOI 10.4049/jimmunol.0712437; Was H, 2006, AM J PATHOL, V169, P2181, DOI 10.2353/ajpath.2006.051365; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; YOSHIDA T, 1991, EUR J BIOCHEM, V199, P729, DOI 10.1111/j.1432-1033.1991.tb16177.x	34	56	57	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2015	34	18					2360	2370		10.1038/onc.2014.166	http://dx.doi.org/10.1038/onc.2014.166			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH2AH	24931165				2022-12-17	WOS:000353824800009
J	Moody, SE; Schinzel, AC; Singh, S; Izzo, F; Strickland, MR; Luo, L; Thomas, SR; Boehm, JS; Kim, SY; Wang, ZC; Hahn, WC				Moody, S. E.; Schinzel, A. C.; Singh, S.; Izzo, F.; Strickland, M. R.; Luo, L.; Thomas, S. R.; Boehm, J. S.; Kim, S. Y.; Wang, Z. C.; Hahn, W. C.			PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; TRASTUZUMAB RESISTANCE; MONOCLONAL-ANTIBODY; SINGLE-AGENT; BETA-CATENIN; PHOSPHORYLATION; LAPATINIB; ACTIVATION; CHEMOTHERAPY; INHIBITION	Targeting HER2 with antibodies or small molecule inhibitors in HER2-positive breast cancer leads to improved survival, but resistance is a common clinical problem. To uncover novel mechanisms of resistance to anti-HER2 therapy in breast cancer, we performed a kinase open reading frame screen to identify genes that rescue HER2-amplified breast cancer cells from HER2 inhibition or suppression. In addition to multiple members of the MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase) signaling pathways, we discovered that expression of the survival kinases PRKACA and PIM1 rescued cells from anti-HER2 therapy. Furthermore, we observed elevated PRKACA expression in trastuzumab-resistant breast cancer samples, indicating that this pathway is activated in breast cancers that are clinically resistant to trastuzumab-containing therapy. We found that neither PRKACA nor PIM1 restored MAPK or PI3K activation after lapatinib or trastuzumab treatment, but rather inactivated the pro-apoptotic protein BAD, the BCl-2-associated death promoter, thereby permitting survival signaling through BCL-XL. Pharmacological blockade of BCL-XL/BCL-2 partially abrogated the rescue effects conferred by PRKACA and PIM1, and sensitized cells to lapatinib treatment. These observations suggest that combined targeting of HER2 and the BCL-XL/BCL-2 anti-apoptotic pathway may increase responses to anti-HER2 therapy in breast cancer and decrease the emergence of resistant disease.	[Moody, S. E.; Schinzel, A. C.; Singh, S.; Izzo, F.; Strickland, M. R.; Luo, L.; Hahn, W. C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Moody, S. E.; Luo, L.; Hahn, W. C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Moody, S. E.; Luo, L.; Wang, Z. C.; Hahn, W. C.] Harvard Univ, Sch Med, Boston, MA USA; [Thomas, S. R.; Boehm, J. S.] Broad Inst MIT & Harvard, Cambridge, MA USA; [Kim, S. Y.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC USA; [Wang, Z. C.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Wang, Z. C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Duke University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital	Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 1538, Boston, MA 02115 USA.	William_Hahn@dfci.harvard.edu		Luo, Leo/0000-0002-3061-4287; Boehm, Jesse/0000-0002-6795-6336	Department of Defense [W81XWH-10-1-0575]; Komen Grant [CCR13262292]; Breast Cancer Research Foundation; NIH [R01 CA130988, U01 CA176058, U54 CA112962]; NATIONAL CANCER INSTITUTE [U01CA176058, R01CA130988, U54CA112962] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); Komen Grant(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank Drs Ines Luis, Nancy Lin and Eric Winer for assistance in obtaining patient tissue samples. This work was supported by the Department of Defense Grant W81XWH-10-1-0575 and the Komen Grant CCR13262292 (to SEM), by the Breast Cancer Research Foundation (to ZCW), and by the NIH grants R01 CA130988, U01 CA176058 and U54 CA112962 (to WCH).	Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Beristain AG, 2015, ONCOGENE, V34, P1160, DOI 10.1038/onc.2014.41; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Beuschlein F, 2014, NEW ENGL J MED, V370, P1019, DOI 10.1056/NEJMoa1310359; Blackwell KL, 2009, ANN ONCOL, V20, P1026, DOI 10.1093/annonc/mdn759; Cao YN, 2014, SCIENCE, V344, P913, DOI 10.1126/science.1249480; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fleming GF, 2012, BREAST CANCER RES TR, V136, P355, DOI 10.1007/s10549-011-1910-7; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gu L, 2009, CLIN CANCER RES, V15, P7196, DOI 10.1158/1078-0432.CCR-09-0585; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Honeyman JN, 2014, SCIENCE, V343, P1010, DOI 10.1126/science.1249484; Iyer GH, 2005, J BIOL CHEM, V280, P8800, DOI 10.1074/jbc.M407586200; Jegg AM, 2012, BREAST CANCER RES TR, V136, P683, DOI 10.1007/s10549-012-2252-9; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Kataoka Y, 2010, ANN ONCOL, V21, P255, DOI 10.1093/annonc/mdp304; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2007, MOL CANCER THER, V6, P667, DOI 10.1158/1535-7163.MCT-06-0423; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002; Vegran F, 2009, BRIT J CANCER, V101, P1357, DOI 10.1038/sj.bjc.6605310; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Vogel C, 2001, EUR J CANCER, V37, pS25, DOI 10.1016/S0959-8049(00)00405-6; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wehrman TS, 2006, P NATL ACAD SCI USA, V103, P19063, DOI 10.1073/pnas.0605218103; Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173; Xia WL, 2004, ONCOGENE, V23, P646, DOI 10.1038/sj.onc.1207166; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	42	56	59	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2061	2071		10.1038/onc.2014.153	http://dx.doi.org/10.1038/onc.2014.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909179	Green Accepted, Green Submitted			2022-12-17	WOS:000353173400006
J	Elias, D; Vever, H; Laenkholm, AV; Gjerstorff, MF; Yde, CW; Lykkesfeldt, AE; Ditzel, HJ				Elias, D.; Vever, H.; Laenkholm, A-V; Gjerstorff, M. F.; Yde, C. W.; Lykkesfeldt, A. E.; Ditzel, H. J.			Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy	ONCOGENE			English	Article							BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; ANTIESTROGEN RESISTANCE; POSTMENOPAUSAL WOMEN; POOR-PROGNOSIS; C-SRC; GROWTH; LETROZOLE; ER; ACTIVATION	To elucidate the molecular mechanisms of tamoxifen resistance in breast cancer, we performed gene array analyses and identified 366 genes with altered expression in four unique tamoxifen-resistant (TamR) cell lines vs the parental tamoxifen-sensitive MCF-7/S0.5 cell line. Most of these genes were functionally linked to cell proliferation, death and control of gene expression, and include FYN, PRKCA, ITPR1, DPYD, DACH1, LYN, GBP1 and PRLR. Treatment with FYN-specific small interfering RNA or a SRC family kinase inhibitor reduced cell growth of TamR cell lines while exerting no significant effect on MCF-7/S0.5 cells. Moreover, overexpression of FYN in parental tamoxifen-sensitive MCF-7/S0.5 cells resulted in reduced sensitivity to tamoxifen treatment, whereas knockdown of FYN in the FYN-overexpressing MCF-7/S0.5 cells restored sensitivity to tamoxifen, demonstrating growth-and survival-promoting function of FYN in MCF-7 cells. FYN knockdown in TamR cells led to reduced phosphorylation of 14-3-3 and Cdc25A, suggesting that FYN, by activation of important cell cycle-associated proteins, may overcome the anti-proliferative effects of tamoxifen. Evaluation of the subcellular localization of FYN in primary breast tumors from two cohorts of endocrine-treated ER+ breast cancer patients, one with advanced disease (N = 47) and the other with early disease (N = 76), showed that in the former, plasma membrane-associated FYN expression strongly correlated with longer progression-free survival (P < 0.0002). Similarly, in early breast cancer patients, membrane-associated expression of FYN in the primary breast tumor was significantly associated with increased metastasis-free (P < 0.04) and overall (P < 0.004) survival independent of tumor size, grade or lymph node status. Our results indicate that FYN has an important role in tamoxifen resistance, and its subcellular localization in breast tumor cells may be an important novel biomarker of response to endocrine therapy in breast cancer.	[Elias, D.; Vever, H.; Gjerstorff, M. F.; Ditzel, H. J.] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, DK-5000 Odense C, Denmark; [Laenkholm, A-V] Slagelse Hosp, Dept Pathol, Slagelse, Denmark; [Yde, C. W.; Lykkesfeldt, A. E.] Danish Canc Soc Res Ctr, Breast Canc Grp, Cell Death & Metab, Copenhagen, Denmark; [Ditzel, H. J.] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark	University of Southern Denmark; Danish Cancer Society; University of Southern Denmark; Odense University Hospital	Elias, D (corresponding author), Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, JB Winsloewsvej 25, DK-5000 Odense C, Denmark.	delias@health.sdu.dk; hditzel@health.sdu.dk		Ditzel, Henrik J./0000-0003-3927-5135; gjerstorff, morten/0000-0002-0845-1952; Laenkholm, Anne-Vibeke/0000-0003-2166-8686	Danish Cancer Society; Danish Cancer Research Foundation; Danish Research Council; Danish Strategic Research Council; A Race Against Breast Cancer; Sino-Danish Breast Cancer Research Centre; NanoCAN Lundbeck Center of Excellence; Region of Southern Denmark Research Foundation; Odense University Hospital Research Council; Danish Center for Translational Breast Cancer research	Danish Cancer Society(Danish Cancer Society); Danish Cancer Research Foundation; Danish Research Council(Det Frie Forskningsrad (DFF)); Danish Strategic Research Council(Danske Strategiske Forskningsrad (DSF)); A Race Against Breast Cancer; Sino-Danish Breast Cancer Research Centre; NanoCAN Lundbeck Center of Excellence; Region of Southern Denmark Research Foundation; Odense University Hospital Research Council; Danish Center for Translational Breast Cancer research	We thank Lisbet Mortensen and Ole Nielsen at the Department of Pathology, Odense University Hospital, for excellent technical assistance and MK Occhipinti-Bender for editorial assistance. This work was supported in part by the Danish Cancer Society, the Danish Cancer Research Foundation, the Danish Research Council, the Danish Strategic Research Council, A Race Against Breast Cancer, Sino-Danish Breast Cancer Research Centre, NanoCAN Lundbeck Center of Excellence, Region of Southern Denmark Research Foundation, Odense University Hospital Research Council and Danish Center for Translational Breast Cancer research.	Ali HR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3061; Assender JW, 2007, J CLIN PATHOL, V60, P1216, DOI 10.1136/jcp.2006.041616; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bertero T, 2013, CELL DEATH DIFFER, V20, P800, DOI 10.1038/cdd.2013.5; Bilal Erhan, 2010, Genes Cancer, V1, P1063, DOI 10.1177/1947601910395583; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BRIAND P, 1984, CANCER RES, V44, P1114; Browne BC, 2013, FEBS J, V280, P5237, DOI 10.1111/febs.12441; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; Campbell EJ, 2008, BRIT J CANCER, V99, P1769, DOI 10.1038/sj.bjc.6604768; Davies C, 2011, LANCET, V378, P771, DOI 10.1016/S0140-6736(11)60993-8; Elsberger B, 2012, J CANCER RES CLIN, V138, P327, DOI 10.1007/s00432-011-1096-8; Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295; Frankel LB, 2007, BREAST CANCER RES TR, V104, P165, DOI 10.1007/s10549-006-9399-1; Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269; Frogne T, 2005, ENDOCR-RELAT CANCER, V12, P599, DOI 10.1677/erc.1.00946; Frogne T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2230; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Giuliano M, 2011, BREAST, V20, pS42, DOI 10.1016/S0960-9776(11)70293-4; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Henriksen K, 2009, ACTA ONCOL, V48, P522, DOI 10.1080/02841860802676383; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Ito Y, 2002, BREAST CANCER RES TR, V76, P261, DOI 10.1023/A:1020860221099; JOHNSTON SRD, 1995, CANCER RES, V55, P3331; Jordan NJ, 2004, BREAST CANCER RES TR, V87, P167, DOI 10.1023/B:BREA.0000041623.21338.47; Leth-Larsen R, 2009, MOL CELL PROTEOMICS, V8, P1436, DOI 10.1074/mcp.M800061-MCP200; Lundholt BK, 2001, BREAST CANCER RES TR, V67, P199, DOI 10.1023/A:1017977406429; LYKKESFELDT AE, 1994, CANCER RES, V54, P1587; LYKKESFELDT AE, 1986, BRIT J CANCER, V53, P29, DOI 10.1038/bjc.1986.5; Madsen MW, 1997, CANCER RES, V57, P585; Masri S, 2008, CANCER RES, V68, P4910, DOI 10.1158/0008-5472.CAN-08-0303; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454; Morgan L, 2009, CANCER BIOL THER, V8, P1550, DOI 10.4161/cbt.8.16.8954; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Mouridsen H, 2007, J CLIN ONCOL, V25, P5715, DOI 10.1200/JCO.2007.12.1665; Mouridsen Henning T, 2005, MedGenMed, V7, P20; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nehra R, 2010, FASEB J, V24, P2040, DOI 10.1096/fj.09-138305; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pancholi S, 2008, ENDOCR-RELAT CANCER, V15, P985, DOI 10.1677/ERC-07-0240; Rasmussen BB, 2008, LANCET ONCOL, V9, P23, DOI 10.1016/S1470-2045(07)70386-8; Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879; Schiff R, 2004, CLIN CANCER RES, V10, p331S, DOI 10.1158/1078-0432.CCR-031212; Schrecengost RS, 2007, CANCER RES, V67, P6174, DOI 10.1158/0008-5472.CAN-06-3455; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sun M, 2001, CANCER RES, V61, P5985; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; Xu XD, 2003, CLIN CANCER RES, V9, P1764; Yde CW, 2012, BREAST CANCER RES TR, V135, P67, DOI 10.1007/s10549-012-2053-1	54	56	57	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1919	1927		10.1038/onc.2014.138	http://dx.doi.org/10.1038/onc.2014.138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882577				2022-12-17	WOS:000352725600006
J	Rajbhandari, P; Schalper, KA; Solodin, NM; Ellison-Zelski, SJ; Lu, KP; Rimm, DL; Alarid, ET				Rajbhandari, P.; Schalper, K. A.; Solodin, N. M.; Ellison-Zelski, S. J.; Lu, K. Ping; Rimm, D. L.; Alarid, E. T.			Pin1 modulates ER alpha levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation	ONCOGENE			English	Article						breast cancer; E3 ligase; proteasome; survival	ESTROGEN-RECEPTOR-ALPHA; PROLYL ISOMERASE PIN1; GENE-EXPRESSION; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; DIFFERENTIAL REGULATION; E6-ASSOCIATED PROTEIN; TAMOXIFEN RESISTANCE; DOWN-REGULATION	Estrogen receptor-alpha (ER alpha) is an important biomarker used to classify and direct therapy decisions in breast cancer (BC). Both ER alpha protein and its transcript, ESR1, are used to predict response to tamoxifen therapy, yet certain tumors have discordant levels of ER alpha protein and ESR1, which is currently unexplained. Cellular ER alpha protein levels can be controlled post-translationally by the ubiquitin-proteasome pathway through a mechanism that depends on phosphorylation at residue S118. Phospho-S118 (pS118-ER alpha) is a substrate for the peptidyl prolyl isomerase, Pin1, which mediates cis-trans isomerization of the pS118-P119 bond to enhance ER alpha transcriptional function. Here, we demonstrate that Pin1 can increase ER alpha protein without affecting ESR1 transcript levels by inhibiting proteasome-dependent receptor degradation. Pin1 disrupts ER alpha ubiquitination by interfering with receptor interactions with the E3 ligase, E6AP, which also is shown to bind pS118-ER alpha. Quantitative in situ assessments of ER alpha protein, ESR1, and Pin1 in human tumors from a retrospective cohort show that Pin1 levels correlate with ER alpha protein but not to ESR1 levels. These data show that ER alpha protein is post-translationally regulated by Pin1 in a proportion of breast carcinomas. As Pin1 impacts both ER alpha protein levels and transactivation function, these data implicate Pin1 as a potential surrogate marker for predicting outcome of ER alpha-positive BC.	[Rajbhandari, P.; Solodin, N. M.; Ellison-Zelski, S. J.; Alarid, E. T.] Univ Wisconsin, UW Carbone Comprehens Canc Ctr, Dept Oncol, Madison, WI 53705 USA; [Schalper, K. A.; Rimm, D. L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Lu, K. Ping] Harvard Univ, Sch Med, Dept Med, Canc Biol Program,Beth Isreal Deaconess Med Ctr, Boston, MA USA	University of Wisconsin System; University of Wisconsin Madison; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rajbhandari, P (corresponding author), Univ Wisconsin, UW Carbone Comprehens Canc Ctr, Dept Oncol, Wisconsin Inst Med Res 6151, Madison, WI 53705 USA.	alarid@oncology.wisc.edu		Rajbhandari, Prashant/0000-0002-8146-3861; Rimm, David/0000-0001-5820-4397	NIH [CA159578, T32 CA009135]; Genoptix/Novartis; NATIONAL CANCER INSTITUTE [R01CA159578, T32CA009135] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genoptix/Novartis; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank McArdle Laboratories for Cancer Research for support of this project. We also thank the UW Carbone Comprehensive Cancer Center (UWCCC) for use of its shared services to complete this research. We thank Drs Pierre Chambon, Vladimir Spiegelman, Robert Kalejta and Greg Finn for providing us appropriate expression plasmids and reagents. We also thank Dr Wei Xu for insightful comments. This work was supported by NIH grants CA159578 (to E.T.A.) and T32 CA009135 (to P.R.) and a sponsored research award from Genoptix/Novartis (to D.R.).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Atsriku C, 2009, MOL CELL PROTEOMICS, V8, P467, DOI 10.1074/mcp.M800282-MCP200; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bordeaux JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036559; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Chen HZ, 2012, ONCOGENE, V31, P2876, DOI 10.1038/onc.2011.463; Cheng JW, 2007, ENDOCRINOLOGY, V148, P4634, DOI 10.1210/en.2007-0148; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Duplessis TT, 2011, ENDOCRINOLOGY, V152, P2517, DOI 10.1210/en.2010-1281; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Faus H, 2006, BIOMED PHARMACOTHER, V60, P520, DOI 10.1016/j.biopha.2006.07.082; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Frech MS, 2005, CANCER RES, V65, P681; Fujimoto Y, 2010, J BIOL CHEM, V285, P3126, DOI 10.1074/jbc.M109.055095; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Gong Y, 2007, LANCET ONCOL, V8, P203, DOI 10.1016/S1470-2045(07)70042-6; Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655; Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Kato K, 1997, ONCOGENE, V15, P3037, DOI 10.1038/sj.onc.1201497; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Khanal P, 2012, ONCOGENE, V31, P3845, DOI 10.1038/onc.2011.548; Kim C, 2011, J CLIN ONCOL, V29, P4160, DOI 10.1200/JCO.2010.32.9615; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Li L, 2006, J BIOL CHEM, V281, P1978, DOI 10.1074/jbc.M508545200; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2007, NAT CHEM BIOL, V3, P619, DOI 10.1038/nchembio.2007.35; Lu PJ, 1999, NATURE, V399, P784; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakajima A, 2007, BIOCHEM BIOPH RES CO, V357, P245, DOI 10.1016/j.bbrc.2007.03.134; Namgoong GM, 2010, J BIOL CHEM, V285, P23829, DOI 10.1074/jbc.M109.092874; Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281; Pulikkan JA, 2010, LEUKEMIA, V24, P914, DOI 10.1038/leu.2010.37; Rajbhandari P, 2012, MOL CELL BIOL, V32, P445, DOI 10.1128/MCB.06073-11; Ramamoorthy S, 2008, NUCL RECEPT SIGNAL, V6, pe006; Ramamoorthy S, 2012, BREAST CANCER RES TR, V132, P97, DOI 10.1007/s10549-011-1567-2; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Stanya KJ, 2008, J CELL BIOL, V183, P49, DOI 10.1083/jcb.200806172; Sun J, 2012, MOL ENDOCRINOL, V26, P1567, DOI 10.1210/me.2012-1140; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Wang YL, 2009, J BIOCHEM, V145, P331, DOI 10.1093/jb/mvn177; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Welsh AW, 2011, J CLIN ONCOL, V29, P2978, DOI 10.1200/JCO.2010.32.9706; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang QY, 2009, J BIOL CHEM, V284, P23980, DOI 10.1074/jbc.M109.022814; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	72	56	58	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1438	1447		10.1038/onc.2013.78	http://dx.doi.org/10.1038/onc.2013.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542176	Green Accepted			2022-12-17	WOS:000332943500011
J	Wolff, F; Loipetzberger, A; Gruber, W; Esterbauer, H; Aberger, F; Frischauf, AM				Wolff, F.; Loipetzberger, A.; Gruber, W.; Esterbauer, H.; Aberger, F.; Frischauf, A. M.			Imiquimod directly inhibits Hedgehog signalling by stimulating adenosine receptor/protein kinase A-mediated GLI phosphorylation	ONCOGENE			English	Article						Gli; imiquimod; basal cell carcinoma; Hedgehog signalling; adenosine receptor	BASAL-CELL CARCINOMAS; IMMUNE-RESPONSE; PROTEIN; PATHWAY; ACTIVATION; RECEPTORS; EXPRESSION; GENE; TRANSDUCTION; MANIPULATION	Imiquimod (IMQ), a nucleoside analogue of the imidazoquinoline family, is used in the topical treatment of basal cell carcinoma (BCC) and other skin diseases. It is reported to be a TLR7 and TLR8 agonist and, as such, initiates a Th1 immune response by activating sentinel cells in the vicinity of the tumour. BCC is a hedgehog (HH)-driven malignancy with oncogenic glioma-associated oncogene (GLI) signalling activated in a ligand-independent manner. Here we show that IMQ can also directly repress HH signalling by negatively modulating GLI activity in BCC and medulloblastoma cells. Further, we provide evidence that the repressive effect of IMQ on HH signalling is not dependent on TLR/MYD88 signalling. Our results suggest a mechanism for IMQ engaging adenosine receptors (ADORAs) to control GLI signalling. Pharmacological activation of ADORA with either an ADORA agonist or IMQ resulted in a protein kinase A (PKA)-mediated GLI phosphorylation and reduction in GLI activator levels. The activation of PKA and HH pathway target gene downregulation in response to IMQ were abrogated by ADORA inhibition. Furthermore, activated Smoothened signalling, which positively signals to GLI transcription factors, could be effectively counteracted by IMQ. These results reveal a previously unknown mode of action of IMQ in the treatment of BCC and also suggest a role for ADORAs in the regulation of oncogenic HH signalling.	[Wolff, F.; Loipetzberger, A.; Gruber, W.; Aberger, F.; Frischauf, A. M.] Salzburg Univ, Dept Mol Biol, A-5020 Salzburg, Austria; [Esterbauer, H.] Med Univ Vienna, Dept Lab Med, Vienna, Austria	Salzburg University; Medical University of Vienna	Frischauf, AM (corresponding author), Salzburg Univ, Dept Mol Biol, Hellbrunner Str 34, A-5020 Salzburg, Austria.	fritz.aberger@sbg.ac.at; annemarie.frischauf@sbg.ac.at	Aberger, Fritz/B-6357-2012; Wolff, Florian/L-4090-2015	Aberger, Fritz/0000-0003-2009-6305; Wolff, Florian/0000-0001-7271-0317; Esterbauer, Harald/0000-0001-7343-7455	international PhD programme Immunity in Cancer and Allergy (ICA) from the Austrian Science fund (FWF); FWF project [P20652]; Austrian Genome Programme GEN-AU; priority program Biosciences and Health of the University of Salzburg; Austrian Academy of Sciences (OAW)	international PhD programme Immunity in Cancer and Allergy (ICA) from the Austrian Science fund (FWF); FWF project(Austrian Science Fund (FWF)); Austrian Genome Programme GEN-AU; priority program Biosciences and Health of the University of Salzburg; Austrian Academy of Sciences (OAW)	We are especially thankful to Dr Matt Scott for providing the SMOM2 construct and to Dr Peter Hammerl for help with murine splenocytes. We are also grateful to Dr Maria Sibilia for the help with the use of IMQ treatment. Furthermore, we are grateful to Sabine Siller for excellent technical support. This work was supported by the international PhD programme Immunity in Cancer and Allergy (ICA) from the Austrian Science fund (FWF), the FWF project P20652, the Austrian Genome Programme GEN-AU and the priority program Biosciences and Health of the University of Salzburg. AL received a PhD Doc-fForte fellowship from the Austrian Academy of Sciences (OAW). We are grateful to Dr Sandra Laner-Plamberger for help with analysis of BCC and skin samples.	Altaba ARI, 2008, CANCER CELL, V14, P281, DOI 10.1016/j.ccr.2008.09.007; Ambach A, 2004, MOL IMMUNOL, V40, P1307, DOI 10.1016/j.molimm.2004.01.002; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Atwood SX, 2012, J CELL BIOL, V199, P193, DOI 10.1083/jcb.201207140; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Buttitta L, 2003, DEVELOPMENT, V130, P6233, DOI 10.1242/dev.00851; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dlugosz A, 2012, NAT REV DRUG DISCOV, V11, P437, DOI 10.1038/nrd3753; Drobits B, 2012, J CLIN INVEST, V122, P575, DOI 10.1172/JCI61034; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020; Gotschel F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065403; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Ingham PW, 2011, NAT REV GENET, V12, P393, DOI 10.1038/nrg2984; JACOBSEN PF, 1985, J NEUROPATH EXP NEUR, V44, P472, DOI 10.1097/00005072-198509000-00003; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Jahnisch H, 2013, CANCER LETT, V335, P119, DOI 10.1016/j.canlet.2013.02.003; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2012, J CLIN INVEST, V122, P455, DOI 10.1172/JCI58779; Kasper Maria, 2007, V397, P67; Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x; Lacarrubba F, 2011, J DERMATOL TREAT, V22, P353, DOI 10.3109/09546634.2010.548503; Lear JT, 2012, NEW ENGL J MED, V366, P2225, DOI 10.1056/NEJMe1202170; Lebre MC, 2007, J INVEST DERMATOL, V127, P331, DOI 10.1038/sj.jid.5700530; Liem KF, 2009, P NATL ACAD SCI USA, V106, P13377, DOI 10.1073/pnas.0906944106; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Mondal BC, 2011, CELL, V147, P1589, DOI 10.1016/j.cell.2011.11.041; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Pan Y, 2009, DEV BIOL, V326, P177, DOI 10.1016/j.ydbio.2008.11.009; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rohatgi R, 2009, P NATL ACAD SCI USA, V106, P3196, DOI 10.1073/pnas.0813373106; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Schon MP, 2007, BRIT J DERMATOL, V157, P8, DOI 10.1111/j.1365-2133.2007.08265.x; Schon MP, 2006, J INVEST DERMATOL, V126, P1338, DOI 10.1038/sj.jid.5700286; Schon M, 2003, J NATL CANCER I, V95, P1138, DOI 10.1093/jnci/djg016; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smith V, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/380371; So PL, 2006, EXP DERMATOL, V15, P742, DOI 10.1111/j.1600-0625.2006.00465.x; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Tang JY, 2012, NEW ENGL J MED, V366, P2180, DOI 10.1056/NEJMoa1113538; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Teperino R, 2012, CELL, V151, P414, DOI 10.1016/j.cell.2012.09.021; Toriyama M, 2012, J BIOL CHEM, V287, P12691, DOI 10.1074/jbc.M111.316307; Trincavelli ML, 2010, CURR TOP MED CHEM, V10, P860, DOI 10.2174/156802610791268756; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang Y, 2009, P NATL ACAD SCI USA, V106, P2623, DOI 10.1073/pnas.0812110106; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Zeng HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015900	68	56	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5574	5581		10.1038/onc.2013.343	http://dx.doi.org/10.1038/onc.2013.343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23995793	Green Published, hybrid			2022-12-17	WOS:000328461400002
J	Rohwer, N; Zasada, C; Kempa, S; Cramer, T				Rohwer, N.; Zasada, C.; Kempa, S.; Cramer, T.			The growing complexity of HIF-1 alpha's role in tumorigenesis: DNA repair and beyond	ONCOGENE			English	Review						HIF-alpha; cancer; hypoxia; metabolism; DNA-damage response; tumour heterogeneity	HYPOXIA-INDUCIBLE FACTOR-1; ENDOTHELIAL GROWTH-FACTOR; CANCER-CELLS; TRANSCRIPTIONAL ACTIVITY; GASTRIC CARCINOGENESIS; INDUCED ACCUMULATION; GLUCOSE-METABOLISM; VEGF EXPRESSION; GENE-EXPRESSION; DAMAGE RESPONSE	Lack of oxygen (hypoxia) is a central hallmark of cancer and a pivotal driving force of malignant progression. Transcriptional activators of the hypoxia-inducible factor a (HIF alpha) family represent the principal molecular mediators of hypoxia under both physiological and pathophysiological conditions. While HIF-2 alpha is expressed in a tissue-and cell-type-restricted manner, stabilization of HIF-1 alpha was reported in tumours of widely different origin, and functional analyses led to the perception of HIF-1 alpha as an oncoprotein. In this review, we aim to acknowledge HIF alpha's growing complexity by outlining its functional relevance for genomic integrity and tumour heterogeneity, two features of paramount importance for basic and clinical oncology. Pharmaceutical companies around the globe are ambitiously hunting for HIF-1 alpha-inhibiting compounds, some of which are currently being evaluated in phase 1 trials. To avoid the rather disappointing clinical efficacy emblematic of most targeted therapeutics, potential resistance mechanisms of, as well as potential combination partners for, HIF-1 alpha-inhibiting drugs should be evaluated. In this regard, the interrelation of HIF-1 alpha with genomic integrity and tumour heterogeneity offers ample possibilities, potentially resulting in more efficient clinical translation of HIF-1 alpha's pathobiology.	[Rohwer, N.; Cramer, T.] Charite, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; [Zasada, C.; Kempa, S.] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Berlin, Germany; [Cramer, T.] Charite, Mol Krebsforsch Zentrum, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Cramer, T (corresponding author), Charite, Med Klin Schwerpunkt Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	thorsten.cramer@charite.de	kempa, stefan/C-5213-2008; Cramer, Thorsten/S-2479-2016	kempa, stefan/0000-0002-0696-9299; Cramer, Thorsten/0000-0002-6462-239X; Zasada, Christin/0000-0003-1547-8317; Rohwer, Nadine/0000-0001-6170-1327	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; Bundesministerium fur Bildung und Forschung; Cancer Research United Kingdom; Senate of Berlin	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Cancer Research United Kingdom(Cancer Research UK); Senate of Berlin	Research in the Cramer laboratory is supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, the Bundesministerium fur Bildung und Forschung and (in collaboration) Cancer Research United Kingdom. Stefan Kempa received funding by the Bundesministerium fur Bildung und Forschung and the Senate of Berlin. We thank the members of our laboratories and our collaborators for helpful discussions.	Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Anderson CJ, 2006, ONCOGENE, V25, P61, DOI 10.1038/sj.onc.1209011; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bertheau P, 1998, J CLIN PATHOL, V51, P370, DOI 10.1136/jcp.51.5.370; Bertout JA, 2009, P NATL ACAD SCI USA, V106, P14391, DOI 10.1073/pnas.0907357106; Biswas S, 2010, J ONCOL, V2010, DOI 10.1155/2010/757908; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; BROWN JM, 1979, BRIT J RADIOL, V52, P650, DOI 10.1259/0007-1285-52-620-650; Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHAPLIN DJ, 1987, CANCER RES, V47, P597; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Coussens M, 2010, P NATL ACAD SCI USA, V107, P13842, DOI 10.1073/pnas.0913834107; Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556; Daskalow K, 2010, J MOL MED, V88, P817, DOI 10.1007/s00109-010-0623-4; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denekamp J, 1999, ACTA ONCOL, V38, P903, DOI 10.1080/028418699432590; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Evans SM, 2001, AM J CLIN ONCOL-CANC, V24, P467, DOI 10.1097/00000421-200110000-00011; Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41; Fojo T, 2010, CLIN CANCER RES, V16, P5972, DOI 10.1158/1078-0432.CCR-10-1277; Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0; Frezza C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024411; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths EA, 2008, BRIT J CANCER, V98, P965, DOI 10.1038/sj.bjc.6604210; Griffiths EA, 2007, BRIT J CANCER, V96, P95, DOI 10.1038/sj.bjc.6603524; Guo SH, 2009, J NEUROCHEM, V108, P1309, DOI 10.1111/j.1471-4159.2009.05877.x; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Huang LE, 2007, J MOL MED, V85, P139, DOI 10.1007/s00109-006-0133-6; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Jacobs T, 1996, LAB INVEST, V74, P88; KALLINOWSKI F, 1987, J CANCER RES CLIN, V113, P209, DOI 10.1007/BF00396375; Kang HJ, 2006, J BIOL CHEM, V281, P13047, DOI 10.1074/jbc.M513033200; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lienard BM, 2008, CHEM COMMUN, P6393, DOI 10.1039/b814440k; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Loenarz C, 2011, TRENDS BIOCHEM SCI, V36, P7, DOI 10.1016/j.tibs.2010.07.002; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Losso JN, 2005, J AGR FOOD CHEM, V53, P3751, DOI 10.1021/jf0479719; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Martinez-Romero R, 2008, J CELL BIOCHEM, V104, P2248, DOI 10.1002/jcb.21781; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Melvin A, 2012, CELL SIGNAL, V24, P35, DOI 10.1016/j.cellsig.2011.08.019; Merighi S, 2007, MOL PHARMACOL, V72, P395, DOI 10.1124/mol.106.032920; Nanduri J, 2009, P NATL ACAD SCI USA, V106, P1199, DOI 10.1073/pnas.0811018106; Nilsson H, 2005, EXP CELL RES, V303, P447, DOI 10.1016/j.yexcr.2004.10.003; Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004; Palayoor ST, 2003, CLIN CANCER RES, V9, P3150; Peng YJ, 2006, J PHYSIOL-LONDON, V577, P705, DOI 10.1113/jphysiol.2006.114033; Rajendran JG, 2004, CLIN CANCER RES, V10, P2245, DOI 10.1158/1078-0432.CCR-0688-3; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Reinhold H S, 1977, Bibl Anat, P270; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Rohwer N, 2009, BRIT J CANCER, V100, P772, DOI 10.1038/sj.bjc.6604919; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038; Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Sendoel A, 2010, NATURE, V465, P577, DOI 10.1038/nature09141; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; Sullivan R, 2009, MOL CANCER THER, V8, P1702, DOI 10.1158/1535-7163.MCT-08-1090; Takiyama Y, 2011, DIABETES, V60, P981, DOI 10.2337/db10-0655; Thomas R, 2005, BIOCHEM BIOPH RES CO, V334, P543, DOI 10.1016/j.bbrc.2005.06.114; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; van der Groep P, 2008, BREAST CANCER RES TR, V111, P475, DOI 10.1007/s10549-007-9817-z; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Wamelink M, 2008, J INHERIT METAB DIS, V31, P703, DOI 10.1007/s10545-008-1015-6; Wang F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010002; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231; Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192; YAMAURA H, 1979, INT J RADIAT BIOL, V35, P201, DOI 10.1080/09553007914550241; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yuan GX, 2005, J BIOL CHEM, V280, P4321, DOI 10.1074/jbc.M407706200; Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198; Zhu XY, 2008, LIFE SCI, V83, P801, DOI 10.1016/j.lfs.2008.09.029	112	56	62	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3569	3576		10.1038/onc.2012.510	http://dx.doi.org/10.1038/onc.2012.510			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	23160373				2022-12-17	WOS:000322638400001
J	Yu, J; Liang, QY; Wang, J; Cheng, Y; Wang, S; Poon, TCW; Go, MYY; Tao, Q; Chang, Z; Sung, JJY				Yu, J.; Liang, Q. Y.; Wang, J.; Cheng, Y.; Wang, S.; Poon, T. C. W.; Go, M. Y. Y.; Tao, Q.; Chang, Z.; Sung, J. J. Y.			Zinc-finger protein 331, a novel putative tumor suppressor, suppresses growth and invasiveness of gastric cancer	ONCOGENE			English	Article						Zinc-finger protein 331 (ZNF331); gastric cancer; tumor suppressor; methylation; invasion; 2-D gel electrophoresis	HUMAN POLYNUCLEOTIDE PHOSPHORYLASE; CPG ISLAND METHYLATION; ZINC-FINGER PROTEINS; DEAD-BOX PROTEINS; POTENTIAL TARGET; CELL-GROWTH; GENE; REPRESSION; HPNPASE(OLD-35); INVOLVEMENT	Zinc-finger protein 331 (ZNF331), a Kruppel-associated box zinc-finger protein gene, was identified as a putative tumor suppressor in our previous study. However, the role of ZNF331 in tumorigenesis remains elusive. We aimed to clarify its epigenetic regulation and biological functions in gastric cancer. ZNF331 was silenced or downregulated in 71% (12/17) gastric cancer cell lines. A significant downregulation was also detected in paired gastric tumors compared with adjacent non-cancer tissues. In contrast, ZNF331 was readily expressed in various normal adult tissues. The downregulation of ZNF331 was closely linked to the promoter hypermethylation as evidenced by methylation-specific PCR, bisulfite genomic sequencing and reexpression by demethylation agent treatment. DNA sequencing showed no genetic mutation/deletion of ZNF331 in gastric cancer cell lines. Ectopic expression of ZNF331 in the silenced cancer cell lines MKN28 and HCT116 significantly reduced colony formation and cell viability, induced cell cycle arrests and repressed cell migration and invasive ability. Concordantly, knockdown of ZNF331 increased cell viability and colony formation ability of gastric cancer cell line MKN45. Two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomic approach were applied to analyze the molecular basis of the biological functions of ZNF331. In all, 10 downstream targets of ZNF331 were identified to be associated with regulation of cell growth and metastasis. The tumor-suppressive effect of ZNF331 is mediated at least by downregulation of genes involved in cell growth promotion (DSTN, EIF5A, GARS, DDX5, STAM, UQCRFS1 and SET) and migration/invasion (DSTN and ACTR3), and upregulation of genome-stability gene (SSBP1) and cellular senescence gene (PNPT1). A novel target of ZNF331 (DSTN) was functionally validated. Overexpression of DSTN in BGC-823 cells increased colony formation and migration ability. In conclusion, our results suggest that ZNF331 possesses important functions for the suppression of gastric carcinogenesis as a novel functional tumor-suppressor gene. Oncogene (2013) 32, 307-317; doi:10.1038/onc.2012.54; published online 27 February 2012	[Yu, J.; Liang, Q. Y.; Wang, J.; Wang, S.; Poon, T. C. W.; Go, M. Y. Y.; Sung, J. J. Y.] Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Cheng, Y.; Tao, Q.] Chinese Univ Hong Kong, Dept Clin Oncol, Canc Epigenet Lab, Shatin, Hong Kong, Peoples R China; [Chang, Z.] Tsinghua Univ, State Key Lab Biomembrane & Membrane Biotechnol, Natl Engn Lab Antitumor Therapeut, Sch Med, Beijing 100084, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Tsinghua University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk; jjysung@cuhk.edu.hk	Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Cheng, Yingduan/J-5507-2015; Liang, Qiaoyi Jessie/G-9612-2019; WANG, JIA/A-2799-2019; Chang, Zhijie/AAH-8109-2019; Tao, Qian/T-4743-2018	Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Liang, Qiaoyi Jessie/0000-0001-8496-3442; Tao, Qian/0000-0001-5383-4808; WANG, JIA/0000-0001-5339-8954	National Basic Research Program of China (973 Program) [2010CB529305]; Research Grants Council RGC CERG CUHK [473008]; CUHK Focused Investment Grant [1903026]; RFCID [10090942, 11100022]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); Research Grants Council RGC CERG CUHK; CUHK Focused Investment Grant; RFCID	This project was supported by the National Basic Research Program of China (973 Program, 2010CB529305), Research Grants Council RGC CERG CUHK (473008), CUHK Focused Investment Grant (1903026) and RFCID (10090942, 11100022).	Anazawa Y, 2005, CANCER RES, V65, P4578, DOI 10.1158/0008-5472.CAN-04-4564; Choi YJ, 2012, J CELL BIOCHEM, V113, P985, DOI 10.1002/jcb.23428; Estornes Y, 2007, INT J CANCER, V121, P2162, DOI 10.1002/ijc.22911; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fredericks WJ, 2000, MOL CELL BIOL, V20, P5019, DOI 10.1128/MCB.20.14.5019-5031.2000; Freist W, 1996, BIOL CHEM H-S, V377, P343; Huang J, 2009, MOL CELL, V35, P384, DOI 10.1016/j.molcel.2009.06.011; Jalal C, 2007, NUCLEIC ACIDS RES, V35, P3590, DOI 10.1093/nar/gkm058; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Jasiulionis MG, 2007, CELL BIOCHEM FUNCT, V25, P109, DOI 10.1002/cbf.1351; Kaneko SJ, 2003, GYNECOL ONCOL, V90, P29, DOI 10.1016/S0090-8258(03)00144-6; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lee JH, 2004, ONCOGENE, V23, P4646, DOI 10.1038/sj.onc.1207588; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Leung SY, 2006, MODERN PATHOL, V19, P854, DOI 10.1038/modpathol.3800593; Li G, 2009, PROTEOMICS, V9, P20, DOI 10.1002/pmic.200701195; Li LL, 2010, CLIN CANCER RES, V16, P2949, DOI 10.1158/1078-0432.CCR-09-3178; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; Meiboom M, 2003, CYTOGENET GENOME RES, V101, P113, DOI 10.1159/000074165; Ohashi Y, 2004, GYNECOL ONCOL, V93, P54, DOI 10.1016/j.ygyno.2004.01.019; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; PENNACCHIO LA, 1995, GENE, V155, P207, DOI 10.1016/0378-1119(94)00683-J; Pollard KS, 2008, HUM GENET, V122, P625, DOI 10.1007/s00439-007-0440-1; Rippe V, 1999, GENE CHROMOSOME CANC, V26, P229, DOI 10.1002/(SICI)1098-2264(199911)26:3<229::AID-GCC7>3.0.CO;2-J; Sarkar D, 2005, MOL CELL BIOL, V25, P7333, DOI 10.1128/MCB.25.16.7333-7343.2005; Sarkar D, 2003, J BIOL CHEM, V278, P24542, DOI 10.1074/jbc.M302421200; Sohn JH, 2010, MOL CANCER RES, V8, P246, DOI 10.1158/1541-7786.MCR-09-0141; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; TIRANTI V, 1995, GENOMICS, V25, P559, DOI 10.1016/0888-7543(95)80058-T; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Wu H, 2001, BBA-GENE STRUCT EXPR, V1518, P190, DOI 10.1016/S0167-4781(01)00172-5; Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421	35	56	61	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2013	32	3					307	317		10.1038/onc.2012.54	http://dx.doi.org/10.1038/onc.2012.54			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370639				2022-12-17	WOS:000314736600005
J	Cork, SM; Kaur, B; Devi, NS; Cooper, L; Saltz, JH; Sandberg, EM; Kaluz, S; Van Meir, EG				Cork, S. M.; Kaur, B.; Devi, N. S.; Cooper, L.; Saltz, J. H.; Sandberg, E. M.; Kaluz, S.; Van Meir, E. G.			A proprotein convertase/MMP-14 proteolytic cascade releases a novel 40 kDa vasculostatin from tumor suppressor BAI1	ONCOGENE			English	Article						angiogenesis; cancer; brain; glioma	BRAIN-SPECIFIC ANGIOGENESIS; IN-VIVO ANGIOGENESIS; COLORECTAL-CANCER; TYPE-1 REPEATS; P53 EXPRESSION; CELL-ADHESION; INHIBITOR-1; PROTEIN; FURIN; GENE	Brain-specific angiogenesis inhibitor 1 (BAI1), an orphan G protein-coupled receptor-type seven transmembrane protein, was recently found mutated or silenced in multiple human cancers and can interfere with tumor growth when overexpressed. Yet, little is known about its regulation and the molecular mechanisms through which this novel tumor suppressor exerts its anticancer effects. Here, we demonstrate that the N terminus of BAI1 is cleaved extracellularly to generate a truncated receptor and a 40-kDa fragment (Vasculostatin-40) that inhibits angiogenesis. We demonstrate that this novel proteolytic processing event depends on a two-step cascade of protease activation: proprotein convertases, primarily furin, activate latent matrix metalloproteinase-14, which then directly cleaves BAI1 to release the bioactive fragment. These findings significantly augment our knowledge of BAI1 by showing a novel post-translational mechanism regulating BAI1 activity through cancer-associated proteases, have important implications for BAI1 function and regulation, and present novel opportunities for therapy of cancer and other vascular diseases. Oncogene (2012) 31, 5144-5152; doi:10.1038/onc.2012.1; published online 13 February 2012	[Saltz, J. H.; Kaluz, S.; Van Meir, E. G.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA; [Cork, S. M.; Kaur, B.; Devi, N. S.; Sandberg, E. M.; Kaluz, S.; Van Meir, E. G.] Emory Univ, Sch Med, Dept Neurosurg, Lab Mol Neurooncol, Atlanta, GA 30322 USA; [Cooper, L.; Saltz, J. H.] Emory Univ, Ctr Comprehens Informat, Atlanta, GA 30322 USA; [Van Meir, E. G.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, 1365C Clifton Rd NE,Room C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	kaur, Balveen/E-3355-2011	Van Meir, Erwin G./0000-0003-2444-7707; Kaluz, Stefan/0000-0002-6273-3766	US National Institutes of Health [R01 CA86335, 29XS193]; Winship Cancer Institute [P30 CA138292]; Emory Neurosciences Initiative; NATIONAL CANCER INSTITUTE [P30CA138292, R01CA086335, R01CA150153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064607, P30NS045758] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Winship Cancer Institute; Emory Neurosciences Initiative; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Paper contributions. SMC performed Vstat40 characterization, angiogenesis, cleavage site detection and furin/MMP-14 protease identification experiments, and SMC and EGVM wrote the manuscript. NSD, BK, EMS and SK performed Vstat40 and protease identification experiments. LC and JHS performed the survival analysis. Experiments were conceived of and planned by the respective authors under the direction of EGVM. We appreciate the helpful advice and assistance of all members of the Laboratory of Molecular Neuro-Oncology. SMC was in the Emory graduate program in Neuroscience and acknowledges project guidance by her thesis committee (Drs Randy Hall, Robert McKeon, Paula Vertino and Wei Zhou). We thank Dr C Dubois (Universitede Sherbrooke) for the kind gift of LoVo cells. The US National Institutes of Health (R01 CA86335 to EGVM and contract 29XS193 to JHS), P30 CA138292 (to the Winship Cancer Institute) and the Emory Neurosciences Initiative (to EGVM) contributed to the funding of this research.	Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; BECKSICKINGER AG, 1992, EUR J BIOCHEM, V206, P957, DOI 10.1111/j.1432-1033.1992.tb17006.x; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cork SM, 2011, J MOL MED, V89, P743, DOI 10.1007/s00109-011-0759-x; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Duckert P, 2004, PROTEIN ENG DES SEL, V17, P107, DOI 10.1093/protein/gzh013; Duda DG, 2002, BRIT J CANCER, V86, P490, DOI 10.1038/sj.bjc.6600067; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Fukushima Y, 1998, INT J ONCOL, V13, P967; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Gupta K, 1999, Angiogenesis, V3, P147, DOI 10.1023/A:1009018702832; Hardcastle J, 2010, MOL THER, V18, P285, DOI 10.1038/mt.2009.232; Hatanaka H, 2000, INT J MOL MED, V5, P181; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Hsiao CC, 2009, FEBS LETT, V583, P3285, DOI 10.1016/j.febslet.2009.09.001; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Jin ZH, 2007, HUM MOL GENET, V16, P1972, DOI 10.1093/hmg/ddm144; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kaur B, 2005, ONCOGENE, V24, P3632, DOI 10.1038/sj.onc.1208317; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Kaur B, 2009, CANCER RES, V69, P1212, DOI 10.1158/0008-5472.CAN-08-1166; Klenotic PA, 2010, AM J PATHOL, V176, P2039, DOI 10.2353/ajpath.2010.090782; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Kudo S, 2007, ONCOL REP, V18, P785; Lin HH, 2004, J BIOL CHEM, V279, P31823, DOI 10.1074/jbc.M402974200; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; Nam DH, 2004, ONCOL REP, V11, P863; Nicholson AC, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-11; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Park D, 2007, NATURE, V450, P430, DOI 10.1038/nature06329; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; Yoon KC, 2005, GENE THER, V12, P617, DOI 10.1038/sj.gt.3302442; Yoshida Y, 1999, INT J ONCOL, V15, P1221; Zhang XF, 2007, MICROVASC RES, V74, P90, DOI 10.1016/j.mvr.2007.04.007; Zhu D, 2011, CANCER RES, V71, P5859, DOI 10.1158/0008-5472.CAN-11-1157	46	56	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5144	5152		10.1038/onc.2012.1	http://dx.doi.org/10.1038/onc.2012.1			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22330140	Green Accepted			2022-12-17	WOS:000312449800003
J	Li, L; Ying, J; Li, H; Zhang, Y; Shu, X; Fan, Y; Tan, J; Cao, Y; Tsao, SW; Srivastava, G; Chan, ATC; Tao, Q				Li, L.; Ying, J.; Li, H.; Zhang, Y.; Shu, X.; Fan, Y.; Tan, J.; Cao, Y.; Tsao, S. W.; Srivastava, G.; Chan, A. T. C.; Tao, Q.			The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas	ONCOGENE			English	Article						cadherin; CDH11; tumor suppressor gene; methylation; carcinoma	EPITHELIAL-MESENCHYMAL TRANSITION; PROSTATE-CANCER CELLS; ABERRANT METHYLATION; GASTRIC-CANCER; NASOPHARYNGEAL CARCINOMA; MULTIPLE CARCINOMAS; COLORECTAL-CANCER; MYELOID-LEUKEMIA; PROMOTER REGION; LUNG CARCINOMAS	Genetic alterations of 16q21-q22, the locus of a 6-cadherin cluster, are frequently involved in multiple tumors, suggesting the presence of critical tumor suppressor genes (TSGs). Using 1 Mb array comparative genomic hybridization (aCGH), we refined a small hemizygous deletion (similar to 1 Mb) at 16q21-22.1, which contains a single gene Cadherin-11 (CDH11, OB-cadherin). CDH11 was broadly expressed in human normal adult and fetal tissues, while its silencing and promoter CpG methylation were frequently detected in tumor cell lines, but not in immortalized normal epithelial cells. Aberrant methylation was also frequently detected in multiple primary tumors. CDH11 silencing could be reversed by pharmacologic or genetic demethylation, indicating an epigenetic mechanism. Ectopic expression of CDH11 strongly suppressed tumorigenecity and induced tumor cell apoptosis. Moreover, CDH11 was found to inhibit Wnt/beta-catenin and AKT/Rho A signaling, as well as actin stress fiber formation, thus further inhibiting tumor cell migration and invasion. CDH11 also inhibited epithelial-to-mesenchymal transition and downregulated stem cell markers. Thus, our work identifies CDH11 as a functional tumor suppressor and an important antagonist of Wnt/beta-catenin and AKT/Rho A signaling, with frequent epigenetic inactivation in common carcinomas. Oncogene (2012) 31, 3901-3912; doi:10.1038/onc.2011.541; published online 5 December 2011	[Li, L.; Ying, J.; Li, H.; Zhang, Y.; Shu, X.; Fan, Y.; Chan, A. T. C.; Tao, Q.] Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China; [Li, L.; Ying, J.; Li, H.; Zhang, Y.; Shu, X.; Fan, Y.; Chan, A. T. C.; Tao, Q.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Shatin, Hong Kong, Peoples R China; [Li, L.; Ying, J.; Li, H.; Zhang, Y.; Shu, X.; Fan, Y.; Chan, A. T. C.; Tao, Q.] CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China; [Ying, J.] Chinese Acad Med Sci, Beijing 100730, Peoples R China; [Ying, J.] Peking Union Med Coll, Canc Hosp, Dept Pathol, Beijing 100021, Peoples R China; [Tan, J.] Johns Hopkins Singapore, Singapore, Singapore; [Cao, Y.] Cent S Univ, Xiangya Hunan Yale Sch Med, Canc Res Inst, Changsha, Hunan, Peoples R China; [Tsao, S. W.] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Srivastava, G.] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Johns Hopkins University; Johns Hopkins Medicine; Central South University; University of Hong Kong; University of Hong Kong	Tao, Q (corresponding author), Chinese Univ Hong Kong, Canc Epigenet Lab, Dept Clin Oncol, Canc Ctr,PWH, Rm 315, Shatin, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Chan, Anthony Tak Cheung/R-3940-2018; Li, Lili/Q-5750-2018; Tao, Qian/T-4743-2018	Chan, Anthony Tak Cheung/0000-0002-6912-8091; Li, Lili/0000-0002-0292-5889; Tao, Qian/0000-0001-5383-4808	Hong Kong RGC [473908]; National Basic Research Program of China [2011CB504305]; National Natural Science Foundation [81172582]	Hong Kong RGC(Hong Kong Research Grants Council); National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	We thank Drs Tzer Jing Seng and Cordelia Langford for their help of array-CGH and Dr Colin D MacCalman for providing the CDH11 cDNA. This study was supported by grants from Hong Kong RGC (GRF #473908), National Basic Research Program of China (2011CB504305) and National Natural Science Foundation (No. 81172582).	ANDERSSON AM, 1994, INT J ANDROL, V17, P174, DOI 10.1111/j.1365-2605.1994.tb01239.x; Andreeva AV, 2010, GENE CHROMOSOME CANC, V49, P775, DOI 10.1002/gcc.20787; Angst BD, 2001, J CELL SCI, V114, P629; Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Callen DF, 2002, CANCER GENET CYTOGEN, V133, P76, DOI 10.1016/S0165-4608(01)00565-9; Chen TT, 2010, STEM CELLS, V28, P1315, DOI 10.1002/stem.456; Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566; Choi P, 2008, ARCH OTOLARYNGOL, V134, P539, DOI 10.1001/archotol.134.5.539; Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541-7786.MCR-08-0077; Conrad S, 2008, NATURE, V456, P344, DOI 10.1038/nature07404; Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990; Eads CA, 2001, CANCER RES, V61, P3410; Feltes CM, 2002, CANCER RES, V62, P6688; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Hiraguri S, 1998, CANCER RES, V58, P1972; Hosokawa K, 2010, CELL STEM CELL, V6, P194, DOI 10.1016/j.stem.2009.04.013; Hu XT, 2009, ONCOGENE, V28, P2466, DOI 10.1038/onc.2009.92; Huang CF, 2010, CANCER RES, V70, P4580, DOI 10.1158/0008-5472.CAN-09-3016; Hui ABY, 1999, INT J CANCER, V82, P498, DOI 10.1002/(SICI)1097-0215(19990812)82:4<498::AID-IJC5>3.3.CO;2-J; Jin HC, 2007, P NATL ACAD SCI USA, V104, P12353, DOI 10.1073/pnas.0700153104; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karpowicz P, 2009, J NEUROSCI, V29, P3885, DOI 10.1523/JNEUROSCI.0037-09.2009; Kashima T, 1999, AM J PATHOL, V155, P1549, DOI 10.1016/S0002-9440(10)65471-5; Kochetkova M, 2002, CANCER RES, V62, P4599; Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281; Kroeger H, 2008, BLOOD, V112, P1366, DOI 10.1182/blood-2007-11-126227; Li LL, 2010, CLIN CANCER RES, V16, P2949, DOI 10.1158/1078-0432.CCR-09-3178; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marchong MN, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000923; Marchong MN, 2004, MOL CANCER RES, V2, P495; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; Miotto E, 2004, CANCER RES, V64, P8156, DOI 10.1158/0008-5472.CAN-04-3000; Nakajima Go, 2008, Cancer Genomics & Proteomics, V5, P37; Nishioka N, 2001, INT J ONCOL, V18, P317; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; Pishvaian MJ, 1999, CANCER RES, V59, P947; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Redmer T, 2011, EMBO REP, V12, P720, DOI 10.1038/embor.2011.88; Roman-Gomez J, 2003, J CLIN ONCOL, V21, P1472, DOI 10.1200/JCO.2003.08.166; Roylance R, 2006, ONCOGENE, V25, P6544, DOI 10.1038/sj.onc.1209659; Sandgren J, 2010, EXP MOL MED, V42, P484, DOI 10.3858/emm.2010.42.7.050; Stanton SE, 2000, GENE CHROMOSOME CANC, V27, P323, DOI 10.1002/(SICI)1098-2264(200003)27:3<323::AID-GCC14>3.0.CO;2-P; Sun XD, 2005, NAT GENET, V37, P407, DOI 10.1038/ng1528; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Toyooka KO, 2001, CANCER RES, V61, P4556; Toyooka S, 2002, CANCER RES, V62, P3382; Wang Y, 2009, CANCER RES, V69, P5194, DOI 10.1158/0008-5472.CAN-08-3694; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; Yagi T, 2000, GENE DEV, V14, P1169; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644	56	56	57	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2012	31	34					3901	3912		10.1038/onc.2011.541	http://dx.doi.org/10.1038/onc.2011.541			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	994IV		Green Published, hybrid			2022-12-17	WOS:000307925000007
J	Kidoya, H; Kunii, N; Naito, H; Muramatsu, F; Okamoto, Y; Nakayama, T; Takakura, N				Kidoya, H.; Kunii, N.; Naito, H.; Muramatsu, F.; Okamoto, Y.; Nakayama, T.; Takakura, N.			The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy	ONCOGENE			English	Article						tumor angiogenesis; immune therapy; vascular normalization; vascular maturation; apelin/APJ	KILLER T-CELLS; V-ALPHA-14 NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; IN-VIVO; ENDOTHELIAL-CELLS; ANGIOGENIC FACTOR; BLOOD-VESSELS; APJ RECEPTOR; CANCER; ACTIVATION	Immature and unstable tumor vasculature provides an aberrant tumor microenvironment and leads to resistance of tumors to conventional therapy. Hence, normalization of tumor vessels has been reported to improve the effect of immuno-, chemo- and radiation therapy. However, the humoral factors, which can effectively induce maturation of tumor vasculature, have not been elucidated. In this study, we found that the novel peptide apelin and its receptor APJ can induce the morphological and functional maturation of blood vessels in tumors. This apelin-induced tumor vascular maturation enhances the efficacy of cancer dendritic cell-based immunotherapy and significantly suppresses tumor growth by promoting the infiltration of invariant natural killer T cells into the central region of the tumor and thereby robustly inducing apoptosis of tumor cells. Additionally, we showed APJ expression to be enhanced in the tumor endothelium in comparison with normal-state endothelial cells. These findings provide a new target for tumor vascular-specific maturation, which is expected to improve the efficacy of conventional cancer therapies. Oncogene (2012) 31, 3254-3264; doi:10.1038/onc.2011.489; published online 31 October 2011	[Kidoya, H.; Naito, H.; Muramatsu, F.; Takakura, N.] Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, Suita, Osaka 5650871, Japan; [Kunii, N.; Okamoto, Y.] Chiba Univ, Grad Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Chiba, Japan; [Kunii, N.; Nakayama, T.] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba, Japan	Osaka University; Chiba University; Chiba University	Takakura, N (corresponding author), Osaka Univ, Res Inst Microbial Dis, Dept Signal Transduct, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	ntakaku@biken.osaka-u.ac.jp	Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007; Naito, Hisamichi/0000-0002-0750-1743	Japan Society for the Promotion of Science (JSPS) and Research [KAKENHI 21890124]; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; YASUDA Medical Foundation	Japan Society for the Promotion of Science (JSPS) and Research; Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); YASUDA Medical Foundation	We thank Ms C Takeshita, Ms K Fukuhara and Ms N Fujimoto for technical assistance. Financial support: This work was supported by Grant-in-Aid for Research Activity Start-up (KAKENHI 21890124) from the Japan Society for the Promotion of Science (JSPS) and Research; a grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; and the YASUDA Medical Foundation.	Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452; Dai TY, 2006, EUR J PHARMACOL, V553, P222, DOI 10.1016/j.ejphar.2006.09.034; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Dings RPM, 2011, CLIN CANCER RES, V17, P3134, DOI 10.1158/1078-0432.CCR-10-2443; Eyries M, 2008, CIRC RES, V103, P432, DOI 10.1161/CIRCRESAHA.108.179333; Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827; Fukuhara S, 2008, NAT CELL BIOL, V10, P513, DOI 10.1038/ncb1714; Gasparini G, 2005, NAT CLIN PRACT ONCOL, V2, P562, DOI 10.1038/ncponc0342; Gerber HP, 2005, CANCER RES, V65, P671; Gerhardt H, 2003, CELL TISSUE RES, V314, P15, DOI 10.1007/s00441-003-0745-x; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635; Kalin RE, 2007, DEV BIOL, V305, P599, DOI 10.1016/j.ydbio.2007.03.004; Kakimi K, 2000, J EXP MED, V192, P921, DOI 10.1084/jem.192.7.921; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Kawamata Y, 2001, BBA-MOL CELL RES, V1538, P162, DOI 10.1016/S0167-4889(00)00143-9; Kawano T, 1999, CANCER RES, V59, P5102; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kidoya H, 2008, EMBO J, V27, P522, DOI 10.1038/sj.emboj.7601982; Kidoya H, 2010, BLOOD, V115, P3166, DOI 10.1182/blood-2009-07-232306; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kunii N, 2009, CANCER SCI, V100, P1092, DOI 10.1111/j.1349-7006.2009.01135.x; Lago F, 2007, CYTOKINE GROWTH F R, V18, P313, DOI 10.1016/j.cytogfr.2007.04.007; Lambrecht NWG, 2006, PHYSIOL GENOMICS, V25, P153, DOI 10.1152/physiolgenomics.00271.2005; Lohela M, 2009, CURR OPIN CELL BIOL, V21, P154, DOI 10.1016/j.ceb.2008.12.012; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Motohashi S, 2009, J IMMUNOL, V182, P2492, DOI 10.4049/jimmunol.0800126; Nieda M, 2001, BLOOD, V97, P2067, DOI 10.1182/blood.V97.7.2067; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Padera TP, 2004, NATURE, V427, P695, DOI 10.1038/427695a; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Seino K, 2005, SPRINGER SEMIN IMMUN, V27, P65, DOI 10.1007/s00281-004-0194-y; Shin T, 2001, INT J CANCER, V91, P523, DOI 10.1002/1097-0215(20010215)91:4<523::AID-IJC1087>3.0.CO;2-L; Singh AK, 2001, J EXP MED, V194, P1801, DOI 10.1084/jem.194.12.1801; Smyth MJ, 2002, BLOOD, V99, P1259, DOI 10.1182/blood.V99.4.1259; Sorli SC, 2007, ONCOGENE, V26, P7692, DOI 10.1038/sj.onc.1210573; Spada FM, 1998, J EXP MED, V188, P1529, DOI 10.1084/jem.188.8.1529; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Willett CG, 2006, SEMIN ONCOL, V33, pS35, DOI 10.1053/j.seminoncol.2006.08.007; Winzell MS, 2005, REGUL PEPTIDES, V131, P12, DOI 10.1016/j.regpep.2005.05.004; Yamada Y, 2006, J EXP MED, V203, P1055, DOI 10.1084/jem.20050373	52	56	66	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	27					3254	3264		10.1038/onc.2011.489	http://dx.doi.org/10.1038/onc.2011.489			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	970FL	22037214	Bronze			2022-12-17	WOS:000306113400005
J	Galluzzi, L; Kepp, O; Kroemer, G				Galluzzi, L.; Kepp, O.; Kroemer, G.			Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy	ONCOGENE			English	Editorial Material							INDEPENDENT CELL-DEATH; APOPTOTIC CELLS; PHOSPHOLIPASE A(2); VITAL FUNCTIONS; REGENERATION; PROLIFERATION; MECHANISMS; MIGRATION; EFFECTORS; RELEASE	Chemo- and radio-therapeutic regimens frequently kill cancer cells by inducing apoptosis, a cell-death subroutine that involves the activation of a particular class of proteases called caspases. In a recent issue of Nature Medicine, Huang et al. (2011) show that caspase activation in dying tumor cells causes the release of soluble lipid messengers, notably prostaglandin E-2, that stimulate tumor cell proliferation. In this short review, we will discuss the clinical and therapeutic implications of these findings. Oncogene (2012) 31, 2805-2808; doi:10.1038/onc.2011.459; published online 3 October 2011	[Kroemer, G.] Inst Gustave Roussy, INSERM, U848, PR1, F-94805 Villejuif, France; [Galluzzi, L.; Kepp, O.] Univ Paris 11, Le Kremlin Bicetre, France; [Kroemer, G.] Inst Gustave Roussy, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europe Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	Galluzzi, Lorenzo/AAG-6432-2019; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Galluzzi, Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi, Lorenzo/K-2709-2012; Kepp, Oliver/GPX-8627-2022	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Galluzzi, Lorenzo/0000-0003-2257-8500; 				Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chera S, 2009, DEV CELL, V17, P279, DOI 10.1016/j.devcel.2009.07.014; Fan Y, 2008, DEV CELL, V14, P399, DOI 10.1016/j.devcel.2008.01.003; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Galluzzi L, 2009, BBA-BIOENERGETICS, V1787, P402, DOI 10.1016/j.bbabio.2008.09.006; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Tait SWG, 2008, ONCOGENE, V27, P6452, DOI 10.1038/onc.2008.311; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Zhao XX, 2006, J BIOL CHEM, V281, P29357, DOI 10.1074/jbc.M513105200	31	56	68	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	23					2805	2808		10.1038/onc.2011.459	http://dx.doi.org/10.1038/onc.2011.459			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958YW	21963852				2022-12-17	WOS:000305277900001
J	Khromova, N; Kopnin, P; Rybko, V; Kopnin, BP				Khromova, N.; Kopnin, P.; Rybko, V.; Kopnin, B. P.			Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms	ONCOGENE			English	Article						metastasis; epithelial-mesenchymal transition (EMT); cancer stem cells (CSCs); cell migration; tumor vascularization; VEGF-C	EPITHELIAL-MESENCHYMAL TRANSITIONS; STEM-CELLS; CLINICAL-SIGNIFICANCE; FACTOR RECEPTOR-3; NUDE-MICE; LYMPHANGIOGENESIS; AUTOCRINE; PROMOTES; CARCINOMA; AXIS	Experimental and clinical studies positively correlate expression of vascular endothelial growth factor (VEGF)-C in cancer cells with accelerated tumor progression and/or unfavorable clinical outcome. However, many aspects of tumor-promoting activity of VEGF-C and consequences of its downregulation for tumor progression remain poorly understood. To clarify these points, we created a set of VEGF receptor 3-positive lung carcinoma A549 and colon carcinoma HCT116 cell sublines with stable repression of VEGF-C synthesis. Analysis of the behavior of these cells revealed multiple effects of VEGF-C downregulation, which, in addition to deceleration of cell proliferation and invasion in vitro and inhibition of lymphangiogenesis in tumor and surrounding tissues observed earlier, included previously undescribed effects, in particular, partial restoration of epithelial phenotype, reduction in the percentage of tumor-initiating cells (cancer stem cells) in the cell population and inhibition of metastasis of orthotopic lung cancer xenografts to other lung lobes. These results are consistent with the idea of high potentiality of VEGF-C as a cancer drug target. Oncogene (2012) 31, 1389-1397; doi:10.1038/onc.2011.330; published online 1 August 2011	[Khromova, N.; Kopnin, P.; Rybko, V.; Kopnin, B. P.] Blokhin Russian Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	N.N. Blokhin Russian Cancer Research Center	Kopnin, BP (corresponding author), Blokhin Russian Canc Res Ctr, Inst Carcinogenesis, Kashirskoye Shosse 24, Moscow 115478, Russia.	bkopnin@mail.ru	Kopnin, Pavel/R-8213-2019; Kopnin, Boris/R-8240-2019	Kopnin, Pavel/0000-0002-2078-4274; Kopnin, Boris/0000-0003-3100-2212	Russian Fund for Basic Research [08-04-00252]; PROTEK-CRC; Russian Federal Program 'Scientific and pedagogical personnel of innovative Russia' [02.740.11.0085]	Russian Fund for Basic Research(Russian Foundation for Basic Research (RFBR)); PROTEK-CRC; Russian Federal Program 'Scientific and pedagogical personnel of innovative Russia'	The work was supported by grants from Russian Fund for Basic Research (BK, # 08-04-00252), PROTEK-CRC Program for Basic Research in Oncology and Russian Federal Program 'Scientific and pedagogical personnel of innovative Russia' (BK, # 02.740.11.0085).	Arinaga M, 2003, CANCER-AM CANCER SOC, V97, P457, DOI 10.1002/cncr.11073; Bahram Fuad, 2010, Pathophysiology, V17, P253, DOI 10.1016/j.pathophys.2009.10.004; Chen YL, 2010, MOL CELL BIOCHEM, V345, P77, DOI 10.1007/s11010-010-0562-y; Gu Y, 2008, CLIN EXP METASTAS, V25, P717, DOI 10.1007/s10585-008-9180-4; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jackson MW, 2002, CANCER RES, V62, P854; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1996, EMBO J, V15, P290; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karpanen T, 2006, FASEB J, V20, P1462, DOI 10.1096/fj.05-5646com; Khromova NV, 2009, CANCER LETT, V276, P143, DOI 10.1016/j.canlet.2008.10.049; Kodama M, 2008, CLIN CANCER RES, V14, P7205, DOI 10.1158/1078-0432.CCR-08-0818; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Miyazaki T, 2008, JPN J CLIN ONCOL, V38, P839, DOI 10.1093/jjco/hyn106; Orlandini M, 2006, J BIOL CHEM, V281, P17961, DOI 10.1074/jbc.M600413200; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Skobe M, 1999, J INVEST DERMATOL, V113, P1047, DOI 10.1046/j.1523-1747.1999.00798.x; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; Su JL, 2008, CANCER CELL, V13, P557, DOI 10.1016/j.ccr.2008.04.021; Su JL, 2006, CANCER CELL, V9, P209, DOI 10.1016/j.ccr.2006.02.018; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Timoshenko AV, 2007, BRIT J CANCER, V97, P1090, DOI 10.1038/sj.bjc.6603993; WANG XE, 1992, ANTICANCER RES, V12, P1399; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Xu YL, 2010, J CELL BIOL, V188, P115, DOI 10.1083/jcb.200903137; Yamashita T, 2010, LUNG CANCER, V70, P320, DOI 10.1016/j.lungcan.2010.02.013; Yamaura T, 2000, NEOPLASIA, V2, P315, DOI 10.1038/sj.neo.7900098; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	36	56	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1389	1397		10.1038/onc.2011.330	http://dx.doi.org/10.1038/onc.2011.330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804602				2022-12-17	WOS:000301780000006
J	Dong, L; Jiang, CC; Thorne, RF; Croft, A; Yang, F; Liu, H; de Bock, CE; Hersey, P; Zhang, XD				Dong, L.; Jiang, C. C.; Thorne, R. F.; Croft, A.; Yang, F.; Liu, H.; de Bock, C. E.; Hersey, P.; Zhang, X. D.			Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress	ONCOGENE			English	Article						melanoma; Mcl-1; XBP-1; Ets-1; endoplasmic reticulum stress	ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR ETS-1; UNFOLDED PROTEIN RESPONSE; TRAIL-INDUCED APOPTOSIS; TRANSLATIONAL CONTROL; MALIGNANT-MELANOMA; BREAST-CANCER; EXPRESSION; INHIBITION; ACTIVATION	Past studies have shown that upregulation of the antiapoptotic Bcl-2 family protein Mcl-1 is a major adaptive mechanism of melanoma cells to endoplasmic reticulum (ER) stress, and has an important role in resistance of the cells to apoptosis. In this study, we show that the increase in transcription of Mcl-1 in melanoma cells triggered by pharmacological ER stress inducers is mediated by the transcription factor Ets-1. By incremental deletion analysis of the Mcl-1 promoter, we identified a DNA fragment containing an Ets-1 binding site that is transcriptionally responsive to ER stress. Mutations in the Ets-1 binding site or knockdown of Ets-1 inhibited the increase in Mcl-1, indicating that Ets-1 has a critical role in transcriptional upregulation of Mcl-1. Similar to Mcl-1, Ets-1 was transcriptionally upregulated by ER stress. This was mediated by the IRE1 alpha/XBP-1 branch of the unfolded protein response, as upregulation of Ets-1 was inhibited in melanoma cell lines deficient in IRE1 alpha or XBP-1 established by short hairpin RNA knockdown. Activation of the PI3k/Akt pathway downstream of XBP-1 was also involved, in that inhibition of the pathway blocked upregulation of Ets-1. Inhibition of Ets-1 enhanced ER stress-induced apoptosis in melanoma cell lines and in fresh melanoma isolates, recapitulating the effect of inhibition of Mcl-1. These results reveal a key mechanism by which Mcl-1 is transcriptionally upregulated in melanoma cells by ER stress, and identify Ets-1 as a potential target for inhibition to sensitize melanoma cells to apoptosis. Oncogene (2011) 30, 3716-3726; doi:10.1038/onc.2011.87; dpublished online 21 March 2011	[Dong, L.; Jiang, C. C.; Croft, A.; Yang, F.; Liu, H.; Hersey, P.; Zhang, X. D.] Calvary Mater Newcastle Hosp, Immunol & Oncol Unit, Newcastle, NSW 2300, Australia; [Thorne, R. F.; de Bock, C. E.] Univ Newcastle, Canc Res Unit, Sch Biomed Sci, Newcastle, NSW 2300, Australia	Calvary Mater Newcastle Hospital; University of Newcastle	Zhang, XD (corresponding author), Calvary Mater Newcastle Hosp, Immunol & Oncol Unit, Room 443,David Maddison Clin Sci Bldg,Cnr King &, Newcastle, NSW 2300, Australia.	Peter.Hersey@newcastle.edu.au; Xu.Zhang@newcastle.edu.au	de Bock, Charles/H-7699-2019; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; Jiang, Chenchen/C-2902-2014; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022	de Bock, Charles/0000-0001-5182-8535; Zhang, Xu Dong/0000-0001-9457-8003	NSW State Cancer Council; Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia; NHMRC	NSW State Cancer Council(Cancer Council New South Wales); Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the NSW State Cancer Council, Cancer Institute NSW, and National Health and Medical Research Council (NHMRC), Australia. L Dong is a recipient of Australia-China Exchange Fellowship of NHMRC. XD Zhang is supported by a senior research fellowship of NHMRC.	Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Davidson B, 2001, AM J SURG PATHOL, V25, P1493, DOI 10.1097/00000478-200112000-00004; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fritsch RM, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702673200; Gillespie S, 2005, MOL CANCER THER, V4, P668, DOI 10.1158/1535-7163.MCT-04-0332; Hahne JC, 2008, MINI-REV MED CHEM, V8, P1095, DOI 10.2174/138955708785909934; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hersey P, 2008, PIGM CELL MELANOMA R, V21, P358, DOI 10.1111/j.1755-148X.2008.00467.x; Hersey P, 2006, INT REV CYTOL, V251, P131, DOI 10.1016/S0074-7696(06)51004-6; Iglesias-Serret D, 2003, ARCH BIOCHEM BIOPHYS, V417, P141, DOI 10.1016/S0003-9861(03)00345-X; Isomoto H, 2005, HEPATOLOGY, V42, P1329, DOI 10.1002/hep.20966; Jiang CC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.48; Jiang CC, 2008, CANCER RES, V68, P6708, DOI 10.1158/0008-5472.CAN-08-0349; Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047; Jiang CC, 2009, NEOPLASIA, V11, P945, DOI 10.1593/neo.09692; Jiang CC, 2009, NEOPLASIA, V11, P436, DOI 10.1593/neo.09208; Jiang CC, 2009, CARCINOGENESIS, V30, P197, DOI 10.1093/carcin/bgn220; Jorcyk CL, 1997, CELL MOL BIOL, V43, P211; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Liu H, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-122; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; Mhaidat NM, 2007, CLIN CANCER RES, V13, P1308, DOI 10.1158/1078-0432.CCR-06-2216; Myers E, 2005, CLIN CANCER RES, V11, P2111, DOI 10.1158/1078-0432.CCR-04-1192; Nguyen T, 2001, CLIN CANCER RES, V7, p966S; Piret JP, 2005, J BIOL CHEM, V280, P9336, DOI 10.1074/jbc.M411858200; Poser I, 2004, HISTOL HISTOPATHOL, V19, P173, DOI 10.14670/HH-19.173; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Torlakovic EE, 2004, MODERN PATHOL, V17, P1400, DOI 10.1038/modpathol.3800206; Wagner N, 2008, ONCOGENE, V27, P3662, DOI 10.1038/sj.onc.1211044; Wang JM, 2003, MOL CELL BIOL, V23, P1896, DOI 10.1128/MCB.23.6.1896-1909.2003; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Warr MR, 2008, CURR MOL MED, V8, P138; Yang F, 2010, CELL DEATH DIFFER, V17, P1354, DOI 10.1038/cdd.2010.29; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhuang LQ, 2007, MODERN PATHOL, V20, P416, DOI 10.1038/modpathol.3800750; Zhuang LQ, 2010, MODERN PATHOL, V23, P45, DOI 10.1038/modpathol.2009.129; Zhuang LQ, 2009, HISTOPATHOLOGY, V54, P462, DOI 10.1111/j.1365-2559.2009.03242.x	51	56	56	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	34					3716	3726		10.1038/onc.2011.87	http://dx.doi.org/10.1038/onc.2011.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21423203	hybrid, Green Published			2022-12-17	WOS:000294244500007
J	Connelly, L; Barham, W; Onishko, HM; Sherrill, T; Chodosh, LA; Blackwell, TS; Yull, FE				Connelly, L.; Barham, W.; Onishko, H. M.; Sherrill, T.; Chodosh, L. A.; Blackwell, T. S.; Yull, F. E.			Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden	ONCOGENE			English	Article						NF-kappa B; mammary; tumorigenesis; apoptosis; proliferation	HUMAN BREAST-CANCER; TRANSCRIPTION FACTOR; CYCLIN D1; IN-VIVO; ACTIVATION; PATHWAY; TUMORIGENESIS; REQUIREMENT; PROGRESSION; GROWTH	The transcription factor nuclear factor kappa B (NF-kappa B) is activated in human breast cancer tissues and cell lines. However, it is unclear whether NF-kappa B activation is a consequence of tumor formation or a contributor to tumor development. We developed a doxycycline (dox)-inducible mouse model, termed DNMP, to inhibit NF-kappa B activity specifically within the mammary epithelium during tumor development in the polyoma middle T oncogene (PyVT) mouse mammary tumor model. DNMP females and PyVT littermate controls were treated with dox from 4 to 12 weeks of age. We observed an increase in tumor latency and a decrease in final tumor burden in DNMP mice compared with PyVT controls. A similar effect with treatment from 8 to 12 weeks indicates that outcome is independent of effects on postnatal virgin ductal development. In both cases, DNMP mice were less likely to develop lung metastases than controls. Treatment from 8 to 9 weeks was sufficient to impact primary tumor formation. Inhibition of NF-kappa B increases apoptosis in hyperplastic stages of tumor development and decreases proliferation at least in part by reducing Cyclin D1 expression. To test the therapeutic potential of NF-kappa B inhibition, we generated palpable tumors by orthotopic injection of PyVT cells and then treated systemically with the NF-kappa B inhibitor thymoquinone (TQ). TQ treatment resulted in a reduction in tumor volume and weight as compared with vehicle-treated control. These data indicate that epithelial NF-kappa B is an active contributor to tumor progression and demonstrate that inhibition of NF-kappa B could have a significant therapeutic impact even at later stages of mammary tumor progression. Oncogene (2011) 30, 1402-1412; doi:10.1038/onc.2010.521; published online 15 November 2010	[Connelly, L.; Barham, W.; Onishko, H. M.; Blackwell, T. S.; Yull, F. E.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; [Connelly, L.] Univ Hawaii, Dept Pharmaceut Sci, Coll Pharm, Hilo, HI 96720 USA; [Sherrill, T.; Blackwell, T. S.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; [Chodosh, L. A.] Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Blackwell, T. S.] Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; University of Hawaii System; University Hawaii Hilo; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Yull, FE (corresponding author), Vanderbilt Univ, Dept Canc Biol, 771 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	fiona.yull@vanderbilt.edu	Connelly, Linda/GVS-4612-2022	Barham, Whitney/0000-0002-1130-1971	NIH [CA113734]; US Department of Veterans Affairs; NATIONAL CANCER INSTITUTE [R01CA113734] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grant CA113734 awarded to FE Yull and a US Department of Veterans Affairs grant awarded to TS Blackwell.	BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basseres DS, 2010, CANCER RES, V70, P3537, DOI 10.1158/0008-5472.CAN-09-4290; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Biswas DK, 2006, J CELL PHYSIOL, V209, P645, DOI 10.1002/jcp.20785; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Cheng DS, 2007, J IMMUNOL, V178, P6504, DOI 10.4049/jimmunol.178.10.6504; Connelly L, 2007, J BIOL CHEM, V282, P10028, DOI 10.1074/jbc.M611300200; Connelly L, 2010, J CELL PHYSIOL, V222, P73, DOI 10.1002/jcp.21922; Cude K, 2007, J CELL BIOL, V177, P253, DOI 10.1083/jcb.200609166; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Han YP, 2001, J CELL SCI, V114, P131; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Jafri SH, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-87; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu MR, 2009, AM J PATHOL, V174, P1910, DOI 10.2353/ajpath.2009.080706; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Mistry P, 2004, J BIOL CHEM, V279, P1482, DOI 10.1074/jbc.M310413200; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Pratt MAC, 2009, ONCOGENE, V28, P2710, DOI 10.1038/onc.2009.131; Roy PG, 2006, BREAST, V15, P718, DOI 10.1016/j.breast.2006.02.005; Sethi G, 2008, MOL CANCER RES, V6, P1059, DOI 10.1158/1541-7786.MCR-07-2088; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stathopoulos GT, 2007, P NATL ACAD SCI USA, V104, P18514, DOI 10.1073/pnas.0705316104; Tapia MA, 2007, CELL CYCLE, V6, P2284, DOI 10.4161/cc.6.18.4721; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0	38	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	12					1402	1412		10.1038/onc.2010.521	http://dx.doi.org/10.1038/onc.2010.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21076466	Green Accepted			2022-12-17	WOS:000288743800003
J	Pittoni, P; Piconese, S; Tripodo, C; Colombo, MP				Pittoni, P.; Piconese, S.; Tripodo, C.; Colombo, M. P.			Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors	ONCOGENE			English	Review						c-Kit; mast cells; tyrosine kinase inhibitors; off-target; mouse mutants	GASTROINTESTINAL STROMAL TUMORS; ADENOID CYSTIC CARCINOMA; DOSE-DEPENDENT MANNER; REGULATORY T-CELLS; STEM-CELL; IN-VIVO; BONE-MARROW; IMATINIB MESYLATE; GROWTH-FACTOR; MOUSE MODEL	c-Kit tyrosine kinase receptor and its ligand stem cell factor have multiple functions during development, whereas in adulthood they are mostly needed for stem cell (SC) maintenance and mast cell (MC) biology. c-Kit plays an essential tumor-cell-intrinsic role in many types of cancer, either providing the tumorigenic force when aberrantly activated or conferring stem-like features characterizing the most aggressive variants. A tumor-cell-extrinsic role occurs through c-Kit-dependent accessory cells (such as MCs) that infiltrate tumors and deeply influence their progression. c-Kit-targeted therapy with tyrosine kinase inhibitors (TKIs) may ideally work against both tumor and stromal cells. Here, we summarize the tumor-intrinsic and -extrinsic roles of c-Kit in cancer and discuss TKIs with their on-and off-targets, with a special emphasis on MCs as paradigmatic c-Kit-dependent accomplices for tumor progression. Oncogene (2011) 30, 757-769; doi:10.1038/onc.2010.494; published online 8 November 2010	[Pittoni, P.; Piconese, S.; Colombo, M. P.] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, I-20133 Milan, Italy; [Tripodo, C.] Univ Palermo, Dept Human Pathol, Palermo, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Palermo	Colombo, MP (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Mol Immunol Unit, Via Amadeo 42, I-20133 Milan, Italy.	mario.colombo@istitutotumori.mi.it	Colombo, Mario P./V-7166-2017; Tripodo, Claudio/O-4536-2016; Tripodo, Claudio/AAB-6004-2022	Colombo, Mario P./0000-0003-0042-7955; Tripodo, Claudio/0000-0002-0821-6231; Tripodo, Claudio/0000-0002-0821-6231; Piconese, Silvia/0000-0002-9685-5227	Italian Ministry of Health; Associazione Italiana Ricerca sul Cancro [8726]; FIRC (Fondazione Italiana Ricerca sul Cancro)	Italian Ministry of Health(Ministry of Health, Italy); Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); FIRC (Fondazione Italiana Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grants from the Italian Ministry of Health and Associazione Italiana Ricerca sul Cancro (to MPC). SP is supported by My First AIRC grant (8726). PP is supported by a fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro).	ANDERSON DM, 1991, CELL GROWTH DIFFER, V2, P373; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; Beaven MA, 2009, EUR J IMMUNOL, V39, P11, DOI 10.1002/eji.200838899; Bellone G, 2006, INT J ONCOL, V29, P851; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berrozpe G, 1999, BLOOD, V94, P2658, DOI 10.1182/blood.V94.8.2658.420k23_2658_2666; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Blatner NR, 2010, P NATL ACAD SCI USA, V107, P6430, DOI 10.1073/pnas.0913683107; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chen J, 2007, INT J ONCOL, V31, P1133; Colombo MP, 2009, CANCER RES, V69, P5619, DOI 10.1158/0008-5472.CAN-09-1351; Corless CL, 2008, ANNU REV PATHOL-MECH, V3, P557, DOI 10.1146/annurev.pathmechdis.3.121806.151538; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crivellato E, 2008, CANCER LETT, V269, P1, DOI 10.1016/j.canlet.2008.03.031; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4; Dietz AB, 2004, BLOOD, V104, P1094, DOI 10.1182/blood-2003-12-4266; Dubreuil P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007258; Freier K, 2005, ORAL ONCOL, V41, P934, DOI 10.1016/j.oraloncology.2005.05.005; Fritsche-Polanz R, 2010, MOL ONCOL, V4, P335, DOI 10.1016/j.molonc.2010.04.008; Frossi B, 2010, TRENDS IMMUNOL, V31, P97, DOI 10.1016/j.it.2009.12.007; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; GADD SJ, 1985, LEUKEMIA RES, V9, P1329, DOI 10.1016/0145-2126(85)90119-5; Galinsky DST, 2008, CRIT REV ONCOL HEMAT, V68, P115, DOI 10.1016/j.critrevonc.2008.06.001; GALLI SJ, 1993, AM J PATHOL, V142, P965; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Gilfillan AM, 2009, IMMUNOL REV, V228, P149, DOI 10.1111/j.1600-065X.2008.00742.x; Gleixner KV, 2006, BLOOD, V107, P752, DOI 10.1182/blood-2005-07-3022; Gomes AL, 2007, CELL ONCOL, V29, P399; Gounaris E, 2007, P NATL ACAD SCI USA, V104, P19977, DOI 10.1073/pnas.0704620104; Gounaris E, 2009, CANCER RES, V69, P5490, DOI 10.1158/0008-5472.CAN-09-0304; Gri G, 2008, IMMUNITY, V29, P771, DOI 10.1016/j.immuni.2008.08.018; Grimbaldeston MA, 2005, AM J PATHOL, V167, P835, DOI 10.1016/S0002-9440(10)62055-X; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Gunawan B, 2008, J PATHOL, V214, P407, DOI 10.1002/path.2315; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hirashima K, 2009, SURG TODAY, V39, P979, DOI 10.1007/s00595-009-3963-3; Huang B, 2008, BLOOD, V112, P1269, DOI 10.1182/blood-2008-03-147033; Huang SY, 1996, ONCOGENE, V13, P2339; Hutt KJ, 2006, MOL HUM REPROD, V12, P61, DOI 10.1093/molehr/gal010; IKEDA H, 1991, BLOOD, V78, P2962; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; Ishikawa T, 2009, LAB INVEST, V89, P1161, DOI 10.1038/labinvest.2009.78; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Johansson A, 2010, AM J PATHOL, V177, P1031, DOI 10.2353/ajpath.2010.100070; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Khalaf WF, 2007, J IMMUNOL, V178, P2527, DOI 10.4049/jimmunol.178.4.2527; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Kinet JP, 2007, IMMUNOL REV, V217, P5, DOI 10.1111/j.1600-065X.2007.00528.x; KITAMURA Y, 1978, BLOOD, V52, P447; Ko CD, 2003, CLIN EXP METASTAS, V20, P593, DOI 10.1023/A:1027323210736; Ko JS, 2010, CANCER RES, V70, P3526, DOI 10.1158/0008-5472.CAN-09-3278; Ko JS, 2009, CLIN CANCER RES, V15, P2148, DOI 10.1158/1078-0432.CCR-08-1332; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Krystal GW, 1996, CANCER RES, V56, P370; Larmonier N, 2008, J IMMUNOL, V181, P6955, DOI 10.4049/jimmunol.181.10.6955; LASSAM N, 1992, ONCOGENE, V7, P51; Laurson J, 2007, CELLS TISSUES ORGANS, V186, P180, DOI 10.1159/000106360; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Liegl-Atzwanger B, 2010, VIRCHOWS ARCH, V456, P111, DOI 10.1007/s00428-010-0891-y; Liu HL, 2007, EMBO J, V26, P891, DOI 10.1038/sj.emboj.7601545; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; LYON MF, 1982, GENET RES, V39, P315, DOI 10.1017/S001667230002098X; MAEDA H, 1992, DEVELOPMENT, V116, P369; Maeyama H, 2001, GASTROENTEROLOGY, V120, P210; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Maltby S, 2009, BBA-REV CANCER, V1796, P19, DOI 10.1016/j.bbcan.2009.02.001; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martin-Orozco N, 2009, CURR OPIN INVEST DR, V10, P543; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MEININGER CJ, 1992, BLOOD, V79, P958; Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008-5472.CAN-07-1882; Menard C, 2009, CANCER RES, V69, P3563, DOI 10.1158/0008-5472.CAN-08-3807; Molin D, 2002, BRIT J HAEMATOL, V119, P122, DOI 10.1046/j.1365-2141.2002.03768.x; Moller C, 2005, BLOOD, V106, P1330, DOI 10.1182/blood-2004-12-4792; Morales JK, 2010, GENES IMMUN, V11, P599, DOI 10.1038/gene.2010.35; Musch W, 2008, GENESIS, V46, P163, DOI 10.1002/dvg.20378; Nakai N, 2008, J PATHOL, V214, P302, DOI 10.1002/path.2296; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; Nigrovic PA, 2008, AM J PATHOL, V173, P1693, DOI 10.2353/ajpath.2008.080407; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Palmu S, 2002, ANTICANCER RES, V22, P411; Pan J, 2007, BLOOD, V109, P315, DOI 10.1182/blood-2006-04-013805; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Perez-Losada J, 2002, BLOOD, V100, P1274, DOI 10.1182/blood.V100.4.1274.h81602001274_1274_1286; Piconese S, 2009, BLOOD, V114, P2639, DOI 10.1182/blood-2009-05-220004; Pierotti MA, 2010, MOL ONCOL, V4, P19, DOI 10.1016/j.molonc.2009.10.003; Robson ME, 2004, CLIN CANCER RES, V10, P1250, DOI 10.1158/1078-0432.CCR-03-0110; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; Rossi F, 2006, P NATL ACAD SCI USA, V103, P12843, DOI 10.1073/pnas.0511076103; Rubin BP, 2005, CANCER RES, V65, P6631, DOI 10.1158/0008-5472.CAN-05-0891; Sakurai S, 2004, HUM PATHOL, V35, P1223, DOI 10.1016/j.humpath.2004.07.008; Scholten J, 2008, TRANSGENIC RES, V17, P307, DOI 10.1007/s11248-007-9153-4; Seggewiss R, 2005, BLOOD, V105, P2473, DOI 10.1182/blood-2004-07-2527; Shah NP, 2006, BLOOD, V108, P286, DOI 10.1182/blood-2005-10-3969; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; STANULLA M, 1995, ACTA NEUROPATHOL, V89, P158; Staser K, 2010, BLOOD, V116, P157, DOI 10.1182/blood-2009-09-242875; Swerdlow SH., 2017, WHO CLASSIFICATION T; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Tang YL, 2010, ORAL ONCOL, V46, P311, DOI 10.1016/j.oraloncology.2010.02.001; Taskinen M, 2008, BLOOD, V111, P4664, DOI 10.1182/blood-2007-11-125823; TAYLOR AM, 1995, IMMUNOLOGY, V86, P427; Teitell M, 1998, HUM PATHOL, V29, P1546, DOI 10.1016/S0046-8177(98)90029-6; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Theoharides TC, 2008, NEW ENGL J MED, V358, P1860, DOI 10.1056/NEJMcibr0801519; TONO T, 1992, BLOOD, V80, P1448; Tournilhac O, 2006, ANN ONCOL, V17, P1275, DOI 10.1093/annonc/mdl109; Tripodo C, 2010, AM J PATHOL, V177, P792, DOI 10.2353/ajpath.2010.091286; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Wasiuk A, 2009, CLIN EXP IMMUNOL, V155, P140, DOI 10.1111/j.1365-2249.2008.03840.x; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Westphal E, 1891, FARBENANALYTISCHE UN, P17; WINSHIP I, 1991, CLIN GENET, V39, P330; Woodman SE, 2010, BIOCHEM PHARMACOL, V80, P568, DOI 10.1016/j.bcp.2010.04.032; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041; Yang ZS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008922; Yared Marwan A, 2004, Breast J, V10, P323, DOI 10.1111/j.1075-122X.2004.21351.x; Young SM, 2007, CELL SIGNAL, V19, P2572, DOI 10.1016/j.cellsig.2007.08.004; Zappulla JP, 2005, J EXP MED, V202, P1635, DOI 10.1084/jem.20050807; Zaruba MM, 2010, CIRCULATION, V121, P1992, DOI 10.1161/CIRCULATIONAHA.109.909093; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U; Zudaire E, 2006, AM J PATHOL, V168, P280, DOI 10.2353/ajpath.2006.050291	141	56	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					757	769		10.1038/onc.2010.494	http://dx.doi.org/10.1038/onc.2010.494			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	21057534				2022-12-17	WOS:000287444600001
J	Pardali, E; van der Schaft, DWJ; Wiercinska, E; Gorter, A; Hogendoorn, PCW; Griffioen, AW; ten Dijke, P				Pardali, E.; van der Schaft, D. W. J.; Wiercinska, E.; Gorter, A.; Hogendoorn, P. C. W.; Griffioen, A. W.; ten Dijke, P.			Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma	ONCOGENE			English	Article						endoglin; tumor cell plasticity; transforming growth factor-beta; bone morphogenetic proteins; Ewing sarcoma; melanoma	VASCULOGENIC MIMICRY; MOLECULAR DETERMINANTS; OSTEOPONTIN EXPRESSION; UVEAL MELANOMA; ANGIOGENESIS; INVASION; PROMOTES; IDENTIFICATION; PROLIFERATION; PROTEIN	Tumor cell plasticity enables certain types of highly malignant tumor cells to dedifferentiate and engage a plastic multipotent embryonic-like phenotype, which enables them to 'adapt' during tumor progression and escape conventional therapeutic strategies. This plastic phenotype of aggressive cancer cells enables them to express endothelial cell-specific markers and form tubelike structures, a phenotype that has been linked to aggressive behavior and poor prognosis. We demonstrate here that the transforming growth factor (TGF)-beta co-receptor endoglin, an endothelial cell marker, is expressed by tumor cells and its expression correlates with tumor cell plasticity in two types of human cancer, Ewing sarcoma and melanoma. Moreover, endoglin expression was significantly associated with worse survival of Ewing sarcoma patients. Endoglin knockdown in tumor cells interferes with tumor cell plasticity and reduces invasiveness and anchorage-independent growth in vitro. Ewing sarcoma and melanoma cells with reduced endoglin levels showed reduced tumor growth in vivo. Mechanistically, we provide evidence that endoglin, while interfering with TGF-beta signaling, is required for efficient bone morphogenetic protein, integrin, focal adhesion kinase and phosphoinositide-3-kinase signaling in order to maintain tumor cell plasticity. The present study delineates an important role of endoglin in tumor cell plasticity and progression of aggressive tumors. Oncogene (2011) 30, 334-345; doi:10.1038/onc.2010.418; published online 20 September 2010	[Pardali, E.; Wiercinska, E.; ten Dijke, P.] Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [van der Schaft, D. W. J.] Eindhoven Univ Technol, Dept Biomed Engn, Soft Tissue Biomech & Engn, NL-5600 MB Eindhoven, Netherlands; [Gorter, A.; Hogendoorn, P. C. W.] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; [Griffioen, A. W.] Vrije Univ Amsterdam Med Ctr, Angiogenesis Lab, Dept Med Oncol, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Eindhoven University of Technology; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Pardali, E (corresponding author), Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol Cell Biol, Bldg 2,Room R-02-024,Postzone S-1-P,Postbus 9600, NL-2300 RC Leiden, Netherlands.	E.Pardali@lumc.nl; p.ten_dijke@lumc.nl	Hogendoorn, Pancras C.W./H-5859-2015; Hogendoorn, Pancras/O-6494-2019; Dijke, Peter ten/AAG-4660-2021	Hogendoorn, Pancras C.W./0000-0002-1513-8104; Hogendoorn, Pancras/0000-0002-1513-8104; Dijke, Peter ten/0000-0002-7234-342X; Wiercinska, Eliza/0000-0002-8434-6492	Centre of Biomedical Genetics, Dutch Cancer Society [RUL 2005-3371]; Ludwig Institute for Cancer Research; EC [504743, 518198, 018814]	Centre of Biomedical Genetics, Dutch Cancer Society(KWF Kankerbestrijding); Ludwig Institute for Cancer Research; EC(European CommissionEuropean Commission Joint Research Centre)	We thank the members of our research groups for help and suggestions during the course of this work. We are grateful to Margriet Ouwens for assistance with PI3K activity assays, Inge Briaire-de Bruijn for excellent technical assistance with the TMA histochemical analysis, Dagmar Berghuis for help with the patient's clinical characteristics, and David de Gorter for critical reading of the paper. This study was supported by grants from the Centre of Biomedical Genetics, Dutch Cancer Society (RUL 2005-3371), the Ludwig Institute for Cancer Research, and FP6 EC Integrated Projects: Angiotargeting (504743), EC STREP Tumor-Host-Genomics (518198) and EuroBoNeT (018814).	Altomonte M, 1996, BRIT J CANCER, V74, P1586, DOI 10.1038/bjc.1996.593; Ben-Haim N, 2006, DEV CELL, V11, P313, DOI 10.1016/j.devcel.2006.07.005; Bernabeu C, 2009, BBA-MOL BASIS DIS, V1792, P954, DOI 10.1016/j.bbadis.2009.07.003; David L, 2007, BLOOD, V109, P1953, DOI 10.1182/blood-2006-07-034124; Dome B, 2005, INT J CANCER, V116, P27, DOI 10.1002/ijc.20991; El Hallani S, 2010, BRAIN, V133, P973, DOI 10.1093/brain/awq044; Guo BQ, 2004, ANTICANCER RES, V24, P1337; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hendrix MJC, 2002, CANCER RES, V62, P665; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2005, CANCER RES, V65, P9851, DOI 10.1158/0008-5472.CAN-05-2172; Hess AR, 2003, CANCER RES, V63, P4757; Hess AR, 2001, CANCER RES, V61, P3250; Hillen F, 2008, BIOCHEM BIOPH RES CO, V368, P364, DOI 10.1016/j.bbrc.2008.01.080; Kadkol SS, 2006, INVEST OPHTH VIS SCI, V47, P802, DOI 10.1167/iovs.05-0422; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Medrano EE, 2003, ONCOGENE, V22, P3123, DOI 10.1038/sj.onc.1206452; Mueller AJ, 1998, ARCH OPHTHALMOL-CHIC, V116, P31, DOI 10.1001/archopht.116.1.31; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182; Rothhammer T, 2005, CANCER RES, V65, P448; Scavelli C, 2008, ONCOGENE, V27, P663, DOI 10.1038/sj.onc.1210691; Seftor EA, 2002, CLIN EXP METASTAS, V19, P233, DOI 10.1023/A:1015591624171; Seon BK, 1997, CLIN CANCER RES, V3, P1031; Sharma N, 2002, PROSTATE, V50, P189, DOI 10.1002/pros.10048; Shirakawa K, 2002, INT J CANCER, V99, P821, DOI 10.1002/ijc.10423; Sood AK, 2001, AM J PATHOL, V158, P1279, DOI 10.1016/S0002-9440(10)64079-5; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Sun BC, 2007, J CANCER RES CLIN, V133, P979, DOI 10.1007/s00432-007-0245-6; Szuhai K, 2006, CANCER GENET CYTOGEN, V166, P173, DOI 10.1016/j.cancergencyto.2005.11.006; ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; van der Schaft DWJ, 2005, CANCER RES, V65, P11520, DOI 10.1158/0008-5472.CAN-05-2468; van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Wong VCL, 2008, INT J CANCER, V123, P2816, DOI 10.1002/ijc.23882; Zhou YW, 2005, J INVEST DERMATOL, V124, P1044, DOI 10.1111/j.0022-202X.2005.23680.x	44	56	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					334	345		10.1038/onc.2010.418	http://dx.doi.org/10.1038/onc.2010.418			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20856203	Green Published			2022-12-17	WOS:000286418800008
J	Sommer, G; Dittmann, J; Kuehnert, J; Reumann, K; Schwartz, PE; Will, H; Coulter, BL; Smith, MT; Heise, T				Sommer, G.; Dittmann, J.; Kuehnert, J.; Reumann, K.; Schwartz, P. E.; Will, H.; Coulter, B. L.; Smith, M. T.; Heise, T.			The RNA-binding protein La contributes to cell proliferation and CCND1 expression	ONCOGENE			English	Article						La autoantigen; La protein; cyclin D1; CCND1; cell proliferation; cervical cancer	CYCLIN D1; GENE-EXPRESSION; FUNCTIONAL-CHARACTERIZATION; HUMAN-PAPILLOMAVIRUS; AUTOANTIGEN; TRANSLATION; SITE; CARCINOMA; NUCLEAR; CANCER	The La protein is an essential RNA-binding protein implicated in different aspects of RNA metabolism. Herein, we report that small interfering (siRNA)mediated La depletion reduces cell proliferation of different cell lines concomitant with a reduction in cyclin D1 (CCND1) protein. To exclude off-target effects we demonstrate that exogenous La expression in La-depleted cells restores cell proliferation and CCND1 protein levels. In contrast, proliferation of immortalized CCND1 knockout cells is not affected by La depletion, supporting a functional coherence between La, CCND1 and proliferation. Furthermore, we document by reversible in vivo crosslinking and ribonucleoprotein (RNP) immunoprecipitation an association of the La protein with CCND1 messengerRNA and that CCND1 internal ribosome entry site (IRES)-dependent translation is modulated by La protein level within the cell. In addition, we show elevated La protein expression in cervical cancer tissue and its correlation with aberrant CCND1 protein levels in cervical tumor tissue lysates. In conclusion, this study establishes a role of La in cell proliferation and CCND1 expression and demonstrates for the first time an overexpression of the RNA-binding protein La in solid tumors. Oncogene (2011) 30, 434-444; doi: 10.1038/onc.2010.425; published online 20 September 2010	[Sommer, G.; Dittmann, J.; Kuehnert, J.; Heise, T.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Dittmann, J.; Reumann, K.; Will, H.; Heise, T.] Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-2000 Hamburg, Germany; [Schwartz, P. E.] Prot Biotechnol Inc, Ramona, CA USA; [Coulter, B. L.; Smith, M. T.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical University of South Carolina; Heinrich Pette Institute; University of Hamburg; Medical University of South Carolina	Heise, T (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	heise@musc.edu			Deutsche Forschungsgemeinschaft [HE 2814/3-2]; Bundesministerium fur Gesundheit and Freie und Hansestadt Hamburg	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Gesundheit and Freie und Hansestadt Hamburg	We thank Arne Du "sedau (HPI) for sorting GFP-positive cells and Rick Peppler for FACS analysis (MUSC). We are grateful to R G Pestell (Thomas Jefferson University) for providing the MEF<SUP>CCND1-/-</SUP> cells, to M Bachmann (Technical University Dresden, Germany) for providing La antibodies, to Josef Gera for providing the CCND1-IRES reporter plasmid pRCD1F, to D Watson (MUSC) for experimental advice during this study, and D Fernandes (MUSC) and J Schnellmann (MUSC) for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft, HE 2814/3-2 (TH). The Heinrich-Pette-Institut (HPI) is financially supported by the Bundesministerium fur Gesundheit and Freie und Hansestadt Hamburg.	Al-Ejeh F, 2007, CLIN CANCER RES, V13, p5509S, DOI 10.1158/1078-0432.CCR-07-0922; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Ali N, 2000, J BIOL CHEM, V275, P27531; Bae DS, 2001, GYNECOL ONCOL, V81, P341, DOI 10.1006/gyno.2001.6196; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Brenet F, 2005, MOL CELL BIOL, V25, P7505, DOI 10.1128/MCB.25.17.7505-7521.2005; Brenet F, 2009, ONCOGENE, V28, P128, DOI 10.1038/onc.2008.376; Calkhoven CF, 2000, GENE DEV, V14, P1920; Carreras R, 2007, HISTOL HISTOPATHOL, V22, P587, DOI 10.14670/HH-22.587; CHANG YN, 1995, J VIROL, V69, P618, DOI 10.1128/JVI.69.1.618-619.1995; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Conesa-Zamora P, 2009, AM J CLIN PATHOL, V132, P378, DOI 10.1309/AJCPO0WY1VIFCYDC; Cordes S, 2008, BIOCHEM BIOPH RES CO, V368, P1014, DOI 10.1016/j.bbrc.2008.01.163; Costa-Mattioli M, 2004, MOL CELL BIOL, V24, P6861, DOI 10.1128/mcb.24.15.6861-6870.2004; Cowling VH, 2010, ONCOGENE, V29, P930, DOI 10.1038/onc.2009.368; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Ehlers I, 2004, J BIOL CHEM, V279, P43437, DOI 10.1074/jbc.M402227200; Frost P, 2009, MOL CANCER THER, V8, P83, DOI 10.1158/1535-7163.MCT-08-0254; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Horke S, 2004, J BIOL CHEM, V279, P26563, DOI 10.1074/jbc.M401017200; Inge LJ, 2008, MOL CANCER THER, V7, P1386, DOI 10.1158/1535-7163.MCT-07-2029; Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200; Kim YK, 2001, NUCLEIC ACIDS RES, V29, P5009, DOI 10.1093/nar/29.24.5009; Knudsen KE, 2006, ONCOGENE, V25, P1620, DOI 10.1038/sj.onc.1209371; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; Maraia RJ, 2001, J CELL BIOL, V153, pF13, DOI 10.1083/jcb.153.4.F13; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Musgrove EA, 2006, GROWTH FACTORS, V24, P13, DOI 10.1080/08977190500361812; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Nichols GE, 1996, MODERN PATHOL, V9, P418; Niranjanakumari S, 2002, METHODS, V26, P182, DOI 10.1016/S1046-2023(02)00021-X; Park JM, 2006, MOL CELL BIOL, V26, P1445, DOI 10.1128/MCB.26.4.1445-1451.2006; Pudi R, 2004, J BIOL CHEM, V279, P29879, DOI 10.1074/jbc.M403417200; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; SVITKIN YV, 1994, J VIROL, V68, P7001, DOI 10.1128/JVI.68.11.7001-7007.1994; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159-6173.2003; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033	48	56	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					434	444		10.1038/onc.2010.425	http://dx.doi.org/10.1038/onc.2010.425			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856207				2022-12-17	WOS:000286621600006
J	West, NR; Watson, PH				West, N. R.; Watson, P. H.			S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer	ONCOGENE			English	Article						breast cancer; S100A7; cytokines; inflammation	CARCINOMA IN-SITU; GENE-EXPRESSION; RECEPTOR; CELLS; IL-6; BINDING; STAT3; FEATURES; JAB1; DIFFERENTIATION	S100A7 promotes aggressive features in breast cancer, although regulation of its expression is poorly understood. As S100A7 associates with inflammation in skin and breast tissue, we hypothesized that inflammatory cytokines may regulate S100A7 in breast cancer. We therefore examined the effects of several cytokines, among which oncostatin-M (OSM) and the related cytokine, interleukin (IL)-6, showed the most significant effects on S100A7 expression in breast tumor cells in vitro. Both cytokines consistently induced S100A7 expression in three cell lines (MCF7, T47D and MDA-MB-468) in a dose- and time-dependent manner. Induction of S100A7 was inhibited by blockade of STAT3, phosphatidylinositol 3 kinase (PI3K) and ERK1/2 signaling and small interference RNA (siRNA)-mediated knockdown of S100A7 eliminated the promigratory effects of OSM treatment. S100A7 mRNA levels in a case-control cohort of breast tumors (n = 20) were significantly associated with expression of the OSM receptor beta (OSMR beta) chain (P = 0.0098). This association was confirmed using publicly available microarray data from an independent breast tumor cohort (n = 201, P = 0.0005) and a correlation between S100A7 and poor patient survival was observed specifically in cases with high OSMRb expression (HR = 2.35; P = 0.0396; n = 85). We conclude that inflammatory cytokines can regulate S100A7 expression and that S100A7 may mediate some of their effects in breast cancer. Oncogene (2010) 29, 2083-2092; doi: 10.1038/onc.2009.488; published online 18 January 2010	[West, N. R.; Watson, P. H.] British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, Victoria, BC V8R 6V5, Canada; [West, N. R.; Watson, P. H.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada; [Watson, P. H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of Victoria; University of British Columbia	Watson, PH (corresponding author), British Columbia Canc Agcy, Trev & Joyce Deeley Res Ctr, 2410 Lee Ave, Victoria, BC V8R 6V5, Canada.	pwatson@bccancer.bc.ca		West, Nathaniel/0000-0001-9991-0503; Watson, Peter/0000-0002-1642-0638	Canadian Institutes of Health Research (CIHR) [MOP-64349, PRG80155]; Manitoba Breast Tumor Bank; US DOD	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Manitoba Breast Tumor Bank; US DOD(United States Department of Defense)	We thank Rebecca Barnes for editorial and Melanie Olson for technical assistance, Dr Robert Burke for assistance with microscopy, and Dr Jiaxu Wang, Dr Julian Lum, Eric Tran and Darin Wick for helpful discussion. We also wish to thank the investigators responsible for making the UNC microarray data set publically available. PHW holds an operating grant from the Canadian Institutes of Health Research (CIHR, grant # MOP-64349). This study was supported by the Manitoba Breast Tumor Bank (supported by CIHR grant # PRG80155), a member of the Canadian Tumor Repository Network. NRW is supported by a US DOD Breast Cancer Research Program predoctoral traineeship award.	Al-Haddad S, 1999, AM J PATHOL, V155, P2057, DOI 10.1016/S0002-9440(10)65524-1; Badache A, 2001, CANCER RES, V61, P383; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bando M, 2007, IMMUNOL CELL BIOL, V85, P532, DOI 10.1038/sj.icb.7100078; Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695; Boniface K, 2007, J IMMUNOL, V178, P4615, DOI 10.4049/jimmunol.178.7.4615; Conze D, 2001, CANCER RES, V61, P8851; Dauer DJ, 2005, ONCOGENE, V24, P3397, DOI 10.1038/sj.onc.1208469; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2004, BREAST CANCER RES, V6, pR308, DOI 10.1186/bcr791; Emberley ED, 2004, BREAST CANCER RES, V6, P153, DOI 10.1186/bcr816; Emberley ED, 2003, CLIN CANCER RES, V9, P2627; Emberley ED, 2003, CANCER RES, V63, P1954; Enerback C, 2002, CANCER RES, V62, P43; Gaffen SL, 2008, CYTOKINE, V43, P402, DOI 10.1016/j.cyto.2008.07.017; Gazel A, 2006, J INVEST DERMATOL, V126, P2647, DOI 10.1038/sj.jid.5700461; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Hsu K, 2005, J IMMUNOL, V174, P2318, DOI 10.4049/jimmunol.174.4.2318; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Knupfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3; Krop I, 2005, CANCER RES, V65, P11326, DOI 10.1158/0008-5472.CAN-05-1523; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu JW, 1998, CYTOKINE, V10, P295, DOI 10.1006/cyto.1997.0283; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Naka T, 2002, ARTHRITIS RES THER, V4, pS233, DOI 10.1186/ar565; Paruchuri V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001741; Perrier S, 2009, FEBS LETT, V583, P259, DOI 10.1016/j.febslet.2008.12.030; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Petersson S, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-205; Rivard CJ, 2007, J BIOL CHEM, V282, P6644, DOI 10.1074/jbc.M609432200; Royuela M, 2004, J PATHOL, V202, P41, DOI 10.1002/path.1476; Sa SM, 2007, J IMMUNOL, V178, P2229, DOI 10.4049/jimmunol.178.4.2229; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shain KH, 2009, CANCER RES, V69, P1009, DOI 10.1158/0008-5472.CAN-08-2419; Skliris GP, 2007, BREAST CANCER RES TR, V104, P75, DOI 10.1007/s10549-006-9390-x; Tan JQ, 1996, J INVEST DERMATOL, V107, P5, DOI 10.1111/1523-1747.ep12294284; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Wang J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2105; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wolf R, 2008, J IMMUNOL, V181, P1499, DOI 10.4049/jimmunol.181.2.1499; Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	53	56	58	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2083	2092		10.1038/onc.2009.488	http://dx.doi.org/10.1038/onc.2009.488			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101226				2022-12-17	WOS:000276402800007
J	Mejias-Luque, R; Linden, SK; Garrido, M; Tye, H; Najdovska, M; Jenkins, BJ; Iglesias, M; Ernst, M; de Bolos, C				Mejias-Luque, R.; Linden, S. K.; Garrido, M.; Tye, H.; Najdovska, M.; Jenkins, B. J.; Iglesias, M.; Ernst, M.; de Bolos, C.			Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors	ONCOGENE			English	Article						gastric tumors; intestinal mucins; inflammatory cytokines; IL-6/gp130	LEWIS ANTIGEN-EXPRESSION; GP130 MUTANT MICE; CANCER-CELLS; HELICOBACTER-PYLORI; HUMAN STOMACH; KAPPA-B; MUC5AC; ACTIVATION; CARCINOMA; GROWTH	Infection of gastric mucosa by Helicobacter pylori induces an inflammatory response with increased levels of proinflammatory cytokines. Among them, tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta and IL-6 induce the activation of signaling pathways that regulate genes expression, such as MUC2 and MUC4 intestinal mucins ectopically detected in gastric tumors. This study evaluated if the predominant inflammatory cell type correlates with MUC2 and MUC4 expression in human intestinal gastric tumors (n = 78). In addition, we analyzed the regulatory effects of the associated inflammatory signaling pathways on their expression in gastric cancer cell lines, and in a mouse model with hyperactivated STAT3 signaling pathway. Tumors with predominant lymphoplasmocytic infiltrate (chronic inflammation), presented higher levels of MUC2 and were more differentiated than tumors with predominant polymorphonuclear infiltrate (acute inflammation). These differences can be attributed to specific cytokines, because TNF-alpha and IL-1 beta induced MUC2 but no MUC4 expression in gastric cancer cell lines. The two groups of tumors expressed similar levels of MUC4 that correlated with the expression of STAT3 transcription factor, implicated in the activation of genes through the IL-6 pathway. In gastric tissues from gp130(+/+), gp130(Y757F/Y757F) and gp130(Y757F/Y757F) Stat3(-/+) mice, Muc2 was not detected, whereas Muc4 was found in the gastric tumors developed in the gp130(Y757F/Y757F) mice, with hyperactivated STAT3. These data indicate that the signaling pathways associated with the inflammatory response can modulate the expression of MUC2 and MUC4 intestinal mucin genes, in human and mouse gastric tumors. Oncogene (2010) 29, 1753-1762; doi:10.1038/onc.2009.467; published online 11 January 2010	[Mejias-Luque, R.; Garrido, M.; Iglesias, M.; de Bolos, C.] IMIM Hosp Mar, Programa Recerca Canc, Barcelona 08003, Spain; [Linden, S. K.] Gothenburg Univ, Sahlgrenska Acad, Mucosal Immunobiol & Vaccine Ctr, Gothenburg, Sweden; [Tye, H.; Najdovska, M.; Jenkins, B. J.] Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic, Australia	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Gothenburg; Monash University	de Bolos, C (corresponding author), IMIM Hosp Mar, Programa Recerca Canc, Parc Recerca Biomed Barcelona,Dr Aiguader 88, Barcelona 08003, Spain.	cbolos@imim.es	Ernst, Matthias/D-5111-2012; jenkins, brendan/J-7854-2012; Lindén, Sara K/A-3271-2011	Ernst, Matthias/0000-0002-6399-1177; Lindén, Sara K/0000-0002-7751-9586; Jenkins, Brendan/0000-0002-7552-4656; Mejias-Luque, Raquel/0000-0002-4602-4927	Marato de TV3 [050930]; Instituto de Investigacion Carlos III [PI061421]; Swedish Cancer Foundation and Research Counsil (Cancerfonden and Vetenskapsradet); Jeansson foundation; Sylvia and Charles Viertel Charitable Foundation; Monash University; Cancer Council of Victoria; Association for International Cancer Research	Marato de TV3; Instituto de Investigacion Carlos III(Instituto de Salud Carlos III); Swedish Cancer Foundation and Research Counsil (Cancerfonden and Vetenskapsradet); Jeansson foundation; Sylvia and Charles Viertel Charitable Foundation; Monash University(Monash University); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Association for International Cancer Research	We thank the scientists providing the antibodies, Sergi Mojal for statistical analysis, and M Pera, A Dalmases, P Navarro and J Gunnarsson for helpful contributions. This work was supported by Marato de TV3 (050930), Instituto de Investigacion Carlos III (PI061421), the Swedish Cancer Foundation and Research Counsil (Cancerfonden and Vetenskapsradet) and the Jeansson foundation, Sylvia and Charles Viertel Charitable Foundation Senior Medical Research Fellowship, Monash University Fellowship, Cancer Council of Victoria Grant-in-aid, and the Association for International Cancer Research Grant awarded to BJJ.	Ahn DH, 2005, CELL PHYSIOL BIOCHEM, V15, P29, DOI 10.1159/000083636; Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DEBOLOS C, 1995, GASTROENTEROLOGY, V109, P723, DOI 10.1016/0016-5085(95)90379-8; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gartner F, 1996, VIRCHOWS ARCH, V428, P91; Gong WD, 2005, CLIN CANCER RES, V11, P1386, DOI 10.1158/1078-0432.CCR-04-0487; Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054; Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim DY, 2004, PHARMACOLOGY, V72, P6, DOI 10.1159/000078626; Kimura YN, 2007, CANCER SCI, V98, P2009, DOI 10.1111/j.1349-7006.2007.00633.x; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Leung WK, 2002, J PATHOL, V197, P582, DOI 10.1002/path.1147; Lidell ME, 2008, FEBS J, V275, P481, DOI 10.1111/j.1742-4658.2007.06215.x; Linden SK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003952; Lopez-Ferrer A, 2000, GUT, V47, P349, DOI 10.1136/gut.47.3.349; Lopez-Ferrer A, 2002, GLYCOCONJUGATE J, V19, P13, DOI 10.1023/A:1022576712961; Lopez-Ferrer A, 2001, AM J RESP CELL MOL, V24, P22, DOI 10.1165/ajrcmb.24.1.4294; Matsuda K, 2008, SCAND J GASTROENTERO, V43, P25, DOI 10.1080/00365520701579795; Mejias-Luque R, 2008, BBA-MOL CELL RES, V1783, P1728, DOI 10.1016/j.bbamcr.2008.05.020; Peek RM, 2006, J PATHOL, V208, P233, DOI 10.1002/path.1868; Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461; Reis CA, 1999, CANCER RES, V59, P1003; Sell S., 2001, IMMUNOLOGY IMMUNOPAT; Senapati S, 2008, HISTOL HISTOPATHOL, V23, P1541, DOI 10.14670/HH-23.1541; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Yakata Y, 2007, INT J ONCOL, V30, P437; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	33	56	58	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	12					1753	1762		10.1038/onc.2009.467	http://dx.doi.org/10.1038/onc.2009.467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062084				2022-12-17	WOS:000276022800005
J	Chua, YL; Ito, Y; Pole, JCM; Newman, S; Chin, SF; Stein, RC; Ellis, IO; Caldas, C; O'hare, MJ; Murrell, A; Edwards, PAW				Chua, Y. L.; Ito, Y.; Pole, J. C. M.; Newman, S.; Chin, S-F; Stein, R. C.; Ellis, I. O.; Caldas, C.; O'hare, M. J.; Murrell, A.; Edwards, P. A. W.			The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene	ONCOGENE			English	Article						breast cancer; NRG1; heregulins; DNA methylation; tumour suppressor gene; chromosome rearrangement	DIFFERENTIATION FACTOR NDF; MALIGNANT HUMAN BREAST; MOUSE MAMMARY-GLAND; CELL-LINES; GAMMA-HEREGULIN; GROWTH-FACTOR; CHROMOSOME-TRANSLOCATION; EPITHELIAL-CELLS; DNA METHYLATION; WERNER-SYNDROME	Neuregulin-1 (NRG1) is both a candidate oncogene and a candidate tumour suppressor gene. It not only encodes the heregulins and other mitogenic ligands for the ERBB family, but also causes apoptosis in NRG1-expressing cells. We found that most breast cancer cell lines had reduced or undetectable expression of NRG1. This included cell lines that had translocation breaks in the gene. Similarly, expression in cancers was generally comparable to or less than that in various normal breast samples. Many non-expressing cell lines had extensive methylation of the CpG island at the principal transcription start site at exon 2 of NRG1. Expression was reactivated by demethylation. Many tumours also showed methylation, whereas normal mammary epithelial fragments had none. Lower NRG1 expression correlated with higher methylation. Small interfering RNA (siRNA)-mediated depletion of NRG1 increased net proliferation in a normal breast cell line and a breast cancer cell line that expressed NRG1. The short arm of chromosome 8 is frequently lost in epithelial cancers, and NRG1 is the most centromeric gene that is always affected. NRG1 may therefore be the major tumour suppressor gene postulated to be on 8p: it is in the correct location, is antiproliferative and is silenced in many breast cancers. Oncogene (2009) 28, 4041-4052; doi:10.1038/onc.2009.259; published online 5 October 2009	[Edwards, P. A. W.] Univ Cambridge, Dept Pathol, Hutchison Med Res Council, Res Ctr, Cambridge CB2 0XZ, England; [Ito, Y.; Chin, S-F; Caldas, C.; Murrell, A.] Univ Cambridge, Dept Oncol, Canc Res UK Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0XZ, England; [Stein, R. C.; O'hare, M. J.] UCL, Ludwig Inst Canc Res, Breast Canc Lab, Univ Coll & Middlesex Sch Med, London, England; [Ellis, I. O.] Univ Nottingham Mol Med Sci, Dept Histopathol, City Hosp Nottingham, Nottingham, England	University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Ludwig Institute for Cancer Research; University of London; University College London; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Edwards, PAW (corresponding author), Univ Cambridge, Dept Pathol, Hutchison Med Res Council, Res Ctr, Cambridge CB2 0XZ, England.	pawe1@cam.ac.uk	Caldas, Carlos/A-7543-2008; Stein, Robert C/N-6679-2015; Newman, Scott/B-4843-2012; Caldas, Carlos/U-7250-2019; Edwards, Paul A/M-8291-2014	Stein, Robert C/0000-0003-2969-0415; Caldas, Carlos/0000-0003-3547-1489; Edwards, Paul A/0000-0002-4789-3374; Ellis, Ian/0000-0001-5292-8474; chin, suet-feung/0000-0001-5697-1082	Breast Cancer Campaign; Cancer Research UK; Hutchison-Whampoa Ltd.; Ludwig Institute for Cancer Research	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Hutchison-Whampoa Ltd.; Ludwig Institute for Cancer Research	We thank Huai-En Huang for some exploratory expression analysis. This study was funded principally by the Breast Cancer Campaign and also by Cancer Research UK, Hutchison-Whampoa Ltd. (who endowed the buildings in which the work was done) and the Ludwig Institute for Cancer Research.	Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amin DN, 2005, EXP CELL RES, V309, P12, DOI 10.1016/j.yexcr.2005.04.034; Birnbaum D, 2003, LANCET ONCOL, V4, P639, DOI 10.1016/S1470-2045(03)01225-7; BRADBURY JM, 1993, ONCOGENE, V8, P1551; BRIAND P, 1987, IN VITRO CELL DEV B, V23, P181, DOI 10.1007/BF02623578; Britsch S, 2007, ADV ANAT EMBRYOL CEL, V190, P1; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; Clarke C, 2005, J MAMMARY GLAND BIOL, V10, P273, DOI 10.1007/s10911-005-9587-3; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; Crabbe L, 2007, P NATL ACAD SCI USA, V104, P2205, DOI 10.1073/pnas.0609410104; Deadwyler GD, 2000, GLIA, V32, P304, DOI 10.1002/1098-1136(200012)32:3<304::AID-GLIA90>3.3.CO;2-Q; EDWARDS PAW, 1986, J CELL SCI, V80, P91; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Grigoriadis A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1604; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Grimm S, 1998, J EXP MED, V188, P1535, DOI 10.1084/jem.188.8.1535; Hayes NVL, 2008, J MAMMARY GLAND BIOL, V13, P205, DOI 10.1007/s10911-008-9078-4; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Kalirai H, 2006, J PATHOL, V208, P7, DOI 10.1002/path.1881; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Liu XF, 1999, ONCOGENE, V18, P7110, DOI 10.1038/sj.onc.1203136; Muraoka-Cook RS, 2008, J MAMMARY GLAND BIOL, V13, P235, DOI 10.1007/s10911-008-9080-x; Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05; Naderi A, 2007, CANCER RES, V67, P6725, DOI 10.1158/0008-5472.CAN-06-4394; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Steinthorsdottir V, 2004, GENE, V342, P97, DOI 10.1016/j.gene.2004.07.029; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Takizawa T, 2001, DEV CELL, V1, P749, DOI 10.1016/S1534-5807(01)00101-0; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Weinstein EJ, 2000, CANCER RES, V60, P3856; Weinstein EJ, 1998, ONCOGENE, V17, P2107, DOI 10.1038/sj.onc.1202428; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	47	56	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2009	28	46					4041	4052		10.1038/onc.2009.259	http://dx.doi.org/10.1038/onc.2009.259			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AE	19802002	Green Submitted, Green Accepted			2022-12-17	WOS:000272560500001
J	Thirkettle, HJ; Mills, IG; Whitaker, HC; Neal, DE				Thirkettle, H. J.; Mills, I. G.; Whitaker, H. C.; Neal, D. E.			Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression	ONCOGENE			English	Article						LYRIC/AEG-1; PLZF; transcription; repression; nucleus	ASTROCYTE-ELEVATED GENE-1; PROSTATE-CANCER; PROTEIN PLZF; BREAST-CANCER; C-MYC; IDENTIFICATION; METASTASIS; ACTIVATION; PROGRESSION; EXPRESSION	LYRIC/AEG-1 and its altered expression have been linked to carcinogenesis in prostate, brain and melanoma as well as promoting chemoresistance and metastasis in breast cancer. LYRIC/AEG-1 function remains unclear, although LYRIC/AEG-1 is activated by oncogenic HA-RAS, through binding of c-myc to its promoter, which in turn regulates the key components of the PI3-kinase and nuclear factor-kappa B pathways. We have identified the transcriptional repressor PLZF as an interacting protein of LYRIC/AEG through a yeast two-hybrid screen. PLZF regulates the expression of genes involved in cell growth and apoptosis including c-myc. Coexpression of LYRIC/AEG-1 with PLZF leads to a reduction in PLZF-mediated repression by reducing PLZF binding to promoters. We have confirmed that nuclear LYRIC/AEG-1 and PLZF interact in mammalian cells via the N- and C termini of LYRIC/AEG-1 and a region C terminal to the RD2 domain of PLZF. Both proteins colocalize to nuclear bodies containing histone deacetylases, which are known to promote PLZF-mediated repression. Our data suggest one mechanism for cells with altered LYRIC/AEG-1 expression to evade apoptosis and increase cell growth during tumourigenesis through the regulation of PLZF repression. Oncogene (2009) 28, 3663-3670; doi:10.1038/onc.2009.223; published online 3 August 2009	[Whitaker, H. C.] Canc Res UK Cambridge Res Inst, Urooncol Res Grp, Li Ka Shing Ctr, Cambridge CB2 0RE, England	Cancer Research UK; CRUK Cambridge Institute	Whitaker, HC (corresponding author), Canc Res UK Cambridge Res Inst, Urooncol Res Grp, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 0RE, England.	Hayley.Whitaker@cancer.org.uk	Mills, Ian/AAK-9292-2020	Mills, Ian/0000-0001-5347-5083; Neal, David/0000-0002-6033-5086	Cancer Research UK; Medical Research Council; Cancer Research UK Cambridge Genomics Core Facility and Microscopy Core Facility; MRC [G0500966] Funding Source: UKRI; Medical Research Council [G0500966] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK Cambridge Genomics Core Facility and Microscopy Core Facility(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funding for this study was provided by Cancer Research UK (DEN, HCW, IGM) and the Medical Research Council (HJT). We thank Jonathon D Licht for the PLZF reporter construct 4xIL-3R-tkLUC, Zhou Wang (Chicago) for PLZF expression construct, Krishna Chatterjee (Cambridge) for pEF-BOS-b-gal construct. We also thank Wendy Bickmore for LYRIC/AEG-1 antibodies (Edinburgh) and Maria Carmo-Fonseca (Lisbon) for the anti-coilin antibody. We are very grateful to Antonio Ramos-Montoya (Cambridge) for help and advice with ChIP and qRT -PCR. We acknowledge the support of the Cancer Research UK Cambridge Genomics Core Facility and Microscopy Core Facility, The University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited.	Ash SC, 2008, BIOCHEM BIOPH RES CO, V371, P333, DOI 10.1016/j.bbrc.2008.04.084; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Bernardo MV, 2007, BIOCHEM BIOPH RES CO, V359, P317, DOI 10.1016/j.bbrc.2007.05.085; Brooke GN, 2008, ONCOGENE, V27, P2941, DOI 10.1038/sj.onc.1210955; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Chao TT, 2007, BIOCHEM BIOPH RES CO, V358, P475, DOI 10.1016/j.bbrc.2007.04.157; Chauchereau A, 2004, ONCOGENE, V23, P8777, DOI 10.1038/sj.onc.1208128; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Jiang F, 2004, PROSTATE, V59, P426, DOI 10.1002/pros.20000; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kang SI, 2003, J BIOL CHEM, V278, P51479, DOI 10.1074/jbc.M309237200; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Kikugawa T, 2006, PROSTATE, V66, P1092, DOI 10.1002/pros.20443; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kwong LN, 2009, CANCER CELL, V15, P1, DOI 10.1016/j.ccr.2008.12.007; Lee SG, 2006, P NATL ACAD SCI USA, V103, P17390, DOI 10.1073/pnas.0608386103; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sutherland HGE, 2004, EXP CELL RES, V294, P94, DOI 10.1016/j.yexcr.2003.11.020; Thirkettle HJ, 2009, CLIN CANCER RES, V15, P3003, DOI 10.1158/1078-0432.CCR-08-2046; Waghray A, 2001, PROTEOMICS, V1, P1327, DOI 10.1002/1615-9861(200110)1:10<1327::AID-PROT1327>3.3.CO;2-2; Whitaker HC, 2007, PROSTATE, V67, P943, DOI 10.1002/pros.20580	28	56	59	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3663	3670		10.1038/onc.2009.223	http://dx.doi.org/10.1038/onc.2009.223			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648967				2022-12-17	WOS:000270851800007
J	Attema, JL; Pronk, CJH; Norddahl, GL; Nygren, JM; Bryder, D				Attema, J. L.; Pronk, C. J. H.; Norddahl, G. L.; Nygren, J. M.; Bryder, D.			Hematopoietic stem cell ageing is uncoupled from p16(INK4A)-mediated senescence	ONCOGENE			English	Article						stem cells; hematopoiesis; ageing; senescence	TUMOR-SUPPRESSOR; BONE-MARROW; PROTEINS; GENE; AGE; PROLIFERATION; METHYLATION; PROGENITORS; POPULATION; EXPRESSION	Somatic stem cells are ultimately responsible for mediating appropriate organ homeostasis and have therefore been proposed to represent a cellular origin of the ageing process-a state often characterized by inappropriate homeostasis. Specifically, it has been suggested that ageing stem cells might succumb to replicative senescence by a mechanism involving the cyclin-dependent kinase inhibitor p16(INK4A). Here, we tested multiple functional and molecular parameters indicative of p16(INK4A) activity in primary aged murine hematopoietic stem cells (HSCs). We found no evidence that replicative senescence accompanies stem cell ageing in vivo, and in line with p16(INK4A) being a critical determinant of such processes, most aged HSCs (>99%) failed to express p16(INK4A) at the mRNA level. Moreover, whereas loss of epigenetically guided repression of the INK4A/ARF locus accompanied replicative senescent murine embryonic fibroblasts, such repression was maintained in aged stem cells. Taken together, these studies indicate that increased senescence as mediated by the p16(INK4A) tumor suppressor has only a minor function as an intrinsic regulator of steady-state HSC ageing in vivo. Oncogene (2009) 28, 2238-2243; doi: 10.1038/onc.2009.94; published online 27 April 2009	[Attema, J. L.; Pronk, C. J. H.; Norddahl, G. L.; Nygren, J. M.; Bryder, D.] Lund Univ, Immunol Unit, Expt Med Res Inst, S-22184 Lund, Sweden	Lund University	Bryder, D (corresponding author), Lund Univ, Immunol Unit, Expt Med Res Inst, BMC D14, S-22184 Lund, Sweden.	David.Bryder@med.lu.se	Bryder, David/Q-6292-2019	Bryder, David/0000-0002-8761-4237; Nygren, Jens M/0000-0002-3576-2393	Swedish Medical Research Council; Swedish Strategic Research Foundation; Swedish Cancer Society; Crafoord foundation and the Medical Faculty at Lund University	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Strategic Research Foundation(Swedish Foundation for Strategic Research); Swedish Cancer Society(Swedish Cancer Society); Crafoord foundation and the Medical Faculty at Lund University	We thank William Agace for critical review of the paper. The expert technical support from Gerd Sten is greatly appreciated. These studies were generously supported by grants to DB from the Swedish Medical Research Council, the Swedish Strategic Research Foundation, The Swedish Cancer Society, The Crafoord foundation and the Medical Faculty at Lund University.	Attema JL, 2007, P NATL ACAD SCI USA, V104, P12371, DOI 10.1073/pnas.0704468104; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bryder D, 2006, AM J PATHOL, V169, P338, DOI 10.2353/ajpath.2006.060312; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Mansson R, 2007, IMMUNITY, V26, P407, DOI 10.1016/j.immuni.2007.02.013; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Nygren JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003710; Oguro H, 2006, J EXP MED, V203, P2247, DOI 10.1084/jem.20052477; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; Pearce DJ, 2007, STEM CELLS, V25, P828, DOI 10.1634/stemcells.2006-0405; Pronk CJH, 2007, CELL STEM CELL, V1, P428, DOI 10.1016/j.stem.2007.07.005; Randall TD, 1998, STEM CELLS, V16, P38, DOI 10.1002/stem.160038; Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918; Ringrose L, 2007, DEVELOPMENT, V134, P223, DOI 10.1242/dev.02723; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Sharpless NE, 2007, NAT REV MOL CELL BIO, V8, P703, DOI 10.1038/nrm2241; Signer RAJ, 2008, GENE DEV, V22, P3115, DOI 10.1101/gad.1715808; Sudo K, 2000, J EXP MED, V192, P1273, DOI 10.1084/jem.192.9.1273; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	26	56	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2009	28	22					2238	2243		10.1038/onc.2009.94	http://dx.doi.org/10.1038/onc.2009.94			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453VF	19398954				2022-12-17	WOS:000266640300006
J	Morrison, BH; Haney, R; Lamarre, E; Drazba, J; Prestwich, GD; Lindner, DJ				Morrison, B. H.; Haney, R.; Lamarre, E.; Drazba, J.; Prestwich, G. D.; Lindner, D. J.			Gene deletion of inositol hexakisphosphate kinase 2 predisposes to aerodigestive tract carcinoma	ONCOGENE			English	Article						inositol hexakisphosphate kinase 2; chemical carcinogenesis; ionizing radiation; proliferation; inositol polyphosphates; apoptosis	DNA-PK; PYROPHOSPHATES; PHOSPHATE; HEAD; 3P; 12P12-13; GROWTH; ASSAY; BETA; KU	Inositol hexakisphosphate kinase 2 (IP6K2), a member of the inositol hexakisphosphate kinase family, functions as a growth suppressive and apoptosis-enhancing kinase during cell stress. We created mice with a targeted deletion of IP6K2; these mice display normal embryogenesis, development, growth and fertility. Chronic exposure to the carcinogen 4-nitroquinoline 1-oxide (4-NQO, a UV-mimetic compound) in drinking water resulted in fourfold increased incidence of invasive squamous cell carcinoma (SCC) formation in the oral cavity and esophagus of the knockout (KO) mice compared to the wild-type (WT) littermates. Paradoxically, KO mice displayed relative resistance to ionizing radiation and exhibit enhanced survival following 8-10 Gy total body irradiation. Primary KO fibroblasts displayed resistance to antiproliferative effects of interferon-beta and increased colony forming units following ionizing radiation. Radioresistance of KO fibroblasts was associated with accelerated DNA repair measured by comet assay. Direct microinjection of 5-PP-Ins(1,2,3,4,6) P-5 (the enzymatic product of IP6K2), but not InsP(6) (the substrate of IP6K2) induced cell death in SCC22A squamous carcinoma cells. Oncogene (2009) 28, 2383-2392; doi:10.1038/onc.2009.113; published online 11 May 2009	[Lindner, D. J.] Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, Cleveland, OH 44195 USA; [Lamarre, E.] Cleveland Clin, Head & Neck Inst, Cleveland, OH 44195 USA; [Drazba, J.] Cleveland Clin, Res Core Adm, Cleveland, OH 44195 USA; [Prestwich, G. D.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA; [Lindner, D. J.] Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Utah System of Higher Education; University of Utah; Cleveland Clinic Foundation	Lindner, DJ (corresponding author), Cleveland Clin, Ctr Hematol & Oncol Mol Therapeut, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.	lindned@ccf.org	Lindner, Daniel/ABB-5440-2020		NIH/NCI [CA095020]; NIH [NS29632]; NATIONAL CANCER INSTITUTE [R01CA095020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Philip Sanford, University of Cincinnati, for design of targeting vector and creation of IHPK2 knockout mice. Donna Kusewitt, Ohio State University, Director, Mouse Phenotyping Shared Resource, kusewitt. 1@osu.edu, conducted the phenotyping studies. Judy Drazba, Cleveland Clinic Imaging Core, performed the time-lapse photography of microinjected cells. Dr Yong Xu, Dr Honglu Zhang and Dr Jianxing Zhang performed the synthesis of 5-PP-Ins( 1,2,3,4,6)P<INF>5</INF>. These studies were supported by grants from NIH/NCI (CA095020) to DJL and from NIH (NS29632) to GDP.	Bhandari R, 2008, P NATL ACAD SCI USA, V105, P2349, DOI 10.1073/pnas.0712227105; Bhandari R, 2007, P NATL ACAD SCI USA, V104, P15305, DOI 10.1073/pnas.0707338104; Byrum J, 2004, NUCLEIC ACIDS RES, V32, P2776, DOI 10.1093/nar/gkh592; Chakraborty SB, 2003, CANCER GENET CYTOGEN, V146, P130, DOI 10.1016/S0165-4608(03)00127-4; Cheung JCY, 2008, NUCLEIC ACIDS RES, V36, P5713, DOI 10.1093/nar/gkn572; Fridy PC, 2007, J BIOL CHEM, V282, P30754, DOI 10.1074/jbc.M704656200; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; HAWKINS BL, 1994, HEAD NECK-J SCI SPEC, V16, P424, DOI 10.1002/hed.2880160506; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Hoornaert I, 2003, ONCOGENE, V22, P7728, DOI 10.1038/sj.onc.1207089; Illies C, 2007, SCIENCE, V318, P1299, DOI 10.1126/science.1146824; Kawata T, 2005, RADIAT RES, V164, P509, DOI 10.1667/RR3382.1; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; Kibel AS, 2004, INT J CANCER, V109, P668, DOI 10.1002/ijc.20060; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; Lu BJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-40; Luo HBR, 2003, CELL, V114, P559, DOI 10.1016/S0092-8674(03)00640-8; MA Y, 2002, J BIOL CHEM, V30, P30; MAESTRO R, 1993, CANCER RES, V53, P5775; Magnusdottir E, 2007, P NATL ACAD SCI USA, V104, P14988, DOI 10.1073/pnas.0707323104; Morrison BH, 2002, ONCOGENE, V21, P1882, DOI 10.1038/sj.onc.1205265; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Mulugu S, 2007, SCIENCE, V316, P106, DOI 10.1126/science.1139099; Nagata E, 2005, J BIOL CHEM, V280, P1634, DOI 10.1074/jbc.M409416200; PANIGRAHI GB, 1990, BIOCHEMISTRY-US, V29, P2122, DOI 10.1021/bi00460a023; Pogach MS, 2007, J CELL BIOCHEM, V100, P1415, DOI 10.1002/jcb.21142; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Teng CH, 2007, J BIOL CHEM, V282, P28395, DOI 10.1074/jbc.M705142200; Wojewodzka M, 2002, MUTAT RES-GEN TOX EN, V518, P9, DOI 10.1016/S1383-5718(02)00070-0; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zhang HL, 2009, ORG LETT, V11, P1551, DOI 10.1021/ol900149x	37	56	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	25					2383	2392		10.1038/onc.2009.113	http://dx.doi.org/10.1038/onc.2009.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462HS	19430495	Green Accepted			2022-12-17	WOS:000267342400003
J	Takai, A; Toyoshima, T; Uemura, M; Kitawaki, Y; Marusawa, H; Hiai, H; Yamada, S; Okazaki, IM; Honjo, T; Chiba, T; Kinoshita, K				Takai, A.; Toyoshima, T.; Uemura, M.; Kitawaki, Y.; Marusawa, H.; Hiai, H.; Yamada, S.; Okazaki, I. M.; Honjo, T.; Chiba, T.; Kinoshita, K.			A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations	ONCOGENE			English	Article						hepatic cancer; stem cell marker; activation-induced cytidine deaminase; Cre recombinase; somatic mutation; animal model	INDUCED CYTIDINE DEAMINASE; HEPATOCELLULAR-CARCINOMA; CONSTITUTIVE EXPRESSION; STEM-CELLS; HBX GENE; CANCER; VIRUS; STEATOHEPATITIS; PROLIFERATION; GENERATION	Activation-induced cytidine deaminase (AID), the only enzyme that is known to be able to induce mutations in the human genome, is required for somatic hypermutation and class-switch recombination in B lymphocytes. Recently, we showed that AID is implicated in the pathogenesis of human cancers including hepatitis C virus (HCV)-induced human hepatocellular carcinoma (HCC). In this study, we established a new AID transgenic mouse model (TNAP-AID) in which AID is expressed in cells producing tissue-nonspeci. c alkaline phosphatase (TNAP), which is a marker of primordial germ cells and immature stem cells, including ES cells. High expression of TNAP was found in the liver of the embryos and adults of TNAP-AID mice. HCC developed in 27% of these mice at the age of approximately 90 weeks. The HCC that developed in TNAP-AID mice expressed alpha-fetoprotein and had deleterious mutations in the tumour suppressor gene Trp53, some of which corresponded to those found in human cancer. In conclusion, TNAP-AID is a mouse model that spontaneously develops HCC, sharing genetic and phenotypic features with human HCC, which develops in the inflamed liver as a result of the accumulation of genetic changes.	[Toyoshima, T.; Uemura, M.; Hiai, H.; Kinoshita, K.] Shiga Med Ctr Res Inst, Shiga 5248524, Japan; [Takai, A.; Marusawa, H.; Chiba, T.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto, Japan; [Kitawaki, Y.; Okazaki, I. M.; Honjo, T.] Kyoto Univ, Grad Sch Med, Dept Immunol & Genom Med, Kyoto, Japan; [Yamada, S.] Immunobiol Labs Co Ltd, Mikasa Lab, Mikasa, Japan	Kyoto University; Kyoto University; Immuno-Biological Laboratories Co. Ltd.	Kinoshita, K (corresponding author), Shiga Med Ctr Res Inst, 5-4-1930, Shiga 5248524, Japan.	kkinoshi.shigamed@mac.com	Honjo, Tasuku/N-4470-2016	Okazaki, Il-mi/0000-0001-8644-0100; Marusawa, Hiroyuki/0000-0002-4286-2712	Grant-in-Aid for Scientific Research [17013042, 18390122]; Takeda Science Foundation	Grant-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank Dr Andras Nagy for his generous gift of TNAP-Cre mice, Dr Takashi Shinohara for suggesting the choice of the Cre mouse strain, Dr Yoshinobu Toda for the preparation of tissue sections and Dr Masayuki Tsuji for technical help with the immunohistochemical analyses. We also thank Dr Sidonia Fagarasan for critical reading of the manuscript and discussions. This study was supported by Grant-in-Aid for Scientific Research (17013042 and 18390122) and the Takeda Science Foundation.	Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Factor VM, 1997, CANCER RES, V57, P2089; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Katzenellenbogen M, 2006, CANCER RES, V66, P4001, DOI 10.1158/0008-5472.CAN-05-2937; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kinoshita K, 2006, INT J HEMATOL, V83, P201, DOI 10.1532/IJH97.06011; KOIKE K, 1994, HEPATOLOGY, V19, P810, DOI 10.1002/hep.1840190403; Koike K, 2002, J GASTROEN HEPATOL, V17, P394, DOI 10.1046/j.1440-1746.2002.02763.x; Komori J, 2008, HEPATOLOGY, V47, P888, DOI 10.1002/hep.22125; Kotani A, 2005, P NATL ACAD SCI USA, V102, P4506, DOI 10.1073/pnas.0500830102; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; Kues WA, 2005, BIOL REPROD, V72, P1020, DOI 10.1095/biolreprod.104.031229; Lomeli H, 2000, GENESIS, V26, P116, DOI 10.1002/(SICI)1526-968X(200002)26:2<116::AID-GENE4>3.0.CO;2-X; Ma W, 2006, ONCOGENE, V25, P4207, DOI 10.1038/sj.onc.1209450; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Marusawa H, 2008, INT J BIOCHEM CELL B, V40, P1399, DOI 10.1016/j.biocel.2008.01.018; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Morgan HD, 2004, J BIOL CHEM, V279, P52353, DOI 10.1074/jbc.M407695200; MURAKAMI H, 1993, CANCER RES, V53, P1719; Muto T, 2006, P NATL ACAD SCI USA, V103, P2752, DOI 10.1073/pnas.0510970103; Nakau M, 2002, CANCER RES, V62, P4549; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Riehle KJ, 2008, J EXP MED, V205, P91, DOI 10.1084/jem.20070820; Sakurai T, 2006, P NATL ACAD SCI USA, V103, P10544, DOI 10.1073/pnas.0603499103; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schreck S, 2006, J PATHOL, V210, P26, DOI 10.1002/path.2014; Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tsuji M, 2008, IMMUNITY, V29, P261, DOI 10.1016/j.immuni.2008.05.014; URVEN LE, 1993, BIOL REPROD, V48, P564, DOI 10.1095/biolreprod48.3.564; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang L, 2005, BIOL REPROD, V73, P149, DOI 10.1095/biolreprod.104.037150; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	37	56	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					469	478		10.1038/onc.2008.415	http://dx.doi.org/10.1038/onc.2008.415			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997814	Green Submitted			2022-12-17	WOS:000262866500001
J	Kurisetty, VV; Johnston, PG; Johnston, N; Erwin, P; Crowe, P; Fernig, DG; Campbell, FC; Anderson, IP; Rudland, PS; El-Tanani, MK				Kurisetty, V. V.; Johnston, P. G.; Johnston, N.; Erwin, P.; Crowe, P.; Fernig, D. G.; Campbell, F. C.; Anderson, I. P.; Rudland, P. S.; El-Tanani, M. K.			RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin	ONCOGENE			English	Article						osteopontin; RAN; breast cancer invasion and metastasis	MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; BINDING-PROTEIN; PLASMA OSTEOPONTIN; NUCLEAR-PROTEIN; RAN/TC4 GTPASE; C-MET; EXPRESSION; METASTASIS	Osteopontin (OPN) is a phosphorylated glycoprotein that binds to alpha v-containing integrins and is important in malignant transformation and cancer. Previously, we have utilized suppressive subtractive hybridization between mRNAs isolated from the Rama 37 (R37) rat mammary cell line and a subclone rendered invasive and metastatic by stable transfection with an expression vector for OPN to identify RAN GTPase (RAN) as the most over-expressed gene, in addition to that of OPN. Here we show that transfection of noninvasive R37 cells with an expression vector for RAN resulted in increased anchorage-independent growth, cell attachment and invasion through Matrigel in vitro, and metastasis in syngeneic rats. This induction of a malignant phenotype was induced independently of the expression of OPN, and was reversed by specifically reducing the expression of RAN using small-interfering RNAs. By using a combination of mutant protein and inhibitors, it was found that RAN signal transduction occurred through the c-Met receptor and PI3 kinase. This study therefore identifies RAN as a novel effector of OPN-mediated malignant transformation and some of its downstream signaling events in a mammary epithelial model of cancer invasion/metastasis.	[Johnston, P. G.; Johnston, N.; Erwin, P.; Crowe, P.; Campbell, F. C.; El-Tanani, M. K.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7LB, Antrim, North Ireland; [Fernig, D. G.; Anderson, I. P.; Rudland, P. S.] Univ Liverpool, Canc & Polio Res Fund Labs, Sch Biol Sci, Liverpool L69 3BX, Merseyside, England	Queens University Belfast; University of Liverpool	El-Tanani, MK (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, 97 Lisburn Rd, Belfast BT9 7LB, Antrim, North Ireland.	m.el-tanani@qub.ac.uk	Fernig, David G/A-3590-2008; Johnston, Nick/C-3028-2008	Fernig, David G/0000-0003-4875-4293; El-Tanani, Mohamed/0000-0002-4735-5445; Campbell, Frederick/0000-0002-0363-9964	Research and Development Office, Queen's University Belfast, Northern Ireland, UK; Cancer and Polio Research Fund, Wirral, UK; Northwest Cancer Research Fund, Liverpool, UK	Research and Development Office, Queen's University Belfast, Northern Ireland, UK; Cancer and Polio Research Fund, Wirral, UK; Northwest Cancer Research Fund, Liverpool, UK	This work was supported by grants from Research and Development Office, Queen's University Belfast, Northern Ireland, UK and The Cancer and Polio Research Fund, Wirral, UK. DGF's post is funded by the Northwest Cancer Research Fund, Liverpool, UK.	Abe H, 2008, INT J CANCER, V122, P2391, DOI 10.1002/ijc.23400; Azuma K, 2004, CLIN CANCER RES, V10, P6695, DOI 10.1158/1078-0432.CCR-04-0818; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; Bramwell VHC, 2006, CLIN CANCER RES, V12, P3337, DOI 10.1158/1078-0432.CCR-05-2354; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Chen HJ, 1997, ONCOGENE, V14, P1581, DOI 10.1038/sj.onc.1200993; Darzynkiewicz Z, 2001, Curr Protoc Cell Biol, VChapter 8, DOI 10.1002/0471143030.cb0804s01; Das R, 2005, IUBMB LIFE, V57, P441, DOI 10.1080/15216540500159424; DAVIES BR, 1993, ONCOGENE, V8, P999; Denti S, 2004, J BIOL CHEM, V279, P13027, DOI 10.1074/jbc.M313515200; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; El-Tanani MK, 2006, J BIOL CHEM, V281, P26587, DOI 10.1074/jbc.M604403200; El-Tanani MK, 2006, CYTOKINE GROWTH F R, V17, P463, DOI 10.1016/j.cytogfr.2006.09.010; Emberley ED, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-28; Furger KA, 2003, MOL CANCER RES, V1, P810; Hafizi S, 2005, INT J BIOCHEM CELL B, V37, P2344, DOI 10.1016/j.biocel.2005.05.006; Hara S, 2008, BIOCHEM BIOPH RES CO, V370, P123, DOI 10.1016/j.bbrc.2008.03.042; Johnston NIF, 2008, FRONT BIOSCI-LANDMRK, V13, P4361, DOI 10.2741/3009; Kilty IC, 1999, J NEUROCHEM, V73, P1859; KURISETTY VV, 2008, BMC RES NOT IN PRESS; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Moye VE, 2004, BRIT J CANCER, V90, P1796, DOI 10.1038/sj.bjc.6601683; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Oates AJ, 1996, ONCOGENE, V13, P97; Ouellet V, 2006, INT J CANCER, V119, P599, DOI 10.1002/ijc.21902; Peruzzi B, 2006, CLIN CANCER RES, V12, P3657, DOI 10.1158/1078-0432.CCR-06-0818; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Rudland PS, 2002, CANCER RES, V62, P3417; Sakata H, 1997, J BIOL CHEM, V272, P9457; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sazer S, 2000, J CELL SCI, V113, P1111; Shinohara ML, 2008, P NATL ACAD SCI USA, V105, P7235, DOI 10.1073/pnas.0802301105; Shulkla S, 2007, INT J CANCER, V121, P1424, DOI 10.1002/ijc.22862; Singhal H, 1997, CLIN CANCER RES, V3, P605; SU LC, 1995, ONCOGENE, V10, P2163; Tuck AB, 2003, ONCOGENE, V22, P1198, DOI 10.1038/sj.onc.1206209; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Wang GZ, 2006, CANCER RES, V66, P1199, DOI 10.1158/0008-5472.CAN-05-2605; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Yuan Y, 2006, NEUROSCI LETT, V407, P26, DOI 10.1016/j.neulet.2006.06.059	51	56	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7139	7149		10.1038/onc.2008.325	http://dx.doi.org/10.1038/onc.2008.325			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794800				2022-12-17	WOS:000261384100001
J	Bellavia, D; Checquolo, S; Campese, AF; Felli, MP; Gulino, A; Screpanti, I				Bellavia, D.; Checquolo, S.; Campese, A. F.; Felli, M. P.; Gulino, A.; Screpanti, I.			Notch3: from subtle structural differences to functional diversity	ONCOGENE			English	Review						Notch receptor structure; Notch3; Jagged1; oncogenic pathways; T-cell leukemia	NF-KAPPA-B; T-CELL DEVELOPMENT; EMBRYONIC LETHALITY; TRANSGENIC MICE; CONSTITUTIVE ACTIVATION; CAENORHABDITIS-ELEGANS; ANKYRIN REPEATS; MAMMARY-GLAND; RECEPTOR; LIGAND	The Notch3 gene was identified, at the beginning of 90s, as the third mammalian Notch and was initially reported as being expressed in proliferating neuroepithelium. Since then, increasing evidence has demonstrated a number of structural and functional differences between Notch3 and both Notch1 and Notch2, which exhibit the highest structural similarity among the four mammalian Notch receptors. Possibly due to its more restricted tissue distribution, targeted deletion of murine Notch3 does not lead to embryonic lethality as is observed with targeted deletion of Notch1 and Notch2. However, genetic mutation, amplification and deregulated expression of Notch3 have been correlated with the disruption of cell differentiation in transgenic mice and to development of diseases in mice and humans. This review discusses the possible relationships between the structural differences and the nonredundant roles that Notch3 plays in the pathogenesis of the human disease cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy and in the regulation of murine T-cell differentiation and leukemogenesis.	[Bellavia, D.; Checquolo, S.; Campese, A. F.; Felli, M. P.; Gulino, A.; Screpanti, I.] Univ Roma La Sapienza, Dept Expt Med, Lab Mol Pathol, I-00161 Rome, Italy	Sapienza University Rome	Screpanti, I (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Lab Mol Pahtol, Vialae Regina Elena,324, I-00161 Rome, Italy.	isabella.screpanti@uniroma1.it	Campese, Antonio/A-9783-2015; Bellavia, Diana/AAO-6348-2021	CHECQUOLO, Saula/0000-0001-5109-8392; FELLI, MARIA PIA/0000-0002-5765-2611; CAMPESE, Antonio Francesco/0000-0002-8535-6609	Associazione Italiana per la Ricerca sul Cancro (AIRC); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR))	We thank members of Screpanti's laboratory, whose comments and work have contributed to the realization of this review. Work in the authors' laboratory is supported by Grants from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and the Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR).	Anastasi E, 2003, J IMMUNOL, V171, P4504, DOI 10.4049/jimmunol.171.9.4504; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; Barrick D, 2006, CELL, V124, P883, DOI 10.1016/j.cell.2006.02.028; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Bellavia D, 2002, P NATL ACAD SCI USA, V99, P3788, DOI 10.1073/pnas.062050599; Bellavia D, 2007, EMBO J, V26, P1670, DOI 10.1038/sj.emboj.7601626; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Cemerski S, 2006, CURR OPIN IMMUNOL, V18, P298, DOI 10.1016/j.coi.2006.03.011; Christensen S, 1996, DEVELOPMENT, V122, P1373; Dang TP, 2003, ONCOGENE, V22, P1988, DOI 10.1038/sj.onc.1206230; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; Felli MP, 2005, ONCOGENE, V24, P992, DOI 10.1038/sj.onc.1208302; Felli MP, 1999, INT IMMUNOL, V11, P1017, DOI 10.1093/intimm/11.7.1017; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Hamada Y, 1999, DEVELOPMENT, V126, P3415; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; Kovall RA, 2007, CURR OPIN STRUC BIOL, V17, P117, DOI 10.1016/j.sbi.2006.11.004; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LaVoie MJ, 2003, J BIOL CHEM, V278, P34427, DOI 10.1074/jbc.M302659200; Li K, 2008, J BIOL CHEM, V283, P8046, DOI 10.1074/jbc.M800170200; Li Yanxia, 2004, BMC Dev Biol, V4, P5, DOI 10.1186/1471-213X-4-5; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Monet M, 2007, HUM MOL GENET, V16, P982, DOI 10.1093/hmg/ddm042; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nehring LC, 2005, J BIOL CHEM, V280, P20349, DOI 10.1074/jbc.M500273200; Ong CT, 2006, J BIOL CHEM, V281, P5106, DOI 10.1074/jbc.M506108200; Park JT, 2006, CANCER RES, V66, P6312, DOI 10.1158/0008-5472.CAN-05-3610; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rothenberg EV, 2001, NAT IMMUNOL, V2, P189, DOI 10.1038/85231; Sakamoto K, 2002, DEV BIOL, V241, P313, DOI 10.1006/dbio.2001.0517; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sansone P, 2007, STEM CELLS, V25, P807, DOI 10.1634/stemcells.2006-0442; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Shimizu K, 1999, J BIOL CHEM, V274, P32961, DOI 10.1074/jbc.274.46.32961; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Talora C, 2003, EMBO REP, V4, P1067, DOI 10.1038/sj.embor.7400013; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Varnum-Finney B, 1998, BLOOD, V91, P4084, DOI 10.1182/blood.V91.11.4084.411k05_4084_4091; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; von Boehmer H, 1998, IMMUNOL REV, V165, P111; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Wu J, 2007, TRENDS BIOCHEM SCI, V32, P477, DOI 10.1016/j.tibs.2007.09.002; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zhang YM, 2007, BIOCHEM BIOPH RES CO, V355, P245, DOI 10.1016/j.bbrc.2007.01.151	66	56	73	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	38					5092	5098		10.1038/onc.2008.230	http://dx.doi.org/10.1038/onc.2008.230			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758477				2022-12-17	WOS:000258914900002
J	Bae, JB; Mukhopadhyay, SS; Liu, L; Zhang, N; Tan, J; Akhter, S; Liu, X; Shen, X; Li, L; Legerski, RJ				Bae, J-B; Mukhopadhyay, S. S.; Liu, L.; Zhang, N.; Tan, J.; Akhter, S.; Liu, X.; Shen, X.; Li, L.; Legerski, R. J.			Snm1B/Apollo mediates replication fork collapse and S Phase checkpoint activation in response to DNA interstrand cross-links	ONCOGENE			English	Article						Snm1B/Apollo; interstrand cross-links; cell cycle checkpoint; ATM	DOUBLE-STRAND BREAKS; FANCONI-ANEMIA PROTEINS; NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE PROGRESSION; SACCHAROMYCES-CEREVISIAE; MITOMYCIN-C; ATAXIA-TELANGIECTASIA; V(D)J RECOMBINATION; SIGNALING PATHWAYS; DAMAGE CHECKPOINT	The removal of DNA interstrand cross-links (ICLs) has proven to be notoriously complicated due to the involvement of multiple pathways of DNA repair, which include the Fanconi anemia/BRCA pathway, homologous recombination and components of the nucleotide excision and mismatch repair pathways. Members of the SNM1 gene family have also been shown to have a role in mediating cellular resistance to ICLs, although their precise function has remained elusive. Here, we show that knockdown of Snm1B/Apollo in human cells results in hypersensitivity to mitomycin C (MMC), but not to IR. We also show that Snm1B-deficient cells exhibit a defective S phase checkpoint in response to MMC, but not to IR, and this finding may account for the specific sensitivity to the cross-linking drug. Interestingly, although previous studies have largely implicated ATR as the major kinase activated in response to ICLs, we show that it is activation of the ATM-mediated checkpoint that is defective in Snm1B-deficient cells. The requirement for Snm1B in ATM checkpoint activation specifically after ICL damage is correlated with its role in promoting double-strand break formation, and thus replication fork collapse. Consistent with this result Snm1B was found to interact directly with Mus81-Eme1, an endonuclease previously implicated in fork collapse. In addition, we also show that Snm1B interacts with the Mre11-Rad50-Nbs1 (MRN) complex and with FancD2 further substantiating its role as a checkpoint/DNA repair protein.	[Bae, J-B; Mukhopadhyay, S. S.; Liu, L.; Zhang, N.; Tan, J.; Akhter, S.; Legerski, R. J.] Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, Houston, TX 77030 USA; [Liu, X.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Shen, X.; Li, L.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Legerski, RJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rlegersk@mdanderson.org		mukhopadhyay, sudit/0000-0001-5888-0598	NCI [CA052461, CA097175]; Cancer Center Support (Core) [CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA097175, R01CA052461] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support (Core); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Tanya Paull and Steve Patrick for the gift of MRN protein, and Jeffrey Parvin for the gift of FancD2 protein. This work was supported by NCI Grants CA052461 and CA097175. DNA sequencing resources were supported by the Cancer Center Support (Core) Grant CA16672.	Ahkter S, 2005, MOL CELL BIOL, V25, P10071, DOI 10.1128/MCB.25.22.10071-10078.2005; Akhter S, 2004, MOL CELL BIOL, V24, P10448, DOI 10.1128/MCB.24.23.10448-10455.2004; Akkari YMN, 2001, MOL GENET METAB, V74, P403, DOI 10.1006/mgme.2001.3259; Andreassen PR, 2004, GENE DEV, V18, P1958, DOI 10.1101/gad.1196104; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barber LJ, 2005, MOL CELL BIOL, V25, P2297, DOI 10.1128/MCB.25.6.2297-2309.2005; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chaturvedi P, 2002, CANCER RES, V62, P1797; Demuth I, 2004, ONCOGENE, V23, P8611, DOI 10.1038/sj.onc.1207895; Dominski Z, 2007, CRIT REV BIOCHEM MOL, V42, P67, DOI 10.1080/10409230701279118; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Freibaum BD, 2006, J BIOL CHEM, V281, P15033, DOI 10.1074/jbc.C600038200; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Grossmann KF, 2001, MUTAT RES-DNA REPAIR, V487, P73, DOI 10.1016/S0921-8777(01)00106-9; HAASE E, 1989, MOL GEN GENET, V218, P64, DOI 10.1007/BF00330566; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; HENRIQUES JAP, 1980, GENETICS, V95, P273; Ho GPH, 2006, MOL CELL BIOL, V26, P7005, DOI 10.1128/MCB.02018-05; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Ishiai M, 2004, MOL CELL BIOL, V24, P10733, DOI 10.1128/MCB.24.24.10733-10741.2004; Lambert S, 2005, BIOCHIMIE, V87, P591, DOI 10.1016/j.biochi.2004.10.020; Lenain C, 2006, CURR BIOL, V16, P1303, DOI 10.1016/j.cub.2006.05.021; Li XR, 2005, DNA REPAIR, V4, P163, DOI 10.1016/j.dnarep.2004.08.012; Li XR, 2003, DNA REPAIR, V2, P121, DOI 10.1016/S1568-7864(02)00192-1; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; Matsusaka T, 2004, J CELL BIOL, V166, P507, DOI 10.1083/jcb.200401139; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; Mladenov E, 2007, J CELL PHYSIOL, V211, P468, DOI 10.1002/jcp.20957; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Nojima K, 2005, CANCER RES, V65, P11704, DOI 10.1158/0008-5472.CAN-05-1214; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Pichierri P, 2004, CELL CYCLE, V3, P698; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Pichierri P, 2002, HUM MOL GENET, V11, P2531, DOI 10.1093/hmg/11.21.2531; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; RUHLAND A, 1981, MUTAT RES, V91, P457, DOI 10.1016/0165-7992(81)90052-X; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; SEYSCHAB H, 1995, BLOOD, V85, P2233, DOI 10.1182/blood.V85.8.2233.bloodjournal8582233; Shen X, 2006, J BIOL CHEM, V281, P13869, DOI 10.1074/jbc.C600071200; Sobeck A, 2006, MOL CELL BIOL, V26, P425, DOI 10.1128/MCB.26.2.425-437.2006; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Summers MK, 2005, ONCOGENE, V24, P2589, DOI 10.1038/sj.onc.1208428; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; van Overbeek M, 2006, CURR BIOL, V16, P1295, DOI 10.1016/j.cub.2006.05.022; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Wang X, 2001, MOL CELL BIOL, V21, P713, DOI 10.1128/MCB.21.3.713-720.2001; WILBORN F, 1989, CURR GENET, V16, P331, DOI 10.1007/BF00340711; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538; Zhang NX, 2007, DNA REPAIR, V6, P1670, DOI 10.1016/j.dnarep.2007.06.002; Zhang NX, 2005, J BIOL CHEM, V280, P40559, DOI 10.1074/jbc.M508453200; Zhang XS, 2004, MOL CELL BIOL, V24, P9207, DOI 10.1128/MCB.24.20.9207-9220.2004; Zheng HY, 2006, DNA REPAIR, V5, P566, DOI 10.1016/j.dnarep.2006.01.010; Zheng HY, 2003, MOL CELL BIOL, V23, P754, DOI 10.1128/MCB.23.2.754-761.2003	68	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2008	27	37					5045	5056		10.1038/onc.2008.139	http://dx.doi.org/10.1038/onc.2008.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469862	Green Accepted			2022-12-17	WOS:000258914800007
J	Du, J; Cai, X; Yao, J; Ding, X; Wu, Q; Pei, S; Jiang, K; Zhang, Y; Wang, W; Shi, Y; Lai, Y; Shen, J; Teng, M; Huang, H; Fei, Q; Reddy, ES; Zhu, J; Jin, C; Yao, X				Du, J.; Cai, X.; Yao, J.; Ding, X.; Wu, Q.; Pei, S.; Jiang, K.; Zhang, Y.; Wang, W.; Shi, Y.; Lai, Y.; Shen, J.; Teng, M.; Huang, H.; Fei, Q.; Reddy, E. S.; Zhu, J.; Jin, C.; Yao, X.			The mitotic checkpoint kinase NEK2A regulates kinetochore microtubule attachment stability	ONCOGENE			English	Article						chromosome instability; mitosis; kinetochore-microtubule attachment; Hec1; NEK2A; phosphorylation	CELL-DIVISION; SPINDLE; MITOSIS; HEC1; PHOSPHORYLATION; CHROMOSOMES; CENTROSOME; INTERACTS; MOVEMENT; COMPLEX	Loss or gain of whole chromosome, the form of chromosome instability commonly associated with cancers is thought to arise from aberrant chromosome segregation during cell division. Chromosome segregation in mitosis is orchestrated by the interaction of kinetochores with spindle microtubules. Our studies show that NEK2A is a kinetochore-associated protein kinase essential for faithful chromosome segregation. However, it was unclear how NEK2A ensures accurate chromosome segregation in mitosis. Here we show that NEK2A-mediated Hec1 ( highly expressed in cancer) phosphorylation is essential for faithful kinetochore microtubule attachments in mitosis. Using phospho-specific antibody, our studies show that NEK2A phosphorylates Hec1 at Ser165 during mitosis. Although such phosphorylation is not required for assembly of Hec1 to the kinetochore, expression of non-phosphorylatable mutant Hec1(S165) perturbed chromosome congression and resulted in a dramatic increase in microtubule attachment errors, including syntelic and monotelic attachments. Our in vitro reconstitution experiment demonstrated that Hec1 binds to microtubule in low affinity and phosphorylation by NEK2A, which prevents aberrant kinetochore-microtubule connections in vivo, increases the affinity of the Ndc80 complex for microtubules in vitro. Thus, our studies illustrate a novel regulatory mechanism in which NEK2A kinase operates a faithful chromosome attachment to spindle microtubule, which prevents chromosome instability during cell division.	[Ding, X.; Wang, W.] Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China; [Du, J.; Cai, X.; Yao, J.; Wu, Q.; Pei, S.; Jiang, K.; Zhang, Y.; Shi, Y.; Lai, Y.; Shen, J.; Teng, M.; Jin, C.; Yao, X.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Peoples R China; [Cai, X.; Ding, X.; Wu, Q.; Jiang, K.; Reddy, E. S.; Yao, X.] Morehouse Sch Med, Canc Biol Program, Atlanta, GA 30310 USA; [Huang, H.] Zhejiang Univ, Affiliated Hosp 1, Dept Hematol, Hangzhou, Peoples R China; [Fei, Q.; Zhu, J.] Shanghai Jiao Tong Univ, Shanghai Canc Inst, Canc Epigenet Program, Shanghai 200030, Peoples R China; [Yao, X.] Cellular Dynam, Hefei, Peoples R China	Beijing University of Chinese Medicine; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Morehouse School of Medicine; Zhejiang University; Shanghai Jiao Tong University	Ding, X (corresponding author), Beijing Univ Chinese Med, Dept Med, Beijing, Peoples R China.	xiading6@yahoo.com; jincj@ustc.edu.cn; yaoxb@ustc.edu.cn	Lai, Ying/E-5220-2015; PEI, SHANSHAN/D-8200-2016; Lai, YING/J-4019-2014	Lai, Ying/0000-0001-5347-5155; PEI, SHANSHAN/0000-0001-9619-2614; 	NCI NIH HHS [CA92080, CA132389, U56 CA092080, CA89019, P50 CA089019, P20 CA132389] Funding Source: Medline; NCRR NIH HHS [G12 RR003034, G-12-RR03034] Funding Source: Medline; NIDDK NIH HHS [R01 DK056292, DK56292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089019, P20CA132389] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; Cheeseman IM, 2006, CELL, V127, P983, DOI 10.1016/j.cell.2006.09.039; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Ciferri C, 2007, FEBS LETT, V581, P2862, DOI 10.1016/j.febslet.2007.05.012; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fang L, 2007, CELL RES, V17, P664, DOI 10.1038/cr.2007.68; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Ke YW, 2003, CELL RES, V13, P69, DOI 10.1038/sj.cr.7290152; Lampson MA, 2005, NAT CELL BIOL, V7, P93, DOI 10.1038/ncb1208; Liu D, 2007, J BIOL CHEM, V282, P21415, DOI 10.1074/jbc.M609026200; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mao YH, 2003, CELL, V114, P87, DOI 10.1016/S0092-8674(03)00475-6; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nicklas R. B., 1971, Adv Cell Biol, V2, P225; NICKLAS RB, 1985, CHROMOSOMA, V92, P313, DOI 10.1007/BF00329815; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	25	56	61	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 3	2008	27	29					4107	4114		10.1038/onc.2008.34	http://dx.doi.org/10.1038/onc.2008.34			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18297113	Green Accepted			2022-12-17	WOS:000257325100010
J	Takano, S; Yoshitomi, H; Togawa, A; Sogawa, K; Shida, T; Kimura, F; Shimizu, H; Tomonaga, T; Nomura, F; Miyazaki, M				Takano, S.; Yoshitomi, H.; Togawa, A.; Sogawa, K.; Shida, T.; Kimura, F.; Shimizu, H.; Tomonaga, T.; Nomura, F.; Miyazaki, M.			Apolipoprotein C-1 maintains cell survival by preventing from apoptosis in pancreatic cancer cells	ONCOGENE			English	Article						apolipoprotein C-1; pancreatic cancer; SELDI-TOF MS; serum marker; apoptosis	GENE-EXPRESSION; PROTEOMIC PATTERNS; PROTEIN EXPRESSION; SERUM; IDENTIFICATION; PROLIFERATION; CARCINOMA; PATHWAY; MARKERS; SURFACE	Pancreatic cancer still remains one of the most lethal diseases and establishment of new therapy is needed. The purpose of this study is to find novel factors involved in pancreatic cancer progression by proteomic approach. We compared pre- and postoperative serum protein pro. ling obtained from pancreatic cancer patients who had curative pancreatectomy using surface-enhanced laser desorption ionization time-of-flight mass spectrometry. The peak intensity levels of both 6630 and 6420 Da were significantly higher in the preoperative serum than in the postoperative serum (P < 0.002). Sequential amino acid analysis identified these proteins to be apolipoprotein C-1 (ApoC-1). The high level of ApoC-1 in preoperative serum significantly correlated with poor prognosis. Furthermore, ApoC-1 was abundantly expressed in pancreas neoplastic epithelium, and was detected in the culture medium of the pancreatic cancer cell line in vitro, which suggests that cancer cells secrete ApoC-1. Inhibition of ApoC-1 expression by short interfering RNA suppressed cell proliferation and induced apoptosis of pancreatic cancer cells. The specific expression of ApoC-1 and its role in preventing from spontaneous apoptosis in pancreatic cancer cells suggest that ApoC-1 contributes to the aggressiveness of pancreatic cancer and will be useful as a new therapeutic target.	[Takano, S.; Yoshitomi, H.; Togawa, A.; Shida, T.; Kimura, F.; Shimizu, H.; Miyazaki, M.] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuo Ku, Chiba 2608670, Japan; [Takano, S.; Sogawa, K.; Tomonaga, T.; Nomura, F.] Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba 2608670, Japan	Chiba University; Chiba University	Yoshitomi, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	yoshitomi@faculty.chiba-u.jp	Yoshitomi, Hideyuki/AAN-8812-2020	Yoshitomi, Hideyuki/0000-0003-2911-8056				Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen X, 2006, CANCER RES, V66, P11323, DOI 10.1158/0008-5472.CAN-06-1536; Chen YC, 2005, CANCER RES, V65, P331; Ehmann M, 2007, PANCREAS, V34, P205, DOI 10.1097/01.mpa.0000250128.57026.b2; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferrone CR, 2006, J CLIN ONCOL, V24, P2897, DOI 10.1200/JCO.2005.05.3934; Goncalves A, 2006, ONCOGENE, V25, P981, DOI 10.1038/sj.onc.1209131; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P91, DOI 10.1016/S0002-9440(10)64353-2; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; LAUER SJ, 1988, J BIOL CHEM, V263, P7277; Melle C, 2005, GASTROENTEROLOGY, V129, P66, DOI 10.1053/j.gastro.2005.05.014; Mitsuhashi N, 2003, HEPATOLOGY, V37, P1105, DOI 10.1053/jhep.2003.50204; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mutaguchi K, 2003, CANCER RES, V63, P7717; Nomura F, 2004, PROTEOMICS, V4, P1187, DOI 10.1002/pmic.200300674; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Rhodes JM, 1999, ANN ONCOL, V10, P118, DOI 10.1023/A:1008369626649; Rosty C, 2002, CANCER RES, V62, P1868; Ryu B, 2001, CANCER RES, V61, P1833; Sato N, 2006, GASTROENTEROLOGY, V130, P548, DOI 10.1053/j.gastro.2005.11.008; SCHAEFER EJ, 1978, J LIPID RES, V19, P667; Shida T, 2006, CANCER BIOL THER, V5, P1530, DOI 10.4161/cbt.5.11.3458; Sobin LH., 2002, INT UNION CANC UICC, V6; Tomonaga T, 2004, CLIN CANCER RES, V10, P2007, DOI 10.1158/1078-0432.CCR-03-0321; Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664; Wroblewski MS, 2006, FEBS J, V273, P4707, DOI 10.1111/j.1742-4658.2006.05473.x; Xiao Z, 2005, MOL CELL ENDOCRINOL, V230, P95, DOI 10.1016/j.mce.2004.10.010; Xiao Z, 2001, CANCER RES, V61, P6029; Yu KH, 2005, J PROTEOME RES, V4, P1742, DOI 10.1021/pr050174l	32	56	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2810	2822		10.1038/sj.onc.1210951	http://dx.doi.org/10.1038/sj.onc.1210951			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037960				2022-12-17	WOS:000255502500002
J	You, JS; Kang, JK; Lee, EK; Lee, JC; Lee, SH; Jeon, YJ; Koh, DH; Ahn, SH; Seo, DW; Lee, HY; Cho, EJ; Han, JW				You, J. S.; Kang, J. K.; Lee, E. K.; Lee, J. C.; Lee, S. H.; Jeon, Y. J.; Koh, D. H.; Ahn, S. H.; Seo, D-W; Lee, H. Y.; Cho, E-J; Han, J-W			Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells	ONCOGENE			English	Article						DNMT1; apicidin; histone modification; histone deacetylase inhibitor	CPG-BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSION; DE-NOVO; MAMMALIAN DEVELOPMENT; CYTOSINE METHYLATION; GENE-EXPRESSION; BREAST-CANCER; DNMT1; ACTIVATION; CHROMATIN	Dysregulation of DN A methyltransferase (DNMT)1 expression is associated with cellular transformation, and inhibition of DNMT1 exerts antitumorigenic effects. Here, we report that DNMT1 abnormally expressed in HeLa cells is downregulated by a histone deacetylase (HDAC) inhibitor apicidin, which is correlated with induction of repressive histone modi. cations on the promoter site. Apicidin selectively represses the expression of DNMT1 among DNMTs in HeLa cells, independent of cell cycle arrest at G(0)/G(1). Furthermore, apicidin causes a significant reduction in the recruitment of RNA polymerase II into the promoter. Chromatin immunoprecipitation analysis shows that even though apicidin causes global hyperacetylation of histone H3 and H4, localized deacetylation ofhistone H3 and H4 occurs at the E2F binding site, which is accompanied by the recruitment of pRB and the replacement of P/CAF with HDAC1 into the sites. In addition, K4-trimethylated H3 on nucleosomes associated with the transcriptional start site is depleted following apicidin treatment, whereas repressive markers, K9- and K27-trimethylation of H3 are enriched on the site. The downregulation of DNMT 1 expression seems to require de novo protein synthesis, because the apicidin effect is antagonized by cycloheximide treatment. Moreover, knock down of DNMT1 with siRNA induces the apoptosis of HeLa cells, indicating that downregulation of DNMT might be a good strategy for therapeutics of human cervix cancer. Collectively, our findings will provide a mechanistic rationale for the use of HDAC inhibitors in cancer therapeutics.	[You, J. S.; Kang, J. K.; Lee, E. K.; Lee, J. C.; Lee, S. H.; Jeon, Y. J.; Koh, D. H.; Cho, E-J; Han, J-W] Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea; [Ahn, S. H.] Hanyang Univ, Div Mol & Life Sci, Ansan, South Korea; [Seo, D-W] Kangwon Natl Univ, Dept Mol Biosci, Chunchon, South Korea; [Lee, H. Y.] Konyang Univ, Coll Med, Dept Pharmacol, Taejon, South Korea	Sungkyunkwan University (SKKU); Hanyang University; Kangwon National University; Konyang University; Konyang University Hospital	Han, JW (corresponding author), Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, 300 Cheoncheon Dong, Suwon 440746, South Korea.	jhhan551@skku.edu	lee, jaecheol/AAS-3747-2020; Cho, Eun-Jung/AAR-1785-2020; Kang, Jaeku/D-4933-2011	lee, jaecheol/0000-0002-2070-7463; Cho, Eun-Jung/0000-0002-6610-5329; Kang, Jaeku/0000-0002-8660-7940; Ahn, Seong-Hoon/0000-0002-9174-4966; Seo, Dong-Wan/0000-0003-4971-834X				Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Baylin SB, 1998, ADV CANCER RES, V72, P141; Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ferguson M, 2003, NUCLEIC ACIDS RES, V31, P3123, DOI 10.1093/nar/gkg403; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuino L, 2003, MOL CANCER THER, V2, P971; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Gupta A, 2003, CANCER RES, V63, P664; Han JW, 2000, CANCER RES, V60, P6068; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kim YK, 2006, CELL DEATH DIFFER, V13, P2033, DOI 10.1038/sj.cdd.4401915; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marsit CJ, 2006, CANCER RES, V66, P10621, DOI 10.1158/0008-5472.CAN-06-1687; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nimmanapalli R, 2003, CANCER RES, V63, P5126; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Park JS, 1999, APPL ENVIRON MICROB, V65, P126; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Rao S, 1998, ONCOGENE, V17, P2393, DOI 10.1038/sj.onc.1202322; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Scott GK, 2002, MOL CANCER THER, V1, P385; SZYF M, 1991, J BIOL CHEM, V266, P10027; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843; Yan PS, 2003, CANCER RES, V63, P6178; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	63	56	60	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2008	27	10					1376	1386		10.1038/sj.onc.1210776	http://dx.doi.org/10.1038/sj.onc.1210776			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17828306				2022-12-17	WOS:000253548200004
J	Ammirante, M; Rosati, A; Gentilella, A; Festa, M; Petrella, A; Marzullo, L; Pascale, M; Belisario, MA; Leone, A; Turco, MC				Ammirante, M.; Rosati, A.; Gentilella, A.; Festa, M.; Petrella, A.; Marzullo, L.; Pascale, M.; Belisario, M. A.; Leone, A.; Turco, M. C.			The activity of hsp90 alpha promoter is regulated by NF-kappa B transcription factors	ONCOGENE			English	Article						hsp90 alpha; NF-kappa B; heat shock proteins	CELL APOPTOSIS; IKK; PROTEIN; HSP90	Heat-shock proteins ( HSP) 90 exert a relevant role in the survival and response to therapy of many neoplastic cell types. Here, we show that the promoter of hsp90 alpha gene, that encodes the inducible form of HSP90, is regulated by nuclear factor-kappa B (NF-kappa B) activity. Indeed, we found that NF-kappa B factors bound to one of the two putative consensus sequences present in the hsp90 alpha-flanking region; mutation of such motif hampered the phorbol-myristate-13-acetate-stimulated expression of a luciferase reporter gene under the control of the hsp90a promoter. Furthermore, the downmodulation of NF-kappa B ( p65) levels by a specific small interfering ( si) RNA resulted in reducing the levels of endogenous HSP90 alpha protein. These findings disclose a previously unrecognized mechanism that contributes to connect NF-kappa B factors and HSPs in cell defence machinery.	[Ammirante, M.; Rosati, A.; Gentilella, A.; Festa, M.; Petrella, A.; Marzullo, L.; Pascale, M.; Belisario, M. A.; Leone, A.; Turco, M. C.] Univ Salerno, Dept Pharmaceut Sci, I-84084 Fisciano, SA, Italy	University of Salerno	Turco, MC (corresponding author), Univ Salerno, Dept Pharmaceut Sci, Via Ponte Don Melillo, I-84084 Fisciano, SA, Italy.	mcturco@unisa.it	Marzullo, Liberato/C-4408-2008; belisario, maria antonietta/B-4762-2012; Petrella, Antonello/E-7708-2012; TURCO, Maria Caterina/AAC-5282-2022; Pascale, Maria/B-4273-2012; Gentilella, Antonio/AAA-9864-2020	Marzullo, Liberato/0000-0001-6133-4483; TURCO, Maria Caterina/0000-0002-7835-359X; PETRELLA, Antonello/0000-0002-6945-5295				Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Maiuri MC, 2004, AM J PATHOL, V165, P115, DOI 10.1016/S0002-9440(10)63280-4; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Richter K, 2007, NAT STRUCT MOL BIOL, V14, P90, DOI 10.1038/nsmb0207-90; Romano MF, 1999, BLOOD, V94, P4060, DOI 10.1182/blood.V94.12.4060.424k23_4060_4066; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	14	56	60	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2008	27	8					1175	1178		10.1038/sj.onc.1210716	http://dx.doi.org/10.1038/sj.onc.1210716			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	262GJ	17724475				2022-12-17	WOS:000253136700017
J	Lee, KC; Goh, WLP; Xu, M; Kua, N; Lunny, D; Wong, JS; Coomber, D; Vojtesek, B; Lane, EB; Lane, DP				Lee, K-C; Goh, W. L. P.; Xu, M.; Kua, N.; Lunny, D.; Wong, J. S.; Coomber, D.; Vojtesek, B.; Lane, E. B.; Lane, D. P.			Detection of the p53 response in zebrafish embryos using new monoclonal antibodies	ONCOGENE			English	Article						zebrafish; p53; monoclonal antibody; immunohistochemistry; p53-activating agents	DANIO-RERIO; MUTANT P53; GENE; EXPRESSION; MUTATIONS; PROTEIN; IDENTIFICATION; ACTIVATION; INDUCTION; NEOPLASIA	The zebrafish has many advantages as a vertebrate model organism and has been extensively used in the studies of development. Its potential as a model in which to study tumour suppressor and oncogene function is now being realized. Whilst in situ hybridization of mRNA has been well developed in this species to study gene expression, antibody probes are in short supply. We have, therefore, generated a panel of anti-zebrafish p53 monoclonal antibodies and used these to study the p53 response in zebrafish embryos. By immunohistochemistry, we show that the exposure of zebrafish embryos to p53-activating agents such as R-roscovitine and c-irradiation results in the accumulation of p53 protein in the gut epithelium, liver and pancreas. A combination of R-roscovitine and gamma-irradiation results in massive p53 induction, not only in the pharyngeal arches, gut region and liver but also in brain tissues. Induction of apoptosis and expression of p53 response genes are seen in regions that correspond to sites of p53 protein accumulation. In contrast, although zebrafish tp53(M214K) mutant embryos showed a similar accumulation of p53 protein, a complete lack of a downstream p53-dependent response was observed. In this system the p53 gene is identified as a p53-responsive gene itself. Our results demonstrate that zebrafish p53 protein can readily be induced in embryos and detected using these new antibody tools, which will increase the usefulness of zebrafish as a model in compound-based screening for novel drugs in cancer research.	[Lee, K-C; Goh, W. L. P.; Xu, M.; Kua, N.; Wong, J. S.; Coomber, D.; Vojtesek, B.; Lane, D. P.] Inst Mol & Cell Biol, Control Pathway Lab P53, Proteos 138673, Singapore; [Lunny, D.; Lane, E. B.] Med Biol Inst, Epithelial Biol Programme, Proteos, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)	Lane, DP (corresponding author), Inst Mol & Cell Biol, Control Pathway Lab P53, 61 Biopolis Dr, Proteos 138673, Singapore.	d.p.lane@imcb.a-star.edu.sg	Lee, Kian-Chung/AAP-9059-2021; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; BARTEK J, 1990, ONCOGENE, V5, P893; Berghmans S, 2005, P NATL ACAD SCI USA, V102, P407, DOI 10.1073/pnas.0406252102; Brand M., 2002, ZEBRAFISH PRACTICAL; Chen J, 2005, GENE DEV, V19, P2900, DOI 10.1101/gad.1366405; Cheng R, 1997, MOL MAR BIOL BIOTECH, V6, P88; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1988, ANTIBODIES LAB MANUA, P186; HARLOW E, 1999, USING ANTIBODIES LAB, P395; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jowett T, 1999, METHOD CELL BIOL, V59, P63; KASTAN MB, 1991, CANCER RES, V51, P6304; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kotala V, 2001, CELL MOL LIFE SCI, V58, P1333, DOI 10.1007/PL00000944; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lu WG, 2001, ONCOGENE, V20, P3206, DOI 10.1038/sj.onc.1204412; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nickels A, 1997, J CLIN PATHOL, V50, P654, DOI 10.1136/jcp.50.8.654; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Ribas J, 2006, EXP CELL RES, V312, P2394, DOI 10.1016/j.yexcr.2006.04.021; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Spitsbergen Jan M., 2003, Toxicologic Pathology, V31, P62, DOI 10.1080/01926230390174959; Spitsbergen JM, 2000, TOXICOL PATHOL, V28, P716, DOI 10.1177/019262330002800512; STANTON MF, 1965, JNCI-J NATL CANCER I, V34, P117, DOI 10.1093/jnci/34.1.117; Stern HM, 2003, NAT REV CANCER, V3, P533, DOI 10.1038/nrc1126; Sutcliffe JE, 2004, FEBS LETT, V567, P86, DOI 10.1016/j.febslet.2004.03.122; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Zhao L, 2003, MOL CANCER RES, V1, P195	41	56	57	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					629	640		10.1038/sj.onc.1210695	http://dx.doi.org/10.1038/sj.onc.1210695			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17684488				2022-12-17	WOS:000252674900007
J	Sekine, Y; Ikeda, O; Hayakawa, Y; Tsuji, S; Imoto, S; Aoki, N; Sugiyama, K; Matsuda, T				Sekine, Y.; Ikeda, O.; Hayakawa, Y.; Tsuji, S.; Imoto, S.; Aoki, N.; Sugiyama, K.; Matsuda, T.			DUSP22/LMW-DSP2 regulates estrogen receptor-alpha-mediated signaling through dephosphorylation of Ser-118	ONCOGENE			English	Article						beta-estradiol; estrogen receptor; phosphatase; transcriptional regulation; breast cancer	DUAL-SPECIFICITY PHOSPHATASE; CELL ANTIGEN RECEPTOR; CROSS-TALK; TRANSCRIPTIONAL ACTIVATION; VACCINIA VIRUS; GERM-CELLS; PHOSPHORYLATION; PATHWAY; KINASE; TRANSDUCER	In the previous study, we demonstrated the involvement of dual specificity phosphatase 22 ( DUSP22/LMW-DSP2) in regulating the leukemia inhibitory factor/interleukin-6/ signal transducer and activator of transcription 3- mediated signaling pathway. In this study, we show beta-estradiol ( E2)- induced DUSP22 mRNA expression in estrogen receptor a ( ER alpha)- positive breast cancer cells, whereas E2- induced phosphorylation and activation of ERa was suppressed by overexpression of DUSP22 but not catalytically inactive mutants. Furthermore, small- interfering RNA- mediated reduction of DUSP22 expression enhanced ER alpha- mediated transcription and endogenous gene expression. In fact, DUSP22 associated with ERa in vivo and both endogenous proteins interacted in ERa- positive breast cancer T47D cells. These results strongly suggest that DUSP22 acts as a negative regulator of the ER alpha-amediated signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Mie Univ, Fac Bioresources, Dept Life Sci, Lab Mol Food Chem & Biohem, Tsu, Mie 514, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan	Hokkaido University; Mie University; Boehringer Ingelheim	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Matsuda, Tadashi/A-3835-2012; Sekine, Yuichi/S-8813-2019	Matsuda, Tadashi/0000-0002-3089-3757; Sekine, Yuichi/0000-0002-2861-603X				Alonso A, 2004, J BIOL CHEM, V279, P32586, DOI 10.1074/jbc.M403442200; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; ALTIOK N, 2006, IN PRESS BREAST CANC; Aoki N, 2001, J BIOCHEM, V130, P133, DOI 10.1093/oxfordjournals.jbchem.a002952; Aoki N, 1996, J BIOL CHEM, V271, P29422, DOI 10.1074/jbc.271.46.29422; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Carreau S, 2002, MOL CELL ENDOCRINOL, V193, P137, DOI 10.1016/S0303-7207(02)00107-7; Castano E, 1998, J STEROID BIOCHEM, V65, P101, DOI 10.1016/S0960-0760(97)00179-9; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Couse JF, 2001, REPROD FERT DEVELOP, V13, P211, DOI 10.1071/RD00128; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Ikeda K, 2004, MOL ENDOCRINOL, V18, P1131, DOI 10.1210/me.2003-0308; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jenab S, 1998, ENDOCRINOLOGY, V139, P1883, DOI 10.1210/en.139.4.1883; Jenab S, 1997, ENDOCRINOLOGY, V138, P2740, DOI 10.1210/en.138.7.2740; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuda T, 2001, BIOCHEM BIOPH RES CO, V283, P179, DOI 10.1006/bbrc.2001.4758; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Medunjanin S, 2005, J BIOL CHEM, V280, P33006, DOI 10.1074/jbc.M506758200; Meyer T, 2003, GENE DEV, V17, P1992, DOI 10.1101/gad.268003; Murphy K, 2005, GENE EXPR PATTERNS, V5, P475, DOI 10.1016/j.modgep.2004.12.007; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Proia DA, 2006, J BIOL CHEM, V281, P7089, DOI 10.1074/jbc.M511839200; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Safe S, 2004, TOXICOLOGY, V205, P3, DOI 10.1016/j.tox.2004.06.032; Sekine Y, 2006, ONCOGENE, V25, P5801, DOI 10.1038/sj.onc.1209578; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Sekine Y, 2004, BIOCHEM BIOPH RES CO, V315, P692, DOI 10.1016/j.bbrc.2004.01.109; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; THEODOSIOU A, 2002, GENOME BIOL, V26; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Wang LH, 2001, J BIOL CHEM, V276, P31839, DOI 10.1074/jbc.M105185200; Yamamoto T, 2002, ENDOCRINOLOGY, V143, P2635, DOI 10.1210/en.143.7.2635; Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1; Zama T, 2002, J BIOL CHEM, V277, P23909, DOI 10.1074/jbc.M200837200	43	56	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6038	6049		10.1038/sj.onc.1210426	http://dx.doi.org/10.1038/sj.onc.1210426			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384676	Green Submitted			2022-12-17	WOS:000249277200007
J	Flotho, C; Steinemann, D; Mullighan, CG; Neale, G; Mayer, K; Kratz, CP; Schlegelberger, B; Downing, JR; Niemeyer, CM				Flotho, C.; Steinemann, D.; Mullighan, C. G.; Neale, G.; Mayer, K.; Kratz, C. P.; Schlegelberger, B.; Downing, J. R.; Niemeyer, C. M.			Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11	ONCOGENE			English	Article						leukemia; JMML; SNP; NF1	BONE-MARROW-CELLS; INACTIVATION; CHILDREN	Juvenile myelomonocytic leukemia (JMML) is a malignant hematopoietic disorder whose proliferative component is a result of RAS pathway deregulation caused by somatic mutation in the RAS or PTPN11 oncogenes or in patients with underlying neurofibromatosis type 1 (NF-1), by loss of NF1 gene function. To search for potential collaborating genetic abnormalities, we used oligonucleotide arrays to analyse over 116000 sing le-nucleotide polymorphisms across the genome in 16 JMML samples with normal karyotype. Evaluation of the SNP genotypes identified large regions of homozygosity on chromosome 17q, including the NF1 locus, in four of the five samples from patients with JMML and NF-1. The homozygous region was at least 55 million base pairs in each case. The genomic copy number was normal within the homozygous region, indicating uniparental disomy (UPD). In contrast, the array data provided no evidence for 17q UPD in any of the 11 JMML cases without NF-1. We used array-based comparative genomic hybridization to confirm 17q disomy, and microsatellite analysis was performed to verify homozygosity. Mutational analysis demonstrated that the inactivating NF1 lesion was present on both alleles in each case. In summary, our data indicate that a mitotic recombination event in a JMML-initiating cell led to 17q UPD with homozygous loss of normal NF1, provide confirmatory evidence that the NF1 gene is crucial for the increased incidence of JMML in NF-1 patients, and corroborate the concept that RAS pathway deregulation is central to JMML pathogenesis.	Univ Freiburg, Div Pediat Hematol Oncol, Freiburg, Germany; Hannover Med Sch, Inst Cell & Mol Pathol, D-3000 Hannover, Germany; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Ctr Human Genet & Lab Med, Martinsried, Germany	University of Freiburg; Hannover Medical School; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Flotho, C (corresponding author), Univ Kinderklin, Mathildenstr 1, D-79106 Freiburg, Germany.	christian.flotho@cuniklinik-freiburg.de	Kratz, Christian/AAC-9726-2021; Mullighan, Charles/H-3253-2011; Downing, James R./N-8102-2018	Mullighan, Charles/0000-0002-1871-1850; 				Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; Dasgupta B, 2003, CURR OPIN GENET DEV, V13, P20, DOI 10.1016/S0959-437X(02)00015-1; EMANUEL PD, 1991, BLOOD, V77, P925; Engle LJ, 2006, ONCOGENE, V25, P1594, DOI 10.1038/sj.onc.1209368; Flotho C, 1999, LEUKEMIA, V13, P32, DOI 10.1038/sj.leu.2401240; FLOTHO C, 2007, IN PRESS CURR DRUG T; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; MITELMAN F, 2006, MITELMAN DATABASE CH; Niemeyer CM, 1997, BLOOD, V89, P3534; Raghavan M, 2005, CANCER RES, V65, P375; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; Steinemann D, 2003, GENE CHROMOSOME CANC, V37, P421, DOI 10.1002/gcc.10231; Stephens K, 2006, BLOOD, V108, P1684, DOI 10.1182/blood-2005-11-011486; Tonnies H, 2003, BLOOD, V101, P3872, DOI 10.1182/blood-2002-10-3243; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	19	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2007	26	39					5816	5821		10.1038/sj.onc.1210361	http://dx.doi.org/10.1038/sj.onc.1210361			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202EP	17353900				2022-12-17	WOS:000248885100013
J	Grabarczyk, P; Przybylski, GK; Depke, M; Volker, U; Bahr, J; Assmus, K; Broker, BM; Walther, R; Schmidt, CA				Grabarczyk, P.; Przybylski, G. K.; Depke, M.; Voelker, U.; Bahr, J.; Assmus, K.; Broeker, B. M.; Walther, R.; Schmidt, C. A.			Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells	ONCOGENE			English	Article						BCL11B; T-ALL; apoptosis; TRAIL; Bcl-xL	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTIONAL REPRESSION; THYMIC LYMPHOMAS; BINDING PROTEIN; NURD COMPLEX; GENE; PROMOTER; LYMPHOCYTES; BCL-X(L); TRAIL	The B-cell chronic lymphocytic leukemia (CLL)/lymphoma 11B gene (BCL11B) encodes a Kruppel-like zinc. finger protein, which plays a crucial role in thymopoiesis and has been associated with hematopoietic malignancies. It was hypothesized that BCL11B may act as a tumor-suppressor gene, but its precise function has not yet been elucidated. Here, we demonstrate that the survival of human T-cell leukemia and lymphoma cell lines is critically dependent on Bcl11b. Suppression of Bcl11b by RN A interference selectively induced apoptosis in transformed T cells whereas normal mature T cells remained unaffected. The apoptosis was effected by simultaneous activation of death receptor-mediated and intrinsic apoptotic pathways, most likely as a result of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) upregulation and suppression of the Bcl-xL antiapoptotic protein. Our data indicate an antiapoptotic function of Bcl11b. The resistance of normal mature T lymphocytes to Bcl11b suppression-induced apoptosis and restricted expression pattern make it an attractive therapeutic target in T-cell malignancies.	Ernst Moritz Arndt Univ Greifswald, Clin Internal Med C, D-17475 Greifswald, Germany; Polish Acad Sci, Inst Human Genet, PL-00901 Poznan, Poland; Ernst Moritz Arndt Univ Greifswald, Lab Funct Genom, D-17475 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Inst Immunol & Transfus Med, D-17475 Greifswald, Germany; Ernst Moritz Arndt Univ Greifswald, Dept Med Biochem & Mol Biol, D-17475 Greifswald, Germany	Ernst Moritz Arndt Universitat Greifswald; Polish Academy of Sciences; Institute of Human Genetics of the Polish Academy of Sciences; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald	Schmidt, CA (corresponding author), Ernst Moritz Arndt Univ Greifswald, Clin Internal Med C, Sauerbruch Str, D-17475 Greifswald, Germany.	christian.schmidt@uni-greifswald.de	Bröker, Barbara M/O-4850-2015	Bröker, Barbara M/0000-0002-5020-8542; Volker, Uwe/0000-0002-5689-3448; Przybylski, Grzegorz/0000-0001-5783-1567				Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bezrookove V, 2004, CANCER GENET CYTOGEN, V149, P72, DOI 10.1016/S0165-4608(03)00302-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Broome HE, 2002, LEUKEMIA RES, V26, P311, DOI 10.1016/S0145-2126(01)00118-7; Cismasiu VB, 2006, BLOOD, V108, P2695, DOI 10.1182/blood-2006-05-021790; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Ehrlich S, 2003, CYTOKINE, V24, P244, DOI 10.1016/S1043-4666(03)00094-2; Gesk S, 2003, LEUKEMIA, V17, P738, DOI 10.1038/sj.leu.2402884; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GRILLOT DAM, 1995, J EXP MED, V182, P1973, DOI 10.1084/jem.182.6.1973; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; Klose R, 2005, TRANSPLANTATION, V80, P222, DOI 10.1097/01.TP.0000164817.59006.C2; Leid M, 2004, GENE EXPR PATTERNS, V4, P733, DOI 10.1016/j.modgep.2004.03.009; MacLeod RAF, 2003, GENE CHROMOSOME CANC, V37, P84, DOI 10.1002/gcc.10194; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nagel S, 2003, CANCER RES, V63, P5329; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Simon AK, 2001, P NATL ACAD SCI USA, V98, P5158, DOI 10.1073/pnas.091100398; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Topark-Ngarm A, 2006, J BIOL CHEM, V281, P32272, DOI 10.1074/jbc.M602776200; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang N, 2005, J IMMUNOL, V174, P6967, DOI 10.4049/jimmunol.174.11.6967	36	56	61	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3797	3810		10.1038/sj.onc.1210152	http://dx.doi.org/10.1038/sj.onc.1210152			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173069				2022-12-17	WOS:000247026400004
J	Goldenberg, DM; Sharkey, RM				Goldenberg, D. M.; Sharkey, R. M.			Novel radiolabeled antibody conjugates	ONCOGENE			English	Review						cancer; monoclonal antibodies; pretargeting; radioimmunotherapy; radionuclides	NON-HODGKINS-LYMPHOMA; MEDULLARY-THYROID CANCER; CEA MONOCLONAL-ANTIBODY; CARCINOEMBRYONIC-ANTIGEN RADIOIMMUNOTHERAPY; GENETICALLY-ENGINEERED ANTIBODIES; INDIUM-111-LABELED DTPA DIMER; I-131-LABELED BIVALENT HAPTEN; METASTATIC COLORECTAL-CANCER; ONCOLOGIC DRUG DEVELOPMENT; PHASE-I TRIAL	This article reviews the development of radioimmuno-conjugates as a new class of cancer therapeutics. Numerous conjugates involving different antigen targets, anti body forms, radionuclides and methods of radiochemistry have been studied in the half-century since radioactive antibodies were first used in model systems to selectively target radiation to tumors. Whereas directly conjugated antibodies, fragments and subfragments have shown promise preclinically, the same approaches have not gained success in patients except in radiosensitive hematological neoplasms, or in settings involving minimal or locoregional disease. The separation of tumor targeting from the delivery of the therapeutic radionuclide in a multistep process called pretargeting has the potential to overcome many of the limitations of conventional, or one-step, radio immunotherapy, with initial preclinical and clinical data showing increased sensitivity, specificity and higher radiation doses delivered. Our particular focus in pretargeting is the use of bispecific, trimeric (three Fab's) constructs made by a new antibody engineering method termed 'dock-and-lock.'	Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ 07109 USA		Goldenberg, DM (corresponding author), Garden State Canc Ctr, Ctr Mol Med & Immunol, 820 Belleville Ave, Belleville, NJ 07109 USA.	dmg.gscancer@att.net			NATIONAL CANCER INSTITUTE [P01CA103985] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA103985] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELNABI HH, 1990, J NUCL MED, V31, P1975; ABDELNABI HH, 1987, RADIOLOGY, V164, P617, DOI 10.1148/radiology.164.3.3303117; Alvarez RD, 1997, GYNECOL ONCOL, V65, P94, DOI 10.1006/gyno.1996.4577; Alvarez RD, 2002, CLIN CANCER RES, V8, P2806; Axworthy DB, 2000, P NATL ACAD SCI USA, V97, P1802, DOI 10.1073/pnas.97.4.1802; BALE W F, 1957, Adv Biol Med Phys, V5, P285; BALE WF, 1960, CANCER RES, V20, P1488; Batra SK, 2002, CURR OPIN BIOTECH, V13, P603, DOI 10.1016/S0958-1669(02)00352-X; BEHR TM, 1995, CANCER RES, V55, P3825; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Boerman OC, 1999, CANCER RES, V59, P4400; Boerman OC, 2003, J NUCL MED, V44, P400; BUCHSBAUM DJ, 1995, CANCER RES, V55, pS5729; Cardillo TM, 2002, INT J CANCER, V97, P386, DOI 10.1002/ijc.1613; Chatal JF, 2006, J CLIN ONCOL, V24, P1705, DOI 10.1200/JCO.2005.04.4917; CHETANNEAU A, 1994, NUCL MED COMMUN, V15, P972, DOI 10.1097/00006231-199412000-00009; Colcher D, 1998, Q J NUCL MED, V42, P225; Crow DM, 2005, BIOCONJUGATE CHEM, V16, P1117, DOI 10.1021/bc0500948; Davis TA, 2004, CLIN CANCER RES, V10, P7792, DOI 10.1158/1078-0432.CCR-04-0756; DENARDO GL, 1995, INT J BIOL MARKER, V10, P67, DOI 10.1177/172460089501000201; DeNardo SJ, 1997, P NATL ACAD SCI USA, V94, P4000, DOI 10.1073/pnas.94.8.4000; DeNardo SJ, 1997, J NUCL MED, V38, P1180; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Forero A, 2005, CANCER BIOTHER RADIO, V20, P467, DOI 10.1089/cbr.2005.20.467; Gautherot E, 1997, CANCER, V80, P2618; Gautherot E, 2000, J NUCL MED, V41, P480; Gestin JF, 2001, J NUCL MED, V42, P146; Goetz C, 2003, J NEURO-ONCOL, V62, P321, DOI 10.1023/A:1023309927635; Gold DV, 2003, CLIN CANCER RES, V9, p3929S; Goldenberg D M, 1990, Cancer Treat Res, V51, P273; Goldenberg D M, 1997, J Nucl Med Technol, V25, P18; Goldenberg D. M., 1992, International Journal of Biological Markers, V7, P183; GOLDENBERG DM, 1980, SCIENCE, V208, P1284, DOI 10.1126/science.7375942; GOLDENBERG DM, 1974, CANCER RES, V34, P1; GOLDENBERG DM, 1990, CANCER RES, V50, pS909; GOLDENBERG DM, 1992, J NUCL MED, V33, P803; Goldenberg DM, 2006, J CLIN ONCOL, V24, P823, DOI 10.1200/JCO.2005.03.8471; GOLDENBERG DM, 1978, NEW ENGL J MED, V298, P1384, DOI 10.1056/NEJM197806222982503; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GOLDENBERG DM, 1993, J NUCL MED, V34, P61; Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195; GOODWIN DA, 1994, CANCER RES, V54, P5937; GOODWIN DA, 1986, NUCL MED BIOL, V13, P383, DOI 10.1016/0883-2897(86)90015-2; Graves SS, 2003, CLIN CANCER RES, V9, P3712; Griffiths GL, 2004, J NUCL MED, V45, P30; Hernandez MC, 2004, INT J RADIAT ONCOL, V59, P1274, DOI 10.1016/j.ijrobp.2004.02.065; JAIN R K, 1991, Current Opinion in Oncology, V3, P1105, DOI 10.1097/00001622-199112000-00020; Jana S, 2006, SEMIN NUCL MED, V36, P51, DOI 10.1053/j.semnuclmed.2005.09.001; KAMINSKI MS, 1993, NEW ENGL J MED, V329, P459, DOI 10.1056/NEJM199308123290703; Karacay H, 2000, BIOCONJUGATE CHEM, V11, P842, DOI 10.1021/bc0000379; Karacay H, 2005, CLIN CANCER RES, V11, P7879, DOI 10.1158/1078-0432.CCR-05-1246; Karacay H, 2002, BIOCONJUGATE CHEM, V13, P1054, DOI 10.1021/bc0200172; Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626; Kelloff GJ, 2005, CLIN CANCER RES, V11, P7967, DOI 10.1158/1078-0432.CCR-05-1302; Kelly MP, 2006, J NUCL MED, V47, P716; Kenanova Vania, 2006, Expert Opin Drug Deliv, V3, P53, DOI 10.1517/17425247.3.1.53; KIM EE, 1980, CANCER RES, V40, P3008; KORNGOLD L, 1954, CANCER RES, V14, P96; Kraeber-Bodere F, 2006, J NUCL MED, V47, P247; Kraeber-Bodere F, 2003, CLIN CANCER RES, V9, p3973S; Kraeber-Bodere F, 2002, MOL CANCER THER, V1, P267; Kraeber-Bodere F, 1999, CLIN CANCER RES, V5, p3190S; LAMKI LM, 1990, RADIOLOGY, V174, P147, DOI 10.1148/radiology.174.1.2294542; LARSON SM, 1990, CANCER RES, V50, pS892; LEDOUSSAL JM, 1993, J NUCL MED, V34, P1662; LEDOUSSAL JM, 1989, J NUCL MED, V30, P1358; Liersch T, 2005, J CLIN ONCOL, V23, P6763, DOI 10.1200/JCO.2005.18.622; MACH JP, 1980, ONCODEV BIOL MED, V1, P49; MACH JP, 1983, CANCER RES, V43, P5593; Mahe MA, 1999, CLIN CANCER RES, V5, p3249S; Masters GR, 2006, GYNECOL ONCOL, V102, P462, DOI 10.1016/j.ygyno.2005.12.004; McBride WJ, 2006, J NUCL MED, V47, P1678; MCCARDLE RJ, 1966, J NUCL MED, V7, P837; Meredith RF, 2001, CANCER BIOTHER RADIO, V16, P305, DOI 10.1089/108497801753131381; Meredith RF, 2006, INT J RADIAT ONCOL, V66, pS23, DOI 10.1016/j.ijrobp.2006.05.068; Meredith RF, 2006, INT J RADIAT ONCOL, V66, pS15, DOI 10.1016/j.ijrobp.2006.04.059; MURRAY JL, 1994, CANCER, V73, P1057, DOI 10.1002/1097-0142(19940201)73:3+<1057::AID-CNCR2820731345>3.0.CO;2-3; Paganelli G, 2006, NEUROL RES, V28, P518, DOI 10.1179/016164106X116782; PATT YZ, 1990, J CLIN ONCOL, V8, P1246, DOI 10.1200/JCO.1990.8.7.1246; PELTIER P, 1993, J NUCL MED, V34, P1267; PRESSMAN D, 1953, CANCER, V6, P619, DOI 10.1002/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; Reardon DA, 2006, J CLIN ONCOL, V24, P115, DOI 10.1200/JCO.2005.03.4082; Richman CM, 2005, CLIN CANCER RES, V11, P5920, DOI 10.1158/1078-0432.CCR-05-0211; Riva P, 1999, ACTA ONCOL, V38, P351; Rossi EA, 2006, P NATL ACAD SCI USA, V103, P6841, DOI 10.1073/pnas.0600982103; Rossi EA, 2005, CLIN CANCER RES, V11, p7122S, DOI 10.1158/1078-0432.CCR-1004-0020; Rossi EA, 2003, CLIN CANCER RES, V9, p3886S; Sharkey RM, 2006, CANCER INVEST, V24, P82, DOI 10.1080/07357900500449553; Sharkey RM, 2005, CLIN CANCER RES, V11, p7109S, DOI 10.1158/1078-0432.CCR-1004-0009; Sharkey RM, 2005, NAT MED, V11, P1250, DOI 10.1038/nm1322; Sharkey RM, 2005, LEUKEMIA, V19, P1064, DOI 10.1038/sj.leu.2403751; Sharkey RM, 2005, J NUCL MED, V46, P620; SHARKEY RM, 1990, CANCER RES, V50, P2330; Sharkey RM, 2005, J NUCL MED, V46, p115S; Sharkey RM, 2003, J NUCL MED, V44, P2000; Sharkey RM, 2003, CLIN CANCER RES, V9, p3897S; Sharkey RM, 2003, CANCER RES, V63, P354; SHARKEY RM, 2007, IN PRESS CLIN CANC R; SIEGEL JA, 1990, CANCER RES, V50, pS1039; SLAVINCHIORINI DC, 1993, INT J CANCER, V53, P97, DOI 10.1002/ijc.2910530119; STICKNEY DR, 1991, CANCER RES, V51, P6650; Unterhalt M, 2006, ANN HEMATOL, V85, P36; VANNAGELL JR, 1980, CANCER RES, V40, P502; Vuillez JP, 1999, CLIN CANCER RES, V5, p3259S; Wittel UA, 2005, NUCL MED BIOL, V32, P157, DOI 10.1016/j.nucmedbio.2004.11.003; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Witzig TE, 2006, BEST PRACT RES CL HA, V19, P655, DOI 10.1016/j.beha.2006.05.002; Wong JYC, 2006, INT J RADIAT ONCOL, V66, pS74, DOI 10.1016/j.ijrobp.2005.05.029; Wong JYC, 2003, CLIN CANCER RES, V9, P5842; Wu Anna M, 2004, Methods Mol Biol, V248, P209; Zalutsky MR, 2006, J NUCL MED, V47, P1238; Zalutsky MR, 2006, CLIN CANCER RES, V12, P1958, DOI 10.1158/1078-0432.CCR-06-0405	113	56	67	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3734	3744		10.1038/sj.onc.1210373	http://dx.doi.org/10.1038/sj.onc.1210373			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530026	Green Published			2022-12-17	WOS:000246816100015
J	Gamble, SC; Chotai, D; Odontiadis, M; Dart, DA; Brooke, GN; Powell, SM; Reebye, V; Varela-Carver, A; Kawano, Y; Waxman, J; Bevan, CL				Gamble, S. C.; Chotai, D.; Odontiadis, M.; Dart, D. A.; Brooke, G. N.; Powell, S. M.; Reebye, V.; Varela-Carver, A.; Kawano, Y.; Waxman, J.; Bevan, C. L.			Prohibitin, a protein downregulated by androgens, represses androgen receptor activity	ONCOGENE			English	Article						prohibitin; prostate cancer; androgen receptor; corepressor; cell cycle	PROSTATE-CANCER CELLS; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTOR; N-COR; MITOCHONDRIAL PROTEINS; TUMOR-SUPPRESSOR; BINDING; DOMAIN; COACTIVATOR	Prohibitin (PHB) is a cell cycle regulatory protein, known to repress E2F1-mediated gene activation via recruitment of transcriptional regulatory factors such as retinoblastoma and histone deacetylase 1 (HDAC1). We previously identified PHB as a target protein of androgen signaling in prostate cancer cells and showed that downregulation of PHB is required for androgen-induced cell cycle entry in these cells. We now present evidence that PHB, which has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen receptor (AR)mediated transcription and androgen-dependent cell growth. Depletion of endogenous PHB resulted in an increase in expression of the androgen-regulated prostatespecific antigen gene. The repression appears to be specific to androgen and closely related receptors, as it is also evident for the glucocorticoid and progesterone, but not oestrogen, receptors. In spite of interaction of PHB with HDAC1, HDAC activity is not required for this repression. Although AR and PHB could be co-immunoprecipitated, no direct interaction was detectable, suggesting that PHB forms part of a repressive complex with the AR. Competition with the co-activator SRC1 further suggests that formation of a complex with AR, PHB and other cofactors is the mechanism by which repression is achieved. It appears then that repression of AR activity is one mechanism by which PHB inhibits androgen-dependent growth of prostate cells. Further, this study implies that the AR itself could, by mediating downregulation of a corepressor, be involved in the progression of prostate tumours to the hormone refractory stage.	Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Harris Lab Prostate Canc Res, London W12 0NN, England	Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Harris Lab Prostate Canc Res, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012; Brooke, Greg/ABF-4859-2020; Bevan, Charlotte/T-7769-2019; Brooke, Greg/C-9426-2013	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Medical Research Council [MC_U120084164] Funding Source: Medline; Worldwide Cancer Research [05-0613] Funding Source: Medline; MRC [MC_U120084164] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Worldwide Cancer Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adegbola O, 2005, BIOCHEM BIOPH RES CO, V334, P702, DOI 10.1016/j.bbrc.2005.06.153; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Berrevoets CA, 2004, BIOCHEM J, V379, P731, DOI 10.1042/BJ20031456; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Smith JR, 1997, IEEE MULTIMEDIA, V4, P12, DOI 10.1109/93.621578; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Thompson WE, 2001, ENDOCRINOLOGY, V142, P4076, DOI 10.1210/en.142.9.4076; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Whitaker HC, 2004, CLIN CANCER RES, V10, P7392, DOI 10.1158/1078-0432.CCR-04-0388; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	44	56	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1757	1768		10.1038/sj.onc.1209967	http://dx.doi.org/10.1038/sj.onc.1209967			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964284				2022-12-17	WOS:000244955600010
J	Ivanov, SV; Salnikow, K; Ivanova, AV; Bai, L; Lerman, MI				Ivanov, S. V.; Salnikow, K.; Ivanova, A. V.; Bai, L.; Lerman, M. I.			Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13	ONCOGENE			English	Article						VHL; HIF-1; hypoxia; STRA13; STAT1; CASP1	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR PROTEIN; INTERFERON-GAMMA; DEACETYLASE ACTIVITY; DOWN-REGULATION; TRANSCRIPTIONAL REPRESSOR; INDEPENDENT MECHANISMS; STRA13 EXPRESSION; INDUCED APOPTOSIS; CLASS-I	DEC1/STRA13 is a bHLH type transcriptional regulator involved with immune regulation, hypoxia response and carcinogenesis. We recently demonstrated that STRA13 interacts with STAT3 in the transcriptional activation of STAT-dependent promoters. Here, we pursue STRA13 involvement in the JAK/STAT pathway by studying its role in STAT1 expression. First, we showed that VHL deficiency or HIF-1 activation resulted in the repression of endogenous STAT1 mediated by STRA13. We then characterized the STAT1 proximal promoter to assess its response to STRA13 by transient coexpression in a luciferase reporter assay. Using sequential truncation and site-directed mutagenesis of the STAT1 promoter with STRA13 deletion constructs, we showed that the STRA13 C-terminal trans-activation domain, which is known to bind HDAC1, mostly determines the repressive activity. Involvement of HDAC activity in STAT1 regulation was validated by TSA inhibition and chromatin immuno-precipitation (ChIP) assay. Thus, we demonstrate that STRA13-mediated repression of STAT1 transcription utilizes an HDAC1-dependent mechanism. Furthermore, we show that targets of unphosphorylated STAT1, such as antigen presenting genes and CASP1, are also repressed by hypoxia possibly through the same STRA13-mediated mechanism. Thus, the newly discovered link between HIF-1 and STAT1 reveals a previously unknown role of STRA13 in hypoxia and carcinogenesis.	SAIC Frederick, Basic Res Program, Ft Detrick, MD 21702 USA; NCI, NIH, Frederick, MD 21701 USA; NYU, Med Ctr, Dept Cardiothorac Surg, New York, NY 10016 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University; University of Michigan System; University of Michigan	Ivanov, SV (corresponding author), SAIC Frederick, Basic Res Program, B 560,POB B, Ft Detrick, MD 21702 USA.	Sergey.Ivanov@med.nyu.edu		Ivanov, Sergey/0000-0001-9770-7237	NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkins D, 2004, J UROLOGY, V171, P885, DOI 10.1097/01.ju.0000094807.95420.fe; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bai LC, 2003, NUCLEIC ACIDS RES, V31, P7264, DOI 10.1093/nar/gkg929; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Dudley Andrew C, 2004, Cell Commun Signal, V2, P8, DOI 10.1186/1478-811X-2-8; Gastl G, 1996, J UROLOGY, V155, P361, DOI 10.1016/S0022-5347(01)66661-8; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Ivanova AV, 2005, CELL MOL LIFE SCI, V62, P471, DOI 10.1007/s00018-004-4423-2; Ivanova AV, 2004, J MOL BIOL, V340, P641, DOI 10.1016/J.Jmb.2004.05.025; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Martin-Puig S, 2004, J BIOL CHEM, V279, P9504, DOI 10.1074/jbc.M310658200; Maxwell PH, 2004, CELL CYCLE, V3, P156; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Sakamoto S, 2004, J BIOL CHEM, V279, P40362, DOI 10.1074/jbc.M406400200; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 2004, TOXICOL APPL PHARM, V196, P258, DOI 10.1016/j.taap.2004.01.003; Salnikow K, 2000, CANCER RES, V60, P38; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Seimiya M, 2004, EUR J IMMUNOL, V34, P1322, DOI 10.1002/eji.200324700; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; van den Elsen PJ, 2004, CURR OPIN IMMUNOL, V16, P67, DOI 10.1016/j.coi.2003.11.015; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong LH, 2002, J BIOL CHEM, V277, P19408, DOI 10.1074/jbc.M111302200; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Yamamoto K, 2003, AUTOIMMUN REV, V2, P13, DOI 10.1016/S1568-9972(02)00121-0; Zagzag D, 2005, LAB INVEST, V85, P328, DOI 10.1038/labinvest.3700233; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	55	56	57	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					802	812		10.1038/sj.onc.1209842	http://dx.doi.org/10.1038/sj.onc.1209842			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878149				2022-12-17	WOS:000244063800002
J	Chirakkal, H; Leech, SH; Brookes, KE; Prais, AL; Waby, JS; Corfe, BM				Chirakkal, H.; Leech, S. H.; Brookes, K. E.; Prais, A. L.; Waby, J. S.; Corfe, B. M.			Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding	ONCOGENE			English	Article						butyrate; colon; BAK; apoptosis; Sp1; Sp3	GENOTOXIN-INDUCED APOPTOSIS; CHAIN FATTY-ACIDS; COLORECTAL-CANCER; DIETARY FIBER; TRANSCRIPTION FACTORS; RESISTANT STARCH; PROMOTER; EXPRESSION; INDUCTION; TRICHOSTATIN	Butyrate is a key bioactive product of dietary fibre fermentation thought to play a key role in cancer prevention. One contributory mechanism in this role is the regulation of apoptosis by butyrate. As butyrate shows lowlevels of toxicity, the mechanisms by which it triggers or regulates apoptosis are of great interest. We and others have shown that the proapoptotic protein BAK is upregulated by butyrate. We show ere that this observation is conserved across multiple cell lines, that it occurs in all cells in a population and is at the transcriptional level. We have used a promoter-reporter construct to identify the regulatory regions of the BAK promoter and found that much of the transcriptional activity occurs via a single Sp1/Sp3 binding site. We have shown that both Sp1 and Sp3 bind, but upon butyrate treatment Sp1 binding decreases in favour of Sp3 binding. We speculate that this may be an acetylation- mediated event.	Univ Sheffield, No Gen Hosp, Human Nutr Unit, Div Clin Sci N, Sheffield S5 7AU, S Yorkshire, England; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England	Northern General Hospital; University of Sheffield; University of Manchester	Corfe, BM (corresponding author), Univ Sheffield, No Gen Hosp, Human Nutr Unit, Div Clin Sci N, Sheffield S5 7AU, S Yorkshire, England.	b.m.corfe@sheffield.ac.uk		Waby, Jennifer/0000-0003-4729-6657; Corfe, Bernard/0000-0003-0449-2228				Arasaradnam RP, 2004, GUT, V53, P155, DOI 10.1136/gut.53.1.155-a; Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1; Blottiere HM, 2003, P NUTR SOC, V62, P101, DOI 10.1079/PNS2002215; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Braun H, 2001, NUCLEIC ACIDS RES, V29, P4994, DOI 10.1093/nar/29.24.4994; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; Chen ZY, 2004, J NUTR, V134, P792, DOI 10.1093/jn/134.4.792; CORFE BM, 1994, MICROBIOL-UK, V140, P3079, DOI 10.1099/13500872-140-11-3079; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hass R, 1997, GASTROENTEROLOGY, V112, P875, DOI 10.1053/gast.1997.v112.pm9041249; Hill MJ, 1997, EUR J CANCER PREV, V6, P219, DOI 10.1097/00008469-199706000-00002; Hill MJ, 2002, EUR J CANCER PREV, V11, P1, DOI 10.1097/00008469-200202000-00001; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Le Leu RK, 2003, CARCINOGENESIS, V24, P1347, DOI 10.1093/carcin/bgg098; Le Leu RK, 2002, CARCINOGENESIS, V23, P713, DOI 10.1093/carcin/23.5.713; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mariadason JM, 2000, CANCER RES, V60, P4561; MCINTYRE A, 1993, GUT, V34, P386, DOI 10.1136/gut.34.3.386; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Perrin P, 2001, GUT, V48, P53, DOI 10.1136/gut.48.1.53; Potten CS, 1997, STEM CELLS, V15, P82, DOI 10.1002/stem.150082; Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Siavoshian S, 2000, GUT, V46, P507, DOI 10.1136/gut.46.4.507; Sowa Y, 1999, CANCER RES, V59, P4266; Steiner E, 2004, BIOCHEM BIOPH RES CO, V317, P235, DOI 10.1016/j.bbrc.2004.03.029; WELTER C, 1991, J EXP CLIN CANC RES, V10, P75; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	34	56	57	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7192	7200		10.1038/sj.onc.1209702	http://dx.doi.org/10.1038/sj.onc.1209702			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16732318				2022-12-17	WOS:000242046900008
J	Minakhina, S; Steward, R				Minakhina, S.; Steward, R.			Nuclear factor-kappa B pathways in Drosophila	ONCOGENE			English	Review						NF-kappaB; Dorsal; Dif; Relish; immunity; embryonic polarity	REL PROTEIN DORSAL; PEPTIDOGLYCAN RECOGNITION PROTEIN; INNATE IMMUNE-RESPONSE; SIGNAL-TRANSDUCTION PATHWAY; MOSQUITO AEDES-AEGYPTI; N-TERMINAL KINASE; DORSOVENTRAL POLARITY; HOST-DEFENSE; MORPHOGEN GRADIENT; DEGRADATION ESTABLISHES	The nuclear factor kappa B (NF-kappa B) pathways in Drosophila are multi-component pathways, as in vertebrates, that regulate the expression of many genes responsible for the formation of dorsal-ventral polarity in the early embryo, the innate immune response to infection with Gram-negative and positive bacteria and fungi, the cellular immune response and hematopoiesis. Overactivation of the fly pathway can result in developmental defects, overproliferation of hemocytes and the formation of melanotic tumors or nodules. The extracellular events leading to the maturation of the ligand for initiation of the Drosophila NF-kappa B pathway is not conserved between flies and vertebrates, but the Toll receptor and downstream events are remarkably similar. NF-kappa B proteins have been identified in mollusks, and arthropods such as horseshoe crabs and beetles, indicating that this pathway has been established more than 500 million years ago. The fly NF-kappa B pathways are less complex than those in vertebrates, with the involvement of fewer proteins, but they are, nonetheless, just as important as their vertebrate counterparts for the life of the fly.	Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Steward, R (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	steward@waksman.rutgers.edu	Gimenez, Luis E Diaz/D-9291-2011					ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BarillasMury C, 1996, EMBO J, V15, P4691, DOI 10.1002/j.1460-2075.1996.tb00846.x; Beremendi A, 2005, NEUROSCIENCE, V134, P397, DOI 10.1016/j.neuroscience.2005.04.046; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Bhattacharya A, 2002, EMBO REP, V3, P378, DOI 10.1093/embo-reports/kvf072; Bian G, 2005, P NATL ACAD SCI USA, V102, P13568, DOI 10.1073/pnas.0502815102; Biemar F, 2005, P NATL ACAD SCI USA, V102, P15907, DOI 10.1073/pnas.0507817102; Bilak H, 2003, BIOCHEM SOC T, V31, P648, DOI 10.1042/bst0310648; Bolatto C, 2003, J NEUROBIOL, V54, P525, DOI 10.1002/neu.10179; Brandt SM, 2004, PLOS BIOL, V2, P2067, DOI 10.1371/journal.pbio.0020418; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Castillejo-Lopez C, 2005, BIOCHEM BIOPH RES CO, V338, P1075, DOI 10.1016/j.bbrc.2005.10.042; Cha GH, 2003, MOL CELL BIOL, V23, P7982, DOI 10.1128/MCB.23.22.7982-7991.2003; Charatsi I, 2003, MECH DEVELOP, V120, P219, DOI 10.1016/S0925-4773(02)00410-0; Cherry S, 2004, NAT IMMUNOL, V5, P81, DOI 10.1038/ni1019; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; Chiu HL, 2005, DEV BIOL, V288, P60, DOI 10.1016/j.ydbio.2005.08.008; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Cornwell WD, 2001, J CELL BIOCHEM, V82, P22, DOI 10.1002/jcb.1144; Cramer P, 1999, STRUCTURE, V7, P841, DOI 10.1016/S0969-2126(99)80107-5; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Drier EA, 2000, CURR BIOL, V10, P23, DOI 10.1016/S0960-9822(99)00267-5; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; Edwards DN, 1997, DEVELOPMENT, V124, P3855; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Govind S, 1996, BIOCHEM SOC T, V24, P39, DOI 10.1042/bst0240039; Govind S, 1996, MOL CELL BIOL, V16, P1103; GOVIND S, 1993, DEVELOPMENT, V117, P135; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; Hashimoto C, 2003, DEV CELL, V5, P945, DOI 10.1016/S1534-5807(03)00338-1; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hedengren-Olcott M, 2004, J BIOL CHEM, V279, P21121, DOI 10.1074/jbc.M313856200; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; Hu XD, 2004, P NATL ACAD SCI USA, V101, P9369, DOI 10.1073/pnas.0307062101; Huang L, 2005, DEV BIOL, V280, P407, DOI 10.1016/j.ydbio.2005.02.006; Huguet C, 1997, ONCOGENE, V15, P2965, DOI 10.1038/sj.onc.1201471; Imler Jean-Luc, 2005, V86, P1, DOI 10.1159/000086648; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kasai Y, 1998, GENE EXPRESSION, V7, P171; Khush RS, 2002, CURR BIOL, V12, P1728, DOI 10.1016/S0960-9822(02)01214-9; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Kim T, 2005, NAT IMMUNOL, V6, P211, DOI 10.1038/ni1159; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Ligoxygakis P, 2003, CURR BIOL, V13, P2097, DOI 10.1016/j.cub.2003.10.062; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Meister M, 2003, CELL MICROBIOL, V5, P573, DOI 10.1046/j.1462-5822.2003.00302.x; Meister S, 2005, P NATL ACAD SCI USA, V102, P11420, DOI 10.1073/pnas.0504950102; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Mengin-Lecreulx D, 2005, J ENDOTOXIN RES, V11, P105, DOI 10.1179/096805105X35233; Minakhina S, 2003, GENES CELLS, V8, P299, DOI 10.1046/j.1365-2443.2002.00634.x; MINAKHINA S, 2006, IN PRESS GENETICS; Montagnani C, 2004, FEBS LETT, V561, P75, DOI 10.1016/S0014-5793(04)00124-3; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Moussian B, 2005, CURR BIOL, V15, pR887, DOI 10.1016/j.cub.2005.10.026; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nappi AJ, 2005, J INSECT PHYSIOL, V51, P197, DOI 10.1016/j.jinsphys.2004.10.013; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; Ooi JY, 2002, EMBO REP, V3, P82, DOI 10.1093/embo-reports/kvf004; Papatsenko D, 2005, P NATL ACAD SCI USA, V102, P4966, DOI 10.1073/pnas.0409414102; Park JM, 2003, MOL CELL BIOL, V23, P1358, DOI 10.1128/MCB.23.4.1358-1367.2003; Pelte N, 2006, INSECT BIOCHEM MOLEC, V36, P37, DOI 10.1016/j.ibmb.2005.10.004; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Qiu P, 1998, DEVELOPMENT, V125, P1909; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roth P, 2003, J CELL BIOL, V163, P701, DOI 10.1083/jcb.200304046; Roth S, 2003, PHILOS T ROY SOC B, V358, P1317, DOI 10.1098/rstb.2003.1325; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; ROTH S, 1994, CURR BIOL, V4, P755, DOI 10.1016/S0960-9822(00)00170-6; Royet J, 2004, CELL MOL LIFE SCI, V61, P537, DOI 10.1007/s00018-003-3243-0; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Sagisaka A, 2004, BBA-GENE STRUCT EXPR, V1678, P85, DOI 10.1016/j.bbaexp.2004.02.001; Schneider D, 2000, SCIENCE, V288, P2376, DOI 10.1126/science.288.5475.2376; SCHUPBACH T, 1989, GENETICS, V121, P101; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Shen BH, 2002, DEVELOPMENT, V129, P1925; Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Stathopoulos A, 2002, CELL, V111, P687, DOI 10.1016/S0092-8674(02)01087-5; Stathopoulos A, 2002, DEV BIOL, V246, P57, DOI 10.1006/dbio.2002.0652; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Tanaka H, 2005, BBA-GENE STRUCT EXPR, V1730, P10, DOI 10.1016/j.bbaexp.2005.05.007; Tanji T, 2005, TRENDS IMMUNOL, V26, P193, DOI 10.1016/j.it.2005.02.006; TATEI K, 1995, MOL CELL BIOL, V15, P3627; Tsuda M, 2005, EMBO REP, V6, P1082, DOI 10.1038/sj.embor.7400537; Uv AE, 2000, GENE DEV, V14, P1945; Uvell H, 2003, MOL CELL BIOL, V23, P8272, DOI 10.1128/MCB.23.22.8272-8281.2003; Vernick KD, 2005, CURR TOP MICROBIOL, V295, P383; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wang XW, 2006, P NATL ACAD SCI USA, V103, P4204, DOI 10.1073/pnas.0507044103; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yagi Y, 2005, EMBO REP, V6, P1088, DOI 10.1038/sj.embor.7400542; Yang J, 1997, P NATL ACAD SCI USA, V94, P14524, DOI 10.1073/pnas.94.26.14524; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102; Zhong WW, 2006, SCIENCE, V311, P1481, DOI 10.1126/science.1123287; Zhou R, 2005, J BIOL CHEM, V280, P34048, DOI 10.1074/jbc.M506655200	130	56	57	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6749	6757		10.1038/sj.onc.1209940	http://dx.doi.org/10.1038/sj.onc.1209940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072326				2022-12-17	WOS:000241666700006
J	Remacle, AG; Rozanov, DV; Fugere, M; Day, R; Strongin, AY				Remacle, A. G.; Rozanov, D. V.; Fugere, M.; Day, R.; Strongin, A. Y.			Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP	ONCOGENE			English	Article						MT1-MMP; furin; internalization; proprotein convertase; PA83; anthrax	TYPE-1 MATRIX-METALLOPROTEINASE; 3-DIMENSIONAL EXTRACELLULAR-MATRIX; TRANS-GOLGI NETWORK; 1-MATRIX METALLOPROTEINASE; ANTHRAX TOXIN; TISSUE INHIBITOR; PROPROTEIN CONVERTASES; CRYSTAL-STRUCTURE; CANCER-CELLS; MEMBRANE	Invasion-promoting membrane type-1 matrix metallo-proteinase (MT1-MMP) functions in cancer cells as an oncogene and as a mediator of proteolytic events on the cell surface. To exert its functional activity, MT1-MMP requires proteolytic removal of the prodomain sequence. There are two potential furin cleavage motifs, R-89-R-P-R-C-93 and R-108-R-K-R-Y-112, in the prodomain sequence of MT1-MMP. Our data suggest an important role of furin and related proprotein convertases (PCs) in mediating both the activation of MT1-MMP and the levels of functionally active MT1-MMP at the surface of cancer cells. We have determined that the peptide sequence that spans the first cleavage site is susceptible to furin and PC5/6, whereas the second sequence is susceptible to furin and also to PC5/6, PC7 and PACE4. In the structure of the MT1-MMP proenzyme, the R-89-R-P-R-C-93 site, however, is inaccessible to PCs. Our studies also demonstrated a direct functional link between the activation and the uptake rate of the proenzyme and the enzyme of MT1-MMP. Thus, the uptake rate of the latent MT1-MMP proenzyme noticeably exceeded that of the active enzyme. We conclude that furin and related PCs are the essential components of the specialized cellular machinery that controls the levels of the functionally active, mature, MT1-MMP enzyme on the cell surface to continually support the potency of pericellular proteolysis.	Burnham Inst Med Rs, La Jolla, CA 92037 USA; Univ Sherbrooke, Fac Med, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1K 2R1, Canada	Sanford Burnham Prebys Medical Discovery Institute; University of Sherbrooke	Strongin, AY (corresponding author), Burnham Inst Med Rs, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NCRR NIH HHS [RR020843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077470, R01CA083017] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bradley KA, 2003, BIOCHEM PHARMACOL, V65, P309, DOI 10.1016/S0006-2952(02)01455-7; Cao J, 2005, J BIOL CHEM, V280, P10974, DOI 10.1074/jbc.M412370200; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Chun TH, 2004, J CELL BIOL, V167, P757, DOI 10.1083/jcb.200405001; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 1997, J CELL SCI, V110, P2473; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Fugere M, 2005, TRENDS PHARMACOL SCI, V26, P294, DOI 10.1016/j.tips.2005.04.006; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Mazzone M, 2004, J CELL SCI, V117, P6275, DOI 10.1242/jcs.01563; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Morgunova E, 2002, P NATL ACAD SCI USA, V99, P7414, DOI 10.1073/pnas.102185399; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Santelli E, 2004, NATURE, V430, P905, DOI 10.1038/nature02763; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; Scobie HM, 2005, CURR OPIN MICROBIOL, V8, P106, DOI 10.1016/j.mib.2004.12.005; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; SITRIN RG, 1990, CANCER RES, V50, P4957; Stawowy P, 2005, CIRCULATION, V111, P2820, DOI 10.1161/CIRCULATIONAHA.104.502617; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Toth M, 2005, BIOCHEM J, V387, P497, DOI 10.1042/BJ20041324; Wang P, 2004, J BIOL CHEM, V279, P20461, DOI 10.1074/jbc.M400264200; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387	50	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5648	5655		10.1038/sj.onc.1209572	http://dx.doi.org/10.1038/sj.onc.1209572			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636666				2022-12-17	WOS:000240599100006
J	Babic, I; Cherry, E; Fujita, DJ				Babic, I.; Cherry, E.; Fujita, D. J.			SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis	ONCOGENE			English	Article						SUMO; Sam68; apoptosis; cyclin D1	NUCLEAR RIBONUCLEOPROTEIN-K; BINDING PROTEIN SAM68; FUNCTIONAL INTERACTION; RNA; PHOSPHORYLATION; PROGRESSION; SUMOYLATION; ACTIVATION; PIAS; SRC	Sam68 (Src associated in mitosis; 68 kDa) is an RNA-binding protein and substrate of Src family kinases. It is thought to play a role in cell cycle progression. Overexpression of Sam68 in fibroblasts was reported to have two separable functions dependent on its ability to bind RNA-cell cycle arrest or the induction of apoptosis. Post-translational modification with SUMO (small ubi-quitinlike modi. er) is common to many transcription factors and can regulate protein localization, stability and function. Here we show Sam68 to be modified by SUMO, and demonstrate that the SUMO E3 ligase (PIAS1) (protein inhibitor of activated STAT1) can enhance Sam68 sumoylation. Lysine 96, the first lysine in the amino-terminal region of Sam68, was found to be the major SUMO acceptor site. Mutation of the SUMO acceptor lysine to arginine enhanced the ability of Sam68 to induce apoptosis but inhibited its ability to act as a transcriptional inhibitor of cyclin D1 expression. A SUMO-1 Sam68 fusion protein, on the other hand, inhibited the ability of Sam68 to induce apoptosis but was a strong repressor of cyclin D1 expression. Thus, SUMO may be an important regulator of Sam68 function in cell cycle progression.	Univ Calgary, So Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, So Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	dfujita@ucalgary.ca						Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Holmstrom S, 2003, P NATL ACAD SCI USA, V100, P15758, DOI 10.1073/pnas.2136933100; Hong W, 2002, MOL CANCER RES, V1, P48; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kim KI, 2002, J CELL PHYSIOL, V191, P257, DOI 10.1002/jcp.10100; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Lee PSW, 2003, J BIOL CHEM, V278, P27853, DOI 10.1074/jbc.M301755200; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Vassileva MT, 2004, MOL CELL BIOL, V24, P3623, DOI 10.1128/MCB.24.9.3623-3632.2004; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yang HP, 2002, ONCOGENE, V21, P7187, DOI 10.1038/sj.onc.1205759; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Zhang H, 2002, MOL CELL BIOL, V22, P6498, DOI 10.1128/MCB.22.18.6498-6508.2002	48	56	62	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2006	25	36					4955	4964		10.1038/sj.onc.1209504	http://dx.doi.org/10.1038/sj.onc.1209504			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568089				2022-12-17	WOS:000239921300001
J	Mariano, AR; Colombo, E; Luzi, L; Martinelli, P; Volorio, S; Bernard, L; Meani, N; Bergomas, R; Alcalay, M; Pelicci, PG				Mariano, A. R.; Colombo, E.; Luzi, L.; Martinelli, P.; Volorio, S.; Bernard, L.; Meani, N.; Bergomas, R.; Alcalay, M.; Pelicci, P. G.			Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal	ONCOGENE			English	Article						NPM; AML; nucleus-cytoplasmic shuttling; NES; CRM1	ACUTE MYELOGENOUS LEUKEMIA; NORMAL KARYOTYPE; NUCLEOPHOSMIN; PROTEIN; ARF	Nucleophosmin (NPM) is a nucleus-cytoplasmic shuttling protein that is implicated in centrosome duplication, cell cycle progression and stress response. At the steady state, NPM localizes mainly in the nucleolus, where it forms a complex with different cellular proteins. One-third of acute myeloid leukemias (AML) are characterized by aberrant cytoplasmic localization of NPM, due to mutations within its last coding exon (exon 12) that cause a frameshift and the formation of novel C-termini. We report here our investigations on the molecular basis for the aberrant localization of mutated NPM. Alignment of the C-terminus of the various NPM mutants revealed the obligatory presence of four amino-acid residues that match a CRM1-dependent nuclear export signal (NES). Single alanine-substitutions at these sites provoked nuclear re-localization, while fusion of the mutated C-terminus to a heterologous nuclear protein induced CRM1-dependent cytoplasmic localization. Molecular characterization of one exceptional AML carrying cytoplasmic NPM and germ line exon 12 revealed a somatic mutation in the splicing donor site of exon 9 that caused the formation of a functional NES. It appears, therefore, that AMLs are frequently characterized by gain-of-function mutations of NPM that create functional NES, suggesting that alterations of nuclear export might represent a general mechanism of leukemogenesis and a novel target for therapeutic intervention.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; IFOM Inst, Milan, Italy; Univ Milan, Dept Med Surg & Dent, Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; University of Milan	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	piergiuseppe.pelicci@ifom-ieo-campus.it	Luzi, Lucilla/K-4350-2018; Pelicci, Pier Giuseppe/AAL-6572-2020; Colombo, Emanuela/AAO-8113-2020; Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016	Luzi, Lucilla/0000-0002-8746-4179; Colombo, Emanuela/0000-0003-2079-7398; Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272; Martinelli, Paola/0000-0002-1643-8731				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cazzaniga G, 2005, BLOOD, V106, P1419, DOI 10.1182/blood-2005-03-0899; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; COLOMBO E, 2006, IN PRESS CANC RES; den Besten W, 2005, CELL CYCLE, V4, P1593; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Engelsma D, 2004, EMBO J, V23, P3643, DOI 10.1038/sj.emboj.7600370; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005; Nakagawa M, 2005, NEW ENGL J MED, V352, P1819; Slape C, 2004, LEUKEMIA LYMPHOMA, V45, P1341, DOI 10.1080/10428190310001659325; Suzuki T, 2005, BLOOD, V106, P2854, DOI 10.1182/blood-2005-04-1733; Wang W, 2005, NAT CELL BIOL, V7, P823, DOI 10.1038/ncb1282; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	14	56	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2006	25	31					4376	4380		10.1038/sj.onc.1209453	http://dx.doi.org/10.1038/sj.onc.1209453			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16501600				2022-12-17	WOS:000239240100013
J	Pretto, D; Barco, R; Rivera, J; Neel, N; Gustavson, MD; Eid, JE				Pretto, D.; Barco, R.; Rivera, J.; Neel, N.; Gustavson, M. D.; Eid, J. E.			The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus andassociates with it in an active complex	ONCOGENE			English	Article						synovial sarcoma; SYT-SSX2; beta-catenin	WNT SIGNALING PATHWAY; SYT-SSX; P120 CATENIN; ACTIVATION; EXPRESSION; GENE; LOCALIZATION; ACCUMULATION; INTERACTS; DOMAINS	Localization of beta-catenin in the cell is a key determinant in its decision to function as a critical mediator of cell adhesion at the surface or a transcription activator in the nucleus. SYT-SSX2 is the fusion product of the chromosomal translocation, t( X; 18)( p11.2; q11.2), which occurs in synovial sarcoma, a soft tissue tumor. SYT-SSX2 is known to associate with chromatin remodeling complexes and is proposed to be involved in controlling gene expression. We report that SYT-SSX2 plays a direct role in b-catenin regulation. When expressed in mammalian cells, SYT-SSX2-induced beta-catenin recruitment to the nucleus. Interestingly, known target genes of canonical Wnt were not activated as a result of SYT-SSX2 expression, nor was the nuclear localization of beta-catenin due to one of the signaling pathways normally implicated in this event. beta-Catenin accumulation in the nucleus led to the formation of a transcriptionally active nuclear complex that contained SYT-SSX2 and beta-catenin. More importantly, depletion of SYT-SSX2 in primary synovial sarcoma cells resulted in loss of nuclear beta-catenin signal and a significant decrease in its signaling activity. These results unravel a novel pathway in the control of beta-catenin cellular transport and strongly suggest that SYT-SSX2 contributes to tumor development, in part through beta-catenin signaling.	Vanderbilt Univ, Ctr Med, Dept Canc Biol, Nashville, TN 37232 USA	Vanderbilt University	Eid, JE (corresponding author), Vanderbilt Univ, Ctr Med, Dept Canc Biol, 23d Ave S Pierce PRB 740, Nashville, TN 37232 USA.	josiane.eid@vanderbilt.edu			NCI NIH HHS [CA68485, CA 15751, R01CA106481-01, K22 CA098008-01] Funding Source: Medline; NIBIB NIH HHS [EB00672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA015751, P30CA068485, R01CA015751, R01CA106481, K22CA098008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000672, R33EB000672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; Doucas H, 2005, EUR J CANCER, V41, P365, DOI 10.1016/j.ejca.2004.11.005; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hasegawa T, 2001, HUM PATHOL, V32, P257, DOI 10.1053/hupa.2001.22764; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287-2297.2003; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tissier F, 2005, CANCER RES, V65, P7622, DOI 10.1158/0008-5472.CAN-05-0593; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Xie YT, 2002, CANCER RES, V62, P3861	34	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2006	25	26					3661	3669		10.1038/sj.onc.1209413	http://dx.doi.org/10.1038/sj.onc.1209413			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KD	16462762				2022-12-17	WOS:000238448300005
J	Ren, Y; Chan, HM; Fan, J; Xie, Y; Chen, YX; Li, W; Jiang, GP; Liu, Q; Meinhardt, A; Tam, PKH				Ren, Y.; Chan, H. M.; Fan, J.; Xie, Y.; Chen, Y. X.; Li, W.; Jiang, G. P.; Liu, Q.; Meinhardt, A.; Tam, P. K. H.			Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma	ONCOGENE			English	Article						MIF; neuroblastoma; antisense; tumor growth and metastasis	SQUAMOUS-CELL CARCINOMA; FACTOR MIF; HEPATOCELLULAR-CARCINOMA; PROSTATIC ADENOCARCINOMA; UP-REGULATION; CANCER CELLS; EXPRESSION; ANGIOGENESIS; INTERLEUKIN-8; MET	Macrophage migration inhibitory factor (MIF) has been defined as a novel oncogene. Our previous results have shown that MIF may contribute to the progression of neuroblastoma by (a) inducing N-Myc expression and (b) upregulating the expression of angiogenic factors. The aim of this study was to test whether tumor growth could be inhibited by reduction of endogenous MIF expression in neuroblastoma and clarify the molecular mechanisms underlying MIF reduction on the control of neuroblastoma growth. We established human neuroblastoma cell lines stably expressing antisense MIF (AS-MIF) cDNA. These stable transfectants were characterized by cell proliferation, gene expression pro. le, tumorigenicity and metastasis in vitro and in vivo. Decreased MIF expression was observed after transfection with AS-MIF in neuroblastoma cells and downregulation of MIF expression significantly correlated with decreased expression of N-Myc, Ras, c-Met and TrkB at protein level. Affymetrix microarray analysis revealed that expression of IL-8 and c-met was inhibited and neuroblastoma-favorable genes such as EPHB6 and BLU were upregulated in MIF reduced cells. Neuroblastoma cell growth exhibited a nearly 80% reduction in AS-MIF transfectants in vitro. Furthermore, mice in which tumors formed after subcutaneous injection of AS-MIF transfectants showed a 90% reduction in tumor growth compared to control. Metastasis in mice was also suppressed dramatically. Our data demonstrate that targeting MIF expression is a promising therapeutic strategy in human neuroblastoma therapy, and also identifies the MIF target genes for further study.	Cleveland Clin Fdn, Ctr Hematol & Oncol Mol Therapeut R40, Taussig Canc Ctr, Cleveland, OH 44195 USA; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Princeton Univ, Stat Lab, ORFE, Princeton, NJ 08544 USA; Univ Giessen, Dept Anat & Cell Biol, Giessen, Germany	Cleveland Clinic Foundation; University of Hong Kong; Princeton University; Justus Liebig University Giessen	Ren, Y (corresponding author), Cleveland Clin Fdn, Ctr Hematol & Oncol Mol Therapeut R40, Taussig Canc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	reny@ccf.org; paultam@hkucc.hku.hk	Meinhardt, Andreas/B-3688-2009; /C-4405-2009	/0000-0001-6231-3035	NIGMS NIH HHS [R01-GM072611] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072611] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Akbar SMF, 2001, CANCER LETT, V171, P125, DOI 10.1016/S0304-3835(01)00606-1; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chambery D, 1999, CANCER RES, V59, P2898; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; del Vecchio MT, 2000, PROSTATE, V45, P51, DOI 10.1002/1097-0045(20000915)45:1<51::AID-PROS6>3.0.CO;2-9; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Edsjo A, 2003, LAB INVEST, V83, P813, DOI 10.1097/01.LAB.0000074895.48776.D8; Fan JQ, 2004, P NATL ACAD SCI USA, V101, P1135, DOI 10.1073/pnas.0307557100; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Hafner C, 2003, INT J ONCOL, V23, P1553; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Hecht M, 2004, CANCER RES, V64, P6109, DOI 10.1158/0008-5472.CAN-04-1014; Kamimura A, 2000, CANCER, V89, P334, DOI 10.1002/1097-0142(20000715)89:2<334::AID-CNCR18>3.0.CO;2-N; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mahloogi H, 2003, CANCER RES, V63, P4997; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Meyer-Siegler K, 2000, J INTERF CYTOK RES, V20, P769, DOI 10.1089/10799900050151030; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; Ren Y, 2005, ANN SURG, V242, P55, DOI 10.1097/01.sla.0000168555.97710.bb; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Ren Y, 2003, CLIN CANCER RES, V9, P5996; Ren Y, 2003, INT J CANCER, V107, P22, DOI 10.1002/ijc.11287; Sasaki Y, 2002, INT J MOL MED, V10, P579; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Tang XX, 2004, CLIN CANCER RES, V10, P5837, DOI 10.1158/1078-0432.CCR-04-0395; Tang XX, 2000, P NATL ACAD SCI USA, V97, P10936, DOI 10.1073/pnas.190123297; TOMIYASU M, 2000, CLIN CANCER RES, V8, P3755; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yang YB, 2000, J CLIN ENDOCR METAB, V85, P4721, DOI 10.1210/jc.85.12.4721	44	56	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3501	3508		10.1038/sj.onc.1209395	http://dx.doi.org/10.1038/sj.onc.1209395			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16449971				2022-12-17	WOS:000238448200002
J	Feng, JT; Shang, S; Beretta, L				Feng, J. T.; Shang, S.; Beretta, L.			Proteomics for the early detection and treatment of hepatocellular carcinoma	ONCOGENE			English	Review						proteomics; hepatocellular carcinoma; biomarkers; diagnostics; therapeutics	HEPATITIS-C-VIRUS; DIFFERENCE GEL-ELECTROPHORESIS; CHROMATOGRAPHY-MASS-SPECTROMETRY; PRIMARY LIVER-CANCER; PROTEIN IDENTIFICATION; 2-DIMENSIONAL ELECTROPHORESIS; SHOTGUN PROTEOMICS; ALPHA-FETOPROTEIN; UNITED-STATES; TUMOR-MARKERS	The prognosis for hepatocellular carcinoma (HCC) is poor and has not improved in recent years, largely owing to lack of early diagnosis, frequent recurrence after surgery and resistance to chemotherapy. Proteomics holds the promise of improving our understanding of HCC carcinogenesis and progression as well as of discovering novel diagnostics and therapeutics. Proteomic analyses of HCC cell lines, animal models and serum and tumor tissue from patients with HCC have been performed to date. Proteomic technologies have greatly improved in the past few years as reviewed here. It is anticipated that with the recent development of protein tagging, protein separation methods and mass spectrometry sensitivity, proteomic studies of HCC will allow the identification of diagnostic and prognostic biomarkers as well as therapeutic targets, which could greatly improve the clinical management of HCC patients.	Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Beretta, L (corresponding author), Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, 1100 Fairview Ave N,M5-A864,POB 19024, Seattle, WA 98109 USA.	lberetta@fhcrc.org		Laura, Beretta/0000-0002-2054-684X				Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Block TM, 2005, P NATL ACAD SCI USA, V102, P779, DOI 10.1073/pnas.0408928102; Cagney G, 2002, NAT BIOTECHNOL, V20, P163, DOI 10.1038/nbt0202-163; Chignard N, 2004, GASTROENTEROLOGY, V127, pS120, DOI 10.1053/j.gastro.2004.09.025; CHIGNARD N, 2006, IN PRESS GASTROERTER; Cho SY, 2002, PROTEOMICS, V2, P1104, DOI 10.1002/1615-9861(200209)2:9<1104::AID-PROT1104>3.0.CO;2-Q; Chu RY, 2002, GENE EXPRESSION, V10, P165, DOI 10.3727/000000002783992460; Comunale MA, 2004, PROTEOMICS, V4, P826, DOI 10.1002/pmic.200300625; Cui JF, 2004, J CANCER RES CLIN, V130, P615, DOI 10.1007/s00432-004-0576-5; Daniele B, 2004, GASTROENTEROLOGY, V127, pS108, DOI 10.1053/j.gastro.2004.09.023; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; El-Serag HB, 2001, HEPATOLOGY, V33, P62, DOI 10.1053/jhep.2001.21041; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Feng JT, 2005, PROTEOMICS, V5, P4581, DOI 10.1002/pmic.200401309; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fernandez-Irigoyen J, 2005, PROTEOMICS, V5, P4964, DOI 10.1002/pmic.200500070; Fujii K, 2005, PROTEOMICS, V5, P1411, DOI 10.1002/pmic.200401004; Gu S, 2004, J PROTEOME RES, V3, P1191, DOI 10.1021/pr049893a; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanash S, 2004, MOL CELL PROTEOMICS, V3, P298, DOI 10.1074/mcp.R400004-MCP200; Hanash S, 2002, MOL CELL PROTEOMICS, V1, P413, DOI 10.1074/mcp.R200002-MCP200; He FC, 2005, MOL CELL PROTEOMICS, V4, P1841, DOI 10.1074/mcp.R500013-MCP200; Hippo Y, 2004, CANCER RES, V64, P2418, DOI 10.1158/0008-5472.CAN-03-2191; Iida M, 2003, CARCINOGENESIS, V24, P757, DOI 10.1093/carcin/bgg011; Kang SM, 2005, PROTEOMICS, V5, P2227, DOI 10.1002/pmic.200401093; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kim J, 2002, ELECTROPHORESIS, V23, P4142, DOI 10.1002/elps.200290032; Kim W, 2003, CLIN CANCER RES, V9, P5493; Le Naour F, 2002, MOL CELL PROTEOMICS, V1, P197, DOI 10.1074/mcp.M100029-MCP200; Lee CL, 2003, PROTEOMICS, V3, P2472, DOI 10.1002/pmic.200300586; Li C, 2005, PROTEOMICS, V5, P1125, DOI 10.1002/pmic.200401141; Li C, 2004, MOL CELL PROTEOMICS, V3, P399, DOI 10.1074/mcp.M300133-MCP200; Liang CRMY, 2005, PROTEOMICS, V5, P2258, DOI 10.1002/pmic.200401256; Lim SO, 2002, BIOCHEM BIOPH RES CO, V291, P1031, DOI 10.1006/bbrc.2002.6547; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Mannova P, 2005, J VIROL, V79, P8742, DOI 10.1128/JVI.79.14.8742-8749.2005; Mehta AI, 2003, DIS MARKERS, V19, P1; Melle C, 2004, INT J ONCOL, V24, P885; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Orchard S, 2004, EXPERT REV PROTEOMIC, V1, P179, DOI 10.1586/14789450.1.2.179; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Parent R, 2005, J HEPATOL, V43, P177, DOI 10.1016/j.jhep.2005.04.001; Park KS, 2002, HEPATOLOGY, V35, P1459, DOI 10.1053/jhep.2002.33204; Park KS, 2002, INT J CANCER, V97, P261, DOI 10.1002/ijc.1585; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pedrioli PGA, 2004, NAT BIOTECHNOL, V22, P1459, DOI 10.1038/nbt1031; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Poon TCW, 2003, CLIN CHEM, V49, P752, DOI 10.1373/49.5.752; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schwegler EE, 2005, HEPATOLOGY, V41, P634, DOI 10.1002/hep.20577; Shalhoub P, 2001, DIS MARKERS, V17, P217, DOI 10.1155/2001/210580; Shui WQ, 2005, J PROTEOME RES, V4, P83, DOI 10.1021/pr049850u; Srisomsap C, 2004, PROTEOMICS, V4, P1135, DOI 10.1002/pmic.200300651; Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Takashima M, 2005, PROTEOMICS, V5, P1686, DOI 10.1002/pmic.200401022; Takashima M, 2003, PROTEOMICS, V3, P2487, DOI 10.1002/pmic.200300621; Tan TL, 2005, J CLIN VIROL, V33, P293, DOI 10.1016/j.jcv.2004.12.015; Tannapfel A, 2003, J PATHOL, V201, P238, DOI 10.1002/path.1420; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Van den Bergh G, 2004, CURR OPIN BIOTECH, V15, P38, DOI 10.1016/j.copbio.2003.12.001; Wang H, 2005, MASS SPECTROM REV, V24, P413, DOI 10.1002/mas.20018; Wang H, 2003, J CHROMATOGR B, V787, P11, DOI 10.1016/S1570-0232(02)00335-5; WIRTH PJ, 1995, ELECTROPHORESIS, V16, P1946, DOI 10.1002/elps.11501601321; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Yates JR, 1998, J MASS SPECTROM, V33, P1; Yates JR, 2004, ANNU REV BIOPH BIOM, V33, P297, DOI 10.1146/annurev.biophys.33.111502.082538; Yokoo H, 2004, HEPATOLOGY, V40, P609, DOI 10.1002/hep.20372; Yokoyama Y, 2004, PROTEOMICS, V4, P2111, DOI 10.1002/pmic.200300712; Yu YL, 2004, PROTEOMICS, V4, P3112, DOI 10.1002/pmic.200300837; Zeindl-Eberhart E, 2004, HEPATOLOGY, V39, P540, DOI 10.1002/hep.20060; Zeindl-Eberhart E, 2001, ELECTROPHORESIS, V22, P3009, DOI 10.1002/1522-2683(200108)22:14<3009::AID-ELPS3009>3.0.CO;2-V; Zhang J, 2004, ELECTROPHORESIS, V25, P2374, DOI 10.1002/elps.200405956; Zhang LH, 2005, WORLD J GASTROENTERO, V11, P463, DOI 10.3748/wjg.v11.i4.463; Zhang Y, 2005, WORLD J GASTROENTERO, V11, P3485, DOI 10.3748/wjg.v11.i22.3485; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4; Zwickl H, 2005, ELECTROPHORESIS, V26, P2779, DOI 10.1002/elps.200410387	84	56	63	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3810	3817		10.1038/sj.onc.1209551	http://dx.doi.org/10.1038/sj.onc.1209551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799622				2022-12-17	WOS:000238559600008
J	Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F				Agirre, X; Roman-Gomez, J; Jimenez-Velasco, A; Garate, L; Montiel-Duarte, C; Navarro, G; Vazquez, I; Zalacain, M; Calasanz, MJ; Heiniger, A; Torres, A; Minna, JD; Prosper, F			ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia	ONCOGENE			English	Article						ASPP; TP53; methylation; MSP	P53-INTERACTING PROTEIN 53BP2; MESSENGER-RNA EXPRESSION; GEL-ELECTROPHORESIS; WILD-TYPE; HYPERMETHYLATION; CANCER; CHILDREN; GENES; CHEMOTHERAPY; MUTATIONS	We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene, in acute lymphoblastic leukemia ( ALL). Expression of ASPP1 was significantly reduced in ALL and was dependent on hypermethylation of the ASPP1 gene promoter. Abnormal ASPP1 expression was associated with normal function of the tumor-suppressor gene TP53 in ALL. The analyses of 180 patients with ALL at diagnosis showed that the ASPP1 promoter was hypermethylated in 25% of cases with decreased mRNA expression. Methylation was significantly higher in adult ALL vs childhood ALL ( 32 vs 17%, P = 0.03) and T-ALL vs B-ALL ( 50 vs 9%, P = 0.001). Relapse rate ( 62 vs 44%, P = 0.05) and mortality ( 59 vs 43%, P = 0.05) were significantly higher in patients with methylated ASPP1. DFS and OS were 32.8 and 33.7% for patients with unmethylated ASPP1 and 6.1 and 9.9% for methylated patients ( P < 0.001 y P < 0.02, respectively). On the multivariate analysis, methylation of the ASPP1 gene promoter was an independent poor prognosis factor in ALL patients. Our results demonstrate that decreased expression of ASPP1 in patients with ALL is due to an abnormal methylation of its promoter and is associated with a poor prognosis.	Univ Navarra, Clin Univ, Fdn Appl Med Res, Div Canc & Area Cell Therapy, Navarra 31008, Spain; Univ Navarra, Clin Univ, Serv Hematol, Navarra 31008, Spain; Hosp Reina Sofia, Dept Hematol, Cordoba, Spain; Univ Navarra, Clin Univ, Dept Pediat, Navarra 31008, Spain; Hosp Carlos Haya, Dept Hematol, Malaga, Spain; Univ Navarra, Dept Genet, Sch Sci, Navarra 31008, Spain; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75230 USA	University of Navarra; University of Navarra; Hospital Universitario Reina Sofia - Cordoba; University of Navarra; Hospital Carlos Haya; University of Navarra; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Prosper, F (corresponding author), Univ Navarra, Clin Univ, Fdn Appl Med Res, Div Canc & Area Cell Therapy, Avda Pio 12 36, Navarra 31008, Spain.	fprosper@unav.es	Agirre, Xabier/ABE-4110-2020; Calasanz, MJ/R-5813-2016; Prosper, Felipe/H-6859-2017; Montiel-Duarte, Cristina/AAB-3758-2019	Calasanz, MJ/0000-0002-0374-3008; Prosper, Felipe/0000-0001-6115-8790; Montiel-Duarte, Cristina/0000-0002-9144-8809				Agirre X, 2003, ONCOGENE, V22, P1070, DOI 10.1038/sj.onc.1206236; Agirre X, 2002, BIOTECHNIQUES, V32, P1064, DOI 10.2144/02325rr01; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; HAMELIN R, 1993, ONCOGENE, V8, P2213; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Mori T, 2000, FEBS LETT, V465, P124, DOI 10.1016/S0014-5793(99)01726-3; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Ortega JJ, 2001, HAEMATOLOGICA, V86, P586; Ribera JM, 2002, HAEMATOLOGICA, V87, P154; Ribera JM, 1998, HAEMATOLOGICA, V83, P222; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Roman-Gomez J, 2004, LEUKEMIA, V18, P362, DOI 10.1038/sj.leu.2403223; Rossi D, 2004, HAEMATOLOGICA, V89, P154; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Smith M, 1996, J CLIN ONCOL, V14, P18, DOI 10.1200/JCO.1996.14.1.18; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001	31	56	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1862	1870		10.1038/sj.onc.1209236	http://dx.doi.org/10.1038/sj.onc.1209236			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16314841	Green Published			2022-12-17	WOS:000236224800003
J	Gomez-Bougie, P; Oliver, L; Le Gouill, S; Bataille, R; Amiot, M				Gomez-Bougie, P; Oliver, L; Le Gouill, S; Bataille, R; Amiot, M			Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex	ONCOGENE			English	Article						multiple myeloma; melphalan; Mcl-1; Bcl-2; BH3-only Bim	BCL-2 FAMILY; SURVIVAL; PROTEIN; DEATH; MITOCHONDRIA; AMPLIFICATION; BCL-X(L); MOLECULE	Multiple myeloma ( MM) is a rapidly fatal plasma-cell malignancy that evolves mainly in the bone marrow. Melphalan is widely used to treat patients with MM but as yet its mechanisms of action are poorly documented. In the current study, we demonstrate that melphalan induces a drastic downregulation of Mcl-1L, Bcl-x(L) and BimEL in human melphalan-sensitive myeloma cells while the most potent proapoptotic isoforms, BimL and S, are affected to a lesser extent. Moreover, Mcl-1L and BimEL disappearance is associated with the generation of proapoptotic cleaved forms generated by a caspase cleavage. In myeloma cells, we have previously shown that Mcl-1 neutralizes the proapoptotic function of Bim and therefore, prevents the activation of death effectors. In this study, we demonstrate that melphalan disrupts the Mcl-1/Bim complex whereas the Bcl-2/Bim complex is not modified. The disappearance of full length Mcl-1 allows the release of Bim isoforms, particularly L and S, which can exert their proapoptotic function and leads to Bax activation and cytochrome c release. Thus, we can hypothesize that the cleaved 26 kDa proapoptotic Mcl-1 and the 19 and 12 kDa of Bim, generated during melphalan treatment could contribute to the amplification loop of apoptosis.	INSERM, UMR601, Dept Rech Cancerol, Equipe 5 Labelisee,Inst Biol, F-44093 Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Amiot, M (corresponding author), INSERM, UMR601, Dept Rech Cancerol, Equipe 5 Labelisee,Inst Biol, LNC 2005,9 Quai Moncousu, F-44093 Nantes, France.	mamiot@nantes.inserm.fr	Oliver, Lisa J/L-3070-2015; Amiot, Martine/K-9076-2015	Oliver, Lisa J/0000-0002-5588-7564; le gouill, steven/0000-0001-9840-2128; Amiot, Martine/0000-0003-0428-7355; Gomez Bougie, Patricia/0000-0002-4846-4782				Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Chen D, 2004, P NATL ACAD SCI USA, V101, P1235, DOI 10.1073/pnas.0308050100; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oliver L, 2000, FEBS LETT, V487, P161, DOI 10.1016/S0014-5793(00)02330-9; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pei XY, 2003, LEUKEMIA, V17, P2036, DOI 10.1038/sj.leu.2403109; Schmelz K, 2004, ONCOGENE, V23, P6743, DOI 10.1038/sj.onc.1207848; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhu YN, 2004, P NATL ACAD SCI USA, V101, P7681, DOI 10.1073/pnas.0402293101	27	56	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8076	8079		10.1038/sj.onc.1208949	http://dx.doi.org/10.1038/sj.onc.1208949			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16091744				2022-12-17	WOS:000233656600013
J	Takada, H; Imoto, I; Tsuda, H; Nakanishi, Y; Ichikura, T; Mochizuki, H; Mitsufuji, S; Hosoda, F; Hirohashi, S; Ohki, M; Inazawa, J				Takada, H; Imoto, I; Tsuda, H; Nakanishi, Y; Ichikura, T; Mochizuki, H; Mitsufuji, S; Hosoda, F; Hirohashi, S; Ohki, M; Inazawa, J			ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation	ONCOGENE			English	Article						CGH-array; gastric cancer; ADAM23; homozygous deletion; methylation	COMPARATIVE GENOMIC HYBRIDIZATION; EPIDERMAL-GROWTH-FACTOR; CELL-LINES; ABNORMAL EXPRESSION; COPY-NUMBER; AMPLIFICATION; DNA; IDENTIFICATION; DISINTEGRIN; CARCINOMA	Array-based comparative genomic hybridization (CGH-array) has a powerful potential for high-throughput identification of genetic aberrations in cell genomes. We identified a homozygous loss of ADAM23 (2q33.3) in the course of a program to screen a panel of gastric cancer ( GC) cell lines (1/32, 3.1%) for genomic copy-number aberrations using our custom-made CGH-array. Infrequent homozygous deletion of ADAM23 was also seen in primary gastric tumors (1/39, 2.6%). ADAM23 mRNA was expressed in normal stomach tissue, but not in the majority of GC cell lines without homozygous deletion of this gene. Expression of ADAM23 mRNA was restored to gene-silenced GC cells after treatment with 5-aza 2'-deoxycytidine. The methylation status of the ADAM23 CpG island, which showed promoter activity, correlated inversely with its expression. Methylation of this CpG island was observed both in GC cell lines and in primary GC tissues; in primary tumors with a hypermethylated CpG island, expression of ADAM23 was lower than in adjacent noncancerous tissues. Moreover, restoration of ADAM23 in GC cells reduced their numbers in colony-formation assays. These results suggest that genetic or epigenetic silencing by hypermethylation of the ADAM23 CpG-rich promoter region leads to loss of ADAM23 function, which may be a factor in gastric carcinogenesis.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Inst Med Res, Bunkyo Ku, Tokyo 1138510, Japan; JST, CREST, Hon Mach Kawaguchi, Saitama, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Div Gastroenterol & Hepatol, Kamigyo Ku, Kyoto, Japan; Natl Def Med Coll, Dept Pathol, Tokorozawa, Saitama 359, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Tokyo 104, Japan; Natl Def Med Coll, Dept Surg 1, Tokorozawa, Saitama 359, Japan; Natl Canc Ctr, Res Inst, Canc Genom Project, Tokyo 104, Japan; Tokyo Med & Dent Univ, COE Program Frontier Res Mol Destruct & Reconstru, Bunkyo Ku, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Kyoto Prefectural University of Medicine; National Defense Medical College - Japan; National Cancer Center - Japan; National Defense Medical College - Japan; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Inst Med Res, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020	Imoto, Issei/0000-0002-4150-7938				Akama Y, 1996, JPN J CANCER RES, V87, P824, DOI 10.1111/j.1349-7006.1996.tb02106.x; Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594; Baylin SB, 1998, ADV CANCER RES, V72, P141; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Carl-McGrath S, 2005, INT J ONCOL, V26, P17; Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Gorringe KL, 2005, GENE CHROMOSOME CANC, V42, P247, DOI 10.1002/gcc.20136; Huiping C, 2002, EUR J CANCER, V38, P728, DOI 10.1016/S0959-8049(01)00432-4; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Kimura Y, 2004, MODERN PATHOL, V17, P1328, DOI 10.1038/modpathol.3800180; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Koo SH, 2000, CANCER GENET CYTOGEN, V117, P97, DOI 10.1016/S0165-4608(99)00152-1; McCulloch DR, 2004, CLIN CANCER RES, V10, P314, DOI 10.1158/1078-0432.CCR-0846-3; Noguchi M, 1997, PATHOL INT, V47, P685, DOI 10.1111/j.1440-1827.1997.tb04442.x; O'Shea C, 2003, INT J CANCER, V105, P754, DOI 10.1002/ijc.11161; Peng DF, 2003, J PATHOL, V201, P439, DOI 10.1002/path.1459; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shintani Y, 2004, CANCER RES, V64, P4190, DOI 10.1158/0008-5472.CAN-03-3235; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; TAHARA E, 1995, WORLD J SURG, V19, P484, DOI 10.1007/BF00294705; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Tanabe C, 2003, GENE CHROMOSOME CANC, V38, P168, DOI 10.1002/gcc.10269; Tay ST, 2003, CANCER RES, V63, P3309; Weiss MM, 2004, CELL ONCOL, V26, P307; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x	32	56	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2005	24	54					8051	8060		10.1038/sj.onc.1208952	http://dx.doi.org/10.1038/sj.onc.1208952			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	989EV	16103878				2022-12-17	WOS:000233656600011
J	Suzuki, A; Iida, S; Kato-Uranishi, M; Tajima, E; Zhan, FH; Hanamura, I; Huang, YS; Ogura, T; Takahashi, S; Ueda, R; Barlogie, B; Shaughnessy, J; Esumi, H				Suzuki, A; Iida, S; Kato-Uranishi, M; Tajima, E; Zhan, FH; Hanamura, I; Huang, YS; Ogura, T; Takahashi, S; Ueda, R; Barlogie, B; Shaughnessy, J; Esumi, H			ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma	ONCOGENE			English	Article						ARK5; multiple myeloma; Large-MAF family; invasion; IGF-1	ACTIVATED PROTEIN-KINASE; INTEGRIN-LINKED KINASE; GROWTH-FACTOR; BONE-MARROW; CHROMOSOMAL TRANSLOCATIONS; TUMOR INVASION; PLASMA-CELLS; INSULIN; PROLIFERATION; EXPRESSION	ARK5, AMP-activated protein kinase (AMPK)-related protein kinase mediating Akt signals, is closely involved in tumor progression, and its stage-associated expression was observed in colorectal cancer. In this study, we found ARK5 expression in multiple myeloma cell lines expressing c-MAF and MAFB. In addition, gene expression profiling of 351 clinical specimens revealed ARK5 expression in primary myelomas expressing c-MAF and MAFB, suggesting that ARK5 may be a transcriptional target of the Large-MAF family. Sequence analysis of the ARK5 gene promoter revealed that it contains two putative MAF-recognition element (MARE) sequences. In support of this hypothesis, ARK5 was induced when an MAFB or c-MAF expression vector was introduced into non-ARK5-expressing colon cancer cells. Furthermore, ARK5 promoter activity was dramatically decreased by mutation or deletion of MARE sequences. Chromatin immunoprecipitation assays revealed an interaction between the Large-MAF family proteins and MARE sequences in the ARK5 promoter. Moreover, in ARK5 mRNA- expressing multiple myeloma lines, but not in ARK5-negative lines, insulin-like growth factor (IGF)-1 increased invasion activity. IGF-1-induced invasion was reproduced when ARK5 was overexpressed in Burkitt's lymphoma and plasmacytoma lines. Based on results, we conclude that ARK5 is a transcriptional target of the Large-MAF family through MARE sequence and that ARK5 may in part mediate the aggressive phenotype associated with c-MAF- and MAFB-expressing myelomas.	Natl Canc Ctr, Res Inst E, Canc Physiol Project, Kashiwa, Chiba 2778577, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Internal Med & Mol Sci, Nagoya, Aichi 4678601, Japan; Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA; Univ Tsukuba, Dept Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan	National Cancer Center - Japan; Nagoya City University; University of Arkansas System; University of Arkansas Medical Sciences; University of Tsukuba	Esumi, H (corresponding author), Natl Canc Ctr, Res Inst E, Canc Physiol Project, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	hesumi@east.ncc.go.jp			NCI NIH HHS [CA55819, CA97513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R33CA097513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Asosingh K, 2003, Verh K Acad Geneeskd Belg, V65, P127; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Drevs J, 2003, ANTICANCER RES, V23, P1159; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Hanamura I, 2001, JPN J CANCER RES, V92, P638, DOI 10.1111/j.1349-7006.2001.tb01142.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hayman S R, 2001, Curr Treat Options Oncol, V2, P205, DOI 10.1007/s11864-001-0034-4; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Huang K, 2000, GENE, V242, P419, DOI 10.1016/S0378-1119(99)00500-4; Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535-6108(04)00019-4; Iida S, 2000, INT J HEMATOL, V72, P85; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Ishikawa H, 2003, LEUKEMIA LYMPHOMA, V44, P1477, DOI 10.1080/1042819031000097339; Kajihara M, 2003, BIOCHEM BIOPH RES CO, V312, P831, DOI 10.1016/j.bbrc.2003.10.196; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Kusakai G, 2004, J EXP CLIN CANC RES, V23, P263; Kusakai G, 2004, AM J PATHOL, V164, P987, DOI 10.1016/S0002-9440(10)63186-0; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Ria R, 2003, LEUKEMIA, V17, P1961, DOI 10.1038/sj.leu.2403076; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Suzuki A, 2004, ONCOGENE, V23, P7067, DOI 10.1038/sj.onc.1207963; Suzuki A, 2004, MOL CELL BIOL, V24, P3526, DOI 10.1128/MCB.24.8.3526-3535.2004; Suzuki A, 2003, ONCOGENE, V22, P6177, DOI 10.1038/sj.onc.1206899; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Tai YT, 2003, CANCER RES, V63, P5850; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Yoshida S, 1999, LEUKEMIA, V13, P1812, DOI 10.1038/sj.leu.2401563; ZHAN F, 2004, BLOOD, V104, P26; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	45	56	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2005	24	46					6936	6944		10.1038/sj.onc.1208844	http://dx.doi.org/10.1038/sj.onc.1208844			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	975ZD	16044163				2022-12-17	WOS:000232701700008
J	Einav, U; Tabach, Y; Getz, G; Yitzhaky, A; Ozbek, U; Amariglio, N; Izraeli, S; Rechavi, G; Domany, E				Einav, U; Tabach, Y; Getz, G; Yitzhaky, A; Ozbek, U; Amariglio, N; Izraeli, S; Rechavi, G; Domany, E			Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer	ONCOGENE			English	Article						gene expression; ALL; class discovery; interferon pathway; viral infection	T-CELLS; CLASSIFICATION; VIRUS; PREDICTION; SEQUENCES; DISCOVERY; HYPERMUTATION; INFLAMMATION; PATHOGENESIS; CHROMOSOMES	On the basis of epidemiological studies, infection was suggested to play a role in the etiology of human cancer. While for some cancers such a role was indeed demonstrated, there is no direct biological support for the role of viral pathogens in the pathogenesis of childhood leukemia. Using a novel bioinformatic tool that alternates between clustering and standard statistical methods of analysis, we performed a 'double-blind' search of published gene expression data of subjects with different childhood acute lymphoblastic leukemia (ALL) subtypes, looking for unanticipated partitions of patients, induced by unexpected groups of genes with correlated expression. We discovered a group of about 30 genes, related to the interferon response pathway, whose expression levels divide the ALL samples into two subgroups; high in 50, low in 285 patients. Leukemic subclasses prevalent in early childhood (the age most susceptible to infection) are over-represented in the high-expression subgroup. Similar partitions, induced by the same genes, were found also in breast and ovarian cancer but not in lung cancer, prostate cancer and lymphoma. About 40% of breast cancer samples expressed the 'interferon-related' signature. It is of interest that several studies demonstrated mouse mammary tumor virus-like sequences in about 40% of breast cancer samples. Our discovery of an unanticipated strong signature of an interferon-induced pathway provides molecular support for a role for either inflammation or viral infection in the pathogenesis of childhood leukemia as well as breast and ovarian cancer.	Safa Childrens Hosp, Sheba Med Ctr, Dept Pediat Hematol & Oncol, IL-52621 Tel Hashomer, Israel; Weizmann Inst Sci, Dept Phys, IL-76100 Rehovot, Israel; Istanbul Univ, DETAE, Dept Genet, Expt Med Res Inst, Istanbul, Turkey; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Weizmann Institute of Science; Istanbul University; Tel Aviv University; Sackler Faculty of Medicine	Rechavi, G (corresponding author), Safa Childrens Hosp, Sheba Med Ctr, Dept Pediat Hematol & Oncol, IL-52621 Tel Hashomer, Israel.	gidi.rechavi@sheba.health.gov.il; eytan.domany@weizmann.ac.il	Ozbek, Ugur/C-9513-2017; DOMANY, EYTAN/K-1560-2012; Tabach, Yuval/Q-8488-2019	Ozbek, Ugur/0000-0001-5319-0547; 				Akyerli CB, 2005, LEUKEMIA RES, V29, P283, DOI 10.1016/j.leukres.2004.07.007; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ben-Dor A, 2000, J COMPUT BIOL, V7, P559, DOI 10.1089/106652700750050943; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Blatt M, 1997, NEURAL COMPUT, V9, P1805, DOI 10.1162/neco.1997.9.8.1805; Blatt M, 1996, PHYS REV LETT, V76, P3251, DOI 10.1103/PhysRevLett.76.3251; Califano A, 2000, Proc Int Conf Intell Syst Mol Biol, V8, P75; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; Cheng Y., 2000, P 8 INT C INT SYST M, P93; Colonna M, 2002, CURR OPIN IMMUNOL, V14, P373, DOI 10.1016/S0952-7915(02)00349-7; Dalgleish AG, 2002, ADV CANCER RES, V84, P231, DOI 10.1016/S0065-230X(02)84008-8; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Ford CE, 2003, CLIN CANCER RES, V9, P1118; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Georgiannos SN, 2003, SURGERY, V134, P827, DOI 10.1016/S0039-6060(03)00292-7; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREAVES MF, 1988, LEUKEMIA, V2, P120; GREAVES MF, 1993, LEUKEMIA, V7, P349; HASLE H, 1995, LEUKEMIA, V9, P605; Heerema NA, 2000, J CLIN ONCOL, V18, P1876, DOI 10.1200/JCO.2000.18.9.1876; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihmels J, 2002, NAT GENET, V31, P370, DOI 10.1038/ng941; Ito C, 1999, BLOOD, V93, P315, DOI 10.1182/blood.V93.1.315.401k35_315_320; KEYDAR I, 1984, P NATL ACAD SCI-BIOL, V81, P4188, DOI 10.1073/pnas.81.13.4188; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; Kinlen LJ, 2001, LANCET, V357, P858, DOI 10.1016/S0140-6736(00)04208-2; Koushik A, 2001, CANCER CAUSE CONTROL, V12, P483, DOI 10.1023/A:1011266413087; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; MacKenzie J, 1999, BRIT J CANCER, V81, P898, DOI 10.1038/sj.bjc.6690783; MacKenzie J, 2001, LEUKEMIA, V15, P415, DOI 10.1038/sj.leu.2402049; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mele A, 2003, BLOOD, V102, P996, DOI 10.1182/blood-2002-10-3230; Ness RB, 2003, J INFECT DIS, V187, P1147, DOI 10.1086/368380; Nzula S, 2003, CANCER RES, V63, P3275; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Rozovskaia T, 2003, P NATL ACAD SCI USA, V100, P7853, DOI 10.1073/pnas.1132115100; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Tabori U, 2001, LEUKEMIA, V15, P866, DOI 10.1038/sj.leu.2402102; Tanay Amos, 2002, Bioinformatics, V18 Suppl 1, pS136; Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wall L, 2003, GYNECOL ONCOL, V88, pS149, DOI 10.1006/gyno.2002.6707; WANG Y, 1995, CANCER RES, V55, P5173; Welsh JB, 2001, CANCER RES, V61, P5974; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wiemels JL, 1999, BLOOD, V94, P1057, DOI 10.1182/blood.V94.3.1057.415k10_1057_1062; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	65	56	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6367	6375		10.1038/sj.onc.1208797	http://dx.doi.org/10.1038/sj.onc.1208797			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007187	Green Submitted			2022-12-17	WOS:000232038200004
J	Minchiotti, G				Minchiotti, G			Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology	ONCOGENE			English	Article						Cripto; cardiomyocytes; neurons; tumors; nodal signaling	ONE-EYED-PINHEAD; MOUSE EMBRYOS; DOPAMINERGIC-NEURONS; MAMMARY-GLAND; NEURAL FATE; IN-VITRO; DIFFERENTIATION; GENE; INDUCTION; FAMILY	Embryonic stem (ES) cells have provided a valid model to understand early events of mammalian lineage specification and differentiation, leading to important insights into the mechanisms that control embryogenesis at the molecular and cellular levels. Furthermore, ES cells have recently evoked great scientific interest as ideal candidates for the generation of tissues for transplantation therapies. In this respect, particular attention has been paid to the molecules and signaling pathways triggering ES cell differentiation. The EGF-CFC Cripto protein is a key regulator of ES cells fate. The cripto gene is expressed both in ES cells and during the early phases of embryo development, while, in the adult, it is reactivated in a wide range of epithelial cancers. This review will discuss recent findings on the molecular basis of Cripto signaling in ES cell differentiation, providing an intriguing link between stem cell and tumor biology.	CNR, Inst Genet & Biophys A Buzzati Traverso, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Minchiotti, G (corresponding author), CNR, Inst Genet & Biophys A Buzzati Traverso, Via Petro Castellino 111, I-80131 Naples, Italy.	minchiot@igb.cnr.it		Minchiotti, Gabriella/0000-0003-0225-9043				Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Arenas E, 2002, BRAIN RES BULL, V57, P795, DOI 10.1016/S0361-9230(01)00772-9; Aubert J, 2002, NAT BIOTECHNOL, V20, P1240, DOI 10.1038/nbt763; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Castelo-Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Chung S, 2002, EUR J NEUROSCI, V16, P1829, DOI 10.1046/j.1460-9568.2002.02255.x; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; Dell'Era P, 2003, CIRC RES, V93, P414, DOI 10.1161/01.RES.0000089460.12061.E1; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Harrison CA, 2005, TRENDS ENDOCRIN MET, V16, P73, DOI 10.1016/j.tem.2005.01.003; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Isacson O, 2003, ANN NEUROL, V53, pS135, DOI 10.1002/ana.10482; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Liguori GL, 2003, DEV BIOL, V264, P537, DOI 10.1016/j.ydbio.2003.08.023; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Loebel DAF, 2003, DEV BIOL, V264, P1, DOI 10.1016/S0012-1606(03)00390-7; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Minchiotti G, 2001, DEVELOPMENT, V128, P4501; Mizuseki K, 2003, P NATL ACAD SCI USA, V100, P5828, DOI 10.1073/pnas.1037282100; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Munoz-Sanjuan I, 2002, NAT REV NEUROSCI, V3, P271, DOI 10.1038/nrn786; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Parish CL, 2005, STEM CELLS, V23, P471, DOI 10.1634/stemcells.2004-0294; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Persico MG, 2001, BBA-REV CANCER, V1552, P87, DOI 10.1016/S0304-419X(01)00039-7; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; ROSA FM, 2002, SCI STKE, pPE47; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Schuldiner M, 2000, P NATL ACAD SCI USA, V97, P11307, DOI 10.1073/pnas.97.21.11307; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 2003, J CLIN INVEST, V112, P500, DOI 10.1172/JCI200319546; Shen MM, 1997, DEVELOPMENT, V124, P429; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Sonntag KC, 2005, MOL CELL NEUROSCI, V28, P417, DOI 10.1016/j.mcn.2004.06.003; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Xu CH, 1999, DEVELOPMENT, V126, P483; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	70	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5668	5675		10.1038/sj.onc.1208917	http://dx.doi.org/10.1038/sj.onc.1208917			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123800				2022-12-17	WOS:000231452800002
J	Hahne, JC; Okuducu, AF; Kaminski, A; Florin, A; Soncin, F; Wernert, N				Hahne, JC; Okuducu, AF; Kaminski, A; Florin, A; Soncin, F; Wernert, N			Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth	ONCOGENE			English	Article						Ets-1; epithelial HeLa-tumor cells; migration; invasion; anchorage-independent growth	TRANSCRIPTION FACTOR; STROMAL EXPRESSION; GENE-EXPRESSION; CHICK-EMBRYO; INTEGRINS; PROTOONCOGENE; ANGIOGENESIS; C-ETS-1; BINDING; PROTEIN	Ets-1 is the prototype of the family of ETS transcription factors. In human tumors, Ets-1 is expressed in endothelial cells and fibroblasts of the tumor stroma and is proposed to play a role in tumor vascularization and invasion by upregulating expression of matrix-degrading proteases. In human carcinomas, Ets-1 is also expressed by neoplastic cells, but little is known about the functional implications of this observation. We have addressed the role of Ets-1 in epithelial HeLa tumor cells by selecting stably Ets-1 over and underexpressing HeLa cells. Ets-1 expression increases the transformed phenotype of HeLa cells, by promoting cell migration, invasion and anchorage-independent growth, while Ets-1 downregulation reduces cell attachment. In correlation with these results, Ets-1 upregulation increases integrin beta 2 expression but not that of other integrins. These results suggest that, in addition to its role in the tumor stroma, Ets-1 may also promote tumor development and progression by increasing neoplastic transformation.	Univ Bonn, Inst Pathol, D-53011 Bonn, Germany; Inst Biol Lille, CNRS, UMR8526, F-59021 Lille, France	University of Bonn; Centre National de la Recherche Scientifique (CNRS)	Wernert, N (corresponding author), Univ Bonn, Inst Pathol, POB 2120, D-53011 Bonn, Germany.	nicolas.wernert@ukb.uni-bonn.de	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				Adam M, 2003, EUR UROL, V44, P329, DOI 10.1016/S0302-2838(03)00262-8; Adriaenssens E, 2002, EXP CELL RES, V275, P215, DOI 10.1006/excr.2002.5500; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; Behrens P, 2003, INT J CANCER, V107, P183, DOI 10.1002/ijc.11336; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Ishii Y, 2003, INT J CANCER, V103, P161, DOI 10.1002/ijc.10808; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Maubant S, 2002, B CANCER, V89, P923; Maurer P, 2003, ONCOGENE, V22, P3319, DOI 10.1038/sj.onc.1206572; Meraro D, 2002, J IMMUNOL, V168, P6224, DOI 10.4049/jimmunol.168.12.6224; Nishikawa A, 2000, GYNECOL ONCOL, V79, P256, DOI 10.1006/gyno.2000.5944; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Peterson EJ, 2003, IMMUNOL REV, V192, P113, DOI 10.1034/j.1600-065X.2003.00026.x; Petrella A, 1998, BLOOD, V91, P4554, DOI 10.1182/blood.V91.12.4554.412k26_4554_4560; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; Sato Y, 1998, Hum Cell, V11, P207; Schwartz MA, 2001, J CELL SCI, V114, P2553; SETH A, 1990, ONCOGENE, V5, P1761; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Waga K, 2003, ONCOGENE, V22, P59, DOI 10.1038/sj.onc.1206072; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119	38	56	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5384	5388		10.1038/sj.onc.1208761	http://dx.doi.org/10.1038/sj.onc.1208761			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	15940256				2022-12-17	WOS:000231158500012
J	Liu, GT; Akasaki, Y; Khong, HT; Wheeler, CJ; Das, A; Black, KL; Yu, JS				Liu, GT; Akasaki, Y; Khong, HT; Wheeler, CJ; Das, A; Black, KL; Yu, JS			Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy	ONCOGENE			English	Article						glioma; TRP-2; drug resistance; cancer vaccine; cytotoxic T lymphocyte	TYROSINASE-RELATED PROTEIN-2; RADIATION-RESISTANCE; FUNCTIONAL-ANALYSIS; INDUCED APOPTOSIS; MELANOMA-CELLS; TUMOR ESCAPE; IMMUNOTHERAPY; VACCINATION; CANCER; DRUG	Tyrosinase-related protein (TRP)-2 is not only expressed on glioma cells, but is naturally processed and presented by their surface MHC molecules and is recognized by TRP-2-specific cytotoxic T cells. After active immunotherapy, we detected TRP-2-specific cytotoxic T lymphocyte (CTL) activity in patients' peripheral blood mononuclear cells (PBMC). Tumor cells from postvaccination resections showed significantly lower TRP-2 expression and higher sensitivity to carboplatin and temozolomide than those autologous cell lines from prevaccination resections in two patients who demonstrated CTL response to TRP-2. One of two patients underwent treatment with temozolomide after recurrence and responded dramatically. TRP-2-transfected cell line (TRP-2-U373) resulted in significant drug resistance to carboplatin and temozolomide compared to wild-type U-373 (W-U373). There was no significant difference, however, in the mRNA expression of other common drug resistance related proteins, such as BCRP-1, MGMT, MDR-1, MRP-1 and MRP-3, after TRP-2 transfection. TRP-2-U373 tumor cells were immunoselected by a TRP-2-specific CTL line. The immunoselected cells (IS-TRP-2-U373) demonstrated significantly increased sensitivity to carboplatin and temozolomide compared to TRP-2-U373. For the first time, we provide evidence that immunological targeting of tumor-associated antigen TRP-2 significantly increases sensitivity to chemotherapy.	Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA; Univ S Alabama, Canc Res Inst, Mobile, AL 36688 USA	Cedars Sinai Medical Center; University of South Alabama	Yu, JS (corresponding author), 8631 W Third St,Suit 800E, Los Angeles, CA 90048 USA.	yuj@cshs.org		Black, Keith/0000-0002-0546-4934; Yu, John/0000-0003-1230-8494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS002232] Funding Source: NIH RePORTER; NINDS NIH HHS [K23 NS02232] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bodey B, 2000, ANTICANCER RES, V20, P2665; Bredel M, 2002, LANCET ONCOL, V3, P397, DOI 10.1016/S1470-2045(02)00786-6; Chi DDJ, 1997, AM J PATHOL, V150, P2143; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; D'Atri S, 1998, MOL PHARMACOL, V54, P334, DOI 10.1124/mol.54.2.334; DENNY BJ, 1994, BIOCHEMISTRY-US, V33, P9045, DOI 10.1021/bi00197a003; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; Fisk B, 1998, CANCER RES, V58, P4790; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Khong HT, 2002, J IMMUNOL, V168, P951, DOI 10.4049/jimmunol.168.2.951; Lee KH, 1999, J IMMUNOL, V163, P6292; Liu G, 2004, CANCER RES, V64, P4980, DOI 10.1158/0008-5472.CAN-03-3504; Liu GT, 2003, J IMMUNOTHER, V26, P301, DOI 10.1097/00002371-200307000-00002; Liu GT, 2004, EUR J IMMUNOL, V34, P1680, DOI 10.1002/eji.200425081; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nair S, 2003, BLOOD, V102, P964, DOI 10.1182/blood-2002-12-3738; Nishioka E, 1999, MELANOMA RES, V9, P433, DOI 10.1097/00008390-199910000-00002; Nowak AK, 2003, CANCER RES, V63, P4490; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Pak BJ, 2004, ONCOGENE, V23, P30, DOI 10.1038/sj.onc.1207007; Pak BJ, 2001, CANCER METAST REV, V20, P27, DOI 10.1023/A:1013175516793; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Wang RF, 1999, IMMUNOL REV, V170, P85, DOI 10.1111/j.1600-065X.1999.tb01331.x; Wheeler CJ, 2004, CLIN CANCER RES, V10, P5316, DOI 10.1158/1078-0432.CCR-04-0497; Yamada A, 2001, CANCER RES, V61, P6459; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5; Yu JS, 2001, CANCER RES, V61, P842; Yu JS, 2004, CANCER RES, V64, P4973, DOI 10.1158/0008-5472.CAN-03-3505; Yung WKA, 2001, SEMIN ONCOL, V28, P43	32	56	64	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5226	5234		10.1038/sj.onc.1208519	http://dx.doi.org/10.1038/sj.onc.1208519			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897911				2022-12-17	WOS:000230964600009
J	Wang, ZL; Mandell, KJ; Parkos, CA; Mrsny, RJ; Nusrat, A				Wang, ZL; Mandell, KJ; Parkos, CA; Mrsny, RJ; Nusrat, A			The second loop of occludin is required for suppression of Raf1-induced tumor growth	ONCOGENE			English	Article						tight junction; occludin; raf	TIGHT JUNCTION STRUCTURE; EXPRESSION DECREASES; POSSIBLE INVOLVEMENT; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; BARRIER FUNCTION; PERMEABILITY; CANCER; DOMAIN; LOCALIZATION	Tight junctions (TJs) regulate epithelial cell polarity and paracellular permeability. Loss of functional TJs is commonly associated with epithelial cell-derived cancers. Raf1-mediated transformation of rat salivary gland epithelial cells (Pa4-Raf1) induces transcriptional down-regulation of the TJ protein occludin and forced reexpression of occludin rescues polarized phenotype of epithelial cells. In the present study, we used this model to examine how specific structural modi. cations in the occludin protein affect its function in vitro and influence tumor growth in vivo. Our results revealed that neither the C-terminal nor the N-terminal half of occludin alone were sufficient to rescue cells from transformation by Raf1. However, forced expression of an occludin mutant lacking the first extracellular loop was sufficient to rescue cells from Raf1-mediated transformation. Interestingly, forced expression of an occludin mutant lacking the second extracellular loop did not rescue the epithelial phenotype in vitro nor did it prevent tumor growth in vivo. These results demonstrate that the TJ protein occludin has a potent inhibitory effect on the Raf1-mediated tumorigenesis, and the second extracellular loop of occludin appears to be critical for this function.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Unity Pharmaceut, Los Altos Hills, CA 94022 USA	Emory University	Nusrat, A (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Room 105E, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nusrat, Asma/B-3887-2009; Parkos, Charles a/B-3896-2009		NIDDK NIH HHS [DK61379, DK72564, DK 59888, DK64399] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK072564, R24DK064399, R01DK061379, R01DK059888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Bamforth SD, 1999, J CELL SCI, V112, P1879; Chen YH, 1997, J CELL BIOL, V138, P891, DOI 10.1083/jcb.138.4.891; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; deVries JE, 1996, PATHOL RES PRACT, V192, P658, DOI 10.1016/S0344-0338(96)80087-2; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Kimura Y, 1997, AM J PATHOL, V151, P45; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Lacaz-Vieira F, 1999, J MEMBRANE BIOL, V168, P289, DOI 10.1007/s002329900518; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li DX, 1997, J BIOL CHEM, V272, P25062, DOI 10.1074/jbc.272.40.25062; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Matter K, 1998, J CELL SCI, V111, P511; McCarthy KM, 1996, J CELL SCI, V109, P2287; Medina R, 2000, J MEMBRANE BIOL, V178, P235, DOI 10.1007/s002320010031; Michl P, 2003, CANCER RES, V63, P6265; Mitic LL, 1999, J CELL BIOL, V146, P683, DOI 10.1083/jcb.146.3.683; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Nottage M, 2002, CURR PHARM DESIGN, V8, P2231, DOI 10.2174/1381612023393107; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sanders SE, 1995, EPITHELIAL CELL BIOL, V4, P25; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; VanItallie CM, 1997, J CELL SCI, V110, P1113; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399	35	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4412	4420		10.1038/sj.onc.1208634	http://dx.doi.org/10.1038/sj.onc.1208634			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806147				2022-12-17	WOS:000229976900010
J	Hirota, T; Irie, K; Okamoto, R; Ikeda, W; Takai, Y				Hirota, T; Irie, K; Okamoto, R; Ikeda, W; Takai, Y			Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by broblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway	ONCOGENE			English	Article						Necl-5; nectin Ras; MAP kinase; AP-1 fibroblast growth factor	ENHANCES CELL-MIGRATION; IMMUNOGLOBULIN SUPERFAMILY; INTERCELLULAR-JUNCTIONS; POLIOVIRUS RECEPTOR; CORE PROMOTER; CD155 GENE; NECTIN; IDENTIFICATION; PROLIFERATION; EXPRESSION	Necl-5/Tage4/poliovirus receptor/CD155 is the poliovirus receptor and upregulated in rodent and human carcinoma. We have recently shown that mouse Necl-5 is upregulated by an oncogenic Ki-Ras (V12Ki-Ras) in NIH3T3 cells and enhances cell movement induced by growth factors, including platelet-derived growth factor and. broblast growth factor (FGF), in an integrin alpha(v)beta(3)-dependent manner in wild type and V12Ki-Ras-transformed NIH3T3 cells. In addition, it enhances the growth factor-induced cell proliferation. We examined here how mouse Necl-5 was upregulated by (V12Ki-Ras in NIH3T3 cells. Expression of the luciferase reporter gene fused to the Necl-5 promoter was induced by (V12Ki-Ras in NIH3T3 cells. This induction was mediated through the Raf-MEK-ERK pathway. The Necl-5 promoter has an AP-1-binding site and this site was required for the V12Ki-Ras-induced activation of the Necl-5 promoter. Expression of the luciferase reporter gene fused to the Necl-5 promoter was also induced by FGF through the Raf-MEK-ERK-AP-1 pathway in NIH3T3 cells. These results indicate that the expression of mouse Necl-5 is induced by FGF or V12Ki-Ras through the Raf-MEK-ERK-AP-1 pathway.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				Bottino C, 2003, J EXP MED, V198, P557, DOI 10.1084/jem.20030788; Chadeneau C, 1996, INT J CANCER, V68, P817; CHADENEAU C, 1994, J BIOL CHEM, V269, P15601; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; Gromeier M, 2000, P NATL ACAD SCI USA, V97, P6803, DOI 10.1073/pnas.97.12.6803; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Kakunaga S, 2004, J BIOL CHEM, V279, P36419, DOI 10.1074/jbc.M406340200; KOIKE S, 1990, EMBO J, V9, P3217, DOI 10.1002/j.1460-2075.1990.tb07520.x; Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Mercer JA, 2000, SEMIN CELL DEV BIOL, V11, P309, DOI 10.1006/scdb.2000.0181; Mueller S, 2003, J BIOL CHEM, V278, P31251, DOI 10.1074/jbc.M304166200; Sato T, 2004, GENES CELLS, V9, P791, DOI 10.1111/j.1365-2443.2004.00763.x; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya K, 2003, J EXP MED, V198, P1829, DOI 10.1084/jem.20030958; Solecki D, 1999, J BIOL CHEM, V274, P1791, DOI 10.1074/jbc.274.3.1791; Solecki D, 2000, J BIOL CHEM, V275, P12453, DOI 10.1074/jbc.275.17.12453; Solecki DJ, 2002, J BIOL CHEM, V277, P25697, DOI 10.1074/jbc.M201378200; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167	23	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2229	2235		10.1038/sj.onc.1208409	http://dx.doi.org/10.1038/sj.onc.1208409			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688018				2022-12-17	WOS:000227857900010
J	Deng, W; Tsao, SW; Guan, XY; Lucas, JN; Si, HX; Leung, CS; Mak, P; Wang, LD; Cheung, ALM				Deng, W; Tsao, SW; Guan, XY; Lucas, JN; Si, HX; Leung, CS; Mak, P; Wang, LD; Cheung, ALM			Distinct profiles of critically short telomeres are a key determinant of different chromosome aberrations in immortalized human cells: whole-genome evidence from multiple cell lines	ONCOGENE			English	Article						telomeres; aberrations; genome; immortalization; human	SURFACE EPITHELIAL-CELLS; MOLECULAR CYTOGENETIC CHARACTERIZATION; G-STRAND OVERHANG; TO-END FUSIONS; MAMMALIAN TELOMERES; HUMAN FIBROBLASTS; LENGTH; CANCER; SENESCENCE; CARCINOMA	Chromosomal aberrations are common in cancers. However, the search for chromosomal aberrations leading to development of specific solid tumors has been severely hindered because the majority of solid tumors have complex chromosomal aberrations that differ within the same tumor types. A similar phenomenon exists in immortalized cell tines. The underlying mechanisms driving these diverse aberrations are largely unknown. Telomeres play crucial roles in protecting the integrity of eucaryotic chromosomes and maintaining genomic stability of human cells. Telomere lengths on individual chromosomes in normal human somatic cells are heterogeneous and undergo progressive shortening with aging process. In this study, for the first time, a molecular cytogenetic method using sequential telomere quantitative fluorescence in situ hybridization and spectral karyotyping on the same human metaphases was applied successfully to examine the dynamic profiles of individual telomere shortening and their relationship to chromosome aberrations in multiple human cell lines undergoing immortalization. Human ovarian surface epithelial cells and esophageal epithetial cells were immortalized by the expression of HPV16 E6 and E7, which drive cells to proliferate by inactivating p53 and Rb genes. In these cell lines, we consistently detected large-scale differences in telomere signal intensities not only among nonhomologous chromosome arms but also between some homologous chromosome arms. The cell lines derived from different donors had different profiles of critically short telomeres (lacking telomere signals). Strikingly, the different profiles of chromosomal structural aberrations in multiple immortalized cell lines were highly significantly associated with the distinct distributions of critically short telomeres in whole-genome. Since cellular immortalization is one of the hallmarks of cancer, our findings suggest that distinct profiles of critically short telomeres in different human individuals might play an essential role in determining the complex and individual-specific chromosomal structural aberrations in human solid tumors.	Univ Hong Kong, Fac Med, Dept Anat, Pokfulam, Hong Kong, Peoples R China; Univ Hong Kong, Dept Clin Oncol, Pokfulam, Hong Kong, Peoples R China; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA; Univ Hong Kong, Fac Med, Dept Pediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China; Henan Med Univ, Ctr Med Expt, Canc Res Lab, Zhengzhou, Henan Province, Peoples R China	University of Hong Kong; University of Hong Kong; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of Hong Kong; Zhengzhou University	Cheung, ALM (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	lmcheung@hkucc.hku.hk	Deng, Wen/M-5208-2019; Deng, Wen/C-4154-2009; Tsao, George/C-4422-2009; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009; /C-4230-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805; /0000-0003-3217-1456				Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; BENN PA, 1976, AM J HUM GENET, V28, P465; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; DELANGE T, 1995, TELOMERES, P265; Deng W, 2003, CYTOM PART A, V51A, P46, DOI 10.1002/cyto.a.10004; Deng W, 2003, GENE CHROMOSOME CANC, V37, P92, DOI 10.1002/gcc.10190; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Drexler HG, 1999, LEUKEMIA, V13, P1601, DOI 10.1038/sj.leu.2401510; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Graakjaer J, 2004, AGING CELL, V3, P97, DOI 10.1111/j.1474-9728.2004.00093.x; Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harris CP, 2003, GENE CHROMOSOME CANC, V36, P233, DOI 10.1002/gcc.10158; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; KARGER S, 1995, INT SYSTEM HUMAN CYT; Karlseder J, 2003, CANCER LETT, V194, P189, DOI 10.1016/S0304-3835(02)00706-1; Kawi K, 2002, GENE CHROMOSOME CANC, V34, P1, DOI 10.1002/gcc.10003; Keys B, 2004, AGING CELL, V3, P103, DOI 10.1111/j.1474-9728.2004.00094.x; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Li GZ, 2003, P NATL ACAD SCI USA, V100, P527, DOI 10.1073/pnas.0235444100; Londono-Vallejo JA, 2001, NUCLEIC ACIDS RES, V29, P3164, DOI 10.1093/nar/29.15.3164; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; Masters J, 2002, INT J CANCER, V99, P154, DOI 10.1002/ijc.10315; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Tsao SW, 2001, CANCER GENET CYTOGEN, V130, P141, DOI 10.1016/S0165-4608(01)00473-3; van Bokhoven A, 2003, PROSTATE, V57, P226, DOI 10.1002/pros.10291; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	52	56	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9090	9101		10.1038/sj.onc.1208119	http://dx.doi.org/10.1038/sj.onc.1208119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489894				2022-12-17	WOS:000225492800010
J	Liu, YM; Lu, CH; Shen, Q; Munoz-Medellin, D; Kim, H; Brown, PH				Liu, YM; Lu, CH; Shen, Q; Munoz-Medellin, D; Kim, H; Brown, PH			AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity	ONCOGENE			English	Article						AP-1; breast cancer; proliferation; apoptosis	DOMINANT-NEGATIVE MUTANT; C-JUN; RETINOIC-ACID; DISTINCT MECHANISMS; E OVEREXPRESSION; FAMILY-MEMBERS; APOPTOSIS; GROWTH; D1; ACTIVATION	The AP-1 transcription factor is a central component of signal transduction pathways in many cells, although the exact role of AP-1 in controlling cell growth and malignant transformation is unknown. We have previously shown that AP-1 complexes are activated by peptide and steroid growth factors in both normal and malignant breast cells, and that blocking AP-1 by overexpressing a dominant-negative form of cJun (cJun-DN, TAM67) inhibits breast cancer cell growth both in vivo and in vitro. We hypothesized that TAM67 inhibits cell growth by altering the expression of cell cycle regulatory proteins, thus causing a cell cycle block. In the present study, we used clones of MCF7 breast cancer cells that express TAM67 under the control of an inducible promoter. First, we determined the effect of AP-1 blockade on cell growth, then we performed H-3-thymidine incorporation and flow cytometry assays to investigate whether TAM67 inhibits the cell cycle. We observed that in the presence of serum TAM67 inhibited cell growth and caused a block in the G1 phase of the cell cycle. Next, we performed Western-blotting and CDK kinase assays to determine the effects of TAM67 on retinoblastoma (Rb) phosphorylation, the expression of cell cycle regulatory proteins, and CDK activity. We discovered that TAM67 inhibited Rb phosphorylation and reduced E2F activity. We also found that TAM67 decreased the expression of D and E cyclins, reduced CDK2 and CDK4 activity, and increased the CDK inhibitor p27. The studies of gene expression at the RNA level showed that TAM67 decreased cyclin Ds mRNA expression. Our study suggests that in the presence of serum, TAM67 inhibits breast cancer growth predominantly by inducing inhibitors of cyclin-dependent kinases ( such as p27) and by reducing the expression of the cyclins involved in transitioning from G1 into S phase of the cell cycle. These studies lay the foundation for future attempt to develop new agents for the treatment and prevention of breast cancer.	Baylor Coll Med, Baylor Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Baylor Breast Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78284 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; University of Texas Health San Antonio	Brown, PH (corresponding author), Baylor Coll Med, Baylor Breast Ctr, Dept Med, 1 Baylor Plaza,MS 600, Houston, TX 77030 USA.	pbrown@breastcenter.tmc.edu		Shen, Qiang/0000-0002-1491-5434; Brown, Powel/0000-0002-3398-163X				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; Chen TK, 1996, MOL CARCINOGEN, V15, P215, DOI 10.1002/(SICI)1098-2744(199603)15:3<215::AID-MC7>3.0.CO;2-G; Chen Y, 1996, J BIOL CHEM, V271, P31602, DOI 10.1074/jbc.271.49.31602; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hennigan RF, 2001, MOL BIOL CELL, V12, P2352, DOI 10.1091/mbc.12.8.2352; HERBER, 1994, ONCOGENE, V9, P2105; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Kim HK, 2001, EUR J SURG ONCOL, V27, P464, DOI 10.1053/ejso.2001.1137; Lin F, 2000, CANCER RES, V60, P3271; Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883; Ludes-Meyers JH, 2001, ONCOGENE, V20, P2771, DOI 10.1038/sj.onc.1204377; Nielsen NH, 1996, BRIT J CANCER, V74, P874, DOI 10.1038/bjc.1996.451; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Preston GA, 1996, MOL CELL BIOL, V16, P211; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; Sauter ER, 1999, CANCER RES, V59, P4876; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHULE R, 1991, COLD SPRING HARB SYM, V56, P119; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SMITH MJ, 1992, BLOOD, V79, P2107; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yang LM, 1997, CANCER RES, V57, P4652; Yang LM, 2001, ONCOGENE, V20, P8025, DOI 10.1038/sj.onc.1204911; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhao BH, 1997, MOL CARCINOGEN, V19, P180, DOI 10.1002/(SICI)1098-2744(199707)19:3<180::AID-MC6>3.0.CO;2-I	38	56	60	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8238	8246		10.1038/sj.onc.1207889	http://dx.doi.org/10.1038/sj.onc.1207889			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378019				2022-12-17	WOS:000224749500006
J	Han, YQ; San-Marina, S; Liu, JA; Minden, MD				Han, YQ; San-Marina, S; Liu, JA; Minden, MD			Transcriptional activation of c-myc proto-oncogene by WT1 protein	ONCOGENE			English	Article						Wilms' tumor 1 gene (WT1); c-myc; transcriptional regulation	TUMOR-SUPPRESSOR GENE; WILMS-TUMOR; INHIBITS PROLIFERATION; PROGENITOR CELLS; BREAST-CANCER; DNA-BINDING; EXPRESSION; APOPTOSIS; BCL-2; DIFFERENTIATION	The Wilms' tumor 1 gene (WT1) plays an essential role in urogenital development and malignancy. Through DNA binding, WT1 can either enhance or repress transcription depending on the context of the DNA-binding sites or the cell type in which it is expressed. WT1 is overexpressed in a variety of human cancers, including leukemia and breast cancer; in these diseases, the expression of WT1 is associated with a poor prognosis. To determine how WT1 affects c-myc expression in the context of breast cancer cells, we have examined the ability of both endogenous and exogenous WT1 proteins in breast cancer cells to bind to the c-myc promoter in vivo. Using c-myc-promoter-driven luciferase constructs, we found that different forms of WT1 could enhance the expression of the reporter. Unlike other studies where WT1 is reported to be a negative regulator of c-myc, we found that both the - and + KTS forms of WT1 could act to enhance c-myc expression, depending on the cell type. The WT1-binding site near the second major transcription start site of the cmyc promoter was confirmed to be involved in upregulation of human c-myc by WT1. Finally, we demonstrated that overexpression of WT1 induced a significant increase in the abundance of endogenous c-myc protein in breast cancer cells, consistent with the upregulation of c-myc transcription following WT1 induction. These observations strongly argue that in the case of breast cancer WT1 is functioning as an oncogene in part by stimulating the expression of c-myc.	Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Minden, MD (corresponding author), Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, 610 Univ Ave,Room 5-217, Toronto, ON M5G 2M9, Canada.	minden@uhnres.utoronto.ca	San-Marina, Serban/ABF-1214-2020	San-Marina, Serban/0000-0002-5312-4774				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Algar EM, 1996, ONCOGENE, V12, P1005; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Ellisen LW, 2001, EMBO J, V20, P1897, DOI 10.1093/emboj/20.8.1897; Englert C, 1997, CANCER RES, V57, P1429; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HABER DA, 1992, NEW BIOL, V4, P97; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; HEWITT SM, 1995, CANCER RES, V55, P5386; Kreidberg JA, 1996, MED PEDIATR ONCOL, V27, P445, DOI 10.1002/(SICI)1096-911X(199611)27:5<445::AID-MPO10>3.0.CO;2-9; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; Loeb DM, 2001, CANCER RES, V61, P921; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; MADDEN SL, 1993, ONCOGENE, V8, P1713; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Menssen HD, 2000, J CANCER RES CLIN, V126, P226, DOI 10.1007/s004320050037; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; NISEN PD, 1986, CANCER RES, V46, P6217; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1993, ADV EXP MED BIOL, V348, P23; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Scharnhorst V, 2001, GENE, V273, P141, DOI 10.1016/S0378-1119(01)00593-5; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Svedberg H, 2001, LEUKEMIA, V15, P1914, DOI 10.1038/sj.leu.2402303; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; TELERMAN A, 1992, ONCOGENE, V7, P2545; Udtha M, 2003, ONCOGENE, V22, P3821, DOI 10.1038/sj.onc.1206597; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896	42	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6933	6941		10.1038/sj.onc.1207609	http://dx.doi.org/10.1038/sj.onc.1207609			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286719				2022-12-17	WOS:000223750700010
J	Yao, R; Natsume, Y; Noda, T				Yao, R; Natsume, Y; Noda, T			MAGI-3 is involved in the regulation of the JNK signaling pathway as a scaffold protein for frizzled and Ltap	ONCOGENE			English	Article						firzzled; MAGI-3; Ltap; JNK; PDZ	CONVERGENT EXTENSION MOVEMENTS; D-ASPARTATE RECEPTORS; TISSUE POLARITY GENE; PDZ DOMAIN; GUANYLATE KINASE; CELL-POLARITY; VERTEBRATE GASTRULATION; PLANAR POLARITY; LOOP-TAIL; DROSOPHILA	A seven-transmembrane protein, frizzled, has been implicated in a planar cell polarity (PCP) pathway as well as the canonical Wnt signaling pathway. Although both pathways require a cytoplasmic protein, dishevelled, the molecular mechanism by which frizzled regulates intracellular signaling remains to be elucidated. In the mouse, nine frizzled family members have been identified and six of them contain a PDZ-binding motif at their carboxyl-termini. In this study, we show that a multi-PDZ containing protein, MAGI-3, specifically binds to frizzled-4 and -7. Furthermore, we also demonstrate that MAGI-3 interacts with Ltap, a mouse homolog of the Drosophila PCP protein, stbm, and that these three molecules can form a ternary complex. In epithelial cells, MAGI-3, frizzled-4, and Ltap colocalized at cell contact sites, indicating that these molecules form a physiologically significant complex. Finally, we found that MAGI-3 strongly activated JNK in conjunction with frizzled-4 and Ltap, and that this activation required the small GTPase, Rac. These results indicate that MAGI-3 functions as a scaffold protein for frizzled-4 and Ltap and regulates the JNK signaling cascade.	Tohoku Univ, Sch Med, Ctr Translat Adv Anim Res Human Dis, Aoba Ku, Sendai, Miyagi 9808575, Japan; JFCR Canc Inst, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; RIKEN, Gen Sci Ctr, Mouse Funct Gen Res Grp, Totsuka Ku, Kanagawa 2440804, Japan	Tohoku University; Japanese Foundation for Cancer Research; RIKEN	Noda, T (corresponding author), Tohoku Univ, Sch Med, Ctr Translat Adv Anim Res Human Dis, Aoba Ku, 2-1 Seiryo Cho, Sendai, Miyagi 9808575, Japan.	tnoda@ims.u-tokyo.ac.jp	Noda, Tetsuo/B-1667-2016					Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Darken RS, 2002, EMBO J, V21, P976, DOI 10.1093/emboj/21.5.976; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Habas R, 2003, GENE DEV, V17, P295, DOI 10.1101/gad.1022203; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hirao K, 2000, J BIOL CHEM, V275, P2966, DOI 10.1074/jbc.275.4.2966; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kibar Z, 2001, NAT GENET, V28, P251, DOI 10.1038/90081; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Murdoch JN, 2001, HUM MOL GENET, V10, P2593, DOI 10.1093/hmg/10.22.2593; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Robitaille J, 2002, NAT GENET, V32, P326, DOI 10.1038/ng957; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Taylor J, 1998, GENETICS, V150, P199; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wang YS, 2002, J NEUROSCI, V22, P8563; Wang YS, 2001, J NEUROSCI, V21, P4761, DOI 10.1523/JNEUROSCI.21-13-04761.2001; Wang YS, 1996, J BIOL CHEM, V271, P4468; Wolff T, 1998, DEVELOPMENT, V125, P1149; Wood JD, 1998, MOL CELL NEUROSCI, V11, P149, DOI 10.1006/mcne.1998.0677; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430	37	56	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6023	6030		10.1038/sj.onc.1207817	http://dx.doi.org/10.1038/sj.onc.1207817			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15195140				2022-12-17	WOS:000223261000001
J	Bao, SL; Lu, T; Wang, X; Zheng, HY; Wang, LE; Wei, QY; Hittelman, WN; Li, L				Bao, SL; Lu, T; Wang, X; Zheng, HY; Wang, LE; Wei, QY; Hittelman, WN; Li, L			Disruption of the Rad9/Rad1/Hus1 (9-1-1) complex leads to checkpoint signaling and replication defects	ONCOGENE			English	Article						RAD1; DNA damage; checkpoint; replication	DNA-DAMAGE RESPONSE; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; MOUSE HUS1; PROTEIN; RAD17; ATR; CHK1; INTERACTS; HOMOLOG	The checkpoint sliding-clamp complex, Rad9/Rad1/Hus1, plays a critical role during initiation of checkpoint signals in response to DNA damage and replication disruption. We investigated the impact of loss of Rad1 on checkpoint function and on DNA replication in mammalian cells. We show that RAD1 is an essential gene for sustained cell proliferation and that loss of Rad1 causes destabilization of Rad9 and Hus1 and consequently disintegration of the sliding-clamp - complex. In Rad1-depleted cells, Atr-dependent Chk1 activation was impaired whereas Atm-mediated Chk2 activation was unaffected, suggesting that the sliding clamp is required primarily in Atr-dependent signal activation. Disruption of sliding-clamp function also caused a major defect in S-phase control. Rad1-depleted cells exhibited an RDS phenotype, indicating that damage-induced S-phase arrest was compromised by Rad1 loss. Furthermore, lack of Rad1 also affected the efficiency of replication recovery from DNA synthesis blockage, resulting in a prolonged S phase. These deficiencies may perpetually generate DNA strand breakage as we have found chromosomal abnormalities in Rad1-depleted cells. We conclude that the Rad9/Rad1/Hus1 complex is essential for Atr-dependent checkpoint signaling, which may play critical roles in the facilitation of DNA replication and in the maintenance of genomic integrity.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Chinese Acad Sci, Inst Genet & Dev Biol, Beijing 100101, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Li, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Unit 66, 1515 Holcombe Blvd, Houston, TX 77030 USA.	leili@mdanderson.org			NCI NIH HHS [CA76172, CA91029] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091029, R01CA076172, R29CA076172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chen FQ, 1996, MUTAT RES-DNA REPAIR, V362, P9, DOI 10.1016/0921-8777(95)00026-7; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo JA, 2001, GENE DEV, V15, P2809; Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Post SM, 2003, NUCLEIC ACIDS RES, V31, P5568, DOI 10.1093/nar/gkg765; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Wang X, 2001, CANCER RES, V61, P7417; Weiss RS, 1999, GENOMICS, V59, P32, DOI 10.1006/geno.1999.5865; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	46	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5586	5593		10.1038/sj.onc.1207753	http://dx.doi.org/10.1038/sj.onc.1207753			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15184880				2022-12-17	WOS:000222629500003
J	Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S				Elhasid, R; Sahar, D; Merling, A; Zivony, Y; Rotem, A; Ben-Arush, M; Izraeli, S; Bercovich, D; Larisch, S			Mitochondrial pro-apoptotic ARTS protein is lost in the majority of acute lymphoblastic leukemia patients	ONCOGENE			English	Article						ARTS; mitochandria; apoptosis; leukemia	ACUTE MYELOID-LEUKEMIA; SEPTIN-LIKE FUSION; DNA METHYLATION; GENE; MLL; HEMATOPOIESIS; EXPRESSION; REGION; TUMORS; DEATH	Acquired resistance towards apoptosis is the hallmark of most if not all types of cancer. We have previously identified and characterized ARTS, a broadly expressed protein localized to mitochondria. ARTS was initially shown to mediate TGF-beta induced apoptosis. Recently, we have found that high levels of ARTS induce apoptosis without additional pro-apoptotic stimuli. Further, ARTS promotes apoptosis in response to a wide variety of proapoptotic stimuli. Here, we report that the expression of ARTS is lost in all lymphoblasts of more than 70% of childhood acute lymphoblastic leukemia (ALL) patients. The loss of ARTS is specific, as the related non-apoptotic protein H5, bearing 83% identity to ARTS, is unaffected. During remission, ARTS expression is detected again in almost all patients. Two leukemic cell lines, ALL-1 and HL-60 lacking ARTS, were resistant to apoptotic induction by ara-C. Transfection of ARTS into these cells restored their ability to undergo apoptosis in response to this chemotherapeutic agent. We found that methylation process contributes to the loss of ARTS expression. We conclude that the loss of ARTS may provide a selective advantage for cells to escape apoptosis thereby contributing to their transformation to malignant lymphoblasts. We therefore propose that ARTS can function as a tumor suppressor protein in childhood ALL.	Rambam Med Ctr, Apoptosis & Carcinogenesis Res Lab, Dept Pathol, IL-31096 Haifa, Israel; Rambam Med Ctr, Pediat Hematooncol Dept, IL-31096 Haifa, Israel; Rambam Med Ctr, Mol Hematol Lab, IL-31096 Haifa, Israel; Tel Aviv Univ, Sackler Fac Med, Sheba Med Ctr, Canc Res Ctr, IL-52621 Tel Hashomer, Israel; Migal Galilee Technol Ctr, IL-11016 Kiryat Shmona, Israel	Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Rambam Health Care Campus; Technion Israel Institute of Technology; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Larisch, S (corresponding author), Rambam Med Ctr, Apoptosis & Carcinogenesis Res Lab, Dept Pathol, IL-31096 Haifa, Israel.	s_larisch@rambam.health.gov.il						Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Domen J, 2000, IMMUNOL RES, V22, P83, DOI 10.1385/IR:22:2-3:83; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ERIKSON J, 1986, P NATL ACAD SCI USA, V83, P1807, DOI 10.1073/pnas.83.6.1807; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Greaves M, 2002, BRIT MED J, V324, P283, DOI 10.1136/bmj.324.7332.283; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kalikin LM, 2000, GENOMICS, V63, P165, DOI 10.1006/geno.1999.6077; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kartmann B, 2001, J CELL SCI, V114, P839; Kinoshita M, 2002, DEV CELL, V3, P791, DOI 10.1016/S1534-5807(02)00366-0; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Malfoy B., 2000, J CELL SCI, V113, P3887; McKenna SL, 1997, ADV CANCER RES, V71, P121, DOI 10.1016/S0065-230X(08)60098-6; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Osaka M, 1999, P NATL ACAD SCI USA, V96, P6428, DOI 10.1073/pnas.96.11.6428; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rubnitz JE, 2003, CANCER TREAT REV, V29, P31, DOI 10.1016/S0305-7372(02)00106-8; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; ZAGONEL V, 1993, LEUKEMIA, V7, P30	36	56	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5468	5475		10.1038/sj.onc.1207725	http://dx.doi.org/10.1038/sj.onc.1207725			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15122323				2022-12-17	WOS:000222588400006
J	Di Stefano, V; Blandino, G; Sacchi, A; Soddu, S; D'Orazi, G				Di Stefano, V; Blandino, G; Sacchi, A; Soddu, S; D'Orazi, G			HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function	ONCOGENE			English	Article						HIPK2; p53; ubiquitination; MDM2; nuclear export; apoptosis	INTERACTING PROTEIN KINASE-2; AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; P53-INDUCED APOPTOSIS; GENE AMPLIFICATION; GROWTH-CONTROL; PHOSPHORYLATION; DEGRADATION; CANCER	The p53 oncosuppressor protein is subject to negative regulation by MDM2, which efficiently inhibits its activity through an autoregulatory loop. In response to stress, however, p53 undergoes post-translational modi. cations that allow the protein to escape MDM2 control, accumulate, and become active. Recent studies have shown that, following DNA damage, the HIPK2 serine/ threonine kinase binds and phosphorylates p53, inducing p53 transcriptional activity and apoptotic function. Here, we investigated the role of HIPK2 in the activation of p53 in the presence of MDM2. We found that HIPK2 rescues p53 transcriptional activity overcoming MDM2 inhibition, and that restoration of this p53 function induces apoptosis. Recovery of p53-dependent apoptosis is achieved by preventing p53 nuclear export and ubiquitination mediated by MDM2 in vitro and in vivo following genotoxic stress. These results shed new light on the mechanisms by which the HIPK2/p53 pathway promotes apoptosis and suppression of tumorigenesis.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, I-00158 Rome, Italy; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara	D'Orazi, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Dept Expt Oncol, Via Messi Oro 156, I-00158 Rome, Italy.	dorazi@ifo.it	Soddu, Silvia/ABH-6774-2020; Soddu, Silvia/K-2467-2018; Blandino, Giovanni/B-1137-2013; D'Orazi, Gabriella/T-2792-2019	Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Blandino, Giovanni/0000-0002-6970-2241; D'Orazi, Gabriella/0000-0001-6876-9105	Telethon [GP0234Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Chen JD, 1996, MOL CELL BIOL, V16, P2445; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Eymin B, 2002, ONCOGENE, V21, P2750, DOI 10.1038/sj.onc.1205359; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUCA RMD, 1995, NATURE, V378, P203; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Polsky D, 2001, CANCER RES, V61, P7642; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Velculescu VE, 1996, CLIN CHEM, V42, P858; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang Y, 2001, BMC Mol Biol, V2, P8, DOI 10.1186/1471-2199-2-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	47	56	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5185	5192		10.1038/sj.onc.1207656	http://dx.doi.org/10.1038/sj.onc.1207656			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122315				2022-12-17	WOS:000222382500008
J	Felicetti, F; Bottero, L; Felli, N; Mattia, G; Labbaye, C; Alvino, E; Peschle, C; Colombo, MP; Care, A				Felicetti, F; Bottero, L; Felli, N; Mattia, G; Labbaye, C; Alvino, E; Peschle, C; Colombo, MP; Care, A			Role of PLZF in melanoma progression	ONCOGENE			English	Article						PLZF; homeobox gene; cDNA expression array; melanoma; tumor progression	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER GENE; GROWTH-FACTOR; TRANSCRIPTION FACTOR; INTEGRIN EXPRESSION; CELL-GROWTH; PROTEIN; HOXB7; ALPHA; ALPHA(V)BETA(3)	The promyelocytic leukemia zinc finger (PLZF) protein has been described as a transcriptional repressor of homeobox (HOX)-containing genes during embryogenesis. As we previously demonstrated a functional link between overexpression of HOXB7 and melanoma progression.. we investigated the lack of PLZF as the possible cause of HOXB7 constitutive activation in these neoplastic cells. Accordingly, we found PLZF expression in melanocytes, but not in melanoma cells, a pattern inversely related to that of HOXB7. PLZF retroviral gene transduction was then performed in a panel of melanoma cell lines, and tumorigenicity was compared with that of empty vector-transduced control cell lines. Evaluation of in vitro migration, invasion and adhesion indicated that PLZF gene transduction induced a less malignant phenotype, as confirmed through in vitro studies performed in athymic nude mice. This reduced tumorigenicity was not coupled with HOXB7 repression. In order to find more about the molecular targets of PLZF, the gene expression profiles of PLZF- and empty vector-transduced A375 melanoma cells were analysed by Atlas Cancer macro-array. Among several genes modulated by PLZF enforced expression, of particular interest were integrin alphavbeta3, osteonectin/SPARC and matrix metalloprotease-9 that were downmodulated, and the tyrosinase-related protein-1 that was upregulated in all the analysed samples. This profile confirms the reduced tumorigenic phenotype with reversion to a more differentiated, melanocyte like, pattern, thus suggesting a suppressor role for PLZF in solid tumors. Moreover, these results indicate that PLZF and HOXB7 are functionally independent and that their coupled deregulation may account for most of the alterations described in melanomas.	Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; CNR, Inst Neurobiol & Mol Med, I-00100 Rome, Italy; Ist Nazl Tumori, Dept Expt Oncol, Immunotherapy & Gene Therapy Unit, I-20133 Milan, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan	Care, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	a.care@iss.it	felli, nadia/G-2088-2012; CARE', Alessandra/H-5090-2016; Alvino, Ester/J-8148-2012; Mattia, Gianfranco/K-5194-2016; Colombo, Mario P./V-7166-2017; Felicetti, Federica/N-7077-2017; Labbaye, Catherine/J-9930-2016	felli, nadia/0000-0001-6763-3361; CARE', Alessandra/0000-0003-4106-3342; Alvino, Ester/0000-0001-9467-7634; Mattia, Gianfranco/0000-0001-7047-6360; Colombo, Mario P./0000-0003-0042-7955; Felicetti, Federica/0000-0003-4628-0696; Labbaye, Catherine/0000-0003-1255-4396				Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; ALBINI A, 1987, CANCER RES, V47, P3239; Alvino E, 2002, J INVEST DERMATOL, V118, P79, DOI 10.1046/j.0022-202x.2001.01611.x; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BOUKERCHE H, 1995, BRIT J CANCER, V72, P108, DOI 10.1038/bjc.1995.285; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Dubrulle J, 2002, CURR OPIN GENET DEV, V12, P519, DOI 10.1016/S0959-437X(02)00335-0; Fang D, 2002, NUCLEIC ACIDS RES, V30, P3096, DOI 10.1093/nar/gkf424; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hofmann UB, 2000, J INVEST DERMATOL, V115, P625, DOI 10.1046/j.1523-1747.2000.00114.x; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Labbaye C, 2002, ONCOGENE, V21, P6669, DOI 10.1038/sj.onc.1205884; Lacal PM, 2000, J INVEST DERMATOL, V115, P1000, DOI 10.1046/j.1523-1747.2000.00199.x; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; Meccia E, 2003, BBA-GENE STRUCT EXPR, V1626, P1, DOI 10.1016/S0167-4781(03)00018-6; Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OHASHI K, 1994, ONCOGENE, V9, P699; Parrado A, 2000, Hematol J, V1, P15, DOI 10.1038/sj.thj.6200012; Pati D, 2002, MOL CELL BIOL, V22, P8267, DOI 10.1128/MCB.22.23.8267-8277.2002; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Satyamoorthy K, 2002, CANCER BIOL THER, V1, P14, DOI 10.4161/cbt.1.1.32; Seftor REB, 1998, AM J PATHOL, V153, P1347, DOI 10.1016/S0002-9440(10)65719-7; Sturm RA, 2002, CANCER RES, V62, P226; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; vandenOord JJ, 1997, AM J PATHOL, V151, P665; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	40	56	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4567	4576		10.1038/sj.onc.1207597	http://dx.doi.org/10.1038/sj.onc.1207597			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077196				2022-12-17	WOS:000221799000006
J	Martin, SS; Ridgeway, AG; Pinkas, J; Lu, Y; Reginato, MJ; Koh, EY; Michelman, M; Daley, GQ; Brugge, JS; Leder, P				Martin, SS; Ridgeway, AG; Pinkas, J; Lu, Y; Reginato, MJ; Koh, EY; Michelman, M; Daley, GQ; Brugge, JS; Leder, P			A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth	ONCOGENE			English	Article						apoptosis.; cytoskeleton; metastasis; breast; cancer; Bcl	CELL-CYCLE ENTRY; TRANSGENIC MICE; BREAST-CANCER; MAMMARY TUMORIGENESIS; LATRUNCULIN-A; MOUSE MODEL; APOPTOSIS; PROGRESSION; BAX; EXPRESSION	Many mouse models of breast cancer form large primary tumors that rarely metastasize. Models with aggressive metastasis express oncoproteins that simultaneously affect growth and apoptosis pathways. To define the role of apoptotic resistance and to model a challenge faced by tumor cells during metastatic dissemination, we focused on apoptosis induced by cell shape change. Inhibiting actin polymerization with Latrunculin-A causes cell rounding and death within hours in nontumorigenic human 10A-Ras mammary epithelial cells. In contrast, MDA-MB-231 metastatic breast tumor cells resist LA-induced death, and survive for days despite cell rounding. Infecting 10A-Ras cells with a MDA-MB-231 retroviral expression library, and selecting with Latrunculin-A repeatedly identified Bcl-xL as a suppressor of cytoskeleton-dependent death. Although Bcl-xL enhances the spread of metastatic breast tumor cell lines, the distinct effects of apoptotic resistance on tumor growth in the mammary gland and during metastasis have not been compared directly. We find that Bcl-xL overexpression in mouse mammary epithelial cells does not induce primary tumor formation or enhance MEK-induced tumorigenesis within the mammary gland environment. However, it strongly enhances metastatic potential. These results with Bcl-xL provide novel evidence that isolated apoptotic resistance can increase metastatic potential, but remain overlooked by assays based on breast tumor growth.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Genzyme Corp, Framingham, MA 01701 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Sanofi-Aventis; Genzyme Corporation; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.	leder@rascal.med.harvard.edu	Reginato, Mauricio/I-6155-2013	Reginato, Mauricio/0000-0002-7541-4094				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Eischen CM, 2002, CANCER RES, V62, P2184; Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fujita M, 2003, ONCOGENE, V22, P627, DOI 10.1038/sj.onc.1206173; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; MARTIN SS, 2004, IN PRESS BBA MOL CEL; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nikiforov MA, 1997, ONCOGENE, V15, P3007, DOI 10.1038/sj.onc.1201723; Olopade OI, 1997, CANCER J SCI AM, V3, P230; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pinkas J, 2002, CANCER RES, V62, P4781; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rubio N, 2001, LAB INVEST, V81, P725, DOI 10.1038/labinvest.3780281; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Shi HY, 2003, HISTOL HISTOPATHOL, V18, P201, DOI 10.14670/HH-18.201; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; WEBSTER MA, 1994, SEMIN CANCER BIOL, V5, P69; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0	31	56	57	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4641	4645		10.1038/sj.onc.1207595	http://dx.doi.org/10.1038/sj.onc.1207595			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064711				2022-12-17	WOS:000221799000014
J	Pandolfi, PP				Pandolfi, PP			Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age	ONCOGENE			English	Article						mRNA translation; ribosome; cell size; nucleolus; tumor suppressor; Dkc1	RIBOSOMAL-RNA; PROTEIN; TRANSFORMATION; B23	As the molecular processes that control mRNA translation and ribosome biogenesis in the eukaryotic cell are extremely complex and multilayered, their deregulation can in principle occur at multiple levels, leading to both disease and cancer pathogenesis. For a long time, it was speculated that disruption of these processes may participate in tumorigenesis, but this notion was, until recently, solely supported by correlative studies. Strong genetic support is now being accrued, while new molecular links between tumor-suppressive and oncogenic pathways and the control of protein synthetic machinery are being unraveled. The importance of aberrant protein synthesis in tumorigenesis is further underscored by the discovery that compounds such as Rapamycin, known to modulate signaling pathways regulatory of this process, are effective anticancer drugs. A number of fundamental questions remain to be addressed and a number of novel ones emerge as this exciting field evolves.	Mem Sloan Kettering Canc Ctr, Mol & Dev Biol Lab, Dept Pathol, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Mol & Dev Biol Lab, Dept Pathol, Program Mol Biol, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandol@ski.mskcc.org						Bader AG, 2004, ONCOGENE, V23, P3145, DOI 10.1038/sj.onc.1207550; Bernardi R, 2003, NAT MED, V9, P24, DOI 10.1038/nm0103-24; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Perrotti D, 2004, ONCOGENE, V23, P3222, DOI 10.1038/sj.onc.1207543; Pianese G., 1896, BEITR PATHOL ANAT AL, V142, P1; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; RUGGERO D, 2004, IN PRESS NATURE MED; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; White RJ, 2004, ONCOGENE, V23, P3208, DOI 10.1038/sj.onc.1207547	24	56	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3134	3137		10.1038/sj.onc.1207618	http://dx.doi.org/10.1038/sj.onc.1207618			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094762				2022-12-17	WOS:000220879700001
J	Zafarana, G; Grygalewicz, B; Gillis, AJM; Vissers, LELM; van de Vliet, W; van Gurp, RJHLM; Stoop, H; Debiec-Rychter, M; Oosterhuis, JW; van Kessel, AG; Schoenmakers, EFPM; Looijenga, LHJ; Veltman, JA				Zafarana, G; Grygalewicz, B; Gillis, AJM; Vissers, LELM; van de Vliet, W; van Gurp, RJHLM; Stoop, H; Debiec-Rychter, M; Oosterhuis, JW; van Kessel, AG; Schoenmakers, EFPM; Looijenga, LHJ; Veltman, JA			12p-Amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH	ONCOGENE			English	Article						testicular germ cell tumors; 12-amplicon; array CGH; architecture; candidate genes	COMPARATIVE GENOMIC HYBRIDIZATION; CANDIDATE ONCOGENE; EXPRESSION; AMPLIFICATION; GENE; AMPLICON; CANCER; TARGET; 12P; IDENTIFICATION	All invasive testicular germ cell tumors of adolescents and adults ( TGCTs), that is, seminomas and nonseminomas, show gain of 12p sequences, mostly as isochromosomes. Although several candidate genes have been suggested, the relevant gene(s) have not been identified yet. About 10% of testicular seminomas, however, show a more restricted amplification of the 12p11.2-p12.1 region, in which the various amplicons show an apparent overlap, allowing for the shortest region of amplification overlap approach, aiming at the identification of pathogenetically relevant sequences residing in this region. Here we report on a high-resolution 12p-amplicon architecture analysis using microarray-based comparative genomic hybridization, the results of which were subsequently confirmed by fluorescent in situ hybridization studies. The 12p-specific microarray contained 63 positionally selected BAC clones, which are more or less evenly distributed over the short arm of chromosome 12 ( average spacing: less than 500 Kb), including 20 clones within the region of amplification. Out of a series of 17 seminomas, seven seminomas showed amplification of the whole amplicon region, of which three showed a dip in T/R value in the center of the amplified area. A more complex amplification pattern was found in the other 10 seminomas: three showed predominant amplification at the centromeric border; one mainly at the telomeric border; six showed a balanced amplification of both the centromeric and telomeric regions. The only nonseminoma investigated showed a structure in which the centromeric border was only amplified. These data support a mechanistic model in which at least two 12p genes, situated at the border regions of the amplicon, are positional candidates capable of actively supporting tumor progression in TGCTs.	Erasmus Univ, Med Ctr, Erasmus MC,Daniel den Hoed Canc Ctr, Pathol Lab Exp Pathooncol, Rotterdam, Netherlands; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Maria Sklodowska Curie Mem Canc Ctr & Inst, Cytogenet Lab, Warsaw, Poland; Univ Med Ctr Nijmegen, Dept Human Genet, Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; KU Leuven; Radboud University Nijmegen	Looijenga, LHJ (corresponding author), Josephine Nefkens Inst, Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.	l.looijenga@erasmusmc.nl	Veltman, Joris A/F-5128-2010; van Kessel, Ad Geurts/A-2810-2010; Vissers, Lisenka ELM/A-2598-2015; Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Veltman, Joris A/0000-0002-3218-8250; Vissers, Lisenka ELM/0000-0001-6470-5497; Looijenga, Leendert/0000-0002-8146-1911; Grygalewicz, Beata/0000-0002-9592-5174; Zafarana, Gaetano/0000-0003-1391-4488				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Bourdon V, 2002, CANCER RES, V62, P6218; Guan XY, 2001, CANCER RES, V61, P3806; Heidenblad M, 2002, GENE CHROMOSOME CANC, V34, P211, DOI 10.1002/gcc.10063; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Looijenga LHJ, 2002, ANAL QUANT CYTOL, V24, P263; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Mostofi F K, 1985, Prog Clin Biol Res, V203, P1; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MULDER MP, 1989, ONCOGENE, V4, P1345; Nonet GH, 2001, CANCER RES, V61, P1250; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; RIDANPAA M, 1993, ENVIRON HEALTH PERSP, V101, P185, DOI 10.2307/3431723; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; Schmidt BA, 2001, CANCER RES, V61, P4214; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Skotheim RI, 2002, CANCER RES, V62, P2359; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; Yasui K, 2001, GENE CHROMOSOME CANC, V32, P112, DOI 10.1002/gcc.1172; Zafarana G, 2002, CANCER RES, V62, P1822; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	36	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7695	7701		10.1038/sj.onc.1207011	http://dx.doi.org/10.1038/sj.onc.1207011			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576833				2022-12-17	WOS:000186113000018
J	Meyers, M; Hwang, A; Wagner, MW; Bruening, AJ; Veigl, ML; Sedwick, WD; Boothman, DA				Meyers, M; Hwang, A; Wagner, MW; Bruening, AJ; Veigl, ML; Sedwick, WD; Boothman, DA			A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage	ONCOGENE			English	Review						fluorouracil; 5-fluoro-2 '-deoxyuridine; 5-fluoro-2 '-deoxycytidine; futile cycles of repair; DNA damage tolerance; colon cancer treatment	CELL-CYCLE CHECKPOINT; DEOXYURIDINE TRIPHOSPHATE NUCLEOTIDOHYDROLASE; HUMAN-COLON ADENOCARCINOMA; TARGET-DIRECTED THERAPIES; BREAST-CARCINOMA-CELLS; DOUBLE-STRAND BREAKS; LYMPHOMA S-49 CELLS; EXPLOIT HIGH-LEVELS; ADENINE BASE PAIR; KINASE C-ABL	The phenomenon of damage tolerance, whereby cells incur DNA lesions that are nonlethal, largely ignored, but highly mutagenic, appears to play a key role in carcinogenesis. Typically, these lesions are generated by alkylation of DNA or incorporation of base analogues. This tolerance is usually a result of the loss of specific DNA repair processes, most often DNA mismatch repair (MMR). The availability of genetically matched MMR deficient and - corrected cell systems allows dissection of the consequences of this unrepaired damage in carcinogenesis as well as the elucidation of cell cycle checkpoint responses and cell death consequences. Recent data indicate that MMR plays an important role in detecting damage caused by fluorinated pyrimidines (FPs) and represents a repair system that is probably not the primary system for detecting damage caused by these agents, but may be an important system for correcting key mutagenic lesions that could initiate carcinogenesis. In fact, clinical studies have shown that there is no benefit of FP-based adjuvant chemotherapy in colon cancer patients exhibiting microsatellite instability, a hallmark of MMR deficiency. MMR-mediated damage tolerance and futile cycle repair processes are discussed, as well as possible strategies using FPs to exploit these systems for improved anticancer therapy.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Gen Med Sci Oncol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Ireland Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Biomed Res Bldg 326 E,2109 Adelbert Rd, Cleveland, OH 44106 USA.	dab30@po.cwru.edu		Boothman, David/0000-0001-7474-9020	NATIONAL CANCER INSTITUTE [R01CA070788, R01CA067409, R01CA083196] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83196-05, CA 70788, R01 CA 67409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; AEBERSOLD PM, 1979, CANCER RES, V39, P808; Agami R, 1999, NATURE, V399, P809; AU KG, 1992, J BIOL CHEM, V267, P12142; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Berry SE, 2000, CANCER RES, V60, P5773; Berry SE, 1999, CANCER RES, V59, P1840; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BOOTHMAN DA, 1987, CANCER RES, V47, P2354; BOOTHMAN DA, 1987, CANCER RES, V47, P2344; BOOTHMAN DA, 1985, MOL PHARMACOL, V27, P584; BOOTHMAN DA, 1988, MUTAT RES, V202, P393, DOI 10.1016/0027-5107(88)90201-1; Buermeyer AB, 1999, CANCER RES, V59, P538; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CARADONNA SJ, 1980, MOL PHARMACOL, V18, P513; CARADONNA SJ, 1984, J BIOL CHEM, V259, P5459; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; COLL M, 1989, NUCLEIC ACIDS RES, V17, P911, DOI 10.1093/nar/17.3.911; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Davis TW, 1998, CANCER RES, V58, P767; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; DOMIN BA, 1993, BIOCHEM PHARMACOL, V46, P503, DOI 10.1016/0006-2952(93)90527-4; DOONG SL, 1988, J BIOL CHEM, V263, P4467; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; DUKER NJ, 1982, P NATL ACAD SCI-BIOL, V79, P4878, DOI 10.1073/pnas.79.16.4878; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELHAJJ HH, 1992, J BACTERIOL, V174, P4450, DOI 10.1128/JB.174.13.4450-4456.1992; FAZAKERLEY GV, 1987, J BIOMOL STRUCT DYN, V5, P639, DOI 10.1080/07391102.1987.10506417; FERNANDES DJ, 1986, CANCER RES, V46, P1741; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHER EF, 1979, NUCLEIC ACIDS RES, V7, P401, DOI 10.1093/nar/7.2.401; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; FREESE E, 1959, J MOL BIOL, V1, P87, DOI 10.1016/S0022-2836(59)80038-3; FRIEDKIN M, 1973, ADV ENZYMOL RAMB, V38, P235; GILL JE, 1974, BIOCHIM BIOPHYS ACTA, V335, P330, DOI 10.1016/0005-2787(74)90157-9; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; GLAZER RI, 1981, MOL PHARMACOL, V19, P117; GLICKMAN BW, 1982, MOL CELLULAR MECHANI, P65; Goel A, 2003, CANCER RES, V63, P1608; Gong JG, 1999, NATURE, V399, P806; GOULIAN M, 1980, J BIOL CHEM, V255, P630; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Grem JL, 1997, SEMIN RADIAT ONCOL, V7, P249, DOI 10.1016/S1053-4296(97)80023-9; GREM JL, 1989, BIOCHEM PHARMACOL, V38, P51, DOI 10.1016/0006-2952(89)90148-2; GREM JL, 1996, CANC CHEMOTHERAPY BI, P149; HABENER JF, 1988, P NATL ACAD SCI USA, V85, P1735, DOI 10.1073/pnas.85.6.1735; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; HAWN MT, 1995, CANCER RES, V55, P3721; HEIDELBERGER C, 1958, P SOC EXP BIOL MED, V97, P470; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; INGRAHAM HA, 1982, MOL PHARMACOL, V21, P211; INGRAHAM HA, 1982, BIOCHEM BIOPH RES CO, V109, P746, DOI 10.1016/0006-291X(82)92003-4; INGRAHAM HA, 1980, CANCER RES, V40, P998; Jacob S, 2001, CANCER RES, V61, P6555; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnston P G, 1996, Cancer Chemother Biol Response Modif, V16, P1; JONES PA, 1976, CANCER RES, V36, P101; KANAMARU R, 1986, CANCER CHEMOTH PHARM, V17, P43, DOI 10.1007/BF00299864; Kane MF, 1997, CANCER RES, V57, P808; Karran P, 1996, CANCER SURV, V28, P69; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; KAYSEN J, 1986, CANCER RES, V46, P4534; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KREMER AB, 1987, BIOCHEMISTRY-US, V26, P391, DOI 10.1021/bi00376a009; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; KUFE DW, 1981, J BIOL CHEM, V256, P9802; KUFE DW, 1981, J BIOL CHEM, V256, P8885; Kunz BA, 1996, MUTAT RES-FUND MOL M, V355, P129, DOI 10.1016/0027-5107(96)00026-7; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; LONN U, 1989, CANCER RES, V49, P1085; LONN U, 1984, CANCER RES, V44, P3414; MAJOR PP, 1982, CANCER RES, V42, P3005; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; MAYBAUM J, 1981, J BIOL CHEM, V256, P2126; McIntosh EM, 1997, ACTA BIOCHIM POL, V44, P159; MEKRAS JA, 1984, CANCER RES, V44, P2551; MEKRAS JA, 1985, CANCER RES, V45, P5270; Meyers M, 2001, CANCER RES, V61, P5193; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Muller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371; Nehme A, 1999, BRIT J CANCER, V79, P1104, DOI 10.1038/sj.bjc.6690176; Nehme A, 1997, CANCER RES, V57, P3253; NEWMAN EM, 1982, P NATL ACAD SCI-BIOL, V79, P6419, DOI 10.1073/pnas.79.21.6419; NILSSON S, 1980, J BIOL CHEM, V255, P9552; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; PARKER WB, 1987, CANCER RES, V47, P979; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1985, GENETIC CONSEQUENCES, P33; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; RICHARDS RG, 1984, ADV ENZYME REGUL, V22, P157, DOI 10.1016/0065-2571(84)90013-X; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SANTI DV, 1972, P NATL ACAD SCI USA, V69, P1855, DOI 10.1073/pnas.69.7.1855; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SCHUETZ JD, 1984, CANCER RES, V44, P1358; SEDWICK WD, 1981, P NATL ACAD SCI-BIOL, V78, P917, DOI 10.1073/pnas.78.2.917; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SOWERS LC, 1989, J MOL BIOL, V205, P437, DOI 10.1016/0022-2836(89)90353-7; SOWERS LC, 1987, J BIOL CHEM, V262, P15436; SOWERS LC, 1988, J BIOL CHEM, V263, P14794; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; Taverna P, 2001, MUTAT RES-DNA REPAIR, V485, P269, DOI 10.1016/S0921-8777(01)00076-3; van Laar JAM, 1998, EUR J CANCER, V34, P296, DOI 10.1016/S0959-8049(97)00366-3; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vikhanskaya F, 1999, CLIN CANCER RES, V5, P937; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wang Y, 2000, GENE DEV, V14, P927; WECKBECKER G, 1991, PHARMACOL THERAPEUT, V50, P367, DOI 10.1016/0163-7258(91)90051-M; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; YOSHIOKA A, 1987, J BIOL CHEM, V262, P8235; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	146	56	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7376	7388		10.1038/sj.onc.1206941	http://dx.doi.org/10.1038/sj.onc.1206941			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576845				2022-12-17	WOS:000186112500010
J	Mikula, M; Gotzmann, J; Fischer, ANM; Wolschek, MF; Thallinger, C; Schulte-Hermann, R; Beug, H; Mikulits, W				Mikula, M; Gotzmann, J; Fischer, ANM; Wolschek, MF; Thallinger, C; Schulte-Hermann, R; Beug, H; Mikulits, W			The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis	ONCOGENE			English	Article						c-Fos; hepatocytes; cell death; tumour suppressor	GROWTH-FACTOR-BETA; CELL-CYCLE PROGRESSION; LIVER-REGENERATION; TRANSGENIC MICE; E-CADHERIN; HA-RAS; MOUSE DEVELOPMENT; MESSENGER-RNA; AP-1 COMPLEX; IN-VIVO	Hepatocytes adopt an invasive and metastatic phenotype caused by the cooperation of transforming growth factor (TGF)-beta and oncogenic Ha-Ras. In the initial phase of this process, c-Fos is rapidly induced by TGF-beta, but then decreases to undetectable levels. Here, we investigated the functional implications of c-Fos activation and its contribution to hepatocellular tumorigenesis. By employing conditional c-Fos expression, we observed that continuous activation of c-Fos and consequently AP-1 activity leads to depolarization of differentiated murine epithelial hepatocytes. Most remarkably, this change in morphology was associated with inhibition of proliferation and induction of cell death. Coexpression of antiapoptotic Bcl-X-L or scavenging of reactive oxygen species was sufficient to prevent the c-Fos-mediated phenotype. In contrast, the cooperation of c-Fos with oncogenic Ha-Ras or a Ras mutant selectively activating the MAPK pathway even enhanced c-Fos-induced effects. Showing the negative role in hepatocellular tumorigenesis, c-Fos repressed oncogenic Ras-driven anchorage-independent growth in vitro and strongly suppressed tumour formation in vivo. Taken together, we demonstrate that c-Fos modulates plasticity of epithelial hepatocytes and acts tumour suppressive in neoplastic hepatocytes by stimulating cell cycle inhibition and cell death.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Vienna Gen Hosp, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mikulits, W (corresponding author), Univ Vienna, Inst Canc Res, Borschke Gasse 8A, A-1090 Vienna, Austria.		Mikulits, Wolfgang/AAH-4043-2021	Mikula, Mario/0000-0001-5782-0681; Gotzmann, Josef/0000-0001-6392-2115; Mikulits, Wolfgang/0000-0003-4612-7106				Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; Andersen H, 2002, ONCOGENE, V21, P4843, DOI 10.1038/sj.onc.1205590; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARMICHAEL J, 1987, CANCER RES, V47, P936; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Factor VM, 1997, CANCER RES, V57, P2089; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Garcia EJ, 2002, APPL IMMUNOHISTO M M, V10, P210, DOI 10.1097/00022744-200209000-00004; Germain S, 2000, GENE DEV, V14, P435; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; Hu L, 1996, J IMMUNOL, V157, P3804; ITO N, 1991, CANCER RES, V51, P4080; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kieslinger M, 2000, GENE DEV, V14, P232; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lee M, 2001, FREE RADICAL BIO MED, V31, P1550, DOI 10.1016/S0891-5849(01)00633-5; MARTI A, 1994, ONCOGENE, V9, P1213; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Mils V, 1997, ONCOGENE, V14, P1555, DOI 10.1038/sj.onc.1200991; Nakai S, 2002, INT J ONCOL, V20, P769; Nakopoulou L, 1999, PATHOL RES PRACT, V195, P19, DOI 10.1016/S0344-0338(99)80089-2; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Papadopoulos MC, 1998, EUR J NEUROSCI, V10, P1252, DOI 10.1046/j.1460-9568.1998.00134.x; Pistoi S, 1996, FASEB J, V10, P819, DOI 10.1096/fasebj.10.8.8666158; Preston GA, 1996, MOL CELL BIOL, V16, P211; Qin LF, 2001, HUM PATHOL, V32, P778, DOI 10.1053/hupa.2001.27105; Rahmani M, 1999, J HEPATOL, V30, P916, DOI 10.1016/S0168-8278(99)80148-2; Ravazoula P, 2002, ANTICANCER RES, V22, P1799; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH MJ, 1992, BLOOD, V79, P2107; Sok J, 1999, MOL CELL BIOL, V19, P495; Spagnoli FM, 1998, J CELL BIOL, V143, P1101, DOI 10.1083/jcb.143.4.1101; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takehara T, 2001, HEPATOLOGY, V34, P55, DOI 10.1053/jhep.2001.25387; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	82	56	62	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6725	6738		10.1038/sj.onc.1206781	http://dx.doi.org/10.1038/sj.onc.1206781			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555986				2022-12-17	WOS:000185799300008
J	Han, BG; Dong, ZZ; Liu, Y; Chen, Q; Hashimoto, K; Zhang, JT				Han, BG; Dong, ZZ; Liu, Y; Chen, Q; Hashimoto, K; Zhang, JT			Regulation of constitutive expression of mouse PTEN by the 5 '-untranslated region	ONCOGENE			English	Article						PTEN; IRES; promoter; 5 '-UTR	INTERNAL RIBOSOME ENTRY; LHERMITTE-DUCLOS-DISEASE; TUMOR-SUPPRESSOR GENE; LONG TERMINAL REPEAT; MESSENGER-RNA; GROWTH-FACTOR; TRANSLATION INITIATION; TRANSCRIPTIONAL ACTIVATION; PROMOTER METHYLATION; NEGATIVE REGULATION	PTEN tumor suppressor serves as a major negative regulator of survival signaling mediated by PI3 kinase/ AKT/protein kinase B pathway, and is inactivated in various human tumors. Elucidation of mechanisms responsible for PTEN expression is important for providing insight into strategies to control the loss of PTEN expression in human cancers. Although recent studies suggested that p53 and Egr-1 can modulate induced PTEN expression, the mechanism responsible for ubiquitous constitutive expression of PTEN remains elusive. PTEN mRNA contains a highly conserved and GC-rich 5-untranslated region (5'-UTR). Recently, it has been shown that the long 5'-UTR sequences of several growth-regulated mRNAs contain promoters that can generate mRNAs with shorter 5'-UTRs. In this paper, we tested whether the 5'-UTR sequence of mouse PTEN contains a promoter that is responsible for constitutive expression of PTEN. We found that the long 5'-UTR sequence of mouse PTEN severely inhibits translation of PTEN and a heterologous gene firefly luciferase. Deletion of the most 5'-UTR sequence would enhance translation efficiency 100-fold. We also showed that the 5'-UTR sequence of mouse PTEN does not have an internal ribosome entry site (IRES) that can mediate cap-independent initiation of translation. Instead, we found that the 5'-UTR sequence of mouse PTEN contains a strong promoter that drives the production of a transcript with shorter 5'-UTRs, which can be translated with higher efficiency. This promoter was mapped to the region between -551 and -220 bases upstream of the translation start codon. Cotransfection analysis using Drosophila SL2 cells showed that Sp1 is one of the major transcription factors that can constitutively activate this promoter. Two endogenous PTEN transcripts with 5'-UTRs of 193 and 109 bases were found in DU145 and H226 cell lines. Based on these observations, we conclude that the PTEN expression may be regulated at both transcriptional and translational levels, and that the 5'-UTR sequence of PTEN contains a promoter that is responsible for constitutive PTEN expression.	Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Walther Canc Inst, Indianapolis, IN 46202 USA; Natl Inst Infect Dis, Tokyo, Japan	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; National Institute of Infectious Diseases (NIID)	Zhang, JT (corresponding author), Indiana Univ, Sch Med, IUCC, Dept Pharmacol & Toxicol, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015		NATIONAL CANCER INSTITUTE [R29CA064539, R01CA064539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059475] Funding Source: NIH RePORTER; NCI NIH HHS [CA64539] Funding Source: Medline; NIGMS NIH HHS [GM59475] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hen BG, 2001, J BIOL CHEM, V276, P7937, DOI 10.1074/jbc.M007470200; Hisatake J, 2001, BLOOD, V97, P2427, DOI 10.1182/blood.V97.8.2427; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kozak M, 2001, MOL CELL BIOL, V21, P1899, DOI 10.1128/MCB.21.6.1899-1907.2001; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Li G, 2002, DEVELOPMENT, V129, P4159; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mutter GL, 2001, AM J PATHOL, V158, P1895, DOI 10.1016/S0002-9440(10)64656-1; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; Ross AH, 2001, NEUROSCIENTIST, V7, P278, DOI 10.1177/107385840100700404; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Suzuki Y, 2000, GENOMICS, V64, P286, DOI 10.1006/geno.2000.6076; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	49	56	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5325	5337		10.1038/sj.onc.1206783	http://dx.doi.org/10.1038/sj.onc.1206783			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917634				2022-12-17	WOS:000184734900012
J	Pei, HP; Yordy, JS; Leng, QX; Zhao, QH; Watson, DK; Li, RZ				Pei, HP; Yordy, JS; Leng, QX; Zhao, QH; Watson, DK; Li, RZ			EAPII interacts with ETS1 and modulates its transcriptional function	ONCOGENE			English	Article						ETS1; EAPII; transcriptional control; migration	LONG TERMINAL REPEAT; NF-KAPPA-B; MATRIX METALLOPROTEINASE-1; HEPATOCELLULAR-CARCINOMA; PROTEIN INTERACTIONS; TERNARY COMPLEXES; ENDOTHELIAL-CELLS; FAMILY PROTEINS; EXPRESSION; PROMOTER	Ets proteins constitute a family of conserved sequence-specific DNA-binding proteins and function as transcription factors. ETS1 plays important roles in differentiation, lymphoid cell development, invasiveness and angiogenesis. Such diverse roles of ETS1 are likely to be dependent on its associated proteins. A yeast two-hybrid screen was conducted and here we describe a novel ETS1 interacting protein designated as ETS1-associated protein II (EAPII). EAPII protein interacts with ETS1 and other Ets proteins (ETS2 and FLI1) both in vitro and in vivo. Indirect immunofluorescence demonstrated that EAPII is predominately localized to the nucleus of mammalian cells. EAPII negatively modulates ETS1 transcriptional activity and attenuates synergistic transactivation by ETS1 and AP-1. Significantly, re-expression of EAPII inhibits the migration of epithelial cancer cells, but does not affect cell viability. Therefore, EAPII is a novel ETS1 modulator that regulates specific aspects of the ETS1 functions.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina	Li, RZ (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Room 315,86 Jonathan Lucas St, Charleston, SC 29425 USA.				NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Chen ZQ, 1997, CANCER RES, V57, P2013; Davidson B, 2001, CLIN CANCER RES, V7, P551; de Nigris F, 2001, CANCER RES, V61, P2267; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GHYSDAEL J, 1997, ETS FAMILY TRANSCRIP; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLZMEISTER J, 1993, BIOCHEM BIOPH RES CO, V197, P1229, DOI 10.1006/bbrc.1993.2608; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; KOIZUMI S, 1990, ONCOGENE, V5, P675; KRAMER B, 1995, J BIOL CHEM, V270, P6577; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; Nimer S, 1996, BLOOD, V88, P66, DOI 10.1182/blood.V88.1.66.bloodjournal88166; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Ozaki I, 2000, CANCER RES, V60, P6519; Pype S, 2000, J BIOL CHEM, V275, P18586, DOI 10.1074/jbc.M000531200; Remy P, 2000, ONCOGENE, V19, P6417, DOI 10.1038/sj.onc.1204044; Rutter JL, 1998, CANCER RES, V58, P5321; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Verger A, 2002, BIOESSAYS, V24, P362, DOI 10.1002/bies.10068; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 2002, ENCY CANC, V2, P751; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wheat W, 1999, MOL CELL BIOL, V19, P2231; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	41	56	59	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2699	2709		10.1038/sj.onc.1206374	http://dx.doi.org/10.1038/sj.onc.1206374			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743594				2022-12-17	WOS:000182569300001
J	Bachelor, MA; Silvers, AL; Bowden, GT				Bachelor, MA; Silvers, AL; Bowden, GT			The role of p38 in UVA-induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT	ONCOGENE			English	Article						UVA; COX-2; p38; HaCaT	MESSENGER-RNA STABILITY; COLON-CANCER CELLS; SINGLET OXYGEN; GENE-EXPRESSION; 3'-UNTRANSLATED REGION; MAP KINASE; HUMAN SKIN; POSTTRANSCRIPTIONAL CONTROL; ULTRAVIOLET-RADIATION; HEME OXYGENASE	We examined the expression of cycloxygenase-2, the rate-limiting enzyme in the production of prostaglandins, in the UVA-irradiated human keratinocyte cell line, HaCaT. UVA induced a dose-dependent increase in COX-2 at the protein level at 2 and 4 h post-irradiation and at the mRNA level at 1 and 2 h post-irradiation. Experiments using semi-quantitative RT-PCR demonstrate that UVA increased the half-life of the COX-2 message by more than fourfold in the presence of Actinomycin D (with a half life between 4 and 8 h post-irradiation), suggesting that UVA induction of COX-2 is post-transcriptionally regulated. Through the use of the specific p38 inhibitor, SB202190, increases in COX-2 message and protein levels were abrogated in UVA-irradiated cells. In UVA-irradiated cells treated with S13202190, the half-life of the COX-2 message was decreased to basal levels (between I and 2 h postirradiation), indicating that p38 was responsible for the stabilization of the message. Luciferase activity was increased in UVA-irradiated cells transfected with reporter constructs containing the 3' UTR of COX-2, a region containing AU-rich elements (AREs). These regulatory sequences of AUUUA have been proposed as one mechanism of post-transcriptional regulation. Increases observed in luciferase activity could be decreased using a p38 dominant-negative construct. We report for the first that UVA can induce COX-2 expression in the human keratinocyte cell line, HaCaT. Additionally, p38 appears to play a critical role in the UVA-induced expression of COX-2 in these keratinocytes and may serve as a potential drug target in the chemoprevention of skin cancer.	Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA23074, CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BASUMODAK S, 1993, CANCER RES, V53, P4505; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HANSON D, 1990, J INVEST DERMATOL, V95, P158, DOI 10.1111/1523-1747.ep12477928; HANSON DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P423, DOI 10.1111/j.1751-1097.1989.tb09190.x; HIAL V, 1976, EUR J PHARMACOL, V37, P367, DOI 10.1016/0014-2999(76)90044-3; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, P396; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MATSUI MS, 1991, CANCER CELL-MON REV, V3, P8; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Nabors LB, 2001, CANCER RES, V61, P2154; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; SCHARFFETTERKOCHANEK K, 1993, FEBS LETT, V331, P304, DOI 10.1016/0014-5793(93)80357-Z; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Silvers AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P302, DOI 10.1562/0031-8655(2002)075<0302:UIIAOA>2.0.CO;2; SNYDERMAN CH, 1995, ARCH OTOLARYNGOL, V121, P1017; Soriani M, 1998, FEBS LETT, V439, P253, DOI 10.1016/S0014-5793(98)01387-8; Subbarayan V, 2001, CANCER RES, V61, P2720; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Thompson EJ, 2001, NEOPLASIA, V3, P402, DOI 10.1038/sj.neo.7900182; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VANDERVEEN EE, 1986, ARCH DERMATOL, V122, P407, DOI 10.1001/archderm.122.4.407; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	54	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7092	7099		10.1038/sj.onc.1205855	http://dx.doi.org/10.1038/sj.onc.1205855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370831				2022-12-17	WOS:000178424900012
J	Conte, N; Charafe-Jauffret, E; Delaval, B; Adelaide, J; Ginestier, C; Geneix, J; Isnardon, D; Jacquemier, J; Birnbaum, D				Conte, N; Charafe-Jauffret, E; Delaval, B; Adelaide, J; Ginestier, C; Geneix, J; Isnardon, D; Jacquemier, J; Birnbaum, D			Carcinogenesis and translational controls: TACC1 is down-regulated in human cancers and associates with mRNA regulators	ONCOGENE			English	Article						microtubules; mitosis; breast cancer; mRNA processing; Sm proteins; TACC proteins	CHROMOSOME ARM 8P; COILED-COIL; TUMOR-SUPPRESSOR; GENE FAMILY; CYCLIN B1; PROTEIN; EXPRESSION; SM; CPEB; INTERACTS	The three human TACC genes encode a family of proteins that are suspected to play a role in carcinogenesis. Their function is not precisely known; a Xenopus TACC protein called Maskin is involved in translational control, while the Drosophila D-TACC associates with microtubules and centrosomes. We have characterized the human TACC1 gene and its products. The TACC1 gene is located in region p12 of chromosome 8; its mRNA is ubiquitously expressed and encodes a protein with an apparent molecular mass of 125 kDa, which is cytoplasmic and mainly perinuclear. We show that TACC1 mRNA gene expression is down-regulated in various types of tumors. Using immunohistochemistry of tumor tissue-microarrays and sections, we confirm that the level of TACC1 protein is down-regulated in breast cancer. Finally, using the two-hybrid screen in yeast, GST pull-downs and co-immunoprecipitations, we identified two potential binding partners for TACC1, LSM7 and SmG. They constitute a conserved subfamily of Sm-like small proteins that associate with U6 snRNPs and play a role in several aspects of mRNA processing. We speculate that down-regulation of TACC1 may alter the control of mRNA homeostasis in polarized cells and participates in the oncogenic processes.	Dept Mol Oncol, INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, Lab Pathol Mol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Mol Oncol, Lab Biol Tumeurs, F-13009 Marseille, France; Inst J Paoli I Calmettes, Atelier Bioimagerie, F-13009 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Dept Mol Oncol, INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017; ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017	Ginestier, Christophe/0000-0002-7477-3837; ADELAIDE, José JA/0000-0003-4364-9857; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Conte, Nathalie/0000-0002-1010-3121				Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kelley JR, 2000, SURGERY, V128, P353, DOI 10.1067/msy.2000.107605; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Popovici C, 2001, FEBS LETT, V491, P237, DOI 10.1016/S0014-5793(01)02187-1; Pribill I, 2001, CANCER GENET CYTOGEN, V129, P23, DOI 10.1016/S0165-4608(01)00419-8; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schweinfest CW, 1997, CANCER RES, V57, P2961; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Ugolini F, 2001, ONCOGENE, V20, P5810, DOI 10.1038/sj.onc.1204706; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950	46	56	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5619	5630		10.1038/sj.onc.1205658	http://dx.doi.org/10.1038/sj.onc.1205658			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165861				2022-12-17	WOS:000177442000012
J	Laghi, L; Orbetegli, O; Bianchi, P; Zerbi, A; Di Carlo, V; Boland, CR; Malesci, A				Laghi, L; Orbetegli, O; Bianchi, P; Zerbi, A; Di Carlo, V; Boland, CR; Malesci, A			Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers	ONCOGENE			English	Article						pancreatic cancer; bile duct cancer; K-RAS; pancreatic intraepithelial neoplasia	GENE-MUTATIONS; ONCOGENE ACTIVATION; ADENOCARCINOMA; PROGRESSION; CARCINOMAS; CODON-12; PATHWAYS	Recent studies on small series of pancreatic cancer (PC) with foci of pancreatic intraepithelial neoplasia (PanIN), a putative precursor lesion, have shown that multiple K-RAS mutations may coexist in the same neoplastic pancreas. To see whether mutant-K-RAS polyclonality is a common and specific feature of pancreatic carcinogenesis, we investigated a unselected series of periampullary cancers (41 pancreatic, 13 biliary and two ampullary adenocarcinomas). After hemi-nested polymerase chain reaction (PCR), mutations identified with single strand conformation polymorphism (SSCP) were confirmed by allele-specific PCR and sequencing. K-RAS codon 12 was mutated in 34 (83%) pancreatic cancers and in 11 (85%) biliary cancers. Multiple distinct K-RAS mutations were found in 16 PC (39% of all cases, 47% of those with mutated K-RAS) and in eight biliary cancers (62 and 72%, respectively). In PC, multiple K-RAS mutations were more frequent (P<0.001) in cancers with (nine of 12, 75%) than in those without detectable PanIN (seven of 29, 24%). Individual precursor lesions of the same neoplastic pancreas were found to harbor distinct mutations. Results show that multiple K-RAS mutations are frequent both in PC with associated PanIN and in biliary cancers, and indicate that clonally distinct precursor lesions of PC might variably contribute to tumor development.	Ist Clin Humanitas, Div Gastroenterol, I-20089 Milan, Italy; Univ Milan, Dept Internal Med, I-20121 Milan, Italy; Ist Clin Humanitas, Dept Pathol, Res Lab, I-20089 Milan, Italy; Osped San Raffaele, Dept Surg, I-20132 Milan, Italy; Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA	IRCCS Humanitas Research Hospital; University of Milan; IRCCS Humanitas Research Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California San Diego	Malesci, A (corresponding author), Ist Clin Humanitas, Div Gastroenterol, Via Manzoni 56, I-20089 Milan, Italy.		Bianchi, Paolo/E-7592-2013; Laghi, Luigi/GZM-5831-2022; Piemonti, Lorenzo/P-7605-2017	Bianchi, Paolo/0000-0001-5786-5644; Piemonti, Lorenzo/0000-0002-2172-2198; Laghi, Luigi/0000-0003-4187-1059; zerbi, alessandro/0000-0002-9176-0448				ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; CALDAS C, 1994, CANCER RES, V54, P3568; CUBILLA AL, 1976, CANCER RES, V36, P2690; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Kern Scott E., 1998, Current Opinion in Oncology, V10, P74, DOI 10.1097/00001622-199801000-00012; LEVI S, 1991, CANCER RES, V51, P3497; Moskaluk CA, 1997, CANCER RES, V57, P2140; MOTOJIMA K, 1991, ANN SURG, V214, P657, DOI 10.1097/00000658-199112000-00003; Rozenblum E, 1997, CANCER RES, V57, P1731; Sherratt EJ, 1996, BIOTECHNIQUES, V20, P430; SUGANO K, 1993, LAB INVEST, V68, P361; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; TADA M, 1993, CANCER RES, V53, P2472; Urrutia R, 1996, GASTROENTEROLOGY, V110, P306, DOI 10.1053/gast.1996.v110.agast960306; WATANABE M, 1994, GASTROENTEROLOGY, V107, P1147, DOI 10.1016/0016-5085(94)90240-2; Yamano M, 2000, AM J PATHOL, V156, P2123, DOI 10.1016/S0002-9440(10)65083-3; YANAGISAWA A, 1993, CANCER RES, V53, P953; Yashiro M, 2001, CANCER RES, V61, P2676; Zhu D, 1997, CANCER RES, V57, P2485	23	56	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 20	2002	21	27					4301	4306		10.1038/sj.onc.1205533	http://dx.doi.org/10.1038/sj.onc.1205533			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562AA	12082617				2022-12-17	WOS:000176174200012
J	Conejo, R; de Alvaro, C; Benito, M; Cuadrado, A; Lorenzo, M				Conejo, R; de Alvaro, C; Benito, M; Cuadrado, A; Lorenzo, M			Insulin restores differentiation of Ras-transformed C2C12 myoblasts by inducing NF-kappa B through an AKT/P70S6K/p38-MAPK pathway	ONCOGENE			English	Article						insulin signaling; differentiation; Ras-transformed; C2C12 cells	ACTIVATED PROTEIN-KINASE; SKELETAL-MUSCLE DIFFERENTIATION; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAYS; DOWN-REGULATION; PI 3-KINASE; IGF-II; K-RAS; MYOGENESIS	v-H-ras transformed C2C12 (C2Ras) myoblasts, over-expressing p21-Ras protein in the Ras-GTP active form, showed a differentiation-defective phenotype when cultured in low serum as compared with C2C12 myoblasts. Accordingly, the purpose of the present study was to delineate the signaling pathways that restore C2Ras myoblasts differentiation. Inhibition of p42/p44-MAPK with the chemical inhibitor PD98059, and activation of AKT/P70S6K and p38-MAPK with insulin, produced growth arrest (precluding the expression of PCNA, cyclin-D1 and retinoblastoma at the hyperphosphorylated state and inducing the expression of the cell cycle inhibitor p21(Cip)) and myogenesis (multinucleated myotubes formation and induction of creatine kinase, caveolin-3 and alpha-actin). Both events were accompanied by down-regulation of AP-1 and up-regulation of NF-kappaB transcriptional activities. Furthermore, inhibition of NF-kappaB transcriptional activity by the use of the proteasome inhibitor MG132 totally precluded differentiation by insulin + PD98059, demonstrating a direct role for NF-kappaB on C2Ras myogenesis. C2Ras myoblasts failed to restore differentiation when rapamycin or PD169316 were added in the presence of insulin + PD98059, indicating that the activation of both P70S6K and p38-MAPK was necessary to reach a fully differentiated phenotype. Finally, transient transfection of a constitutively active Myr-EGFP-AKT-HA construct (in the presence of PD98059) restored C2Ras myogenesis by its ability to activate P70S6K and p38-MAPK. A crosstalk between P70S6K and p38-MAPK was observed under rapamycin treatment in both insulin or active AKT induced myogenesis. Our results are delineating an AKT/P70S6K/p38-MAPK pathway involved in skeletal muscle differentiation.	Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, Madrid 28040, Spain; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid 28029, Spain	Complutense University of Madrid; Autonomous University of Madrid	Lorenzo, M (corresponding author), Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, Madrid 28040, Spain.	mlorenzo@farm.ucm.es	; Benito, Manuel/J-5637-2014	Cuadrado, Antonio/0000-0002-4039-7140; Benito, Manuel/0000-0002-7218-406X; Cuadrado, Antonio/0000-0002-3444-9012				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACH LA, 1995, ENDOCRINOLOGY, V136, P5061, DOI 10.1210/en.136.11.5061; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bertrand F, 1999, J BIOL CHEM, V274, P30596, DOI 10.1074/jbc.274.43.30596; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canicio J, 2001, J BIOL CHEM, V276, P20228, DOI 10.1074/jbc.M100718200; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Dorman CM, 1999, ONCOGENE, V18, P5167, DOI 10.1038/sj.onc.1202907; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Genth H, 1999, J BIOL CHEM, V274, P29050, DOI 10.1074/jbc.274.41.29050; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KONIECZNY SF, 1989, ONCOGENE, V4, P473; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAM K, 1994, J BIOL CHEM, V269, P20648; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LYONS AB, 1992, CYTOMETRY, V13, P809; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mitin N, 2001, ONCOGENE, V20, P1276, DOI 10.1038/sj.onc.1204223; Mockridge JW, 2000, BIOCHEM BIOPH RES CO, V270, P947, DOI 10.1006/bbrc.2000.2522; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Navarro P, 1998, EXP CELL RES, V243, P213, DOI 10.1006/excr.1998.4168; Noda Satoshi, 2000, Journal of Medical Investigation, V47, P47; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salinas M, 2001, MOL CELL NEUROSCI, V17, P67, DOI 10.1006/mcne.2000.0921; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; STRATTON MR, 1989, CANCER RES, V49, P6324; STRAUCH AR, 1986, J BIOL CHEM, V261, P849; Suzuki J, 2000, ONCOGENE, V19, P1138, DOI 10.1038/sj.onc.1203402; Tabata M, 2001, J BIOL CHEM, V276, P8029, DOI 10.1074/jbc.M009831200; Tang Y, 1999, MOL CELL BIOL, V19, P1881; Teruel T, 1998, J CELL PHYSIOL, V176, P99, DOI 10.1002/(SICI)1097-4652(199807)176:1<99::AID-JCP12>3.3.CO;2-6; TILLY JL, 1995, ENDOCRINOLOGY, V136, P242, DOI 10.1210/en.136.1.242; Tsakiridis T, 1996, J BIOL CHEM, V271, P19664, DOI 10.1074/jbc.271.33.19664; Valverde AM, 1997, MOL ENDOCRINOL, V11, P595, DOI 10.1210/me.11.5.595; Valverde AM, 1997, ENDOCRINOLOGY, V138, P3195, DOI 10.1210/en.138.8.3195; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Zarich N, 2000, ONCOGENE, V19, P5872, DOI 10.1038/sj.onc.1203955; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	63	56	61	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3739	3753		10.1038/sj.onc.1205469	http://dx.doi.org/10.1038/sj.onc.1205469			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032842				2022-12-17	WOS:000175676000009
J	Guan, BX; Yue, P; Lotan, R; Sun, SY				Guan, BX; Yue, P; Lotan, R; Sun, SY			Evidence that the human death receptor 4 is regulated by activator protein 1	ONCOGENE			English	Article						DR4; AP-1; death receptors; gene expression; apoptosis	APOPTOSIS-INDUCING LIGAND; LUNG-CARCINOMA CELLS; FAS LIGAND; IN-VIVO; TRAIL; AP-1; EXPRESSION; INDUCTION; CANCER; AGENTS	Death receptor 4 (DR4; also called TRAIL-RI), a member of the tumor necrosis factor receptor superfamily, is a cell surface receptor that triggers the apoptotic machinery upon binding to its ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Although several chemotherapeutic agents were reported to induce DR4 expression, the mechanism of this effect remains largely unknown. To begin to understand its regulation, we cloned a 1.8 Kb 5'-flanking region of the human DR4 gene and identified several putative binding sites for transcription factors including activator protein I (AP-1). Among the three putative AP-1 binding sites, the site located at -350/-344 is functionally active as evidenced by a combination of electrophoretic mobility shift and luciferase reporter assays. The AP-1 activator phorbol 12-myristate 13-acetate (TPA) enhanced the binding of this DR4 AP-1 binding site to protein(s) in a nuclear extract from TPA-treated cells, increased luciferase activity of a reporter construct containing this site and induced DR4 expression at the transcription level. These results indicate that AP-1 regulates DR4 expression via the AP-1 binding site located at -350/-344. AP-1 has been implicated in many critical cellular processes including apoptosis, and is a major target of the c-Jun NH3-terminal kinase signaling pathway that is activated by many anticancer drugs. Therefore, our findings may increase the understanding of the mechanisms underlying AP-1-mediated apoptosis as well as drug-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Sun, SY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Fan MY, 2001, CANCER RES, V61, P4450; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Fricker J, 1999, MOL MED TODAY, V5, P374, DOI 10.1016/S1357-4310(99)01555-5; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kim JH, 2000, INTELL AUTOM SOFT CO, V6, P3, DOI 10.1080/10798587.2000.10768155; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Nagane M, 2000, CANCER RES, V60, P847; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Ozoren N, 2000, INT J ONCOL, V16, P917; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sambrook J., 1989, MOL CLONING LAB MANU, P79; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin MS, 2001, CANCER RES, V61, P4942; Sun SY, 1999, ONCOGENE, V18, P2357, DOI 10.1038/sj.onc.1202543; Sun SY, 1997, CANCER RES, V57, P4931; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247	39	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 9	2002	21	20					3121	3129		10.1038/sj.onc.1205430	http://dx.doi.org/10.1038/sj.onc.1205430			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082627				2022-12-17	WOS:000175373600003
J	Hurd, C; Waldron, RT; Rozengurt, E				Hurd, C; Waldron, RT; Rozengurt, E			Protein kinase D complexes with C-Jun N-terminal kinase via activation loop phosphorylation and phosphorylates the C-Jun N-terminus	ONCOGENE			English	Article						protein kinase D; c-Jun N-terminal kinase; c-Jun phosphorylation	NECROSIS-FACTOR-ALPHA; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; INTACT-CELLS; MU; JNK; IDENTIFICATION; INVOLVEMENT; EXPRESSION; SUPPRESS	Protein kinase D (PKD), a downstream effector of protein kinase C (PKC), is implicated in suppression of the c-Jun N-terminal kinase (JNK) signaling pathway, however, its mechanism of action is unclear. Transphosphorylation of the PKD activation loop at serines 744/ 748 by a PKC mediated signal transduction pathway enhances its catalytic activity. Here we show that PKD activation loop phosphorylation at serines 744/748 via PKC, or mutation of these serines to glutamic acid (PKD-S744/748E) also results in complex formation with JNK, indicating that suppression of JNK signaling by PKD involves a direct interaction with JNK. Because catalytically active PKD associates with JNK we determined whether it could phosphorylate the e-Jun N-terminus as a potential mechanism by which it suppresses c-Jun Ser 63 phosphorylation when it complexes with JNK. Purified human PKD and either wild-type PKD from phorbol 12, 13-dibutyrate (PDB)-stimulated cells or unstimulated constitutively active PKD (PKD-S744/ 748E), phosphorylated the c-Jun N-terminus between amino acids 1-89 at sites distinct from those phosphorylated by JNK. These results demonstrate, for the first time, phosphorylation dependent association of PKD with another signaling molecule and reveal a potential mechanism by which PKD could modulate the ability of JNK to phosphorylate e-Jun by phosphorylating alternative sites in the c-Jun N-terminus when it is complexed with JNK.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis,Unit Signal Transduct & Gastronint, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Digest Dis,Unit Signal Transduct & Gastronint, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002	NCI NIH HHS [P50 CA90388-01] Funding Source: Medline; NIDDK NIH HHS [K01 DK 02834-01, DK 55003, DK56930] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, K01DK002834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akkaraju GR, 2000, BIOCHEM BIOPH RES CO, V279, P103, DOI 10.1006/bbrc.2000.3903; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Chen CY, 1998, J BIOL CHEM, V273, P16700, DOI 10.1074/jbc.273.27.16700; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Guo BC, 2001, CELL RES, V11, P101, DOI 10.1038/sj.cr.7290074; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Hurd C, 2001, BIOCHEM BIOPH RES CO, V282, P404, DOI 10.1006/bbrc.2001.4591; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johannes FJ, 1999, FEBS LETT, V461, P68, DOI 10.1016/S0014-5793(99)01424-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Paolucci L, 2000, AM J PHYSIOL-CELL PH, V278, pC33, DOI 10.1152/ajpcell.2000.278.1.C33; Ruiz-Ruiz C, 1999, J IMMUNOL, V163, P4737; Shinohara H, 2001, BIOCHEM BIOPH RES CO, V284, P1162, DOI 10.1006/bbrc.2001.5104; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Waldron RT, 1999, ELECTROPHORESIS, V20, P382, DOI 10.1002/(SICI)1522-2683(19990201)20:2<382::AID-ELPS382>3.0.CO;2-N; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; ZHUKOVA E, 2001, J BIOL CHEM, V20, P20; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	37	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2154	2160		10.1038/sj.onc.1205290	http://dx.doi.org/10.1038/sj.onc.1205290			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948398	Bronze			2022-12-17	WOS:000174555300004
J	Morrison, BH; Bauer, JA; Hu, JD; Grane, RW; Ozdemir, AM; Chawla-Sarkar, M; Gong, BD; Almasan, A; Kalvakolanu, DV; Lindner, DJ				Morrison, BH; Bauer, JA; Hu, JD; Grane, RW; Ozdemir, AM; Chawla-Sarkar, M; Gong, BD; Almasan, A; Kalvakolanu, DV; Lindner, DJ			Inositol hexakisphosphate kinase 2 sensitizes ovarian carcinoma cells to multiple cancer therapeutics	ONCOGENE			English	Article						inositol hexakisphosphate kinase; apoptosis; radiation; interferon	IONIZING-RADIATION; APOPTOSIS; INDUCTION; EXPRESSION; RECEPTORS; CASPASE-8; BINDING; LIGAND; TRAIL; IDENTIFICATION	dWe recently identified inositol hexakisphosphate kinase 2 (IP6K2) as a positive regulator of apoptosis. Overexpression of IP6K2 enhances apoptosis induced by interferon-beta (IFN-beta) and cytotoxic agents in NIH-OVCAR-3 ovarian carcinoma cells. In this study, we contrast and compare IFN-beta and radiation-induced death, and show that IP6K2 expression sensitizes tumor cells. Unirradiated NIH-OVCAR-3 cells transfected with IP6K2 formed fewer colonies compared to unirradiated vector-expressing cells. IP6K2 overexpression caused increased radiosensitivity, evidenced by decreased colony forming units (CFU). Both IFN-beta and radiation induced caspase 8. IFN-beta, but not gamma-irradiation, induced TRAIL in NIH-OVCAR-3 cells. Gamma irradiation, but not IFN-beta, induced DR4 mRNA. Apoptotic effects of IFN-beta or gamma-irradiation were blocked by expression of a dominant negative mutant death receptor 5 (DR5Delta) or by Bcl-2. Caspase-8 mRNA induction was more pronounced in IP6K2-expressing cells compared to vector-expressing cells. These data suggest that overexpression of IP6K2 enhances sensitivity of some ovarian carcinomas to radiation and IFN-beta. IP6K2 may function to enhance the expression and/or function of caspase 8 and DR4 following cell injury. Both IFN-beta and gamma-irradiation induce apoptosis through the extrinsic, receptor-mediated pathway, IFN-beta through TRAIL, radiation through DR4, and both through caspase 8. The function of both death inducers is positively regulated by IP6K2.	Cleveland Clin Fdn, Ctr Canc Drug Discovery & Dev, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Maryland; University of Maryland Baltimore	Lindner, DJ (corresponding author), 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.	lindned@cc.ccf.org	Almasan, Alex/C-2715-2008; Lindner, Daniel/ABB-5440-2020	Almasan, Alex/0000-0002-8916-6650; Bauer, Joseph/0000-0003-4972-6008	NCI NIH HHS [R01 CA082858-02, R01 CA081504, CA71401, CA81504, R01 CA081504-02, R01 CA082858, R01 CA078282, CA82858, R01 CA081504-03, R01 CA082858-01, CA78282, R01 CA095020-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082858, R01CA081504, R01CA071401, R01CA078282, R01CA095020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Gaidarov I, 1999, EMBO J, V18, P871, DOI 10.1093/emboj/18.4.871; Gong BD, 2000, CANCER RES, V60, P5754; Guan BX, 2001, J CELL PHYSIOL, V188, P98, DOI 10.1002/jcp.1101; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mehrotra B, 2000, BIOCHEMISTRY-US, V39, P9679, DOI 10.1021/bi000487o; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; MURAKAMI M, 1995, EUR J ENDOCRINOL, V133, P80, DOI 10.1530/eje.0.1330080; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; RIMESSI P, 1994, ONCOGENE, V9, P3467; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Taneja N, 2001, ONCOGENE, V20, P167, DOI 10.1038/sj.onc.1204054; Togashi S, 1997, BIOCHEM J, V326, P221, DOI 10.1042/bj3260221; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; YAGINUMA Y, 1992, CANCER RES, V52, P4196; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; Yount GL, 2001, ONCOGENE, V20, P2826, DOI 10.1038/sj.onc.1204393; Zhang HF, 1999, EXP CELL RES, V247, P133, DOI 10.1006/excr.1998.4329	35	56	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1882	1889		10.1038/sj.onc.1205265	http://dx.doi.org/10.1038/sj.onc.1205265			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896621	Green Accepted			2022-12-17	WOS:000174284500011
J	Pavey, S; Russell, T; Gabrielli, B				Pavey, S; Russell, T; Gabrielli, B			G2 phase cell cycle arrest in human skin following UV irradiation	ONCOGENE			English	Article						p16; UV; skin; G2 checkpoint	ULTRAVIOLET-RADIATION; HUMAN MELANOCYTES; G(1) ARREST; HUMAN KERATINOCYTES; MSH RECEPTORS; GROWTH-FACTOR; DNA-DAMAGE; EXPRESSION; KINASE; MELANOGENESIS	The contribution of the short wavelength ultraviolet (UV) component of sunlight to the aetiology of skin cancer has been widely acknowledged, although its direct contribution to tumour initiation or progression is still poorly understood. The loss of normal cell cycle controls, particularly checkpoint controls, are a common feature of cancer. UV radiation causes both GI and G2 phase checkpoint arrest in vitro cultured cells. In this study we have investigated the cell cycle responses to suberythemal doses of UV on skin. We have utilized short-term whole organ skin cultures, and multi parameter immunohistochemical and biochemical analysis to demonstrate that basal and suprabasal layer melanocytes and keratinocytes undergo a G2 phase cell cycle arrest for up to 48 h following irradiation. The arrest is associated with increased p16 expression but no apparent p53 involvement. This type of organ culture provides a very useful model system, combining the ease of in vitro manipulation with the ability to perform detailed molecular analysis in a normal tissue environment.	Univ Queensland, Sch Med, Dept Pathol, Joint Expt Oncol Program, Brisbane, Qld 4006, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Joint Expt Oncol Program, Herston Rd, Brisbane, Qld 4006, Australia.		Gabrielli, Brian G/B-3655-2011; Pavey, Sandra/B-3662-2011	Gabrielli, Brian G/0000-0003-3933-1651; Pavey, Sandra/0000-0003-4519-5932				CAMPBELL C, 1993, CANCER RES, V53, P2697; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; CHAKRABORTY A, 1993, J CELL PHYSIOL, V157, P344, DOI 10.1002/jcp.1041570218; Chakraborty AK, 1999, ANN NY ACAD SCI, V885, P100; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; FREEMAN SE, 1987, J INVEST DERMATOL, V88, P430, DOI 10.1111/1523-1747.ep12469778; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; Gabrielli BG, 1997, J BIOL CHEM, V272, P28607, DOI 10.1074/jbc.272.45.28607; Gabrielli BG, 1997, ONCOGENE, V15, P749, DOI 10.1038/sj.onc.1201254; Haddad MM, 1999, EXP CELL RES, V253, P561, DOI 10.1006/excr.1999.4688; HERZINGER T, 1995, ONCOGENE, V11, P2151; HONIGSMANN H, 1987, J PHOTOCH PHOTOBIO B, V1, P33, DOI 10.1016/1011-1344(87)80004-0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Im SB, 1998, CANCER RES, V58, P47; IYENGAR B, 1994, MELANOMA RES, V4, P293; LEY KD, 1992, CARCINOGENESIS, V13, P183, DOI 10.1093/carcin/13.2.183; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCLANE JA, 1988, BIOCHEMISTRY-US, V27, P3743, DOI 10.1021/bi00410a033; MEDRANO EE, 1995, CANCER RES, V55, P4047; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; Pavey S, 1999, CANCER RES, V59, P4185; Petrocelli T, 1996, ONCOGENE, V12, P1387; QUEVEDO WC, 1969, AM ZOOL, V9, P531; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Soufir N, 1999, ONCOGENE, V18, P5477, DOI 10.1038/sj.onc.1202915; Tada A, 1998, CELL GROWTH DIFFER, V9, P575; TAM SW, 1994, CANCER RES, V54, P5816; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; Wang XQ, 1996, CANCER RES, V56, P2510; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; Wikonkal NM, 1999, J INVEST DERM SYMP P, V4, P6, DOI 10.1038/sj.jidsp.5640173; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	40	56	59	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6103	6110		10.1038/sj.onc.1204707	http://dx.doi.org/10.1038/sj.onc.1204707			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593418				2022-12-17	WOS:000171206300001
J	Abe, K; Hirai, M; Mizuno, K; Higashi, N; Sekimoto, T; Miki, T; Hirano, T; Nakajima, K				Abe, K; Hirai, M; Mizuno, K; Higashi, N; Sekimoto, T; Miki, T; Hirano, T; Nakajima, K			The YXXQ motif in gp 130 is crucial for STAT3 phosphorylation at Ser727 through an H7-sensitive kinase pathway	ONCOGENE			English	Article						STAT3; ser phosphorylation; IL-6; gp 130; YXXQ motif; transcription	TRANSCRIPTIONALLY ACTIVE STAT1; CYTOKINE RECEPTOR GP130; IL-6 RESPONSE ELEMENT; CRE-LIKE SITE; SERINE PHOSPHORYLATION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; JUNB PROMOTER; GROWTH ARREST	The signal transducer and activator of transcription (STAT) 3 is essential for mediating signals from the receptors for a variety of cytokines and growth factors, including IL-6 and EGF, and from cytoplasmic tyrosine kinases, Upon stimulation, STAT3 is phosphorylated at Ser727 and Tyr705, However, the role of phosphorylation at Ser727, and the kinase pathways responsible for this phosphorylation in IL-6 signaling remain obscure. Here we show that IL-6 activates at least two distinct STAT3 serine kinase pathways and that an H7-sensitive pathway is dominant over a PD98059-sensitive one in HepG2 cells stimulated with a low concentration of IL-6, The analysis, using a series of chimeric receptors containing the extracellular domain of the G-CSF receptor, the truncated form of gp 130, and additional short peptides at the gp 130 carboxy-terminus, shelved that the YXXQ motif of gp 130 was sufficient for the H7-sensitive STAT3 Ser727 phosphorylation, This YXXQ-mediated pathway does not involve Erk, p38, JNK, or PKC delta, and requires a site in the region from 533 to 711 of STAT3 for phosphorylation in vivo. Moreover, we show that Ser727 is required for full transcriptional activity of STAT3 for two different response elements, Thus, the YXXQ motif regulates STAT3 activities in two ways in response to even a low concentration of IL-6: it recruits STAT3 to the receptor for tyrosine phosphorylation, and activates an unidentified H7-sensitive pathway leading to the serine phosphorylation of STAT3.	Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Oncol, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University	Nakajima, K (corresponding author), Osaka City Univ, Grad Sch Med, Dept Immunol, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.		Hirano, Toshio/C-8194-2009					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Chakraborty A, 1999, BLOOD, V93, P15, DOI 10.1182/blood.V93.1.15.401a46_15_24; Cho SS, 1996, J IMMUNOL, V157, P4781; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; COFFER P, 1995, ONCOGENE, V10, P985; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kojima H, 1996, ONCOGENE, V12, P547; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Schaefer LK, 1999, BIOCHEM BIOPH RES CO, V266, P481, DOI 10.1006/bbrc.1999.1853; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STAHL N, 1994, SCIENCE, V263, P91; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uddin S, 1997, J IMMUNOL, V158, P2390; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	55	56	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2001	20	27					3464	3474		10.1038/sj.onc.1204461	http://dx.doi.org/10.1038/sj.onc.1204461			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429693				2022-12-17	WOS:000169478300002
J	Jopling, CL; Willis, AE				Jopling, CL; Willis, AE			N-myc translation is initiated via an internal ribosome entry segment that displays enhanced activity in neuronal cells	ONCOGENE			English	Article						N-myc; translation initiation; IRES; neuronal	FACTOR MESSENGER-RNA; HUMAN NEUROBLASTOMA-CELLS; C-MYC; ALTERNATIVE TRANSLATION; MURINE DEVELOPMENT; RETINOIC ACID; SITE; EXPRESSION; GROWTH; PROTEIN	Eukaryotic translation can be initiated either by a cap-dependent mechanism or by internal ribosome entry, a process by which ribosomes are directly recruited to structured regions of mRNA upstream of the initiation codon, We analysed the 5' untranslated region (UTR) of the proto-oncogene N-myc, and demonstrated by transfections in a dicistronic vector system that it contains a potent internal ribosome entry segment (IRES), The IRES is similar in length to the c-myc [RES and the activities of these IRESs are comparable in non-neuronal cells. Transfections were also carried out in cell lines derived from neuroblastomas, in which N-myc is expressed, and in a neuronal precursor cell line. In these cells the N-myc IRES is up to seven times more active than that of c-myc, suggesting that neuronal-specific non-canonical trans-acting factors are used by the N-myc but not the c-myc IRES, N-myc expression is increased by gene amplification in many neuroblastomas, but this is the first example of a translational mechanism by which N-myc expression could be further increased. The discovery of an IRES that displays enhanced activity in neuronal cell lines has important potential as a tool for protein expression in neural tissue.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Willis, AE (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Jopling, Catherine/0000-0001-6046-1456; Willis, Anne/0000-0002-1470-8531				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Dang CV, 1999, MOL CELL BIOL, V19, P1; Derrington EA, 1999, HUM GENE THER, V10, P1129, DOI 10.1089/10430349950018120; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IBSON JM, 1988, ONCOGENE, V2, P399; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; KATOH K, 1988, NUCLEIC ACIDS RES, V16, P3589, DOI 10.1093/nar/16.8.3589; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; Lutz W, 1998, ONCOGENE, V17, P339, DOI 10.1038/sj.onc.1200201; Lutz W, 1996, ONCOGENE, V13, P803; Malynn BA, 2000, GENE DEV, V14, P1390; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pilipenko EV, 2000, GENE DEV, V14, P2028; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SHEA TB, 1994, NEUROREPORT, V5, P797, DOI 10.1097/00001756-199403000-00015; Sivak LE, 1999, MOL CELL BIOL, V19, P155; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SUGIYAMA A, 1991, ONCOGENE, V6, P2027; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	56	57	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2664	2670		10.1038/sj.onc.1204404	http://dx.doi.org/10.1038/sj.onc.1204404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420678				2022-12-17	WOS:000168652600007
J	Kalma, Y; Marash, L; Lamed, Y; Ginsberg, D				Kalma, Y; Marash, L; Lamed, Y; Ginsberg, D			Expression analysis using DNA microarrays demonstrates that E2F-1 up-regulates expression of DNA replication genes including replication protein A2	ONCOGENE			English	Article						E2F; cell cycle; DNA chips; RPA	NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CELL-CYCLE; TOPOISOMERASE-II; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; DEREGULATED EXPRESSION; MAMMALIAN CDC6	The transcription factor E2F-1 plays a pivotal role in the regulation of G1/S transition in higher eukaryotes cell cycle. We used a cell line containing an inducible E2F-1 and oligonucleotide microarray analysis to identify novel E2F target genes. We show that E2F-1 up-regulates the expression of a number of genes coding for components of the DNA replication machinery. Among them is the gene coding for the 32 Kd subunit of replication protein A (RPA2). Replication protein A is the most abundant single strand DNA binding complex and it is essential for DNA replication. We demonstrate that RPA2 is a novel E2F target gene whose expression can be directly regulated by E2F-1 via E2F binding sites in its promoter. In addition, expression of Topoisomerase II alpha and subunit IV of DNA polymerase alpha is also up-regulated upon E2F-1 induction. Taken together, these results provide novel links between components of the DNA replication machinery and the cell growth regulatory pathway involving the Rb tumor suppressor and E2F.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			ginsberg, doron/0000-0002-1257-4920				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Blattner C, 1999, MOL CELL BIOL, V19, P3704; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FANG F, 1993, J CELL SCI, V106, P983; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HASEGAWA T, 1993, BIOCHEM BIOPH RES CO, V195, P409, DOI 10.1006/bbrc.1993.2058; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KENNY MK, 1990, J BIOL CHEM, V265, P769; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; LI L, 1995, MOL CELL BIOL, V15, P5396; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nishikawa NS, 2000, NUCLEIC ACIDS RES, V28, P1525, DOI 10.1093/nar/28.7.1525; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOESSNER RD, 1991, CELL GROWTH DIFFER, V2, P209; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	51	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1379	1387		10.1038/sj.onc.1204230	http://dx.doi.org/10.1038/sj.onc.1204230			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313881				2022-12-17	WOS:000167495000011
J	Maeda, R; Mood, K; Jones, TL; Aruga, J; Buchberg, AM; Daar, IO				Maeda, R; Mood, K; Jones, TL; Aruga, J; Buchberg, AM; Daar, IO			Xmeis1, a protooncogene involved in specifying neural crest cell fate in Xenopus embryos	ONCOGENE			English	Article						Xmeis1; neural crest; homeodomain; Xenopus	HEDGEHOG SIGNALING PATHWAY; COOPERATIVE DNA-BINDING; HOMEOBOX GENES; FLOOR PLATE; MESSENGER-RNA; GLI PROTEINS; NUCLEAR-LOCALIZATION; ZIC FAMILY; HOX GENES; EXPRESSION	Meis1 (Myeloid Ecotropic viral Integration Site 1) is a homeobox gene that was originally isolated as a common site of viral integration in myeloid tumors of the BXH-2 recombinant inbred mice strain. We previously isolated a Xenopus homolog of Meis1 (Xmeis1), Here we show that Xmeis1 may play a significant role in neural crest development. In developing Xenopus embryos, Xmeis1 displays a broad expression pattern, but strong expression is observed in tissue of neural cell fate, such as midbrain, hindbrain, the dorsal portion of the neural tube, and neural crest derived branchial arches. In animal cap explants, overexpression of Xmeis1b, an alternatively spliced form of Ymeis1, induces expression of neural crest marker genes in the absence of mesoderm, Moreover, Xmeis1b induces XGli-3 and XZic3, pre-pattern genes involved at the earliest stages of neural crest development, and like these two genes, can induce ectopic pigmented cell masses when overexpressed in developing embryos. Misexpression of Ymeis1b also induces ectopic expression of neural crest markers along the antero-posterior axis of the neural tube in developing Xenopus embryos. In contrast, Xmeis1a, another splice variant, is much less effective at inducing these effects. These data suggest that Xmeis1b is involved in neural crest cell fate specification during embryogenesis, and can functionally intersect with the Gli/Zic signal transduction pathway.	NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); RIKEN; Jefferson University	Daar, IO (corresponding author), NCI, Regulat Cell Growth Lab, Bldg 560 Room 22-3, Frederick, MD 21702 USA.		Aruga, Jun/H-5837-2011	Aruga, Jun/0000-0001-7936-1375; Buchberg, Arthur/0000-0002-0543-5631; Daar, Ira/0000-0003-2657-526X	NCI NIH HHS [N01-CO-5600] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; BRADLEY LC, 1993, MECH DEVELOP, V40, P73, DOI 10.1016/0925-4773(93)90089-G; Brewster R, 1998, NATURE, V393, P579, DOI 10.1038/31242; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Ding Q, 1998, DEVELOPMENT, V125, P2533; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kurant E, 1998, DEVELOPMENT, V125, P1037; LaBonne C, 1999, ANNU REV CELL DEV BI, V15, P81, DOI 10.1146/annurev.cellbio.15.1.81; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; LEVINE M, 1988, CELL, V55, P537, DOI 10.1016/0092-8674(88)90209-7; LU QA, 1995, MOL CELL BIOL, V15, P3786; Maeda R, 1997, DEVELOPMENT, V124, P2553; Mancilla A, 1996, DEV BIOL, V177, P580, DOI 10.1006/dbio.1996.0187; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marine JC, 1997, MECH DEVELOP, V63, P211, DOI 10.1016/S0925-4773(97)00050-6; Matise MP, 1999, ONCOGENE, V18, P7852, DOI 10.1038/sj.onc.1203243; Matise MP, 1998, DEVELOPMENT, V125, P2759; Mayor R, 1999, CURR TOP DEV BIOL, V43, P85; MAYOR R, 1995, DEVELOPMENT, V121, P767; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297-105; MCGREW LL, 1995, DEV BIOL, V172, P337, DOI 10.1006/dbio.1995.0027; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; MIYATANI S, 1986, J CELL BIOL, V103, P1957, DOI 10.1083/jcb.103.5.1957; Mizuseki K, 1998, NEURON, V21, P77, DOI 10.1016/S0896-6273(00)80516-4; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nakata K, 1998, MECH DEVELOP, V75, P43, DOI 10.1016/S0925-4773(98)00073-2; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; Nakata K, 2000, MECH DEVELOP, V99, P83, DOI 10.1016/S0925-4773(00)00480-9; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; SALZBERG A, 1994, NEURON, V13, P269, DOI 10.1016/0896-6273(94)90346-8; Salzberg A, 1999, MECH DEVELOP, V80, P3, DOI 10.1016/S0925-4773(98)00187-7; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, MOL CELL BIOL, V17, P6448, DOI 10.1128/MCB.17.11.6448; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; SUZUKI A, 1993, ZOOL SCI, V10, P175; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Tada M, 1997, DEVELOPMENT, V124, P2225; Theil T, 1998, DEVELOPMENT, V125, P443; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; Wallingford JB, 1999, TRENDS GENET, V15, P385, DOI 10.1016/S0168-9525(99)01800-4; Wicking C, 1999, ONCOGENE, V18, P7844, DOI 10.1038/sj.onc.1203282; WINNING RS, 1991, NUCLEIC ACIDS RES, V19, P3709, DOI 10.1093/nar/19.13.3709; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; Yang SS, 1998, J BIOL CHEM, V273, P13746, DOI 10.1074/jbc.273.22.13746; ZIMMERMAN K, 1993, DEVELOPMENT, V119, P221	81	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1329	1342		10.1038/sj.onc.1204250	http://dx.doi.org/10.1038/sj.onc.1204250			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313877				2022-12-17	WOS:000167495000007
J	Garcia-Cuellar, MP; Zilles, O; Schreiner, SA; Birke, M; Winkler, TH; Slany, RK				Garcia-Cuellar, MP; Zilles, O; Schreiner, SA; Birke, M; Winkler, TH; Slany, RK			The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3	ONCOGENE			English	Article						leukemia; MLL; translocation; ENL; polycomb	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTORS; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; MUTANT MICE; ALL-1 GENE; HRX-ENL; PROTEIN; FUSION; TRANSFORMATION	The translocation t(11;19) is frequently found in acute leukemia in infants. This event truncates the protooncogene MLL and fuses the 5' end of MLL in frame with the ENL gene. ENL contributes a crucial protein-protein interaction domain to the resulting oncoprotein MLL-ENL. Here we show by yeast two-hybrid assays, GST-pull-down experiments and in a far western blot analysis that this domain is necessary and sufficient to recruit a novel member of the human Polycomb protein family (hPc3), hPc3 RNA was detected throughout the human hematopoietic system. Similar to other Polycomb proteins hPc3 acts as a transcriptional repressor. The ENL-hPc3 interaction was verified by mutual coprecipitation of the proteins from cell extracts. ENL and hPc3 tagged with fluorescent proteins co-localized in living cells in a nuclear dot pattern. An internal region of hPc3 was responsible for binding to ENL. Finally, hPc3 binds to the C-terminus of AF9, another common MLL fusion partner. The recruitment of a repressive function by ENL opens up a new insight into a possible mechanism of leukemogenesis by the fusion protein MLL-ENL.	Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Internal Med 3, Div Mol Immunol, D-91056 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5, D-91058 Erlangen, Germany.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Fidanza V, 1996, CANCER RES, V56, P1179; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Garcia-Cuellar MP, 2000, ONCOGENE, V19, P1744, DOI 10.1038/sj.onc.1203506; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hemenway CS, 2000, GENE, V242, P31, DOI 10.1016/S0378-1119(99)00540-5; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; IIDA S, 1993, ONCOGENE, V8, P3085; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; James P, 1996, GENETICS, V144, P1425; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slack JL, 1999, CANC TREAT, V99, P75; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yano T, 1997, P NATL ACAD SCI USA, V94, P7286, DOI 10.1073/pnas.94.14.7286; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	39	56	59	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					411	419		10.1038/sj.onc.1204108	http://dx.doi.org/10.1038/sj.onc.1204108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313972				2022-12-17	WOS:000166562500001
J	Gatei, M; Shkedy, D; Khanna, KK; Uziel, T; Shiloh, Y; Pandita, TK; Lavin, MF; Rotman, G				Gatei, M; Shkedy, D; Khanna, KK; Uziel, T; Shiloh, Y; Pandita, TK; Lavin, MF; Rotman, G			Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by alpha-lipoic acid	ONCOGENE			English	Article						ataxia-telangiectasia; ATM; p53; p21(WAF1/CIP1); cdc2; alpha-lipoic acid; oxidative stress	DOUBLE-STRAND BREAKS; CELL-CYCLE CHECKPOINTS; ATM-DEFICIENT MICE; DNA-DAMAGE; OXIDATIVE DAMAGE; INDUCED PHOSPHORYLATION; GENOTOXIC STRESS; GENE-PRODUCT; P53; REPAIR	Cells from patients with the genetic disorder ataxia-telangiectasia (A-T) are hypersensitive to ionizing radiation and radiomimetic agents, both of which generate reactive oxygen species capable of causing oxidative damage to DNA and other macromolecules. We describe in A-T cells constitutive activation of pathways that normally respond to genotoxic stress, Basal levels of p53 and p21(WAF1/CIP1), phosphorylation on serine 15 of p53, and the Tyr15-phosphorylated form of cdc2 are chronically elevated in these cells. Treatment of A-T cells with the antioxidant alpha -lipoic acid significantly reduced the levels of these proteins, pointing to the involvement of reactive oxygen species in their chronic activation. These findings suggest that the absence of functional ATM results in a mild but continuous state of oxidative stress, which could account for several features of the pleiotropic phenotype of A-T.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel; PO Royal Melbourne Hosp, Queensland Inst Med Res, Queensland Canc Fund Res Labs, Brisbane, Qld 4029, Australia; Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Univ Queensland, PO Royal Melbourne Hosp, Dept Surg, Brisbane, Qld 4029, Australia	Tel Aviv University; Sackler Faculty of Medicine; QIMR Berghofer Medical Research Institute; Royal Melbourne Hospital; Columbia University; Royal Melbourne Hospital; University of Queensland	Rotman, G (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Tel Aviv, Israel.		Lavin, Martin F/F-5961-2014; Khanna, Kum Kum/I-1747-2013; Pandita, Tej K/AAM-9188-2020	Lavin, Martin F/0000-0002-5940-4769; Khanna, Kum Kum/0000-0001-8650-5381	NINDS NIH HHS [NS31763, NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746, R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Appella E, 2000, PATHOL BIOL, V48, P227; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CANMAN CE, 1994, CANCER RES, V54, P5054; CONFORTH MN, 1985, SCIENCE, V227, P1589; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gansauge S, 1997, FEBS LETT, V404, P6, DOI 10.1016/S0014-5793(97)00059-8; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Kachnic LA, 1999, J BIOL CHEM, V274, P13111, DOI 10.1074/jbc.274.19.13111; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Lavin MF, 1998, RADIOTHER ONCOL, V47, P113, DOI 10.1016/S0167-8140(98)00027-9; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; PACKER L, 1995, FREE RADICAL BIO MED, V19, P227, DOI 10.1016/0891-5849(95)00017-R; Pagano G, 1998, MED HYPOTHESES, V51, P253, DOI 10.1016/S0306-9877(98)90084-6; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; PAULES RS, 1995, CANCER RES, V55, P1763; Reichenbach J, 1999, CLIN EXP IMMUNOL, V117, P535; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; SHILOH Y, 1985, ATAXIA TELANGIECTASI, P111; SiddooAtwal C, 1996, CANCER RES, V56, P443; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SINGH SP, 1990, MOL CELL BIOL, V10, P5279, DOI 10.1128/MCB.10.10.5279; TAYLOR AMR, 1989, INT J RADIAT BIOL, V56, P677, DOI 10.1080/09553008914551901; TEALE B, 1993, J BIOL CHEM, V268, P22450; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Varghese S, 1998, ARCH PHARM RES, V21, P640, DOI 10.1007/BF02976750; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Westphal CH, 1997, CANCER RES, V57, P1664; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	50	56	56	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					289	294		10.1038/sj.onc.1204111	http://dx.doi.org/10.1038/sj.onc.1204111			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313957				2022-12-17	WOS:000166411000002
J	Gil, J; Rullas, J; Garcia, MA; Alcami, J; Esteban, M				Gil, J; Rullas, J; Garcia, MA; Alcami, J; Esteban, M			The catalytic activity of dsRNA-dependent protein kinase, PKR, is required for NF-kappa B activation	ONCOGENE			English	Article						PKR; IKK; NF-kappa B; dsRNA	DOUBLE-STRANDED-RNA; IKK-BETA; IN-VIVO; INTERFERON; EXPRESSION; ALPHA; PHOSPHORYLATION; REPLICATION; INHIBITION; COMPLEX	The double stranded RNA-dependent protein kinase (PKR), in addition to its role as a translational controlling factor, is a key transcriptional regulator exerting antiviral and antitumoral activities. We have previously shown that induction of NF-kappaB by PKR is involved in apoptosis commitment and this process is mediated through activation of the IKK complex. To gain insights into the mechanism of activation of NF-kappaB by PKR, we have analysed the domains of PKR involved in IKK activation and subsequent NF-kappaB induction. In PKR0/0 cells infected with a collection of vaccinia virus (VV) recombinants expressing different mutant forms of PKR, we found that only PKR forms conserving the catalytic activity are able to activate NF-kappaB. An inactive PKR mutant (K296R), was unable to induce NF-kappaB activation despite full expression of the protein in a wide range of concentrations, as defined by Western blot, EMSA, IKK kinase activity and NF-kappaB transactivation assays. Moreover, the mutant PKR (K296R) acts as a dominant negative of PKR-induced eIF-2 alpha phosphorylation and NF-kappaB activation. However, PKR mutants unable to activate NF-kappaB still retain their ability to associate with the IKK complex, as confirmed by immunoprecipitation analysis. We conclude that the catalytic activity of PKR and not only a protein-protein interaction with the IKK complex, is needed for activation of the transcription factor NF-kappaB.	CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, E-28049 Madrid, Spain; Inst Salud Carlos III, Ctr Biol Fundamental, AIDS Immunopathogenesis Unit, Madrid 28220, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Instituto de Salud Carlos III	Esteban, M (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Campus Univ Autonoma, E-28049 Madrid, Spain.		Esteban, Mariano/ABG-5375-2020; Gil, Jesus/C-7739-2012; Garcia, Maria Angel MA/I-5116-2016; Alcami, Pepe/T-2242-2018	Esteban, Mariano/0000-0003-0846-2827; Gil, Jesus/0000-0002-4303-6260; Garcia, Maria Angel MA/0000-0003-2003-3769; Alcami, Pepe/0000-0003-0023-7377				Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; ARENZANASEISDEDOS F, 1993, J VIROL, V67, P6596, DOI 10.1128/JVI.67.11.6596-6604.1993; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DiazGuerra M, 1997, VIROLOGY, V227, P220, DOI 10.1006/viro.1996.8294; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; George CX, 1996, VIROLOGY, V221, P180, DOI 10.1006/viro.1996.0364; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 1999, MOL CELL BIOL, V19, P4653; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee SB, 1996, J INTERF CYTOK RES, V16, P1073, DOI 10.1089/jir.1996.16.1073; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; Rivas C, 1999, J INTERF CYTOK RES, V19, P1229, DOI 10.1089/107999099312885; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; Tan SL, 1998, MOL CELL BIOL, V18, P2431, DOI 10.1128/MCB.18.5.2431; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	54	56	61	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					385	394		10.1038/sj.onc.1204109	http://dx.doi.org/10.1038/sj.onc.1204109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313968	Bronze			2022-12-17	WOS:000166411000013
J	Stewart, ZA; Tang, LJ; Pietenpol, JA				Stewart, ZA; Tang, LJ; Pietenpol, JA			Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner	ONCOGENE			English	Article						taxol; vincristine; nocodazole; adriamycin; ionizing radiation; ATM	ACTIVATED PROTEIN-KINASE; DAMAGE-INDUCED PHOSPHORYLATION; TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; SPINDLE DISRUPTION; IN-VITRO; CHECKPOINT; BINDING; MDM2	p53 is present at low levels in unstressed cells. Numerous cellular insults, including DNA damage and microtubule disruption, elevate p53 protein levels. Phosphorylation of p53 is proposed to be important for p53 stabilization and activation after genotoxic stress; however, p53 phosphorylation after microtubule disruption has not been analysed. The goal of the current study was to determine if p53 phosphorylation increases after microtubule disruption, and if so, to identify specific p53 residues necessary for microtubule inhibitor-induced phosphorylation, Two dimensional gel analyses demonstrated that the number of p53 phosphoforms in cells increased after treatment with microtubule inhibitors (MTIs) and that the pattern of p53 phosphorylation was distinct from that observed after DNA damage, p53 phosphorylation also varied in a MTI-dependent manner, as Taxol and Vincristine induced more p53 phospho-forms than nocodazole. Further, MTI treatment increased phosphorylation of p53 on serine-15 in epithelial tumor cells, In contrast, serine-15 phosphorylation of p53 did not increase in MTI-treated primary cultures of human fibroblasts. Analysis of ectopically expressed p53 phospho-mutant proteins from Taxol- and nocodazole-treated cells indicated that multiple p53 amino terminal residues, including serine-15 and threonine-18, were required for Taxol-mediated phosphorylation of p53, Taken together, the results of this study demonstrate that distinct p53 phospho-forms are induced by MTI treatment as compared to DNA damage and that p53 phosphorylation is mediated in a MTI- and cell-specific manner.	Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Pietenpol, JA (corresponding author), Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [R01CA070856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; NCI NIH HHS [CA70856] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347 , +] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hecker D, 1996, ONCOGENE, V12, P953; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Khan SH, 1998, CANCER RES, V58, P396; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lavin MF, 1996, CURR OPIN IMMUNOL, V8, P459, DOI 10.1016/S0952-7915(96)80030-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Mayo LD, 1997, CANCER RES, V57, P5013; MILNE DM, 1992, ONCOGENE, V7, P1361; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stewart ZA, 1999, CANCER RES, V59, P3831; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691	51	56	57	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					113	124		10.1038/sj.onc.1204060	http://dx.doi.org/10.1038/sj.onc.1204060			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244509				2022-12-17	WOS:000166361400013
J	Scully, R; Puget, N; Vlasakova, K				Scully, R; Puget, N; Vlasakova, K			DNA polymerase stalling, sister chromatid recombination and the BRCA genes	ONCOGENE			English	Article						BRCA1; BRCA2; DNA polymerase; genomic integrity; homologous recombination; sister chromatid	DOUBLE-STRAND BREAKS; WERNERS-SYNDROME GENES; CELL-CYCLE REGULATION; BLOOMS-SYNDROME; MEIOTIC CELLS; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; TARGETED DISRUPTION	Heritable predisposition to breast and/or ovarian cancer is determined, in part, by germline mutation affecting one of two tumor suppressor genes, BRCA1 and BRCA2 (Miki et al., 1994; Wooster et al., 1995). These genes are required for the maintenance of genomic integrity and for control of homologous recombination in somatic and meiotic cells. Here, we explore the hypothesis that a major role of the BRCA gene products in the somatic DNA damage response centers upon the control of recombination between sister chromatids during S phase. By analogy with model organisms, we suggest that stalling of a mammalian DNA polymerase complex by its encounter with abnormal DNA structure calls forth a series of responses that collaborate to enforce appropriate recombinational outcomes, and to suppress inappropriate or 'illegitimate' recombination.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Scully, R (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.		PUGET, Nadine/AAB-9689-2020; Scully, Ralph/F-5008-2013	PUGET, Nadine/0000-0003-4046-737X	NATIONAL CANCER INSTITUTE [K01CA079576] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akgun E, 1997, MOL CELL BIOL, V17, P5559, DOI 10.1128/MCB.17.9.5559; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Bertwistle D, 1997, CANCER RES, V57, P5485; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Boddy Michael N., 1999, Frontiers in Bioscience, V4, pd841, DOI 10.2741/Boddy; Bridges BA, 1999, CURR BIOL, V9, pR475, DOI 10.1016/S0960-9822(99)80299-1; Brown EJ, 2000, GENE DEV, V14, P397; Burgess SM, 1999, GENE DEV, V13, P1871, DOI 10.1101/gad.13.14.1871; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x; FORNACE AJ, 1983, NATURE, V304, P552, DOI 10.1038/304552a0; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; HAND R, 1977, HUM GENET, V38, P297, DOI 10.1007/BF00402156; HOWARD-FLANDERS P., 1966, Radiation Research, V6, P156, DOI 10.2307/3583555; HUANG CC, 1975, P SOC EXP BIOL MED, V148, P1244; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KADYK LC, 1992, GENETICS, V132, P387; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; KLEIN HL, 1995, BIOESSAYS, V17, P147, DOI 10.1002/bies.950170210; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LEHMANN AR, 1972, J MOL BIOL, V66, P319, DOI 10.1016/0022-2836(72)90418-4; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Merrill BJ, 1998, GENETICS, V148, P611; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTEIRO ANA, 2000, IN PRESS TRENDS BIOC; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; RUPP WD, 1968, J MOL BIOL, V31, P291, DOI 10.1016/0022-2836(68)90445-2; SARASIN AR, 1980, J MOL BIOL, V138, P299, DOI 10.1016/0022-2836(80)90288-0; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SMITH KC, 1970, J MOL BIOL, V51, P459, DOI 10.1016/0022-2836(70)90001-X; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Vaughn JP, 1996, CANCER RES, V56, P4590; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang Y, 2000, GENE DEV, V14, P927; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; WU X, 2000, SCIENCE, V289, pA11; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	80	56	60	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6176	6183		10.1038/sj.onc.1203971	http://dx.doi.org/10.1038/sj.onc.1203971			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156531				2022-12-17	WOS:000166121400011
J	Wu, CJ; Chen, ZJ; Ullrich, A; Greene, MI; O'Rourke, DM				Wu, CJ; Chen, ZJ; Ullrich, A; Greene, MI; O'Rourke, DM			Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs)	ONCOGENE			English	Article						apoptosis; erbB; EGFR; phosphoinositide-3-OH kinase (PI3-K); SHP2; Signal-Regulatory Proteins (SIRPs)	EPIDERMAL GROWTH-FACTOR; TYROSINE-PHOSPHATASE SHP-2; CONFERS ENHANCED TUMORIGENICITY; PHOSPHORYLATED 100-KDA PROTEIN; SRC HOMOLOGY-2 DOMAINS; TUMOR-SUPPRESSOR PTEN; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GLIOMA-CELLS; ERBB FAMILY	Several growth factors and cytokines, including EGF, are known to induce tyrosine phosphorylation of Signal Regulatory Proteins (SIRPs). Consistent with the idea that increased phosphorylation activates SIRP function, we overexpressed human SIRP alpha 1 in U87MG glioblastoma cells in order to examine how SIRP alpha 1 modulates EGFR signaling pathways. Endogenous EGFR proteins are overexpressed in U87MG cells and these cells exhibit survival and motility phenotypes that are influenced by EGFR kinase activity. Overexpression of the SIRP alpha 1 cDNA diminished EGF-induced phosphoinositide-3-OH kinase (PI3-K) activation in U87MG cells. Reduced EGF-stimulated activation of PI3-K was mediated by interactions between carboxyl terminus of SIRP alpha 1 and the Src homology-2 (SH2)-containing phosphotyrosine phosphatase, SHP2. SIRP alpha 1 overexpression also reduced the EGF-induced association between SHP2 and the p85 regulatory subunit of PI3-K. Inhibition of transformation and enhanced apoptosis following gamma-irradiation were observed in SIRP alpha 1-overexpressing U87MG cells, and enhanced apoptosis was associated with reduced levels of bcl-x(L) protein. Furthermore, SIRP alpha 1-overexpressing U87MG cells displayed reduced cell migration and cell spreading that was mediated by association between SIRP alpha 1 and SHP2. However, SIRP alpha 1-overexpressing U87MG clonal derivatives exhibited no differences in cell growth or levels of mitogen-activated protein kinase (MAPK) activation. These data reveal a pathway that negatively regulates EGFR-induced PI3-K activation in glioblastoma cells and involves interactions between SHP2 and tyrosine phosphorylated SIRP alpha 1. These results also suggest that negative regulation of PI3-K pathway activation by the SIRP family of transmembrane receptors may diminish EGFR-mediated motility and survival phenotypes that contribute to transformation of glioblastoma cells.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Ctr, Philadelphia, PA 19104 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China; Univ Penn, Sch Med, Abramson Family Canc Inst, Philadelphia, PA 19104 USA; Philadelphia Vet Adm Med Ctr, Dept Surg Neurosurg, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Max Planck Society; Chinese Academy of Sciences; University of Science & Technology of China, CAS; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 502 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Coggeshall KM, 1999, IMMUNOL RES, V19, P47, DOI 10.1007/BF02786476; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Davies MA, 1998, CANCER RES, V58, P5285; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Manes S, 1999, MOL CELL BIOL, V19, P3125; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; O'Rourke DM, 1998, P NATL ACAD SCI USA, V95, P10842, DOI 10.1073/pnas.95.18.10842; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Okada N, 1996, BIOCHEM BIOPH RES CO, V229, P607, DOI 10.1006/bbrc.1996.1851; ORourke DM, 1997, P ASSOC AM PHYSICIAN, V109, P209; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takahashi Y, 1999, J CELL PHYSIOL, V178, P69, DOI 10.1002/(SICI)1097-4652(199901)178:1<69::AID-JCP9>3.0.CO;2-Z; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tan M, 1999, CANCER RES, V59, P1620; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu CJ, 1999, DNA CELL BIOL, V18, P731, DOI 10.1089/104454999314872; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yamada M, 1999, J NEUROCHEM, V73, P41, DOI 10.1046/j.1471-4159.1999.0730041.x; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959	70	56	59	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3999	4010		10.1038/sj.onc.1203748	http://dx.doi.org/10.1038/sj.onc.1203748			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962556				2022-12-17	WOS:000088825300005
J	Sasaki, S; Ito, E; Toki, T; Maekawa, T; Kanezaki, R; Umenai, T; Muto, A; Nagai, H; Kinoshita, T; Yamamoto, M; Inazawa, J; Taketo, MM; Nakahata, T; Igarashi, K; Yokoyama, M				Sasaki, S; Ito, E; Toki, T; Maekawa, T; Kanezaki, R; Umenai, T; Muto, A; Nagai, H; Kinoshita, T; Yamamoto, M; Inazawa, J; Taketo, MM; Nakahata, T; Igarashi, K; Yokoyama, M			Cloning and expression of human B cell-specific transcription factor BACH2 mapped to chromosome 6q15	ONCOGENE			English	Article						Bach2; Maf; non-Hodgkin's lymphoma; CNC family; NF-E2	SMALL MAF PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; LEUCINE ZIPPER PROTEIN; FACTOR NF-E2; FUNCTIONAL-CHARACTERIZATION; BINDING PROTEINS; GENE-EXPRESSION; DNA-BINDING; LONG ARM; FAMILY	The transcription factor Bach2, a member of the BTB-basic region leucine zipper (bZip) factor family, binds to a 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive element and the related Maf-recognition element (MARE) by forming homodimers or heterodimers with Maf-related transcription factors. Bach2 regulates transcription by binding to these elements. To understand the function in hematopoiesis, lye isolated a cDNA clone for human Bach2 (BACH2) encoding a protein of 841 amino acid residues with a deduced amino acid sequence having 89.5% identity to mouse homolog, Among human hematopoietic cell lines, BACH2 is expressed abundantly only in some B-lymphocytic cell lines. RT-PCR analysis of hematopoietic cells revealed that BACH2 mRNA is expressed in primary B-cells, Enforced expression of BACH2 in a human Burkitt cell line, RAJI that does not express endogenous BACH2, resulted in marked reduction of clonogenic activity, indicating that BACH2 possesses an inhibitory effect on cell proliferation. By fluorescent in situ hybridization, the BACH2 gene was localized to chromosome 6q15. Because deletion of the long arm of chromosome 6 (6q) is one of the commonest chromosomal alterations in human B-cell lymphoma, we examined for the loss of heterozygosity (LOH) of the BACH2 gene in human B-cell non-Hodgkin's lymphomas (NHL). Among 25 informative cases, five (20%) shelved LOH. These results indicate that BACH2 plays important roles in regulation of B cell development.	Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan; Hirosaki Univ, Fac Sci, Dept Biol, Hirosaki, Aomori 0368563, Japan; Univ Tokyo, Inst Med Sci, Dept Transfus Med & Cell Therapy, Minato Ku, Tokyo 1130033, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Tohoku Univ, Sch Med, Dept Biochem, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Oncol, Minato Ku, Tokyo 1130033, Japan; Nagoya Univ, Sch Med, Dept Internal Med 1, Nagoya, Aichi 4668560, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Div Genet,Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Hirosaki University; Hirosaki University; University of Tokyo; University of Tsukuba; University of Tsukuba; Tohoku University; University of Tokyo; Nagoya University; Tokyo Medical & Dental University (TMDU); University of Tokyo	Ito, E (corresponding author), Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan.		Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Ito, Etsuro/0000-0002-0168-2475; Igarashi, Kazuhiko/0000-0002-2470-2475				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; CALIGARISCAPPIO F, 1985, J CLIN INVEST, V76, P1243, DOI 10.1172/JCI112080; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Guan XY, 1996, BLOOD, V88, P1418, DOI 10.1182/blood.V88.4.1418.bloodjournal8841418; HAYASHI Y, 1990, BLOOD, V76, P1626; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IMAI T, 1991, BLOOD, V78, P1969; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P26, DOI 10.1002/gcc.2870100105; Merup M, 1998, BLOOD, V91, P3397, DOI 10.1182/blood.V91.9.3397.3397_3397_3400; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOHLER J, 1995, DEVELOPMENT, V121, P237; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; NAKAO J, 1995, J NEUROCHEM, V64, P2396; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Nishihara M, 1998, EUR J IMMUNOL, V28, P855, DOI 10.1002/(SICI)1521-4141(199803)28:03<855::AID-IMMU855>3.0.CO;2-X; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V91, P9926; OFFIT K, 1993, BLOOD, V82, P2157; OFFIT K, 1994, BLOOD, V83, P2611, DOI 10.1182/blood.V83.9.2611.bloodjournal8392611; Oyake T, 1996, MOL CELL BIOL, V16, P6083; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; Yoshimatsu T, 1998, HUM GENE THER, V9, P161, DOI 10.1089/hum.1998.9.2-161	48	56	67	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3739	3749		10.1038/sj.onc.1203716	http://dx.doi.org/10.1038/sj.onc.1203716			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949928				2022-12-17	WOS:000088568400006
J	Shtrichman, R; Sharf, R; Kleinberger, T				Shtrichman, R; Sharf, R; Kleinberger, T			Adenovirus E4orf4 protein interacts with both B alpha and B ' subunits of protein phosphatase 2A, but E4orf4-induced apoptosis is mediated only by the interaction with B alpha	ONCOGENE			English	Article						protein phosphatase 2A (PP2A); adenovirus E4orf4 protein; apoptosis	CATALYTIC SUBUNIT; REGULATORY SUBUNITS; TRANSFORMED-CELLS; EARLY REGION-4; CORE ENZYME; PP2A; PHOSPHORYLATION; BINDING; KINASE; IDENTIFICATION	Adenovirus E4orf4 protein is a multifunctional viral regulator, which is involved in down regulation of virally-modulated signal transduction, in control of alternative splicing of viral mRNAs? and in induction of apoptosis in transformed cells. It has been previously shown that E4orf4 interacts with protein phosphatase 2A through the phosphatase B alpha subunit. It was further shown that PP2A is required for performing the various E4orf4 functions. We report here that E4orf4 interacts with multiple isoforms of the PP2A-B' subunit, as well as with B alpha. We map the interaction sites of the B subunits on E4orf4 and show that they overlap but are not identical. We identify a dominant negative E4orf4 mutant, which disrupts the PP2A holoenzyme. We show that induction of apoptosis by E4orf4, which we previously reported to require the interaction with B alpha, is not affected by the interaction with B'. Our results suggest that the interaction of E4orf4 with various PP2A subpopulations may mediate the different E4orf4 functions.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinberger, T (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Gonda Ctr Mol Microbiol, POB 9649, IL-31096 Haifa, Israel.							AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Ogris E, 1997, ONCOGENE, V15, P911, DOI 10.1038/sj.onc.1201259; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; SAITO T, 1995, BIOCHEMISTRY-US, V34, P7376, DOI 10.1021/bi00022a010; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 1997, MOL BRAIN RES, V49, P15, DOI 10.1016/S0169-328X(97)00117-4; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Zhao Y, 1997, J BIOL CHEM, V272, P8256, DOI 10.1074/jbc.272.13.8256	48	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2000	19	33					3757	3765		10.1038/sj.onc.1203705	http://dx.doi.org/10.1038/sj.onc.1203705			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949930				2022-12-17	WOS:000088568400008
J	Tsygankova, OM; Kupperman, E; Wen, W; Meinkoth, JL				Tsygankova, OM; Kupperman, E; Wen, W; Meinkoth, JL			Cyclic AMP activates Ras	ONCOGENE			English	Article						cAMP; Ras; proliferation; thyroid cells	DEPENDENT PROTEIN-KINASE; NERVE GROWTH-FACTOR; THYROID EPITHELIAL-CELLS; DNA-SYNTHESIS; THYROGLOBULIN EXPRESSION; NEURITE OUTGROWTH; SIGNALING PATHWAY; CAMP; RAP1; INHIBITION	In addition to protein kinase A (PKA), cAMP regulates the activity of cAMP-gated channels and Rap1-specific guanine nucleotide exchange factors, We tested the hypothesis that the targets of cAMP might also include regulators of the Ras protooncogene. In rat thyroid cells, thyrotropin (TSH) stimulates proliferation through a cAMP-mediated pathway that requires Ras activity, interference with Res impairs DNA synthesis stimulated by TSH as well as cAMP elevating agents and analogs, demonstrating that the requirement for Ras lies down-stream of cAMP. Although cAMP stimulates proliferation, microinjection of the purified PKA catalytic subunit failed to do so, suggesting that factors in addition to PKA are required for cAMP-stimulated cell cycle progression. When added to thyroid cells expressing human Ha-Ras, TSH rapidly and markedly increased the proportion of GTP-bound Ras. Ras activity was increased within 1 min of TSH addition, maximal at 5-15 min, and declined to basal levels 30-60 min after hormone treatment. Cyclic AMP elevating agents elicited similar effects on Ras, indicating that TSH activates Ras through a cAMP-mediated pathway. Although cAMP-mediated, Ras activation by TSH and cAMP was independent of PKA activity. Moreover, cAMP-stimulated Ras activation was not impaired by tyrosine kinase inhibitors. These results indicate that cAMP activates targets in addition to PKA in thyroid cells, and that these targets may include regulators of Ras. The ability of cAMP elevating agents to activate Ras in addition to PKA may explain the inability of the PKA catalytic subunit to stimulate DNA synthesis in thyroid cells.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Meinkoth, JL (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Meinkoth, Judy L/G-2900-2010		NIDDK NIH HHS [DK02494, DK45696] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045696, K02DK002494] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dremier S, 1997, MOL CELL BIOL, V17, P6717, DOI 10.1128/MCB.17.11.6717; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; FAGIN JA, 1994, ANNU REV MED, V45, P45; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KOLCH W, 1996, ONCOGENE, V6, P1304; Kupperman E, 1996, ENDOCRINOLOGY, V137, P96, DOI 10.1210/en.137.1.96; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MEINKOTH JL, 1992, J BIOL CHEM, V267, P13239; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MUCA C, 1994, ONCOGENE, V9, P3647; Ohno M, 1999, MOL CELL BIOL, V19, P2051; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SCHUBERT D, 1978, NATURE, V273, P718, DOI 10.1038/273718a0; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SUAREZ HG, 1991, ONCOGENE, V6, P677; WynfordThomas D, 1997, HORM RES, V47, P145, DOI 10.1159/000185458; Zufall F, 1997, CURR OPIN NEUROBIOL, V7, P404, DOI 10.1016/S0959-4388(97)80070-0	45	56	56	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3609	3615		10.1038/sj.onc.1203680	http://dx.doi.org/10.1038/sj.onc.1203680			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951566				2022-12-17	WOS:000088568300006
J	Gire, V; Marshall, C; Wynford-Thomas, D				Gire, V; Marshall, C; Wynford-Thomas, D			PI-3-kinase is an essential anti-apoptotic effector in the proliferative response of primary human epithelial cells to mutant RAS	ONCOGENE			English	Article						RAS; intra-cellular signals; PI-3-kinase; MAP kinase; epithelial; thyroid	ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; DNA-SYNTHESIS; IN-VITRO; TRANSFORMATION; SUFFICIENT; PATHWAYS; GROWTH; DIFFERENTIATION; EXPRESSION	In contrast to its growth-inhibitory effect on primary mesenchymal cells, RAS oncogene activation induces a proliferative phenotype in normal human thyroid epithelial cells in vitro, consistent with its putative role in tumour initiation. Using this model, we previously showed that activation of the MAP kinase (MAPK) pathway is necessary, but not sufficient for the proliferative response to mutant (V12) H-RAS. Were we extend this work to show that another major RAS effector - phosphatidylinositol-3-kinase (PI-3-K) - while also insufficient alone, is able to synergize with MAPK activation to mimic the effect of mutant RAS, albeit at reduced efficiency. Furthermore we show that PI-3-K is an absolute requirement for the proliferative response to RAS in these cells, acting via suppression of RAS-induced apoptosis. These data extend our understanding of RAS signalling in a clinically-relevant cell context and point to the use of PI-3-K inhibitors as potential therapeutic agents for targetting human cancers induced by RAS mutation.	Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales; Inst Canc Res, Chester Beatty Labs, Ctr Cellular & Mol Biol, Canc Res Campaign, London SW3 6JB, England	Cardiff University; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Wynford-Thomas, D (corresponding author), Univ Wales Coll Med, Dept Pathol, Canc Res Campaign Labs, Cardiff CF14 4XN, S Glam, Wales.		Gire, Véronique/AAC-2218-2020; Gire, Veronique/N-7553-2017	Gire, Veronique/0000-0002-9009-2185				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cass LA, 1999, MOL CELL BIOL, V19, P5882; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gallagher AP, 1998, CANCER RES, V58, P2029; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SUAREZ HG, 1990, ONCOGENE, V5, P565; Treinies I, 1999, MOL CELL BIOL, V19, P321; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586	40	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 4	2000	19	19					2269	2276		10.1038/sj.onc.1203544	http://dx.doi.org/10.1038/sj.onc.1203544			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	312ZR	10822377				2022-12-17	WOS:000086974300001
J	Tian, EM; Sawyer, JR; Largaespada, DA; Jenkins, NA; Copeland, NG; Shaughnessy, JD				Tian, EM; Sawyer, JR; Largaespada, DA; Jenkins, NA; Copeland, NG; Shaughnessy, JD			Evi27 encodes a novel membrane protein with homology to the IL17 receptor	ONCOGENE			English	Article						insertional mutagenesis; novel cytokine receptor; IL-17R related gene; myeloid leukemia	MYELOPROLIFERATIVE LEUKEMIA-VIRUS; MYELOID-LEUKEMIA; CHROMOSOME-TRANSLOCATION; CYTOKINE RECEPTOR; INTEGRATION SITE; CELL-LINES; T-CELL; GENE; MOUSE; EXPRESSION	Evi27 is a common site of retroviral integration in BXH2 murine myeloid leukemias. Here me show that integration at Evi27 occurs in a CpG island similar to 6 kb upstream from a novel gene (designated Evi27) with homology to the IL17 receptor (Il17r) and that proviral integrations result in increased expression of the Evi27 protein on the cell surface. The human EVI27 homology was also cloned and mapped to chromosome 3p21, Multiple Evi27 isoforms were detected at the RNA and protein level in both human and mouse, indicating that Evi27 expression is complex. Some of the isoforms are shown to likely represent secreted soluble forms of the protein produced by intron incorporation or by proteolytic cleavage. In the mouse, highest Evi27 expression occurs in liver and testes with lower expression in kidney and lung, In humans, EVI27 is expressed at high levels in the kidney, with moderate levels in the liver, brain, and testes. Within hematopoietic cells, Evi27 expression is restricted. Northern and Western analysis showed that Evi27 is expressed in selected T-cell B-cell and myeloid cell lines. These results suggest that Evi27 expression is tightly regulated during hematopoietic differentiation. Collectively, these studies identify a nea member of the cytokine receptor family whose increased and uncoordinated expression may lead to myeloid leukemia by altering Evi27's normal ability to control the growth and/or differentiation of hematopoietic cells.	Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Ctr Canc, Minneapolis, MN 55455 USA; NCI, Frederick Canc Res & Dev Ctr, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Shaughnessy, JD (corresponding author), Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Little Rock, AR 72205 USA.		Largaespada, David/C-9832-2014					Bagby G.C.J., 1994, MOL BASIS BLOOD DIS, P71; BAUMBACH WR, 1988, J VIROL, V62, P3151, DOI 10.1128/JVI.62.9.3151-3155.1988; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CHRETIEN S, 1994, BLOOD, V83, P1813; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COPELAND NG, 1999, ANIMAL MODELS CANC P, P53; FLUBACHER MM, 1994, J VIROL, V68, P7709, DOI 10.1128/JVI.68.12.7709-7716.1994; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; GILBERT DJ, 1993, J VIROL, V67, P2083, DOI 10.1128/JVI.67.4.2083-2090.1993; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HINO M, 1991, MOL CELL BIOL, V11, P5527, DOI 10.1128/MCB.11.11.5527; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; Johansson B, 1997, LEUKEMIA, V11, P1207, DOI 10.1038/sj.leu.2400718; Kennedy J, 1996, J INTERF CYTOK RES, V16, P611, DOI 10.1089/jir.1996.16.611; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liao XB, 1997, ONCOGENE, V14, P1023, DOI 10.1038/sj.onc.1200929; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Ogawa S, 1996, ONCOGENE, V13, P183; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; Shaughnessy JD, 1999, ONCOGENE, V18, P2069; Shi G, 1996, CYTOGENET CELL GENET, V74, P295, DOI 10.1159/000134439; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P228, DOI 10.1002/(SICI)1098-2264(199708)19:4<228::AID-GCC4>3.0.CO;2-Z; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yao ZB, 1997, CYTOKINE, V9, P794, DOI 10.1006/cyto.1997.0240; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; YOO ZB, 1995, J IMMUNOL, V155, P5483; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	45	56	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2098	2109		10.1038/sj.onc.1203577	http://dx.doi.org/10.1038/sj.onc.1203577			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815801				2022-12-17	WOS:000086728000003
J	Kataoka, M; Wiehle, S; Spitz, F; Schumacher, G; Roth, JA; Cristiano, RJ				Kataoka, M; Wiehle, S; Spitz, F; Schumacher, G; Roth, JA; Cristiano, RJ			Down-regulation of bcl-2 is associated with p16(INK4)-mediated apoptosis in non-small cell lung cancer cells	ONCOGENE			English	Article						apoptosis; adenovirus; p16; p53; non-small cell lung cancer	WILD-TYPE P53; MYOCYTE DIFFERENTIATION; CYCLE CONTROL; GENE-PRODUCT; RB; TUMOR; EXPRESSION; PROTEIN; DEATH; LINES	We introduced a functional p16 cDNA into non-small cell lung cancer (NSCLC) cell lines expressing different combinations of normal and mutated p16, p53, and Rb genes via a recombinant adenovirus to determine the effect of exogenous p16 expression on cell growth. Analysis of p16-deficient cells infected with Adv/p16 identified growth arrest of the cells in the G(0)-G(1) phase early on, Apoptosis was identified to occur by the 5th day after infection which corresponded with increased p16 expression, reduced Rb expression, and increased Rb hypophosphorylation, but only occurred in cells expressing functional p53. Further analysis indicated that the expression of the anti-apoptotic protein bcl-2 was greatly reduced in the NSCLC cell lines H460 and A549 (both -p16, +p53, +Rb), again only by the 5th day after Adv/p16 infection, but no affect on Bar expression was observed, H1299 cells (-p16, -p53, +Rb) infected with Adv/p16 only exhibited apoptosis by an additional infection with Adv/p53 which also corresponded with a down-regulation of bcl-2, In addition, the infection of A549 cells with Adv/p16 followed by a subsequent infection with Adv/Rb lead to a significant decrease in apoptosis which correlated with an increase in bcl-2 expression. These studies suggest that p16 is capable of mediating apoptosis in NSCLC cell lines expressing wild-type p53, through a direct down-regulation of Rb and an indirect down-regulation of the anti-apoptotic protein bcl-2.	Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Cardiovasc & Thorac Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Cristiano, RJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, 1515 Holcombe Blvd,Box 13, Houston, TX 77030 USA.				PHS HHS [T3209599-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Fang XJ, 1998, ONCOGENE, V16, P1, DOI 10.1038/sj.onc.1201525; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GORCZYCA W, 1993, CANCER RES, V53, P1945; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; JIN XM, 1995, CANCER RES, V55, P3250; Kataoka A, 1996, ONCOL REP, V3, P111; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; McConkey DJ, 1996, ONCOGENE, V13, P1693; Mitra J, 1999, MOL CELL BIOL, V19, P3916; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Naruse I, 1998, ANTICANCER RES, V18, P4275; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Sakaguchi M, 1996, INT J CANCER, V65, P442, DOI 10.1002/(SICI)1097-0215(19960208)65:4<442::AID-IJC8>3.0.CO;2-X; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHAPIRO GI, 1995, CANCER RES, V55, P6200; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Spitz FR, 1996, CLIN CANCER RES, V2, P1665; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHANG WW, 1994, CANCER GENE THER, V1, P5	28	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	2000	19	12					1589	1595		10.1038/sj.onc.1203466	http://dx.doi.org/10.1038/sj.onc.1203466			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734319				2022-12-17	WOS:000086108100012
J	Perissi, V; Menini, N; Cottone, E; Capello, D; Sacco, M; Montaldo, F; De Bortoli, M				Perissi, V; Menini, N; Cottone, E; Capello, D; Sacco, M; Montaldo, F; De Bortoli, M			AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen	ONCOGENE			English	Article						ERBB2; oestrogen repression; AP-2; ER	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR; PROTEIN EXPRESSION; MAMMARY-CARCINOMA; GROWTH; AP2; OVEREXPRESSION; AMPLIFICATION; SUPPRESSION; MECHANISMS	Transcription of the ERBB2 oncogene is repressed by oestrogen in human breast cancer cells. We show that a 218 bp fragment of the human ERBB2 gene promoter is responsive to oestrogen in transient transfection in ZR75.1 and SKBR.3 cells when the oestrogen receptor is expressed. Deletion analysis of this fragment shows that a sequence located at the 5' end, which is known to mediate ERBB2 overexpression in breast cancer, is also responsible for the oestrogen response. This sequence binds AP-2 transcription factors and appears functionally identical to an element of the oestrogen-dependent enhancer described in the first intron of human ERBB2, We observed that oestrogen treatment down-regulates expression of AP-2 proteins but does not affect the DNA binding activity of AP-2. Constitutive expression of AP-2 beta or AP-2 gamma, but not AP-2 alpha, abrogates the estrogenic repression. Our results demonstrate that AP-2 transcription factors are implicated in the oestrogenic regulation of ERBB2 gene expression and suggest a complex interplay involving the different AP-2 isoforms and other unidentified factors.	Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Turin, Dept Anim & Human Biol, I-10124 Turin, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	De Bortoli, M (corresponding author), Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Capello, Daniela/J-4110-2012; De Bortoli, Michele/B-5418-2013	Capello, Daniela/0000-0001-9157-8753; De Bortoli, Michele/0000-0002-6666-9052; Perissi, Valentina/0000-0002-3716-0003				ANTONIOTTI S, 1992, EUR J CANCER, V28A, P318, DOI 10.1016/S0959-8049(05)80045-0; ANTONIOTTI S, 1994, BRIT J CANCER, V70, P1095, DOI 10.1038/bjc.1994.454; Bates NP, 1997, J MAMMARY GLAND BIOL, V2, P153, DOI 10.1023/A:1026303814855; Bates NP, 1997, ONCOGENE, V15, P473, DOI 10.1038/sj.onc.1201368; Benson LQ, 1999, J BIOL CHEM, V274, P28794, DOI 10.1074/jbc.274.40.28794; Bisgrove DA, 1999, DEV DYNAM, V214, P195, DOI 10.1002/(SICI)1097-0177(199903)214:3<195::AID-AJA3>3.0.CO;2-8; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; DATI C, 1990, ONCOGENE, V5, P1001; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUEGE PM, 1986, NUCLEIC ACIDS RES, V14, P9329, DOI 10.1093/nar/14.23.9329; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; Kannan F, 1999, MOL CELL BIOL, V19, P899; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Miyamoto T, 1999, MOL CELL BIOL, V19, P2644; Moser M, 1997, GENE DEV, V11, P1938, DOI 10.1101/gad.11.15.1938; OuladAbdelghani M, 1996, EXP CELL RES, V225, P338, DOI 10.1006/excr.1996.0184; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; READ LD, 1990, CANCER RES, V50, P3947; RUSSEL KS, 1992, CANCER RES, V50, P3947; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; TAVERNA D, 1994, INT J CANCER, V56, P522, DOI 10.1002/ijc.2910560411; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Turner BC, 1998, CANCER RES, V58, P5466; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; WARRI AM, 1991, INT J CANCER, V49, P616, DOI 10.1002/ijc.2910490425; WHITE MRA, 1992, ONCOGENE, V7, P677; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	38	56	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2000	19	2					280	288		10.1038/sj.onc.1203303	http://dx.doi.org/10.1038/sj.onc.1203303			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10645007				2022-12-17	WOS:000084844400014
J	Topcu, Z; Mack, DL; Hromas, RA; Borden, KLB				Topcu, Z; Mack, DL; Hromas, RA; Borden, KLB			The promyelocytic leukemia protein PML interacts with the proline-rich homeodomain protein PRH: a RING may link hematopoiesis and growth control	ONCOGENE			English	Article						PML; PRH; HEX; APL; Z	ALPHA FUSION PROTEIN; HOMEOBOX GENE PRH; NUCLEAR-BODIES; SACCHAROMYCES-CEREVISIAE; ONCOPROTEIN PML; BINDING-PROTEIN; FINGER DOMAIN; CELLS; EXPRESSION; MOUSE	Acute promyelocytic leukemia (APL) is characterized by a block in myeloid cell differentiation. As a result of a chromosomal translocation in these patients, the promyelocytic leukemia protein PML is disrupted as are the nuclear bodies it forms. Disruption of PML and PML nuclear bodies in APL is linked to a loss of growth control and subsequent leukemogenesis, PML contains a zinc-binding domain known as the RING which is required for formation of these bodies. Using yeast 2-hybrid techniques, we found that PML and a related RING protein, Z, bind the proline rich homeodomain protein (PRH) through their RING domains, Previous reports indicate that PRH functions in hematopoiesis and may act as a transcriptional repressor. Our data indicate that PML and Z both bind the repressor domain of PRH and are the first protein partners reported for PRH, We observe that PRH has a punctate pattern in both the nucleus and cytoplasm of chronic myelogenous leukemia K562 cells and in the APL cell line, NB4. Immunoprecipitation and co-localization studies indicate that PML and PRH interact in both cell lines. The effect on cell growth by PML and the hematopoietic actions of PRH raises the possibility that the interaction between PML and PRH represents a link between growth control and hematopoiesis.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Indiana Canc Res Inst, Indianapolis, IN 46202 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Borden, KLB (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218, New York, NY 10029 USA.		Mack, David/AAE-5437-2022		NCI NIH HHS [R01 CA80728-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BEDFORD FK, 1993, NUCLEIC ACIDS RES, V21, P1245, DOI 10.1093/nar/21.5.1245; Boddy MN, 1996, ONCOGENE, V13, P971; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Borden KLB, 1996, P NATL ACAD SCI USA, V93, P1601, DOI 10.1073/pnas.93.4.1601; Borden KLB, 1997, FEBS LETT, V418, P30, DOI 10.1016/S0014-5793(97)01344-6; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Borden KLB, 1998, J VIROL, V72, P3819, DOI 10.1128/JVI.72.5.3819-3826.1998; Carlile GW, 1998, BIOCHEM J, V335, P691, DOI 10.1042/bj3350691; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLENGHI L, 1995, BLOOD, V85, P1871, DOI 10.1182/blood.V85.7.1871.bloodjournal8571871; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; GRIGNANI F, 1995, CANCER RES, V55, P440; Guthrie C, 1991, GUIDE YEAST GENETICS; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HROMAS R, 1993, BIOCHEM BIOPH RES CO, V195, P976, DOI 10.1006/bbrc.1993.2140; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; Mayfield S, 1996, CHEM BIOL, V3, P415, DOI 10.1016/S1074-5521(96)90088-5; MELNICK A, 1999, IN PRESS BLOOD; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; Miller J.H., 1972, EXPT MOL GENETICS; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Petter R, 1997, INFECT IMMUN, V65, P4909, DOI 10.1128/IAI.65.12.4909-4917.1997; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; ROGAIA D, 1995, LEUKEMIA, V9, P1467; SALVATO MS, 1996, ARENAVIRUSES, P629; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; STUURMAN N, 1992, J CELL SCI, V101, P773; TABILIO A, 1983, CANCER RES, V43, P4569; Tanaka T, 1999, BIOCHEM J, V339, P111, DOI 10.1042/0264-6021:3390111; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; TERRIS B, 1995, CANCER RES, V55, P1590; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073	49	56	56	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7091	7100		10.1038/sj.onc.1203201	http://dx.doi.org/10.1038/sj.onc.1203201			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597310				2022-12-17	WOS:000083901900016
J	Juang, JL; Hoffmann, FM				Juang, JL; Hoffmann, FM			Drosophila Abelson interacting protein (dAbi) is a positive regulator of Abelson tyrosine kinase activity	ONCOGENE			English	Article						Abi; Abl; tyrosine kinase; phosphorylation; Drosophila	C-ABL; BINDING-PROTEIN; SIGNAL-TRANSDUCTION; SH3 DOMAINS; CELL-CYCLE; DEGRADATION; IDENTIFICATION; SUPPRESSOR; GENE; DNA	Human and mouse Abelson interacting proteins (Abi) are SH3-domain containing proteins that bind to the proline-rich motifs of the Abelson protein tyrosine kinase, We report a new member of this gene family, a Drosophila Abi (dAbi) that is a substrate for Abl kinase and that coimmunoprecipitates with Abl if the Abi SH3 domain is intact. We have identified a new function for both dAbi and human Abi-2 (hAbi-2), Both proteins activate the kinase activity of Abl as assayed by phosphorylation of the Drosophila Enabled (Ena) protein. Removal of the dAbi SH3 domain eliminates dAbi's activation of Abl kinase activity. dAbi is an unstable protein in cells and is present at low steady state levels but its protein level is increased coincident with phosphorylation by Abl kinase, Expression of the antisense strand of dAbi reduces dAbi protein levels and abolishes activation of Abl kinase activity. Modulation of Abi protein levels may be an important mechanism for regulating the level of Abl may level kinase activity in the cell.	Natl Hlth Res Inst, Taipei, Taiwan; Univ Wisconsin, Canc Res Lab, Madison, WI 53706 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	National Health Research Institutes - Taiwan; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Juang, JL (corresponding author), Natl Hlth Res Inst, 128 Yen Chiu Yuan Rd,Sec 2, Taipei, Taiwan.		Juang, Jyh-Lyh/E-3944-2010	Hoffmann, F. Michael/0000-0002-2770-9656	NATIONAL CANCER INSTITUTE [R01CA049582] Funding Source: NIH RePORTER; NCI NIH HHS [CA49582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Baskaran R, 1996, MOL CELL BIOL, V16, P3361; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fernandes RS, 1996, LEUKEMIA, V10, pS17; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; Lavin MF, 1996, EXPERIENTIA, V52, P979, DOI 10.1007/BF01920107; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Shah GN, 1997, BIOCHEM J, V327, P617; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; Wang BL, 1996, ONCOGENE, V12, P1921; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Ziemnicka-Kotula D, 1998, J BIOL CHEM, V273, P13681, DOI 10.1074/jbc.273.22.13681	32	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	1999	18	37					5138	5147		10.1038/sj.onc.1202911	http://dx.doi.org/10.1038/sj.onc.1202911			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498863				2022-12-17	WOS:000082555700002
J	Bertucci, F; Van Hulst, S; Bernard, K; Loriod, B; Granjeaud, S; Tagett, R; Starkey, M; Nguyen, C; Jordan, B; Birnbaum, D				Bertucci, F; Van Hulst, S; Bernard, K; Loriod, B; Granjeaud, S; Tagett, R; Starkey, M; Nguyen, C; Jordan, B; Birnbaum, D			Expression scanning of an array of growth control genes in human tumor cell lines	ONCOGENE			English	Article						cancer; breast cancer; gene expression; cDNA; gene array	HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; HYBRIDIZATION ANALYSIS; MICROARRAY SYSTEM; DNA AMPLIFICATION; CDNA MICROARRAY; PATTERNS; CHIPS	Analysis of gene expression on a medium- or large-scale is an increasingly recognized method for functional and clinical investigations based on the now extensive catalog of known or partially sequenced genes, The accessibility of this approach can be enhanced by using readily available technology (macroarrays on Nylon, radioactive detection) and the IMAGE resource to assemble sets of targets. We have set up such a medium-scale, flexible system and validated it by the study of quantitative expression levels for 120 genes in six cell lines, including three mammary carcinoma cell lines. A number of important parameters are identified as necessary for the assembly of a valid set and the obtention of good-quality quantitative data. The extensive data assembled in this survey identified potential targets of carcinogenesis, for example the CRABP2 and GATA3 transcription factor genes. We also demonstrate the feasibility of this procedure for relatively small tumor samples, without recourse to probe amplification methods.	INSERM, U119, F-13009 Marseille, France; Inst J Paoli I Calmettes, Lab Biol Tumeurs, IFR 57, F-13009 Marseille, France; TAGC, Marseille, France; UK Human genome Mapping Project Resource Ctr, Cambridge, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.		Granjeaud, Samuel/AAE-6488-2022; Nguyen, Catherine/M-4119-2016; loriod, beatrice bl/L-2948-2016	Granjeaud, Samuel/0000-0001-9245-1535; Nguyen, Catherine/0000-0001-9376-6360; loriod, beatrice bl/0000-0001-5801-2264				Bernard K, 1996, NUCLEIC ACIDS RES, V24, P1435, DOI 10.1093/nar/24.8.1435; Boige V, 1997, CANCER RES, V57, P1986; Chen JJW, 1998, GENOMICS, V51, P313, DOI 10.1006/geno.1998.5354; Courjal F, 1997, CANCER RES, V57, P4368; Courjal F, 1997, CANCER RES, V57, P4360; DeRisi J, 1996, NAT GENET, V14, P457; Granjeaud S, 1996, GENET ANAL-BIOMOL E, V12, P151, DOI 10.1016/1050-3862(95)00128-X; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Jordan BR, 1998, J BIOCHEM-TOKYO, V124, P251, DOI 10.1093/oxfordjournals.jbchem.a022104; Kerangueven F, 1997, CANCER RES, V57, P5469; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mertens F, 1997, CANCER RES, V57, P2765; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; PENAULTLLORCA F, 1994, J PATHOL, V173, P65, DOI 10.1002/path.1711730111; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; Rocha D, 1997, IMMUNOGENETICS, V46, P142, DOI 10.1007/s002510050253; Sambrook J, 1989, MOL CLONING LAB MANU; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; STRAUSBERG RL, 1997, NATURE GENET S, V16, pS415; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Tsou AP, 1998, GENOMICS, V50, P331, DOI 10.1006/geno.1998.5338; WINTER RM, 1995, HUM MOL GENET, V4, P1699, DOI 10.1093/hmg/4.suppl_1.1699; Wodicka L., 1997, NAT BIOTECHNOL, V15, P1539; YUAN H, 1995, GENE DEV, V1, P2635	28	56	59	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3905	3912		10.1038/sj.onc.1202731	http://dx.doi.org/10.1038/sj.onc.1202731			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445855				2022-12-17	WOS:000081171700013
J	McPherson, RA; Harding, A; Roy, S; Lane, A; Hancock, JF				McPherson, RA; Harding, A; Roy, S; Lane, A; Hancock, JF			Interactions of c-Raf-1 with phosphatidylserine and 14-3-3	ONCOGENE			English	Article						Ras; Raf-1; 14-3-3; phosphatidylserine	ACTIVATED PROTEIN-KINASE; DISTINCT BINDING DOMAINS; CYSTEINE-RICH DOMAIN; PLASMA-MEMBRANE; RAF-1 KINASE; IN-VITRO; TYROSINE PHOSPHORYLATION; AMINO-TERMINUS; RAS; 14-3-3-PROTEINS	Activation of Raf-1 occurs at the plasma membrane. We recently showed that 14-3-3 must be complexed with Raf-1 for efficient recruitment to the plasma membrane and activation by Ras, but that 14-3-3 is completely displaced from Raf-1 following plasma membrane binding. We show here that the Raf-1 zinc finger is not absolutely required for 14-3-3 binding but is required to stabilize the interaction between Raf-1 and 14-3-3, Incubation of Raf-1 with phosphatidylserine, an inner plasma membrane phospholipid, results in removal of 14-3-3 and an increase in Raf-1 kinase activity, whereas removal of 14-3-3 from Raf-1 using specific phosphopeptides substantially reduces Raf-1 basal kinase activity. Displacement of 14-3-3 from activated Raf-1 by phosphopeptides has no effect on kinase activity if Raf-1 is first removed from solution, but completely eradicates kinase activity of soluble activated Raf-1. These results suggest a mechanism for the removal of 14-3-3 from Raf-1 at the plasma membrane and show that removal of 14-3-3 from Raf-1 has markedly different effects depending on experimental conditions.	Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston, Qld 4006, Australia	University of Queensland	Hancock, JF (corresponding author), Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Herston, Qld 4006, Australia.		Harding, Angus/B-4120-2012	Hancock, John/0000-0003-0542-4710				Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BUNDAY L, 1993, CELL, V73, P611; Chang HC, 1997, GENE DEV, V11, P1132, DOI 10.1101/gad.11.9.1132; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kockel L, 1997, GENE DEV, V11, P1140, DOI 10.1101/gad.11.9.1140; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Pritchard C, 1997, NAT GENET, V16, P214, DOI 10.1038/ng0797-214; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUEN KL, 1995, ONCOGENE, V11, P825; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	46	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3862	3869		10.1038/sj.onc.1202730	http://dx.doi.org/10.1038/sj.onc.1202730			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445849				2022-12-17	WOS:000081171700007
J	Dejong, V; Degeorges, A; Filleur, S; Ait-Si-Ali, S; Mettouchi, A; Bornstein, P; Binetruy, B; Cabon, F				Dejong, V; Degeorges, A; Filleur, S; Ait-Si-Ali, S; Mettouchi, A; Bornstein, P; Binetruy, B; Cabon, F			The Wilms' tumor gene product represses the transcription of thrombospondin 1 in response to overexpression of c-Jun	ONCOGENE			English	Article						angiogenesis; c-Jun; EGR1; thrombospondin 1; transcription factors; transformation; WT1	NEOPLASTIC HUMAN BREAST; ZINC-FINGER PROTEINS; DNA-BINDING; ENDOTHELIAL-CELLS; SUBNUCLEAR LOCALIZATION; MOUSE THROMBOSPONDIN-1; SUPPRESSOR GENE; SPLICE VARIANTS; IN-VITRO; WT1	Thrombospondin 1 (TSP1) is known for its significant anti-angiogenic properties. In a previous study, we have shown that transient or stable overexpression of the transcription factor c-Jun, in rat fibroblasts, leads to repression of TSP1, We now demonstrate that the c-Jun-induced repression of TSP1 does not occur directly and does not require binding of c-Jun to the TSP1 promoter. Instead, repression involves a factor secreted by c-Jun-overexpressing cells. This secreted factor triggers a signal transduction pathway from the membrane to the nucleus, and these signals lead to the binding of the product of the Wilms' tumor suppressor gene, WT1, to the -210 region of the TSP1 promoter, This region binds WT1 and SP1, but not EGR1, although its sequence fits the consensus binding site for this transcription factor. WT1 overexpression in transfected cells inhibits endogenous TSP1 gene expression and TSP1 transcription in experiments using TSP1 promoter-reporter constructs. The WT1-KTS isoform is more active in repressing TSP1 transcription than WT1+KTS, while EGR1 is inactive, Enhancement of WT1 binding to DNA in response to c-Jun does not require de novo protein synthesis. The above mechanism for TSP1 repression could apply to other genes, thus coordinating their regulation in the vicinity of a c-Jun-overexpressing cell. We conclude that WT1, which was discovered as a result of its tumor suppressor properties, may also possess oncogenic characteristics in the c-Jun transformation process, and thus repress the antiangiogenic protein, TSP1.	CNRS, UPR 9079, F-94801 Villejuif, France; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Centre National de la Recherche Scientifique (CNRS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Cabon, F (corresponding author), CNRS, UPR 9079, 7 Rue Moquet,BP8, F-94801 Villejuif, France.		Binetruy, Bernard/AAG-7139-2022; Binetruy, Bernard/AFL-7188-2022; Cabon, Florence/B-3284-2013; Binetruy, Bernard/S-2062-2019; Binetruy, Bernard/A-6465-2009	Cabon, Florence/0000-0002-6149-082X; Binetruy, Bernard/0000-0001-8012-7092; Filleur, Stephanie/0000-0002-3420-5536; METTOUCHI, Amel/0000-0003-1453-6482	NHLBI NIH HHS [HL 18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertin N, 1997, CANCER RES, V57, P396; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAO XM, 1993, J BIOL CHEM, V268, P16949; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; CASTLE VP, 1993, J BIOL CHEM, V268, P2899; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEZARDIN P, 1993, CANCER RES, V53, P1421; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIPIETRO LA, 1994, J VASC RES, V31, P178, DOI 10.1159/000319585; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Englert C, 1995, P NATL ACAD SCI USA, V92, P11960, DOI 10.1073/pnas.92.26.11960; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; Hamilton TB, 1998, BIOCHEMISTRY-US, V37, P2051, DOI 10.1021/bi9717993; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; Kleymenova EV, 1998, ONCOGENE, V16, P713, DOI 10.1038/sj.onc.1201583; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; Menke AL, 1996, ONCOGENE, V12, P537; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Qian XH, 1996, P SOC EXP BIOL MED, V212, P199; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; Sakamoto Y, 1997, ONCOGENE, V15, P2001, DOI 10.1038/sj.onc.1201391; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851, DOI 10.1128/MCB.14.1.851; SCHUG J, 1997, U PENNSYLVANIA; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; Sheibani N, 1996, CANCER LETT, V107, P45, DOI 10.1016/0304-3835(96)04341-8; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; Svedberg H, 1998, ONCOGENE, V16, P925, DOI 10.1038/sj.onc.1201613; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Tolsma SS, 1997, MICROVASC RES, V54, P13, DOI 10.1006/mvre.1997.2015; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Webster NJG, 1997, BIOCHEM MOL MED, V62, P139, DOI 10.1006/bmme.1997.2648; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Ye Y, 1996, EMBO J, V15, P5606, DOI 10.1002/j.1460-2075.1996.tb00945.x	52	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3143	3151		10.1038/sj.onc.1202654	http://dx.doi.org/10.1038/sj.onc.1202654			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340386				2022-12-17	WOS:000080388000010
J	Miyake, M; Adachi, M; Huang, CL; Higashiyama, M; Kodama, K; Taki, T				Miyake, M; Adachi, M; Huang, CL; Higashiyama, M; Kodama, K; Taki, T			A novel molecular staging protocol for non-small cell lung cancer	ONCOGENE			English	Article						MRP-1/CD9; KA11/CD82; K-ras; p53; lung cancer; metastasis; prognosis; TM4SF	K-RAS; POOR-PROGNOSIS; GENE-EXPRESSION; SUPPRESSOR GENE; P53 GENE; MUTATIONS; MOTILITY; MRP-1/CD9; METASTASIS; CARCINOMA	A molecular staging protocol using reliable markers is of importance in predicting the prognosis of patients with non-small cell lung cancer (NSCLC) and for instituting their appropriate post-surgical treatment. We analysed tumor tissues from 187 NSCLC patients. The DNA and mRNA mere extracted from frozen specimens, and then polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and direct sequencing were performed to investigate mutations of p53 from exons 5-8, and mutations of K-ras at exon 1, To determine MRP-1/CD9 gene and KA11/CD82 gene expression, which have been postulated to be metastasis suppressor genes, we have applied quantitative RT-PCR, A Cox multivariate regression analysis showed that nodal status, MRP-1/CD9 and K-ras status were significant factors for prognosis (P<0.0001, P=0.0083 and P=0.0004, respectively). Based on these results, me classified the patients into three groups according to their MRP-1/CD9 and K-ras status. Patients with both MRP-1/CD9 positive and wild Ii-ras tumors were defined as group A, patients with either reduced MRP-1/CD9 or mutant Kr as tumors were defined as group B and patients with both reduced MRP-1/CD9 and mutant Ii-ras tumors were designated as group C, This new classification was significantly correlated with the tumor status and pathological stage (P=0.0098 and P=0.0017, respectively). The overall survival rate of the group A patients was significantly better than the group B patients (59.6% vs 27.9%, P=0.0001) and also that of group B patients mas better than the group C patients (27.9% vs 20.0%, P=0.0378), This tendency was also found in patients with 110 node-negative NSCLCs (A vs B vs C=75.8% vs 34.9%,fs 0.0%, P<0.0001), A Cox multivariate regression analysis in NSCLC patients demonstrated that an evaluation for both MRP-1/CD9 expression and K-ras mutations had a significant prognostic effect as well as nodal status (P<0.0001).	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 530, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Osaka 530, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Osaka 537, Japan	Kitano Hospital; Kitano Hospital; Osaka Medical Center for Cancer & Cardiovascular Diseases	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Osaka 530, Japan.							Adachi M, 1996, CANCER RES, V56, P1751; BAINS MS, 1991, CHEST, V100, P826, DOI 10.1378/chest.100.3.826; Cajot JF, 1997, CANCER RES, V57, P2593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COX DR, 1972, J R STAT SOC B, V34, P187; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; HONGYO T, 1995, CANCER RES, V55, P2665; Huang C, 1998, ONCOGENE, V16, P2469, DOI 10.1038/sj.onc.1201776; Huang CL, 1997, INT J ONCOL, V11, P1045; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEE JS, 1995, J CLIN ONCOL, V13, P1893, DOI 10.1200/JCO.1995.13.8.1893; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASTERS GA, 1996, ADV ONCOL, V12, P16; MITSUDOMI T, 1993, JNCI-J NATL CANCER I, V85, P2018, DOI 10.1093/jnci/85.24.2018; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; Miyake M, 1996, CANCER RES, V56, P1244; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; ROSELL R, 1993, ONCOGENE, V8, P2407; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; SAMBROOK J, 1989, LAB MANUAL, V3, pE3; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; SUNDARESAN V, 1995, ANN ONCOL, V6, P27, DOI 10.1093/annonc/6.suppl_1.S27; TAKAHASHI H, 1992, ELECTRON LETT, V28, P380, DOI 10.1049/el:19920238; ZHANG YJ, 1993, HUM GENE THER, V4, P451, DOI 10.1089/hum.1993.4.4-451	32	56	60	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	1999	18	14					2397	2404		10.1038/sj.onc.1202556	http://dx.doi.org/10.1038/sj.onc.1202556			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327061				2022-12-17	WOS:000079595500013
J	Englaro, W; Bahadoran, P; Bertolotto, C; Busca, R; Derijard, B; Livolsi, A; Peyron, JF; Ortonne, JP; Ballotti, R				Englaro, W; Bahadoran, P; Bertolotto, C; Busca, R; Derijard, B; Livolsi, A; Peyron, JF; Ortonne, JP; Ballotti, R			Tumor necrosis factor alpha-mediated inhibition of melanogenesis is dependent on nuclear factor kappa B activation	ONCOGENE			English	Article						TNF alpha; inhibition of melanogenesis; tyrosinase; NF kappa B; melanoma cells	MELANOCYTE-STIMULATING HORMONE; TYROSINASE ACTIVITY; ULTRAVIOLET-LIGHT; PROTEIN-KINASES; CELL-DEATH; PHOSPHORYLATION; DEGRADATION; KERATINOCYTES; TRANSCRIPTION; CYTOKINES	Melanogenesis is a physiological process resulting in the synthesis of melanin pigments which play a crucial protective role against skin photocarcinogenesis. lit vivo, solar ultraviolet light triggers the secretion of numerous keratinocyte-derived factors that are implicated in the regulation of melanogenesis. Among these, tumor necrosis factor alpha. (TNF alpha), a cytokine implicated in the pro-inflammatory response, down-regulates pigment synthesis in vitro. In this report, we aimed to determine the molecular mechanisms by which this cytokine inhibits melanogenesis in B16 melanoma cells. First, we show that TNF alpha inhibits the activity and protein expression of tyrosinase which is the key enzyme of melanogenesis, Further, we demonstrate that this effect is subsequent to a down-regulation of the tyrosinase promoter activity in both basal and cAMP-induced melanogenesis, Finally, we present evidence indicating that the inhibitory effect of TNF alpha on melanogenesis is dependent on nuclear factor kappa B (NF kappa B) activation. Indeed, overexpression of this transcription factor in B16 cells is sufficient to inhibit tyrosinase promoter activity, Furthermore, a mutant of inhibitory kappa B (I kappa B), that prevents NF kappa B activation, is able to revert the effect of TNF alpha on the tyrosinase promoter activity. Taken together, our results clarify the mechanisms by which TNF alpha inhibits pigmentation and point out the key role of NF kappa B in the regulation of melanogenesis.	Fac Med, INSERM, U385, F-06107 Nice 2, France; Fac Med, CJF 9605, F-06107 Nice, France; Fac Sci, Ctr Biochim, CNRS, UMR 134, F-06018 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016; Bertolotto, Corine/AAF-6634-2021; BALLOTTI, Robert/F-8825-2013; Bertolotto-Ballotti, Corine/O-2155-2016	Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X; Bertolotto, Corine/0000-0001-6971-7753; Bahadoran, Philippe/0000-0002-2481-0556; BALLOTTI, Robert/0000-0002-7322-4908				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bennicelli J L, 1993, Exp Dermatol, V2, P186, DOI 10.1111/j.1600-0625.1993.tb00031.x; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HUNT G, 1994, J CELL SCI, V107, P205; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MartinezEsparza M, 1997, J BIOL CHEM, V272, P3967, DOI 10.1074/jbc.272.7.3967; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; OKEEFE E, 1974, P NATL ACAD SCI USA, V71, P2500, DOI 10.1073/pnas.71.6.2500; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OXHOLM A, 1988, BRIT J DERMATOL, V118, P369, DOI 10.1111/j.1365-2133.1988.tb02430.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; SWOPE VB, 1989, J IMMUNOL, V142, P1943; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	33	56	59	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1553	1559		10.1038/sj.onc.1202446	http://dx.doi.org/10.1038/sj.onc.1202446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102625				2022-12-17	WOS:000078770700005
J	Elly, C; Witte, S; Zhang, ZH; Rosnet, O; Lipkowitz, S; Altman, A; Liu, YC				Elly, C; Witte, S; Zhang, ZH; Rosnet, O; Lipkowitz, S; Altman, A; Liu, YC			Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulation	ONCOGENE			English	Article						protein tyrosine kinase; Cbl; proto-oncogene; Crk-L	EXCHANGE PROTEIN C3G; C-CBL; ANTIGEN RECEPTOR; V-CBL; ASSOCIATION; ACTIVATION; ZAP-70; PROTOONCOGENE; KINASE; 14-3-3-PROTEINS	Cbl-b, a mammalian homolog of Cbl, consists of an N-terminal region (Cbl-b-N) highly homologous to oncogenic v-Cbl, a Ring finger, and a C-terminal region containing multiple proline-rich stretches and potential tyrosine phosphorylation sites. In the present study, we demonstrate that upon engagement of the T cell receptor (TCR), endogenous Cbl-b becomes rapidly tyrosine-phosphorylated, In heterogeneous COS-1 cells, Cbl-b was phosphorylated on tyrosine residues by both Syk(Syk/Zap-70) and Src- (Fyn/Lck) family kinases, with Syk kinase inducing the most prominent effect. Syk associates and phosphorylates Cbl-b in Jurkat T cells, A Tyr-316 Chi-binding site in Syk was required for the association with and for the maximal tyrosine phosphorylation of Cbl-b, Mutation at a loss-of-function site (Gly-298) in Cbl-b-N disrupts its interaction with Syk, Cbl-b constitutively binds Grb2 and becomes associated with Crk-L upon TCR stimulation. The Grb2- and the Crk-L-binding regions were mapped to the C-terminus of Cbl-b, The Crk-L-binding sites were further determined to be (YDVP)-D-655 and (YKIP)-K-709, With th, latter being the primary binding site. Taken together, these results implicate that Cbl-b is involved in TCR-mediated intracellular signaling pathways.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; INSERM U119, Mol Oncol Lab, F-13009 Marseille, France; NCI, Navy Med Oncol Branch, Gaithersburg, MD 20899 USA	La Jolla Institute for Immunology; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.		Rosnet, Olivier/G-3536-2013	LIU, YUN-CAI/0000-0002-0996-7109; Rosnet, Olivier/0000-0002-3020-910X	NATIONAL CANCER INSTITUTE [Z01SC007263, ZIASC007263] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andoniou CE, 1996, ONCOGENE, V12, P1981; BLAKE TJ, 1991, ONCOGENE, V6, P653; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; KEANE MM, 1995, ONCOGENE, V10, P2367; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Latour S, 1996, J BIOL CHEM, V271, P22782, DOI 10.1074/jbc.271.37.22782; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Rellahan BL, 1997, J BIOL CHEM, V272, P30806, DOI 10.1074/jbc.272.49.30806; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; ZHANG Z, 1998, UNPUB; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	33	56	61	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1147	1156		10.1038/sj.onc.1202411	http://dx.doi.org/10.1038/sj.onc.1202411			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022120				2022-12-17	WOS:000078510700003
J	Yamochi, T; Kaneita, Y; Akiyama, T; Mori, S; Moriyama, M				Yamochi, T; Kaneita, Y; Akiyama, T; Mori, S; Moriyama, M			Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X-L	ONCOGENE			English	Article						BCL-6; apoptosis; cell cycle; BCL-2; recombinant adenovirus	GERMINAL-CENTER FORMATION; CENTER B-CELLS; PROTEIN INTERACTION MOTIF; FINGER ENCODING GENE; IN-VIVO; BTB/POZ DOMAIN; TRANSCRIPTIONAL REPRESSION; RECOMBINANT ADENOVIRUS; DNA-BINDING; LYMPHOMA	The BCL-6 proto-oncogene encodes a 92- to 98-kDa transcriptional repressor containing the BTB/POZ domain at its N-terminal region and the zinc finger domain at its C-terminal region, respectively. In the present study, we examined the function of BCL-6 by using a recombinant adenovirus expressing BCL-6 (Ax1CA-BCL-6) and the lacZ reporter gene (Ax1CA-lacZ), Viability of CV-1 and HeLa cells infected, with Ax1CA-BCL-6 was markedly reduced due to apoptosis, suggesting that BCL-6-overexpression induces apoptosis in CV-1 and HeLa cells. FAGS analysis revealed that BCL-6-overexpressing cells are accumulated not only at the sub-G1 but also at G2/M phase. Induction of apoptosis by BCL-6 was preceded by down-regulation of apoptosis repressors BCL-2 and BCL-X-L. These results suggest that BCL-6 induces apoptosis by regulating the expression of these apoptosis-regulating genes.	Univ Tokyo, Inst Med Sci, Dept Pathol, Minato Ku, Tokyo 108, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Suita, Osaka 565, Japan	University of Tokyo; Osaka University	Moriyama, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Pathol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 108, Japan.							Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1995, GENE CHROMOSOME CANC, V13, P221, DOI 10.1002/gcc.2870130314; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DEWEINDT C, 1995, CELL GROWTH DIFFER, V6, P1495; Dhordain P, 1995, ONCOGENE, V11, P2689; FAN SJ, 1995, CANCER RES, V55, P1649; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, P366, DOI 10.1006/bbrc.1994.2468; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LO CF, 1994, BLOOD, V83, P1757; MartinezValdez H, 1996, J EXP MED, V183, P971, DOI 10.1084/jem.183.3.971; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; MIKI T, 1994, BLOOD, V83, P26; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moriyama M, 1997, ONCOGENE, V14, P2465, DOI 10.1038/sj.onc.1201084; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Seyfert VL, 1996, ONCOGENE, V12, P2331; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596	41	56	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					487	494		10.1038/sj.onc.1202334	http://dx.doi.org/10.1038/sj.onc.1202334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927205				2022-12-17	WOS:000078166500021
J	Jian, YC; Schmidt-Grimminger, DC; Chien, WM; Wu, X; Broker, TR; Chow, LT				Jian, YC; Schmidt-Grimminger, DC; Chien, WM; Wu, X; Broker, TR; Chow, LT			Post-transcriptional induction of p21cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes	ONCOGENE			English	Article						HPV E7 protein; p21cip1 protein induction; post-transcription regulation; inhibition of DNA synthesis	CYCLIN-DEPENDENT KINASES; CELL NUCLEAR ANTIGEN; P21(WAF1/CIP1) EXPRESSION; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; UP-REGULATION; REPLICATION; P53; P21; PROLIFERATION	Productive infection by human papillomaviruses (HPVs) occurs only in differentiated squamous epithelial cells in papillomas, condylomata, and low grade intraepithelial neoplasias, Host DNA replication is reactivated in a fraction of terminally differentiated keratinocytes in benign human lesions and in organotypic raft cultures of primary human keratinocytes (PHKs) transduced with retroviruses expressing HPV-18 E7 oncogene from its native upstream regulatory region (URR), Thus the natural function of E7 protein, which inactivates pRB family proteins, is to induce host genes essential to support viral DNA replication in post-mitotic cells, Using this raft culture model system, we show that HPV-18 URR-E7 induces the universal cyclin-dependent kinase inhibitor p21cip1 protein in a fraction of differentiated PHKs, Induction is mediated by posttranscriptional mechanisms independent of p53, Double immunofluorescence studies demonstrate that, in raft cultures and in laryngeal papillomas, p21cip1 induction and reactivated host DIVA synthesis take place in a mutually exclusive manner in PCNA-positive, differentiated keratinocytes, We suggest that p21cip1 induction effectively blocks unscheduled DNA synthesis reactivated by E7, These results begin to explain the inverse relationship between p21cip1 induction and HPV activities previously observed in a spectrum of benign lesions regardless of HPV types present.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 1918 Univ Blvd,Room 508, Birmingham, AL 35294 USA.				NCI NIH HHS [CA36200, T32 CA09467] Funding Source: Medline; NIAID NIH HHS [AI34674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009467, R01CA036200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BLANTON RA, 1992, CELL GROWTH DIFFER, V3, P791; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; Chow Louise T., 1997, P267; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEMETER LM, 1994, HUM PATHOL, V25, P343, DOI 10.1016/0046-8177(94)90141-4; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fuchs E, 1990, CURR OPIN CELL BIOL, V2, P1028, DOI 10.1016/0955-0674(90)90152-5; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Harper JW, 1997, CANCER SURV, V29, P91; HEALY E, 1995, J INVEST DERMATOL, V105, P274, DOI 10.1111/1523-1747.ep12318430; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Inohara S, 1996, BRIT J DERMATOL, V135, P717; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KUO SR, 1994, J BIOL CHEM, V269, P24058; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsuta M, 1997, J DERMATOL SCI, V14, P233, DOI 10.1016/S0923-1811(96)00579-8; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Palazzo JP, 1997, HUM PATHOL, V28, P60, DOI 10.1016/S0046-8177(97)90280-X; PARKER JN, 1997, CELL GROWTH DIFFER, V8, P75; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Ruesch MN, 1997, J VIROL, V71, P5570, DOI 10.1128/JVI.71.7.5570-5578.1997; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Schmidt-Grimminger DC, 1998, AM J PATHOL, V152, P1015; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHEVCHUK MM, 1982, CANCER, V49, P489, DOI 10.1002/1097-0142(19820201)49:3<489::AID-CNCR2820490316>3.0.CO;2-U; Steenbergen RDM, 1998, J VIROL, V72, P749, DOI 10.1128/JVI.72.1.749-757.1998; STOLER MH, 1986, HUM PATHOL, V17, P1250, DOI 10.1016/S0046-8177(86)80569-X; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VOUSDEN KH, 1994, ADV CANCER RES, V64, P1, DOI 10.1016/S0065-230X(08)60833-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WILSON JL, 1992, CELL GROWTH DIFFER, V3, P471; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; Zeng YX, 1996, ONCOGENE, V12, P1557; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	60	56	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2027	2038		10.1038/sj.onc.1202142	http://dx.doi.org/10.1038/sj.onc.1202142			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798674				2022-12-17	WOS:000076540900002
J	Ulrich, E; Duwel, A; Kauffmann-Zeh, A; Gilbert, C; Lyon, D; Rudkin, B; Evan, G; Martin-Zanca, D				Ulrich, E; Duwel, A; Kauffmann-Zeh, A; Gilbert, C; Lyon, D; Rudkin, B; Evan, G; Martin-Zanca, D			Specific TrkA survival signals interfere with different apoptotic pathways	ONCOGENE			English	Article						survival signals; signal transduction; Akt; TrK	NERVE-GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; PC12 CELLS; ACTIVATION; FIBROBLASTS; RECEPTORS; PROTOONCOGENE; TRANSDUCTION; REQUIREMENT	Survival signalling by ligand-activated tyrosine kinase receptors plays a crucial role in maintaining the balance between cell viability and apoptosis in multicellular organisms. To identify receptor domains and pathways involved in survival signalling, the nerve growth factor receptor TrkA was expressed in Rat-1/MycER(TM) fibroblasts. We demonstrate that wt-TrkA receptor delays c-Myc-, U.V.- and Cycloheximide-induced apoptosis and activates targets such as the mitogen-activated protein kinase (MAPK) Erk2 and the serine/threonine kinase Akt/PKB, both of which have been implicated in survival signalling. TrkA mutated within its SHC binding site (Y490F) delays c-Myc-induced apoptosis without activating endogenous Akt/PKB. In contrast, the TrkA Y490F mutant receptor does not delay U.V.-induced apoptosis whilst TrkA mutated at its PLC-gamma binding site (Y785F) is capable of protecting from apoptosis induced by c-Myc or U.V. treatment. The double mutant TrkA YY490/785FF fails to block either of these two apoptotic stimuli. While PI3-kinase inhibitors LY294002 and Wortmannin competely block survival signalling following U.V. treatment, neither drug affects the ability of TrkA to block c-Myc-induced apoptosis. We show that the Akt/PKB pathway is essential for NGF stimulated TrkA survival signalling in the case of U.V.-induced apoptosis, but that apoptosis induced by c-Myc is also blocked by a novel, Akt/PKB-independent, pathway. These observations suggest that TrkA can activate different survival signalling pathways, which can interfere with specific apoptotic pathways.	Imperial Canc Res Fund Labs, London WC2A 3PX, England; Univ Salamanca, CSIC, Inst Microbiol Bioquim, Salamanca 37007, Spain; Ecole Normale Super Lyon, Lab Cell & Mol Biol, Lyon, France	Cancer Research UK; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; Ecole Normale Superieure de Lyon (ENS de LYON)	Evan, G (corresponding author), Imperial Canc Res Fund Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.			RUDKIN, Brian B./0000-0003-3700-1982				BAXTER RM, 1995, EUR J BIOCHEM, V234, P84, DOI 10.1111/j.1432-1033.1995.084_c.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARTER AN, 1992, J BIOL CHEM, V267, P14563; Creedon DJ, 1996, J BIOL CHEM, V271, P20713, DOI 10.1074/jbc.271.34.20713; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; D'Mello SR, 1997, J NEUROSCI, V17, P1548; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Minshall C, 1996, J IMMUNOL, V156, P939; MITRA G, 1991, ONCOGENE, V6, P2237; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; Parrizas M, 1997, J BIOL CHEM, V272, P154; Price BD, 1996, CANCER RES, V56, P246; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SMEYNE RJ, 1994, NATURE, V368, P245; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; Spear N, 1997, J NEUROCHEM, V69, P53; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Virdee K, 1996, J NEUROCHEM, V67, P1801; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; Zhai S, 1996, EXP CELL RES, V224, P335, DOI 10.1006/excr.1996.0143	44	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					825	832		10.1038/sj.onc.1201842	http://dx.doi.org/10.1038/sj.onc.1201842			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484773				2022-12-17	WOS:000072053200001
J	Hogg, A; Schirm, S; Nakagoshi, H; Bartley, P; Ishii, S; Bishop, JM; Gonda, TJ				Hogg, A; Schirm, S; Nakagoshi, H; Bartley, P; Ishii, S; Bishop, JM; Gonda, TJ			Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2	ONCOGENE			English	Article						Myb; differentiation; target genes; bcl-2; apoptosis	RNA INHIBITS PROLIFERATION; MURINE HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA CELLS; HUMAN LYMPHOCYTES-T; V-MYB; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ERYTHROID-DIFFERENTIATION; DEPENDENT TRANSFORMATION; CONSTITUTIVE EXPRESSION	Primary murine fetal hemopoietic cells were transformed with a fusion protein consisting of the ligand-binding domain of the estrogen receptor and a carboxyl-terminally truncated c-Myb protein (ERMYB), The ERMYB-transformed hemopoietic cells exhibit an immature myeloid phenotype when grown in the presence of beta-estradiol. Upon removal of beta-estradiol, the ERMYB cells display increased adherence, decreased clonogenicity and differentiate to cells exhibiting granulocyte or macrophage morphology, The expression of the c-myc, c-kit, cdc2 and bcl-2 genes, which are putatively regulated by Myb, was investigated in ERMYB cells grown in the presence or absence of beta-estradiol. Neither c-myc nor cdc2 expression was down-regulated after removal of beta-estradiol demonstrating that differentiation is not a consequence of decreased transactivation of these genes by ERMYB. While bcl-2 expression was reduced by 50% in ERMYB cells grown in the absence of beta-estradiol, there was no increase in DNA laddering, suggesting that Myb was not protecting ERMYB cells from apoptosis, In contrast, a substantial (200-fold) decrease in c-kit mRNA level was observed following differentiation of ERMYB cells, and c-kit mRNA could be partially re-induced by the re-addition of beta-estradiol. Furthermore, a reporter construct containing the c-kit promoter was activated when cotransfected with a Myb expression vector, providing further evidence of a role for Myb in the regulation of c-kit.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143; RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	Institute Medical & Veterinary Science Australia; University of California System; University of California San Francisco; RIKEN			NAKAGOSHI, Hideki/B-2145-2011; Gonda, Thomas J/A-3620-2012; Ishii, Shunsuke/A-5271-2016	NAKAGOSHI, Hideki/0000-0003-0850-1814; Ishii, Shunsuke/0000-0002-6530-2478				ANDRE C, 1989, ONCOGENE, V4, P1047; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; EVAN GI, 1992, CELL, V69, P19; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1993, BLOOD, V82, P2813; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAYASHI SI, 1995, DNA RES, V2, P21; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KU DH, 1993, J BIOL CHEM, V268, P2255; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MACMILLAN EM, 1994, BLOOD, V83, P209; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9; YASUDA H, 1993, BIOCHEM BIOPH RES CO, V191, P893, DOI 10.1006/bbrc.1993.1301; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	73	56	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2885	2898		10.1038/sj.onc.1201472	http://dx.doi.org/10.1038/sj.onc.1201472			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416832				2022-12-17	WOS:A1997YK37700001
J	Kitanaka, C; Namiki, T; Noguchi, K; Mochizuki, T; Kagaya, S; Chi, S; Hayashi, A; Asai, A; Tsujimoto, Y; Kuchino, Y				Kitanaka, C; Namiki, T; Noguchi, K; Mochizuki, T; Kagaya, S; Chi, S; Hayashi, A; Asai, A; Tsujimoto, Y; Kuchino, Y			Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-x(L) on Bax-induced caspase activation and apoptosis	ONCOGENE			English	Article						Bax; Bcl-2; Bcl-x(L); apoptosis; caspase; CPP32	CRMA-INHIBITABLE PROTEASE; INTERLEUKIN-1-BETA-CONVERTING ENZYME; POLY(ADP-RIBOSE) POLYMERASE; DEATH; FAMILY; HETERODIMERIZATION; CPP32; GENE; CHEMOTHERAPY; MITOCHONDRIA	Bcl-2 family proteins and ICE/CED-3 family proteases (caspases) are regarded as the basic regulators of apoptotic cell death. They are evolutionarily conserved and implicated in a variety of apoptosis. However, the precise mechanism by which these two families interact to regulate cell death is not yet known. In this study, we found that the overexpression of the Bcl-2 family member Bax induced apoptotic cell death in COS-7 cells through the activation of CPP32 (caspase-3)-like proteases that cleaved the DEVD tetrapeptide. This apoptotic cell death was suppressed by the viral proteins CrmA and p35, as well as by the chemically synthesized caspase inhibitors Z-Asp-CH2-DCB and zVAD-fmk. We also found that the Bax-induced apoptosis of COS-7 cells was suppressed by Bcl-x(L) and Bcl-2, though both Bcl-x(L) and Bcl-2 similarly prevented etoposide-induced apoptosis in COS-7 cells, In addition, Bcl-x(L) inhibited the activation of caspase-3-like proteases accompanying Bax-induced COS-7 cell death but Bcl-2 did not. These results indicate that the caspase activation is essential for Bax-induced apoptosis, and that the ability of Bcl-2 and Bcl-x, to prevent the Bax-induced caspase activation and apoptosis in COS-7 cells could be differentially regulated. Our results also suggest that Bcl-2 family proteins function upstream of caspase activation and control apoptosis through the regulation of caspase activity.	NATL CANC CTR, RES INST, DIV BIOPHYS, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, SCH MED, DEPT NEUROSURG, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, SCH MED, CTR BIOMED RES, DEPT MED GENET, SUITA, OSAKA 565, JAPAN	National Cancer Center - Japan; University of Tokyo; Osaka University								Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boulakia CA, 1996, ONCOGENE, V12, P529; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; DOLE M, 1994, CANCER RES, V54, P3253; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Estoppey S, 1997, CELL DEATH DIFFER, V4, P34, DOI 10.1038/sj.cdd.4400205; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Gottschalk AR, 1996, CELL DEATH DIFFER, V3, P113; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1996, CANCER RES, V56, P4743; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jung YK, 1996, J BIOL CHEM, V271, P5112; KITANAKA C, 1995, CELL DEATH DIFFER, V2, P123; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SAMBROOK J, 1989, EXPRESSION CLONED GE; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Shimizu S, 1996, ONCOGENE, V12, P2251; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	51	56	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1763	1772		10.1038/sj.onc.1201349	http://dx.doi.org/10.1038/sj.onc.1201349			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362442				2022-12-17	WOS:A1997XZ72500002
J	Chen, G; Shu, JY; Stacey, DW				Chen, G; Shu, JY; Stacey, DW			Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide	ONCOGENE			English	Article						oncogene; apoptosis; SAPK; cell cycle; etoposide	SIGNAL-TRANSDUCTION PATHWAYS; CYCLIN-DEPENDENT KINASES; PROGRAMMED CELL-DEATH; PROTEIN-KINASES; C-MYC; INTERCALATING AGENTS; ANTICANCER AGENTS; GAMMA-RADIATION; JNK ACTIVATION; CANCER-THERAPY	The exact mechanisms for the selective toxicity of chemotherapeutic drugs against tumor cells are not fully understood, We designed a series of experiments to test the possibility that the positive proliferative signal initiated by oncogenes might change the sensitivity for apoptosis induction by the anticancer drug etoposide (VP16), an inhibitor of topoisomerase IT (Topo II), Treatment with VP16 induced significantly increased apoptosis in NIH3T3 cells transformed by oncogenic src, ras or raf, compared with the normal 3T3 cells, Apopototic changes involved nuclear DNA fragmentation, morphological alterations and decreased viability, Furthermore it was shown that stress-activated protein kinase (SAPK) was activated much more strongly in all three transformed lines compared to untransformed cells by VP16 treatment, while slight activation of extracellular signal-regulated kinase (ERK1) was observed in all four cell lines, In addition, the transformed cells displayed arrest in mid-S-phase following the treatment, whereas NIH3T3 cells were primarily arrested in late S and G(2)/M phase. Finally, the cyclin-dependent kinase inhibitor p21 WAF1 was induced in all four cell lines, although induction of p53 was not detected in any of these cell lines. Taken together our results demonstrated that oncogenic transformation can sensitize the cells to apoptosis induction, stress kinase activation and cell cycle arrest in response to VP16 treatment, These results may have important implications for understanding the selective toxicity of anti-cancer drugs in tumor cells.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NIGMS NIH HHS [GM52271] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELANI CP, 1994, CANCER CHEMOTH PHARM, V34, pS118, DOI 10.1007/BF00684875; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chresta CM, 1996, CANCER RES, V56, P1834; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7274; GLISSON B, 1986, CANCER RES, V46, P1939; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIU YO, 1994, BIOCHEM PHARMACOL, V48, P1265; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOCK RB, 1994, CANCER RES, V54, P4933; Lock RB, 1996, CANCER RES, V56, P4006; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Shu JY, 1996, ONCOGENE, V13, P2421; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TEODORO JG, 1995, ONCOGENE, V11, P467; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trent JC, 1996, EMBO J, V15, P4497, DOI 10.1002/j.1460-2075.1996.tb00827.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	56	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1643	1651		10.1038/sj.onc.1201347	http://dx.doi.org/10.1038/sj.onc.1201347			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349497				2022-12-17	WOS:A1997XY63100003
J	Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO				Gabrielli, BG; Clark, JM; McCormack, AK; Ellem, KAO			Ultraviolet light-induced G2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis	ONCOGENE			English	Article						cdc25; cell cycle checkpoint; UV	MATURATION-PROMOTING FACTOR; CDK2 PROTEIN-KINASE; IONIZING-RADIATION; HUMAN FIBROBLASTS; HELA-CELLS; DEPENDENT KINASES; NITROGEN-MUSTARD; DNA-REPLICATION; B IRRADIATION; G1 ARREST	In response to low doses of ultraviolet (U.V.) radiation, cells undergo a G2 delay. In this study we have shown that the G2 delay results in the accumulation of inactive forms of cyclin B1/cdc2 and both the G2 and mitotic complexes of cyclin A/cdk. This appears to be through a block in the cdc25-dependent activation of these complexes. The expression and localisation of cyclin A and cyclin B1/cdk complexes are similar in U.V.-induced G2 delay and normal early G2 phase cells, Cdc25B and cdc25C also accumulate to normal G2 levels in U.V. irradiated cells, but the mitotic phosphorylation associated with increased activity of both cdc25B and cdc25C is absent. The cdc25B accumulates in the nucleus of U.V. irradiated cells and in normal G2 phase cells. Thus the block in cyclin B/cdc2 activation is in part due to the physical separation of cyclin B/cdc2, localised in the cytoplasm, from the cdc25B and cdc25C phosphatases localised in the nucleus, The data positions the U.V.-induced G2 checkpoint at either the S/G2 transition or early G2 phase, prior to the activation of cyclin A/cdk2.			Gabrielli, BG (corresponding author), ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,JOINT ONCOL PROGRAM,QUEENSLAND CANC FUND RES LAB,HERSTON,QLD 4029,AUSTRALIA.		Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAILLY E, 1992, J CELL SCI, V101, P529; BARKER D, 1995, CANCER RES, V55, P4041; Barth H, 1996, CANCER RES, V56, P2268; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GABRIELLI B, 1994, ADV PROT PHOSPHATASE, V8, P209; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kovelman R, 1996, MOL CELL BIOL, V16, P86; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NAGATA A, 1991, NEW BIOL, V3, P959; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; Petrocelli T, 1996, ONCOGENE, V12, P1387; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WANG XQ, 1994, EXP CELL RES, V212, P176, DOI 10.1006/excr.1994.1133; Wang XQ, 1996, CANCER RES, V56, P2510	49	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					749	758		10.1038/sj.onc.1201254	http://dx.doi.org/10.1038/sj.onc.1201254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266961				2022-12-17	WOS:A1997XQ11700001
J	Thron, CD				Thron, CD			Bistable biochemical switching and the control of the events of the cell cycle	ONCOGENE			English	Article						biochemical switch; bistability; cell cycle; cyclin-dependent kinase inhibitors; positive feedback	DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN; NEGATIVE REGULATION; CDK INHIBITORS; FISSION YEAST; E2F-1 GENE; G1 PHASE; ACTIVATION; TRANSCRIPTION; EXPRESSION	Some of the events of the cell cycle appear to be triggered by a bistable mechanism. A bistable biochemical system can respond to a small, slow signal and is carried by positive feedback from one stable steady state directly to another, in an all-or-none manner. Slow or subthreshold stimuli do not cause accommodation or loss of excitability. Switching is not readily reversible by removing the stimulus, i.e. there is hysteresis: reversal generally requires a stronger, opposite stimulus. Biochemically, bistable biochemical switching requires positive feedback, and mechanisms for stabilizing the system against premature activation and for destabilization in response to a biological signal. Three bistable biochemical models, all suggested by reported experimental observations, are described and analysed. These models suggest that a titratable inhibitor may play an important part in bistable switching, because the end-point of titration can form a natural threshold for enhancement of positive feedback.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755	Dartmouth College								ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; EDELSTEIN BB, 1971, J THEOR BIOL, V32, P191, DOI 10.1016/0022-5193(71)90146-9; Edelstein-Keshet L., 1988, MATH MODELS BIOL; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fotedar R, 1996, ONCOGENE, V12, P2155; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Geng Y, 1996, ONCOGENE, V12, P1173; GRAY P, 1990, CHEM OSCILLATIONS IN; Hale J, 1991, DYNAMICS BIFURCATION; HALL M, 1995, ONCOGENE, V11, P1581; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; HIGGINS J, 1967, IND ENG CHEM, V59, P18, DOI 10.1021/ie50689a006; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; Lee TH, 1996, P NATL ACAD SCI USA, V93, P352, DOI 10.1073/pnas.93.1.352; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MEINHARDT H., 1982, MODELS BIOL PATTERN; Murray A., 1993, CELL CYCLE INTRO; Murray J.D., 1989, MATH BIOL, DOI DOI 10.1007/978-3-662-08539-4; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NOVAK B, 1993, J THEOR BIOL, V165, P101, DOI 10.1006/jtbi.1993.1179; NOVAK B, 1995, J THEOR BIOL, V173, P283, DOI 10.1006/jtbi.1995.0063; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OSWALD F, 1994, ONCOGENE, V9, P2029; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1995, MOL CELL BIOL, V15, P742; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roy LM, 1996, ONCOGENE, V12, P2203; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEELIG FF, 1972, FEBS LETT, V24, P283, DOI 10.1016/0014-5793(72)80373-9; SHEER CJ, 1996, SCIENCE, V274, P1672; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; Thron CD, 1996, BIOPHYS CHEM, V57, P239, DOI 10.1016/0301-4622(95)00075-5; THRON CD, 1994, BIOSYSTEMS, V32, P97, DOI 10.1016/0303-2647(94)90035-3; THRON CD, 1997, IN PRESS P 2 WORLD C; THRON CD, 1997, ADV MATH POPULATION; Tyson J J, 1995, Prog Cell Cycle Res, V1, P1; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3	73	56	56	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					317	325		10.1038/sj.onc.1201190	http://dx.doi.org/10.1038/sj.onc.1201190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233766				2022-12-17	WOS:A1997XK99900008
J	Qian, M; Kralova, J; Yu, WP; Bose, HR; Dvorak, M; Sanders, BG; Kline, K				Qian, M; Kralova, J; Yu, WP; Bose, HR; Dvorak, M; Sanders, BG; Kline, K			c-Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells	ONCOGENE			English	Article						AP-1; dominant negative c-Jun; c-Jun; vitamin E succinate; apoptosis; avian retrovirus transformed lymphoid cells	EXPRESSION; GROWTH; AP-1; FOS; PROTEINS; INVITRO; GENES	Previous studies have shown that treatment of avian reticuloendotheliosis virus-transformed RECC-UTC4-1 (C4-1) lymphoblastoid cells with 10 mu g/ml (18.8 mu M) of RRR-alpha-tocopheryl succinate (vitamin E succinate, VES) for 3 days induced approximately 50% of the cells to undergo apoptosis, Elevated and prolonged expression of c-jun mRNA and protein was temporally correlated with VES-induced cell death, Data presented in this paper show that the elevated and prolonged expression of c-jun message and protein are not accounted for by enhanced stability, and show the involvement of c-Jun in VES-induced apoptosis in this lymphoblastoid cell type, C4-1 cells infected with a virus carrying a dominant, negatively acting mutant form of c-Jun, supjun-1, exhibited: (i) 71% reduction in VES-induced apoptosis, (ii) a 2.0-2.5-fold decrease in wildtype, endogenous c-Jun expression, and (iii) a 2.4-2.6-fold reduction in AP-1 binding activity, Additionally, cells co-treated with VES plus RRR-alpha-tocopherol, exhibited a 70% reduction in apoptosis, a marked reduction in c-Jun expression and a 1.6-fold reduction in AP-1 binding activity, These studies suggest that c-Jun plays a crucial role in VES-induced apoptosis in C4-1 cells, and add to understanding of mechanisms of action involved VES-mediated tumor cell growth inhibition.	ACAD SCI CZECH REPUBL, GENET INST, PRAGUE, CZECH REPUBLIC; ACAD SCI CZECH REPUBL, INST MOL GENET, PRAGUE, CZECH REPUBLIC; UNIV TEXAS, DEPT MICROBIOL, AUSTIN, TX 78712 USA; UNIV TEXAS, DIV NUTR, AUSTIN, TX 78712 USA	Czech Academy of Sciences; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	NCI NIH HHS [CA33192, CA45422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192, R01CA045422, R29CA045422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; CHEN YR, 1996, BIOL CHEM J, V271, P31929; COLLOTTA F, 1992, BIOL CHEM J, V267, P18278; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KLINE K, 1991, VITAMINS AND MINERALS IN THE PREVENTION AND TREATMENT OF CANCER, P189; KLINE K, 1990, NUTR CANCER, V14, P27, DOI 10.1080/01635589009514075; KLINE K, 1995, NUTR CANC PREVENTION, P39; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; NISHIMURA T, 1988, ONCOGENE, V3, P659; OFFORD EA, 1993, CARCINOGENESIS, V14, P2447, DOI 10.1093/carcin/14.12.2447; OKUNO H, 1991, ONCOGENE, V6, P1491; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRASAD KN, 1992, J AM COLL NUTR, V11, P487; Qian M, 1996, NUTR CANCER, V25, P9, DOI 10.1080/01635589609514424; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHWARTZ J, 1993, ADJUVANT NUTRITION C, P173; SLACK R, 1989, NUTR CANCER, V12, P75, DOI 10.1080/01635588909514004; Sutterluety H, 1996, J MOL BIOL, V259, P383, DOI 10.1006/jmbi.1996.0327; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TRABER MG, 1988, AM J CLIN NUTR, V48, P605, DOI 10.1093/ajcn/48.3.605; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VANDEWERKEN R, 1993, EUR J BIOCHEM, V217, P781; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yu WP, 1997, NUTR CANCER, V27, P267, DOI 10.1080/01635589709514537; Yu WP, 1997, NUTR CANCER, V27, P92, DOI 10.1080/01635589709514508	37	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	1997	15	2					223	230		10.1038/sj.onc.1201181	http://dx.doi.org/10.1038/sj.onc.1201181			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK372	9244357				2022-12-17	WOS:A1997XK37200010
J	McConnell, MJ; Cunliffe, HE; Chua, LJ; Ward, TA; Eccles, MR				McConnell, MJ; Cunliffe, HE; Chua, LJ; Ward, TA; Eccles, MR			Differential regulation of the human Wilms tumour suppressor gene (WTI) promoter by two isoforms of PAX2	ONCOGENE			English	Article						PAX2; WT1; transcription factor; tumour suppressor; kidney development	HUMAN FETAL KIDNEY; PAIRED DOMAIN; DNA-BINDING; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION PROPERTIES; SEQUENCE RECOGNITION; PROTEIN WT1; EXPRESSION; MUTATION; ACTIVATION	PAX2 is a member of the paired box family of genes with an important role in kidney, genital tract and eye development. Another gene essential for kidney and genital tract development is the Wilms tumour gene, WT1. PAX2 and WT1 encode transcription factors expressed during fetal kidney development in patterns that overlap both spatially and temporally. The overlap of PAX2 and WT1 expression in fetal kidney prompted us to determine whether PAX2 regulates the WT1 gene. To investigate this possibility, the WT1 promoter and a series of WT1 promoter deletion fragments were cloned into a luciferase reporter vector, and used in cotransfection experiments with PAX2 expression constructs. PAX2 transactivated the WT1 promoter up to 35-fold in CHO-K1 cells, and from four- to sevenfold in 293 cells. Two regions of the WT1 promoter were required in the same promoter construct for efficient transactivation by PAX2 in CHO-K1 cells, and purified recombinant PAX2 protein was found to bind to two sites in the WT1 promoter, at -205/-230 and +377/ +402. Removal of WT1 promoter sequences containing the -205/-230, or + 377/ + 402 binding sites abolished transactivation of the WT1 promoter by PAX2 in CHO-K1 cells, and had a differential effect on transactivation of the WT1 promoter in 293 cells, depending on the PAX2 isoform used. A fragment containing the -205/ -230 site alone could be transactivated by PAX2. These findings suggest that PAX2 is a tissue-specific modulator of WT1 expression, and is involved in cell growth control via WT1.	UNIV OTAGO, DEPT BIOCHEM, CANC GENET LAB, DUNEDIN, NEW ZEALAND	University of Otago				McConnell, Melanie J./0000-0003-3840-1347				ANANT S, 1994, ONCOGENE, V9, P3113; BARD JBL, 1994, MECH DEVELOP, V48, P3, DOI 10.1016/0925-4773(94)00273-8; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CVEKL A, 1995, P NATL ACAD SCI USA, V92, P4681, DOI 10.1073/pnas.92.10.4681; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; Dehbi M, 1996, ONCOGENE, V13, P447; Dehbi M, 1996, EMBO J, V15, P4297, DOI 10.1002/j.1460-2075.1996.tb00804.x; Dorfler P, 1996, EMBO J, V15, P1971, DOI 10.1002/j.1460-2075.1996.tb00548.x; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1994, ONCOGENE, V9, P2059; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Hildebrandt Friedhelm, 1995, Current Opinion in Pediatrics, V7, P182, DOI 10.1097/00008480-199504000-00012; HOFMANN W, 1993, ONCOGENE, V8, P3123; HOLST BD, 1994, J BIOL CHEM, V269, P22245; JACKSON P, 1993, ONCOGENE, V8, P589; KELLER SA, 1994, GENOMICS, V23, P309, DOI 10.1006/geno.1994.1506; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; MATSUNAGA E, 1981, HUM GENET, V57, P231; NISEN PD, 1986, CANCER RES, V46, P6217; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; POLEEV A, 1995, EUR J BIOCHEM, V228, P899, DOI 10.1111/j.1432-1033.1995.tb20338.x; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REDDY JC, 1995, J BIOL CHEM, V270, P29976; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Sanyanusin P, 1996, GENOMICS, V35, P258, DOI 10.1006/geno.1996.0350; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SANYANUSIN P, 1995, HUM MOL GENET, V4, P2183, DOI 10.1093/hmg/4.11.2183; Saxen L., 1987, ORGANOGENESIS KIDNEY; SHAW APW, 1988, ONCOGENE, V3, P143; Song DL, 1996, DEVELOPMENT, V122, P627; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TAKEHANA K, 1991, GENE, V103, P219, DOI 10.1016/0378-1119(91)90276-H; Torban E, 1996, J AM SOC NEPHROL, V7, pA1785; Torres M, 1995, DEVELOPMENT, V121, P4057; Torres MA, 1996, DEVELOPMENT, V122, P3381; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	66	56	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	1997	14	22					2689	2700		10.1038/sj.onc.1201114	http://dx.doi.org/10.1038/sj.onc.1201114			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178767				2022-12-17	WOS:A1997XB97800008
J	Muller, S; Sideras, P; Smith, CE; Xanthopoulos, KG				Muller, S; Sideras, P; Smith, CE; Xanthopoulos, KG			Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members	ONCOGENE			English	Article						Bruton's tyrosine kinase; transcription factors; cell restricted expression	X-LINKED AGAMMAGLOBULINEMIA; BOX-BINDING-PROTEINS; GENOMIC ORGANIZATION; TRANSCRIPTIONAL ACTIVATION; FAMILY; SITE; MUTATIONS; EVOLUTION; ONCOGENE; LINEAGE	Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase involved in the human disease X-linked agammaglobulinemia (XLA), The gene is expressed in all hematopoietic cells with the exception of T-cells and plasma cells, For this expression pattern the first 280 bp upstream of the major transcriptional start site seems to be sufficient, In vitro footprinting analysis within this part of the promoter revealed two Spl binding sites as web as a PU-box, The transcription factor Spi-1/PU.1 as well as the closely related factor Spi-B bound to the PU-box in B-cells, In the erythroleukemia cell line K562, due to the absence of Spi-B, only PU.1 bound to the Btk promoter, Mutation of either site reduced the expression in transient transfection experiments, However, mutation of the PU box had no effect in the T-cell line Jurkat, where none of the Spi-1 family members is expressed, In addition Spi-B as well as PU.1 were able to transactivate Btk expression, Tn fetal liver of PU.1(-)/(-) mice, which lack lymphoid and myeloid cells, expression of Btk was reduced two- to threefold but not abolished, Collectively this study shows that expression of the Btk gene is regulated by the combined action of Sp1- and PU.1-family members.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN; UMEA UNIV, DEPT MOL & CELL BIOL, S-90187 UMEA, SWEDEN; HUDDINGE UNIV HOSP, DEPT IMMUNOL MICROBIOL PATHOL & INFECT DIS, DIV CLIN IMMUNOL, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet; Umea University; Karolinska Institutet				SMITH, C. I. Edvard/0000-0003-1907-3392				BRUTON OC, 1952, PEDIATRICS, V9, P722; CHEN HM, 1995, ONCOGENE, V11, P1549; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GACHELIN FM, 1993, BIOCHIM BIOPHYS ACTA, V1198, P149; GENEVIER HC, 1994, EUR J IMMUNOL, V24, P3100, DOI 10.1002/eji.1830241228; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HROMAS R, 1993, BLOOD, V82, P2998; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1995, EMBO J, V13, P6524; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Maniatis T, 1989, MOL CLONING; Mao C, 1996, ONCOGENE, V12, P863; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NILSSON L, 1995, INT IMMUNOL, V7, P1191, DOI 10.1093/intimm/7.8.1191; NILSSON L, 1993, INT IMMUNOL, V5, P271; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROHRER J, 1994, IMMUNOGENETICS, V40, P319, DOI 10.1007/BF01246672; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SIDERAS P, 1992, J IMMUNOL, V149, P244; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SMITH CIE, 1994, J IMMUNOL, V152, P557; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160	41	56	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1955	1964						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934542				2022-12-17	WOS:A1996VR79500015
J	Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM				Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM			A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident	ONCOGENE			English	Article						RET oncogene; RT-PCR; 5'RACE; RET/PTC3; RET/Delta PTC3; papillary thyroid carcinoma	MOLECULAR CHARACTERIZATION; PROTOONCOGENE; ACTIVATION; ONCOGENE; RET/PTC3; D10S170; FUSION; CANCER; GENE; PTC	Intrachromosomal rearrangements involving the RET and the adjacent H4 or ELE1 gene are very frequent events in thyroid cancer of children from Belarus after the Chernobyl reactor accident (Klugbauer et al., 1995), The fusion product between ELE1 and RET (RET/PTC3) seems to be the prevailing type of rearrangement as shown in a recently published study using a novel RT multiplex PCR approach in combination with the identification of the rearrangement type by RT-PCR and direct sequencing. Now we found a new type of RET rearrangement: By the 5'RACE method we demonstrated in cDNA the fusion of the tyrosine kinase domain of RET with a truncated ELE1 gene shorter than the ELE1 in RET/PTC3, Sequencing of genomic DNA revealed a rearrangement breakpoint at position 41 of a new ELE1 intron (522 bp in length), The new oncogene RET/Delta PTC3 is shortened by one ELE1 exon of 144 bp in length, Structural considerations of the ele1 amino terminal of RET/Delta PTC3 suggest that the transforming activity of the fusion protein is apparently not affected by this truncation, The exon lacking in RET/Delta PTC3 was found to code in the reciprocal transcript RET/Delta ELE1 and increased its size by 144 bp, Obviously the new and possibly additional ELE/RET fusion molecules might even increase the high prevalence of ELE1/RET rearrangements in thyroid carcinomas of children after the Chernobyl reactor accident.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; UNIV MUNICH, INST RADIAT BIOL, MUNICH, GERMANY; MED HIGH SCH MINSK, CHAIR ONCOL, MINSK, BELARUS	University of Munich; University of Munich								BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; ITO T, 1993, CANCER RES, V53, P2940; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; TONG Q, 1995, ONCOGENE, V10, P1781; TSUZUKI T, 1995, ONCOGENE, V10, P191	17	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1099	1102						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806700				2022-12-17	WOS:A1996VG76600024
J	Li, WL; Park, JW; Nuijens, A; Sliwkowski, MX; Keller, GA				Li, WL; Park, JW; Nuijens, A; Sliwkowski, MX; Keller, GA			Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells	ONCOGENE			English	Article						heregulin; ErbB2/HER2/neu; growth factor internalization; nuclear transport; c-myc	EPIDERMAL GROWTH-FACTOR; LOCALIZATION; ACTIVATION; RECEPTORS; PROTEINS	Heregulins (neuregulins) are a family of proteins known to interact and activate the receptor tyrosine kinases ErbB2 in association with ErbB3 or ErbB4. Using immunofluorescence microscopy, electron microscopy autoradiography, and SDS-PAGE analysis of nuclear fractions, we show that the heregulin-beta 1(1-244) isoform is rapidly internalized and translocated to the nucleus of SK-BR-3 breast cancer cells as an intact molecule. Heregulin-beta 1(1-244) treatment up-regulated expression of c-myc mRNA and protein, which was also observed to undergo its own translocation from the cytosol to the nucleus. c-myc thus appears to be a cellular target gene of HRG beta 1(1-244) and its induction may be related to the nuclear translocation of heregulin.	GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GARCIA G, 1987, CANCER RES, V49, P6675; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; PEITRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K	20	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2473	2477						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649790				2022-12-17	WOS:A1996UQ22000027
J	Theodorakis, P; DSaEipper, C; Subramanian, T; Chinnadurai, G				Theodorakis, P; DSaEipper, C; Subramanian, T; Chinnadurai, G			Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1	ONCOGENE			English	Article						Bcl-2 family; EBV-BHRF1; apoptosis; oncogenesis; p53; E1A; R-ras	PROGRAMMED CELL-DEATH; B-CELLS; BCL-2 GENE; C-MYC; VIRUS; P53; EXPRESSION; E1A; ONCOGENES; HOMOLOG	The BHRF1 protein of Epstein-Barr virus (EBV) is a structural and functional homolog of the Bcl-2 protein, Both BHRF1 and Bcl-2 proteins promote the survival of cells exposed to various apoptotic stimuli. This promotion of cell survival is associated with a block in proliferation, It is believed that the Bcl-2 family of anti-apoptosis proteins contribute to oncogenesis merely by promoting cell survival. We have discovered that mutations within a regulatory domain of the BHRF1 protein not only suppress apoptosis induced by the tumor suppressor protein p53, but also permit efficient proliferation of cells that would otherwise undergo total apoptosis, These gain-of-function mutants of BHRF1 cooperate more efficiently with the E1a oncogene in transformation of primary rat kidney cells where E1A expression results in apoptosis. Our results suggest that such mutational inactivation of a proliferation-restraining activity in the BHRF1 gene may play a direct role in oncogenesis.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA033616, R01CA031719] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31719, CA-33616, R01 CA033616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAKHSHI A, 1985, CELL, V41, P889; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COX AD, 1994, ONCOGENE, V9, P3281; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HELLER M, 1981, J VIROL, V38, P632, DOI 10.1128/JVI.38.2.632-648.1981; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SAEZ R, 1994, ONCOGENE, V9, P2877; Subramanian T, 1995, ONCOGENE, V11, P2403; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; TAKAYAMA S, 1994, DNA CELL BIOL, V13, P679, DOI 10.1089/dna.1994.13.679; TARODI B, 1994, VIROLOGY, V201, P404, DOI 10.1006/viro.1994.1309; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WANG HG, 1994, ONCOGENE, V9, P2751; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	44	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1707	1713						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622891				2022-12-17	WOS:A1996UG45800013
J	George, RE; Kenyon, RM; McGuckin, AG; Malcolm, AJ; Pearson, ADJ; Lunec, J				George, RE; Kenyon, RM; McGuckin, AG; Malcolm, AJ; Pearson, ADJ; Lunec, J			Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma	ONCOGENE			English	Article						N-myc; gene amplification; neuroblastoma; DDX1; pG21	HUMAN NEURO-BLASTOMA; DEPENDENT RNA HELICASE; CELL-LINES; DNA; EXPRESSION; ONCOGENE; FAMILY; TUMOR; COAMPLIFICATION; ASSOCIATION	Although N-myc amplification is strongly associated with a poor prognosis, not all patients with neuroblastomas having N-myc amplification fare badly. To investigate whether genes other than N-myc are responsible for contributing to the prognosis, we examined seven cell lines and 87 primary tumours for co-amplification of candidate genes known to be present near the normal N-myc locus: ornithine decarboxylase (ODC), ribonucleotide reductase (RRM2), syndecan-1 and a DEAD box protein gene, DDX1. Sequence analysis of the pG21 cDNA clone previously reported to represent an expressed gene frequently co-amplified with N-myc, showed this to be from the DDX1 gene. No coamplification with the first three genes was found in any of the cell lines or tumour samples. DDX1, however was found to be amplified along with N-myc in 4/6 (67%) cell lines and 6/16 (38%) of the N-myc amplified tumours. Co-amplification of DDX1 and N-myc was found more frequently in stage 4 or 4S tumours than lower stage (1-3) tumours. With the exclusion of a single 4S case, there was a highly significant reduction in the mean disease-free interval from 24.4 +/- 4.7 (SE, n = 10) months for cases with co-amplification of N-myc and DDX1 compared with 9.2 +/- 1.8 (SE, n = 5) months for those cases showing amplification of N-myc alone (P = 0.0056, Welch's unpaired t-test). No amplification of DDX1, ODC, RRM2, or syndecan-1 was found in the absence of N-myc amplification. These observations indicate that the N-myc amplicon is of varied size and/or position relative to the N-myc gene, with DDX1 representing at least one other gene frequently coamplified with N-myc. Further studies are required to confirm the biological and prognostic significance of DDX1 co-amplification and to elucidate the role that DDX1 plays in tumour genesis and progression.	UNIV NEWCASTLE UPON TYNE,SCH MED,CANC RES UNIT,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT CHILD HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT PATHOL,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK								AKIYAMA K, 1994, NUCLEIC ACIDS RES, V22, P187, DOI 10.1093/nar/22.2.187; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; AMLER LC, 1995, IN PRESS GENES CHROM; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARACHI R, 1987, BRIT J CANCER, V55, P407, DOI 10.1038/bjc.1987.80; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GRADYLEOPARDI EF, 1986, CANCER RES, V44, P5444; GURURAJAN R, 1991, NATURE, V349, P717, DOI 10.1038/349717a0; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIEMSTRA JL, 1994, ADV NEUROBLASTOMA RE, V4, P51; KHATIB ZA, 1993, CANCER RES, V53, P5535; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LONGO L, 1988, J CANCER RES CLIN, V114, P636, DOI 10.1007/BF00398190; MALI M, 1990, J BIOL CHEM, V265, P6884; MOSHIER JA, 1990, J BIOL CHEM, V265, P4884; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER HR, 1976, CANCER RES, V36, P3094; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; Seeger R C, 1988, Prog Clin Biol Res, V271, P41; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHILOH Y, 1986, CANCER RES, V46, P5297; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; SLAVC I, 1990, CANCER RES, V50, P1459; SMITH K, 1993, ONCOGENE, V8, P933; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SQUIRE JA, 1995, ONCOGENE, V10, P1417; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WHELDON TE, 1985, BRIT J RADIOL, V58, P661, DOI 10.1259/0007-1285-58-691-661	42	56	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1583	1587						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622876				2022-12-17	WOS:A1996UF07600024
J	Martinerie, C; Chevalier, G; Rauscher, FJ; Perbal, B				Martinerie, C; Chevalier, G; Rauscher, FJ; Perbal, B			Regulation of nov by WT1: A potential role for nov in nephrogenesis	ONCOGENE			English	Article						novH; nephrogenesis; Wilms' tumor; WT1; IGF-binding-protein	WILMS-TUMOR GENE; GROWTH FACTOR-II; IMMEDIATE-EARLY GENE; ZINC FINGER PROTEIN; FACTOR-A-CHAIN; PROMOTER ACTIVITY; BINDING-PROTEIN; RECEPTOR GENE; KIDNEY DEVELOPMENT; SUPPRESSOR WT1	The nov gene encodes a putative Insulin-like-Growth Factor-Binding Protein (IGFBP) of a novel type which is structurally related to a family of growth-factors likely to play a role in the control of cell proliferation. In the kidney, nov is expressed essentially at the embryonic stage and alterations of nov expression, relative to the normal kidney, have been detected in both avian nephroblastomas and human Wilms' tumors. The levels of human nov (novH) and WT1 mRNA in individual Wilms' tumors have been shown to be inversely correlated, suggesting that the expression of novH could be under the negative control of WT1. We have now established the nucleotide sequence of the 5' flanking region,and identified two transcription start sites by RNase protection assays and primer extension. We report that in transient cotransfection experiments the transcription activity of novH promoter constructs was repressed by two isoforms of WT1 proteins (WT1 and WT1 + KTS). Repression of the novH promoter required both intact zinc finger regions and the NH, transcription repression domain of WT1. Inasmuch as the minimal region of novH promoter required to mediate WT1 repression irt vivo failed to bind recombinant WT1 protein in in vitro footprinting assays this repression may be mediated by either (i) low affinity sites cooperative interactions or (ii) indirectly via protein-protein interactions with another factor(s). Furthermore, constitutive expression of wild type WT1 into 293 cells resulted in a decrease of endogenous NOVH protein levels, suggesting that novH may be a physiological target for WT1. The downregulation of novH expression by WT1 might represent a key element in normal and tumoral nephrogenesis.	INST CURIE,LAB ONCOL VIRALE & MOL,F-91405 ORSAY,FRANCE; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PARIS 07,UFR BIOCHIM,F-75221 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; The Wistar Institute; UDICE-French Research Universities; Universite Paris Cite								ARAKI E, 1987, J BIOL CHEM, V262, P16186; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DESSEN P, 1990, FRENCH SERVICE ACCES; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANSLER T, 1989, AM J PATHOL, V135, P961; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GERALD WL, 1992, AM J PATHOL, V140, P1031; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASELBACHER GK, 1987, P NATL ACAD SCI USA, V84, P1104, DOI 10.1073/pnas.84.4.1104; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LIU XW, 1993, NUCLEIC ACIDS RES, V21, P4954, DOI 10.1093/nar/21.21.4954; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MADDEN SL, 1993, ONCOGENE, V8, P405; MAHASWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100; MALOISEL V, 1990, Methods in Molecular and Cellular Biology, V1, P245; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1991, CR ACAD SCI III-VIE, V313, P345; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MORRIS JF, 1991, ONCOGENE, V6, P2339; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; PATCHNIS V, 1993, DEVELOPMENT, V119, P1005; PATWARDHAN S, 1991, ONCOGENE, V6, P917; Perbal B, 1995, INFECT AGENT DIS, V4, P212; PERBAL B, 1994, CRIT REV ONCOGENESIS, V5, P589; PERBAL B, 1994, B CANCER, V81, P957; Perbal B., 1988, PRACTICAL GUIDE MOL; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saxen L., 1987, DEV CELL BIOL SERIES, V19; Scholz G, 1996, MOL CELL BIOL, V16, P481; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1995, ONCOGENE, V10, P1243; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1994, J BIOL CHEM, V269, P12577; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WYANG ZY, 1995, ONCOGENE, V10, P415; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	75	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1479	1492						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622864				2022-12-17	WOS:A1996UF07600012
J	Kato, MV; Sato, H; Tsukada, T; Ikawa, Y; Aizawa, S; Nagayoshi, M				Kato, MV; Sato, H; Tsukada, T; Ikawa, Y; Aizawa, S; Nagayoshi, M			A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells	ONCOGENE			English	Article						mac25; follistatin; p53; growth suppressor	ACTIVIN-BINDING PROTEIN; MICE; P53; PROTEOGLYCANS; INHIBITION; RECEPTOR; KINASES; P21	mac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma, Although the homology of its product with members of family of insulin-like growth factor-binding proteins was suggested, the product also exhibits strong homology to follistatin, an activin-binding protein, However, a domain corresponding to the carboxyl terminus of follistatin is not found in mac25, The carboxyl-terminally truncated form of follistatin, generated by alternative splicing, has stronger activin-binding activity than the complete form, This result suggests that mac25 might act as an activated follistatin, Clonal growth of a p53-deficient osteosarcoma cell line was strongly inhibited when the murine mac25 gene, as well as the p53 gene, was introduced, Resembling activins that belong to the transforming growth factor-beta (TGF-beta) superfamily, mac25 and p53 might associate with similar but distinct targets, namely cyclin-dependent kinase inhibitors. However, there is no evidence for compensation of p53 function by mac25 in the development of p53-deficient mice, as judged from the pattern of expression of mac25 in mice, mac25 might act as a tumor suppressor, modulating signaling of the TGF-beta family, as does alpha-inhibin.	SAITAMA UNIV,FAC SCI,DEPT REGULAT BIOL,URAWA,SAITAMA 338,JAPAN; TOKYO MED & DENT UNIV,DEPT RETROVIRAL REGULAT,DIV MED RES,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,INST EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN	Saitama University; Tokyo Medical & Dental University (TMDU); Kumamoto University	Kato, MV (corresponding author), RIKEN,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,3-1-1 KOYODAI,TSUKUBA,IBARAKI 305,JAPAN.		Kato, Mitsuo/D-5411-2009	Kato, Mitsuo/0000-0002-1783-1084				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SATO H, 1995, BIOCHEM BIOPH RES CO, V214, P468, DOI 10.1006/bbrc.1995.2310; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUKADA T, 1993, ONCOGENE, V8, P3313; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1361	1364						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649839				2022-12-17	WOS:A1996UC06700022
J	HILDT, E; URBAN, S; HOFSCHNEIDER, PH				HILDT, E; URBAN, S; HOFSCHNEIDER, PH			CHARACTERIZATION OF ESSENTIAL DOMAINS FOR THE FUNCTIONALITY OF THE MHBS(T) TRANSCRIPTIONAL ACTIVATOR AND IDENTIFICATION OF A MINIMAL MHBS(T) ACTIVATOR	ONCOGENE			English	Article						HEPATITIS B VIRUS; MHBS(T) ACTIVATOR; SURFACE PROTEIN	HEPATITIS-B VIRUS; HUMAN HEPATOCELLULAR-CARCINOMA; LARGE ENVELOPE POLYPEPTIDE; NF-KAPPA-B; SURFACE-ANTIGEN; RNA-POLYMERASE; TRANSACTIVATOR MHBS(T); ENDOPLASMIC-RETICULUM; TRANSGENIC MICE; MAMMALIAN-CELLS	Integrated hepatitis B virus DNA derived from hepatocellular carcinomas can express, in one third of the cases investigated so far, a transcriptional activator encoded from 3' terminal truncated surface (preS/S) genes resulting in a C-terminally truncated middle surface protein (MHBs(t). Since MHBs(t), in contrast to the secreted MHBs, is retained in the secretory pathway at the ER, the question as to whether the retention generates the transcriptional activator function was investigated. Through fusion of MHBs to the ER-retention signal KDEL, it was shown that the intracellular retention does not generate the transcriptional activator function. Tryptic digestions of microsomal vesicles revealed that the amino terminal domain of MHBs(t) directs into the cytoplasmic compartment, whereas in MHBs this domain directs into the lumen of the ER. This structural difference appears to be why transcriptional activator function arises. Through deletion analysis it was shown that non-membrane-associated MHBs(t) proteins are also functional activators. Non-membrane associated MHBs(t) proteins represent a second class of MHBs(t) proteins. These MHBs(t)-proteins are homogenously distributed all over the cell and show no difference in functionality as compared to the membrane-associated MHBs(t) proteins. MHBs(t53) (truncated at aa53) was shown to be a minimal activator of this class. Both classes of MHBs(t) proteins were found to form dimers; an amphiphatic alpha helix was identified within aa 41-52, which is involved in mediating the dimerization. The integrity of this domain was also revealed to be a prerequisite for the functionality of the activator, suggesting a linkage between dimerization and functionality.			HILDT, E (corresponding author), MAX PLANCK INST BIOCHEM,DEPT VIRUS RES,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Hildt, Eberhard/A-1040-2015					BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; CASELMANN WH, 1990, P NATL ACAD SCI USA, V87, P2790; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBLE BE, 1987, MOL CELL BIOL, V7, P3591, DOI 10.1128/MCB.7.10.3591; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HILDT E, 1993, ONCOGENE, V8, P3359; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; IMAI M, 1987, J VIROL, V61, P3555, DOI 10.1128/JVI.61.11.3555-3560.1987; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LAUER U, 1994, HEPATOLOGY, V19, P23, DOI 10.1002/hep.1840190106; MATSUBARA K, 1991, MOL BIOL HEPATITIS B, P245; Meyer D I, 1991, Trends Cell Biol, V1, P154, DOI 10.1016/0962-8924(91)90016-3; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; MIMMS LT, 1990, VIROLOGY, V176, P604, DOI 10.1016/0042-6822(90)90031-L; NAGAYA T, 1987, GENE DEV, V1, P773, DOI 10.1101/gad.1.8.773; NATOLI G, 1992, VIROLOGY, V187, P663, DOI 10.1016/0042-6822(92)90469-6; NEURATH AR, 1987, MOL IMMUNOL, V24, P975, DOI 10.1016/0161-5890(87)90009-5; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Sambrook J., 1989, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; STIBBE W, 1983, DEV BIOL STAND, V54, P33; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WILL H, 1985, P NATL ACAD SCI USA, V82, P891, DOI 10.1073/pnas.82.3.891; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; YAMAMOTO S, 1993, BIOCHEM BIOPH RES CO, V197, P1209, DOI 10.1006/bbrc.1993.2605; ZAHM P, 1988, ONCOGENE, V3, P169	39	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2055	2066						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478525				2022-12-17	WOS:A1995TF29700016
J	LUCA, M; XIE, SH; GUTMAN, M; HUANG, SY; BARELI, M				LUCA, M; XIE, SH; GUTMAN, M; HUANG, SY; BARELI, M			ABNORMALITIES IN THE CDKN2 (P16(INK4)/MTS-1) GENE IN HUMAN-MELANOMA CELLS - RELEVANCE TO TUMOR-GROWTH AND METASTASIS	ONCOGENE			English	Note						CDKN2 (P16(INK4)/MTS-1); HUMAN MELANOMA; METASTASIS	P53 MUTATIONS	The inhibitor of cyclin-dependent kinase 4, CDKN2 (also known as p16(INK4) Or MTS-1, multiple tumor suppressor gene 1), has been mapped to 9p21, The gene has been shown to be deleted or mutated in high frequency in human melanoma cell lines and familial melanoma patients, suggesting that it could be a melanoma suppressor gene. How these observations are related to tumorigenicity and metastasis of human melanoma is not clear however, To test the role of CDW2 in human melanoma metastasis, 14 human melanoma cell lines with different metastatic abilities in nude mice were analysed for possible abnormalities in the CDKN2 gene, Homozygous deletions that resulted in a lack of gene expression were found in six of 14 cell lines tested. SSCP-direct sequencing revealed point mutations in three other cell lines, One cell line displayed CC to TT transitions which constitute a hallmark of ultraviolet-induced DNA damage, Overall, abnormalities in the CDKN2 gene were found in nine of 14 (64%) cell lines tested, Homozygous deletion and lack of gene expression were found in several low tumorigenic and nonmetastatic melanoma lines, whereas other metastatic cells did not exhibit abnormalities in the CDKN2 gene, These data suggest that the absence of normal CDKN2 does not confer growth advantage to melanoma cells in vivo and that the production of metastasis by human melanoma cells can occur in the absence of CDKN2 gene abnormalities.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA 41525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FIDLER IJ, 1991, CANCER METAST REV, V10, P229, DOI 10.1007/BF00050794; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; HEALY E, 1995, GENE CHROMOSOME CANC, V12, P152, DOI 10.1002/gcc.2870120211; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEEJACKSON D, 1993, BIOTECHNIQUES, V15, P363; LIU Q, 1995, ONCOGENE, V10, P1061; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1993, INT J ONCOL, V3, P19; NOBORI T, 1994, NATURE, V363, P753; OHTA M, 1994, CANCER RES, V54, P5269; RADINSKY R, 1994, ONCOGENE, V9, P1877; ROSTAD EK, 1994, BRIT J CANCER, V70, P804; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211	17	56	61	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1399	1402						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478563				2022-12-17	WOS:A1995RY96700023
J	LUO, XN; REDDY, JC; YEYATI, PL; IDRIS, AH; HOSONO, S; HABER, DA; LICHT, JD; ATWEH, GF				LUO, XN; REDDY, JC; YEYATI, PL; IDRIS, AH; HOSONO, S; HABER, DA; LICHT, JD; ATWEH, GF			THE TUMOR-SUPPRESSOR GENE WT1 INHIBITS RAS-MEDIATED TRANSFORMATION	ONCOGENE			English	Article						WT1; TUMOR SUPPRESSORS; RAS-TRANSFORMATION	WILMS-TUMOR; HUMAN CHROMOSOME-11; PROMOTER ACTIVITY; NUDE MICE; CELL-LINE; GROWTH; PRODUCT; EXPRESSION; ONCOGENE; KIDNEY	Wilms' tumor belongs to a small group of pediatric neoplasms that have served as paradigms of human cancers in which recessive mutations play a primary role in tumorigenesis. WT1 is a candidate tumor suppressor gene that is mutationally inactivated in a proportion of both familial and sporadic Wilms' tumors. Recent studies demonstrated that WT1 can partially suppress growth of a Wilms' tumor cell line in vitro and in vivo. We investigated the ability of WT1 to inhibit the expression of the transformed phenotype in non-Wilms' tumor cells. The expression of WT1 cDNA in ras-transformed NIH3T3 cells yielded large, flat cells that exhibited complete contact-inhibition. These morphologic changes were associated with decreased proliferation, suppression of clonogenicity in soft agar and inhibition of tumor growth in nude mice. Moreover, expression of WT1 in non-transformed NIH3T3 cells resulted in similar morphologic changes and profound resistance to transformation by an activated uas oncogene. These studies suggest that tumor inhibition by WT1 in these cells may be achieved by interference with the ras-mediated signalling pathway.	CUNY MT SINAI SCH MED, DEPT MED, NEW YORK, NY 10029 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; MASSACHUSETTS GEN HOSP, CTR CANC, GENET MOLEC LAB, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02129 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369	NATIONAL CANCER INSTITUTE [R01CA059998, R01CA037887, R23CA037887] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042919] Funding Source: NIH RePORTER; NCI NIH HHS [CA59998, CA37887] Funding Source: Medline; NHLBI NIH HHS [HL42919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAREL JC, 1989, J IMMUNOL, V143, P923; CARMICHAEL J, 1987, CANCER RES, V47, P943; CHANG KS, 1993, BLOOD, V82, pA191; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Favaloro J, 1980, Methods Enzymol, V65, P718; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HUANG RP, 1994, ONCOGENE, V9, P1367; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KIVINEN L, 1993, ONCOGENE, V8, P2703; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	44	56	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					743	750						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651738				2022-12-17	WOS:A1995RQ46900016
J	CHALLETON, C; BOUNACER, A; DUVILLARD, JA; CAILLOU, B; DEVATHAIRE, F; MONIER, R; SCHLUMBERGER, M; SUAREZ, HG				CHALLETON, C; BOUNACER, A; DUVILLARD, JA; CAILLOU, B; DEVATHAIRE, F; MONIER, R; SCHLUMBERGER, M; SUAREZ, HG			PATTERN OF RAS AND GSP ONCOGENE MUTATIONS IN RADIATION-ASSOCIATED HUMAN THYROID-TUMORS	ONCOGENE			English	Note						RADIATION-ASSOCIATED TUMORS; ONCOGENES; RAS; GSP; ACTIVATION	ACTIVATION; CANCER	The preferential activation of the Ki-ras oncogene in follicular radiation-associated human thyroid carcinomas, has been suggested by Wright et al. (1991). However, only 12 thyroid tumors were analysed in this study. In order to confirm if radiation favours, in human thyroid tumorigenesis, the appearance of a particular molecular lesion, we studied 33 benign and malignant human radiation-associated thyroid tumors. We used polymerase chain reaction (PCR) amplification and allele-specific hybridization with mutant-specific probes for the three ras genes and the gsp oncogene. Compared to 85 'spontaneous' human thyroid tumors, the radiation-associated cases: (1) show a similar overall frequency of uas and gsp mutations (about 30% and 6% respectively); (2) present a similar frequency of mutation of the three ras genes without any predominance in adenomas and papillary carcinomas and (3) all Ki-ras mutations were found in papillary carcinomas (4/15). ras and gsp genes were never found mutated simultaneously, suggesting an alternative role for both oncogenes in the thyroid tumorigenic radiation-associated process.	IFC HO1,MOLEC GENET GRP,F-94801 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT HISTOPATHOL,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,DEPT NUCL MED,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,F-94805 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy			de Vathaire, Florent/L-2983-2016	de Vathaire, Florent/0000-0002-8374-9281				BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; DEVRIES MV, 1986, GENE, V50, P313; DUFFY BJ, 1950, CANCER, V3, P1018, DOI 10.1002/1097-0142(1950)3:6<1018::AID-CNCR2820030611>3.0.CO;2-H; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KOSAZA T, 1988, P NATL ACAD SCI USA, V85, P2081; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, ONCOGENE, V3, P541; SAID S, 1994, J ENDOCRINOL INVEST, V17, P371, DOI 10.1007/BF03349004; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHORE RE, 1992, RADIAT RES, V131, P98, DOI 10.2307/3578322; SUAREZ HG, 1989, ANTICANCER RES, V9, P1331; SUAREZ HG, 1991, ONCOGENE, V6, P677; SUAREZ HG, 1990, ONCOGENE, V5, P565; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; WRIGHT PA, 1991, ONCOGENE, V6, P471; YASHIMOTO K, 1993, CANCER, V72, P1386	17	56	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					601	603						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630645				2022-12-17	WOS:A1995RN53000022
J	ZHAO, JF; NAKANO, H; SHARMA, S				ZHAO, JF; NAKANO, H; SHARMA, S			SUPPRESSION OF RAS AND MOS TRANSFORMATION BY RADICICOL	ONCOGENE			English	Article						RADICICOL; RAS; MOS; SUPPRESSION; ERKS; GAP-P62	GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; XENOPUS OOCYTES; MAP KINASE; IN-VITRO; PHOSPHORYLATION; RECEPTOR	Activated versions of ras and mos oncogenes subvert the signal transduction pathway by mimicking transducers at the plasma membrane and cytosol respectively. Radicicol (UCS1006), an antifungal antibiotic, had the ability to suppress transformation by ras and mos oncogenes in a rapid, reversible and dose-dependent manner. UCS1006 inhibited MAP kinase activity (both ERK1 and ERK2) in untransformed as well as uas and mos transformed cells. However, ERK2 but not ERK1 activity was constitutively elevated in ras and mos transformed cells used in this study. In addition, a 62 kDa (kilodalton) phosphoprotein was identified whose tyrosine phosphorylation was inhibited by UCS1006, in both ras and mos transformed cells. This 62 kDa phosphoprotein, which was found to be heavily phosphorylated on tyrosine residues only in the ras and mos transformed cells but not in untransformed NIH3T3 cells, was identical to the previously described GAP-associated tyrosine phosphoprotein, p62, that is the major target for phosphorylation in cells transformed by tyrosine kinase oncogenes. These results suggest that agents such as radicicol can suppress transformation by diverse oncogenes such as src, ras and mos at least in part by inhibiting the function of key signal transduction intermediates such as MAP kinase and GAP-associated p62.	UNIV TENNESSEE,DEPT MICROBIOL & IMMUNOL,MEMPHIS,TN 38163; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO 194,JAPAN	University of Tennessee System; University of Tennessee Health Science Center; Kyowa Kirin Ltd					NCI NIH HHS [CA 55983] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055983] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOS JL, 1989, CANCER RES, V49, P4682; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OIKAWA T, 1993, EUR J PHARMACOL, V241, P221, DOI 10.1016/0014-2999(93)90206-W; PARK S, 1993, J BIOL CHEM, V268, P25728; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SHARMA SV, 1993, ONCOGENE, V8, P939; SHARMA SV, 1992, ONCOGENE, V7, P193; SINGH B, 1992, MOL CARCINOGEN, V6, P182, DOI 10.1002/mc.2940060303; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOPOL LZ, 1995, CELL GROWTH DIFFER, V6, P27; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANDEWOUDE GF, 1990, ORIGINS HUMAN CANCER; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINBERG RA, 1991, ORIGINS HUMAN CANCER; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P45; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHENG XF, 1993, NATURE, V364, P308	65	56	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					161	173						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624124				2022-12-17	WOS:A1995RJ29500019
J	SUZUKITAKAHASHI, I; KITAGAWA, M; SAIJO, M; HIGASHI, H; OGINO, H; MATSUMOTO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A				SUZUKITAKAHASHI, I; KITAGAWA, M; SAIJO, M; HIGASHI, H; OGINO, H; MATSUMOTO, H; TAYA, Y; NISHIMURA, S; OKUYAMA, A			THE INTERACTIONS OF E2F WITH PRB AND WITH P107 ARE REGULATED VIA THE PHOSPHORYLATION OF QRB AND P107 BY A CYCLIN-DEPENDENT KINASE	ONCOGENE			English	Article						PRB; P107; E2F; CDK; PHOSPHORYLATION	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; MAMMALIAN FIBROBLASTS; CELL-PROLIFERATION; CDC2 KINASE; PROTEIN; RB; CDK2; COMPLEX; IDENTIFICATION	It has been postulated that the product (pRB) of the retinoblastoma gene dissociates from the E2F-pRB complex upon phosphorylation by cyclin-dependent kinase(s) (cdk). However, there is no direct evidence for the regulation of formation of the E2F-pRB complex via phosphorylation by purified cdk, Therefore,we investigated the regulation of formation of this complex by phosphorylation using pRB and purified cyclin A-cdk2, cyclin E-cdk2 or cyclin D1-cdk4. Purified pRB was incubated with nuclear extracts prepared from pRB-defective cells and then subjected to gel mobility shift assays, We confirmed that unphosphorylated pRB associated with various types of E2F but pRB has been phosphorylated by cyclin A-cdk2 did not. We found that E2F-pRB complexes were disrupted as a consequence of phosphorylation by cyclin A-cdk2, and the levels of the free forms of E2Fs increased. We also found that not only the E2F-pRB complexes but also the E2F-p107 complexes were disrupted upon phosphorylation by cyclin A-cdk2. Furthermore, E2F-pRB complexes were disrupted through phosphorylation by cyclin D1-cdk4 and cyclin E-cdk2, as web as by cyclin A-cdk2. These results clearly demonstrate that the phosphorylation of pRB and p107 by cdks regulates the formation of complexes between E2F and pRB or p107.	BANYU TSUKUBA RES INST,MERCK RES LABS,TSUKUBA,IBARAKI 30033,JAPAN; NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN	Merck & Company; National Cancer Center - Japan			Higashi, Hideaki/F-6872-2012					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KITAGAWA M, 1995, ONCOGENE, V10, P229; KITAGAWA M, 1993, ONCOGENE, V8, P2425; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MORI N, 1990, ONCOGENE, V5, P1713; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAN ZQ, 1993, J BIOL CHEM, V268, P20443; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SAVOYSKY E, 1992, BIOCHEM BIOPH RES CO, V187, P697, DOI 10.1016/0006-291X(92)91251-K; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	39	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 4	1995	10	9					1691	1698						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QX469	7753545				2022-12-17	WOS:A1995QX46900001
J	BALDARI, CT; PELICCI, G; DISOMMA, MM; MILIA, E; GIULI, S; PELICCI, PG; TELFORD, JL				BALDARI, CT; PELICCI, G; DISOMMA, MM; MILIA, E; GIULI, S; PELICCI, PG; TELFORD, JL			INHIBITION OF CD4/P56LCK SIGNALING BY A DOMINANT-NEGATIVE MUTANT OF THE SHC ADAPTER PROTEIN	ONCOGENE			English	Article						T-CELL ACTIVATION; RAS; TYROSINE PHOSPHORYLATION	T-CELL ACTIVATION; CYCLOSPORINE-A; TYROSINE KINASES; LYMPHOCYTES-T; RAS PROTEIN; RECEPTOR; ASSOCIATION; TRANSFORMATION; PROLIFERATION; TRANSDUCTION	T-cell antigen receptor stimulation results in phosphorylation of the SH2 containing She proteins and recruitment of the Grb2/mSos complex suggesting that She proteins are involved in transducing T-cell activating signals to Ras, We have measured the effects of the isolated Shc-SH2 domain and the dominant negative Ras(N17) protein on activation of the T-cell specific transcription factor NF-AT, The isolated Shc-SH2 domain was designed to compete with endogenous She binding to upstream tyrosine phosphorylated proteins and to interfere with coupling to regulators of Ras activation, We have demonstrated that both the Shc-SH2 domain and the Ras(N17) protein significantly inhibited NF-AT activation by the CD4 coreceptor and the CD4 associated tyrosine kinase p56(lcK). Tn contrast, only the Ras(N17) protein reduced NF-AT activation by the TCR/CD3 complex, Furthermore, tyrosine kinase activity and p56(lcK) protein were found in complexes immunoprecipitated with She specific antisera after CD4 triggering but not after CD3 triggering, These results indicate that both CD4 and CD3 signal to Ras and that this signaling is mediated by independent pathways of activation of the She adaptor protein.	IMMUNOBIOL RES INST SIENA,I-53100 SIENA,ITALY; UNIV SIENA,DEPT EVOLUTIONARY BIOL,I-53100 SIENA,ITALY; UNIV PERUGIA,MONTELUCE POLICLIN,IST CLIN MED 1,I-06100 PERUGIA,ITALY	University of Siena; University of Perugia			Pelicci, Pier Giuseppe/AAL-6572-2020; Telford, John Laird/ABG-8144-2020; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255; Baldari, Cosima/0000-0002-4414-6744				ALCALAY M, 1990, ONCOGENE, V5, P267; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; CARREL S, 1988, EUR J IMMUNOL, V18, P333, DOI 10.1002/eji.1830180303; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINKEL TH, 1991, IMMUNOL TODAY, V12, P79, DOI 10.1016/0167-5699(91)90162-M; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GLEICHENHAUS N, 1991, CELL, V64, P511; HAIGWOOD NL, 1990, VACCINES 90, P313; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PELICCI G, 1991, CELL, V70, P93; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J., 1989, MOL CLONING; SEFTON BM, 1991, ONCOGENE, V6, P683; Signoret N, 1993, Trends Microbiol, V1, P328, DOI 10.1016/0966-842X(93)90072-Y; STEIMER KS, 1988, VACCINES 88, P347; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS D, 1990, IMMUNOLOGY, V71, P10; WOODROW MA, 1993, J IMMUNOL, V9, P3853; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	31	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1141	1147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700640				2022-12-17	WOS:A1995QN35300015
J	WHITE, DW; ROY, A; GILMORE, TD				WHITE, DW; ROY, A; GILMORE, TD			THE V-REL ONCOPROTEIN BLOCKS APOPTOSIS AND PROTEOLYSIS OF I-KAPPA-B-ALPHA IN TRANSFORMED CHICKEN SPLEEN-CELLS	ONCOGENE			English	Article						V-REL; I-KAPPA-B; APOPTOSIS; TEMPERATURE-SENSITIVE MUTANTS	DEATH GENE CED-3; C-REL; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RECOGNITION SEQUENCE; PROTEIN; FIBROBLASTS; EXPRESSION; ENCODES	The v-Rel oncoprotein of the avian Rev-T retrovirus malignantly transforms chicken spleen cells in vivo and in vitro. We previously described two temperature-sensitive (ts) mutants of v-Rel (v-G37E and v-R273H) that show a ts ability to transform chicken spleen cells and to bind to DNA in vitro. We now show that spleen cell lines transformed by ts v-Rel proteins at the permissive temperature undergo apoptosis when cells are shifted to the nonpermissive temperature. The levels of most proteins (including v-Rel, p53, c-Myc, Rb and Bcl-2) do not change in these cells even at advanced stages of apoptosis, However, the chicken I kappa B-alpha protein (also called p40), which is in a complex with v-Rel in transformed cells, is degraded when ts v-Rel-transformed cells are shifted to the nonpermissive temperature. In v-R273H-transformed cells, p40 is degraded without the appearance of proteolytic intermediates. In contrast, in v-G37E-transformed cells, p40 is cleaved to an intermediate species that is missing approximately 3-4 kDa from its amino terminus, This truncated form of p40 is found in a detergent-insoluble fraction and can also be detected in wild-type v-Rel-transformed cells that are induced to undergo apoptosis by treatment with cycloheximide, Both ts v-Rel proteins are ts for interaction with p40 in vitro. The results reported here indicate that v-Rel blocks a normal pathway of programmed cell death and that I kappa B-alpha can undergo multiple degradative pathways, which can be induced by alterations in the structure of the Rel protein to which it is bound.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215; W VIRGINIA UNIV,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	Boston University; West Virginia University					NCI NIH HHS [CAY1450, CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1992, CANCER SURV, V15, P69; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HRDLICKOVA R, 1995, IN PRESS J VIROL, V69; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; MORRISON LE, 1991, ONCOGENE, V6, P1657; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5858; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RICHARDSON PM, 1991, J VIROL, V65, P1322; Sambrook J., 1989, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	68	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					857	868						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898928				2022-12-17	WOS:A1995QL03800007
J	TONJES, RR; LOHLER, J; OSULLIVAN, JF; KAY, GF; SCHMIDT, GH; DALEMANS, W; PAVIRANI, A; PAUL, D				TONJES, RR; LOHLER, J; OSULLIVAN, JF; KAY, GF; SCHMIDT, GH; DALEMANS, W; PAVIRANI, A; PAUL, D			AUTOCRINE MITOGEN IGEGF COOPERATES WITH C-MYC OR WITH THE HCS LOCUS DURING HEPATOCARCINOGENESIS IN TRANSGENIC MICE	ONCOGENE			English	Note						LIVER CANCER; TRANSGENIC MICE; EGF; C-MYC; ONCOGENE COOPERATION	GROWTH-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; CHEMICAL CARCINOGENESIS; LIVER NEOPLASIA; TGF-ALPHA; GENE; TUMORS; OVEREXPRESSION; ONCOGENESIS; PANCREAS	Hepatocarcinogenesis is deterministic in transgenic mice expressing in the liver gene construct Alb-DS4 that encodes\autocrine growth factor IgEGF (D Stern et al, (1987), Science 235: 321-324), causing their death within 7.1 months. Hepatic expression of construct AAT-myc encoding murine c-myc causes liver cancer in 44% of the mice at 14.8 months. Cooperation of these genes was evident in CD2F1 transgenics bearing Alb-DS4 plus AAT-myc, in which accelerated hepatocellular carcinoma (HCC) formation caused death of all mice within 4.4 months. Alb-DS4 also cooperates with the Hcs locus, which in C3H/HeJ mice mediates high susceptibility to spontaneous hepatocarcinogenesis, causing accelerated formation of HCC to which mice succumbed at 5.1 months. Thus, genes that predispose to HCC formation cooperate in transgenic mice and their interaction is a key to understand mechanisms that cause liver cancer.	FRAUNHOFER INST TOXICOL & MOLEK BIOL,DEPT CELL BIOL,D-30625 HANNOVER,GERMANY; UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; TRANSGENE SA,F-67082 STRASBOURG,FRANCE	Fraunhofer Gesellschaft; Heinrich Pette Institute; University of Hamburg; Transgene SA			Kay, Graham F/A-4130-2011					AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; BUCHMANN A, 1991, P NATL ACAD SCI USA, V88, P911, DOI 10.1073/pnas.88.3.911; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5224; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HOFFMANN B, 1989, J CELL PHYSIOL, V139, P654, DOI 10.1002/jcp.1041390328; HOFFMANN B, 1990, J CELL PHYSIOL, V142, P149, DOI 10.1002/jcp.1041420118; Hogan B., 1986, MANIPULATING MOUSE E; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HWANG DL, 1990, REGUL PEPTIDES, V29, P103, DOI 10.1016/0167-0115(90)90073-6; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; LEE GH, 1992, CANCER RES, V52, P5162; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MURAKAMI H, 1993, CANCER RES, V53, P1719; ORIAN JM, 1990, JNCI-J NATL CANCER I, V82, P393, DOI 10.1093/jnci/82.5.393; OSULLIVAN JF, 1991, NATURE, V352, P200, DOI 10.1038/352200a0; PERRAUD F, 1991, EXP CELL RES, V195, P59, DOI 10.1016/0014-4827(91)90500-T; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Sambrook J., 1989, MOL CLONING LAB MANU; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SCHULTEHERMANN R, 1985, ARCH TOXICOL, V57, P147, DOI 10.1007/BF00290879; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TAKAGI H, 1992, CANCER RES, V52, P5171; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; YUSPA SH, 1988, ADV CANCER RES, V50, P25, DOI 10.1016/S0065-230X(08)60434-0	34	56	59	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					765	768						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862454				2022-12-17	WOS:A1995QH61200017
J	DOBROWOLSKI, SF; STACEY, DW; HARTER, ML; STINE, JT; HIEBERT, SW				DOBROWOLSKI, SF; STACEY, DW; HARTER, ML; STINE, JT; HIEBERT, SW			AN E2F DOMINANT-NEGATIVE MUTANT BLOCKS E1A INDUCED CELL-CYCLE PROGRESSION	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; DNA-BINDING PROPERTIES; MURINE THYMIDINE KINASE; HUMAN MYC PROMOTER; ESCHERICHIA-COLI; GROWTH SUPPRESSION; FUNCTIONAL DOMAINS; TRANS-ACTIVATION; S-PHASE	E2F is a cellular transcription factor that is regulated during the cell cycle through interactions with the product of the retinoblastoma susceptibility gene (RB1) and the pRb-like p107 and p130 proteins. Analysis of mutations within both adenovirus E1A and pRb, which affected their ability to regulate cellular proliferation and alter E2F activity, suggested that E2F may play a role in cell cycle progression. Microinjection of a GST-E2F-1 fusion protein into quiescent Balb/c 3T3 cells induced DNA synthesis whereas co-injection of GST-E2F-1 and GST-E2F(95-191) protein, encoding only the DNA binding domain of E2F-1, blocked the induction of S-phase. While E1A likely targets multiple cellular pathways, co-injection of the GST-E2F(95-191) dominant inhibitory protein with 12S E1A protein blocked E1A-mediated induction of DNA synthesis, suggesting that the E2F-dependent pathway is dominant. Analysis of the interval required for microinjected quiescent cells to enter S-phase indicated that E2F-1 acted faster than either E1A or serum.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	St Jude Children's Research Hospital; Cleveland Clinic Foundation					NCI NIH HHS [5 P30 CA 21765, CA53496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRUNER M, 1988, J BIOL CHEM, V263, P3984; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KO JL, 1986, EMBO J, V5, P1645, DOI 10.1002/j.1460-2075.1986.tb04407.x; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEVINS JR, 1990, UCLA SYM BI, V124, P417; NEVINS JR, 1992, SCIENCE, V258, P424; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2181; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; ROUSSEL MF, 1994, ONCOGENE, V9, P405; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1993, IN PRESS EMBO J; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	64	56	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2605	2612						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058324				2022-12-17	WOS:A1994PC05400020
J	GRANA, X; CLAUDIO, PP; DELUCA, A; SANG, NL; GIORDANO, A				GRANA, X; CLAUDIO, PP; DELUCA, A; SANG, NL; GIORDANO, A			PISSLRE, A HUMAN NOVEL CDC2-RELATED PROTEIN-KINASE	ONCOGENE			English	Article							GLUTATHIONE-S-TRANSFERASE; TRANSLATIONAL INITIATION; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SEQUENCE HOMOLOGY; CDC28 MUTATION; GENE ENCODES; CYCLIN-A; FAMILY	The cell division cycle have been shown to be regulated by a closely-related family of protein kinases named CDKs (by cyclin-dependent kinases). Using a PCR-based cloning technique, we have isolated cDNAs encoding a human CDC2-related protein kinase. The full-length cDNA accommodates an open reading frame that does not contain any ATG initiation codon upstream of the sequence encoding the catalytic domain of this putative kinase. Three putative non-ATG initiation codons have been detected. Starting at the most 5' non-ATG initiation site, the encoded product is 316 amino acids long with a predicted molecular weight of 35.8 kDa. Analysis of the deduced amino acid sequence showed it to contain the XI subdomains present in all known protein kinases and a PSTAIRE-like motive, PISSLRE, which temporarily names this kinase. PISSLRE is most related to p58/GTA (55% identity in the catalytic domain), the galactosyl transferase associated protein, which has been shown to inhibit entry into S-phase when over-expressed in CHO cells. PISSLRE shares 38-45% identity with all CDKs and contains the regulatory Tyr and Thr residues present in most of the members of the CDK family of protein kinases, which suggests similar modes of regulation. PISSLRE is expressed in all human tissues tested, including those which contain high proportion of terminally differentiated cells. However, the levels of the PISSLRE transcripts are dissimilar among different tissues.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	GRANA, X (corresponding author), TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, DEPT PATHOL, 3307 N BROAD ST, PHILADELPHIA, PA 19140 USA.		Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021	Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; Grana, Xavier/0000-0001-7134-0473	NCI NIH HHS [R01 CA 6099-01A1] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEW J, 1992, J BIOL CHEM, V267, P25922; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; OKUDA T, 1992, ONCOGENE, V7, P2249; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	43	56	60	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2097	2103						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208557				2022-12-17	WOS:A1994NR68500037
J	KEEN, N; ELSTON, R; CRAWFORD, L				KEEN, N; ELSTON, R; CRAWFORD, L			INTERACTION OF THE E6 PROTEIN OF HUMAN PAPILLOMAVIRUS WITH CELLULAR PROTEINS	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; LARGE TUMOR-ANTIGEN; CERVICAL-CARCINOMA; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; TYPE-16; P53; E7; KERATINOCYTES; TRANSCRIPTION	The E6 proteins of the oncogenic Human Papillomavirus (HPV) types 16 and 18 are known to bind two cellular proteins, the tumour suppressor protein p53 and a 100 kDa protein named E6-AP. In this paper we describe the expression and purification of biologically active E6 fusion proteins and their specific association with additional cellular proteins. HPV16E6 specifically associated with at least seven cellular proteins which have been designated pp212, pp182, p100, p81, p75, p53 and p33 respectively, on the basis of molecular mass and phosphorylation. We have also shown that the complex of cellular proteins associated with HPV16, 18, 6 and 11 E6 proteins contains a protein kinase. This protein kinase phosphorylated exogenous histone H1 and the E6 associated protein pp182.	UNIV CAMBRIDGE,DEPT PATHOL,DIV VIROL,CAMBRIDGE CB2 1QP,CAMBS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND,TUMOUR VIRUS GRP,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge; University of Cambridge	KEEN, N (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,CAMBS,ENGLAND.							BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GUIS D, 1988, J VIROL, V62, P665; Harlow E., 1988, ANTIBODIES LABORATOR, P341; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LIANG XH, 1993, ONCOGENE, V8, P2645; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Maniatis T., 1982, MOL CLONING; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MUNGER K, 1989, J VIROL, V63, P4417; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TOMMASINO M, 1993, ONCOGENE, V8, P195; Vousden K H, 1990, Semin Cancer Biol, V1, P415; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; 1991, PHARM ANALECTS, V19, P1	39	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1493	1499						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152813				2022-12-17	WOS:A1994NH40100024
J	FAVIER, D; GONDA, TJ				FAVIER, D; GONDA, TJ			DETECTION OF PROTEINS THAT BIND TO THE LEUCINE-ZIPPER MOTIF OF C-MYB	ONCOGENE			English	Note							PROTO-ONCOGENE PRODUCT; LEUKEMIA-CELL LINE; HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA; HOMEOBOX GENE; DNA-BINDING; V-MYB; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; EXPRESSION	The product of the c-myb proto-oncogene, c-Myb, binds DNA and can enhance transcription of genes bearing copies of the DNA sequence it recognises. Deletion or disruption of a negative regulatory domain (NRD) in the carboxyl portion of c-Myb results in enhanced transactivating capacity and in parallel, leads to activation of its ability to transform haemopoietic cells. Since mutational analysis has shown that one critical element within the NRD is a leucine zipper motif, we have sought to identify cellular proteins that can interact with the c-Myb leucine zipper. Using fusion proteins containing this region as an affinity reagent, we have identified two nuclear proteins, p67 and p160, that bind to the wildtype, but not to a mutated c-Myb leucine zipper. These two proteins were shown to be related by comparison of peptides generated by partial digestion. While p160 was found to be ubiquitous amongst different murine haemopoietic cell lines, and was also present in NIH3T3 fibroblasts, p67 was detected in a restricted set of immature myeloid cells. Intriguingly p160, but not p67, could also bind to the c-Jun leucine zipper.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; INST MED & VET SCI,DIV HUMAN IMMUNOL,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia								ALEXANDER B, 1992, GENE CHROMOSOME CANC, V5, P286, DOI 10.1002/gcc.2870050404; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BAUERLE PA, 1988, SCIENCE, V242, P540; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLATT C, 1988, EMBO J, V7, P4283, DOI 10.1002/j.1460-2075.1988.tb03326.x; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; COOPER PC, 1982, LEUKEMIA RES, V6, P313, DOI 10.1016/0145-2126(82)90093-5; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GONDA TJ, 1993, IN PRESS BLOOD; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P308; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDO T, 1992, ONCOGENE, V7, P1999; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; ZOBEL A, 1991, ONCOGENE, V6, P1397	44	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					305	311						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302594				2022-12-17	WOS:A1994MW24700037
J	WILSON, RE; TAYLOR, SL; ATHERTON, GT; JOHNSTON, D; WATERS, CM; NORTON, JD				WILSON, RE; TAYLOR, SL; ATHERTON, GT; JOHNSTON, D; WATERS, CM; NORTON, JD			EARLY RESPONSE GENE SIGNALING CASCADES ACTIVATED BY IONIZING-RADIATION IN PRIMARY HUMAN B-CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; LYMPHOCYTIC-LEUKEMIA CELLS; INDUCED PLASMACYTOID DIFFERENTIATION; IONIZING-RADIATION; MYC PROTEIN; TRANSCRIPTION FACTORS; BINDING-ACTIVITY; CULTURED-CELLS; GROWTH-FACTORS; EXPRESSION	We have used a panel of 13 protein kinase C-responsive immediate early gene probes to dissect the cellular signalling pathways activated by ionising gamma radiation in primary human B cells. Of these 13 genes, a delayed transient induction was observed for only 8: c-fos, c-jun, jun-B, jun-D, c-myc, ergI/krox 24 and two 'anonymous' genes, 3L3 and 19A. Expression of c-myc and c-fos mRNAs was paralleled by the appearance of their encoded proteins suggesting that these oncoproteins may couple radiation signalling to cellular responses. Of three protein kinase C-coupled transcription factors examined by gel retardation assay, (AP1, NF kappa B, EgrI/Krox24) only NF kappa B and, to a lesser extent, AP1 was stimulated in response to irradiation. These observations are not obviously compatible with a simple model invoking protein kinase C in radiation signalling in primary B cells and suggest that the pleiotropic effects of ionising radiation on this cell type are mediated through a distinct cellular signalling cascade.	CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,CRC,DEPT CARCINOGENESIS,MANCHESTER M20 9BX,ENGLAND; CHRISTIE HOSP NHS TRUST,PATERSON INST CANC RES,DEPT GENE REGULAT,MANCHESTER M20 9BX,ENGLAND; UNIV MANCHESTER,DEPT PHYSIOL SCI,MOLEC PHARMACOL & TOXICOL GRP,MANCHESTER M13 9PT,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; University of Manchester			Atherton, Graham/GZK-4237-2022	Atherton, Graham/0000-0002-7425-3153	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AZZI A, 1992, EUR J BIOCHEM, V208, P547, DOI 10.1111/j.1432-1033.1992.tb17219.x; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BRACH MA, 1993, BIOL CHEM, V268, P8466; CELANO P, 1989, BIOFEEDBACK, V7; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHILES TC, 1991, J IMMUNOL, V146, P1730; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEED RW, 1993, ONCOGENE, V8, P599; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACHINI A, 1976, RADIAT RES, V68, P339; FOLCH H, 1982, IMMUNOL LETT, V5, P337, DOI 10.1016/0165-2478(82)90124-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL EJ, 1988, RADIOBIOLOGY RADIOLO, P17; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; HALLAHAN DE, 1989, P NATL ACAD SCI USA, V86, P10104, DOI 10.1073/pnas.86.24.10104; HALLAHAN DE, 1991, CANCER RES, V51, P4565; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEEK DW, 1992, BIOCHEM J, V287, P1; MOORE JP, 1988, BIOCHIM BIOPHYS ACTA, V965, P60, DOI 10.1016/0304-4165(88)90151-1; MURPHY JJ, 1990, FEBS LETT, V267, P242, DOI 10.1016/0014-5793(90)80935-C; MURPHY JJ, 1990, BIOCHIM BIOPHYS ACTA, V1049, P261; MURPHY JJ, 1991, BIOCHIM BIOPHYS ACTA, V1092, P110, DOI 10.1016/0167-4889(91)90184-Y; MURPHY JJ, 1993, IN PRESS LEUKAEMIA R; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; OJEDA F, 1990, INT J RADIAT BIOL, V59, P53; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARKCHAE H, 1993, CANCER RES, V53, P447; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SHERMAN ML, 1991, J CLIN INVEST, V87, P1794, DOI 10.1172/JCI115199; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONOBE MH, 1991, ONCOGENE, V6, P1531; SULLIVAN NF, 1989, ONCOGENE, V4, P1497; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1993, P NATL ACAD SCI USA, V90, P252, DOI 10.1073/pnas.90.1.252; WATERS CM, 1990, ONCOGENE, V5, P669; WATERS CM, 1991, ONCOGENE, V6, P797; WITTE L, 1989, CANCER RES, V49, P5066; WOLOSCHAK GE, 1990, CANCER RES, V50, P3963; WOLOSCHAK GE, 1990, CANCER RES, V50, P339; WOLTERS H, 1987, INT J RADIAT BIOL, V51, P619, DOI 10.1080/09553008414552151; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	62	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3229	3237						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247526				2022-12-17	WOS:A1993MG78200005
J	TOMINAGA, O; HAMELIN, R; TROUVAT, V; SALMON, RJ; LESEC, G; THOMAS, G; REMVIKOS, Y				TOMINAGA, O; HAMELIN, R; TROUVAT, V; SALMON, RJ; LESEC, G; THOMAS, G; REMVIKOS, Y			FREQUENTLY ELEVATED CONTENT OF IMMUNOCHEMICALLY DEFINED WILD-TYPE P53 PROTEIN IN COLORECTAL ADENOMAS	ONCOGENE			English	Article								Mutations of the p53 tumour-suppressor gene are considered to be rare in human colorectal adenomas, a premalignant state of the digestive tract. We have analysed a series of 32 exophytic tumours of the colon and rectum for the presence of p53 protein. In 26 of the 28 pure adenomas, the presence of significant levels of p53 proteins was established by a sensitive two-point enzyme-linked immunosorbent assay. The detectability of p53 protein was frequently limited to PAb 1801, recognizing an N-terminal epitope. Immunoblotting of the fractions captured by the monoclonal antibodies revealed that PAb 421 reacted exclusively with a 53-kDa species, whereas an additional 48-kDa band was detected after incubation with PAb 1801. In the adenomas, the mutant conformation-specific PAb 240 was always negative and no mutations were detected on exons 5-8 in three large and highly dysplastic lesions, selected for their high p53 protein content. The remaining four of the 32 tumours presented foci of cancer. Three of these were shown to contain 'mutant' PAb 240-reactive p53, and gene mutations were identified in two by denaturing gradient gel electrophoresis and sequencing of the amplified products. Intense p53 nuclear immunohistochemical staining was associated with the malignant areas. We conclude that a novel mechanism affecting the regulation of p53 protein could occur in colorectal adenomas	INST CURIE, RADIOPATHOL LAB, 26 RUE ULM, F-75231 PARIS, FRANCE; LAB ANALYSE CELLULAIRE & PATHOL, F-03200 VICHY, FRANCE; INST CURIE, GENET TUMEURS LAB, F-75231 PARIS, FRANCE; INST CURIE, DEPT CHIRURG, F-75231 PARIS, FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BARTEK J, 1990, ONCOGENE, V5, P893; BAUNOCH DA, 1992, ONCOGENE, V7, P2351; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROOK T, 1991, ONCOGENE, V6, P873; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1990, ONCOGENE, V5, P1701; FARRELL PJ, 1991, EMBO J, V10, P2879, DOI 10.1002/j.1460-2075.1991.tb07837.x; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAMELIN R, 1993, ONCOGENE, V8, P2213; HAMMEL PR, 1991, GASTROEN CLIN BIOL, V15, P529; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUBBERT M, 1988, J EXP MED, V167, P873, DOI 10.1084/jem.167.3.873; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIGNATELLI M, 1992, INT J CANCER, V50, P683, DOI 10.1002/ijc.2910500503; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHIRASAWA S, 1991, CANCER RES, V51, P2874; SHOHAT O, 1987, ONCOGENE, V1, P277; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302	42	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2653	2658						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378077				2022-12-17	WOS:A1993LX34300006
J	OOKAWA, K; SHISEKI, M; TAKAHASHI, R; YOSHIDA, Y; TERADA, M; YOKOTA, J				OOKAWA, K; SHISEKI, M; TAKAHASHI, R; YOSHIDA, Y; TERADA, M; YOKOTA, J			RECONSTITUTION OF THE RB GENE SUPPRESSES THE GROWTH OF SMALL-CELL LUNG-CARCINOMA CELLS CARRYING MULTIPLE GENETIC ALTERATIONS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN PROSTATE CARCINOMA; CANCER-CELLS; TUMOR SUPPRESSOR; OSTEO-SARCOMA; P53 GENE; C-MYC; EXPRESSION; TUMORIGENICITY; PROTEIN	Multiple genetic alterations, including inactivation of the RB gene, occur commonly in small-cell lung carcinoma (SCLC). To assess a functional role of RB inactivation in the development of SCLC, an RB expression plasmid was introduced by stable transfection into SCLC cell lines, Lu-135 and N417, in which the RB gene was inactivated. Lu-135 and N417 cells transfected with the wild-type RB gene formed G418-resistant colonies twofold less efficiently than those with a mutated RB gene or with the control vector. Intact exogenous wild-type RB genes were detected only in approximately 20% of G418-resistant clones; three of 14 in Lu-135 and three of 16 in N417, respectively. Transcripts from the transfected RB gene were also detected in two of these three clones from Lu-135 and two of three from N417 but the amount of RB mRNA and protein was less than one fifth of that in normal fibroblast celts WI-38. Furthermore, clones with exogenous wild-type RB expression showed either reduced growth rates in culture or suppressed tumorigenicity in nude mice. These findings suggest that functional correction of the RB gene is sufficient to suppress the growth of SCLC cells, even though several other genetic alterations in the cells remain uncorrected.	NATL CANC CTR,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN; KYOTO UNIV,FAC MED,DEPT PATHOL 2,KYOTO 606,JAPAN; HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN	National Cancer Center - Japan; Kyoto University; Hirosaki University								BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GAZDAR AF, 1985, CANCER RES, V45, P2924; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MORI N, 1989, CANCER RES, V49, P5130; MORI N, 1990, ONCOGENE, V5, P101; MUNCASTER MM, 1992, CANCER RES, V52, P654; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RABITTS P, 1990, GENE CHROMOSOME CANC, V2, P231; REISSMANN PT, 1989, ONCOGENE, V4, P839; Sambrook J., 1989, MOL CLONING LAB MANU; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TERASAKI T, 1986, JPN J CLIN ONCOL, V16, P203; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, CANCER RES, V51, P4481; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471; YOKOTA J, 1988, ONCOGENE, V2, P607	40	56	58	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2175	2181						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393162				2022-12-17	WOS:A1993LP17100018
J	JACKSON, P; BOS, E; BRAITHWAITE, AW				JACKSON, P; BOS, E; BRAITHWAITE, AW			WILD-TYPE MOUSE-P53 DOWN-REGULATES TRANSCRIPTION FROM DIFFERENT VIRUS ENHANCER PROMOTERS	ONCOGENE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELL NUCLEAR ANTIGEN; P53 GENE-MUTATIONS; LARGE T-ANTIGEN; TUMOR-ANTIGEN; CHLORAMPHENICOL ACETYLTRANSFERASE; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; EUKARYOTIC CELLS; DNA-REPLICATION	The protein encoded by the tumour-suppressor gene p53 can complex with SV40 virus large T antigen, the adenovirus E1B 58-kDa protein and the E6 protein of human papillomavirus type 16. The functions of these complexes are unclear, but there is some evidence to suggest that binding of p53 to these viral proteins may inactivate p53 function. Recent reports have shown that p53 is involved in regulation of transcription. We have considered the possibility that p53 may regulate transcription of viral genes important for virus replication and/or transformation. Inactivation of p53 function by formation of such complexes might then permit correct expression of these viral genes. Since p53 can bind to the SV40 virus enhancer/promoter, we have investigated the effect of p53 on transcription from this promoter and report here that mouse p53 is a potent repressor of the SV40 enhancer/promoter. Mutations within p53 severely inhibited this activity and provided some evidence to show that the N-terminus of p53 contains residues essential for this function. We also show that mouse p53 represses transcription from the promoters of viruses that do not express proteins that complex with p53: the human cytomegalovirus early promoter and the Rous sarcoma virus long terminal repeat. By studying the effect of p53 on transcription in different cell lines, we show that the effects of p53 on promoters may be cell type specific.			JACKSON, P (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,CELL TRANSFORMAT GRP,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; BRAITHWAITE AW, 1991, NEW BIOL, V3, P18; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN YM, 1991, ONCOGENE, V6, P1799; CHENG J, 1992, CANCER RES, V52, P222; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; ISAACS WB, 1991, CANCER RES, V51, P4716; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERCER WF, 1990, J CELL BIOCHEM, V14, P285; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRIDMORE RD, 1987, GENE, V56, P309, DOI 10.1016/0378-1119(87)90149-1; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J., 1989, MOL CLONING LAB MANU; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TKAHASHI T, 1991, ONCOGENE, V6, P1775; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHANG XL, 1990, VIROLOGY, V180, P199	58	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					589	597						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382357				2022-12-17	WOS:A1993KN00800009
J	MYERS, RL; PAYSON, RA; CHOTANI, MA; DEAVEN, LL; CHIU, IM				MYERS, RL; PAYSON, RA; CHOTANI, MA; DEAVEN, LL; CHIU, IM			GENE STRUCTURE AND DIFFERENTIAL EXPRESSION OF ACIDIC FIBROBLAST GROWTH-FACTOR MESSENGER-RNA - IDENTIFICATION AND DISTRIBUTION OF 4 DIFFERENT TRANSCRIPTS	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; FACTOR-II GENE; FACTOR FAMILY; HUMAN GLIOMAS; TISSUES; MENINGIOMAS; PROMOTERS; SEQUENCE; CULTURE; CLASS-1	We have isolated four cDNA clones coding for human acidic fibroblast growth factor (aFGF) containing alternative 5' untranslated exons. Using RNAase protection analyses, we demonstrated the presence of at least four upstream, untranslated exons that are alternatively spliced to the first protein-coding exon. We designate these four untranslated exons, - 1A, - 1B, - 1C and - 1D. Splicing of these exons to the first coding exon will generate mRNA 1.A, 1.B, 1.C and 1.D respectively. Expression of these transcripts is regulated in a tissue-specific manner, as the major aFGF transcript in human brain frontal cortex differs from that in kidney. Furthermore, the pattern of aFGF transcripts in several glioblastoma cell fines tested is different from that in normal brain tissue. We isolated nine overlapping genomic clones containing these four upstream, untranslated exons. These four exons were localized on these clones by Southern hybridization and nucleotide sequence analysis. The overlapping clones are shown to be contiguous with our previously isolated genomic clones that contain the three aFGF-coding exons. The sizes of the four introns are 82.9, 71.1, 29.3 and 6.9 kbp. The transcriptional start sites of the two most upstream exons (- 1A and - 1B) have been mapped using RNAase protection and primer extension analyses. The sequences upstream of the start sites for aFGF 1.B mRNA do not contain a consensus TATA box. In contrast, the canonical CCAAT and TATA sequences are located at the proper distances from the transcription start site of aFGF 1.A mRNA.	OHIO STATE UNIV, DEPT INTERNAL MED, DAVIS MED RES CTR, 480 W 9TH AVE, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR COMPREHENS CANC, COLUMBUS, OH 43210 USA; LOS ALAMOS NATL LAB, CTR HUMAN GENOME STUDIES, LOS ALAMOS, NM 87545 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; United States Department of Energy (DOE); Los Alamos National Laboratory			Chiu, Ing-Ming/B-1534-2008; Chotani, Maqsood/E-2891-2011		NATIONAL CANCER INSTITUTE [T32CA009338, P30CA016058, R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16058, T32 CA09338, R01 CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALTERIO J, 1990, BIOCHEM BIOPH RES CO, V166, P1205, DOI 10.1016/0006-291X(90)90994-X; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU IM, 1990, FID RES FDN, V3, P57; CHIU IM, 1990, ONCOGENE, V5, P755; CHIU IM, 1989, MOL CHEM NEUROPATHOL, V10, P37, DOI 10.1007/BF02969485; COOK PW, 1990, MOL ENDOCRINOL, V4, P1377, DOI 10.1210/mend-4-9-1377; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CRUMLEY G, 1990, BIOCHEM BIOPH RES CO, V171, P7, DOI 10.1016/0006-291X(90)91348-V; DEPAGTERHOLTHUIZEN P, 1987, FEBS LETT, V214, P259, DOI 10.1016/0014-5793(87)80066-2; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOSPODAROWICZ D, 1987, METHOD ENZYMOL, V147, P106; GROSS JL, 1990, J NEUROSCI RES, V27, P689, DOI 10.1002/jnr.490270429; HALL JA, 1990, J CELL BIOCHEM, V43, P17, DOI 10.1002/jcb.240430103; HALLEY C, 1988, NUCLEIC ACIDS RES, V16, P10913, DOI 10.1093/nar/16.22.10913; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; KOZAK M, 1988, J CELL BIOL, V107, P1, DOI 10.1083/jcb.107.1.1; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; MARICS I, 1989, ONCOGENE, V4, P335; MORRISON RS, 1981, P NATL ACAD SCI-BIOL, V78, P7205, DOI 10.1073/pnas.78.11.7205; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUSSELL DS, 1963, PATHOLOGY NERVOUS SY, P93; Sambrook J., 1989, MOL CLONING LAB MANU; SOARES MB, 1986, J MOL BIOL, V192, P737, DOI 10.1016/0022-2836(86)90025-2; TAKAHASHI JA, 1991, BIOCHEM BIOPH RES CO, V177, P1, DOI 10.1016/0006-291X(91)91939-A; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VANDEWINKEL JGJ, 1991, J BIOL CHEM, V266, P13449; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; Weich HA, 1990, GROWTH FACTORS, V2, P313, DOI 10.3109/08977199009078019; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WINKLES JA, 1987, P NATL ACAD SCI USA, V84, P7124, DOI 10.1073/pnas.84.20.7124; WINKLES JA, 1991, CELL GROWTH DIFFER, V2, P531; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9; ZAGZAG D, 1990, CANCER RES, V50, P7393; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	48	56	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					341	349						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678925				2022-12-17	WOS:A1993KN00600013
J	CONRAD, KE; GUTIERREZHARTMANN, A				CONRAD, KE; GUTIERREZHARTMANN, A			THE RAS AND PROTEIN KINASE-A PATHWAYS ARE MUTUALLY ANTAGONISTIC IN REGULATING RAT PROLACTIN PROMOTER ACTIVITY	ONCOGENE			English	Article								In an attempt to characterize the ras signaling pathway, we studied the effects of expression vectors encoding the valine 12 mutant ras oncogene on rat prolactin (rPRL) promoter activity. Using this approach we have been able to dissect the interplay between the ras and the protein kinase A (PKA) pathways as they relate to neuroendocrine gene activation. Here we show that the ras oncogene product induces rPRL promoter activity selectively from 5- to 14-fold in GH, rat pituitary tumor cells, whereas it has a minimal effect on the SV40 early promoter and no effect on the Rous sarcoma virus (RSV) or rat growth hormone promoters. By contrast, an inactivated form of ras (N-17 ras) did not stimulate the rPRL promoter, but rather inhibited it to 40% of control. Of note, activation of the PKA pathway by two different methods decreased the fold activation mediated by ras by at least 50%, whereas inhibition of the PKA pathway accentuated ras activation of the rPRL promoter. Although rPRL promoter activity is consistently induced by PKA activation in control GH4 cells, acute ras oncogene expression inhibited forskolin induction of rPRL promoter activity. Moreover, this ras-mediated interference of the forskolin activation of rPRL promoter activity was also noted in GH, cells stably expressing ras. Taken together, these data show that the valine 12 ras oncogene activates the rPRL promoter selectively and, more importantly, that the ras and PKA signaling pathways are mutually antagonistic with respect to specific transcriptional activation of a neuroendocrine gene.	UNIV COLORADO, HLTH SCI CTR,DEPT MED,PROGRAM MOLEC BIOL, 4200 E 9TH AVE,BOX B-151, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM BIOPHYS & GENET, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, COLORADO CANC CTR, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Gutierrez-Hartmann, Arthur/F-1295-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037667] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 37667] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BERK AJ, 1989, BIOCHIM BIOPHYS ACTA, V1009, P103, DOI 10.1016/0167-4781(89)90087-0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BUNZOW JR, 1988, NATURE, V336, P783, DOI 10.1038/336783a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266; GALIEN R, 1991, ONCOGENE, V6, P849; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GUTIERREZHARTMA.A, 1991, MOL CLIN ADV PITUITA, P47; GUTIERREZHARTMANN A, 1987, P NATL ACAD SCI USA, V84, P5211, DOI 10.1073/pnas.84.15.5211; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOEFFLER JP, 1990, TRENDS ENDOCRIN MET, V1, P155, DOI 10.1016/1043-2760(90)90028-2; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; KEDAR PS, 1990, MOL CELL BIOL, V10, P3852, DOI 10.1128/MCB.10.7.3852; KEECH CA, 1991, MOL CELL ENDOCRINOL, V78, P55, DOI 10.1016/0303-7207(91)90185-U; KEECH CA, 1989, MOL ENDOCRINOL, V3, P832, DOI 10.1210/mend-3-5-832; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; Matsumoto K, 1985, Yeast, V1, P15, DOI 10.1002/yea.320010103; MAURER RA, 1981, NATURE, V294, P94, DOI 10.1038/294094a0; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; NAKAGAWA T, 1987, P NATL ACAD SCI USA, V84, P5923, DOI 10.1073/pnas.84.16.5923; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ONALI P, 1981, P NATL ACAD SCI-BIOL, V78, P6531, DOI 10.1073/pnas.78.10.6531; OSBORNE R, 1981, ENDOCRINOLOGY, V108, P1164, DOI 10.1210/endo-108-4-1164; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SADLER SE, 1990, MOL CELL BIOL, V10, P1689, DOI 10.1128/MCB.10.4.1689; SCHONTHAL A, 1990, CELL SIGNAL, V2, P215, DOI 10.1016/0898-6568(90)90049-G; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; STANLEY F, 1988, J BIOL CHEM, V263, P13444; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WHITE BA, 1983, J BIOL CHEM, V258, P4618; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670	61	56	56	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1992	7	7					1279	1286						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620544				2022-12-17	WOS:A1992HZ97100005
J	TAYLOR, WR; EGAN, SE; MOWAT, M; GREENBERG, AH; WRIGHT, JA				TAYLOR, WR; EGAN, SE; MOWAT, M; GREENBERG, AH; WRIGHT, JA			EVIDENCE FOR SYNERGISTIC INTERACTIONS BETWEEN RAS, MYC AND A MUTANT FORM OF P53 IN CELLULAR-TRANSFORMATION AND TUMOR DISSEMINATION	ONCOGENE			English	Article							C-MYC; MURINE FIBROBLASTS; EMBRYO FIBROBLASTS; MULTISTAGE CARCINOGENESIS; METASTATIC PHENOTYPE; GENE-PRODUCT; ONCOGENES; CELLS; EXPRESSION; INHIBITION	Mouse 10T1/2 cells were transfected with combinations of F24 H-ras, human c-myc and the proline 193 mutant form of p53. The three-gene ras/myc/p53 combination was significantly more efficient than single genes or double gene combinations in inducing transformed foci in vitro. An analysis of cell lines isolated after transfections with ras, ras/myc, ras/p53 and ras/myc/p53 indicated that the last combination contained significantly higher levels of ras protein than the other combinations, produced tumors in syngeneic mice with a shorter latency period, and exhibted an increased ability to form lung tumors in an in vivo experimental metastasis assay. Synergistic interactions between ras, myc and mutant p53 genes were observed in focus formation and metastasis assays, suggesting that the action of the three oncogenes in malignant transformation occurs along separate but interactive pathways. These results support a working model of oncogene cooperativity in which alterations in myc and p53 permit elevated expression of ras, which is important in a mechanism affecting both cellular transformation in vitro and tumor dissemination in vivo.	UNIV MANITOBA,MANITOBA INST CELL BIOL,100 OLIVIA ST,WINNIPEG R3E 0V9,MANITOBA,CANADA	University of Manitoba								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BICHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENEVIXTRENCH G, 1990, ONCOGENE, V5, P1187; CRAIG AM, 1990, INT J CANCER, V46, P133, DOI 10.1002/ijc.2910460124; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DAMEN JE, 1989, J NATL CANCER I, V81, P628, DOI 10.1093/jnci/81.8.628; DENHARDT DT, 1987, ONCOGENE, V2, P55; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1989, INT J CANCER, V43, P443, DOI 10.1002/ijc.2910430317; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; EGAN SE, 1989, J CELL BIOCH B, V13, P62; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GINGRAS MC, 1990, CANCER RES, V50, P4061; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HICKS GG, 1988, J VIROL, V62, P4752, DOI 10.1128/JVI.62.12.4752-4755.1988; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V80, P5602; HSIAO WLW, 1987, MOL CELL BIOL, V7, P3380, DOI 10.1128/MCB.7.10.3380; KOHL NE, 1987, ONCOGENE, V2, P41; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROVINSKI B, 1988, ONCOGENE, V2, P445; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; RULEY HE, 1987, ADV VIRAL ONCOL, V6, P1; SCHWARZ LC, 1988, CANCER RES, V48, P6999; Schwarz LC, 1990, GROWTH FACTORS, V3, P115, DOI 10.3109/08977199009108274; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUGARBAKER EV, 1981, CANCER BIOL REV, V2, P235; TANIGUCHI S, 1989, CANCER RES, V49, P6738; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WAITZ W, 1991, ONCOGENE, V6, P29; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WRIGHT JA, 1990, ANTICANCER RES, V10, P1247; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	55	56	59	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1383	1390						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1620551				2022-12-17	WOS:A1992HZ97100017
J	HALEVY, O; RODEL, J; PELED, A; OREN, M				HALEVY, O; RODEL, J; PELED, A; OREN, M			FREQUENT P53 MUTATIONS IN CHEMICALLY-INDUCED MURINE FIBROSARCOMA	ONCOGENE			English	Article							CELLULAR TUMOR-ANTIGEN; WILD-TYPE P53; TRANSFORMED-CELLS; MUTANT P53; GENE-EXPRESSION; SARCOMA-CELLS; FRIEND-VIRUS; LUNG-CANCER; COS CELLS; ONCOGENE	Patterns of p53 expression were investigated in chemically induced fibrosarcoma tumors and cell lines. Most, if not all, cell lines were found to carry alterations at the protein level, reflected in the overproduction of greatly stabilized p53 proteins. In many cases, this was accompanied by formation of complexes with hsc70. Hence, all of these lines may be expressing one sort or another of mutant p53. The mutant nature of the p53 gene was directly verified, in a number of cases, by PCR-amplified cDNA cloning. In one line, no p53 protein was made at all; this turned out to be because of a mutation in a splice donor site, resulting in the production of an aberrant mRNA. In all other cases, mRNAs carrying mis-sense mutations were present, and were sometimes expressed along with wt p53 mRNA. When tested in an in vitro transformation assay, all cloned mutants possessed a discrete oncogenic activity, while having lost the ability to interfere with oncogene-mediated transformation. The system described here could potentially be very helpful in elucidating the significance of p53 mutations.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,POB 26,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,FAC AGR,DEPT ANIM SCI,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem					NCI NIH HHS [R01 CA 40099] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BENDAVID Y, 1987, J VIROL, V61, P2771; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOW V, 1985, NATURE, V314, P633; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; ELIYAHU D, 1990, ONCOGENES CANCER RES, P125; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IGGO R, 1990, LANCET, V335, P651; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MALTZMAN W, 1981, VIROLOGY, V112, P145, DOI 10.1016/0042-6822(81)90620-6; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHILLIPS DH, 1979, CHEM CARCINOGENS DNA, V2; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REIHSAUS E, 1990, ONCOGENE, V5, P137; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROVINSKI B, 1988, ONCOGENE, V2, P445; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	57	56	57	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1593	1600						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923526				2022-12-17	WOS:A1991GX27400014
J	DENIS, N; KITZIS, A; KRUH, J; DAUTRY, F; CORCOS, D				DENIS, N; KITZIS, A; KRUH, J; DAUTRY, F; CORCOS, D			STIMULATION OF METHOTREXATE RESISTANCE AND DIHYDROFOLATE-REDUCTASE GENE AMPLIFICATION BY C-MYC	ONCOGENE			English	Article							PRIMARY EMBRYO FIBROBLASTS; TUMOR PROMOTERS; MOUSE 3T6-CELLS; GROWTH-FACTOR; CELLS; EXPRESSION; DNA; ONCOGENES; MECHANISMS; RADIATION	We have hypothesized that the c-myc oncogene might promote DNA amplification. Resistance to methotrexate (MTX), a widely used cancer chemotherapeutic agent, often results from amplification of the gene coding for the target enzyme, dihydrofolate reductase (DHFR). We report here that gratuitously induced expression of c-myc in rat fibroblasts grown in the presence of MTX greatly increases the number of colonies resistant to the drug. This effect is not related to an alteration of cell growth, and it can also be observed to a lesser extent when c-myc is induced prior to selection in MTX. The DHFR gene is amplified in nearly half of the colonies cultured under selection conditions. Given the likely role of the c-myc product in DNA replication, these results strongly suggest that expression of c-myc plays a role in methotrexate resistance by promoting DNA amplification.	INST COCHIN GENET MOLEC,CNRS,URA 1147,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,CNRS,UNITE 257,F-75251 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			Corcos, Daniel/M-1296-2016	Corcos, Daniel/0000-0002-4572-186X				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BARSOUM J, 1983, P NATL ACAD SCI-BIOL, V80, P5330, DOI 10.1073/pnas.80.17.5330; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CERNI C, 1987, EXP CELL RES, V168, P438; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DENIS N, 1988, NUCLEIC ACIDS RES, V16, P2354, DOI 10.1093/nar/16.5.2354; DOTTO GP, 1985, NATURE, V318, P472; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HANSON C, 1990, CYTOGENET CELL GENET, V53, P23, DOI 10.1159/000132888; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEINBERGER T, 1988, MOL CELL BIOL, V8, P1366, DOI 10.1128/MCB.8.3.1366; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUCKEHUHLE C, 1987, INT J CANCER, V39, P94, DOI 10.1002/ijc.2910390117; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; NOWELL PC, 1986, CANCER RES, V46, P2203; RONAI ZA, 1988, ONCOGENE, V2, P201; SAGER R, 1985, P NATL ACAD SCI USA, V82, P7015, DOI 10.1073/pnas.82.20.7015; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIMKE RT, 1984, CANCER RES, V44, P1735; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SHARMA RC, 1989, CANCER RES, V49, P3861; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; VARSHAVSKY A, 1981, CELL, V25, P561, DOI 10.1016/0092-8674(81)90074-X; WAHL GM, 1989, CANCER RES, V49, P1333; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; [No title captured]	34	56	57	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1453	1457						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886715				2022-12-17	WOS:A1991GX27200023
J	ZWILLER, J; SASSONECORSI, P; KAKAZU, K; BOYNTON, AL				ZWILLER, J; SASSONECORSI, P; KAKAZU, K; BOYNTON, AL			INHIBITION OF PDGF-INDUCED C-JUN AND C-FOS EXPRESSION BY A TYROSINE PROTEIN-KINASE INHIBITOR	ONCOGENE			English	Article							GROWTH-FACTORS; SIGNAL TRANSDUCTION; LEUCINE ZIPPER; 3T3 CELLS; MOUSE FIBROBLASTS; ONCOGENE; INDUCTION; FAMILY; TRANSCRIPTION; STIMULATION	The expression of the proto-oncogenes c-fos, c-jun, jun B and jun D was monitored in quiescent C3H10T1/2 fibroblasts after stimulation with PDGF. The mRNA level of c-fos, c-jun and jun B, but not of jun D, was stimulated by PDGF. The inductions were abolished when genistein, a specific tyrosine protein kinase inhibitor, was added concomitantly with PDGF, a condition in which DNA synthesis is known to be inhibited. As already shown previously, treatment with PDGF and genistein for 4 h followed by the replacement with fresh medium induces the progression of the cells through the G1 phase of their growth-division cycle, without phospholipase C activation. The removal of PDGF and genistein was accompanied by an important increase in c-fos, c-jun and jun B mRNA expression, which correlated with the entrance of cells into G1 phase. Thus, the proto-oncogene expressions induced by PDGF are also obtained in the absence of phospholipase C activation. This result also suggests that the mRNA levels of c-jun, jun B and to a lesser degree c-fos are positively regulated by tyrosine protein kinase activity, whereas jun D is negatively regulated.	CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE; UNIV HAWAII,CANC RES CTR HAWAII,HONOLULU,HI 96813	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cancer Research Center of Hawaii; University of Hawaii System	ZWILLER, J (corresponding author), CNRS,CTR NEUROCHIM,5 RUE PASCAL,F-67084 STRASBOURG,FRANCE.		Sassone-Corsi, Paolo/H-6182-2011		NCI NIH HHS [CA42942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLAH Z, 1990, CANCER RES, V31, pA76; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STILES CD, 1985, CANCER RES, V45, P5215; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	30	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					219	221						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900355				2022-12-17	WOS:A1991FZ13400006
J	KUGOH, HM; HASHIBA, H; SHIMIZU, M; OSHIMURA, M				KUGOH, HM; HASHIBA, H; SHIMIZU, M; OSHIMURA, M			SUGGESTIVE EVIDENCE FOR FUNCTIONALLY DISTINCT, TUMOR-SUPPRESSOR GENES ON CHROMOSOME-1 AND CHROMOSOME-11 FOR A HUMAN FIBROSARCOMA CELL-LINE, HT1080	ONCOGENE			English	Article									TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOLEC & CELL GENET,NISHIMACHI 86,YONAGO,TOTTORI 683,JAPAN; KANAGAWA CANC CTR,RES INST,CELL BIOL LAB,ASAHI KU,YOKOHAMA 241,JAPAN	Tottori University; Kanagawa Prefectural Cancer Center								ATKIN NB, 1979, CANCER, V44, P604, DOI 10.1002/1097-0142(197908)44:2<604::AID-CNCR2820440230>3.0.CO;2-G; ATKIN NB, 1986, CANCER GENET CYTOGEN, V21, P279, DOI 10.1016/0165-4608(86)90206-2; BENEDICT WF, 1984, CANCER RES, V44, P3471; BRODEUR GM, 1981, CANCER RES, V41, P4678; COWELL JK, 1989, HUM GENET, V82, P123, DOI 10.1007/BF00284042; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; HARPER ME, 1981, P NATL ACAD SCI-BIOL, V78, P4458, DOI 10.1073/pnas.78.7.4458; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEIN G, 1971, J CELL SCI, V8, P659; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KUGOH MH, 1989, CHROMOSOME INFORMATI, V46, P25; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MITELMAN F, 1985, PROGR TOPICS CYTOGEN, V5; OSHIMURA M, 1988, CANCER RES, V48, P1623; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PATERSON H, 1987, CELL, V51, P803, DOI 10.1016/0092-8674(87)90103-6; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; SANDBERG AA, 1988, CANCER RES, V48, P1049; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SHIMIZU M, 1990, ONCOGENE, V5, P185; SRIVATSAN ES, 1986, CANCER RES, V46, P6174; STANBRIDGE EJ, 1981, SOMAT CELL GENET, V7, P699, DOI 10.1007/BF01538758; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; STOLER A, 1985, P NATL ACAD SCI USA, V82, P570, DOI 10.1073/pnas.82.2.570; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; THAKKER RV, 1989, NEW ENGL J MED, V321, P218, DOI 10.1056/NEJM198907273210403; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMADA H, IN PRESS ONCOGENE; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	39	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1637	1644						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267132				2022-12-17	WOS:A1990EL40100004
J	PAQUETTE, RL; BERENSON, J; LICHTENSTEIN, A; MCCORMICK, F; KOEFFLER, HP				PAQUETTE, RL; BERENSON, J; LICHTENSTEIN, A; MCCORMICK, F; KOEFFLER, HP			ONCOGENES IN MULTIPLE-MYELOMA - POINT MUTATION OF N-RAS	ONCOGENE			English	Article									VET ADM WADSWORTH MED CTR,DIV HEMATOL,LOS ANGELES,CA 90073; CETUS CORP,DEPT MOLEC BIOL,EMERYVILLE,CA 94608		PAQUETTE, RL (corresponding author), UNIV CALIF LOS ANGELES,DIV HEMATOL ONCOL,FACTOR BLDG 11-240,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [R01CA026038, R01CA033936, P01CA032737] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32737, CA 33936, CA 26038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; AHUJA HG, 1990, IN PRESS BLOOD; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERENSON J, 1989, LEUKEMIA, V3, P133; BERENSON J, 1987, BLOOD, V70, P1550; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWETT PJ, 1989, ONCOGENE, V4, P1029; BROWETT PJ, 1988, LEUKEMIA RES, V12, P25, DOI 10.1016/S0145-2126(98)80005-2; CALIGARISCAPPIO F, 1985, J CLIN INVEST, V76, P1243, DOI 10.1172/JCI112080; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1982, NATURE, V299, P61; DEWALD GW, 1985, BLOOD, V66, P380; ERNST TJ, 1988, BLOOD, V72, P1163; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GROGAN TM, 1987, BLOOD, V70, P932; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; INCE C, 1988, LEUKEMIA, V2, P343; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KUBAGAWA H, 1979, J EXP MED, V150, P792, DOI 10.1084/jem.150.4.792; LIANG W, 1979, CANCER, V44, P630; LUBBERT M, IN PRESS BLOOD; Marshall CJ, 1985, RNA TUMOR VIRUSES MO, P487; MCCOY MS, 1983, NATURE, V302, P79, DOI 10.1038/302079a0; MELTZER P, 1987, BLOOD, V70, pA985; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; PADUA RA, 1988, LEUKEMIA, V2, P503; PERRY RP, 1979, J CELL PHYSIOL, V98, P553, DOI 10.1002/jcp.1040980313; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELVANAYAGAM P, 1987, P AM ASSOC CANC RES, V28, P19; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SREMETIS S, 1989, SCIENCE, V243, P660; STEENVOORDEN ACM, 1988, LEUKEMIA, V2, P325; TSUCHIYA H, 1988, BLOOD, V72, P796; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; WRISCHNIK LA, 1987, NUCLEIC ACIDS RES, V15, P529, DOI 10.1093/nar/15.2.529; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	45	56	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1659	1663						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267133				2022-12-17	WOS:A1990EL40100007
J	RADER, JS; GOLUB, TR; HUDSON, JB; PATEL, D; BEDELL, MA; LAIMINS, LA				RADER, JS; GOLUB, TR; HUDSON, JB; PATEL, D; BEDELL, MA; LAIMINS, LA			INVITRO DIFFERENTIATION OF EPITHELIAL-CELLS FROM CERVICAL NEOPLASIAS RESEMBLES INVIVO LESIONS	ONCOGENE			English	Article									UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; MICHAEL REESE HOSP & MED CTR, DEPT OBSTET & GYNECOL, CHICAGO, IL 60616 USA	Howard Hughes Medical Institute; University of Chicago; Michael Reese Hospital & Medical Center								ASSELINEAU D, 1985, EXP CELL RES, V159, P536, DOI 10.1016/S0014-4827(85)80027-6; BEDELL MA, 1987, J VIROL, V61, P3635, DOI 10.1128/JVI.61.11.3635-3640.1987; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CAMPION MJ, 1986, LANCET, V2, P237; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, ONCOGENE, V1, P251; FERENCZY A, 1987, BLAUSTEINS PATHOLOGY, P141; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; GRUNEBAUM AN, 1983, OBSTET GYNECOL, V62, P448; HAUSEN HZ, 1985, PROG MED VIROL, V32, P15; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; KAUR P, 1988, J VIROL, V62, P1917, DOI 10.1128/JVI.62.6.1917-1924.1988; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; KOSS LG, 1956, ANN NY ACAD SCI, V63, P1245, DOI 10.1111/j.1749-6632.1956.tb32134.x; LORINCZ AT, 1986, J VIROL, V58, P225, DOI 10.1128/JVI.58.1.225-229.1986; MACNAB JCM, 1986, NEW ENGL J MED, V315, P1052, DOI 10.1056/NEJM198610233151703; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCCANCE DJ, 1985, BRIT J OBSTET GYNAEC, V92, P1101, DOI 10.1111/j.1471-0528.1985.tb03019.x; MOORE KL, 1977, DEV HUMAN, P240; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; WAGNER D, 1984, OBSTET GYNECOL, V64, P767; WOODRUFF JD, 1980, OBSTET GYNECOL, V56, P727; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989	26	56	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					571	576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	1691480				2022-12-17	WOS:A1990DB85300017
J	KAMATA, T; SULLIVAN, NF; WOOTEN, MW				KAMATA, T; SULLIVAN, NF; WOOTEN, MW			REDUCED PROTEIN-KINASE-C ACTIVITY IN A RAS-RESISTANT CELL-LINE DERIVED FROM KI-MSV TRANSFORMED-CELLS	ONCOGENE			English	Article									COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [P01CA013106, R01CA039811] Funding Source: NIH RePORTER; NCI NIH HHS [CA39811, CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO S, 1986, FEBS LETT, V195, P352, DOI 10.1016/0014-5793(86)80192-2; AGRANOFF BW, 1983, J BIOL CHEM, V258, P2076; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1984, BIOCHEM J, V222, P195, DOI 10.1042/bj2220195; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FARESE RV, 1985, BIOCHEM J, V231, P269, DOI 10.1042/bj2310269; FARESE RV, 1984, J BIOL CHEM, V259, P7094; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; FEARN JC, 1985, CELL, V40, P991, DOI 10.1016/0092-8674(85)90359-9; FEARON CW, 1985, J BIOL CHEM, V260, P8366; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GRINSTEIN S, 1986, J BIOL CHEM, V261, P512; HONG SL, 1981, J BIOL CHEM, V256, P5215; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPEUCH CJ, 1983, P NATL ACAD SCI-BIOL, V80, P6858; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACARA IG, 1985, CANCER CELL, V3, P365; MAJERUS PW, 1985, TRENDS BIOCHEM SCI, V10, P168, DOI 10.1016/0968-0004(85)90160-4; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; NEL AE, 1986, BIOCHEM J, V233, P145, DOI 10.1042/bj2330145; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; RODBELL M, 1980, NATURE, V284, P17, DOI 10.1038/284017a0; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SALOMON DS, 1984, J CELL PHYSIOL, V121, P22, DOI 10.1002/jcp.1041210105; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SOLARO RJ, 1976, CIRC RES, V39, P8, DOI 10.1161/01.RES.39.1.8; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TAYLOR D, 1985, J BIOL CHEM, V260, P2011; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WOOTEN MW, 1984, FEBS LETT, V171, P183, DOI 10.1016/0014-5793(84)80484-6; WRENN RW, 1984, BIOCHIM BIOPHYS ACTA, V775, P1, DOI 10.1016/0005-2736(84)90227-X	60	56	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1987	1	1					37	46						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6351	2830575				2022-12-17	WOS:A1987J635100005
J	KOHL, NE; RULEY, HE				KOHL, NE; RULEY, HE			ROLE OF C-MYC IN THE TRANSFORMATION OF REF52 CELLS BY VIRAL AND CELLULAR ONCOGENES	ONCOGENE			English	Article									MIT,CTR CANC RES,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NCI NIH HHS [CA 42603, CA 4062, CA 14051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON NH, 1980, DNA TUMOR VIRUSES, P125; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BIGGIN M, 1984, EMBO J, V3, P1083, DOI 10.1002/j.1460-2075.1984.tb01933.x; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HIRAKAWA T, 1988, IN PRESS P NATL ACAD; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PELLEGRINI S, 1986, J CELL PHYSIOL, V126, P107, DOI 10.1002/jcp.1041260115; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1984, CANCER CELL, V2, P481; RULEY HE, 1987, ADV VIRAL ONCOL, V6, P1; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; VANDOREN K, 1984, J VIROL, V50, P606, DOI 10.1128/JVI.50.2.606-614.1984; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WOLFE J, 1984, EMBO J, V3, P1997, DOI 10.1002/j.1460-2075.1984.tb02081.x; ZERLIN M, 1987, ONCOGENE, V1, P19	34	56	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					41	48						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	2830582				2022-12-17	WOS:A1987L481300006
J	Zhou, PT; Li, YY; Li, B; Zhang, MC; Liu, YH; Yao, Y; Li, D				Zhou, Pingting; Li, Yanyan; Li, Bo; Zhang, Meichao; Liu, Yuanhua; Yao, Yuan; Li, Dong			NMIIA promotes tumor growth and metastasis by activating the Wnt/beta-catenin signaling pathway and EMT in pancreatic cancer	ONCOGENE			English	Article							NONMUSCLE MYOSIN-II; EPITHELIAL-MESENCHYMAL TRANSITION; HEAVY-CHAIN; BETA-CATENIN; EXPRESSION; PHOSPHORYLATION; CDC42; MECHANISMS; INVASION; CLONING	Non-muscle myosin IIA (NMIIA) protein plays an important role in cell cytokinesis and cell migration. The role and underlying regulatory mechanisms of NMIIA in pancreatic cancer (PC) remain elusive. We found that NMIIA is highly expressed in PC tissues and contributes to PC poor progression by using open microarray datasets from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and PC tissue arrays. NMIIA regulates beta-catenin mediated EMT to promote the proliferation, migration, invasion, and sphere formation of PC cells in vitro and in vivo. NMIIA controls the beta-catenin transcriptional activity by interacting with beta-catenin. Moreover, MEK/ERK signaling is critical in MLC2 (Ser19) phosphorylation, which can mediate NMIIA activity and regulate Wnt/beta-catenin signaling. These findings highlight the significance of NMIIA in tumor regression and implicate NMIIA as a promising candidate for PC treatment.	[Zhou, Pingting; Li, Yanyan; Zhang, Meichao; Yao, Yuan; Li, Dong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China; [Li, Bo] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai, Peoples R China; [Liu, Yuanhua] Nanjing Med Univ, Dept Chemotherapy, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China	Shanghai Jiao Tong University; Naval Medical University; Nanjing Medical University	Yao, Y; Li, D (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Radiat Oncol, Sch Med, Shanghai, Peoples R China.; Liu, YH (corresponding author), Nanjing Med Univ, Dept Chemotherapy, Affiliated Canc Hosp, Canc Inst Jiangsu Prov, Nanjing, Jiangsu, Peoples R China.	Yuanhualiu02@hotmail.com; yaoyuan@shsmu.edu.cn; lidong@shsmu.edu.cn			National Natural Science Foundation of China [81370600]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [TP2015022]; Shanghai Pujiang Program [15PJ1404800]; Innovation Program of Shanghai Municipal Education Commission [15ZZ056]; Innovation Program for Ph.D. students in Shanghai Jiaotong University School of Medicine [BXJ201731]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Pujiang Program(Shanghai Pujiang Program); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Innovation Program for Ph.D. students in Shanghai Jiaotong University School of Medicine	This work was supported by National Natural Science Foundation of China (grant 81370600, DL); The Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (TP2015022, DL); Shanghai Pujiang Program (15PJ1404800, DL); Innovation Program of Shanghai Municipal Education Commission (15ZZ056, DL); and Innovation Program for Ph.D. students in Shanghai Jiaotong University School of Medicine (BXJ201731).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Beach JR, 2011, P NATL ACAD SCI USA, V108, P17991, DOI 10.1073/pnas.1106499108; Betapudi V, 2006, CANCER RES, V66, P4725, DOI 10.1158/0008-5472.CAN-05-4236; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brower V, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv195; Chew TL, 1998, J MUSCLE RES CELL M, V19, P839, DOI 10.1023/A:1005417926585; Choi OH, 1996, J MUSCLE RES CELL M, V17, P69, DOI 10.1007/BF00140325; Coaxum SD, 2017, ONCOTARGET, V8, P22991, DOI 10.18632/oncotarget.14967; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COTE GP, 1984, J BIOL CHEM, V259, P2781; Cowen D, 2002, CLIN CANCER RES, V8, P1148; D'Apolito M, 2002, GENE, V286, P215, DOI 10.1016/S0378-1119(02)00455-9; Derycke L, 2011, INT J DEV BIOL, V55, P835, DOI 10.1387/ijdb.113336ld; Diala I, 2013, EMBO REP, V14, P356, DOI 10.1038/embor.2013.16; Du M, 2012, J BIOL CHEM, V287, P15330, DOI 10.1074/jbc.M112.349787; Dulyaninova NG, 2007, MOL BIOL CELL, V18, P3144, DOI 10.1091/mbc.E06-11-1056; Fagotto F, 2013, EMBO REP, V14, P422, DOI 10.1038/embor.2013.45; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Golomb E, 2004, J BIOL CHEM, V279, P2800, DOI 10.1074/jbc.M309981200; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hoelzle MK, 2012, MOL BIOL CELL, V23, P310, DOI 10.1091/mbc.E11-08-0719; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Ivanov AI, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-36; Jacobs K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-255; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim JH, 2011, J CELL PHYSIOL, V226, P2881, DOI 10.1002/jcp.22631; Li CX, 2014, J CLIN INVEST, V124, P2172, DOI 10.1172/JCI71103; Li D, 2010, J CELL BIOL, V191, P631, DOI 10.1083/jcb.201006094; Liao Q, 2017, BRIT J CANCER, V117, P563, DOI 10.1038/bjc.2017.193; Liu CC, 2017, ONCOGENE, V36, P1779, DOI 10.1038/onc.2016.339; Liu DN, 2012, INT J MOL SCI, V13, P15291, DOI 10.3390/ijms131115291; Liu T, 2016, MOL MED REP, V13, P1639, DOI 10.3892/mmr.2015.4742; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Nakashima M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-79; Newell-Litwa KA, 2015, DIS MODEL MECH, V8, P1495, DOI 10.1242/dmm.022103; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Schramek D, 2014, SCIENCE, V343, P309, DOI 10.1126/science.1248627; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; Smith BN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104987; Stewart CJR, 2013, HISTOPATHOLOGY, V62, P31, DOI 10.1111/his.12057; Strohm C, 2000, J CARDIOVASC PHARM, V36, P218, DOI 10.1097/00005344-200008000-00012; Thaker PH, 2004, CLIN CANCER RES, V10, P5145, DOI 10.1158/1078-0432.CCR-03-0589; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Wang C, 2017, MOL ONCOL, V11, P455, DOI 10.1002/1878-0261.12036; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; WINKELMANN DA, 1984, NATURE, V307, P758, DOI 10.1038/307758a0; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093; Zeng Q, 2000, J CELL SCI, V113, P471; Zhou PT, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0624-9	61	55	61	1	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5500	5515		10.1038/s41388-019-0806-6	http://dx.doi.org/10.1038/s41388-019-0806-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967633				2022-12-17	WOS:000473842500012
J	Gooding, AJ; Zhang, B; Gunawardane, L; Beard, A; Valadkhan, S; Schiemann, WP				Gooding, Alex J.; Zhang, Bing; Gunawardane, Lalith; Beard, Abigail; Valadkhan, Saba; Schiemann, William P.			The lncRNA BORG facilitates the survival and chemoresistance of triple-negative breast cancers	ONCOGENE			English	Article							NF-KAPPA-B; LONG NONCODING RNAS; CELL-CYCLE; OXIDATIVE STRESS; PROTEIN; TUMOR; GENE; DOXORUBICIN; ACTIVATION; PATTERNS	Disseminated breast cancer cells employ adaptive molecular responses following cytotoxic therapeutic insult which promotes their survival and subsequent outgrowth. Here we demonstrate that expression of the pro-metastatic lncRNA BORG (BMP/OP-Responsive Gene) is greatly induced within triple-negative breast cancer (TNBC) cells subjected to environmental and chemotherapeutic stresses commonly faced by TNBC cells throughout the metastatic cascade. This stress-mediated induction of BORG expression fosters the survival of TNBC cells and renders them resistant to the cytotoxic effects of doxorubicin both in vitro and in vivo. The chemoresistant traits of BORG depend upon its robust activation of the NF-kappa B signaling axis via a novel BORG-mediated feed-forward signaling loop, and via its ability to bind and activate RPA1. Indeed, genetic and pharmacologic inhibition of NF-kappa B signaling or the DNA-binding activity of RPA1 abrogates the pro-survival features of BORG and renders BORG-expressing TNBCs sensitive to doxorubicin-induced cytotoxicity. These findings suggest that therapeutic targeting of BORG or its downstream molecular effectors may provide a novel means to alleviate TNBC recurrence.	[Gooding, Alex J.; Beard, Abigail; Schiemann, William P.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Zhang, Bing; Gunawardane, Lalith; Valadkhan, Saba] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Schiemann, WP (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.; Valadkhan, S (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.	saba.valadkhan@case.edu; william.schiemann@case.edu	Valadkhan, Saba/G-7271-2012	Valadkhan, Saba/0000-0002-6859-4883	National Institutes of Health [CA129359, CA177069, CA194518, T32GM007250, F30CA203233]; METAvivor Foundation; Case Comprehensive Cancer Center's Research Innovation Fund - Case Council; Friends of the Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [F30CA203233] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [TL1TR002549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); METAvivor Foundation; Case Comprehensive Cancer Center's Research Innovation Fund - Case Council; Friends of the Case Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Members of the Schiemann Laboratory are thanked for critical comments and reading of the manuscript. We thank Dr. Ricky Chan for assistance in our analyses of RNA-seq data. We also acknowledge the expertise provided by members of the Case Comprehensive Cancer Center's Core Facilities, including the Gene Expression & Genotyping Core, the Imaging Research Core, Tissue Resources Core, and the Genomics Core. Research support was provided in part by the National Institutes of Health to W.P.S. (CA129359, CA177069, and CA194518) and A.J.G (T32GM007250 and F30CA203233). Additional support was graciously provided by the METAvivor Foundation (W.P.S.), and by pilot funding from the Case Comprehensive Cancer Center's Research Innovation Fund, which is supported by the Case Council and Friends of the Case Comprehensive Cancer Center (W.P.S. and S.V.).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Ahmed KM, 2006, ANTICANCER RES, V26, P4235; Alluri P, 2014, SURG ONCOL CLIN N AM, V23, P567, DOI 10.1016/j.soc.2014.03.003; BARAL E, 1990, INT J RADIAT ONCOL, V19, P963, DOI 10.1016/0360-3016(90)90019-G; Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052; Boutet-Robinet E, 2013, BIO PROTOC, V3, P12; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Catalano V, 2013, SEMIN CANCER BIOL, V23, P522, DOI 10.1016/j.semcancer.2013.08.007; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Courilleau C, 2012, J CELL BIOL, V199, P1067, DOI 10.1083/jcb.201205059; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Di Gesualdo F, 2014, ONCOTARGET, V5, P10976, DOI 10.18632/oncotarget.2770; DiPaola RS, 2002, CLIN CANCER RES, V8, P3311; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Furlow PW, 2015, NAT CELL BIOL, V17, P943, DOI 10.1038/ncb3194; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Goldman M, 2019, UCSC XENA PLATFORM P, DOI DOI 10.1101/326470; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gooding AJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12716-6; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Haring SJ, 2008, J BIOL CHEM, V283, P19095, DOI 10.1074/jbc.M800881200; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Israel A, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000158; Jezierska-Drutel A, 2013, ADV CANCER RES, V119, P107, DOI 10.1016/B978-0-12-407190-2.00003-4; Khan S, 2013, CANCER LETT, V337, P90, DOI 10.1016/j.canlet.2013.05.020; Klein CA, 2011, CURR OPIN GENET DEV, V21, P42, DOI 10.1016/j.gde.2010.10.011; Kouroukis TC, 2014, CURR ONCOL, V21, pE573, DOI 10.3747/co.21.1798; Labun K, 2016, NUCLEIC ACIDS RES, V44, pW272, DOI 10.1093/nar/gkw398; Lakhotia SC, 2012, WIRES RNA, V3, P779, DOI 10.1002/wrna.1135; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030; Li SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098021; Ling YH, 1996, MOL PHARMACOL, V49, P832; Lopez JS, 2017, NAT REV CLIN ONCOL, V14, P57, DOI 10.1038/nrclinonc.2016.96; Lu SQ, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-13; Lupertz R, 2010, TOXICOLOGY, V271, P115, DOI 10.1016/j.tox.2010.03.012; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Mahadevan NR, 2011, J IMMUNOL, V187, P4403, DOI 10.4049/jimmunol.1101531; Malhotra A, 2017, ONCOTARGET, V8, P110671, DOI 10.18632/oncotarget.22577; Mao XH, 2017, IMMUNOLOGY, V150, P379, DOI 10.1111/imm.12698; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Montagut C, 2006, ENDOCR-RELAT CANCER, V13, P607, DOI 10.1677/erc.1.01171; Neil JR, 2008, CANCER RES, V68, P1462, DOI 10.1158/0008-5472.CAN-07-3094; Neil JR, 2009, J BIOL CHEM, V284, P21209, DOI 10.1074/jbc.M109.018374; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Piva R, 2006, ANTIOXID REDOX SIGN, V8, P478, DOI 10.1089/ars.2006.8.478; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Senft D, 2016, TRENDS CANCER, V2, P429, DOI 10.1016/j.trecan.2016.06.004; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shuck SC, 2010, CANCER RES, V70, P3189, DOI 10.1158/0008-5472.CAN-09-3422; Somaiah C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145068; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeda K, 1998, J BIOL CHEM, V273, P17079, DOI 10.1074/jbc.273.27.17079; Tiligada E, 2006, ENDOCR-RELAT CANCER, V13, pS115, DOI 10.1677/erc.1.01272; Tong AJ, 2016, CELL, V165, P165, DOI 10.1016/j.cell.2016.01.020; Tornatore L, 2014, CANCER CELL, V26, P495, DOI 10.1016/j.ccr.2014.07.027; Torre LA, 2017, CANCER EPIDEM BIOMAR, V26, P444, DOI 10.1158/1055-9965.EPI-16-0858; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tyagi AK, 2002, CLIN CANCER RES, V8, P3512; Valadkhan S, 2016, CURR TOP MICROBIOL, V394, P203, DOI 10.1007/82_2015_489; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Victorino VJ, 2014, CURR MED CHEM, V21, P3211, DOI 10.2174/0929867321666140601164647; Wan FY, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000067; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490; Wullaert A, 2011, CELL RES, V21, P146, DOI 10.1038/cr.2010.175; Yap WT, 2013, TISSUE ENG PT A, V19, P2361, DOI [10.1089/ten.tea.2013.0033, 10.1089/ten.TEA.2013.0033]; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Zanotto A, 2016, MOL CANCER THER, V15, P3000, DOI 10.1158/1535-7163.MCT-16-0271; Zhang B, 2014, MOL CELL BIOL, V34, P2318, DOI 10.1128/MCB.01673-13; Zhao MM, 2017, CELL REP, V20, P1997, DOI 10.1016/j.celrep.2017.08.015; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	83	55	56	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2020	2041		10.1038/s41388-018-0586-4	http://dx.doi.org/10.1038/s41388-018-0586-4			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30467380	Green Accepted			2022-12-17	WOS:000461822600003
J	Wen, Y; Zhou, XQ; Lu, MT; He, ML; Tian, Y; Liu, LX; Wang, MN; Tan, WC; Deng, YT; Yang, XS; Mayer, MP; Zou, F; Chen, XM				Wen, Ying; Zhou, Xueqiong; Lu, Meiting; He, Meiling; Tian, Ye; Liu, Lixia; Wang, Mengnan; Tan, Wenchong; Deng, Yaotang; Yang, Xushan; Mayer, Matthias P.; Zou, Fei; Chen, Xuemei			Bclaf1 promotes angiogenesis by regulating HIF-1 alpha transcription in hepatocellular carcinoma	ONCOGENE			English	Article							HYPOXIA; CANCER; APOPTOSIS; GROWTH; VEGF; BTF	The development of hepatocellular carcinomas (HCC) depends on their local microenvironment and the induction of neovascularization is a decisive step in tumor progression, since the growth of solid tumors is limited by nutrient and oxygen supply. Hypoxia is the critical factor that induces transcription of the hypoxia inducible factor-1 alpha (HIF-1 alpha) encoding gene HIF1A and HIF-1 alpha protein accumulation to promote angiogenesis. However, the basis for the transcriptional regulation of HIF1A expression in HCC is still unclear. Here, we show that Bcalf1 levels are highly correlated with HIF-1 alpha levels in HCC tissues, and that knockdown of Bcalf1 in HCC cell lines significantly reduces hypoxia-induced HIF1A expression. Furthermore, we found that Bcalf1 promotes HIF1A transcription via its bZIP domain, leading subsequently to increased transcription of the HIF-1 alpha downstream targets VEGFA, TGFB, and EPO that in turn promote HCC-associated angiogenesis and thus survival and thriving of HCC cells. Moreover, we demonstrate that HIF-alpha levels and microvessel density decrease after the shRNA-mediated Bcalf1 knockdown in xenograft tumors. Finally, we found that Bcalf1 levels increase in hypoxia in a HIF-1 alpha dependent manner. Therefore, our study identifies Bcalf1 as a novel positive regulator of HIF-1 alpha in the hypoxic microenvironment, providing new incentives for promoting Bcalf1 as a potential therapeutic target for an anti-HCC strategy.	[Wen, Ying; Zhou, Xueqiong; Lu, Meiting; He, Meiling; Tian, Ye; Liu, Lixia; Wang, Mengnan; Tan, Wenchong; Deng, Yaotang; Yang, Xushan; Zou, Fei; Chen, Xuemei] Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Med, Guangdong Prov Key Lab Trop Dis Res, 1838 Guangzhou Rd North, Guangzhou 510515, Guangdong, Peoples R China; [Mayer, Matthias P.] Heidelberg Univ ZMBH, Ctr Mol Biol, DKFZ ZMBH Alliance, Neuenheimer Feld 282, D-69120 Heidelberg, Germany	Southern Medical University - China; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Zou, F; Chen, XM (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Occupat Hlth & Med, Guangdong Prov Key Lab Trop Dis Res, 1838 Guangzhou Rd North, Guangzhou 510515, Guangdong, Peoples R China.; Mayer, MP (corresponding author), Heidelberg Univ ZMBH, Ctr Mol Biol, DKFZ ZMBH Alliance, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	m.mayer@zmbh.uni-heidelberg.de; zfei@smu.edu.cn; cxmcsz@smu.edu.cn	Mayer, Matthias P./B-9340-2013	Mayer, Matthias P./0000-0002-7859-3112	National Natural Science Foundation of China (NSFC) [81673216, 81741131, 81671860]; Deutsche Forschungsgemeinschaft [SFB/TRR77 C5, SFB1036 TP09]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by National Natural Science Foundation of China (NSFC): No. 81673216 to Xuemei Chen, Nos. 81741131 and 81671860 to Fei Zou; Deutsche Forschungsgemeinschaft (SFB/TRR77 C5, SFB1036 TP09) to Matthias P. Mayer. We like to thank the kind gifts of plasmid from Prof. J. Tang (China Agricultural University, China).	Azoitei N, 2014, CANCER RES, V74, P7125, DOI 10.1158/0008-5472.CAN-14-1017; Bao H, 2018, FASEB J, V32, P3912, DOI 10.1096/fj.201701073R; Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen TT, 2010, J CELL BIOL, V188, P595, DOI 10.1083/jcb.200906044; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; Dell'Aversana C, 2017, LEUKEMIA, V31, P2315, DOI 10.1038/leu.2017.64; Doe MR, 2012, CANCER RES, V72, P949, DOI 10.1158/0008-5472.CAN-11-2371; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; Finn RS, 2009, EXPERT REV ANTICANC, V9, P503, DOI [10.1586/era.09.6, 10.1586/ERA.09.6]; Fontoura BMA, 2005, IUBMB LIFE, V57, P65, DOI 10.1080/15216540500078608; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gorlach A, 2009, CURR PHARM DESIGN, V15, P3844, DOI 10.2174/138161209789649420; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ju UI, 2015, BIOCHEM BIOPH RES CO, V464, P1008, DOI 10.1016/j.bbrc.2015.07.037; Kang YB, 2013, CANCER CELL, V23, P573, DOI 10.1016/j.ccr.2013.04.017; Kasof GM, 1999, MOL CELL BIOL, V19, P4390; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Koukourakis MI, 2000, CANCER RES, V60, P3088; Lee YY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.76; Li Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep12495; Li YS, 2015, CELL REP, V12, P388, DOI 10.1016/j.celrep.2015.06.033; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; McPherson JP, 2009, CELL DEATH DIFFER, V16, P331, DOI 10.1038/cdd.2008.167; McPherson JP, 2011, ATLAS GENET CYTOGENE, V15, P994; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Sarras H, 2010, THESCIENTIFICWORLDJO, V10, P1450, DOI 10.1100/tsw.2010.132; Savage KI, 2014, MOL CELL, V54, P445, DOI 10.1016/j.molcel.2014.03.021; Shao AW, 2016, CELL DEATH DIFFER, V23, P865, DOI 10.1038/cdd.2015.150; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Thurnherr T, 2016, SCI REP-UK, V6, DOI 10.1038/srep20065; Varia S, 2013, NUCLEUS-AUSTIN, V4, P229, DOI 10.4161/nucl.25187; Vohhodina J, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx1046; Wang D, 2016, IUBMB LIFE, V68, P748, DOI 10.1002/iub.1537; Wei H, 2014, MOL CARCINOGEN, V53, P1, DOI 10.1002/mc.21917; Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025; Yoshitomi T, 2011, ONCOL REP, V25, P1661, DOI 10.3892/or.2011.1253; Zhou XQ, 2019, HEPATOLOGY, V69, P1564, DOI 10.1002/hep.30172; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581; Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30; Zundel W, 2000, GENE DEV, V14, P391	44	55	58	1	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1845	1859		10.1038/s41388-018-0552-1	http://dx.doi.org/10.1038/s41388-018-0552-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30367150	Green Published, hybrid			2022-12-17	WOS:000461164400005
J	Wang, SJ; Li, JJ; Xie, J; Liu, F; Duan, YC; Wu, Y; Huang, SL; He, XH; Wang, ZL; Wu, XH				Wang, Shaojia; Li, Jiajia; Xie, Jie; Liu, Fei; Duan, Yachen; Wu, Yong; Huang, Shenglin; He, Xianghuo; Wang, Ziliang; Wu, Xiaohua			Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin beta 4/SNAI1/SIRT3 signaling pathway	ONCOGENE			English	Article							PD-L1 EXPRESSION; OVARIAN-CANCER; CELL; CARCINOMA; SIRT3; MICROENVIRONMENT; PROLIFERATION; TOLERANCE; PROGNOSIS; BREAST	Although PD-L1 has been shown to play a well-characterized role in inhibiting antitumor immunity via engagement of its receptor PD-1 in T lymphocytes, little is known about the tumor cell-intrinsic function of PD-L1 and its association with prognosis. Here, we investigate this issue and dissect the molecular mechanisms underlying the role of PD-L1 in glucose metabolism, proliferation, migration, and invasion in human cervical cancer cells. As a result, we found that PD-L1 overexpression in cervical cancer cells increases glucose metabolism and metastasis-related behaviors. Mechanistically, PDL1 bound directly to integrin beta 4 (ITGB4), activating the AKT/GSK3 beta signaling pathway and consequently inducing the expression of the transcriptional repressor SNAI1. SNAIL in turn influenced the expression of genes involved in the epithelial-to-mesenchymal transition and regulated glucose metabolism by inhibiting SIRT3 promoter activity. High expression of PD-L1 and ITGB4 in human cervical carcinomas was significantly associated with lymph node metastasis and poor prognosis. Finally, F-18-fluorodeoxyglucose microPET/CT and bioluminescence imaging analyses of cervical xenograft tumors in mice revealed that PD-L1 overexpression markedly increases tumor glucose uptake and promotes lymph node metastasis. Together, these results demonstrate that PD-L1 can promote the growth and metastasis of cervical cancer by activating the ITGB4/SNAI1/SIRT3 signaling pathway, and also suggest the possibility of targeting PD-L1 and its downstream effectors as a potential approach for interfering with cervical cancer growth and metastasis.	[Wang, Shaojia; Li, Jiajia; Liu, Fei; Duan, Yachen; Wu, Yong; Huang, Shenglin; He, Xianghuo; Wang, Ziliang; Wu, Xiaohua] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200032, Peoples R China; [Wang, Shaojia; Li, Jiajia; Liu, Fei; Duan, Yachen; Wu, Yong; Huang, Shenglin; He, Xianghuo; Wang, Ziliang; Wu, Xiaohua] Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China; [Wang, Shaojia; Li, Jiajia; Xie, Jie; Liu, Fei; Duan, Yachen; Wu, Yong; Wang, Ziliang; Wu, Xiaohua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Xie, Jie] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Wang, ZL; Wu, XH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200032, Peoples R China.; Wang, ZL; Wu, XH (corresponding author), Fudan Univ, Shanghai Canc Ctr, Canc Inst, Shanghai 200032, Peoples R China.; Wang, ZL; Wu, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.	huf_zlwang@126.com; wu.xh@fudan.edu.cn	Huang, Shenglin/N-9472-2018; He, Xianghuo/I-1497-2014	Huang, Shenglin/0000-0003-1279-0794; He, Xianghuo/0000-0001-8872-668X	National Nature Science Foundation of China [81672569]; National Nature Science Young Foundation of China [81502235]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Nature Science Young Foundation of China	We thank RuiBi for the samples for the TMA study, Guangqi Qin for manufacturing the TMAs, and Jun Chen and Jianping Zhang for help with animal imaging. This work was supported in part by grants from the National Nature Science Foundation of China (81672569 to X.W.) and the National Nature Science Young Foundation of China (81502235 to Z.W.).	Ata R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010189; Atahan IL, 2007, INT J GYNECOL CANCER, V17, P833, DOI 10.1111/j.1525-1438.2007.00895.x; Bertsias GK, 2009, ARTHRITIS RHEUM-US, V60, P207, DOI 10.1002/art.24227; Bouvier C, 2016, ONCOTARGET, V7, P64702, DOI 10.18632/oncotarget.11876; Cai GF, 2004, CELL IMMUNOL, V230, P89, DOI 10.1016/j.cellimm.2004.09.004; Cao YJ, 2011, CANCER RES, V71, P1235, DOI 10.1158/0008-5472.CAN-10-2217; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chen MF, 2016, ONCOTARGET, V7, P7913, DOI 10.18632/oncotarget.6861; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chowdhury S, 2016, ONCOTARGET, V7, P32318, DOI 10.18632/oncotarget.8698; Clark CA, 2016, CANCER RES, V76, P6964, DOI 10.1158/0008-5472.CAN-16-0258; Dai SY, 2014, CELL IMMUNOL, V290, P72, DOI 10.1016/j.cellimm.2014.05.006; Dong HD, 1999, NAT MED, V5, P1365; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Heeren AM, 2015, ONCOTARGET, V6, P32484, DOI 10.18632/oncotarget.5398; Heeren AM, 2015, CANCER IMMUNOL RES, V3, P48, DOI 10.1158/2326-6066.CIR-14-0149; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Kang T, 2017, ACS NANO, V11, P1397, DOI 10.1021/acsnano.6b06477; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Leong SPL, 2014, CA-CANCER J CLIN, V64, P196, DOI 10.3322/caac.21217; Liu EY, 2017, ONCOTARGET, V8, P19467, DOI 10.18632/oncotarget.14444; Liu F, 2016, ONCOTARGET, V7, P8896, DOI 10.18632/oncotarget.6840; Nathanson SD, 2015, SEMIN CELL DEV BIOL, V38, P106, DOI 10.1016/j.semcdb.2014.10.002; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Paul NR, 2015, J CELL BIOL, V210, P1013, DOI 10.1083/jcb.201502040; Qin T, 2015, ONCOTARGET, V6, P33972, DOI 10.18632/oncotarget.5583; Qorraj M, 2017, LEUKEMIA, V31, P470, DOI 10.1038/leu.2016.214; Schreiner B, 2008, EUR J IMMUNOL, V38, P2706, DOI 10.1002/eji.200838137; Schumacker PT, 2011, CANCER CELL, V19, P299, DOI 10.1016/j.ccr.2011.03.001; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Sun ZJ, 2015, CANCER RES, V75, P1635, DOI 10.1158/0008-5472.CAN-14-3016; Udager AM, 2016, ANN ONCOL, V27, P1706, DOI 10.1093/annonc/mdw216; Verdin E, 2010, TRENDS BIOCHEM SCI, V35, P669, DOI 10.1016/j.tibs.2010.07.003; Wang SJ, 2016, AM J CANCER RES, V6, P1108; Wang ZL, 2015, ONCOTARGET, V6, P6670, DOI 10.18632/oncotarget.3118; Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403; Wu SF, 2017, ONCOTARGET, V8, P16421, DOI 10.18632/oncotarget.14851; Zhang YH, 2015, AM J REPROD IMMUNOL, V74, P201, DOI 10.1111/aji.12365; ZHOU XL, 2015, MED ONCOL, V32, DOI DOI 10.1007/S12032-015-0655-2; Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118	46	55	57	3	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4164	4180		10.1038/s41388-018-0252-x	http://dx.doi.org/10.1038/s41388-018-0252-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706653				2022-12-17	WOS:000439847000009
J	Jinesh, GG; Sambandam, V; Vijayaraghavan, S; Balaji, K; Mukherjee, S				Jinesh, G. G.; Sambandam, V.; Vijayaraghavan, S.; Balaji, K.; Mukherjee, S.			Molecular genetics and cellular events of K-Ras-driven tumorigenesis	ONCOGENE			English	Review							POTENTIAL TUMOR-SUPPRESSOR; ONCOGENIC KRAS; LUNG-CANCER; MUTANT KRAS; COLORECTAL-CANCER; NONCODING RNA; STEM-CELLS; CHROMOSOMAL INSTABILITY; EMERGENCY PROGRAM; EPITHELIAL-CELLS	Cellular transformation and the accumulation of genomic instability are the two key events required for tumorigenesis. K-Ras (Kirsten-rat sarcoma viral oncogene homolog) is a prominent oncogene that has been proven to drive tumorigenesis. K-Ras also modulates numerous genetic regulatory mechanisms and forms a large tumorigenesis network. In this review, we track the genetic aspects of K-Ras signaling networks and assemble the sequence of cellular events that constitute the tumorigenesis process, such as regulation of K-Ras expression (which is influenced by miRNA, small nucleolar RNA and lncRNA), activation of K-Ras (mutations), generation of reactive oxygen species (ROS), induction of DNA damage and apoptosis, induction of DNA damage repair pathways and ROS detoxification systems, cellular transformation after apoptosis by the blebbishield emergency program and the accumulation of genomic/chromosomal instability that leads to tumorigenesis.	[Jinesh, G. G.] Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Sambandam, V.] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol Dept, Houston, TX 77030 USA; [Vijayaraghavan, S.; Balaji, K.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Mukherjee, S.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Jinesh, GG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	goodwinjinesh@gmail.com	Jinesh, Goodwin G./M-5956-2013; Vijayaraghavan, Smruthi/O-3576-2018; Sambandam, Vaishnavi/I-4247-2018	Jinesh, Goodwin G./0000-0002-2170-3245; Vijayaraghavan, Smruthi/0000-0002-8131-0988; Sambandam, Vaishnavi/0000-0003-0013-8838				Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H; Alvarez-Moya B, 2010, ONCOGENE, V29, P5911, DOI 10.1038/onc.2010.298; Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Balaji K, 2017, MOL CANCER RES, V15, P45, DOI 10.1158/1541-7786.MCR-16-0157; Barcelo C, 2014, CANCER RES, V74, P1190, DOI 10.1158/0008-5472.CAN-13-1750; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bartos JD, 2004, MUTAT RES-FUND MOL M, V568, P283, DOI 10.1016/j.mrfmmm.2004.06.052; Baykara O, 2015, J CANCER, V6, P270, DOI 10.7150/jca.10638; Beyer K, 2015, PATHOL RES PRACT, V211, P646, DOI 10.1016/j.prp.2015.05.008; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Castellano L, 2017, NUCLEIC ACIDS RES, V45, P4401, DOI 10.1093/nar/gkx022; Chan IT, 2004, J CLIN INVEST, V113, P528, DOI 10.1172/JCI200420476; Chin LJ, 2008, CANCER RES, V68, P8535, DOI 10.1158/0008-5472.CAN-08-2129; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Danial NN, 2008, ONCOGENE, V27, pS53, DOI 10.1038/onc.2009.44; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fehrmann RSN, 2015, NAT GENET, V47, P115, DOI 10.1038/ng.3173; Feijoo P, 2014, CURR PHARM DESIGN, V20, P6375, DOI 10.2174/1381612820666140630085416; Fiala O, 2016, TUMOR BIOL, V37, P6823, DOI 10.1007/s13277-015-4523-7; Hahnel PS, 2014, BLOOD, V123, P2355, DOI 10.1182/blood-2013-01-477620; Han ZY, 2012, CARCINOGENESIS, V33, P131, DOI 10.1093/carcin/bgr226; Hara T, 2014, ONCOTARGET, V5, P7635, DOI 10.18632/oncotarget.2284; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Hjortland GO, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-455; Hobbs GA, 2016, CANCER CELL, V29, P251, DOI 10.1016/j.ccell.2016.02.015; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hoogwater FJH, 2010, GASTROENTEROLOGY, V138, P2357, DOI 10.1053/j.gastro.2010.02.046; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jayakumar S, 2015, MUTAT RES-FUND MOL M, V779, P33, DOI 10.1016/j.mrfmmm.2015.06.007; Jinesh GG, 2016, CELL DEATH DIFFER, V23, P757, DOI 10.1038/cdd.2016.26; Jinesh GG, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.3; Jinesh GG, 2013, CELL DEATH DIFFER, V20, P382, DOI 10.1038/cdd.2012.140; Jinesh G, 2012, J LEUKOCYTE BIOL, V92, P233, DOI 10.1189/jlb.1211623; Jinesh GG, 2016, CELL DEATH DISCOV, V2; Jinesh GG, 2017, CANCER RES, V77, P6144, DOI 10.1158/0008-5472.CAN-17-0522; Jinesh GG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08796-z; Jinesh GG, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.23; Jinesh GG, 2017, BIOFACTORS, V43, P181, DOI 10.1002/biof.1335; Jinesh GG, 2016, APOPTOSIS, V21, P1203, DOI 10.1007/s10495-016-1289-3; Jinesh GG, 2016, SCI REP-UK, V6, DOI 10.1038/srep23965; Jinesh GG, 2016, BIOCHEM J, V473, P99, DOI 10.1042/BJ20150877; Jinesh GG, 2014, CURR STEM CELL RES T, V9, P89; Jinesh GG, 2012, ONCOIMMUNOLOGY, V1, P1161, DOI 10.4161/onci.20928; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Keohavong P, 1996, CLIN CANCER RES, V2, P411; Kerr EM, 2016, NATURE, V531, P110, DOI 10.1038/nature16967; Kim WY, 2012, CANCER-AM CANCER SOC, V118, P3993, DOI 10.1002/cncr.26656; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Kotake Y, 2016, CYTOTECHNOLOGY, V68, P1591, DOI 10.1007/s10616-014-9834-9; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar Shalini Sree, 2014, Gastrointest Cancer Res, V7, P23; Lagarda H, 2001, J PATHOL, V193, P193, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH769>3.0.CO;2-9; Liu RL, 2015, INT J BIOL MACROMOL, V81, P491, DOI 10.1016/j.ijbiomac.2015.08.016; Lo AWI, 2002, NEOPLASIA, V4, P531, DOI 10.1038/sj.neo.7900267; Ma CC, 2014, TUMOR BIOL, V35, P9163, DOI 10.1007/s13277-014-2185-5; Meng LY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13964; MILO GE, 1985, FEBS LETT, V179, P332, DOI 10.1016/0014-5793(85)80546-9; Monticone M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-92; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Nadal E, 2015, J THORAC ONCOL, V10, pE9, DOI 10.1097/JTO.0000000000000438; Nie FQ, 2015, MOL CANCER THER, V14, P268, DOI 10.1158/1535-7163.MCT-14-0492; Niemela JE, 2011, BLOOD, V117, P2883, DOI 10.1182/blood-2010-07-295501; Ortega J, 2015, P NATL ACAD SCI USA, V112, P5667, DOI 10.1073/pnas.1417711112; Ostrem JML, 2016, NAT REV DRUG DISCOV, V15, P771, DOI 10.1038/nrd.2016.139; Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Purdom-Dickinson SE, 2007, MOL PHARMACOL, V72, P1074, DOI 10.1124/mol.107.035360; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Rodrigues CFD, 2009, MUTAT RES-FUND MOL M, V670, P42, DOI 10.1016/j.mrfmmm.2009.07.004; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Schimanski CC, 2010, INT J COLORECTAL DIS, V25, P181, DOI 10.1007/s00384-009-0843-7; Serra RW, 2014, ELIFE, V3, DOI 10.7554/eLife.02313; Shi Y, 2014, CELL DEATH DIFFER, V21, P612, DOI 10.1038/cdd.2013.186; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tang FH, 2017, INT J CANCER, V140, P1860, DOI 10.1002/ijc.30591; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Taoka R, 2017, APOPTOSIS, V22, P719, DOI 10.1007/s10495-017-1359-1; Tape CJ, 2016, CELL, V165, P910, DOI 10.1016/j.cell.2016.03.029; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Tran MN, 2010, CURR STEM CELL RES T, V5, P387; Tsai FD, 2015, P NATL ACAD SCI USA, V112, P779, DOI 10.1073/pnas.1412811112; Tsang WP, 2009, CARCINOGENESIS, V30, P953, DOI 10.1093/carcin/bgp094; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wang XR, 2013, NEURO-ONCOLOGY, V15, P1491, DOI 10.1093/neuonc/not107; Wang YA, 2005, ONCOGENE, V24, P3042, DOI 10.1038/sj.onc.1208390; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weiss MB, 2010, ONCOGENE, V29, P4715, DOI 10.1038/onc.2010.220; Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905; Xu SD, 2016, ONCOTARGET, V7, P45687, DOI 10.18632/oncotarget.9920; Yilmaz A, 2014, INT J ENV RES PUB HE, V11, P9491, DOI 10.3390/ijerph110909491; Yin Y, 2014, CELL RES, V24, P1164, DOI 10.1038/cr.2014.121; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; You CY, 2016, SCI REP-UK, V6, DOI 10.1038/srep37459; Zhang XH, 2013, CANCER BIOL THER, V14, P597, DOI 10.4161/cbt.24592; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160; Zhou Y, 2016, CANCER RES, V76, P5777, DOI 10.1158/0008-5472.CAN-15-2936	105	55	57	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					839	846		10.1038/onc.2017.377	http://dx.doi.org/10.1038/onc.2017.377			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059163	Green Published, hybrid			2022-12-17	WOS:000425281800002
J	Stelloo, S; Nevedomskaya, E; Kim, Y; Hoekman, L; Bleijerveld, OB; Mirza, T; Wessels, LFA; van Weerden, WM; Altelaar, AFM; Bergman, AM; Zwart, W				Stelloo, S.; Nevedomskaya, E.; Kim, Y.; Hoekman, L.; Bleijerveld, O. B.; Mirza, T.; Wessels, L. F. A.; van Weerden, W. M.; Altelaar, A. F. M.; Bergman, A. M.; Zwart, W.			Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis	ONCOGENE			English	Article							DNA-REPAIR; XENOGRAFT MODELS; RNA-BINDING; CANCER; TRANSCRIPTION; CHROMATIN; IDENTIFICATION; HOXB13; COACTIVATOR; ENHANCERS	Androgen receptor (AR) is a key player in prostate cancer development and progression. Here we applied immunoprecipitation mass spectrometry of endogenous AR in LNCaP cells to identify components of the AR transcriptional complex. In total, 66 known and novel AR interactors were identified in the presence of synthetic androgen, most of which were critical for AR-driven prostate cancer cell proliferation. A subset of AR interactors required for LNCaP proliferation were profiled using chromatin immunoprecipitation assays followed by sequencing, identifying distinct genomic subcomplexes of AR interaction partners. Interestingly, three major subgroups of genomic subcomplexes were identified, where selective gain of function for AR genomic action in tumorigenesis was found, dictated by FOXA1 and HOXB13. In summary, by combining proteomic and genomic approaches we reveal subclasses of AR transcriptional complexes, differentiating normal AR behavior from the oncogenic state. In this process, the expression of AR interactors has key roles by reprogramming the AR cistrome and interactome in a genomic location-specific manner.	[Stelloo, S.; Nevedomskaya, E.; Kim, Y.; Mirza, T.; Bergman, A. M.; Zwart, W.] Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands; [Nevedomskaya, E.; Kim, Y.; Wessels, L. F. A.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands; [Hoekman, L.; Bleijerveld, O. B.; Altelaar, A. F. M.] Netherlands Canc Inst, Mass Spectrometry & Prote Facil, Amsterdam, Netherlands; [Wessels, L. F. A.] Delft Univ Technol, Fac EEMCS, Delft, Netherlands; [van Weerden, W. M.] Erasmus Univ, Erasmus MC Canc Inst, Dept Urol, Med Ctr, Rotterdam, Netherlands; [Altelaar, A. F. M.] Univ Utrecht, Biomol Mass Spectrometry & Prote Grp, Bijvoet Ctr Biomol Res, Utrecht, Netherlands; [Altelaar, A. F. M.] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Netherlands Prote Ctr, Utrecht, Netherlands; [Bergman, A. M.] Netherlands Canc Inst, Div Med Oncol, Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute; Delft University of Technology; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Utrecht University; Utrecht University; Netherlands Cancer Institute	Stelloo, S; Zwart, W (corresponding author), Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	s.stelloo@nki.nl; w.zwart@nki.nl		Zwart, Wilbert/0000-0002-9823-7289; Kim, Yongsoo/0000-0002-2995-2131	Movember [NKI01]; KWF Dutch Cancer Society/Alpe d'HuZes Bas Mulder Award [NKI 2014-6711]; Netherlands Organisation for Scientific Research (NWO) [016.156.401]; NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands [184.032.201]; VIDI grant [723.012.102]	Movember; KWF Dutch Cancer Society/Alpe d'HuZes Bas Mulder Award; Netherlands Organisation for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands; VIDI grant	We thank the NKI Genomics Core Facility for Illumina sequencing and bioinformatic support. SS is supported by Movember (NKI01). We thank Corrina MA de Ridder for dedicated maintenance and biobanking of the PDX models. WZ is supported by a KWF Dutch Cancer Society/Alpe d'HuZes Bas Mulder Award (NKI 2014-6711) and a VIDI grant (016.156.401) from The Netherlands Organisation for Scientific Research (NWO). This work is further supported by NWO as part of the National Roadmap Large-scale Research Facilities of the Netherlands, Proteins@Work (184.032.201) to OBB and AFMA and a VIDI grant (723.012.102) to AFMA.	Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Ameziane N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9829; Andreu-Vieyra C, 2011, MOL CELL BIOL, V31, P4648, DOI 10.1128/MCB.05934-11; Asangani IA, 2016, MOL CANCER RES, V14, P324, DOI 10.1158/1541-7786.MCR-15-0472; Barfeld SJ, 2017, EBIOMEDICINE, V18, P83, DOI 10.1016/j.ebiom.2017.04.006; Beltran M, 2016, GENOME RES, V26, P896, DOI 10.1101/gr.197632.115; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bose DA, 2017, CELL, V168, P135, DOI 10.1016/j.cell.2016.12.020; Chen Z, 2015, EMBO J, V34, P502, DOI 10.15252/embj.201490306; Comuzzi Barbara, 2006, Cellscience, V3, P61; Cross DS, 2008, MED ONCOL, V25, P287, DOI 10.1007/s12032-007-9033-z; Etani T, 2015, ONCOTARGET, V6, P2865, DOI 10.18632/oncotarget.3067; Fan SL, 2006, BIOCHEM BIOPH RES CO, V341, P192, DOI 10.1016/j.bbrc.2005.12.167; Fang YF, 1996, J BIOL CHEM, V271, P28697, DOI 10.1074/jbc.271.45.28697; Fei T, 2017, P NATL ACAD SCI USA, V114, pE5207, DOI 10.1073/pnas.1617467114; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Goodwin JF, 2013, CANCER DISCOV, V3, P1254, DOI 10.1158/2159-8290.CD-13-0108; Goto K, 2003, J STEROID BIOCHEM, V85, P201, DOI 10.1016/S0960-0760(03)00196-1; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hendrickson DG, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0878-3; Hsiao JJ, 2016, J BIOL CHEM, V291, P18818, DOI 10.1074/jbc.M116.732313; Hsiao JJ, 2015, MOL ENDOCRINOL, V29, P1195, DOI 10.1210/me.2015-1021; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; Imberg-Kazdan K, 2013, GENOME RES, V23, P581, DOI 10.1101/gr.144774.112; Jangal M, 2014, NUCLEIC ACIDS RES, V42, P11339, DOI 10.1093/nar/gku791; Jasavala R, 2007, MOL CELL PROTEOMICS, V6, P252, DOI 10.1074/mcp.M600169-MCP200; Jia L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003645; Jin H, 2014, BIOMED RES INT, V2014, P1; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Kim SD, 2010, ANAT CELL BIOL, V43, P284, DOI 10.5115/acb.2010.43.4.284; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mooslehner KA, 2012, INT J ENDOCRINOL, V2012, DOI 10.1155/2012/381824; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Paltoglou S, 2017, CANCER RES, V77, P3417, DOI 10.1158/0008-5472.CAN-16-1616; Polkinghorn WR, 2013, CANCER DISCOV, V3, P1245, DOI 10.1158/2159-8290.CD-13-0172; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Schiewer MJ, 2016, TRENDS ENDOCRIN MET, V27, P216, DOI 10.1016/j.tem.2016.02.004; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Stelloo S, 2015, EMBO MOL MED, V7, P1450, DOI 10.15252/emmm.201505424; van der Steen T, 2013, INT J MOL SCI, V14, P14833, DOI 10.3390/ijms140714833; Van Tilborgh N, 2013, J ENDOCRINOL INVEST, V36, P699, DOI 10.3275/8927; van Weerden WM, 2009, BRIT J CANCER, V100, P13, DOI 10.1038/sj.bjc.6604822; Vander Griend DJ, 2014, INT J BIOL SCI, V10, P627, DOI 10.7150/ijbs.8756; VANSTEENBRUGGE GJ, 1984, PROSTATE, V5, P639, DOI 10.1002/pros.2990050610; vanWeerden WM, 1996, AM J PATHOL, V149, P1055; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Yang YA, 2015, GENES DIS, V2, P144, DOI 10.1016/j.gendis.2015.01.003; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou XE, 2010, J BIOL CHEM, V285, P9161, DOI 10.1074/jbc.M109.085779	57	55	56	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					313	322		10.1038/onc.2017.330	http://dx.doi.org/10.1038/onc.2017.330			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925401				2022-12-17	WOS:000422753900004
J	Pistore, C; Giannoni, E; Colangelo, T; Rizzo, F; Magnani, E; Muccillo, L; Giurato, G; Mancini, M; Rizzo, S; Riccardi, M; Sahnane, N; Del Vescovo, V; Kishore, K; Mandruzzato, M; Macchi, F; Pelizzola, M; Denti, MA; Furlan, D; Weisz, A; Colantuoni, V; Chiarugi, P; Bonapace, IM				Pistore, C.; Giannoni, E.; Colangelo, T.; Rizzo, F.; Magnani, E.; Muccillo, L.; Giurato, G.; Mancini, M.; Rizzo, S.; Riccardi, M.; Sahnane, N.; Del Vescovo, V.; Kishore, K.; Mandruzzato, M.; Macchi, F.; Pelizzola, M.; Denti, M. A.; Furlan, D.; Weisz, A.; Colantuoni, V.; Chiarugi, P.; Bonapace, I. M.			DNA methylation variations are required for epithelial-to-mesenchymal transition induced by cancer-associated fibroblasts in prostate cancer cells	ONCOGENE			English	Article							STEM-CELLS; EXPRESSION ANALYSIS; MIRNA EXPRESSION; TUMOR-SUPPRESSOR; FEEDBACK LOOP; PROMOTES; ZEB1; METASTASIS; METHYLTRANSFERASES; INHIBITION	Widespread genome hypo-methylation and promoter hyper-methylation of epithelium-specific genes are hallmarks of stable epithelial-to-mesenchymal transition (EMT), which in prostate cancer (PCa) correlates with castration resistance, cancer stem cells generation, chemoresistance and worst prognosis. Exploiting our consolidated 'ex-vivo' system, we show that cancer-associated fibroblasts (CAFs) released factors have pivotal roles in inducing genome methylation changes required for EMT and stemness in EMT-prone PCa cells. By global DNA methylation analysis and RNA-Seq, we provide compelling evidence that conditioned media from CAFs explanted from two unrelated patients with advanced PCa, stimulates concurrent DNA hypo-and hyper-methylation required for EMT and stemness in PC3 and DU145, but not in LN-CaP and its derivative C4-2B, PCa cells. CpG island (CGI) hyper-methylation associates with repression of genes required for epithelial maintenance and invasion antagonism, whereas activation of EMT markers and stemness genes correlate with CGI hypo-methylation. Remarkably, methylation variations and EMT-regulated transcripts almost completely reverse qualitatively and quantitatively during MET. Unsupervised clustering analysis of the PRAD TCGA data set with the differentially expressed (DE) and methylated EMT signature, identified a gene cluster of DE genes defined by a CAF+ and AR-phenotype and worst diagnosis. This gene cluster includes the relevant factors for EMT and stemness, which display DNA methylation variations in regulatory regions inversely correlated to their expression changes, thus strongly sustaining the ex-vivo data. DNMT3A-dependent methylation is essential for silencing epithelial maintenance and EMT counteracting genes, such as CDH1 and GRHL2, that is, the direct repressor of ZEB1, the key transcriptional factor for EMT and stemness. Accordingly, DNMT3A knock-down prevents EMT entry. These results shed light on the mechanisms of establishment and maintenance of coexisting DNA hypo-and hyper-methylation patterns during cancer progression, the generation of EMT and cell stemness in advanced PCa, and may pave the way to new therapeutic implications.	[Pistore, C.; Magnani, E.; Rizzo, S.; Riccardi, M.; Mandruzzato, M.; Macchi, F.; Bonapace, I. M.] Univ Insubria, Dept Biotechnol & Life Sci, Busto Arsizio, VA, Italy; [Giannoni, E.; Chiarugi, P.] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy; [Colangelo, T.; Muccillo, L.; Colantuoni, V.] Univ Sannio, Dept Sci & Technol, Benevento, Italy; [Rizzo, F.; Muccillo, L.; Weisz, A.] Univ Salerno, Dept Med Surg & Dent, Schola Med Salernitana, Lab Mol Med & Gen, Baronissi, SA, Italy; [Sahnane, N.; Furlan, D.] Univ Insubria, Dept Surg & Morphol Sci, Anat Pathol Unit, Varese, Italy; [Kishore, K.; Pelizzola, M.] Italian Inst Technol, Ctr Genom Sci, Milan, Italy; [Del Vescovo, V.; Denti, M. A.] Univ Trento, Ctr Integrat Biol, Trento, Italy; [Colangelo, T.] IRCCS, Casa Sollievo Sofferenza, Inst Stem Cell Biol Regenerat Med & Innovat Thera, San Giovanni Rotondo, Italy	University of Insubria; University of Florence; University of Sannio; University of Salerno; University of Insubria; Istituto Italiano di Tecnologia - IIT; University of Trento; IRCCS Casa Sollievo Della Sofferenza	Bonapace, IM (corresponding author), Univ Insubria I, Dept Biotechnol & Life Sci, Via Manara 7, I-21052 Busto Arsizio, Lombardia, Italy.	ian.bonapace@uninsubria.it	Giurato, Giorgio/K-3859-2018; FURLAN, DANIELA/AAB-8271-2022; Rizzo, Francesca/K-3057-2016; Sahnane, Nora/L-1983-2019; Chiarugi, Paola/CDD-7988-2022; Denti, Michela A./ABI-4085-2020; Giannoni, Elisa/AAE-2092-2020; Weisz, Alessandro/A-1317-2014; COLANGELO, TOMMASO/B-6119-2017	Giurato, Giorgio/0000-0002-0538-8978; FURLAN, DANIELA/0000-0002-5958-5379; Rizzo, Francesca/0000-0003-1783-5015; Sahnane, Nora/0000-0002-6227-8628; Denti, Michela A./0000-0001-7203-7062; Weisz, Alessandro/0000-0003-0455-2083; Pelizzola, Mattia/0000-0001-6672-9636; Chiarugi, Paola/0000-0001-7655-2969; BONAPACE, IAN MARC/0000-0001-6580-8893; Macchi, Filippo/0000-0001-8226-4816; Mancini, Monica/0000-0003-4128-9018; COLANGELO, TOMMASO/0000-0002-6927-403X; Kishore, Kamal/0000-0002-4650-8745	Epigenomics Flagship Project (EPIGEN-CNR-IT); Italian Association for Cancer Research (AIRC) [IG-8797, IG-17426]; AIRC [19548]	Epigenomics Flagship Project (EPIGEN-CNR-IT); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Epigenomics Flagship Project (EPIGEN-CNR-IT: to IMB, VC, DF and AW); Italian Association for Cancer Research (AIRC: grants IG-8797 to PC and IG-17426 to AW). TC is now supported by a three year AIRC fellowship (Project code: 19548). The Ethics approval and consent to participate at the study named 'Ruolo del microambiente stromale nella immunomodulazione e nella progression del carcinoma prostatico (Role of the stromal microenvironment for immunomodulation and for cancer progression in prostatic carcinoma)' was released with reference number 'BIO 15.016' from the Ethics committee 'Area Vasta Centro' of the 'Azienda Ospedaliera Universitaria Correggi' in Florence-Italy on the 26th of June 2015.	Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Aue A, 2015, J AM SOC NEPHROL, V26, P2704, DOI 10.1681/ASN.2014080759; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Babbio F, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-19; Bernhart SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep37393; Bhatt T, 2013, CELL COMMUN ADHES, V20, P189, DOI 10.3109/15419061.2013.854778; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608; Carmona FJ, 2014, CANCER RES, V74, P5608, DOI 10.1158/0008-5472.CAN-13-3659; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Cheung AKL, 2015, ONCOTARGET, V6, P13434; Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Cui H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123926; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Ficz G, 2015, J EXP BIOL, V218, P14, DOI 10.1242/jeb.107961; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; de Herreros AG, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00071; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Giannoni E, 2013, J MOL MED, V91, P103, DOI 10.1007/s00109-012-0941-9; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Grega-Larson NE, 2015, MOL BIOL CELL, V26, P3803, DOI 10.1091/mbc.E15-06-0443; Guo M, 2012, CANCER RES, V72, P2017, DOI 10.1158/0008-5472.CAN-11-3985; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hong T, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004569; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669; Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687; Kgatle MM, 2016, PROSTATE CANCER, V2016, DOI 10.1155/2016/5653862; Krisenko MO, 2015, BBA-MOL CELL RES, V1853, P254, DOI 10.1016/j.bbamcr.2014.10.022; Lawlor H, 2015, TUMOR BIOL, V36, P6019, DOI 10.1007/s13277-015-3278-5; Lee B, 2014, DEV CELL, V29, P47, DOI 10.1016/j.devcel.2014.03.005; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002; Liu FT, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-66; Lu ZX, 2015, MOL CANCER RES, V13, P305, DOI 10.1158/1541-7786.MCR-14-0366; Malouf GG, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r144; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Morita S, 2013, INT J MOL SCI, V14, P14647, DOI 10.3390/ijms140714647; Nogales V, 2016, ONCOTARGET, V7, P3084, DOI 10.18632/oncotarget.6413; Ohka F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023332; Parpart S, 2014, HEPATOLOGY, V60, P872, DOI 10.1002/hep.27200; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Preca BT, 2015, INT J CANCER, V137, P2566, DOI 10.1002/ijc.29642; Roca H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076773; Rodriguez J, 2008, P NATL ACAD SCI USA, V105, P19809, DOI 10.1073/pnas.0810133105; Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100; Sauer E, 2014, FORENSIC SCI INT-GEN, V13, P217, DOI 10.1016/j.fsigen.2014.08.005; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Schubert M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065064; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Spans L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090002; Stefanoli M, 2014, NEUROENDOCRINOLOGY, V100, P26, DOI 10.1159/000365449; Steinestel K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-17; Taddei ML, 2014, MOL ONCOL, V8, P1729, DOI 10.1016/j.molonc.2014.07.009; Taddei ML, 2011, MOL CANCER RES, V9, P149, DOI 10.1158/1541-7786.MCR-10-0298; Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383; Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Vastenhouw NL, 2012, CURR OPIN CELL BIOL, V24, P374, DOI 10.1016/j.ceb.2012.03.009; von Meyenn F, 2016, MOL CELL, V62, P848, DOI 10.1016/j.molcel.2016.04.025; Warzecha CC, 2009, RNA BIOL, V6, P546, DOI 10.4161/rna.6.5.9606; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Yang LL, 2012, CARCINOGENESIS, V33, P1863, DOI 10.1093/carcin/bgs226; Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13; Yaqinuddin A, 2009, J UROLOGY, V182, P756, DOI 10.1016/j.juro.2009.03.082; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Zhang YJ, 2015, DEVELOPMENT, V142, P3383, DOI 10.1242/dev.125393; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	80	55	57	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2017	36	40					5551	5566		10.1038/onc.2017.159	http://dx.doi.org/10.1038/onc.2017.159			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI8ZW	28581528	Green Submitted			2022-12-17	WOS:000412293600001
J	Lau, TS; Chan, LKY; Wong, ECH; Hui, CWC; Sneddon, K; Cheung, H; Yim, SF; Lee, JHS; Yeung, CSY; Chung, TKH; Kwong, J				Lau, T-S; Chan, L. K-Y; Wong, E. C-H; Hui, C. W-C; Sneddon, K.; Cheung, T-H; Yim, S-F; Lee, J. H-S; Yeung, C. S-Y; Chung, T. K-H; Kwong, J.			A loop of cancer-stroma-cancer interaction promotes peritoneal metastasis of ovarian cancer via TNF alpha-TGF alpha-EGFR	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; THERAPEUTIC TARGET; MESOTHELIAL CELLS; DNA METHYLATION; EXPRESSION; MODEL; FIBROBLASTS; CARBOPLATIN; CARCINOMA	Peritoneum is the most common site for ovarian cancer metastasis. Here we investigate how cancer epigenetics regulates reciprocal tumor-stromal interactions in peritoneal metastasis of ovarian cancer. Firstly, we find that omental stromal fibroblasts enhance colony formation of metastatic ovarian cancer cells, and de novo expression of transforming growth factor-alpha (TGF-alpha) is induced in stromal fibroblasts co-cultured with ovarian cancer cells. We also observed an over-expression of tumor necrosis factoralpha (TNF-alpha) in ovarian cancer cells, which is regulated by promoter DNA hypomethylation as well as chromatin remodeling. Interestingly, this ovarian cancer-derived TNF-alpha induces TGF-alpha transcription in stromal fibroblasts through nuclear factor-kappa B (NF-kappa B). We further show that TGF-alpha secreted by stromal fibroblasts in turn promotes peritoneal metastasis of ovarian cancer through epidermal growth factor receptor (EGFR) signaling. Finally, we identify a TNF alpha-TGF alpha-EGFR interacting loop between tumor and stromal compartments of human omental metastases. Our results therefore demonstrate cancer epigenetics induces a loop of cancer-stroma-cancer interaction in omental microenvironment that promotes peritoneal metastasis of ovarian cancer cells via TNF alpha-TGF alpha-EGFR.	[Lau, T-S; Chan, L. K-Y; Sneddon, K.; Cheung, T-H; Yim, S-F; Lee, J. H-S; Yeung, C. S-Y; Chung, T. K-H; Kwong, J.] Chinese Univ Hong Kong, Fac Med, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Wong, E. C-H; Hui, C. W-C] Chinese Univ Hong Kong, Fac Med, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Kwong, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Block E,1-F, Shatin, Hong Kong, Peoples R China.	josephkwong@cuhk.edu.hk	Kwong, Joseph/H-2368-2013; Wong, Chi Hang/C-6909-2015; Wong, Chi Hang/ABE-8673-2021; Lau, Tat San/R-6722-2019	Kwong, Joseph/0000-0002-3380-6882; Wong, Chi Hang/0000-0003-4157-6287; Wong, Chi Hang/0000-0003-4157-6287; Lee, Ho Sze Jacqueline/0000-0002-3175-1144; CHUNG, Tony/0000-0002-6362-8546; Lau, Tat San/0000-0003-2315-9690	CUHK Research Committee Funding; Hong Kong Obstetrical and Gynaceological Trust Fund; Charlie Lee Charitable Foundation	CUHK Research Committee Funding; Hong Kong Obstetrical and Gynaceological Trust Fund; Charlie Lee Charitable Foundation	This research was supported by CUHK Research Committee Funding (Direct Grants for Research), Hong Kong Obstetrical and Gynaceological Trust Fund, and The Charlie Lee Charitable Foundation. The authors give special thanks to Alex Shu-Wing NG (Brigham and Women's Hospital, Harvard Medical School) and Ronny Drapkin (The Penn Ovarian Cancer Center, University of Pennsylvanian) for the FTSEC190 and FTSEC194 cell lines. The authors give thanks to Dr Gene Chi-Wai MAN, Mr Jianzhang WANG, Mr Long CUI, and Mr John Chun-Kit LI for technical supports; to Ms. Flora Pui-Ling TAM for processing clinical samples; and to Dr Amy Kit-Ying CHUNG for revising the manuscript.	Alt E, 2011, BIOL CELL, V103, P197, DOI 10.1042/BC20100117; Andersen P, 2008, INT J CANCER, V122, P342, DOI 10.1002/ijc.23109; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BAUKNECHT T, 1991, ANTICANCER RES, V11, P1523; Blank SV, 2010, GYNECOL ONCOL, V119, P451, DOI 10.1016/j.ygyno.2010.08.008; Brustmann H, 2008, INT J GYNECOL PATHOL, V27, P380, DOI 10.1097/PGP.0b013e31815d060d; Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864; BUY JN, 1988, RADIOLOGY, V169, P691, DOI 10.1148/radiology.169.3.3186993; Cai J, 2012, CARCINOGENESIS, V33, P20, DOI 10.1093/carcin/bgr230; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Coscia F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12645; D'Antonio A, 2002, INT J ONCOL, V21, P941; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Glaysher S, 2013, BRIT J CANCER, V109, P1786, DOI 10.1038/bjc.2013.529; Gui T, 2012, CANCER EPIDEMIOL, V36, P490, DOI 10.1016/j.canep.2012.06.005; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He C, 2015, ONCOGENE, V34, P6040, DOI 10.1038/onc.2015.52; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karki P, 2017, MOL NEUROBIOL, V54, P964, DOI 10.1007/s12035-016-9705-9; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; KOHLER M, 1992, EUR J CANCER, V28A, P1432, DOI 10.1016/0959-8049(92)90538-D; Kwong J, 2009, NEOPLASIA, V11, P529, DOI 10.1593/neo.09112; LANGDON SP, 1988, CANCER RES, V48, P6166; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lassus H, 2006, J MOL MED-JMM, V84, P671, DOI 10.1007/s00109-006-0054-4; Lau TS, 2014, J PATHOL, V232, P43, DOI 10.1002/path.4258; Li HX, 2014, ARCH GYNECOL OBSTET, V290, P1067, DOI 10.1007/s00404-014-3377-3; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Milagrel CS, 2015, CANCER RES, V75, P1255, DOI 10.1158/0008-5472.CAN-14-1801; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ohta T, 2012, CANCER BIOL THER, V13, P408, DOI 10.4161/cbt.19292; Psyrri A, 2005, CLIN CANCER RES, V11, P8637, DOI 10.1158/1078-0432.CCR-05-1436; Qiu X, 2015, BIOCHEM BIOPH RES CO, V461, P128, DOI 10.1016/j.bbrc.2015.03.180; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Radjabi AR, 2008, J BIOL CHEM, V283, P2822, DOI 10.1074/jbc.M704855200; Rizvi I, 2010, CANCER RES, V70, P9319, DOI 10.1158/0008-5472.CAN-10-1783; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Stadlmann S, 2006, MODERN PATHOL, V19, P607, DOI 10.1038/modpathol.3800575; Steffensen KD, 2008, CLIN CANCER RES, V14, P3278, DOI 10.1158/1078-0432.CCR-07-4171; Szlosarek PW, 2006, MOL CANCER THER, V5, P382, DOI 10.1158/1535-7163.MCT-05-0303; Teplinsky E, 2015, TRANSL CANCER RES, V4, P107, DOI 10.3978/j.issn.2218-676X.2015.01.01; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Vergote IB, 2014, J CLIN ONCOL, V32, P320, DOI 10.1200/JCO.2013.50.5669; Wang C, 2014, CANCER RES, V74, P3084, DOI 10.1158/0008-5472.CAN-13-3198; Wen W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0366-5; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	54	55	58	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3576	3587		10.1038/onc.2016.509	http://dx.doi.org/10.1038/onc.2016.509			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166193	Green Published, hybrid			2022-12-17	WOS:000403878600007
J	Ghoochani, A; Schwarz, MA; Yakubov, E; Engelhorn, T; Doerfler, A; Buchfelder, M; Bucala, R; Savaskan, NE; Eyupoglu, IY				Ghoochani, A.; Schwarz, M. A.; Yakubov, E.; Engelhorn, T.; Doerfler, A.; Buchfelder, M.; Bucala, R.; Savaskan, N. E.; Eyupoglu, I. Y.			MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis	ONCOGENE			English	Article							MIGRATION-INHIBITORY FACTOR; MACROPHAGE; CELL; EXPRESSION; CD74; MIF; GLIOMAS; PROGRESSION; ACTIVATION; REGULATOR	Microglial cells in the brain tumor microenvironment are associated with enhanced glioma malignancy. They persist in an immunosuppressive M2 state at the peritumoral site and promote the growth of gliomas. Here, we investigated the underlying factors contributing to the abolished immune surveillance. We show that brain tumors escape pro-inflammatory M1 conversion of microglia via CD74 activation through the secretion of the cytokine macrophage migration inhibitory factor (MIF), which results in a M2 shift of microglial cells. Interruption of this glioma-microglial interaction through an antibody-neutralizing approach or small interfering RNA (siRNA)-mediated inhibition prolongs survival time in glioma-implanted mice by reinstating the microglial proinflammatory M1 function. We show that MIF-CD74 signaling inhibits interferon (IFN)-gamma secretion in microglia through phosphorylation of microglial ERK1/2 (extracellular signal-regulated protein kinases 1 and 2). The inhibition of MIF signaling or its receptor CD74 promotes IFN-gamma release and amplifies tumor death either through pharmacological inhibition or through siRNAmediated knockdown. The reinstated IFN-gamma secretion leads both to direct inhibition of glioma growth as well as inducing a M2 to M1 shift in glioma-associated microglia. Our data reveal that interference with the MIF signaling pathway represents a viable therapeutic option for the restoration of IFN-gamma-driven immune surveillance.	[Ghoochani, A.; Schwarz, M. A.; Yakubov, E.; Buchfelder, M.; Savaskan, N. E.; Eyupoglu, I. Y.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Neurosurg, Univ Klinikum Erlangen, Fac Med, Schwabachanlage 6, D-91054 Erlangen, Bayern, Germany; [Engelhorn, T.; Doerfler, A.] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Neuroradiol, Univ Klinikum Erlangen, Fac Med, Schwabachanlage 6, D-91054 Erlangen, Bayern, Germany; [Bucala, R.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Savaskan, N. E.] BiMECON Ent, Kurfurstenstr 21, Berlin, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Yale University	Eyupoglu, IY (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Neurosurg, Univ Klinikum Erlangen, Fac Med, Schwabachanlage 6, D-91054 Erlangen, Bayern, Germany.	ilker.eyupoglu@uk-erlangen.de	Yakubov, Eduard/ABH-6173-2020; Savaskan, Nicolai/D-2923-2018	Yakubov, Eduard/0000-0002-5828-6609; Savaskan, Nicolai/0000-0003-1348-094X	German Research Foundation [DFG Ey 94/2-1]	German Research Foundation(German Research Foundation (DFG))	Our work is supported by the German Research Foundation (DFG Ey 94/2-1).	Baron N, 2011, J NEUROSCI RES, V89, P711, DOI 10.1002/jnr.22595; Becker-Herman S, 2005, MOL BIOL CELL, V16, P5061, DOI 10.1091/mbc.E05-04-0327; Bernhagen J, 2007, NAT MED, V13, P587, DOI 10.1038/nm1567; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Bryan KJ, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-13; Butrym A, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0560-5; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Engelhorn T, 2009, CANCER SCI, V100, P1856, DOI 10.1111/j.1349-7006.2009.01259.x; Eyupoglu IY, 2013, NAT REV NEUROL, V9, P141, DOI 10.1038/nrneurol.2012.279; Eyupoglu IY, 2005, J NEUROSURG, V102, P738, DOI 10.3171/jns.2005.102.4.0738; Eyupoglu IY, 2003, FASEB J, V17, P1110, DOI 10.1096/fj.02-0825fje; Fingerle-Rowson G, 2009, MOL CELL BIOL, V29, P1922, DOI 10.1128/MCB.01907-08; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Gupta P, 2012, BLOOD, V119, P3767, DOI 10.1182/blood-2011-09-381988; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heneka M, 2014, J EXP MED, V211, P1500, DOI 10.1084/jem.2118insight1; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaufman JL, 2013, BRIT J HAEMATOL, V163, P478, DOI 10.1111/bjh.12565; Kitange GJ, 2010, J NEURO-ONCOL, V100, P177, DOI 10.1007/s11060-010-0186-9; Komohara Y, 2012, CANCER SCI, V103, P2165, DOI 10.1111/cas.12015; Komohara Y, 2009, CANCER SCI, V100, P2160, DOI 10.1111/j.1349-7006.2009.01296.x; Ku MC, 2013, ACTA NEUROPATHOL, V125, P609, DOI 10.1007/s00401-013-1079-8; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lubetsky JB, 2002, J BIOL CHEM, V277, P24976, DOI 10.1074/jbc.M203220200; Lyons SA, 2007, CANCER RES, V67, P9463, DOI 10.1158/0008-5472.CAN-07-2034; Mittelbronn M, 2011, ACTA NEUROPATHOL, V122, P353, DOI 10.1007/s00401-011-0858-3; Muller A, 2015, INT J CANCER, V137, P278, DOI 10.1002/ijc.29379; Nagata S, 2009, ANN SURG ONCOL, V16, P2531, DOI 10.1245/s10434-009-0532-3; Prosniak M, 2013, CLIN CANCER RES, V19, P3776, DOI 10.1158/1078-0432.CCR-12-1940; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Savaskan NE, 2011, ONCOGENE, V30, P43, DOI 10.1038/onc.2010.391; Savaskan NE, 2008, NAT MED, V14, P629, DOI 10.1038/nm1772; Schwartz V, 2009, FEBS LETT, V583, P2749, DOI 10.1016/j.febslet.2009.07.058; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Sielska M, 2013, J PATHOL, V230, P310, DOI 10.1002/path.4192; Smith Amy M, 2013, Methods Mol Biol, V1041, P41, DOI 10.1007/978-1-62703-520-0_6; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Yaddanapudi K, 2016, CANCER IMMUNOL RES, V4, P101, DOI 10.1158/2326-6066.CIR-15-0070-T; Zeiner PS, 2015, BRAIN PATHOL, V25, P491, DOI 10.1111/bpa.12194; Zhai HY, 2011, GLIA, V59, P472, DOI 10.1002/glia.21117	51	55	55	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6246	6261		10.1038/onc.2016.160	http://dx.doi.org/10.1038/onc.2016.160			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157615				2022-12-17	WOS:000388857700009
J	Zhang, ZM; Wu, JF; Luo, QC; Liu, QF; Wu, QW; Ye, GD; She, HQ; Li, BA				Zhang, Z-M; Wu, J-F; Luo, Q-C; Liu, Q-F; Wu, Q-W; Ye, G-D; She, H-Q; Li, B-A			Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/beta-catenin pathway	ONCOGENE			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; GENE-EXPRESSION; CELLS; NEUROBLASTOMA; COMPLEX; TRANSACTIVATION; TRANSCRIPTION; METHYLATION; MECHANISMS	The Wnt/beta-catenin pathway has important roles in chemoresistance and multidrug resistance 1 (MDR1) expression in some cancers, but its involvement in breast cancer and the underlying molecular mechanism are undefined. In this study, we demonstrated that the Wnt/beta-catenin pathway is activated in chemoresistant breast cancer cells. Using a Wnt pathway-specific PCR array screening assay, we detected that Pygo2, a newly identified Wnt/beta-catenin pathway component, was the most upregulated gene in the resistant cells. Additional experiments indicated that Pygo2 activated MDR1 expression in the resistant cells via the Wnt/beta-catenin pathway. Moreover, the inhibition of Pygo2 expression restored the chemotherapeutic drug sensitivity of the resistant cells and reduced the breast cancer stem cell population in these cells in response to chemotherapy. Importantly, these activities induced by Pygo2 were mediated by MDR1. We also determined the effect of Pygo2 on the sensitivity of breast tumors resistant to doxorubicin in a mouse model. Finally, RNA samples from 64 paired patient tumors (before and after chemotherapy) highly and significantly overexpressed Pygo2 and/or MDR1 after treatment, thus underlining a pivotal role for the Pygo2-mediated Wnt/beta-catenin pathway in the clinical chemoresistance of breast cancer. Our data represent the first implication of the Wnt/beta-catenin pathway in breast cancer chemoresistance and identify potential new targets to treat the recurrence of breast cancer.	[Zhang, Z-M; Luo, Q-C; Wu, Q-W; She, H-Q] Xiamen Univ, Affiliated Hosp 1, Dept Breast Surg, 55 Zhenhai Rd, Xiamen 361003, Fujian, Peoples R China; [Zhang, Z-M; Wu, J-F; Liu, Q-F; Ye, G-D; Li, B-A] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen, Fujian, Peoples R China; [Wu, J-F] Henan Univ Sci & Technol, Dept Bioengn, Coll Food & Bioengn, Luoyang, Peoples R China; [Liu, Q-F; Ye, G-D; Li, B-A] Xiamen Univ, Sch Life Sci, Engn Res Ctr Mol Diagnost, Minist Educ, Xiamen, Fujian, Peoples R China	Xiamen University; Xiamen University; Henan University of Science & Technology; Xiamen University	She, HQ (corresponding author), Xiamen Univ, Affiliated Hosp 1, Dept Breast Surg, 55 Zhenhai Rd, Xiamen 361003, Fujian, Peoples R China.; Li, BA (corresponding author), Xiamen Univ, Dept Biomed Sci, Sch Life Sci, D212 Huang Chaoyang Hall,Xiangan Campus, Xiamen 361100, Fujian, Peoples R China.	hongqiangshe68@163.com; bali@xmu.edu.cn	LUO, QI/GQH-7209-2022		'973' Project of the Ministry of Science and Technology [2013CB530600]; National Natural Science Foundation of China [U1205023, 81472457, 81201616, 81201617, 81272384]; Health-Education Joint Research Project of Fujian Province [WKJ-FJ-23]; Major Project of Science and Technology from the Department of Education [313051]; Natural Science Foundation of Fujian Province [2011D017]; Science and Technology Program of Xiamen [3502Z20114003]; 'Project 111' - State Bureau of Foreign Experts and Ministry of Education [B06016]	'973' Project of the Ministry of Science and Technology(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Health-Education Joint Research Project of Fujian Province; Major Project of Science and Technology from the Department of Education; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Science and Technology Program of Xiamen; 'Project 111' - State Bureau of Foreign Experts and Ministry of Education	This work was supported by grants from the '973' Project of the Ministry of Science and Technology (grant numbers 2013CB530600 to B-AL); the National Natural Science Foundation of China (grant numbers U1205023, 81472457, 81201616, 81201617 and 81272384 to B-AL, Q-CL and Q-FL); the Health-Education Joint Research Project of Fujian Province (grant numbers WKJ-FJ-23 to B-AL and Z-MZ); the Major Project of Science and Technology from the Department of Education (grant number 313051 to B-AL); the Natural Science Foundation of Fujian Province (grant numbers 2011D017 to Z-MZ); the Science and Technology Program of Xiamen (grant numbers 3502Z20114003 to H-QS) and 'Project 111' sponsored by the State Bureau of Foreign Experts and Ministry of Education (grant number B06016).	Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3; Andrews PGP, 2007, INT J ONCOL, V30, P357; Andrews PGP, 2009, BIOCHEM J, V422, P493, DOI 10.1042/BJ20090134; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Cai WY, 2013, J CELL SCI, V126, P2877, DOI 10.1242/jcs.123810; Cantu C, 2013, DEVELOPMENT, V140, P2377, DOI 10.1242/dev.093591; Carrera I, 2008, P NATL ACAD SCI USA, V105, P6644, DOI 10.1073/pnas.0709749105; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80; Gu BN, 2013, CELL STEM CELL, V13, P48, DOI 10.1016/j.stem.2013.04.012; Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133; Haber M, 1997, EUR J CANCER, V33, P2031, DOI 10.1016/S0959-8049(97)00229-3; Han CY, 2008, CARCINOGENESIS, V29, P1837, DOI 10.1093/carcin/bgn092; Huang Chenghui, 2009, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V34, P369; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Krieghoff E, 2006, J CELL SCI, V119, P1453, DOI 10.1242/jcs.02864; Li B, 2007, GENESIS, V45, P318, DOI 10.1002/dvg.20299; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-346; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Milovanovic T, 2004, INT J ONCOL, V25, P1337; Moghbeli M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0516-9; Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285; Nagahata T, 2003, CANCER SCI, V94, P515, DOI 10.1111/j.1349-7006.2003.tb01475.x; Polakis P, 2000, GENE DEV, V14, P1837; Popadiuk CM, 2006, CLIN CANCER RES, V12, P2216, DOI 10.1158/1078-0432.CCR-05-2433; Sun P, 2014, P NATL ACAD SCI USA, V111, P10215, DOI 10.1073/pnas.1311395111; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Townsley FM, 2004, NAT CELL BIOL, V6, P626, DOI 10.1038/ncb1141; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wang ZX, 2010, J NEURO-ONCOL, V100, P31, DOI 10.1007/s11060-010-0144-6; Watanabe K, 2014, ONCOGENE, V33, P632, DOI 10.1038/onc.2012.620; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wright KJ, 2009, P NATL ACAD SCI USA, V106, P55, DOI 10.1073/pnas.0811914106; Yamada T, 2000, CANCER RES, V60, P4761; Zardawi SJ, 2009, HISTOL HISTOPATHOL, V24, P385, DOI 10.14670/HH-24.385	38	55	60	3	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2016	35	36					4787	4797		10.1038/onc.2016.10	http://dx.doi.org/10.1038/onc.2016.10			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0IS	26876203				2022-12-17	WOS:000383324700011
J	Kumaraswamy, E; Wendt, KL; Augustine, LA; Stecklein, SR; Sibala, EC; Li, D; Gunewardena, S; Jensen, RA				Kumaraswamy, E.; Wendt, K. L.; Augustine, L. A.; Stecklein, S. R.; Sibala, E. C.; Li, D.; Gunewardena, S.; Jensen, R. A.			BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function	ONCOGENE			English	Article							DUCTAL CARCINOMA; MUTATIONS; PHENOTYPE; MIR-146A; DYSREGULATION; ASSOCIATION; PROGENITORS; MECHANISMS	Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-grade ductal carcinomas that frequently overexpress epidermal growth factor receptor (EGFR). Aberrant EGFR expression is correlated with disease progression, resistance to radiation and chemotherapy, and poor clinical prognosis. Although BRCA1 is involved in multiple cellular processes, its functional role in EGFR regulation remains enigmatic. Here, we report a previously unrecognized posttranscriptional mechanism by which BRCA1 regulates EGFR expression through the induction of miR-146a. We demonstrate that EGFR expression correlates negatively with BRCA1, whereas miR-146a levels increase with BRCA1. We show that BRCA1 binds to MIR146A promoter and activates transcription, which in turn attenuates EGFR expression. Knockdown of miR-146a in BRCA1-overexpressing cells negated this effect and suppressed its ability to inhibit proliferation and transformation. In archived triple-negative breast cancer samples, we show a strong positive correlation between BRCA1 and miR-146a expression. We also show that low expression of miR-146a strongly predicts positive lymph node status and is associated with distinctively poor overall survival of patients. Together, these observations provide an insight into a novel BRCA1 -> miR-146a -> EGFR paradigm by which BRCA1 carries out an aspect of tumor suppressor function that is potentially amenable to therapeutic intervention.	[Kumaraswamy, E.; Stecklein, S. R.; Jensen, R. A.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Kumaraswamy, E.; Wendt, K. L.; Augustine, L. A.; Sibala, E. C.; Li, D.; Jensen, R. A.] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA; [Gunewardena, S.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Gunewardena, S.] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66160 USA; [Jensen, R. A.] Univ Kansas, Med Ctr, Dept Canc Biol, Kansas City, KS 66160 USA; [Jensen, R. A.] Univ Kansas, Med Ctr, Dept Anat & Cell Biol, Kansas City, KS 66160 USA; [Jensen, R. A.] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas	Kumaraswamy, E (corresponding author), Univ Kansas, Ctr Canc, 3901 Rainbow Blvd,Mail Stop 1016, Kansas City, KS 66160 USA.	ekumaraswamy@kumc.edu; rjensen@kumc.edu		Stecklein, Shane/0000-0001-8322-5886	University of Kansas Cancer Center;  [P30 CA168524];  [P20 RR016443]; NATIONAL CANCER INSTITUTE [P30CA168524] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016443] Funding Source: NIH RePORTER	University of Kansas Cancer Center; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Vargheese Chennathukuzhi and Lisa Harlan-Williams for critical review of the manuscript. The HA-tagged wild-type and deletion mutant adenoviruses were a kind gift from Jeffrey Parvin (The Ohio State University Medical Center). We thank Dr David Baltimore (Caltech Institute of Technology) for the miR-146a promoter luciferase construct. We thank Dr Ossama Tawfik, Tim Metcalf, Marsha Danley and the Biospecimen Shared Resources for assistance with clinical samples. We also thank Flow-Cytometry Shared Resource (supported by P30 CA168524 and P20 RR016443) of the University of Kansas Medical Center. This work was supported by the University of Kansas Cancer Center.	Arnes JB, 2009, J CLIN PATHOL, V62, P139, DOI 10.1136/jcp.2008.056291; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Booth BW, 2010, EXP CELL RES, V316, P422, DOI 10.1016/j.yexcr.2009.11.006; Buckley NE, 2012, STEM CELL REV REP, V8, P982, DOI 10.1007/s12015-012-9354-y; Burga LN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2850; Chang S, 2012, MOL CELLS, V34, P425, DOI 10.1007/s10059-012-0118-y; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiba N, 2002, CANCER RES, V62, P4222; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Kawai S, 2012, J CELL BIOL, V197, P201, DOI 10.1083/jcb.201110008; Kumaraswamy E, 2007, MOL CELL BIOL, V27, P6733, DOI 10.1128/MCB.00961-07; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Lian H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031615; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Mei J, 2011, MOL CELL BIOL, V31, P3584, DOI 10.1128/MCB.05821-11; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; SAINSBURY JRC, 1987, LANCET, V1, P1398; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Shuen AY, 2011, J MAMMARY GLAND BIOL, V16, P3, DOI 10.1007/s10911-011-9213-5; Silver DP, 2012, CANCER DISCOV, V2, P679, DOI 10.1158/2159-8290.CD-12-0221; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tanic M, 2012, BREAST CANCER RES TR, V134, P41, DOI 10.1007/s10549-011-1905-4; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Toyama T, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-309; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100; Viale G, 2009, BREAST CANCER RES TR, V116, P317, DOI 10.1007/s10549-008-0206-z; Xu B, 2012, PROSTATE, V72, P1171, DOI 10.1002/pros.22466; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108	50	55	59	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4333	4346		10.1038/onc.2014.363	http://dx.doi.org/10.1038/onc.2014.363			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417703	Green Accepted			2022-12-17	WOS:000359494400005
J	Finlay-Schultz, J; Cittelly, DM; Hendricks, P; Patel, P; Kabos, P; Jacobsen, BM; Richer, JK; Sartorius, CA				Finlay-Schultz, J.; Cittelly, D. M.; Hendricks, P.; Patel, P.; Kabos, P.; Jacobsen, B. M.; Richer, J. K.; Sartorius, C. A.			Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a	ONCOGENE			English	Article							MICRORNA EXPRESSION PROFILES; MAMMARY-GLAND DEVELOPMENT; MESENCHYMAL TRANSITION; MIR-200 FAMILY; ESTROGEN; DIFFERENTIATION; IDENTIFICATION; SUPPRESSION; PROGESTINS; PROLACTIN	Progesterone (P4) has emerged as an important hormone-regulating mammary stem cell (MaSC) populations. In breast cancer, P4 and synthetic analogs increase the number of stem-like cells within luminal estrogen receptor (ER)- and progesterone receptor (PR)-positive breast cancers. These cells gain expression of de-differentiated cell markers CD44 and cytokeratin 5 (CK5), lose luminal markers ER and PR, and are more therapy resistant. We previously described that P4 downregulation of microRNA (miR)-29a contributes to the expansion of CD44(high) and CK5(+) cells. Here we investigated P4 downregulation of miR-141, a member of the miR-200 family of tumor suppressors, in facilitating an increase in stem-like breast cancer cells. miR-141 was the sole member of the miR-200 family P4-downregulated at the mature miRNA level in luminal breast cancer cell lines. Stable inhibition of miR-141 alone increased the CD44(high) population, and potentiated P4-mediated increases in both CD44(high) and CK5(+) cells. Loss of miR-141 enhanced both mammosphere formation and tumor initiation. miR-141 directly targeted both PR and signal transducer and activator of transcription 5A (Stat5a), transcription factors important for MaSC expansion. miR-141 depletion increased PR protein levels, even in cell lines where PR expression is estrogen dependent. Stat5a suppression via small interfering RNA or a small-molecule inhibitor reduced the P4-dependent increase in CK5(+) and CD44(high) cells. These data support a mechanism by which P4-triggered loss of miR-141 facilitates breast cancer cell de-differentiation through deregulation of PR and Stat5a, two transcription factors important for controlling mammary cell fate.	[Finlay-Schultz, J.; Cittelly, D. M.; Hendricks, P.; Patel, P.; Jacobsen, B. M.; Richer, J. K.; Sartorius, C. A.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Kabos, P.] Univ Colorado, Dept Med, Div Med Oncol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Finlay-Schultz, J (corresponding author), Univ Colorado, Dept Pathol, MS8104,Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA.	Jessica.Finlay-Schultz@ucdenver.edu; Carol.Sartorius@ucdenver.edu		Cittelly, Diana/0000-0002-8392-0800; Jacobsen, Britta/0000-0001-8234-1690; Finlay-Schultz, Jessica/0000-0002-7855-9870	Department of Defense BCRP grants [W81XWH-11-1-0210, W81XWH-11-1-0101]; NIH [R01 CA140985, K08 CA164048];  [P30CA046934]; NATIONAL CANCER INSTITUTE [R01CA140985, K08CA164048, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER	Department of Defense BCRP grants(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank the University of Colorado Cancer Center Flow Cytometry and Tissue Culture Cores supported by P30CA046934 and the University of Colorado, Department of Pathology Sequencing Core for their technical assistance and services. This work was supported by Department of Defense BCRP grants W81XWH-11-1-0210 (CAS, JKR) and W81XWH-11-1-0101 (DMC) and NIH R01 CA140985 (CAS). PK was supported by NIH K08 CA164048.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Axlund SD, 2013, HORM CANCER-US, V4, P36, DOI 10.1007/s12672-012-0127-5; Bocker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chatterjee S, 2009, NATURE, V461, P546, DOI 10.1038/nature08349; Cittelly DM, 2013, ONCOGENE, V32, P2555, DOI 10.1038/onc.2012.275; CLARK GM, 1983, BREAST CANCER RES TR, V3, pS69, DOI 10.1007/BF01855130; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V357, P50, DOI 10.1016/j.mce.2011.09.022; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V355, P15, DOI 10.1016/j.mce.2011.12.020; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Edwards DP, 2000, J SOC GYNECOL INVEST, V7, pS22, DOI 10.1177/1071557600007001S08; Finnegan EF, 2013, CRIT REV BIOCHEM MOL, V48, P51, DOI 10.3109/10409238.2012.738643; Gantier MP, 2011, NUCLEIC ACIDS RES, V39, P5692, DOI 10.1093/nar/gkr148; Gonzalez-Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495; Graham JD, 2009, ENDOCRINOLOGY, V150, P3318, DOI 10.1210/en.2008-1630; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grosshans H, 2010, ADV EXP MED BIOL, V700, P140; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Horwitz KB, 2008, J CLIN ENDOCR METAB, V93, P3295, DOI 10.1210/jc.2008-0938; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Howell SJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2129; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2012, BREAST CANCER RES TR, V135, P415, DOI 10.1007/s10549-012-2164-8; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Li Z, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-731; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nelson EA, 2011, BLOOD, V117, P3421, DOI 10.1182/blood-2009-11-255232; Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219; Obr AE, 2012, MOL CELL ENDOCRINOL, V357, P4, DOI 10.1016/j.mce.2011.10.030; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pillai MM, 2014, BREAST CANCER RES TR, V146, P85, DOI 10.1007/s10549-014-3004-9; Reid Brian G, 2014, Curr Chem Genom Transl Med, V8, P27, DOI 10.2174/2213988501408010027; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Rouet V, 2010, P NATL ACAD SCI USA, V107, P15199, DOI 10.1073/pnas.0911651107; Santos SJ, 2008, ENDOCRINOLOGY, V149, P329, DOI 10.1210/en.2007-0594; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Sato T, 2014, ONCOGENE, V33, P2215, DOI 10.1038/onc.2013.172; Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387; Schwab R, 2013, EMBO REP, V14, P615, DOI 10.1038/embor.2013.58; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Tanos T, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005654; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Vafaizadeh V, 2012, FRONT BIOSCI-LANDMRK, V17, P1232, DOI 10.2741/3983; Vafaizadeh V, 2010, STEM CELLS, V28, P928, DOI 10.1002/stem.407; Wagner KU, 2008, J MAMMARY GLAND BIOL, V13, P93, DOI 10.1007/s10911-008-9062-z; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095	62	55	59	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3676	3687		10.1038/onc.2014.298	http://dx.doi.org/10.1038/onc.2014.298			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241899	Green Accepted			2022-12-17	WOS:000357679100006
J	Subramanian, M; Francis, P; Bilke, S; Li, XL; Hara, T; Lu, X; Jones, MF; Walker, RL; Zhu, Y; Pineda, M; Lee, C; Varanasi, L; Yang, Y; Martinez, LA; Luo, J; Ambs, S; Sharma, S; Wakefield, LM; Meltzer, PS; Lal, A				Subramanian, M.; Francis, P.; Bilke, S.; Li, X. L.; Hara, T.; Lu, X.; Jones, M. F.; Walker, R. L.; Zhu, Y.; Pineda, M.; Lee, C.; Varanasi, L.; Yang, Y.; Martinez, L. A.; Luo, J.; Ambs, S.; Sharma, S.; Wakefield, L. M.; Meltzer, P. S.; Lal, A.			A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis	ONCOGENE			English	Article							P53 MUTANTS; ACTIVATION; P63; P73; MYC; EXPRESSION; REPRESSION; MICRORNAS; GAIN; TRANSACTIVATION	Most p53 mutations in human cancers are missense mutations resulting in a full-length mutant p53 protein. Besides losing tumor suppressor activity, some hotspot p53 mutants gain oncogenic functions. This effect is mediated in part, through gene expression changes due to inhibition of p63 and p73 by mutant p53 at their target gene promoters. Here, we report that the tumor suppressor microRNA let-7i is downregulated by mutant p53 in multiple cell lines expressing endogenous mutant p53. In breast cancer patients, significantly decreased let-7i levels were associated with missense mutations in p53. Chromatin immunoprecipitation and promoter luciferase assays established let-7i as a transcriptional target of mutant p53 through p63. Introduction of let-7i to mutant p53 cells significantly inhibited migration, invasion and metastasis by repressing a network of oncogenes including E2F5, LIN28B, MYC and NRAS. Our findings demonstrate that repression of let-7i expression by mutant p53 has a key role in enhancing migration, invasion and metastasis.	[Subramanian, M.; Francis, P.; Bilke, S.; Li, X. L.; Hara, T.; Jones, M. F.; Walker, R. L.; Zhu, Y.; Pineda, M.; Meltzer, P. S.; Lal, A.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Lu, X.; Sharma, S.] Howard Univ, Dept Biochem & Mol Biol, Coll Med, Washington, DC 20059 USA; [Lee, C.; Luo, J.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA; [Varanasi, L.; Martinez, L. A.] Univ Mississippi, Med Ctr, Inst Canc, Dept Biochem, Jackson, MS 39216 USA; [Yang, Y.; Wakefield, L. M.] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA; [Ambs, S.] NCI, Lab Human Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Mississippi; University of Mississippi Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lal, A (corresponding author), NCI, Regulatory RNAs & Canc Sect, Genet Branch, NIH, Bldg 37,Room 6134,37 Convent Dr, Bethesda, MD 20892 USA.	ashish.lal@nih.gov	Sharma, Sudha/AAV-6152-2021; Wakefield, Lalage M/M-1963-2017	Sharma, Sudha/0000-0003-2765-2482; Wakefield, Lalage M/0000-0003-4124-5250; Walker, Robert/0000-0001-8235-4686; Ambs, Stefan/0000-0001-7651-9309	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research; National Institute of General Medical Sciences of the National Institutes of Health [SC1GM093999]; NATIONAL CANCER INSTITUTE [ZIABC011400, ZIABC011399, ZIABC011091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [SC1GM093999] Funding Source: NIH RePORTER	Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of General Medical Sciences of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. Sudha Sharma was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number SC1GM093999. We thank K Prasanth, W Bodmer, B Hassel, M Thomas, J Lieberman and M Gorospe for their comments on this manuscript. We thank B Vogelstein for the DLD1 isogenic cell lines, K Vousden for the H1299-EV and H1299-p53R273H cells, S O'Hara for the pGL4-let-7i and Z Mourelators for the Ago2 (2A8) antibody.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chi SW, 2012, NAT STRUCT MOL BIOL, V19, P321, DOI 10.1038/nsmb.2230; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691; Do PM, 2012, GENE DEV, V26, P830, DOI 10.1101/gad.181685.111; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Lal A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002363; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Li Y, 2007, ONCOGENE, V26, P2220, DOI 10.1038/sj.onc.1210311; Liu K, 2011, MOL CELL BIOL, V31, P4464, DOI 10.1128/MCB.05574-11; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Neilsen PM, 2013, ONCOGENE, V32, P2992, DOI 10.1038/onc.2012.305; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; O'Hara SP, 2010, J BIOL CHEM, V285, P216, DOI 10.1074/jbc.M109.041640; Prueitt RL, 2007, INT J CANCER, V120, P796, DOI 10.1002/ijc.22336; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Thomas M, 2010, NAT STRUCT MOL BIOL, V17, P1169, DOI 10.1038/nsmb.1921; Thomson DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055214; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.97; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	53	55	55	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1094	1104		10.1038/onc.2014.46	http://dx.doi.org/10.1038/onc.2014.46			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662829	Green Accepted			2022-12-17	WOS:000350122100003
J	Liao, JM; Zhou, X; Gatignol, A; Lu, H				Liao, J-M; Zhou, X.; Gatignol, A.; Lu, H.			Ribosomal proteins L5 and L11 co-operatively inactivate c-Myc via RNA-induced silencing complex	ONCOGENE			English	Article						c-Myc; TRBP2; microRNA; RPL11; RPL5; ribosomal stress	EMBRYONIC STEM-CELLS; P53 ACTIVATION; NEOPLASTIC PHENOTYPE; COLORECTAL-CANCER; MDM2; INHIBITION; STRESS; BIOGENESIS; PROLIFERATION; DEGRADATION	Oncogene MYC is highly expressed in many human cancers and functions as a global regulator of ribosome biogenesis. Previously, we reported that ribosomal protein (RP) L11 binds to c-Myc and inhibits its transcriptional activity in response to ribosomal stress. Here, we show that RPL5, co-operatively with RPL11, guides the RNA-induced silencing complex (RISC) to c-Myc mRNA and mediates the degradation of the mRNA, consequently leading to inhibition of c-Myc activity. Knocking down of RPL5 induced c-Myc expression at both mRNA and protein levels, whereas overexpression of RPL5 suppressed c-Myc expression and activity. Immunoprecipitation revealed that RPL5 binds to 3'UTR of c-Myc mRNA and two subunits of RISC, TRBP (HIV-1 TAR RNA-binding protein) and Ago2, mediating the targeting of c-Myc mRNA by miRNAs. Interestingly, RPL5 and RPL11 co-resided on c-Myc mRNA and suppressed c-Myc expression co-operatively. These findings uncover a mechanism by which these two RPs can co-operatively suppress c-Myc expression, allowing a tightly controlled ribosome biogenesis in cells.	[Liao, J-M; Zhou, X.; Lu, H.] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Liao, J-M; Zhou, X.; Lu, H.] Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; [Gatignol, A.] McGill Univ, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ, Canada	Tulane University; Tulane University; Lady Davis Institute; McGill University	Lu, H (corresponding author), Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.	hlu2@tulane.edu	Gatignol, Anne/AAA-6501-2020; Zhou, Xiang/J-5046-2017	Gatignol, Anne/0000-0002-4553-0836; Zhou, Xiang/0000-0002-1172-7948	National Institutes of Health (NIH)-National Cancer Institute (NCI) [CA095441, CA079721, CA129828, CA172468]; NATIONAL CANCER INSTITUTE [R01CA095441, R01CA079721, R01CA172468, R01CA129828] Funding Source: NIH RePORTER	National Institutes of Health (NIH)-National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Karen Vousden for providing us with the RPL11 mutant plasmid, Mu-shui Dai for offering some reagents and Shelya X Zeng as well as other members of the Lu laboratory for advices and active discussion. This work was supported in part by National Institutes of Health (NIH)-National Cancer Institute (NCI) grants CA095441, CA079721, CA129828 and CA172468 to H. L.	Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109; Challagundla KB, 2011, MOL CELL BIOL, V31, P4007, DOI 10.1128/MCB.05810-11; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Flores I, 2004, ONCOGENE, V23, P5923, DOI 10.1038/sj.onc.1207796; Gallant P, 2005, CANCER RES, V65, P6485, DOI 10.1158/0008-5472.CAN-05-1101; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; GOURSE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2722, DOI 10.1073/pnas.78.5.2722; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Jin Y, 2008, MOL CELL BIOL, V28, P1218, DOI 10.1128/MCB.01198-07; Jin YT, 2006, EMBO J, V25, P1207, DOI 10.1038/sj.emboj.7601010; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Koscianska E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028548; Liao JM, 2011, J BIOL CHEM, V286, P33901, DOI 10.1074/jbc.M111.262030; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lu H, 2011, NAT MED, V17, P930, DOI 10.1038/nm.2434; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Ota H, 2013, CELL, V153, P575, DOI 10.1016/j.cell.2013.03.024; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PFEIFEROHLSSON S, 1984, CELL, V38, P585, DOI 10.1016/0092-8674(84)90513-0; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Zarnack K, 2013, CELL, V152, P453, DOI 10.1016/j.cell.2012.12.023; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540; Zhang Q, 2011, J BIOL CHEM, V286, P38264, DOI 10.1074/jbc.M111.277012; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	57	55	55	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4916	4923		10.1038/onc.2013.430	http://dx.doi.org/10.1038/onc.2013.430			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141778	Green Accepted			2022-12-17	WOS:000343767900004
J	Nam, S; Chang, HR; Kim, KT; Kook, MC; Hong, D; Kwon, CH; Jung, HR; Park, HS; Powis, G; Liang, H; Park, T; Kim, YH				Nam, S.; Chang, H. R.; Kim, K-T; Kook, M-C; Hong, D.; Kwon, C. H.; Jung, H. R.; Park, H. S.; Powis, G.; Liang, H.; Park, T.; Kim, Y. H.			PATHOME: an algorithm for accurately detecting differentially expressed subpathways	ONCOGENE			English	Article							SET ENRICHMENT ANALYSIS; GASTRIC-CANCER; INTEGRATIVE ANALYSIS; SIGNALING PATHWAY; DATABASE; GENOME; NETWORK; TRANSCRIPTION; MEDICINE; ONTOLOGY	The translation of high-throughput gene expression data into biologically meaningful information remains a bottleneck. We developed a novel computational algorithm, PATHOME, for detecting differentially expressed biological pathways. This algorithm employs straightforward statistical tests to evaluate the significance of differential expression patterns along subpathways. Applying it to gene expression data sets of gastric cancer (GC), we compared its performance with those of other leading programs. Based on a literature-driven reference set, PATHOME showed greater consistency in identifying known cancer-related pathways. For the WNT pathway uniquely identified by PATHOME, we validated its involvement in gastric carcinogenesis through experimental perturbation of both cell lines and animal models. We identified HNF4 alpha-WNT5A regulation in the cross-talk between the AMPK metabolic pathway and the WNT signaling pathway, and further identified WNT5A as a potential therapeutic target for GC. We have demonstrated PATHOME to be a powerful tool, with improved sensitivity for identifying disease-related dysregulated pathways.	[Nam, S.; Hong, D.; Kwon, C. H.] Natl Canc Ctr Korea, Canc Genom Branch, Goyang Si 410769, Gyeonggi Do, South Korea; [Chang, H. R.; Jung, H. R.; Park, H. S.; Kim, Y. H.] Natl Canc Ctr Korea, New Expt Therapeut Branch, Goyang Si 410769, Gyeonggi Do, South Korea; [Kim, K-T] Natl Canc Ctr Korea, Mol Epidemiol Branch, Goyang Si 410769, Gyeonggi Do, South Korea; [Kook, M-C] Natl Canc Ctr Korea, Dept Pathol, Goyang Si 410769, Gyeonggi Do, South Korea; [Powis, G.] Sanford Burnham Med Res Inst, Ctr Canc, La Jolla, CA USA; [Liang, H.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Park, T.] Seoul Natl Univ, Dept Stat, Seoul, South Korea	National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); National Cancer Center - Korea (NCC); Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center; Seoul National University (SNU)	Liang, H (corresponding author), Natl Canc Ctr Korea, New Expt Therapeut Branch, Goyang Si 410769, Gyeonggi Do, South Korea.	hliang1@mdanderson.org; tspark@stats.snu.ac.kr; yhkim@ncc.re.kr	Nam, Seungyoon/ACO-0914-2022	Nam, Seungyoon/0000-0002-0966-7915	National Cancer Center of the Republic of Korea [NCC-1210350-2, NCC-1210460]; National Research Foundation of Korea (NRF) - Republic of Korea (MSIP) [2012R1A3A2026438, 2008-0062618, 2013M3A9C4078158]; US National Institutes of Health [CA95060, CA129616, CA17094, CA98920, CA143883]; University of Texas MD Anderson Cancer Center-GS Hogan Gastrointestinal Research Fund; Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine; NATIONAL CANCER INSTITUTE [P50CA098258, R01CA129616, P50CA095060, P30CA016672, R01CA098920, R01CA163541, P01CA017094, U24CA143883] Funding Source: NIH RePORTER	National Cancer Center of the Republic of Korea; National Research Foundation of Korea (NRF) - Republic of Korea (MSIP); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center-GS Hogan Gastrointestinal Research Fund; Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants from the National Cancer Center of the Republic of Korea, NCC-1210350-2 (to YHK), NCC-1210460 (to SN); the National Research Foundation of Korea (NRF) grant funded by the Republic of Korea (MSIP) 2012R1A3A2026438, 2008-0062618, 2013M3A9C4078158 (to TP); grants from the US National Institutes of Health, CA95060, CA129616, CA17094 and CA98920 (to GP), CA143883 (to HL); the University of Texas MD Anderson Cancer Center-GS Hogan Gastrointestinal Research Fund and the Lorraine Dell Program in Bioinformatics for Personalization of Cancer Medicine (to HL). The Korea Institute of Science and Technology Information provided SN with a high-performance computing resource. We thank LeeAnn Chastain for editorial assistance.	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Backes C, 2007, NUCLEIC ACIDS RES, V35, pW186, DOI 10.1093/nar/gkm323; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chen XJ, 2011, BIOINFORMATICS, V27, P649, DOI 10.1093/bioinformatics/btq714; Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180; Colletti M, 2009, GASTROENTEROLOGY, V137, P660, DOI 10.1053/j.gastro.2009.05.038; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; Euskirchen GM, 2007, GENOME RES, V17, P898, DOI 10.1101/gr.5583007; Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huerta AM, 1998, NUCLEIC ACIDS RES, V26, P55, DOI 10.1093/nar/26.1.55; Kanehisa M, 1997, TRENDS GENET, V13, P375, DOI 10.1016/S0168-9525(97)01223-7; Karp PD, 2002, NUCLEIC ACIDS RES, V30, P59, DOI 10.1093/nar/30.1.59; Kato K, 2012, MOL CANCER THER, V11, P549, DOI 10.1158/1535-7163.MCT-11-0594; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375; Kim YH, 2012, CANCER RES, V72, P2512, DOI 10.1158/0008-5472.CAN-11-3870; Kim YH, 2011, CANCER CHEMOTH PHARM, V68, P405, DOI 10.1007/s00280-010-1500-0; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Nam D, 2008, BRIEF BIOINFORM, V9, P189, DOI 10.1093/bib/bbn001; Nam S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031685; Parkinson H, 2011, NUCLEIC ACIDS RES, V39, pD1002, DOI 10.1093/nar/gkq1040; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Soon WW, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.61; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeno A, 2010, ANN SURG ONCOL, V17, P1033, DOI 10.1245/s10434-009-0854-1; Tarca AL, 2009, BIOINFORMATICS, V25, P75, DOI 10.1093/bioinformatics/btn577; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28	34	55	55	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4941	4951		10.1038/onc.2014.80	http://dx.doi.org/10.1038/onc.2014.80			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24681952	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000343767900007
J	Iliou, MS; da Silva-Diz, V; Carmona, FJ; Ramalho-Carvalho, J; Heyn, H; Villanueva, A; Munoz, P; Esteller, M				Iliou, M. S.; da Silva-Diz, V.; Carmona, F. J.; Ramalho-Carvalho, J.; Heyn, H.; Villanueva, A.; Munoz, P.; Esteller, M.			Impaired DICER1 function promotes stemness and metastasis in colon cancer	ONCOGENE			English	Article						DICER1; miRNA; colon cancer; stemness; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR MICRORNAS; MIR-200 FAMILY; BREAST-CANCER; CELL-LINES; PANCREATIC-CANCER; PROSTATE-CANCER; INVASIVE STATES; REPRESSORS ZEB1	Disruption of microRNA (miRNA) expression patterns is now being recognized as a hallmark of human cancer. The causes of these altered profiles are diverse, and, among them, we found the existence of defects in the miRNA processing machinery. However, little is known about how these alterations affect the biology of the underlying tumors. Herein, we show that colorectal cancer cells with an impairment in DICER1, a major miRNA biogenesis gene, undergo enrichment of tumor stemness features and an epithelialto- mesenchymal transition. These phenotypes are associated with the downregulation of miRNAs, such as miR-34a, miR-126 and those of the miR-200 family, that target critical coding genes in these pathways. Most importantly, DICER1 impairment also induces the acquisition of a greater capacity for tumor initiation and metastasis, two properties associated with cancer stem cells.	[Iliou, M. S.; da Silva-Diz, V.; Carmona, F. J.; Ramalho-Carvalho, J.; Heyn, H.; Munoz, P.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Lab Translat Res, Barcelona, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] IDIBELL, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Munoz, P (corresponding author), Hosp Duran I Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Catalonia, Spain.	p.munoz@idibell.cat; mesteller@idibell.cat	Esteller, Manel/L-5956-2014; Ramalho-Carvalho, João/U-2356-2017	Esteller, Manel/0000-0003-4490-6093; Ramalho-Carvalho, João/0000-0001-6140-7363; Carmona Sanz, F Javier/0000-0001-7904-8493; Heyn, Holger/0000-0002-3276-1889	Spanish Ministry of Science and Innovation [SAF200801173, SAF2011-22803]; European Research Council Advanced Grant EPINORC [268626]; European Community's Seventh Framework Programme (FP7) [HEALTH-F2-2011-259015-COLTHERES, HEALTH-F5-2010-258236-SYSCOL]; Cellex Foundation; Botin Foundation; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Spanish Ministry of Science and Innovation fellowship	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Research Council Advanced Grant EPINORC; European Community's Seventh Framework Programme (FP7)(European Commission); Cellex Foundation(Foundation CELLEX); Botin Foundation; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Spanish Ministry of Science and Innovation fellowship(Ministry of Science and Innovation, Spain (MICINN))	We thank Dr Bert Vogelstein (Johns Hopkins Kimmel Comprehensive Cancer Center) for the generous gift of the parental and Dicerex5 isogenic cell lines; R Alvarez, J Comas and E Castanco (Universitat de Barcelona-SCT) for technical support with flow cytometry; and the staff of the IDIBELL animal facility for mouse care. This work was supported by grants from the Spanish Ministry of Science and Innovation (SAF200801173 and SAF2011-22803), the European Research Council Advanced Grant EPINORC no. 268626, the European Community's Seventh Framework Programme (FP7/ 2007-2013) under grant agreements no. HEALTH-F2-2011-259015-COLTHERES project and HEALTH-F5-2010-258236-SYSCOL project, Cellex Foundation, Botin Foundation, and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya). MSI was an ESTOOLS Postdoctoral Research Fellow. VdS-D was funded by a Spanish Ministry of Science and Innovation fellowship. ME is an ICREA Research Professor.	Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anton R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026257; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Cho SH, 2012, INT J ONCOL, V41, P211, DOI 10.3892/ijo.2012.1453; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; Faber C, 2011, EUR J CANCER, V47, P1414, DOI 10.1016/j.ejca.2011.01.006; Faggad A, 2012, HISTOPATHOLOGY, V61, P552, DOI 10.1111/j.1365-2559.2011.04110.x; Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004; Fukagawa T, 2004, NAT CELL BIOL, V6, P784, DOI 10.1038/ncb1155; Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698; Ghislin S, 2012, CELL CYCLE, V11, P1634, DOI 10.4161/cc.20095; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Gosens MJEM, 2007, MODERN PATHOL, V20, P221, DOI 10.1038/modpathol.3800733; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Guo XF, 2012, J CANCER RES CLIN, V138, P49, DOI 10.1007/s00432-011-1058-1; Hamada S, 2012, MOL CANCER RES, V10, P3, DOI 10.1158/1541-7786.MCR-11-0272; Henry JC, 2010, BIOCHEM BIOPH RES CO, V403, P120, DOI 10.1016/j.bbrc.2010.10.130; Heravi-Moussavi A, 2012, NEW ENGL J MED, V366, P234, DOI 10.1056/NEJMoa1102903; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iliou MS, 2011, EPIGENETICS-US, V6, P1344, DOI 10.4161/epi.6.11.18021; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jeyapalan Z, 2011, NUCLEIC ACIDS RES, V39, P3026, DOI 10.1093/nar/gkq1003; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233; Khoshnaw SM, 2012, BREAST CANCER RES TR, V135, P403, DOI 10.1007/s10549-012-2169-3; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Luo ZH, 2013, CARCINOGENESIS, V34, P415, DOI 10.1093/carcin/bgs329; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006; Munz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610; Negrini M, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1867; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Shu GS, 2012, PATHOL RES PRACT, V208, P392, DOI 10.1016/j.prp.2012.05.001; Sparks AB, 1998, CANCER RES, V58, P1130; Stratmann J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-345; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Tang F, 2007, GENE DEV, V21, P644, DOI 10.1101/gad.418707; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tome M, 2011, CELL DEATH DIFFER, V18, P985, DOI 10.1038/cdd.2010.167; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Wang CH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002420; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Wu DY, 2012, MOL MED REP, V5, P695, DOI 10.3892/mmr.2011.711; Yu Zuoren, 2012, Frontiers in Genetics, V3, P191, DOI 10.3389/fgene.2012.00191; Zhu DX, 2012, CANCER SCI, V103, P875, DOI 10.1111/j.1349-7006.2012.02234.x	88	55	56	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					4003	4015		10.1038/onc.2013.398	http://dx.doi.org/10.1038/onc.2013.398			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24096488	Green Published, hybrid			2022-12-17	WOS:000339394700012
J	Huang, TH; Chu, TY				Huang, T-H; Chu, T-Y			Repression of miR-126 and upregulation of adrenomedullin in the stromal endothelium by cancer-stromal cross talks confers angiogenesis of cervical cancer	ONCOGENE			English	Article							GROWTH-FACTOR EXPRESSION; VASCULAR INTEGRITY; CARCINOMA CELLS; TUMOR; MICRORNA-126; NEOPLASIA; LYMPHANGIOGENESIS; ACTIVATION; ISCHEMIA	miR-126 is an endothelial-specific microRNA essential for maintaining vessel integrity during development. Its role of tumor angiogenesis in cancer stroma is unclear. This study investigated the temporal and spatial expression and the role of miR-126 in the course of cervical carcinogenesis. miR-126 was found to be mainly expressed in the stromal endothelium of the uterine cervix. This downregulation was recapitulated in a cell coculture model, wherein cross talk of cervical cancer cells and fibroblasts induced a downregulation of miR-126 in human umbilical vein endothelial cells, with consequent increase of tube formation. Coinjection of cancer-associated fibroblasts of human cervix enhanced tumorigenesis of cervical cancer cells, with an increase of microvessel density and dye retention in the tumor vasculature. In association with angiogenesis, host-originated miR-126 in these xenograft tumors was progressively downregulated, whereas supplement of the miR-126 precursor in the coinjection suppressed angiogenesis and tumor growth. A proangiogenic gene adrenomedullin (ADM), which was found to be upregulated in the stroma of cervical cancer and which localized mainly in the blood and lymphatic vessels, was identified as a target of inhibition by miR-126 at the carcinoma in situ-to-invasion stage. The study suggests a cancer stroma cross talk induced repression of miR-126 and upregulation of ADM, and probably other proangiogenic factors, to facilitate angiogenesis and invasion growth of cervical cancer.	[Huang, T-H; Chu, T-Y] Tzu Chi Gen Hosp, Dept Res, Ctr Cerv Canc Prevent, Hualien 970, Taiwan; [Huang, T-H; Chu, T-Y] Tzu Chi Univ, Inst Med Sci, Hualien, Taiwan; [Chu, T-Y] Tzu Chi Univ, Tzu Chi Gen Hosp, Dept Obstet & Gynecol, Hualien, Taiwan	Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University	Chu, TY (corresponding author), Tzu Chi Gen Hosp, Dept Obstet & Gynecol, 707,Sect 3,Chung Yang Rd, Hualien 970, Taiwan.	hidrchu@gmail.com		Chu, Tang-Yuan/0000-0003-2717-2681	National Science Council of the Republic of China, Taiwan [NSC 97-2314-B-303-008-MY3]; Buddhist Tzu Chi General Hospital, Hualien, Taiwan [TCRD100-54-01]	National Science Council of the Republic of China, Taiwan(Ministry of Science and Technology, Taiwan); Buddhist Tzu Chi General Hospital, Hualien, Taiwan	We thank Ms Yen-Jen Shih for the technical assistance. We also thank Dr Lu-Hai Wang for his comments during the preparation of this manuscript. Ted Knoy is appreciated for his editorial assistance. This study was supported by the National Science Council of the Republic of China, Taiwan (contract number NSC 97-2314-B-303-008-MY3) and by the Buddhist Tzu Chi General Hospital, Hualien, Taiwan (contract number TCRD100-54-01).	Bai YY, 2011, EXP MOL PATHOL, V91, P471, DOI 10.1016/j.yexmp.2011.04.016; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Botting SK, 2010, TRANSL ONCOL, V3, P170, DOI 10.1593/tlo.09292; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; Cooley LS, 2010, J CELL SCI, V123, P3808, DOI 10.1242/jcs.064279; Dellas A, 1997, GYNECOL ONCOL, V67, P27, DOI 10.1006/gyno.1997.4835; Dobbs SP, 1997, BRIT J CANCER, V76, P1410, DOI 10.1038/bjc.1997.571; Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; Frede S, 2005, CANCER RES, V65, P4690, DOI 10.1158/0008-5472.CAN-04-3877; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hamada S, 2012, MOL CANCER RES, V10, P3, DOI 10.1158/1541-7786.MCR-11-0272; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Iwase T, 2005, CIRCULATION, V111, P356, DOI 10.1161/01.CIR.0000153352.29335.B9; Karpinich NO, 2011, CURR HYPERTENS REV, V7, P228, DOI 10.2174/157340211799304761; Karpinich NO, 2013, FASEB J, V27, P590, DOI 10.1096/fj.12-214080; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231; Liu B, 2009, LUNG CANCER, V66, P169, DOI 10.1016/j.lungcan.2009.01.010; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; McCall MN, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-78; Nikitenko LL, 2006, BRIT J CANCER, V94, P1, DOI 10.1038/sj.bjc.6602832; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ribatti D, 2005, PEPTIDES, V26, P1670, DOI 10.1016/j.peptides.2005.02.017; Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330; Sun YQ, 2010, BIOCHEM BIOPH RES CO, V391, P1483, DOI 10.1016/j.bbrc.2009.12.098; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang KH, 2009, CANCER SCI, V100, P2175, DOI 10.1111/j.1349-7006.2009.01285.x; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610; Zhang L, 2003, CANCER RES, V63, P3403; Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7	36	55	58	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3636	3647		10.1038/onc.2013.335	http://dx.doi.org/10.1038/onc.2013.335			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	24037526				2022-12-17	WOS:000338942900003
J	Barckhausen, C; Roos, WP; Naumann, SC; Kaina, B				Barckhausen, C.; Roos, W. P.; Naumann, S. C.; Kaina, B.			Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair	ONCOGENE			English	Article						metastatic melanoma; interstrand cross-links; p53; drug resistance; DDB2; XPC	NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; GROUP-C GENE; ANTICANCER DRUGS; GLIOMA-CELLS; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; INDUCED APOPTOSIS; P53; FOTEMUSTINE	Malignant melanoma is a cancer characterized by high chemoresistance although p53 is rarely mutated. Here, we show that p53 wild-type melanoma cells acquire resistance to cell death induced by fotemustine (FM), which is a representative of alkylating DNA interstrand cross-linking agents used in melanoma therapy. We show that drug-induced resistance is a result of p53-dependent upregulation of the nucleotide excision repair (NER) genes xeroderma pigmentosum complementation group C (XPC) and damaged DNA-binding protein 2 (DDB2), which stimulate the repair of DNA interstrand cross-links (ICLs) arising from O-6-chloroethylguanine. Consequently, TP53 mutated cells are unable to repair ICLs, leading to prolonged ATM, ATR and checkpoint kinase 1 (CHK1) activation, and finally apoptosis. The roles of p53 and NER in ICL-triggered cell death were confirmed by knockdown of p53 and XPC. Upregulation of XPC and DDB2 in p53wt cells following a single drug treatment is a robust and sustained response that lasts for up to 1 week. Pretreatment with an inducing dose followed by a high and toxic dose of FM provoked an adaptive response as the killing outcome of the challenge dose was reduced. Upregulation of XPC and DDB2 was also observed in a melanoma mouse xenograft model following systemic administration of FM. Additionally, XPC and DDB2 induction occurred upon treatment with other cross-linking anticancer drugs, such as cisplatin and mafosfamide, indicating it is a general response of cancer cells to this group of chemotherapeutics. Collectively, the data indicate that p53-dependent upregulation of XPC and DDB2 is a key mechanism upon genotoxic stress, whereby melanoma cells acquire resistance towards DNA cross-linking agents. To our knowledge, this is the first demonstration of upregulation of NER following a single dose of a DNA interstrand cross-linker, which is a robust and long-lasting effect that impacts the killing response of cancer cells to subsequent treatments.	[Barckhausen, C.; Roos, W. P.; Naumann, S. C.; Kaina, B.] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Inst Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Roos, Wynand/B-4846-2008; Kaina, Bernd/AAE-4692-2020	Roos, Wynand/0000-0002-0474-7414; 	DFG [KA724, RO3617]	DFG(German Research Foundation (DFG))	We gratefully acknowledge a gift of DDB2 antibodies from Dr Vesna Rapic- Otrin, University of Pittsburgh and Dr Beate Koberle for her help. We thank Rebekka Kitzinger for technical assistance, Georg Nagel for his help with animal experiments and Christian Henninger for helpful advice concerning tumor sample processing. Work was supported by DFG KA724 and RO3617.	Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964; Batista LFZ, 2009, MOL CANCER RES, V7, P237, DOI 10.1158/1541-7786.MCR-08-0428; Berdelle N, 2011, MOL CANCER THER, V10, P2224, DOI 10.1158/1535-7163.MCT-11-0534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT TP, 1987, CANCER RES, V47, P3384; Carson C, 2012, PIGM CELL MELANOMA R, V25, P514, DOI 10.1111/j.1755-148X.2012.01010.x; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JM, 1992, CARCINOGENESIS, V13, P1503; Chen ZW, 2003, CARCINOGENESIS, V24, P1111, DOI 10.1093/carcin/bgg051; Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOLAN ME, 1989, CARCINOGENESIS, V10, P1613, DOI 10.1093/carcin/10.9.1613; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FETY R, 1992, CANCER CHEMOTH PHARM, V31, P118, DOI 10.1007/BF00685097; Garbe C, 2010, EUR J CANCER, V46, P270, DOI 10.1016/j.ejca.2009.10.032; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Hayes MT, 1997, BIOCHEMISTRY-US, V36, P10646, DOI 10.1021/bi970791q; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jaspers NGJ, 2007, AM J HUM GENET, V80, P457, DOI 10.1086/512486; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; KLEEBERG UR, 1995, MELANOMA RES, V5, P195, DOI 10.1097/00008390-199506000-00009; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Ludlum DB, 1986, IARC SCI PUBL, V70, P137; McHugh PJ, 2006, CELL CYCLE, V5, P1044, DOI 10.4161/cc.5.10.2763; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muniandy PA, 2009, J BIOL CHEM, V284, P27908, DOI 10.1074/jbc.M109.029025; Naumann SC, 2009, BRIT J CANCER, V100, P322, DOI 10.1038/sj.bjc.6604856; Padget K, 2000, BIOCHEM PHARMACOL, V59, P629, DOI 10.1016/S0006-2952(99)00372-X; Passagne I, 2003, J PHARMACOL EXP THER, V307, P816, DOI 10.1124/jpet.103.051938; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; Raschle M, 2008, CELL, V134, P969, DOI 10.1016/j.cell.2008.08.030; Rafferty JA, 1996, ONCOGENE, V12, P693; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785; Roos WP, 2011, CANCER RES, V71, P4150, DOI 10.1158/0008-5472.CAN-10-3498; Roos WP, 2009, DNA REPAIR, V8, P72, DOI 10.1016/j.dnarep.2008.09.003; Roos WP, 2009, MOL PHARMACOL, V76, P927, DOI 10.1124/mol.109.058131; Sasaki MS, 2004, CYTOGENET GENOME RES, V104, P28, DOI 10.1159/000077463; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Tarhini AA, 2004, CURR OPIN ONCOL, V16, P161, DOI 10.1097/00001622-200403000-00014; Tellez CS, 2009, MELANOMA RES, V19, P146, DOI 10.1097/CMR.0b013e32832b274e; Thoma BS, 2005, NUCLEIC ACIDS RES, V33, P2993, DOI 10.1093/nar/gki610; Tian M, 2004, MOL CELL BIOL, V24, P1200, DOI 10.1128/MCB.24.3.1200-1205.2004; Tsaryk R, 2006, CANCER LETT, V239, P305, DOI 10.1016/j.canlet.2005.08.036; Usanova S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-248; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wu YH, 2007, ONCOGENE, V26, P4761, DOI 10.1038/sj.onc.1210284; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	55	55	55	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1964	1974		10.1038/onc.2013.141	http://dx.doi.org/10.1038/onc.2013.141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604128				2022-12-17	WOS:000334346300009
J	Liu, L; Dong, Z; Liang, J; Cao, C; Sun, J; Ding, Y; Wu, D				Liu, L.; Dong, Z.; Liang, J.; Cao, C.; Sun, J.; Ding, Y.; Wu, D.			As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3 beta pathway	ONCOGENE			English	Article						FAT10; hepatocellular carcinoma; hepatitis B virus; prognosis; progression; Akt	EPITHELIAL-MESENCHYMAL TRANSITION; CLASS-I REGION; POOR-PROGNOSIS; NASOPHARYNGEAL CARCINOMA; INCREASED EXPRESSION; UBIQUITIN-BINDING; CANCER; LIVER; GENE; PATHOGENESIS	FAT10 is an oncogene that is localized at 6q21.3, a region frequently amplified in hepatocellular carcinoma (HCC). Recently, growing attention has been paid to its effect in the initiation of various cancers. However, there has been little research into the influence of FAT10 on the progression and prognosis of HCC, especially in hepatitis B virus (HBV)-related HCC. Here, we aimed at investigating clincopathological significance of FAT10 in HBV-related HCC and its underlying mechanisms. Based on the analysis of FAT10 expression in a reliable and large number of cases with 5-year follow-up, we showed that FAT10 was significantly increased in 260 samples from HBV-related HCC patients, compared with 30 normal tissue, 50 cirrhosis and matched adjacent nontumor tissues. FAT10 expression is correlated with recurrence and poor prognosis in HBV-related HCC. In addition, ectopic expression of FAT10 enhanced cell proliferation, inhibited apoptosis and induced cell cycle progression, whereas silencing FAT10 expression suppressed cell proliferation and induced apoptosis. FAT10 also induced the epithelial-mesenchymal transition (EMT) and promoted invasion of HCC cells. Furthermore, we found Akt/GSK3 beta pathway contributed to the effects of FAT10 in HCC cells. Blocking the Akt pathway significantly inhibited the actions of FAT10. Taken together, the ubiquitin-like protein FAT10 has a central role in regulating diverse aspects of the pathogenesis of HCC, indicating that it might be a potential therapeutic target.	[Liu, L.; Ding, Y.] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou 510515, Guangdong, Peoples R China; [Liu, L.; Ding, Y.] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China; [Dong, Z.; Liang, J.; Cao, C.; Sun, J.; Ding, Y.; Wu, D.] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Hepatol Unit, 1838 Guangzhoudadaobei Rd, Guangzhou 510515, Guangdong, Peoples R China.	liuli.fimmu@gmail.com; wudehua.gd@gmail.com		Liu, Li/0000-0002-5265-4159; Dong, Zhong-Yi/0000-0001-9967-0060; Wu, De-Hua/0000-0003-0560-0016	National Nature Science Foundation of China [81172056, 81172586]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Nature Science Foundation of China (Grant No. 81172056 and 81172586).	Bardag-Gorce F, 2010, EXP MOL PATHOL, V88, P353, DOI 10.1016/j.yexmp.2010.03.001; Bett JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030866; Canaan A, 2006, MOL CELL BIOL, V26, P5180, DOI 10.1128/MCB.00966-05; Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865; Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2; Chung JS, 2012, GASTROENTEROLOGY, V143, P1084, DOI 10.1053/j.gastro.2012.06.038; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; French SW, 2010, EXP MOL PATHOL, V88, P219, DOI 10.1016/j.yexmp.2010.01.005; Fu J, 2011, HEPATOLOGY, V53, P181, DOI 10.1002/hep.24015; Gong PF, 2010, J AM SOC NEPHROL, V21, P316, DOI 10.1681/ASN.2009050479; Groettrup M, 2008, TRENDS BIOCHEM SCI, V33, P230, DOI 10.1016/j.tibs.2008.01.005; Gruen JR, 1996, GENOMICS, V36, P70, DOI 10.1006/geno.1996.0427; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Li JC, 2010, GASTROENTEROLOGY, V139, P2146, DOI 10.1053/j.gastro.2010.08.004; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Lim CB, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-20; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Lukasiak S, 2008, ONCOGENE, V27, P6068, DOI 10.1038/onc.2008.201; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Oliva J, 2008, EXP MOL PATHOL, V84, P102, DOI 10.1016/j.yexmp.2007.12.003; Poon RTP, 2011, HEPATOLOGY, V54, P757, DOI 10.1002/hep.24569; Qing X, 2011, EXP MOL PATHOL, V90, P51, DOI 10.1016/j.yexmp.2010.09.005; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Rani N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1752; Ren JW, 2011, J CELL SCI, V124, P3665, DOI 10.1242/jcs.087403; Ren JW, 2006, J BIOL CHEM, V281, P11413, DOI 10.1074/jbc.M507218200; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Teufel A, 2012, J HEPATOL, V56, P279, DOI 10.1016/j.jhep.2011.05.035; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tommasi S, 2007, CURR PHARM DESIGN, V13, P3279, DOI 10.2174/138161207782360663; Wangsa D, 2008, BRIT J CANCER, V99, P1121, DOI 10.1038/sj.bjc.6604633; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Wu D, 2010, ANN ONCOL, V21, P589, DOI 10.1093/annonc/mdp333; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Zhang DW, 2006, ONCOGENE, V25, P2318, DOI 10.1038/sj.onc.1209220; Zou JJ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-97	44	55	63	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					909	920		10.1038/onc.2013.236	http://dx.doi.org/10.1038/onc.2013.236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23812429				2022-12-17	WOS:000331626900012
J	Adhikary, T; Brandt, DT; Kaddatz, K; Stockert, J; Naruhn, S; Meissner, W; Finkernagel, F; Obert, J; Lieber, S; Scharfe, M; Jarek, M; Toth, PM; Scheer, F; Diederich, WE; Reinartz, S; Grosse, R; Muller-Brusselbach, S; Muller, R				Adhikary, T.; Brandt, D. T.; Kaddatz, K.; Stockert, J.; Naruhn, S.; Meissner, W.; Finkernagel, F.; Obert, J.; Lieber, S.; Scharfe, M.; Jarek, M.; Toth, P. M.; Scheer, F.; Diederich, W. E.; Reinartz, S.; Grosse, R.; Mueller-Bruesselbach, S.; Mueller, R.			Inverse PPAR beta/delta agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion	ONCOGENE			English	Article						peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) angiopoietin-like 4 (ANGPTL4); transforming growth factor beta (TGF beta); transcriptional repression; invasion; ChIP-Seq	ANGIOPOIETIN-LIKE 4; ACTIVATED RECEPTOR-DELTA; PROMOTES VENOUS INVASION; TGF-BETA; ANOIKIS RESISTANCE; GAMMA LIGANDS; EXPRESSION; PROTEIN; MIGRATION; METASTASIS	Besides its established functions in intermediary metabolism and developmental processes, the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) has a less defined role in tumorigenesis. In the present study, we have identified a function for PPAR beta/delta in cancer cell invasion. We show that two structurally divergent inhibitory ligands for PPAR beta/delta, the inverse agonists ST247 and DG172, strongly inhibit the serum- and transforming growth factor beta (TGF beta)-induced invasion of MDA-MB-231 human breast cancer cells into a three-dimensional matrigel matrix. To elucidate the molecular basis of this finding, we performed chromatin immunoprecipitation sequencing (ChIP-Seq) and microarray analyses, which identified the gene encoding angiopoietin-like 4 (ANGPTL4) as the major transcriptional PPAR beta/delta target in MDA-MB-231 cells, previously implicated in TGF beta-mediated tumor progression and metastatic dissemination. We show that the induction of ANGPTL4 by TGF beta and other oncogenic signals is strongly repressed by ST247 and DG172 in a PPAR beta/delta-dependent fashion, resulting in the inhibition of ANGPTL4 secretion. This effect is attributable to these ligands' ability to induce a dominant transcriptional repressor complex at the site of transcription initiation that blocks preinitiation complex formation through an histone deacetylase-independent, non-canonical mechanism. Repression of ANGPTL4 transcription by inverse PPAR beta/delta agonists is functionally linked to the inhibition of cancer cell invasion into a three-dimensional matrix, as (i) invasion of MDA-MB-231 cells is critically dependent on ANGPTL4 expression, (ii) recombinant ANGPTL4 stimulates invasion, and (iii) reverses the inhibitory effect of ST247 and DG172. These findings indicate that a PPAR beta/delta-ANGPTL4 pathway is involved in the regulation of tumor cell invasion and that its pharmacological manipulation by inverse PPAR beta/delta agonists is feasible.	[Adhikary, T.; Kaddatz, K.; Stockert, J.; Naruhn, S.; Meissner, W.; Finkernagel, F.; Obert, J.; Lieber, S.; Mueller-Bruesselbach, S.; Mueller, R.] Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35032 Marburg, Germany; [Brandt, D. T.; Grosse, R.] Univ Marburg, Pharmacol Inst, D-35032 Marburg, Germany; [Scharfe, M.; Jarek, M.] Helmholtz Ctr Infect Res HZI, Braunschweig, Germany; [Toth, P. M.; Scheer, F.; Diederich, W. E.] Univ Marburg, Inst Pharmaceut Chem, D-35032 Marburg, Germany; [Reinartz, S.] Univ Marburg, Dept Gynecol Gynecol Endocrinol & Oncol, D-35032 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Helmholtz Association; Helmholtz-Center for Infection Research; Philipps University Marburg; Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35032 Marburg, Germany.	rmueller@imt.uni-marburg.de	Müller, Rolf/L-4997-2016; Adhikary, Till/O-5678-2018	Müller, Rolf/0000-0003-3339-4248; Grosse, Robert/0000-0002-3380-5273; Adhikary, Till/0000-0003-1951-5605	Deutsche Forschungsgemeinschaft [SFB/TRR17-A3, MU601/13]; LOEWE research cluster 'Tumor and Inflammation'	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); LOEWE research cluster 'Tumor and Inflammation'	This work was supported by research grants from the Deutsche Forschungsgemeinschaft to RM (SFB/TRR17-A3 and MU601/13) and by the LOEWE research cluster 'Tumor and Inflammation'.	Adhikary T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016344; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Borland MG, 2011, CELL SIGNAL, V23, P2039, DOI 10.1016/j.cellsig.2011.07.020; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Du J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015940; Farrow B, 2003, SURGERY, V134, P206, DOI 10.1067/msy.2003.221; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J LIPID RES, V45, P2071, DOI 10.1194/jlr.M400138-JLR200; Gealekman O, 2008, AM J PHYSIOL-ENDOC M, V295, pE1056, DOI 10.1152/ajpendo.90345.2008; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Hu ZY, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-9; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Huang XF, 2012, ONCOL REP, V27, P1541, DOI 10.3892/or.2012.1672; Kaddatz K, 2010, J BIOL CHEM, V285, P29469, DOI 10.1074/jbc.M110.142018; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Koliwad SK, 2009, J BIOL CHEM, V284, P25593, DOI 10.1074/jbc.M109.025452; Kramer DK, 2007, J BIOL CHEM, V282, P19313, DOI 10.1074/jbc.M702329200; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Lei X, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.217638; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Lieber S, 2012, J MED CHEM, V55, P2858, DOI 10.1021/jm2017122; Lim HJ, 2009, ATHEROSCLEROSIS, V202, P446, DOI 10.1016/j.atherosclerosis.2008.05.023; Liu H, 2003, BREAST CANCER RES TR, V79, P63, DOI 10.1023/A:1023366117157; Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Mannelqvist M, 2011, AM J PATHOL, V178, P861, DOI 10.1016/j.ajpath.2010.10.040; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Michalik L, 2011, PROSTAG LEUKOTR ESS, V85, P235, DOI 10.1016/j.plefa.2011.04.016; Muller R, 2008, PPAR RES, V2008; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Nakayama T, 2010, ONCOL REP, V24, P599, DOI 10.3892/or_00000897; Naruhn S, 2011, MOL PHARMACOL, V80, P828, DOI 10.1124/mol.111.074039; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Papi A, 2009, ONCOL REP, V21, P1083, DOI 10.3892/or_00000327; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Peters JM, 2009, BBA-REV CANCER, V1796, P230, DOI 10.1016/j.bbcan.2009.06.002; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Rieck M, 2008, MOL PHARMACOL, V74, P1269, DOI 10.1124/mol.108.050625; Shearer BG, 2010, J MED CHEM, V53, P1857, DOI 10.1021/jm900464j; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Stockert J, 2011, NUCLEIC ACIDS RES, V39, P119, DOI 10.1093/nar/gkq773; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tan NS, 2007, MOL CELL BIOL, V27, P7161, DOI 10.1128/MCB.00436-07; Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008-5472.CAN-09-2067; Toth PM, 2012, CHEMMEDCHEM, V7, P159, DOI 10.1002/cmdc.201100408; Van Ginderachter JA, 2008, PPAR RES, V2008, DOI 10.1155/2008/169414; Verine J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010421; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zaytseva YY, 2011, ANTICANCER RES, V31, P813; Zhang ZY, 2008, CANCER LETT, V267, P106, DOI 10.1016/j.canlet.2008.03.010; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	59	55	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5241	5252		10.1038/onc.2012.549	http://dx.doi.org/10.1038/onc.2012.549			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23208498	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000326497100007
J	Rubio, R; Gutierrez-Aranda, I; Saez-Castillo, AI; Labarga, A; Rosu-Myles, M; Gonzalez-Garcia, S; Toribio, ML; Menendez, P; Rodriguez, R				Rubio, R.; Gutierrez-Aranda, I.; Saez-Castillo, A. I.; Labarga, A.; Rosu-Myles, M.; Gonzalez-Garcia, S.; Toribio, M. L.; Menendez, P.; Rodriguez, R.			The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development	ONCOGENE			English	Article						mesenchymal stem cells; leiomyosarcoma; osteosarcoma; osteogenic differentiation; p53; Rb	HUMAN OSTEOSARCOMA; P53; RB; MICE; RETINOBLASTOMA; INACTIVATION; LEIOMYOSARCOMAS; TRANSPLANTATION; TRANSFORMATION; TUMORIGENESIS	Increasing evidence suggests that mesenchymal stem/stromal cells (MSCs) carrying specific mutations are at the origin of some sarcomas. We have reported that the deficiency of p53 alone or in combination with Rb (Rb-/- p53 (-/-)) in adipose-derived MSCs (ASCs) promotes leiomyosarcoma-like tumors in vivo. Here, we hypothesized that the source of MSCs and/or the cell differentiation stage could determine the phenotype of sarcoma development. To investigate whether there is a link between the source of MSCs and sarcoma phenotype, we generated p53(-/-) and Rb-/- p53(-/-) MSCs from bone marrow (BM-MSCs). Both genotypes of BM-MSCs initiated leiomyosarcoma formation similar to p53(-/-) and Rb-/- p53(-/-) ASCs. In addition, gene expression profiling revealed transcriptome similarities between p53-or Rb-p53-deficient BM-MSCs/ASCs and muscle-associated sarcomagenesis. These data suggest that the tissue source of MSC does not seem to determine the development of a particular sarcoma phenotype. To analyze whether the differentiation stage defines the sarcoma phenotype, BM-MSCs and ASCs were induced to differentiate toward the osteogenic lineage, and both p53 and Rb were excised using Cre-expressing adenovectors at different stages along osteogenic differentiation. Regardless the level of osteogenic commitment, the inactivation of Rb and p53 in BM-MSC-derived, but not in ASC-derived, osteogenic progenitors gave rise to osteosarcoma-like tumors, which could be serially transplanted. This indicates that the osteogenic differentiation stage of BM-MSCs imposes the phenotype of in vivo sarcoma development, and that BM-MSC-derived osteogenic progenitors rather than undifferentiated BM-MSCs, undifferentiated ASCs or ASC-derived osteogenic progenitors, represent the cell of origin for osteosarcoma development.	[Rubio, R.; Labarga, A.; Menendez, P.; Rodriguez, R.] Univ Granada, Andalusian Reg Govt, GENYO Ctr Genom & Oncol Res Pfizer, Granada 18007, Spain; [Gutierrez-Aranda, I.; Saez-Castillo, A. I.] Andalusian Publ Hlth Syst Biobank, Granada, Spain; [Rosu-Myles, M.] Hlth Canada, Biol & Genet Therapies Directorate, Ctr Vaccine Evaluat, Ottawa, ON K1A 0L2, Canada; [Gonzalez-Garcia, S.; Toribio, M. L.] UAM, Ctr Biol Mol Severo Ochoa CSIC, Madrid, Spain; [Rodriguez, R.] Hosp Univ Cent Asturias, Oviedo 33006, Spain; [Rodriguez, R.] Inst Univ Oncol Principado Asturias, Oviedo 33006, Spain	Pfizer; University of Granada; Health Canada; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Central University Hospital Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Menendez, P (corresponding author), Univ Granada, Andalusian Reg Govt, GENYO Ctr Genom & Oncol Res Pfizer, Avda Ilustrac 114, Granada 18007, Spain.	pablo.menendez@genyo.es; renerg@ficyt.es	Bujan, Pablo Menendez/W-3736-2017; González-García, Sara/Y-9913-2019; Rodriguez, Rene/P-2168-2018; Labarga, Alberto/AAA-9341-2019; Labarga, Alberto/J-9077-2014; Toribio, Maria L/C-2039-2017	Bujan, Pablo Menendez/0000-0001-9372-1007; González-García, Sara/0000-0002-0315-2136; Rodriguez, Rene/0000-0002-0768-7306; Labarga, Alberto/0000-0001-6781-893X; Labarga, Alberto/0000-0001-6781-893X; Toribio, Maria L/0000-0002-8637-0373; Rubio Amador, Ruth/0000-0003-3263-0819	Instituto de Salud Carlos III/FEDER [PI10/00449, CP11/00024, RD12/0036/0015]; Junta de Andalucia/FEDER [P08-CTS-3678]; MINECO; Spanish Association Against Cancer (Junta Provincial de Albacete) [CI110023]; Health Canada [H4084-112281]; ISCIII/FEDER;  [PLE-2009-0111]	Instituto de Salud Carlos III/FEDER(Instituto de Salud Carlos IIIEuropean Commission); Junta de Andalucia/FEDER(Junta de AndaluciaEuropean Commission); MINECO(Spanish Government); Spanish Association Against Cancer (Junta Provincial de Albacete); Health Canada; ISCIII/FEDER(Spanish Government); 	We thank the Andalusian Platform of Bioinformatics (PAB; University of Malaga) for providing access to IPA software. This work was supported by the Instituto de Salud Carlos III/FEDER (PI10/00449 to PM, CP11/00024-Miguet Servet Program-to RRo and RTICC RD12/0036/0015); the Junta de Andalucia/FEDER (P08-CTS-3678 to PM), the MINECO (Fondo Especial del Estado para Dinamizacion de la Economia y Empleo PLE-2009-0111 to PM and SAF2010-15106 to MLT), The Spanish Association Against Cancer (Junta Provincial de Albacete-CI110023 to PM and Junta Provincial de Granada to RRo), Health Canada (H4084-112281 to PM, RRo and MR-M) and Obra Social Cajastur-IUOPA. RRu was supported by a fellowship of the ISCIII/FEDER. Author contributions: RRu: conception and design, collection and/or of assembly data, data analysis, interpretation and manuscript writing. SG-G: collection of data, data analysis and interpretation IG-A, AIS-C, AL, MR-M and MLT: data analysis and interpretation. PM and RRo: conception and design, financial support, data analysis and interpretation and manuscript writing. The manuscript has been seen and approved by all authors.	Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; Barroso-delJesus A, 2011, FASEB J, V25, P1497, DOI 10.1096/fj.10-172221; Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Bueno C, 2010, CYTOTHERAPY, V12, P45, DOI 10.3109/14653240903377052; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Chillon MC, 2012, LEUKEMIA, V26, P2360, DOI 10.1038/leu.2012.161; Choi J, 2010, AM J PATHOL, V177, P2645, DOI 10.2353/ajpath.2010.100306; Clark-Knowles KV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008534; Danielson LS, 2010, AM J PATHOL, V177, P908, DOI 10.2353/ajpath.2010.091150; De Falco G, 2006, ONCOGENE, V25, P5244, DOI 10.1038/sj.onc.1209623; Garcia-Castro J, 2008, J CELL MOL MED, V12, P2552, DOI 10.1111/j.1582-4934.2008.00516.x; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Gutierrez-Aranda I, 2010, STEM CELLS, V28, P1568, DOI 10.1002/stem.471; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Li H, 2007, CANCER RES, V67, P10889, DOI 10.1158/0008-5472.CAN-07-2665; Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180; Lopez-Guerrero JA, 2004, DIAGN MOL PATHOL, V13, P81; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; Menendez P, 2002, BRIT J HAEMATOL, V119, P135, DOI 10.1046/j.1365-2141.2002.03794.x; Menendez P, 2009, J EXP MED, V206, P3131, DOI 10.1084/jem.20091050; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Rodriguez R, 2012, ADV EXP MED BIOL, V741, P187, DOI 10.1007/978-1-4614-2098-9_13; Rodriguez R, 2012, CELL RES, V22, P62, DOI 10.1038/cr.2011.157; Rodriguez R, 2011, STEM CELLS, V29, P179, DOI 10.1002/stem.571; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Rubio R, 2010, CANCER RES, V70, P4185, DOI 10.1158/0008-5472.CAN-09-4640; Sanchez L, 2011, STEM CELLS, V29, P251, DOI 10.1002/stem.569; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shojaei F, 2008, EXP HEMATOL, V36, P1436, DOI 10.1016/j.exphem.2008.06.001; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Tataria M, 2006, J PEDIATR SURG, V41, P624, DOI 10.1016/j.jpedsurg.2005.12.001; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005-0620; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808	42	55	55	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4970	4980		10.1038/onc.2012.507	http://dx.doi.org/10.1038/onc.2012.507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23222711				2022-12-17	WOS:000325717800013
J	Chapman-Rothe, N; Curry, E; Zeller, C; Liber, D; Stronach, E; Gabra, H; Ghaem-Maghami, S; Brown, R				Chapman-Rothe, N.; Curry, E.; Zeller, C.; Liber, D.; Stronach, E.; Gabra, H.; Ghaem-Maghami, S.; Brown, R.			Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells	ONCOGENE			English	Article						bivalent genes; ChIPseq; tumor sustaining cells; chemo-resistant cells; ovarian cancer	EMBRYONIC STEM-CELLS; MANAGEMENT; POLYCOMB; CHIP; IDENTIFICATION; CHEMOTHERAPY; STRATEGIES; PATHWAY; GENOME; MEMORY	In embryonic stem (ES) cells, bivalent chromatin domains containing H3K4me3 and H3K27me3 marks silence developmental genes, while keeping them poised for activation following differentiation. We have identified gene sets associated with H3K27me3 and H3K4me3 marks at transcription start sites in a high-grade ovarian serous tumour and examined their association with epigenetic silencing and malignant progression. This revealed novel silenced bivalent marked genes, not described previously for ES cells, which are significantly enriched for the PI3K (P < 10(-7)) and TGF-beta signalling pathways (P < 10(-5)). We matched histone marked gene sets to gene expression sets of eight normal fallopian tubes and 499 high-grade serous malignant ovarian samples. This revealed a significant decrease in gene expression for the H3K27me3 and bivalent gene sets in malignant tissue. We then correlated H3K27me3 and bivalent gene sets to gene expression data of ovarian tumour 'stem cell-like' sustaining cells versus non-sustaining cells. This showed a significantly lower expression for the H3K27me3 and bivalent gene sets in the tumour-sustaining cells. Similarly, comparison of matched chemo-sensitive and chemo-resistant ovarian cell lines showed a significantly lower expression of H3K27me3/bivalent marked genes in the chemo-resistant compared with the chemo-sensitive cell line. Our analysis supports the hypothesis that bivalent marks are associated with epigenetic silencing in ovarian cancer. However it also suggests that additional tumour specific bivalent marks, to those known in ES cells, are present in tumours and may potentially influence the subsequent development of drug resistance and tumour progression.	[Chapman-Rothe, N.; Zeller, C.; Liber, D.; Ghaem-Maghami, S.; Brown, R.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London W12 0NN, England; [Curry, E.; Liber, D.; Stronach, E.; Gabra, H.; Brown, R.] Univ London Imperial Coll Sci Technol & Med, Ovarian Canc Act Res Ctr, London W12 0NN, England	Imperial College London; Imperial College London	Brown, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, IRDB 4th Floor,Hammersmith Hosp Campus,Cane Rd, London W12 0NN, England.	b.brown@imperial.ac.uk		Curry, Edward/0000-0002-5603-6956; Ghaem-Maghami, Sadaf/0000-0002-7369-5080; Gabra, Hani/0000-0002-3322-4399; Brown, Robert/0000-0001-7960-5755	Ovarian Cancer Action; Cancer Research UK; Imperial Experimental Cancer Research and Biomedical Research Centres; Cancer Research UK [13086] Funding Source: researchfish; Ovarian Cancer Action [OCA3] Funding Source: researchfish	Ovarian Cancer Action(Ovarian Cancer Action); Cancer Research UK(Cancer Research UK); Imperial Experimental Cancer Research and Biomedical Research Centres; Cancer Research UK(Cancer Research UK); Ovarian Cancer Action(Ovarian Cancer Action)	This work was supported by funding from Ovarian Cancer Action; and Cancer Research UK; as well as the Imperial Experimental Cancer Research and Biomedical Research Centres. We are grateful for help from the Gynaecological Oncology team at Hammersmith Hospital and members of the Ovarian Cancer Action Research Centre, in particular Elham Shamsaei, Nona Rama, and Kay Dawson from Dept Pathology. We thank Prof Edison T Liu, Genome Institute of Singapore, and the Agency for Science Technology and Research of Singapore for supporting the microarray expression data on the ovarian tumour and benign samples. Gene expression data generated by The Cancer Genome Atlas (TCGA) Pilot Project established by the NCI and NHGRI were used in the study.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Aletti GD, 2007, MAYO CLIN PROC, V82, P751; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berkenblit A, 2005, J REPROD MED, V50, P426; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Ho JWK, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-134; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2009, STAT METHODS MED RES, V18, P565, DOI 10.1177/0962280209351908; LANGDON SP, 1988, CANCER RES, V48, P6166; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110; Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611; Zhang HY, 2009, EUR J OBSTET GYN R B, V146, P81, DOI 10.1016/j.ejogrb.2009.04.035; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004	32	55	57	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4586	4592		10.1038/onc.2012.477	http://dx.doi.org/10.1038/onc.2012.477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23128397				2022-12-17	WOS:000324831300015
J	Kerr, BA; McCabe, NP; Feng, W; Byzova, TV				Kerr, B. A.; McCabe, N. P.; Feng, W.; Byzova, T. V.			Platelets govern pre-metastatic tumor communication to bone	ONCOGENE			English	Article						platelet; bone metastasis; bone remodeling; tumor	ENDOTHELIAL GROWTH-FACTOR; PROSTATE-CANCER GROWTH; CELL-PROLIFERATION; RICH PLASMA; FACTOR-BETA; ANGIOGENESIS; MICROENVIRONMENT; DIFFERENTIATION; ACTIVATION; EXPRESSION	Although the survival rate for early detected cancers is high, once a cancer metastasizes to bone, it is incurable. Interestingly, patients without visible metastases display abnormal bone formation and resorption, suggesting a link between primary cancers and the bone microenvironment prior to metastasis, and this link likely facilitates preparation of the pre-metastatic niche. We hypothesized that communication with the primary tumor would result in bone remodeling alterations, and that platelets could facilitate this communication. By using three tumor models, we demonstrate that primary tumor growth stimulates bone formation measured by microcomputed tomography. Further, platelet depletion prevented tumor-induced bone formation, highlighting the importance of platelets in the communication between tumors and the bone microenvironment. Finally, we determine that platelets sequester a variety of tumor-derived proteins, TGF-beta 1 and MMP-1 in particular, which regulate bone formation. Thus, our data reveal that platelets function as mediators of tumor-bone communication prior to metastasis.	[Kerr, B. A.; McCabe, N. P.; Feng, W.; Byzova, T. V.] Cleveland Clin, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Dept Mol Cardiol, Lerner Res Inst, Cleveland, OH 44195 USA; [Feng, W.] Xi An Jiao Tong Univ, Sch Med, Affiliated Hosp 1, Xian 710049, Shaanxi, Peoples R China; [Byzova, T. V.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Xi'an Jiaotong University; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin, Taussig Canc Ctr, Dept Mol Cardiol, 9500 Euclid Ave,NB-50, Cleveland, OH 44195 USA.	byzovat@ccf.org	Kerr, Bethany/D-1644-2012	Kerr, Bethany/0000-0002-2995-7549; Byzova, Tatiana/0000-0002-2615-875X	NIAMS Core Cente [1P30 AR050953]; Ruth L Kirschstein NRSA award from the NIH/NCI [F32 CA142133]; Ruth L Kirstein NRSA award [F32 CA117262]; NIH/NCI [CA126847]; NATIONAL CANCER INSTITUTE [F32CA142133, R01CA126847] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000439] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL073311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050953] Funding Source: NIH RePORTER	NIAMS Core Cente; Ruth L Kirschstein NRSA award from the NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirstein NRSA award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Miroslava Tischenko, Steven Maximuk and Richard Rozic for their technical assistance. Dr Amit Vasanji developed the software and techniques for the microCT analysis. Cleveland Clinic Biomedical Imaging and Analysis Core Center was funded, in part by NIAMS Core Center, grant no. 1P30 AR050953. BAK was supported by a Ruth L Kirschstein NRSA award (F32 CA142133) from the NIH/NCI. NPM was supported by a Ruth L Kirstein NRSA award (F32 CA117262). This study was supported by research funding from the NIH/NCI (grant no. CA126847) to TVB.	*AM CANC SOC, 2008, MEL SKIN CANC; American Cancer Society, 2008, PROSTATE CANC; Baselga J, 2008, BIOMARKERS, V13, P217, DOI 10.1080/13547500701676019 ; Blouin S, 2008, BRIT J CANCER, V98, P809, DOI 10.1038/sj.bjc.6604238; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Borsig L, 2008, EXPERT REV ANTICANC, V8, P1247, DOI 10.1586/14737140.8.8.1247; Coleman RE, 2008, CLIN CANCER RES, V14, P6387, DOI 10.1158/1078-0432.CCR-08-1572; Edlund M, 2004, J CELL BIOCHEM, V91, P686, DOI 10.1002/jcb.10702; Feng WY, 2011, BLOOD, V117, P3893, DOI 10.1182/blood-2010-08-304808; Feng WY, 2008, J CELL BIOL, V183, P1145, DOI 10.1083/jcb.200802179; GASIC GJ, 1968, P NATL ACAD SCI USA, V61, P46, DOI 10.1073/pnas.61.1.46; Gomes RR, 2009, CLIN EXP METASTAS, V26, P641, DOI 10.1007/s10585-009-9263-x; Gruber R, 2002, BONE, V30, P726, DOI 10.1016/S8756-3282(02)00697-X; Haeusler G, 2005, CALCIFIED TISSUE INT, V76, P326, DOI 10.1007/s00223-004-0161-6; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; Kawasumi M, 2008, J BONE JOINT SURG BR, V90B, P966, DOI 10.1302/0301-620X.90B7.20235; Kerr BA, 2012, COMPUT TOMOGR, P211; Kerr BA, 2010, NEOPLASIA, V12, P388, DOI 10.1593/neo.10166; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Klement GL, 2009, BLOOD, V113, P2835, DOI 10.1182/blood-2008-06-159541; McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429; McCabe NP, 2008, CLIN EXP METASTAS, V25, P581, DOI 10.1007/s10585-008-9175-1; McCabe NP, 2011, NEOPLASIA, V13, P31, DOI 10.1593/neo.10998; Mishra A, 2009, TISSUE ENG PART C-ME, V15, P431, DOI 10.1089/ten.tec.2008.0534; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Nair MB, 2009, TISSUE ENG PT A, V15, P1619, DOI 10.1089/ten.tea.2008.0229; Oprea WE, 2003, J CRANIOFAC SURG, V14, P292, DOI 10.1097/00001665-200305000-00006; Reinholz GG, 2000, CANCER RES, V60, P6001; Rhee JS, 2004, THROMB HAEMOSTASIS, V92, P394, DOI 10.1160/TH03-04-0213; Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140; Saadeh PB, 1999, AM J PHYSIOL-CELL PH, V277, pC628, DOI 10.1152/ajpcell.1999.277.4.C628; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sims NA, 2008, SEMIN CELL DEV BIOL, V19, P444, DOI 10.1016/j.semcdb.2008.07.016; Stellos K, 2007, THROMB HAEMOSTASIS, V98, P922, DOI 10.1160/TH07-02-0147; Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099; Uggeri J, 2007, J PERIODONTOL, V78, P1985, DOI 10.1902/jop.2007.070116; Zelzer E, 2002, DEVELOPMENT, V129, P1893	42	55	57	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4319	4324		10.1038/onc.2012.447	http://dx.doi.org/10.1038/onc.2012.447			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23069656	Green Accepted			2022-12-17	WOS:000324168000014
J	Boreddy, SR; Srivastava, SK				Boreddy, S. R.; Srivastava, S. K.			Deguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model	ONCOGENE			English	Article						NF kappa B; TGF-beta; RKIP; Snail; metastasis; apoptosis	NF-KAPPA-B; CANCER-CELLS; E-CADHERIN; TGF-BETA; SMAD PATHWAYS; AKT INHIBITOR; EXPRESSION; APOPTOSIS; KINASE; ACTIVATION	Deguelin is known to suppress the growth of cancer cells; however, its anti-metastatic effects have not been studied so far in any cancer model. In the present study, we aimed to evaluate the anti-metastatic potential of deguelin in vivo and in tumor growth factor-beta 1 (TGF beta 1)-stimulated cells. Our results demonstrate that tumor growth, peritoneal dissemination and liver/lung metastasis of orthotopically implanted PanC-1-luc cells were significantly reduced in deguelin-treated mice along with the induction of apoptosis. Furthermore, deguelin-treated tumors showed increased epithelial signature such as increased expression of E-Cadherin and cytokeratin-18 and decreased expression of Snail. Similar observations were made when PanC-1, COLO-357 and L3.6pl cells were treated in vitro with deguelin. Moreover, E-cadherin was transcriptionally upregulated and accumulated in the membrane fraction of deguelin-treated cells, as indicated by increased interaction of E-Cadherin with beta-catenin. TGF beta 1-induced downregulation of E-Cadherin and upregulation of Snail were abrogated by deguelin treatment. In addition, deguelin inhibited TGF beta 1-induced Smad3 phosphorylation and Smad4 nuclear translocation in PanC-1 cells. Furthermore, when TGF beta 1-induced nuclear factor kappa B (NF kappa B) activation was inhibited, TGF beta 1-induced Snail upregulation or E-Cadherin downregulation was blocked. Deguelin also significantly downregulated the constitutive phosphorylation and DNA binding of NF kappa B in a dose-dependent manner. Interestingly, overexpression of either NF kappa B or Snail completely abrogated deguelin-mediated epithelial-to-mesenchymal transition (EMT) inhibition, whereas overexpression of NF kappa B but not Snail rescued cells from deguelin-induced apoptosis. Hence, deguelin targets NF kappa B to induce reversal of EMT and apoptosis but downstream effectors might be different for both processes. Taken together, our results suggest that deguelin suppresses both pancreatic tumor growth and metastasis by inducing apoptosis and inhibiting EMT.	Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, Amarillo, TX 79106 USA; [Srivastava, S. K.] Texas Tech Univ, Hlth Sci Ctr, Canc Biol Ctr, Amarillo, TX 79106 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Srivastava, SK (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biomed Sci, ARB, 1406 Coulter,Suite 1103, Amarillo, TX 79106 USA.	Sanjay.Srivastava@ttuhsc.edu	Srivastava, Sanjay K./AAE-7635-2020		National Cancer Institute [CA106953, CA129038]; NATIONAL CANCER INSTITUTE [R01CA106953, R01CA129038] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to acknowledge National Cancer Institute for supporting the present study in part by R01 grants CA106953 and CA129038 (to SKS). The technical assistance of Kartick C Pramanik, Prabodh K Kandala and Parul Gupta in the in vivo experiment is greatly appreciated. We would also like to thank Dr Thomas L Brown (Wright State University, Dayton, OH, USA), Dr Ming H Wang (Texas Tech Health Sciences Center, Amarillo, TX, USA), Dr Fazlul H Sarkar (Wayne State University, Detroit, MI, USA), Dr Paul Chiao (MD Anderson Cancer Center, Houston, TX, USA), Dr Frank C Marini (MD Anderson Cancer Center, Houston, TX, USA) and Dr Ming-Sound Tsao (University of Toronto, Toronto, Ontario, Canada) for providing the cell lines.	Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Baritaki S, 2009, ONCOGENE, V28, P3573, DOI 10.1038/onc.2009.214; Batra S, 2010, MOL CANCER THER, V9, P1596, DOI 10.1158/1535-7163.MCT-09-1146; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Besmer DM, 2011, CANCER RES, V71, P4432, DOI 10.1158/0008-5472.CAN-10-4439; Boreddy SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025799; Boreddy SR, 2011, CLIN CANCER RES, V17, P1784, DOI 10.1158/1078-0432.CCR-10-1891; Brinck U, 2004, ANTICANCER RES, V24, P2237; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cates JMM, 2009, PANCREAS, V38, pE1, DOI 10.1097/MPA.0b013e3181878b7f; Chen Y, 2009, INT J HEMATOL, V89, P618, DOI 10.1007/s12185-009-0307-4; Dell'Eva R, 2007, CARCINOGENESIS, V28, P404, DOI 10.1093/carcin/bgl162; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Gingery A, 2008, EXP CELL RES, V314, P2725, DOI 10.1016/j.yexcr.2008.06.006; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Ito S, 2010, LEUKEMIA RES, V34, P352, DOI 10.1016/j.leukres.2009.09.003; Javle MM, 2007, ANN SURG ONCOL, V14, P3527, DOI 10.1245/s10434-007-9540-3; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kandala PK, 2012, J BIOL CHEM, V287, P28745, DOI 10.1074/jbc.M112.351379; Kang HW, DIG DIS SCI; Lee HY, 2005, J NATL CANCER I, V97, P1695, DOI 10.1093/jnci/dji377; Lee H, 2010, ONCOL REP, V24, P957, DOI 10.3892/or_00000942; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Murillo G, 2002, EUR J CANCER, V38, P2446, DOI 10.1016/S0959-8049(02)00192-2; Murillo G, 2009, CANCER PREV RES, V2, P942, DOI 10.1158/1940-6207.CAPR-08-0232; Nakajima S, 2004, CLIN CANCER RES, V10, P4125, DOI 10.1158/1078-0432.CCR-0578-03; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oh SH, 2007, J NATL CANCER I, V99, P949, DOI 10.1093/jnci/djm007; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Pramanik KC, ANTIOXID REDOX SIGNA; Sahu RP, 2009, JNCI-J NATL CANCER I, V101, P176, DOI 10.1093/jnci/djn470; Salahshor S, 2008, MODERN PATHOL, V21, P271, DOI 10.1038/modpathol.3800990; Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434-007-9583-5; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tang HH, 2010, FEBS LETT, V584, P662, DOI 10.1016/j.febslet.2009.12.051; Udeani GO, 2001, CANCER CHEMOTH PHARM, V47, P263, DOI 10.1007/s002800000187; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Weinel RJ, 1996, INT J PANCREATOL, V19, P25; Wu K, 2009, CRIT REV IMMUNOL, V29, P241, DOI 10.1615/CritRevImmunol.v29.i3.40; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yan Y, 2005, NEOPLASIA, V7, P1053, DOI 10.1593/neo.05532; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	47	55	60	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3980	3991		10.1038/onc.2012.413	http://dx.doi.org/10.1038/onc.2012.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22986522	Green Accepted			2022-12-17	WOS:000323748100006
